58th EASD Annual Meeting of the European Association for the Study of Diabetes
Stockholm, Sweden, 19 - 23 September 2022

Abstracts

Index of Oral Presentations

OP 01 Diet: from plants to cans
OP 02 SGLT2 inhibitors: promiscuous pleiotropy
OP 03 Risk for CVD and CKD
OP 04 Walking with diabetes
OP 05 How to become a fat cell
OP 06 Intracellular regulation of insulin release
OP 07 Finding a phenotype for diabetic kidney disease
OP 08 Cardiovascular disease mechanisms: something new on the table?
OP 09 Fighting diabetes with tubes, scanners, and catheters
OP 10 Beta cells: protecting what is precious
OP 11 Adipose tissue profiling and cardio-metabolic risk
OP 12 GWAS and more
OP 13 Beyond type 1 and type 2
OP 14 Exercising your tissues in shape
OP 15 Preserving kidney function
OP 16 Flames and scars in the liver
OP 17 Toying with monitoring: from Present Continuous to Future Perfect
OP 18 Cross-talk communication in the pancreas
OP 19 GLP1 agonists: from here to eternity
OP 20 NAFLD and treatment
OP 21 Retinopathy future vision
OP 22 Giving birth with diabetes
OP 23 Are we too slow to outlaw the low?
OP 24 How to burn energy
OP 25 Lipid in and out of the liver
OP 26 The dark side of diabetes
OP 27 Improving your insulin sensitivity: lessons from human studies
OP 28 Desirable diets
OP 29 Saving sweet souls
OP 30 Novel ways of beta cell replacement
OP 31 Diabetes: size matters
OP 32 Pain or no pain?
OP 33 Therapy outside the box
OP 34 Insulin signalling, novelties from the petri dish!
OP 35 Different pathways involved in killing the beta cell
OP 36 Central aspects of diabetes
OP 37 Insulin deficiencies and cardiovascular disease
OP 38 It is always a D-D-Day: diabetes, digital, device
OP 39 Too little sugar is also bad: understanding hypoglycaemia
OP 40 When the clock ticks
OP 41 Viruses and diabetes: more than COVID-19
OP 42 Moving towards the beta cell plasma membrane
OP 43 Microvascular cocktail
OP 44 Grading insulin therapy: simple, simpler, the safest
OP 45 Newer agents, better outcomes

OP 46 Profiling human diabetes risk
OP 47 Novel mechanistic insights in peripheral insulin sensitivity
OP 48 How we loose our beta cells

Index of Short Oral Discussions

SO 01 Epigenetics rules
SO 02 Pregnancy and diabetes
SO 03 Food, drinks and spices
SO 04 Starting with autoimmunity
SO 05 Genetics of type 2 diabetes
SO 06 Sometimes one gene is enough
SO 07 SARS-CoV2 and other viruses
SO 08 Benefits of a healthy lifestyle
SO 09 Type 1 diabetes: from molecules to treatment
SO 10 Diversity in diabetes
SO 11 Novel biomarkers and risk factors
SO 12 Different facets of type 2 diabetes treatment
SO 13 It's getting complicated
SO 14 COVID-19 around the globe
SO 15 Calcium signalling in the islet: we are still learning
SO 16 A new niche to replace beta cells
SO 17 Intracellular signalling balancing beta cell survival and death
SO 18 Stressing the beta cell into dysfunction
SO 19 How complicated is type 1 diabetes?
SO 20 The other diabetes and islet function
SO 21 The fat burning the islets
SO 22 Exercise and diabetes: much to learn!
SO 23 Gestational diabetes and pregnancy
SO 24 Life with diabetes from conception to delivery
SO 25 Insulin sensitivity: lessons from cellular and animal models
SO 26 Novel markers and omics signatures
SO 27 If you cannot measure it, you cannot improve it: novel methods in diabetes research
SO 28 Understanding insulin sensitivity: lessons from the clinic
SO 29 Glucose homeostasis regulation beyond insulin
SO 30 Non-classical regulators of metabolism
SO 31 Gut feelings are good
SO 32 Latest drug avenues to treatment
SO 33 Insulin in action
SO 34 The hepato-skeletal impact on metabolic control
SO 35 Metabolic inflexibility and complications in humans
SO 36 Modelling obesity and type 2 diabetes
SO 37 Dietary and nutritional interventions
SO 38 SGLT2 inhibitors and renal outcomes
SO 39 Newer agents - cardiovascular outcomes
SO 40 Incretins: impact on BMI
SO 41 Incretins: basic science
SO 42 Clinical epidemiology and pharmacotherapy
SO 43 Glucose lowering agents
SO 44 Lessons from trials
SO 45 Beta cell function and glucose control
SO 46 Incretins everywhere
SO 47 Treatments, molecules and outcomes: a smorgasbord
SO 48 Hypoglycaemia: hip hip hooray yet to come
SO 49 Is newer (insulin) always better?
SO 50 Is longer better? Looking for different basal insulin approaches
SO 51 Even "old dogs" can learn new tricks
SO 52 Money isn't everything?
SO 53 Pumping, looping, freeing
SO 54 Making sense out of sensors and data
SO 55 From low to high and back: the many faces of insulin therapy
SO 56 Diversity of life with diabetes
SO 57 Type 1 diabetes: still the challenge number one
SO 58 Autonomic rhythm
SO 59 Getting a grip on nerves
SO 60 Preventing microvascular complications
SO 61 Saving the feet
SO 62 Brain, nerve, and heart interaction
SO 63 Diversity of the diabetic kidney
SO 64 New treatment avenues for the diabetic kidney
SO 65 Translating signals in the diabetic kidney
SO 66 Mechanisms of diabetic kidney disease
SO 67 Flames and scars in NAFLD: pathogenesis and therapy
SO 68 From brain circulation to cognitive dysfunction
SO 69 Type 1 diabetes: new findings and complications
SO 70 Circulating markers of cardiovascular risk
SO 71 Prevention and treatment of cardiovascular complications
SO 72 Diabetes dysmetabolism dialogues with the cardiovascular component
SO 73 Diabetes in the vessels
SO 74 Weighing risks of cardiovascular complications
SO 75 Emerging comorbidities in diabetes: clinical associations and mechanisms
SO 76 Cancer and type 2 diabetes: interconnections and mortality
SO 77 Disclosing fatty liver disease mechanisms
SO 78 Screening tools, lipids and novel biomarkers
SO 79 Focus on the heart and beyond
OP 01 Diet: from plants to cans

1 Diet and all-cause mortality in individuals with type 2 diabetes: a systematic review and meta-analysis of prospective studies
J. Barbaresko1, A. Lang1, E. Szczepanowska1,2, C. Baechle1,2, L. Schwingshackl1, M. Neuenschwander1,2, S. Schlesinger1,2
1Institute for Biometrics and Epidemiology, German Diabetes Center, Düsseldorf, 2German Center for Diabetes Research (DZD), Munich-Neuherberg

Background and aims: Type 2 diabetes (T2D) is a major health concern associated with several comorbidities and mortality. Dietary factors may influence the progression of diabetes; however, high-quality systematic reviews are lacking. Therefore, the aim was to systematically summarise and evaluate the evidence on dietary factors and the risk of all-cause mortality in individuals with T2D from observational prospective studies.

Materials and methods: A systematic literature search was conducted in PubMed and Web of Science up to September 2021 to identify prospective observational studies investigating any dietary factor (dietary patterns, food groups, macro- and micronutrients, and secondary plant compounds) in association with all-cause mortality in individuals with T2D. We conducted pairwise analysis (high vs. low intake) and dose-response meta-analyses to calculate summary risk ratios (SRR) with corresponding 95% confidence intervals (CI) using random effects models. The inconsistency between the study results was assessed using I². The certainty of evidence of the associations was evaluated by applying a validated tool.

Results: In total, we identified 97 studies and performed 38 meta-analyses. Moderate certainty of evidence was found for decreased all-cause mortality with higher intakes of fish (SRR per serving/week: 0.95; 95% CI: 0.92, 0.99; I²=0%; n=6 studies), whole grain (SRR per 20 g/d: 0.84; 95% CI: 0.71, 0.99; I²=0%; n=2), fibre (SRR per 5 g/d: 0.86; 95% CI: 0.81, 0.91; I²=0%; n=3) and n-3 polyunsaturated fatty acids (SRR per 0.1 g/d: 0.87; 95% CI: 0.82, 0.92; I²=0%; n=2). There was low certainty of evidence for an inverse association of vegetable consumption (SRR per 100 g/d: 0.97; 95% CI: 1.03, 1.08; I²=56%; n=7), and protein intake (SRR per 10 g/d: 0.91; 95% CI: 0.87, 0.96; I²=42%; n=3), as well as positive associations of egg consumption (SRR per 10 g/d: 1.05; 95% CI: 1.03, 1.08; I²=56%; n=7), and cholesterol intake (SRR per 300 mg/d: 1.19; 95% CI: 1.13, 1.26; I²=0%; n=2). For other dietary factors such as dietary patterns, other food groups, macro- and micronutrients, evidence was limited.

Conclusion: This meta-analysis showed that intake of fish, whole grain, fibre and n-3 polyunsaturated fatty acids may be inversely associated with all-cause mortality in individuals with T2D. There is limited evidence for other dietary factors and all-cause mortality in individuals with T2D and thus, more research is needed.

Disclosure: J. Barbaresko: None.

2 Appropriate consumption of different animal-based foods to reduce type 2 diabetes risk: an umbrella review of meta-analyses of prospective studies
A. Giosuè1, I. Calabrese, G. Riccardi, O. Vaccaro, M. Vitale
Clinical Medicine and Surgery, "Federico II" University of Naples, Naples, Italy.

Background and aims: Dietary recommendations for the prevention of type 2 diabetes (T2D) clearly indicate the most appropriate choices for plant-based foods; as for foods of animal origin, a limited consumption of all items is generally recommended. However, not all animal protein sources are equal; moreover, they are largely used worldwide. Therefore, we have reviewed data on the relationship between the consumption of various foods of animal origin and the incidence of T2D to support dietary recommendations for T2D prevention with updated and reliable scientific evidence on the appropriate choices for animal-based foods.

Materials and methods: The study is an umbrella review of dose-response meta-analyses of prospective cohort studies. A systematic search of the literature was conducted in PubMed, Web of Science, Scopus and Embase according to PRISMA guidelines. The methodological quality of each meta-analysis was evaluated through AMSTAR (A Measurement Tool to Assess Systematic Reviews). For each food group, we meta-analyzed the risk ratios (RR) for T2D incidence reported in the primary studies included in the available meta-analyses. The quality of evidence was evaluated with a modified version of NutriGrade.

Results: 13 meta-analyses met the criteria for inclusion in the review with 175 summary RR on consumption of total meat (n=13), red meat (n=21), white meat (n=8), processed meats (n=24), fish (n=12), total dairy (n=21), full-fat dairy (n=14), low-fat dairy (n=15), milk (n=11), cheese (n=10), yogurt (n=10) and eggs (n=16) in relation to T2D incidence. There was a substantial increase in T2D risk with the consumption of 100 g/day of total meat (RR 1.20, 95% CI 1.13-1.27) or red meat (RR 1.22, 95% CI 1.14-1.30) or 50 g/day of processed meats (RR 1.30, 95% CI 1.22-1.39), with a moderate quality of evidence; also 50 g/day of white meat showed a positive relationship with T2D risk (RR 1.04, 95% CI 1.00-1.08). As for dairy foods, we found an inverse association for T2D incidence with the intake of 200 g/day of total dairy (RR 0.95, 95% CI 0.92-0.98), low-fat dairy (RR 0.97, 95% CI 0.93-1.00) or milk (RR 0.90, 95% CI 0.83-0.98), as well as 100 g/day of yogurt (RR 0.94, 95% CI 0.90-0.98); conversely, a neutral relationship emerged for 200 g/day of full-fat dairy (RR 0.98, 95% CI 0.93-1.03) or 30 g/day of cheese (RR 0.97, 95% CI 0.91-1.04), with a quality of evidence scored between moderate and low. Finally, the consumption of 100 g/day of fish and 1 egg/day showed a neutral association with T2D risk (RR 1.04, 95% CI 0.99-1.09 and 1.07, 95% CI 0.99-1.15, respectively), with low quality of evidence.

Conclusion: The scientific evidence we have extensively reviewed shows that the habitual consumption of dairy foods in moderate amounts - especially low-fat types, milk and yogurt - could be appropriate for the optimization of T2D prevention. Within this context, moderate amounts of fish and eggs could represent suitable substitutes for red and processed meats in most eating occasions.

Clinical Trial Registration Number: PROSPERO CRD42022306145

Disclosure: A. Giosuè: None.

3 Ultra-processed food consumption and risk of type 2 diabetes: results from three prospective cohort studies in the US
Z. Chen1, N. Khandpur1, C. Monteiro1, S. Rossatto2, T. Fung3, J.E. Manson1, W. Willett1, E.B. Rimm1, F.B. Hu1, Q. Sun1, J.-P. Drouin-Chartier4

Disclosure: None.
Background and aims: Prospective evidence on the association between ultra-processed food (UPF) consumption and type 2 diabetes (T2D) risk remains limited. We aimed to prospectively examine associations between UPF intake and T2D in US men and women.

Materials and methods: We prospectively followed 62,583 women in the Nurses’ Health Study (NHS, 1984-2014), 88,633 women in the Nurses’ Health Study II (NHSII, 1991-2017), and 38,837 men in the Health Professionals Follow-up Study (HPFS, 1986-2016). Diet was assessed using validated food frequency questionnaires every 2-4 years. UPF were categorized according to the Nova classification. Associations with T2D were assessed using Cox proportional hazards models with adjustments for demographics, dietary and lifestyle factors, and medical history.

Results: During 4,784,680 person-years of follow-up, we documented 17,432 T2D cases. In multivariable-adjusted analyses, higher UPF intake was associated with a higher risk of T2D: the pooled hazard ratio (HR) comparing extreme quintiles of intake in servings of UPF per day was 1.29 (95% confidence interval (CI): 1.21, 1.37; P trend <0.0001). The association remained significant after further adjustment for overall diet quality, assessed using the Alternative Healthy Eating Index (pooled HR comparing extreme quintiles: 1.21, 95% CI: 1.13, 1.28; P trend <0.0001). The results were consistent across subgroups in analyses stratified by age, sex, BMI, diet quality and physical activity, as well as when symptomatic diabetes at diagnosis was used at the outcome.

Conclusion: UPF consumption is associated with a higher risk of T2D, independent of overall diet quality. These findings provide further support for the current recommendations of limiting UPF consumption as part of a healthy diet for the prevention of type 2 diabetes.

Disclosure: Z. Chen: None.

5 Longitudinal serum branched-chain amino acids, lifestyle intervention and the risk of type 2 diabetes in the Finnish Diabetes Prevention study

J. Kivelä1, J. Meinilä2, M. Uusitupa3, J. Tuomilehto1,4, J. Lindström1;
1Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland, 2Department of Food and Nutrition, University of Helsinki, Helsinki, Finland, 3Public Health and Welfare, University of Eastern Finland, Kuopio, Finland, 4Saudi Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia.

Background and aims: Circulating branched-chain amino acids (BCAA) are associated with the risk of type 2 diabetes (T2D). We examined to what extent lifestyle intervention aiming to prevent T2D interacts with this association and how BCAA concentrations change during the intervention.

Materials and methods: We comprised trajectory clusters by k-means clustering of serum fasting BCAA analysed annually during the four-year intervention by sandwich ELISA. We investigated whether the baseline BCAA, BCAA trajectories and BCAA change trajectories predict T2D in a median 11-year follow-up and whether BCAA predicts T2D differently in the intervention (n=198) and control group (n=196) participants of the Finnish Diabetes Prevention Study.

Results: Elevated baseline BCAA predicted the incidence of T2D in the entire study cohort (HR 1.04; 95% CI 1.01, 1.06) and control group (HR 1.06; 95% CI 1.03, 1.09), but not in the intervention group. BCAA concentration decreased during the first year in the whole cohort (-14.9 μmol/l [SD 58.5], p<0.001), with no significant difference between the intervention and control groups. We identified five BCAA trajectory clusters and five trajectory clusters for the change in BCAA. Trajectories with high mean BCAA levels were associated with an increased hazard ratio for T2D compared to a trajectory with low BCAA levels (trajectory with highest vs lowest mean BCAA, HR 3.99; 95% CI 1.46, 10.93). A trajectory with increasing BCAA levels had a higher hazard ratio for T2D compared with a decreasing trajectory in the intervention group only (HR 25.39; 95% CI 2.83, 227.62).

Conclusion: Lifestyle intervention modified the association of the baseline BCAA concentration and BCAA trajectories with the incidence of T2D.
6 Fasting ketone bodies and incident type 2 diabetes in the general population

1Internal Medicine, University Medical Center Groningen (UMCG), Groningen, Netherlands, 2Laboratory Corporation of America Holdings (Labcorp), Morrisville, USA, 3Division of Clinical Chemistry, Karolinska Institutet, Stockholm, Sweden.

Background and aims: With a rising incidence and prevalence of type 2 diabetes, prevention strategies including identification of prospective biomarkers become increasingly relevant. Ketone bodies recently received a renewed interest in this respect; however, data on a relationship between these metabolites and diabetes risk are scarce. Therefore, we investigated in the present prospective study the association between fasting ketone bodies and type 2 diabetes incidence in the general population.

Materials and methods: This study from the PREVEND cohort included 3786 participants from the general population initially free of diabetes. Baseline fasting ketone body concentrations were measured by nuclear magnetic resonance spectroscopy.

Results: 276 participants (7.3%) developed type 2 diabetes during a median [IQR] follow-up of 7.3 [5.6-7.7] years. In Kaplan-Meier analysis sex-stratified ketone body levels were strongly positively associated with incident type 2 diabetes (log rank test, p<0.001), which was confirmed in Cox regression analyses adjusted for several relevant confounders including age, sex, BMI, diastolic and systolic blood pressure, hsCRP, HOMA-IR, total cholesterol, HDL cholesterol, triglycerides, serum creatinine, 3-beta-hydroxybutyrate, 28.53, p<0.001) and acetoacetate/acetone (3.87 [2.1, 7.13], p<0.001) were associated with incident type 2 diabetes. In sensitivity analyses the addition of ketone body levels to the Framingham diabetes risk score has resulted in an improved model fit (p<0.001). There was no significant interaction by sex. Further, individually 3-beta-hydroxybutyrate (13.27 [6.18, 28.53], p<0.001) and acetoacetate/acetone (3.87 [2.1, 7.13], p<0.001) were associated with incident type 2 diabetes. In sensitivity analyses including only metabolic syndrome-free individuals the conclusions did not change (9.18 [2.99, 28.22], p<0.001). The addition of ketone body levels to the Framingham diabetes risk score has resulted in an improved model fit (p<0.001).

Conclusion: Fasting plasma ketone body levels are strongly associated with incident type 2 diabetes in the general population independent of several other recognized risk factors. These results may have important implications for diabetes prevention including dietary strategies.

Disclosure: T. Szili-Torok: None.

OP 02 SGLT2 inhibitors: promiscuous pleiotropy

7 Effect of SGLT2 inhibitor dapagliflozin on skeletal muscle fatty acid metabolism in patients with type 2 diabetes

1Nutrition and Movement Sciences, Maastricht University, Maastricht, Netherlands, 2BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA, 3Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, Netherlands, 4Human Nutrition and Health, Wageningen University, Wageningen, Netherlands, 5Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands, 6Medicine, Duke University, Durham, USA, 7BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Background and aims: SGLT2 inhibitors increase urinary glucose excretion and have beneficial effects on whole-body energy and substrate metabolism, which may be facilitated by altered muscle metabolism. This may be the consequence of the adaptive response to the loss of about 50-100g glucose per day in the urine, which can be regarded as a form of mild calorie restriction. Here, we investigated the effects of 5 weeks of dapagliflozin (10 mg orally once daily) treatment on skeletal muscle fat metabolism in type 2 diabetes patients.

Materials and methods: Twenty-six type 2 diabetes patients were randomized to a 5-week double-blind, cross-over study with 6-8 weeks of wash-out. 31P- and 1H-Magnetic resonance spectroscopy was used to determine intramyocellular lipid content (IMCL) and phosphocreatine (PCr) recovery rate. Muscle biopsies were analyzed for lipid droplet (LD) morphology, mitochondrial network integrity and mitochondrial-LD interaction with confocal microscopy. Furthermore, biopsies were analyzed for levels of acylcarnitines, amino acids and Krebs cycle intermediates, and gene expression levels of CPT1A and CPT1B. Results are presented as Least Squares Means (95% CI).

Results: IMCL content increased after dapagliflozin treatment (0.27 [0.21-0.34] vs. 0.33 [0.25-0.40], p<0.05) due to larger (0.25 [0.19-0.31] vs. 0.28 [0.20-0.36] µm², p<0.05) and more LDs (0.015 [0.009-0.021] vs. 0.0018 [0.012-0.018] µm², p=0.09). Dapagliflozin increased levels of several long-chain acylcarnitine species, while acetylcarnitine levels (154.63 [131.24-178.03] vs. 114.56 [91.16-137.95] pmol*mg tissue⁻¹, p<0.001) were decreased. Dapagliflozin treatment reduced levels of several amino acids and Krebs cycle intermediates in skeletal muscle. PCr recovery rate (23.1 [20.7-25.5] vs. 23.1 [20.7-25.5] s, p=0.88), mitochondrial network integrity (1.59 [1.31-1.87] vs. 1.73 [1.33-2.12], p=0.44), and mitochondrial-LD interaction (13.45 [10.41-16.49] vs. 12.51 [9.70-15.32], p=0.20) were unaffected by dapagliflozin. CPT1A (1.33 fold, p<0.001) and CPT1B (1.13 fold, p<0.05) gene expression increased upon dapagliflozin treatment.

Conclusion: The increase in IMCL levels and changes in LD morphology mainly resemble changes induced by fasting. Changes in long-chain acylcarnitine and acetylcarnitine levels suggest enhanced fatty acid metabolism in skeletal muscle. Reduced amino acid levels and Krebs cycle intermediates suggest enhanced amino acid utilization for gluconeogenesis. Taken together, these findings indicate that dapagliflozin induces a change in skeletal muscle substrate metabolism favoring fatty acid oxidation and a reduced glycolytic flux without changes in mitochondrial function and mitochondrial-LD interaction.

Disclosure: A. Gemmink: None.
The effect of SGLT2 inhibitor dapagliflozin on substrate metabolism in humans with prediabetes

A. Veenen 1, C. Andriessen 1, Y. Op den Kamp 1, E. Erazo Tapia 1, M. de Ligt 2, J. Mevenkamp 2, J. Jörgensen 1, E. Moonen-Kornips 1, G. Schaart 1, N. Netherlands, 2Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, Netherlands.

Background and aims: Metabolic flexibility is defined as the capacity to switch from fat oxidation in the overnight fasted state to glucose oxidation in the postprandial state. We recently showed that individuals with prediabetes have impaired 24-hour and nocturnal fat oxidation. Inhibition of sodium-glucose cotransporter 2 (SGLT2) results in glucosuria, which could divert energy away from fat oxidation. We aimed to determine whether dapagliflozin, a SGLT2 inhibitor, would improve 24-hour and nocturnal fat oxidation, improve mitochondrial function and lead to enhanced overnight glucosuria in individuals with prediabetes.

Materials and methods: Seventeen individuals with prediabetes (BMI 30.3 ± 2.1 kg/m²; age 66.3 ± 6.2 years) underwent 2-weeks of treatment with dapagliflozin (10 mg/day) or placebo in a randomized, placebo-controlled, cross-over design. Outcome parameters include 24-hour and nocturnal fat oxidation, improve mitochondrial function and lead to enhanced overnight glucosuria in individuals with prediabetes.

Results: Dapagliflozin treatment resulted in a urinary glucose excretion of 36 gram/24-hour, leading to a negative energy balance. Twenty-four-hour blood glucose levels decreased upon dapagliflozin (AUC; \( p = 0.017 \)), while 24-hour free fatty acids and nocturnal \( \beta \)-hydroxybutyrate were elevated (AUC; \( p = 0.002 \) and \( p = 0.012 \), respectively), indicating a more pronounced reliance on fat oxidation. Indeed, following dapagliflozin, 24-hour RER was lower (0.814 ± 0.006 versus 0.827 ± 0.004; \( p = 0.051 \)), in line with an increased 24-hour fat oxidation (\( p = 0.033 \)) and a reduced 24-hour carbohydrate oxidation (\( p = 0.041 \)). Nocturnal fat oxidation was increased by 82% with dapagliflozin (\( p = 0.039 \)). Coupled, and maximally uncoupled mitochondrial respiration upon lipid-derived substrates were higher after dapagliflozin (\( Q_{O2,\text{flux}} \); 68.2 ± 3.2 versus 64.6 ± 3.2 pmol/mg/s; \( p = 0.071 \) and 87.6 ± 5.4 versus 78.1 ± 5.5 pmol/mg/s; \( p = 0.007 \), respectively). No changes were observed in hepatic glycogen or lipid content and composition.

Conclusion: Dapagliflozin treatment for 2 weeks in humans with prediabetes improves 24 and nocturnal fat oxidation. Dapagliflozin treatment also had significant effects on 24h glucose and free fatty acids, and on nocturnal \( \beta \)-hydroxybutyrate levels. These data indicated a more pronounced fasted state, although no changes were observed in hepatic glycogen. In addition, dapagliflozin improved \( \text{ex vivo} \) skeletal muscle mitochondrial oxidative capacity. These results show that dapagliflozin in prediabetes individuals elicits metabolic health effects that may mimic the effects of calorie restriction.

Clinical Trial Registration Number: NCT03721874

Supported by: AstraZeneca

Disclosure: A. Veenen: None.
Background and aims: We previously have shown that both acute and chronic SGLT-2 inhibitors increase endogenous glucose production (EGP). However, the relative contribution of liver versus kidney - responsible for the increase in EGP has not been identified.

Materials and methods: We assessed the effect of a single dose of Dapagliflozin or Placebo on renal glucose production in 13 T2DM (age=57.5±1.8 yrs, BMI=30±1.4 kg/m²) and 9 NGT (age 42±2 yrs, BMI= 30±1.1 kg/m²) subjects. Renal glucose production was measured using arteriovenous balance technique across the kidney combined with [3-3H] glucose infusion and PAH infusion (for determination of renal blood flow) before and 4 hours after administration of Dapagliflozin (10 mg) or Placebo; thus, each subject served as their own control.

Results: EGP increased following Dapagliflozin (DAPA) in both T2DM (2.00±0.11 to 2.43±0.15, P<0.05) and NGT (1.72±0.11 to 2.1±0.16, p<0.05), while it decreased after placebo in T2DM (2.02±0.12 to 1.15±0.06) and NGT (2.10±0.2 vs 2.05±0.1) (both p<0.01, DAPA vs placebo). The fractional renal extraction of glucose (0.02±0.004 vs 2.99±1.0, p=0.001 in T2DM, and 0.02±0.004 vs 1.62±1.4 in NGT, p=NS) and renal glucose uptake (0.067±0.02 vs 0.347±0.06 in T2DM and 0.08±0.02 vs 0.27±0.08 mg/kg/min in NGT) were higher following DAPA vs placebo (p<0.05) and were entirely explained by the increase in glucosuria. There was a small, non-significant increase (0.065 & 0.032 mg/kg/min, respectively) in renal glucose production (RGP) following dapagliflozin in T2DM and NGT compared to the 0.45 mg/kg/min increase in total body EGP.

Conclusion: A single dose of Dapagliflozin significantly increases EGP which primarily is explained by an increase in hepatic glucose production.

Clinical Trial Registration Number: NCT02981966

Disclosure: D. Tripathy: None.

12

Empagliflozin-induced metabolic changes and cardiac function in patients with type 2 diabetes: a randomised cross-over MRI study with insulin as comparator

R. Thirumathy1, G. Hall2, J.P. Gøtze3, J.J. Holst3, U. Dixon4, E.A. Richter5, N. Vejsstrup5, S. Madsbad5, P.L. Madsen7, N.B. Jørgensen5; 1Department of Endocrinology, Hvidovre Hospital, Hvidovre, 2Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, 3Department of Biomedical Sciences, University of Copenhagen, Copenhagen, 4Department of Cardiology, Hvidovre Hospital, Hvidovre, 5Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, 6Department of Cardiology, Rigshospitalet, Copenhagen, 7Department of Cardiology, Herlev Gentofte Hospital, Herlev, Denmark.

Disclosure: B.J. Kasperova: None.
Materials and methods: 17 subjects (13 M) with T2D, aged 58±3 years
changes on cardiac function in patients with T2D.

Materials and methods: 17 subjects (13 M) with T2D, aged 58±3 years (mean±sem), BMI 32.9±0.9 kg/m2, HbA1c 52.4±2.4 mmol/L, T2D duration of 8.9±1.3 years were treated with empagliflozin (E) and NPH-insulin (I) for 5 weeks in a cross-over design with 3 weeks of washout between treatments. Insulin was titrated to produce similar glycemic control as during empagliflozin. Patients were studied before and at the end of each treatment period. Metabolic changes were evaluated with fasting glucose, insulin, FFAs and 3-0H butyrate concentrations. Cardiac function with cardiac MRI during rest and chronotropic stress on two separate days without and with acute lowering of FFAs with acipimox. Cardiac endpoints were changes between treatments and washout (E vs WO or I vs WO) and between treatments (E vs I) in left ventricular peak filling rate (ΔLVPFR) and left ventricular ejection fraction (ΔLVEF).

Results: Fasting glucose was reduced from 8.7±0.5 mM during washouts to 7.6±0.3 mM on both treatments, while serum insulin was lower (E: 103±14; I: 141±16 PM (p=0.01)) and FFAs (E: 0.60±0.03; I: 0.50±0.05 mM (p=0.02)) and 3-OH butyrate higher (E: 0.27±0.03; I: 0.23±0.02 mM (p=0.03)) on empagliflozin compared with insulin treatment. Cardiac function was largely unchanged with any treatment and was not improved with empagliflozin compared with insulin in rest or during stress (ΔLVPFR Rest: E vs WO: -38±19 (p=0.08);I vs WO: 8±25 ml/s; E vs I: -55±19 ml/s (p<0.01); ΔLVEF Rest: E vs WO: 2±1 (p=0.11), I vs WO: 1±1%, E vs I: -0±2%; ΔLVPFR Stress: E vs WO: -4±45, I vs WO: -16±28 ml/s, E vs I: -11±47 ml/s; ΔLVEF Stress: E vs WO: -1±2; I vs WO: -1±1%; E vs: I 1±1%). Acipimox reduced FFAs by ~35% at all visits, without affecting ketone body concentration. Cardiac diastolic function was unchanged by acipimox administration, but LVEF was similarly reduced during both treatments (E: -6±2% I: -5.4±1%) under resting condition.

Conclusion: Neither empagliflozin nor insulin treatment improve cardiac function in patients with T2D. Treatment specific metabolic effects play no role for cardiac function under the studied conditions.

Clinical Trial Registration Number: EudraCT no. 2017-002101-35
Supported by: Boehringer Ingelheim
Disclosure: R. Thirumathyam: None.

OP 03 Risk for CVD and CKD

13

CSII is associated with lower NAFLD indices in patients with type 1 diabetes
L. Bozzetto, G. Della Pepa, E. Raso, R. Boccia, S. Gianfrancesco, A.A. Rivellese, G. Annuzzi; Federico II University, Naples, Italy.

Background and aims: NAFLD is a raising concern also in type 1 diabetes (T1D) and is associated with micro and macrovascular complications. This study evaluated whether different ways of insulin administration (multiple daily injections [MDI] or continuous subcutaneous insulin infusion [CSII]) may affect NAFLD indices.

Materials and methods: We performed a cross-sectional study on 658 patients with T1D (37±13 years, 51% male, HbA1c 7.8±1.2%, body mass index 25±4 kg/m²) who had no history of excessive alcohol consumption or other secondary chronic liver disease, regularly attending the Diabetes Unit of an University Teaching Hospital. NAFLD was assessed by the Fatty Liver Index (FLI) and Hepatic Steatosis Index (HSI). Anthropometric, biochemical, and clinical parameters were retrieved by electronic records. Differences in NAFLD indices between patients on MDI or CSII were evaluated by univariate analysis, adjusted for possible confounders.

Results: Patients on CSII (n=259), compared with those on MDI (n=399), differed for gender distribution (men: 47% vs 55%, p=0.046), diabetes duration (22±11 vs 18±12; p<0.001), prevalence of retinopathy (26% vs 18%, p=0.018), and nephropathy (15% vs 10%, p=0.035), respectively. According to univariate analysis adjusted for gender and diabetes duration, patients on CSII had a significantly lower HSI (36±5 vs 37±6; p=0.003), FLI (20±21 vs 25±24; p=0.003), waist circumference (85±12 vs 87±14 cm; p=0.047), triglycerides (76±44 vs 85±60 mg/dl; p=0.035), and insulin daily dose (0.53±0.22 vs 0.64±0.25 UI/kg body weight; p<0.001).

Conclusion: Patients with T1D on CSII had better NAFLD indices, despite a longer diabetes duration and a higher prevalence of diabetes microvascular complications. Lower and more physiologically distributed daily insulin doses may have contributed to a better regulation of lipogenic pathways.

Disclosure: L. Bozzetto: None.

14

Increased prevalence of NAFLD in adults with glomerular hyperfiltration: a 8 year cohort study based on 147,162 Koreans
D.-J. Koo1, S. Park2;
1Division of Endocrinology and Metabolism, Department of Internal Medicine, Changwon Fatima Hospital, Changwon, 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Seoul, Republic of Korea.

Background and aims: Finding an indicator that can predict the development of nonalcoholic fatty liver disease (NAFLD) at an early stage is of clinical significance. Renal function and liver status are interconnected and share several physiological pathways. This study aimed to evaluate whether glomerular hyperfiltration (GHF) could predict the development of NAFLD and fibrosis progression.

Materials and methods: We performed a longitudinal cohort study of 147,479 participants who underwent comprehensive medical examinations annually or biennially from January 3, 2011 to December 31, 2018. Study subjects were the age group between 20 and 65 years of age without baseline kidney disease and NAFLD. Age- and sex-specific estimated glomerular filtration rate (eGFR) above the 95th percentile was defined as the GHF cutoff value, and eGFR values between the 50th and...
Increased risk for microvascular outcome in NAFLD: a nationwide, population-based cohort study

T. Ebert1, L. Widman2, P. Stenvinkel3, H. Hagström4;
1Medical Department III - Endocrinology, Nephrology, Rheumatology, University of Leipzig, Leipzig, Germany, 2Division of Biostatistics, Karolinska Institutet, Stockholm, Sweden, 3Division of Renal Medicine, Karolinska Institutet, Stockholm, Sweden, 4Karolinska Institutet, Stockholm, Sweden.

Background and aims: Non-alcoholic fatty liver disease (NAFLD) is considered a multisystemic disease, as it is bidirectionally linked to other cardiometabolic disorders, such as type 2 diabetes (T2D). However, the long-term risk for microvascular outcomes in NAFLD is unclear.

Materials and methods: Using the outpatient part of the nationwide Swedish Patient Register, we identified all individuals with a first NAFLD diagnosis (N=4,943) and matched these (age, sex, and municipality) with up to ten reference individuals from the general population (N=44,606). Using population-based registers, we ascertained the development of microvascular diseases. The primary outcome was defined as a composite outcome of any diagnosis representative of microvascular disease (chronic kidney disease, retinopathy, and neuropathy). As secondary outcomes, we separately examined the risk of each specific microvascular outcome. Hazard ratios (aHR, adjusted for cirrhosis, T2D, hypertension, hyperlipidemia, malignant tumors) for time-to-event analyses were investigated by Cox proportional-hazards models.

Results: Median follow-up times was 5.0 years. The incidence rate of microvascular diseases was twice as high in patients with NAFLD (11.6 per 1000 person-years [95% confidence interval (CI)=10.5-13.0]) vs. reference individuals (5.8 per 1000 person-years [95%CI=5.6-6.1]). Kaplan-Meier estimates for the development of (A) microvascular diseases and (B) chronic kidney disease are shown in Figure 1. NAFLD was independently and positively associated with the development of microvascular diseases compared to non-NAFLD subjects (aHR=1.41 [95%CI=1.23-1.61]). When stratifying the analysis by follow-up time, sex, or age categories, results remain virtually unchanged.

Conclusion: NAFLD is positively associated with the development of microvascular diseases, independent of available confounders, e.g. T2D. Individuals with NAFLD should be screened for microvascular diseases in addition to macrovascular and metabolic diseases.

A) Microvascular diseases

B) Chronic kidney disease

Supported by: EFSD Future Leaders Mentorship Programme, Novo Nordisk postdoctoral fellowship, Swedish Research Council, CIMED ALF

Disclosure: T. Ebert: Grants; EFSD Mentorship Programme supported by AstraZeneca, Novo Nordisk postdoctoral fellowship run in partnership with Karolinska Institutet, Stockholm, Sweden, Karolinska Institutet Research Foundation, Swedish Kidney Foundation, Stiftelsen Stig och Gunborg Westman. Lecture/other fees; Sanofi, CME-Verlag, Santis.

16 Fatty liver index is an independent risk factor for all-cause mortality and major cardiovascular events in type 1 diabetes: a 10-year observational study

G. Penno1, M. Garofolo1, D. Lucchesi1, E. Gualdani2, P. Falcetta1, M. Giambalvo1, P. Francesconi2, S. Del Prato2;
1Department of Clinical and Experimental Medicine, University of Pisa, Pisa, 2Epidemiology Unit, Regional Health Agency of Tuscany, Firenze, Italy.

Background and aims: Non-alcoholic fatty liver disease (NAFLD), also known as metabolic dysfunction-associated fatty liver disease (MAFLD), has been associated with increased risk of death, with CVD as the most common cause of death in people with and without type 2 diabetes. Whether this also applies to type 1 diabetes (T1D) has not been yet reported.

Materials and methods: We prospectively observed 774 T1D (males 52%, 30.3±11.1 years old, diabetes duration (DD) 18.5±11.6 years, HbA1c 7.8±1.2%) to assess whether fatty liver index (FLI, based on BMI, waist, GGT and triglycerides), a proxy of NAFLD, predicts the risk of all-cause death and major CVD (combined endpoint of myocardial infarction, stroke, ischemic amputation or coronary, carotid and peripheral revascularizations).

Results: Over a median follow-up of 11 years (IQR 9.9-13.0), 57 out of 774 subjects died (7.4%) while 49 major CV events (6.7%) occurred in 736 individuals for whom incidence data were retrieved (95.1%). FLI score was <30 in 515 subjects (66.5%), ≥30-60 in 169 (21.8%), and ≥60 in 90 (11.6%). Mortality rate increased across FLI scores: 3.9, 10.1, and 22.2%, K-M log-rank 40.367, p<0.0001. In unadjusted Cox, with score <30 as reference, the risk of death increased in score ≥30-60 (HR 2.85, [95% CI 1.49-5.45], p=0.002) and even more in score ≥60 (HR 6.07, [3.27-11.29], p<0.0001). After adjustment for the Steno Type 1
Risk Engine (ST1-RE; inclusive of age, sex, DD, systolic BP, LDL-cholesterol, HbA1c, albuminuria, GFR, smoking and exercise), that enters first, HRs for death was 1.52 (0.78-2.97, \( p=0.222 \)) for FLI \( \geq 30-60 \) and 3.041 (1.59-5.82, \( p=0.001 \)) for FLI \( \geq 60 \). Inclusion of prior CVD among covariates modified HRs only slightly. The effect of FLI was unchanged when analysis was restricted to 733 subjects without prior CVD. Adjustment for the EURODIAB PCS Risk Engine (EURO-RE: age, HbA1c, WHR, ACR and HDL-cholesterol) instead of ST1-RE, confirms the independent role of FLI (HRs of 1.24 [0.62-2.48] for FLI \( \geq 30-60 \) and 2.54 [1.30-4.95], \( p=0.007 \)) for FLI \( \geq 60 \), also after inclusion of prior CVD as a confounder, or when analysis was restricted to subjects without prior CVD. Incidence of major CV events increased across FLI scores: 3.5, 10.5 and 17.2%, K-M log-rank 29.16, \( p<0.0001 \). In unadjusted Cox, with score \( \leq 30 \) as reference, risk of CV events increased in score \( \geq 30-60 \) (HR 3.24, [95% CI 1.65-6.34], \( p=0.001 \)) and in score \( \geq 60 \) (HR 5.41, [2.70-10.83], \( p<0.0001 \)). After adjustment for the ST1-RE, that enters first, HRs for death was 1.80 (0.90-3.61, \( p=0.096 \)) for FLI \( \geq 30-60 \) and 2.98 (1.45-6.13, \( p=0.003 \)) for FLI \( \geq 60 \). Inclusion of prior CVD among covariates modified HRs only moderately. The effect of FLI became weaker when analysis was restricted to 733 subjects without prior CVD. Adjustment for the EURODIAB PCS risk engine instead of ST1-RE, confirms the independent role of FLI (HRs of 1.49 [0.73-3.03] for FLI \( \geq 60 \)) and 2.44 [1.17-5.09, \( p=0.017 \]) for FLI \( \geq 60 \), also after inclusion of prior CVD as a confounder.

**Conclusion:** This is the first observational prospective study to demonstrate that FLI is associated with higher all-cause mortality and increased risk of incident major CV events in T1D, independently of validated risk engines based on established CV risk factors and diabetes-related variables.

**Disclosure:** G. Penno: None.

17 Sub-optimal glycaemic control and insulin resistance in young adults with type 1 diabetes increases platelet expression of P-selectin and phosphatidylserine

R.C. Sagar, S.M. Pearson, N. Kietsiriroje, M. Hindle, K. Naseem, R. Ajjan; Leeds Institute of Cardiovascular and Metabolic Medicine, Leeds, UK.

**Background and aims:** Patients with Type 1 Diabetes Mellitus (T1D) have increased risk of morbidity and mortality associated with earlier onset cardiovascular disease (CVD) and those with a combination of T1D and insulin resistance (IR) may be at even greater risk. Platelet hyperactivity has been described in diabetes and is associated with adverse cardiovascular complications. However, the factors driving pathological platelet function and the relative contribution of glycaemia and IR remain unclear. Our aim was to investigate the impact of glycaemic control and IR on platelet activation in young adults with T1D through use of four-colour multi-paramater flow cytometry.

**Materials and methods:** Patients aged 18-40 with T1D (>3 years since diagnosis) were recruited (n=23). Glycaemic control was evaluated using HbA1c and time in range (TIR) over 14 days using FreeStyle Libre Pro. Estimated glucose disposal rate (eGDR), a clinical marker of insulin resistance, was calculated using a validated equation. eGDR <8 mg/kg/min confers IR status. Using whole blood, we applied 4-colour multiparameter flow cytometry to measure 3 distinct markers of platelet activation; both at rest and in response to activation with dual agonists Protease-activated receptor-1 (PAR-1) and Collagen related peptide XL (CRP-XL). Statistics were conducted via Prism v9.3.1.

**Results:** Mean age of participants was 24 (range 19-30) (69% males). All were on insulin therapy [1 with adjunctive metformin]. Mean HbA1c (SD) was 67 mmol/mol (±14). Individuals were split into 2 equal groups based on 1) HbA1c (≥67 and <67 mmol/mol), 2) TIR (<=50% vs >50%), 3) eGDR (<8 vs >8 mg/kg/min). Platelet data are expressed as mean±(SD) Mean Fluorescence intensity (MFI) of each marker. Those with HbA1c ≥67 expressed higher basal P-selectin MFI (641±290 vs 354 ±202; \( p=0.01 \)) and following dual agonist stimulation (7345±62376 versus 25829±8607; \( p=0.02 \)). Phosphatidylserine (PS) expression at the platelet surface was measured as a marker of procoagulant platelets. Basal PS expression appeared higher in those with HbA1c ≥67 mmol/mol compared with <67 (1112±1037 vs 505±125; \( p=0.13 \)). Following dual agonist stimulation, PS exposure was higher in those with HbA1c ≥67 mmol/mol compared to those with lower HbA1c (21531±10214 vs 10858±3478; \( p=0.07 \)). Patients were also stratified using TIR, with largely similar findings. Participants with eGDR <8 mg/kg/min showed a trend towards higher mean basal PS expression, but not P-selectin, compared with higher eGDR (PS 1216±1152 vs 458±163, \( p=0.09 \)). Following dual agonist stimulation, those with eGDR <8 mg/kg/min had a greater activation induced PS expression (23718±10200 vs 13649±6017; \( p=0.02 \)), while P-selectin failed to show a statistical difference (57782±52949 vs 34991±30283; \( p=0.16 \)).

**Conclusion:** In young adults with T1D, suboptimal glycaemic control appears to enhance platelet activation through increased expression of P-selectin and PS both basally, suggestive of elevated circulating platelet activity and following agonist stimulation, demonstrating a greater propensity to activate. The presence of low eGDR in this cohort may further exacerbate platelet activation, indicating both glycaemia and IR contribute to platelet reactivity in individuals with T1D.

**Disclosure:** BHF Clinical Research Fellowship

Supported by: BHF Clinical Research Fellowship

R.C. Sagar: None.

18 Non-invasive fibrosis scores as prognostic biomarkers of liver and cardiovascular events and all-cause mortality in adults with type 2 diabetes in the UK: a longitudinal study

M. Jara1, Q.M. Anstee2,3, T.L. Berenzen7, L.M. Nitz1, M.S. Kjær1, K.K. Mangla1, J.M. Tarpi1, K. Khunti2;

1Novo Nordisk A/S, Søborg, Denmark, 2Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK, 3Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, 4Diabetes Research Centre, Leicester General Hospital, Leicester, UK.

**Background and aims:** Non-alcoholic steatohepatitis is associated with type 2 diabetes (T2D), life-threatening liver-related complications, increased liver-specific and all-cause mortality and cardiovascular (CV) disease. Biopsy-confirmed liver fibrosis is an important predictor of severe outcomes but biopsies are not scalable for widespread use. This real-world study investigated the prognostic utility of six non-invasive fibrosis scores on clinical outcomes in patients with T2D seen in routine general practice.

**Materials and methods:** Using a longitudinal cohort design, patients ≥18 years with T2D, ≥1 fibrosis score calculable from the UK Clinical Practice Research Datalink (CPRD) after 1 January 2001, no alcohol-related disorders and/or other chronic liver diseases in Hospital Episodes Statistics (HES), and/or no prescriptions of drugs inducing liver disease in CPRD were included. Patients were followed from date of inclusion until time of first clinical outcome event (liver-related hospitalisation or death [liver event], CV-related hospitalisation or death [CV event] or all-cause death) recorded in HES or Office for National Statistics Death Registration; database migration; 10 years’ follow-up; or 1 January 2020, whichever came first. Fibrosis-4 Index (FIB-4), the score of focus, was categorised as low (<1.30), indeterminate (1.30-2.67) or high (>2.67) risk according to established cut-offs previously shown to be associated with fibrosis. Cumulative incidence functions were calculated and hazard ratios (HRs) were estimated using Cox proportional hazard models with calendar time as underlying timescale.

© Springer
Results: In total, 17,793 eligible patients (55% male, median age 66.7 years) had T2D and measures available for FIB4 calculation. Among these patients there were 584 liver events, of which ascites (n=233), cirrhosis (n=113) and gastro-oesophageal varices (n=110) were the most common. Cumulative incidence proportions for an incident event after 10 years' follow-up in the high FIB4 group were 16% (liver), 36% (CV) and 69% (death). HRs for patients in the indeterminate and high FIB4 groups vs the low-risk group indicated a significantly higher risk of all three event types (Table), also after adjustment for sex and age. For the other scores, HRs were also higher in patients with a high vs low score.

Conclusion: In this real-world population of patients with T2D and no other clinically recognised liver disease, the risk of a clinical event was significantly higher in patients with a high vs low FIB4 score, highlighting the prognostic potential of FIB4 (and other non-invasive fibrosis scores) in this population.

Supported by: Novo Nordisk

Disclosure: M. Jara: Employment/Consultancy; Novo Nordisk A/S. Stock/Shareholding; Minority shareholder in Novo Nordisk A/S.

OP 04 Walking with diabetes

Prevalence, incidence and risk factors for Charcot foot in patients with diabetes: a nationwide Swedish study

G. Tsatsaris1, N. Rajamand Ekberg1, T. Fall2, S. Catrina3
1Department for Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, 2Department of Medical Sciences, Molecular Epidemiology, Uppsala Universitet, Uppsala, Sweden.

Background and aims: Charcot foot (CF) is a serious complication of diabetes mellitus (DM) with potential disastrous consequences. Despite being reported for the first time in 1868, the epidemiology of this condition is still unknown since just a few studies are available. We report here the prevalence, incidence and risk factors for the CF in a nationwide Swedish retrospective register-based study of patients with DM.

Materials and methods: The prevalence and incidence of CF in patients with DM were established based on data from the Swedish National Patient Registry and the Swedish Prescribed Drug Register for the period 2006 - 2016. Risk factors of CF were assessed using logistic regression based on data from 2001 - 2016 from the Swedish National Diabetes Register in a matched design with a control diabetes group without CF (1:10). In order to examine the effect of HbA1c, diabetes duration, macro- and microalbuminuria, atherosclerosis and retinopathy on CF risk, direct acyclic graphs (DAGs) were used to select potential confounders to be included in the statistical analysis.

Results: 3449 patients with DM and CF were included in the study. The prevalence of CF in the total diabetic population increased during the observation period from 0.55% in 2006 to 0.79% in 2016, whereas the incidence remained stable under the same time period. The increase in prevalence was observed in both type 1 (T1D) and type 2 diabetes (T2D) patients, with higher prevalence in T1D (1.97% in 2016) than in T2D (0.60% in 2016). Female gender was identified as a risk factor for the development of CF in T1D (OR: 1.29, 95% CI: 1.14 - 1.45, p-value <0.001) but not in T2D (OR: 0.72, 95% CI: 0.64 - 0.81, p-value <0.001). Atherosclerotic disease was associated with increased risk for CF in both types of DM (T1D OR: 4.73, 95% CI: 3.54 - 6.32, p-value <0.001) (T2D OR: 6.14, 95% CI: 5.12 - 7.36, p-value <0.001). Diabetes duration, HbA1c, pre-existing diabetic microangiopathic complications, body mass index (BMI), osteoporosis and peripheral vascular disease were identified as risk factors of CF in both types of DM. Area under the curve in our prediction model was 0.78 in T1D and 0.71 in T2D.

Conclusion: The prevalence of CF was higher in patients with T1D than in patients with T2D with progressive increase in both types of diabetes during period of observation. This might reflect a longer survival time after CF diagnosis in patients with DM especially in T1D. Identification of risk factors for CF offer the possibility of a predictive model for the development of CF.

Supported by: Stockholm County Research Council, Bert von Kantsows Foundation, Frimurarestifelse


Genome wide association meta study of diabetic foot ulcers

S. Alitina1, G. Bouland2, A. Veluchamy1, M. Thangam1, E. Lindholm1, W. Meng1, J.A. Andersen1, C.S. Hansen1, L.T. Dulgaard1, C. Palmer2, E. Ahlqvist1, L.M.T. Hart2, A. Rasmussen1, P. Rossing1, T.S. Ahluwalia1; 1Steno Diabetes Center Copenhagen, Herlev, Denmark, 2Leiden University Medical Center, Leiden, Netherlands, 3University of Dundee, Dundee, Scotland, UK, 4Lund University Diabetes Center,
Diabetic foot ulcers (DFUs) are a severe complication of diabetes mellitus. Globally, a lower limb is amputated due to diabetes every 30 seconds; foot ulceration precedes 85% of diabetes-related amputations. While several risk factors are known—including sensorimotor peripheral neuropathy (DSPN), peripheral artery disease, foot deformities, and poor glycemic control—the genetics of DFUs are poorly understood. In this study, we conducted the first genome-wide association study of diabetic foot ulcers with the aim of identifying genetic loci associated with DFU risk in diabetic (type 1 and type 2) individuals with DSPN.

Materials and methods: A meta-analysis of DFUs was conducted, comprising four independent genome-wide association studies from diabetes cohorts of European ancestry (AfterEU, Denmark; SDR, Sweden; GoShare, Scotland; DCS, Netherlands). This case-control study comprised a total of 980 cases (with DFU and DSPN) and 6196 controls (no history of DFU, but with DSPN). DSPN was defined as bilateral vibration sensation threshold ≥25V or absent sensation to monofilament. Logistic regression models were applied adjusting for sex, duration of diabetes, and principal components. Summary statistics from the four European cohorts were meta-analysed using fixed effects inverse-variance based meta-analysis.

Results: In the GWAS meta-analysis, we identified three common single nucleotide polymorphisms (SNPs) that were suggestive (p-value<1×10^-6), from three loci; an overview of these results is given in Table 1. Two common variants—rs11069845 (intronic), and rs1534545 (missense variant)—were located in COL4A2 and ALK. The third, rs12129159, was located within 1mb from HS2ST1 and PKN2-ASI.

Conclusion: Three suggestive loci associated with DFU risk were identified in the current ongoing study. Two loci were located in COL4A2 and ALK, which have known roles in small vessel disease and neuronal development. Additional GWAS data from other participating centers will be added to the current analyses towards identification of loci associated with diabetic foot ulcers of neuropathic origin.

Disclosure: S. Altintas: None.

22

Novel topical esmolol hydrochloride for diabetic foot ulcer: phase 3, randomised, double-blind, placebo-controlled, multi-centre study


Background and aims: Diabetic foot ulcers is the leading cause of prolonged hospital admission, health-related costs, and reduced quality of life for diabetic patients. Bone morphogenetic protein-7 (BMP7) is a protein of the transforming growth factor beta (TGF beta) superfamily. Some known properties of BMP7, such as the modulation of inflammation, indicate that it may promote tissue regeneration. However, the role of BMP7 in the skin is not fully understood, particularly in conditions of diabetes during wound healing. Our main aim was to evaluate the role of BMP7 in diabetic wound healing and study the underlying mechanisms.

Materials and methods: We used male C57BL/6 mice, and diabetes was induced with intraperitoneal administration of streptozotocin (50mg/kg) for 5 consecutive days. After six weeks of diabetes, two wounds of 6 mm in diameter, were induced on the back of diabetic mice and treated topically with BMP7 (0.5 μg per wound/day) or vehicle. The wound size was measured every day up to day 10 post wounding, and the wounded skin was collected. The number of inflammatory cells present at the wound site, macrophages (CD68) and lymphocytes (CD4), was determined by immunohistochemistry. The expression of inflammatory markers (IL6, keratinocyte-derived chemokine - CXCL1/KC, TNF alpha, IL1 beta), and matrix metalloproteinase-9 (MMP9) was measured by quantitative PCR. Finally, H&E and Masson's Trichrome were used to assess histology and collagen deposition.

Results: BMP7 accelerated wound closure by 20% (p<0.05) in diabetic mice when compared to vehicle-treated wounds. The number of lymphocytes in diabetic wounds did not change with BMP7 treatment, but the number of macrophages was reduced by 30% (p<0.05) when compared to vehicle-treated wounds. In addition, BMP7 significantly decreased (p<0.05) the expression of inflammatory mediators and MMP9 expression in diabetic wounds. We also observed that in diabetic wounds treated with BMP7, the area of granulation tissue was significantly increased by 50% (p<0.05), and the collagen deposition was 35% higher (p<0.05) when compared to vehicle-treated wounds, indicating that BMP7 promotes better wound healing progression and a decrease in extracellular matrix degradation.

Conclusion: BMP7 promotes wound healing in diabetes by decreasing local inflammation and, consequently, MMP9 expression, known to be increased in inflammatory conditions. This effect of BMP7 treatment in diabetic wounds prevented the high degradation of the extracellular matrix, evident in the diabetic condition. It also led to an increase in tissue regeneration and in collagen deposition, so a better progression of wound healing. This study suggests that BMP7 is a therapeutic agent of interest for the treatment of diabetic foot ulcers.

S21

Support: EFS/Lilly EXPAND Programme, FCT, SPD Disclosure: E.C. Leal: None.

21

Bone morphogenetic protein-7 promotes diabetic wound healing by decreasing inflammation and matrix metalloproteinase-9 expression

E.C. Leal1,2, J. da Silva1,2, A. Figueredo1, Y.-H. Tseng3, E. Carvalho1,2; 1Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal, 2Institute of Interdisciplinary Research, University of Coimbra, Coimbra, Portugal, 3Joslin Diabetes Center, Boston, USA.

Background and aims: Diabetic foot ulcers is the leading cause of prolonged hospital admission, health-related costs, and reduced quality of life for diabetic patients. Bone morphogenetic protein-7 (BMP7) is a protein of the transforming growth factor beta (TGF beta) superfamily. Some known properties of BMP7, such as the modulation of inflammation, indicate that it may promote tissue regeneration. However, the role of BMP7 in the skin is not fully understood, particularly in conditions of diabetes during wound healing. Our main aim was to evaluate the role of BMP7 in diabetic wound healing and study the underlying mechanisms.

Materials and methods: We used male C57BL/6 mice, and diabetes was induced with intraperitoneal administration of streptozotocin (50mg/kg) for 5 consecutive days. After six weeks of diabetes, two wounds of 6 mm in diameter, were induced on the back of diabetic mice and treated topically with BMP7 (0.5 μg per wound/day) or vehicle. The wound size was measured every day up to day 10 post wounding, and the wounded skin was collected. The number of inflammatory cells present at the wound site, macrophages (CD68) and lymphocytes (CD4), was determined by immunohistochemistry. The expression of inflammatory markers (IL6, keratinocyte-derived chemokine - CXCL1/KC, TNF alpha, IL1 beta), and matrix metalloproteinase-9 (MMP9) was measured by quantitative PCR. Finally, H&E and Masson’s Trichrome were used to assess histology and collagen deposition.

Results: BMP7 accelerated wound closure by 20% (p<0.05) in diabetic mice when compared to vehicle-treated wounds. The number of lymphocytes in diabetic wounds did not change with BMP7 treatment, but the number of macrophages was reduced by 30% (p<0.05) when compared to vehicle-treated wounds. In addition, BMP7 significantly decreased (p<0.05) the expression of inflammatory mediators and MMP9 expression in diabetic wounds. We also observed that in diabetic wounds treated with BMP7, the area of granulation tissue was significantly increased by 50% (p<0.05), and the collagen deposition was 35% higher (p<0.05) when compared to vehicle-treated wounds, indicating that BMP7 promotes better wound healing progression and a decrease in extracellular matrix degradation.

Conclusion: BMP7 promotes wound healing in diabetes by decreasing local inflammation and, consequently, MMP9 expression, known to be increased in inflammatory conditions. This effect of BMP7 treatment in diabetic wounds prevented the high degradation of the extracellular matrix, evident in the diabetic condition. It also led to an increase in tissue regeneration and in collagen deposition, so a better progression of wound healing. This study suggests that BMP7 is a therapeutic agent of interest for the treatment of diabetic foot ulcers.

Disclosure: S. Altintas: None.

22

Novel topical esmolol hydrochloride for diabetic foot ulcer: phase 3, randomised, double-blind, placebo-controlled, multi-centre study


Background and aims: Pre-clinical and phase 2 study with esmolol suggest its potential role in treatment of diabetic foot (DFU). We aimed to study the efficacy of topical esmolol for DFU healing.

Materials and methods: This is the FIRST randomized, double-blind, placebo-controlled, parallel-group, multi-centre, phase-3 study done at 27 centers across India to evaluate efficacy of topical esmolol hydrochloride gel for uninfected diabetic foot ulcers (DFU). Participants with non-infected full thickness (UTS 1B) DFU of duration>4 week, size 2cm2-15cm2 and ABI 0.7-1.3 were randomized after a run-in phase (1 week) to receive Esmolol + standard of Care (SoC), SoC only, or vehicle + SoC (3:3:1 proportion) for 12 week (treatment phase) and followed further till 24 week. Participants visited the investigational site once a week during the 12-week treatment phase for wound measurement and at week 14, 16, 20 and 24 during follow-up phase. SoC included debridement, moist wound environment and off-loading with modified insole and shoes. The primary outcome was proportion of wound closure within 12-week in Esmolol + SoC and SoC only groups. The secondary outcomes included proportion of participants achieving target ulcer closure (24-weeks), and time to ulcer closure during treatment phase. Target ulcer closure was defined as 100% re-epithelialization, confirmed on two consecutive site visits (two weeks apart). All analyses were performed for intention-to-treat (ITT) i.e., safely evaluable population.
Results: Overall, 251 participants were screened and 176 were randomised to the three groups with baseline characteristics in Table 1. The proportion of participants who achieved target ulcer closure within 12 weeks was 41 of 68 (60.3%) participants in Esmolol + SoC group compared to 30 of 72 (41.7%) participants in SoC only group (OR = 2.126, 95% CI 1.08-4.17, p = 0.0276). Proportion of target ulcer closure by the end of study (week 24) was achieved in 44 of 57 (77.2%) participants in Esmolol + SoC group and 35 of 63 (55.6%) participants in SoC only group (OR = 2.708, 95% CI 1.22-5.99, p = 0.0126). The mean time for ulcer closure was similar (74.3 days for Esmolol + SoC group and 72.5 days for SoC only group). The Esmolol + SoC group showed significant advantage over SoC (p<0.05) in participants with BMI>25 kg/m², high HbA1c, longer ulcer duration, hemoglobin<11 g/dl, low eGFR and ulcers that did not achieve 50% area reduction within initial 4 weeks of treatment. The percent ulcer area reduction from end-of-treatment to end-of-study was 60.7% for Esmolol + SoC group compared to a negligible reduction of 2.7% in SoC only group (p = 0.021).

Conclusion: Topical Esmolol is a novel treatment that significantly improves healing of DFU compared to SoC.

Clinical Trial Registration Number: NCT03998436

Disclosure: A. Rastogi: None.

23

Flexor tendon tenotomy treatment of the diabetic foot: a multicentre randomised controlled trial

J. Askø Andersen1,2, A. Rasmussen3, S. Engberg4, J. Bencke5, M. Fritnodt-Møller6, K. Kirketerp-Møller1,6, P. Rosling1;
1Complication Research, Steno Diabetes Center Copenhagen, Gentofte, 2Orthopedic Department, North Zealand Hospital, Hilleroed, 3Foot Clinic,
Clinical Trial Registration Number: NCT04154020 & NCT04154046
Supported by: the Jascha Foundation and the Aase og Ejnar Danielsen Foundation
Disclosure: J. Askø Andersen: None.

24
Saving the foot: simple orthopaedic intervention to adjust the mechanics of the ulcerated neuropathic foot improves outcomes by reducing sepsis, amputation and mortality
J. Blong1, A. Sharpe2, J. Cairney-Hill1, A. Gorman2, M. Allen2, S. Haycocks2, M. Stedman1, A. Robinson1, E. Gee1, A. Heald6;
1Orthopaedic Surgery, Salford Royal NHS Foundation Trust, Salford,
2Podiatry, Salford Royal NHS Foundation Trust, Salford,
3Res Consortium, Andover, 4Endocrinology & Diabetes, Salford Royal NHS Foundation Trust, Salford, UK.

Background and aims: Ulceration of a neuropathic foot is a poor prognostic indicator for individuals with diabetes and presents a considerable financial burden for the health economy. Orthopaedic and vascular surgeons have become embedded within most specialist diabetes foot multidisciplinary teams (DF MDT) to offer reactive interventions in the context of acute diabetic foot sepsis, such as incision and drainage of abscess, or amputation. We describe how a day-case procedure list within a DF MDT has improved outcomes by performing proactive simple surgical procedures, with a view to expediting ulcer resolution and thus minimising subsequent morbidity and mortality.

Materials and methods: Patients with ulceration (without associated abscess) were offered a percutaneous procedure performed under local anaesthetic by an orthopaedic surgeon. Purpose of surgery was to adjust the mechanics of the foot and offload the ulcerated region, expediting healing. We anticipated improved rates of ulcer resolution and reduced complication rates including diabetic foot sepsis (£11,998 per admission), amputation (£8,221 per patient) and mortality. Percutaneous tenotomies (PT) performed for toe apex ulcers. Procedure cost £501. Patient able to mobilise full weight-bearing in normal footwear immediately post-

procedure. Percutaneous tendoachilles lengthening (TAL) performed for plantar metatarsal head ulcers. Procedure cost £1140. Patient partial weight-bears for four weeks in total contact cast, followed by two weeks full weight-bearing in a walker boot.


Results: Results - see table. Key findings from the intervention cohorts: successful ulcer resolution achieved for all individuals. No admissions for diabetic foot sepsis. Reduced recurrence and amputation rates. No mortality within 12 months. One complication of Achilles tendon rupture following TAL (non-concordant with immobilisation instructions). *3 of the 15 conservative cohort achieved ulcer resolution (average 20 weeks). Conservative cohort average cost £9902. Intervention cohort average cost £1211, giving average savings of £8691 per patient. This demonstrates an 88% reduction in healthcare costs.

Conclusion: These simple daycase percutaneous procedures support accelerated ulcer healing, with reduced rates of recurrence, amputation and mortality. We have demonstrated significant patient benefit and cost savings for this simple intervention, which merits full evaluation in a clinical trial.

<table>
<thead>
<tr>
<th>Total patients</th>
<th>PT</th>
<th>TAL</th>
<th>Conservative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total foot</td>
<td>20</td>
<td>9</td>
<td>11</td>
</tr>
<tr>
<td>Age (mean)</td>
<td>70.8 years</td>
<td>58.8 years</td>
<td>69.8 years</td>
</tr>
<tr>
<td>Wound (mean)</td>
<td>84.3</td>
<td>56.5</td>
<td>63.4</td>
</tr>
<tr>
<td>Pre-procedural ulcer duration (mean)</td>
<td>30.8 weeks</td>
<td>38.2 weeks</td>
<td>N/A</td>
</tr>
<tr>
<td>Time to ulcer resolution post-procedure (mean)</td>
<td>3.3 weeks</td>
<td>4.5 weeks</td>
<td>N/A*</td>
</tr>
<tr>
<td>Complete ulcer resolution</td>
<td>100%</td>
<td>100%</td>
<td>36%</td>
</tr>
<tr>
<td>Ulcer recurrence</td>
<td>0%</td>
<td>10%</td>
<td>66%</td>
</tr>
<tr>
<td>Admission for foot sepsis</td>
<td>0%</td>
<td>0%</td>
<td>46%</td>
</tr>
<tr>
<td>Amputation</td>
<td>0%</td>
<td>10%</td>
<td>46%</td>
</tr>
<tr>
<td>Mortality</td>
<td>0%</td>
<td>0%</td>
<td>40%</td>
</tr>
</tbody>
</table>

Disclosure: J. Blong: None.
**OP 05 How to become a fat cell**

25

Fas (CD95) activation inhibits browning of white adipose tissue in obesity

S. Wueest 1,2, P.P. van Krieken 1,2, N.K. Konrad 1,3, C. Koch 2,3, M.S.F. Wiedemann 1, M. Borsigova 1,2, S. Boettcher 2,3, M. Blüher 4,5, D. Konrad 1,2

1Children’s Hospital, Zurich, Switzerland, 2University of Zurich, Zurich, Switzerland, 3University Hospital Zurich, Zurich, Switzerland, 4University of Leipzig, Leipzig, Germany, 5University Hospital Leipzig, Leipzig, Germany.

**Background and aims:** We previously observed that adipocyte-specific Fas (CD95) knockout mice were protected from the development of high-fat diet (HFD)-induced adipose tissue inflammation, hepatic steatosis and insulin resistance. In these mice, Cre recombinase was under the control of the Fabp4-promotor questioning adipocyte specificity of Fas knockdown. Herein, we aimed to reassess the adipocyte-specific role of Fas on glucose metabolism in newly generated mice expressing Cre recombinase controlled by the Adipoq-promotor.

**Materials and methods:** 6-week-old adipocyte-specific Fas knockout (Fas Δadipo) and control (Fas Δ) littermates were fed a regular chow or HFD (~60% kcal fat) for 20 weeks. Glucose metabolism was assessed by intraperitoneal glucose and insulin tolerance tests. After 20 weeks, liver and fat depots were analyzed using Western blotting, qPCR and histological staining. *In vitro*, p53 or Fas was knocked down in subcutaneous adipocytes using CRISPR-Cas9 and siRNA, respectively, and lysates were analyzed using Western blotting. Moreover, FAS expression was determined in human subcutaneous adipose tissue and correlated to p53 and UCP1.

**Results:** HFD-fed Fas Δadipo mice displayed improved glucose and insulin tolerance (AUC in mmol/l:min: GTT 2474±879 in Fas Δ vs. 2071±646 in Fas Δadipo, p<0.05; ITT 1044±94 in Fas Δ vs. 739±35 in Fas Δadipo, p<0.01), reduced adipose tissue inflammation as well as decreased hepatic lipid content compared to control littermates. Importantly, HFD-induced weight gain was significantly reduced in Fas Δadipo mice (23.1 ±1.7g in Fas Δ vs. 16.7±1.6g in Fas Δadipo, p<0.01). The latter was associated with increased expression of browning markers such as UCP1 in inguinal adipose tissue as well as highly reduced protein levels of the UCP1-repressor p53 in isolated adipocytes. Preliminary data in cultured subcutaneous adipocytes revealed that Fas knockdown increased and Fas ligand (FasL) stimulation decreased isoenergolen-induced UCP1 protein levels, respectively. Moreover, FasL-induced downregulation of UCP1 was blunted in p53-depleted cells, indicating that Fas activation reduces browning of white adipocytes in a p53-dependent manner. In agreement, FAS (CD95) expression correlated positively with p53 but negatively with UCP1 in human subcutaneous adipose tissue.

**Conclusion:** Fas activation in adipocytes contributes to HFD-associated adiposity through inhibition of adipose tissue browning.

Supported by: Swiss National Science Foundation (#310030-179344 to DK)

Disclosure: S. Wueest: None.

Background and aims: Second-generation antipsychotics (SGAs) are the cornerstone treatment of schizophrenia and other mental disorders. However, they can cause adverse metabolic effects, such as obesity and diabetes, and the exact mechanisms behind this are unknown. Different SGAs carry different propensities to induce metabolic adverse effects, e.g. olanzapine (OLA) is a high-risk drug associated with worse metabolic outcomes, while aripiprazole (ARI) is considered more neutral. We aimed to investigate the effects of SGAs on adipocyte differentiation and glucose and lipid metabolism.

**Materials and methods:** Human subcutaneous primary preadipocytes obtained from healthy subjects (n=6) were differentiated without or with therapeutic and supra-therapeutic concentrations of ARI (1, 2, and 10 μM), its active metabolite dehydroaripiprazole (DARI; 0.4 and 4 μM), and OLA (0.2 and 2 μM) for 14 days when differentiation rate and glucose uptake were assessed. Furthermore, the expression of genes related to cell differentiation and glucose and lipid metabolism were measured. In addition, adipose tissue samples obtained from mice treated *in vivo* without or with ARI or OLA for 7 months were used for gene expression analyses (n=9, control; n=9, OLA; n=8, ARI).

**Results:** Supra-therapeutic concentrations of ARI reduced preadipocyte differentiation rate (up to ~80%), assessed by the number of cells accumulating lipids and expression of adipogenic genes (PPARG, CEBPA, CD36; p<0.05). The expression of lipid storage genes (FASN, LPL, DGAT2, ATGL; p<0.05), and mitochondrial function genes (TFAM, PDK4, ACO1; p<0.05) were also reduced compared to control. Conversely, therapeutic levels of ARI and supra- and therapeutic levels of DARI increased the expression of mitochondrial biogenesis and lipid oxidation genes (TFAM, PDK4, CPT1B, ACO1; p<0.05), and LEP (p<0.05). Basal and insulin-stimulated glucose uptake was dose-dependently reduced (up to ~70%) in cultures exposed to ARI and DARI during differentiation (p<0.05), which corresponded to reduced expression of GLUT1 and GLUT4 (p<0.05), OLA, when present during differentiation, did not affect adipogenesis or lipid and glucose metabolism but increased LEP expression by ~2 fold (p<0.05). ARI- and OLA-treated mice had decreased expression of PPARG and GLUT4 (p<0.05), as well as increased expression of lipid oxidation genes PDK4 (p<0.05) in epididymal, but not inguinal adipose tissue. LEP expression was increased, while FASN expression was decreased in both inguinal and epididymal adipose tissues in ARI- and OLA-treated mice (p<0.05).

**Conclusion:** Therapeutic levels of ARI and DARI, but not OLA, negatively affected adipocyte glucose metabolism and increased the expression of lipid oxidation markers, suggesting a potential substrate switch from glucose to lipid oxidation in adipocytes. OLA, instead, increased leptin levels, which may contribute to the development of obesity in humans, potentially via CNS effects. Our results suggest that while ARI directly affects adipocyte metabolism, OLA might require long-term exposure as well as the involvement of other organs, such as the brain, in mediating its adverse metabolic effects.

Supported by: H2020 Marie Skłodowska-Curie ITN TREATMENT; SS; M; EXODIAB; UU ALF

Disclosure: M. Vranic: None.

27

Senescent adipose stromal cells-derived CCL5 induces endothelial dysfunction, a key step in the onset of atherosclerosis

L. Le Pelletier 1, K. Ngono Ayissi 1, J. Gorwood 1, F. Boccara 2, M. Auclair 3, M. Atlani 2, B. Févé 1, J. Capeau 1, C. Lagathu 3, V. Béréziat 1,2

1Sorbonne Université - INSERM - Centre de Recherche Saint Antoine, 2AP-H, Saint-Antoine Hospital, Department of Cardiology, 3Tenon Hospital, Department of Plastic Surgery, 4AP-H, Saint-Antoine Hospital, Department of Endocrinology, Paris, France.

**Background and aims:** Adipose tissue plays a major role in the regulation of metabolism through its storage/mobilisation and endocrine...
function. Aging is associated with adipose tissue redistribution, oxidative stress, and fibrosis. These alterations lead to decreased storage capacities and insulin-resistance, leading to the onset of cardiometabolic complication such as atherosclerosis. We recently demonstrated that adipose tissue aging is associated with an accumulation of senescent adipose stromal cells (ASCs) from which arise insulin-resistance and dysfunctional adipocytes. Here, we hypothesize that senescent ASCs can also contribute to the onset of endothelial dysfunction, early key step in the development of cardiometabolic disease. Our aims were firstly, to establish the proof of concept that senescent ASCs can induce endothelial dysfunction, secondly, to identify a potential candidate involved in the dialogue between ASCs and endothelial cells.

**Materials and methods:** ASCs were isolated from adipose tissue of young (mean ± error of the mean (SEM) age: 18.6 ± 2.6 years; mean ± SEM BMI: 24.4 ± 0.6 Kg/m²) or aged (mean ± SEM age: 60.3 ± 0.9 years; mean ± SEM BMI: 25.6 ± 0.4 Kg/m²) healthy female donors. The impact of senescent ASCs on Human Coronary Artery Endothelial Cells (HCAECs) from healthy donors was analysed through conditioned media experiments.

**Results:** We found that conditioned media from aged-donor ASCs, but not from young-donor ASCs, induced endothelial dysfunction, characterized by a decrease in Nitric Oxide (NO) production, increased senescence markers (Senescence-associated-β-galactosidase activity, and cell cycle arrest protein P16 and P21) and the acquisition of a pro-adherent phenotype (increased InterCellular Adhesion Molecule (ICAM) and Vascular Cell Adhesion Molecule (VCAM) expression). Preventing the onset of aged-donor ASC's senescence allowed to maintain the endothelial function. To identify molecules implicated in ASC - HCAEC cell communication, we compared the secretory profile of aged- versus young-donor ASCs. The secretion of CCL5 was found to be specifically increased in the conditioned media obtained from aged-donor ASCs. HCAECs exposed to CCL5 displayed endothelial dysfunction (decrease in NO production, senescence, pro-adherent phenotype, pro-migratory effect, and amplified vascular networks formation). Conversely, the addition of a CCL5 receptor antagonist was able to prevent the deleterious effect of conditioned media from aged-donor ASCs and maintain the endothelial function of HCAECs.

**Conclusion:** Overall, our data demonstrate the key role of ASCs and CCL5 in age-related endothelial dysfunction. They allow to a better understanding of the contribution of adipose tissue to aged-related vascular complications, thus opening new therapeutic perspectives on the support of cardiometabolic diseases.

**Disclosure:** L. Le Pelletier: None.

---

28

**Requirement of plakoglobin during the early stages of adipogenesis**

F. Abou Azar1,2, S. Allali1,2, M. Abayomi1,2, S. Yuen1,2, S. Del Veliz1,2, Y. Mugabo1,2, F. Pare2, G. Lavoie2, P.P. Roux1,2, G.E. Lim2,3, L. Le Pelletier2,3, M. Abayomi1,2, S. Yuen1,2, S. Del Veliz1,2, Y. Mugabo1,2, F. Pare2, G. Lavoie2, P.P. Roux1,2, G.E. Lim2,3, L. Le Pelletier2,3, M. Abayomi1,2, S. Yuen1,2, S. Del Veliz1,2, Y. Mugabo1,2, F. Pare2, G. Lavoie2, P.P. Roux1,2, G.E. Lim2,3

1Université de Montréal, 2Centre de Recherche du Centre hospitalier de l'Université de Montréal, 3Institut de recherche en immunologie et en cancérologie, Université de Montréal, Montréal, Canada.

**Background and aims:** Plakoglobin, also known as γ-catenin, is primarily involved in cell-cell adhesion; however, its additional roles in cellular processes have not been extensively studied. Its close homolog, β-catenin, is the main transcriptional coactivator of the Wnt signaling pathway. Previous studies have highlighted the Wnt/β-catenin signalling pathway’s anti-adipogenic properties and its ability to repress the expression of adipogenic genes to preferentially induce osteogenesis in vitro. While plakoglobin is capable of inhibiting β-catenin activity in a context-dependent manner, its role in adipogenesis remains unclear. Over-expression of the scaffold protein 14-3-3ζ in mice exacerbated high-fat diet-induced obesity. Following comparison of the 14-3-3ζ interactome in visceral adipose tissue between lean and obese mice, an enrichment of plakoglobin in the 14-3-3ζ interactome was detected, suggesting a contribution of plakoglobin to weight gain. Thus, we hypothesize that plakoglobin is an essential regulator of adipogenesis.

**Materials and methods:** In vitro assessment of plakoglobin’s role in adipogenesis was performed in murine 3T3-L1 pre-adipocytes and human adipose-derived stem cells, which were transfected with either overexpressing plasmids or siRNA targeting plakoglobin or β-catenin. RT-qPCR, immunoblotting, SuperTOPFlash, and Oligo-Redo-O (ORO) staining were used to assess gene expression, protein abundance, Wnt/β-catenin transcriptional activity, and lipid content, respectively.

**Results:** Plakoglobin knockdown prior to adipocyte differentiation in 3T3-L1 pre-adipocytes reduces PPARγ2 protein abundance by 60% (p < 0.05 based on two-way ANOVA and post-hoc tests), indicating an inhibition of adipogenesis. Conversely, β-catenin depletion upregulated PPARγ2 expression 180% (p < 0.05 based on two-way ANOVA and post hoc tests). Rescue experiments via double knockdown of both plakoglobin and β-catenin did not affect PPARγ2 expression. In preliminary studies, plakoglobin depletion in human derived-adipose stem cells diminished PPARγ2 expression by 87% (n=2), while β-catenin knockdown led to a 270% (n=2) increase in PPARγ2 protein abundance. ORO staining showed that decreasing plakoglobin expression led to decreased lipid content in differentiated 3T3-L1 and human adipose-derived stem cells. Wnt transcriptional activity was diminished following knockdown of β-catenin by 46% (p < 0.05 based on one-way ANOVA), while it was unaffected by plakoglobin depletion. Plakoglobin and β-catenin overexpression downregulated PPARγ2 abundance during adipogenesis by 63 and 34%, respectively (p < 0.05 based on two-way ANOVA and post hoc tests).

**Conclusion:** Our study has revealed a novel and complex role for plakoglobin in adipogenesis. Comparable trends were observed in both 3T3-L1 pre-adipocytes and human adipose-derived stem cells, suggesting plakoglobin holds a species conserved effect. Additional in-depth studies are required to understand the mechanisms by which plakoglobin influences adipocyte differentiation.

**Disclosure:** F. Abou Azar: None.

---

29

**Ampk γ2 is an essential player in adipogenesis and adipocyte function**

Y. Cheng1, X. Hu2;

1Medicine, Hong Kong University, 2School of Biomedical Sciences, Chinese University of Hong Kong, Hong Kong, Hong Kong.

**Background and aims:** Adipogenesis is the process in which the multipotent mesenchymal stem cells (MSCs) are differentiated into mature adipocytes through the pre-adipocyte stage. Adenosine monophosphate-activated protein kinase (Ampk) is a heterotrimeric serine/threonine kinase composed of one catalytic α subunit and two regulatory subunits β and γ. Ampk γ2 subunit has been overlooked and has long been believed to simply serve as a binding partner of the nucleotide. Here we uncovered the unique function of Ampk γ2 in determining adipogenesis and adipocyte function.

**Materials and methods:** Ampk γ2 over-expression or knockdown stromal vascular cells (SVCs) were established. We also generate adipocyte-specific Ampk γ2 knockout mice (AKO) via the Cre-LoxP strategy to elucidate the physiological effects of Ampk γ2 in adipose tissue. SVCs were isolated from the inguinal subcutaneous adipose tissue of AKO and wildtype (WT) mice. Selective deletion of the Ampk γ2 gene was induced by Tamoxifen. SVCs were differentiated to white adipocytes in vitro.

**Results:** Ampk γ2 was abundantly expressed in mature adipocytes. The expression of Ampk γ2 was gradually increased during adipogenesis but selectively reduced in obese adipose tissue. Knockdown or deletion of Ampk γ2 significantly compromises the adipogenic differentiation of SVCs into lipid-laden adipocytes with reduced expression of Fas, Pparγ,
Ciebpo, and Fabp4. The worst adipogenesis was shown if Ampk γ2 was deleted on the first two days of differentiation, suggesting that Ampk γ2 was mainly involved in the mitotic cloning expansion phase of adipogenesis. In addition, the deletion of Ampk γ2 in mature adipocytes mitigates beige cell biogenesis. By immunofluorescence staining, we found that Ampk γ2 harbors a unique nucleus-targeting sequence. We also identified the genes that are altered by Ampk γ2 in mature adipocytes by RNA sequencing. **Conclusion:** Ampk γ2 plays an essential role in adipogenesis and holds potential as a therapeutic target for obesity and metabolic diseases. **Supported by:** Health and Medical Research Fund (06172346) **Disclosure:** Y. Cheng: None.

30 Estrogen receptor beta knockdown reduces differentiation of preadipocytes from postmenopausal women


**Background and aims:** Estrogen deficiency in postmenopausal women is linked to redistribution of body fat, insulin resistance, and T2D. E2 signaling occurs mainly through estrogen receptors alpha (ESR1) and beta (ESR2). We have previously shown that ESR2 expression, but not ESR1, is higher in subcutaneous adipose tissue (SAT) from postmenopausal compared to premenopausal women. The functional impact of this on adipose tissue metabolism is not fully known. This study investigates the association between ESR2 expression and lipid and glucose metabolism in human subcutaneous adipose tissue (SAT) in subjects with and without T2D.

**Materials and methods:** SAT were obtained by needle biopsies from 20 control and 20 T2D subjects with T2D matched for sex (10M/10F per group), age (58±11 vs 58±9 years) and BMI (30.8±4.6 vs 30.7±4.9 kg/m²). ESR2 gene expression in SAT was correlated to markers of obesity and glucose metabolism. ESR2 knockdown (KD) was performed in preadipocytes from postmenopausal women (age: 63±13 years, BMI 30.3±6.2 kg/m², n=4) using CRISPR/Cas9 gene editing. In vitro differentiated KD adipocytes were characterized for differentiation rate, lipid storage, and glucose uptake.

**Results:** Postmenopausal females express higher levels of ESR2 in SAT compared to premenopausal women and males (1.5-fold; p<0.05) whereas ESR1 expression was not dependent on sex or menopausal status. We found that ESR2 expression was lower in subjects with obesity (BMI>30) compared to non-obese subjects, independent of sex (p<0.05). Additionally, ESR2 expression did not differ between control and subjects with T2D. ESR2 expression in SAT from females, but not males, was negatively correlated with weight, markers of central adiposity (e.g. waist-to-hip ratio, visceral adipose tissue volume), and markers of fatty acid oxidation (e.g. CPT1A, CPT1B), and positively correlated with subcutaneous adipocyte size and markers related to lipid storage (e.g. LPL, ACACA), and glucose transport (e.g. GLUT4, AKT2) (p<0.05 all). In preadipocytes, ESR2 KD reduced preadipocyte differentiation (10-30%; p<0.05) compared to wild-type cultures on day 7 and day 14 of differentiation. This corresponded to transient reductions in the expression of differentiation markers (e.g. PPARG), markers of lipogenesis (e.g. LPL, FAS), lipolysis (e.g. HSL, PLIN1), and adipokines (e.g. ADIPOQ) (p<0.05 all). Glucose uptake was reduced in adipocytes in KD cultures (p<0.05), however, this effect was lost after normalizing for preadipocyte differentiation rate.

**Conclusion:** Our results indicate that ESR2 is involved in regulating human adipocyte differentiation and lipid storage, and higher ESR2 expression may promote greater energy deposition into SAT as seen after menopause. This provides insight into a potential molecular target to promote a healthy obesity phenotype.

**Supported by:** Swedish Diabetes Foundation, EXODIAB, the Erfjors Foundation, the Swedish Society for Medical Research **Disclosure:** F. Ahmed: None.

OP 06 Intracellular regulation of insulin release

31 Glucose metabolites upstream of glyceraldehyde 3-phosphate dehydrogenase trigger activation of the mechanistic target of rapamycin complex 1 pathway in diabetic islets


**Background and aims:** Hyperglycaemia leads to impaired mitochondrial respiration and hyperactivation of the nutrient-sensing mechanistic target of rapamycin complex 1 (mTORC1) pathway in pancreatic islets. Recent studies in non-islet cells suggest that glycolytic intermediates upstream of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), fructose-1,6-bisphosphate (F1,6BP) and dihydroxyacetone phosphate (DHAP), signal glucose availability to mTORC1, leading to its activation. Thus, the aims of this study were to determine if this mechanism exists in beta cells/islets and if mTORC1 hyperactivation mediates mitochondrial dysfunction in diabetes.

**Materials and methods:** We utilised the B6VM/M mouse model where hyperglycaemia/diabetes is initiated via a tamoxifen-inducible KATP<sup>γ2</sup> channel activating mutation in pancreatic beta cells. Islets were studied after 2 weeks of diabetes (>20mmol/L). Additionally, INS1 832/13 insulina cells were cultured at high (HG:25mM) or low (LG:5mM) glucose +/- the GAPDH inhibitor, koningic acid (5μM:KA), for 48hrs. To examine the impact of mTORC1 hyperactivation on mitochondrial efficiency, islets were incubated with/without the S6 kinase inhibitor PF-4708671 (10μM:S6Ki) for 48 hours. Metabolomics was performed using anion exchange chromatography mass spectrometry. GAPDH activity was measured biochemically. mTORC1 signalling was determined by the ratio of phosphorylated (p-S6) and total ribosomal protein S6 (total-S6) using standard western blotting methods. Oxygen Consumption Rate (OCR) was monitored using an extracellular flux analyser.

**Results:** mTORC1 signalling was increased in diabetic islets (p-S6/total-S6 ratio: control = 0.36±0.02 vs diabetic = 0.70±0.08; p<0.05; n=6). Compared to control islets, diabetes led to an increase in the relative abundance of F1,6BP (8.23±1.93-fold; p<0.01, n=4) and DHAP (1.43±0.04-fold, p<0.01, n=3). INS1 cells cultured at LG + KA recapitulated the effects of hyperglycaemia, with increased relative abundances of F1,6BP and DHAP, activation of mTORC1 and impaired GSIS. Diabetic islets displayed an attenuated glucose-stimulated OCR, relative to control islets, but this was significantly improved by incubation with S6Ki (diabetic = 34.4±10.72 vs diabetic+S6Ki 203.94±39.24% increase in OCR above baseline, p<0.01; n=7-8). The ATP-synthase inhibitor, oligomycin, produced significantly less inhibition of OCR in diabetic islets, compared to control islets, an effect that was prevented by mTORC1 inhibition (diabetic = 55.01±9.71% decrease in OCR, p<0.001; n=7-8).

**Conclusion:** We provide evidence that diabetes/hyperglycaemia leads to a build-up of glycolytic metabolites upstream of GAPDH which chronically activates mTORC1 in pancreatic islets. Additionally, our results suggest that hyperactivation of mTORC1 signalling is partially responsible for mitochondrial dysfunction in diabetic islets and may be involved in regulating ATP-synthase activity.

**Supported by:** MRC, Wellcome trust, Novo Nordisk **Disclosure:** E. Haythorne: None.

32 Deletion of Carboxypeptidase E in beta cells disrupts proinsulin processing and accelerates streptozotocin-induced hyperglycaemia in mice

Y.-C. Chen<sup>1,2</sup>, A.J. Taylor<sup>2</sup>, K. Fok<sup>2</sup>, M. Komba<sup>2</sup>, X.-Q. Dai<sup>3</sup>, J.W. Eriksson; University of Oxford, Oxford, UK.

**Disclosure:** None.
Background and aims: Carboxypeptidase E (CPE) facilitates the conversion of prohormones into mature hormones, and is highly expressed in neuroendocrine tissues. Carriers of CPE mutations have elevated plasma proinsulin and develop severe obesity and hyperglycemia. In this study, we aimed to determine whether loss of Cpe in pancreatic beta cells is sufficient to disrupt proinsulin processing and accelerate development of diabetes in mice.

Materials and methods: Mice with Cpe deletion in pancreatic beta cells (βCpeKO; Cpe<sup>fl/fl</sup> x Ins1<sup>Cre/lox</sup>) and littermate control mice (Wt; Cpe<sup>fl/fl</sup> and Cpe<sup>β-cre</sup>) were treated with high fat diet (HFD) or multiple low dose streptozotocin (STZ), and body weight, plasma proinsulin, glucose tolerance, exocytosis, in vitro cell proliferation, metabolic flux, and live cell imaging. Mice with inducible beta-cell-specific Cpe deletion (iβCpeKO; Cpe<sup>fl/fl</sup> x Pdx1<sup>Cre/lox</sup>) were treated with HFD, and pancreatic beta-cell proliferation was analyzed.

Results: βCpeKO mice lack mature insulin granules in beta cells. Instead, they have 4.5-fold increased proinsulin protein in islets, and significantly elevated proinsulin immunoreactivity in plasma (37 vs. 1084 pm, Wt vs. βCpeKO, p < 0.05). However, glucose- and KCl-stimulated insulin secretion dynamics in βCpeKO islets, and insulin granule exocytosis in βCpeKO beta cells, remained largely intact. Upon HFD challenge, male and female βCpeKO mice showed comparable weight gain, glucose tolerance, and insulin sensitivity compared to Wt littermates. Interestingly, beta-cell area was increased in chow-fed βCpeKO mice (0.8 vs 1.6%, p < 0.05), and beta-cell Edu incorporation was elevated in HFD-fed iβCpeKO mice (2.6 vs 6.5%, p < 0.05). Consistent with these observations, islets from βCpeKO mice displayed increased proinsulin biosynthesis and elevated beta-cell proliferation (4.9 vs 7.4%, p < 0.05) upon high glucose treatment. In addition, transcriptomic analysis showed that βCpeKO beta cells have elevated glycolysis and HIF1α-target gene expression. Yet, high glucose treatment also led to mildly reduced mitochondrial membrane potential (1.53 vs. 1.27, p < 0.05), and increased mitochondrial (0.41 vs. 0.56, p < 0.05) and cytosolic (0.065 vs. 0.077, p < 0.05) reactive oxygen species in beta cells from βCpeKO mice. Lastly, after multiple low dose STZ treatment, βCpeKO mice had accelerated development of hyperglycemia (16.0 vs 12.2 mmol/l 7 days post-STZ, p < 0.05).

Conclusion: These findings confirm that Cpe mediates proinsulin processing in pancreatic beta cells. Lack of Cpe and impaired proinsulin processing is associated with beta-cell mass compensation via increased beta-cell proliferation. Under acute metabolic and oxidative stress challenges, Cpe and proper proinsulin processing are required to maintain beta-cell function and glucose homeostasis.

Supported by: This work is supported by JDRF and CIHR Disclosure: Y. Chen: None.
specific signature of α- and β-cells response to glucose stimulation in living human islets (Hls).

**Materials and methods:** To tackle this issue we used here a combination of label-free Fluorescence Lifetime Imaging Microscopy (FLIM) in living Hls with post-fixation immunofluorescence. More in detail, by the phasor approach to FLIM we discriminated the free and protein-bound forms of NAD(P)H molecules in optical sections of living Hls and, by means of their ratio, we defined the tissue metabolic shift upon pulsed glucose stimulation. Then, by using post-fixation immunofluorescence, we identified α and β cells, finally matching single-cell identities with their metabolic response. A cohort of 4 healthy donor patients was included in this study.

**Results:** A total of 15 islets were measured from the above-mentioned cohort, with 312 α cells and 654 β cells identified. We observed a neat metabolic shift towards oxidative phosphorylation in the great majority of β cells, in keeping with previous results from rat/mouse β cells. By contrast, we observed a wide spectrum of metabolic shifts in α cells, from glycolysis- to oxidative-phosphorylation-oriented ones, apparently contradicting previous reports which assessed an univocal glycolytic response to glucose in rat/mouse α cells. Interestingly, at the patient level, the heterogeneous α-cell responses reveal an inverse proportionality with respect to the amount of insulin secreted (independently probed by an ELISA assay): the higher the insulin secreted, the more glycolysis-orient-ed the metabolic shift measured. Noteworthy, such inverse proportionality transforms into marked linear anti-correlation (Pearson’s correlation coefficient: -0.997) if α- and β-cell responses are summed and plotted against the amount of secreted insulin (see Graph).

**Conclusion:** The emerging picture indicates the synergistic action of α and β cells as key signature of HI metabolic response to glucose and, in turn, as a basic constituent for the regulation of systemic glycaemia. While demonstrating the effectiveness of an optical-microscopy-based protocol to measure the specific responses of α and β cells in a living human Langerhans islet, present results pave the way to similar investigations to be conducted in diabetes and/or using drugs to restore cell functionality.

**Background and aims:** Aminoadipate-Semialdehyde Synthase (AASS) is a mitochondrial-located bifunctional enzyme with lysine-ketoglutarate reductase and saccharopine dehydrogenase activities, involved in the first two steps in the catabolic pathway of L-lysine, an insulinotropic amino acid in humans. AASS-mediated L-lysine catabolism may contribute to fueling insulin secretion since Acetyl-CoA and L-glutamate are generated in the pathway; the former feeds the TCA cycle while L-glutamate acts as a metabolic coupling factor (MCF) for glucose-stimulated insulin secretion (GSIS). In addition, L-lysine cell accumulation is cytotoxic and a mutation in AASS was recently identified as responsible for familial hyperlysinaemia, an autosomal recessive disorder. Thus, AASS-mediated degradation of L-lysine may play a dual role in β cell function by maintaining L-lysine levels at physiological levels and providing L-lysine-derived metabolites that amplify GSIS.

**Materials and methods:** AASS mRNA levels in human islets from non-diabetic (ND) and type 2 diabetes (T2D) subjects were assessed. Human islets and INS1 832/13 cells were transfected with scramble (control) and AASS siRNAs (AASS-KD) and GSIS was assessed by ELISA. Live cell cytosolic calcium was measured by Fluo4 dye and confocal microscopy. Glucose-stimulated mitochondrial metabolism was investigated in AASS-KD INS1 832/13 cells by extracellular flux analyzer, confocal microscopy and mass spectrometry-based metabolomics analysis.

**Results:** AASS mRNA levels were reduced in pancreatic islets from T2D vs ND donors (p=2.7e-5, n=188) and correlated negatively with hyperglycemia (HbA1c (r=-0.158, p=0.009, n=169) but positively with GSIS (r=-0.10, p=0.026, n=182)). In vitro studies showed that AASS silencing reduced basal and GSIS in human islets. Accordingly, AASS silencing reduced insulin secretion in INS1 832/13 cells in response to basal and high glucose, as well as in response to pyruvate and AMP-promoting agents (IBMX-FSK), but not in response to high K+. Increased cytosolic calcium responses were accompanied by reduced cytosolic ATP-ADP ratio and ATP-linked mitochondrial respiration in AASS-KD vs control cells. Metabolomics analysis indicated altered glutamate metabolism and mitochondrial TCA cycle activity, and a Warburg effect.

**Conclusion:** Our data suggest that AASS-mediated lysine degradation is an active metabolic pathway required to maintain normal glucose production, mitochondrial TCA cycle andOXPHOS function, and cellular calcium homeostasis, as well as insulin secretion. Reduced AASS expression with consequent decreased AASS-mediated L-lysine degradation pathway may contribute to β cell dysfunction in T2D.

**Disclosure:** L. Cataldo: None.

---

**35 Mitochondrial AASS-mediated L-lysine degradation is required to maintain beta cell function**

L. Cataldo1,2, Q. Gao1, K. Trost1, M. Fex2, H. Mulder2, T. Moritz1; 1The Novo Nordisk Foundation Centre for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark; 2Lund University Diabetes Center, Lund University, Malmo, Sweden.

**Background and aims:** In pancreatic β-cells, the insulin gene has been shown to be expressed in a wide distribution, with examples of “extreme” β-cells exhibiting >2 fold higher insulin gene activity. Pseudo-time analyses of human single cell RNA sequencing data have suggested that cells may transition between high and low expression states of the INS gene. However, the mechanisms of these dynamics have yet to be elucidated. The phenomenon of switching between low and high INS gene activity states has also yet to be observed in real-time.

**Materials and methods:** Ins2GFp knock-in mice, with the second exon of the wild-type Ins2 gene being replaced with GFP, were used for

---

**36 Quantification of the dynamics of Ins2 gene activity**

J.C.M. Chu1, H. Mod1, S. Skovsø1, C. Ellis1, N.A.J. Krentz2, Y.B. Zhao1, H. Cen1, N. Noursadeghi1, E. Panzhinskiy1, Y. Xia1, S. Xuan1, M.O. Huising1, T.J. Kieffer1, F.C. Lynn2, J.D. Johnson2; 1Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, Canada, 2Department of Surgery, University of British Columbia, Vancouver, Canada.

**Background and aims:** In pancreatic β-cells, the insulin gene has been shown to be expressed in a wide distribution, with examples of “extreme” β-cells exhibiting >2 fold higher insulin gene activity. Pseudo-time analyses of human single cell RNA sequencing data have suggested that cells may transition between high and low expression states of the INS gene. However, the mechanisms of these dynamics have yet to be elucidated. The phenomenon of switching between low and high INS gene activity states has also yet to be observed in real-time.

**Materials and methods:** Ins2GFp knock-in mice, with the second exon of the wild-type Ins2 gene being replaced with GFP, were used for
monitoring of endogenous insulin gene expression. We investigated the temporal kinetics of endogenous insulin gene activity using live-cell imaging, with complementary experiments employing FACS and single-cell RNA sequencing analyses in β-cells isolated from Ins2<sup>GFP</sup> knock-in mice. We applied inhibitors and activators of pathways related to insulin production, endoplasmic reticulum stress, and insulin secretion to determine how perturbations to β-cell function may impact Ins2 gene behavior.

**Results:** Live-cell imaging captured Ins2 gene activity dynamics in single β-cells over time and revealed two states in GFP expression (Ins2<sup>GFP(high)</sup>, Ins2<sup>GFP(low)</sup>), consistent with bimodal expression states observed with our FACS analysis and immunofluorescence staining experiments. Autocorrelation analysis identified cells with oscillating behavior, with oscillation periods of ~17 hours. RNA velocity and hierarchical clustering analyses on single cell RNA sequencing data on cells from Ins2<sup>GFP</sup> mice revealed that β-cells with higher levels of Ins2 gene activity had a more mature β-cell profile, with genes such as Pdx1, Ucn3, and Nkx6-1 being significantly correlated with high GFP mRNA (p<0.01). Perturbation of insulin gene activity with inhibitors and activators of insulin production were shown to influence Ins2 gene activity, with some small molecules, including GLP-1, arginine, and sodium butyrate inducing transitions from Ins2<sup>GFP(low)</sup> states to Ins2<sup>GFP(high)</sup> states.

**Conclusion:** In conclusion, we identify a subset of pancreatic β-cells with dynamic Ins2 gene activity. Our observations define a previously uncharacterized form of β-cell plasticity in both basal and induced conditions. Understanding the dynamics of insulin production has relevance for understanding the pathobiology of diabetes and for regenerative therapy research.

**Supported by:** CIHR operating grant

**Disclosure:** J.C.M. Chu: None.

### OP 07 Finding a phenotype for diabetic kidney disease

37

**Genome-wide analysis of treatment-resistant hypertension in individuals with and without diabetes**

**A.A. Antikainen**<sup>1,2</sup>, H. Sánez Tahtisalo<sup>2,3</sup>, S. Mutter<sup>1,2</sup>, R. Lithiovius<sup>1,2</sup>, P.-H. Groop<sup>1,2</sup>, K. Kontula<sup>2,3</sup>, T. Hiltunen<sup>1,3</sup>, N. Sandholm<sup>1,2</sup>

<sup>1</sup>Folkhälsan Research Center, <sup>2</sup>Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, <sup>3</sup>Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

**Background and aims:** Hypertension is a major risk factor for CVD. Almost half of individuals with hypertension fail to reach blood pressure (BP) targets despite pharmacological treatments. A subset of them have treatment-resistant hypertension (RHTN), which is defined as BP above the treatment target with at least three antihypertensive drugs, of which one is a diuretic, or controlled BP with four or more drugs. RHTN increases the risk for CVD, especially in diabetes. RHTN genetics has not been excessively studied, thus, we aimed to find genomic loci linked to RHTN in type 1 diabetes (T1D) and in the general population.

**Materials and methods:** We performed genome-wide association studies for RHTN in T1D in the Finnish Diabetic Nephropathy Study (606 individuals, 288 with RHTN) and in the general population in the LIFE-Fin Study (625 individuals, 297 with RHTN). Analyses were adjusted for age, sex, and genic data principal components in the minimal model, and additionally for BMI, albuminuria, and eGFR in the full model. We meta-analysed the cohorts and attempted replication in a third Finnish cohort, GENRES (N=220), where standardized mean BP response to four different antihypertensive monotherapies was used as an indicator of drug treatment responsiveness. Finally, we performed gene and gene-set analyses with MAGMA on the FUMA platform.

**Results:** We discovered two variants in the minimal model with near genome-wide significance: rs1484486 (minor allele frequency (MAF)=32%, odds ratio (OR)=0.54, p=7.76×10<sup>-9</sup>) within LOC105369168, and rs11151487 (MAF=14%, OR=0.47, p=5.36×10<sup>-9</sup>) within an intron of CCDC102B. In the full model, we found also rs1009649 (MAF=38%, OR=1.81, p=4.34×10<sup>-7</sup>) close to a pseudogene. We were unable to replicate these in GENRES. Of note, we discovered further suggestive loci of which one from the full model (rs138242, MAF=10%, OR=0.44, p=9.26×10<sup>-5</sup>) replicated for systolic office BP response in GENRES (β=0.21, p=0.03, N=226). The variant is located within an intron of DCN, coding for decorin, which plays an important role in connective tissues. Interestingly, the variant is an expression QTL of DCN in fibroblasts (https://gtexportal.org/). Gene-set scoring revealed significant biological pathways (e.g., the SLRP pathway, p=5.0×10<sup>-7</sup>), and enrichment of genes with expression in heart tissues (Figure 1).

**Conclusion:** We studied the genetics of RHTN in individuals with and without diabetes and identified multiple candidate loci, including a variant linked to expression of decorin, and performed gene scoring revealing a significant enrichment of genes with heart tissue expression stressing the link between RHTN and CVD.
DNA methylation is a risk factor for kidney failure in individuals with type 1 diabetes

A. Syreeni1,2, E.H. Dahlström1, I.J. Smyth3, Y. Gupta3, C. Forsblom1,2, J. Kilner3, G.J. McKay3, A. Maxwell3, A. McKnight1,2, P.-H. Groop3, N. Sandholm1,2;

1Folkhälsan Research Center, Helsinki, Finland, 2Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 3Molecular Epidemiology Research Group, Centre for Public Health, Queen’s University Belfast, Belfast, UK.

Background and aims: We previously identified DNA methylation differences at multiple CpG loci in a cross-sectional study of individuals with or without diabetic kidney disease (DKD). Here, we aimed to study DNA methylation as a risk factor for the development of kidney failure in individuals with type 1 diabetes and DKD.

Materials and methods: The study included 397 individuals with type 1 diabetes and macroalbuminuria at baseline from the Finnish Diabetic Nephropathy (FinnDiane) Study. At baseline, the mean (SD) age was 43 (±10.8) years, and 38% were women. Macroalbuminuria (≥200 μg/min or ≥300 mg/24h) was determined from two of three overnight or 24 h urine collections. The study participants were followed up until either kidney failure developed or December 31, 2017. Data on kidney failure requiring dialysis and/or a transplant was collected from the Finnish Care Register for Health Care, study visits, or medical files. Genome-wide blood-derived DNA methylation data was generated for the Infinium HD Methylation EPIC BeadChips (Illumina) in Helsinki. After quality control, we extracted M-values (M = log2 (β/(1-β))) for 763,064 CpG sites using RnBeads v.2.6.0. M-values for each CpG site were analysed separately with the Cox proportional-hazards model with sex, baseline age, and six estimated white blood cell counts as covariates.

Results: During a median of 7.2 (interquartile range: 2.9-14.0) years of follow-up, 196 individuals developed kidney failure. Eleven CpGs were associated with developing kidney failure with p < 6.6×10^-8 - a p-value threshold corrected for the number of studied CpGs. The top CpG cg17944885 is located on chromosome 19 between genes ZNF788P and ZNF625-ZNF20. Higher methylation at this locus was a risk factor for kidney failure (HR [95%CI] = 2.32 [1.95, 2.76], p = 1.4×10^-21). Seven significant CpGs were located in or near genes; cg23597162 in ARHGEF7, cg19942083 in the promoter of PTPN6, and cg03262246 <1500 bp from the transcription start site of CDKN2APNL. In an independent cohort look-up from Belfast of kidney failure vs controls with no evidence of kidney disease (n = 519), 10 of these CpGs were significantly associated (p < 10^-5). Additionally, cg17944885 was strongly associated with DKD in our cross-sectional meta-analysis of the FinnDiane and Belfast cohorts (t0 n = 1,304, p = 2.0×10^-16). In a cohort of 473 individuals with diabetes from the Chronic Renal Insufficiency cohort, six of eleven significant CpGs were associated with eGFR in the whole blood DNA methylation analysis (3.7×10^-13 ≤ p ≤ 0.05). Furthermore, all six of our eleven top CpGs that were available in the epigenome-wide meta-analysis for eGFR in 33,605 individuals from the Chronic Kidney Disease Genetics Consortium were significantly (p < 1.1×10^-2); cg17944885 and CpGs in JAZF1 and PQLC2) or nominally (p < 0.05; CpGs in or near DAZAP1, AHCYL2, and PTPN6) associated with eGFR in their study.

Conclusion: DNA methylation at several CpGs show consistent associations with kidney function and the risk of developing kidney failure.

Disclosure: A.A. Antikainen: None.
Conclusion: Our data demonstrated that the allelic forms of the analyzed SNPs are linked to different renal lesions in diabetic patients. These results could provide the starting point for the creation of a new non-invasive diagnostic system based on clinical and genetic data.

Supported by: BeatDKD IMI2 Project
Disclosure: P. Pontrelli: None.

40
Loss of the transcription factor Tcf21 in adult podocytes leads to susceptibility in diabetic kidney disease

Y. Matamoto1, Y. Maezawa1, T. Minamizuka1, M. Koshizaka1, Y. Endo1, Y. Akimoto2, Y. Yokote3;
1Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Inohana, Chuo-ku, Chiba, Japan;
2Kazusa DNA Research Institute Laboratory of Medical Omics Research, Kazusakamataki, Kisarazu, Chiba, Japan;
3Department of Microscopic Anatomy, Kyorin University School of Medicine, Mitaka city, Tokyo, Japan.

Background and aims: Diabetic kidney disease (DKD) is the most common cause of dialysis induction in Europe. Tcf21/Pod1 is a basic helix-loop-helix transcription factor that is essential for the development of the lungs, heart, and kidneys. Previously, we reported that Tcf21 regulates podocyte development. However, the precise role of Tcf21 in mature individuals and DKD remains unclear.

Materials and methods: We generated mice that lacked Tcf21 only in mature individuals and DKD remains unclear.

Results: When the Tcf21 gene was deleted specifically in podocytes in 3-week-old mice, urinary protein was not observed. In contrast, when diabetes was induced in these mice, massive urinary protein and strong glomerulosclerosis was present in 60% of iKO mice. Ultrastructural analysis revealed glomerular basement membrane thickening and podocyte foot process effacement, suggesting that acquired podocyte-specific Tcf21 KO mice are susceptible to DKD. In addition, RNA-seq analysis of Tcf21-overexpressing podocytes showed accumulation of genes involved in the interferon pathway, extracellular matrix production, senescence, and autophagy in gene ontology analysis. Analysis of individual genes showed upregulation of interferon-related genes such as IFI6 and IFI27, increased expression of SERPINE1 (PAI-1), which is one of the senescence-associated secreted phenotypes, and decreased expression of HMG2A, whose SNP is known to correlate with susceptibility to DKD. In addition, Tcf21 expression was suppressed by 58% and 27% after TGF-β and high glucose plus insulin stimulation, respectively.

Conclusion: Our results suggest that Tcf21 protects against DKD in mature individuals. Elucidation of the mechanism by which Tcf21 prevents DKD may lead to the identification of novel therapeutic targets.

Disclosure: N. Teramoto: None.

41
Empagliflozin attenuates obesity-related kidney dysfunction and NLRP3 inflammasome activity through the HO-1/adiponectin axis

T. Ye, J. Zhang, J. Shi, C. Kan, F. Han, N. Hou, X. Sun;
Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.

Background and aims: Empagliflozin (EMPA) is a novel sodium-glucose cotransporter 2 inhibitor (SGLT2i) that produces protective cardiovascular-renal outcomes in patients with diabetes. The heme oxygenase-1 (HO-1)/adiponectin axis is an essential antioxidant system with anti-apoptotic and anti-inflammatory properties. This study explored whether EMPA improves obesity-related kidney disease by regulating the renal HO-1-mediated adiponectin axis.

Materials and methods: Four-week male C57BL/6J mice were randomly assigned to control, high-fat diet (HFD) and EMPA (10 mg/kg) groups. Mice in the control group were fed a regular diet, while mice in the other groups were fed an HFD. After receiving an HFD for 24 weeks, mice in the EMPA group were administered EMPA (10 mg/kg/day) by oral gavage for another 8 weeks. Blood biochemical and urinary albumin-to-creatinine ratios (UACR) were measured. The morphology and microstructure of the kidney were analyzed by histopathology and transmission electron microscopy. RNA-seq analysis of differential gene expression in kidneys was performed. Renal NLRP3 inflammasome with related cytokines and HO-1/adiponectin were determined.

Results: HFD mice showed significant metabolic abnormality and renal injury, including increased body weight, fat mass, urinary albumin excretion, morphologic changes, and lipid accumulation. EMPA treatment significantly decreased the final body weight (44.87 ± 1.42 g vs. 49.67 ± 1.48 g, P<0.05), fat mass (11.75 ± 0.78 g vs. 14.56 ± 0.43 g, P<0.05), and fat/weight (26.08 ± 1.09% vs. 29.37 ± 0.75%, P<0.05), compared with HFD alone. Besides, EMPA significantly improved glucose homeostasis, decreased FFA (746.30 ± 56.59 μmol/L vs. 1300.00 ± 81.14 μmol/L, P<0.05) but had no beneficial effects on triglyceride (29.31 ± 2.71 mg/dL vs. 32.87 ± 1.69 mg/dL, P>0.05). Furthermore, EMPA decreased UACR (21.01±1.99 μg/μmol vs. 45.24±4.71 μg/μmol, P<0.05), attenuated kidney injury, including reduced glomerular hypertrophy, renal fibrosis, mitochondria swell, and lipid accumulation. RNA-seq analysis showed that the differentially expressed genes shared in EMPA vs. HFD and HFD vs. control were enriched in GO and KEGG categories associated inflammation process. HFD mice showed increased renal NLRP3 activity and reduced HO-1/adiponectin axis, indicating excessive inflammation. However, EMPA significantly enhanced renal HO-1/adiponectin axis and decreased NLRP3 activity, recovering the anti-inflammation.

Conclusion: EMPA treatment improved metabolic disorders and protected against obesity-related kidney disease by activating the HO-1/adiponectin axis and reducing NLRP3 inflammasome activity. Kidney transcriptome analysis revealed that EMPA affects essential genes closely associated with inflammation. Our findings provide new knowledge concerning the mechanism for SGLT2i-mediated renal protection in obesity.

Supported by: NSFC (81870593, 82170865)
Disclosure: T. Ye: None.

42
Identification of markers for predicting the onset of chronic kidney disease in older people with type 2 diabetes by metabolomic profiling: Edinburgh Type 2 Diabetes Study

J. Krasauskaitë1, B.R. Conway2, C.J. Weir1, Z. Huang1, J.F. Price1;
1Usher Institute, University Of Edinburgh, 2The Queen’s Medical Research Institute, University Of Edinburgh, Edinburgh, UK.

Background and aims: Renal disease affects a large proportion of people with type 2 diabetes and it is associated with excess morbidity/mortality. While well-established clinical biomarkers, namely estimated glomerular filtration rate (eGFR) and albuminuria are used in routine screening, these markers do not explain all of the risk. Hence, the search for new markers is a high priority. Metabolomics may reveal novel markers of chronic kidney disease (CKD) that could aid identification of patients at higher risk of renal impairment and improve risk prediction of incident CKD. We aimed to identify significant associations between metabolites and the clinically relevant outcome of incident CKD in a Scottish population of older people with type 2 diabetes and to evaluate the ability of metabolites to predict CKD onset.
Materials and methods: The Edinburgh type 2 diabetes Study (ET2DS) is a population-based cohort of 1,058 adults (49% female) with type 2 diabetes, aged 60-75 years. Nightingale metabolomic platform was used to measure 149 serum metabolite concentrations at baseline. Kidney function was determined by eGFR, calculated using the CKD-EPI equation. Incident CKD was defined as 2 of 3 eGFR records <60mL/min/1.73 m² during follow-up. An initial multivariable-adjusted discovery screen considered the correlation between each metabolite and baseline eGFR during follow-up. An initial multivariable-adjusted discovery screen considered the correlation between each metabolite and baseline eGFR (adjusted for age and sex). Metabolites that were significantly associated with eGFR were then related to incident CKD events in logistic regression analysis adjusted for known clinical risk factors. Risk prediction with eGFR were then related to incident CKD events in logistic regression analysis adjusted for known clinical risk factors. Risk prediction analysis involved refitting a published risk prediction model for incident CKD to evaluate the complementary value of significant metabolites.

Results: There were 823 participants in ET2DS with no CKD based on eGFR records at baseline and 217 (26%) experienced new onset CKD during follow-up (median= 6.8 years [IQR 0.9- 7.6]). Corrected for multiple testing, 68 metabolites were significantly associated with baseline eGFR (Bonferroni corrected p<0.00034). Of these, only amino acid phenylalanine (Phe) was significantly associated with incident CKD after adjustment for known clinical risk factors (OR 0.73 [95% CI 0.60- 0.89], p=0.002). Phe was added to the published risk prediction model containing the clinical variables (eGFR, age, sex, BMI, use of diabetes medications, cardiovascular disease history, smoking, hypertension, HbA1c, albumin-to-creatinine ratio). Phe remained significant in this model and higher levels of Phe reduced risk of CKD onset (HR 0.80, [95% CI 0.68- 0.93] per unit of SD, p-value= 0.004). However, Phe yielded only a small improvement in risk prediction (original model concordance (c )-statistic 0.81 [95% CI 0.79- 0.84], model +Phe c-statistic 0.82 [95% CI 0.79- 0.84].

Conclusion: Amino acid Phe was associated with incident CKD in people with type 2 diabetes, although, it did not improve an already well performing risk prediction model. It is possible to hypothesise that a more sophisticated multivariable analysis may reveal a combination of metabolites associated with CKD onset that together may improve the risk prediction.

Supported by: MRC

Disclosure: J. Krasauskaite: None.

OP 08 Cardiovascular disease mechanisms: something new on the table?

43 C-reactive protein, C-peptide, and risk of cardiovascular events and mortality after type 2 diabetes diagnosis: a Danish cohort study

A.D. Kjaeraard1 2, A. Gedejberg1 3, M. Bjerre2 3, J. Nielsen1, J. Runghy1, I. Brandslund3, M. Maeng1, H. Beck-Nielsen1, A.A. Vaag2, H.T. Sorensen1 9, T.K. Hansen2 9, R.W. Thomsen1 9

1Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus. 2Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus. 3Clinical Medicine, Aarhus University, Aarhus. 4Steno Diabetes Center Odense, Odense University Hospital, Odense. 5Endocrinology, Bispebjerg, Copenhagen University Hospital, Copenhagen. 6Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle. 7Department of Cardiology, Aarhus University Hospital, Aarhus. 8Steno Diabetes Center Copenhagen, Copenhagen University Hospital, Copenhagen. 9Clinical Medicine, Aarhus University, Aarhus N, Denmark.

Background and aims: We investigated the relationship between high-sensitivity C-reactive protein (hsCRP, a marker of low-grade inflammation), alone or in combination with C-peptide (a marker of insulin resistance), and risk of cardiovascular events (CVEs) and mortality in patients with recent-onset type 2 diabetes (T2D) and no hospital history of CVEs.

Materials and methods: We measured serum hsCRP in 7,301 patients with recent-onset type 2 diabetes (T2D) and no hospital history of CVEs. We measured serum hsCRP in 7,301 patients with recent-onset type 2 diabetes and followed them in 5,765 patients with recent-onset T2D and followed them for a first CVE, including myocardial infarction, stroke, coronary revascularization, and cardiovascular death, and death from any cause.

Results: High (>3 mg/L) versus low (<1 mg/L) hsCRP was associated with an increased CVE risk during a median follow-up of 4.8 years (adjusted hazard ratio: 1.45 [95% confidence interval: 1.08-1.96]), and with strongly increased all-cause mortality (2.49 [1.90-3.27]), mainly driven by cancer mortality. Compared to patients with low levels of both hsCRP (<3 mg/L) and C-peptide (<1470 pmol/L), those with high levels of both biomarkers had highest risks of CVE (1.62 [1.11-3.26]) and all-cause mortality (2.42 [1.77-3.29]). The risk of CVE increased more with high C-peptide alone (1.54 [1.09-2.18]) than high hsCRP alone (1.37 [1.00-1.88]). In contrast, the risk of all-cause mortality increased much more with high hsCRP alone (1.90 [1.46-2.49]) than with high C-peptide alone (1.15 [0.82-1.61]).

Conclusion: In a contemporary cardiovascular prevention setting, elevated hsCRP is a much weaker predictor of future CVE than of all-cause mortality in patients with early T2D. C-peptide is a more accurate predictor of CVE risk than hsCRP, emphasizing the importance of targeting insulin resistance for prevention of CVE.
Materials and methods: Adult patients with type 2 diabetes (T2D) and HF with either left ventricular ejection fraction (LVEF) ≤ 45% (EFFORT-1) or LVEF > 45% (EFFORT-2) were recruited. The patients received either 25 mg empagliflozin or placebo and were followed up for 48 weeks. Endothelin-1, galectin-3, insulin-like growth factor binding protein (IGFBP)-7 and kidney injury molecule (KIM)-1 were measured using ELISA at baseline and after 2, 12, 24 and 48 weeks of randomization. Left ventricular end-diastolic diameter (LVEDD) and posterior wall diameter were evaluated at baseline, week 12, 24 and 48. Change from baseline and the corresponding differences between treatment groups were determined with a mixed effects repeated measure analysis using treatment, visit and treatment-by-visit interaction as fixed effects and baseline value as a covariate. The means and differences between log-transformed data were back transformed to original scale as ratios. Pearson or Spearman correlation coefficients were calculated. The expression of inflammatory proteins was measured in HUVECs after high glucose and TNF-α stimulation ± empagliflozin.

Results: 63 patients were recruited, 24 in EFFORT-1 and 39 in EFFORT-2. Empagliflozin significantly reduced KIM-1 levels by 38% at week 48 in EFFORT-2 compared to placebo (95% CI: -57%, -13%), with no significant differences observed in EFFORT-1. Empagliflozin improved cardiac remodelling parameters via reduction of LVEDD at all time points in EFFORT-1, reaching significance only at week 24 with difference -7.88 (95% CI: -12.2, -3.61) from placebo, whereas borderline non-significant differences were shown at week 48 [-4.40 (95% CI: -8.84, 0.042)]. In EFFORT-2, empagliflozin significantly reduced posterior wall diameter at week 48 [-2.29 (95% CI: -3.63, -0.909)]. No clinically meaningful correlations were observed between the plasma biomarkers and any of the measured parameters. In HUVECs, empagliflozin did not significantly impact the expression of inflammatory markers.

Conclusion: Empagliflozin demonstrated as shown by a decrease in the biomarker KIM-1 a renal tubular protective effect in HF patients, while it contributed to the reduction of adverse cardiac remodelling. These CV benefits of empagliflozin can most likely not be explained by anti-inflammatory actions.

Supported by: This trial was funded through an IIT Grant by Boehringer Ingelheim. A. E. was supported by DAAD
Disclosure: A. Elrakaybi; Grants; This trial was funded through an IIT Grant by Boehringer Ingelheim. A. E. was supported by the German Academic Exchange Service (DAAD) – German Egyptian Research Long-Term Scholarship (GERLS) Program.

44 Mechanistic insights into the effects of empagliflozin in patients with type 2 diabetes and heart failure

A. Elrakaybi1,2, K. Lauben1, Q. Zhou1,2, G. Päth1, H. Schmitt3, M.J. Hug3, J. Seufert1;
1Division of Endocrinology and Diabetology, Department of Medicine II, Medical Center – University of Freiburg, Freiburg, Germany,
2Department of Clinical Pharmacy, Ain Shams University, Cairo, Egypt,
3Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany,
4Department of Cardiology, University Hospital Basel, Basel, Switzerland,
5Pharmacy, Medical Center – University of Freiburg, Freiburg, Germany.

Background and aims: Sodium-glucose co-transporter (SGLT) 2 inhibitors were the first antidiabetic drugs to demonstrate remarkable reductions in CV mortality and hospitalisation for heart failure (HF) in patients with and without diabetes. However, the exact mechanisms are still under debate. We aimed to investigate the effect of empagliflozin on certain plasma biomarkers and potential cardiac remodelling parameters, while also determining their possible associations in diabetic patients with HF. In-vitro experiments aimed to evaluate potential anti-inflammatory effects of empagliflozin.

45 Effect of semaglutide on MACE by baseline kidney function in participants with type 2 diabetes and high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc analysis

P. Rossing1, S. Bain2, H. Bosch-Traberg3, O. Frenked1, H.L. Heerspink4, S. Rasmussen1, L. Mellbin5;
1Sterno Diabetes Center Copenhagen, Gentofte, Denmark, 2Swansea University Medical School, Swansea, UK, 3Novo Nordisk A/S, Søborg, Denmark, 4University Medical Center Groningen, Groningen, Netherlands, 5Karolinska Institutet, Stockholm, Sweden.

Background and aims: People with type 2 diabetes (T2D) are at increased risk of cardiovascular (CV) disease and chronic kidney disease (CKD). As shown in a previous post hoc analysis, semaglutide (pooled s.c. once-weekly [OW] and oral once-daily) reduces the risk of major adverse CV events (MACE) vs placebo. The current post hoc analysis investigated the association between baseline kidney function and risk of MACE (composite of CV death, nonfatal myocardial infarction and nonfatal stroke), and the effect of semaglutide on risk of MACE by baseline kidney function.
Materials and methods: Participants with T2D and at high CV risk (N=6,480) receiving semaglutide (s.c. OW 0.5 or 1.0 mg or oral 14 mg) or placebo in SUSTAIN 6 and PIONEER 6 were categorised according to baseline kidney parameters: eGFR <45 (CKD stage 3b or worse), ≥45-<60 (CKD stage 3a) and ≥60 mL/min/1.73 m² (CKD stage 1 or 2) and urine albumin-to-creatinine ratio (UACR) <30, ≥30-<300 and ≥300 mg/g. eGFR subgroup analyses used pooled SUSTAIN 6 and PIONEER 6 data; UACR subgroup analyses used SUSTAIN 6 data only (no PIONEER 6 data available). MACE risk by baseline kidney function was analysed with a Cox proportional hazards model (reference groups: eGFR ≥60 mL/min/1.73 m² and UACR <30 mg/g). The effect of semaglutide on MACE across kidney function subgroups was assessed with unadjusted and adjusted (for important baseline predictors of CV and renal diseases) analyses.

Results: Most participants included in the SUSTAIN 6 and PIONEER 6 trials had normal or mildly decreased kidney function (eGFR ≥45-<60 and ≥60 mL/min/1.73 m²; n=731, n=968 and n=4,762, respectively) and were normoalbuminuric (UACR <30, ≥30-<300 and ≥300 mg/g; n=1,934, n=884 and n=420, respectively). Regardless of treatment, MACE risk was higher in participants with eGFR ≥45 mL/min/1.73 m² (HR 1.52, 95% CI [1.15;1.99], p=0.0026) and ≥45-<60 mL/min/1.73 m² (1.36, [1.04;1.76], p=0.022) vs those with ≥60 mL/min/1.73 m² at baseline. Similarly, MACE risk was higher in participants with UACR ≥30-<300 mg/g (HR 1.53, 95% CI [1.14;2.04], p=0.0043) and >300 mg/g (2.52, [1.84;4.42], p<0.0001) vs those with <30 mg/g at baseline. Semaglutide reduced the risk of MACE consistently across baseline kidney function subgroups in both the unadjusted and adjusted analyses (pinteraction >0.05 for all analyses; Figure).

Conclusion: The risk of MACE was greater for participants with impaired kidney function than in those with normal kidney function. Semaglutide showed consistent reductions in MACE risk across eGFR and UACR subgroups. These findings indicate that semaglutide provides CV benefits in people with T2D and high CV risk across a broad spectrum of kidney function and damage.

Clinical Trial Registration Number: NCT01720446; NCT02692716

Supported by: Novo Nordisk A/S


46

Overexpression of miR-210 attenuates endothelial dysfunction in a mouse model of obesity and type 2 diabetes

A. Collado 1, T. Jiao 1, G. Zaccagnini 2, J. Yang 1, M. Carlström 1, F. Martelli 1, J. Pernow 1,4, Z. Zhou 1;
1Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 2Laboratory of Molecular Cardiology, IRCCS Policlinico San Donato, Milan, Italy, 3Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, 4Karolinska University Hospital, Stockholm, Sweden.

Background and aims: MicroRNA (miR)-210 plays a protective role in many cardiometabolic diseases, and its levels are decreased in whole blood, erythrocytes, and plasma in type 2 diabetes (T2D). We recently demonstrated that miR-210 levels are lower in carotid artery plaques from patients with T2D compared to non-diabetic patients. However, the role of miR-210 in the modulation of endothelial function is not fully understood. We test the hypothesis that overexpression of miR-210 has therapeutic potential by reversing endothelial dysfunction in mice with Western diet (WD)-induced obesity and T2D.

Materials and methods: Eight weeks old miR-210 transgenic mice were treated with a WD for 12 weeks. During the last 10 days of the diet regime, doxycycline or vehicle dissolved in drinking water was given to switch on miR-210 (miR-210/on, n=7) expression or keep it off (miR-210/off, n=7), respectively. Age-matched wild-type (WT, n=7) control mice received standard chow within the same period. At the end of the treatment, body weight and glucose levels were measured. Aortic segments were isolated, and endothelial function was determined by acetylcholine-induced endothelium-dependent relaxation (EDR) using wire myographs. The expression of the miR-210 target protein tyrosine phosphatase 1B (PTP1B) and the levels of the oxidative stress marker 4-hydroxynonenal (4-HNE) were quantified by immunohistochemistry. All animal experiments and procedures were performed according to the guidelines by the U.S National Institutes of Health (NIH publication no 85-23, revised 1996). Differences in concentration-dependent relaxations were analyzed using two-way ANOVA with repeated measures. Multiple comparisons between groups were performed with one-way ANOVA followed by the Bonferroni post hoc test. Data are shown as mean ± SD.

Results: miR-210/off mice fed with a WD had a significant increase in body weight (BW; 39.0±5.7 g miR-210/off vs. 25.5±2.2 g WT, p<0.001) and glucose levels (10.0±1.2 mM miR-210/off vs. 7.6±0.4 mM WT, p<0.01). A similar increase was found in miR-210/on mice (BW: 34.3±6.4 g, p=0.05 vs. WT; glucose: 9.8±1.9 mM, p=0.05 vs. WT). EDR in aortas from miR-210/off mice fed with WD was significantly impaired compared to vessels from WT fed with regular chow. Notably, EDR was markedly improved in aortas of miR-210/on mice fed with WD. Furthermore, the expression of PTP1B and the levels of 4-HNE were significantly elevated in the aortas from miR-210/off mice fed with WD when compared to WT (~4.3 fold, p<0.001 and 6 fold, p<0.01 increase of PTP1B and 4-HNE vs. WT, respectively). The expression was attenuated in aortas of miR-210/off mice fed with WD compared to miR-210/off mice (~2.2 fold, p<0.01 and 3 fold, p<0.05 decrease of PTP1B and 4-HNE vs. miR-210/off mice, respectively).

Conclusion: Overexpression of miR-210 ameliorates endothelial dysfunction in mice fed with WD without affecting BW or glucose levels. Increasing miR-210 levels may become a therapeutic strategy for T2D to attenuate cardiovascular dysfunction.

Supported by: the Härt-Lungfonden (20190341 and 20200326 to ZZ, 20190266 to JP, and 20210431 to MC).

Disclosure: A. Collado: None.

47

Inhibition of microRNA-181c rescues diabetes-impaired angiogenesis through activation of key angiogenesis mediators

E.L. Solly 1,2, J. Mulangala 3, B.A. Di Bartolo 4, S.J. Nicholls 5, P.J. Psaltis 1,2, C.A. Bursill 1,2, J.T.M. Tan 1,2;
1Vascular Research Centre, Lifelong Health Theme, South Australian Health & Medical Research Institute, Adelaide, 2Adelaide Medical School, The University of Adelaide, Adelaide, 3Vascular Biology Program, Centenary Institute of Cancer and Inflammation, The
University of Sydney, Sydney. Faculty of Medicine and Health, The University of Sydney, Sydney. Monash Cardiovascular Research Centre, Monash University, Melbourne, Australia.

**Background and aims:** Diabetic vascular complications are characterized by impaired angiogenic responses to ischemia. Many patients remain refractory to current therapies, highlighting the need to identify novel therapeutic targets. We recently identified an anti-angiogenic role for miRNA-181c. However, its role in diabetes-impaired angiogenesis was unknown. This study aimed to elucidate the role of miRNA-181c in diabetes-impaired angiogenesis.

**Materials and methods:** Human coronary artery endothelial cells were transfected with a miRNA-181c inhibitor (anti-miR-181c) or negative control (anti-miR-Neg), exposed to glucose (5mM or 25mM, 48h) then subjected to Matrigel tubulogenesis assay or Boyden Chamber migration assay. Protein levels of angiogenic mediators (VEGFA) and activation of angiogenesis pathways (p-ERK2, p-eNOS, p-p38 MAPK) was determined by Western Blot. In vivo, we assessed the effect of miR-181c inhibition on diabetes-impaired angiogenesis using murine models of hindlimb ischemia and wound healing. Hindlimb blood-flow reperfusion was measured longitudinally by Laser Doppler imaging and gene expression was assessed 3-days post-ischemic induction when angiogenesis is important. Wound area was calculated daily. Neovascularization was assessed by CD31 (capillaries) and smooth muscle α-actin (arterioles) immunostaining in hindlimbs and wounds.

**Results:** Inhibition of miRNA-181c increased tubule formation (anti-miR-181c: 99.9±7.1 vs. anti-miR-Neg: 74.7±3.9, n=11, P<0.01) and cellular migration (anti-miR-181c: 115.7±23.4 vs. anti-miR-Neg: 37.9±7.1, n=6, P<0.05) in high glucose. Mechanistically, this was associated with increased VEGFA levels (anti-miR-181c: 112.8±7.9 vs. anti-miR-Neg: 90.8±5.8, n=17, P<0.05) and activated ERK2 signalling (anti-miR-181c: 113.9±11.9 vs. anti-miR-Neg: 79.9±8.9, n=12, P<0.05) in high glucose. In diabetic mice, inhibition of miRNA-181c increased blood flow reperfusion to the ischemic hindlimb, compared to diabetic control mice (Diabetic anti-miR-181c: 0.432±0.04 vs. Diabetic anti-miR-Neg: 0.282 ±0.03, n=11, P<0.001), returning it back to non-diabetic levels (0.373 ±0.04). This was associated with improved early induction of the pro-angiogenic mediator Erk2 (Diabetic anti-miR-181c: 93.8±10.1 vs. Diabetic anti-miR-Neg: 60.9±9.3, n=8, P<0.05) and an increase in hindlimb arteriolar density (Diabetic anti-miR-181c: 133.6±23.8% vs. Diabetic anti-miR-Neg: 72.8±10.3%, n=11, P<0.05). Inhibition of miRNA-181c significantly increased the rate of wound closure (Diabetic anti-miR-181c: 76.8±3.6% vs. Diabetic anti-miR-Neg: 59.7±4.3%, n=11, P<0.01) and increased the number of CD31 wound neovessels (Diabetic anti-miR-181c: 142.5±39.2% vs. Diabetic anti-miR-Neg: 54.3±13.3%, n=11, P<0.05) in diabetic mice.

**Conclusion:** Inhibition of miRNA-181c rescues diabetes-impaired angiogenesis. This presents miRNA-181c as a novel therapeutic target for the prevention of diabetic vascular complications.

**Supported by:** THRF, Diabetes Australia

**Disclosure:** E.L. Solly: None.

**Materials and methods:** We included 699 patients (male/female 54%/46%) with type 2 diabetes (T2D), free of cardiocvascular history and symptom but with other cardiocvascular risk factors. They were separated in 4 groups according to the number (from 0 to 3) of microangiopathic complications among retinopathy, nephropathy and peripheral neuropathy (G0 to G3). An echocardiography was performed, with measurement of structural and functional parameters. Silent coronary disease was assessed by performing a stress myocardial scintigraphy to detect silent myocardial ischemia (SMI), and a coronary angiography in the patients with SMI. NT-proBNP was measured in 243 of them.

**Results:** A higher number of microangiopathic complications was associated with male gender, age, diabetes duration, hypertension and SMI (p<0.005 for all comparisons). Left ventricle systolic dysfunction (ejection fraction <50%), dilatation, hypokinesia and hypertrophy were detected in 3.9%, 8.4%, 7.6% and 34.1% of the population, respectively. The prevalence of hypokinesia and hypertrophy increased from G0 to G3 (p=0.02 and 0.03), as well as interventricular septal and posterior wall thickness and NT-proBNP levels (p<0.0001 for all comparisons). Multivariate analyses showed that hypertrophy, septal thickness and NT-proBNP were significantly associated with the number of microangiopathic complications, independently from gender, diabetes duration, hypertension and SMI.

**Conclusion:** The association between the number of microangiopathic complications and these left ventricle structural and functional alterations, independent from major potential confounding factors, particularly silent coronary disease, stands for a microvascular contribution to the development of diabetic cardiomyopathy.

**Disclosure:** M. Nguyen: None.

**48**

**Association between microangiopathic complications and cardiac structure and function in asymptomatic patients with type 2 diabetes**

M. Nguyen, S. Pinto, P. Poignard, P. Valens; Jean Verdier hospital - APHP, Bondy, France.

**Background and aims:** Diabetic retinopathy has been associated with an increased risk of cardiac events including heart failure and with echocardiographic alterations. The pathophysiology of diabetic cardiomyopathy is complex and multifactorial. The present study aimed to examine the relationship between microangiopathic complications and these alterations in patients with type 2 diabetes (T2D).
OP 09 Fighting diabetes with tubes, scanners, and catheters

49 Advances in diabetes management: has pregnancy glycaemic control in women with type 1 diabetes changed in the last decades?
F. Citro¹, F. Nicolò¹, M. Aragona¹, L. Battin², C. Bianchi², S. Del Prato¹, A. Bertolotto¹;
¹Department of Clinical and Experimental Medicine, University of Pisa, ²Department of Medicine, University Hospital of Pisa, ³Maternal-Infant Department, University Hospital of Pisa, Pisa, Italy.

Background and aims: Over the recent years, multiple therapeutic and management opportunities have been made available to treat pregnant women with type 1 diabetes (T1DM). However, analysis assessing whether these different approaches may have any specific advantage/disadvantage in metabolic control and outcomes is still limited.

Materials and methods: We performed a retrospective analysis on pregnant women with T1DM, managed between 2008 and 2020 at the Pisa University Hospital, to analyze metabolic data according to types of basal insulin (NPH, detemir or glargine), insulin administration ways (Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSI)) and glucose monitoring systems [Self-Monitoring of Blood Glucose (SMBG) or Continuous/Flash Glucose Monitoring (CGM/FGM)] that were adopted during pregnancy.

Results: We identified 136 T1DM women (age: 32 [IQR 30-35] years old; preconception HbA1c: 58.1±11.6 mmol/mol). Of them, 103 (76%) were on MDI based on NPH (n: 53, 51%), detemir (n: 35, 34%) or glargine (n: 15, 15%). The remaining 33 women (24%) were on CSI. A CGM/FGM system was used in 33 (24%) women (20 (19%) on MDI and 13 (39%) on CSI). HbA1c, fasting plasma glucose, lipid profile and weight gain at baseline and during pregnancy were comparable among women treated with different basal insulins. Pregnancy planning was more common in women on CSI (94% vs. 60%, P=0.001) and, as compared to women on MDI treatment, they had better pregestational HbA1c (54±5.4 vs. 60±13 mmol/mol; P=0.044), first trimester fasting plasma glucose (103±38 vs. 140±59 mg/dL; P=0.004), lower pregnancy weight gain (10.7±4.0 vs. 13.8±6.2 kg, P=0.018) and lower pre-prandial plasma glucose (103±38 vs. 140±59 mg/dL, P=0.004), lower insulin dose at first (0.25±0.09 vs. 0.38±0.18 UI/kg, P=0.002), second (0.30±0.11 vs. 0.43±0.20 UI/kg, P=0.003) and third trimester (0.42±0.20 vs. 0.54±0.24 UI/kg; P=0.017) trimester. Women using CGM/FGM had significantly lower pregestational (54±3.1 vs. 59.1±9.3 mmol/mol; P=0.041) and first trimester (46.5±5.5 vs. 51.2±7.1 mmol/mol, P=0.034) HbA1c levels than those on SMBG. Mode of delivery (vaginal or caesarean section) and neonatal outcomes (birth weight, macrosomia, Large for Gestational Age (LGA), Small for Gestational Age (SGA), preterm birth, Apgar score at 5 min) were similar between groups. In logistic regression analysis, in the whole group, third trimester HbA1c remained the strongest risk factor for LGA.

Disclosure: F. Citro: None.

50 Fully automated closed-loop insulin delivery vs standard insulin therapy in adults with type 2 diabetes: an open-label, single-centre randomised crossover trial
C.K. Boughton¹, A.B. Daly¹, M. Nwokolo¹, S. Hartnell², M.E. Wilinska³, A. Cezar³, M.L. Evans¹, R. Hovorka³;
¹Box 289, University of Cambridge, ²Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Background and aims: Despite advances in oral and injectable therapies for type 2 diabetes (T2D), many adults with T2D requiring insulin do not reach the recommended target HbA1c levels and there is a clear need for novel therapeutic approaches. We evaluated the safety and efficacy of fully closed-loop insulin delivery, not requiring meal bolusing, compared with standard insulin therapy in adults with T2D.

Materials and methods: In an open-label, single-centre, randomised, crossover study, 26 adults with T2D (7 females, mean±SD age 59±11y, diabetes duration 18±8y, baseline HbA1c 75±15 mmol/mol [9.0±1.4%], BMI 35.3±8.6kg/m²) underwent two 8-week periods of unrestricted living comparing CamAPS HX fully closed-loop using Fiasp (CL), with standard insulin therapy and a masked continuous glucose monitor (control) in random order. There was a 2-4 week washout between intervention periods. Primary endpoint was time spent in target glucose range (3.9 to 10.0 mmol/L).

Results: The proportion of time spent in target glucose range was mean ±SD 66.3±14.9% with CL vs. 32.3±24.7% with control (mean difference 33.5 percentage points [95%CI 28.0, 42.6; P<0.001]). The proportion of time spent above target glucose range (>10.0 mmol/L) was 33.2±14.8% with CL vs. 67.0±25.2% with control (mean difference 32.5 percentage points [95%CI -42.8, -27.5]; P<0.001). Mean glucose was lower during CL use (9.2±1.2 mmol/L vs. 12.6±3.0 mmol/L; mean difference 3.6 mmol/L [95%CI 2.5, 4.6]; P<0.001). There was a reduction in HbA1c at the end of the CL period at 57.9±9 mmol/mol [7.3±0.8%] compared to 72±13 mmol/mol [8.7±1.2%] at the end of the control period (mean-adjusted difference 15 mmol/mol [95%CI 11, 20]; 1.4% [95%CI 1.0, 1.8]; P<0.001). The proportion of time in hypoglycaemia (<3.9 mmol/L) was low and similar between treatment periods (median [IQR] 0.43% [0.20, 0.77] in the CL period vs. 0.08% [0.00, 1.05] in the control period; P=0.751). There were no episodes of severe hypoglycaemia in either group.

Conclusion: Fully closed-loop insulin delivery improved glucose control without increasing the risk of hypoglycaemia compared to standard insulin therapy in adults with T2D. The treatment may represent a safe and effective method of achieving glycaemic target in this group.

Clinical Trial Registration Number: NCT04701424

Supported by: The study was supported by the National Institute for Health Research Cambridge Biomedical Research Centre.

Disclosure: C.K. Boughton: None.

51 Important decrease of hospitalisations for acute diabetes events before and after FreeStyle Libre⁴ system initiation in type 2 diabetes with basal insulin therapy in France
Background and aims: Glycemic management in people with T2D (PwT2D) who are not on intensive insulin regimens is of considerable importance. Due to the progressive nature of T2D, initiation of insulin treatment may be necessary to achieve glycemic target. Initiation of basal-insulin therapy in PwT2DM is associated with serious diabetes-related acute events, such as severe hypoglycemia or diabetes ketoacidosis (DKA) that can be life-threatening. We assessed the impact of initiating FreeStyle Libre® glucose monitoring system (FSL) as compared to the usual self-glucose monitoring of glycemia on hospitalizations for acute diabetes events (ADEs) in PwT2D on basal insulin scheme +/- other hypoglycemic agents.

Materials and methods: A retrospective study on the overall French national SNDS reimbursement claims database (=66 million people) was conducted on all French PwT2D on basal insulin therapy receiving a first reimbursement of FreeStyle Libre between 01/08/2017 to 31/12/2018. The analysis looked at claims data for the 12 months before, and up to 24 months after FSL initiation. Hospitalizations for diabetes-related acute events were identified, using ICD-10 codes as main or related diagnosis: severe hypoglycemia (SH) events (E160, E161, E162 and T383); DKA events (ICD-10 codes E101 and E111), coma (ICD-10 codes E100, E110 and E140) and hyperglycemia related stays (ICD 10 code R739).

Results: We identified 5,933 PwT2D on a basal insulin therapy who initiated FSL during the selection period. Only 78.9% of patients were on both basal insulin and other hypoglycemic agents, of which 40% were documented as receiving sulphonylurea. Amongst PwT2D on a basal insulin therapy, 2.01% experienced at least one hospitalization for any ADE in the year before FSL initiation compared to 0.75% (1 year after) and 0.60% (2 years after) (Fig. 1), and these results are similar independently of the sulfonylurea use or not. This reduction in ADEs was mainly driven by 75% fewer DKA admissions, with a 44% reduction in admissions for SH. These patterns of reduction in ADEs persisted after 2 years, with a further 43% reduction in DKA rates.

Conclusion: This sub-group analysis of our previous RELIEF study initially treated with basal insulin therapy in reducing diabetes related acute events and their long-term consequences.

Supported by: Funded by Abbott Diabetes Care
Disclosure: J. Riveline: Honorarium; Abbott.
Management Associates, Lee's Summit, USA, 4Accelerated Enrolment Solutions, Orlando, USA, 5Touchstone Interventional Pain Center, Medford, USA, 6IPM Medical Group, Walnut Creek, USA, 7Ochsner Clinic Foundation, New Orleans, USA, 8Cleveland Clinic Foundation, Cleveland, USA, 9Swedish Pain & Headache Center, Seattle, USA, 10Reno Tahoe Pain Associates, Reno, USA, 11Nevada Advanced Pain Specialists, Reno, USA, 12Pain Care, Stockbridge, USA, 13University of Glasgow, Glasgow, UK, 14Nevro, Redwood City, USA.

Background and aims: Painful diabetic neuropathy (PDN) can lead to severe deterioration in quality of life, loss of function, and increased health care costs. A large randomized controlled study was undertaken to provide high level clinical evidence for the use of 10kHz spinal cord stimulation (SCS), which does not cause paresthesias like traditional SCS, for the treatment of PDN.

Materials and methods: Prospective, multicenter, RCT to document the impact of 10kHz SCS on PDN. Participants had PDN symptoms ≥12 months (M), refractory to medications, lower limb pain intensity ≥5cm (0-10cm visual analog scale [VAS]), and hemoglobin A1c ≤10%. Patients (N=216) were allocated 1:1 to 10kHz SCS (Nevro Corp.) plus conventional medical management (CMM) or CMM alone with optional crossover at 6 M.

Results: There were 90 patients implanted in the 10kHz arm after meeting 50% pain relief requirement in a temporary trial, and 84 (93%) remained in follow-up at 24 months. The 10kHz SCS patients maintained substantial pain relief from 3 M, averaging an 81.9% (95%CI 77.3 - 86.5) decrease at 24 M. At 6 M follow up, 0% of 10kHz SCS participants but 93% of eligible CMM patients elected to crossover. At 18 M follow-up after SCS, both groups (n=138) reported similar significant improvements in pain, sleep disturbance, and in pain interference with mood and daily activities (see Fig 1). In addition, the neurological assessment found a majority of patients treated with SCS experienced sensory improvements. In terms of health care utilization, hospitalizations were 38% less in the 10kHz group at 6 M. There were no stimulation-related neurological deficits and 6 total explants (3.9%), 5 due to procedure-related infections and 1 as a precaution for endocarditis.

Conclusion: The largest RCT to date of SCS management of PDN demonstrates safety, durable pain relief, and clinically meaningful improvement on neurological examination over 24 M with 10kHz SCS. These PDN patients with moderate to severe pain that was refractory to CMM achieved clinically important improvements in quality of life, and reduced health care utilization with a safe, reversible, minimally invasive procedure.

Clinical Trial Registration Number: NCT03228420
Supported by: Nevro

54 Duodenal jejunal bypass liner (DJBL) treatment for type 2 diabetes and obesity: glycaemic and CVD risk factor improvements vs risks in patients treated worldwide
R.E.J. Ryder¹, P. Sen Gupta², T. Battelino³, P. Kotnik³, J. Teare⁴, A. Ruban⁵, H. Frydenberg⁶, L. Munro⁶, S. Fishman⁶, R. Cohen⁶, C. de Jonge⁶, J.-W. Greve⁷, H. Sourj⁸, K. Laubner⁸, J. Seufert⁸; ¹City Hospital, Birmingham, UK, ²Guy’s and St Thomas’ Hospitals, London, UK, ³University Medical Center, Ljubljana, Slovenia, ⁴Imperial College, London, UK, ⁵Epworth Hospital, Richmond, Australia, ⁶Sourasky Medical, Tel Aviv, Israel, ⁷Oswaldo Cruz Hospital, Sao Paulo, Brazil, ⁸Catharina Hospital, Eindhoven, Netherlands, ⁹Zuyderland MC, Heerlen, Netherlands, ¹⁰Medical University, Graz, Austria, ¹¹Freiburg University, Freiburg, Germany.

Background and aims: There is uncertainty over the balance of benefits and risks of proximal intestinal exclusion with a temporarily inserted DJBL for treatment of type 2 diabetes and obesity. An online registry was established under the auspices of the Association of British Clinical Diabetologists (ABCD) in 2017.

Materials and methods: DJBL safety and efficacy data were entered into the ABCD registry from patients worldwide. To evaluate the glycaemic effectiveness of DJBL, we categorised patients into groups according to baseline HbA1c.

Results: As of March 2022, data had been submitted on 1022 patients (mean ± SD age 51.3 ± 11.4 years, 52.5% male, 84.9% type 2 diabetes, BMI 41.1 ± 8.7 kg/m²) from 34 centres in 10 countries (table). In those with both baseline and time of removal data, mean ± SD weight fell by 13.3 ± 9.7 kg from 120.2 ± 25.3 to 106.9 ± 23.8 kg (n=811, p<0.001), HbA1c by 13.7 ± 15.9 from 67.6 ± 19.8 to 54.0 ± 13.9 mmol/mol (by 1.3
Supported by: ABCD.

Disclosure: R.E.J. Ryder: None.

OP 10 Beta cells: protecting what is precious

55 Early effects of treatment with intralymphatic administration of rhGAD65 in LADA appear similar to those observed in type 1 diabetes
I. Hals1,2, A. Björklund3, C.N.D. Balasuriya2, R. Casas4, J. Ludvigsson5, V. Grill1;
1Dept of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway, 2Clinic of Medicine, St Olavs hospital, Trondheim University Hospital, Trondheim, Norway, 3Dept. of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden, 4Dept of Biomedical and Clinical Sciences, Linköping university, Linköping, Sweden, 5Crown Princess Victoria Children’s Hospital, University Hospital, Linköping, Sweden.

Background and aims: We perform an investigator-initiated open-labelled 12 months pilot study in which treatment with intralymphatic administration of the antigen specific immunotherapy Diamyd® (rhGAD65) is tested for the first time in patients with LADA. We aim to evaluate safety, immune response and insulin secretion after intralymphatic treatment with rhGAD65 in LADA.

Materials and methods: Fourteen LADA individuals, women/men: 7/7, with high anti-GAD titers (>190 RU/ml) and not on insulin therapy received 3 intralymphatic injections of 4 μg rhGAD65, one month apart. Safety parameters, immune responses and insulin secretion capacity were summarized in an interim analysis 5 months after baseline.

Results: Baseline values (mean ± SD) were: fasting C-peptide 0.65 ± 0.36 nmol/L, HbA1c 43 ± 7 mmol/mol and BMI 26.5 ± 5.2 kg/m²; diabetes duration 5.9 ± 3.8 months, age 47 ± 8 years. Half the study population was HLA-DR3DQ2 positive. Interim analysis at 5 months from baseline showed no treatment-related serious adverse events. There was a clear GAD-specific immune response both in terms of anti-GAD and T-cell reactions. At 2 and 5 months from baseline, median (Q1, Q3) GAD65 stimulation index of PBMC proliferation was 2.16 (1.25, 3.8) and 2.34 (1.81, 3.58) respectively, p< 0.01 for increase from baseline. There was a clear GAD-specific immune response both in terms of anti-GAD and T-cell reactions. At 2 and 5 months from baseline, median (Q1, Q3) GAD65 stimulation index of PBMC proliferation was 2.16 (1.25, 3.8) and 2.34 (1.81, 3.58) respectively, p< 0.01 for increase from baseline.

Conclusion: Intralymphatic treatment with rhGAD65 in LADA appears safe. It induces important immune responses that are similar to those observed after intralymphatic rhGAD65 in type 1 diabetes.

Clinical Trial Registration Number: NCT04262479
Supported by: Liaison committee between Central Norway RHA and NTNU
Disclosure: I. Hals: None.

56 Loss of beta cell Scn9a Na⁺ channel activity is protective in the context of type 1 diabetes while suppressing glucose stimulated insulin secretion
P. Overby, S. Provenzano, G. Sun, N. Nahimey, J. Kolic, S. Skovsø, J.D. Johnson;

Supported by: Liaison committee between Central Norway RHA and NTNU
Disclosure: I. Hals: None.
Background and aims: Type 1 diabetes is caused by β-cell death resulting in insulin insufficiency. Somewhat paradoxically, the recent clinical success of verapamil provides rationale for identifying protective therapeutic targets that suppress insulin secretion by limiting excitotoxicity. We previously used high-throughput screening to identify the FDA-approved Na+ channel inhibitor carbamazepine as a drug that protects mouse β-cells from multiple stressors. Follow-up studies demonstrated a decrease in spontaneous diabetes incidence in non-obese diabetic (NOD) mice treated with carbamazepine. Here, we aimed to characterize the effects of carbamazepine and related drugs on human islet survival and function, and to investigate the specific role of Scn9a (Nav 1.7), which is the most highly expressed voltage-dependent Na+ channel gene in β-cells and the likely cellular target of carbamazepine.

Materials and methods: Human islet cell death in the presence of carbamazepine and its analogues (e.g. oxcarbazepine), structurally unrelated Nav1.7 inhibitors (e.g. ProTx-II), and a Nav1.7 agonist (e.g. veratridine) were investigated using high-content imaging. The dynamics of glucose-stimulated insulin secretion from human and mouse islets were assessed by perfusion. The specific role of Scn9a in β-cell function and type 1 diabetes was assessed in ‘floxed’ NOD mice crossed with the Ins1Cre knockin allele or injected at 7 weeks with adeno-associated virus (AAV8) carrying Cre under the control of an Ins1 promoter.

Results: Carbamazepine and oxcarbazepine protected human β-cells from cytokine- and ER stress-induced death, while veratridine increased cell death under these conditions. Glucose-stimulated insulin secretion was moderately reduced in perfused human islets in combination with carbamazepine (p=0.0044), while veratridine increased insulin secretion (p=0.035). We observed a significant reduction in glucose stimulated insulin secretion between NOD:Scn9a<sup>fl/fl</sup>;Ins1<sup>Cre</sup> knockout mice and their wildtype littermate NOD:Scn9a<sup>wt/wt</sup>;Ins1<sup>Cre</sup> controls (p<0.0001). NOD:Scn9a<sup>fl/fl</sup> injected with AAV8-Ins1Cre showed reduced type 1 diabetes incidence relative to injected NOD:Scn9a<sup>wt/wt</sup> controls.

Conclusion: Collectively, our studies to date point to Scn9a as a potential pre-clinical drug target to protect β-cells from excitotoxicity in type 1 diabetes.

Supported by: JDRF

Disclosure: P. Overby: None.

57 Tirzepatide improves multiple aspects of beta cell function

K. Mather<sup>1</sup>, A. Mari<sup>2</sup>, J. Li<sup>1</sup>, S. Urvia<sup>1</sup>, T. Heise<sup>1</sup>, J. DeVries<sup>3</sup>, E. Pratt<sup>1</sup>, R. Heine<sup>1</sup>, M. Thomas<sup>1</sup>, Z. Milicevic<sup>1</sup>;

<sup>1</sup>Eli Lilly and Company, Indianapolis, USA, <sup>2</sup>National Research Council Institute, Rome, Italy, <sup>3</sup>Profil Institute for Clinical Research, Neuss, Germany, <sup>4</sup>Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany.

Background and aims: In this study we investigated the effect of tirzepatide (TZP) 15 mg (novel GIP-GLP-1 dual receptor agonist), placebo and semaglutide 1 mg (SEMA) on beta-cell function. Materials and methods: In a 28-week double-blind randomised controlled trial in people with type 2 diabetes the effect of TZP 15 mg (GIP-GLP-1 dual receptor agonist), placebo and SEMA 1 mg on beta-cell function was analysed using euglycaemic and hyperglycaemic glucose clamps (EGC, HGC) and Mixed Meal Tolerance Tests (MMTT).

Results: (Table): During EGC and HGC, TZP improved insulin sensitivity (M-value), first and second phase insulin secretion (ISR) and beta-cell glucose sensitivity (ratio of ISR and glucose increments) more than SEMA and placebo. During MMTT, both fasting and AUC glucose were reduced more with TZP than with SEMA or placebo, while incremental glucose AUC was reduced similarly with TZP and SEMA vs placebo.

Despite a similar glucose response the total and incremental insulin AUC were reduced by TZP but not by SEMA. Model-derived beta-cell glucose sensitivity was similarly increased with TZP and SEMA from baseline. In contrast, ISR at 7.2 mmol/L glucose increased more with TZP than with placebo and SEMA.

Conclusion: The glucose-lowering effect of TZP is mediated through improvements in multiple aspects of beta-cell function, including beta-cell glucose sensitivity and ISR, and in insulin sensitivity, resulting in pronounced lowering of fasting and postprandial glucose. These effects help explain the superior improvement in glucose control seen with TZP vs comparators in clinical trials.

Clinical Trial Registration Number: NCT03882970


58 Shotgun proteomics unveils mechanisms behind metformin-induced protection against pro-inflammatory cytokine-induced human islet cell damage

M. Tesi<sup>1</sup>, L. Giusti<sup>2</sup>, F. Ciregia<sup>1</sup>, L. Marselli<sup>1</sup>, L. Zallocco<sup>1</sup>, M. Suleiman<sup>2</sup>, C. De Luca<sup>3</sup>, S. Del Guerra<sup>3</sup>, D.L. Eizirik<sup>3</sup>, M.C. Napolitano<sup>3</sup>, P. Marchetti<sup>1</sup>, A. Lucacchini<sup>1</sup>, M. Ronchi<sup>2</sup>;

<sup>1</sup>University of Pisa, Pisa, Italy, <sup>2</sup>University of Camerino, Camerino, Italy, <sup>3</sup>Université Libre de Bruxelles, Brussels, Belgium, <sup>4</sup>University of Chieti-Pescara, Chieti, Italy.

Background and aims: Metformin (Met), a drug commonly used for the treatment of type 2 diabetes (T2D), has been shown to have direct protective actions on human β-cells exposed to glucose- and/or lipotoxic conditions and on islets from T2D donors. We presently assessed whether Met could relieve stress induced by pro-inflammatory cytokines in human β-cells and investigated the underlying mechanisms by shotgun proteomic analysis.

Materials and methods: Altogether, 14 human islet preparations were used. Islets were exposed to 50 U/ml interleukin-1β plus 1000 U/ml interferon-γ for 48 h, with or without 2.4 µg/ml Met, a therapeutic concentration of the drug. Glucose-stimulated insulin secretion studies, caspase 3/7 activity assay, shotgun label free proteomics and Western blots were performed.

Results: Met prevented the reduction in the insulin stimulation index (control islets, Ctrl: 5.4±1.7; cytokines: 3.4±1.1, p<0.05 vs Ctrl; cytokines plus Met: 4.7±1.6; mean±SEM) and the increase of caspase 3/7 activity (Ctrl: 1.1±1; cytokines: 1.5±1.1, p<0.001 vs Ctrl; cytokines plus Met: 1.2±0.1, p<0.01 vs cytokines and Ctrl) induced by cytokine exposure. Proteomics analysis identified 2,304±392 proteins. Cytokines significantly altered 244 proteins (145 up- and 99 downregulated), while in the presence of Met cytokines modified 231 proteins (128 up- and 103 downregulated). There were 212 differentially expressed proteins in common. Among the proteins regulated in opposite direction in the two conditions, were proteins involved in vesicle motility (e.g. transgelin, Ras-related
protein Rab14), defence from oxidative stress (e.g. peroxiredoxins, PRDX2 and PRDX5), metabolism (e.g. flavin reductase, mitochondrial ATP synthase subunit O), protein synthesis (e.g. 40S ribosomal proteins and eukaryotic translation initiation factor 4E), glycolysis and its regulation (e.g. triosephosphate isomerase and pyruvate kinase), cytoskeletal proteins and proteins interacting with the cytoskeleton (e.g. myosin light polypeptide 6, Ras-related protein Rab-A and coactosin-like protein). Met inhibited pathways linked to inflammation, immune reactions, mammalian target of rapamycin (mTOR) signaling and cell senescence. Some of the key changes were confirmed by Western blot.

**Conclusion:** Met prevents part of the deleterious actions of pro-inflammatory cytokines on human β-cells, which is accompanied by islet proteome modifications. These results suggest that Met, a widely used drug for the treatment of T2D, might be repurposed for other types of diabetes.

**Supported by:** INNODIA, INNODIA HARVEST, PRIN2017, CAPTURING

**Disclosure:** M. Tesi: None.

### 59

**Irisin administration restores beta cell functional mass in a mouse model of type 2 diabetes**

N. Marrano1, G. Biondi1, A. Borrelli1, M. Rella1, L. Roberto2, A. Cignarelli2, S. Perrin1, L. Laviola1, F. Giorgi1, A. Natale91;1

1Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, 2Transgenic Mice Facility, Biogem S.c.a.r.l., Ariano Irpino (AV), Italy.

**Background and aims:** Irisin is a hormone secreted by skeletal muscle following physical activity or excess of saturated fatty acids (SFAs), able to improve metabolic homeostasis and promote energy expenditure. Serum irisin levels are reduced in type 2 diabetes (T2D), while exogenous irisin administration improves glycemic control in diabetic mice. We have previously demonstrated that irisin protects human and rodent beta-cells and pancreatic islets from SFAs-induced apoptosis, increases insulin biosynthesis and glucose-stimulated insulin secretion (GSIS), and promotes beta-cell proliferation, both *in vitro* and *in vivo* in healthy wild type mice. We have also demonstrated that irisin restores the defective GSIS and reduces the high rate of apoptosis characteristic of islets from T2D patients. The beta-cellular effects of irisin administration to T2D mice are still unknown.

**Materials and methods:** 6-weeks-old C57Bl/6 mice (*n* = 8) were fed a high-fat diet (HFD, 60% of energy deriving from fat) for 10 weeks and then intraperitoneally injected with streptozotocin (STZ, 100 mg/Kg) to induce diabetes. 4 standard diet (SD)-fed mice were used as control. HFD/STZ mice were treated with 0.5 mg/g irisin (*n* = 4) or vehicle (*n* = 4), for 14 days. Fasting glycemia, insulinemia, and body weight have been measured throughout the study. Glucose tolerance and pancreatic islets function have been assessed on the last day of the study through an intraperitoneal glucose tolerance test. Pancreatic islets architecture has been evaluated through immunofluorescence analyses.

**Results:** As expected, compared to SD mice, HFD/STZ mice showed higher glycemia and body weight, glucose intolerance, and reduced GSIS; in addition, HFD/STZ mice showed reduced islets volume (-78%; *p* < 0.001 vs SD), beta-cell area (-35%; *p* < 0.001 vs SD), and insulin content (-60%; *p* < 0.001 vs SD), while increased alpha-cell area (+54%; *p* < 0.01 vs SD). Irisin administration significantly restored glycemia (+31%; *p* < 0.05 vs HFD/STZ), body weight (-13%; *p* < 0.001 vs HFD/STZ), glucose tolerance (-27% AUC; *p* < 0.001 vs HFD/STZ), GSIS (+23% AUC; *p* < 0.005 vs HFD/STZ), islets volume (+61%; *p* < 0.01 vs HFD/STZ), beta-cell (+34%; *p* < 0.001 vs HFD/STZ) and alpha-cell (-49%; *p* < 0.01 vs HFD/STZ) area, and insulin content (+36%; *p* < 0.001 vs HFD/STZ). Of note, irisin induced a 9-fold increase in beta-cell proliferation rate (*p* < 0.001 vs SD and HFD/STZ).

**Conclusion:** These results show for the first time that irisin restores beta-cell functional mass also when administered *in vivo* to diabetic mice, likely by promoting beta-cell proliferation. In conclusion, irisin could be considered a valid new anti-diabetes therapeutic strategy. **Supported by:** “EU–ESF PON R&I 2014-20, AIM” and “Tecnopoli per la Medicina di Precisione CUP B84118000540002”

**Disclosure:** N. Marrano: None.
61 The effect of ovariectomy and estradiol substitution on metabolic parameters and transcriptomic profile of adipose tissue in a prediabetic model

L. Markova1, M. Hutt1, D. Miklankova1, L. Sedova2, O. Seda2, H. Malinsky3

1Centre for Experimental Medicine, Institute for Clinical & Experimental Medicine, 2Institute of Biology and Medical Genetics, the First Faculty of Medicine, Prague, Czech Republic.

Background and aims: The postmenopausal period leads to the development of abdominal obesity, insulin resistance, hepatic steatosis, and other lipid and carbohydrate metabolism disorders. Adipose tissue, its metabolic and endocrine activity, partially regulated by sex hormones, may play a significant role in the development of these metabolic changes. The pathogenesis of these disorders and the possible effect of hormonal substitution are not precisely known. The study aimed to analyse the effect of ovariectomy and estradiol substitution in a prediabetic model with insulin resistance - females of the hereditary hypertriglyceridemic rat strain (HHTg).

Materials and methods: HHTg females underwent bilateral ovariectomy (HHTg-OVX) or sham surgery (SHAM) at 8 weeks. Two weeks after surgery half of the HHTg-OVX rats were substituted with 17-β estradiol (OVX-E) at a dose of 12.5 μg/kg b.wt./day for 12 weeks subcutaneously.

Results: Ovariectomy in HHTg females was accompanied by weight gain, increased serum leptin levels, impaired glucose tolerance, and decreased adipose tissue insulin sensitivity (p<0.05). Serum concentrations of glucose, insulin, cholesterol, NEFA, adiponectin and inflammatory cytokines MCP-1 and hsCRP did not differ between groups. In contrast, ovariectomy resulted in significant ectopic deposition of triacylglycerols (TAG) in the liver (p<0.001) and kidneys (p<0.001), although serum TAG levels were reduced after ovariectomy. Estradiol substitution alleviated the development of only some of the metabolic disorders associated with ovariectomy; in particular, it improved insulin sensitivity and reduced ectopic TAG deposition (liver: -16%, p<0.01; kidneys: -23%, p<0.001). Transcriptomic analysis of visceral adipose tissue revealed 813 differentially expressed transcripts in HHTg-OVX vs. SHAM, mostly pertaining to the regulation of lipid and glucose metabolism, cell cycle and oxidative stress (AMPK, FoxO, PI3-Akt signaling pathways). Estradiol substitution affected 1059 transcripts with significant overrepresentation in the signaling pathways of lipid metabolism, especially steroid biosynthesis, regulation of lipolysis in adipocytes and glycerol lipid metabolism. The principal component and hierarchical clustering analyses of transcriptome shifts corroborated the metabolic data, showing higher similarity of transcript clusters between OVX-E and SHAM groups, both contrasting with HHTg-OVX. Still, there was a clear distinction between OVX-E and SHAM with regard to transcript clusters related to steroid biosynthesis, glycerolipid or glutathione metabolism.

Conclusion: Ovariectomy in HHTg females worsens adipose tissue insulin resistance and significantly potentiates ectopic lipid deposition. Changes in the visceral adipose tissue transcriptome, especially in pathways relevant to lipid metabolism, oxidative stress, and insulin signaling, may contribute to metabolic abnormalities. Estradiol substitution may partially alleviate some of these disorders.

Supported by: MH CZ No. NU20-01-00083 and Iarem, IN00023001
Disclosure: I. Markova: None.

62 Mir-15b mediates the obesity-induced adipocyte insulin resistance by targeting insulin receptor

L. Xingjing

Diabetes mellitus (T2DM) is characterized by defects in the regulation of glucose homeostasis. Adipose tissue, being a key player in insulin resistance, has been extensively studied for its role in the development of diabetes. Mir-15b, a microRNA, has been implicated in various cellular processes, including insulin resistance. In this study, the authors aimed to investigate the role of Mir-15b in obesity-induced adipocyte insulin resistance.

The study involved several steps: first, the authors induced obesity in mice by a high-fat diet (HFD) and found increased serum leptin levels, impaired glucose tolerance, and increased expression of Mir-15b at the mRNA level. Next, they overexpressed Mir-15b in 3T3-L1 adipocytes and observed a decrease in insulin sensitivity, mimicking obesity-induced insulin resistance. Furthermore, when Mir-15b was inhibited, adipocyte insulin resistance was partially alleviated.

In conclusion, the study suggests that Mir-15b plays a significant role in obesity-induced adipocyte insulin resistance by targeting insulin receptor. The findings provide insights into the molecular mechanisms underlying obesity and could potentially lead to novel therapeutic strategies.

Disclosure: None.

63 Impact of rare heterozygous mutations of PCSK1 on obesity: implication for treatment with MC4R agonists

L. Folon1, M. Baroin2, M. Derhourel1, B. Balkan1, G. Charpentier2, S. Frane3, R. Rousset4, M. Canoul1, P. Farguel15, A. Bonnefond15,1

1Inserm UMR1283, CNRS UMR5199, Lille, France, 2Inserm U1018, Villejuif, France, 3CEIRDF, Ery, France, 4Inserm U1138, Paris, France, 5Imperial College London, London, UK.

Background and aims: Pathogenic mutations in key genes involved in the leptin-melanocortin pathway (critical for the control of food intake) are well-established causes of monogenic forms of obesity. Recently, the melanocortin-4 receptor (MC4R) agonist setmelanotide has been developed to efficiently treat obese patients with monogenic mutations in POMC and LEPR. Its relevance to other forms of monogenic obesity is currently discussed. PCSK1 encodes the PC1/3 enzyme that is involved in this pathway. Bi-allelic pathogenic mutations in PCSK1 lead to early-
onset obesity associated with severe endocrinopathy, but the clinical impact of heterozygous pathogenic PCSK1 mutations on obesity is still elusive. We performed large-scale functional genetic studies to clarify the link between heterozygous PCSK1 mutations and obesity.

**Materials and methods:** All 14 coding exons of PCSK1 were sequenced in 10,000 individuals (including obese and/or diabetic patients and controls) by next-generation sequencing. The detected heterozygous variants were created by mutagenesis and inserted into plasmids. Functional assays of each variant were performed in HEK293 cells: enzymatic activity was analysed using a fluorescent PC1/3 substrate and protein expression in cell lysates was studied by western blotting. Then, we determined different pathogenicity groups of these rare variants by clustering them through machine learning (k=5). Finally, we compared the pathogenicity of PCSK1 variants predicted by *in silico* REVEL (rare exome variant ensemble learner) test with results of *in vitro* analyses.

**Results:** We identified 66 rare heterozygous variants of PCSK1 (minor allele frequency < 1%). The variants were classified into 5 groups (A-E) based on their enzymatic activity, compared to the activity of the wild-type protein. The 17 variants in group A had complete loss of enzymatic activity whereas group B included 11 variants with partial loss of enzymatic activity. These loss of function variants were located mostly in catalytic domain but also in the prodomain and P domain of PC1/3. They strongly affect the structure of the protein preventing the expression of the mature active form of PC1/3. We found that class A variants increased the risk of developing obesity by 6-fold in both children (P=0.097; OR=6.0) and adults (P=0.038; OR=5.6). In contrast, class B variants were not associated with obesity risk (P=0.86; OR=1.1). Importantly, we observed a lack of sensitivity and specificity of the large-ensemble learner) test with results of *in vitro* tools predicting putative heterozygous pathogenic PCSK1 mutations. Indeed, the pathogenic variants predicted by REVEL showed 4 false negatives and 11 false positives compared to the results of *in vitro* functional assays.

**Conclusion:** Our results strongly suggest that only obese individuals carrying PCSK1 heterozygous mutations proven pathogenic through *in vitro* functional testing (i.e. category A) may be eligible for setmelanotide treatment, but not the carriers of mutations with only intermediate *in vitro* deleterious effect. Therefore, *in vitro* tests are required following the molecular diagnosis of rare heterozygous PCSK1 mutations before initiating expensive medication.

**Disclosure:** L. Folon: None.

### 64

**Obesity specific N6-methyladenosine (m6A) RNA modification in human adipose tissue**

T. Ronningen1, Y. Zeng2, M. Visnovska1, M.B. Dahl1, J. Wang3, L. la Cour Poulsen4, J.A. Kristinsson2, T. Mala2, J.K. Hertel2, J. Hjelmesth2, T.G. Valderhaug2, H.H. He3, Y. Böttcher1

1Department of Clinical Molecular Biology (EpiGen), Akershus University Hospital, Lørenskog, Norway, 2Princess Margaret Cancer Centre, Toronto, Canada, 3Department of Clinical Molecular Biology (EpiGen), University of Oslo, Oslo, Norway, 4Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway, 5Morbid Obesity Centre, Vestfold Hospital Trust, Tønsberg, Norway, 6Department of Endocrinology, Akerhus University Hospital, Lørenskog, Norway.

**Background and aims:** Omental visceral adipose tissue (OVAT) has distinct gene expression and epigenetic profiles compared to subcutaneous adipose tissue (SAT), contributing to metabolic dysfunction. Post-transcriptional RNA modifications such as N6-methyladenosine (m6A) play important roles in regulating RNA metabolism. The FTO gene, whose genetic variants associate with obesity, encodes one of two known m6A demethylases, suggesting a mechanistic role for m6A in obesity. The aim of this study was (i) to map m6A signatures genome wide in paired samples of human adipose tissue and primary adipocytes, (ii) to identify obesity specific signatures and (iii) to decipher whether m6A discriminates for its depot of origin.

**Materials and methods:** RNA was extracted from intra-individually paired biopsies of SAT and OVAT from patients with obesity (BMI >35, n=10) and normal-weight controls (BMI <25, n=3). RNA was also obtained from primary adipocytes from 5 patients with obesity. M6A signatures were mapped using methylated RNA immunoprecipitation combined with next generation sequencing (meRIP-seq). meRIP-seq data were analyzed using established bioinformatics pipelines; peak calling was performed using MeTPeak and differential methylation analysis was performed using RADAR.

**Results:** We identified an average of ~6000 mRNA transcripts containing m6A in OVAT and SAT. Of those, we identified a number of genes (n=100) with differential m6A methylation in patients with obesity compared to normal weight controls. Further, by intersecting gene lists with m6A data from primary adipocytes, we also identified whether the specific m6A signature originates from adipocytes or cells from the stromal vascular fraction. Whilst most of the ~6000 methylated transcripts were conserved between SAT and OVAT, we identified a catalogue of genes (n=338) showing depot specific methylation.

**Conclusion:** We here present the first genome wide mapping of m6A in paired samples of human adipose tissue, identifying several novel targets linking m6A to obesity. Functional analyses of target genes will further elaborate on their role in obesity and metabolic dysfunction.

**Supported by:** South-Eastern Norway Regional Health Authority

**Disclosure:** T. Ronningen: None.
males compared to females (OR per SD of genetically-predicted WHR (95% CI): 1.51 (1.32 - 1.72); genetically-predicted BMI (95% CI): 1.29 (1.20 - 1.38); genetically-predicted FMI (95% CI): 1.26 (1.20 - 1.32), \( P \) for all analyses and comparisons < 0.05). Unlike BMI or FMI, the relationship between genetically-determined WHR and all-cause mortality was consistent across all percentiles of BMI, FMI, or WHR (\( P > 0.05 \)).

**Conclusion:** In contrast to BMI, WHR has the strongest causal effect on risk of mortality regardless of the levels of adiposity and body composition, but show evidence of differential effects according to sex. Clinical recommendations and interventions should prioritize setting healthy WHR targets for males and females rather than general BMI targets. More precise recommendations for body shape may make a significant difference in disease burden and deaths due to excess of adiposity.

*Supported by: OGS-M*

*Disclosure: I. Khan: None.*

---

**66**

**Single-cell RNA sequencing of human visceral adipose tissue identifies new macrophage clusters in health and obese type 2 diabetes**

Y. Yuan, H. Wang, H. Sun, Y. Bi; Department of Endocrinology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.

**Background and aims:** Adipose tissue macrophages are closely associated with type 2 diabetes mellitus (T2DM). However, in the development of obese T2DM, the atlas of human visceral adipose tissue macrophages and its evolvement remain unrevealed. This study aims to decipher the composition of human visceral adipose tissue macrophages and investigate their roles in T2DM.

**Materials and methods:** Non-obese non-T2DM, obese non-T2DM and obese T2DM subjects were enrolled for single-cell RNA sequencing of the stromal vascular fraction (SVF) of visceral adipose tissue. The sequencing data was analyzed to identify and annotate macrophage clusters and functional analysis was performed. Weighted gene correlation network analysis (WGCNA) was performed to reveal the distinct genetic and functional changes of macrophage clusters in obesity and T2DM. Flow cytometry was employed to validate the macrophage clusters, and to evaluate their abilities of lipid-buffering and tumor necrosis factor-\( \alpha \) (TNF-\( \alpha \)) production.

**Results:** Four macrophage clusters were identified in human visceral adipose tissue, including 1) perivascular macrophages (PVMs) with potential angiogenic and anti-inflammatory capacities. 2) Phagocytic macrophages (PMs) with endocytic potentials. 3) Monocyte-derived macrophages (MMs) that could regulate inflammatory response and the activation of T cells; 4) Lipid-associated macrophages (LAMs) that harbored lipid metabolic potentials. PVMs were located adjacent to blood vessels, while the other three clusters infiltrated between adipocytes, with PMs forming crown-like structures (CLSs). Among the four macrophage clusters, PVMs, MMs and LAMs have been reported previously, while PMs were discovered and defined for the first time. Flow cytometric analysis revealed that the levels of PMs raised significantly in T2DM patients, and their levels positively correlated with fasting blood glucose and HbA1c. Further functional experiments suggested that PMs had the highest lipid-uptake capacities and intracellular lipid content among the four macrophage clusters, which increased significantly in obese non-T2DM subjects and dropped in obese T2DM subjects. In addition, PMs had the highest levels of TNF-\( \alpha \)+ cells, which were significantly higher in obese non-T2DM and obese T2DM subjects as compared to non-obese non-T2DM subjects.

**Conclusion:** The study analyzed the atlas of human visceral adipose tissue macrophages in non-obese non-T2DM, obese non-T2DM and obese T2DM states for the first time. Four distinct macrophage clusters were identified, among which PMs were newly discovered and defined. Flow cytometric analysis revealed that PMs may be closely involved in the pathogenesis of T2DM. The results deepened the understanding of human visceral adipose tissue macrophages and laid foundations for the understanding of the role of adipose tissue macrophages in obesity and T2DM, as well as the development of novel therapeutical strategies targeting obese T2DM.

*Supported by: NSFC, China*

*Disclosure: Y. Yuan: None.*
Background and aims: Heritability of serum C-peptide (CP) in type 1 diabetes (T1D) is 26%. Two independent genome-wide association studies (GWAS) of CP in T1D have identified multiple loci in the HLA region, insulin gene (INS), and a locus on chromosome 1. Although some of these loci overlap with those for T1D, some are independent. However, the identified loci together account for only a small proportion of CP variation. Here, we performed a large meta-GWAS of CP, including studies from the two prior GWAS, to improve the statistical power and detect new loci. We also investigated the association of T1D genetic risk score (GRS) at the HLA region with CP.

Materials and methods: 7,248 unrelated European subjects with T1D from four studies were included: the Scottish Diabetes Research Network Type 1 Bioresource (SDRNT1BIO) (n = 4,824, random CP), Diabetes Control and Complications Trial (DCCT) (n = 1,304, fasting CP), Coronary Artery Calcification in Type 1 Diabetes (CACTI) (n = 529, fasting CP) and Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) (n = 591, random CP). GWAS genotyping was performed with Illuma arrays. Ungenotyped variants were imputed using TOPMed, the largest imputation reference panel to date, which imputes lower frequency variants with better quality than previous panels. SNPs with minor allele frequency >0.01 and high imputation quality (INFO >0.80) present in both SDRNT1BIO and DCCT (the two large cohorts) were included in the meta-GWAS (n = 8,150,645). Classical HLA alleles, amino acid sequences and additional SNPs in the HLA region were imputed using multi-ethnic HLA reference panel on Michigan imputation server. Study-specific effect sizes and standard errors for scores and/or loci were estimated by multiple linear regressions of log (CP) with adjustment for covariates (sex, age at diagnosis, T1D duration). Meta-GWAS analysis was performed using METAL v1.5 weighting effect sizes using the inverse of the standard errors. We also tested association of T1D GRS at the HLA region with CP. T1D GRS at the HLA region was explored in total and separately for DR-DQ and non-DR-DQ haplotypes. Non-DR-DQ haplotypes were divided into class I, DPB1, and intergenic regions between DRB1 and DQA1 which do not track classic HLA alleles but regulate class II gene expression.

Results: We identified association at the HLA region (rs9271349, AA>G, Chr6:32616053, β (SE) = 0.57 (0.08), p = 1.62E-12). In the HLA imputation, DRB1*06:02 (β (SE) = 0.90 (0.11), p = 1.18E-16) and DRB1*15:01 (β (SE) = 0.70 (0.10), p = 1.68E-12) haplotypes were associated. Five amino acid changes within HLA-DRB1, HLA-DQB1 and HLA-A reached the genome-wide significance threshold. DR-DQ GRS was not associated with CP whereas non-DR-DQ GRS was associated with lower CP levels in all four studies: SDRNT1BIO (β = -0.17, p = 2.00E-8), DCCT (β = -0.06, p = 0.045), CACTI (β = -0.08, p = 0.015) and WESDR (β = -0.10, p = 6.44E-4). The signal mostly came from class I haplotypes (A2*2402, B*3906 and A*2902); and intergenic regions (rs9271346, rs116522341 and rs12819394). HLA-A*2402, HLA-B*3906 and intergenic GRSs were associated with lower CP whereas HLA-A*2902 GRS was associated with higher CP.

Conclusion: There is heterogeneity of T1D HLA variants in terms of their associations with CP. T1D DR-DQ GRS is not associated with CP. This could eventually provide insight into mechanisms and opportunities to preserve beta cell function.

Supported by: MRC: MR/T032340/1; CHRP: UCD-170583

Disclosure: A.D. Paterson: None.

Background and aims: The risk of stroke is markedly increased in type 1 diabetes. In addition, individuals with type 1 diabetes experience stroke at a considerably younger age. Despite the elevated risk of stroke, few studies have assessed genetic factors influencing stroke risk in type 1 diabetes. Therefore, our aim was to identify genetic risk factors for stroke in a genome-wide association study (GWAS).

Materials and methods: This study included 4,916 individuals with type 1 diabetes from the Finnish Diabetic Nephropathy (FinnDiane) Study with data available on stroke. Cases had experienced a stroke based on Finnish nationwide registry data (ICD: 160, 161, 162, 163, 164), with majority of the events verified from medical records by a neurologist. Controls were required to be older than 35 years and have a diabetes duration of more than 20 years. Genotyping was performed with Illumina HumanCoreExome chips at the University of Virginia, US. Imputation was done with Beagle at the Finnish Institute for Molecular Medicine (FIMM), using a Finnish reference panel (SISu v.3). We performed GWAS with the score test adjusted for the calendar year of diabetes onset, sex, and genotyping batches using the RVTESTS software. We included 8,812,836 variants with minor allele frequency (MAF) >1% and good imputation quality (r² >0.60).

Results: One locus, containing 8 variants, was significant at a genome-wide threshold (p<5×10⁻8) and associated with stroke in type 1 diabetes (lead variant: rs146444827, MAF=1.2%, OR=4.25, p=2.2×10⁻8). The variants were located on chromosome 16 near or in the intronic region of the ADAMTS18 gene—a member of the ADAMTS gene family containing genes important in angiogenesis and coagulation. Variants within or near this gene have previously been associated with human cortical structure in brain MRI, brain sulcal depth, and body mass index (BMI) in GWAS. Furthermore, two other variants were suggestively associated with stroke (p<5×10⁻7). These were located on chromosome 14 within the NRXV3 gene, which has also been associated with BMI and specifically expressed in the brain (rs77936402, MAF=1.8%, OR=2.91, p=3.7×10⁻7), and on chromosome 1 in the PTPR gene (rs45968355, MAF=1.2%, OR=3.77, p=1.7×10⁻7).

Conclusion: We have performed the largest GWAS to date on stroke in type 1 diabetes, and identified one new locus near ADAMTS18 gene, and two additional loci suggestively associated with stroke.

Supported by: EFSD/Sanofi European Diabetes Research Programme in Macrovascular Complications

Disclosure: E.H. Dahlstrom: None.
Background and aims: Type 2 diabetes (T2D) results from progressive pancreatic beta cell failure. It is tightly related with glycemic traits, e.g. HbA1c, fasting and 2h post-challenge glucose and fasting insulin. Type 1 diabetes (T1D) results from an autoimmune destruction of beta cells. In both diseases genetic factors play a key role, but how genetic variants lead to beta cell failure remains poorly understood. Here, we analyzed the relationship between genetic variants associated with T2D, T1D, and glycemic traits (from genome-wide association studies, GWAS) and cis-expression quantitative trait loci (eQTL) in human islets. We developed a novel colocalization approach to assess whether genetic variants associated with traits share association signals with gene expression, leveraging a dataset of >400 samples.

Materials and methods: Colocalization analyses were performed between human islet eQTL from TIGER (http://tiger.bsc.es/) and GWAS from DIAMANTE (T2D), Type 1 Diabetes Genetics Consortium and MAGIC (glycemic traits). A novel colocalization method was developed that prioritizes candidate variants prior to testing with color R package. It shortlists candidate variants with specifically tailored rank-rank hypergeometric overlap analysis detecting linkage disequilibrium-induced overlap of variants. It identifies overlapping signals when multiple GWAS SNPs exist in the region of interest, a scenario in which color performs suboptimally. As a further improvement, the shortlisting method uses eQTL effect (up- or downregulation) and GWAS directions (increasing or decreasing risk) to further reduce the analyzed set of variants. The function of some of the novel genes was investigated in human islets and EndoC-bH1 cells.

Results: In total, 158 colocalizations were identified: 27 for T1D, 84 for T2D, 21 for fasting glucose, 21 for fasting insulin, 4 for 2h post-challenge glucose, 1 for fasting insulin. The novel shortlisting method followed by color identified 58 new colocalizations of GWAS and eQTL SNPs that were not detected by color alone. Out of the 84 T2D eGenes, 16 also show colocalization with at least one additional glycemic trait. Five variants with low minor allele frequency (MAF<0.01) colocalized for T2D. Among them we discovered colocalization between MYOSC expression and T2D risk (MAF=0.05), with the protective allele being associated with increased MYOSC expression. A well-known eQTL for ADCY5 colocalized with T2D and all glycemic traits. T1D and T2D co-localizations were detected in the intronic region of GLIS3 that has been reported to modulate apoptosis in beta cells in both diseases. A FUT2 eQTL colocalized with a T1D GWAS signal; with the T2D protective allele being associated with increased FUT2 expression. Interestingly, infection of human beta cells by coxsackievirus B1 decreased expression. A well-known eQTL for GLIS3 that has been reported to affect diabetes clinical criteria. Genetic screening may be useful for precision medicine, as GLIS3 deficiency may severely impair insulin secretion and seem to respond to sulfonylureas as MODY1 and 3 do.

Conclusion: We conclude that heterozygous P/LP variants of GLIS3 strongly increase the risk to develop T2D, and can not be clinically distinguished from the other common forms of T2D using classic monogenic diabetes clinical criteria. Genetic screening may be useful for precision medicine, as GLIS3 deficiency may severely impair insulin secretion and seem to respond to sulfonylureas as MODY1 and 3 do.

Disclosure: S. Meulebrouck: None.

70

The impact of rare pathogenic variants of GLIS3 on type 2 diabetes


Inserm UMR1283, CNRS UMR8199 - EGIS, Lille, France; Inserm U1018, Villejuif, France; INserm U1138, Paris, France; Imperial College London, London, UK.

Background and aims: Type 2 diabetes (T2D) is due to a combination of environmental and genetic factors. There are monogenic forms, caused by a mutation in a single gene, that are usually (but not always) more severe and appear earlier than polygenic forms. Among the more than 30 genes responsible for monogenic diabetes, the biallelic pathogenic mutations of GLIS3, which encodes a key transcription factor for β cell lineage, are known to cause a rare autosomal recessive syndromic form of neonatal diabetes. We hypothesized that pathogenic heterozygous GLIS3 variants could also be associated with a dominantly transmitted form of monogenic diabetes or even contribute to common T2D.

Materials and methods: We sequenced GLIS3 in 5,471 individuals. The identified rare heterozygous variants were then functionally investigated through luciferase assays based on their ability to bind to the promoter region of the INS gene and activate its transcription. The pathogenicity of each variant was then assessed by combining our luciferase results with the other criteria from the American College of Medical Genetics and Genomics (ACMG). Finally, we performed adjusted association studies between the cluster of pathogenic or likely pathogenic (P/LP) variants and T2D risk, and we analyzed the phenotype of carriers and non-carriers.

Results: We identified 105 rare heterozygous variants of GLIS3. Through luciferase assays, we subsequently found 49 loss-of-function variants, presenting a decrease in luciferase activity compared to the wild-type GLIS3. By combining our functional results with the other ACMG criteria, we identified 18 P/LP variants. These variants were enriched at the C-terminus of the protein, containing its transactivation domain. Finally, the association studies showed that these P/LP variants were strongly associated with T2D risk (P = 0.003; OR = 3.91). Strikingly, all the T2D patients carrying a rare P/LP GLIS3 variant were treated with sulfonylureas, suggesting an early alteration of insulin secretion that responded to this class of medication. Importantly, both age of onset of diabetes and body mass index were similar between carriers and non-carriers.

Conclusion: We conclude that heterozygous P/LP variants of GLIS3 strongly increase the risk to develop T2D, and can not be clinically distinguished from the other common forms of T2D using classic monogenic diabetes clinical criteria. Genetic screening may be useful for precision medicine, as GLIS3 deficiency may severely impair insulin secretion and seem to respond to sulfonylureas as MODY1 and 3 do.

Disclosure: S. Meulebrouck: None.
with Maturity Onset Diabetes of the Young (MODY) in the Greenlandic population.

Materials and methods: Using combined data from Greenlandic population cohorts of 4497 individuals, including 448 whole genome sequenced individuals, we screened 14 MODY genes for known and novel variants. We functionally characterised an identified novel variant and assessed its association with diabetes prevalence and cardiometabolic traits and population impact.

Results: We identified a novel HNF1A variant with an allele frequency of 1.9% in the Greenlandic Inuit and absent elsewhere. Functional assays indicate that it prevents normal splicing of the gene. The variant caused lower 30-min insulin (β=-232 pmol/L, βSD=-0.695, P=4.43×10^-4) and higher 30-min glucose (β=1.20 mmol/L, βSD=0.441, P=0.0271) during an oral glucose tolerance test. Furthermore, the variant was associated with type 2 diabetes (OR 4.4, P=7.24×10^-6) and HbA1c (β=0.11 HbA1c%, βSD=0.21, P=0.0052). The variant explained 2.5% of diabetes variance in Greenland.

Conclusion: The reported variant has the largest population impact of any previously reported variant within a MODY gene. Together with the recessive TBC1D4 variant, we show that close to 1 in 5 cases of diabetes (18%) in Greenland has a monogenic diabetes aetiology compared to 1-3% in large populations.

Supported by: Novo Nordisk Foundation, Independent Research Fund Denmark, and Karen Elise Jensen’s Foundation.

Disclosure: M.E. Jørgensen: None.

A common variant in the ketohexokinase gene is associated with fructosuria and cardiometabolic outcomes

A.M. Buziau1, C.G. Schalkwijk1, J.L.J. Scheijen1, P.I.H. Simons1, C.J.H. van der Kallen1, S.J.P. Eussen1, N.C. Schaper2, P.C. Dagnelie1, M.M.J. van Greevenbroek1, A. Wesselius2, C.D.A. Stehouwer2, M.C.G. Brouwers2; 1Internal Medicine, Maastricht University, 2Maastricht University Medical Center+, Maastricht, Netherlands.

Background and aims: There is an ongoing discussion on whether fructose per se is disadvantageous for cardiometabolic health. Recently, pharmacological inhibition of ketohexokinase (KHK), the first enzymatic step of fructolysis, was shown to reduce intrahepatic lipid content in humans. The study of individuals carrying functional variants in the KHK gene will provide more insight into the lifelong effects of inhibition of KHK, as these individuals have been exposed from birth to a KHK protein with less enzymatic activity. The aims of the present study were: 1) to study whether a common missense variant in KHK (rs2304681) is a functional variant that affects fructosuria (similar to pharmacological inhibition of KHK); and 2) to study the association between rs2304681 and cardiometabolic outcomes.

Materials and methods: First, linear regression analyses were performed to study the association between rs2304681 and 24h urinary fructose levels (quantified by tandem mass spectrometry), with adjustment for age, sex, and type 2 diabetes (T2D), in the Maastricht Study, a population-based cohort. Second, we used summary-level data on the association of rs2304681 with non-alcoholic fatty liver disease, T2D, hypertension, and myocardial infarction, obtained from publicly available databases.

Results: First, the rs2304681 minor A allele (frequency: 0.36) was associated with higher 24h urinary fructose levels (unstandardized beta: 0.064; 95% CI: 0.027-0.100; n=1,471). Second, the rs2304681 minor A allele protected from hepatic steatosis (OR: 0.972; 95% CI: 0.957-0.988; n=36,703; UK Biobank), T2D (OR: 0.985; 95% CI: 0.975-0.999; n=1,331,670; fixed-effects meta-analysis in the AGENT and the European DIAMANTE cohorts) and myocardial infarction (OR: 0.976; 95% CI: 0.961-0.992; n=583,191; fixed-effects meta-analysis in the CARioGRAMplusC4D and the UK Biobank cohorts). Two studies both showed a protective effect on the risk of hypertension (OR: 0.988; 95% CI: 0.976-0.999; n=440,285; UK Biobank; and Z-score: -2.59; p = 0.01; n=192,763; the combined CHD Exome+, ExomeBP, and GoT2D cohorts).

Conclusion: Lifelong impairment of KHK activity (reflected by rs2304681) is associated with fructosuria and protection from cardiometabolic disease. These findings suggest that fructose per se has harmful cardiometabolic effects, which may be mitigated by pharmacological inhibition of KHK.

Supported by: Dutch Diabetes Research Foundation
Disclosure: A.M. Buziau: None.
OP 13 Beyond type 1 and type 2

Clusters of prediabetes and type 2 diabetes stratify all-case mortality in a cohort of participants undergoing invasive coronary diagnostics

K. Prystupa1,2, G.E. Delgado3,4, A.P. Moissl3,5, M.E. Kleber2,6, M. Hen1,2, A.L. Birkenfeld1,2, A. Fritsche1,2, W. März1,7, R. Wagner1,2

1Department of Internal Medicine IV, Division of Endocrinology, Diabetology and Nephropathy, University of Tuebingen, Tuebingen, 2Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, 3Vth Department of Medicine (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Diabetology), Medical Faculty Mannheim, University of Heidelberg, Mannheim, 4Center for Preventive Medicine and Digital Health Baden-Württemberg (CPDBW), Medical Faculty Mannheim, Heidelberg University, Mannheim, 5Institute of Nutritional Sciences, Friedrich Schiller University Jena, Jena, 6SYNLAB MVZ für Humangenetik Mannheim GmbH, Mannheim, 7SYNLAB Academy, SYNLAB Holding Deutschland GmbH, Mannheim, Germany.

Background and aims: The risk for complications and mortality among patients with type 2 diabetes (T2D) is heterogeneous. Different trajectories can be identified in the prediabetic state, which comprises heterogeneous metabolic clusters. It is not known whether such pathophysiological clusters of prediabetes and diabetes affect survival in at-risk persons being evaluated for coronary heart disease.

Materials and methods: The LURIC Study recruited patients referred for coronary angiography at a median age of 63 (IQR 56-70) who have since been followed up for an average of 20 years. Clustering of 1269 subjects without diabetes was performed with oGTT-derived glucose and insulin; fasting triglyceride, high-density lipoprotein, BMI, waist, and hip circumference. Patients with T2D (n=794) were clustered using age, BMI, glycemia, homeostasis model assessment, and islet autoantibodies. Associations of clusters with mortality were evaluated using Cox regression.

Results: Individuals without diabetes were classified into six subphenotypes, with 884 assigned to subjects at low-risk (cluster 1,2,4) and 385 at high-risk (cluster 3,5,6) for diabetes. We found significantly increased mortality in clusters 3 (hazard ratio (HR) 1.42), 5 (HR 1.43), and 6 (HR 1.46) age-, BMI-, HbA1c- and sex-adjusted. In the T2D group, 508 were assigned to mild age-related diabetes (MARD), 183 to severe insulin-resistant diabetes (SIRD), 84 to mild obesity-related diabetes (MOD), 19 to severe insulin-deficient diabetes (SIDD). Compared to the low-risk non-diabetes group, crude mortality was not different in MOD. Increased mortality was found for MARD (HR 2.2), SIRD (HR 2.2), and SIDD (HR 2.5).

Conclusion: Metabolic clustering successfully stratifies survival even among persons already undergoing invasive coronary diagnostics. Novel clustering approaches based on glucose metabolism can identify persons who require specific attention as they have an increased mortality risk.

Supported by: BMGF
Disclosure: K. Prystupa: None.

74

Novel clusters of prediabetes and their association with progression and regression: a 3-year follow-up study

Y. Liu, M. Sang, S. Qiu, Z. Sun;
Southeast University, Nanjing, China.

Background and aims: Cluster analysis may assist in stratifying heterogeneous clinical presentations of prediabetes. However, the association of cluster-based subgroups of prediabetic with its progression to diabetes and regression to normoglycemia remains unclear. This study was aimed to address this issue with novel clusters of prediabetes derived from four parameters.

Materials and methods: We developed a k-means clustering model in participants with prediabetes (N=4,138) from the SENSIBLE and SENSIBLE-Addition studies, based on body mass index (BMI), age, triglyceride-and-glucose (TyG) index, and hemoglobin A1c (HbA1c). TyG index was used to assess insulin resistance. Of the included participants with prediabetes at baseline, 1,629 were followed-up for 3 years. Prediabetes was defined as impaired fasting glucose and/or impaired glucose tolerance based on World Health Organization 1999 criteria. Logistic regression analyses were performed to obtain the odds ratios (ORs) and 95% confidence intervals (CIs).

Results: Three clusters were identified, with cluster 0, 1 and 2 accounting for 28.7%, 30.6% and 40.7%, respectively. Participants with prediabetes were featured by the youngest and the lowest HbA1c in cluster 0, the highest BMI and TyG index in cluster 1, and the oldest and the lowest BMI in cluster 2. After the adjustment for gender, ethnic groups, serum uric acid, total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and estimated glomerular filtration rate, cluster 1 (OR 3.61, 95% CI: 1.87-4.84) were both associated with increased risk of progression to diabetes when compared with cluster 0. Moreover, cluster 1 and cluster 2 were both associated with decreased chance of regression to normoglycemia (OR 0.42, 95% CI: 0.31-0.57; and OR 0.48, 95% CI: 0.37-0.63, respectively).

Conclusion: Our cluster-based analysis showed that participants featured by older age and higher degree of insulin resistance, obesity, or insulin resistance had higher risk of progression to diabetes and lower risk of regression to normoglycemia. While young participants with sufficient attention to BMI and blood glucose management were more likely to regress to normoglycemia.

Supported by: the National Key R&D Program of China (2016YFC1305700)
Disclosure: Y. Liu: None.

75

Incidence of HbA1c-defined prediabetes and progression to type 2 diabetes: a nationwide study with routine care laboratory data

S.K. Nicolaisen1, R.W. Thomsen1, D. Witte2, H.T. Sørensen1, L. Pedersen1;

Springer
Antibody positive patients with type 2 diabetes who rapidly progress to insulin have similar characteristics and type 1 genetic risk scores as patients with type 1 diabetes.

Background and aims: New EASD/ADA guideline recommend testing islet autoantibodies in all clinically suspected adult-onset type 1 diabetes (T1D), including those treated as type 2 diabetes (T2D) with early progression to insulin, and advise that a positive islet antibody in this setting confirms type 1 diabetes. We assessed whether a positive islet autoantibody in the setting of initial treatment as type 2 diabetes and early progression to insulin confirmed the genetic and C-peptide progression characteristics of type 1 diabetes.

Materials and methods: In 1793 participants with recently diagnosed adult-onset diabetes (duration at recruitment <12 months, median 5 months) we compared the baseline characteristics, T1D genetic risk score (T1DGRS) and rate of loss of beta-cell function (annual urine c-peptide change) in patients with and without islet autoantibodies.

Results: Among 1,348 patients with recent-onset diabetes, T1DGRS was 14.1 (95% CI 13.7-14.5) and 13.9 (95% CI 13.5-14.4) in antibody negative and positive patients respectively (p=0.12). Similarly, the annual c-peptide change was -45% (95% CI -50,-41) in antibody negative patients and -40% (95% CI -44,-36) in antibody positive patients (p=0.05).

Conclusion: Antibody positive patients with type 2 diabetes who rapidly progress to insulin have similar characteristics and type 1 genetic risk scores as patients with type 1 diabetes.

Disclosure: V. Simpson: None.
monogenic diabetes in children, who were negative for T1D related auto-
antibodies (AAB) or positive only for low titer islet cell antibodies (ICA) at diagnosis.

**Materials and methods:** A next generation sequencing gene panel
including 42 genes was used to identify monogenic diabetes in partici-
pants of the Finnish Pediatric Diabetes Register, covering approximately
90% of newly-diagnosed diabetes in Finland (<16 years). Five AAB
(ICA, IAA, GADA, IA-2A, ZnT8A) and HLA class II genotypes were
analysed at diagnosis.

**Results:** Out of 6482 participants initially registered with T1D, we
sequenced DNA for 152 (2.3%) testing negative for all AAB and 49
(0.8%) positive only for ICA ≤10 JDFU (ICA-low). Monogenic diabetes
was revealed in 19 (12.5%) of the AAB-negative and 2 (4%) of the
ICA-low individuals. The genes involved were GCK, HNF1A, HNF4A,
HNF1B, INS, KCNJ11, RFX6, LMNA and WFS1. None of these patients
had ketoacidosis at diagnosis or carried an HLA genotype conferring high
risk for T1D. The diagnosis of monogenic diabetes led to a change in the
treatment of many patients. A switch from insulin treatment to oral medi-
ication has been successful in patients with variants in HNF1A, HNF4A or
KCNJ11, significantly improving their glycemic control and quality of
life. The figure illustrates continuous glucose monitoring before and after
a transfer from insulin pump to sulfonylurea in a patient with KCNJ11
variant. Next, we will proceed to exome sequencing of the AAB-negative
children without genetic diagnosis.

**Conclusion:** More than 10% of AAB-negative children had a genetic
variant associated with monogenic diabetes. Because diagnosis of mono-
genetic diabetes can lead to major changes in the treatment, we recommend
referring all children with newly-diagnosed diabetes who are AAB-nega-
tive to genetic testing. Low-titer ICA in the absence of other AAB does
not always indicate a diagnosis of T1D.

**Disclosure:** M. Harsunen: None.

78

**Penetration of MODY is substantially lower in clinically unselected
cohort: important implications for opportunistic genomic testing**

K. Patel1, U. Mirshahi2, K. Coleclough3, C. Wright4, A. Wood1, R.
Beaumont1, T. Laver1, R. Stahl2, A. Golden2, J. Goehringer2, Geisinger-Regeneron DiscovEHR Collaboration, T. Frayling4, A.
Hattersley1, D. Carey2, M. Weedon1; 
1University of Exeter, Exeter, UK, 2Geisinger Health System, Danville,
USA, 3Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.

**Background and aims:** Accurate estimates of penetrance are needed for
counselling of individuals with a mutation in common MODY (Maturity
Onset Diabetes of the Young) genes. We aimed to comprehensively
assess the penetrance of the three most common causes of MODY
(HNF1A, HNF4A and GCK) in large genotype-first (clinically unselect-
ed) and phenotype-first (clinically selected) cohorts.

**Materials and methods:** We analysed clinical and genetic sequencing
data from four different cohorts: 1742 probands referred for clinical
MODY testing; 2194 family members of the MODY probands; clinically
unselected 132,194 individuals from an American hospital-based cohort;
and 198,748 individuals from a UK population-based cohort.

**Results:** Age-related penetrance of diabetes for pathogenic variants in
HNF1A and HNF4A was substantially lower in the clinically unselected
cohorts compared to clinically referred probands (ranging from 32% to
98% at age 40yrs for HNF1A, and 21% to 99% for HNF4A). The back-
ground rate of diabetes, but not clinical features or variant type, explained
the reduced penetrance in the unselected cohorts. In contrast, the pene-
trance of mild hyperglycaemia for pathogenic GCK variants was similarly
high across cohorts (ranging from 89 to 97%) despite substantial variation
in the background rates of diabetes.

**Conclusion:** Penetration of HNF1A/HNF4A-MODY but not GCK-
MODY is substantially lower in the genotype-first approach and has
important implications for opportunistic screening during genomic test-
ing. Our finding suggests the need to tailor genetic interpretation and
counselling for individuals based on the context in which a pathogenic
variant was identified.

**Supported by:** Wellcome Trust, MRC

**Disclosure:** K. Patel: None.
OP 14 Exercising your tissues in shape

79 Does exercise matter? The effects of different volumes of exercise on beta cell function in patients with newly diagnosed type 2 diabetes

M. Lyngbæk1, G. Legaard3, N. Nielsen1, T. Almdal2, M. Ried-Larsen1, K. Karstoft2

1Centre for Physical Activity Research, Copenhagen University Hospital - Rigshospitalet; 2Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

Background and aims: Dietary weight loss may lead to improved beta-cell function (disposition index: DI = insulin sensitivity x insulin secretion) in persons with type 2 diabetes (T2D). However, the role of exercise in adjunct to diet therapy remains unclear. Thus, we performed a study assessing beta-cell function both at supraphysiological conditions using the gold standard hyperglycemic clamp, and at physiological conditions using a mixed meal tolerance test. We expected to observe a dose-dependent improvement in beta-cell function when adding exercise to dietary weight loss.

Materials and methods: Persons with T2D duration < 7 years and obesity/overweight were randomized 1:1:1:1 (stratified by sex) to either 16 weeks of 1) Standard care 2) Dietary intervention 3) Dietary intervention + exercise 3 times/week 4) Dietary intervention + exercise 6 times/week. The exercise interventions consisted of both aerobic and resistance training. The dietary intervention aimed at a 25% caloric deficit and weight loss. The primary outcome was the change in beta-cell function assessed with clamp-derived late-phase disposition index. Major secondary outcomes included clamp- and mixed meal-derived changes in beta-cell function, insulin secretion, and insulin sensitivity from baseline to 16-weeks follow-up. The full protocol has been published.

Results: We randomized 82 participants (35% females, mean age (SD) of 58.2 (9.8) years, BMI 33.1 (3.7) kg/m², median T2D duration (IQR) of 4.0 (1.9 to 5.5) years. Adherence to the diet (25-30% energy reduction) and exercise (>85%) was similar across intervention groups. Five persons (6%) were lost to follow-up. From the hyperglycemic clamp we observed improvement in late-phase disposition index in all three intervention groups. The mean difference (MD) from standard care (95% confidence interval) was 58 (16 to 116)%, 105 (49 to 182)% and 137 (73 to 225)% for diet only, moderate volume exercise, and the high volume exercise, respectively. While the improvement was larger in the high volume exercise group compared to diet group (MD (95% CI): 50 (10 to 104)%), no difference where observed between the exercise groups (high volume exercise vs. moderate volume exercise MD (95% CI): 16 (-16 to 59)% or between moderate volume exercise and the diet group (MD (95% CI): 29 (-5 to 77)%). No differences in glucose-stimulated insulin secretion were observed between the groups. Improvements in insulin sensitivity followed a similar pattern as observed for the disposition index. The observations during the meal test confirmed the findings from the hyperglycemic clamp.

Conclusion: Sixteen weeks of high volume of exercise in combination with dietary weight loss improves beta-cell function more than standard care or diet alone in persons with T2D. However, there was no significant difference between moderate and high volume of exercise in beta-cell function, suggesting that increasing exercise volume from 3 to 6 times/week, may not amplify the beta-cell function. The improvement in beta-cell function was mainly mediated by improved insulin sensitivity, whereas adding exercise to the dietary intervention did not seem to increase glucose- or meal-stimulated insulin secretion beyond dietary weight loss alone.

Clinical Trial Registration Number: NCT03769883
Supported by: TryggFonden ID 124708 and Svend Andersen Fonden
Disclosure: M. Lyngbæk: Grants; Danish Diabetes Academy NNF17SA0031406.

80 Improved beta cell function following eight weeks high-intensity interval training combining rowing and cycling in type 2 diabetes

M.H. Petersen1, M.E. de Almeida2, E.K. Wentorff2, J.V. Stidsen1, N. Ortenblad1, K. Højlund1

1Steno Diabetes Center Odense; 2Department of Sports Science and Clinical Biomechanics, Odense, Denmark.

Background and aims: High-intensity interval training (HIIT) and recruitment of several muscle groups seem to enhance the effect of exercise training on glucose homeostasis in type 2 diabetes. However, the effect of these factors on beta-cell function in type 2 diabetes remains to be established. Here, we investigated the effect of a novel HIIT-protocol engaging upper and lower body muscles on the beta-cell function in individuals with type 2 diabetes compared with glucose-tolerant obese and lean controls.

Materials and methods: Fifteen obese men with type 2 diabetes, and age-matched, glucose-tolerant obese (n=15) and lean (n=18) men underwent an 8-week, supervised, HIIT-protocol combining rowing and cycling. Before and after the training period, the participants were evaluated by the Botnia clamp combining an IVGTT with a hyperinsulinemic-euglycemic clamp to measure first- and second-phase insulin secretion, insulin sensitivity and estimate beta-cell function adjusted for insulin sensitivity (disposition index).

Results: At baseline, insulin sensitivity was ~40% lower, and first-phase insulin secretion and the disposition index were >90% lower in men with type 2 diabetes compared with both lean and obese controls (all p<0.05). The HIIT-protocol induced a marked increase (~30-40%) in insulin sensitivity in all groups (all p<0.05). In patients with type 2 diabetes, this was accompanied by a large (>200%) but highly variable improvement in the disposition index (p<0.05), and a clinically relevant reduction in HbA1c (~4 mmol/mol). However, first-phase insulin secretion and the disposition index were still markedly reduced in men with type 2 diabetes (all p<0.05). In lean and obese controls, HIIT also improved (~30%) the disposition index (all p<0.05) and tended to reduce the second-phase insulin response (p<0.10). No group-differences were seen in the HIIT-induced responses on insulin secretion and insulin sensitivity.

Conclusion: HIIT combining rowing and cycling induces a large, but highly variable increase in beta-cell function adjusted for insulin sensitivity in men with type 2 diabetes, and to a numerically smaller extent in obese and lean glucose-tolerant men. However, after the HIIT-protocol, the beta-cell function was still severely impaired in men with type 2 diabetes, even when adjusted for the improvement in insulin sensitivity, suggesting that this component of type 2 diabetes is less reversible than insulin sensitivity.

Clinical Trial Registration Number: 17/31977
Supported by: Novo Nordisk Foundation and Sawmill owner Jeppe Juhl and wife Ovita Juhls Memorial Bursary
Disclosure: M.H. Petersen: None.

81 Exercise-responsive non-coding RNAs in the regulation of skeletal muscle metabolism

E. Caria1, I. Sen1, M. Katayama1, M. Savikj2, A.M. Abdelmoez2, J.A.B. Smith3, N.J. Pillow1, J.R. Zierath4, A. Krook1

1Department of Physiology and Pharmacology, Karolinska Institutet; 2Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Background and aims: Exercise triggers profound structural and metabolic adaptations in skeletal muscle. While this largely accounts for the benefits of exercise in the treatment or prevention of type 2 diabetes
(T2D), a detailed understanding of the molecular mechanisms involved remains unclear and warrants further research. Non-coding RNAs, such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), have recently emerged as important regulators of skeletal muscle physiology, and their expression in skeletal muscle is modulated by different exercise training programs. miRNAs are also incorporated into exosomes and secreted upon exercise to exert autocrine, paracrine and/or endocrine effects on tissue-specific or whole-body glucose homeostasis. Here, we aimed to identify exercise-responsive serum exosomal miRNAs (study A) or skeletal muscle-derived lncRNAs (study B) that mediate skeletal muscle adaptations to exercise training or acute exercise in individuals with or without T2D.

**Materials and methods:** In study A, young healthy individuals (n=12) underwent three weeks of aerobic exercise training, and serum was collected before and after for exosome isolation. Differentially expressed exosomal miRNAs were identified using a miRNA focus PCR panel. Functional characterization of the identified candidates was performed by transfecting primary human skeletal muscle cells with miRNA mimics, and effects on glucose metabolism were assessed using radiola-belled substrate assays. In study B, a separate cohort of individuals with T2D (n=19) or normal glucose tolerance (NGT, n=17) underwent 30 minutes of cycling exercise at 85% of their maximum heart rate. *Vastus lateralis* muscle biopsies were taken at baseline, immediately after, and three hours after exercise, and RNA sequencing was performed to identify differentially expressed, skeletal muscle-derived lncRNAs.

**Results:** In study A, exosomal miR-136-3p and miR-139-5p were increased in the circulation following three weeks of aerobic exercise training. Overexpression of miR-136-3p or miR-139-5p in human primary skeletal muscle cells elicited exercise-like metabolic effects, in terms of increased glucose uptake (miR-136-3p) and glycogen synthesis (miR-139-5p). In study B, a single bout of exercise changed the expression of more than 200 IncRNAs in the T2D group, whereas this number was much lower in the NGT group (24). We identified exercise-responsive lncRNAs that were co-expressed with metabolic genes and shortened the candidate list to 41 IncRNAs for screening, according to their fold-chang-es versus baseline and expression level in human myotubes.

**Conclusion:** Exosomal miR-136-3p and miR-139-5p are increased in serum following exercise training. Increased miR-136-3p or miR-139-5p lead to metabolic adaptations in skeletal muscle. An acute exercise bout alters the expression of several lncRNAs specifically in skeletal muscle from subjects with T2D. Further functional characterization of these candidates could provide mechanistic insights into the regulation of skeletal muscle metabolism by exercise, particularly in the context of T2D.

**Disclosure:** E. Caria: None.

---

**82 Exercise-induced crosstalk between immune cells and adipocytes in humans: role of oncostatin-M**

L. Dollet1, L.L. Lundell1, A.V. Chibalin1, L.A. Pendergrast3, N.J. Pillon1, K. Caidahl1, A.S. Deshmukh1, T. De Castro Barbosa4, M. Ryden1, R. Barres2, H. Wallberg-Henriksson1, J.R. Zierath1, A. Krook1; 1Department of Physiology and Pharmacology, Karolinska Institutet, Solna, Sweden; 2Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark; 3Department of Molecular Medicine and Surgery, Karolinska Institute, Solna, Sweden; 4Department of Medicine (H7), Karolinska Institutet, Stockholm, Sweden.

**Background and aims:** The discovery of novel exercise-regulated circu-latory factors has fueled interest in the role of organ-crosstalk, especially between skeletal muscle and adipose tissue in conferring the beneficial effects of exercise on insulin sensitivity and metabolism. We aimed to study the adipose tissue secretome in the context of exercise, and its potential role in inter- and intra-organ crosstalk in the response to exercise in individuals with normal glucose tolerance or type 2 diabetes.

**Materials and methods:** Men and women with normal glucose tolerance (NGT, n=20) or type 2 diabetes (T2D; n=28) performed an acute exercise bout (30 min cyclometer). Leg adipose tissue biopsies were collected from the participants at rest, immediately after exercise, and after 3h recovery for RNA sequencing analysis. Putative exercise-induced secreted proteins were selected, and cultured human adipocytes were exposed *in vitro* to recombinant candidate proteins. Phosphorylation arrays and immunoblot analysis were performed to track signalling events, and lipolytic responses were measured. Plasma measurements were performed using ELISA. THP1 human monocytes were differentiated *in vitro*, and gene expression of candidates were measured after acute exposure to an adrenergic agonist and conditioned media from contracted cultured myotubes.

**Results:** Transcriptomic analysis revealed time-dependent changes, with 712 and 893 genes altered post exercise, and 1353 and 4316 genes altered after recovery in adipose tissue from individuals with NGT or T2D respectively (FDR<0.05). The differential response in T2D adipose tissue was associated with a sustained activation of inflammatory pathways as shown by gene ontology analysis. Oncostatin-M was identified as one of the most upregulated putative secreted factors post exercise (logFC=3.35 and 2.95 for NGT and T2D). Oncostatin-M plasma level was increased after exercise in both groups (2-way ANOVA p<0.001). Exposure of isolated human adipocytes to recombinant oncostatin-M activated phospho-ERK and MAPK signalling and stimulated basal lipolysis (+47%, p<0.001). RNA sequencing in adipose tissue cell populations showed that oncostatin-M expression mainly arises from the macrophage fraction, while the corresponding receptors are expressed in adipocytes. Accordingly, oncostatin-M expression was induced in Thp1 macrophages in response to adrenergic stimuli (+620%, p<0.001), as well as in response to conditioned media from exercised myotubes (+ 79% at 3h, 2-way ANOVA p<0.001).

**Conclusion:** Collectively, our findings reveal that the adipose tissue transcriptome profile is robustly altered by exercise in a time-dependent manner, with a sustained increase in an inflammatory signature unique to Type 2 diabetes. Our results suggests that immune cells may be an important player in the crosstalk between skeletal muscle and adipose tissue during exercise, through the secretion of factors such as oncostatin-M to regulate adipocyte metabolism.

**Supported by:** NNF

**Disclosure:** L. Dollet: Grants; NNF200OC0060969.

---

**83 High intensity interval training improves whole-body insulin sensitivity and skeletal muscle oxidative capacity and favourably affects hepatic fat storage**

M. Bergman1, R. Mancilla1, P. Veenaiia2, V.H.W. de Wit-Verheggen1, Y.M.H. Bruls1, J. Hoeks1, V.B. Schrauwen-Hinderling1,2, M.K.C. Hesselink1,2; 1Department of Nutrition and Movement Sciences, Maastricht University, 2Department of Radiology and Nuclear Medicine, Maastricht University Medical Center+, Maastricht, Netherlands.

**Background and aims:** High intensity interval training (HIIT) is a time-effiecient alternative for conventional exercise training and considered a promising exercise modality to counteract obesity-related metabolic impairments. We studied if HIIT prompts beneficial effects on insulin sensitivity, muscle oxidative capacity and intrahepatic lipid (IHL) content in overweight/obese individuals. Since carbohydrate-rich and insulinogetic sports drinks are frequently consumed after training and may impact the outcome of the training, we also explored if co-ingestion of a standardized glucose and casein hydrolysate post-exercise affects the anticipated HIIT-mediated metabolic improvements.
Materials and methods: Twenty-three overweight and obese adults (10 males and 13 females, mean age: 64 ± 7.5 years, BMI: 31.8 ± 3.3 kg/m²) completed 12 weeks of progressive HIIT on a stationary bike while consuming either water during/post exercise (HIIT+WAT) or with co-ingestion of a glucose and casein hydrolysate immediately post-exercise (HIIT+CHO/PRO). Before and after the HIIT program, muscle oxidative capacity (expressed as the PCr recovery rate constant) was assessed via phosphorus magnetic resonance spectroscopy (133P-MRS) and IHL content and composition were determined by proton magnetic resonance spectroscopy (1H-MRS). Whole-body insulin sensitivity was assessed by a 2-step hyperinsulinemic-euglycemic clamp (10 - 40 mU), along with maximal aerobic capacity (VO2max) on a cycle ergometer and body composition by BodPod.

Results: VO2max improved significantly from 41.0 ± 1.7 to 44.8 ± 1.8 ml/FFM/min in the HIIT+WAT group and from 42.8 ± 1.9 to 47.5 ± 2.0 ml/FFM/min in HIIT+CHO/PRO, whereas the PCr recovery rate constant improved in the HIIT+WAT group from 0.030 ± 0.002 to 0.041 ± 0.003 s⁻¹ and in the HIIT+CHO/PRO group from 0.031 ± 0.002 to 0.038 ± 0.003 s⁻¹. In the combined group, HIIT tended (P=0.06) to decrease IHL content significantly (P=0.048), increased the polyunsaturated fatty acid (PUFA) fraction and tended (P=0.08) to decrease the monounsaturated fatty acid (MUFA) hepatic fat content, whereas the saturated fatty acid fraction did not change. Whole-body insulin sensitivity, as reflected by the M-value, improved significantly upon HIIT, to a similar extent in the HART group and composition were observed upon HIIT in either of the groups.

Conclusion: HIIT promotes both insulin sensitivity and muscle oxidative capacity in overweight/obese individuals. Moreover, IHL composition changes slightly (a shift towards more PUFA and less MUFA) in overweight/obese individuals. These benefits can be attained regardless of co-ingesting glucose and proteins after exercise and occurred in the absence of changes in body weight or body composition.

Clinical Trial Registration Number: NCT03405545

Disclosure: M. Bergman: None.

The plasma and tissue metabolomics responses to high intensity interval training and its importance in insulin resistance in obesity and type 2 diabetes

P.M. Møller1, M.H. Petersen1, M.E. De Almeida2, N. Ørtenblad2, J. Havelund2, N.J.K. Færgeman3, K. Højlund1;
1Steno Diabetes Center Odense, Odense University Hospital, Odense C, 2Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense M, 3Biochemistry and Molecular Biology, Villum Center for Bioanalytical Sciences, University of Southern Denmark, Odense M, Denmark.

Background and aims: Insulin resistance (IR) links obesity with type 2 diabetes (T2D). Evidence suggests that IR is associated with a range of specific changes in circulating and inter-tissue metabolites. Physical activity improves insulin sensitivity in obesity and T2D. Recent data suggests that high-intensity interval training (HIIT) and recruitment of several muscle groups enhance the beneficial effects of exercise on glucose homeostasis. Here, we aimed to uncover the nearly undiscovered plasma and tissue metabolomics signatures of a novel HIIT protocol engaging upper and lower body muscles in obesity and T2D.

Materials and methods: Plasma samples and skeletal muscle and subcutaneous adipose tissue (SAT) biopsies were obtained from obese patients with T2D (n=15) and matched glucose-tolerant obese (n=15) and lean (n=18) individuals before and after their participation in an 8-week HIIT protocol combining rowing and cycling 3 times/week. Insulin sensitivity, VO2max, and body composition were assessed before and after the HIIT protocol. Plasma and tissue samples were investigated by untargeted metabolomics analyses using LC-MS. The metabolomics data will be used for biocomputational analyses, including clustering and correlation analyses.

Results: The HIIT protocol markedly increased insulin sensitivity (~30-40%) in all groups (p<0.05), and also improved VO2max (p<0.05), and reduced total body fat (p<0.001). These physiological changes in response to HIIT were accompanied by changes in the plasma metabolome, predominantly in T2D patients. The changes included the induction of lactate and amino acid derivatives (p<0.05), including BCAA degradation products, previously observed to increase glucose and fatty acid uptake in primary human adipocytes. The largest baseline differences were observed in the lipidome of T2D patients compared with the obese and lean groups (p<0.05). This included increased levels of sphingolipids, and diacylglycerols, previously coupled to tissue IR. The plasma data will be supplemented and compared to metabolomics and lipidomic analyses of fat and muscle biopsies, and further enrichment and correlation analyses with clinical data will be performed.

Conclusion: T2D patients display an altered lipidomic profile in plasma, whereas HIIT induces changes in the plasma metabolome, which could suggest a switch in energy metabolism and organ crosstalk.

Supported by: SDCO PhD grant. Region Syddanmark PhD grant

Disclosure: P.M. Møller: None.
**OP 15 Preserving kidney function**

85

Effects of treatment with semaglutide, empagliflozin and the combination on kidney function in type 2 diabetes: impact of oxygenation and perfusion

S. Gullaksen1,2, L. Vernstrøm1,2, S.S. Sorensen1,2, K.L. Funk2, P.L. Poulsen2, E.G. Laugesen2;
1Dept. of Clinical Medicine, Aarhus University, Aarhus, 2Aarhus University Hospital, Dept. of Endocrinology and Internal Medicine, Denmark.

**Background and aims:** Glucagon-like peptide-1 receptor agonists (GLP-1ra) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have each shown kidney protective effects in large clinical outcome-studies. The mechanisms behind these effects are sparsely elucidated and the effects of combination therapy remains obscure. In this randomized clinical trial, we compared kidney function in persons with type 2 diabetes receiving either the GLP1-ra semaglutide (SEMA), the SGLT2-i empagliflozin (EMPA) or the combination (COMBI). EMPA treatment was double blinded. Kidney oxygenation was primary outcome and regional (cortex and medulla) assessments were included.

**Materials and methods:** 80 participants with type 2 diabetes (age 68.1 ± 6.5 years, male 76.25 %, diabetes duration 8[4;12] years), were randomized to either placebo, EMPA, SEMA or COMBI for 32 weeks. Kidney excretory function was assessed by urinary albumin/creatinine ratio (UACR) and glomerular filtration rate (GFR). Magnetic resonance imaging was used to assess kidney oxygenation with R2*(Hz) (higher values indicating lower oxygenation) by a blood oxygen level dependent sequence (BOLD) and renal perfusion (arterial spin labelling (ASL)).

**Results:** UACR was reduced significantly for the COMBI group (-35% 95% CI [-46; -22]%, p < 0.05), with the same tendency for each of the separate treatment arms. GFR decreased significantly from baseline and compared to placebo in all three treatment groups (SEMA -19 mL/min 95% CI [-7; -31]mL/min, p=0.001; EMPA -18 mL/min 95% CI [-6; -30]mL/min, p<0.001 and COMBI -26mL/min 95% CI [-14; -38]mL/min, p<0.001). Medullary renal oxygenation was reduced compared to placebo in both EMPA and the COMBI groups (figure 1A) (0.91±1 95% CI [0.16;1.65]s−1, p=0.01 and 0.91±1 95% CI [0.26;1.57]s−1, p<0.01, respectively). EMPA reduced medullary oxygenation significantly compared to SEMA (1.03±1 95% CI [0.22;1.84]s−1, p=0.01). No significant changes were observed in cortical oxygenation (figure 1A). Compared to placebo, cortical perfusion was reduced in SEMA and COMBI, whereas medullary perfusion was reduced across treatments, figure 1B.

**Conclusion:** Our data demonstrate joined effects of EMPA and SEMA on UACR and GFR and reveal important differential effects of EMPA and SEMA on renal physiology. As hypoxia is considered a main driver in kidney disease, we hypothesized that EMPA and/or SEMA would exert their beneficial effects through improved kidney oxygenation. Contrary to our hypothesis, EMPA treatment for 32 weeks was not associated with improved medullary oxygenation but even slightly reduced it. This is in line with recent rodent studies. SEMA treatment is associated with a substantial reduction in kidney perfusion, probably leading to reduced hyperfiltration. To our knowledge, these effects have not previously been demonstrated in humans.

86

Low blood oxygen saturation is associated with microvascular complications in individuals with type 1 diabetes


**Background and aims:** Blood oxygen saturation (SpO2) is lower in both type 1 diabetes (T2D) and type 2 diabetes (T2D) as compared with non-diabetes (CON). Hypoxia is thought to play a role in the progression of diabetic complications, but it is unknown whether low SpO2 is associated with diabetic complications.

**Materials and methods:** Cross-sectional study in T1D and T2D separately. SpO2 was measured in the supine body position with pulse oximetry and patients were divided in low SpO2 (< 96%) and high SpO2 (≥ 96%) which has been proposed as a threshold. Outcomes were albuminuria (two out of three consecutive measurements ≥ 30 mg/g), any retinopathy (fundus photography), neuropathy (symmetric vibration perception threshold ≥ 25 V), and cardiovascular disease (CVD) (history). Odds ratios (OR) were adjusted for diabetes duration, gender, smoking, exercise, body mass index, and blood hemoglobin.

**Results:** We included 663 patients with T1D (23 with low vs. 640 with high SpO2) and 425 with T2D (43 with low vs. 382 with high SpO2). In T1D, the OR (95% CI, p-value) with low vs. high SpO2 was for albuminuria 3.3 (1.3 to 8.3, p<0.01), for retinopathy 2.9 (1.1 to 7.8, p=0.03), for neuropathy 5.3 (1.9 to 14.9, p<0.01), and non-significant for CVD (1.0 (0.3 to 3.5, p=0.95)). In T2D, there were no significant differences between low vs. high SpO2 in the odds of having albuminuria, retinopathy, neuropathy, or CVD (Figure 1).

**Conclusion:** SpO2 below 96% was associated with the microvascular complications, albuminuria, retinopathy, and neuropathy in T1D, but not with the macrovascular complication CVD. This could reflect that microvascular lung damage is related to hypoxia. No associations were observed in T2D.
Development in eGFR trajectories in people with diabetic nephropathy
C.G. Poulsen¹, K. Jesse¹, B. Carstensen¹, M. Frimodt-Moeller¹, T.W. Hansen¹, F. Persson¹, D. Vistisen¹,², P. Rossing¹,²,¹Steno Diabetes Center Copenhagen, ²University of Copenhagen, Copenhagen, Denmark.

Background and aims: Diabetic nephropathy (DN) is a frequent and serious complication to both type 1 diabetes (T1D) and type 2 diabetes (T2D) and is characterized by a progressive loss of kidney function, elevated blood pressure and increased risk of cardiovascular disease and death. The effect of advancing diabetes care over the past decades on progression and prognosis for persons diagnosed with DN requires updating. In this study we analyzed the development over calendar time in eGFR trajectories from the time of DN diagnosis.

Materials and methods: In a retrospective cohort study, data was collected from electronic health records from persons attending the outpatient clinic at Steno Diabetes Center Copenhagen, Denmark between 2001-2020. Inclusion criteria were: T1D/T2D and DN, defined as urine albumin to creatinine ratio (UACR) > 300mg/g or urine albumin excretion rate (UAER) > 300 mg/24hours in two separate measurements > 60 days apart. Individual eGFR trajectories were calculated separately for T1D and T2D, using mixed-effects models with fixed effects of age, sex, date of DN diagnosis, duration of DN, and random effects of person and duration of DN.

Results: The T1D cohort included 891 persons, 59.7% were male and median (IQR) age at DN diagnosis was 50 (38-62) years. Figure 1A shows the estimated trajectories for eGFR for a person diagnosed with T1D and DN at age 50 in 2000, 2005, 2010 and 2015. eGFR at the time of DN diagnosis increased over time with 1.8 ml/min/1.73m² per calendar year. The T2D cohort included 1447 persons, 71.9% were male and median (IQR) age at DN diagnosis was 65 (58-72) years. Figure 1B shows the estimated trajectories for eGFR for a person diagnosed with DN at age 65 in 2000, 2005, 2010 and 2015. eGFR at the time of DN diagnosis increased with 0.7 ml/min/1.73m² per calendar year. For both T1D and T2D, the trajectories depict a tendency towards an attenuating decline in eGFR over time, when diagnosed with DN in more recent years, but with a faster decline in the first five years after diagnosis of DN.

Conclusion: Kidney function at time of DN diagnoses has increased over the past 20 years, especially in T1D. Moreover, the eGFR decline after diagnosis seems attenuating when diagnosed in more recent years. This may be explained by improved awareness and treatment.
Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, reduces the risk of cardiovascular and renal disease as assessed by Steno Risk Engines in adults with type 1 diabetes

E.B. Stougaard1, P. Rossing1,2, D. Vistisen1,3, P. Banks4, M. Girard4, M.J. Davies5, F. Persson1

1Steno Diabetes Center Copenhagen, Herlev, Denmark, 2Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, 3Department of Public Health, University of Copenhagen, Copenhagen, Denmark, 4Lexicon Pharmaceuticals, Inc., The Woodlands, USA.

Background and aims: Sotagliflozin (SOTA) as an adjunct to insulin therapy improves glycemic control, without an increased risk of hypoglycaemia, reduces body weight and blood pressure (BP), and increases time in range in adults with type 1 diabetes (T1D). Treatment with SOTA is associated with an increased risk of diabetic ketoacidosis (DKA). SOTA demonstrated CV and renal benefits in high-risk adults with type 2 diabetes. The cardiorenal benefits along with the cardiometabolic effects may collectively outweigh the risk of DKA when evaluating SOTA for adults with T1D. The present analysis estimated the risk of CVD and end-stage kidney disease (ESKD) in adults with T1D treated with SOTA.

Materials and methods: Patient-level data were used from the three Phase 3 inTandem trials evaluating 2977 adults with T1D randomized to once-daily placebo, SOTA 200 mg, or SOTA 400 mg for 24 weeks. Analyses focused on 3 cohorts (1. SOTA 200 mg; 2. SOTA 400 mg; 3. SOTA pooled). A subgroup analysis was performed in patients with a BMI ≥27 kg/m². For each patient, the cumulative risks of developing CVD and ESKD were estimated using the Steno T1 Risk Engines, which are validated prediction models for predicting 5- and 10-year risk of CVD and 5-year risk of ESKD. For CVD risk estimation, only patients without previous CVD (98% of overall cohort) at baseline were included. Baseline values for age and duration of diabetes were used in the model at Week 24. Missing albuminuria values were set to normal. Smoking and exercise history were not collected, and these variables were set to No. The estimated risk was calculated at baseline and Week 24 in both treatment groups. If a participant did not have a Week 24 assessment, a baseline observation carried forward approach was used. The difference in least-square mean percent change in estimated risk from baseline (95% CI and p-value) was compared between groups using a mixed model with percent change from baseline as dependent and including the treatment group as fixed effect, and the baseline value as covariate.

Results: SOTA significantly reduced 5- and 10-year CVD risk scores by approximately 4 to 7% compared to placebo at 24 weeks (Table). ESKD risk score was numerically reduced with SOTA 200 mg and significantly reduced with SOTA 400 mg relative to placebo. Similar results were observed with SOTA pooled in patients with baseline BMI ≥27 kg/m².

Conclusion: Using the Steno T1 Risk Engines, the estimated risk of CVD and ESKD was significantly reduced with SOTA compared to placebo in adults with T1D. This analysis provides additional clinical results that may positively enhance the benefit/risk assessment of SOTA use in T1D.

Clinical Trial Registration Number: EMPA-REG OUTCOME (NCT01131676)

Supported by: Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance


89

Morphological and functional ultrasound features of diabetic kidney disease phenotypes in people with type 2 diabetes

M. Garofolo1, V. Napoli2, D. Lucchesi1, S. Accogli2, M. Mazzeo2, P. Rossi2, P. Falcetta1, M. Giambalvo1, E. Neri2, G. Penno1, S. Del Prato1

1Department of Clinical and Experimental Medicine, University of Pisa, 2Department of Translational Research, Academic Radiology, University of Pisa, Pisa, Italy.

90
**Background and aims:** Diabetic kidney disease (DKD) develops in 40% of people with type 2 diabetes (T2D) and is the leading cause of end stage kidney disease. Non-albuminuric DKD has become the prevailing DKD phenotype (PH) and exhibits distinct clinico-pathological characteristics from those with albuminuria, including a higher proportion of females, better risk factors profile, and possibly distinct renal structural lesions on biopsy. Whether DKD PHs may also recognize differences in kidney morphological and vascular features has not been yet explored. We evaluated to which extent kidney ultrasonography (US) may differentiate DKD PHs in T2D subjects, in a cross-sectional, single-center study.

**Materials and methods:** DKD PHs were defined by KDIGO baseline eGFR strata and albuminuria categories: no-DKD (preserved eGFR and normoalbuminuria), albuminuria and preserved eGFR (DKD stages 1-2), decreased eGFR and normoalbuminuria (NA-DKD), and albuminuria with decreased eGFR (MA-DKD). Total and parenchymal renal volumes were calculated applying the ellipsoid formula for conventional (2D) US and with manual segmentation for 3D US (by X-matrix array technology); total and parenchymal renal volumes were adjusted for body surface area (aTRV, aPRV). Renal resistive index (RI) was also determined at the renal interlobar arteries. All US procedures were made by a radiologist blinded to patients’ characteristics.

**Results:** Out of 256 subjects, 26.2% had no-DKD, 24.6% DKD stages 1-2, 24.2% NA-DKD and 25.0% MA-DKD. No difference in albuminuria were observed between DKD stages 1-2 and MA-DKD (or between no-DKD and NA-DKD). Consistently, eGFRcreat levels did not differ in MA-DKD as compared to NA-DKD (or between no-DKD and DKD stages 1-2). Compared to no-DKD, RI was higher in all DKD PHs, being the highest in MA-DKD and with a significant trend of RI >0.70 prevalence to increase across PHs (p=0.02). aTRV3D and aPRV3D significantly differed across PHs (p<0.0001 for both). Compared to no-DKD (aTRV3D 180 ml/m² [IQR 162-205], and aPRV3D 150 ml/m² [122-162]), volumes were higher in DKD stages 1-2 (aTRV3D 198 ml/m² [170-224] and aPRV3D 163 ml/m² [140-184]) and reduced in both NA-DKD and MA-DKD, with significantly lower volumes in NA-DKD (aTRV3D 153 ml/m² [136-168], and aPRV3D 127 ml/m² [106-141]) as compared to MA-DKD (aTRV3D 164 ml/m² [143-186], and aPRV3D 138 ml/m² [122-150]; p=0.017 and 0.011 for aTRV3D and aPRV3D, respectively). These differences were confirmed for 2D volumes, and for DKD PHs established by GFR estimation based on creatinine and cystatin C CKD-EPI equation. In adjusted logistic regression models, compared to no-DKD, RI and aPRV3D were associated with DKD stages 1-2 and MA-DKD; only aPRV3D with NA-DKD. Compared to no-DKD, ROC curves, traced on top of conventional risk factors, showed that US parameters did not improve characterization of DKD stages 1-2 and MA-DKD, while aPRV3D significantly improved phenotyping of NA-DKD.

**Conclusion:** In type 2 diabetes, the emerging NA-DKD phenotype showed reduced TRVs and PRVs even when compared with MA-DKD with similar eGFR reduction. These findings support the hypothesis that different damage pathways underly the progression of different DKD phenotypes.

**Disclosure:** M. Garofolo: None.

---

**OP 16 Flames and scars in the liver**

**91 Role of the constitutive androstane receptor CAR in sex- and gut microbiota-dependent non-alcoholic fatty liver disease**

**M. Huillet**1, F. Lasserre1, A. Polizzi1, V. Alquier-Bacquie1, A. Fougerat1, C. Rives1, C. Martin1, J. Bruse1, J.H. Wan2, B. Chassaing2, S. Lotersztajn2, L. Gamet-Payrastre1, H. Guillou1, N. Loiseau1, S. Ellero-Simatos1;

1Toxalim, UMR 1331, INRAE, Université de Toulouse, Toulouse;
2INSERM UMR 1149, Centre de Recherche sur l'Inflammation, Paris;
3INSERM U1016, CNRS UMR 8104, Université de Paris, Paris, France.

**Background and aims:** Non-alcoholic fatty liver diseases (NAFLD), including steatosis, non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocarcinoma, are sexually-dimorphic diseases, in which the gut microbiota seems to play a causal role. Mechanisms involved in disease progression remain incompletely understood. The constitutive androstane receptor (CAR, official name NR1I3) is a liver enriched-nuclear receptor, that regulates the transcription of genes involved in both xenobiotic detoxification and energy metabolism. In addition, CAR represents a potential candidate for the recognition of microbial signals by its ability to bind a large number of exogenous molecules. In this context, we aimed to investigate the potential role of CAR in the progression of NAFLD.

**Materials and methods:** First, we analyzed hepatic CAR expression using publicly available transcriptomic data from NAFLD human cohorts of the Gene Expression Omnibus (GEO) repository. Then, we used adult C57Bl6/J CARWT (WT) or CARKO (KO) female and male mice fed a chow diet (CD) or a sucrose and lipid enriched diet (western-diet, WD) for 14 weeks (n=8-12/group). Gut microbiota composition, glucose and lipid metabolism and hepatic phenotype were studied using 16S-sequencing, glucose tolerance test, hepatic histology (H&E and sinus red staining), hepatic qPCR and plasma biochemical analysis.

**Results:** In clinical studies, CAR expression was lower in NASH patients with advanced fibrosis than in those with mild fibrosis (adjusted p-value (padj)=0.04 GSE163211, p adj=0.01 GSE49541), and in patients with cirrhosis or hepatocarcinoma compared to healthy patients (padj=3x10-19 GSE10143, padj =10-40 GSE14520). Thus, hepatic expression of CAR seems to decrease during NAFLD progression in humans. In preclinical mouse studies, WD feeding increased body weight and induced liver triglyceride deposition (steatosis) in both males and females, with no significant effect of CAR deletion. KO WD fed males had significantly higher circulating levels of alanine aminotransferase (584±175 vs. 202±113 U.L-1, p=10-5) and alkaline phosphatase (242±48 vs. 113±37 U.L-1, p=10-5), indicative of liver damages, as well as increased liver fibrosis (% sirus red staining: 0.3±0.3, 0.7±0.3, p=0.005; Col1a1 mRNA: 2.5 fold increase, p=10-5), compared with WT males. In females, we observe no influence of genotype on WD-induced liver damages or fibrosis. Caecal microbiota composition of KO WD-fed males was significantly different from WT WD-fed males.

To assess the role of gut microbiota in CAR-dependent liver dysfunctions, KO and WT male mice were co-housed in same cages and fed a WD. There were no differences in liver damages between WT and KO co-housed males, indicating that gut microbiota transfer by coprophagy attenuated WD-induced CAR-dependent liver damages.

**Conclusion:** CAR plays a sex- and gut microbiota-dependent role in WD-induced NAFLD in mice. We hypothesize that hepatic CAR is involved in the detoxification of gut microbial metabolites and we will further investigate this using portal vein metabolomics to unravel potential deleterious metabolites involved in sexually-dimorphic NAFLD.

**Disclosure:** Supported by: JPI HDHL ANR FATMAL.

**Disclosure:** M. Huillet: None.
92 Hepatic fat and macrophages are increased in livers of diabetic patients without NAFLD

A. Korn1,2, C. Nadeem1, E. Bos1, H.W.M. Niessen1,2, S. Simsek3,4, P.A.J. Krijnen1,2;
1Pathology, Amsterdam UMC, Location VUmc, Amsterdam, 2Amsterdam Cardiovascular Sciences, Amsterdam, 3Internal Medicine, Northwest Clinics, Alkmaar, 4Internal Medicine, Amsterdam UMC, Location VUmc, Amsterdam, Netherlands.

Background and aims: Diabetes mellitus (DM) is strongly associated with non-alcoholic fatty liver disease (NAFLD), which increases risk of severe liver disease as well as extra-hepatic microvascular disorders. NAFLD is diagnosed in liver biopsies when fat accumulation, lymphocytes, ballooning of hepatocytes and/or fibrosis are found, but it is often diagnosed relatively late due to limitations of current diagnostic techniques and minor clinical manifestations in the early stages of development. This study aimed to analyse putative early changes in the liver of deceased DM patients that were without clinical diagnosis of NAFLD and did not have histopathological characteristics of NAFLD at autopsy, and analysed age/sex effects hereon.

Materials and methods: Liver tissue was obtained at autopsy from 24 DM patients and 66 non-diabetic control patients. All patients did not have histopathological characteristics of NAFLD. Hepatic fat (percentage and number of cells) and inflammatory cells (CD45-positive lymphocytes and CD68-positive macrophages) were studied through (immuno)histochemical analysis.

Results: We observed a 5-fold increase in percentage of fat (0.7±1.1, p=0.0007) and an 8-fold increase in amount of fat cells in DM patients (94.6±133.5, p<0.0001) compared with the non-diabetic controls (% fat: 0.4±0.9; fat cells: 19.9±47.8). The number of CD45-positive lymphocytes was not affected in the diabetic livers (p=0.06), whereas the number of CD68-positive cells was increased in DM patients (p=0.0002) compared to controls. Fat percentage and fat cells were significantly higher in DM2 patients compared to both DM1 (p=0.02 and p=0.04 respectively) and non-diabetic controls (p=0.0007 and p<0.0001 respectively), while the number of CD68-positive cells was significantly elevated in both DM groups, regardless of type (DM1: p=0.0008; DM2: p=0.007). We found no significant differences between men and women in the non-diabetic control groups nor in the diabetic patient group, regardless of age. No correlation was found between hepatic fat and inflammation.

Conclusion: Hepatic fat and the number of macrophages is increased in the liver in DM patients that are not yet diagnosed with NAFLD, warranting early clinical investigation for signs of NAFLD in patients with DM.

93 Ubiquitin-proteasome system dysfunction in the liver of severely obese men with and without type 2 diabetes

B. Stocks1, E. Näslund2, J.R. Zierath3, A.S. Deshmukh1;
1Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen N, Denmark, 2Department of Clinical Sciences, Karolinska Institutet, Stockholm, Sweden, 3Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Background and aims: Dysregulated liver metabolism, in particular insulin resistance, is a predominant factor in the pathogenesis of type 2 diabetes. Protein degradation via the ubiquitin-proteasome system has been implicated in the development of type 2 diabetes. Through a diversity of signals, ubiquitination regulates a range of cellular processes such as protein degradation, enzyme activation and sub-cellular localisation. Nonetheless, a global understanding of ubiquitin-proteasome system dysfunction in obesity and type 2 diabetes has yet to be established. As the human genome encodes more than 600 E3 ligases (which catalyse the transfer of ubiquitin to protein substrates) and over 100 deubiquitinases, a systems approach is required to truly understand ubiquitin-proteasome system dysfunction. We aimed to characterise the regulation of the ubiquitin-proteasome system in the liver of severely obese men with and without type 2 diabetes.

Materials and methods: Liver samples from 9 non-obese men, 8 severely obese men (Ob) and 10 severely obese men with type 2 diabetes (Ob-T2D) were collected during cholecystectomy (non-obese) or Roux-en-Y gastric bypass surgery (Ob and Ob-T2D). Samples were lysed in 4% SDS and digested using Lys-C and trypsin. Peptides were measured via liquid chromatography tandem mass spectrometry (LC-MS/MS) using an EASY-nanoLC coupled to an Exploris 480 Orbitrap on a 100-min gradient using data independent acquisition. Protein ubiquitination was assessed via immunoblotting in human and rodent liver.

Results: We identified the regulation of 4319 proteins in the livers of 9 non-obese, 8 severely obese non-diabetic men (Ob) and 10 severely obese men with type 2 diabetes (Ob-T2D), collected during cholecystectomy (non-obese) or Roux-en-Y gastric bypass surgery (Ob and Ob-T2D). We found 162 proteins that were differentially regulated in Ob and/or Ob-T2D compared to non-obese men. Of these, 11 ubiquitin-proteasome system proteins were regulated, including the E3 ligases COPB2, DCAF11, DCUN1D1, EML2, LRSAM1, SEC13, SEC31A, STRN and TBL2, the deubiquitinase UCHL1, and the 26S proteasome protein PSMD7. Furthermore, protein ubiquitination is dysregulated in the liver of Ob and Ob-T2D patients.

Conclusion: These data identify ubiquitin-proteasome system dysfunction in the liver of severely obese men with and without type 2 diabetes, providing protein targets for future mechanistic and therapeutic research.

Supported by: EFSD Rising Star Fellowship Programme
Disclosure: B. Stocks: Grants; EFSD Rising Star Fellowship Programme.

94 Liver inflammation increases the proliferation of oval cells during non-alcoholic fatty liver disease

S. Calero Pérez1,2, I. Barahona1,2, P. Valdecantos1,2, Á.M. Valverde1,2;
1IBim Alberto Sols (CSIC-UAM), 2CIBERdem (ISCIII), Madrid, Spain.

Background and aims: Oval cells (OCs) are hepatic progenitor cells with an emerging role in repopulation capacity and differentiation towards hepatocytes or cholangiocytes under conditions of liver damage. However, their susceptibility to an inflammatory environment in the context of obesity-associated insulin resistance and non-alcoholic liver disease (NAFLD) is unknown. On that basis, the aim of this study was, first, to identify the impact of an environment mimicking...
metainflammation in obesity and NAFLD in OC expansion in mice and, second, to study the interaction between OCs and immune cells of the liver at the molecular and cellular levels.

**Materials and methods:** To induce NAFLD, eight week-old male mice (C57Bl6j x 129 sv) were fed a Western Diet (WD) containing 21.1% fat, 41% sucrose, and 1.25% cholesterol and a high sugar solution (23.1 g/L d-fructose and 18.9 g/L d-glucose) for 12 weeks. Additionally, CCl₄ (0.32 μg/g body weight) was injected intra-peritoneally (i.p.) once per week, starting one week after the WD. OCs were isolated from mouse livers and established in culture. To generate a NAFLD-like proinflammatory environment, peritoneal macrophages or bone marrow-derived macrophages (BMDM) were treated with a mixture of palmitate (400 μM) and LPS (150 ng/ml) (PA/LPS) for 8 h, after which the culture medium was replaced with fresh medium for a further 16 h. The conditioned medium (CM) was used to stimulate OCs for different time-periods.

**Results:** NAFLD was evaluated in mice upon 12 weeks of intervention and histopathological analysis of liver sections showed features of non-alcoholic steatohepatitis (NASH) including steatosis, ballooning, inflammation and fibrosis, as revealed by the NAS score (p<0.001, n=6-11), alcoholic steatohepatitis (NASH) including steatosis, ballooning, inflammatory environment, peritoneal macrophages or bone marrow-derived macrophages (BMDM) were treated with a mixture of palmitate (400 μM) and LPS (150 ng/ml) (PA/LPS) for 8 h, after which the culture medium was replaced with fresh medium for a further 16 h. The conditioned medium (CM) was used to stimulate OCs for different time-periods.

**Results:** NAFLD was evaluated in mice upon 12 weeks of intervention and histopathological analysis of liver sections showed features of non-alcoholic steatohepatitis (NASH) including steatosis, ballooning, inflammation and fibrosis, as revealed by the NAS score (p<0.001, n=6-11), serum transaminases (p<0.001, n=6-11), Colla1 mRNA levels (p<0.001, n=6-11) and hydroxyproline (p<0.001, n=6-11). Importantly, a marked increase in A6/SOX9 positive cells (p<0.001, n=6-11), surrounded by inflammatory monocytes (Ly6c+) was found in all mice with NASH (p<0.01, n=3), together elevated mRNA levels of the progenitor markers EpCAM and Krt19 (p<0.001, n=6-11), pointing to a major presence of OCs in livers with NASH. Stimulation of OCs with CM collected from PA/LPS-stimulated macrophages for 5-30 min triggered a rapid activation of proinflammatory signaling cascades including phosphorylation of STAT3 (p<0.001, n=3), p65-NFκB (p<0.05, n=3), degradation of IκBα (p<0.05, n=3) and nuclear translocation of p65-NFκB (p<0.001, n=3). Treatment for 24 h with PA/LPS/CM increased the proliferation of OCs as reflected by increased PCNA levels (p<0.05, n=3). Gene expression levels related to OCs were obtained from the NCBI Gene Expression Omnibus database based on the gene chips of fibrotic livers associated to NAFLD (GSE130970, GSE49541, GSE162694 and GSE48452). In line with data in mice, expression of the progenitor markers SOX9, EPCAM and KRT7, was significantly increased in NAFLD patients with advanced fibrosis (p<0.001 n=8-103).

**Conclusion:** Our results have demonstrated that OC expansion concurs with inflammatory features during NAFLD progression in mice. The molecular studies revealed that the interaction between liver inflammatory cells and OCs favors OCs proliferation, an effect that opens therapeutic perspectives to preserve OCs proliferation under liver damage associated to NAFLD, but favoring their plasticity.

**Disclosure:** S. Calero Pérez: None.

96

**The fibrotic NASH index: a simple non-invasive score to screen for liver disease in individuals with metabolic risk factors**


1Clinical Medicine and Hepatology Unit, Campus Bio-Medico University, Rome, Italy, 2Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 3Internal Medicine Unit, Campus Bio-Medico University, Rome, Italy, 4Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 5Bariatric Surgery Unit, Campus Bio-Medico University, Rome, Italy, 6Department of Pathology, Campus Bio-Medico University, Rome, Italy, 7Department of Endocrinology and Diabetes, Campus Bio-Medico University, Rome, Italy, 8Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy, 9Clinical Nutrition Unit, Department of Medical and Surgical Sciences, University Magna Graecia, Catanzaro, Italy.

95

**Phthalate exposure is associated with NAFLD, but not with liver fibrosis in the United States**

S. Ciardullo1, E. Muraca2, R. Cannistraci2, G. Lattuada2, G. Perseghin1; 1University of Milano Bicocca, 2Policlinico di Monza, Monza, Italy.

**Background and aims:** Recent epidemiological observations have reported an association between phthalates exposure and insulin resistance and obesity while data are scarce on the association between these pollutants and nonalcoholic fatty liver disease (NAFLD) and liver fibrosis.

**Materials and methods:** To address this gap in knowledge we performed a population-based cross-sectional study using data from the 2017-2018 cycle of the National Health and Nutrition Examination Survey, a complex survey conducted to gain information on the health status of the general population of the United States. The target population consisted in all adult participants with available data on vibration controlled transient elastography (VCTE) and on urinary phthalate concentrations, with the exclusion of individuals with chronic viral hepatitis and/or significant alcohol consumption (>1 standard drink/day in women and >2 standard drink/day in men). Concentrations of mono(2-ethylhexyl) phthalate (MEHP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) and mono(2-ethyl-5-oxohexyl) phthalate (MOEH) were measured in a spot morning urine sample using liquid chromatography-electrospray ionization-tandem mass spectrometry. Multivariable logistic regression analysis was used to evaluate the association between phthalate concentrations and liver steatosis (controlled attenuation parameter > 274 dB/m) and significant liver fibrosis (liver stiffness measurement > 8 kPa) after adjustment for confounders.

**Results:** A total of 1793 participants were included. Weighted prevalence of NAFLD and significant fibrosis were 40.3% and 6.8%, respectively. Patients with NAFLD showed higher levels of both MEOHP and MEHHP, while no difference was found in MEHHP. Concentrations of all three metabolites did not differ significantly between participants with and without significant liver fibrosis. After adjustment for potential confounders including age, race-ethnicity, body mass index, glomerular filtration rate and diabetes, we found a significant positive association between both MEOHP (OR 1.01, 95% CI 1.00-1.02 per unit increase, p=0.014) and MEHHP (OR 1.01, 95% CI 1.00-1.03 per unit increase, p=0.031) and NAFLD, while no significant association was found for MEHP. None of the three molecules was associated with fibrosis in the multivariable model.

**Conclusion:** Our findings have revealed an association between phthalate exposure and NAFLD, but not liver fibrosis independently of diabetes and obesity. Further studies elucidating potential pathophysiological mechanisms are needed.

**Disclosure:** S. Ciardullo: None.
steatohepatitis (NASH) defined as NASH, NAFLD activity score (NAS) ≥4, and fibrosis stage ≥2.

**Materials and methods:** The derivation cohort included 264 morbidly obese individuals undergoing intraoperative liver biopsy in Rome, Italy. The best predictive model was developed and internally validated using a bootstrapping stepwise logistic regression analysis (2000 bootstrap samples). Performance was estimated by the area under the receiver operating characteristic curve (AUROC). External validation was assessed in three independent European cohorts (Finland, n=370; Italy n=947; England n=5,368) of individuals at high risk of NAFLD, namely with type 2 diabetes, overweight/obesity, and/or metabolic syndrome. All cohorts received local Research Ethics approval and all participants gave written informed consent to the study.

**Results:** The final predictive model, designated as Fibrotic NASH Index (FNI), combined aspartate aminotransferase (AST), high-density lipoprotein (HDL) cholesterol, and hemoglobin A1c (HbA1c). Performance for fibrotic NASH was satisfactory in both derivation and external validation cohorts (AUROCs 0.78 and 0.80-0.95, respectively). In the derivation cohort, rule-out and rule-in cut-offs were 0.10 for sensitivity ≥0.89 (negative predictive value [NPV] 0.93) and 0.33 for specificity ≥0.90 (positive predictive value [PPV] 0.57), respectively. In external validation cohorts, sensitivity ranged from 0.87 to 1 (NPV 0.99–1) and specificity from 0.73 to 0.94 (PPV 0.12-0.49) for rule-out and rule-in cut-off, respectively.

**Conclusion:** FNI is the first score for fibrotic NASH based on simple blood tests, namely AST, HDL cholesterol, and HbA1c. FNI may represent an accurate and affordable non-invasive tool to screen for liver disease individuals with metabolic risk factors in primary healthcare and diabetology clinics.

**Supported by:** VR; VINNOVA; Svenska Diabetesstiftelsen; Hjärt-Lungfonden; KAW; NNF; SSF; AZN

**Disclosure:** F. Tavaglione: None.

---

**OP 17 Toying with monitoring: from Present Continuous to Future Perfect**

97

Gaps remain in achieving target type 1 diabetes glycemic goals despite advanced technologies


1Dept of Pediatric & Adoles. Med., Joslin Diabetes Centre, Boston, 2TID Exchange, Boston, 3Vertex Pharmaceuticals, Boston, 4Evidera PPD, Wallham, 5International Diabetes Center, HealthPartners Institute, Minneapolis, USA.

**Background and aims:** Continuous glucose monitoring (CGM) metrics and self-reported disease characteristics (severe hypoglycaemic events [SHEs], HbA1c) warrant further description in people with T1D using CGM and pumps, including hybrid closed-loop systems (HCLS).

**Materials and methods:** We conducted a one-time online survey of adults with T1D in the T1D Exchange registry in the USA or online communities, where ~50% of participants contributed up to 1 year of CGM data. Patients were asked about their medical history (SHEs, HbA1c) while glucose management indicator (GMI), prolonged hypoglycaemic events (<54 mg/dL), time in and below range (TIR/TBR), and coefficient of variation (CV) were derived from CGM data.

**Results:** Patients who completed the survey and contributed CGM data (N=926) had a mean age of 42 y and T1D duration of 25 y; 73% were female, 96% white; 94% had ≥1 year of CGM use. Mean HbA1c was 6.6% (69.0% had HbA1c <7%). While most patients met consensus glycemic targets (HbA1c, GMI, TIR, TBR, and CV), with higher proportions observed in those using HCLS versus those using pump + CGM (not HCLS) and MDI + CGM (Table), patients continued to have significant hypoglycaemia based on CGM data and an average of 1.1 SHEs in the prior year.

**Conclusion:** Despite improvements in glycemic control (TIR, TBR, and self-reported HbA1c) with advanced technologies, many patients are still unable to achieve clinical targets and experience significant hypoglycaemia, highlighting the unmet need for novel T1D treatments.

**Supported by:** Vertex Pharmaceuticals

**Disclosure:** L. Laffel: Other; Advisory boards/consulting for Medtronic, Dexcom, Janssen, Boehringer Ingelheim, Provention, Dompe, Lilly, Roche, and Insulet.

---

<table>
<thead>
<tr>
<th>Table: Self-reported disease characteristics and CGM metrics: total and in the month prior to study</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td><strong>HbA1c &lt;7%</strong></td>
<td><strong>Pump + CGM (HCLS)</strong></td>
</tr>
<tr>
<td><strong>N=926</strong></td>
<td><strong>n=702</strong></td>
<td><strong>n=570</strong></td>
</tr>
<tr>
<td>Mean HbA1c (mmol/L)</td>
<td>6.60±0.21</td>
<td>6.07±0.21</td>
</tr>
<tr>
<td>% with HbA1c &lt;7%</td>
<td>59.0%</td>
<td>70.9%</td>
</tr>
<tr>
<td>Mean GMI</td>
<td>0.58±0.19</td>
<td>0.56±0.19</td>
</tr>
<tr>
<td>% with GMI &lt;3.0</td>
<td>69.0%</td>
<td>73.0%</td>
</tr>
<tr>
<td>Mean CV</td>
<td>3.98±1.56</td>
<td>4.99±1.56</td>
</tr>
<tr>
<td>% with CV &lt;3.0</td>
<td>94.0%</td>
<td>93.0%</td>
</tr>
</tbody>
</table>

**Results**

- The survey was conducted among adults with T1D in the T1D Exchange registry in the USA or online communities.
- The study included 926 participants with ≥1 year of CGM data.
- Mean HbA1c was 6.6% (70.0% had HbA1c <7%).
- GMI and CV were below the target levels in most patients.
- The HbA1c and CV were lower in those using HCLS compared to those using pump + CGM.

**Conclusion**

Despite improvements in glycemic control, many patients continue to experience significant hypoglycaemia, highlighting the need for novel T1D treatments.

**Disclosure:** L. Laffel: Other; Advisory boards/consulting for Medtronic, Dexcom, Janssen, Boehringer Ingelheim, Provention, Dompe, Lilly, Roche, and Insulet.

**Supported by:** Vertex Pharmaceuticals
98
Inte\nmittently \nscanned \ncontinuous \nglucose \nmonitoring is \nassociated \nwith a long-term \nglucose-lowering \neffect for type 1 diabetes \npatients \nin poor \nglycaemic control

M.H. Jensen1,2, S.L. Cichosz2, P. Gustenhoff3, A. Nikontovic1, O. Hejlesen1, P. Vestergaard1;1
1Steno Diabetes Center North Denmark, Aalborg University Hospital, 2Department of Health Science and Technology, Aalborg University, 3Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark.

Background and aims: Lowering glucose levels is a complex task for patients with type 1 diabetes and they often lack close contact to health care professionals. Several studies have shown that reduced HbA1c can be obtained from use of intermittently scanned continuous glucose monitoring (iSCGM), but the studies are typically of a shorter duration of 3-6 months with strict inclusion/exclusion criteria or with patient populations with mixed indications. The aim of this study was to investigate the long-term effect of isCGM on HbA1c in type 1 diabetes patients with poor glycaemic control in a region-wide real-world setting.

Materials and methods: All type 1 diabetes patients receiving an isCGM device due to poor glycaemic control (≥70 mmol/mol) in the period of 2020-21 in Region North Denmark (“TID-CGM”) were compared with all T1D patients without isCGM (“TID-NOCGM”) in the same period. Patients in the T1D-NOCGM group inherited the date of initiation of iSCGM as an index date from the T1D-CGM patient with the closest year of birth. A multiple linear regression model adjusted for age, sex, diabetes duration and use of continuous subcutaneous insulin infusion was constructed to estimate the difference in change from baseline HbA1c between the two groups. Change from baseline HbA1c was for each person calculated as the difference between the average of all values one year before initiation of isCGM (baseline HbA1c) and the average of all values two years after.

Results: The cohort consisted of 897 patients receiving isCGM and 1,630 without isCGM. Included T1D-CGM patients were 47% female, had an average age of 46 years (SD: 16 years), a diabetes duration of 12 years (SD: 8 years) and a baseline HbA1c of 80 mmol/mol (SD: 12 mmol/mol). T1D-NOCGM patients were 41% female, had an average age of 54 years (SD: 17 years), a diabetes duration of 12 years (SD: 10 years) and a baseline HbA1c of 64 mmol/mol (SD: 16 mmol/mol). The estimated adjusted difference in change from baseline HbA1c between T1D-CGM vs T1D-NOCGM was -5.9 mmol/mol (95% CI: -6.7 to -4.7 mmol/mol; p<0.0001) and the development in average HbA1c levels can be seen in the figure below.

Conclusion: Our results indicate that type 1 diabetes patients with poor glycaemic control from Region North Denmark benefit from using iSCGM with a sustained 24-month improvement in HbA1c. However, results should be interpreted with care, as the study was not randomized. Results need to be further investigated, for example, with subgroup analysis to clarify if all subgroups benefit equally from CGM.

Disclosure: M.H. Jensen: Employment/Consultancy; Abbott Laboratories A/S. Stock/Shareholding; Novo Nordisk A/S.

99
Conversion from FreeStyle Libre to Freestyle Libre 2 is associated with improvements in continuous glucose monitoring metrics

F.W. Gibb, R.H. Stimson, R.J. Wright, S. Forbes, M.W.J. Strachan, A. Dover; Edinburgh Centre for Endocrinology & Diabetes, Edinburgh, UK.

Background and aims: Real-time continuous glucose monitoring (rtCGM) is associated with improvements in glycaemic control in comparison to Freestyle Libre. The ALERTT1 study indicated improvements in both high and low glucose metrics favouring rtCGM over the original Freestyle Libre system. We sought to assess whether Freestyle Libre 2, with alarm functions, was associated with similar improvements.

Materials and methods: An observational study to assess changes in CGM metrics, at six months, in 415 adults with type 1 diabetes (≥ 1 year’s duration) after converting from Freestyle Libre to Freestyle Libre 2. Secondary outcomes included predictors of reduction in time below range (TBR) ≥ 0.5% (<3.9 mmol/l) and increase in time in range (TIR) ≥ 5.0% (3.9 - 10 mmol/l). Participants were included if ≥70% CGM data (2 week block) was available both at baseline and six months.

Results: Low and high glucose alarms were used by 74.5% and 58.6%, respectively. In all users, TBR fell by a median of 1.0% (IQR -2.7 - 0.3, p <0.001) after 6 months but TIR was unchanged (p = 0.920) (table). Average duration of low glucose events (<3.9 mmol/l) fell by 14 minutes (<41 - 13, p <0.001) and the number of low glucose events per 2 weeks fell from 7 to 4 (p <0.001). Low alarm thresholds were significantly correlated with baseline TBR (R 0.168, p = 0.009) and high alarm thresholds were significantly correlated with baseline time above range (R 0.123, p <0.001) and high alarm thresholds were independently associated with glycaemic response, however low alarm use was independently associated with a fall in TBR of ≥0.5% (OR 2.9 [95% CI 1.5 - 5.6], p = 0.002) and high alarm use was associated with a rise in TIR of ≥5% (OR 2.17 [1.2 - 4.2], p = 0.013).

Conclusion: Freestyle Libre 2 was associated with modest but clinically relevant improvements in hypoglycaemia metrics but did not improve TIR or average glucose. Low and high glucose alarms were independently associated with improvements in TBR and TIR, respectively, and users of this system should be encouraged to use alarms at thresholds appropriate for the individual’s circumstances.

100 Efficacy and safety of real-time continuous glucose monitoring guiding insulin administration in the hospital: a randomised clinical trial
G.E. Umpierrez1, R.J. Galindo1, M.A. Urrutia1, P. Velanki1, A.L. Migdal2, G.M. Davis3, E.J. Pasquel4, M. Fayfman1, T. Idrees1, L. Peng1, L.G. Singh1, E.K. Spanakis2; 1Div. of Endocrinology, Emory University School of Medicine, Atlanta, 2Div. of Endocrinology, University of Maryland Medical Center, Baltimore, USA.

Background and aims: Inpatient studies in insulin-treated patients have reported high accuracy and higher detection of hypo- and hyperglycaemic events with the use of real-time continuous glucose monitoring (RT-CGM) compared to capillary point-of-care (POC) glucose testing. In a randomised controlled study, we tested the efficacy and safety of RT-CGM in adjusting inpatient insulin therapy.

Materials and methods: A total of 173 general medicine and surgery patients with type 1 and type 2 diabetes treated with a basal bolus insulin regimen were randomised to a standard of care (POC group, n=85) wearing a blinded Dexcom G6 CGM for up to 10 days with insulin dose adjusted based on POC results, or to a RT-CGM group (n=88) who had their insulin adjustment based on daily Dexcom G6 RT-CGM profile. Primary endpoints were differences in time in range (TIR: 3.9–10 mmol/L) and hypoglycaemia (<3.9 and <3.0 mmol/L).

Results: There were no significant differences in TIR (54.51%±27.72 vs 48.64%±24.25, p=0.14), mean daily glucose (10.2±2.2 mmol/L vs 10.4±1.54 mmol/L, p=0.36), percent of patients with CGM values <3.9 mmol/L (36% vs 39%, p=0.68) or <3.0 mmol/L (14% vs 24%, p=0.12) between RT-CGM-guided and POC group. Among patients with ≥1 hypoglycaemic event, compared to POC, the RT-CGM group experienced a significant reduction in hypoglycaemia reoccurrence (1.80±1.54 vs 2.94±2.76 events/patient, p=0.037), lower percentage of time below range (TBR) <3.9 mmol/L (1.89%±3.27 vs 5.47%±8.49, p=0.024), lower recurrent nocturnal hypoglycaemic events (1.21±0.43 vs 1.93±0.92, p=0.02) and lower incidence-rate ratio <3.9 mmol/L (0.53, 95% CI:0.31-0.92) and <3.0 mmol/L (0.37, 95% CI:0.17-0.83).

Conclusion: Our results indicate that the inpatient use of Dexcom G6 RT-CGM system is safe and effective in guiding insulin-adjustment resulting in a similar improvement in glycaemic control and in a significant reduction of recurrent hypoglycaemic events compared to POC-guided insulin adjustment.

101 Cutaneous reactions associated with diabetes adhesives devices: results of the CutaDiab study
M. Diedicke1, A. Sola-Gazagnes1, A. Carlier2, L. Potier2, A. Hartemann2, S. Jacqueminet1, C. Peccue2, J.-B. Jullia2, T. Vidal-Trecan3, J.-F. Gautier1, E. Langer4, D. Dubois Laforgue1, R. Roussel2, J.-P. Riveline5; 1Diabetology, Cochin Hospital, APHP, 2Diabetology, Bichat Hospital, APHP, 3Diabetology, Pitie-Salpetriere Hospital, APHP, 4Dermatology, Tenon Hospital, APHP, 5Diabetology, Lariboisiere Hospital, APHP, Paris, France.

Background and aims: The use of devices adhering to the skin for between 2 and 14 days is constantly increasing, as continuous glucose measurement systems (CGM) and insulin pumps. Skin reactions have been observed in patients with diabetes using these new technologies, sometimes leading to discontinuation. Prevalence and consequences of these skin intolerances are unknown. The objective of this study is to determine the prevalence and consequences of cutaneous reactions to CGM or pumps.

Materials and methods: This is an observational, cross-sectional, multicentre study involving four university hospital diabetology departments (Paris, France). A form with about fifty questions concerning diabetes evolution, use of pump and CGM, and description and consequences of possible cutaneous reaction was drawn up on touchpad. All adult patients with diabetes seen in consultation over a period of 6 months and using or having used in the last 10 years a system with skin adhesives were included. Included devices were insulin patch pump (e.g. OMNIPOD®, cell Novo®), pump with externalized catheter (e.g. PARADIGM®, ANIMAS®, MINIMED 640G®, YpsoPump®) and CGM system (FreeStyle®, DexCom® sensors, Enlite® sensors). Non-parametric tests were used for quantifiable values (Mann-Whitney or Kruskal-Wallis tests), and chi-squared test for qualitative values.

Results: 851 patients were included. At least one cutaneous reaction was reported in 28% of CGM users (231/833) and in 29% of pump users (108/374). Patients with cutaneous reaction were more often women for CGM (84 vs 73%, p<0.001) and for pump (73 vs 58%, p=0.006), and had more often type 1 diabetes than type 2 diabetes for CGM (84 vs 73%, p<0.001) and for pump (73 vs 58%, p=0.006), and had more often type 1 diabetes than type 2 diabetes for CGM (84 vs 73%, p<0.001), without difference of type of diabetes for pump (91 vs 90% of type 1 diabetes). Symptoms were similar for CGM and pump reactions: erythema and pruritus in 70-75% of patients, pain in 20-25%, vesicle and peeling in 12-15%. The first symptom appeared within 24 hours of the first use of the device for 2-14 days is constantly increasing, as continuous glucose measurement systems (CGM) and insulin pumps. Skin reactions have been observed in patients with diabetes using these new technologies, sometimes leading to discontinuation. Prevalence and consequences of these skin intolerances are unknown. The objective of this study is to determine the prevalence and consequences of cutaneous reactions to CGM or pumps. Skin reactions have been observed in patients with diabetes using these new technologies, sometimes leading to discontinuation. Prevalence and consequences of these skin intolerances are unknown. The objective of this study is to determine the prevalence and consequences of cutaneous reactions to CGM or pumps. Skin reactions have been observed in patients with diabetes using these new technologies, sometimes leading to discontinuation. Prevalence and consequences of these skin intolerances are unknown. The objective of this study is to determine the prevalence and consequences of cutaneous reactions to CGM or pumps.
reaction does not modify the use of the device for 82% of reactions to CGM, and 80% for pump. Device use was definitely stopped for 12% of CGM reaction (3.2% of all users, 27/833), and for 7% of pump reaction (2.1% of all users, 8/374). The other reactions led to a decrease in use or to a change of device (6% for CGM, 13% for pump). Cutaneous reaction was more common for tubeless pumps than tubed pumps (31 vs 23%, p=0.03). These cutaneous reactions were no larger than the adhesive in 89% of cases for CGM and 93% for pump, suggesting skin irritation rather than an allergy.

**Conclusion:** Cutaneous reaction is a common reaction in pump or CGM users, but without consequences for the use of the device in the vast majority of cases, with very similar symptoms between CGMs and pump reactions. However, this reaction, which can appear more than 6 months after initiation of the device, leads to the interruption of its use in 2-3% of patients.

*Clinical Trial Registration Number: NCT04853810*

*Disclosure: M. Diedisheim: None.*

---

**Impact of treatment costs on the cost-effectiveness of real-time continuous glucose monitoring vs self-monitoring of blood glucose in type 1 diabetes patients in the United Kingdom**

**H. Alshannaq**

**1,2, G. Cogswell**, G.J. Norman**1, P.M. Lynch**1, S. Roze**1;

1Dexcom, San Diego, USA, 2University of Cincinnati, Cincinnati, USA, 3Vyoo Agency, Lyon, France.

**Background and aims:** Previous studies have shown that real-time continuous glucose monitoring (rt-CGM) is cost-effective for patients with Type 1 diabetes (T1D) in multiple countries including the UK. However, rt-CGM technology is a rapidly evolving field with continued advancements in clinical efficacy and production efficiency. New generations of the technology are expected to be introduced into clinical practice, which will vary in price and budget impacts to global healthcare systems. The aim of this analysis was to examine the sensitivity of existing cost-effectiveness evidence to changes in treatment costs of rt-CGM technology from a UK health care system perspective.

**Materials and methods:** The IQVIA CORE diabetes model was used to conduct the treatment costs impact analysis. We used base case baseline data from a published cost-effectiveness analysis for rtCGM in patients with T1D in the UK compared to self-monitoring of blood glucose (SMBG). Clinical data were sourced from the DIAMOND trial of adults with T1D on multiple daily injections of insulin and adapted to the UK. The baseline mean age (SD) of the cohort was 47.6 years (12.7) and proportion of female 56%. Mean baseline HbA1c for the cohort was 8.6% (70 mmol/mol). Reduction in HbA1c was -1.0% and -0.4% for rt-CGM and SMBG, respectively. For treatment costs impact, we conducted sensitivity analyses for -20%, -30%, and -50% reduction from the published treatment cost of GBP 1850. The analysis was conducted from the UK National Health Service payer perspective over a lifetime horizon.

**Results:** Rt-CGM was associated with a 1.489 incremental gain in quality-adjusted life years (QALYs) compared with SMBG (mean [SD] 11.47 [2.04] versus 9.985 [1.84] QALYs). Variation in treatment costs had a significant impact on the incremental cost-effectiveness ratio (ICER). The ICER was reduced by 46% when treatment costs were reduced by 20% (ICER 9,558 to 5,140 GBP/QALY gained) and by 69% when treatment costs decreased by 30% (ICER 9,558 to 2,933 GBP/QALY gained). Rt-CGM became dominant compared to SMBG when treatment costs decreased by 50% (ICER -1490).

**Conclusion:** Our analysis shows that treatment cost for rt-CGM is a significant driver of cost-effectiveness against SMBG. Reductions in treatment cost will position rtCGM as a long-term economic strategy to manage diabetes for patients with T1D in the UK.

**Disclosure:** H. Alshannaq: Employment/Consultancy; Dexcom.
OP 18 Cross-talk communication in the pancreas

103 Chronic hyperglycaemia leads to dysregulated δ-cell metabolism and reduced glucose-stimulated somatostatin secretion from the pancreatic islets

1Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, 2School of Biomedical Sciences, Ulster University, Coleraine, 3Wellcome Centre for Human Genetics, University of Oxford, Oxford, 4Department of Physiology, Anatomy, and Genetics, University of Oxford, Oxford, UK.

Background and aims: Reduced islet β-cell glucose metabolism-insulin secretion coupling and elevated postprandial α-cell glucagon secretion represent hallmark features of type-2 diabetes (T2D). Glucotoxicity has been extensively shown to trigger β-cell metabolic dysregulation, causing reduced glucose-stimulated insulin release. Chronic hyperglycaemia also leads to dysregulated glucagon secretion although the underlying causes remain largely obscure. We explored whether chronic hyperglycaemia alone also interferes with islet δ-cell function and glucose-stimulated somatostatin (Sst) secretion.

Materials and methods: Isolated WT (C57BL/6J), transgenic δ-cell specific (δGCaMP6 and δPerceval) mice, and non-diabetic cadaver donor human islets were chronically cultured under either normo-(Cont, control) or hyperglycaemic (Hyp, 25 mmol/l) glucose conditions for 14 days. Diabetic mouse islets were isolated from tamoxifen-inducible β-cell-specific Kiri2.V59M (βV59M) mice subjected to 14 days of chronic in vivo hyperglycaemia (plasma glucose ≥ 25 mmol/l). δ-cell intracellular Ca2+ ([Ca2+]i) and ATP ([ATP]i) were measured using GCaMP6 and Perceval sensors respectively and a wide-field Zeiss Axio Zoom V16. Results were performed on single δ-cell to study effects on exocytosis.

Results: (i) Mouse islet δ-cells exposed to chronic hyperglycaemia in vitro demonstrated a smaller increase in [Ca2+]i in response to stimulation with 20 mmol/l glucose (δGCaMP6/F/F0 AUC at 20 mmol/l glucose; Cont, 5.89 ± 0.20 vs Hyp, 1.74 ± 0.72, p < 0.05), when compared to normoglycaemia-exposed controls. (ii) Mouse islet δ-cells subjected to chronic in vitro or in vivo hyperglycaemia, also revealed impaired [ATP] responses when subjected to acute glucose stimulation (δPerceval islets transfected with Perceval F/F0 AUC at 20 mmol/l glucose: Cont, 6.28 ± 0.21 vs Hyp, 2.06 ± 0.52, p < 0.01, δV59M islets transfected with Perceval F/F0 AUC at 20 mmol/l glucose: Cont, 2.87 ± 0.21 vs Hyp, 1.30 ± 0.17, p < 0.05) and (iii) lower glucose-stimulated Sst secretion (fold-change 20 mmol/l glucose vs 1 mmol/l glucose vs 1 mmol/l glucose; WT islets: Cont, 4.30 ± 0.13 vs Hyp, 2.36 ± 0.84; p < 0.05; δV59M islets: Cont, 24.75 ± 4.67 vs Hyp, 9.73 ± 3.49, p < 0.01), when compared to normoglycaemia-exposed controls. (iv) Similarly, human islets exposed to chronic in vitro hyperglycaemia also showed decreased glucose-stimulated Sst secretion when compared to normoglycaemia control islets.

Conclusion: These data demonstrate that chronic hyperglycaemia alone results in dysregulation of glucose-stimulated δ-cell function and reduced Sst secretion. This may, via loss of normal paracrine regulation of the α-cells, contribute to the abnormal increase in postprandial α-cell glucagon secretion seen in T2D patients.

Supported by: Novo Nordisk-Oxford Fellowship
Disclosure: T.G. Hill: None.

104 Paracrine signalling in delta cells is disturbed in human type 2 diabetes

L. Matusiweiciene1, O.M. Hmeadi2, P.E. Lund2, S. Barg2
1Uppsala University, 2Uppsala University, Uppsala, Sweden.

Background and aims: Pancreatic delta cells secrete somatostatin in response to elevated glucose, which in turn suppresses insulin and glucagon secretion from beta and alpha cells, respectively. In type 2 diabetes, this paracrine regulation is disturbed, but the underlying mechanisms remain unclear. Research on isolated delta cells is rare and relatively little is known about the cellular control of somatostatin release. The aim of this study was to quantify the effects of intra-islet signalling pathways on exocytosis and membrane potential in delta cells from non-diabetic and type 2 diabetic islets.

Materials and methods: Live cell imaging and electrophysiology were performed in dispersed pancreatic islets of non-diabetic (ND) or type 2 diabetic (T2D) cadaveric human donor islets. To identify delta cells and for imaging exocytosis by TIRF-microscopy, dispersed islet cells were transduced with adeno virus coding for fluorescent granular marker under control of somatostatin promoter. Exocytosis was evoked by elevated K+ in presence of 10mM glucose/200μM diazoxide (control) and either of the following: 100nM insulin, 10nM glucagon, 400nM somatostatin, 400nM GABA and 5μM adrenaline, 2μM forskolin, or 10nM exendin4. In addition, standard whole-cell voltage clamp and capacitance recordings were performed on single delta cells to study effects on exocytosis, ion channels. Somatostatin receptor 2 (SSTR2) expression was analysed by confocal microscopy of immunostained human pancreatic tissue sections.

Results: K+-stimulated exocytosis of somatostatin granules followed a biphasic timecourse, with a tendency towards reduced exocytosis in delta cells of T2D donors (-28%, p<0.08, 6 ND donors, n=50 cells; 4 T2D donors; n=25 cell). This was strengthened by capacitance recordings (-40%, p<0.018; 10 ND donors, n=68 cells; 4 T2D donors, n=42 cells). There were no changes in Ca2+-currents that could explain the decrease in exocytosis, but Na+-currents were reduced in T2D cells, compared with ND (-31%, p=0.02; 10 ND donors, n=66 cells; 4 T2D donors, n=34 cells). K+-stimulated exocytosis decreased in presence of somatostatin when compared with diazoxide only (-39%, p<0.03, 4 ND donors, n=18 cells) and robustly increased by glucagon (+50%, p<0.0001; 5 ND donors, n=28 cells), exendin4 (+61%, p<0.0001; 4 ND donors, n=17 cells), forskolin (+68%, p<0.0001, 5 ND donors, n=23 cells), and GABA (+66%, p<0.0001, 5 ND donors, n=22 cells). No significant difference in the compounds’ effects were detected between ND and T2D, or in 1 mM vs 10 mM glucose. In contrast, adrenaline inhibited exocytosis in ND delta cells (-59%, p<0.0001; 8 ND donors, n=41 cells), but significantly increased in T2D delta cells (+56%, p<0.0001; 2 T2D donors, n=13 cells; 6 ND donors, n=50 cells). In addition, short term exposure to GABA depolarized the membrane potential of delta cells, while somatostatin repolarized and inhibited electrical activity. Finally, immunostaining of human pancreas sections revealed internalization and reduced surface expression of SSTR2 in beta cells of T2D donors.

Conclusion: Human delta cells are responsive to autocrine inhibition by somatostatin, as well as a variety of paracrine signalling pathways. Type 2 diabetes is associated with decreased delta cell secretory capacity and a prominent reversal of adrenalin’s effect from inhibitory to stimulatory. The latter may indirectly contribute to hyperglycaemia in type 2 diabetes by strengthening somatostatin-dependent inhibition of insulin secretion.

Supported by: NNF, DF, BDF, VR, MF-UU, EXODIAB, Ernfor, Rudbergs
Disclosure: L. Matusiweiciene: None.

105 The requirement of beta cells to the glucose responsiveness of alpha cells depends on the depolarisation status of alpha cells

F. Khattab, P. Gilon;
IREC EDIN, UCLouvain, Brussels, Belgium.

Background and aims: The mechanisms by which glucose controls glucagon release are largely unknown. In particular, it is unclear whether...
glucose controls α-cell activity directly or indirectly via β- or δ-cells. In this study, we used mouse pseudo-Islets (PI) of various compositions to investigate the role of β- and δ-cells in the control of glucagon secretion by glucose.

**Materials and methods:** Several mouse models expressing a fluorescent protein specifically in α-, β-, or δ-cells were used. Islets were dispersed and cells were FACS-sorted. Highly pure populations of α-, β-, and δ-cells were then reaggregated into various types of pseudo-islets by culturing them during 5-6 days. The effect of a change of the glucose (G) concentration between 1 (G1) and 10 mmol/l (G10) was tested on glucagon and insulin secretions from islets or PI in perifusion experiments. Perifusion media contained a 2.1 mmol/l mixture of amino acids present at physiological concentrations and containing (in mmol/l) 0.4 alanine, 0.5 glutamine, 0.2 lysine, 0.25 glycine, 0.15 leucine, 0.25 valine, 0.15 threonine, 0.1 serine, and 0.1 arginine.

**Results:** Dispersed islets cells, including pure α-cells, spontaneously reaggregated into pseudo-islets within 5-6 days. As expected, control islets showed an increase in glucagon secretion in response to a drop of glucose concentration from G10 to G1. The response was similar in pseudoislets obtained after reaggregation of all cell types. However, glucagon release from pseudo-islets made of pure α-cells (α-PI) was impaired in response to glucose. The addition of β-cells (α/β-PI), but not δ-cells (α/δ-PI) to α-cells restored normal glucagon secretion in response to G1. To determine whether this restoration was specifically due to the presence of β-cells or simply to the reestablishment of cell-to-cell contacts with another cell type, α-cells were reaggregated with mouse embryonic fibroblasts (α/MEF-PI). The presence of MEF did not restore a normal glucagon response to G1. We also generated α/β/MEF-PI to verify that MEF did not interfere with glucagon secretion. α/β/MEF-PI showed a normal simulation of glucagon secretion in response to G1, further confirming the importance of β-cells. Interestingly, in the presence of diazoxide (a KATP channel opener) and high potassium (30 mmol/l K+) which, together, clamp the membrane potential at a depolarized level, a drop of glucose concentration from G10 to G1 stimulated glucagon release from α-PI, suggesting that glucose modulates the efficacy of Ca2+ on exocytosis in α-cells independently of β and δ-cells.

**Conclusion:** We show, for the first time, that mouse α-cells can reaggregate into pseudo-islets. We demonstrate that, in conditions where the plasma membrane is not clamped, glucagon secretion in response to glucose from pure α-PI is impaired, and that the addition of β-cells, but not δ-cells, restores a normal control of glucagon secretion by α-cells. However, in conditions where the plasma membrane is clamped at a depolarized level, low glucose efficiently stimulates glucagon release from pure α-PI, i.e. independently of β- and δ-cells.

**Supported by:** FRIA, FNRS, Helmsley, ARC, SFD, EFSD/JDRF/Lilly Programme

**Disclosure:** F. Khattab: None.

107 Insulin-like growth factor binding protein 7 reduces glucose stimulated insulin secretion and downregulates key beta cell transcription factors

E. Westholm, A. Karagiannopoulos, A. Wendt, L. Eliasson; Islet Cell Exocytosis Group, Faculty of Medicine, Malmö, Sweden.

**Background and aims:** Cystic fibrosis (CF) is one of the most prevalent genetic diseases in the world and is caused by loss-of-function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The most common non-pulmonary complication of CF is cystic fibrosis-related diabetes mellitus (CFRD), which is characterised by impaired insulin secretion. In a ferret CFTR-KO model, the secretome from pancreatic ductal epithelium showed an upregulation of transforming growth factor β1 (TGFβ1). In the same study TGFβ1 stimulated an increased expression of insulin-like growth factor binding protein 7 (IGFBP7) in the surrounding pancreatic stromal cells.
IGFBP7 can bind insulin with high affinity and interact with the insulin receptor and IGF receptors. The aim of this project is to investigate if IGFBP7 affects β-cell physiology, especially insulin secretion.

**Materials and methods:** EndoC-βH1 cells were used in glucose-stimulated insulin secretion (GSIS) experiments. In acute IGFBP7 treatment, the GSIS assay buffer was supplemented with 100 nM IGFBP7. C-peptide was measured as a proxy for secreted insulin using ELISA and the results were normalised to total protein (ng/mg prot/h). In long-term treatment, cells were cultured 72 h with 100 nM IGFBP7 prior to GSIS, and secreted insulin was normalised to total insulin (%/h). Gene expression after long-term treatment was assessed with RT-qPCR. RNA from EndoC-βH1 cells, 4 passages, and primary human islets from 4 donors was prepared using the TruSeq library kit and sequenced on an Illumina platform. Transcripts were quantified with Salmon v. 0.14 and results were processed using the DESeq2 tool and are reported as normalised counts. For GSIS and RT-qPCR data, statistical analysis was done using paired T-test.

**Results:** In acute treatment experiments, IGFBP7 reduced the secretion of C-peptide at 20 mM glucose stimulation (CTRL 111 ng/mg prot/h vs. IGFBP7 90 ng/mg prot/h, n=5, P=0.018). A similar effect was observed with long-term treatment of IGFBP7 (CTRL 5.2 %/h vs. IGFBP7 4.0 %/h, n=4, P=0.0083). Long-term treatment with IGFBP7 did not significantly change total insulin content of EndoC-βH1 cells. With long-term treatment, there was a decreased expression of genes encoding for important β-cell transcription factors such as PDX1, NKX6-1, Pax4, Foxo1 (n=4, P<0.05). We also saw a reduction of VAMP2 (n=4, P<0.05). In RNA sequencing data, there was similar expression of potential IGFBP7 binding receptor genes INSR, IGFR1, IGFR2 as with TGFBR1 and KCNJ11, in EndoC-βH1 cells and primary human islets. However, the expression of IGFBP7 was almost 50 times higher in primary human islets in comparison to EndoC-βH1 cells.

**Conclusion:** Combined, these experiments show that IGFBP7 cause impaired β-cell function with reduced insulin secretion and decreased gene expression levels of important β-cell genes. In the context of cystic fibrosis and CFRD, we hypothesize that elevated IGFBP7 functions as a mediator of pathophysiological intra-pancreatic crosstalk between defect ductal cells and islet cells. Such cross talk likely plays a role in disease development.

**Disclosure:** F. Brozzi: None.

108 Role of tRNA-derived fragments in the cross-talk between immune cells and beta cells during type 1 diabetes pathogenesis

**F. Brozzi**1, C. Cosentino1, C. Jacovetti1, K. Wu2, V. Menoud1, M.B. Bayazi1, C. Guay1, R. Regazzi1, 2
1Department of Fundamental Neurosciences, University of Lausanne, 2Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland.

**Background and aims:** Type 1 diabetes (T1D) is an autoimmune disease characterized by immune cell infiltration in the islets of Langerhans (insulitis). Immune cells release pro-inflammatory cytokines and extracellular vesicles (EVs) in the site of infiltration, causing β-cell death. This study focuses on decoding the dialogue between T-cells and β-cells during T1D pathogenesis, on the analysis of T-cell EV content and of their functional impact on β-cells. We have previously demonstrated that specific miRNAs are transferred from T-cells to β-cells via EVs during insulitis, causing β-cell inflammation and apoptosis. tRNA-derived fragments (tRFs) are also emerging as major components of T-cell EVs and may potentially be delivered to β-cells during the autoimmune attack. tRFs are fragments originating from transfer RNAs (tRNAs) and have several functions in the control of cellular processes, including apoptosis. Indeed, our preliminary results show an increase in tRF expression in islet cells of pre-diabetic NOD mice. The aim of the present study is to identify the tRFs that are transferred from T-cells to islet cells during T1D pathogenesis and affect β-cell function, inflammation, and survival.

**Materials and methods:** Small RNAseq analysis was performed in EVs isolated from NOD CD4+/CD25- T-cells and in pancreatic islet cells treated for 24 h with NOD T-cell EVs. To prove the direct transfer of selected tRFs, the RNA in the CD4+/CD25- T-cells was tagged with a uridine analogue (EU), and then isolated form the β-cells treated with the EVs produced from EU-tagged T-cells. The tagged RNA was analyzed by qPCR to identify selected tRFs transferred to β-cells. RNA mimics were used to overexpress the candidate tRFs in β-cells, with the aim of reproducing the EV-dependent rise of the selected RNA and study its effect. Apoptosis was assessed with Propidium Iodide (PI)/ Hoechst staining and cleaved caspase-3 assay.

**Results:** The small RNA data sets from T-cell EVs and from islet cells treated with EVs were compared with the tRFs that are significantly upregulated in the islets of pre-diabetic NOD mice (265 tRFs in 8 weeks-old vs 4 weeks-old mouse islets, adjusted p-value<0.05, n=4). From this comparison we identified a subset of 7 tRFs that are transferred from T-cells to β-cells in the initial phases of T1D. Their expression increased in islets during insulitis (2.0 to 6.2 Fold Change (FC), in 8 weeks-old vs 4 weeks-old mouse islets, p-value<0.05, n=4, t-Test) and after in-vitro incubation with T-cell EVs (2.0 to 4.8 FC in EV treated vs control islets, p-value<0.05, n=4, t-Test). Moreover, with an RNA-tagging strategy, we were able to recover in EV-treated β-cells some of the miRNAs and tRFs that were increased in NOD islet cells during insulitis. The overexpression of three tRFs candidates increased β-cell apoptosis in primary islet cells (1.6 to 1.8 FC, tRFs vs Ctrl, p-value<0.05, ANOVA).

**Conclusion:** We provide a direct “proof of concept” that tRFs can be shuttled between T-cells and β-cells via EVs, and identify a new mechanism through which T-cells may trigger β-cell dysfunction and apoptosis in T1D pathogenesis. Mechanistic studies will be done to evaluate the mode of action of selected tRFs and to evaluate the potential design of new strategies for the treatment of diabetic patients.

**Disclosure:** F. Brozzi: None.
OP 19 GLP1 agonists: from here to eternity

Dulaglutide in youth with type 2 diabetes: results of the AWARD-PEDS randomised, placebo-controlled trial

S. Arslanian1, T. Hannon2, P. Zeitzer3, L. Chao4, C. Boucher-Berry5, M. Barrientos-Pérez6, E. Bismuth7, S. Dhib8, J. Cho9, D. Cox6, 1UPMC Children’s Hospital of Pittsburgh, Pittsburgh, USA, 2Riley Hospital for Children, Indianapolis, Indiana, USA, 3Children’s Hospital Colorado, Aurora, USA, 4Children’s Hospital of Los Angeles, Los Angeles, USA, 5Children’s Hospital of the University of Illinois, Chicago, USA, 6Angeles Hospital of Puebla, Puebla, Mexico, 7University Robert Debré Hospital, Paris, France, 8Federal University of São Paulo State, São Paulo State, Brazil, 9Eli Lilly and Company, Indianapolis, USA.

Background and aims: AWARD-PEDS was a Phase 3 trial to assess the efficacy and safety of dulaglutide (DU), a once-weekly GLP-1 receptor agonist, in youth (10 to <18 years old) with type 2 diabetes (T2D) treated with lifestyle alone or on stable metformin with or without basal insulin. The primary aim was to demonstrate superiority of DU (pooled doses) vs placebo for change in HbA1c at 26 weeks.

Materials and methods: Participants (mean age, 14.5 yrs; mean BMI, 34.1 kg/m²) were randomised to placebo (N=51), DU 0.75 mg (N=51), or DU 1.5 mg (N=52). Analyses included all patients with ≥1 dose of study drug, excluding data after initiation of rescue therapy.

Results: DU was superior to placebo (figure) in improving glycaemic control measured by change in HbA1c, percent of patients with HbA1c <53 mmol/mol (7%), and change in fasting glucose at Week 26. No effect of DU was observed on BMI change (p=0.776). Fewer patients assigned to DU compared to placebo required rescue therapy (2.9% vs 17.6% respectively, p=0.003). Incidence of common GI adverse events was higher in DU group vs placebo (nausea (14.6% vs 7.8%), vomiting (15.5% vs 3.9%), diarrhoea (18.4% vs 13.7%)) but comparable to that observed in adults.

Conclusion: In conclusion, in youth with inadequately controlled T2D treated with or without metformin and/or basal insulin, once weekly DU 0.75 mg or 1.5 mg was superior to placebo in improving glycaemic control measured by change in HbA1c, percent of patients with HbA1c <53 mmol/mol (7%), and change in fasting glucose at Week 26. No effect of DU was observed on BMI change (p=0.776). Fewer patients assigned to DU compared to placebo required rescue therapy (2.9% vs 17.6% respectively, p=0.003). Incidence of common GI adverse events was higher in DU group vs placebo (nausea (14.6% vs 7.8%), vomiting (15.5% vs 3.9%), diarrhoea (18.4% vs 13.7%)) but comparable to that observed in adults.

Materials and methods: Nine patients with obesity and T2D (5 women, age: 45±3 years, weight: 127.4±8.1 kg, BMI: 42.7±2.3 kg/m²) were examined with a 75 g OGTT and three 90-min hyperglycemic clamps at ~15 mM plasma glucose (CV 2%) with primed continuous co-inusions of either GIP (1.5 pmol/kg/min), GLP-1 (1 pmol/kg/min) or saline before (pre) and 3 months (3mo) after RYGB. Beta-cell function was calculated separately for the OGTT (as beta-cell glucose sensitivity (βGS): slope between insulin secretion rates and plasma glucose concentrations) and the intravenous stimulation (first phase as the acute insulin response to glucose (AIR) (positive incremental (pi)AUC-0-10 min) and second phase (piAUC-20-90 min) during clamps).

Results: After RYGB, fasting plasma glucose decreased (pre: 7.9±0.3 mmol/L, 3mo: 5.4±0.3, p<0.01) and insulin sensitivity improved (HOMA2 IR: pre 4.1±0.3, 3mo: 2.4±0.2, p<0.01). Weight loss was 19.7±0.7 kg (14.9%). During the OGTT, 2-hour plasma glucose decreased (pre: 13.6±0.7 mmol/L, 3mo: 7.3±0.8, p<0.01) and insulin secretion increased resulting in a two-fold increase in β-GS (pre: 0.9±0.1 (mmol/ kg/min)/(mmol/L, 3 mo: 1.8 ±0.1, p<0.01). GIP secretion decreased slightly after RYGB (piAUC pre: 5270±913 pmol/L· min, 3mo: 4310±339, p=0.01), whereas GLP-1 secretion increased markedly (pre: 1156±583 pmol/L·min: 3mo: 6007±691, p<0.01). During the clamp both first and second phase of insulin secretion increased after RYGB (AIR pre: 15 ±5 pmol/kg·min, 3mo: 58±15, p<0.01; piAUC-20-90 min pre: 296±54, 3mo: 445 ±54, p<0.05), GIP-Infusion augmented second phase of insulin secretion equally before and after RYGB (pre: +96±16% vs saline-clamp, 3mo: +90±14%, p=0.57), GLP-1 infusions increased insulin secretion even more, with a small decline in the potentiation effect after RYGB (Pre: +390±84%, 3mo: +233±32%, p<0.03).

Conclusion: In patients with obesity and T2D, beta-cell function increases after RYGB both in response to oral and iv glucose. An insulinotrophic effect of GIP was demonstrated before surgery and this effect was maintained postoperatively. The potentiation effect of GLP-1 on insulin secretion was pronounced both before and after surgery with a slight decline observed after RYGB. Thus, the improved beta cell function in response to an oral glucose stimulus after RYGB is the result of GLP-1 hyperssecretion, rather than an increased insulinotropic action of the incretins.

Clinical Trial Registration Number: NCT04782999

Supported by: European Research Council, Horizon 2020, Grant: BYPASSWITHOUTSURGERY

Disclosure: M.S. Svane: Grants; European Research Council, Novo Nordisk Foundation, Danish Diabetes Association.

100 Beta cell function and sensitivity to incretins before and after Roux-en-Y gastric bypass in patients with type 2 diabetes

M.S. Svane1, M. Hindso1, C. Martinussen1, C. Dirksen1, N.B. Jørgensen1, B. Hartmann2, V.B. Kristiansen1, J.J. Holst2, K.N. Bojesen-Møller2, S. Madsbad1;

1Copenhagen University Hospital Hvidovre, Hvidovre, 2University of Copenhagen, Copenhagen, Denmark.

Background and aims: Roux-en-Y gastric bypass (RYGB) improves glucose tolerance in patients with type 2 diabetes (T2D), but whether RYGB affects beta-cells independently of signals from the gut is unclear. Also, the sensitivity of the beta-cell to glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) remains to be clarified. We aimed to investigate beta-cell function before and after RYGB, and particularly, the sensitivity of the beta-cell to the incretin hormones. We hypothesized that sensitivity to GIP would be increased after RYGB because of relieve of glucotoxicity.

Materials and methods: Nine patients with obesity and T2D (5 women, age: 45±3 years, weight: 127.4±8.1 kg, BMI: 42.7±2.3 kg/m²) were examined with a 75 g OGTT and three 90-min hyperglycemic clamps at ~15 mM plasma glucose (CV 2%) with primed continuous co-inusions of either GIP (1.5 pmol/kg/min), GLP-1 (1 pmol/kg/min) or saline before (pre) and 3 months (3mo) after RYGB. Beta-cell function was calculated separately for the OGTT (as beta-cell glucose sensitivity (β-GS): slope between insulin secretion rates and plasma glucose concentrations) and the intravenous stimulation (first phase as the acute insulin response to glucose (AIR) (positive incremental (pi)AUC-0-10 min) and second phase (piAUC-20-90 min) during clamps).

Results: After RYGB, fasting plasma glucose decreased (pre: 7.9±0.3 mmol/L, 3mo: 5.4±0.3, p<0.01) and insulin sensitivity improved (HOMA2 IR: pre 4.1±0.3, 3mo: 2.4±0.2, p<0.01). Weight loss was 19.7±0.7 kg (14.9%). During the OGTT, 2-hour plasma glucose decreased (pre: 13.6±0.7 mmol/L, 3mo: 7.3±0.8, p<0.01) and insulin secretion increased resulting in a two-fold increase in β-GS (pre: 0.9±0.1 (mmol/ kg/min)/(mmol/L, 3 mo: 1.8 ±0.1, p<0.01). GIP secretion decreased slightly after RYGB (piAUC pre: 5270±913 pmol/L· min, 3mo: 4310±339, p=0.01), whereas GLP-1 secretion increased markedly (pre: 1156±583 pmol/L·min: 3mo: 6007±691, p<0.01). During the clamp both first and second phase of insulin secretion increased after RYGB (AIR pre: 15 ±5 pmol/kg·min, 3mo: 58±15, p<0.01; piAUC-20-90 min pre: 296±54, 3mo: 445 ±54, p<0.05), GIP-Infusion augmented second phase of insulin secretion equally before and after RYGB (pre: +96±16% vs saline-clamp, 3mo: +90±14%, p=0.57), GLP-1 infusions increased insulin secretion even more, with a small decline in the potentiation effect after RYGB (Pre: +390±84%, 3mo: +233±32%, p<0.03).

Conclusion: In patients with obesity and T2D, beta-cell function increases after RYGB both in response to oral and iv glucose. An insulinotrophic effect of GIP was demonstrated before surgery and this effect was maintained postoperatively. The potentiation effect of GLP-1 on insulin secretion was pronounced both before and after surgery with a slight decline observed after RYGB. Thus, the improved beta cell function in response to an oral glucose stimulus after RYGB is the result of GLP-1 hyperssecretion, rather than an increased insulinotropic action of the incretins.

Clinical Trial Registration Number: NCT04782999

Supported by: European Research Council, Horizon 2020, Grant: BYPASSWITHOUTSURGERY

Disclosure: M.S. Svane: Grants; European Research Council, Novo Nordisk Foundation, Danish Diabetes Association.

**Background and aims:** Multi-receptor incretin agonists are being developed for several metabolic disorders. LY is an investigational triple agonist with potent activity on glucose-dependent insulinotropic polypeptide (GIP), glucagon-like polypeptide-1 (GLP-1), and glucagon receptors. LY was safely studied in a prior first-in-human study, and pharmacokinetic properties supported once weekly dosing. The primary objective of this randomized, double-blind, placebo-controlled, Phase 1 proof-of-concept study was to assess the safety and tolerability of multiple ascending doses of LY in patients with type 2 diabetes (T2D).

**Materials and methods:** Seventy-two patients were randomized (9:3:1) to 5 rising dose cohorts of subcutaneous LY, placebo, and dulaglutide 1.5mg, respectively. Within cohort, dose-escalation was implemented at highest 2 cohorts. Vital signs, laboratory data and adverse events (AEs) were monitored to assess safety and tolerability. Efficacy was assessed by monitoring change in glycated hemoglobin (HbA1c) and body weight at week 12.

**Results:** The most common treatment-emergent AEs were gastrointestinal (nausea and diarrhea), which were mostly mild in severity. By week 12, mean systolic and diastolic blood pressure decreased from baseline in LY compared to placebo group, while pulse and heart rate increased from baseline within most of the LY cohorts and the dulaglutide cohort, but not with placebo. By week 12, mean HbA1c decreased from baseline in all groups, with higher doses of LY showing statistically significant, placebo-adjusted decreases of up to 17.1 mmol/mol. Except at the initial cohort, dose-dependent decreases in mean placebo-adjusted body weight of up to 8.96 kg were observed with LY.

**Conclusion:** LY3437943 exhibits a safety and tolerability profile similar to other incretins. The promising glycemic and body weight loss efficacy within this study highlights the potential for LY to provide additional benefit versus existing therapies in treatment of T2D and obesity.

*Clinical Trial Registration Number: NCT04143802*


112

**Effect of liraglutide on muscle fat infiltration in adults with overweight or obesity: a randomised clinical trial**

K.V. Patel¹, A. Pandey², C. Ayers³, J. Linge³, O.D. Leinhard³, P.H. Joshi³, J.J. Neeland³;¹Houston Methodist Hospital, Houston, USA, ²University of Texas Southwestern Medical Center, Dallas, USA, ³AMRA Medical and Linköping University, Linköping, Sweden, ⁴University Hospitals Harrington Heart and Vascular Institute and Case Western Reserve University School of Medicine, Cleveland, USA.

**Background and aims:** Excess muscle fat is observed in obesity and associated with greater burden of cardiovascular risk factors and higher risk of mortality. Liraglutide reduces total body weight and visceral fat but its effect on muscle fat infiltration (MFI) is unknown.

**Materials and methods:** This study is an analysis of a randomized, double-blind, placebo-controlled trial that examined the effects of liraglutide plus a lifestyle intervention on visceral adipose tissue among adults with body mass index ≥30 kg/m² or ≥27 kg/m² and metabolic syndrome associated with greater burden of cardiovascular risk factors and higher risk of mortality. Liraglutide reduces total body weight and visceral fat but its effect on muscle fat infiltration (MFI) is unknown.

**Materials and methods:** This study is an analysis of a randomized, double-blind, placebo-controlled trial that examined the effects of liraglutide plus a lifestyle intervention on visceral adipose tissue among adults with body mass index ≥30 kg/m² or ≥27 kg/m² and metabolic syndrome associated with greater burden of cardiovascular risk factors and higher risk of mortality. Liraglutide reduces total body weight and visceral fat but its effect on muscle fat infiltration (MFI) is unknown.

**Materials and methods:** This study is an analysis of a randomized, double-blind, placebo-controlled trial that examined the effects of liraglutide plus a lifestyle intervention on visceral adipose tissue among adults with body mass index ≥30 kg/m² or ≥27 kg/m² and metabolic syndrome associated with greater burden of cardiovascular risk factors and higher risk of mortality. Liraglutide reduces total body weight and visceral fat but its effect on muscle fat infiltration (MFI) is unknown.

**Materials and methods:** This study is an analysis of a randomized, double-blind, placebo-controlled trial that examined the effects of liraglutide plus a lifestyle intervention on visceral adipose tissue among adults with body mass index ≥30 kg/m² or ≥27 kg/m² and metabolic syndrome associated with greater burden of cardiovascular risk factors and higher risk of mortality. Liraglutide reduces total body weight and visceral fat but its effect on muscle fat infiltration (MFI) is unknown.

**Materials and methods:** This study is an analysis of a randomized, double-blind, placebo-controlled trial that examined the effects of liraglutide plus a lifestyle intervention on visceral adipose tissue among adults with body mass index ≥30 kg/m² or ≥27 kg/m² and metabolic syndrome associated with greater burden of cardiovascular risk factors and higher risk of mortality. Liraglutide reduces total body weight and visceral fat but its effect on muscle fat infiltration (MFI) is unknown.

**Results:** Among the 128 participants with follow-up imaging (92.2% women, 36.7% Black), median MFI at baseline was 7.8%. The percent change in MFI over follow-up was greater among participants randomized to liraglutide (n = 73) compared with placebo (n = 55) (-2.81% vs. -0.29%, p-value = 0.001) (Figure). Longitudinal change in MFI was significantly correlated with change in body weight (r = 0.30), visceral adipose tissue (r = 0.41), and abdominal subcutaneous adipose tissue (r = 0.32) but not with change in total body lean tissue or total thigh muscle.

**Conclusion:** Among adults with overweight or obesity free of diabetes, once daily subcutaneous liraglutide reduced mean anterior thigh MFI compared with placebo independent of changes in thigh muscle volume. The contribution of MFI improvement to the cardiometabolic benefits of liraglutide require further study.

![Figure. Participant-level relative change in mean muscle fat infiltration across treatment groups](image-url)

*Clinical Trial Registration Number: ClinicalTrials.gov Identifier: NCT03038620*

*Disclosure: K.V. Patel: None.*

113

**Glucagon-like peptide 1 receptor agonists and gallbladder or biliary diseases: data from the FDA Adverse Event Reporting System**

H. Zhang, L. He, J. Wang, N. Yang, W. Li, L. Xu, Y. Li, F. Ping; Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking U, Beijing, China.

**Background and aims:** Associations between glucagon-like peptide 1 receptor agonists (GLP-1RAs) and gallbladder or biliary diseases remains controversial in real-world settings. We aimed to make a detailed analysis of the gallbladder or biliary diseases reports for GLP-1RAs versus sodium-glucose cotransporter-2 inhibitors (SGLT-2i) or non-GLP-1RAs in the United States Food and Drug Administration Adverse Event Reporting System (FAERS).

**Materials and methods:** The FAERS database was mined from the first quarter of 2013 to the fourth quarter of 2020. Disproportional analyses with proportional reporting ratios (PRR) and 95% confidence intervals (CI) and multiple logistic analyses with odds ratios (OR) and 95% CI were performed.
Results: 1,109 cases of gallbladder or biliary diseases were extracted from the FAERS database. Significant associations between GLP-1RAs and increased reporting of gallbladder or biliary diseases were observed in the disproportional analyses (PRR: 2.366 [95% CI: 2.057-2.721]) and multiple-adjusted analyses (OR: 2.992 [95% CI: 2.533-3.534], P<0.0001), which remained consistent across the subcategories. Liraglutide (PRR: 5.001 [95% CI: 4.277-5.847]) and semaglutide (PRR: 6.267 [95% CI: 5.143-7.635]) showed significant signals of gallbladder or biliary diseases; exenatide and dulaglutide showed significant signals of only cholelithiasis and biliary obstruction, respectively. More gallbladder or biliary diseases reports with GLP-1RAs were observed in males than females (P=0.0134) and groups with indications of weight reduction than glycemic control (P<0.0001).

Conclusion: GLP-1RAs was associated with increased reporting of not only gallbladder disorders but also biliary diseases in a large pharmacovigilance database, particularly semaglutide and liraglutide, adding to available evidence from trials through real-word data.

Supported by: Natural Science Foundation of Beijing Municipality Beijing (M22014)
Disclosure: H. Zhang: None.
OP 20 NAFLD and treatment

115
One night of prolonged fasting improves nocturnal substrate oxidation without modulating hepatic glycogen in individuals with NAFL and healthy age-matched individuals.

K.H.M. Roumans1, A. Veelen1, C. Andriessen1, J. Mevenkamp1,2, P. Veeraiah1,2, B. Havekes3, H.P.F. Peters4, L. Lindeboom1,2, P. Schrauwen1, V.B. Schrauwen-Hinderling1,2;

1Department of Nutrition and Movement Sciences, Maastricht University, Maastricht, 2Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, 3Department of Internal Medicine, Maastricht University Medical Center, Maastricht, 4Unilever Food Innovation Center, Wageningen, Netherlands.

Background and aims: Increasing overnight fasting time, as with time-restricted eating, has been shown to improve metabolic health. The mechanisms underlying these beneficial metabolic effects remain inconclusive, but may be related to larger fluctuations in hepatic glycogen which in turn could induce a higher fat oxidation during the night. Increasing fat oxidation may especially be an interesting therapeutic strategy for people with a high amount of ectopic fat accumulation, as with non-alcoholic fatty liver (NAFL). Here, we investigated whether acutely prolonging an overnight fast from 9.5-hours to 16-hours, without changing total daily energy intake, reduces overnight hepatic glycogen and improves substrate metabolism in individuals with NAFL compared to age-matched healthy lean individuals.

Materials and methods: Eleven participants with NAFL and ten control participants participated in a randomized cross-over trial, restricting food intake to either a 14.5- or 8-hour time period, thereby creating an overnight period of 9.5-hours of fasting or 16-hours of fasting. Hepatic glycogen was measured with 13C-MRS after a standardized lunch at 2 pm and the next morning at 6:30 am in both arms. Nocturnal substrate oxidation was measured with whole-room indirect calorimetry (respiration chamber) and a meal test was performed in the morning after the overnight fast to assess the metabolic response to a meal using indirect calorimetry (ventilated hood) and assessment of plasma metabolites from blood draws.

Results: Hepatic glycogen levels were not affected by extending overnight fasting time in the NAFL or control group. Extending fasting time led to a lower nocturnal carbohydrate oxidation and higher fat oxidation in both groups (intervention * time, p < 0.005; for carbohydrate and fat oxidation). However, in both arms, the respiratory exchange ratio measured during the night remained higher in the NAFL group compared with the control group (population p < 0.001, figure 1). During the meal test, the AUC of triglycerides appeared higher with a 16-hour versus 9.5-hour fast in both the NAFL and control group (intervention, p = 0.014), but no other postprandial differences between short and extended fasting were observed.

Conclusion: These results suggest that a prolonged overnight fast can improve nocturnal substrate oxidation, and that these improvements are not mediated by changes in hepatic glycogen depletion.

Figure 1: Nocturnal respiratory exchange ratio during 9.5 hours and 16 hours overnight fasting. During the course of the night, substrate oxidation reflected by the RER changed differently in response to the 16-hour fast compared to the 9.5-hour fast (intervention * time, p = 0.002). Furthermore, RER remained higher in the NAFL group as compared to the control group (population, p = 0.001).

Clinical Trial Registration Number: NCT03593343 and NCT04510155
Supported by: PPP Allowance by top Sector Life Sciences & Health and by Unilever R&D Wageningen
Disclosure: K.H.M. Roumans: None.

116
Therapeutic benefits of 17α-estradiol in hepatic fibrosis

S. Ali Mondal, R. Sathiaselvan, B. Miller, M. Stout; Aging & Metabolism, Oklahoma Medical Research Foundation, Oklahoma City, USA.

Background and aims: Diabetes is an independent risk factors for the development of non-alcoholic steatohepatitis (NASH), the leading cause of liver transplant in the world. Moreover, liver fibrosis is the best determinant of mortality in NASH, therefore the reversal of liver fibrosis is a major focus in the field. There is currently no approved therapy for treating liver fibrosis. Men and postmenopausal women are at a higher risk of developing liver fibrosis compared to premenopausal women, thereby indicating a role of endogenous estrogens in controlling the progression of liver fibrosis. In this study, we sought to determine if 17α-E2 can prevent and/or reverse collagen deposition and/or increase collagen degradation in a CCl4-induced liver fibrosis mice model.

Materials and methods: 12-14 weeks old C57BL/6J male mice were used and randomized into five groups: (a) Vehicle group (n=15): mice were injected with olive oil intraperitoneally(i.p.) twice weekly for 8 weeks. (b) CCl4 group (n=15): mice were injected with 40% CCl4 (at a dose of 1ul/g bodymass) i.p. weekly twice for 8 weeks. Mice were maintained on Chow TestDiet 58YP (c) CCl4-17α-E2-Preventive group: Chow+17α-E2 (TestDiet 58YP + 17α-E2, 14.4ppm) treatment started on day 29 (after week 4) of CCl4 injection (1ul/g bodymass), i.p., weekly twice for 8 weeks. (d) CCl4-17α-E2-Therapeutic group: Chow+17α-E2 (TestDiet 58YP + 17α-E2, 14.4ppm) treatment started on day 29 (after week 4) of CCl4 injection (1ul/g bodymass, i.p.) injections to find out the effect of 17α-E2 in treating already developed fibrotic liver. (e) A short-term liver injury group (CCl4 -Baseline; n=18) was introduced using 40% CCl4 injected (i.p.), weekly twice at a dose of 1ul/g bodymass for 4 weeks to check the baseline development of liver fibrosis. The preventive and therapeutic effects of 17α-E2 treatment on collagen turnover rates were evaluated using stable isotope (D2O) labeling techniques.

Results: Compared with control mice, mice receiving CCl4 displayed a robust upregulation of hepatic collagen synthesis rates (P<0.0001) and declines in collagen degradation (P=0.0001) and desmin in collagen degradation (P=0.0001) in parallel with significant elevations in TGF 1(P<0.0001) and lysyl oxidase like-2 protein (LOXL2)(P<0.0001), which are responsible for hepatic stellate cell activation and collagen crosslinking, respectively. Conversely, mice receiving 17α-E2 demonstrated significantly reduced collagen synthesis rates(P=0.0001) and greater collagen degradation rates(P<0.001), which was mirrored by declines in TGF 1(P<0.05) and LOXL2 protein(P<0.05), especially in the therapeutic group. These improvements were associated
with increased matrix metalloproteinase-2 activity ($P<0.05$) and elevated levels of PPARα ($P<0.05$) in both the preventive and therapeutic groups, which are established mechanisms related to the regression of liver fibrosis.

**Conclusion:** These findings indicate that 17α-E2 acts in a multimodal fashion to reduce fibrotic burden in the liver. Future studies will be needed to determine the cell-type-specific mechanisms by which 17α-E2 affects collagen deposition and degradation in the liver.

Supported by: NIH [R00 AG051661; R01 AG070035]

Disclosure: S. Ali Mondal: None.

---

**177** The effect of a 16-week diet intervention with or without differing amounts of exercise volume on hepatic fat content in people with type 2 diabetes

C. Durrer$^1$, M. Lyngbæk$^1$, B. Liebetrau$^1$, G.E. Legård$^1$, T.P. Almdal$^2$, M.A.V. Lund$^3$, M. Ried-Larsen$^1$

$^1$Centre for Physical Activity Research, Rigshospitalet, $^2$Hormone and Metabolic Diseases, Rigshospitalet, $^3$Department of Biomedical Sciences, Copenhagen University, Copenhagen, Denmark.

**Background and aims:** Diet and exercise with the goal of weight loss continue to be the first line treatment for non-alcoholic fatty liver disease (NAFLD) and represent a means to treat the disease which otherwise has no approved pharmacological treatment. Exercise, even independent of weight loss, can relieve hepatic insulin resistance and decrease fat liver content but its effectiveness in addition to dietary changes is unclear. The aim of this project was to test the hypothesis that an energy-reduced diet, with or without concomitant exercise training (at two different levels of exercise volume) in people with type 2 diabetes (T2D) will reduce liver fat in a dose-dependent manner.

**Materials and methods:** The study was a secondary analysis of a 16-week parallel group, 4-arm assessor blinded randomized controlled trial. People with T2D aged 18-80 years, diabetes duration <7 years, absence of severe comorbidities were eligible for the study. Participants were randomly allocated (1:1:1:1, stratified by sex) to either 1) No intervention control (CON), 2) Dietary intervention (DIET), 3) DIET + moderate volume exercise (MVE), or 4) DIET + high volume exercise (HVE). Medications were managed using a pre-defined algorithm by a study endocrinologist blinded to participant allocation. Hepatic fat content was quantified via magnetic resonance imaging-derived proton density-fat fraction (MRI-PDFF) in patients with nonalcoholic fatty liver disease (NAFLD).

**Results:** Following the 16-week intervention there were reductions in liver fat by -53% [CI: -75 to -10]; $P=0.022$ in the DIET group, -72% [CI: -85 to -47]; $P<0.001$ in the MVE group, and -83% [CI: -91 to -68]; $P=0.001$ in the HVE group compared to CON. There were no significant differences in liver fat reduction between the DIET and MVE group or the MVE and HVE group, but there was a larger reduction in liver fat in the HVE group compared to the DIET group (-63% [CI: -79 to -35]; $P=0.001$). Marginal means and associated 95% confidence intervals at follow-up are presented in Figure 1, the dashed red line represents the constrained baseline.

**Conclusion:** A 16-week intervention with a 25% caloric deficit is able to reduce liver fat in people with T2D. There is an additional reduction in liver fat only when a high-volume of exercise training is added to the diet intervention.

---

**118** Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: a randomised controlled trial (ESSENTIAL study)

Y. Kim

Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea.

**Background and aims:** The effect of ezetimibe, Niemann-Pick C1-Like 1 inhibitor, on liver fat is not clearly elucidated. Our primary objective was to evaluate the efficacy of ezetimibe plus rosuvastatin versus rosuvastatin monotherapy to reduce liver fat using magnetic resonance imaging-derived proton density-fat fraction (MRI-PDFF) in patients with nonalcoholic fatty liver disease (NAFLD).

**Materials and methods:** A randomized controlled, open-label trial of 70 participants with NAFLD confirmed by ultrasound were assigned to receive either ezetimibe 10 mg plus rosuvastatin 5 mg daily or rosuvastatin 5 mg for up to 24 weeks. Liver fat change was measured as average values in each of nine liver segments by MRI-PDFF. Magnetic resonance elastography (MRE) was used to measure liver fibrosis change.

**Results:** Combination therapy significantly reduced liver fat compared with monotherapy by MRI-PDFF (mean difference: 3.2%; $p=0.020$).

There were significant reductions from baseline to study completion by MRI-PDFF for both the combination and monotherapy groups, respectively (18.1% to 12.3%; $p<0.001$ and 15.0% to 12.4%; $p=0.003$). Individuals with higher body mass index, type 2 diabetes, insulin resistance, and severe liver fibrosis were likely to be good responders to treatment with ezetimibe. MRE-derived change in liver fibrosis was not significantly different (both groups, $p>0.05$). CAP (controlled attenuation parameter) by transient elastography was significantly reduced in the combination group (321 dB/m to 287 dB/m; $p=0.018$), but not in the monotherapy group (323 dB/m to 311 dB/m; $p=0.104$).

**Conclusion:** Ezetimibe and rosuvastatin were found to be safe to treat participants with NAFLD. Further, ezetimibe combined with rosuvastatin significantly reduced liver fat in this population.

Clinical Trial Registration Number: NCT03434613

Supported by: Yuhan Corporation

Disclosure: Y. Kim: None.
119

Time-restricted feeding and obeticholic acid/semaglutide drug combination have a different impact on non-alcoholic steatohepatitis in diet-induced obese mice

F. Briand, N. Breyner, E. Grasset, T. Sulpice;
PHYSIOGENEX, Escalquens, France.

Background and aims: Combination of therapies is a promising strategy for the treatment of NASH and liver fibrosis. Here we evaluated whether the Farnesoid X Receptor agonist obeticholic acid (OCA) combined with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (SEMA) would show superior effects than weight loss induction with time-restricted feeding (TRF) in mice.

Materials and methods: Mice were fed a 60% high fat/2% cholesterol diet with 10% fructose supplemented drinking water (HFCF diet) for 25 weeks to induce obesity and NASH/liver fibrosis. After the diet-induction period, mice were kept on HFCF diet and treated with vehicle (control) or OCA 30mg/kg p.o. QD + SEMA 0.06mg/kg s.c. QD, or placed on TRF from the last 3 hours of the dark cycle till the end of the light cycle, without access to food, but free access to normal drinking water (i.e. without fructose) every day, for 6 weeks.

Results: OCA+SEMA induced a 20% lower caloric intake, which led to a 27% lower body weight (p<0.001 vs. control). TRF had a weaker effect on caloric intake (-9%) but also reduced body weight (-11%, p<0.05 vs. control). Both OCA+SEMA and TRF reduced the HOMA-IR index of insulin resistance and significantly reduced plasma ALT and AST levels, but these effects were more pronounced with OCA+SEMA. TRF, and to a greater extent OCA+SEMA, significantly reduced liver weight, hepatic fatty acids, triglycerides, and total cholesterol levels. Both OCA+SEMA and TRF led to significantly lower NAFLD activity score. However, OCA+SEMA did not alter liver fibrosis, while TRF showed a clear anti-fibrotic effect in the liver, with lower % Sirius Red labelling (p<0.05 vs. control).

Conclusion: OCA+SEMA combination reduced body weight and NAFLD activity score but did not improve hepatic fibrosis, while TRF improved both NASH and liver fibrosis. These TRF benefits should be further investigated in obese NASH patients.

Disclosure: F. Briand: Employment/Consultancy; PHYSIOGENEX. Stock/Shareholding; PHYSIOGENEX.

120

Cellular resistance to reactive metabolites is reversely affected by acute glucose stress and caloric restriction in type 2 diabetes patients with complications

A. Sulaj1,2, E. von Rauchhaupt1,2, C. Rodemer1, R. Bulkescher1, E. Kliemank1, S. Kopf1,2, P.P. Nawroth1,2, J. Szendroedi1,2, J. Zemvá1, E. Grasset, T. Sulpice, N. Breney, E. Grasset, A. Sulaj, F. Briand, N. Breyner, E. Grasset, T. Sulpice

1University Hospital of Heidelberg, Heidelberg, 2German Center for Diabetes Research, Neuherberg, Germany.

Background and aims: Reactive oxygen (ROS) and reactive dicarbonyl species (RCS) such as methylglyoxal (MG), are reactive metabolites (RM) known to contribute to the progression of diabetic complications. Depending on the dose, RM can also act protective by inducing hormetic reactions rendering cells more resistant to potentially harmful RM. This study investigated the cellular resistance to ROS and RCS in patients with type 2 diabetes with (T2D+) and without (T2D-) diabetic complications compared to healthy subjects (Ctrl) under acute glucose stress as well as under caloric restriction, to test whether these conditions have an impact on hormesis.

Materials and methods: An oral glucose tolerance test (oGTT) was performed before and after 5 days of fasting-mimicking diet (FMD) in T2D+ and T2D- patients and in healthy subjects (n=10: 6 males, 4 females per group). Study participants were matched for age, BMI, diabetes duration, HbA1c and antihyperglycemic medication. Peripheral blood mononuclear cells (PBMCs) were isolated before and 2h after the oGTT. PBMCs were immediately plated on a 96-well plate. To test resistance to ROS and RCS, cells were incubated with increasing levels of H2O2 and MG respectively for 24hrs. Afterwards, cell viability was measured with a CellTiter-Glo assay to calculate the corresponding EC50-value. Differences in EC50-value before and after oGTT were expressed as percentage changes (ΔEC50).

Results: Age and BMI were as expected comparable between study groups (T2D+: 66.3 [61.6, 71.0] yrs, 29.0 [26.5, 31.5] kg/m2; T2D-: 63.8 [60.2, 67.4] yrs, 27.9 kg/m2 [25.7, 30.2]; Ctrl: 63.8 [58.6, 69.0] yrs, 28.8 [25.5, 32.2] kg/m2. HbA1c was comparable between T2D+ and T2D- patients, but significantly higher in T2D+ (7.4 [6.9, 7.9] %, p < 0.0001) and T2D- (7.0 [6.2, 7.7] %, p < 0.0001) compared to Ctrl (5.5 [5.1, 5.8] %). ΔEC50 of MG increased in healthy controls before (+12.9 %) and after (+12.6 %) FMD, whereas ΔEC50 of MG was unaffected in T2D- (before FMD: +1.8 %; after FMD: -1.7 %). In T2D+ ΔEC50 of MG significantly decreased after FMD (before FMD: -3.9 %; after FMD: -19.0 %, p = 0.005) and was reduced compared to T2D- (-1.7 % vs. -19.0 %, p = 0.035) and healthy controls (+12.6 % vs. -19.0 %, p = 0.035). ΔEC50 of H2O2 showed the same trend in all groups as for MG, but did not reach significance. However, H2O2 of H2O2 before oGTT was significantly higher in T2D+ as compared to T2D- (before FMD: 134.3 μM vs. 91.8 μM, p = 0.028; after FMD: 134.0 μM vs. 98.6 μM, p = 0.032) and Ctrl (before FMD: 134.3 μM vs. 116.5 μM, p = 0.030; after FMD: 134.0 μM vs. 125.8 μM, p = 0.038). These results could mainly be attributed to higher EC50 values in female study participants.

Conclusion: Acute glucose stress induces cellular resistance to ROS and RCS in a hormetic manner in healthy subjects, a response which in diabetic patients seems to be lost during progression into diabetic complications. This response could not be restored after 5 days of caloric restriction. Furthermore, our data suggest for different capacities in handling of RM between female and male diabetic patients.

Supported by: German Research Foundation DFG (SFB 1118), German Center for Diabetes Research DZD (82DZD07C2G)

Disclosure: A. Sulaj: None.
121
An early window of opportunity: risk factors for diabetic retinopathy are associated with early retinal neurodegenerative changes: The Maastricht Study
F. van der Heide1, S. Mokhtar1, R. Henry1, A. Kroon1, P. Dagnec1, T. Berendschot1, S. Eussen1, J. Schouwen2, M. Schram1, C. van der Kallen1, M. van Greevenbroek1, H. Savelberg1, N. Schaper1, C. Webers1, C. Stelhouwer1;
1University of Maastricht, Maastricht, 2Canisius ziekenhuis, Nijmegen, Netherlands.

Background and aims: If determinants of retinal neurodegeneration, which precedes diabetic retinopathy, can be identified, there may already be an opportunity for the early prevention of diabetic retinopathy in individuals who are at risk for type 2 diabetes (e.g., individuals with prediabetes or obesity). We investigated the associations of risk factors for diabetic retinopathy with retinal neurodegenerative changes, using population-based data from an observational cohort study.

Materials and methods: We used cross-sectional data from The Maastricht Study (up to 5,666 participants, 50.5% men, mean ± SD age 59.7 ± 8.7 years, and 22.6% with type 2 diabetes [the latter oversampled by design]). We investigated the associations of risk factors for diabetic retinopathy with retinal sensitivity, an index of retinal function, and retinal nerve fibre layer (RNFL) thickness, an index of retinal neural structure. We used linear regression analyses (results expressed as standardized betas) and adjusted for potential confounders (age, sex, educational level and key cardiovascular risk factors). We tested for interaction by sex and type 2 diabetes status.

Results: After full adjustment, greater HbA1c and lower healthy diet score (quantified with the Dutch healthy Diet index) were associated with lower retinal sensitivity (standardized betas [95%CI] -0.05 [-0.08; -0.02] and -0.06 [-0.09; -0.03], respectively) and lower RNFL thickness (-0.05 [-0.08; -0.02] and -0.03 [-0.06; -0.00]; high versus light alcohol consumption was associated with lower RNFL thickness (-0.08 [-0.16; -0.01]) and lower retinal sensitivity (0.04 [-0.04; 0.10]); current versus never smoking was associated with lower retinal sensitivity (-0.14 [-0.22; -0.06]), but not with RNFL thickness (0.09 [-0.00; 0.18]); in individuals with, but not in individuals without, type 2 diabetes greater 24-hour ambulatory systolic blood pressure was associated with lower retinal sensitivity and lower RNFL thickness (in individuals with type 2 diabetes, -0.06 [-0.12; -0.04] and -0.06 [-0.13; 0.00], respectively); and, higher total cholesterol level was associated with greater retinal sensitivity (0.05 [0.02; 0.08]) and greater RNFL thickness (the latter only in individuals with type 2 diabetes; in individuals with type 2 diabetes, 0.09 [0.03; 0.16]). Sex did not modify any of the associations under study.

Conclusion: This population-based study found that most risk factors for diabetic retinopathy were independently associated with retinal neurodegenerative changes. Hence, early prevention of risk factors for diabetic retinopathy, already in individuals with prediabetes or obesity, may contribute to the prevention of diabetic retinopathy.

Supported by: ERDF, PL, DMEA, SW, PSID, CVCM, CARIM, CAPHRI, NUTRIM, SA. Periméd, DF, OF, HE, JC, NNF, SAN
Disclosure: F. van der Heide: None.

122
Transcriptome analysis reveals that retinal neuromodulation is the main underlying mechanism of the neuroprotective effect of sitagliptin in diabetic retina
H. Ramos, P. Bogdanov, J. Huerta, A. Deas-Just, C. Hernández, R. Simó;

Background and aims: The neurovascular unit (NVU) is a functional coupling between neurons, glial cells and blood vessels that integrates vascular flow with metabolic activity. Its impairment is an early event in the pathogenesis of diabetic retinopathy (DR), which participates in the neurodegeneration and the early microvascular impairment of the diabetic retina. Consequently, NVU becomes an emergent therapeutic target of DR. The reduction of synaptic protein expression, the impairment of neurotransmission and alterations in neuronal morphology have been described as underlying mechanisms of NVU impairment. We previously reported that topical administration (eye drops) of sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i), prevented retinal neurodegeneration induced by diabetes in db/db mice. To further explore the mechanisms involved in the beneficial effects of DPP-4i on diabetes-induced retinal neurodegeneration, we have compared by transcriptomic analysis the retinal expression patterns of mRNA in vehicle-treated db/db mice (an experimental model of DR) vs. db/db mice treated with sitagliptin.

Materials and methods: Ten db/db mice, aged 10 weeks, were topically treated with sitagliptin eye drops (5 μL/eye; concentration: 10 mg/mL) for 2 weeks twice per day, while other ten db/db received a topical administration of vehicle (5 μL/eye). Ten db/+ mice (non-diabetic mice) were assigned as control group. Before euthanasia, full-field electroretinogram recordings were used to address retinal functionality. At 12 weeks, after euthanasia, one eye was used for a transcriptome analysis and the other for its validation through RT-PCR and for protein assays through Western Blotting (WB) and Immunohistochemistry (IHC). Biological relevance of the transcriptome analysis was assessed through gene set enrichment analyses (GSEA) on two different annotation databases [Gene Ontology and Reactome Pathway Knowledge base].

Results: Diabetic mice topically treated with sitagliptin presented different expression patterns of mRNA in the retina in comparison to those treated with vehicle. GSEA revealed a positive enrichment, after sitagliptin treatment, of multiple candidates linked to synaptic transmission. Additionally, we observed in both, RT-PCR and WB/IHC assays, that presynaptic proteins involved in vesicle biogenesis, mobilization, docking, fusion and recycling, were down-regulated in db/db mice retinas in comparison with non-diabetic controls. Topical administration of sitagliptin inhibits this diabetes-induced down-regulation and improves the functionality of diabetic retinas without any effect on blood glucose levels.

Conclusion: Sitagliptin exerts neuroprotective effects in db/db mice retinas by inhibiting the down-regulation of key presynaptic proteins induced by diabetes. Notably, this effect is unrelated to the improvement of metabolic control. This finding opens up a new strategy for treating not only DR but also other retinal diseases in which synaptic abnormalities/neurodegeneration play a crucial role.

Supported by: UEB-VHIR, UAT-VHIR, VHIR, MICCIN, CIBERDEM, UAB
Disclosure: H. Ramos: None.

123
Presence of retinopathy and kidney and cardiovascular events in type 2 diabetes and normoalbuminuria: a post-hoc analysis of The PRIORITY study
T. Hansen1, Y. Rotbain Curovic1, N. Tofte1, M.K. Lindhards1, C. Delles2, M. Frimodt-Møller1, H. Mischaik1, F. Persson1, H. von der Leyen3, P. Rossing1, on behalf of the PRIORITY Study Group;
1Steno Diabetes Center Copenhagen, Herlev, Denmark, 2Department of Medicine, Holbæk Hospital, Holbæk, Denmark, 3Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK, 4Mosaiques Diagnostics, Hannover, Germany,

Disclosure: H. Ramos: None.
Background and aims: To evaluate the association between diabetic retinopathy and development of albuminuria, impaired kidney function and cardiovascular events in persons with type 2 diabetes and normoalbuminuria.

Materials and methods: Post-hoc analysis of the prospective observational PRIORITY study including 1756 persons with type 2 diabetes and normoalbuminuria followed for three years. The study was originally designed to investigate the prediction of a urinary proteomic risk classifier (CKD273) for development of albuminuria. Diabetic retinopathy included information from medical records on non-proliferative and proliferative changes, presence of macular oedema and history of laser treatment. Cox proportional hazard models were fitted to investigate baseline retinopathy status to development of 1) microalbuminuria (urinary albumin-creatinine ratio >30mg/g on ≥2 out of 3 urine samples); 2) chronic kidney disease (eGFR <60 ml/min/1.73m²); and 3) cardiovascular events (myocardial infarction, stroke, coronary intervention, and hospitalization for heart failure). Adjustment included sex, baseline age, diabetes duration, HbA1c, systolic blood pressure, eGFR, urinary albumin-creatinine rate and urinary proteomic risk classifier status. Baseline LDL cholesterol, body mass index and history of cardiovascular disease were also included in the adjustment for cardiovascular events.

Results: At baseline, 287 (16.3%) had retinopathy. Compared to persons without retinopathy, they were older (mean ±SD: 62.7±7.7 vs 61.4±8.3 years, p=0.019), had longer diabetes duration (17.9±8.4 vs. 10.6±7.0 years, p<0.001) and higher HbA1c (62±13 vs. 56±12 mmol/mol, p<0.001). The adjusted hazard ratios of retinopathy at baseline for development of albuminuria (n=197), chronic kidney disease (n=166) and cardiovascular events (n=64) were: 1.54 (95%CI: 1.06, 1.38), 2.56 (95%CI: 1.40, 4.66), compared to persons without retinopathy.

Conclusion: Individuals with normoalbuminuric type 2 diabetes and retinopathy had higher risk of developing albuminuria, but not impaired kidney function, and had a markedly higher risk of cardiovascular disease during the 3-year follow-up, compared to individuals without retinopathy.

Clinical Trial Registration Number: NCT02040441
Supported by: European Union Seventh Framework Programme (FP7/2007-2013)
Disclosure: T. Hansen: None.

124 Stroke incidence increases with severity of diabetic retinopathy and maculopathy in people with type 1 diabetes
M.I. Eriksson1-7, K. Hietala1,2, P. Summanen4,3, C. Forsblom1,2, J. Putaala6, A. Ylinen1,2, S. Hägg-Holmberg1,2, P.-H. Groop1,5, L.M. Thörn1,7, on behalf of the FinnDiane Study;
1Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki,
2Research Program in Clinical and Molecular Metabolism, University of Helsinki, Helsinki, 3Department of Ophthalmology, Central Finland Hospital, Jyväskylä, 4Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, 5Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, 6Department of Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, 7Department of General Practice and Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Background and aims: Although the retinal vessels are suggested to mirror the brain’s vasculature, there are limited data on this association in type 1 diabetes. We therefore aimed to study the link between severity of diabetic retinopathy (DR) and stroke in type 1 diabetes.

Materials and methods: We included 1,327 participants with type 1 diabetes from the Finnish Diabetic Nephropathy Study (mean age 38.9±10.9 years, men 51.9%, kidney disease 35.9%). Exclusion criteria were stroke before baseline or missing DR data at baseline. Baseline visits were conducted in 1994-2006. Strokes were identified from registers, until the end of 2017, and verified from medical files. DR was graded according to the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. Data on macular oedema were available for 637 (48.0%) participants, and any clinically relevant macular oedema was considered as maculopathy.

Results: During a median of 17.7 (14.0-19.2) follow-up-years, 133 (10.4%) had a stroke (97 ischemic, 27 haemorrhagic, 9 unclassified). At baseline, 45.1% had no or mild DR (ETDRS 10-30), 16.0% moderate to severe DR (ETDRS 40-55), and 39.0% proliferative DR (ETDRS 60-80). Of the participants with available macula oedema data, 74.9% had maculopathy. Table 1 presents incidence rates and HR for stroke by severity of DR and maculopathy. In Cox regression analysis, adjusted for diabetes duration, sex, systolic and diastolic blood pressure, BMI, LDL cholesterol, triglycerides, and smoking, ETDRS 40-55 and ETDRS 60-80 were predictors of stroke (Table 1). Additionally, maculopathy was a predictor of stroke when analysed separately in a similar model (Table 1). After further adjustment for kidney disease, retinopathy severity (p=0.081 and p=0.171), and maculopathy (p=0.06) were no longer significant for any stroke. ETDRS 60-80 remained a significant predictor of haemorrhagic stroke (HR 10.2, 95% CI 1.2-86.2, p=0.033) in the final Cox model.

Conclusion: In our study, the incidence of stroke increased by the severity of DR and prevalence of maculopathy. Proliferative DR was a predictor of haemorrhagic stroke even in the presence of kidney disease.

Table 1. Incidence rate (IR) per 100,000 person years and HR (95% CI) by severity of diabetic retinopathy and maculopathy

<table>
<thead>
<tr>
<th></th>
<th>Any stroke</th>
<th>Ischemic stroke</th>
<th>Haemorrhagic stroke</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETDRS 10-30</td>
<td>IR 272 (181-393)</td>
<td>243 (157-358)</td>
<td>10 (5-54)</td>
</tr>
<tr>
<td>HR 1 (reference)</td>
<td>1 (reference)</td>
<td>1 (reference)</td>
<td></td>
</tr>
<tr>
<td>ETDRS 40-55</td>
<td>IR 796 (520-1167)</td>
<td>613 (374-946)</td>
<td>123 (33-114)</td>
</tr>
<tr>
<td>HR 1.9 (1.1-3.2)</td>
<td>1.6 (0.9-3.0)</td>
<td>8.1 (0.9-74.0)</td>
<td></td>
</tr>
<tr>
<td>ETDRS 60-80</td>
<td>IR 1.091 (864-1360)</td>
<td>718 (537-942)</td>
<td>304 (190-480)</td>
</tr>
<tr>
<td>HR 2.0 (1.3-3.2)</td>
<td>1.5 (0.9-2.6)</td>
<td>17.4 (2.2-139.6)</td>
<td></td>
</tr>
<tr>
<td>No maculopathy</td>
<td>IR 420 (209-761)</td>
<td>306 (132-601)</td>
<td>114 (24-334)</td>
</tr>
<tr>
<td>HR 1 (reference)</td>
<td>1 (reference)</td>
<td>1 (reference)</td>
<td></td>
</tr>
<tr>
<td>Maculopathy</td>
<td>IR 1.089 (854-1360)</td>
<td>751 (567-1000)</td>
<td>208 (156-388)</td>
</tr>
<tr>
<td>HR 2.1 (1.1-4.0)</td>
<td>2.1 (1.0-4.4)</td>
<td>1.6 (0.5-5.6)</td>
<td></td>
</tr>
</tbody>
</table>

Supported by: Folkhälsan Research Foundation, EVO governmental grant, Academy of Finland, Stockmann Foundation
Disclosure: M.I. Eriksson: Grants; Medical Society of Finland, Stockmann Foundation.
125

Fenofibrate use and diabetic retinopathy progression in patients with type 2 diabetes: a propensity-matched cohort study

N. Kim, J. Kim, K. Kim, J. Bae, K. Kim, S. Kim; Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.

Background and aims: To determine the association between fenofibrate use and diabetic retinopathy progression in patients with type 2 diabetes (T2D) and metabolic syndrome undergoing statin therapy in a real-world database.

Materials and methods: In this propensity-matched cohort study, patients with T2D and metabolic syndrome (≥ 30 years) receiving statin therapy were matched 1:2 by propensity score into the statin plus fenofibrate group (n=23,692) and statin-only group (n=46,223). The primary outcome was a composite of diabetic retinopathy progression including vitreous hemorrhage, vitrectomy, laser photocoagulation, intra-vitreous injection therapy and retinal detachment.

Results: For the primary outcome, the incidence rate per 1,000 person years was 14.25 in the statin-only group and 12.65 in the statin plus fenofibrate group. The risk of the primary outcome was significantly lower (hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.83 to 0.96; p=0.001) in the statin plus fenofibrate group than in the statin-only group. Patients with retinopathy at baseline showed marked benefits of fenofibrate treatment (HR, 0.86; 95% CI, 0.78 to 0.94; p=0.001). In addition, the statin plus fenofibrate group exhibited significantly lower risks of vitreous hemorrhage (HR, 0.87; 95% CI, 0.78 to 0.96; p=0.008), laser photocoagulation (HR, 0.89; 95% CI, 0.81 to 0.98; p=0.022) and intravitreal injection therapy (HR, 0.78; 95% CI, 0.66 to 0.92; p=0.003) than those in the statin-only group. There was no significant interaction between the different characteristics at baseline and the treatment effect.

Conclusion: In this propensity-weighted cohort study, the addition of fenofibrate to statins was associated with significantly lower risk of diabetic retinopathy progression than statin therapy alone in patients with T2D and metabolic syndrome.

Disclosure: N. Kim: None.

126

Blocking haemopexin with specific antibodies: a new experimental strategy for treating diabetic retinopathy

R. Simó1, P. Bogdanov1, A. Durarr2, A. Salas2, D. Sabater1, H. Ramos1, H. Isla2, C. Hernández2;
1Diabetes and Metabolism Research Unit, Vall d’Hebron Research Institute, CIBERDEM; 2Ophthalmology Research Group, Vall d’Hebron Research Institute, Barcelona, Spain.

Background and aims: By means of a proteomic analysis we identified hemopexin (Hpx) as a genuine and abundant protein in the vitreous fluid of patients with diabetic macular edema (DME). In addition, we provided first evidence that Hpx is overexpressed in the retina of diabetic patients, and induces hyperpermeability due to the breakdown of the blood-retinal barrier (BRB), an essential pathogenic mechanism for the development of DME. The aims of the present study are: 1) To evaluate whether the inhibition of Hpx by specific antibodies (intravitreally administered) is able to arrest vascular leakage in two experimental models of diabetes 2) To explore in in vitro models whether Hpx antibodies are able to inhibit microvascular angiogenesis.

Materials and methods: In vivo studies: An intravitreal (IVT) injection of 1.5 μL of anti-Hpx antibody (1 mg/mL), (n=10) or saline (n=10) in each eye was administered to db/db mice at age of 12 weeks. Ten non-diabetic mice (db/+), matched by age served as a control group. Retinal vascular permeability was examined 5 days after intravitreal injection using the Evans Blue albumin method. Hpx expression (mRNA) was determined by RT-PCR. The same protocol and assessments were performed using Long-Evans rats without diabetes (n=9) and with STZ-induced diabetes (n=9). In vitro studies: The microvascular angiogenesis was tested by using the scratch wound healing technique and sprouting assay, both stimulated by VEGF treatment (25 ng/mL). For the former we used human retinal endothelial cells (HRECs) and the inhibitory effect of anti-Hpx antibodies (0.36 mcg/mL) was tested. To examine sprouting we measured the area (mm²) of sprouted cells using choroidal explants from Long-Evans rats which were cultured under different conditions: 5.5 mM glucose, 30 mM glucose, 30 mM + bevacizumab (125 and 250 mcg/mL), 30 mM glucose + 0.1 microM dexamethasone, 30 mM glucose + anti-Hpx antibodies (0.36 mcg/mL). In addition, explants from Long-Evans rats with STZ-induced diabetes treated with IVT injection of anti-Hpx antibodies (1mg/ml) vs. treated with vehicle were compared.

Results: A higher expression of Hpx was detected in retina from diabetic animals in comparison with non-diabetic animals (p<0.05). IVT injections of anti-Hpx antibodies significantly reduced vascular leakage in the two diabetic models in comparison with vehicle (p<0.01). Treatment with Hpx antibodies was able to significantly reduce the HRECs migration induced by high glucose concentration with and without VEGF after scratch (p<0.01). In addition, Hpx neutralization inhibited the vessel outgrowth from choroidal explants in non-diabetic rats (60% of reduction of the sprouting area; p<0.01) and STZ-induced diabetic rats (75% reduction; p<0.01 of the sprouting area). Notably, this effect was similar to obtained with bevacizumab or dexamethasone.

Conclusion: The blockade of Hpx-induced permeability by using IVT injections of anti-Hpx antibodies can be envisaged as a new strategy for treating DME. The in vitro and ex-vivo antiangiogenic effect also suggest proliferative retinopathy as a potential target, but in vivo experiments are lacking. Further research is needed to confirm Hpx not only as a therapeutic target of advanced diabetic retinopathy but also to explore its role as an alternative to anti-VEGF agents.

Disclosure: R. Simó: None.

Supported by: ISCiii (DTS19/00171)
OP 22 Giving birth with diabetes

127 Glycaemic control and complication rate through pregnancy and thirteen-years post-partum in women with microalbuminuria (type 1 diabetes)
N. Asatiani, R. Kurashvili, E. Inashvili, E. Shelestova, T. Akhobadze; Diabetes in Pregnancy, National Center for Diabetes Research, Tbilisi, Georgia.

Background and aims: The aim of the present work was to assess the degree of glycemcic control and complications rate through pregnancy and thirteen-years post-partum in women with microalbuminuria (T1DM).

Materials and methods: In total 191 patients with T1DM were enrolled in the study. Based on albuminuria levels in the 1st trimester women were separated into 2 groups (Gr.). Gr.1 - 116 women with normoalbuminuria, Gr.2 - 75 women with microalbuminuria. Preconception care was performed in 46.5%-Gr.1 and 57.3%-Gr.2. Strict metabolic control was maintained and fetal surveillance was performed throughout the pregnancy. Repeated examinations were performed 13 years' post-partum.

Results: At entry HbA1c(%) levels for Gr.1 and 2 were: 7.42 (0.15) and 7.25 (0.14); by the end of the pregnancies they statistically decreased in both groups (Gr.1- P=0.000, Gr.2 - P=0.000). At entry percent (%) of retinopathy for Gr.1-8.6 and Gr.2 - 20.0; by term the percent has not increased. The percent of women with macroalbuminuria increased, together with the growth of gestational age. By term microalbuminuria was observed in 2.5% (Gr.1) and in 14.6% (Gr.2) of patients (P=0.0094, OR-5.67). In Gr.1 percent of pre-eclampsia and preterm deliveries before 37 weeks of gestation was lower, than in Gr.2 (pre-eclampsia - P = 0.0064, OR -4.64; preterm deliveries P = 0.048; OR -2.8). Perinatal mortality was observed in Gr.1 - 0.8% and in Gr.2 - 6.6% of women (P - 0.006, OR -7.73). Repeated examinations 13 years post-partum showed that HbA1c levels were statistically higher, than at the end of pregnancy: Gr.1-7.7 (0.41) (P=0.0002), Gr.2 - 8.05 (0.26) (P=0.000). Repeated examinations showed that percent of retinopathy, neuropathy, micro and macroalbuminuria, increased in both groups. Besides, patients from Gr.2 had statistically higher complications rate, than patients from Gr.1 (retinopathy - P=0.0002, OR - 3.45; microalbuminuria - P=0.0001, OR - 10.2; macroalbuminuria -P=0.0032, OR - 3.03). Chronic kidney disease were observed in 36 patients. Nine patients from Gr.2 are on regular hemodialysis, and in two patient kidney transplantation was performed.

Conclusion: If microalbuminuria was detected in the 1st trimester, the risk of preeclampsia increased 4.6 times, the risk of preterm delivery increased 2.8 times and risk of perinatal mortality increased 7.3 times, compared to patients with normoalbuminuria. In both groups glycaemia control deterioration was observed thirteen years post-partum. The higher complication percent was found if pregnancy proceeded with microalbuminuria, the risk of retinopathy increased 3.4 times and the risk of CKD increased 3 times compared to patients with normoalbuminuria.

Disclosure: N. Asatiani: None.

128 Glucose response patterns based on 75g OGTTs during pregnancy and their association with the risk of macrosomia: a latent class analysis of three cohort studies
1Institute for Diabetes Research and Metabolic Diseases, Helmholtz Center Munich, Tuebingen, Germany, 2Steno Diabetes Center, Aarhus, Denmark, 3Department of Internal Medicine, Division of Endocrinology, Diabetology and Nephrology, University Hospital Tuebingen, Tuebingen, Germany, 4Institute for Clinical Chemistry and Pathobiocchemistry, Department for Diagnostic Laboratory Medicin, University Hospital Tuebingen, Tuebingen, Germany, 5Department of Women and Children’s Health, King's College London, London, UK, 6Department of Internal Medicine, Division of Endocrinology, Diabetology and Nephrology, University Hospital Tuebingen, Tuebingen, Germany, 7Department of Obstetrics & Gynaecology, Tolna County Balassa János Hospital, Szekszárd, Hungary, 8Department of Public Health, Faculty of Medicine, Semmelweis University, Budapest, Hungary, 9German Center for Diabetes Research, Neuberger, Germany.

Background and aims: Studies in the general population show that different glucose response patterns based on oral glucose tolerance tests (OGTT) are associated with different clinical characteristics and long-term outcomes. We aimed to identify comparable glucose response patterns in pregnancy and their association with maternal and fetal outcomes.

Materials and methods: We used latent class trajectory modelling to identify glucose response patterns using a 5-point 75g OGTT in 470 pregnant women at 27.3±2.2 weeks of gestation. We assessed these classes and examined pregnancy outcomes in two independent European cohorts with 3-point OGTTs: a population based Hungarian cohort with 7037 pregnant women and the control group of the UK pregnancies Better Eating and Activity Trial comprising of 610 obese women. Pregnancy outcomes in the different classes were analysed using generalized estimating equations (GEE).

Results: We identified five different glucose response patterns (classes, Fig.1). Rate of gestational diabetes (GDM) was lowest in class 1 (<7%) and highest in class 5 (100%) for all three cohorts. Class 3 was characterized by transient hyperinsulinemia at 30 minutes (Fig.1) but the prevalence of GDM was only 25-36%. Compared to class 1, women in class 3 had higher gestational weight gain (GWG, \(\beta=0.76\ SE: 0.28\)kg, \(p=0.0076\), adjusted for study, age, gestational age, pre-gestational BMI, GWG treatment and \(AUC_{Glucose}\)). New-borns in class 3 had the highest risk of macrosomia (OR 1.49 95%CI: [1.17, 1.90] vs. class 1) after adjustment for study, age, gestational age, pre-gestational BMI, GDM treatment and \(AUC_{Glucose}\). New-borns in class 3 had the highest risk of macrosomia (OR 1.49 95%CI: [1.17, 1.90] vs. class 1) after adjustment for study, age, gestational age, pre-gestational BMI, GWG treatment and \(AUC_{Glucose}\). New-borns in class 3 had the highest risk of macrosomia (OR 1.49 95%CI: [1.17, 1.90] vs. class 1) after adjustment for study, age, gestational age, pre-gestational BMI, GWG treatment and \(AUC_{Glucose}\).

Conclusion: We identified five different glucose response patterns (classes, Fig.1). Rate of gestational diabetes (GDM) was lowest in class 1 (<7%) and highest in class 5 (100%) for all three cohorts. Class 3 was characterized by transient hyperinsulinemia at 30 minutes (Fig.1) but the prevalence of GDM was only 25-36%. Compared to class 1, women in class 3 had higher gestational weight gain (GWG, \(\beta=0.76\ SE: 0.28\)kg, \(p=0.0076\), adjusted for study, age, gestational age, pre-gestational BMI, GWG treatment and \(AUC_{Glucose}\)). New-borns in class 3 had the highest risk of macrosomia (OR 1.49 95%CI: [1.17, 1.90] vs. class 1) after adjustment for study, age, gestational age, parity and smoking, but this was attenuated by additional adjustment for pre-pregnancy BMI and GWG.

Disclosure: N. Asatiani: None.

Clinical Trial Registration Number: NCT04270578, ISRCTN89971375
Supported by: BMBF (01GI0925) to D2D
Disclosure: L. Fritsche: None.
Changes in body fat partitioning and insulin resistance between preconception and postpartum in Singaporean women: the SPRESTO study

S. Sadananthan1, N. Michael1, Y. Manuel1,2, K. Thirumurugan1, J. Yaligar3, M. Tint1,2, K. Tan3, K.M. Godfrey3, P.D. Gluckman1, Y. Chong1,2, Y. Lee1,2, J.K.Y. Chan1, S.-Y. Chan1,2, J.G. Eriksson1,2, S. Velan1;

1Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore, 2National University of Singapore, Singapore, Singapore, 3IK Women’s and Children’s Hospital, Singapore, Singapore, 4MRC Life Course Epidemiology Unit & NIHR Southampton Biomedical Research Centre, University of Southampton & University Hospital Southampton NHS Foundation Trust, Southampton, UK.

Background and aims: Pregnancy is a period when the body experiences dynamic changes in body composition, hormone levels, insulin resistance, and a build-up of energy reserves in the form of fat to support lactation. While postpartum weight retention has been linked to increased metabolic risk, the role of changes in body fat partitioning has not been well investigated. In the Singapore Preconception Study of Long-Term Maternal and Child Outcomes (S-PRESTO), we characterized the changes in body weight, body fat partitioning, and insulin resistance between preconception and 3 months postpartum.

Materials and methods: 1039 women (aged 18-45 years, Chinese, Malay, and Indians) who intended to get pregnant within the next 12 months were recruited; those who conceived were followed through their pregnancy and at 3 months postpartum. 68 participants underwent MRI at both preconception and postpartum time points; volumetric abdominal MRI was used for the segmentation and quantification of deep subcutaneous (DSAT), superficial subcutaneous (SSAT), and visceral adipose tissue (VAT) volumes. Ectopic fat accumulation within the liver and muscle (intramyocellular lipids (IMCL)) was determined using magnetic resonance spectroscopy. Insulin resistance was assessed using homeostatic model assessment for insulin resistance 2 (HOMA2-IR) preconception, at week 24-28 of gestation, and at 3 months postpartum.

Results: As expected, both body weight and HOMA2-IR significantly increased during pregnancy. At 3 months postpartum, HOMA2-IR returned to preconception levels, while body weight was higher than preconception (Table 1); subcutaneous fat depots (DSAT and SSAT) and IMCL at postpartum were similar to the preconceptual levels, but VAT (p = 0.001) and liver fat (p = 0.027) were increased 3 months after delivery. There were no associations between the changes in fat depots and the change in HOMA2-IR.

Conclusion: Our findings indicate that subcutaneous fat depots may be preferentially mobilized in the early postpartum period, relative to VAT and ectopic fat in the liver. While elevated VAT and liver fat have been generally linked to elevated insulin resistance, increases in both these depots were not accompanied by an increase in HOMA2-IR in the early postpartum period. Further assessments are required to evaluate whether the dissociation between these pathogenic fat depots and HOMA2-IR is a transient phenomenon.

Table 1. Mean weight, adiposity measures and HOMA2-IR preconception and postpartum.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Preconception (Mean ± SD)</th>
<th>Postpartum (Mean ± SD)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight (kg)</td>
<td>58.32 ± 11.03</td>
<td>61.16 ± 11.37</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SAT (cc)</td>
<td>2806.22 ± 1421.63</td>
<td>2795.14 ± 1253.48</td>
<td>0.890</td>
</tr>
<tr>
<td>DSAT (cc)</td>
<td>1093.46 ± 565.87</td>
<td>1079.49 ± 517.26</td>
<td>0.702</td>
</tr>
<tr>
<td>SSAT (cc)</td>
<td>1712.75 ± 904.05</td>
<td>1715.64 ± 780.56</td>
<td>0.950</td>
</tr>
<tr>
<td>VAT (cc)</td>
<td>919.06 ± 548.58</td>
<td>1037.31 ± 510.72</td>
<td>0.001</td>
</tr>
<tr>
<td>Liver fat (%)</td>
<td>1.78 ± 2.85</td>
<td>2.77 ± 3.99</td>
<td>0.027</td>
</tr>
<tr>
<td>IMCL (%)</td>
<td>0.85 ± 0.52</td>
<td>0.85 ± 0.52</td>
<td>0.988</td>
</tr>
<tr>
<td>VAT/SAT</td>
<td>0.33 ± 0.10</td>
<td>0.38 ± 0.11</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HOMA2-IR</td>
<td>0.89 ± 0.66</td>
<td>0.81 ± 0.66</td>
<td>0.063</td>
</tr>
</tbody>
</table>

Significant (p < 0.05) differences are highlighted in bold.

Clinical Trial Registration Number: NCT03531658
Supported by: NMRC/TCR/004-NUS/2008; NMRC/TCR/012-NUHS/2014

130 Maternal diabetes and attention-deficit/hyperactivity disorder in childhood


1Karolinska Institutet, Stockholm, Sweden, 2The University of Hong Kong, Hong Kong, Hong Kong, 3UCL School of Pharmacy, London, UK, 4Norwegian Institute of Public Health, Oslo, Norway, 5University of Groningen, Groningen, Netherlands, 6National Cheng Kung University, Tainan, Taiwan, 7University of Iceland, Reykjavik, Iceland, aUNSW Sydney, Sydney, Australia.

Background and aims: Recent studies suggest an increased risk of attention-deficit/hyperactivity disorder (ADHD) in the children born to mothers with diabetes mellitus during pregnancy, including pregestational diabetes (PGDM) and gestational diabetes mellitus (GDM). However, current evidence remains inconclusive. This study aims to assess the association between prenatal exposure to maternal diabetes mellitus (MDM) and the risk of ADHD in childhood.

Materials and methods: This is a multinational cohort study with linked mother-child pairs using healthcare databases from Asia (Hong Kong (HK), Taiwan) and Northern Europe (NorPreSS: Finland, Iceland, Norway, Sweden) including children born between 2001-2018 with follow-up through 2020 (subject to data availability). Cox proportional hazard regression models and propensity score fine stratification, including demographic, comorbidity, and comedication covariates, were used to calculate hazard ratios (HR) with a 95% confidence interval (CI) for each comparison.

Results: We included 4,554,325 million mother-child pairs (HK: 535,924; Taiwan: 887,120; NorPreSS: 3,131,281) in the analyses, of which 6.1% of children were prenatally exposed to MDM (71,232 to PGDM; 207,171 to GDM). A total of 158,154 children had ADHD (HK: 16,453; Taiwan: 85,471; NorPreSS: 56,230). Children born to mothers with MDM were at a higher risk of developing ADHD (HK: PS-weighted HR 1.18, 95%CI 1.11-1.26; Taiwan: 1.13, 1.09-1.18; NorPreSS: 1.22, 1.18-1.26). The elevated risk was present separately for PGDM (HK=1.20, 0.98-1.46; Taiwan=1.63, 1.45-1.83; NorPreSS=1.31, 1.24-1.38) and for GDM (HK=1.18, 1.10-1.25; Taiwan=1.11, 1.07-1.15; NorPreSS=1.17, 1.12-1.22). Study sized allowed for a sibling-matched GDM analysis, which showed no
association between prenatal exposure to GDM and the risk of ADHD (HK: 1.00, 0.86-1.16; Taiwan: 0.96, 0.85-1.07).

**Conclusion:** Our findings suggest that children prenatally exposed to maternal diabetes in general, and specifically to PGDM and GDM, have an increased risk of ADHD in childhood. However, for at least GDM exposure the risk is largely due to unmeasured familial confounding. Further investigation will assess the role of pharmaceutical treatment of MDM during pregnancy and glycaemic control on the association between maternal diabetes and child ADHD.

Supported by: Hong Kong Research Council (no.1711202), NordForsk (no.83539), MSCA (no.844728)

Disclosure: C.E. Cesta: Grants; EU Horizon 2020 MSCA global fellowship (no. 844728).

**131**

Pregestational diabetes and risk of congenital heart defects in the offspring: French nationwide study using the French PMSI-MCO database

M. Lemaitre, G. Bourdon, A. Bruandet, X. Lenne, D. Subtil, T. Rakza, A. Vambergue;\footnote{CHRU Lille, Lille, France.} A. Sharma;\footnote{South Asian and Nordic women after gestational diabetes Beta cell function, hepatic insulin clearance and insulin sensitivity in a large national cohort in France.} S. Solliid;\footnote{University of Oslo, Oslo, Norway.} C. Sommer;\footnote{NordForsk,挪威奥斯陆,挪威。} T. Rakza;\footnote{Vestre Viken Drammen Hospital, Drammen, Norway.} G. Bourdon, A. Bruandet, X. Lenne, D. Subtil, T. Rakza, A. Vambergue

**Background and aims:** Congenital Heart defects (CHD) are the most common type of congenital malformations in offspring of women with pregestational diabetes. Our aim was first to estimate the incidence of CHDs in the offspring of mothers with type 1 diabetes and those with type 2 diabetes using data from the national French Medical Information System Program in Medicine, Surgery and Obstetrics database (PMSI-MCO), compared to the general population. Secondly, we investigated if the association between maternal diabetes and CHD varied with type of diabetes (Type 1 diabetes (T1D) or type 2 diabetes (T2D)) in a large national cohort in France.

**Materials and methods:** The presence of CHDs and maternal diabetes were screened for according to the International Classification of Diseases, 10th [Revision], in the PMSI-MCO database, from 2012 to 2020. A logistic model was used to estimate risk factors for maternal-fetal prognostic indicators in women with T1D, in women with T2D, and in the control population by adjusting for maternal age, gender of the newborn, prematurity, Small for gestational Age (SGA), Large for gestational Age (LGA) and, mode of delivery.

**Results:** 6,076,251 mother-infant pairs were included. The rate of congenital malformations was 6.2% in the control group, 8.0% in women with T1D and 8.4% in women with T2D (p<0.001). The incidence of CHD was 8.0 per 1000 births in the control group, 29.6/1000 and 27.4/1000 in women with T1D and those with T2D, respectively (p<0.001). The risk of CHD was 2.07 times higher in women with type 1 diabetes [CI 95% [1.91-2.24], p<0.001] and 2.20 times higher in women with type 2 diabetes [CI 95% [1.99-2.44], p<0.001] with no difference found between T1D and T2D (p=0.336). Cesarean section, SGA, LGA, and prematurity were also associated with an excess risk of CHD.

**Conclusion:** Pregestational diabetes is a risk factor for the development of CHD in the offspring without a significant difference between the two types of diabetes. Metabolic control is a modifiable risk factor that can be addressed to reduce the risk of CHD.

Disclosure: M. Lemaitre: None.

**132**

Beta cell function, hepatic insulin clearance and insulin sensitivity in South Asian and Nordic women after gestational diabetes

A. Sharma;\footnote{South Asia and Nordic women after gestational diabetes Beta cell function, hepatic insulin clearance and insulin sensitivity in a large national cohort in France.} I. Nermo\footnote{South Asia and Nordic women after gestational diabetes Beta cell function, hepatic insulin clearance and insulin sensitivity in a large national cohort in France.}; E. Qvigstad;\footnote{South Asia and Nordic women after gestational diabetes Beta cell function, hepatic insulin clearance and insulin sensitivity in a large national cohort in France.} C. Sommer;\footnote{South Asia and Nordic women after gestational diabetes Beta cell function, hepatic insulin clearance and insulin sensitivity in a large national cohort in France.} N. Sattar;\footnote{South Asia and Nordic women after gestational diabetes Beta cell function, hepatic insulin clearance and insulin sensitivity in a large national cohort in France.} J. Gill;\footnote{South Asia and Nordic women after gestational diabetes Beta cell function, hepatic insulin clearance and insulin sensitivity in a large national cohort in France.} H. Gulseth;\footnote{South Asia and Nordic women after gestational diabetes Beta cell function, hepatic insulin clearance and insulin sensitivity in a large national cohort in France.} S. Solliid;\footnote{South Asia and Nordic women after gestational diabetes Beta cell function, hepatic insulin clearance and insulin sensitivity in a large national cohort in France.} K. Birkeland;\footnote{South Asia and Nordic women after gestational diabetes Beta cell function, hepatic insulin clearance and insulin sensitivity in a large national cohort in France.} S. Lee-Odegård;\footnote{South Asia and Nordic women after gestational diabetes Beta cell function, hepatic insulin clearance and insulin sensitivity in a large national cohort in France.} A. Sharma;\footnote{South Asia and Nordic women after gestational diabetes Beta cell function, hepatic insulin clearance and insulin sensitivity in a large national cohort in France.} H. Gulseth;\footnote{South Asia and Nordic women after gestational diabetes Beta cell function, hepatic insulin clearance and insulin sensitivity in a large national cohort in France.}

**Background and aims:** The risk of developing type 2 diabetes (T2D) after gestational diabetes mellitus (GDM) is twice as high in South Asian compared to Nordic women. We aimed to assess and compare ethnic differences in β-cell function and insulin sensitivity (IS) in women with normal glucose tolerance (NGT), prediabetes and T2D, 1-3 years after a GDM pregnancy.

**Materials and methods:** We performed an OGTT in South Asian (n=179) and Nordic (n=108) women living in Norway. Based on the OGTT, we calculated the pre-hepatic insulin secretion rate (ISR) by deconvolution of C-peptide kinetics, and hepatic insulin clearance (HIC) as the ratio of ISR to peripheral insulin levels. First phase insulin secretion was assessed by the insuliniogen index (IGI). Fasting insulin secretion was represented by the homeostasis model assessment (HOMA2-β). β-cell glucose sensitivity (β-C-GS) was approximated from cross-correlation of ascending glucose and ISR levels during the OGTT. Hepatic insulin sensitivity (IS) was estimated by HOMA2-S, peripheral IS by the muscle IS index (muscle-ISI) and whole-body IS by the Matsuda index (Matsuda-ISI). β-cell function adjusted for insulin resistance was estimated by the disposition index (DI); estimated by IGI and either HOMA2-IR (DI-HOMA2-IR) or Matsuda-ISI (DI-Matsuda).

**Results:** Compared to Nordic women, South Asians had higher levels of glucose, insulin, C-peptide and ISR during the OGTT. HOMA2-β and β-C-GS (p<0.05) were higher in South Asian vs. Nordic women. HIC was lower, and so were HOMA2-S, muscle-ISI, Matsuda-ISI and both DI-HOMA2-IR and DI-Matsuda. In NGT women, our results were similar, expect for a higher IGI, but similar DI-HOMA2-IR and DI-Matsuda between South Asian and Nordic women. In women with prediabetes or T2D, both ethnicities displayed similar OGTT glucose levels, but South Asian exhibited higher OGTT insulin and IS levels than Nordic women (Table 1).

**Conclusion:** In women examined 1-3 years after a GDM pregnancy, South Asians displayed a ‘stressed’ β-cell function compared to Nordic women. South Asians also displayed lower IS and HIC across all glucose tolerance categories. In spite of NGT, South Asian women exhibited higher fasting and first-phase insulin secretion. Hence, a more ‘stressed’ β-cell function in addition to lower IS and HIC in South Asian women may increase their propensity to develop T2D after GDM.

Supported by: The Research Council of Norway, grant number 273252.

Disclosure: A. Sharma: None.

Diabetologia (2022) 65 (Suppl 1):S1–S469
OP 23 Are we too slow to outlaw the low?

133

Severe hypoglycaemia presenting to a hospital emergency department: clinical characteristics and mortality outcomes

S.H. Song1, B.M. Frier2

1Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, 2The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK.

Background and aims: The prevalence of young-onset type 2 diabetes (YOT2D), diagnosed below age 40, is increasing with many requiring insulin. Severe hypoglycaemia (SH) is common in insulin-treated diabetics and may be a marker of underlying illness. The frequency of SH in YOT2D was ascertained in all people requiring treatment in a hospital emergency department (ED), and clinical characteristics and mortality outcomes were examined.

Materials and methods: Patients with SH who attended ED at Northern General Hospital, Sheffield, UK between January 2019 and March 2022 were identified. Complete collection of SH events was ensured by interrogating several sources: ambulance service, hospital ED, inpatient and general practice records. Data included diabetes type, clinical characteristics and comorbidities, and were analysed by age of diabetes onset, below and above age 40. Charlson score quantified the comorbidity burden.

Results: A total of 537 episodes of SH occurred in 442 patients, of whom 155 (35.1%) had type 1 diabetes (T1D), 184 (41.6%) had type 2 diabetes (T2D), 7 (1.6%) had insulin-treated secondary pancreatic diabetes and 96 (21.7%) were non-diabetic, with mean blood glucose concentrations at presentation of 1.8±0.7, 2.0±0.7, 1.8±0.8 and 2.0±0.7 mmol/L respectively. SH events recurred in 61 (13.8%) patients (2-10 ED visits per person), totalling 153 (28.5%) attendances. Forty-five (24.5%) patients with T2D were taking neither sulfonylureas nor insulin. T1D had more impaired hypoglycaemia awareness (51.0% vs 14.6%, p<0.005) and history of SH (56.1% vs 15.8%, p<0.005) than T2D, while cognitive impairment was less prevalent (7.1% vs 19.6%, p=0.001). T2D had higher Charlson score (8.5±3.1 vs 4.3±3.1, p<0.005) and greater socioeconomic deprivation than T1D (20% most deprived decile; 53.3% vs 38.1%, p=0.006). More T2D required hospital admission than T1D (74.4% vs 60.3%, p=0.002).

Of those diagnosed age <40, 131 (84.5%) had T1D (YOT1D) and 24 (13%) had T2D (YOT2D) with median (range) age of diabetes onset 18 (1-39) and 35 (18-39) years respectively. YOT2D had more cardiorenal disease (66.7% vs 42.7%, p=0.04) and heart failure (41.7% vs 13.7%, p=0.003) than YOT1D. Mental illness was equally common in both types of diabetes (YOT1D vs YOT2D; 50.4% vs 45.8%, p=NS). Of those diagnosed age >40, T2D had more cardiorenal disease (84.0% vs 47.8%, p=0.005), heart failure (30.8% vs 8.7%, p=0.026) and liver disease (20.5% vs 4.3%, p=0.046) than T1D. Most SH occurred in YOT1D (188 episodes) and older-onset T2D (179 episodes). Only 28 episodes occurred in YOT2D. Mortality after index presentation to ED was higher in T2D than T1D (38.0% vs 14.2%, p=0.005) with shorter mean time to death (239.8±290.6 vs 470.0±318.2 days, p=0.002). Compared to T1D, the T2D cohort had more cancer (34.3% vs 9.1%, p=0.029), respiratory disease (40.0% vs 9.1%, p=0.008) and cardiorenal disease (87.1% vs 63.6%, p=0.024). The mortality was similar in non-diabetics to T2D (37.5% vs 38.0%, p=NS) but death occurred significantly earlier (113.7±218.4 vs 239.8±290.6 days, p=0.014). Charlson score was elevated (non-diabetic vs T2D; 7.7±2.8 vs 9.9±2.7, p<0.005) and cardiorenal disease was prevalent in both groups (non-diabetic vs T2D; 94.4% vs 87.1%, p=NS).

Conclusion: SH is uncommon in YOT2D except when certain comorbid conditions co-exist. SH may be a biochemical marker of severe underlying medical disorders that predicts a poor prognosis.

Disclosure: S.H. Song: None.

134

Determining the incidence and clinical predictors of severe hypoglycaemia in patients receiving insulin and sulphonylureas for type 2 diabetes


Background and aims: The most serious adverse effect of sulphonylureas (SU) and insulin treatment of patients with type 2 diabetes (T2DM) is hypoglycaemia, which may result in significant morbidity and mortality. We aimed to investigate the incidence and clinical predictors of severe hypoglycaemia (SH) requiring paramedic intervention in patients treated with SU or insulin for T2DM in real-world data from patients in Tayside and Fife regions of Scotland.

Materials and methods: We undertook a retrospective cohort study of n=23016 patients with T2DM treated with insulin or SU in NHS Tayside and Fife between 2008 and 2016. Data were from a SCI-diabetes extract linked to unique Scottish Ambulance Service data in the region. We calculated the incidence rates of severe hypoglycaemia (SH) per 1000 person years. Chi-Squared tests were conducted to evaluate clinical and biochemical characteristics of patients who had experienced SH episodes within the region. A fixed effect Poisson regression model was developed to identify predictors of SH. We then developed and validated a clinical prediction tool to predict individual risk for SH.

Results: The incidence of SH in SU treated T2DM was 0.5% per year, and 1.8% in those treated with insulin. SH was less common in males treated with SU (0.47%/year male; 0.66% female, Chi-Squared Test p<0.0001), but more common in males treated with insulin (1.9%/year male; 1.7%/year female, Chi-Squared Test p<0.0001). The incidence of SH in females treated with gliclazide was almost double that of males (0.41%/male, 0.75%/female, Chi-Squared Test p<0.0001). There was increased risk of SH with increasing age, duration of diabetes and creatinine, and lower HbA1c and a BMI <30 kg/m². Modified release gliclazide was the SU with lowest risk of SH, with incidence of 0.02% per year versus 1.3% with glibenclamide. The model was trained on the observation period data from the Tayside population (n=8903) with replication in Fife (n=8737), the mean model error was 0.037 per 1000 person years, suggesting that the model performed well with little error and could have potential clinical utility.

Conclusion: The incidence of SH associated with SU is low, more than a third lower than that of insulin. However, some individuals are at high risk even when treated with SU - e.g. older women with long duration of diabetes and low HbA1c. Our validated prediction tool has the clinical potential to identify those at high risk of SH and optimise their treatment to minimise risk (by switching of insulin or SU, reducing dose, or changing to gliclazide MR).

Supported by: Wellcome Trust New Investigator Award

We recently proposed that IAH develops as a form of adaptive memory (Habituation) to repeated hypoglycaemia. Consistent with this, we found that introduction of a single novel stress stimulus [high intensity exercise (HIE)] partially restored counterregulatory (CRR) hormonal and symptomatic responses to hypoglycaemia in people with T1D and IAH; a process referred to as Dishabitation. For HIE to prove to be an effective therapeutic intervention, it is important to demonstrate sustained efficacy in individuals with TID who suffer from IAH.

Materials and methods: To address this question, we conducted a 4-week pilot, single centre, randomised parallel-group study using HIE in people with T1D and IAH. HIT significantly increased glucagon (Δ mean [SEM] 0.9 [3.89] vs 16.2 [6.21] ng/l, p < 0.01) and maintained noradrenaline (-987.71 [447.37] vs 514.03 [731.73] pmol/l, p < 0.01), but not adrenaline responses (298.1 [687.42] vs 112.9 [747.40] pmol/l; p = 0.11) during equivalent hypoglycaemia. Post intervention total symptom scores across hypoglycaemia were greater in the HIT group than the Control group (Edinburgh Hypoglycaemia scale; 25.0 +/- 2.0 vs 20.4 +/- 2.4, p < 0.05).

Conclusion: These findings suggest that 4 weeks of HIE provide sustained benefits on the hormonal and symptomatic CRR to hypoglycaemia in people with T1D and IAH. Of note there was a small but significant increase in hypoglycaemia-induced glucagon. Therefore, HIT may represent a novel therapeutic intervention for people with T1D and IAH.

Clinical Trial Registration Number: ISRCTN15373978
Supported by: Diabetes UK and JDRF
Disclosure: C.M. Farrell: Grants; Diabetes UK 17/0005591, JDRF 3-SRA-2017-485-S-B.

136
Decreased branched-chain amino acids and elevated fatty acids during antecedent hypoglycaemia in type 1 diabetes
R. She1,2, N. Al-Sari3, I. Mattila4, P. Henriksson3, J. Pedersen1, A.-S. Sejling1,5, C. Legido-Quigley1,6, U. Pedersen-Bjergaard1,2
1Department of Endocrinology and Nephrology, Nordsjællands Hospital, Hillerød, Denmark, 2Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, 3Steno Diabetes Center Copenhagen, Herlev, Denmark, 4Department of Internal Medicine, Herlev and Gentofte Hospital, Herlev, Denmark, 5Novo Nordisk A/S, Bagsværd, Denmark, 6King’s College London, Institute of Pharmaceutical Science, UK.

Background and aims: Hypoglycaemia is a major limiting factor in achieving recommended glycaemic targets for individuals in insulin treatment and can lead to late diabetes complications, incremental morbidity, and mortality. While counterregulatory hormonal responses have been studied extensively in patients with type 1 diabetes, a more comprehensive assessment of the metabolic responses has not been done previously. This post hoc study explored potential responses of the metabolome to hypoglycaemia.

Materials and methods: A post hoc study examining the metabolome from participants with euglycaemia and hypoglycaemia during hyperinsulinenic clamps. Setting and Participants: Twenty-one outpatients with type 1 diabetes were recruited in the outpatient clinic. Intervention: On two consecutive days participants underwent a period of euglycaemia (5.0–5.5 mmol/l) and a period of hypoglycaemia (2.0–2.5 mmol/l) during the hyperinsulinenic glucose clamp. Primary Outcome Measure: Plasma samples were taken 40 min after reaching euglycaemia and 20 min and 40 min after reaching hypoglycaemia. Non-targeted plasma metabolic analyses were conducted using two-dimensional gas chromatography/mass spectrometry. Metabolites were analysed by an linear mixed effect model, adjusting for age and sex. P-values were adjusted for multiple testing using the Benjamini-Hochberg method.

Results: In total, 79 metabolites were identified. Concentrations of the branched-chain amino acids, leucine, and isoleucine, decreased during hypoglycaemia at day 1: isoleucine (β±SE: -0.72±0.16, p = 2.2x10^-3), leucine (β±SE: -0.78±0.18, p = 3.8x10^-3). At day 2, five amino acids including all three branched-chained amino acids decreased: Leucine (β±SE: -0.62±0.13, p = 0.002), isoleucine (β±SE: -0.59±0.19, p = 0.026), valine (β±SE: -0.52±0.12, p = 0.002), methionine (β±SE: -0.62 ±0.19, p = 0.026) and phenylalanine (β±SE: -0.65±0.20, p = 0.026). Two fatty acids were increased, oleic acid (β±SE: 0.50±0.14, p = 0.016) and tetradecanoic acid (β±SE: 0.63±0.17, p = 0.013). More metabolites responded to hypoglycaemia on day 2; however, metabolic responses were not significantly different between the two days. Hormonal counter-regulatory responses to hypoglycaemia were not different between the two days.

Conclusion: In conclusion, this study found that the metabolome alternates in response to insulin-induced hypoglycaemia, resulting in decrement of several amino acids and increment of two fatty acids. The hormonal counterregulatory response was indifferent between the first and subsequent hypoglycaemic episode, and while we also could not find a significant change in metabolic responses, the additional significant changes in metabolites during day 2 suggest an altered metabolic response to a subsequent hypoglycaemic episode, which is not a result of an attenuation of the hormonal counterregulatory response.

Clinical Trial Registration Number: NCT01337362
Supported by: Steno Collaborative Grants research programme
Disclosure: R. She: None.
Participants were randomised 1:1 to use the unblinded so that participants were able to see their glucose data. At the end of the 10 days, the RT-CGM was living their normal lives including their usual activity which was recorded in a crossover study. Participants undertook 10 days of blinded CGM, whilst further 40 days. Participants recorded their carbohydrate and insulin doses throughout the study.

Results: 24 participants were randomised. The participants (8 men, 16 women) had a mean (SD) age of 35 (11) years, duration of diabetes of 14 (7) years, BMI 26 (4.7)kg/m2 and HbA1c of 58 (12) mmol/mol. 1 person was excluded from the analysis due to incomplete data. The baseline median percentage time < 3.0mmol/l was 0.25 (0.0-5.0-9.0)%.

Conclusion: A CGM device with a an urgent low soon alert reduces exposure to level 2 hypoglycaemia compared to real time continuous glucose monitoring with a threshold alarm. Additionally an urgent low soon alert reduces exposure to disabling hypoglycaemia below 2.8mmol/L in the 24 hours after exercise compared to a threshold alert. These data suggest people with T1D undertaking regular exercise benefit most from a predictive alert monitoring system.

Clinical Trial Registration Number: NCT04142944

Disclosure: S. Rilstone: Grants; Dexcom.

Supported by: DUK PhD studentship

K.M. Partridge: None.

The impact of CGM with a predictive hypoglycaemia alert function on hypoglycaemia in physical activity for people with type 1 diabetes: PACE study

S. Rilstone1, N. Oliver1, B. Tanushi1, N. Hill2
1Imperial College London, 2Imperial College Healthcare NHS Trust, London, UK.

Background and aims: The benefits of exercise for people Type 1 Diabetes (T1D) are significant, and include improvement in cardiovascular risk factors. Uptake of exercise is low in people with T1D, with fear of hypoglycaemia cited as the main barrier to exercise. Insulin and fuelling strategies are complex, and varying insulin sensitivity associated with different exercises regimes can make diabetes management challenging, resulting in hypoglycaemia. Technology has great potential to improve self-management of diabetes during exercise, offering real time glucose feedback with trend arrows, and alarms to alert the user of impending hypoglycaemia during exercise when close observation of glycaemia may be challenging. The aim of the study is to assess the impact of Dexcom G6 real-time CGM (RT-CGM) with a predictive hypoglycaemia alert function on the frequency, duration and severity of hypoglycaemia occurring before, during and after regular physical activity in people with type 1 diabetes.

Materials and methods: People with type 1 diabetes on multiple daily injections or insulin pump therapy who exercised regularly (150min/week or more) have been recruited to this observational, within subject crossover study. Participants undertook 10 days of blinded CGM, whilst living their normal lives including their usual activity which was recorded using a sports watch. At the end of the 10 days, the RT-CGM was unblinded so that participants were able to see their glucose data. Participants were randomised 1:1 to use the “urgent low soon” alert switched on or off. The urgent low soon alert is an alarm that sounds when the algorithm predicts that the wearer will be 3.1mmol/l or less in the next 20 minutes. Participants continued to undertake and record their usual exercise. After 40 days the participants crossed over, so the participants that had the alarm off now switched it on, and vice versa for a further 40 days. Participants recorded their carbohydrate and insulin doses throughout the study.

Results: We demonstrate for the first time that intrinsic metabolic adaptations in an alpha cell line are induced by prior bouts of antecedent low glucose. RLG increased alpha cell basal glycolytic flux and glucose utilisation, even at low/hypoglycaemic levels of glucose. RLG also enhanced basal oxidative metabolism suggesting that mitochondria are working harder at baseline. These data suggest that enhanced glucose utilisation may play a role in driving the alpha cell dysfunction associated with defective counterregulatory responses to hypoglycaemia.

Supported by: DUK PhD studentship

Disclosure: K.M. Partridge: None.

Conclusion: The benefits of exercise for people Type 1 Diabetes (T1D) are significant, and include improvement in cardiovascular risk factors. Uptake of exercise is low in people with T1D, with fear of hypoglycaemia cited as the main barrier to exercise. Insulin and fuelling strategies are complex, and varying insulin sensitivity associated with different exercises regimes can make diabetes management challenging, resulting in hypoglycaemia. Technology has great potential to improve self-management of diabetes during exercise, offering real time glucose feedback with trend arrows, and alarms to alert the user of impending hypoglycaemia during exercise when close observation of glycaemia may be challenging. The aim of the study is to assess the impact of Dexcom G6 real-time CGM (RT-CGM) with a predictive hypoglycaemia alert function on the frequency, duration and severity of hypoglycaemia occurring before, during and after regular physical activity in people with type 1 diabetes.

Materials and methods: People with type 1 diabetes on multiple daily injections or insulin pump therapy who exercised regularly (150min/week or more) have been recruited to this observational, within subject crossover study. Participants undertook 10 days of blinded CGM, whilst living their normal lives including their usual activity which was recorded using a sports watch. At the end of the 10 days, the RT-CGM was unblinded so that participants were able to see their glucose data. Participants were randomised 1:1 to use the “urgent low soon” alert switched on or off. The urgent low soon alert is an alarm that sounds when the algorithm predicts that the wearer will be 3.1mmol/l or less in the next 20 minutes. Participants continued to undertake and record their usual exercise. After 40 days the participants crossed over, so the participants that had the alarm off now switched it on, and vice versa for a further 40 days. Participants recorded their carbohydrate and insulin doses throughout the study.

Conclusion: The benefits of exercise for people Type 1 Diabetes (T1D) are significant, and include improvement in cardiovascular risk factors. Uptake of exercise is low in people with T1D, with fear of hypoglycaemia cited as the main barrier to exercise. Insulin and fuelling strategies are complex, and varying insulin sensitivity associated with different exercises regimes can make diabetes management challenging, resulting in hypoglycaemia. Technology has great potential to improve self-management of diabetes during exercise, offering real time glucose feedback with trend arrows, and alarms to alert the user of impending hypoglycaemia during exercise when close observation of glycaemia may be challenging. The aim of the study is to assess the impact of Dexcom G6 real-time CGM (RT-CGM) with a predictive hypoglycaemia alert function on the frequency, duration and severity of hypoglycaemia occurring before, during and after regular physical activity in people with type 1 diabetes.

Materials and methods: People with type 1 diabetes on multiple daily injections or insulin pump therapy who exercised regularly (150min/week or more) have been recruited to this observational, within subject crossover study. Participants undertook 10 days of blinded CGM, whilst living their normal lives including their usual activity which was recorded using a sports watch. At the end of the 10 days, the RT-CGM was unblinded so that participants were able to see their glucose data. Participants were randomised 1:1 to use the “urgent low soon” alert switched on or off. The urgent low soon alert is an alarm that sounds when the algorithm predicts that the wearer will be 3.1mmol/l or less in the next 20 minutes. Participants continued to undertake and record their usual exercise. After 40 days the participants crossed over, so the participants that had the alarm off now switched it on, and vice versa for a further 40 days. Participants recorded their carbohydrate and insulin doses throughout the study.
OP 24 How to burn energy

139

The oxidative phenotype of abdominal and femoral adipose tissue in women with normal weight or obesity

E.E. Blaak2, K.N. Manolopoulos1, G.H. Goossens2;
1Institute of Metabolism and Systems Research (IMSR), College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; 2Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, Netherlands.

Background and aims: Body fat distribution is closely associated with the risk for developing obesity-related cardiometabolic diseases. Rodent and human studies suggest that mitochondrial dysfunction in adipose tissue (AT) contributes to obesity-related metabolic complications. However, whether mitochondrial function differs between AT depots remains unknown. Here, we aimed to explore whether the oxidative phenotype differs between upper and lower body subcutaneous AT in humans.

Materials and methods: We investigated the abdominal and femoral AT oxidative machinery in 21 postmenopausal women (age 50-65 yrs) with normal weight (PwNW; BMI 18.25 kg/m²) versus obesity (PwOB; BMI 30-40 kg/m²). In vivo fractional extraction (FE) and release (FR) of oxygen, carbon dioxide, and several metabolites across abdominal and femoral AT were determined using the arterio-venous balance technique. Oxidative phosphorylation (OXPHOS) protein levels were determined in abdominal and femoral AT biopsies and differentiated adipocytes derived from the same donors. Finally, we assessed in vivo mitochondrial respiration in abdominal and femoral adipocytes (SeaHorse XF96 analyzer).

Results: The FE of oxygen (22.6 ± 2.1% vs. 35.8 ± 3.1%; p=0.009) and the FR of carbon dioxide (4.1 ± 0.8 vs. 7.0% ± 1.2; p=0.076) across abdominal AT were lower compared to femoral AT. Adipocyte size (68.5 ± 1.9% vs. 68.4 ± 1.6 μm; p=0.791) and blood flow (9.3 ± 2.1 vs. 5.8 ± 1.8 mL/min; p=0.296) were not different between abdominal and femoral AT. OXPHOS protein expression was lower both in AT (complexes I and III) and in adipocytes (complexes III and V) in PwOB than PwNW but did not differ between depot. Basal respiration (p=0.020), maximal respiration (p=0.001) and spare respiratory capacity (p=0.001) were lower in abdominal compared to femoral adipocytes derived from both PwNW and PwOB.

Conclusion: These findings demonstrate for the first time that AT oxygen extraction and adipocyte oxygen consumption are lower in ABD than FEM AT in postmenopausal women with normal weight or obesity, already at the preclinical stage, independent of adipocyte size.

Disclosure: E.E. Blaak: None.

140

Pdgfrα-specific deletion of Alms1 in mice recapitulates the obesity and insulin resistance of global Alms1 KO and this cannot be explained by discoordinated ciliary dynamics

E.J. McKay1, I.H. Luijten1, D. McCormick1, P. Mill2, R.K. Semple1;
1Centre for Cardiovascular Science, University of Edinburgh; 2Institute for Genetics and Cancer, University of Edinburgh, Edinburgh, UK.

Background and aims: Alström Syndrome (AS) is a rare autosomal recessive disease featuring early onset, severely insulin resistant diabetes, fatty liver and heart failure among other features. These cardiometabolic complications occur in the face of only moderate obesity in many patients. AS is caused by biallelic loss-of-function mutations in the ALMS1 gene, encoding a large centrosomal protein. The precise derangement of centrosomal and/or primary cilia function caused by loss of ALMS1 is unknown, as most studies have reported primary cilia to be morphologically normal. Abnormal cell cycle kinetics have been suggested to play a role in some facets of the syndrome. Several global knockout (KO) mouse models have been described to recapitulate key metabolic components of AS, but none have used tissue-specific KO to tease out contributions of different cell types to pathology. Hypotheses: 1) 1) The metabolic profile of AS closely resembles that of lipodystrophy. We thus hypothesised that loss of Alms1 function in mesenchymal stem cell populations, such as adipose precursor cells, would recapitulate the metabolic derangement in AS. 2) 2) Alms1 loss leads to disco-ordination of ciliary and cell cycles, and it is such discoordination rather than normal ciliary structure, that compromises tissue homeostasis.

Materials and methods: 1) A novel global KO mouse was generated by crossing the EUCOMM Tm1c Alms1 line with global CAG-Cre mice. A Pdgfrα-Cre driver was used to abrogate Alms1 function only in mesenchymal progenitor cells and their descendants including preadipocytes and adipocytes. We undertook metabolic phenotyping of global and Pdgfrα-Alms1-KO mice on a 45% high-fat diet. 2) 2) NIH-3T3 flp-in cells were edited using CRISPR-Cas9 to cause biallelic loss-of-function mutations of Alms1. The cycle and ciliary biosensor, Arl13bCerulean-Fucci2a, was stably expressed in Alms1-/- and WT control cells using the flp-in system. Live cell imaging of these cells was then performed, followed by analysis of cell cycle and ciliary coordination dynamics.

Results: 1) Consistent with previous models and the human disease, global Alms1 KO mice were hyperphagic, obese, insulin resistant, and had severe hepatosteatosis. KO of Alms1 only in MSCs and their descendants recapitulated key metabolic phenotypes of global KO animals including obesity and insulin resistance. Interestingly hyperphagia was also seen despite preservation of neuronal Alms1. 2) No significant difference in the time between deciliation and cytokinesis, or the time between the two events, was observed.

Conclusion: 1) MSC-derived lineages are critical in driving the severe metabolic syndrome in AS 2. Hyperphagia in AS does not depend on neuronal Alms1 deficiency 3. Discoordinated ciliary and cell cycles do not appear to explain the critical role of MSCs in the metabolic syndrome of AS.

Disclosure: E.J. McKay: None.

141

A larger brown fat volume and lower mean radiodensity are related to a greater cardiometabolic risk, especially in young men

F. Acosta1, G. Sanchez-Delgado2,3, B. Martinez-Tellez2,4, F. Osuna-Prieto5, A. Mendez-Gutierrez6,7, C. M. Aguilera6,8, A. Gil6,8, J. Llamas Elvira9, J. Ruiz Ruiz2,8;
1Turku PET Centre, University of Turku, Turku, Finland; 2PROFHT research group, University of Granada, Granada, Spain; 3Pennington Biomedical Research Center, Baton Rouge, USA; 4Department of Medicine, Division of Endocrinology, Eindhoven Lab for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, Netherlands; 5Department of Analytical Chemistry, University of Granada, Granada, Spain; 6Department of Biochemistry and Molecular Biology II, Biomedical Research Centre, Granada, Spain; 7Biohealth Research Institute in Granada, Granada, Spain; 8Biohealth Research Institute, Granada, Spain; 9University Hospital Virgen de las Nieves, Granada, Spain.

Background and aims: Brown adipose tissue (BAT) is important in the maintenance of cardiometabolic health in rodents. Recent reports appear
to suggest the same in humans, although if this is true remains elusive, partly because of the methodological bias that affected previous research. The present cross-sectional work reports the relationships of cold-induced BAT volume, activity (peak standardized uptake, SUV_{peak}) and mean radiodensity (an inverse proxy of the triacylglycerols content) with the cardiometabolic and inflammatory profile of 131 young adults, and how these relationships are influenced by sex and body weight.

**Materials and methods:** This was a cross-sectional study carried out in Granada (south of Spain) during October-December 2015 and 2016. Subjects underwent personalized cold exposure for 2 h to activate BAT, followed by static ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography scanning to determine BAT variables. Information on cardiometabolic risk (CMR) and inflammatory markers was gathered, and a CMR score and fatty liver index (FLI) calculated. Anthropometry, body composition and lifestyle behaviors (potential confounders) were also measured.

**Results:** In men, BAT volume was positively related to homocysteine and liver damage markers concentrations (independently of BMI and seasonality) and the FLI (all P<0.05). In men too, BAT mean radiodensity was negatively related to the glucose and insulin concentrations, alanine aminotransferase activity, insulin resistance, total cholesterol/HDL-C, LDL-C/HDL-C, the CMR score, and the FLI (all P<0.02). In women it was only negatively related to the FLI (P<0.001). These associations were driven by the results for the overweight and obese subjects (see figure below). No relationship was seen between BAT and inflammatory markers (P>0.05).

**Conclusion:** These findings show that a larger BAT volume and a lower BAT mean radiodensity are related to a higher CMR, especially in young men, which may support that BAT acts as a compensatory organ in states of metabolic disruption.

**Clinical Trial Registration Number:** NCT02365129

**Supported by:** Potential support (not decided yet) - Turku Foundation, University of Turku

**Disclosure:** F. Acosta: None.

---

142

**Brown adipose tissue content of triglycerides, but not SUV, is associated with cardiovascular risk markers in volunteers from a tropical region**

M. Monfort-Pires¹, G.R. Silva², P. Dadson¹, G.A. Nogueira¹, M. U-Din¹, K.A. Virtanen¹, L.A. Velloso³;
¹Turku PET Centre, Turku, Finland, ²University of California, Davis, USA, ³University of California, Davis, USA, 4University of California, Davis, USA, 5University of Tennessee, Memphis, 6University of California, Davis, USA.

**Background and aims:** Since the discovery of active brown adipose tissue (BAT) in human adults, the tissue has been considered a potential target for the treatment of obesity, diabetes, and cardiovascular diseases. A detailed characterization of BAT structure and function could help understand its role in metabolism, but most studies evaluating BAT structure and function were performed in temperate climate regions, while 40% of the world’s population are living in tropical areas.

**Materials and methods:** We used ¹⁸F-fluorodeoxyglucose positron emission tomography - combined with magnetic resonance imaging to evaluate BAT activity (FDG standardized uptake value - SUV), BAT volume and BAT content of triglycerides (TG) in 30 lean and 15 subjects with overweight or obesity living in a tropical area in Southeast Brazil. Body composition was analyzed using DXA and magnetic resonance imaging and fasting blood samples were withdrawn for several determinations. The study was approved by the Local Ethics Committee, and it has been performed in accordance with the ethical standards laid down in the Helsinki Declaration.

**Results:** We observed that BAT activity (FDG SUV) and BAT volume are not correlated with leanness (p<0.05 for all); instead, BAT triglyceride content is correlated with waist circumference (correlation coefficient r=0.71; p<0.01) and markers of cardiovascular risk, such as Castelli Index I (correlation coefficient r=0.51; p<0.01) and II (correlation coefficient r=0.47; p<0.01). Also, it was inversely associated with HDL (correlation coefficient r=-0.48; p<0.05). To further investigate this association, we performed an analysis of variance (ANOVA) comparing BMI, waist circumference, total fat mass, visceral adipose tissue, HDL, Castelli I and Castelli II indexes against BAT activity, volume, and TG content. BAT mean SUV and volume did not differ across categories of BMI or waist circumference, or across tertiles of total fat mass and visceral adipose tissue. HDL, Castelli I and II indexes (p>0.05 for all). However, we detected a difference between low and high BMI (68.8 ± 6.1 versus 77.8 ± 5.1 % of TG) and waist circumference (68.7 ± 4.9 versus 77.6 ± 5.3 % of TG) and between the first and 3rd tertile of visceral fat mass (68.3 ± 4.2 versus 78.4 ± 4.3 % of TG) for the BAT TG content (p<0.05 for all). In addition, differences between tertiles were observed for HDL cholesterol, Castelli I and Castelli II indexes (p<0.05 for all).

**Conclusion:** This study expands knowledge regarding the structure and function of BAT in people living in tropical areas. In addition, we provide evidence that BAT triglyceride content could be a marker of cardiovascular risk.

**Supported by:** FAPESP: #2016/10616-7/#2017/22586-8/2019/02055-3

**Disclosure:** M. Monfort-Pires: None.

---

143

**Humans with metabolically active brown fat demonstrate higher capacity to catabolise branched chain amino acids**

M. U-Din¹, V. de Mello Laaksonen², K. Hanhineva², J. Newman³, K. Kristiansen³, M. Klingenspor³, T. Fromme³, T. Niemi³, M. Taittinen³, T. Saari³, J. Raiko¹, P. Nuutila¹, K.A. Virtanen¹;
¹Turku PET Centre, Turku, Finland, ²University of Eastern Finland, Kuopio, Finland, ³University of California, Davis, USA, 4University of Copenhagen, Copenhagen, Denmark, 5Technical University Munich, Freising, Germany, 6Turku University Hospital, Turku, Finland.

**Background and aims:** Branched chain amino acids (BCAA: valine, leucine, isoleucine) may synergize with circulating lipids to induce insulin resistance. Metabolically active brown adipose tissue (BAT) may be a potent site for BCAA catabolism that participates in systemic clearance of BCAA. The study aimed to investigate the systemic and BAT-specific metabolism of BCAA in healthy human adults.

**Materials and methods:** Seventy-nine (25M/54F) humans with BMI 27 ± 6 kg/m² and whole-body insulin sensitivity (M-value) of 39 ± 20 μmol/kg/min participated. M-value was determined with hyperinsulinemic-euglycemic clamp. Circulatory BCAA were determined without targeted metabolomics on serum samples. Tissue BCAA were determined with non-targeted metabolomics, and tissue transcriptomics were...
Hepatocyte PPARα is required for the sensing of adipose-derived fatty acids and for full brown adipose tissue activation during lipolysis

A. Fougerat1, G. Schoiswohl2, A. Polizzi1, M. Régnier1, C. Wagner2, B. Tramut1, S. Ellero-Simatos1, L. Payrastre1, C. Postic2, W. Wahl1, N. Loiseau1, A. Montagner3, D. Langin1, A. Lass2, H. Guillou1:
1Texalim, INRAE, Toulouse, France, 2Institute of Molecular Biosciences, Graz, Austria, 3Institute of Metabolic and Cardiovascular Diseases, Toulouse, France, 4INSERM U1151/CNRS UMR 8253, Institut Necker-Enfants Malades (INEM), Paris, France, 5Center for Integrative Genomics, Lausanne, Switzerland.

Materials and methods: We used mouse models of selective deletion of PPARα in hepatocytes and of adipose triglyceride lipase (ATGL) in adipocytes as a model of defective lipolysis. First, we performed liver whole genome expression analysis in fasted mice upon cell-specific deletion of adipocyte ATGL or hepatocyte PPARα. Second, we tested the consequences of hepatocyte PPARα deficiency during pharmacological induction of adipocyte lipolysis with a β3-adrenergic receptor agonist.

Conclusion: Altogether, our results support a dominant role for adipose ATGL in generating fatty acids that trigger hepatocyte PPARα activity and underscore the critical role of hepatic PPARα not only in the sensing of lipolysis-derived lipids but also in triggering BAT activation independent of hepatocyte FGF21 production. Intact PPARα activity in hepatocytes is required for cross-talk between adipose tissues and the liver during fat mobilization.

Disclosure: A. Fougerat: None.
Skeletal muscle derived myokine affects insulin sensitivity and lipogenesis in a human hepatocyte spheroid model

J.-B. Potier,1,2 A. Dumond,2 A. Fardellais,1 M. Pinger,1 M. Aouadi,1 K. Bouzakri1,2
1Ilonov, Strasbourg, France, 2Université de Strasbourg, Centre européen d’étude du diabète, Strasbourg, France, 3Karolinska Institutet, Center for Infectious Medicine, Huddinge, Sweden.

Background and aims: Inter-organ crosstalk has recently emerged as a crucial aspect of body homeostasis, especially in metabolic diseases such as type 2 diabetes (T2D) and NAFLD. Skeletal muscle is highly implied in this crosstalk, through the secretion of specific cytokines called myokines. Among those, our laboratory has focused on the myokine X (MyoX). Due to our previous results on the prevention of diabetes and to the pathophysiological link between this disease and NAFLD, we chose to investigate the effect of the MyoX on the liver. Primary human hepatocytes (PHH) spheroids, the gold standard model for the in vitro study of liver diseases, were used for our experiments.

Materials and methods: PHH spheroids were cultured in lean and metabolic syndrome (MetS) conditions treated, or not, with different concentrations of MyoX: 0.1, 1 and 10 μg/ml. Spheroids were then stimulated with insulin and protein lysates were collected. Effects of MyoX on the expression of proteins related to glucose (Akt, ERK1/2, GLUT2) and lipid (SREBP1c, FAS, CPT1A) metabolism, two pathways implied in NAFLD development, were assayed by western blot. Furthermore, Nile Red staining was performed for the measurement of triglyceride accumulation.

Results: Concerning glucose metabolism, noticeable effects were observed for the phosphorylation of Akt, which was stronger at a dose of 10 μg/ml in lean condition, suggesting that the MyoX might enhance the intensity of the insulin downstream. Likewise, in the same condition, the slight increase in triglyceride accumulation, observed with the Nile Red staining, could be explained by an insulin-dependent de novo lipogenesis mechanism confirmed by the increase of SREBP1c phosphorylation (an insulin-dependent transcription factor responsible for the storage of fatty acid as triglycerides). Concerning MetS conditions, beneficial effects were observed at the lower dose of MyoX, with a decrease in triglyceride amount related to the reduction of SREBP1c phosphorylation, associated with no detrimental effect on p-Akt.

Conclusion: Taken together, our analysis suggest that high doses of MyoX might act as a sensitizer and exacerbates the effects of insulin in PHH in lean condition, enhancing the de novo lipogenesis. In MetS condition, potential beneficial effects were noticed for the lower dose of MyoX, suggesting that our protein might be of interest for the prevention of NAFLD. Further studies should be performed to determine the optimal dose of the myokine.

Disclosure: J. Potier: None.

The PNPLA3 I148M variant increases intrahepatic lipolysis and beta oxidation and decreases de novo lipogenesis and hepatic mitochondrial function in vivo in humans

P.K. Luukkonen1,2, K. Porthan1, N. Ahlholm1, F. Rosqvist1,4, S. Dufour1, X.-M. Zhang4, J. Dabek1, T.E. Lehtimäki1, W. Seppänen1, M. Ortho-Melander1, L. Hudson1, K.F. Petersen3, G.I. Shulman1, H. Yki-Järvinen2
1Yale University, New Haven, USA, 2Minerva Foundation Institute for Medical Research, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 3Uppsala University, Uppsala, Sweden, 4University of Oxford, Oxford, UK, 5University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 6Lund University, Malmö, Sweden.

Background and aims: The PNPLA3 I148M variant is the strongest genetic risk factor of non-alcoholic fatty liver disease (NAFLD) but the underlying mechanisms remain unknown. We studied the effect of this variant on hepatic metabolism in vivo under multiple physiological conditions by combining a recruit-by-genotype approach with state-of-the-art stable isotope techniques.

Materials and methods: We recruited 93 healthy participants (mean age 53±1 yrs, BMI 30±1 kg/m2, 19% men; 37 homozygous carriers [148MM] and 56 non-carriers [148II]). Hepatic de novo lipogenesis (DNL) was assessed after an overnight fast using D2O (148MM, n=19; 148II, n=36). Hepatic fate of exogenous fatty acids (FA) was determined using a mixed meal enriched in [1-13C]-labeled FA (148MM, n=12; 148II, n=14). Endogenous glucose production, ketogenesis and hepatic mitochondrial citrate synthase flux (VCS) were assessed before and after a 4-day ketogenic diet by Positional Isotopomer NMR Tracer Analysis (PINTA) by infusing [3-13C]-lactate, [13C4]-β-hydroxybutyrate (β-OHB) and [1H5]-glucose (148MM, n=6; 148II, n=6). Intrahepatic triglycerides (IHTG) were assessed by NMR spectroscopy and hepatic mitochondrial redox state by plasma [β-OHB]/[acetate].

Results: After an overnight fast, the 148MM group had higher plasma [β-OHB] (+104%, p<0.05) and lower DNL (-47%, p<0.01) than the 148II group, independent of plasma [NEFA] and [insulin]. After a mixed meal, exogenous [1-13C]-labeled FAs in the 148MM group were channeled more to ketogenesis (+265%, p<0.001), which associated with an increased hepatic mitochondrial redox state (+36%, p<0.05). During a ketogenic diet, the 148MM group had greater intrahepatic lipolysis as reflected by a larger reduction in IHTG (77%, p<0.05) than the 148II group, which associated with: 1) increased plasma [β-OHB] (+90%, p<0.05), 2) increased mitochondrial redox state and 3) decreased VCS (-31%, p<0.01). Plasma [GDF-15], a mitochondrial stress marker, was increased by 40% (p<0.01) in the 148MM group compared to the 148II group.

Conclusion: The PNPLA3 I148M carriers have alterations in both intrahepatic anabolic/catabolic processes and mitochondrial function as reflected by increased intrahepatic lipolysis, decreased DNL and increased hepatic mitochondrial β-oxidation/ketogenesis. These changes associated with an increased mitochondrial redox state and reductions in hepatic mitochondrial VCS. These results provide new insights in the mechanisms by which the PNPLA3 I148M promotes NAFLD (Figure).
Effect of tirzepatide on fasting lipids in patients with type 2 diabetes: meta-analysis of randomised controlled trials

T. Karagiannis1, I. Avgerinos1, A. Tsapou1,2, E. Bekiar1; 1Clinical Research and Evidence-Based Medicine Unit, Aristotle University of Thessaloniki, Thessaloniki, Greece, 2Harris Manchester College, Oxford, UK.

Background and aims: Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has been shown to reduce HbA1c and body weight in patients with type 2 diabetes. We aimed to assess whether the salutary metabolic effects of tirzepatide extend to improvements in patients’ lipid profile.

Materials and methods: We searched PubMed, Embase and the Cochrane Library up to January 2022 for randomised controlled trials (RCTs) of at least 12 weeks’ duration that compared tirzepatide 5, 10 or 15 mg once weekly with placebo or other glucose lowering drugs in adults with type 2 diabetes, and reported results on fasting lipids. Outcomes included change from baseline in the concentrations of triglycerides, total cholesterol (T-C), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C) and high-density lipoprotein cholesterol (HDL-C). We conducted random effects meta-analyses pooling mean differences (MDs) with 95% confidence intervals (CIs).

Results: We included data from six RCTs (n = 6527 participants). Comparator was placebo, GLP-1 RA and basal insulin in two, one and two trials respectively, while one trial had both a placebo and a GLP-1 RA control arm. Duration of intervention was 26, 40 and 52 weeks in one, three and two trials respectively. Compared to placebo, tirzepatide induced dose-dependent reductions in fasting triglycerides, total cholesterol (T-C), LDL-C and VLDL-C (Table), and had no effect on HDL-C. Compared to GLP-1 receptor agonists (dulaglutide and semaglutide), tirzepatide reduced triglycerides (MDs ranging from -12.51 mg/dL with tirzepatide 5 mg to -24.98 mg/dL with tirzepatide 15 mg) and VLDL-C (MDs ranging from -1.89 mg/dL to -4.08 mg/dL). Compared to basal insulin, tirzepatide dose-dependently decreased levels of triglycerides, T-C, LDL-C and VLDL-C (MDs ranging from -1.89 mg/dL to -4.08 mg/dL). Compared to placebo, tirzepatide reduced triglycerides (MDs ranging from -12.51 mg/dL with tirzepatide 5 mg to -24.98 mg/dL with tirzepatide 15 mg) and VLDL-C (MDs ranging from -1.89 mg/dL to -4.08 mg/dL).

Conclusion: Based on pooled data from RCTs, treatment with tirzepatide dose-dependently decreased levels of triglycerides, total cholesterol (T-C), LDL-C and VLDL-C versus placebo. As such, in addition to its glucose lowering effect, tirzepatide could be used to improve the atherogenic lipoprotein profile in patients with type 2 diabetes by complementing the effect of lipid lowering drugs.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Tirzepatide dose</th>
<th>MD (95% Cl)</th>
<th>I², %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triglycerides, mg/dL</td>
<td>5 mg QW</td>
<td>-35.42 (-66.5 to -4.29)</td>
<td>84</td>
</tr>
<tr>
<td></td>
<td>10 mg QW</td>
<td>-43.57 (-83.67 to -4.46)</td>
<td>85</td>
</tr>
<tr>
<td></td>
<td>15 mg QW</td>
<td>-50.39 (-90.64 to -10.14)</td>
<td>84</td>
</tr>
<tr>
<td></td>
<td>5 mg QW</td>
<td>-11.73 (-16.24 to -7.21)</td>
<td>0</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>5 mg QW</td>
<td>-15.10 (-21.74 to -8.46)</td>
<td>44</td>
</tr>
<tr>
<td></td>
<td>10 mg QW</td>
<td>-18.13 (-23.47 to -12.78)</td>
<td>27</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>5 mg QW</td>
<td>-7.52 (-11.52 to -3.53)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>10 mg QW</td>
<td>-9.39 (-14.18 to -4.60)</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>15 mg QW</td>
<td>-13.09 (-17.05 to -9.15)</td>
<td>0</td>
</tr>
<tr>
<td>VLDL cholesterol, mg/dL</td>
<td>5 mg QW</td>
<td>-4.58 (-7.17 to -1.98)</td>
<td>66</td>
</tr>
<tr>
<td></td>
<td>10 mg QW</td>
<td>-5.54 (-7.77 to -3.30)</td>
<td>48</td>
</tr>
<tr>
<td></td>
<td>15 mg QW</td>
<td>-6.37 (-7.93 to -4.82)</td>
<td>0</td>
</tr>
</tbody>
</table>

Disclosure: T. Karagiannis: None.

Lipidomic and metabolomics profiling in low birth weight men reveals a dysmetabolic phenotype associated with increased liver fat

L. Elingaard-Larsen1, C. Bruns1, S. Villumsen1, L. Justesen1, A. Thuesen2, M. Ali1, M. Kim1, C. Legido-Quigley1, G. van Hall1, E. Rubek Danielsen2, T. Hansen2, A. Vaag1; 1Steno Diabetes Center Copenhagen, Herlev, 2University of Copenhagen, Copenhagen, 3Rigshospitalet, Copenhagen, Denmark.

Background and aims: Being born with a low birth weight (LBW) is associated with an increased risk of developing Type 2 Diabetes (T2D) in adulthood. The subcutaneous adipose tissue (SAT) plays a central role in T2D pathophysiology. We hypothesized, that LBW individuals have an impaired SAT expandability, resulting in ectopic lipid deposition in the liver, thereby contributing to the pathophysiological events linking LBW with T2D development. Using untargeted metabolomics and lipidomics analyses, as well as state-of-the-art magnetic resonance (MR) spectroscopy for liver fat determinations, we aimed to assess the extent to which increased liver fat is associated with dysmetabolic traits in early middle-aged, non-obese LBW men.

Materials and methods: Forty-eight healthy, non-obese males aged 35-39 years, born at term with a LBW (BW<10th percentile, n=26) and age- and BMI-matched NBW controls (BW: 50-90th percentile, n=22) were included in the study. We measured body composition, hepatic fat content using 1H MR spectroscopy and hepatic glucose production determined by isotopic tracers. Untargeted serum metabolomics and lipidomics were performed using mass-spectrometry.

Results: LBW subjects had a significantly increased hepatic fat content compared to NBW controls (P<0.014). Interestingly, 5 of the LBW subjects (20%) and none of the NBW subjects, fulfilled the diagnostic criteria of non-alcoholic fatty liver disease (NAFLD), displaying a mean hepatic fat content of 9.45%. This subgroup showed several metabolic derangements compared with NBW and LBW men without NAFLD, including hepatic insulin resistance (P=0.02) and increased fasting levels of triglycerides (TG) (P=0.03). Untargeted serum metabolomics of 65 distinct metabolites, identified 7 metabolites which showed different levels between LBW subjects with NAFLD and NBW controls (P<0.05). This included ornithine and citrulline, suggesting an upregulation of the urea cycle in LBW subjects with NAFLD. Furthermore, a pathway analysis highlighted tRNA charging as the top canonical pathway, driven by differences in amino acid levels between NBW and LBW subjects, in which LBW subjects with NAFLD exhibited elevated levels of nearly all the amino acids. Lipidome profiling included 279 lipids and revealed increased levels of phosphatidycholines and TGs (P<0.05) in the LBW subjects with NAFLD compared to both LBW without NAFLD and NBW subjects. Both lipid species had differential structural composition in the LBW subjects with NAFLD, including an increased amount of long chain fatty acids and fewer double bonds (0-7 bonds).

Conclusion: Increased liver fat content may play a key role linking LBW with increased risk of developing T2D. The most adverse metabolic phenotype was seen in the LBW subgroup with NAFLD, displaying hepatic insulin resistance and dyslipidemia. Metabolomics and lipidomics analysis emphasize this phenotype by revealing an altered amino acid profile as well as changes in the composition and structural organization of lipids known to be associated with overt T2D.

Clinical Trial Registration Number: NCT02902408

Supported by: NNF, EFSF Organ Crosstalk Program, Trygfonfond, Augustinus Fonden and Aase and Ejnar Danielsen Fond, EFSF/Boehringer Ingelheim Research Programme

Disclosure: L. Elingaard-Larsen: None.
3-hydroxybutyrate infusion suppresses free fatty acid concentrations in type 1 diabetes patients and healthy men

M. Bangshaab1,2, M.V. Svartr3,2, N. Rittig1,2, M.G. Pedersen1,2, N. Møller1,3; 1Medical Research Laboratory, Department of Clinical Medicine, Aarhus University, 2Steno Diabetes Center Aarhus, Aarhus University Hospital, 3Department of Internal Medicine and Endocrinology, Aarhus University Hospital, Aarhus, Denmark.

Background and aims: Diabetic ketoacidosis (DKA) remains the most important cause of premature death in younger persons with type 1 diabetes (T1DM). Recent data have revealed the existence of a feedback loop whereby the most prominent ketone body 3-hydroxybutyrate (3-OHB) inhibits adipose tissue release of free fatty acids (FFA), which are the major ketogenic precursors. The current study was designed to test whether this feedback mechanism is disrupted in men with T1DM, as a potential pathophysiological mechanism in DKA.

Materials and methods: We used a 2x2 crossover design to study 10 men with T1DM and 10 age-matched healthy men (CTR) randomly receiving 3-hours intravenous infusion of i) Na-D/L-3-OHB and ii) NaCl, separated by a 1-hour wash-out period. Participants were fasting during examinations. Two-way repeated measures ANOVA analyses were performed to evaluate the effect of time, group and time x group interactions.

Results: During the 3-OHB infusion blood D-3-OHB concentrations rose from 0.2±0.06 to 1.2±0.12 mmol/l in T1DM, a slightly higher concentration compared to CTR, 0.2±0.03 to 1.0±0.1 mmol/l (time, p<0.001 and time x group, p=0.031). 3-OHB infusion decreased circulating FFA concentrations from 0.68±0.12 to 0.15±0.03 mmol/l in T1DM and from 0.48±0.09 to 0.21±0.04 mmol/l in CTR (time, p<0.001 and time x group, p=0.06) while during NaCl infusion, FFA were slowly increasing (time, p=0.002) in both groups. Plasma glucose concentrations were 8.3±0.1 mmol/l in T1DM and 4.7±0.04 m mol/l in CTR (group, p<0.001). Peripheral plasma insulin concentrations were 59.2±2.8 pmol/l in T1DM and 16.3±1.1 pmol/l in CTR (group, p<0.001) and plasma glucagon concentrations were 5.5±0.1 pmol/l in T1DM and 7.8±0.3 pmol/l in CTR (group, p=0.01).

Conclusion: In conclusion our data show similar suppression of blood FFA concentrations by 3-OHB in T1DM compared with CTR, thus strongly suggesting that the inhibition of lipolysis (the negative feedback) by 3-OHB is intact in men with T1DM.

Clinical Trial Registration Number: NCT04656236

Supported by: Novo Nordisk Foundation

Disclosure: M. Bangshaab: None.

Inhibition of VEGF-B signalling prevents non-alcoholic fatty liver disease development and progression

A. Falkevall1, A. Mehlem1, E. Folestad1, M. Zeitelhofer1, P. Scotney2, U. Eriksson3; 1Dept of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, 2CSL Innovations Ltd, Melbourne, Australia.

Background and aims: Non-alcoholic fatty liver disease (NAFLD) is a common co-morbidity of type 2 diabetes entailing a range of pathologies from hepatic steatosis to hepatocellular carcinoma. We aimed to explore the role of VEGF-B signaling in this disease complex.

Materials and methods: Mice with adipocyte specific over-expression of VEGF-B, or adipocyte-specific deletion of Vegfb were used to investigate the role of VEGF-B signaling in adipose tissue lipolysis and the development of NAFLD.

Results: We describe a novel function of Vascular Endothelial Growth Factor B (VEGF-B) and show by using mice with adipocyte specific over-expression of VEGF-B, or adipocyte-specific deletion of Vegfb that VEGF-B signaling in adipose tissue regulates lipolysis and directly control hepatic steatosis and NAFLD development in diabetic mice. Inhibiting VEGF-B signaling, using both pharmacological and genetic strategies, in mouse models of NAFLD lowers hepatic steatosis and reduces NAFLD associated-pathologies. Mechanistically we show that VEGF-B signaling in the adipose tissue ameliorates NAFLD by resolving adipose tissue insulin resistance and the activity of the hormon sensitive lipase, a rate-limiting enzyme in lipolysis.

Conclusion: We conclude that VEGF-B antagonism represents a novel approach to combat NAFLD by targeting steatosis through suppressing adipose tissue lipolysis.

Supported by: VR Distinguished Professor Award, EFSDF/Boehringer Ingelheim Research Programme

OP 26 The dark side of diabetes

151 Risk of incident diabetes after hysterectomy: results from the E3N cohort study
F. Bonnet1,2, P. Vaduva1, N. Laouali1,2, G. Fagherazzzi1,2, M. Kvaskoff3; 1CHU de Rennes, Rennes, France, 2Centre for Research in Epidemiology and Population Health, Inserm U1018, Villejuif, France, 3Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts at Amherst, Amherst, USA, 4Deep Digital Phenotyping Research Unit. Department of Population Health, Luxembourg Institute of Health, Luxembourg, Luxembourg.

Background and aims: Hysterectomy has been associated with the risk of hypertension and cardiovascular disease but few studies have examined the relation between hysterectomy and the risk of type 2 diabetes. These studies mostly included post-menopausal women. Furthermore, the potential influence of diet and physical activity has not been addressed in previous reports. The aim of our study was to investigate whether hysterectomy was associated with an increased risk of incident diabetes in a large French cohort of women. In addition, we aimed to examine whether an unhealthy lifestyle influenced the risk of diabetes among women who had a hysterectomy.

Materials and methods: We studied 81,444 women from the E3N cohort who were free of diabetes at baseline; they were followed-up for a mean of 16.4 years. Assessment of diet and physical activity was by questionnaire. Women with gynecological cancers were excluded from the analyses. Cox proportional hazard models with age as the timescale were used to estimate Hazard Ratios (HR) and 95% confidence intervals (CI). Covariates included educational level, physical activity, type of diet, body mass index, smoking status, family history of diabetes, age at menarche, menopausal status, age at menopause, use of oral contraceptives.

Results: A total of 4,367 women developed type 2 diabetes during the follow-up. Women with a history of hysterectomy had an increased risk of incident diabetes, which persisted after adjustment for the main confounding factors (adjusted HR= 1.18, 95% CI 1.10-1.27, p<0.0001). The association was not altered after further adjustment for reproductive factors or hormonal treatments. The type of diet and the level of physical activity did not modify the association with incident diabetes. An increased risk of diabetes was observed irrespective of the cause of hysterectomy; for women who had a hysterectomy for endometriosis or fibroids (adjusted HR= 1.19, 95% CI 1.11-1.28). There was no interaction between the presence of overweight at baseline (BMI≥25 kg/m²) and an increased risk of diabetes. Hysterectomy with (HR: 1.23, 95% CI 1.13-1.35, p<0.0001) and without oophorectomy (HR: 1.13, 95% CI 1.03-1.25, p=0.013) were both associated with an increased risk of diabetes. The risk of incident diabetes was greater for women who had a hysterectomy before the age of 50: before 40 years (adjusted HR: 1.27, 95% CI 1.07-1.50, p=0.006); between the age of 40 and 50 years (adjusted HR: 1.27, 95% CI 1.16-1.40, p<0.0001); after age 50 (adjusted HR: 1.06, 95% CI 0.95-1.18, p=0.28) as compared to those without a hysterectomy in these age groups.

Conclusion: Our findings show that women who had a hysterectomy before the age of 50 had an increased risk of developing incident diabetes. This elevated risk appears to be independent of oophorectomy and is not explained by an unhealthy diet or physical inactivity. The underlying mechanisms leading to diabetes among these women remain to be elucidated.

Disclosure: F. Bonnet: None.

152 Association between endometriosis and risk of type 2 diabetes: results of the E3N prospective cohort study
P. Vaduva1, N. Laouali1,2, G. Fagherazzzi1, F. Bonnet1,2, M. Kvaskoff3; 1Department of Endocrinology, Diabetes and Nutrition, Rennes University Hospital, Rennes, France, 2Exposome and Heredity Team, Centre for Research in Epidemiology and Population Health, Inserm U1018, Villejuif, France, 3Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts at Amherst, Amherst, USA, 4Deep Digital Phenotyping Research Unit. Department of Population Health, Luxembourg Institute of Health, Luxembourg, Luxembourg.

Background and aims: Endometriosis is a chronic inflammatory disease estimated to occur in 10% of women of reproductive age, with an unknown etiology. It is associated with signs and symptoms such as chronic pelvic pain, chronic fatigue and infertility. Several studies suggest an association between this disease and the risk of chronic cardio-metabolic conditions such as hypertension, hypercholesterolaemia, atherosclerosis, and myocardial infarction, but its association with the risk of type 2 diabetes (T2D) is poorly documented. The aim of this study is to analyze the relationship between endometriosis and occurrence of T2D.

Materials and methods: E3N (Etude Epidemiologique après de femmes de l’Education Nationale) is a prospective cohort involving French women born in 1925-1950 followed-up since 1990. We considered here both prevalent (diagnosed before the initial questionnaire in 1992, retrospectively reported) and incident cases (diagnosed after the initial questionnaire, prospectively reported) of endometriosis. Data on laparoscopically confirmed endometriosis were collected every 2-3 years through self-report. T2D cases were identified using diabetes-specific questionnaires and drug reimbursement insurance databases. Statistical analysis used Cox models, and stratified analyses examined the influence of age, body mass index (BMI) (<25 or ≥25 kg/m²), infertility, and menopausal status on the associations between endometriosis and T2D risk.

Results: Among the 83,582 women, free of T2D at baseline, followed up for nearly 17 years, 4606 reported a diagnosis of endometriosis. Age at inclusion was 51±6 years. Compared with prevalent cases, incident cases were younger at inclusion and more likely to be parous and to have ever used hormonal treatments, while they had similar height, BMI, age at menarche, and menstrual cycle length. Women with endometriosis were more likely to have a family history of diabetes (p<0.0001), personal history of elevated cholesterol (p=0.0007) or hypertension (p=0.001), younger age of menarche (p=0.0002), more frequent bilateral oophorectomy (p<0.0001), more frequent oral contraceptives use (p<0.0001) and a higher education level (p=0.017). In a model adjusted for age, BMI, physical activity, smoking, education, age at menarche, and oral contraceptive use, endometriosis was not associated with the risk of T2D (HR=1.09, 95% CI=0.92-1.29). This relationship was similar after further adjustment for family history of diabetes, hypertension, and menopausal status (HR=0.99; 95% CI=0.83-1.19). The relationship between endometriosis and T2D risk did not differ by age at inclusion, BMI, use of infertility treatments, or menopausal status.

Conclusion: Laparoscopically confirmed endometriosis was not associated with risk of type 2 diabetes in this large French cohort. These results are consistent with a recent prospective American study, suggesting that endometriosis is neither a marker nor a risk factor for type 2 diabetes.

Disclosure: P. Vaduva: None.

153 Cardiovascular and metabolic morbidity in women with previous gestational diabetes: a nationwide register-based cohort study
M.H. Christensen1,2, K.H. Rubin3,4, T.G. Petersen5, E.A. Nohr3,3, C.A. Vinter1,2, M.S. Andersen3,5, D.M. Jensen1,2; 1Steno Diabetes Center Odense, Odense University Hospital, 2Department of Gynecology and Obstetrics, Odense University Hospital, 3Department of Clinical Research, University of Southern Denmark, 4OPEN - Odense Patient data Explorative Network, Odense
Background and aims: Gestational diabetes mellitus (GDM) is associated with increased risk of cardiovascular disease (CVD). To our knowledge, the metabolic component of dyslipidemia has not been addressed as an outcome after GDM before, and nor has it been investigated whether the severity of morbidity is associated with previous GDM. Also, insulin treatment during GDM pregnancy and development of manifest diabetes mellitus (as proxies for impaired β-cell function) may further increase the risk of cardiovascular and metabolic morbidity (CVMM). Aims of this study were to investigate incidence and severity of CVMM in women with previous GDM in a Danish population and to study whether proxies of impaired β-cell function influence the incident CVMM risk.

Materials and methods: This study is a nationwide register-based cohort study on the complete cohort of 700,648 women delivering in Denmark during 1997-2018. Exposure was GDM based on ICD-10 diagnosis code. Primary outcome was an overall CVMM outcome consisting of ICD-10 diagnosis code for ischemic heart disease, heart failure, stroke/transient cerebral ischemia (TCI), hypertension, dyslipidemia, venous thrombosis, cardiac arrhythmia, and/or redemptions of prescribed medication within antihypertensive, antithrombotic and/or lipid modifying agents. Secondary outcomes were: major CVD (ischemic heart disease, heart failure, stroke/TCI), hypertension (diagnosis code and/or medication), dyslipidemia (diagnosis code and/or medication), and venous thrombosis. Insulin treatment during GDM pregnancy was defined as diagnosis code of insulin treated GDM and/or redemptions of insulin during GDM pregnancy. The associations were studied using multiple cox regression models with GDM entering as a time-varying exposure. Severity of morbidity was investigated as number of CVMM related hospital contacts and of redemptions of prescribed CVMM related medication in women with incident CVMM.

Results: The median follow-up period was 10.2-11.9 years depending on specific outcome (total range 0-21.9 years). GDM was associated with significantly increased risk of any CVMM (adjusted hazard ratio (aHR) 2.13 [95% CI 2.07-2.20]), major CVD (aHR 1.69 [95% CI 1.55-1.84]), hypertension (aHR 1.89 [95% CI 1.82-1.96]), dyslipidemia (aHR 4.48 [95% CI 4.28-4.69]), and venous thrombosis (aHR 1.32 [95% CI 1.16-1.50]). Insulin treatment during pregnancy added to the diagnosis code of insulin treatment GDM and/or redemptions of insulin during GDM pregnancy. The associations were studied using multiple cox regression models with GDM entering as a time-varying exposure. Severity of morbidity was investigated as number of CVMM related hospital contacts and of redemptions of prescribed CVMM related medication in women with incident CVMM.

Conclusion: Previous GDM was associated with significantly higher risk of cardiovascular and metabolic morbidity, especially for incident dyslipidemia where a 4.5-fold increased risk was found. The risk was exacerbated by proxies of β-cell impairment. Severity of morbidity was significantly worse, if GDM preceded CVMM.

Supported by: Research grant from the Danish Diabetes Academy which is funded by the Novo Nordisk Foundation

Disclosure: M.H. Christensen: Grants; Danish Diabetes Academy, Region of Southern Denmark, University of Southern Denmark.
Disclosure
NUTRIM, SA, HFL, JCBV, NNF, SAN, ZonMW, NCDC, MP, DHF
Supported by: ERDF, PoL, DMeOA, SDW, PSID, CVC, CARIM, MHeNS, CAPHRI, NUTRIM, SA, HFL, PERIMED, UGfJ-C, NNF, SAN
Disclosure: None.

156
Multimorbidity in type 1 diabetes is common and associated with increased mortality
A. Ylilens1,2, S. Hägg-Holmberg1,3, S. Mutter1,2, S. Satuli-Autener1,2, V. Harjutsalo1,3, C. Forsblom1,4, P.-H. Groop1,4, L.M. Thorn1,2, The FinnDiane Study Group; 1Folkhälsan Institute of Genetics, Folkhälsan Research Center, 2Department of General Practice and Primary Health Care, University of Helsinki, 3Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, 4Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Background and aims: Multimorbidity is commonly defined as the coexistence of two or more chronic conditions or diseases, and it is associated with increased mortality and decreased quality of life. Type 1 diabetes is an example of a disease accompanied by other chronic conditions at a relatively young age. The number of chronic conditions correlates with the probability of depression and severe hypoglycemic episodes, but otherwise, data on multimorbidity in type 1 diabetes are scarce. Our aim was, therefore, to study the prevalence of multimorbidity and its impact on mortality in type 1 diabetes.

Materials and methods: This study included 4,069 adults (51.4% men) with type 1 diabetes from the Finnish Diabetic Nephropathy Study, mean age at baseline 38.1±12.0 and duration of diabetes 22.2±12.4 years. The accumulation of diseases was defined based on the number of chronic conditions at baseline from a list of 32 conditions. Conditions were grouped into three subcategories: vascular comorbidities, autoimmune disorders, and other conditions. Data on conditions were collected from clinical records, questionnaires, and registers. Data on mortality were retrieved until the end of 2017. Hazard ratios for all-cause mortality were calculated in sex and age adjusted Cox regression models.

Results: The prevalence of multimorbidity was 60.4% (n=2,458) at baseline. We did not observe a difference between women and men, but an evident association with age: 31.1% in those below 30 years, 59.8% in the 30-40 years age group, 74.8% in the 40-50 group, 84.3% in the 50-60 group, and 93.2% in those above 60 years (p<0.001). We observed vascular comorbidities in 49.2% (n=2,000), autoimmune disorders in 12.7% (n=515), and other conditions in 19.8% (n=807). During a median follow-up of 16.7 (IQR 13.6-18.8) years, 784 (19.3%) participants died. Multimorbidity clearly increased mortality (HR 6.0 [95% CI 4.6-7.9], p<0.001). The figure (showing baseline prevalence of different disease

Conclusion: This study is the first population-based study to show that a more adverse glucose metabolism status and higher levels of glycemia are linearly and independently associated with corneal neurodegeneration; these data suggest that glycemia-associated corneal neurodegeneration is a continuous process that already starts before the onset of type 2 diabetes. Further research is needed to investigate whether early reduction of hyperglycemia can prevent corneal neurodegeneration.

Supported by: ERDF, PoL, DMeOA, SDW, PSID, CVC, CARIM, MHeNS, CAPHRI, NUTRIM, SA, HFL, PERIMED, UGfJ-C, NNF, SAN
Disclosure: None.

155
Pre(diabetes) and a higher level of glycemia are continuously associated with corneal neurodegeneration: The Maastricht Study
S.B.A. Mokhtar1,2, F.C.T. van der Heide1,2, K.A.M. Oyaert1, C.J.H. van der Kallen1,2, T.T.M. Berendschot1,2, A. Colonna3, B.E. de Galan1,2, M.M.J. van Greevenbroek1,2, C.G. Schalkwijk1,2, R.M.A. Nuijts1, M.T. Schram1, C.A.B. Webers3, C.D.A. Stouthaer1,2; 1Department of Internal Medicine, Maastricht University Medical Center+ (MUMC+), Maastricht, Netherlands, 2CARIM School for Cardiovascular Diseases, Maastricht, Netherlands, 3University Eye Clinic Maastricht, Maastricht University Medical Center+ (MUMC+), Maastricht, Netherlands, 4MHeNS School of Mental Health and Neuroscience, Maastricht, Netherlands, 5Information Engineering, University of Padova, Padova, Italy.

Background and aims: Diabetic neuropathy is a hallmark complication of type 2 diabetes. In the cornea, early morphological changes of small nerve fibers are demonstrable using corneal confocal microscopy. We aim to assess the association of glucose metabolism status and different continuous measures of glycemia with corneal nerve fiber measures. We studied the associations, after adjustment for demographic, cardiovascular risk, and lifestyle factors, between glucose metabolism status (prediabetes and type 2 diabetes vs normal glucose metabolism status) and measures of glycemia (fasting plasma glucose, 2-hour post-load glucose, HbA1c, skin autofluorescence, and duration of diabetes) with a Z-score of corneal nerve fiber measures or with individual corneal nerve fiber measures (corneal nerve branch density, fiber density, fiber length, and fractal dimension). We used linear regression analyses and, for glucose metabolism status, P for trend analyses.

Results: After full adjustment, a more adverse glucose metabolism status was associated with a lower Z-score of corneal nerve fiber measures (beta [95% CI], prediabetes vs normal glucose metabolism status -0.08 [-0.17; -0.03]; type 2 diabetes vs normal glucose metabolism status -0.14 [-0.25; -0.04]; P for trend = 0.001). Analogously, higher levels of fasting plasma glucose (per SD, -0.09 [-0.13; -0.05]), 2-hour post-load glucose (-0.07 [-0.11; -0.03]), HbA1c (-0.08 [-0.11; -0.04]), skin autofluorescence (-0.05 [-0.08; -0.01]), and duration of diabetes (-0.09 [-0.17; -0.00]) were all significantly associated with a lower Z-score of corneal nerve fiber measures. In general, directionally similar associations were observed for individual corneal nerve fiber measures.

Conclusion: This is the first population-based study to show that a more adverse glucose metabolism status and higher levels of glycemia are linearly and independently associated with corneal neurodegeneration; these data suggest that glycemia-associated corneal neurodegeneration is a continuous process that already starts before the onset of type 2 diabetes. Further research is needed to investigate whether early reduction of hyperglycemia can prevent corneal neurodegeneration.

Supported by: ERDF, PoL, DMeOA, SDW, PSID, CVC, CARIM, MHeNS, CAPHRI, NUTRIM, SA, HFL, PERIMED, UGfJ-C, NNF, SAN
Disclosure: None.

Figure. UK-urologic adjusted effect estimates for incident major depressive disorder (Panel A) and incident depressive symptoms (Panel B) according to number of risk factors on target among individuals with type 2 diabetes as compared to controls without diabetes or prediabetes. All analyses are adjusted for age, sex and education. Analysis in the UK-urologic database on incident depressive symptoms was censored. A chi-squared threshold for interaction between education and mental health examination was set.
combinations and their mortality HR [95% CI], compared to those with diabetes alone) highlights the increased mortality risk in those with vascular comorbidities from a HR of 5.9 (4.4-7.9) when only vascular comorbidities are present to 11.0 (7.2-16.8) when all three are present.

**Conclusion:** The prevalence of multimorbidity in individuals with type 1 diabetes is high and increases with age. The increased mortality related to multimorbidity is largely driven by vascular comorbidities, and the risk is further attenuated by the presence of other chronic conditions, but not by autoimmune disorders.

Supported by: Folkhälsan Research Foundation, EVO governmental grant, Academy of Finland, Stockmann foundation

**Disclosure:** A. Ylinen: Grants; Biomedicum Helsinki Foundation, Stiftelsen Dorothea Olivia, Karl Walter och Jarl Walter Perkléns Minne, Finska läkarörsföreningen.

---

**OP 27 Improving your insulin sensitivity: lessons from human studies**

**157 Circulating microRNA signatures in prepubertal children with obesity and insulin resistance**

D. Santos1,2, P. Porter-Gill1, S. Bennun3, G. Good1, L. Delhaey1, A.E. Sorensen2, R. Shannon1,2, L.T. Dalgaard1, B. Elisabets1, E. Carvalho1,4; 1Obesity, Diabetes and Complications, CNC - Center for Neurosciences and Cell Biology, University fo Coimbra, Coimbra, Portugal, 2PhD program in Experimental Biology and Biomedicine, Institute for Interdisciplinary Research, Coimbra, Portugal, 3Arkansas Children’s Research Institute, Little Rock, USA, 4Department of Science and Environment, Roskilde University, Roskilde, Denmark, 5Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, USA, 6Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, USA.

**Background and aims:** The higher rates of diabetes in childhood reflect unhealthy life-style habits, observed by the high prevalence of obesity and related complications. Circulating microRNAs (miRs) have been suggested as biomarkers and predictors of insulin resistance. We aimed to identify an insulin resistance miR profile, in prepubertal children before development of obesity-induced glucose intolerance.

**Materials and methods:** Sixty-three prepubertal children (5-9 years of age) were included in a cross-sectional study. Peripheral blood was collected, and plasma miRs were evaluated using TaqMan Advanced miRNA Human Serum/Plasma plates and then were validated by RT-qPCR. Subjects were first divided into normal weight (n=20, NW) and overweight or obese (n=43, OW/OB) according to the BMI z-score. The OW/OB were subdivided into insulin sensitive or metabolically healthy obese (n=26, MHO) and insulin resistant or metabolically unhealthy obese (n=17, MUO), based on HOMA-IR ≥ 1.95.

**Results:** Fasting plasma glucose levels were normal across the groups [NW: 4.92 ± 0.35 vs OW/OB: 5.07 ± 0.65 vs MHO: 4.98 ± 0.52 vs MUO: 5.23 ± 0.81, p<0.05]. Insulin levels were significantly decreased in the NW when compared with OW/OB [NW: 3.49 (2.38 - 4.71) vs OW/OB: 7.27 (4.91 - 11.10), p = 0.001] and with MHO groups [NW: 3.65 ± 1.55 vs MHO: 5.43 ± 1.77, p = 0.001]. Insulin levels were also different among the OW/OB group when stratified by HOMA-IR >1.95 [MHO: 5.43 ± 1.77 vs MUO: 18.16 ± 10.38, p = 0.001]. Higher levels of miR-146a-5p and miR-18a-5p were observed in the OW/OB group [NW: 0.03 (0.01-0.13) vs OW/OB: 0.04 - 0.30, p = 0.003 and NW: 0.04 (0.04 - 0.07) vs OW/OB: 0.08 (0.04 - 0.18), p = 0.017]. Both miR-18a-5p and miR-146a were positively correlated with BMI z-score (r = 0.32, p = 0.010 and r = 0.30, p = 0.018). miR-146a-5p was also correlated with the HOMA-IR (r = 0.26, p = 0.038). However, only miR-18a-5p was correlated with BMI z-score independently of the degree of insulin sensitivity [B = 0.42 (0.19), p = 0.032], while miR-146-5p [B = 0.16 (0.14), p = 0.28], miR-423-3p [B = -0.01 (0.11), p = 0.94] and miR-152-3p [B = -0.14 (0.12), p = 0.26] were associated with insulin resistance. Twenty genes, regulators of key metabolic pathways in insulin resistance development, with a positive enrichment by more than 3-fold, p ≤ 0.001, including Metal Regulatory Transcription Factor 1 (MTF1), RAR Related Orphan Receptor A (RORA) and Nuclear Receptor Coactivator 1 (NCOA1), were identified as predicted targets from at least two or more of the identified miRs.

**Conclusion:** We identified four miRs associated with obesity and insulin resistance, providing evidence of key alterations that occur early in prepubertal obesity. These miRs could potentially be used as biomarkers of insulin resistance.

**Clinical Trial Registration Number:** NCT03323294

Supported by: FCT, NIH/NICAMS, USDA/ARS, DDA

**Disclosure:** D. Santos: None.
Background and aims: Insulin resistance is an under-recognised cardiovascular risk factor in type 1 diabetes (TID). The mechanisms linking insulin resistance to increased cardiovascular risk in T1D remain unknown. Our aim was to determine if insulin resistance is associated with adverse body composition in T1D. We hypothesised that adults with type 1 diabetes would display insulin resistance, increased visceral adipose tissue (VAT) and hepatic steatosis.

Materials and methods: Forty adults with T1D (age 37.4±8.8 years, HbA1c 7.5±0.9%, diabetes duration 22.9±8.8 years, BMI 26.4±0.9 kg/m²) and 20 age- gender- and BMI-matched non-diabetic controls (age 37.0±8.4 years, HbA1c 5.1±0.3%, BMI 26.2±4.3 kg/m²) participated in the cross-sectional component of INTIMET (Insulin Resistance in Type 1 Diabetes Managed with Metformin), a randomised double-blind placebo-controlled study. Insulin sensitivity was determined by the hyperinsulinaemic-euglycaemic clamp (60 μM/m² per min, 5.5 mmol/L). Body composition was assessed by dual-energy x-ray absorptiometry (DXA) and abdominal and anterior thigh magnetic resonance imaging (MRI). Hepatic steatosis was estimated by transient elastography and arterial stiffness by radial artery applanation tonometry. Data was expressed as mean ± standard deviation. Skewed data was log-transformed prior to analysis. T-tests and Mann-whitney U tests were used to detect between group differences. Pearson correlation was used to determine linear correlations.

Results: Participants with T1D had 29.5% lower insulin sensitivity than adults without diabetes (glucose infusion rate [GIR] 62±20 vs 88±18 μmol/min·kgFFM respectively; p=0.0004). Despite the difference in insulin sensitivity, there was no difference in DXA VAT (593±530 vs 665±590g T1D vs controls; p=0.6) or degree of hepatic steatosis (controlled attenuation parameter 229±37.0 vs 231±35.7 dB/m, respectively; p=0.9). MRI-determined liver fat (2.8±5.8 vs 2.5±2.3%, respectively; p=0.9) and anterior thigh muscle fat infiltration (4.0±1.0 vs 4.5±1.5%, respectively; p=0.3) were also comparable. T1D had increased arterial stiffness (augmentation index [Alx] 11.2±11.4 vs 4.7±13.1%, respectively; p=0.05). Alx did not correlate significantly with GIR. However, Alx correlated with VAT mass (r=0.281, p=0.03) and anterior thigh fat infiltration (r=0.473, p=0.004), largely driven by controls (r=0.716, p=0.013 vs T1D: r=0.391, p=0.059).

Conclusion: Adults with T1D demonstrated 1) a unique phenotype of insulin resistance, without the expected features of increased visceral adiposity, ectopic liver and muscle fat; 2) increased arterial stiffness; and 3) an association between aberrant fat distribution and arterial stiffness. These findings raise the possibility that insulin resistance and altered fat distribution exert independent effects on cardiometabolic complications in TID, with visceral and anterior thigh fat being possible important drivers of cardiovascular risk. Future analyses in INTIMET will determine the relative effects of muscle vs liver insulin resistance on these metabolic parameters.

Clinical Trial Registration Number: ACTRN12619001440112
Supported by: Diabetes Australia, St Vincent's Clinic Foundation, NHMRC, UNSW
Disclosure: J.R. Snaith: None.
160

Repeated exposure to cold-induced shivering thermogenesis improves glucose homeostasis in overweight and obese adults

A.J. Sellers1, S.M.M. van Beek1, D. Hashim1, H. Pallubinsky1, E. Moonen-Kornips1, G. Schaart1, A. Gemmink1, T. van de Weijer1, M.K.C. Hesselink1, P. Schrauwen1, J. Hoeks1, W. van Marken Lichtenbelt1; 1Department of Nutrition and Movement Sciences, Maastricht University, 2Department of Radiology and Nuclear Medicine, Maastricht University, Maastricht, Netherlands.

Background and aims: Previously, we demonstrated that 10 days of mild cold acclimation (14-15°C, 6h/day) robustly improved insulin sensitivity in patients with type 2 diabetes, partly via an enhanced glucose transporter 4 (GLUT4) translocation in skeletal muscle, as assessed in the overnight fasted state. Although non-shivering thermogenesis is involved in mild cold acclimation, a follow-up study indicated that some level of (mild) muscle activity/shivering appears crucial in provoking the beneficial metabolic effects of cold acclimation. Therefore, we here investigated the effects of repeated bouts of cold-induced shivering thermogenesis on glucose homeostasis.

Materials and methods: In a single-arm intervention study, 15 overweight/obese men and (postmenopausal) women (n = 11 and 4, respectively, 40-75 years, BMI: 27-35 kg/m²) were exposed to 10 consecutive days of intermittent cold-induced shivering thermogenesis (10°C with 1h of shivering per day) via a water-perfused suit. Shivering thermogenesis was confirmed, by surface electromyography and visual observation, and the 1h of shivering was started when resting energy expenditure increased by 50%. Before and after the intervention, a 2-hour oral glucose tolerance test (OGTT) was performed in the overnight fasted state, under thermoneutral conditions. Prior to the OGTTs, heart rate and blood pressure were measured and muscle biopsies were taken.

Results: Repeated exposure to cold-induced shivering thermogenesis significantly reduced fasting plasma glucose concentrations (5.84 ± 0.38 vs 5.67 ± 0.32 mmol/L, p=0.013) and improved glucose tolerance during the OGTT by 6% (total area under the glucose curve: p=0.041). Plasma insulin concentrations at baseline and during the OGTT were robustly decreased by 32% and 11% (p=0.001 and p=0.036, respectively). Additionally, repeated cold exposure markedly reduced systolic and diastolic blood pressure by 7.4% (p<0.001) and 8.1% (p=0.001), respectively, and tended to decrease resting heart rate (p=0.062) when measured at thermoneutrality. Analyses of muscle GLUT4 translocation are currently ongoing and will be presented during the meeting.

Conclusion: Repeated exposure to cold, leading to cold-induced shivering thermogenesis, improved glucose homeostasis and other clinically relevant metabolic health parameters in overweight/obese individuals, and hence presents an alternative strategy for the treatment and prevention of type 2 diabetes.

Diabetes Clinical Trial Registration Number: NCT04516018

Disclosure: A.J. Sellers: None.
targeting the production of prostanoids and sex-specific exercise regimens have potential to improve glucose control and overall metabolic health in individuals with type 2 diabetes.

Supported by: EFSDD/Novo Nordisk Foundation Future Leaders Award NNF21SA0072747, Diabetes Wellness Sverige PG21-6524

Disclosure: A.M. Abdelmoez: None.

162

High dietary fat intake increases glucagon levels and the glucagon-to-insulin ratio in healthy lean subjects

B. Schuppelius1, R. Schüller2, O. Pivovarova-Ramisch3,4, S. Hornemann2, A. Bujahn2, J. Machann3,4, M. Kruse5, A.F.H. Pfeiffer1

1Department of Endocrinology and Metabolism, Charité - University Medicine Berlin, Berlin, 2Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, 3Research Group Molecular Nutritional Medicine, Dept. of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, 4German Center for Diabetes Research (DZD), Munich-Neuherberg, 5HealthTwist GmbH, Berlin, 6Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Centre Munich, Tübingen, Germany.

Background and aims: Emerging data support an essential role of glucagon (GCGN) for lipid metabolism. However, data on the role of dietary fat intake on GCGN secretion is limited, particularly in humans. We analyzed whether altering nutritional fat intake affects glucagon levels in healthy lean subjects.

Materials and methods: 92 twins (age: 31 ± 14 years; BMI: 22.8 ± 2.7 kg/m²) consumed 2-6 weeks diets: a low fat healthy diet (LFD: 30 %Energy (%E) fat, 15 %E protein, 55 %E carbohydrate) followed by an isocaloric high fat diet (HFD: 45 %E fat, 15 %E protein, 40 %E carbohydrate), 24 twins additionally continued with a high protein diet (HPD: 30 %E protein, 30 %E fat, 40 %E carbohydrate). Clinical investigation days were performed after 6 weeks of LFD, after 1 and 6 weeks of HFD and after 6 weeks of HPD. GCGN and insulin were measured with specific Mercodia sandwich assays. Liver fat content was determined by 1H-MR spectroscopy. For estimation of heritability, the “ACE” structural equation model was applied.

Results: The LFD caused a significant decrease of basal GCGN (27 %, p ≤ 0.001) compared to screening. After 6 weeks of HFD and minimal weight gain (0.6 %, p = 0.124) GCGN increased significantly (117 %, p ≤ 0.001) while triglycerides remained similar and FFA decreased. 6 weeks of HFD further increased GCGN levels -72 % (p = 0.502). Meal tolerance tests in a subgroup of 14 twins showed increased postprandial GCGN responses after 1 week of HFD that further increased after 6 weeks. Fasting insulin and HOMA-IR increased moderately after one week of HFD, while 6 weeks of HPD significantly decreased both. The fasting GCGN-to-insulin ratio decreased through LFD (p ≤ 0.001) but increased after HFD (p ≤ 0.001) and even further after HPD (p = 0.18). Liver fat content did not increase during the HFD and did not correlate with GCGN levels after the different diets. Heritability of GCGN was 45% after the LFD. The change of GCGN through the diets was not heritable at any time point.

Conclusion: Under isocaloric conditions high fat intake strongly increases basal and postprandial GCGN levels in healthy young subjects. The increased GCGN-to-insulin ratio suggests a reduced insulin-mediated inhibition of GCGN secretion as one potential mechanism. Nevertheless, the postprandial elevated GCGN levels indicate an additional effect of dietary fat intake. As body weight, liver fat and insulin resistance showed no clinically relevant increases, the observed rise in glucagon may represent a protective metabolic response to high dietary fat intake which increases fat oxidation to prevent fatty liver.

Clinical Trial Registration Number: NCT01631123

Supported by: BMBF (NUGAT 0 315 424 OP-R, MK, AB, AFHP), DFG grant (KFO218 PF164/16–1 OP-R, AK, AFHP)

Disclosure: B. Schuppelius: None.

163

Undesired side effects of a formula diet on erythropoietic parameters: data from two randomised controlled trials

S. Kabisch1, S.L. Jahn1, U. Dambeck1, M. Kemper2, C. Gerbrach1, C. Horsek3, N.M.T. Meyer1,2, M.A. Osterhoff4, A.F.H. Pfeiffer1, J. Spranger1,2

1Charité University Hospital Berlin, Berlin, 2German Center of Diabetes Research e.V., Neuberger, 3Clinical Nutrition, German Institute of Human Nutrition, Nuthetal, Germany.

Background and aims: Prevention and therapy of type 2 diabetes are based on lifestyle interventions. Apart from classic low-fat or low-carb dietary concepts, formula diets have been proven to be very effective due to rapid and strong weight loss, even supporting diabetes remission. These drastic dietary approaches elicit widespread benefits on various fat depots, lipid profile, glycemia and blood pressure, depending on the achieved weight loss. Thus, long-term meal replacement of up to three months is proposed to allow rapid weight reductions of >15 kg. However, the spectrum of undesired side effects of formula diets is still insufficiently described. We intended to assess detrimental effects on iron metabolism and erythropoiesis in two comparable dietary RCTs using a formula diet and/or conventional food products.

Materials and methods: 269 subjects with high-risk prediabetes and 177 patients with overt type 2 diabetes participated in our two studies on Diabetes Nutrition Algorithms for Prediabetes / Diabetes* (DiNA-P/DiNA-D). Both trials started with a 3-week 1:1-randomised hypocaloric diet phase (1200-1500 kcal/d), being characterised as either low-carb (< 40 g/d) or low-fat (< 30 kcal%). DiNA-P used conventional food products for both diets, while in DiNA-D the low-fat approach was designed as formula diet (MODIFAST/Vitalkost Nr. 1) with small amounts of vegetables. Clinical tests included a full metabolic assessment with oGTT/MMTT, body imaging and the analysis of blood counts and iron parameters as safety outcomes. In both studies, blood sampling amounts were 180 ml before and after the diet. The statistical analysis was done by two-sided paired (within-group) and unpaired (between-group) comparisons according to the respective data distribution pattern (t-test or Mann-Whitney-U test). P values below 0.05 were considered statistically significant.

Results: In DiNA-P, both diet groups showed significant, but clinically possibly irrelevant reductions of hemoglobin, hematocrit, MCV and iron after 3 weeks, among which the effect on iron was stronger for the low-carb diet. MCH and ferritin decreased under low-fat regime, only. Erythrocyte counts remained unchanged. No patient fulfilled criteria of anaemia. In DiNA-D, both diets led to a significant reduction of erythrocyte count, hematocrit, iron and transferrin saturation. Additionally, the low-fat formula diet markedly reduced hemoglobin levels and RDW-CV, while only the low-carb diet decreased ferritin. The low-fat formula diet had a significantly stronger impact on erythrocyte count (-0.14±0.26 vs. -0.05±0.24 Tl/dL, p=0.032), hematocrit (-1.4±2.5 vs. -0.6±2.1 %, p=0.044), hemoglobin (-0.44±0.77 vs. -0.16±0.69 g/dL, p=0.020) and RDW-CV (-0.3±0.5 vs. -0.0±0.7 %, p<0.001).

Conclusion: To our knowledge, this is the first report of a consistent, qualitative alteration of erythropoietic parameters as a specific, early-onset side effect of a formula diet. In prolonged regimes - as done in trials and clinical practice for up to three months - this could lead to anaemia. Rheologically desired hemodilution and a potential impact on the validity of HbA1c measurements in these patients are additional aspects worth considering. Further clinical trials are warranted.

Clinical Trial Registration Number: NCT012459496

Supported by: German Center of Diabetes Research (DDZ), German Diabetes Association (DDG), California Walnut Comm.

Disclosure: S. Kabisch: Employment/Consultancy; German Center of Diabetes Research e.V. (DDZ) Grants; German Center of Diabetes Research e.V. (DDZ), German Diabetes Association (DDG). Lecture/
Background and aims: Very little is known about the effect of diet composition per se, independently of body weight reduction, on pancreatic fat (PF). We evaluated the effect of an isocaloric multifactorial diet with a diet rich in monounsaturated fatty acids (MUFA) and similar macronutrient composition on PF and postprandial insulin response in Type 2 Diabetes (T2D).

Materials and methods: According to a randomized controlled parallel group design, 39 individuals with T2D, 35-75 years-old, in satisfactory blood glucose control, were assigned to an 8-week isocaloric intervention with a multifactorial diet rich in MUFA, polyunsaturated fatty acids, fibre, polyphenols, and vitamins (n=18) or a MUFA rich diet (n=21). Before/after the intervention, PF content was measured by the proton-density fat fraction using a 3.0 T dixon MRI sequence, plasma insulin and glucose concentrations were measured over a 4h test-meal with a similar composition as the assigned diet.

Results: After 8 weeks, PF significantly decreased after the multifactorial diet (15.7±6.5% vs. 14.1±6.3%, p=0.024) while it did not change after the MUFA diet (17.1±10.1% vs. 18.6±10.6%, p=0.139) with a significant difference between diets (p=0.014). Postprandial glucose response was similar in the two groups. Early postprandial insulin response (iAUC0-120) significantly increased with the multifactorial diet (36340±34954 vs. 15.7±6.5% body weight reduction, p=0.014). Postprandial glucose response was similar in the two groups. Early postprandial insulin response (iAUC0-120) significantly increased with the multifactorial diet (36340±34954 vs. 15.7±6.5% body weight reduction, p=0.014).

Conclusion: In T2D patients, an isocaloric multifactorial diet including several beneficial dietary components markedly reduced PF. This reduction was associated with an improved postprandial insulin response.

Clinical Trial Registration Number: NCT03380416

Disclosure: G. Della Pepa: None.

166

The role of glucagon in type 2 diabetes remission by weight loss E. Lalama 1, K. Raether 2, J. Zhang 1, B. Schuppelius 1, N. Kraenkel 2, M. Csanoslov 1, S. Kabisch 1, E. Latz 2, A. Christ 3, A.F.H. Pfeiffer 3; 1Department of Endocrinology and Metabolic Diseases, Charité, Berlin, 2Medizinische Klinik für Kardiologie, Charité, Berlin, 3University of Bonn, Bonn, Germany.

Background and aims: Remission of type 2 diabetes (T2D) was achieved by weight loss of 15kg in over 80% of patients within 6 years after diagnosis in the DIRECT study due to improvements of insulin sensitivity and insulin secretion. The role of Glucagon (GCG) has not been evaluated although GCG is thought to play a central role in the early development of diabetes by increasing hepatic glucose production and thereby insulin secretion resulting in a feed forward cycle of hyperinsulinemia and insulin resistance. The opposite view emphasizes that intra-islet alpha- to beta-cell cross talk is essential for intact insulin secretion and GCG determines hepatic fat oxidation, thus supporting intact metabolism. We investigated the role of GCG in diabetes remission within our “FAIR” study - Fasting-Associated Immune-metabolic Remission of Diabetes.

Materials and methods: Participants (n=36) with overt T2D and BMI over 27 kg/m² were studied before (V1) and 3 months after (V3) consuming an 800 (males) or 600 kcal/day (females) formula diet. Mixed Meal Tests (MMT) were done at V1 and V3, GCG, insulin, and C-peptide (all Merodia Assays) and glucose as well as clinical routine and anthropometric values were collected. We compared tertiles of low, middle and high GCG levels and areas under the curve (AUC) in the MMTs regarding GCG, insulin, glucose, as well as HbA1c and calculated insulin sensitivity and secretion.

Results: The body weight loss of 16 ± 8.0 kg of 34 participants was associated with strong improvements of insulin sensitivity (HOMA, Matsuda and PREDIM indices) and insulin secretion (disposition index, DIO2), GCG baseline levels did not change in the lowest tertile (V1: 3.5 ± 0.4 to V3: 3.0 ± 0.5 pmol/L, ns) but decreased significantly in the middle (V1: 7.1 ± 0.3 to V3: 5.1 ± 0.6, p=0.016) and highest tertile (V1: 13.5 ± 1.1 to V3: 8.0 ± 1.2 pmol/L, p=0.003). Insulin secretion (DIO2) improved significantly in the middle (V1: 63.2 ± 15 to V3: 172.3 ± 40.2, p=0.001) and higher tertile (V1: 44 ± 7.4 to V3: 109.3 ± 18.1, p=0.006) but not in the lower tertile. The fasting and MMT-AUC glucose, HbA1c, HOMA and Matsuda index significantly improved in all groups and insulin decreased throughout the cohort, although the changes were more pronounced in the higher GCG tertiles. Of note, we identified a subgroup of 9 participants who showed a small to no change in MMT-AUC insulin (~50 to 50 mU/L) secretion but large decreases of fasting and MMT-AUC GCG, HbA1c, HOMA-IR, Matsuda-index and fasting and MMT-AUC glucose.

Conclusion: GCG responses to weight loss-induced diabetes remission vary extensively. Higher GCG before intervention is associated with greater decreases of fasting and postprandial GCG and greater improvements of insulin secretion while improvements of insulin sensitivity were independent of GCG dynamics. Diabetes remission may be primarily GCG-dependent in a subgroup of patients which will be further characterized. Overall, our data support a protective role of GCG in early diabetes.

Clinical Trial Registration Number: NCT05295160

Supported by: EFSD/Boehringer Ingelheim Research Programme Disclosure: E. Lalama: Grants; EFSD Boehringer Ingelheim European Research Programme.

166


Background and aims: Postprandial glycaemia is a key determinant of overall glycaemic control in type 2 diabetes (T2D), particularly when glycated haemoglobin (HbA1c) is < 8.5%. Understanding the determinants of postprandial hyperglycaemia in T2D is therefore of major importance to optimising management. We have employed a multiple linear regression model to determine the association of blood glucose concentrations over 4 hours after a high carbohydrate meal with fasting blood glucose concentrations, the rate of gastric emptying, insulin sensitivity, and postprandial insulin, glucagon and glucagon-like peptide-1 (GLP-1) responses, in T2D patients with relatively good glycaemic control.

Materials and methods: 71 patients with T2D managed by diet and/or metformin monotherapy (39 male, age 64.7 ± 8.0 years, BMI 30.1 ± 0.6 kg/m², HbA1c 6.6 ± 0.1 %, duration of known diabetes 5.4 ± 0.6 years)

 Disclosure: Springer
consumed a mashed potato meal (1541.8 kJ, labelled with 100 μL 13C-octanoic acid) between t = 0 to 5 min, after an overnight fast. Venous blood was sampled at t = 0, 15, 30, 60, 90, 120, 180 and 240 min for the measurement of blood glucose and plasma insulin, glucagon and total GLP-1 concentrations. Gastric emptying (expressed in kcal/min) was measured by a breath test, and insulin sensitivity by the Matsuda index. Multiple linear regression analysis was performed to examine relationships of blood glucose concentrations at each time point with fasting blood glucose, gastric emptying, insulin sensitivity, and changes from baseline in plasma insulin, glucagon and total GLP-1, with adjustment for age, sex and BMI. Data are mean values ± SEM. P < 0.05 was considered statistically significant.

Results: Postprandial blood glucose concentrations were positively associated with fasting blood glucose between t = 15 to 240 min (P < 0.001 each), and the rate of gastric emptying between t = 30 to 60 min (P < 0.001 each), and inversely associated with the increments in plasma GLP-1 between t = 90 to 180 min (P = 0.04 at t = 90 min, 0.07 at t = 120 min and < 0.001 at t = 180 min, respectively). In contrast, blood glucose was negatively associated with the rate of gastric emptying at t = 180 min (P = 0.03). At t = 240 min, blood glucose was directly associated with the Matsuda index and change in plasma insulin, but inversely with the change in plasma glucagon (P < 0.05 each).

Conclusion: In relatively well-controlled T2D, postprandial glycaemia is predictably related to fasting blood glucose concentrations, but also to the rate of gastric emptying in the early postprandial phase (within the first hour), whereas in the late phase blood glucose is dependent on GLP-1 concentrations. These observations support the concept of slowing gastric emptying to minimise postprandial glycaemic excursions in T2D.

Clinical Trial Registration Number: ACTRN12614001131640
Supported by: NHMRC
Disclosure: C. Xie: None.

167
The 'early' postprandial glucagon response to a mixed meal is dependent on the rate of gastric emptying in type 2 diabetes
W. Huang1, C. Xie1, N.J.W. Albrechtsen1, K.L. Jones1, M. Horowitz1, C.K. Rayner1, T. Wu1; 1Adelaide Medical School, The University of Adelaide, Adelaide, Australia, 2Department of Clinical Biochemistry, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.

Background and aims: Gastric emptying (GE), which exhibits a substantial inter-individual variation, is a major determinant of postprandial glycaemic and insulinaemic responses in both health and type 2 diabetes (T2D). T2D is characterised by attenuated suppression of plasma glucagon after meals, which contributes to postprandial hyperglycaemia. The relationship between the postprandial glucagon response and GE has not been reported. We examined the relationship between plasma glucagon and GE of a standardised mixed meal in well-controlled T2D.

Materials and methods: 94 patients with T2D managed by diet and/or metformin monotherapy (61 male, age 64.6 ± 7 years, BMI 29.8 ± 0.5 kg/m2, HbA1c 6.6 ± 0.1% and duration of known diabetes 5.3 ± 0.5 years) were evaluated on a single study day. After an overnight fast, participants consumed a mashed potato meal (1541.8 kJ; 61.4g carbohydrate, 7.4g protein and 8.9g fat, labelled with 100 μL 13C-octanoic acid) between 0-5 min. Venous blood was sampled at t = 0, 15, 30, 60, 90, 120, 180, 240 min for measurements of blood glucose (glucometer) and plasma glucagon (radioimmunoassay). Gastric emptying was assessed by breath test. Data are mean values ± SEM. P < 0.05 was considered statistically significant.

Results: After the meal, blood glucose concentrations increased progressively from 8.2 ± 0.1 mmol/L to the peak of 14.0 ± 0.31 mmol/L at t = 90 min, followed by a decline towards baseline. Plasma glucagon increased from a fasting level of 76.1 ± 2.1 pg/ml to a peak of 92.7 ± 2.6 pg/ml at t = 30 min and then decreased to a nadir of 65.6 ± 1.9 pg/ml at t = 180 min. The gastric half-emptying time (T50) was 68.2 ± 1.4 min (range 39-116 min). The incremental area under the plasma glucagon curve between t = 0-30min (glucagon iAUC0-30min) was inversely related to the T50 (r = -0.3, P = 0.007). The magnitude of increases in blood glucose from baseline at t = 30 (r = -0.3, P = 0.0003), 60 (r = -0.5, P < 0.0001) and 90 min (r = -0.3, P = 0.004) were related inversely to the T50. The increase in blood glucose at t = 30 min was related directly to the glucagon iAUC0-30min (r = 0.3, P = 0.008).

Conclusion: In well-controlled T2D, the early postprandial glucagon response to a mixed meal is related to the rate of gastric emptying, and predictive of the initial glycaemic response. These observations support the concept of slowing gastric emptying to minimise postprandial glycaemic excursions in T2D.

Clinical Trial Registration Number: ACTRN12614001131640
Supported by: NHMRC
Disclosure: W. Huang: None.

168
Disparities in blood glucose and incretin responses to intraduodenal glucose infusion in healthy young males and females

Background and aims: Premenopausal women are at lower risk of type 2 diabetes compared to men, but the underlying mechanism(s) remain elusive. The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) released from the small intestine, modulate insulin and glucagon secretion and play a key role in the regulation of glucose homeostasis. Incretin hormone responses to small intestinal nutrient stimulation are known to vary substantially between individuals, but the potential influence of sex has not been evaluated. We have compared blood glucose and plasma insulin, GIP and GLP-1 responses to intraduodenal glucose infusions in healthy young males and females.

Materials and methods: Data from two independent studies were included in the analysis. In Study 1, 9 females and 20 males, matched for age (female vs. male: 25.0 ± 1.5 vs. 26.3 ± 2.5 years, P = 0.2) and BMI (21.6 ± 0.6 vs. 23.5 ± 0.8 kg/m2, P = 0.3), received an intraduodenal glucose infusion at 2 kcal/min between t = 0 to 60 min. In Study 2, 10 females and 26 males, matched for age (26.4 ± 2.3 vs. 25.2 ± 1.2 years, P = 0.5) and BMI (25.2 ± 2.0 vs. 26.3 ± 1.3, P = 0.5), received an intraduodenal glucose infusion at 3 kcal/min between t = 0 to 60 min. Blood was sampled at t = 0, 15, 30, 45 and 60 min for measurements of blood glucose.
glucose and plasma insulin, total GLP-1 and GIP levels. Data are means ± SEM. P < 0.05 was considered significant.

**Results:** Fasting blood glucose, and plasma insulin, GLP-1 and GIP, did not differ between male and female subjects in either study. In Study 1, the incremental areas under the curve between t = 0 to 60 min (iAUC<sub>i=0</sub> to 60min) for blood glucose (females vs. males: 135.7 ± 13.1 vs. 140.6 ± 8.5 mmol/L·min, P = 0.8) and plasma GIP (females vs. males: 1937.9 ± 159.5 vs. 1946.2 ± 98.7 pmol/L·min, P = 0.9) during intraduodenal glucose infusion (2kcal/min) did not differ between males and females. However, the iAUC<sub>i=0</sub> to 60min for plasma GLP-1 (females vs. males: 524.8 ± 89.7 vs. 264.3 ± 57.2 pmol/L·min, P = 0.03) and insulin (females vs. males: 1787.4 ± 229.5 vs. 1030.0 ± 153.4 mU/L·min, P = 0.005) were ~2-fold higher in females than males. In Study 2, the iAUC<sub>i=0</sub> to 60min for blood glucose (females vs. males: 99.8 ± 11.7 vs. 110.4 ± 8.0 mmol/L·min, P = 0.5), plasma GIP (females vs. males: 1006.2 ± 124.8 vs. 1030.3 ± 67.3 pmol/L·min, P = 0.9) and plasma insulin (females vs. males: 2829.8 ± 746.1 vs. 2739.9 ± 433.8 mU/L·min, P = 0.9) during intraduodenal glucose infusion (3kcal/min) did not differ between males and females. However, the iAUC<sub>i=0</sub> to 60min for plasma GLP-1 was 2.5-fold higher in females than males (645.3 ± 135.7 vs. 262.4 ± 54.2 pmol/L·min, P = 0.01).

**Conclusion:** Healthy young females exhibit comparable GIP but a markedly greater GLP-1 response to small intestinal glucose infusion than males. This disparity warrants further studies to delineate the underlying mechanisms and may also be of relevance to the reduced risk of diabetes in premenopausal women than men.

**Figure 1.** Plasma total GLP-1 response during intraduodenal glucose infusion at 2 (Study 1) or 3 (Study 2) kcal/min in females and males. Data are means ± SEM.

**Supported by:** NHMRC

**Disclosure:** T. Wu: None.

**OP 29 Saving sweet souls**

**169**

**Psychological resilience is predictive of future HbA<sub>1c</sub>, and mental health status in adults with new onset type 1 diabetes**

S.M. Brackley<sup>1,2</sup>, N. Thomas<sup>1,2</sup>, A. Hill<sup>1,2</sup>, B. Shields<sup>1</sup>, T. McDonald<sup>1</sup>, C. Fox<sup>1</sup>, J. Huber<sup>4</sup>, A. Jones<sup>1,2</sup>,

<sup>1</sup>College of Medicine & Health, National Institute for Health Research (NIHR) Exeter Clinical Research Facility, Exeter, <sup>2</sup>Research and Development, Royal Devon and Exeter NHS Foundation Trust, Exeter, <sup>3</sup>Leicester Diabetes Centre, University of Leicester, Leicester, <sup>4</sup>School of Sport and Health Sciences, University of Brighton, Brighton, UK.

**Background and aims:** Psychological resilience is the successful adaptation in the face of adversity. It is thought to be important for effective self-management of Type 1 diabetes, and is associated with glycaemic control in cross-sectional studies. We aimed to determine the relationship between baseline resilience following a recent diagnosis of diabetes with future glycaemic control and perceived health status, in Type 1 and 2 diabetes.

**Materials and methods:** We prospectively assessed the relationship between resilience with future HbA<sub>1c</sub> and health status in 1267 participants with recently diagnosed Type 1 and 2 diabetes (duration <12 months, age >=18 years) in the StartRight Study. Psychological resilience was measured using the Connor-Davidson Resilience Scale (CD-RISC) 10-item questionnaire and health status was measured using the Short Form 12-item (SF12) questionnaire. These questionnaires and HbA<sub>1c</sub> were assessed annually for up to 3 years.

**Results:** Mean resilience was 30.3 (SD 7.3, scale 0-40) at the first study visit (median 4 months diabetes duration) and reduced by one point over a median 24 months of follow-up \([p<0.001]\). At baseline, resilience was strongly correlated with the mental health component of the SF12 \([Pearson’s r=0.57]\) and weakly correlated to the physical health component \([Pearson’s r=0.20]\). In all participants, a difference of +10 points in baseline CD-RISC was associated with a 1.8mmol/mol lower HbA<sub>1c</sub> at 2 years \([95% CI 0.7-2.8, p<0.01]\). In type 1 diabetes \((n=462)\), a difference of +10 points associated with a 4.1mmol/mol lower 2-year HbA<sub>1c</sub> \([95% CI 2.0-5.7, p<0.001]\) and in the subgroup developing insulin deficiency \((urinary c-peptide : creatinine ratio <0.2nmol /mmol, n=91)\) tended towards a numerically stronger association of 6.6mmol/mol lower HbA<sub>1c</sub> \([95% CI -0.5 to 9.8, p=0.07]\). In type 2 diabetes \((n=573)\), CD-RISC was associated with a 1.1mmol/mol lower follow-up HbA<sub>1c</sub> per +10pts CDRISC \([95% CI 0.0-2.2, p=0.06]\). In all subgroups, lower baseline resilience was associated with greater decline in SF-12 assessed mental health \((Standardised beta = +0.38, 95% CI 0.32-0.45, p<10^{-5})\) but not physical health \((Standardised beta = +0.07, 95% CI 0.00-0.14, p=0.06)\).

**Conclusion:** A short, validated psychological resilience questionnaire close to diagnosis of type 1 diabetes is predictive of future glycaemic control and decline in perceived mental health status. This supports a need for studies to determine whether targeted interventions may improve outcomes for people with type 1 diabetes and low resilience.
Caregiver-report adherence in diabetes questionnaire is predictive of 10-year HbA1c trajectories in children and adolescents with type 1 diabetes (T1D) and determine whether the caregiver- and/or child/adolescent-reported answers to Adherence in Diabetes Questionnaire (ADQ) predict membership to these HbA1c trajectories, controlling for sex, age of T1D diagnosis, and insulin pump status.

**Materials and methods:** We analyzed longitudinal, population-based data from a 2009 Danish national survey cohort (N=672, ages 10-17 years). The survey included the caregiver- and child/adolescent-report on ADQ. HbA1c levels were obtained annually (2010-2020) from the Danish Registry of Childhood and Adolescent Diabetes and Danish Adult Diabetes Registry. First, four distinct HbA1c trajectories from early adolescence to emerging adulthood (12-27 years) were identified with group-based trajectory modeling. Second, associations of baseline ADQ scores with HbA1c trajectory/group membership were investigated by use of a multinomial logit model. We controlled for sex, age at T1D onset, and insulin pump status.

**Results:** Baseline participant characteristics were: n= 672 (321 [47.8%] males); mean (SD) age 14.4 (2.2) years; mean (SD) age of T1D diagnosis 8.46 (3.50) years; n= 282 (42%) insulin pump users. Four HbA1c trajectories/groups were identified: group 1 (“stable on target [HbA1c 53 mmol/mol (7.0 %)], gradual decrease”, 30% of the sample), group 2 (“above target, small wave”, 40% of the sample), group 3 (“well above target, moderate wave”, 22% of the sample), and group 4 (“well above target, large wave”, 8% of the sample). A higher caregiver-reported ADQ score was predictive of less likely membership to group 2 (coef.= -0.68, SE= 0.24, p< 0.005) and group 3 (coef.= -1.27, SE= 0.24, p< 0.001) and group 4 (coef.= -1.74, SE= 0.29, p< 0.001) as compared to group 1. The child/adolescent-reported ADQ score was not a significant predictor once the caregiver-reported ADQ was included in the model. Males were less likely than females to be members of group 2 (coef.= -0.45, SE= 0.23, p< 0.05) compared to group 1, whereas age of T1D diagnosis, and insulin pump status were not predictive of any group membership.

**Conclusion:** About 30% of the children and adolescents had a very unfavorable HbA1c trajectory. Caregiver-reported ADQ should be used to identify children at risk of a high or increasing HbA1c trajectory across adolescence and young adulthood.

**Supported by:** KPM; grant # NNF17SA0031406, Danish Diabetes Academy. NHB: grant from Poul and Erna Sehested's Fond

**Disclosure:** K.P. Marks: Grants; KPM’s PhD scholarship and work was supported by a research grant from the Danish Diabetes Academy, which is funded by the Novo Nordisk Foundation, grant number NNF17SA0031406. Other; MT and NHB are coauthors of the Adherence in Diabetes Questionnaire, which is freely available and in the public domain. MT and NHB have no financial conflicts of interest.

**Background and aims:** Adherence or self-care skills comprise of all child/adolescent or family’s efforts that are required to fulfill an array of diabetes-specific recommendations, in collaboration with health care providers. We seek to identify distinct 10-year HbA1c trajectories in children/adolescents with type 1 diabetes (T1D) and determine whether the caregiver- and/or child/adolescent-reported answers to Adherence in Diabetes Questionnaire (ADQ) predict membership to these HbA1c trajectories, controlling for sex, age of T1D diagnosis, and insulin pump status.

**Materials and methods:** We analyzed longitudinal, population-based data from a 2009 Danish national survey cohort (N=672, ages 10-17 years). The survey included the caregiver- and child/adolescent-report on ADQ. HbA1c levels were obtained annually (2010-2020) from the Danish Registry of Childhood and Adolescent Diabetes and Danish Adult Diabetes Registry. First, four distinct HbA1c trajectories from early adolescence to emerging adulthood (12-27 years) were identified with group-based trajectory modeling. Second, associations of baseline ADQ scores with HbA1c trajectory/group membership were investigated by use of a multinomial logit model. We controlled for sex, age at T1D onset, and insulin pump status.

**Results:** Baseline participant characteristics were: n= 672 (321 [47.8%] males); mean (SD) age 14.4 (2.2) years; mean (SD) age of T1D diagnosis 8.46 (3.50) years; n= 282 (42%) insulin pump users. Four HbA1c trajectories/groups were identified: group 1 (“stable on target [HbA1c 53 mmol/mol (7.0 %)], gradual decrease”, 30% of the sample), group 2 (“above target, small wave”, 40% of the sample), group 3 (“well above target, moderate wave”, 22% of the sample), and group 4 (“well above target, large wave”, 8% of the sample). A higher caregiver-reported ADQ score was predictive of less likely membership to group 2 (coef.= -0.68, SE= 0.24, p< 0.005) and group 3 (coef.= -1.27, SE= 0.24, p< 0.001) and group 4 (coef.= -1.74, SE= 0.29, p< 0.001) as compared to group 1. The child/adolescent-reported ADQ score was not a significant predictor once the caregiver-reported ADQ was included in the model. Males were less likely than females to be members of group 2 (coef.= -0.45, SE= 0.23, p< 0.05) compared to group 1, whereas age of T1D diagnosis, and insulin pump status were not predictive of any group membership.

**Conclusion:** About 30% of the children and adolescents had a very unfavorable HbA1c trajectory. Caregiver-reported ADQ should be used to identify children at risk of a high or increasing HbA1c trajectory across adolescence and young adulthood.

**Supported by:** KPM; grant # NNF17SA0031406, Danish Diabetes Academy. NHB: grant from Poul and Erna Sehested's Fond

**Disclosure:** K.P. Marks: Grants; KPM’s PhD scholarship and work was supported by a research grant from the Danish Diabetes Academy, which is funded by the Novo Nordisk Foundation, grant number NNF17SA0031406. Other; MT and NHB are coauthors of the Adherence in Diabetes Questionnaire, which is freely available and in the public domain. MT and NHB have no financial conflicts of interest.
the United Kingdom took an online survey in which they reported their most recent HbA1c, if they knew it (n=2,561). Glucose sensor users (n=2,011) also reported the percentage of time in a typical day spent in the target range (70-180 mg/dl), otherwise known as Time in Range (TIR). All respondents completed the Generalized Anxiety Disorder diagnostic tool (GAD-7), a 7-item validated measure assessing the severity of generalized anxiety disorder (GAD). The subsequent responses (66% type 1, 52% female) were scored and analyzed. Statistical testing was conducted using two-proportion Z-tests.

Results: PWD in Italy and the UK report the highest rates of anxiety (63% and 51%, respectively), while PWD in the Netherlands report the lowest rates (39%). Across all European countries studied, women with diabetes are more likely to report experiencing anxiety than men with diabetes (57% vs. 39%, p<0.001). Anxiety is more prevalent among adults with diabetes under 45 years of age than those 45 and above (59% and 34%, p<0.001). PWD with HbA1c levels greater than 7% are significantly more likely than those with HbA1c levels less than or equal to 7% to have moderate (13% vs. 10%, p=0.03) or severe anxiety (6% vs. 4%, p=0.04). PWD using glucose sensors with TIR under 70% have significantly higher rates of moderate or severe anxiety relative to those who spend 70% or more of time in the target range (22% vs. 14%, p<0.001).

Conclusion: This research reveals mental health disparities in nationality, gender, and age among PWD in Europe. Further, these findings highlight a link between the glycemic management of diabetes and anxiety severity. To both minimize anxiety and improve diabetes management, this study emphasizes the need for an integrated approach to mental health support and diabetes management, targeted specifically at at-risk demographic groups.

Disclosure: E. Cox: Employment/Consultancy; EC, EY, RW, and CP are employees of dQ&A, a company that provides research services for a fee to several clients (>10) in the diabetes field.

173 High burden of depression, anxiety and severe obesity in young women with newly diagnosed type 2 diabetes: reports from a Swedish multicentre study of 1027 patients
E.O. Melin1, P. Wanby2, T. Neumark3, S. Holmberg3, A.-S. Nilsson Neumark4, K. Johansson5, M. Landin-Olsson1, H. Thulesius6, M. Hillman2, M. Thunander6; 1Diabetology and Endocrinology, Lund University, Lund, 2Medicine and Optometry, Linnaeus University, Kalmar, 3RaD, Region Kronoberg, Region Kalmar, Regional Executive Office - Coordination of Health Care, Kalmar, 4Department of Research, Region Kalmar County, Kalmar, 5Department of Health and Caring Sciences, Linnaeus University, Växjö, 6Linnaeus University, Kalmar, 7Lund University, Lund, Sweden.

Background and aims: Depression is a risk factor for type 2 diabetes mellitus and cardiovascular disease. The aims were to explore the prevalence of depression, anxiety, antidepressant use, obesity, Hemoglobin A1c, life-style factors, and pre-existing cardiovascular disease, in patients with newly diagnosed T2D; to explore associations with depression; and to compare with general population data.

Materials and methods: Multicentre, cross-sectional study. Inclusion criteria: adults with serologically verified newly diagnosed type 2 diabetes mellitus. Data collection and analyses included age, sex, current depression and anxiety (Hospital Anxiety and Depression Scale), previous depression, antidepressant use, body mass index (BMI), Hemoglobin A1c, and pre-existing myocardial infarction and stroke.

Results: In all 1027 participants, aged 18-94 years, the depression prevalence was 12%, and depression was associated with age (per year) (inversely) (odds ratio (OR) 0.97), anxiety (OR 12.2), previous depression (OR 7.1), antidepressant use (OR 4.2), obesity (BMI ≥ 30 and ≥ 40 kg/m²) (OR 1.7 and OR 2.3 respectively), smoking (OR 1.9), physical inactivity (OR 1.8), and women (OR 1.6) (all p<0.013). Younger, ≤59 years, women (n=113) compared to younger men (n=217) had higher prevalence of current depression (31% vs 12%), previous depression (43 vs 19%), anxiety (42% vs 25%), antidepressant use (37% vs 12%), obesity (BMI ≥ 30 and ≥ 40 kg/m²) (73% vs 60% and 18% vs 9% respectively), and smoking (26% vs 16%) (all p<0.029). Older, ≥60 years, women (n=297) compared to older men (n=400) had higher prevalence of previous depression (45% vs 12%), anxiety (18% vs 10%), antidepressant use (20% vs 8%), and obesity (BMI ≥ 30 and ≥ 40 kg/m²) (55% vs 47% and 7% vs 3% respectively) (all p ≤0.048). Compared to the Swedish general population (prevalence of depression
(women 11.2%/men 12.3%) and antidepressant use (women 9.8%/men 5.3%), younger women with T2D had higher prevalence of current depression, and all patients had higher prevalence of antidepressant use. **Conclusion:** Three risk factors for cardiovascular disease, obesity, smoking, and physical inactivity, were associated with depression in patients with newly diagnosed type 2 diabetes mellitus. The younger women had the highest prevalence of depression, anxiety, and severe obesity. All patients had higher prevalence of antidepressant use than people in the Swedish population.

Prevalence of depression and obesity presented for all and for 7 age-groups

---

Supported by: FORSS, Region Kronoberg
Disclosure: E.O. Melin: None.

---

**174**
Let the patient choose! Patient preferences for type 2 diabetes therapy in the trimaster double-blind three-way randomised crossover trial
B. Shields¹, C. Angwin¹, A.G. Jones¹, R.R. Holman², N. Sattar³, N. Britten⁴, E. Pearson⁴, M. Shepherd⁴, A.T. Hattersley¹
¹University of Exeter Medical School, Exeter, ²University of Oxford, Oxford, ³University of Glasgow, Glasgow, ⁴University of Dundee, Dundee, UK.

**Background and aims:** Determining optimal glucose lowering drugs for a person with type 2 diabetes requires balancing the benefits and side effects of alternative therapies. No randomised trials have allowed patients to compare their own experience on different drugs to decide their own preference. We aimed to examine patient preference to second/third line glucose-lowering drugs in a three-way double blind randomised crossover trial.

**Materials and methods:** People with poorly controlled type 2 diabetes (HbA1c >58mmol/mol) on stable metformin +/- sulfonylurea therapy received, in randomly assigned order, 16 weeks each of pioglitazone 30mg, sitagliptin 100mg, and canagliflozin 100mg. At the end of each treatment period, HbA1c, and weight were measured, and patient-reported benefits, side effects, and willingness to take the drug long-term were recorded. At the end of the study, patients were asked to rank the three drugs in order of preference and state why. Reasons were coded, by 2 independent observers, as “feeling better” or “lack of side effects” compared with the other drugs.

**Results:** 457 participants tried all three study drugs. For each drug, achieved HbA1c was similar (pioglitazone 59.5, sitagliptin 59.9 canagliflozin 60.5 mmol/mol, p=0.19) and similar proportions of participants stated they would take it long term (54%, 58%, 59% respectively, p=0.48). 448/457 stated a drug preference. 115 (25%) preferred pioglitazone, 158 (35%) sitagliptin, 175 (38%) canagliflozin. The drug chosen as preferred, compared with the other two, was associated with a lower HbA1c (4.8[95%CI 4.1, 5.5]mmol/mol lower, p<0.001) and less side effects (0.5[0.36, 0.65] fewer, p<0.001). Regardless of preference, pioglitazone was associated with the highest weight on therapy (2.6 [2.3, 2.9]kg higher, p<0.001). Overall, 51% chose the preferred drug because of “feeling better”, whereas 39% chose it due to “lack of side effects”, with 10% unclassifiable. Canagliflozin was less often chosen by patients because of lack of side effects (27%) compared to pioglitazone (50%) and sitagliptin (42%). However, it was most often chosen due to “feeling better” (68%) compared with sitagliptin (48%) or pioglitazone (39%).

**Conclusion:** After trying all three drugs, that were equally effective overall, patients preferred the drug that gave them lowest HbA1c and least side effects. We propose that in the absence of a specific indication for a particular drug, patients should be offered a brief trial of potential alternative therapies to allow them to decide which they prefer.

Clinical Trial Registration Number: NCT02633209
Supported by: MRC
Disclosure: B. Shields: None.
OP 30 Novel ways of beta cell replacement

175
A highly oxygenated hydrogel enhanced the survival of human islets encapsulated within macroencapsulation devices

D.A. Domingo-Lopez1, D. Brandhorst2, E. O’Cearbhallí3, F. Coulter1, L. McDonough1, H. Brandhorst2, S. Deotti3, P. Johnson2, H. Kelly4, G.P. Duffy1;
1College of Medicine, Nursing and Health Sciences, Anatomy and Regenerative Medicine Institute, National University of Ireland Galway, Galway, Ireland, 2Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Oxford University, Oxford, UK, 3School of Mechanical Engineering, Centre for Biomedical Engineering, University College of Dublin, Dublin, Ireland, 4School of Pharmacy & Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.

Background and aims: Islet transplantation aims to reverse type 1 diabetes by restoring insulin production. Post-transplantation islet survival is limited by the lack of suitable support matrix and insufficient oxygen supply (hypoxia), which is aggravated when using macroencapsulation devices. Graft failure can be overcome by cell encapsulation in highly oxygenated biomaterials, like Oxygel (OxG), able to provide O2 and extracellular matrix (ECM) support when incorporated in macroencapsulation devices.

Materials and methods: OxG was formulated by the shear mixing of Hyaluronic acid hydrogel (HA) with a Perfluorocarbon nanoemulsion and oxygenated by simultaneous O2 and gel infusion using a customized set-up (n=3). Mechanical properties; viscosity (n), storage (G’), and loss (G”) modulus, were characterized using oscillatory rheology and creep recovery test. O2 levels of oxygenated OxG (O2-OxG) and controls were monitored by oxygen microsensors. Oxygen diffusion coefficient (D0) was estimated by experimentally fitting the O2 release to a Fickian diffusion model. Human islets were isolated (n = 7) and mixed with different matrices: (A) supplemented CMRL; (B) HA; (C) OxG or (D) O2-OxG. Afterwards, silicone macrodevices were loaded with 600 IEQ and cultured for 5 days. Islets were recovered and islet death was characterized by FDA-PI staining. Data was normalized to IEQ and related to preculture (PC) data.

Results: OxG mechanical properties showed a shear thinning behavior with a transition from viscoelastic solid to viscoelastic liquid behavior at 3-4 Pa. OxG recovered its initial viscosity after 4 min of stress removal. High O2 tension was achieved in O2-OxG and O2-PFD emulsion (475-641 torr) that was released for 90 h compared to a fast oxygen release found in O2-PBS (14 hours). Significantly smaller D0 was found in OxG (2.71 ± 0.04 x 10^-10 m2 s^-1) and PFD emulsion (2.75 ± 0.05 x 10^-10 m2 s^-1, p > 0.05 vs OxG) compared to PBS (3.93 ± 0.17 x 10^-9 m2 s^-1, p < 0.001 vs OxG and PFD emulsion). Human islets loss was reduced when encapsulated in O2-OxG (20.10 ± 6.36%, p > 0.05 vs PC) compared to OxG (36.80 ± 4.87%, p < 0.001 vs PC), HA (65.40 ± 7.80%, p < 0.001 vs PC) and CMRL (89.07 ± 2.88%, p < 0.001 vs PC). A decrease in cell death was also observed in O2-OxG (37.57 ± 1.96%, p > 0.05 vs PC) compared to O2-PBS (31.71 ± 2.14%) compared to OxG (42.79 ± 1.37%, p < 0.001 vs PC), HA (43.23 ± 2.07, p = 0.001 vs PC) and CMRL (49.19 ± 1.57%, p < 0.001 vs PC).

Conclusion: Oxygen gel was developed as an ECM-based hydrogel with optimal mechanical properties (shear-thinning and self-healing), high O2 loading capacity and slow O2 diffusion ability. The preliminary in vitro evaluation of Oxygen gel’s influence on human islets indicates that the incorporation of a suitable ECM within macrodevices helps maintaining the integrity of encapsulated islets/cells over time. Additionally, O2 delivery within macroencapsulation devices appears to be highly beneficial in overcoming hypoxia-mediated islet death.

Supported by: DELIVER EU Horizon 2020 MSCA programme (812865)
Disclosure: D.A. Domingo-Lopez: None.

176
Microsphere-based bioartificial islet with beta cells and mesenchymal stem cells co-encapsulation for diabetes treatment

J. Sun, L. Li;
Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.

Background and aims: Recent therapeutic approaches of type 1 diabetes mellitus (T1DM) target restoration of endogenous insulin production rather than the traditional insulin injection therapy. Thus, β-cell replacement therapy is the practical cell treatment option for the management of T1DM. However, the broad application of β-cell transplantation is greatly limited by donor shortage, side effects of immunosuppressants and persistent post-transplantation loss of β-cells due to hypoxia. Co-transplantation with mesenchymal stem cells (MSCs) could contribute to enhancing function and survival of β-cells. Biocompatible hydrogels have potential to facilitate implantation, which could eliminate direct contact of β-cells with immunocompetent cells. This study aimed to develop porous hydrogel microspheres to co-encapsulate β cells and MSCs to construct novel biological artificial islets for hyperglycemia treatment.

Materials and methods: We used microfluidic technology to co-encapsulate β-cells and MSCs in porous hydrogel microspheres based on the hybrid solution of gelatin methacrylate (GelMA) and poly (ethylene oxide) (PEO) within fast response time. The β-cell viability and insulin secretory function was examined in vitro. Naked β cells and MSCs, microspheres encapsulated with β cells alone and microspheres co-encapsulated with β cells and MSCs were implanted into the omentum of diabetic mice, and blood glucose and body weight changes were monitored. The glucose tolerance test was performed at 4 weeks of implantation and cell-laden microspheres were removed at six weeks post-transplantation to assess β-cell function.

Results: Three dimensional (3D) porous structure in microspheres facilitated β-cell proliferation in clusters. β-cells co-encapsulated with MSCs increase glucose-stimulated insulin secretion and content in vitro. The transplantation results suggested that bioartificial islets significantly reversed diabetes in diabetic mice within a week post-transplantation and continuously regulate the dynamic balance of blood glucose levels in vivo. Fluorescence microscopy showed distinct insulin-expressing cells in bioartificial islets removed after 6 weeks of implantation.

Conclusion: The bioartificial islet could be endowed with the high glucose responsiveness and ability of insulin secretion, achieving highly simulation of islet survival environment. The results of transplantation further confirmed the therapeutic potential of bioartificial islets to significantly improve hyperglycemia and achieve stable blood glucose control in diabetic mice. Overall, the novel bioartificial islet has a distinctive function in the treatment of diabetes, and could suggest a suitable platform for β cell transplantation in clinical application.

Supported by: National Natural Science Foundation of China (No 6590009658)
Disclosure: J. Sun: None.

177
Parallel single cell RNA sequencing and spatial transcriptomics analysis of the developing human pancreas

O. Olaniru1, U. Kadolsky2, S. Kannambath2, H. Vaikkinen2, K. Fung2, P. Dham2, S.J. Persaud1;
1Department of Diabetes, King’s College London, 2BRC, King’s College London, London, UK.

Background and aims: There is a global research effort to generate unlimited amounts of human beta-cells in vitro for type 1 diabetes transplantation therapy but current stem cell differentiation protocols are mostly derived from mouse pancreas development, and they do not generate
fully functional beta cells. We have therefore generated and integrated single cell RNA sequencing (scRNA-seq) and spatial transcriptomics of the developing human pancreas at multiple timepoints to provide detailed transcriptional analysis of the various pancreatic cell types.

**Materials and methods:** Using scRNA-seq, we determined the transcriptome of over 53,000 human fetal pancreatic cells at 8, 10, 12, 13, 14, 15, 18, 19 and 20 post conception weeks. We performed 10x Visium spatial transcriptomics on 8 pancreas sections at four developmental time points covering over 10,000 barcoded spots to spatially localise the pancreatic cells. scRNA-seq and spatial transcriptomics data were integrated by canonical correlation analysis. Using time-series and pseudotime trajectory inferences including a deep-learning based spatial trajectory analysis, we uncovered differentiation transitions occurring in temporal and spatial contexts. We validated novel genes driving endocrine differentiation by smFISH and analysed the influence of pancreas microenvironment on endocrine progenitor differentiation by a connectome-based network analysis.

**Results:** scRNA-seq revealed distinct clusters of acinar, ductal, endocrine progenitors, alpha, beta, delta, immune, endothelial, Schwann and mesenchymal cells. Spatial transcriptomics samples were sequenced to a median depth of 177.5 x 10^6 reads (interquartile range 116.9-294.4 x 10^6), which yielded a mean of 1692 genes and 3395 unique molecular identifiers per spot. We identified spatially correlated genes and spatially proximal cells and found that spatial neighbourhoods were shared by acinar and endocrine cells, by endocrine, ductal, acinar and pancreatic progenitors, and also by endothelial and mesenchymal cells, suggesting that these neighbouring cell populations are more likely to interact together. Cell trajectory inference identified three endocrine progenitor populations and novel branch-specific genes as the endocrine progenitors differentiate towards alpha and beta cells, which were confirmed by smFISH. By integrating scRNAseq with spatial transcriptomics, we showed that mesenchymal cells undergo transition in the presence of immune cells to increase acinar cell number, with upregulation of CTRB2, SYCN, CEL and CPA1 (p<2.8x10e-4) and downregulation of COL3A1, EEF1A1, SNX3, COL1A2, RPL9 (p<3.9x10e-5). Spatial differentiation trajectories in situ indicated that Schwann precursor cells are spatially co-located with endocrine progenitors and contribute to beta cell maturation via the LIKAM-EPHB2 pathway.

**Conclusion:** We have characterised and spatially resolved multiple human pancreatic cell populations at multiple developmental stages. We have identified sub-populations of human endocrine progenitors, novel genes that may direct their differentiation to beta or alpha cell lineage, and the influence of pancreas microenvironment on endocrine progenitor differentiation. Our data identified the roles of Schwann precursor cells and mesenchymal cells in the differentiation of endocrine progenitors and acinar cells, respectively.

**Supported by:** Novo Nordisk UK Research Foundation and NC3Rs

Disclosures: O. Olaniru: None.

178

Stem cell-derived islets display functional and metabolic maturation post-engraftment


University of Helsinki, Helsinki, Finland.

**Background and aims:** Pluripotent stem cell-derived islets (SC-islets) are a promising tool for the development of translational therapies for diabetes. Following murine engraftment, SC-islets respond dynamically to glucose challenge, humanize blood glucose levels, and display gene network expression patterns closely related to those of primary human islets. However, it is unknown to what extent SC-islets maintain important features of beta cell function post-engraftment and little is known about how nutrient-sensitive metabolic pathways develop during in vivo maturation. Here we generate SC-islets and follow their functional acquisition in parallel with metabolite tracing analyses and mitochondrial morphology throughout in vivo engraftment in mice.

**Materials and methods:** SC-islets were differentiated in vitro using an optimised 7-stage protocol and engrafted into the kidney capsules of NOD-SCID-Gamma mice for up to 4 months. Dynamic graft function assays as well as blood glucose and C-peptide measurements were conducted throughout the engraftment time course. Grafts were retrieved at 1- and 4-months post-implantation for immunohistochemical and electron microscopic assays of insulin granule and mitochondrial morphology. Retrieved grafts were also acutely exposed to basal and stimulatory

rs950994 (A>G) as an expression quantitative trait locus (eQTL). The risk (AA) allele is associated with reduced islet TFB1M expression, reduced β-cell mass, metabolic coupling and impaired insulin secretion. The rs950994 SNP is also prognostically associated with T2D traits. Therefore, we aimed to understand the pathogenetic effects of the rs950994 SNP specifically on β-cell dysfunction in T2D.

**Materials and methods:** We created a humanized β-cell model by utilizing human induced pluripotent stem cells (hiPSCs) differentiated into β-like cells. Fibroblasts in skin biopsies from one female and one male TFB1M rs950994 risk (AA) carrier were reprogrammed to hiPSCs and subsequently differentiated into β-like cells. The efficiency of differentiation was determined by stage-specific RNA/protein marker expression via FACS, qPCR, Western and ICC. Genome editing by CRISPR/Cas12a was performed in donor hiPSCs via homology-directed repair and the risk (AA) alleles were successfully edited to non-risk (GG) alleles. Insulin-expressing β-like cells from risk and non-risk donors were FACs-sorted using a lentivirus GFP reporter and analyzed for TFB1M mRNA expression. Insulin secretion was quantified by insulin ELISA.

**Results:** The hiPSCs from both donors were differentiated to insulin-expressing β-like cells with 3-5% efficiency. Rs950994 risk (AA) to non-risk (GG) allele correction was 41%, and 59% efficient in male and female hiPSCs, respectively. Compared to non-risk (GG) allele β-like cells, the insulin-producing β-like cells from a heterozygous allele-corrected population of risk (AA) background exhibited decreased IBMX-induced insulin secretion (3.76-fold change over basal versus a 4.66-fold change) and total insulin content (486.3 versus 1297.5 mU/g total protein) and a 22% decreased TFB1M mRNA expression. Insulin data was derived from β-like cells differentiated from one female donor.

**Conclusion:** These data demonstrate a reduced expression of TFB1M mRNA in risk (AA) allele β-like cells coupled with reduced insulin secretion capacity and insulin content compared to non-risk (GG) variants. Thus, we have provisionally shown that the TFB1M risk variant (AA) is indeed an eQTL, which may underlie the increased risk of T2D conferred by rs950994. Further mechanistic explanations are warranted to explain this effect at the β-like cell level, including analysis of additional donors.

Disclosures: F. Roberts: None.
MicroRNAs predictive of islet graft function in islet transplant recipients
W.K.M. Wong¹, M.V. Joglekar¹, V. Saini¹-², C.X. Dong³, P.S. Kunte³, B.L. Anderson³, K.Z. Dajani⁴, A.M. Simpson⁴, P.E. MacDonald⁴, P.A. Senior⁴, K.K. Danielson⁴, A.M.J. Shapiro⁴, A.A. Hardikar⁴; ¹School of Medicine, Western Sydney University, Campbelltown, Australia, ²School of Life Sciences and the Centre for Health Technologies, University of Technology Sydney, Sydney, Australia, ³KEM Hospital and Research Center, Pune, India, ⁴University of Alberta, Edmonton, AB, Canada, ⁵University of Illinois, Chicago, USA.

Background and aims: Human islet transplantation is the only approved cell-based therapy for type 1 diabetes in some countries. However, several pancreatic islets die immediately after transplantation. The success of islet transplantation depends on the number of surviving and functional islet cells, which have been difficult to estimate using current methodologies. We aimed to assess microRNAs as surrogate markers of beta-cell function/death, and identify their potential to predict subsequent graft function in islet transplant recipients.

Materials and methods: Plasma samples were collected from islet transplant recipients (n=15) before and at 1-hour, 24-hours (in Edmonton) or from n=18-23 recipients at 1-week and 20-weeks (in Chicago) after transplantation of allogeneic human islets. Real-time qPCR was used to measure a panel of microRNAs that we had identified to be associated with insulin gene transcription. Significantly altered circulating microRNAs were identified using appropriate statistical methods based on data distribution and variance. We also employed machine-learning (ML) workflows to identify important microRNAs associated with fasting C-peptide levels and exogenous insulin requirement at one month post-transplant.

Results: Nineteen of the insulin transcript-associated microRNAs demonstrated an overall increase in abundance at 1-hour post-transplantation, compared to their pre-transplant levels. Two of the measured microRNAs (miR-375-3p, and miR-216b-5p) had significant increase (p<0.05) at the 1-hour post-transplant stage and then reduced at 24-hours post-transplant. Interestingly, these two microRNAs continued to remain low at 1-week and 20-weeks post-transplant. ML workflows (penalised regression with bootstrapping) identified microRNAs measured at 1-hour post islet transplant that could predict post-transplantation C-peptide levels at 1-month (spearman R=0.79, p=0.0008). Insulin requirement at 1-month post-transplant was determined with microRNAs measured at 1-hour post islet transplant using ML methodologies. The important microRNAs for determining insulin requirement at 1-month yielded an area under the curve of 0.85 (n=15, Sensitivity=0.60, specificity=0.83) in a Receiver Operating Characteristics curve analysis using leave one out cross-validation ML technique.

Conclusion: Upregulation of insulin transcript-associated microRNAs in just 1-hour post-transplant, indicates that they may be released as a result of islet cell death and could be used as biomarkers to assess beta-cell function in islet transplant recipients. Validation of these microRNAs in other sample sets will confirm the utility of these microRNAs in predicting islet graft function within an hour post-transplantation.

Supported by: JDRF International, JDRF Australia and Helmsley Trust.
Disclosure: W.K.M. Wong: None.
OP 31 Diabetes: size matters

IDF diabetes atlas: global prevalence estimates of prediabetes for 2021 and projections for 2045
D.J. Magliano1, M. Fang2, M. Rooney3, K. Ogurtsova1, E. Boyko1, E. Selvin2
1Baker Heart and Diabetes Institute, Melbourne, Australia, 2Epidemiology, John Hopkins University, Baltimore, USA, 3German Diabetes Center of the Leibniz Association, Dusseldorf, Germany.

Background and aims: Persons with prediabetes—impaired glucose tolerance (IGT) or impaired fasting glucose (IFG)—are at high risk for developing diabetes and microvascular and macrovascular complications. We aimed to estimate the global prevalence of IGT and IFG.

Materials and methods: We systematically reviewed 7,014 articles and reports published after 2000 to identify reliable estimates of IGT (2-hour glucose concentration of 7.8-11.0 mmol/L) and IFG (fasting glucose of 6.1-6.9 mmol/L) for each country. Studies were assessed for quality using pre-established criteria. Extracted data were modelled using logistic regression to produce smoothed age-specific prevalence estimates of IGT and of IFG for 2021, and for 2045. For countries without in-country data, estimates were extrapolated from countries with similar economies, ethnicity, geography, and language.

Results: There were 51 high-quality studies for IGT (from 43 countries) and 42 high-quality studies for IFG (from 39 countries). Approximately 80% of countries did not have high quality IFG or IGT data. The global prevalence of IGT in 2021 was 9.1% (464 million adults) and is projected to increase to 10.0% (640 million) in 2045 (Figure A). The global prevalence of IFG in 2021 was 5.6% (286 million) and is projected to increase to 10.0% (640 million) in 2045 (Figure A). The prevalence of IGT and IFG was highest in high income countries.

Conclusion: The global burden of prediabetes is substantial and growing. There is pressing need to implement interventions which will halt this increase, and to avoid the future diabetes epidemic that currently threatens to overwhelm global healthcare systems.

Figure: Global prevalence of IGT and IFG in 2021 and 2045 (projected), overall and by country-level income

Disclosure: D.J. Magliano: None.
Type 2 diabetes, and its modulating effect on the aging body, studied using voxel-wise analysis of whole-body MR images

J. Kullberg², A. Martinez Mora¹, N. Ahmad¹, F. Malmberg¹, R. Strand¹, L. Johansson¹, T. Fall⁴, S.C. Larsson¹, L. Lind⁶, H. Ahlström¹,²
¹Department of Surgical Sciences, Uppsala University, Uppsala. ²Antaros Medical, Mölndal. ³Department of Information Technology, Uppsala University, Uppsala. ⁴Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala. ⁵Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm. ⁶Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Background and aims: Morphology of multiple organs and tissues have been associated with type 2 diabetes (T2D) and aging. Magnetic Resonance Imaging (MRI) can be used for detailed studies of body composition. Studies are typically performed after explicit quantification of targets of interest. Here we studied perturbations in body composition in T2D and aging at the voxel-level using a statistical image analysis approach (Imiomics) that utilizes all image data collected.

Materials and methods: Neck-to-knee water-fat MRI from participants in the UK Biobank imaging study (18 778 males, age 65.0±7.7, T2D 6.5% and 20 120 females, age 63.7±7.4, T2D 2.8%) were investigated. T2D was classified using a previously validated algorithm. Image registrations of the water-fat MRI scans were used for sex-stratified voxel-wise analysis of tissue volume and fat content throughout the body. Multiple regression was used to model voxel-wise association to T2D and age using what can be described as association imaging. Interactions between T2D and age were also studied. Key findings were confirmed using explicit measurements. This research used the UK Biobank resource (applic. no. 14237) and SNIC (sens2019016).

Results: Volume and fat content of multiple tissues were associated with both T2D (Figure 1) and age. Findings of particular interest included findings in liver, skeletal muscle, and bone marrow as well as regional differences within the subcutaneous adipose tissue (SAT), including differences in the upper vs lower body and in the anterior vs posterior lower abdomen. A lower fat content in long bones was found in T2D, especially in females and was confirmed by explicit measurements. Most tissue volumes correlated negatively with age. However, visceral adipose tissue (VAT) and lower anterior SAT show positive correlations. Liver and muscle showed higher fat contents in T2D and muscle fat fraction increased with age. T2D patterns were relatively similar in both sexes except for lower thigh muscle volumes in males. T2D and age interactions were found in upper body SAT and VAT, especially in females, as well as in liver volume, liver fat and bone marrow fat content in long bones in both sexes. Most deviations seen in T2D in middle aged subjects tended to normalize during aging.

Conclusion: This voxel-wise study of T2D and age confirmed many previous reported findings but also identified and visualized multiple findings that would be very difficult to study using other techniques.

Supported by: Swedish Research Council, Heart-Lung Foundation, EXODIAB

Disclosure: J. Kullberg: Employment/Consultancy; Antaros Medical. Stock/Shareholding; Antaros Medical.
Low birth weight is associated with lower age and BMI at the time of type 2 diabetes diagnosis in the Danish DD2 cohort

A.L. Hansen1, R.W. Thomsen2, C. Brons3, H.M.L. Svane2, J.S. Nielsen3, P. Vestergaard3, K. Højlund1, N. Jessen2, M.H. Olsen1, T. Hansen1, H.T. Sørensen2, A.A. Vaag1; 1Steno Diabetes Center Copenhagen, Herlev, 2Dept. of Clinical Epidemiology, Aarhus University, Aarhus, 3Steno Diabetes Center Odense, Odense, 4Steno Diabetes Center North, Aalborg, 5Steno Diabetes Center Aarhus, Aarhus, 6Steno Diabetes Center Zealand, Holbæk, 7Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.

Background and aims: Low birthweight (LBW) is a risk factor for type 2 diabetes (T2D), but the extent to which LBW influences the clinical presentation of T2D is unknown. We examined whether LBW is associated with a range of key clinical characteristics, including age at diagnosis, family history of diabetes, obesity, hypertension, subclinical inflammation, HbA1c, insulin secretion and action, as well as comorbidities in patients with newly diagnosed T2D in the nationwide Danish Centre for Strategic Research in Type 2 diabetes (DD2) cohort.

Materials and methods: Our analysis included 7,297 newly diagnosed T2D patients enrolled in the DD2 cohort by general practitioners and outpatient hospital clinics in Denmark during 2010-2018. We retrieved birthweight data from midwife records in the Danish National Archives. Birthweight was divided into three groups: the lowest 25% (<3000g = LBW), the middle 50% (3,000-3,700 g = normal birthweight (NBW)), and the highest 25% (>3700g = high birthweight (HBW)). Log-binomial and Robust Poisson regression analyses were used to calculate sex- and age-adjusted prevalence ratios (PRs) with 95% confidence intervals (95% CIs) of T2D characteristics associated with LBW and HBW exposure, using NBW as the reference category.

Results: In total, 1,556 (21.3%) patients had LBW, 3,279 (44.9%) NBW, and 1,544 (21.1%) HBW. Compared with NBW (median age at T2D onset = 62.3 years), LBW was associated with a lower age (59.6 years) and HBW conversely with a higher age at T2D onset (64.8 years), as reflected by opposite directed PR’s in LBW versus HBW in patients with onset before age 45 versus after 75 years (LBW: PR 1.36 (95% CI, 1.13-1.64) at age <45 versus 0.74 (95% CI, 0.59-0.92) at age >75 years. HBW: PR 0.65 (95% CI, 0.52-0.83) at age <45 versus 1.48 (95% CI, 1.24-1.76) at age >75 years). At T2D onset, patients with LBW were leaner (BMI <25: PR 1.11 (95% CI, 1.03-1.21)), less often severely obese (BMI >40: PR 0.55 (95% CI, 0.42-0.72), and had lower waist circumference (<94/80 cm for men/women: PR 1.34 (95% CI, 1.13-1.59)). After adjustments for sex, age, and BMI, LBW patients had a higher Charlson Comorbidity Index score (≥2: PR 1.36 (95% CI, 1.06-1.75)), used more antihypertensive medications (≥3 antihypertensive drugs: PR 1.33 (95% CI, 1.06-1.67)), had increased subclinical inflammation (hsCRP ≥3 mg/L: PR 1.09 (95% CI, 1.00, 1.19)), and were less likely to have a family history of diabetes (no affected first-degree relatives: PR 1.08 (95% CI, 1.02-1.15)) versus 3 or more affected relatives: PR 0.68 (95% CI, 0.52-0.90).

Conclusion: LBW was associated with younger age, less obesity and less genetic predisposition at time of T2D diagnosis. Furthermore, LBW was associated with increased subclinical inflammation, hypertension and overall comorbidity burden. There is a need for prospective studies of disease trajectories, comorbidities, complications, and mortality in T2D patients with LBW.

Supported by: Novo Nordisk Foundation

Low birth weight is a well-known risk factor for development of type 2 diabetes (T2D) later in life. This is particularly apparent when exposed to an affluent dietary lifestyle. Data from our group has indicated that impaired subcutaneous adipose tissue expandability, associated with increased ectopic (hepatic) fat deposition, may be on the critical path of T2D development in LBW subjects. We aimed to study whether a 4-week overfeeding (+25% energy) challenge, consisting of simple carbohydrates (COF), would result in differential dysmetabolic effects, including increased hepatic fat content, in LBW men compared with normal birth weight (NBW) controls.

Materials and methods: We included 22 healthy, early middle-aged, and non-obese LBW men (mean BW 2797±175 g) as well as 21 NBW controls (mean BW 3807±176 g) matched for age and BMI. We measured body composition by DXA, hepatic fat content by magnetic resonance spectroscopy, glucose and insulin metabolism, hepatic glucose production (HGP) by deuterium glucose, energy metabolism by indirect calorimetry, selected plasma biomarkers by multiplex Mesoscale Discovery technology as well as untargeted serum metabolomics and lipidomics by mass spectrometry before and after 4 weeks COF.

Results: In response to COF LBW, but not NBW subjects, displayed increased fasting plasma levels of glucose (P=0.03), C-peptide (P=0.01), leptin (P=0.0002) and FGF21 (P=0.005), as well as increased energy expenditure (P=0.0002) and fat oxidation rates (P=0.02) compared to baseline. COF resulted in significant increases in body weight in both groups. Hepatic fat content increased slightly in both LBW (P=0.023) and NBW (P=0.018) subjects after COF, however, with the LBW group having significantly increased hepatic fat content before and after COF compared with NBW controls. Fasting plasma adiponectin was significantly reduced in LBW compared with NBW subjects both before and after COF. Among 65 metabolites, 8 were differentially abundant between the groups (P<0.05) after COF. Ingenuity pathway analyses (IPA) revealed accumulation and increased lipid peroxidation in LBW subjects after COF. Further, IPA showed activation of the PPARGC1A pathway in LBW subjects contrasting a minor downregulation of the pathway in NBW subjects after COF. Finally, among 279 lipids identified by lipidomics, the LBW subjects exhibited a significantly (FDR<0.0004) higher number of lipids to be increased after COF (n=26) compared to NBW subjects (n=6). This finding was further supported by a network analysis showing a general upregulation of the lipid profile in LBW subjects opposing a slight downregulation in NBW controls after COF.

Conclusion: LBW subjects at increased risk of T2D respond to COF with differential increases in plasma glucose, C-peptide, leptin and FGF21 levels, as well as with increased fat oxidation rates and severe differential perturbations of lipid metabolism, compared to NBW controls. The findings stress the importance of LBW individuals refraining from overeating simple carbohydrates. Additional studies are needed to further understand the role of increased hepatic fat accumulation in LBW subjects in T2D development.

Clinical Trial Registration Number: NCT02902408
Supported by: EFSD/Lilly Research Programme, Organ Cross-talk, NNF, Augustinus Foundation, Aase and Ejnar Danielsen Foundation, TrygFonden
Background and aims: Impaired glucose regulation (IGR) is an important risk factor for the development of diabetes, and includes impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). Pharmacological agents can decrease the rate of progression from IGT to diabetes, with the ADA stating that metformin currently has the strongest body of evidence. The objectives of this study were to determine whether lifestyle intervention (LSI) plus metformin was superior to LSI alone in preventing diabetes, and to assess the effect of metformin on weight loss and blood pressure in Chinese subjects with IGR.

Materials and methods: In this study, 1,706 subjects with IGR, including IFG (fasting plasma glucose 6.1-6.9 mmol/L and 2-hour postprandial glucose <7.8 mmol/L) and IGT (fasting plasma glucose <7.0 mmol/L and 2-hour postprandial glucose 7.8-11.1 mmol/L) by OGTT, were randomly assigned (1:1) to LSI plus metformin (n=848) or to LSI only (n=858). The primary endpoint was the incidence of diabetes based on OGTT. Secondary endpoints were weight and blood pressure reduction. Safety was assessed by the incidence of adverse events (AEs).

Results: The mean follow-up time was 1.99±0.62 and 1.94±0.60 years in the LSI plus metformin and LSI groups, respectively; incidence of diabetes was 18.23 and 20.72 per 100 person-years. The risk of diabetes was 17% lower in the LSI plus metformin group vs the LSI group (HR 0.84; 95% CI 0.55-1.30). Progression to diabetes was significantly delayed in the LSI plus metformin group (Figure). The LSI plus metformin group showed a greater weight reduction after 2 years (1.03 kg) than the LSI group (−2.43±0.28 vs −1.40±0.27 kg respectively, p<0.0002). In subjects who were hypertensive at baseline but not receiving an anti-hypertensive agent, the mean change in systolic/diastolic BP was not significantly different between groups: −9.4/−3.9 mmHg (LSI plus metformin group) and −8.97/−3.4 mmHg (LSI group). The incidences of AEs and serious AEs were 34.55% and 1.71% in the LSI plus metformin group, and 22.68% and 1.29% in the LSI group, respectively.

Conclusion: This study demonstrated that LSI plus metformin is more effective than LSI alone in reducing the risk of diabetes, delaying progression to diabetes, and reducing body weight in Chinese adults with IGR. The effects for subjects with IFG alone remain uncertain.

Clinical Trial Registration Number: ClinicalTrials.gov ID: NCT03441750
Supported by: Chinese Association of Geriatric Research (CAGR) and Merck Serono China Co. Ltd.
Disclosure: L. Zhang: Other; This study was sponsored by the Chinese Association of Geriatric Research (CAGR) and was funded by Merck Serono China Co. Ltd., an affiliate of Merck KGaA, Darmstadt, Germany.

OP 32 Pain or no pain?

187

Painful diabetic peripheral neuropathy in type 1 diabetes in the Epidemiology of Diabetes Interventions and Complications (EDIC) study

1George Washington University, Rockville, USA, 2University of Michigan, Ann Arbor, USA, 3Case Western Reserve University, Cleveland, USA, 4University of Pittsburgh, Pittsburgh, USA, 5University of Toronto, Toronto, Canada, 6Washington University St. Louis, St Louis, USA.

Background and aims: We evaluated the prevalence and incidence as well as risk factors associated with painful diabetic peripheral neuropathy (DPN) in participants with type 1 diabetes (T1D) enrolled in the Epidemiology of Diabetes Interventions and Complications (EDIC) study, an observational follow-up of the Diabetes Control and Complications Trial (DCCT).

Materials and methods: Data were obtained from 1,401 participants followed for 26 years during EDIC. The Michigan Neuropathy Screening Instrument (MNSI) questionnaire, which includes specific neuropathic pain questions (Q2: “Do you ever have any burning pain in your legs and/or feet?”, Q6: “Does it hurt when the bed covers touch your skin?”), was administered annually. Painful DPN was defined as a positive response to Q2 and/or Q6 plus a MNSI examination score >2. Sustained painful DPN was defined as occurring on 2 or more consecutive annual visits. In addition, Kaplan-Meier estimates were used to describe the 26-year cumulative incidence of the first occurrence of any sustained painful DPN.

Results: Over the 26-year duration in EDIC, the prevalence of neuropathic pain (Q2 and/or Q6) increased from 8.5% to 19.8% while the prevalence of a MNSI examination score >2 increased from 22.9% to 43.5%. During EDIC, 889 (63.5%) participants did not experience any painful DPN while 512 (36.5%) experienced painful DPN at least once, of which 263 (18.8%) met the criteria for sustained painful DPN. After adjusting for age at DCCT closeout and DCCT treatment group, participants with sustained painful DPN had significantly higher BMI, waist circumference, systolic blood pressure, pulse pressure, heart rate, total and LDL cholesterol, triglycerides and HbA1c levels over time versus participants without any painful DPN during the study (p<0.0005 for all). Among the 1,348 participants without painful DPN at EDIC year 1, the 26-year cumulative incidence of sustained painful DPN was 18% (Figure).

Conclusion: In this large cohort of well-characterized T1D participants, the prevalence of neuropathic pain and DPN increased steadily over the 26-year follow-up. These data also suggest that differences in several cardiometabolic risk factors, in addition to glucose control, may contribute to differences in painful DPN risk.
Increased functional connectivity of the Thalamus and primary somatosensory cortex and insular cortex following treatment withdrawal: a potential biomarker of painful-DPN

D. Selvarajah1, K. Teh2, J. Mcallister1, A. Anandhanarayanan1, J. Fan1, G. Sloan2, S. Tesfaye1.

1Department of Oncology and Metabolism, University of Sheffield, 2Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, 3Diabetes Research Department, Sheffield Teaching Hospitals, Sheffield, UK.

Background and aims: Altered functional connectivity has been identified in key brain regions involved in somatosensory perception in patients with painful diabetic peripheral neuropathy (painful-DPN), using resting state functional-magnetic resonance imaging (fMRI). However, these studies have not looked at the impact of neuropathic pain treatments. A greater understanding of treatment upon these pain processing areas might lead to greater understanding of the mechanisms of these pharmacotherapeutic agents and also development of new treatments that target these brain regions.

Materials and methods: A total 15 participants (Age, 62.1 ± 9.0; HbA1c 65.4 ± 16.2 mmol/mol; 13 type 2 diabetes, 1 type 1 diabetes and 1 MODY; 13% female) enrolled in the OPTION-DM clinical trial (ISRCTN17545443) underwent neuroimaging. All participants had clinical and neurological assessments, including the modified Toronto Clinical Neuropathy Score, Doleur Neuropathique 4 and Neuropathic Pain Symptom Inventory. Participants underwent fMRI imaging using 3T (Achieva, Phillips Healthcare) when the participants were on maximum tolerated medication (Treatment Scan) and one week after washout of these medications (Washout Scan). The data was analysed using Conn Functional Connectivity Toolbox in SPM.

Results: There was a significant increase in Pain Numeric Rating Scale (NRS) from Treatment Scan (4.0 ± 2.1) to the Washout Scan (6.1 ± 2.4, p=0.044). There was a significantly greater functional connectivity between the Primary Somatosensory Cortex (S1) and the Thalamus, and the Insular Cortex and Thalamus (p false discovery rate [FDR] = 0.041) during the Treatment Scan compared with the Washout Scan. Moreover, there was a significant difference in the change between scans in S1 - Thalamic functional connectivity in participants with Severe-Pain (NRS ≥8 at baseline: Age, 64.5 ± 10.1; 10% Female; -0.372 ± 0.275) compared to participants with Moderate-Pain (NRS ≤7; Age, 57.4 ± 3.0; 20% Female; -0.051 ± 0.180, p=0.035). The change in S1-Thalamic connectivity also correlated with a number of variables including baseline pain (r = -0.585, p=0.022), NPSI (r = -0.597, p=0.019) and the difference in NRS at the Treatment Scan and Baseline pain (r = -0.513, p=0.050).

Conclusion: This is the first study to look at the impact of neuropathic pain medication withdrawal on functional connectivity of pain matrix brain regions. On neuropathic pain medication withdrawal there is an increase S1 - Thalamus and Insular Cortex - Thalamus functional connectivity. Moreover, the change in S1 - Thalamic functional connectivity from the Treatment Scan to Withdrawal Scan differentiated participants with high and low baseline neuropathic pain and correlated with baseline pain. This study further demonstrates that the thalamus is a key area for the central mechanisms of painful-DPN and its functional connectivity to the S1 and Insular Cortex has the potential to act as a biomarker of painful-DPN.

Disclosure: G. Sloan: None.
major diabetic complications, such as cardiovascular disease, renal disease, blindness and amputation, has been decreasing in many countries over the last few decades. However, it is unknown if this applies to diabetic neuropathy. The aim of this study was to estimate temporal changes in the incidence rates of DSPN in individuals with type 1 diabetes (DM1) and type 2 diabetes (DM2) in a longitudinal cohort at a tertiary diabetes treatment facility. In addition, differences in age-related incidence rates were investigated.

**Materials and methods:** In the period between 1996-2018, we identified 13,650 individuals with DM1 and DM2, with repeated measures of vibration perception threshold (VPT) and a height measure. Individuals with prevalent neuropathy at the first performed foot exam were excluded. In total 2783 individuals, 1071 individuals with DM1 and 1712 individuals with DM2 were included in the further incidence analysis. VPT was measured with Bio-Thesiometer and age- sex- and height-specific cut-off values were used to assess the presence of DSPN. DSPN was defined as decreased VPT in both feet. Incidence rates of DSPN, sex, age and calendar time were modelled by Poisson regression for time-split data and separate for DM1 and DM2.

**Results:** From 1996 to 2018, 737 cases of incident DSPN occurred during 18,677.5 person-years (PY) among individuals with DM1 corresponding to an overall incidence rate of 19.5/100 PY, and 709 cases of incident DSPN occurred during 18,677.5 PY among individuals with DM2 corresponding to an overall incidence rate of 15.6/100PY. For both DM1 and DM2 we observe a decreasing incidence rate in the period 2007-2017, similar in all ages (data not shown). For DM1 decreasing incidence rate occurs with increasing age, and there are no sex differences (figure 1A). However, we observe an increasing incidence rate with increasing age for DM2, and we see no sex differences (figure 1B).

**Conclusion:** This cohort study shows that the incidence rate for DSPN in both DM1 and DM2 has been declining from 2007 to 2017. With increasing age, individuals with DM1 and DM2 have, respectively, declining and increasing incidence rates of DSPN.

**Disclosure:** H. Mizrak: None.

---

**Type 2 diabetes phenotypes and polyneuropathy: a prevalence study in the DD2 Cohort**

1Dept. of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, 2Dept. of Neurology, University of Michigan, Ann Arbor, USA, 3Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark, 4Dept. of Neurology, Aarhus University Hospital, Aarhus, Denmark, 5Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark, 6Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark, 7Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.

**Background and aims:** Hyperinsulinemia may cause diabetic polyneuropathy (DPN), but large-scale studies are scarce. Three phenotypes of type 2 diabetes (T2D) have recently been proposed: hyperinsulinemic (low insulin sensitivity, high beta cell function), classical (low insulin sensitivity, low beta cell function), and insulinopenic (high insulin sensitivity, low beta-cell function). We aimed to investigate the association of hyperinsulinemia with DPN.

**Materials and methods:** We included 3,397 recently diagnosed T2D patients prospectively enrolled from general practitioners and outpatient hospital clinics in Denmark, 2010-2015. Insulin sensitivity and beta-cell function were quantified with the HOMA2 model based on fasting serum C-peptide and plasma glucose levels measured at enrollment. DPN was defined as a score of ≥4 on the Michigan Neuropathy Screening Instrument questionnaire sent out median 3 years after study enrollment. We imputed missing values of potential confounders and applied Poisson regression to calculate adjusted prevalence ratios (PR) of DPN.

**Results:** We identified 900 (27%) hyperinsulinemic, 2,150 (63%) classical, and 347 (10%) insulinopenic T2D patients. Hyperinsulinemic patients had the highest prevalence of central obesity (waist circumference ≥88/102 cm [F/M]; 89% of hyperinsulinemic, 75% of classical, and 36% of insulinopenic) and had more dyslipidemia and hypertension, but less dysregulated HbA1c (≥53 mmol/L; 9%, 16%, 22%). The age-, sex-, and diabetes duration adjusted PR of DPN was 1.44 (95% CI 1.23-1.68) for hyperinsulinemic T2D patients, compared with the classical phenotype. The prevalence remained elevated (1.32 [1.13-1.55]) after further adjustment for waist circumference, dyslipidemia, hypertension, and HbA1c. For the insulinopenic patients, the adjusted PRs of DPN were 0.87 (0.65-1.15) and 1.16 (0.86-1.55), respectively. In spline analyses, both hyperinsulinemia (i.e., higher beta-cell function) and lower insulin sensitivity associated with increased prevalence of DPN. The association between increasing hyperinsulinemia and increasing DPN prevalence persisted among patients with low insulin sensitivity (classical or hyperinsulinemic patients). In contrast, among hyperinsulinemic (high beta-cell function) patients, decreasing insulin sensitivity was not associated with DPN.

**Conclusion:** The prevalence of DPN is increased in T2D patients with the hyperinsulinemic phenotype. Hyperinsulinemia per se is associated with DPN, irrespectively of insulin resistance and other metabolic factors. Supported by: Novo Nordisk Foundation.

**Disclosure:** F.P. Kristensen: None.

---

**Environmental risk factors of incident distal sensorimotor polyneuropathy: results from the population-based KORA F4/FF4 study**

**C. Herder**1,2, S. Zhang3, K. Wolf1,2, H. Maalmi1,2, G.J. Bünhof4, W. Rathmann1,2, L. Schwettmann1,5, B. Thorand1,2, M. Roden1,4, A. Schneider1, D. Ziegler1,4, A. Peters1,2;
1German Diabetes Center, Düsseldorf, 2German Center for Diabetes Research, München-Neuherberg, 3Helmholtz Zentrum München, Neuherberg, 4Heinrich Heine University Düsseldorf, Düsseldorf, 5Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.

**Background and aims:** Distal sensorimotor polyneuropathy (DSPN) is a common condition in older populations with high prevalences of obesity and type 2 diabetes. We hypothesised that the risk of DSPN is affected by ubiquitous environmental risk factors, particularly in people with obesity.
Materials and methods: The study was based on 423 participants aged 62-81 years without DSPN who participated in the population-based Cooperative Health Research in the Region of Augsburg (KORA) F4 survey (2006-2008) in Southern Germany. During a mean follow-up of 6.5 years, 188 participants developed DSPN, which was defined using the Michigan Neuropathy Screening Instrument. Environmental exposures, including annual and seasonal mean air temperature, greenness (assessed with the normalised difference vegetation index [NDVI]), road traffic noise and annual mean air pollution, were assessed at participants’ residences. The cumulative risk index (CRI) was calculated to evaluate the joint effects of co-occurring exposures on the risk of DSPN based on effect estimates from multi-exposure Poisson regression models. The models were adjusted for age, sex, height, waist circumference, smoking, alcohol consumption, physical activity, education and neighbourhood socioeconomic status.

Results: In the total study sample, the co-occurrence of an interquartile range (IQR) decrease in temperature of the warm season and NDVI in a 100-m buffer and an IQR increase in night-time average traffic noise and particle number concentration (PNC) was associated with an increased risk of DSPN (CRI [95% CI] 1.39 [1.02, 1.91]). Additional adjustment for HbA1c and other covariables did not change associations between the exposures and DSPN. Effect estimates for exposure combinations were generally higher in individuals with obesity (CRI between 1.34 and 2.01) than in those without obesity (CRI between 0.90 and 1.33). The four-exposure model showed a twofold increased risk of DSPN among obese (CRI [95% CI] 2.01 [1.10, 3.67]), but not among non-obese individuals (CRI [95% CI] 1.18 [0.83, 1.67]), P for interaction=0.13.

Conclusion: Ubiquitous environmental exposures modulate the risk of DSPN in the older population. The joint effects of lower air temperature in the warm season, less greenness close to participants’ residences, and higher noise and air pollution levels identified people with obesity as a particularly vulnerable subgroup.

Disclosure: C. Herder: None.

OP 33 Therapy outside the box

193

Discovery of malonic acid as a novel adipocyte beiging molecule
C. Luk, N.J. Haywood, K.I. Bridge, K.J. Simmons, N.Y. Yuldasheva, P. Sukumar, L.D. Roberts, S.B. Wheatcroft, R.M. Cubbon, M.T. Kearney; Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, UK.

Background and aims: Pilot data from our group show that endothelial insulin-like growth factor 1 receptor knockdown (ECIFGFR1-KD) mice are protected from diet-induced insulin resistance. In vitro, we found their endothelial cells secrete a small molecule capable of inducing adipocyte beiging and used metabolomics to identify candidate small molecule metabolites. With the hypothesis that adipose remodelling is the primary contributor to the improved metabolic phenotype and is mediated by an endothelial-derived small molecule, we aim to screen the adipocyte beiging effect of these hits.

Materials and methods: Mature murine 3T3-L1 adipocytes were stimulated with the different metabolites before measuring gene expression of various white and beige adipocyte markers by qPCR. To probe the beiging mechanism, adipocytes were stimulated with malonic acid at different doses or for different duration, with or without pre-treatment with relevant inhibitors. To begin to examine functional readouts, the concentration of adiponectin secreted by stimulated adipocytes was measured by ELISA. Finally, to determine the translational potential, mature human white adipocytes were stimulated with malonic acid and its derivative, di-tert-butyl malonate (DBM). To determine the dose-dependent effect of DBM, different doses of DBM were applied to human adipocytes. Mitochondrial respiration of stimulated adipocytes was measured by Seahorse respirometry.

Results: Among 28 screened metabolites, only malonic acid induced gene expression of beige adipocyte markers in mature 3T3-L1 adipocytes. 24-hour treatment with 10mM malonic acid induced gene expression of various beige adipocyte markers including Ucp1 (15-fold, n=6-7, p<0.05), Cited1 (12-fold, n=5, p=0.01) and Fgf21 (by 6-fold, n=5, p<0.05). Time-course study showed malonic acid-induced Fgf21 gene upregulation (first determined at 6-hour time-point, p=0.05) preceded Ucp1 gene upregulation (first determined at 8-hour time-point, p<0.05). Lower doses of malonic acid did not induce beige marker gene expression. Malonic acid-induced Ucp1 gene upregulation is partly attenuated in adipocytes pre-treated with either 100nM MitoQ (-59.3%, n=5, p<0.001), 20nM PD173074 (-50.0%, n=5, p=0.05) or 3μM A485 (-47.7%, n=5, p<0.01), suggesting malonic acid-induced beiging is partly mediated by mitochondrial oxidative stress, FGF receptors and Cbp/p300 signalling, respectively. In addition, malonic acid enhanced adipocyte secretion of adiponectin (+21.5%, n=3, p<0.05). 24-hour treatment with 10mM DBM recapitulated malonic acid-induced UCP1 gene upregulation in human adipocytes (13-fold, p<0.05). Dose-response study showed 100μM DBM was sufficient to induce UCP1 gene upregulation in human white adipocytes (+143%, n=5, p<0.05). Preliminary data from respirometry study suggest DBM may increase basal respiration in adipocytes (+78.75%, n=3, p=ns).

Conclusion: Malonic acid can induce adipocyte beiging and adiponectin secretion in vitro. Malonic acid-induced beiging is partly mediated by mitochondrial oxidative stress, FGF receptors and Cbp/p300 signalling. DBM may have therapeutic potential in diet-induced diabetes. Future work will focus on examining the pathway by which IGF-1R deficiency leads to increased endothelial malonic acid secretion and the translational relevance of DBM in treating diabetes.

Disclosure: C. Luk: Grants; British Heart Foundation 4-year PhD studentship.

Supported by: BHF 4-year PhD studentship
Hepatic S100A9-TLR4-MTORC1 axis normalises diabetic ketogenesis

G. Ursino1, G. Ramadori1, A. Höfler2, S. Odouard1, P. Teixeira1, F. Visentin1, C. Veyrat-Durebex1, G. Lucibello1, R. Firnkes1, S. Ricci1, J. Elmiquis1, T. Vogl1, A. Boland2, R. Coppari3; 1Physiology & Cell Metabolism, University of Geneva, Geneva, Switzerland, 2Molecular Biology, University of Geneva, Geneva, Switzerland, 3Centre of Hypothalamic Research, University of Texas Southwestern Medical Centre, Dallas, USA, 4Institute of Immunology, University of Munster, Munster, Germany, 5Molecular Biology, University of Geneva, Geneva, Switzerland.

Background and aims: Type 1 Diabetes (T1D) afflicts millions of people and is usually diagnosed in children and young adults with an incidence that has been increasing at an alarming annual rate of ~3%. T1D is mainly characterized by hyperglycaemia, however β-cell loss also leads to other serious metabolic derangements such as hypertriglyceridaemia, hyperglucagonemia and diabetic ketoacidosis (DKA). DKA is often life threatening (accounting for up to 263 yearly hospitalization events for each 1000 patients) and occurs due to unregulated ketogenesis, whose incidence is high in diabetic patients. While insulin therapy reduces ketogenesis this approach is sub-optimal and currently available insulin adjuvants actually increase the risk of developing DKA. To this end, we have identified a ketone normalizing action of S100A9 in T1D. The aims of our study were to uncover where (cell types and tissues) and how (molecular mechanism) S100A9 was exerting this beneficial effect on ketogenesis and to assess its therapeutic potential and clinical relevance.

Materials and methods: We generated insulin deficient mice lacking or re-expressing Toll-Like Receptor 4 (TLR4) only in liver or hepatocytes and mice with hepatic-restricted and hepatocyte restricted loss of Tuberous Sclerosis Complex 1 (TSC1, an mTORC1 inhibitor) in the context of liver overexpression of S100A9. We assessed cellular signaling pathways and circulating metabolic parameters in-vivo and ex-vivo fatty acid oxidation in these mice to determine the mechanism of action of S100A9. We tested the translational feasibility and safety of an S100A9 based therapeutic in insulin deficient mice through administration of recombinant mouse and human S100A9 (acute and chronic treatment). We analyzed plasma samples of decompensated diabetic patients to determine clinical feasibility of S100A9 treatment.

Results: S100A9 suppresses diabetic ketogenesis via activating mTORC1 signaling downstream of the TLR4-Akt pathway in hepatic non-parenchymal cells. This activation suppresses fatty acid oxidation in the liver. Extracellular S100A9 activates mTORC1 signaling in a cell-autonomous fashion. Administration of recombinant mouse and human S100A9 suppresses DKA in insulin deficient rodents. Chronic treatment of recombinant S100A9 suppresses DKA and displays a promising safety profile in insulin deficient patients. Plasmatic S100A9 content was only modestly increased in decompensated diabetic patients (possibly indicating a compensatory mechanism to reduce ketogenesis) therefore providing scope for further increasing plasmatic S100A9 as a potential therapeutic clinical avenue in diabetes.

Conclusion: Our results indicate that it acts through the hepatic TLR4-mTORC1 axis in non-parenchymal cells; hence suggesting the existence of an insulin-independent intra-hepatic network able to regulate lipid and ketone metabolism in T1D. S100A9 shows promise as a therapeutic, holding potential to reduce insulin needs and consequently diminish unwanted side effects of insulin treatment while improving metabolic control.

Supported by: B&KH, GVM, ERC, JDRF, INNOGAP, SNF
Disclosure: G. Ursino: None.

Validation of duodenal targeting by oral pharmacologic duodenal exclusion therapy for treatment of type 2 diabetes

T. Carlson1, A. Nimgaonkar2, T. Guerina1, K. Colbert1, S. Polomoscanik1, J. Petersen1, T. Jozeffak1, M. Fineman1; 1Glyscend Inc, Lowell, 2Glyscend Inc, Baltimore, USA.

Background and aims: Metabolic surgery is the most successful long-term therapy for T2DM and obesity, reducing macro, microvascular complications, and mortality. The acute and chronic metabolic improvements observed with these surgeries are believed to be, at least in part, a direct consequence of preventing nutrient exposure to the proximal small intestine (duodenum and proximal jejunum exclusion). The use of metabolic surgery and duodenal exclusion devices is limited, however, due to their invasive nature. We developed oral, non-absorbed polymers (GLY100, GLY200) designed to mimic the effects of metabolic surgery non-invasively by augmenting the natural mucus lining of the proximal small intestine to create a temporary barrier. In chronic rodent models of T2DM (DK- Rat and ZDF-Rat), these polymers produced progressive reductions in post-prandial glucose of up to 70% following standardized caloric loads. Improvements in fasting plasma glucose, HOMA-IR, and bodyweight were also observed. The aim of this study was to visualize the retained duodenal barrier in rats using appropriate imaging modalities.

Materials and methods: Imaging of GLY200 after gavage administration to fasted Sprague-Dawley rats was performed using 2 methods: Computed Tomography (CT), and an In Vivo Imaging System (IVIS). For CT imaging, GLY200 was covalently conjugated with diatrizoate via an efficient amide forming reaction and unconjugated diatrizoate was administered as a control. CT images were obtained after transient isoflurane administration 1, 2, and 4 hours after gavage. For IVIS imaging, GLY200 was reacted with FITC to produce a fluorescein-GLY200 conjugate, and FITC-dextran70 was administered as a control. Rats were euthanized 0.5, 1.0, 2, 4, and 8 hours after dosing and the GI-tracts were immediately removed for imaging.

Results: CT imaging (see figure) clearly demonstrated retention of GLY200-diatrizoate within the proximal small intestine 1- and 2-hours after administration, with an intense signal only in the duodenum. In comparison, the diatrizoate control was broadly distributed over the small intestine distal to the duodenum by 1-hour. In IVIS imaging, GLY200-FITC showed intense fluorescence in the proximal small intestine that persisted for 4-hours after administration and was undetectable by 8-hours. In comparison, FITC-dextran70 was distributed broadly throughout the distal intestine and cecum by 30 minutes with no retention in the duodenum.

Conclusion: Our imaging studies confirm that GLY200 conjugate is effectively retained in the duodenum after oral administration. These observations, along with previously reported glycemic improvements in chronic rodent models of T2DM, support the hypothesis that orally administered polymers designed to target the proximal small intestinal gut wall could potentially be used to non-invasively recapitulate the glycemic and weight effects observed with metabolic surgery and duodenal exclusion devices.

Disclosure: T. Carlson: None.
**196**

**Human engineered skeletal muscle to treat insulin resistance in type 2 diabetes**

**H. Shoyhet**¹, Y. Herman¹, M. Beckerman¹, E. Karnieli², S. Levenberg¹; 
¹Biomedical engineering, Technion- Israel Technion Israel of Technology, ²Medicine, Technion- Israel Technion Israel of Technology, Haifa, Israel.

**Background and aims:** Diabetes Mellitus type II (DM2) is the most common type of diabetes, widely spread in developed countries and responsible for more than 1 million deaths every year. It is characterized by skeletal and adipose tissues insulin resistance and is usually non-insulin dependent. However, progression of the disease can cause various complications, including insulin impairment. Glucose transporter type 4 (GLUT4), mainly expressed in skeletal muscle tissue, is the key factor in glucose homeostasis overall and in DM2 specifically; Many studies have shown reduction in GLUT4 expression and translocation levels in DM2 patients. Therefore, we hypothesize GLUT4 can be part of the solution. Previous study in our group showed that implantation of GLUT4 over-expressing (GLUT4 OE) mouse skeletal muscle tissue in diabetic mice can improve blood glucose levels. To bring the technology closer to the clinic, we aim to prove that the concept works in human cells as well. Moreover, to improve patient’s compliance, less invasive delivery methods must be developed. In this study we have two aims: 1. Engineer GLUT4 OE human skeletal muscle tissue and implant it in diabetic mice. 2. Develop a new delivery method of the engineered skeletal muscle tissue using minimally invasive procedure

**Materials and methods:** Human myoblasts are genetically modified to overexpress GLUT4 via viral transduction. The cells are seeded on 3D PLLA/PLGA scaffolds for differentiation and maturation. The 3D tissue is characterized using immunostaining and glucose uptake assays to assess their anti-diabetic properties. The scaffolds are implanted in diabetic mice, and their blood glucose levels are monitored prior and following implantation. We have also developed a novel scaffold to deliver the functional muscle tissue using non-invasive procedure. The scaffold is characterized using the same methods listed above. We are also assessing the scaffolds mechanical properties and injectability.

**Results:** We have genetically modified human myoblasts to overexpress GLUT4. The modified cells can be grown on 3D PLLA/PLGA scaffolds and differentiated to functional skeletal muscle tissue. Immunostaining and molecular assays are used to characterize and quantify the GLUT4 expression. Glucose uptake assays show the engineered tissue has ~50% (p>0.05) enhanced uptake capacity compared to WT cells. We also developed new scaffold to deliver functional skeletal muscle tissue via injection. The novel injectable scaffold was fine-tuned to enable skeletal muscle growth and differentiation which was confirmed via immunostaining for myogenic markers. Tissue survival and functionality following injection were assessed using Alamar-Blue and glucose uptake assays showing no significant differences prior and following injection. Glucose uptake assays also confirm that GLUT4 OE skeletal muscle tissue can develop on the scaffold.

**Conclusion:** New routes to treatment for type II diabetes are needed to fight this global issue. We present a concept of therapy based on GLUT4 and skeletal muscle tissue engineering. Preliminary results indicate this approach has great potential to tackle one of the key issues in type II diabetes and insulin resistance.

**Supported by:** RAS fund, TEVA fellowship

**Disclosure:** H. Shoyhet: None.

**197**

**Oral long-acting menin inhibitor normalises type 2 diabetes in two rat models**

**T. Butler,** S. Mourya, W. Li, B. Law, T. Archer, T. Kinoshita, P. Somanath;

**Biomea Fusion, Inc., Redwood City, USA.**

**Background and aims:** Menin is a scaffold protein that has been recognized for its role in T2DM as a key regulator of β-cell proliferation. Menin inhibition has previously been shown to improve glycemic control in diabetic mice. Herein, we report the first evidence that BMF-219, an orally bioavailable, selective, covalent menin inhibitor, restores glycemic control in Zucker Diabetic Fatty (ZDF) Rat and Streptozotocin-induced (STZ) Rat models of T2DM.

**Materials and methods:** Rats were treated daily with BMF-219, vehicle, or pioglitazone for 16 days and analyzed for fasting and non-fasting blood glucose levels, insulin, c-peptide, and blood lipemic levels. Oral Glucose Tolerance Test (OGTT) was conducted up to Day 15 in both models and two-weeks post-treatment in the ZDF model. Body weight of all rats was also monitored.

**Results:** BMF-219 was well tolerated throughout the conduct of the study. BMF-219 treatment resulted in a significant 50% reduction in fasting and non-fasting blood glucose levels, reduced serum insulin and c-peptide levels (p<0.05), and reduced HOMA-IR (p<0.001) after two weeks of treatment in ZDF rats. BMF-219 decreased glucose levels at all timepoints during an OGTT at Day 15 (AUC reduction of 54%, p<0.001) and at Day 29 (AUC reduction of 40%, p<0.05, ~2 weeks after the last dose in the ZDF model, indicating prolonged glycemic control. Strikingly, BMF-219, but not pioglitazone, reduced blood glucose levels during an OGTT in STZ animals (AUC reduction of 41%, p<0.05, see figure). Significant reductions in blood lipemic levels (p<0.01) and body weight were observed in both models.

**Conclusion:** Collectively, our data indicate the novel and marked potential of BMF-219 as an oral, long-acting treatment for T2DM.

**Disclosure:** T. Butler: Employment/Consultancy; Biomea Fusion, Inc. Stock/Shareholding; Biomea Fusion, Inc.
Materials and methods: The in vitro assays in this report were conducted in the absence and presence of human serum albumin (HSA) to demonstrate the impact of fatty acid-protraction on molecules’ potencies. In vivo tests were carried in DIO and db/db mice, and obese cynomolgus monkeys to demonstrate the pharmacological efficacy of QL1005 on body weight, food intake, plasma glucose, circulating lipids and other metabolic parameters as compared to the benchmark molecules.

Results: QL1005 is an engineered dual agonist protein, designed via fusing GLP-1 and GDF15 analogs by a peptide linker conjugated with a fatty acid for time-action extension. In cell-based assays QL1005 is superior in potency to GLP-1 analog semaglutide with its pharmacokinetic parameters are comparable to this GLP-1 agonist. When dosed in obese mice, QL1005 demonstrated dose-dependent lowering of body weight, food intake, fasting glucose and triglyceride with all these effects being greater in magnitude to the efficacy of semaglutide or long-acting GDF15. Of importance, QL1005-induced metabolic improvements come as the result of activity emanating from both therapeutic components within this dual agonist molecule, GLP-1 and GDF15. Indeed, the individual pathway-inactivated QL1005 analogs are approximately 50% efficacious compared to the parental QL1005 suggestive that this co-agonist in animals is therapeutically efficacious to treat obesity, diabetes and related co-morbidities thus demonstrating the promise of the poly-pharmacological approach in metabolic drug discovery and developments.

Disclosure: Y.Y. Zhang: None.

Conclusion: Altogether, this novel GLP-1/GDF15 fusion protein in animals reveals itself therapeutically efficacious to treat obesity, diabetes and related co-morbidities thus demonstrating the promise of the poly-pharmacological approach in metabolic drug discovery and developments.

Disclosure: Y.Y. Zhang: None.

Background and aims: Finnish-specific gene variant p.P50T/AKT2 (MAF=1.1%), is associated with higher fasting insulin concentrations, in vivo insulin resistance, and increased predisposition to type 2 diabetes. Here, we have investigated in vitro the impact of the gene variant on glucose metabolism and intracellular signaling in human primary myotubes, that were established from 14 male p.P50T/AKT2 variant carriers and 14 controls.

Materials and methods: Insulin-stimulated glucose uptake and its incorporation into glycogen were detected with [3H]-2-Deoxy-D-glucose and [14C]-D-Glucose, respectively, and the rate of glycolysis was measured with Seahorse XF96 analyzer. Insulin signaling was investigated with Western blotting. Binding of the p.P50T/AKT2 and control-form PH domains to phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P3) was assayed using PIP Strips™ Membranes.

Results: Insulin increased glucose uptake and glycogen synthesis in human primary myotubes, with no difference between p.P50T/AKT2 variant carriers (n=10) and controls (n=8) (2-way ANOVA with repeated measures). Insulin-stimulation led to a significant increase in glycolytic rate (p<0.001) and in compensatory glycolysis (p<0.01) in control myotubes (n=14), but not in p.P50T/AKT2 variant myotubes (n=14, p=NS). Comparison between the genotypes revealed a significant reduction in insulin-stimulated glycolysis and compensatory glycolysis in myotubes from p.P50T/AKT2 variant carriers (p<0.05, 2-way ANOVA). Insulin-stimulated phosphorylation of AKT-Thr308 (p<0.05), AS160-Thr223 (p<0.05) and GSK3β-Ser9 (p<0.05) was reduced in p.P50T/AKT2 variant carriers (n=10) compared to controls (n=8) (2-way ANOVA with repeated measures). Binding of the variant form of p.P50T/AKT2-PH domain to PI(3,4,5)P3 was reduced when compared to the control protein (p<0.001, n=4 repeated assays, unpaired t-test).

Conclusion: p.P50T/AKT2 leads to impaired insulin signaling in human primary myotubes, which may be a result of a defective PI(3,4,5)P3-binding capacity of the p.P50T/AKT2-PH domain.

Supported by: Diabetes Wellness Sverige, Finnish Diabetes Research Foundation, Finska Läkaresällskapet.

Disclosure: S. Mäkinen: None.

Role of Diacylglycerol kinase δ in skeletal muscle glucose metabolism in type 2 diabetes

F. Tramontana, M. Kuefner, A. Krook, J.R. Zierath; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Background and aims: Reduced Diacylglycerol Kinase δ (DGKδ) protein abundance and activity have been observed in skeletal muscle from people with type 2 diabetes (T2D), resulting in increased diacylglycerol (DAG) levels - a widely recognized lipotoxic mediator of insulin...
resistance. Thus, downregulation of DGKδ may play a role in the regulation of DAG and the development of insulin resistance in type 2 diabetes. However, the underlying mechanisms by which reduction of DGKδ levels lead to the development of insulin resistance are still unknown. We hypothesized that lower of DGKδ in skeletal muscle impairs glucose homeostasis by disrupting the canonical insulin signaling pathway, thus contributing to skeletal muscle insulin resistance.

Materials and methods: Primary human skeletal muscle cells were isolated from vastus lateralis biopsies obtained from people with type 2 diabetes (n=6) or normal glucose tolerance (NGT) (n=6). Cells were differentiated to mature myotubes and transfected with DGKδ siRNA (siDGKδ). Cells were harvested 48 hours after transfection, under basal and insulin-stimulated (120nM) conditions. Western blot, qPCR analysis, glycerone synthesis assay, and lactate measurements were performed to assess glucose homeostasis and insulin signaling.

Results: Cells transfected with DGKδ were characterized. DGKδ gene expression was reduced 80% after silencing. Further characterization revealed that siDGKδ silencing in myotubes derived from people with type 2 diabetes showed impaired abundance of proteins involved in the insulin signaling cascade as compared to myotube cultures derived from people with NGT. Insulin signal transduction was also impaired, including reduced pAKT T308 (-53.8%, p=0.03) and its downstream substrate, pAS160 (-47.5%, p=0.02), along with a trend towards increased levels of the inactive form of glycogen synthase (pGSI S641) (+121%, p=0.07). Moreover, insulin-stimulated levels of PKC substrates were reduced in myotubes cultured from people with T2D transfected with siDGKδ as compared to myotube cultures from people with NGT (+17.6%, p=0.07), suggesting increased PKC activity. DGKδ silencing decreased insulin-stimulated glucose incorporation into glycogen as compared to control cells (+8.9%, p=0.05), although no differences were seen between diagnosis groups. siDGKδ treatment of myotubes from people with type 2 diabetes displayed a 75% increase in lactate production under basal conditions as compared to myotube cultures from people with NGT (p<0.001).

Conclusion: Reduced levels of DGKδ may contribute to dysregulation of glucose metabolism in skeletal muscle through impairments in insulin signaling. Therefore, reductions in DGKδ abundance may further aggravate glycemic control and insulin sensitivity in type 2 diabetes. Level and activity of DGKδ may influence cellular processes as diverse as insulin signaling, glucose metabolism and energy homeostasis.

Supported by: EPSD/Novo Nordisk Programme for Diabetes Research in Europe

Disclosure: F. Tramontana: None.

201 Pharmacological inhibition of Integrin α5β1 improves insulin sensitivity in H9C2 cells and cardiac performance in obese mice
A.K. Banah, V. Musale, C.K. Hennayake, C.E. Murdoch, L. Kang; University of Dundee, Dundee, UK.

Background and aims: Extracellular matrix (ECM) remodelling has recently emerged as a key contributor to the development of insulin resistance (IR). Inhibition of ECM collagen and hyaluronan deposition by clinical and preclinical antifibrotic drugs attenuated cardiac IR and cardiac dysfunction in diet-induced obese mice. Fibronectin is a multifunctional-glycerone protein in the ECM known to communicate with cells mainly via the integrin α5β1 receptor. The present study investigated the effects of CLT-28643, an α5β1 integrin antagonist, on insulin sensitivity in H9C2 cardiomyocytes, and cardiac function in high-fat-high-sucrose (HFHS) fed obese mice.

Materials and methods: In vitro effect of ECM on insulin signalling was investigated by culturing H9C2 cells on fibronectin coated plate for 5 days followed by 15 min treatment with insulin (10nM). Furthermore, insulin resistant H9C2 cells, induced by high glucose (33.3 mM) and palmitic acid incubation (100 μM) for 24-h, were subjected to CLT-28643 treatment for 3 hrs followed by 15 min incubation with insulin (100nM). Insulin sensitivity of treated cells was examined by phosphorylation of Akt using western blot. In vivo, male C57BL/6 mice fed 45% high-fat diet and 30% sucrose water for 10 weeks received twice-daily oral gavage of either vehicle or CLT-28643 (75 mg/kg body weight) for 4 weeks. A separate group of mice fed with chow diet for 14 weeks were used as lean controls (n=8). Cardiac function was measured by Pressure-Volume (PV) loop analysis (Transonic) using PV conductance catheter in closed-chest preparation. Immunohistochemical analysis was performed to assess changes in collagen and alpha-smooth muscle actin (α-SMA) expression in the left ventricle (LV) of the heart.

Results: In H9C2 cells, FB coating decreased insulin-stimulated phosphorylation of Akt (Ser473); CLT-28643 prevented high glucose & palmitate-induced IR as indicated by an increased ratio of the phosphorylated Akt (Ser473) to total AKT compared to vehicle-treated cells (2.67 ±1.55 fold increase, P<0.05). In mice, HFHS diet resulted in significant increases in body weight (29.05 ± 0.82 (chow) vs 40.86 ± 1.34 (HFHS) gram, P<0.0001), %fat mass (15.52 ± 0.80 vs. 51.30 ± 5.89%, P<0.0001) and decreases in %lean mass (78.29 ± 0.98 vs. 58.61 ± 1.01%, P<0.0001) compared to chow-fed mice. CLT-28643 displayed a trend of decrease in %fat mass, despite no changes in body weight or %lean mass. HFHS diet impaired cardiac function in mice as evidenced by a decrease in end-systolic elastance (31.06 ± 6.23 (chow) vs 10.88 ± 1.47 (HFHS) mmHg/L, P<0.01), ejection fraction (86.14 ± 4.24 vs 72.82 ± 3.60%, P<0.05) and an increase in heart rate (554.3 ± 21.41 vs 603.7 ± 9.72 bpm, P<0.05) and ventricular arterial coupling (VAC) index (0.19 ± 0.06 vs. 0.46 ± 0.07, P<0.05) compared to lean controls. Interestingly, elevated heart rate was reversed by CLT-28643 treatment, suggesting an improved cardiac performance; while the slope of the end-systolic pressure-volume relationship (ESPVR) and end-diastolic pressure-volume relation (EDPVR) were not different among groups. Immunohistochemical analysis revealed no significant changes in LV collagen and α-SMA expression in experimental mice.

Conclusion: Pharmacological inhibition of integrin α5β1 improved insulin signalling in H9C2 cells and cardiac performance in obese mice. These findings suggest that therapies targeting FB-α5β1 interaction may be beneficial to obesity-associated cardiometabolic complications.

Supported by: BHF
Disclosure: A.K. Banah: None.

202 Impact of protein kinase D2 in the regulation of hepatic insulin sensitivity
P. Rada1,2, A.B. Hitos1,2, E. Rey3, E. Carceller-López1, J. Pose-Utrilla1,4, C. García-Monzón4, G. Sabio4, T. Iglesias1,4, A. González-Rodríguez2,3, A.M. Valverde1,2.
1Instituto de Investigaciones Biomédicas Alberto Sols (CSIC/UAM), 2Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 3Instituto de Investigación Sanitaria Princesa, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERHEID), 4Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 5Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.

Background and aims: Protein Kinase D2 (PKD2) is a Ser/Thr kinase of the Ca2+-Calmodulin kinase superfamily. Recently, emerging evidences indicate that PKD2 regulates glucose homeostasis in several tissues. Two previous studies, one in global PKD2-null mice, and other in mice lacking PKD2 in intestine, reported opposite results with metabolic dysfunction or protection against High Fat Diet (HFD)-induced obesity, respectively. Given that insulin resistance is a key initial trigger for NAFLD.
progression, unravelling PKD2 contribution to the initial stages of this disease will add fundamental knowledge to metabolic liver dysfunction with potential therapeutic value.

Materials and methods: PKD pharmacological and genetic inhibition was analyzed in primary hepatocytes and in Huh7 cells. Huh7 cells were transfected with EFGP-PKD2-CA, a constitutively active PKD2 fused to EGFP. Insulin signalling was examined in hepatocytes stimulated with insulin (10 nM, 5-15 min). As an in vivo model of hepatic insulin resistance, mice with a liver-specific PKD2 depletion (PKD2Δhep) were fed HFD. Parameters assessing glucose homeostasis and hepatic insulin sensitivity were analyzed. PKD2 was overexpressed in liver by an injection of AAV-EGFP-PKD2-CA and insulin sensitivity was evaluated. PKD signature was analyzed in liver biopsies from NAFLD patients.

Results: PKD pharmacological inhibition resulted in higher AKT phosphorylation upon insulin stimulation in both primary mouse hepatocytes (p<0.001, n=5) and Huh7 cells (p<0.01, n=6). Similar results were obtained in PKD2Δhep hepatocytes (p<0.05, n=5) in which IRS1 was upregulated (p<0.001, n=6). Moreover, PKD2 knocking down by shRNA enhanced the insulin response (p<0.01, n=8). Alternatively, EGFP-PKD2-CA overexpression reduced insulin-stimulated AKT phosphorylation compared to EGFP-transfected cells (p<0.01 t=5 min; p<0.001 t=15 min; n=4-10). In this line, in vivo injection of AAV-EGFP-PKD2-CA resulted in moderate impairment of glucose homeostasis and reduced IR and AKT phosphorylation in liver (p<0.05 pIR, pAKT(Ser473); p<0.001 pAKT(Thr308), n = 5-6 mice/group). Importantly, HFD-fed PKD2Δhep mice displayed a tendency to improve glucose tolerance and insulin sensitivity compared to control mice, being statistically significant at different time points (GTG: p<0.05 at 15 min; ITT: p<0.05 at 30, 60 and 90 min; PTT: p<0.05 at 60 min) (n=7-10 mice/group). Our preliminary data showed an increase in insulin-induced AKT phosphorylation in livers from HFD-fed PKD2Δhup mice compared to controls. Moreover, PKD immunostaining showed that PKD2 was increased in NAFLD patients.

Conclusion: Results herein strongly suggest a role of PKD2 in the control of hepatic insulin signalling and point PKD2 as a new therapeutic target in the progression of hepatic insulin resistance-related pathologies.

Supported by: MICINN RTI2018-094052-B-100; CAM S2017/BMD-3684; CIBERDEM (ISCIII)

Disclosure: P. Rada: None.

204

Abrogation of circular dorsal ruffles by hyper insulinemia impairs insulin receptor internalization and recycling

A. Teshima1, M.A. Correia1, L.M. Oliveira1, D.C. Barral1, R.M. de Oliveira1, M.P. Macedo1,2

1Chronnic Diseases Research Centre (CEDOC), NOVA Medical School, Faculdade de Ciencias Medicas, Universidade NOVA de Lisboa, Lisbon
2Department of Medical Science, Departamento de Ciencias Medicas, Universidade de Aveiro, Aveiro, Portugal.

Background and aims: Insulin resistance is a hallmark for type 2 diabetes mellitus (T2DM) and occurs when the body cannot respond appropriately to circulating insulin levels. Hyperinsulinemia is both a trigger and a consequence of insulin resistance. Insulin mediates its physiological effects through binding to the extracellular subunit of the insulin receptor (InsR) at the plasma membrane. Impairing the activity of any component of this complex, from insulin binding to InsR internalization, trafficking and signal propagation, can lead to insulin resistance. However, how altered InsR internalization contributes to the development of insulin resistance and T2DM is understudied. Ligand-activated InsR is internalized and trafficked to early endosome (EE), where InsR is dephosphorylated and sorted. InsR can be subsequently conducted to lysosome for degradation or recycled back to the plasma membrane. Previous results from our group showed that InsR is internalized through actin-rich ring-shaped structures circular dorsal ruffles (CDRs), which form exclusively at the dorsal surface of hepatocytes, upon insulin stimulation. Our group also showed that chronic exposure to elevated insulin concentration inhibits CDRs formation. Having these findings in mind, we hypothesized that inhibition of CDRs formation by exposing hepatocytes to hyper insulin concentration compromises InsR internalization and subsequent trafficking to EE and recycling to membrane.

Materials and methods: Hepa 1-6 mouse hepatoma cells were used to study InsR internalization and subsequent trafficking. Cells were maintained in normal medium or, to mimic hyperinsulinemia condition, they were maintained in medium supplemented with 200 nM of insulin for 48h. Cells were serum-starved for 3 hours, then stimulated with 100nM insulin for 1, 3, 15 and 30 mins. To observe EE and recycling endosomes (RE), cells were fixed and processed for immunofluorescence, being labeled with EEA1, a marker for EE, and Rab1a a marker for RE and colocalization was measured respectively.
Results: We observed that in normal condition, InsR colocalizes with EEA1 peaking at 5 minutes, then we observed a decrease of colocalization along time, suggesting that the vesicles containing InsR are maturating along the endocytic route. On the other hand, hyper insulin incubated cells, mimicking prediabetes, showed significant decrease of InsR colocalization with EEA1 in every timepoint, indicating an abrogation of the internalization in early endocytosis. Subsequently, we looked at recycling endosomes by staining for Rab11a. While in control condition Rab11a co-localizes with InsR at 15 minutes upon insulin stimulation, when CDR formation is blocked in cells exposed to chronic hyperinsulin, recycling to the plasma membrane is impaired.

Conclusion: Here we show for the first time that hyperinsulinemia inhibits InsR internalization through CDRs and subsequent trafficking to EE and RE. In toto, our results suggest that abrogation of CDRs formation in a condition mimicking prediabetes impairs InsR internalization and thus contributing to the onset and/or exacerbation of insulin resistance.

Supported by: PTDC/MEC-MET/29314/2017, UIDB/Multi/04462/2020, Programa Gilead GÉNESE—Edição de 2019
Disclosure: A. Teshima: None.

OP 35 Different pathways involved in killing the beta cell

205 IER3IP1 mutations lead to ER stress-induced neonatal diabetes
H. Montaser, S. Leppänen, H. Ibrahim, S. Eurola, J. Saarimäki-Vire, T. Otonkoski;
University of Helsinki, Helsinki, Finland.

Background and aims: IER3IP1, a highly conserved protein in humans, is highly expressed in the developing brain cortex and β-cells. The endoplasmic reticulum-transmembrane protein is thought to play a major role in regulating ER secretion and cell apoptosis. Homozygous mutations in IER3IP1 have been associated with neonatal diabetes and microcephaly. The aim of this study is to characterize the role of IER3IP1 in the development, function, and survival of human β-cells using human embryonic stem cell (hESC)-derived pancreatic islets (SC-islets).

Materials and methods: Utilizing CRISPR/Cas9, we deleted the first exon of IER3IP1 in hESCs to generate a knockout (KO) model. Alongside their wild-type (WT) counterparts, the KO clones were differentiated into SC-islets using an optimized 7-stage protocol. The effect of IER3IP1-KO on β-cell development was characterized using flow cytometry, qPCR, and immunohistochemistry for β-cell and ER stress markers. Additionally, the survival of IER3IP1-KO β-cells was tested by treating the cells with chemical ER-stress inducers and measuring their apoptosis using TUNNEL assay. Furthermore, the functionality of SC-islets was tested in-vitro through glucose-stimulated insulin secretion assay, and in-vivo after implanting the SC-islets under the kidney capsule of immunodeficient mice.

Results: We confirmed the successful generation of IER3IP1-KO hESC clones using Sanger sequencing and qPCR. Intriguingly, IER3IP1-KO SC-islets showed significantly lower percentage of β-cells (41% in WT vs 21% in KO, p= 0.001, n= 3), reduced INS transcript levels, and drastically diminished insulin content (766 ng hINS/μg DNA in WT vs 111 ng hINS/μg DNA, p= 0.02, n= 3). Additionally, immunostaining of IER3IP1-KO β-cells showed notably higher accumulation of proinsulin, and significantly higher levels of the ER stress marker BiP when compared to their wild-type controls. Furthermore, IER3IP1-KO β-cells were more vulnerable to apoptosis upon inducing ER stress using chemical stressors. Testing their functionality, IER3IP1-KO SC-islets were able to respond to high glucose treatment by increasing their insulin secretion; however, their total insulin secretion was substantially lower than WT SC-islets. Moreover, the levels of circulating human C-peptide detected in mice implanted with WT SC-islets were significantly higher than those detected in the mice with KO implants, since the first month of implantation (606 pmol/L human C-peptide in WT-grafted mice vs 82 pmol/L human C-peptide in KO-grafted mice, p= 0.009, n= 3). After three months of implantation, the WT grafts were able to regulate the blood glucose during an intraperitoneal glucose tolerance test, while the KO grafts failed to upregulate their C-peptide secretion and the mice showed impaired glucose tolerance.

Conclusion: Our results indicate the essential role of IER3IP1 in maintaining normal ER homeostasis and regulating the function and survival of human beta cells.

Supported by: ILS doctoral program, UH and Orion research foundation.
Disclosure: H. Montaser: None.
206

Inhibition of the type 1 diabetes candidate gene PTPN2 aggravates tumor necrosis factor alpha-induced human beta cell dysfunction and death

A. Roca Rivada, S. Marin Cañas, M.L. Colli, D.L. Eizirik; ULB Center for Diabetes Research, Université Libre de Bruxelles, Brussels, Belgium.

Background and aims: Tumor necrosis factor alpha (TNF-α) is a proinflammatory cytokine produced by macrophages/monocytes during acute inflammation. The cytokine plays a role in insulitis and pancreatic beta-cell loss in type 1 diabetes mellitus (T1D) and a phase 2 clinical study showed that TNF-α inhibition in newly diagnosed T1D patients preserves C-peptide production (PMID: 33207093). In this study, we evaluated the effects of TNF-α (as compared to type I IFNs, previously shown by us to be affected by PTPN2) in human pancreatic beta-cells silenced for the protein tyrosine phosphatase PTPN2, a candidate risk gene for T1D.

Materials and methods: EndoC-βH1 cells, dispersed human islets, and iPSC-derived beta-like cells were transfected with siCTRL, siPTPN2, siJNK1, or siBIM. After 24h of recovery cells were left untreated (vehicle) or treated for 48h with IFN-α (2000 units/mL), TNF-α (1000 units/mL), or the combination IFN-α + TNF-α (2000 and 1000 units/mL respectively). Apoptosis was evaluated using Hoechst and propidium iodide staining; mRNA levels were assessed by RT-PCR. PTPN2, pJNK1, pP38, pBIM, and GAPDH protein expression were examined by immunoblot. Results are the mean of 6-7 independent experiments; statistical analysis was done by one-way ANOVA with Bonferroni correction.

Results: 48 hours treatment with IFN-α or TNF-α in EndoC-βH1, dispersed human islets or iPSC-derived β-like cells silenced for PTPN2 induced a significant increase in cellular apoptosis (17.7-50.5% for IFN-α, and 26.5-50.5% for TNF-α; P < 0.01) compared to cells exposed to the cytokines without PTPN2 silencing); a similar result was observed with the combination of IFN-α + TNF-α (24.7-43.8%; P < 0.01 in iPSC-derived β-like cells, and P < 0.01 in EndoC-βH1 cells and dispersed human islets). There was no potentiation between IFN-α + TNF-α suggesting that these cytokines may act through a similar intracellular pathway. To test this hypothesis, we co-silenced PTPN2 and JNK1 or BIM, known to be involved in IFN-induced apoptosis, in EndoC-βH1 and iPSC-derived β-like cells (>50-60% silencing each). This abolished the proapoptotic effects of IFN-α, TNF-α, or the combination of both cytokines with (P < 0.05) or without TNF-α inhibition (P < 0.01). Interestingly, silencing PTPN2 increased by 2-fold TNFα-induced phosphorylation of JNK1 (P < 0.05), P38 (P < 0.01) and BIM (P < 0.01), suggesting a critical and protective role for PTPN2 against TNF-α toxic effect in beta-cells. These findings also point to an unexpected common pathway for signaling between IFNα and TNFα.

Conclusion: TNF-α has been shown to play a role in the pathogenesis of human T1D. We presently show that PTPN2 is a key regulator of the deleterious effects of TNF-α in human beta-cells. PTPN2 is a candidate risk gene for T1D, and it is conceivable that patients carrying risk-inducing PTPN2 polymorphisms may particularly benefit from therapies targeting TNF-α.

Disclosure: A. Roca Rivada: None.

207

GDF11 improve age-dependent beta cell deterioration in mouse and man

R. Wu;
Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.

Background and aims: GDF11 is a member of the transforming growth factor (TGFβ) superfamily. An age-dependent decline in serum GDF11 levels can be observed in multiple mammalian species. In mice, GDF11 treatment protects glucotoxicity-induced beta-cell dysfunction and apoptosis. GDF11 deficient mice exhibit decreased beta-cell mass and reduced expression of MafA in beta cells during embryonic development. However, the roles of GDF11 in the regulation of age-related cell functions are rather controversial. Here we aim to explore the underlying function of GDF11 in controlling beta-cell deterioration in ageing rodents and islets from human donors.

Materials and methods: All human islets were collected from the Nordic Network for Islet Transplantation (Uppsala University, Sweden) via EXODIAB Human Tissue Lab in Lund University Diabetes Centre. In vivo insulin secretion experiments and immunostaining were performed in human islets from 7 non-diabetic and 3 diabetic donors with > 50 years of age. Aged diabetic db/db mice (24 weeks) and GK rats were used in the study. The db/db mice were intraperitoneally injected with GDF11 (100 ug/kg body weight) or vehicle (12 mice in each group) every other day for 30 days. Blood samples were collected from vena in the mice, and both blood glucagon and insulin were analyzed by ELISA. Blood glucose was also measured during the period of GDF11 injection and continued for 5 months. A 100 ng/mL GDF11 was used for in vitro experiments in the insulin-secreting INS-1 832/13 cells, primary rodent and human islets for three days.

Results: In our study, we found GDF11 expression was reduced by more than 80% in the aged human donors (~66 years old) with diabetes in comparison with non-diabetic donors (n=3, p<0.01). Similarly, GDF11 expression was 50% lower in diabetic GK rats than Wistar rats (n=3, p<0.01). After GDF11 treatment, Pdx1, the transcription factor indicating pancreatic beta cell identity, significantly increased (n=3, p<0.01). Notably, injection of GDF11 in aged db/db mice decreased both blood glucose and blood insulin significantly, while the blood glucose continued to be improved even 150 days after withdrawal of treatment (n=3, p<0.05). GDF11 treatment elevated insulin content in both diabetic human islets (n=3, p<0.01) and INS1 832/13 cells (n=3, p<0.005). Notably, glucose-stimulated insulin secretion appeared to be affected differentially in the GDF11-treated isolated islets from db/db mice: increased at low secretion rates (n=4, p<0.05) but decreased at high secretion rates (n=4, p<0.01).

Conclusion: Our findings suggest a novel role of GDF11 in reversing the age-dependent decline in beta-cell function and therefore hold promise for therapy of age-related diabetes.

Supported by: The Swedish Research Council (2019-01567, 2018-03238); Clinical research (ALF); Crafoord foundation
Disclosure: R. Wu: None.

208

Insulin, proinsulin and PC1/3 expression heterogeneity and beta cell function in diabetes

P.S. Apaolaza Gallegos1, Y.C. Chen2, K. Grewal2, Y. Lurz2, B. Vercher2, T. Rodriguez-Calvo1;
1Helmholtz Zentrum München, Munich, Germany, 2Department of Surgery, University of British Columbia, Vancouver, Canada.

Background and aims: The detection of proinsulin (PI), insulin (INS), or C-peptide in the blood may help predict the delay in beta-cell mass and function during diabetes progression. However, their expression in the pancreas is still not well-understood. Thus, we aimed to provide an in-depth characterization of INS, PI, and the prohormone convertase PC1/3 (PC1) expression in the islets of non-diabetic (ND), autoantibody-positive (AAab+), type 1 diabetic (T1D) and type 2 diabetic (T2D) donors using confocal imaging and state-of-the-art image analysis. Moreover, we investigated islet beta-cell phenotype and islet morphology during disease progression.
Materials and methods: FFPE-Pancreatic sections from 20 age-matched ND, 7 AAb+ (4 single (s) and 3 double (d)), 8 T1D with short disease duration (<5y), 9 with long-duration T1D (>15y), and 6 T2D donors were included in the study. Confocal microscopy images for INS, PI, and PC1 from up to 30 islets/donor were analyzed using the software QuPath. Different cell populations were defined as follows: 1) INS+P1+P1C1+, triple+; 2) INS+P1+P1C1-, INS+P1-PI+P1C1, INS-P1+P1C1+ double+; and 3) INS+P1-PI-1, INS+P1-PI-1, INS-PI-1PI-1 single+ cells. Proportion and density (number of cells/islet area) of each population as well as islet cellularity/ morphology were analyzed. The sum of triple+, double+, and single+ cells was used to determine total INS+, PI+, and PC1+ cells.

Results: In dAAb+, in comparison with the ND group, the density, and proportion of INS+P1-PI-1+ and INS-PI-1PC+1 cells was increased, while there was a decrease in INS+P1-PI1+ cells, suggesting active PI and insulin cellular accumulation without high PC1 expression. After onset, the proportion and density of total+ and triple+ (INS+P1+PC1+) cells were low in most T1D donors due to beta-cell loss. Conversely, INS- PI-PI+1 doubled, and INS-PI-PI+1 increased between 16% and 40% in T1D, and 5% in T2D compared to ND donors. No differences were observed in INS-PI+PC1+ cells among groups, with the exception of T1D (>15y) donors (8 times lower values). In general, single PI+ or INS+ cells were rare. The study of islet morphology revealed that the number of cells per islet was comparable in all groups while endocrine cell density was reduced in dAAb+ donors, yet increased in all T1D and T2D donors compared to ND donors. Last, no differences were found between ND and sAAb+ donors in all categories.

Conclusion: Beta-cells undergo functional and morphological changes as diabetes progresses. We observed a decrease in cells expressing INS, PI, and PC1 from dAAb+ to T1D, reflecting the ongoing beta cell loss. Changes in distinct double+ cell subpopulations may represent different stages of beta-cell dysfunction, as suggested by the increase in cells lacking PC1 in the islets of dAAb+ donors. Conversely, the increase in single PC1+ cells in T1D and T2D could be due to an increase in PC1+ alpha cells, possibly driven by dedifferentiation or to the presence of beta cells that cannot produce PI and INS. Lastly, islet morphological analysis suggests that beta-cell hypertrophy first and then atrophy might occur during disease progression. Our findings reveal intriguing dynamics of proinsulin/insulin production and conversion and could contribute to our understanding of diabetes pathogenesis at a beta-cell level.

Disclosure: P.S. Apaolaza Gallegos: None.

Materials and methods: WT and Ffar1 KO Bl6Ncr1 mice harboring a RIP-Cre driven EGFP expression were bred and 1, 6, 11 and 26d old offspring (P1, P6, P11, P26) were used for analysis. Pancreatic insulin content was measured in P1-P26 pancreatic. Beta cell proliferation and mass were determined in P1-P26 pancreatic sections by estimating the number of Ki67-stained/EGFP-positive islet cells and the EGFP-positive islet area, respectively. Insulin secretion was performed in static incubations with WT and Ffar1 KO P6 islets using palmitate (600 and 60 μM), TUG469 (FGFT agonist, 10 μM), exendin-4 (GLP-1R agonist, 100 nM), FR900359 (Gq inhibitor, 1 μM), pertussis toxin (PTX, Go/Gi inhibitor, 100 ng/ml), CT3 toxin (RhoA inhibitor, 2 μg/ml) and H1152 (ROCK inhibitor, 1μM).

Results: WT islets displayed glucose (12 mM) stimulated insulin secretion (GSIS, 6-fold change (FC) over 2.8G) mirroring the ongoing functional maturation. WT islets showed also a robust secretion in response to palmitate (600 μM) and exendin-4 (5-FC over 12G). In KO islets both glucose- and palmitate-stimulated insulin secretion were impaired, indicating that FFA1 signalling is critical for both secretagogues. As expected, palmitate (60 μM)- and TUG469-stimulated (2.25- and 3.4-FC over 12G, respectively) insulin secretion was inhibited by FR900359 (0.34- and 0.13-FC over 12G, respectively) in WT islets. Surprisingly, Gq inhibitor canceled also GSIS (from 10.6- to 1.7-FC over 2.8G) of WT islets. When the inhibitory Go/ Gi signalling was blocked with PTX, GSIS was massively increased (100-FC over 2.8G), an effect that was up to 90% inhibited by FR900359 in WT islets. Noteworthy, PTX rescued GSIS in KO islets (from 1.6- to 11-FC over 2.8G). In addition, inhibition of RhoA and ROCK improved GSIS in KO islets. The secretory defects of KO islets do not originate in insufficient insulin production, since pancreatic insulin content increased with offspring’s age irrespective of Ffar1 genotype. Deletion of Ffar1 augmented beta cell proliferation in P6 offspring. Nevertheless, we found no genotype-driven differences in beta cell mass of P1-P26 offspring.

Conclusion: These findings indicate that (i) glucose responsiveness of the neonatal islets fully depends on active Gq and (ii) FFA1/Gq inactivation unlocks Go/Gi- and G12/13/RhoA/ROCK-mediated signals with negative impact on GSIS. Thus, FFA1/Gq signaling is essential for the gain of function of neonatal beta cells.

Supported by: 01GI0925

Disclosure: F. Gerst: None.

210 Oral administration of the small molecule cathepsin S inhibitor LY3000328 accelerates disease onset and impairs glucose tolerance in non-obese diabetic mice

T. Floye1, C. Friorp1, M. Hauptsärgers2, L.J. Holm3, K. Pedersen4, M.O. Mønsted2, K. Buschard1, J. Stirling1,3, F. Pociot1,4; 1Translational Type 1 Diabetes Research, Clinical Research, Steno Diabetes Center Copenhagen, Herlev, 2Bartholin Institute, Department of Pathology, Rigshospitalet, Copenhagen, 3Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 4Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Background and aims: Accumulating data suggest a role for lysosomal cathepsin S proteases in β-cell destruction and development of type 1 diabetes (T1D). We recently showed that cathepsin S (CTSS) is upregulated by proinflammatory cytokines in human pancreatic islets and β-cell lines. CTSS is increased in plasma from individuals with TID compared to healthy individuals. Previous studies have investigated the involvement of CTSS in autoimmune diabetes and regulation of blood glucose, however, whether CTSS has protective or deleterious effects is not clear. The aim of this study was to confirm that circulating CTSS is increased in individuals with TID and to examine if oral administration of the CTSS
inhibitor LY3000328 affects autoimmunity, glucose tolerance, and diabetes incidence in non-obese diabetic (NOD) mice.

**Materials and methods:** CTSS was measured in serum from 148 children with T1D and 147 healthy siblings by ELISA (CV%<10). NOD mice were fed chow diet with LY3000328 ~10 mg/kg/day (CTSSi) or a standard diet (CTRL) from 3 weeks of age throughout life. Mice were euthanized at diabetes diagnosis (defined as two blood glucose measurements >12 mmol/l with an interval of two days) or at 310 days of age. 13-weeks-old mice were used for investigation of glucose tolerance and insulitis. Three days post intravenous glucose tolerance test, mice were anaesthetized for collection of heart blood (serum), pancreas, and spleen. Insulitis was evaluated from H&E stainings of pancreatic sections. Serum concentrations of IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-10, TNFα, IP10, KC/GRO, MCP-1, MIP-1α, and MIP-2 were measured by MSD multiplex immunoassays. The effect of LY3000328 on CTSS activity was examined in serum using CTSS activity assay and in spleen by immunoblotting of the CTSS substrate invariant chain p10 (lip10).

**Results:** Serum CTSS was increased by 8% in children with T1D compared to healthy siblings (p<0.01). Oral administration of LY3000328 led to increased diabetes incidence (CTRL, n=20; CTSSi, n=20; p<0.01) and lower glucose tolerance (CTRL, n=7; CTSSi, n=6; p<0.05) in NOD mice. There were no differences in weight, food intake, water intake, or insulitis score (p>0.05). Oral administration of LY3000328 correlated with lower serum levels of IL-6 (CTRL, n=8; CTSSi, n=4; p<0.05). CTSS inhibition was confirmed by detecting lower CTSS activity in serum (CTRL, n=8; CTSSi, n=5; p<0.001) and accumulation of lip10 in spleen from mice treated with LY3000328 (CTRL, n=8; CTSSi, n=5; p<0.0001).

**Conclusion:** Our results demonstrate that LY3000328-mediated inhibition of CTSS accelerates onset of autoimmune diabetes and impairs glucose tolerance, suggesting that CTSS may have a protective role during development of T1D. CTSS may regulate β-cell sensitivity via IL-6 which previously has been shown to have a protective effect on β cells.

**Supported by:** JDRF, DFF/FSS

**Disclosure:** T. Fløyel: None.

OP 36 Central aspects of diabetes

### 211

**Involvement of hypothalamic de novo ceramide synthesis in central resistin-induced glucose intolerance: impact on hypothalamic and hepatic inflammation**

J. Guittton1, C. Alexandre1, M. Taouis1, M. López2, Y. Benomar1, H. Le Stunff1;

1Institut des Neurosciences Paris-Saclay (NeuroPSI), Saclay, France,
2Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Santiago de Compostela, Spain.

**Background and aims:** In obesity, ectopic lipid accumulation in non-adipose tissues causes functional impairments in several metabolic pathways leading to lipotoxicity that promotes peripheral inflammation and insulin resistance (IR). Recently, the hypothalamus, a brain area involved in energy homeostasis, has also been reported as a target of lipotoxicity. Interestingly, it has been shown that accumulation of reactive lipid species, such as ceramide, in the hypothalamus induces central IR and impaired glucose homeostasis. Besides, in an over-nutrition environment, the hypothalamus is also subjected to changes in circulating factors such as resistin, a key mediator linking obesity with IR and type 2 diabetes. Recently, we have reported that resistin induces whole body IR and promotes hypothalamic inflammation. Moreover, several studies reported resistin as a regulator of peripheral lipid metabolism impairing insulin sensitivity through a central mechanism. In this context, we investigated the potential involvement of hypothalamic de novo ceramide synthesis in central resistin-induced hypothalamic inflammation and dysregulation of glucose homeostasis.

**Materials and methods:** C57BL/6J mice (n=5/group) were intracerebroventricularly (ICV) infused with resistin for 15 days. To investigate the role of hypothalamic de novo ceramide synthesis in ICV resistin-induced hypothalamic inflammation and glucose intolerance we selectively knocked down the serine palmitoyltransferase (SPT) 1, a de novo ceramide synthesis enzyme, in the hypothalamus through stereotaxic adenovirus injection (shRNA-SPT1) into the third ventricle. In the hypothalamus, we evaluated microgliosis and astrogliosis by immunohistochemistry. Hypothalamic and hepatic inflammation as well as enzymes driving gluconeogenesis were evaluated by RTqPCR. Glucose homeostasis was assessed by an intraperitoneal glucose tolerance test (IP-GTT).

**Results:** Injection of shRNA-SPT1 adenovirus in the third ventricle decreases hypothalamic SPT1 mRNA expression by 62% (p<0.001). Resistin ICV infusion induces hypothalamic inflammation as evidenced by increased IL-1β expression (p<0.01) in association with significant changes in microglia and astrocyte morphology in the hypothalamus as a sign of reactive gliosis. Concomitantly, ICV resistin-treated mice exhibit marked glucose intolerance and increased hepatic expression of key proinflammatory markers IL-6 (p<0.05), TNFα (p<0.05), IL-1β (p<0.01) and NF-Kβ (p<0.01) in addition to the upregulation of hepatic glucose 6-phosphatase (p<0.05) as a sign of increased hepatic gluconeogenesis. Importantly, the selective deletion of SPT1 in the hypothalamus prevents ICV resistin-induced hypothalamic inflammation. At the periphery, hypothalamic down-regulation of SPT1 improves glucose tolerance by counteracting hepatic inflammation and gluconeogenesis induced by resistin.
Conclusion: These findings reveal hypothalamic de novo ceramide synthesis as a new regulatory pathway of resistin-induced hypothalamic inflammation and dysregulation of glucose homeostasis. Targeting this signaling pathway may constitute a significant breakthrough to overcome obesity-induced hypothalamic inflammation and related metabolic dysfunction.

Supported by: SFD Société Francophone du Diabète
Disclosure: J. Guitton: None.

212
Effect of high fat diet and exendin 4 on inhibitory neurotransmission markers and insulin signalling in the brain in high fat fed mice
V. Sancho1, A. Faraoe2, A. Dardano1, S. Del Prato1, M. Mainardi1,2, G. Daniele1;
1Clinic and Experimental Medicine, Pisa University, 2Laboratory of Biology, Scuola Normale Superiore, 3National Research Council, Pisa, Italy.

Background and aims: Brain plasticity (induced by visual deprivation) is modulated by the tone of GABAergic neurotransmission. In a previous study, we have shown that visual cortical plasticity was altered in morbidly obese patients, and it is completely rescued 6 months after bariatric surgery. Brain plasticity improvement was related to increased GLP-1 levels post-RYGB. To shed light on the molecular mediators of this effect, we explored the impact of high-fat diet (HFD) on GABA and insulin signaling in the visual cortex and hippocampus of HFD mice. We also have assessed Exendin-4 (Ex4; a GLP-1 agonist) effects on the same molecular pathways.

Materials and methods: 60-days old male C57BL/6J mice were fed HFD (23% proteins; 42% CHO - 28% starch, 9% sucrose, 5% maltodextrin; 34% fats; 60% fat caloric content) or standard chow diet (SD: 18.5% proteins; 46% CHO - 42% starch, 4% sucrose; 3% fats; 6.55% fat caloric content) for 8 weeks followed by Ex4 (25ng/kg; N=XX) or vehicle (VC; N=XX) intraperitoneal injection administration and blood samples collection 1h post-injection, before animals were sacrificed for hippocampus and visual cortex dissection. Glycemia was determined by YLS 2300 STAT Plus glucometer and insulinemia by ELISA. Western blotting was used to assess expression levels of total and phosphorylated Akt and ERK kinases, and GABAergic markers GAD2 and vGAT, all adjusted for β-Actin expression.

Results: HFD was associated with body weight gain compared to SD (35.2±0.7 vs 32.4±0.4 g; p<0.003), hyperglycemia (319±18 vs 238.4±16 mg/dl, p<0.02) and hyperinsulinemia (72.2±19.5 vs 28.4±7.9 pmol/l, p<0.05). In HFD mice, GAD2 levels were increased by 156±15% as compared to SD (p=0.03) in the visual cortex and reduced in the hippocampus (79±4% of SD, p=0.027) with no difference in vGAT expression. As far as insulin signaling is concerned, in HFD mice, phospho-Akt expression was reduced in the visual cortex (HFD 71±9% of SD, p=0.048) and increased in the hippocampus (HFD-vehicle 139±7% of SD-vehicle, p=0.004). One hr after Ex-4, both glucose (99.8±12.0 vs 70.8±23.9 mg/dl) and insulin levels 7.9±6.5 vs 33.5±9.3 pmol/l) were decreased in HFD mice as compared to VC (both p<0.001). Ex4 did not affect Akt phosphorylation in the visual cortex of both SD and HFD mice, while a significant reduction was observed in the hippocampus of HFD mice (HFD-Ex4 99±7 vs HFD-vehicle 139±7% of SD-vehicle, p=0.002). ERK phosphorylation in the visual cortex was not affected by Ex4, but it was increased in SD mice (175±17% of SD-vehicle, p=0.015).

Conclusion: HFD differentially affects the expression of GABAergic markers and activation of insulin-related signaling in the visual cortex and hippocampus. HFD is followed by increased Akt phosphorylation in the hippocampus and Exendin-4 acutely normalizes this alteration, suggesting a potential beneficial effect in rescuing altered insulin-related signaling in the brain caused by high-fat diets.

Disclosure: V. Sancho: None.

213
Central action of FGF19 improves energy homeostasis in diet-induced obese mice
University of Campinas, Campinas, Brazil.

Background and aims: Fibroblast growth factor-19 (FGF19) is a gut-derived hormone released postprandially, which is emerging as a potential therapeutic agent for metabolic disorders, including diabetes and obesity. It is known that the (hypothalamic) action of FGF19 reduces body weight (BW) in diet-induced obese (DIO) mice, however, the mechanisms involved in this phenomenon remain poorly understood. Considering the crucial role of the hypothalamus in activating thermogenic mechanisms in brown adipose tissue (BAT), we aimed to investigate the central actions of FGF19 upon the energy homeostasis of DIO mice, focusing on the thermogenic capacity of BAT.

Materials and methods: In this study, C57BL/6J lean and DIO (8 weeks of high-fat diet) mice were used. For chronic (10 days) central FGF19 administration (2 μg/day), mice received a cannula into the lateral ventricle of the brain. A micro-osmotic pump (Alzet) filled with recombinant FGF19 or saline was subcutaneously implanted in mice and were connected to the newly implanted brain cannula via a catheter. Food intake and BW were monitored throughout the treatment. Energy expenditure (EE) and respiratory quotient (RQ) were measured by indirect calorimetry. Fat depots weights were obtained at the time of euthanasia and the adipocytes area was evaluated by histological analysis. Insulin sensitivity was measured by insulin tolerance test and through the homeostasis model assessment-estimated insulin resistance (HOMA-IR). BAT temperature was acquired by infrared thermography (FLIR Systems) and gene expression was evaluated by qPCR. Data were analyzed by one-way ANOVA and are displayed as mean ± SEM. The difference between the groups was considered statistically significant if P ≤ 0.05.

Results: DIO mice treated with FGF19 displayed reduced BW gain (0.30 ± 0.10 Lean x 2.03 ± 0.08 DIO x 1.18 ± 0.22 DIO+FGF19) during the treatment, which was associated with lower food intake (kcal) (158.50 ± 5.67 Lean x 210.00 ± 16.84 DIO x 152.40 ± 7.11 DIO+FGF19), diminished fat depots (% BW) (epididimal: 0.38 ± 0.04 Lean x 2.81 ± 0.27 DIO x 1.95 ± 0.30 DIO+FGF19; inguinal: 0.40 ± 0.04 Lean x 1.89 ± 0.34 DIO x 0.99 ± 0.16 DIO+FGF19), and smaller adipocyte size (μm²) (1606 ± 213 Lean x 11685 ± 1016 DIO x 6572 ± 179 DIO+FGF19). The central action of FGF19 also improved peripheral insulin sensitivity, kITT (%min) (4.95 ± 0.22 Lean x 3.10 ± 0.20 DIO x 4.63 ± 0.24 DIO+FGF19), as well as HOMA-IR (0.77 ± 0.07 Lean x 5.61 ± 1.10 DIO x 2.04 ± 0.89 DIO+FGF19) in treated mice. Furthermore, central administration of FGF19 ameliorated EE (Kcal/day/kg0.75) (191.24 ± 2.56 Lean x 164.19 ± 4.12 DIO x 182.46 ± 2.61 DIO+FGF19) and RQ (0.92 ± 0.01 Lean x 0.79 ± 0.01 DIO x 0.87 ± 0.02 DIO+FGF19) in mice during the dark cycle. This improvement observed in FGF19 treated DIO
mice was also associated with higher BAT temperature (°C) (35.58 ± 0.33 Lean x 34.60 ± 0.14 DIO x 36.76 ± 0.35 DIO+FGF19), as well as increased expression of thermogenic marker genes in the BAT (UCP1: 0.27 ± 0.06 DIO x 0.64 ± 0.09 DIO+FGF19; DIO2: 0.25 ± 0.03 DIO x 0.68 ± 0.18 DIO+FGF19; PPARγC1c: 0.52 ± 0.09 DIO x 1.39 ± 0.30 DIO+FGF19; PRDM16: 0.33 ± 0.05 DIO x 0.73 ± 0.15 DIO+FGF19, and CIDEA: 0.35 ± 0.06 DIO x 0.79 ± 0.11 DIO+FGF19, fold change of Lean).

Conclusion: Our results show that central delivery of FGF19 improves energy metabolism in DIO mice, and the increased thermogenic capacity of BAT must be involved, at least in part, in the observed beneficial effects.

Supported by: FAPESP

214
Modulation of hypothalamic AMPK phosphorylation by Olanzapine controls energy balance and body weight
V. Ferreira1, C. Folgueira2, M. Guillén3, P. Zubiar4, D. Grajales3, A. Sarsenbayereva4, P. López Larrubia1, J.W. Eriksson1, M.J. Pereira1, F. Abad-Santos1, G. Sabio1, P. Rada1, A.M. Valverde1;
1IIBm Alberto Sols (CSIC-UAM), Madrid, Spain, 2Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain, 3Instituto de Investigación Sanitaria La Princesa, Madrid, Spain, 4Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden.

Background and aims: Second-generation antipsychotics (SGAs) are mainstay therapy for psychiatric disorders. SGA-treated patients present risk for weight gain and insulin resistance. Since overweight/obesity favors insulin resistance and Type 2 Diabetes, we evaluated the effect of olanzapine (OLA), a widely prescribed SGA, in mice, focusing on body weight, energy balance and insulin sensitivity. We also explored OLA effects in protein tyrosine phosphatase-1B deficient (PTP1B-KO) mice, a preclinical model of insulin resistance and Type 2 Diabetes.

Results: Specifically, after i.p. OLA treatment, WT mice presented insulin markers of insulin resistance in WT mice by both administration routes. OLA induces a reduction in insulin receptor (p<0.05, n=4-5) and Akt (p<0.05, n=4-5) phosphorylation in liver, muscle and primary hepatocytes from OLA-treated WT mice concomitantly with inflammatory hallmarks (p<0.05, n=5).

Importantly, PTP1B-KO mice were protected against OLA-induced insulin resistance.

Conclusion: Mechanically, we found that OLA reduces hypothalamic phospho-AMPK inducing weight loss through thermogenesis activation. In conclusion, we unraveled an unexpected metabolic rewiring controlled by hypothalamic AMPK that avoids weight gain in male mice treated i.p. with OLA by activating BAT thermogenesis and iWAT browning, as well as a therapeutic benefit of PTP1B inhibition against OLA-induced insulin resistance and weight gain.

Supported by: ITN-TREATMENT (721236); FCT/FEDER (2020.08388.BD); MICINN/AEI/FEDER, EU (RTI2018-094052-B-100)
Disclosure: V. Ferreira: None.

215
Effect of interesterified fat and its metabolites on inflammation and insulin resistance in hypothalamus
J.E. Miyamoto1,2, R.M.A. Santos1, B.P. Siqueira1, A. Reginato3, J. Guittton3, P.R. Menta1, T.G. Ramalheira1, A.S. Torsoni2, L.M. Ignácio-Souza1, M.A. Torsoni1, H. Le Stunff4, C. Magnan2, M. Milanski1;
1Laboratory of Metabolic Disorders, University of Campinas, Limeira, Brazil, 2Biologie Fonctionnelle et Adaptative (BFA) - CNRS UMR 8251, Université Paris Cité, Paris, France, 3Medicine/Endocrinology, Albert Einstein College of Medicine, Bronx, USA, 4Neuroscience Paris-Saclay Institute (NeuroPSI) - UMR CNRS 9197, Université Paris Saclay, Paris, France.

Background and aims: The overconsumption of dietary fats leads to inflammation in peripheral tissues, which is implicated in the development of obesity and insulin resistance (IR). More recently, hypothalamus has become a key target of dietary fat in the development of central and peripheral IR. Nevertheless, the role of different types of dietary lipids, particularly the nature of triacylglycerols (TAGs) in the development of IR are still poorly understood. TAGs occur naturally or they can be manufactured from vegetable oils and animal fats by interesterification. This latter process becomes a key target of dietary fat in the development of central and peripheral IR. Nevertheless, the role of different types of dietary lipids, particularly the nature of triacylglycerols (TAGs) in the development of IR are still poorly understood. TAGs occur naturally or they can be manufactured from vegetable oils and animal fats by interesterification. This latter process leads to an enrichment of saturated fatty acids (SAFA) on the sn-2 position of TAGs. Recently, we provided evidence that a normocaloric interesterified lipid diet impaired glucose tolerance in mice. In the present study, we evaluated the role of interesterified palm oil and their metabolites on insulin signaling and inflammation in mice and in hypothalamic neuronal cells.

Materials and methods: Adult male Swiss mice were divided into four experimental groups: normocaloric palm oil diet (PO), normocaloric interesterified palm oil diet (IPO), PO high fat diet (POHFD) or IPO high fat diet (IPOHFD) during 8 weeks. Glucose homeostasis was assessed by GTT. Hypothalamus were processed and RNA-seq was performed. For in vitro analysis, miHypoA 2/28 hypothalamic cell was treated for 16h with TAG derivatives namely monoacylglycerol either linked to palmitate on sn-2 position (2-palmitoylgllycerol (2-PG)) or to oleic acid (Oleic acid) on sn-2 position (2-oleoylgllycerol (2-OG)). Free palmitic acid (Palm) or oleic acid were used as controls. Pro-inflammatory mediators expression were assessed by RTqPCR. Insulin signaling pathway was evaluated by quantifying Akt phosphorylation. Involvement of de novo ceramide synthesis was determined by the use of the serine palmitoyl transferase inhibitor, myriocin.
Results: The interesterification generates new TAGs, which is characterized by increased SAFA on sn-2, induced glucose intolerance. In vivo, normocaloric IPO diet induced the regulation of various genes in hypothalamus including cellular stress markers. In vitro studies with hypothalamic cell lines (mHypoA-2/28) evidenced that the treatment with 2-PG as free palmitate impaired insulin signaling by decreasing AKT phosphorylation. 2-PG also promoted inflammation by increasing IL-6 levels. Interestingly, treatment 2-OG or free oleic acid did not induce inflammation. Importantly, lipid profile analysis revealed that both Palm and 2-PG treatment increased intracellular levels of palmitate in mHypo 2/28 cells. Finally, myriocin treatment counteracted the impairment of insulin signaling induced by 2-PG.

Conclusion: Altogether, our data showed that interesterified fats targets hypothalamus to mediate their metabolic effect. This preliminary data also allowed us to assert that SAFA on sn-2 position of TAG could as free fatty acids to alter insulin signaling and inflammation in neuronal cells and contributed therefore to the development of obesity and IR.

Supported by: FAPESP 2016/24768-3 and 2020/16040-5 (Fellowship), 2017/15925-0 and 2019/26538-3 (Grant)
Disclosure: J.E. Miyamoto: None.

A role for GIP in the regulation of food intake and body weight in mice
J.E. Lewis, T. Darwish, F. Reimann, F.M. Gribble;
Institute of Metabolic Science, University of Cambridge, Cambridge, UK.

Background and aims: Hormones from the gut that signal nutrient uptake and availability to the brain are key elements in the control of appetite. Glucagon-like peptide-1 (GLP-1) based pharmacotherapies are licensed for the treatment of type 2 diabetes and obesity and dual agonist peptides stimulating both GLP-1R and glucose-dependent insulinotropic peptide receptors (GIPR) have been shown to promote greater weight reduction. GIP is well established to regulate blood glucose via its insulinotropic and glucagonotropic action on the pancreas, however, the role of GIP in the regulation of food intake and body weight remains controversial. This study addressed the metabolic roles of endogenous GIP by directly activating the GIP-secreting cell population.

Materials and methods: Utilising a novel rodent model (GIP-Cre x Dq), targeting the Designer Receptor Activated by Designer Drugs (Dq-DREADD) to GIP expressing cells, we measured intraperitoneal glucose tolerance, acute food intake and whole-body physiology/feeding behaviour in metabolic cages in the lean and diet induced obese state with and without activation of cells through Dq with the DREADD-ligand CNO in a cross-over design (n=14).

Results: In lean GIP-Cre x Dq mice, CNO resulted in an increase in plasma GIP, akin to that in the postprandial state in mice. In lean and diet induced obese mice, the increase in GIP was associated with improved glucose tolerance (p<0.0001) and a reduction in food intake both in the ad lib fed state at the onset of the dark phase (p<0.01) and in a fast-refeed paradigm (p<0.001). The reduction in food intake was a consequence of reduced feeding time (p<0.05) and an increase in the time between meals (p<0.001). No change in energy expenditure or activity was detected following GIP cell activation, however, a transient reduction in body weight was apparent (p<0.05). In lean mice, the effects on glucose tolerance and food intake were blocked by pre-treatment with a GIPR antagonistic antibody, suggesting the effects were specific to GIP and mediated through an antibody accessible receptor site.

Conclusion: These studies provide new insights into the physiological roles of GIP, suggesting that it contributes to the control of appetite as well as blood glucose levels.

Supported by: EFSD/Lilly European Diabetes Research Programme
Disclosure: J.E. Lewis: None.
Background and aims: Latent autoimmune diabetes in adults (LADA) is a slowly progressing form of autoimmune diabetes with an adult onset. Our aim was to contribute to the limited knowledge on the risk of CVD in LADA with varying degrees of autoimmunity.

Materials and methods: This population-based Swedish study followed individuals with newly diagnosed LADA (n = 587) and type 2 diabetes (T2D, n=2013) and matched diabetes-free controls (n=2385) between 2007 and 2019 through National Diabetes, Patient and Cause-of-Death Registers. HR (95% CI) for a first occurrence of CVD (ischemic heart disease, stroke, and heart failure) in LADA and T2D compared to controls were estimated by Cox regression and adjusted for age, sex, calendar year and lifestyle factors. LADA patients were stratified based on the median level (250 IU/ml) of glutamic acid decarboxylase antibodies (GADA) into LADA-high and LADA-low.

Results: During a median follow-up of 6.05 years, we recorded 328 CVD events (37 in LADA and 173 in T2D). The risk of a first occurrence of CVD was increased in T2D (HR: 1.58, 95% CI: 1.22, 2.06) but not in LADA (HR: 1.25, 95% CI: 0.86, 1.83) when compared to people without diabetes. However, stratification by GADA levels revealed that patients with LADA-high had excess risk of CVD (HR: 1.72, 95% CI: 1.09, 2.71) that was on par with that observed in T2D (Figure 1). LADA-high patients had worse beta-cell function (median HOMA-B 30.9 vs 46.8, p<0.001) and glycemic control (median HbA1c during follow-up: 49.7 vs 55.3 mmol/mmol, p<0.001), but lower prevalence of CVD (6.7% vs 14.8%, p=0.002) at baseline compared to LADA-low patients.

Conclusion: Among LADA patients free of CVD at the time of diabetes diagnosis, those with high GADA levels have higher future risk of CVD, which might be driven by worse β cell function and glucose control. However, attention should also be paid to LADA patients with low GADA given their much higher CVD prevalence at diabetes diagnosis.

Results: A doubling of serum endotrophin was independently associated with the composite renal endpoint (n=36, HR: 3.69, 95% CI: 2.24-6.07), MACE (n=140, HR: 1.46, 95% CI: 1.12-1.89), all-cause mortality (n=93, HR: 1.44, 95% CI: 1.03-2.0), and progression of albuminuria (n=80, HR: 1.69, 95% CI: 1.22-2.35), but not with incident HF or sight-threatening eye disease after adjustment for conventional risk factors. The associations remained significant after further adjustment for prevalent disease at baseline: composite renal endpoint (HR: 3.27, 95% CI: 1.89-5.65) and MACE (HR: 1.43, 95% CI: 1.06-1.93). A doubling of urine endotrophin was not associated with any of the endpoints after adjustment.

Conclusion: Serum endotrophin released during COL6 formation is an independent risk marker of mortality, cardiovascular and renal complications in persons with type 1 diabetes.

Supported by: This work was supported by the Innovation Fund Denmark (0172-00270B)

Disclosure: A.L. Moller: None.
and long-term parameters of glycemic control, physical performance and activity level in patients with type 1 diabetes free from overt CVD.

Materials and methods: Cross-sectional study in patients with a type 1 diabetes duration of at least ten years and still free from known CVD. Current level and 10-years history of HbA1c was evaluated, as well as skin AGEs. Arterial stiffness was assessed with carotid-femoral pulse wave velocity (cf-PWV). CGM for 7 days was used to determine time in range (TIR), time in hyper- and hypoglycaemia, and glycemic variability. Levels of physical activity and exercise capacity were evaluated. Pearson (r) and Spearman (rs) correlations, and multiple linear regression were used to investigate associations with cf-PWV.

Results: 54 patients (MF: 32/22; age: 46 ± 9.5 yrs; type 1 diabetes duration: 27 ± 8.8 yrs; HbA1c: 7.8 ± 0.83%) were included. cf-PWV showed significant associations with traditional risk factors age (rs= +0.69), type 1 diabetes duration (rs= +0.41) and 24-hours mean arterial pressure (rs= +0.45); cf-PWV was significantly associated with current HbA1c (rs= +0.28), mean 10-years HbA1c (rs= +0.36) and AGEs (rs= +0.40), but not with any of the CGM-derived parameters; and negatively associated with VO2max (rs= -0.41) and physical activity level (rs= -0.60). Multiple linear regression for cf-PWV showed that the model with the best fit included age, type 1 diabetes duration, 24-hour mean arterial pressure and mean 10-years HbA1c (adjusted R²= 0.645); and that VO2max had independent predictive value.

Conclusion: This study demonstrated that long-term glycemic exposure as reflected by mean 10-years HbA1c and AGEs is a main predictor of arterial stiffness in patients with type 1 diabetes, while no relationship was found with any of the CGM-parameters. Importantly, physical activity level and exercise capacity were inversely associated with arterial stiffness. Our findings stress the importance of early and sustained good glycemic control and of engagement in physical activity to prevent premature CVD in patients with type 1 diabetes.

Fig 1. Multiple linear regression for predicting carotid-femoral pulse wave velocity (cf-PWV) with age, type 1 diabetes duration, 24-hours-MAP and mean 10-years HbA1c. (Regression equation: cf-PWV (m/s) = -0.1045 + 0.0068 × Age (years) + 0.0025 × Type 1 diabetes duration (years) - 0.058 × 24-hours-MAP (mmHg) + 0.795 × Mean 10-years HbA1c (%)). Supported by: The first author (S.H.) is supported by a PhD grant Fundamental Research from FWO Vlaanderen.

Disclosure: S. Helleputte: Grants; Fonds Wetenschappelijk Onderzoek (FWO) Vlaanderen PhD fellowship grant.

Hyperglycaemia and hypoglycaemia exposure are differentially associated with micro- and macrovascular complications in adults with type 1 diabetes


1Endocrinology and Nutrition Department, Hospital Clinic de Barcelona, Barcelona, 2IDIBAPS (Institut d’investigacions biomèdiques August Pi i Sunyer), Barcelona, 3Endocrinology and Nutrition Department, Hospital Mutua de Terrassa, Terrassa, 4Endocrinology and Nutrition Department, Althaia – Xarxa Assitencial Universitària de Manresa, Manresa, Spain.

Background and aims: Information on the association between continuous glucose monitoring (CGM) data and chronic complications in type 1 diabetes (T1D) is scarce. We explored the relationship between high and low glucose exposure glucometrics obtained by CGM and micro- and macrovascular complications in this population.

Materials and methods: Cross-sectional study in T1D patients without cardiovascular disease (CVD) and with at least one of the following: ≥40 years, diabetic nephropathy or ≥10 years of T1D duration with CVD risk factors. CGM data were obtained from a CGM sensor regularly used by each patient (Dexcom G5, Guardian Sensor 3 or FreeStyle Libre). CGM-derived glucometrics from 14 consecutive days were collected: glucose management indicator (GMI), coefficient of variation and proportion of time (%), time above range; TBR<54, <70, 70-180 (time in range; TIR), >180 (time above range; TAR). Carotid plaque (intima-media thickness ≥1.5 mm) was evaluated by standardized ultrasonography protocol. Logistic regression models adjusted for CGM sensor, age, sex, diabetes duration and other CVD risk factors were constructed to test the independent association between CGM-derived glucometrics and chronic complications.

Results: We included 152 patients (54.6% men, mean age 48.7±10.0 years, T1D duration 28.6±11.3 years, 5-year mean HbA1c 7.31% (6.86-7.89), insulin pump therapy 36.2%, TIR 61.3±15.3%, TBR<54 1.0 ±1.5%, TAR 33.3±15.7%, GMI 7.11±0.71%). Sixty-seven patients showed carotid plaque and 71 microvascular complications (retinopathy and/or nephropathy). TAR (OR 1.28 [1.09-1.51], p=0.003; 5% increase) and GMI (OR 3.05 [1.46-6.36], p=0.003; 1% increase) were directly associated with the presence of microvascular complications, while TIR had an inverse relationship (OR 0.79 [0.66-0.93], p=0.005; 5% increase). TBR<54 was directly associated with the presence of plaques, even after adjusting for 5-year mean HbA1c (p<0.05; Figure).

Conclusion: Glucometrics related to high glucose exposure were independently associated with microvascular complications. Only low glucose exposure glucometrics was significantly associated with preclinical atherosclerosis. Our data supports the role of hypoglycaemia in the development of CVD in this population.

Supported by: Contracte Clínic Recerca "Josep Font-Emili Letang" and Ajut programa doctorat ACD
OP 38 It is always a D-D-Day: diabetes, digital, device

221

Long-term weight loss in a primary care-anchored eHealth lifestyle coaching programme in Denmark: a randomised controlled trial

L. Hesseldal1, J.R. Christensen1, T.B. Olsesen2, M.H. Olsen3, P.R. Jørgensen4, J.T. Lauridsen5, D.H. Laurlsen6, J.B. Nielsen6, J. Søndergaard1, C.J. Brandt1;
1Research Unit for General Practice, Research Unit for General Practice, Institute of Public Health; University of Southern Denmark, Odense, 2Steno Diabetes Center Odense, Steno Diabetes Center Odense, Odense University Hospital (OUH), Odense, 3Department of Internal Medicine, Holbaek Hospital and Steno Diabetes Center Zealand, Holbaek, 4Research Unit for General Practice, Research Unit for General Practice, Institute of Public Health; University of Southern Denmark, Odense, 5Department of Business and Economics, University of Southern Denmark, Odense, 6Department of Public Health, University of Copenhagen, Copenhagen, Denmark.

Background and aims: Long-term weight loss among subjects with obesity can reduce the risk and progression of noncommunicable diseases (NCDs) such as cardiovascular disease, respiratory disease, and type 2 diabetes (T2D). Unfortunately, long-term weight loss has been historically difficult for patients with obesity and T2D to achieve and maintain. Observational studies suggest that digital coaching can lead to long-term weight loss and potentially reduce the risk of developing NCDs. To assess whether an eHealth lifestyle coaching program (LIVA) for motivated subjects with obesity with or without T2D leads to significant long-term (more than 6 months) weight loss compared to usual care.

Materials and methods: In an open, randomized controlled trial, 340 subjects with obesity with or without T2D were enrolled from March 2018 to March 2019 and randomized to the intervention (200) and control (140) groups. The digital lifestyle intervention comprised an initial one hour face-to-face motivational interview followed by digital coaching using behavioral change techniques enabled by individual live monitoring.

Results: At 6 and 12 months, data were assessed for 235 participants, 149 from the intervention group and 86 from the control group. After 12 months mean body weight and body mass index were reduced significantly in both groups but significantly more in the intervention group (-4.6(95%CI, -5.7; -3.4) kg vs. -1.4(95%CI,-2.6;-0.1) kg, P<0.005 and -1.5(95%CI,-1.9;-1.2) kg/m² vs. -0.5(95%CI,-0.9;-0.1) kg/m², P<0.005).

HbA1c was significantly reduced in both the intervention (-6.0(95%CI,-7.7;-4.3)mmol/mol) and control group (-4.9(95%CI,-7.4;-2.4)mmol/mol) without significant group difference. Blood pressures and lipid profiles did not change significantly.

Conclusion: Compared to usual care, digital lifestyle coaching can induce significant weight loss in obese subjects with or without T2D.

Clinical Trial Registration Number: NCT03788915

Disclosure: L. Hesseldal: None.

222

Telehealth versus in-person standard care in patients with type 1 diabetes treated with multiple doses of insulin: an open-label randomised controlled trial

S. Ballesta1,2, J.J. Chilarón1,2, Y. Ingладa1, A. Rodriguez3, E. Climent2, G. Llaurado2, H. Camell4, J.A. Flores1,2, D. Benaiges1,2;
1Endocrinology and Nutrition, Hospital Comarcal de l’Alt Penedès, Vilafranca del Penedès, 2Endocrinology and Nutrition, Hospital del Mar, Barcelona, 3Research department, Hospital Comarcal de l’Alt Penedès, Vilafranca del Penedès, 4Internal Medicine, Hospital Comarcal de l’Alt Penedès, Vilafranca del Penedès, Spain.
Background and aims: Increasing evidence indicates that telehealth (TH) is non-inferior to in-person approach regarding metabolic control in type 1 diabetes (T1D) patients, and offers advantages such as a decrease in travelling-time to outpatient clinic and increased accessibility for shorter and more frequent visits. This point has been even more important during the COVID-19 pandemic in rural zones, where distances are longer and time spent travelling are greater. The primary aim of our study was to compare, in T1D patients assisted in a rural area, the change in HbA1c at 6-month between TH and in-person visits. As secondary objectives we compared glaucometric parameters, hypoglycemic events, EsDQoL questionnaire, direct and indirect costs, and patient’s satisfaction.

Materials and methods: Randomized controlled study, open-label, parallel arms, among T1D subjects. In the conventional group, patients were submitted to standard in-person visits (30 minutes) in outpatient clinic (baseline, 3 and 6 months). In the TH group, patients were submitted to teleconsultation (10 minutes) in month 1, 2, 3 and 4; baseline and 6-month visits were in-person. Mean-differences in change of included variables during follow-up were analyzed.

Results: 55 subjects were included (29 conventional, 26 TH). Mean age was 50.6 years ± 12.0, 48% were females, T1D evolution was 21.5 years ± 11.6 and mean HbA1c was 7.56 % ± 0.7. No differences in baseline characteristics between groups were observed. At 6-month follow-up, the mean change in HbA1c was 0.2% (range: 0.6 - 3.7) in the control group and -0.05% (range: -0.8 - 1.7) in the TH group (mean difference 0.013, P = 0.932). Changes in EsDQoL questionnaire, glaucometry parameters, mild hypoglycemic events and costs are shown in Table 1. No severe hypoglycemia was detected. Total time spent by endocrinologist was 93.2 minutes ± 12.0 in conventional group vs 102.9 minutes ± 7.6 in TH group (P= 0.001). 46% of patients in TH group preferred alternation between both types of visits. The main concern about telehealth was non-compliance with visiting hours, and main advantages were no need to travel to hospital and time saving.

Conclusion: TH is comparable to in-person visits regarding HbA1c levels at 6-month follow-up among T1D subjects, with significant improvement in time in range (TIR) and EsDQoL. Despite increased costs for national care system, teleconsultations imply a decrease in direct and indirect costs for patients. Further studies about telemedicine in T1D are necessary to evaluate a more efficient timing of the TH visits, as well as long-term cost analysis studies.

Disclosure: None.

Supported by: Novo Nordisk A/S

Disclosure: E. Kjöhlhed: Honorarium; Novo Nordisk: consulting fee for reviewing and revising survey content.
Accuracy of continuous glucose monitoring systems during exercise-related hypoglycaemia in patients with type 1 diabetes


1Clinical Research, Steno Diabetes Center Copenhagen, University of Copenhagen, Herlev, ²Department of Endocrinology and Nephrology, Nordsjællands Hospital Hillerød, University of Copenhagen, Hillerød, ³Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

Background and aims: Hypoglycaemia is common in patients with type 1 diabetes, especially during exercise. Continuous glucose monitoring (CGM) accuracy is clinically important since low sensor precision may lead to undetected events of hypoglycaemia or unnecessary meal intake resulting in hyperglycaemia. We investigated sensor accuracy in available CGM devices during exercise-related hypoglycaemia.

Materials and methods: Fifteen patients with type 1 diabetes participated in two separate euglycaemic-hypoglycaemic clamp days (Clamp-exercise and Clamp-rest) with five different phases: 1) a baseline-euglycemic phase, 2) a plasma glucose decline phase ± exercise, 3) a 15-minute hypoglycaemic phase ± exercise, 4) a 45-minute hypoglycaemic phase (at rest), and 5) a plasma glucose incline phase. Plasma glucose was determined every five minutes, using Dexcom G6 and FreeStyle Libre 1. Yellow Spring Instruments 2900 (YSI) was used as a plasma glucose reference method, enabling mean absolute relative difference (MARD) assessment during each phase and Clarke error grid analysis during each day. We defined $\Delta$MARD = MARD$_c$ (Clamp-exercise) - MARD$_r$ (Clamp-rest).

Results: We observed an overall higher MARD for Dexcom G6 compared to FreeStyle Libre 1 throughout both clamp days. CGM accuracy during phase 2 was more accurate during exercise compared to rest for Dexcom G6 ($\Delta$MARD = -6.2 percentage points) while FreeStyle Libre 1 showed opposite results ($\Delta$MARD = +5.3 percentage points) (Figure 1). During phase 3, exercise had no effect on Dexcom G6 accuracy, whereas FreeStyle Libre 1 was more accurate during rest ($\Delta$MARD = +13.5 percentage points). During phase 4 (post-exercise versus post-rest) Dexcom G6 was more accurate after exercise than after rest ($\Delta$MARD = -8.4 percentage points), whereas FreeStyle Libre 1 showed no differences between days. Clarke error grid analysis showed a decrease in clinically acceptable treatment decisions during Clamp-exercise for FreeStyle Libre 1 while a corresponding increase was observed for Dexcom G6.

Conclusion: Dexcom G6 had an overall lower accuracy compared to FreeStyle Libre 1. Exercise negatively impacted FreeStyle Libre 1 sensor performance during both declining plasma glucose and hypoglycaemia, whereas it improved Dexcom G6 sensor performance. Thus, physical exercise can affect the accuracy of different sensor systems in different manners, which may be of clinical importance, especially in detecting episodes of hypoglycaemia.

Clinical Trial Registration Number: NCT04650646
Supported by: DFF
Disclosure: K. Maytham: None.
OP 39 Too little sugar is also bad: understanding hypoglycaemia

225
Tmem117 in AVP neurons regulates the counterregulatory response to hypoglycaemia
S. Gaspari, G. Labouèbe, A. Picard, A. Rodriguez Sanchez-Archidona, B. Thorens;
University of Lausanne, Lausanne, Switzerland.

Background and aims: The counterregulatory response to hypoglycaemia (CRR), which ensures a sufficient glucose supply to the brain, is an essential survival function. It is orchestrated by incompletely characterized glucose-sensing neurons, which trigger a coordinated autonomous and hormonal response that restores normoglycaemia. A genetic-genomic screen for insulin-induced glucagon (GCG) secretion was conducted using a panel of 36 BXD recombinant inbred mouse strains. Tmem117, located on chromosome 15, was identified as a potential regulator of GCG secretion. Here, we aimed at characterizing the role of Tmem117 in hypoglycaemia-induced GCG secretion.

Materials and methods: Immunofluorescence microscopy (IF); physiological characterization of mice with conditional, cell-specific gene inactivation; electrophysiological and in vivo fiber photometry measurements were used.

Results: We found that Tmem117 expression in the hypothalamus of the BXD mice was negatively correlated with the GCG response (Pearson’s R: -0.55; p=0.0003). IF found Tmem117 to be expressed in vasopressin (AVP) magnocellular neurons of the paraventricular and the supraoptic nuclei of the hypothalamus. Inactivation of Tmem117 specifically in AVP neurons (AVP\textsuperscript{TM117KO}) led to higher hypoglycaemia-induced copeptin (CPP; surrogate for AVP) secretion and higher plasma GCG levels in male mice [CPP: 89±5 vs 121±13 pg/ml, GCG: 124±19 vs 186±21 pg/ml, in Ctrl and AVP\textsuperscript{TM117KO} mice, respectively; p<0.01; 2way-ANOVA RM]. In female mice this secretory phenotype was present only during the proestrous phase [CPP: 66±9 vs 107±16 pg/ml, GCG: 224±30 vs 377±22 pg/ml, in Ctrl and AVP\textsuperscript{TM117KO} mice, respectively; p<0.05; t-test]. c-Fos IF and electrophysiological recordings performed on acute brain slices revealed that a large proportion (50%) of AVP magnocellular neurons were activated by hypoglycaemia (glucose-inhibited, GI neurons). Inactivation of Tmem117 did not affect the glucose responsiveness of the AVP neurons. However, it led to their progressive elimination (number of AVP neurons in the SON: 91±9 vs 54±3 in Ctl and AVP\textsuperscript{TM117KO} mice, respectively; 35 days after Tmem117 inactivation; p<0.05; t-test) and a loss of the increased secretory phenotype (CPP: 55±14 vs 83±6 pg/ml, GCG: 81±11 vs 119±19 pg/ml in Ctrl and AVP\textsuperscript{TM117KO} mice, respectively; 34 days after Tmem117 inactivation; p<0.05; 2way-ANOVA RM). Overexpression of Tmem117 in the insulin secreting MIN6B1 cells reduced K+–induced [Ca\textsuperscript{2+}]\textsuperscript{i} and insulin secretion (Fho-4: 3545±1030 vs 3088±2513 RFU, insulin: 145±11 vs 88±11 μg/L in Ctrl and Tmem117 overexpressing cells, respectively; p<0.01; t-test). Inversely, fiber photometry experiments showed that Tmem117 inactivation increased [Ca\textsuperscript{2+}]\textsuperscript{i} both at baseline (GCaMP7: 15±2 vs 42±10 z-score in Ctrl and AVP\textsuperscript{TM117KO} mice, respectively; p<0.01; 2way-ANOVA RM) and during insulin-induced hypoglycaemia (GCaMP7: 196±54 vs 249±64 AUC in Ctrl and AVP\textsuperscript{TM117KO} mice, respectively; p<0.01; 1way-ANOVA).

Conclusion: Our study shows that AVP magnocellular neurons are activated by hypoglycaemia to secrete AVP, leading to enhanced GCG secretion. It identifies Tmem117 as a regulator of hypoglycaemia-induced CPP and GCG secretion, whose effect depends on the modulation of intracellular calcium dynamics. Finally, as these data were based on an unbiased genetic screen, they highlight the physiologically important contribution of AVP neuroendocrine cells to the counterregulatory response.

Supported by: INTEGRATE 694798, SNSF 310030-182496,
Disclosure: S. Gaspari: None.

226
Molecular investigations of defective hypoglycaemia counter-regulation in a murine model of type-2 diabetes: a multi-omics study
J. Castillo-Armengol\textsuperscript{1,2}, A. Rodriguez Sanchez-Archidona\textsuperscript{2}, C. Fledelius\textsuperscript{3}, F. Marzetta\textsuperscript{4}, B. Thorens\textsuperscript{2};
\textsuperscript{1}Novo Nordisk A/S, Måløv, Denmark, \textsuperscript{2}Center for Integrative Genomics (CIG), University of Lausanne, Lausanne, Switzerland, \textsuperscript{3}Vital-IT Group, SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.

Background and aims: Repeated exposures to insulin-induced hypoglycaemia in diabetic patients progressively impair the counter-regulatory response (CRR), characterised by reduced secretion of glucagon and other counter-regulatory hormones. Increasing evidence indicates that glucose responsive neuronal networks, in particular located in the hypothalamus, orchestrate the CRR. However, how these neuronal networks become dysfunctional remains to be elucidated. Here we characterised the hypothalamic transcript profiles and chromatin structures in a mouse model of impaired CRR.

Materials and methods: Type-2 diabetes mellitus (T2DM) was induced in C57BL6N mice by high fat diet feeding and low dose streptozotocin injections. Mice were exposed to one (acute hypoglycaemia, AH) or multiple (recurrent hypoglycaemia, RH) insulin-induced hypoglycaemic episodes and plasma glucagon levels were measured. Single nucleus RNA sequencing (snRNAseq) and ATAC sequencing (snATACseq) data were obtained from the hypothalamus and cortex of AH and RH mice.

Results: A defective counter-regulatory response was observed in the T2DM mice exposed to RH as shown by the significant impairment of glucagon secretion in response to insulin injection (AH, n=33, 94.52±9.20 pg/mL vs RH, n=37, 59±pg/mL, p<0.001). Analysis of snRNAseq data revealed identical hypothalamic cell subpopulations in the hypothalamus of AH and RH mice. However, in the neuronal population, a total of 2373 genes were differentially expressed (FDR<0.05) between both mouse groups. Functional enrichment analysis revealed that these genes were strongly associated to the organisation of the synapses and cell projections. Interestingly, numerous genes related to the mitochondrial electron transport chain were also affected. The analysis of open chromatin regions confirmed the observations of the transcriptomic profiling. A subsequent analysis of the cortex of these animals showed that the effects observed in the hypothalamus were also identified in the cortex, suggesting that other brain regions might be similarly affected by the RH. A proteomic profiling of the synaptosomes from the hypothalami of these animals is currently being investigated and will provide additional characterisation of the synaptic proteome.

Conclusion: The present study provides a model of T2DM and defective counter-regulation in mice. Moreover, we show that the impairment of the gluco-regulatory response is related to genes controlling synaptic function and organisation. These changes in synaptic gene expression were observed not only in the hypothalamus, but also in the cortex suggesting that repeated exposure to hypoglycaemia impacts not only glucose sensing cells but may also induce neuronal dysfunctions in multiple brain regions.

Supported by: Novo Nordisk A/S, Innovative Medicines Initiative 2 Joint Undertaking (JU)
Disclosure: J. Castillo-Armengol: Employment/Consultancy; Novo Nordisk A/S. Grants; It has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 777460.
Heart rate variability, an index of autonomic function, is associated with C-peptidogenic index, an index of beta cell function: The Maastricht study

E. Rinaldi
1, F. van der Heide2, R. Henry3, A. Kroon2, C. van der Kallen2, S. Eussen4, E. Bonora4, R. Bonadonna4, M. Trombetta1, C. Zusi1, C. Schalkwijk2, M. van Greevenbroek3, C. Stehouwer2;

1Department of Medicine, University Hospital of Verona, Verona, Italy, 2Maastricht University, Maastricht, Netherlands, 3University of Maastricht, Maastricht, Netherlands, 4Department of Medicine, University Hospital of Parma, Parma, Italy.

Background and aims: Beta cell dysfunction is an important contributor to the early pathobiology of type 2 diabetes and its causes are matter of intensive investigation. Autonomic dysfunction may contribute to the pathobiology of beta cell dysfunction. We investigated, using population-based data, whether autonomic function is associated with beta cell function.

Materials and methods: We used cross-sectional data from The Maastricht Study, a population-based cohort study (N=2,007; mean ± SD age 60 ± 8 years; 52% men; and 24% with type 2 diabetes [the latter oversampled by design]). We assessed autonomic function from 24-hour ECGs as time- and frequency-domain heart rate variability (HRV); and we, using data from a 7-point oral glucose tolerance test, estimated beta cell function as C-peptidogenic index, beta cell glucose sensitivity, beta cell potentiation factor, overall insulin secretion, and beta cell rate sensitivity. Then, we used linear regression analyses to study the associations of standardized indices of HRV with standardized indices of beta cell function; and adjusted for age, sex, educational level, insulin sensitivity and major cardiovascular risk factors. In addition, we tested for interaction by sex and glucose metabolism risk factors. In children we explored whether associations differed by strength in these factors.

Results: After full adjustment, greater time and frequency domain HRV were significantly associated with a higher C-peptidogenic index (standardized beta [95% CI], 0.05 [0.00;0.09] and 0.05 [0.00;0.09], respectively) and numerically similarly, though not statistically significantly, associated with higher beta cell glucose sensitivity (0.04 [0.00;0.08] and 0.04 [-0.00;0.08]), higher beta cell potentiation factor (0.04 [-0.00;0.08] and 0.03 [-0.01;0.08]), and higher overall insulin secretion (0.04 [-0.00;0.08] and 0.03 [-0.01; 0.07]). However, neither time nor frequency domain HRV were associated with beta cell rate sensitivity. Last, sex did not modify associations and glucose metabolism did not consistently modify associations.

Conclusion: The present population-based study found that better autonomic function, estimated from greater HRV, was associated with better beta cell function, estimated from C-peptidogenic index. Hence, autonomic dysfunction may contribute to the beta cell dysfunction and, ultimately, to deterioration of glucose metabolism.

Supported by: ERDF, PL, DMEA, SD, PSID, CVM, CARIM, CAPHRI, NUTRIM, SA, HFL, DF, OF, JC, NNF, SA.

Disclosure: E. Rinaldi: None.

228

Agpat5 in AgRP neurons is required for hypoglycaemia-induced glucagon secretion

A. Strembistska1, G. Labouebe1, A. Picard1, X.P. Berney1, D. Tarussio1, M. Jar1, B. Thorens1;

1University of Lausanne, 2Vital-IT, Lausanne, Switzerland.

Background and aims: The counter-regulatory response to hypoglycemia restores blood glucose levels by stimulating glucagon secretion and hepatic glucose release. This response is coordinated by still poorly characterized brain hypoglycemia sensing mechanisms, which control autonomic nervous activity and the hypothalamus-pituitary-adrenal axis. In a previous genetic and genomic screen for hypothalamic regulators of hypoglycemia-induced glucagon secretion we identified Agpat5, located on mouse chromosome 8, as a candidate gene. Here we aimed at characterizing the role of Agpat5, a mitochondrial membrane-associated enzyme that uses fatty acyl-CoAs and lysophosphatidic acid to produce phosphatidic acid.

Materials and methods: We generated mice lacking Agpat5 expression in AgRP neurons of the arcuate nucleus of the hypothalamus (AgRPAgpat5KO). Glucagon secretion was assessed following insulin-induced hypoglycemia (IIH). AgRP neurons activation was assessed by c-Fos immunostaining, patch clamp analysis and fiber photometry. Mitochondrial respiration experiments were conducted using a Seahorse instrument.

Results: We found that AgRPAgpat5KO (KO) mice had reduced glucagon secretion upon IIH as compared to control mice (29.0±4.1pM (Ctrl) vs 16.1±1.7pM (KO), n=18-22, p<0.001, two-way ANOVA, Tukey’s post hoc). c-Fos immunostaining showed reduced number of AgRP neurons activated by hypoglycemia in KO vs. Ctrl mice. Patch clamp analysis performed on acute brain slices revealed that inactivation of Agpat5 reduced by half the percentage of glucose inhibited (GI) AgRP neurons (72.2% (Ctrl) vs 33.3% (KO), n=18 neurons/group, p<0.05, Fisher’s exact test). In vivo fiber photometry revealed that AgRP neurons of KO mice were less activated by hypoglycemia than those of Ctrl mice. These hypoglycemia sensing defects were associated with defective activation of the vagal nerve. To find how Agpat5 could interfere with hypoglycemia sensing, we first assessed a hypothalamic cell line. We found that silencing Agpat5 expression increased Cpt1a-dependent mitochondrial fatty acid β-oxidation (FAO), oxygen consumption rate (OCR), and ATP production (49.8% increase in mitochondrial OCR with Agpat5 silencing (p<0.05) vs 3.4% decrease in OCR with Agpat5/Cpt1a silencing (p<0.05) when compared to Ctrl, n=5, two-way ANOVA, Tukey’s post hoc). In mice, inactivating Cpt1a in AgRPAgpat5KO mice (AgRPAgpat5KO/Cpt1aKO) restored the number of hypoglycemia-activated AgRP neurons as determined by c-Fos immunostaining and patch clamp analysis. This suggests that limiting FAO in AgRP neurons is necessary for effective hypoglycemia detection.

Conclusion: Collectively, these data indicate that Agpat5 is required to partition acyl-CoA away from mitochondrial FAO and ATP generation. This is required to ensure that the hypoglycemia-dependent fall in ATP production, which triggers AgRP firing through inhibition of the Na+/K+ATPase, is not prevented by increased FAO. This mechanism is especially important during the fasted state when circulating free fatty acid concentrations increase. Our study thus describes a so far unknown protective mechanism that ensures proper hypoglycemia sensing by AgRP neurons and the control of glucagon secretion.

Supported by: FNS, ERC-INTEGRATE, Hypo-Resolve

Disclosure: A. Strembistska: None.
**OP 40 When the clock ticks**

229

**Time-of-day effects of exercise training on multi-tissue metabolome and skeletal muscle proteome profiles in men with type 2 diabetes**

M. Savijoki1, S. Ben2, S. Shogo3, K. Caidahl1,4, A. Krook5, A.S. Deshmukh6, J.R. Ziernath1,2, H. Wallberg-Henriksson7;

1Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden, 2Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, 3Center for Epigenetics and Metabolism, INSERM U1233, Department of Biological Chemistry, School of Medicine, University of California, Irvine, USA, 4Department of Clinical Physiology, Karolinska University Hospital, Stockholm, Sweden, 5Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, 6The Novo Nordisk Foundation Center for Protein Research, Clinical Proteomics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

**Background and aims:** Metabolic effects of exercise may partly depend on the time-of-day when exercise is performed. We tested the hypothesis that exercise timing affects the adaptations in multi-tissue metabolome and skeletal muscle proteome profiles in men with type 2 diabetes.

**Materials and methods:** Men fitting the inclusion (type 2 diabetes, age 45-68 years and body mass index 23-33 kg/m²) and exclusion criteria (insulin treatment, smoking, and concurrent systemic disease) were included in a randomized crossover trial (n=15). Participants that fully completed all exercise sessions (n=8) were analysed. The trial consisted of two weeks of high-intensity interval training (HIT) (three sessions/week) either in the morning (08:00, n=5) or afternoon (16:45, n=3), a two-week wash-out period, and an additional two weeks of HIT at the opposing time. Blood, skeletal muscle and subcutaneous adipose tissue were obtained before the first, and after each training period. Broad-spectrum, untargeted proteomic analysis was performed on skeletal muscle, and metabolomic analysis was performed on all biosamples. Differential content was assessed by linear regression and pathway set enrichment analysis. The same islet cross-section was re-identified during each imaging session and calcium oscillations of individual beta-cells were recorded. First responder cells during a wave of calcium activity were identified and all beta-cell calcium traces were subjected to independent Granger causal analysis. Coordinated metabolic changes across tissues were identified by Spearman correlation analysis.

**Results:** Metabolic and proteomic profiles remained stable after two weeks of HIT, and individual metabolites and proteins were not altered. However, coordinated changes in relevant metabolic pathways and protein categories were identified. Morning and afternoon HIT similarly increased plasma diacylglycerols, skeletal muscle acyl-carnitines, and subcutaneous adipose tissue sphingomyelins and lysophospholipids. Acyl-carnitines were central to training-induced metabolic cross-talk across tissues. Plasma carbohydrates, via the penthose phosphate pathway, were increased and skeletal muscle lipids were decreased after morning compared to afternoon HIT. Skeletal muscle lipoproteins were higher, and mitochondrial complex III abundance was lower after morning compared to afternoon HIT.

**Conclusion:** We provide a comprehensive analysis of a multi-tissue metabolomic and skeletal muscle proteomic responses to training at different times of the day in men with type 2 diabetes. Increased circulating lipids and changes in adipose tissue lipid composition were common between morning and afternoon HIT. However, afternoon HIT increased skeletal muscle lipids and mitochondrial content to a greater degree than morning training. This diurnal component in the metabolomic and proteomic training response may be clinically relevant and warrants further investigation.

**Clinical Trial Registration Number:** Pilot study for: NCT03553524

**Supported by:** KAW, Swedish Diabetes and HLF Foundations, Vetenskapsrådet, SLL, EFSD/Lilly and SRP Programmes

**Disclosure:** M. Savijoki: None.

---

230

**Beta cell functional heterogeneity underpinning coordinated oscillatory activity is not fixed**

K. Suba1, B. Hansen1, Y. Pate12, B.M. Owen3, W. Distaso4, V. Salem1;

1Department of Bioengineering, Imperial College London, London, 2Department of Surgery, Imperial College London, London, 3Department of Metabolism, Digestion and Reproduction, Imperial College London, London, 4Imperial College London, London, UK.

**Background and aims:** There is increasing recognition that pancreatic islets work as functional units. Electrically coupled beta-cells subserve pulsatile insulin release, co-ordinated by sub-populations of leader cells in vivo. It remains unknown whether this beta-cell functional heterogeneity is associated with a fated or fixed identity of these highly connected hubs. We identified the same cross-section of pancreatic islets in vivo, at single-cell resolution, in repeated imaging sessions over months to longitudinally track the activity of leader cells.

**Materials and methods:** We implanted Ins1CreGCaMP6fGp-expressing islets into the anterior eye chamber of wild-type C57BL/6 syngeneic recipients. Calcium dynamics of reporter islets were imaged over a period of 4months; at baseline (normal chow), after high-fat diet and following daily injections of gut-hormone analogues or weight-matching intervention. The same islet cross-section was re-identified during each imaging session and calcium oscillations of individual beta-cells were recorded. First responder cells during a wave of calcium activity were identified and all beta-cell calcium traces were subjected to independent Granger causality analysis.

**Results:** We found that first responder cells were among the top 25% of cells with the highest number Granger links. Granger leaders emerged from the same area in the islet cross-section during our recordings (≤4minutes) however their identity changed dynamically over a longer period of time (months) in vivo.

**Conclusion:** The identity of Granger leader cells remains stable in the acute setting (minutes to hours) but changes dynamically over longer periods of time (months). Investigating the mechanisms underlying these changes will improve our understanding of pulsatile insulin release and how to sustain it.

**Disclosure:** K. Suba: None.

---

231

**Time-of-day influences post-exercise metabolism in mouse adipose tissue**

L.A. Pendergrast1, L. Doller1,2,3, L.S. Lundell3, A.M. Ehrlich3, S.P. Ashcroft3, J.T. Treebak5, A. Krook5, J.R. Ziernath1,2;

1Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden, 2Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, 3Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.

**Background and aims:** Exercise is an effective approach to reduce the risk of type 2 diabetes, as well as to improve glucose uptake and mitochondrial activity in adipose tissue. Physiological events such as hormononal secretion, feeding behavior, and tissue metabolism follow a diurnal pattern regulated by central and peripheral circadian clocks. We hypothesized that the circadian clock may interact with exercise in regulating adipose tissue function and thus investigated the time-of-day response to exercise on the adipose tissue transcriptionome and metabolism.

**Materials and methods:** Mice performed a 60-minute exercise bout (or sham) during the early rest (day, ZT3) or early active (night, ZT15) phase. Tissue and serum samples were collected at 0, 4, 8, 12, 16, and 20th post-exercise (n=6 per group), and RNA sequencing was performed on inguinal adipose tissue at t=0h after exercise. An additional group of mice was
exercised (or sham) during the early rest phase in either an ad libitum or 10h-fasted state, with samples collected immediately following intervention (n=7 per group). Adipose tissue response and whole-body metabolic adaptation were evaluated by measuring gene expression, hepatic and skeletal muscle glycogen, serum lipid, and hormone levels.

**Results:** The exercise intervention did not modulate rhythmic expression of core clock genes Arntl and Nr1d1 in adipose tissue. Exercise-mediated adrenaline and corticosterone levels were similar between the early rest and early active phase, yet plasma non-esterified fatty acids (NEFA) were increased with early active phase exercise only (two-way ANOVA; p<0.05). Transcriptomic data revealed a time-of-day specific exercise response in adipose tissue, with changes specific to active phase only (79 transcripts altered in active phase versus 0 in rest phase, FDR<0.05). Among genes altered by early active phase exercise were those related to stress and thermogenesis, such as Nr4a3 and Ucp1. To decipher if feeding status and differential substrate availability are responsible for these time-of-day specific effects, we replicated the “unfed” state of the early active phase mice by fasting mice 10-hours prior to the early rest phase. Fasted early rest mice showed an increase in plasma NEFA (0.94± 0.06 mmol/L versus 0.66± 0.05 mmol/L; p=0.0001) and a depletion of liver glycogen (26.12±9.5 μmol/g versus 98.31±14.3 μmol/g; p=0.0001) similar to early active phase mice. However, fasted early rest phase exercise did not recapture expression patterns of early active phase exercise-responsive genes.

**Conclusion:** Exercise in the active phase influences adipose tissue gene expression and increases exercise-induced lipolysis. However, fasted early rest phase exercise does not replicate the time-of-day profile in gene expression observed with early active phase exercise, and implicates a role of the circadian clock in the adipose tissue post-exercise transcriptome. Our results provide evidence to suggest that exercise timing can fine-tune the metabolic benefits of exercise—particularly within adipose tissue. Time of day is a central variable to consider in prescribing exercise interventions for humans with metabolic syndrome.

**Supported by:** KID funding from Karolinska Institutet. Novo Nordisk Foundation Challenge Program

**Disclosure:** L.A. Pendergrast: None.

---

232

**The effects of hyperglycaemia on the circadian clock in TALLYHO/JngJ mice**

S.P. Ashcroft1, A.M. Ehrlich1, T.S. Nielsen1, S. Larsen2, J.T. Treebaak1, J.R. Zierath1

1Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark, 2Center for Healthy Aging Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, 3Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

**Background and aims:** Perturbed circadian rhythms have been associated with metabolic dysfunction and type 2 diabetes (T2D) however, little is known regarding how hyperglycaemia influences the circadian clock in peripheral tissues. To investigate this further, we utilised the TALLYHO/JngJ mouse which is a polygenic rodent model of T2D characterised by hyperglycaemia, hyperinsulinemia, peripheral insulin resistance and hepatic steatosis. Interestingly, the hyperglycemic phenotype is not 100% penetrant allowing us to segregate these mice into normoglycemic (TALLY-Low) and hyperglycemic (TALLY-High) groups. Therefore, the aim of the study is to determine how the degree of hyperglycaemia influences the circadian clock in TALLY-Low and TALLY-High mice. To do this, we performed a multi-tissue transcriptomic analyses of skeletal muscle, adipose tissue and liver samples collected across a circadian cycle.

**Materials and methods:** Male TALLY-Low and TALLY-High mice were studied between the ages of 6 to 18 weeks. Age and sex matched C57BL/6NTac mice were utilised as a healthy control mouse in all experiments. To characterise the development of hyperglycaemic phenotype, body weight, blood glucose and insulin were monitored on a weekly basis from 6 to 18 weeks of age (n=10/group). To assess tissue specific alterations to the circadian clock, liver, quadriceps and white adipose tissue samples were collected across a 24-hour period at zeitgeber times (ZT) 0, 4, 8, 12, 16 and 20 for RNA-sequencing (n=4/group) in 10-week-old mice. Finally, metabolic caging was utilised to assess daily rhythms in whole-body metabolism (n=12/group).

**Results:** TALLY-High mice displayed overt hyperglycaemia by 9 weeks of age (20.9 ± 7.2 mmol) in comparison to TALLY-Low (10.9 ± 1.1 mmol) and C57BL/6NTac (8.9 ± 0.5 mmol) mice (P<0.05). At 8 weeks of age, both TALLY-Low (1.4 ± 0.4 ng/ml) and TALLY-High (1.0 ± 0.4 ng/ml) display hyperinsulinemia in comparison to C57BL/6NTac mice (0.6 ± 0.1 ng/ml) (P< 0.05). Insulin production is, however, almost completely reduced in TALLY-High mice by 18 weeks of age (0.5 ± 0.4 ng/ml) whereas hyperinsulinemia is maintained in TALLY-Low mice of the same age (1.6 ± 0.3 ng/ml). Both TALLY-Low and TALLY-High mice display reduced activity, energy expenditure and RER in comparison to C57BL/6NTac mice (P< 0.05). Finally, preliminary data revealed time-of-day dependent alterations in the expression of circadian clock genes Bmal1, Cry1 and Cry2 in TALLY-High liver samples collected at ZT4 and ZT16. Further analyses will determine the effects of hyperglycaemia on the circadian clock in skeletal muscle and adipose tissue.

**Conclusion:** In conclusion, the TALLYHO/JngJ mouse is characterised by the divergent development of the hyperglycemic phenotype. This divergence is exacerbated by a reduction in insulin production in TALLY-High mice and preliminary analyses have revealed disruptions to the circadian transcriptome in the liver of TALLY-High mice.

**Disclosure:** S.P. Ashcroft: None.
OP 41 Viruses and diabetes: more than COVID-19

233 SARS-CoV-2 infection and subsequent risk of type 1 diabetes in 1.2 million children
H.L. Gulseth1, P.L.D. Ruiz1,2, K. Stordal1, G. Karlstad1, N. Gunnes1,2, N.A. Lund-Blix1, H. Boa1, L.C. Stene1, G. Tapia1; 1Norwegian Institute of Public Health, 2Oslo University Hospital, Oslo, Norway.

Background and aims: Viral infections, including respiratory viruses, are hypothesized to increase the risk of type 1 diabetes. Several case reports suggest an association between new onset type 1 diabetes and SARS-CoV-2 infection. In this nationwide register-based study we aimed to test whether SARS-CoV-2 infection was associated with an increased risk of developing type 1 diabetes in children and adolescents.

Materials and methods: We linked individual-level data from national health registries for all children and adolescents in Norway (1.2 million individuals). Data were obtained from the Norwegian preparedness register that is updated daily with individual-level data on PCR-confirmed SARS-CoV-2 infections, COVID-19 vaccinations and disease diagnoses from primary and secondary health care. Children were followed from March 1st 2020 (the start of the pandemic) until diagnosis of type 1 diabetes from primary and secondary health care. Children were followed from the days surrounding diabetes presentation. In those aged 0-14 years the rate ratio for incident type 1 diabetes associated with first negative test for SARS-CoV-2 (reference category: no previous infection) was 0.88 (95% CI 0.63 to 1.23) for infection more than 30 days earlier and 2.62 (95% CI 1.81 to 3.79) for infection in the previous 30 days. However negative and positive SARS-CoV-2 tests were more frequent in the days surrounding diabetes presentation. In those aged 0-14 years incidence of type 1 diabetes in the population from 2015-2021 were also estimated in a generalised additive model.

Results: There were 365080 in the cohort with at least one detected SARS-CoV-2 infection during follow-up and 1074 who developed type 1 diabetes. The rate ratio for incident type 1 diabetes associated with first positive test for SARS-CoV-2 (reference category: no previous infection) was 0.88 (95% CI 0.63 to 1.23) for infection more than 30 days earlier and 2.62 (95% CI 1.81 to 3.79) for infection in the previous 30 days. However negative and positive SARS-CoV-2 tests were more frequent in the days surrounding diabetes presentation. In those aged 0-14 years incidence of type 1 diabetes during 2020-2021 was 20% higher than the 7-year average.

Conclusion: Type 1 diabetes incidence in children increased during the pandemic. However the cohort analysis suggests that SARS-CoV-2 infection itself was not the cause of this increase.

Supported by: DiabetesUK 17/0005627
Disclosure: H.M. Colhoun: None.

234 Relation of incident type 1 diabetes to recent COVID-19 infection: cohort study using e-health record linkage in Scotland
H.M. Colhoun1, S. McGurnaghan1, L. Blackbourn1, L.E. Bath2, D.A. McAllister1, T.M. Caparrotta1, S.H. Wild3, S.N. Wood4, D. Stockton5, P.M. McKeigue6; 1Institute of Genetics & Cancer, University of Edinburgh, Edinburgh, 2Royal Infirmary of Edinburgh, Edinburgh, 3University of Glasgow, Glasgow, 4University of Edinburgh, Edinburgh, 5Public Health Scotland, Edinburgh, UK.

Background and aims: Studies using claims databases reported that SARS-CoV-2 infection >30 days earlier increased the incidence of type 1 diabetes. Using exact dates of diabetes diagnosis from the national register in Scotland linked to virology laboratory data we sought to replicate this finding.

Materials and methods: A cohort of 1849411 individuals aged <35 years without diabetes, including all those in Scotland who subsequently tested positive for SARS-CoV-2, was followed from 1 March 2020-22 November 2021. Incident type 1 diabetes was ascertained from the national registry. Using Cox regression we tested the association of time-updated infection with incident diabetes. Trends in incidence of type 1 diabetes in the population from 2015-2021 were also estimated in a generalised additive model.

Results: There were 365080 in the cohort with at least one detected SARS-CoV-2 infection during follow-up and 1074 who developed type 1 diabetes. The rate ratio for incident type 1 diabetes associated with first positive test for SARS-CoV-2 (reference category: no previous infection) was 0.88 (95% CI 0.63 to 1.23) for infection more than 30 days earlier and 2.62 (95% CI 1.81 to 3.79) for infection in the previous 30 days. However negative and positive SARS-CoV-2 tests were more frequent in the days surrounding diabetes presentation. In those aged 0-14 years incidence of type 1 diabetes during 2020-2021 was 20% higher than the 7-year average.

Conclusion: Type 1 diabetes incidence in children increased during the pandemic. However the cohort analysis suggests that SARS-CoV-2 infection itself was not the cause of this increase.

Supported by: DiabetesUK 17/0005627
Disclosure: H.M. Colhoun: None.

235 Modifiable risk factors including HbA1c and BMI are consistently associated with severe influenza, pneumonia, and Covid-19 infection outcomes in people with type 2 diabetes
R. Hopkins, K.G. Young, J. Godwin, D. Raja, N.J. Thomas, B.M. Shields, J.M. Dennis, A.P. McGovern; Institute of Biomedical & Clinical Science, University of Exeter Medical School, Exeter, UK.

Background and aims: Previous UK population-based research has identified risk factors for severe Covid-19 outcomes in people with type 2 diabetes, but it is unclear whether these are specific to Covid-19 or general to respiratory infections. We aimed to compare risk factors for hospitalisation from Covid-19 (pre-vaccination roll-out) to those for pneumonia and influenza.

Materials and methods: UK routine primary care data were accessed from the Clinical Practice Research Datalink (CPRD) and linked to Hospital Episode Statistics (HES). We followed adults with type 2 diabetes from 01/09/2018-31/05/2019 (influenza and pneumonia hospitalisation cohort, n = 655,677) and from 01/02/2020-31/10/2020 (Covid-19 hospitalisation cohort, n = 583,185). We used multivariable Cox proportional hazard models to identify sociodemographic risk factors (sex, age, ethnicity, index of multiple deprivation quintile) and modifiable risk factors (HbA1c and BMI) for hospitalisation in each cohort. Models...
were adjusted for macrovascular and microvascular complications, and other key comorbidities.

**Results:** We observed 6,061 (1.04%) hospitalisations for Covid-19, 1,358 (0.21%) for influenza, and 13,987 (2.13%) for pneumonia. When assessing sociodemographic risk factors, for Covid-19 we replicated previously reported associations between male sex, older age, greater deprivation, non-white ethnicities, and severe outcomes. However, these differed from the associations found for the other respiratory infections. We observed a differential effect of ethnicity, where compared to people of white ethnicity, black and south Asian groups had increased Covid-19 hospitalisation (adjusted hazard ratio [aHR] 1.84 [95% CI 1.67-2.03], p<0.001, and 1.42 [1.30-1.54], p<0.001, respectively), but lower hospitalisation for pneumonia (aHR 0.74 [95% CI 0.68-0.82], p<0.001, and 0.87 [0.81-0.93], p<0.001, respectively). There was a stronger association between age and hospitalisation for pneumonia (aHR per 10 year increase in age: 1.51 [95%CI 1.48-1.54], p<0.001) than for Covid-19 (aHR 1.23 [1.19-1.26], p<0.001) and influenza (aHR 1.15 [1.08-1.22], p<0.001). Assessing modifiable risk factors, high HbA1c (>86 mmol/mol) was a consistent risk factor for all three respiratory infections: aHR for HbA1c ≥86 vs 48-53 mmol/l: 1.48 [95% CI 1.33-1.65], p<0.001 for Covid-19, 1.62 [1.29-2.05], p<0.001 for influenza, 1.33 [1.23-1.44], p<0.001 for pneumonia. Similarly, marked obesity (BMI>40) was a consistent risk factor: BMI >40 vs 25-29.9 kg/m² aHR 1.50 [1.36-1.67], p<0.001 for Covid-19, 1.48 [1.21-1.81], p<0.001 for influenza, 1.34 [1.24-1.44], p<0.001 for pneumonia.

**Conclusion:** In people with type 2 diabetes, sociodemographic risk factors, such as ethnicity and age, are differentially associated with hospitalisation for Covid-19, influenza, and pneumonia. Therefore existing Covid-19 risk models cannot be assumed to be entirely applicable to new respiratory infections. However, higher HbA1c and BMI are consistently associated with hospitalisation for all three infections studied. This supports that good glycaemic and weight control may lower the risk of severe respiratory infection outcomes.

**Disclosure:** R. Hopkins: None.

### 236

**Enterovirus infection and risk of islet autoimmunity and type 1 diabetes: systematic review and meta-analysis of molecular studies**

S.R. Isaacs1,2, A. Roy3, B. Dance1, D.B. Foskett1,2, A.J. Maxwell1,2, W.D. Rawlinson1,2, K.W. Kim1,2, M.E. Craig1,4,

1School of Women’s and Children’s Health, Faculty of Medicine, University of New South Wales, 2Serology and Virology Division, NSW Health Pathology, Virology Research Laboratory, Prince of Wales Hospital, 3School of Medical Sciences, Faculty of Medicine, University of New South Wales, 4Institute of Endocrinology and Diabetes, Children’s Hospital at Westmead, Sydney, Australia.

**Background and aims:** Molecular methods of enterovirus (EV) detection have been widely adopted in recent years, especially within large prospective cohort studies of islet autoimmunity (IA) and type 1 diabetes (T1D). Here, we present a major update to our previous systematic review of molecular detection of EV infection and (i) IA or (ii) T1D.

**Materials and methods:** A systematic search of controlled observational human studies was performed using PubMed and Embase databases until August 2021 (PROSPERO #CRD42021236044), with no language restrictions. Eligible studies included cohort or case-control studies measuring EV RNA or protein in blood, stool, or tissue of individuals with IA or T1D, and in controls. Studies were assessed for bias using the Newcastle-Ottawa Scale and NHMRC levels of evidence, with meta-analysis performed in RevMan v5.4 using the Mantel-Haenszel method and random effects models, producing ORs with 95% CIs and p-values for each outcome.

**Results:** The initial search returned 3266 publications; removal of 570 duplicates and 1799 irrelevant studies left 897 relevant articles for full-text screening. After consolidation of participant overlap, the 113 records meeting eligibility criteria were assigned to 61 study units (50 case-control/NHMRC-III, 11 nested case-control/NHMRC-II), where 41 examined T1D, nine IA, and 11 both outcomes. NOS scores ranged from 2 to 8, with 34 studies scoring ≥6, indicating good methodological quality. For 25 studies, cases could be further separated into multiple groups, resulting in 91 case sub-groups overall (24 for IA, 67 for T1D). There were 11975 participants altogether, including 6003 cases (900 with IA, 5103 with T1D) and 5972 controls. Study design, quality, and method of EV detection demonstrated high levels of statistical heterogeneity. Meta-analysis of 56 studies demonstrated a significant association between EV infection and IA (17 studies, OR 2.16 [1.23-3.74]; p=0.004; χ²/df=2.77) and T1D (48 studies, OR 8.41; 5.16-13.69; p<0.00001; χ²/df=6.59); within one month of T1D onset (27 studies, OR 18.01; 9.37-34.60; TBC p<0.00001; χ²/df=3.50).

**Conclusion:** There is a clinically significant association between EV infection, and both IA and T1D. This further supports the rationale for development of EV-targeted vaccines and antiviral therapy to prevent and reduce the impact of T1D. Large prospective studies commencing from pregnancy (e.g., ENDA and DIPP-novum) will provide insight into the temporal relation between EV infection and the development of IA and T1D in early life.

**Disclosure:** S.R. Isaacs: None.

© Springer
OP 42 Moving towards the beta cell plasma membrane

237

OSBP-mediated PI(4)P-cholesterol exchange at endoplasmic reticulum-secretory granule contact sites controls insulin secretion

S. Panagiotou 1, P.M. Nguyen 1, A. Wendt 1, L. Eliasson 2, A. Tengholm 1, O. Idevall-Hagren 2

1Medical Cell Biology, Uppsala University, Uppsala, 2Clinical science, Lund University Diabetes Centre, Malmö, Sweden.

Background and aims: Insulin granule biogenesis is a multi-stage process that involves cargo loading and processing and intracellular transport. Mature granules dock with the plasma membrane and undergo exocytosis to release insulin. We recently identified phosphatidylinositol-4 phosphate (PI[4]P) dephosphorylation by Sac2 on the surface of insulin granules as a key step in granule docking and finding that Sac2 levels were reduced in islets from type-2 diabetics. The aim of this study was to determine how Sac2 and its lipid substrate PI(4)P contribute to the regulation of insulin secretion from β-cells.

Materials and methods: Clonal MIN6 β-cells expressing fluorescently tagged proteins were imaged by spinning disk confocal and TIRF microscopy. Cellular cholesterol distribution was determined using fluorescently labeled cholesterol (TopFlour-cholesterol, live cells) or Filipin (fixed cells). Insulin secretion from MIN6 cells and mouse islets was determined by ELISA. Ultrastructural analysis of mouse and human islet cells was performed by transmission electron microscopy. For visualization of ER-granule contact sites in living cells, we developed a method based on dimerization-dependent red fluorescent protein monomers.

Results: Sac2 knockdown resulted in pronounced cholesterol accumulation on insulin granules, seen as increased TopFlour-cholesterol fluorescence (0.117 for control, 0.161 for Sac2-KD, n = 25-26 cells, P < 0.05) and enhanced Filipin staining (control = 98 ± 3, Sac2-KD = 136 ± 5, n = 54, P < 0.001). Oxysterol-binding protein (OSBP) can exchange PI(4)P for cholesterol at membrane contact sites, and we found that OSBP knockdown normalized insulin granule cholesterol levels in Sac2 knockdown cells. OSBP localized to the trans-Golgi compartment under resting conditions but redistributed to insulin granules following inhibition of lipid exchange with 20 nM OSW-1 (n=6, P<0.001 for comparison to control). Similar redistribution was seen in mouse islets immunostained for OSBP and insulin. Depolarization of MIN6 cells also resulted in physical contacts between these two organelles and revealed that OSBP resides at these locations. siRNA-mediated knockdown of OSBP in MIN6 cells caused a 10±2% (n=4, P<0.05) reduction in GSIS and acute inhibition of OSBP with OSW-1 impaired second phase insulin secretion from mouse islets (n=6, P<0.05) without affecting cytosolic Ca2+.

Conclusion: Sac2 controls granule PI(4)P levels, which in turn fuel cholesterol transport to granules through the action of OSBP at ER-insulin granule contact sites. Defects in this lipid exchange result in impaired insulin secretion. This study identifies ER-granule contacts as important reaction centers in β-cells where lipid exchange occurs, but these sites are likely involved in additional processes, and identifying these is an important future goal.

Supported by: Swedish Research Council, NNF

Disclosure: S. Panagiotou: None.

238

Presynaptic scaffold protein, liprin, regulates glucose stimulated insulin secretion and the spatial organisation of exocytosis in pancreatic beta cells

K. Deng, N. Hallahan, P. Thom;
Charles Perkins Centre, The University of Sydney, Sydney, Australia.

Background and aims: A key feature of insulin secretion is that it is targeted towards specialised regions (or hot spots) of the β-cell membrane. Recent evidence has shown that these exocytotic hotspots lie at the interface between β-cells and extracellular matrix (ECM) proteins of the islet capillaries. However, how insulin secretion is targeted towards these regions of cell-capillary contact remains elusive. Analogous to targeted insulin exocytosis in the β-cell, neurotransmitter release in neurons is confined to a specialized region of the presynaptic membrane known as the active zone; here, exocytosis is spatially regulated by a large multiprotein complex consisting of presynaptic scaffolds which dock and tether synaptic vesicles to specific sites for fusion. Interestingly, several of these presynaptic scaffold proteins (liprin, ELKS, RIM and piccolo) that are typically associated with the neuronal active zone have also been identified in β-cells and are enriched at the β-cell-capillary interface where secretion is targeted; however, whether these scaffold proteins facilitate targeted exocytosis in β-cells, as they do in neurons, is unknown. This research investigates presynaptic-like mechanisms for the spatial regulation of exocytosis in the β-cell, particularly, the role of liprin in positioning sites of β-cell insulin exocytosis.

Materials and methods: β-cells were isolated from humanely sacrificed C57BL/6 mice (approved by local and national ethics). We performed 3D live-cell two-photon imaging on β-cells expressing GFP-tagged liprin, to visualise the precise location of liprin with respect to sites of insulin exocytosis. We then optimised a protocol for the knockdown of liprin using an adovanol-investigated shRNA system. We measured glucose-stimulated insulin secretion (GSIS) in control (scramble shRNA) and knockdown (liprin shRNA) β-cells using homogenous time resolved fluorescence and performed immunofluorescence staining. Finally, we expressed various liprin mutant constructs (designed to specifically interfere with binding to other presynaptic scaffold proteins) in β-cells to test whether liprin interacts or assembles with other scaffold proteins in a β-cell 'presynaptic-like' complex.

Results: We show that liprin assembles in small ‘islands’ or microdomes at the β-cell-capillary interface, where insulin granules preferentially fuse near (<0.3 μm) liprin structures (p<0.01) but are excluded from regions directly overlapping with liprin (p<0.01), suggesting that liprin may be involved in tethering insulin granules to specific sites for fusion. Western blot confirmed shRNA-knockdown of liprin (42.1%±4.0) in β-cells to test whether liprin interacts or assembles with other scaffold proteins in a β-cell 'presynaptic-like' complex.

Conclusion: We show that liprin is involved in spatially regulating insulin exocytosis through mechanisms analogous to a neuronal synapse.

Supported by: NHMRC, The Bioscientifica Trust

239  
**Vamp8 is an endosomal v-SNARE involved in GLP1R trafficking and inhibits insulin exocytosis**

L. Liu, M. Marshall, J. Saras, S. Barg;  
Medical Cell Biology, Uppsala University, Uppsala, Sweden.

**Background and aims:** Insulin is released by Ca²⁺-dependent-dependent exocytosis of secretory granules, while many receptors, ion channels and transporters reach the membrane by constitutive exocytosis of vesicles that belong to the endosomal system. Both processes rely on distinct sets of SNARE proteins for membrane fusion. Beta cells express both VAMP2 on insulin granules and VAMP8 (endobrevin), which is an endosomal vesicular SNARE that has been proposed to have an additional role in “newcomer” exocytosis of insulin granules. The differential role of VAMP isoforms in insulin secretion is not well understood.

**Materials and methods:** Live cell TIRF-microscopy was performed in INS1 cells and in dispersed beta cells of cadaveric human donors. Vesicle behavior, exocytosis, and protein location was studied by expressing EGFP- or mCherry-tagged versions. Exocytosis was evoked by elevated K⁺ in presence of 10mM glucose/200μM diazoxide. Association of proteins with vesicular compartments was analyzed by quantitative image analysis. Gene expression was studied in publicly available expression data.

**Results:** VAMP8-EGFP was found on rab5-, rab7, and rab11-positive endosomal vesicles, but not on rab3- or NPY-labeled insulin granules. Depolarization with elevated K⁺ promoted exocytosis of the VAMP8/rab11-positive vesicles; these vesicles were distinct from insulin granules since exocytosis proceeded with a slower monophasic time course, was insensitive to tetanus toxin cleavage of VAMP2, and was accelerated by somatostatin but not exendin-4. VAMP8-positive vesicles underwent exocytosis within seconds of their arrival at the plasma membrane, in contrast to minutes for secretory granules. These vesicles also contained GLP1-receptor, GLUT2, and the autophagosome marker LC3. Expression of full-length VAMP8, VAMP8 lacking its transmembrane domain (but not VAMP2) inhibited exocytosis of insulin granules. The latter is consistent with negative correlation between VAMP8 gene expression and secretory index (SI) in human donor islets (p-uncorr.=0.00016, n=125).

**Conclusion:** We conclude that VAMP8 associates with early, late and recycling endosome compartment, but not insulin containing secretory granules. VAMP8 traffics to the plasma membrane with, and likely promotes, exocytosis of a rab11-positive endosomal recycling compartment. While Ca²⁺-dependent exocytosis of these vesicles controls surface expression of important membrane proteins (GLP1R and GLUT2), the associated release of VAMP8 may also regulate insulin secretion. Finally, the data suggest that the previously described “newcomer” exocytosis reflects release from an endosomal compartment, rather than exocytosis of insulin containing secretory granules.

Supported by: VR, NNF, DiabF, Ernfors, Rudberg  
**Disclosure:** None.

240  
**Villin interacts with Snap25 and its expression increases in tamoxifen-treated EndoC-βH3 cells**

H. Mziaut1, J. Kalaidzidis1, J. Dehghany2, A. Gheisari1, M. Herbig1, J.-C. Escolano4, A. Sümmez3, M. von Bülow5, M. Lohmann3, Y. Kalaidzidis6, M. Meyer-Hermann2, J. Guck4,7, A. Schulte3, R. Scharfmann3, M. Solimena1,6;  
1Paul Langerhans Institute Dresden, Dresden, Germany, 2Helmholtz Centre for Infection Research, Braunschweig, Germany, 3Biopolis Dresden Imaging Platform (BioDIP), TU Dresden, Dresden, Germany, 4Biotechnology Center, Center for Molecular and Cellular Bioengineering, Dresden, Germany, 5Diabetes, Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany, 6Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany, 7Max Planck Institute for the Science of Light & Max-Planck-Zentrum für Physik und Medizin, Erlangen, Germany, 8INSERM, U1016, Institut Cochin, Paris, France.

**Background and aims:** Ica512/Ptprn is a transmembrane cargo of the insulin secretory granules (ISGs). In Ica512⁻/⁻ mouse islets, ISG stores as well as mRNA and protein levels of the F-actin modifier villin are strongly reduced. In rat insulinoma INS-1 cells, villin dynamically modulates the size of actin cages surrounding cortical ISGs, hence regulating their mobility and exocytosis. Evidence that villin acts downstream of Ica512 suggests that ISGs directly influence the remodelling of the cortical cytoskeleton for tight control of glucose-stimulated insulin secretion (GSIS). In the present studies we tested this hypothesis further.

**Materials and methods:** ISG motility in siRNA villin-depleted INS-1 cells was analyzed by total internal reflection fluorescence microscopy and in silico modelling. Protein-protein interactions in INS-1 cells were investigated by Förster-resonance energy transfer (FRET) and microscale thermophoresis (MST). Gene expression and protein localization in tamoxifen (TAM)-treated and untreated EndoC-βH3 cells, a surrogate model of human pancreatic β-cells, were assessed by next generation sequencing and confocal microscopy, respectively. Stiffness of TAM-treated and untreated EndoC-βH3 cells was quantified by atomic force microscopy (AFM) and real-time deformability cytometry (RT-DC).

**Results:** In silico modelling of siRNA villin-depleted INS-1 cells suggested that increased ISG motility could not account alone for enhanced basal insulin release unless more docking sites for ISG exocytosis were accessible. Overexpression in INS-1 cells of villin and Snap25-mCherry for MST, and villin-TQ2, Snap25-Venus and positive and negative control reporters for FRET indicated that villin interacts with the SNARE Snap25. This finding is reminiscent of previous studies indicating that the villin paralogue gelsolin interacts with the SNARE Syntaxin4. Accordingly, in siRNA villin-depleted INS-1 cells, Snap25 was less restricted at the plasma membrane. Reduced proliferation as well as enhanced ISG stores and GSIS of TAM-treated EndoC-βH3 cells correlated with increased mRNA and protein expression of ICA512 and villin. Furthermore, TAM-treated EndoC-βH3 cells, as measured by RT-DC and AFM were 32% larger and had significantly higher apparent elastic modulus, while the processive mobility of ISGs was increased.

**Conclusion:** Based on these data we propose that: a) villin-induced remodelling of the F-actin cytoskeleton modulates ISG exocytosis by regulating their mobility and access to Snap25; b) upon β-cell differentiation villin expression is upregulated through Ica512 to adapt the plasticity of the cortical cytoskeleton to the enlarged ISG stores, thus enabling a tight control of GSIS.  
**Supported by:** RHAPSODY, EFPIA, SERI, BMBF, SMWK and DZD  
**Disclosure:** H. Mziaut: None.
OP 43 Microvascular cocktail

241

Prognostic value of diabetes microvascular complication for 21-years all-cause mortality

L. Sacchetta1, M. Chiriacò1, G. Forotti1, S. Leonetti2, L. Netti1, A. Natali1, A. Solini1, D. Tricò1;
1University-Hospital of Pisa, 2Sant’Anna School of advanced studies, Pisa, Italy.

Background and aims: Diabetes mellitus is associated with microvascular complications that impair patients’ prognosis and quality of life. Here we aimed to evaluate the impact of directly-measured diabetes microvascular complications, alone or in combination, on long term all-cause mortality.

Materials and methods: 497 subjects were screened for microvascular complications from 1999 to 2001. Diabetic kidney disease (DKD) was defined as glomerular filtration rate (GFR) <60 ml/min measured by dynamic renal scintigraphy and/or overnight albuminuria >20 μg/min; diabetic retinopathy (DR) by presence of pre-proliferative or proliferative retinopathy at dilated fundus oculi examination; and cardiac autonomic neuropathy (CAN) by presence of at least 2 cardiovascular test abnormalities and/or postural hypotension. Mortality data were retrieved from administrative databases for 303 (61.0%) patients in April 2021. Multivariate models were adjusted for age, sex, BMI, HbA1c, type and duration of diabetes.

Results: After 5,244 person-years of follow-up among 303 participants (median follow-up 21.0 [14.0-21.0] years, age 55.5±13.8 years, 155 [51%] women, BMI 28.6±5.9 kg/m², HbA1c 9.0±2.1%, 218 [71.9%] with type 2 diabetes and 85 [28.1%] with type 1 diabetes), a total of 133 (43.9%) deaths occurred. The prevalence of DKD, DR, and CAN at baseline was 23.1%, 33.3%, and 24.1%, respectively. The presence of DKD reduced the mean overall survival (OS) by 2.6 years (-14.4%; log-rank test p<0.0001) and increased the adjusted all-cause mortality risk by 117% (aHR 2.17 [1.45-3.26]) (panel A). Patients with CAN showed 8.1% reduction in mean OS (-1.4 years; log-rank test p=0.046) and 54% increase in the adjusted risk for all-cause mortality (aHR 1.54 [1.01-2.36]). DR showed a mean OS reduction of 1.3 years (-7.4%; log-rank test p=0.02) but only numerically higher mortality risk (HR 1.23 [0.82-1.84]). A significant interaction emerged between CAN and type of diabetes (p=0.04), with CAN increasing all-cause mortality risk only in type 2 diabetes patients (HR 1.78 [1.32-2.81]). Patients with one, two, or three complications showed, respectively, a reduction in mean OS of 0.48 years (-2.7%), 2.52 years (-14%), and 2.96 years (-16.4%) (log-rank test p=0.0016). The presence of two or three concomitant microvascular complications increased the adjusted risk for all-cause mortality by 203% (HR 3.03 [1.62-5.68]) and 692% (HR 7.92 [2.93-21.37]), respectively (panel B).

Conclusion: Chronic microvascular complications significantly increase the 21-year all-cause mortality risk in patients with diabetes, regardless of age, sex, BMI, glycaemic control, diabetes type and duration. Multiple microvascular complications reduce life expectancy and have additive effects on the incidence of all-cause death in a real-life population with diabetes.

Supported by: EFSD Rising Star Fellowship
Disclosure: L. Sacchetta: None.

242

Three-years follow up of retinal neurodegeneration and neuropathic characteristics in pediatric type 1 diabetic patients

M. Menduni1, F. Picconi1, M.C. Parravano2, B. Russo1, A. Maiorino1, L. Chioma1, S. Cianfarani1, D. Ylli4, P.I. Patena1, S. Frontoni1;
1Unit of Endocrinology, Diabetes and Metabolism, S. Giovanni Calibita Fatebenefratelli Hospital, Rome, Italy, 2IRCCS G.B. Bietti Foundation, Rome, Italy, 3Diabetes Unit, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy, 4Division of Endocrinology, MedStar Washington Hospital Center, MedStar Health Research Institute, Washington DC, USA.

Background and aims: Retinal neurodegeneration (RN) is considered an early marker of diabetic retinopathy. Few data are available on the possible association between RN and diabetic neuropathy (DN) and the predictive role of glycemic variability (GV) and lipid profile on early RN signs in the pediatric population with type 1 diabetes mellitus (T1DM). We previously demonstrated, in adult T1DM patients, a significant association between
GV and triglyceride (TG) with early RN and between TG and the risk for early peripheral DN, independent of glucose control. The aim of our study is to evaluate the 3-year progressions of structural alteration of neuroretina, the possible association between these early alterations and DN and the predictive role of GV and lipids on these precocious changes in pediatric T1DM subjects.

**Materials and methods:** 25 patients with T1DM (ages 10-20 years), using continuous glucose monitoring and continuous subcutaneous insulin infusion, without any complication, and 18 healthy controls (C), comparable in age and gender, were enrolled and followed for 3 years. All subjects underwent an Optical Coherence Tomography Heidelberg Spectralis, with analysis of macular neuroretinal layers. In T1DM, metabolic parameters, GV indexes, peripheral (Michigan Neuropathy Screening Instrument-MNSI), thermal threshold and vibration perception threshold-VPT) and autonomic assessment (using cardiovascular autonomic reflex tests) were investigated. Data were collected at baseline (V0) and after 12 (V1), 24 (V2) and 36 months (V3).

**Results:** During the 3-year follow up, among neuroretinal layers, Retinal Nerve Fiber Layer (RNFL), Outer Plexiform Layer (OPL) and Inner Retinal Thickness (IRT) were significantly thinner in T1DM versus C and a progressive reduction in OPL was observed in T1DM (p<0.05). In T1DM patients, negative correlations were observed between GV and neuroretinal layers, specially between continuous overall net glycemic action-1h and RNFL at V0 (r=0.4, p=0.05), between mean absolute glucose (MAG) and OPL (r=0.5, p=0.04) at V2 and between IRT delta thickness (V2-V1) and Lability Index (r=-0.6, p=0.01). No significant correlation between HbA1c and macular layer thickness was observed (p>0.05). Among metabolic parameters, a negative correlation between TG and IRT delta thickness (V2-V1) r=-0.5, p=0.01) was found. Among neuropathic characteristics, at V3, a negative correlation between the systolic blood pressure fall and OPL (r=-0.9 p=0.04) and a positive correlation between the VPT and RNFL (r=0.2 p=0.05) were observed. Moreover, there was a positive correlation between low blood glucose index and VPT (r=0.7 p=0.01) and between MAG and MNSI (r=0.7 p=0.02).

**Conclusion:** Very early morphological alterations of neuroretina are already present in pediatric T1DM patients without both vascular retinopathy and DN, and there is a possible association between these variations and early signs of peripheral and autonomic DN. These data corroborate the hypothesis that RN is, in fact, an early sign of DN and GV and TG should be efficaciously addressed in the early stage of T1DM.

**Disclosure:** M. Menduni: None.

### 244 Circulating proteins associated with risk of progression to ESKD in type 1 diabetes: results of multi-cohort study

**J.K. Haukka**1,2, Z.M. Dom1,4, V. Curovic3, K. Ihara1, E. Satake3,4, S. Mutter3, C. Forsblom1,2, A. Doria3,4, N. Sandholm1,2, P. Rossing2, P.-H. Groop1, A. Galecki3,6, A. Krolewski1,4

1Folkhälsan Research Center, Helsinki, Finland, 2Abdominal Center, Nephrology, Helsinki, Finland, 3Research Division, Joslin Diabetes Center, Boston, USA, 4Harvard Medical School, Boston, USA, 5Steno Diabetes Center, Copenhagen, Herlev, Denmark, 6Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, USA.

**Background and aims:** Recently, many circulating proteins were found to be associated with the development of diabetic kidney disease (DKD) and its progression to ESKD. To facilitate research on the development of prognostic tests and on the role of circulating proteins in the etiology of DKD, a small set of 21 important proteins, referred to as the Joslin Kidney Panel, was developed. The assays to quantify these proteins were developed by OLINK Inc (Uppsala Sweden). The aim of this study was to examine whether the proteins included in the JK Panel were associated with progression to ESKD.

**Materials and methods:** Three international cohorts of patients with T1D, macro-albuminuria and eGFR >45 ml/min had been assembled and followed for 7 - 20 years to ascertain onset of ESKD: at Joslin (Boston) 387 patients (127 ESKD), at Steno (Denmark) 435 patients (104 ESKD), and at FinnDiane (Finland) 387 patients (127 ESKD). Methods of the assembly and follow-up of these cohorts were described previously (Skupien et al, 2019). Serum concentrations of the 21 proteins were measured with the OLINK platform. Association with DKD
progression to ESRD was analyzed with Cox regression adjusted for baseline urinary albumin excretion rate, eGFR, and HbA1c.

**Results:** On average, patients who progressed to ESKD in comparison with those who did not progress had shorter duration of diabetes (26 vs. 28 years), higher baseline HbA1c (9.5 % vs. 8.9 %) and lower baseline eGFR (69 vs. 89 ml/min/1.73m²). Across the 3 cohorts all 21 proteins with nominally significant P-values show positive association with DKD progression (Figure 1). Strikingly, in the Joslin and the FinnDiane Cohorts almost all circulating proteins included in the JK Panel had strong association with progression to ESKD except for TNFRSF6B and PI3. In the Steno cohort, examined proteins showed weaker association with progression to ESKD compared to the two other cohorts. We are presently using the above data to develop a prognostic algorithm to estimate time to onset of ESKD in patients with DKD.

**Conclusion:** The JK Panel of circulating proteins measured using a custom-made OLINK platform showed extremely similar findings in two international cohorts. The weaker association with progression to ESKD of the majority proteins examined in Steno Cohort is difficult to explain at present. The JK Panel should be examined further not only for prediction of time to ESKD but also for identification of patients who will respond to specific reno-protective therapies and for monitoring the effectiveness of such therapies.

**OP 44 Grading insulin therapy: simple, simpler, the safest**

245 Delayed prandial insulin boluses are frequent and associated with glucose control in type 1 diabetes patients on advanced technologies

**R. Triggiani,** R. De Angelis, L. Bozzetto, G. Annuzzi; Federico II University, Naples, Italy.

**Background and aims:** Advanced technologies (Hybrid Closed Loop Systems (HCLS) and Sensor Augmented Pump (SAP)) significantly improve blood glucose control in patients with type 1 diabetes. However, the optimization of their performances requires patient’s compliance to proper pre-meal insulin bolus administration. We explored how timely patients on HCLS or SAP inject the pre-meal bolus and whether delayed boluses may affect blood glucose control.

**Materials and methods:** One-hundred fifty-three type 1 diabetes patients, 79 women and 54 men, aged 41.9±14.2 on HCLS (n=121) or SAP (n=32) were consecutively recruited for this study. Two diabetologists (RT, RDA) independently reviewed two-week CGM and pump reports. Delayed boluses were assigned when a prandial bolus was preceded on CGM by a steep increase in blood glucose clearly indicating a postprandial response. An online questionnaire on Fear of Hypoglycemia was completed by participants Two-week CGM metrics were evaluated in relation to the number of delayed boluses by Pearson correlation

**Results:** At least one delayed bolus was identified in all patients, with a mean total number over two weeks of 9.2±4.4 delayed boluses. The number of delayed boluses was directly associated with GMI (r=0.356, p<0.001), Coefficient of variation (r=0.290, p<0.001), TAR>250 (r=0.412, p<0.001), TAR>180 (r=0.303, p<0.001), TBR<70 (r=0.063, p=0.436), TBR<54 (r=0.082, p=0.311), and inversely associated with TIR (r=-0.441, p<0.001). The number of delayed boluses was directly associated with fear of hypoglycemia at work, during night and being alone.

**Conclusion:** Delayed insulin boluses in patients on advanced technologies are very common (on average 1 out of 5 meals) and are associated with a significant worsening of blood glucose control. Adequate attention should be given to the timing of bolus injection also in patients on advanced technologies, mainly acting on fear of hypoglycemia.

**Disclosure:** R. Triggiani: None.

246 With which dose of NPH insulin to start at bedtime? Study in a cohort of 1006 patients with type 2 diabetes and failure of oral anti-diabetic drugs

**B. Mertes**1, S. Gödde1, G. Egidi2, T. Uebel3, G. Kramer4, N. Kunii5,6,1Abteilung Diabetes, Neuropathie, Fußsyndrom, Cardioangiologisches Centrum Bethanien, Frankfurt am Main, 2Hausarztpraxis, Bremen, 3Hausarztpraxis, Neckargemünd, 4FB Endokrinologie und Stoffwechsel, Universitätsklinikum Jena, Klinik für Innere Medizin III, Jena, 5Dr. med. Kielsiel Ambulante Medizinische Versorgung GmbH, Erfurt, Germany.

**Background and aims:** In the updated German National Health Care Guideline “Therapy of diabetes type 2”, for the first time, NPH insulin (Neutral Protamine Hagedorn, isophane insulin) at bedtime is recommended, if the HbA1c therapy target is missed after failure of oral medication. As a starting dose, various research groups worldwide recommend 0.1-0.2 IU/kg body weight. However, systematic studies investigating the starting dose of an insulin therapy with NPH insulin do not exist.

**Materials and methods:** A cohort of 1006 patients with diabetes type 2 and failure of oral anti-diabetic drugs was treated additionally with NPH
insulin at bedtime (63% male, age 59.5±11.5 years, weight 91.8±19.1 kg, body mass index 31.4±5.9 kg/m², diabetes duration 7.5±5.7 years, HbA1c 8.6±1.1%, number of different oral antidiabetic agents 1.2±0.5/patient). Blood glucose levels were checked twice during the night (22:00, 2:00, 5:00, and 7:00 h) to detect hypoglycaemia from a dose of 12 IU. All patients participated in structured education programme for individuals with insulin therapy at baseline. The combination of oral antidiabetic agents remained unchanged. Multiple linear regression was used to determine which factors influence final insulin dose.

**Results:** The NPH insulin dose of initially 9.4±2.0 IU was adapted within 20.2±24.9 days to 9.8±2.7 IU. This corresponds to a final insulin dose of 0.1±0.03 IU/kg body weight. In 77 patients (7.7%) the initial insulin dose had to be reduced by 2.4±1.09 IU due to low blood glucose levels during the night. Severe hypoglycaemia did not occur. Body weight and HbA1c were significantly associated with the final insulin dose. The lower the BMI (p<0.001) and the higher the HbA1c (p<0.001), the higher the insulin dose.

**Conclusion:** The NPH insulin dose of up to 0.2 IU/kg recommended by various research groups worldwide is too high. For example, a patient with body weight of 90 kg would need to inject 18 IU NPH insulin at baseline, but only 10 IU according to our study. A too high dose can be associated with nocturnal hypoglycaemia. A limitation of this study is the retrospective setting. If oral medication fails in type 2 diabetes, NPH insulin should be started at night with 0.1 IU/kg body weight. At a NPH insulin dose of 12 IU and above, monitoring blood glucose levels during the night is recommended.

**Disclosure:** B. Mertes: None.

---

**Background and aims:** InRange is the first large randomised controlled trial to use continuous glucose monitoring (CGM) time-in-range (TIR) as a primary efficacy endpoint to compare second-generation basal insulin analogues, insulin glargine 300 U/mL (Gla-300) and insulin degludec 100 U/mL (IDeg-100) in adults with type 1 diabetes (T1D).

**Materials and methods:** Multicentre, randomised, active-controlled, parallel-group, 12-week open-label study comparing efficacy of Gla-300 and IDeg-100 using 28-day CGM profiles (≥10 days evaluable) at Week 12. Inclusion: adults with T1D treated with multiple daily injections and subsequently after 3 months of treatment after switching to IDeg-Lira. The study enrolled 147 patients with DM2T with duration > 5 years, on IIT treatment > 12 months, with HbA1c > 7%, with preserved insulin secretion and total daily insulin dose (TDDI) <0.7 U/kg body weight or <70 U/day. Parameters of glycemic control (HbA1c, glycemia in glycemic profiles) were compared during the treatment of IIT and subsequently after 3 months of treatment after switching to IDeg-Lira. In a subgroup (n=31) of patients, continuous glucose monitoring (CGM) was performed and parameters time in range (TIR), time above range (TAR), and time below range (TBR) were evaluated. Other endpoints were body weight (BW), body mass index (BMI), blood pressure, lipids.
the prevalence of hypoglycemia, and insulin doses. Switching from IIT to IDEgLira was performed in a single ambulatory session with an initial dose of IDEgLira up to 16 U followed by titration of ± 2-4 U/3 days.

**Results:** Analysis of the results after the first 3 months of treatment showed that switching from IIT to IDEgLira was associated with a significant improvement both with HbA1c (8.6±0.9 vs 7.7±1.2, p<0.0001) and plasma glucose levels in glycemic profiles. TIR and TAR values were also improved, but the difference was not statistically significant. Change of treatment has also been associated with significant reductions in BW (97.7±18.3 vs 94.2±17.9 kg, p<0.0001), BMI, systolic blood pressure, triglycerides, total cholesterol, and LDL-cholesterol. There was also a significant reduction in frequency of hypoglycaemia both in self-monitoring (0.52 vs 0.03 episodes per patient, 19.7% vs 3.4% of patients) and TBR (2.8% vs 0.8%, p<0.05 in CGM), and a significant reduction in insulin doses (55.6±14.3 vs 30.9±9.4 U, p<0.0001).

**Conclusion:** Switching from IIT to IDEgLira in DM2T with HbA1c >7%, preserved insulin secretion and TDDI <70U was a safe, effective, and less demanding form of treatment, the benefit of which manifests already after three months of treatment.

**Disclosure:** E. Martinka: Lecture/other fees; Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi.
Clinical Trial Registration Number: EUDRACT Code 2016-0022250-10

Supported by: Investigator-initiated study supported at 49% by an unrestricted grant from Boehringer Ingelheim

Disclosure: L. Nesti: None.

250

Novel subgroups of patients with type 2 diabetes show differential cardiovascular and kidney benefits with canagliflozin: a data-driven proteomic cluster analysis

M. Schechter1, A. Koshino1, N. Jongs1, B. Neal2, C. Arnott2, V. Perkovic2, M.K. Hansen3, H.J. L. Heerspink1,2

1Dept of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, Netherlands, 2The George Institute for Global Health, UNSW Sydney, Sydney, Australia, 3Janssen Research and Development, LLC, Spring House, USA.

Background and aims: Canagliflozin (CANA) improves cardiovascular (CV) and kidney outcomes in patients with type 2 diabetes (T2D) at high CV or kidney risk. By applying a data-driven approach, we tested whether a combination of novel protein biomarkers could identify patients that are more likely to experience CV or kidney benefits with CANA treatment.

Materials and methods: The CANVAS trial randomized 4330 participants with T2D at high CV risk to receive CANA or placebo. The primary CV outcome was a composite of non-fatal myocardial infarction or stroke or CV death. The prespecified kidney outcome was a composite of sustained ≥40% estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, or death due to kidney failure. K-mean clustering, relying on eight novel biomarkers (IL-6, TNFR1, TNFR2, KIM1, GDF15, MMP7) and urine (EGF, MCP1) protein biomarkers, was used to classify patients into subgroups. The elbow, silhouette, and gap statistic methods were applied to determine the optimal clusters’ number. Treatment effects of CANA on CV and kidney outcomes across biomarker clusters were assessed using Cox proportional hazard models.

Results: Complete biomarkers values at baseline were available in 3381 (78.1%) participants, followed for a median [IQR] of 6.1 [5.9, 6.4] years. Cluster 1, N=1957; Cluster 2, N=1424. Compared with Cluster 1, participants in Cluster 2 had lower baseline eGFR (mean [SD]= 69.6 [16.6] vs 86.2 [13.8] mL/min/1.73 m2), higher urine albumin to creatinine ratio (UACR; median [IQR]= 19.6 [8.3,82.7] vs 8.9 [5.8,18.5] mg/g), and were more likely to have established CV disease (78.1%) participants, followed for a median [IQR] of 6.1 [5.9, 6.4] years. All biomarkers’ levels were higher in Cluster 2, except for urine EGF which was higher in Cluster 1. Within each cluster, baseline characteristics were balanced between the CANA and placebo groups. Compared with placebo, CANA improved the cardiovascular outcome in Cluster 2 but not in Cluster 1 (P-interaction =0.011; table). In contrast, its effect on the kidney outcome was statistically significant in Cluster 1 but not in Cluster 2 (P-interaction =0.004). The interaction remained statistically significant after model adjustment for other baseline clinical characteristics.

Conclusion: This data-driven analysis, relying on a combination of novel biomarkers, suggested two separate clusters among participants in the CANVAS trial – in one cluster CANA improves the CV outcome, and in the other CANA improves the kidney outcome. These hypothesis-generating findings warrant validation in a separate clinical trial.

Perkovic2, M.K. Hansen 3, H.J. L. Heerspink1,2; 1Endocrinology, Clinical Sciences, Lund University, 2Endocrinology, Skane University hospital, Lund, Sweden.

Background and aims: Type 2 diabetes is a significant risk factor for cardiovascular disease and death. In people with type 2 diabetes and higher risks of cardiovascular disease, several large randomised controlled trials have identified a reduction in cardiovascular mortality and non-fatal cardiovascular complications after initiating treatment with sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP1-RA). Although the first data were published in 2015, the prescription of these drugs in people with high-cardiovascular risk has been modest. This study aimed to evaluate the effect of prescription of SGLT-2 inhibitors and/orGLP1-RA on all-cause mortality in people younger than 70 years with type 2 diabetes having their first myocardial infarction.

Materials and methods: This study is an observational, population-based cohort study of individuals with type 2 diabetes, aged between 40 and 69 years, and the first diagnosis of myocardial infarction between January 2016 and December 2020 in Sweden using data from national registries. People with type 2 diabetes were identified in the National Drug Prescription Registry and defined as people who at least twice had been prescribed an anti-diabetic drug. Prescription of any of these drugs. The primary endpoint, all-cause mortality in people younger than 70 years with type 2 diabetes having their first myocardial infarction.

Results: Complete biomarkers values at baseline were available in 3381 (78.1%) participants, followed for a median [IQR] of 6.1 [5.9, 6.4] years. K-mean clustering, based on the eight novel biomarkers, discovered two different patients’ clusters (Cluster 1, N=1957; Cluster 2, N=1424). Compared with Cluster 1, participants in Cluster 2 had lower baseline eGFR (mean [SD]= 69.6 [16.6] vs 86.2 [13.8] mL/min/1.73 m2), higher urine albumin to creatinine ratio (UACR; median [IQR]= 19.6 [8.3,82.7] vs 8.9 [5.8,18.5] mg/g), and were more likely to have established CV disease (61.4% vs. 57.5% of patients). All biomarkers’ levels were higher in Cluster 2, except for urine EGF which was higher in Cluster 1. Within each cluster, baseline characteristics were balanced between the CANA and placebo groups. Compared with placebo, CANA improved the cardiovascular outcome in Cluster 2 but not in Cluster 1 (P-interaction =0.011; table). In contrast, its effect on the kidney outcome was statistically significant in Cluster 1 but not in Cluster 2 (P-interaction =0.004). The interaction remained statistically significant after model adjustment for other baseline clinical characteristics.

Conclusion: This data-driven analysis, relying on a combination of novel biomarkers, suggested two separate clusters among participants in the CANVAS trial – in one cluster CANA improves the CV outcome, and in the other CANA improves the kidney outcome. These hypothesis-generating findings warrant validation in a separate clinical trial.

Clinical Trial Registration Number: NCT01032629

Supported by: Janssen Research & Development Disclosure: M. Schechter: None.
GLP1-RA, while 26.8% was prescribed an SGLT-2 inhibitor, 9.4% a GLP-1 RA and 13.6% drugs from both these classes. During the follow-up period (median three years), 1001 events (11.0%) occurred. The five-year mortality is given in Figure 1.

**Conclusion:** In this population of younger people with type diabetes and a first myocardial infarction between 2016 and 2020, prescription of an SGLT-2 inhibitor or a GLP1-RA was associated with lower five-year mortality. The number of high-risk patients with access to the drugs still seems too low.

Supported by: Unrestricted grant from Boehringer-Ingelheim.

Disclosure: M. Löndahl: Grants; Unrestricted grant from Boehringer-Ingelheim. Lecture/other fees; AstraZeneca, Boehringer-Ingelheim, EliLilly, NovoNordisk.

---

**Efficacy of ertugliflozin (ERTU) on hospitalisation for heart failure (HHF) across the spectrum of pre-trial ejection fraction (EF): post hoc analyses of VERTIS CV**

A. Pandey¹, A.A. Kolkailah¹, F. Cosentino², C.P. Cannon³, R. Frederich⁴, D.Z.I. Cherney⁵, S. Dagogo-Jack⁶, R.E. Pratley⁷, N.B. Cater⁸, I. Gantz⁹, J.P. Mancuso¹⁰; ¹Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, USA, ²Unit of Cardiology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, ³Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA, ⁴Pfizer Inc., Collegeville, USA, ⁵University of Toronto, Toronto, Canada, ⁶University of Tennessee Health Science Center, Memphis, USA, ⁷AdventHealth Translational Research Institute, Orlando, USA, ⁸Pfizer Inc., New York, USA, ⁹Mercer & Co., Inc., Kenilworth, USA, ¹⁰Pfizer Inc., Groton, USA.

**Background and aims:** There is controversy over whether SGLT2 inhibitors have efficacy in high-risk patients (pts) with HF and EF >60% with or without T2D. VERTIS CV studied pts with T2D and atherosclerotic CVD (ASCVD); 23% had a history of HF. In VERTIS CV, ERTU significantly reduced risk of first and total HHF vs placebo (PBO). Whether efficacy in VERTIS CV is consistent across the spectrum of pre-trial EF is unknown, particularly for pts with EF >60%. These post hoc analyses explored the effects of ERTU vs PBO on time to first and total HHF in VERTIS CV across pre-trial EF.

**Materials and methods:** ERTU 5 and 15 mg groups were combined for all analyses. Treatment effects of ERTU vs PBO on risk of first and total HHF were analysed using adjusted Cox models for first and Andersen-Gill models for total (i.e., first + recurrent) events. Data on pre-trial EF were from medical records at trial entry. Multiplicative interaction terms (EF * treatment arm) were used to determine if ERTU efficacy was modified by pre-trial EF.

**Results:** 8246 pts were randomised to ERTU 5 or 15 mg or PBO (mean follow up 3.5 years). Overall, 5006 pts had pre-trial EF data available; 959 had EF ≤45%, 2860 had EF >45-60%, and 1187 had EF >60%. Overall, the event rate for first HHF was lower with ERTU vs PBO (HR 0.70; 95% CI 0.54-0.90). The findings were generally consistent across pre-trial EF (P-interaction=0.26; Figure), including pts with pre-trial EF >60% (HR 0.72; 95% CI 0.34-1.55). Overall, the event rate for total HHF was lower with ERTU vs PBO (HR 0.70; 95% CI 0.56-0.87). A significant interaction was observed between pre-trial EF and treatment arm for the risk of total HHF events (P-interaction=0.02), with a greater magnitude of risk reduction in pts with a low pre-trial EF (<45%; HR 0.39; 95% CI 0.26-0.57). However, the 95% CIs for the HR for total HHF for those with EF >45-60% and >60% nearly entirely or entirely contained the 95% CI of the overall population, respectively (Figure).

**Conclusion:** In the VERTIS CV trial of pts with T2D and ASCVD, the efficacy of ERTU in preventing first HHF was generally comparable across the spectrum of pre-trial EF. The trend for greater benefit at lower EF was statistically significant for total HHF events. Findings for pts with EF >45-60% and >60% appeared quantitively consistent with the overall findings for both first and total HHF.

Clinical Trial Registration Number: NCT01986881

Supported by: Merck Sharp & Dohme Corp., Kenilworth, NJ, USA; Pfizer Inc., New York, NY, USA

Disclosure: A. Pandey: Grants; Texas Health Resources Clinical Scholarship, Gilead Sciences Research Scholar Program, National Institute of Aging GEMSSTAR Grant (1R03AG067960-01), Applied Therapeutics. Non-financial support; A.P. has served on the advisory board of Roche Diagnostics.
OP 46 Profiling human diabetes risk

Clustering analysis based on parameters of glucose metabolism shows different lipidomic profile among men and women

A. Pina1, M.J. Meneses1,2, R. Ribeiro3, R. Patarrão4, F. Carli5, J. Boavida5, J.F. Raposo7, A. GAstaldelli7, M.P. Macedo1,2; 1MEDIR, CEDOC, Lisbon, Portugal, 2APDP - Associação Protetora dos Diabéticos de Portugal, Lisbon, Portugal, 3National Research Council (CNR), Pisa, Italy.

Background and aims: Clustering analysis has been used to identify different phenotypes and to identify subjects at risk of developing Type 2 diabetes (T2D) and related comorbidities. Not only glucose but also lipids have a relevant role in the development and progression of T2D. Lipids (such as fatty acids, diacylglycerol (DAG) and sphingolipids) can act as signaling molecules and impact insulin action and metabolism through the regulation of intracellular pathways. Thus, we hypothesized that subjects stratified according to parameters related to insulin and glucose metabolism might have a different lipidomic profile.

Materials and methods: We studied 953 subjects from the PREVADIAB2 cohort (follow up of subjects that were without diabetes 5 years before, PREVADIAB1) and performed hierarchical clustering analysis based on fasting insulin secretion (fISR), resistance (HOMA-IR) and clearance (fIC) and insulinogenic index (IGI) during OGTT. The resulting clusters were profiled according to insulin resistance in different tissues (liver, muscle or adipose tissue) and insulin secretion, and the lipidome of a subset (n=488, 273 women and 215 men) was assessed by LC/MS-QTOF.

Results: Among the 488 subjects of PREVADIAB2 here reported, 41% did not change their glucose tolerance status while 19% had a worsening status (with prediabetes or T2D). We identified four clusters (Figure), that were named according to their main metabolic features: Liver Sensitive (LS); Pancreas Glucose Sensitive (PGS); Insulin Deficient (ID); and Insulin Resistant (IR). The LS cluster had the most advantageous lipid profile, whereas the other clusters presented lipid associated to glucose dysmetabolism. Although the pattern of glucose metabolism parameters were similar in men and women among clusters, the lipidomic profiles were different. Overall, women presented lower lysophosphatidylcholine (LPC) and long chain ceramides (CER 26:1) and higher sphingomyelins (SM) compared to men. Women presented lower TG in the LS group but slightly higher TG in the IR group. CER with less than 18 Carbons were higher in women than men in PGS, ID and IR groups (Figure).

Conclusion: In conclusion, our work shows that not only glucose but also lipidomic profile should be included in the analysis of phenotypes, but furthermore differentiated by gender for the increased risk of T2D.

Dynamics of intramyocellular lipid content during the initial course of type 1 and type 2 diabetes

M. Schön1,2, K. Strassburger1,2, Y. Kupriyanova1,2, O.P. Zaharia1,4, K. Bödis1,4, I. Yurchenko1,2, C. Möser1,2, M. Huttenbach1,2, M. Bombrich1,2, V. Schrauwen-Hinderling1,2, V. Burkart1,2, M. Roden1,4; 1Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, 2German Center for Diabetes Research (DZD), München-Neuherberg, 3Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, 4Department of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Background and aims: Ectopic fat accumulation in skeletal muscle associates with insulin resistance and is frequently higher in both type 1 (T1D) and type 2 (T2D) diabetes. Recent studies also suggest an important role of intramyocellular lipid (IMCL) for the development of diabetes-related comorbidities, such as non-alcoholic fatty liver disease (NAFLD). However, the dynamics of IMCL over the course of diabetes remain unknown. The aim of this study was (i) to compare IMCL in humans with recent-onset (known diabetes duration <1 year) T1D and T2D, (ii) to monitor the dynamics of IMCL during the initial 5 years of diabetes, and (iii) to examine whether worsening of insulin resistance and increase in liver fat is associated with accelerated IMCL accumulation.

Materials and methods: Participants of the German Diabetes Study (GDS) with recent-onset T1D (n=132, male/female=72/60) and T2D (n=139, m/f=95/44), and glucose-tolerant humans (CON; n=128; m/f=87/41) underwent 1H magnetic resonance spectroscopy for the assessment of IMCL in tibialis anterior muscle and liver fat content. Whole-body insulin sensitivity (WBIS) was assessed by hyperinsulinenmic-euglycemic clamps, and body composition and skeletal muscle mass by bioelectrical impedance. All measurements were repeated after 5 years in subgroups of T1D (n=27, m/f=12/15), T2D (n=29, m/f=24/5) and CON (n=20, m/f=16/4).

Results: At diabetes diagnosis, humans with T2D had lower WBIS, but higher IMCL than persons with T1D and CON (all p<0.01), even after adjustments for age, sex and body mass index (BMI). Adults with T1D had lower IS, but similar IMCL when compared with CON (p<0.01). IMCL were positively correlated with BMI in all groups (CON/T1D/ T2D: ß=2.12/1.62/2.74, p=0.04/0.03/0.01) and negatively with WBIS in T1D and T2D (ß=-3.03/-4.12, both p<0.01). In T2D, IMCL also correlated negatively with skeletal muscle mass (ß=3.61, p<0.01), but positively with liver fat content (ß=2.47, p=0.01). After 5 years of overt diabetes, WBIS decreased in T1D and T2D (both p<0.01) and liver fat increased in T2D (p<0.01) without any change in IMCL.

Conclusion: In conclusion, ectopic fat accumulation is elevated already at diagnosis of T2D. However, IMCL remain largely unchanged within 5 years after diagnosis demonstrating that muscle triglyceride content does not necessarily mirror progression of insulin resistance and NAFLD in T2D.

Clinical Trial Registration Number: NCT01055093
Supported by: BMFB, DZD
Disclosure: M. Schön: None.

256

Machine-learning prediction of obesity-related multi-morbidities
L.E. Lund1, R.L. Nielsen2, Z. McVey1, R.R. Kitchen1, L.G. Leal1, A.T.H. Schreyer1, T. Monfeuq1, K.S. Matthiessen1, M.L. Wolden1, R. Gupta1, D. Romeres2, C. Cobelli3


Background and aims: Obesity is a risk factor for the onset of several clinical complications. The clinical trajectory of a person with obesity varies; although some patients do not develop any obesity-related complications (ORCs), others develop multi-morbidities with fast progression. There is a clinical need to understand which ORCs frequently co-occur as well as the time of progression to these, and to identify prognostic biomarkers of multi-morbidities for early patient identification and intervention. We developed a predictive risk model to assess the progression of ORCs. Our focus in this study is early diagnosis and optimising treatment opportunities.

Materials and methods: Participants in UK biobank (N=500K) with linked electronic health records data from primary and secondary care data were used in this study to identify progression of ORCs. Individual

255

Diabetes remission by weight loss in 'normal' weight people with type 2 diabetes: the ReTUNE study
R. Taylor1, A.C. Barnes2, K.M. Irvine2, L. Clark2, A. Al-Mrabeh2, A. Solovyova2, T.L. Kelly2, K.G. Hollingsworth2, C. Martin-Ruiz3, R.R. Holman4, D. Romeres2, C. Cobelli3,

1Newcastle University, Newcastle upon Tyne, UK, 2Human Nutrition Research Centre, Newcastle University, Newcastle upon Tyne, UK, 3Centre for Cardiovascular Science, Edinburgh University, Edinburgh, UK, 4Professional Services, Newcastle University, Newcastle upon Tyne, UK, 5Biosciences, Newcastle University, Newcastle upon Tyne, UK, 6OCDEM, University of Oxford, Oxford, UK, 7Department of Endocrinology, University of Virginia, Charlottesville, USA, 8Department of Women and Child's Health, University of Padova, Padova, Italy.

Background and aims: Pathophysiological changes underlying weight loss-induced remission of type 2 diabetes (T2DM) have been reported only in people with BMI >27kg/m². The Personal Fat Threshold hypothesis predicted that the same pathophysiological mechanisms would operate in people with BMI <27kg/m², but at a lower individual threshold for overflow of fat from subcutaneous to intraorgan sites. ReTUNE aimed to test the hypothesis in this population.

Materials and methods: People with T2DM (mean±SD) 59.3±7.1 years, BMI 24.8±1.7kg/m², 13/20 female) were studied before and after up to three induced 5% weight loss cycles, each comprising a 2-4 week low energy diet (800kcal/day formula meal replacements plus non starchy vegetables), followed by 4-6 weeks of weight maintenance. All hypoglycaemic agents were stopped after baseline tests and before weight loss. Studies were repeated at 12 months. Outcomes were compared to normoglycaemic controls matched for post-weight loss (n=20; data shown in square brackets). Intrahepatic and intrapancreatic fat was quantified by magnetic resonance, plasma very low density lipoprotein triglyceride (VLDL-1TG) by ultracentrifugation and insulin secretion by Disposition Index (DI) after standard meal. Data are shown as mean ±SE or median (interquartile range).

Results: 70% (14/20) achieved sustained remission (HbA1c <48mmol/mol off all hypoglycaemic agents). After the 1st weight loss cycle 10 were in remission, 3 after the 2nd cycle and 1 after the 3rd cycle of weight loss, with median time to remission of 8 (IQR 8-14) weeks. There was no weight regain from the the final weight loss visit to 12 months (64.1 ±2.9 to 64.11 ±2.6kg p=0.86). Weight loss was accompanied by decrease in some signals of adipose tissue distress (PAI-1 4.6±1.1 to 3.99±0.77, p<0.02 [control 4.8±3.4-7.03]) ng/ml; GDF-15 39±d(439-872) to 44±d(395-554) [44±d(383-614)] (p<0.05). Between baseline and 12 months: BMI fell 24.8±0.4 to 22.5±0.4 kg/m² (p<0.0001) [21.5 ±0.5]; total body fat 32.1±1.5 to 27.6±1.8% (p<0.0001) [24.6±1.5]; liver fat 4.1±2.0-6.1% (p<0.01) [1.3(1.0-2.0)]; VLDL-1TG 0.32(0.28-0.57) to 0.22(0.15-0.25)mmol/l (p<0.05) [0.21(0.15-0.29)]; pancreas fat 6.1±0.5 to 5.0±0.7% (p<0.01) [4.1±0.3]. Fasting plasma insulin decreased from 47±6 to 24±6pmol/l (p<0.001) [23±2] and DI increased from 289 (183-373) to 774 (486-1709) dl/kg/min per pmol/l (p<0.05) but remained subnormal [2751 (1524-3526).

Conclusion: The mechanistic changes underpinning weight loss-induced remission of T2DM in people with BMI <27 are the same previously observed in those with BMI >27kg/m². T2DM occurs if a person exceeds their personal fat threshold and becomes too heavy for their own constitution, irrespective of BMI.

Clinical Trial Registration Number: ISRCTN15177113
Supported by: Diabetes UK 17/0005645
Disclosure: R. Taylor: None.
patients’ journeys were mapped in the context of first clinical obesity indication (BMI ≥ 30 or obesity diagnosis; N=−145K) to map risk of developing ten of the more commonly occurring ORCs. These ORCs are cardiovascular disease, chronic back pain, chronic respiratory diseases, dyslipidaemia, gastroesophageal reflux disease, hypertension, knee osteoarthritis, mental disorders, obstructive sleep apnoea, and type 2 diabetes (T2D). Machine-learning models (Extreme gradient boosting; XGB) were trained to predict the risk among the subpopulation with obesity to develop multi-morbidity (two or more ORCs) within 10 years of the first indication of obesity with no previous history of the selected ORCs. The XGB models integrated multi-faceted data including blood biomarker data as well as anthropometrics, lifestyle and nutrition, questionnaires, socioeconomic status, and genetic data to estimate individual risk.

Results: 81,504 people with obesity had no diagnosis of the ORCs before obesity onset. 42% of these people (N=34,629) developed no complications, 25% developed one, 15% developed two (time of onset 6.2 ± 7.3 years), and 18% developed ≥3. Hypertension was most common (39%), followed by dyslipidaemia (12%), and T2D (11%). When predicting ORCs within 1-10 years following first obesity indication, XGB models performed slightly better when predicting risk of developing 3+ ORCs [Receiver operating characteristic (ROC) AUC: 95% CI 0.72-0.76] compared to 2+ ORCs [ROC AUC: 95% CI 0.70-0.72]. The most predictive model identified 69% of the non-progressors and 68% of the progressors where age, HbA1c, albuminuria, and self-reported health ratings were signatures of ORC archetypes.

Conclusion: Sub-groups of individuals with obesity progress to multi-morbidity. Predictive models help distinguish people with obesity at high risk of developing ORCs from non-progressors. Such predictive models can potentially assist in identification of appropriate intervention and treatment strategies that are tailored to meet the needs of the individual.

Disclosure: L.E. Lund: None.

OP 47 Novel mechanistic insights in peripheral insulin sensitivity

257 Proteome-wide mechanisms of hyperinsulinemia and sucrose-induced, tissue-specific insulin resistance

H.H. Cen1, V.R. Richard2, Y.H. Xia3, S. Skovso1, J.D. Botezelli1, X. Hu1, J. Collier2, R.P. Zahedi2, C.H. Borchers2, J.D. Johnson1; 1Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, Canada, 2Segal Cancer Proteomics Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Canada, 3Pennington Biomedical Research Center, Baton Rouge, USA, 4Gerald Bronfman Department of Oncology, Jewish General Hospital, McGill University, Montreal, Canada.

Background and aims: Hyperinsulinemia has been shown to play a causal role in obesity and insulin resistance during the progression to type 2 diabetes, challenging the long-held dogma that it is solely an adaptive response. Added sucrose in food and beverages also has been shown to influence obesity and diabetes in human and pre-clinical models, but the mechanisms are not well defined. We aim to study the roles of hyperinsulinemia in sucrose-induced insulin resistance and obesity and to dissect the tissue-specific molecular mechanisms involved.

Materials and methods: Genetically modified mice that produce less insulin (Ins1+/−;Ins2−/+ vs Ins1+/+;Ins2−/−) were fed with water or 30% liquid sucrose in the context of a chow diet (Cat. # 5L15, PicoLab) and phenotyped for 26 weeks. To assess molecular changes in signaling pathways in multiple tissues, the total proteome and phosphoproteome of the liver, skeletal muscle and inguinal white adipose tissue were measured by label-free quantitative mass spectrometry. Pathways enriched from differentially expressed proteins and phospho-sites were analyzed using multiple bioinformatic tools.

Results: Ten weeks of sucrose-feeding increased body weight and fasting glucose while impairing glucose tolerance and insulin sensitivity in female mice. These effects were abrogated in mice with reduced insulin gene dosage. Proteomics and phosphoproteomics revealed distinct molecular changes in the liver, muscle and adipose tissue. The liver had the highest number of altered proteins and phospho-sites (>1000), followed by adipose tissue, while muscle had the least changes. The changes induced by sucrose were largely attenuated in mice with reduced insulin in all tissues. In the liver, pathways related to EIF2/4 and p70S6K signaling and glucose metabolism were downregulated by sucrose, while pathways related to amino acid metabolism and fatty acid oxidation were upregulated. Total and phospho-proteomics data were compared to transcriptomic data for a multi-omics analysis that allowed us to infer tissue-specific effects of hyperinsulinemia in the context of sucrose supplementation.

Conclusion: Sucrose induced weight gain and insulin resistance, which were rescued by preventing hyperinsulinemia. A large number of sucrose-induced changes in protein expression and phosphorylation status were identified in the peripheral tissues, especially in the liver. These data will offer new insights into the underlying molecular changes leading to obesity and type 2 diabetes.

Supported by: CIHR
Disclosure: H.H. Cen: None.
Impact of human Kallistatin on the metabolic phenotype of diet induced obese mice
1University Hospital Tuebingen, Tuebingen, Germany, 2Charité University School of Medicine, Berlin, Germany, 3University Clinic Dresden, TU Dresden, Dresden, Germany, 4University of Oklahoma Health Sciences Center, Oklahoma City, USA, 5Yale University School of Medicine, New Haven, USA, 6German Aerospace Center, Cologne, Germany, 7Hannover Medical School (MHU), Hannover, Germany.

Background and aims: Kallistatin (KST), also known as SERPIN A4, is a circulating, broadly acting human plasma protein with anti-angiogenic and anti-inflammatory properties. Clinical studies in humans revealed increased levels of KST in poor glycemic control and microvascular disease. Whether or not KST has a direct effect on glucose homeostasis in the setting of insulin resistance and Type 2 diabetes is currently unknown.

Materials and methods: To address this question, the expression of human KST in subcutaneous white adipose tissue (sWAT) of obese patients (n=47) before and after 6 months of dietary intervention (B-SMART study) was measured. Additionally, transgenic mice systemically overexpressing human KST (hKST-TG) and littermate-control wildtype mice (WT) were studied under chow (ND) and high fat diet (HFD) conditions. Metabolic phenotyping was performed using 1H nuclear magnetic resonance (NMR), intraperitoneal glucose tolerance test (IPGTT), hyperinsulinemic-euglycemic clamp, measurement of membrane and cytosolic diacylglycerides (DAGs) in liver and muscle, triglycerides (TAGs) in liver lysates, mRNA expression of inflammatory marker genes in liver and muscle and inflammatory markers in plasma. Furthermore, protein level of total β-catenin and β-actin protein level in liver tissue was analyzed using Western Blot Analysis.

Results: In human subjects, there was a more than 1.5-fold increase in KST with a body weight loss of more than 6% after intervention. Mice body weights were similar between hKST-TG and WT mice up to an age of 24 weeks on both diets. Intraperitoneal glucose tolerance tests (IPGTT) yielded similar glucose and insulin excursion curves in ND animals. In the weight matched HFD cohort, an IPGTT revealed an improvement in insulin sensitivity in hKST-TG mice. Additionally, the HOMA-IR was significantly lower in hKST-TG on HFD (2.2±0.27, hKST-TG vs. 4.4±2.87, WT, p<0.05), also indicating improved insulin sensitivity in hKST-TG mice. To better understand the tissue specific contribution to the protective effect of hKST, hyperinsulinemic euglycemic clamp studies with tracer labelled glucose were performed. Glucose infusion rates were assessed but did not reveal differences between genotypes. In contrast, hKST overexpression protected against HFD induced hepatic insulin resistance (clamp hepatic glucose output: 7.7±1.9 mg/kg/min, hKST-TG vs. 12.1±0.8 mg/kg/min, WT, p=0.05). To further gain mechanistic insight, body composition, energy metabolism, tissue lipid and inflammatory markers, with and without LPS stimulation, were assessed but did not reveal differences between genotypes. In contrast, changes in the β-catenin pathway were observed, potentially explaining the phenotype.

Conclusion: These data show that human KST protects against diet induced insulin resistance in mice. We speculate that increased KST levels in the setting of poor glycemic control and microvascular complications are rather protective than harmful.

Clinical Trial Registration Number: NCT00956566
Disclosure: L. Sandforth: None.

Down-regulated FXR signalling in the gut in subjects with prediabetes and type 2 diabetes
F. De Vito1, E. Suraci1, R. Marasco1, F. Andreozzi1, M.L. Hribal1, F. Luzzà1, G. Sesti1, T.V. Fiorentino1, F. De Vito:
1Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, 2Department of Clinical and Molecular Medicine, University Sapienza of Rome, Rome, Italy.

Background and aims: The bile acids farnesoid X receptor (FXR) is emerging to be implicated in the regulation of energy homeostasis. Treatment with obeticholic acid (OCA), a FXR agonist, has been found to improve glucose metabolism in subjects with type 2 diabetes (T2DM) with mechanisms not completely elucidated. In the gut, FXR is mainly expressed in the ileum and promotes transcription of fibroblast growth factor-19 (FGF19), a hormone with positive effects on energetic and glucose homeostasis. Additionally, preclinical evidence suggests that FXR regulates expression of the tight-junction (TJ) proteins, which control intestinal barrier permeability. Altered gut permeability has been associated with cardiometabolic disorders. Herein, we examined whether subjects with altered glucose tolerance have reduced ileal FXR abundance along with a downregulation of FGF19 and TJ expression, and whether these aberrations are reverted by treatment with OCA.

Materials and methods: Study population includes 32 subjects subdivided on the basis of their glucose tolerance in: normal glucose tolerance (NGT) (n=12), prediabetes (n=10) and T2DM (n=10). All subjects underwent to a colonoscopy with terminal ileum endoscopy and collection of ileum mucosa biopsies. Intestinal levels of FXR, FGF19 and TJ protein were assessed by WB and RT-PCR. Serum levels of FGF-19 were measured by a specific ELISA kit. To investigate the effect of OCA treatment, ileal mucosa specimens collected from subjects with T2DM were cultured in absence or presence of OCA.

Results: Ileal levels of FXR were progressively reduced in individuals with prediabetes (-15%, P=0.01) and T2DM (-25%, P=0.01) as compared to those with NGT. The reduced ileal FXR abundance observed in subjects with dysglycemic conditions was paralleled by a reduction in ileal levels of FGF-19 mRNA, with subjects with prediabetes exhibiting a 25% reduction, and those with T2DM a 50% reduction (both P<0.05). These changes were accompanied by a similar reduction in serum FGF-19 concentration (-25% and -45% in subjects with prediabetes and T2DM, respectively, as compared to NGT group, P<0.05). Additionally, we observed a progressive decrease in ileal mRNA and protein levels of the TJ zonulin (ZO)-1, claudin-1 and occludin in subjects with prediabetes and T2DM (P<0.05). Next, in order to explore whether FXR stimulation by OCA treatment may revert dysglycemic related aberrations in ileal FXR/FGF-19/TJ integrity axis we performed intestinal organ culture experiments. Ileal mucosa specimens collected from subjects with T2DM were cultured in presence or absence of OCA (20 µM) for 6 hours. We found that OCA treatment resulted in an upregulation of FGF-19 mRNA and release in the culture media by 10-fold and 1.4-fold, respectively, and in 6-fold increased TJ protein ZO-1 and occludin expression (P<0.01).

Conclusion: Our findings demonstrate that a downregulation of FXR/FGF-19/TJ axis occurs in subjects with prediabetes and T2DM, indicating intestinal FXR signaling as a novel target in prevention and/or treatment of T2DM.

Supported by: EFSD/Lilly Young Investigator Research Award Programme
Disclosure: F. De Vito: None.
Expression, phosphorylation, and oligomerisation of TBC1D1 splice variants from human skeletal muscle cells

A.D. Bedou1,2, T. Stemmann1,2, S. Eckelschulte1,2, A. Chadt1,2, H. Al-Hasani1,2,
1Institute for Clinical Biochemistry and Pathobiocchemistry, German Diabetes Center, Heinrich Heine University, Leibniz Center for Diabetes Research, Düsseldorf, 2German Center for Diabetes Research, Munich-Neuherberg, Germany.

Background and aims: The 160kDa RabGTPase-activating protein TBC1D1 is a crucial factor in skeletal muscle insulin- and contraction-stimulated glucose uptake. Phosphorylation of the 600kDa oligomeric TBC1D1 by AKT or AMPK leads to increased translocation of the glucose transporter GLUT4 to the plasma membrane and enhanced glucose uptake. Genetic variation in TBC1D1 confers risk for severe obesity. For the human TBC1D1 gene, 3 major isoforms are annotated in the NCBI RefSeq database, however, the properties and function of these splice variants are not clear. We aim to determine the expression profile of the 3 different TBC1D1 variants in human primary skeletal muscle cells (HSMCs) and to analyze their function in cell-free in vitro systems.

Materials and methods: Expression levels of TBC1D1 were determined in un- and differentiated HSMCs by RT-PCR. TBC1D1 isoforms were cloned in mammalian expression vectors, overexpressed in HEK-293 cells and purified via co-immunoprecipitation. Oligomerization of TBC1D1 isoforms was assessed using pulldown assays and Western Blot analysis. AKT2 and AMPK were applied to analyze the kinase-dependent phosphorylation kinetics of purified recombinant full-length His6-TBC1D1 variants expressed in Sf9 insect cells via the Baculovirus system.

Results: HSMCs displayed expression of two TBC1D1 variants, encoding for a SHORT 1168 aa and a LONG 1262 aa TBC1D1 isoform. Interestingly, the third annotated variant missing 103 amino acids in the TBC1D1 RabGAP domain (GAP-VAR) was not detected. Expression of the LONG variant was 11-times higher in differentiated than in undifferentiated HSMCs (p < 0.0001). Combined co-immunoprecipitation and immunoblotting analysis showed interconvertible oligomerization of all three isoforms: LONG vs. GAP-VAR 1.17% (p = 0.03) and SHORT vs. GAP-VAR 4.29% (p = 0.0005), respectively, as well as GAP-VAR and SHORT 0.37% (p = 0.08). While phosphorylation of all TBC1D1 isoforms was detected in both homo- and heterooligomers, TBC1D1 heterooligomerization resulted in reduced phosphorylation levels compared to the homodimers. Both AKT2 and AMPK showed a strong preference for Ser660 in the LONG variant (Km pSer660: ~8 μM; Km pSer660: ~3 μM), whereas corresponding Km values for AKT2 and AMPK were about 14-times higher in the GAP-VAR variant (Km pSer660: ~117 μM; Km pSer660: ~42 μM). Interestingly, Km values for the phosphorylation sites Thr596 and Ser700 were in the same order of magnitude for AKT2 and AMPK for the LONG and the GAP-VAR variant. Moreover, AMPK Ser700 phosphorysiet showed Km values about 5-times higher in the GAP-VAR variant compared to the LONG variant (Km pSer700: ~1.5 μM; Km pSer700: ~8 μM).

Conclusion: Our findings suggest that the abundance of TBC1D1 splice variants switches from predominant expression of the SHORT variant in undifferentiated myoblasts to the LONG variant as predominant isoform in differentiated myotubes. Moreover, TBC1D1 protein isoforms generate both homo- and heterooligomers independent of phosphorylation by AKT2 and AMPK. Phosphorylation levels of the main AKT target site Thr596 are not different between the LONG and the GAP-VAR variant. In contrast, both AMPK target sites Ser660 and Ser700 show a stronger affinity for the LONG variant compared to the GAP-VAR TBC1D1 variant.

Disclosure: A.D. Bedou: None.
262

GLP-1R modulates the alloimmune response as a T cells negative costimulatory molecule

V. Usuelli1, M. Ben Nasser1, A. Seelam1, V. Fiorentino2, F. D’Addio1, C. Loretteli1, E. Assi1, G. Zuccotti1, F. Foti1, P. Fiorina1
3

1Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, DIBIC, University of Milan, Milan, 2University of Catanzano, Catanzano, 3University of Milan, ASST Santi Paolo e Carlo, Milan, Italy.

Background and aims: Glucagon Like Peptide-1 (GLP-1) regulates glucose metabolism by activating its receptor (GLP-1R), which is expressed by pancreatic beta-cells, gastric mucosa and the hypothalamic appetite center. A GLP-1R agonist, Exendin-4 (Exe-4), has reduced the incidence and severity of severe diabetes complications. Beside these metabolic effects, an increasing body of evidences suggests that GLP-1R may have a role in the immune system. GLP-1R expression has been detected in various populations of immune cells, including dendritic cells and T lymphocytes. However, there is no conclusive evidence about a possible immune role of GLP-1R and its signaling. In this present study, we seek to clarify the role of GLP-1R in T lymphocytes during the alloimmune response using murine models of islet and cardiac allotransplantation.

Materials and methods: Cardiac allografts from BALB/c mice were transplanted intra-abdominally in C57BL/6 mice. Rejection was determined as cessation of cardiac contractility. Pancreatic islets from BALB/c mice were inoculated under the renal capsule of each C57BL/6 recipient rendered diabetic with streptozotocin. Rejection of islet allotransplantation.

Results: Our data showed that CD4 and CD8 T lymphocytes expressed GLP-1R (human T cells: CD4+=66%, CD8+=28%; murine T cells: CD4+=6%, CD8+=4.5%). The presence of a discrete GLP-1R+ population was mainly confined to CD4+, CD8+ effector T cells and to CD4+ regulatory T cells. When C57BL/6 mice received islet or cardiac allotransplantation from a fully mismatched BALB/c donors, an expansion of GLP-1R+ CD4+ and GLP-1R+CD8+ T cells occurred in the spleen and were found to infiltrate the graft at high percentage. The treatment with Exendin-4 significantly prolonged islet (p<0.001) and cardiac allograft survival (p<0.01), and reduced graft T lymphocytes infiltrates. A strong synergism in mitigating alloimmunity was observed between Exendin-4 and Rapamycin showing a prolongation of graft survival (p=0.0001). The beneficial effects of Exendin-4 were partly abolished by the co-administration of its antagonist Exendin 9-39. To get further insight into the molecular mechanism responsible for T cell modulation by GLP-1R, we observed that mitogen stimulation of splenocytes rendered CD4+ GLP-1R+ and CD8+GLP-1R+ T cells more apoptotic as compared to their negative counterparts. Notably, our transcriptomic profiling on CD4+GLP-1R+ and CD8+GLP-1R+ T cells revealed their tendency toward an apoptotic and anergic profile as compared to their counterparts CD4+GLP-1R- and CD8+GLP-1R- T cells.

Conclusion: Altogether, our findings suggested that GLP-1R appeared to act as a negative costimulatory molecule and the GLP-1R agonist Exendin-4 prolongs allograft survival, mitigates alloimmunity during alloimmune response, reduces T lymphocytes graft infiltration and skews the effector/regulatory T cell balance.

Disclosure: V. Usuelli: None.
mg/dL and 165 ± 21 mg/dL) when compared to controls (314 ± 28 mg/dL and 308 ± 38 mg/dL). In contrast, transplantation of Casp1−/− islets did not restore physiological blood glucose levels (217 ± 37 mg/dL).

Conclusion: This study demonstrates that suppression of NLRP3 in isolated islets markedly improves their revascularization after transplantation in an insulin-dependent manner.

Disclosure: S. Wrublewsky: None.

264 Metabolic stress by high fat diet increased diabetes incidence in the LEW.1AR1-iddm rat model of autoimmune diabetes without trigger by systemic inflammation

J.-N. Dahmen1,2, T. Schöppe2, M. Tiedge2;

1Dept. of Internal Medicine and Cardiology | CVK, Charité - Universitätsmedizin Berlin, Berlin, 2Dept. of Medical Biochemistry & Molecular Biology, Rostock University Medical Center, Rostock, Germany.

Background and aims: Metabolic stress and systemic inflammation are not only considered factors in the pathogenesis of non-insulin dependent diabetes mellitus (NIDDM) but may also play a role in the activation of autoaggressive T-cells in autoimmune diabetes. The crosstalk between metabolism, immune system and beta cells may affect the trigger period of autoimmunity. To clarify the mechanisms of metabolic stress on beta cell autoimmunity we fed a hypercaloric high fat diet (HFD) to LEW.1AR1-iddm rats. This strain develops spontaneous autoimmune diabetes beginning at about 60 days of age. Infiltration of pancreatic islets starts within a narrow time frame between 40 and 45 days of life. We investigated the effect of the HFD high fat diet on the inflammatory and metabolic state during the development of beta cell autoimmunity. We also tested whether a HFD increases the incidence of diabetes and diabetes onset occurs earlier in life.

Materials and methods: LEW.1AR1-iddm rats and diabetes-resistant LEW.1AR1 rats received a high fat diet (HFD; 60 % of energy from fat) or a standard diet (SD; 9 % of energy from fat). Key parameters of metabolism (indirect calorimetry; body weight; blood glucose) and systemic inflammation (gene expression patterns in peripheral blood mononuclear cells -PBMCs) were determined at different ages between day 35 and 60. Animals were monitored for hyperglycemia until the age of 120 days.

Results: Under standard diet LEW.1AR1-iddm rats showed higher gain of body weight and higher respiratory quotients than the diabetes-resistant background strain. Gene expression signatures in PBMCs were characterized by proinflammatory cytokines IL-1β and IFN-γ at the beginning of insulitis. After day 50 low levels of FOXP3 expression and an increase of T-cell markers could be observed. The HFD lowered the respiratory quotient to 0.7 and resulted in a higher energy uptake, metabolic rate and activity scores in both strains. Prediabetic LEW.1AR1-iddm rats showed significantly lower blood glucose concentrations and a lower gain of body weight under HFD. Interestingly, expression of pro-inflammatory (IFN-γ, IL-1β, IL-6, IL-17) and anti-inflammatory (IL-4; FOXP3) genes of PBMCs were significantly lower under HFD. The median diabetes-free survival was 79 days in LEW.1AR1-iddm rats under SD (n = 49) and 71 days under HFD (n = 22). LEW.1AR1-iddm rats on HFD had a higher incidence of diabetes in comparison to the SD (95 % vs. 65 %). Log rank test showed significant differences of diabetes free survival between the two diets (p = 0.019).

Conclusion: A HFD increased the incidence of diabetes with earlier onset in LEW.1AR1-iddm rats. In contrast to the situation in T2D, an increase in systemic inflammation does not seem to be responsible for the increased beta cell autoimmunity. However, possible mechanisms may be due to the functional overload of beta cells by metabolic stress, which promotes the recruitment of autoaggressive T-cells via enhanced release of antigens.

Supported by: DDG (German Diabetes Foundation)

Disclosure: J. Dahmen: Grants; Supported by German Diabetes Foundation (DDG).
SO 01 Epigenetics rules

265

Sorting of human pancreatic islets by flow cytometry into alpha and beta cells reveals unique novel genes expressed in the different cell types

J.K. Ofori1, K. Bacso1, A. Perfiliev1, A. Wendt2, U. Krus3, L. Eliasson2, C. Ling1; 1Dept. of Clinical Sciences, Epigenetic and Diabetes Unit, Lund University. 2Dept. of Clinical Sciences, Islet Cell Exocytosis Unit, Lund University, 3Dept. of Clinical Sciences, Lund University, Malmö, Sweden.

Background and aims: Human islets have several distinct cell types that regulate glucose homeostasis. The two main cell types are α-cells, which secrete glucagon to raise plasma glucose levels in the fasted state, and β-cells that release insulin to decrease plasma glucose levels in the fed state. Dysfunction in these cell types contributes to pathogenesis of type 1 diabetes and type 2 diabetes. Here, we aimed to sort α- and β-cells from human pancreatic islets and use RNA sequencing to identify unique and abundant transcripts expressed in respective cell type.

Materials and methods: Human islets from 16 multi-organ donors were sorted by flow cytometry into α- and β-cells subsequent RNA isolation was performed according to the MARIS protocol. We performed RNA sequencing on the sorted α- and β-cells using NextSeq 500 (Illumina). Downstream analysis was done using R, and the data was filtered to only include protein-coding genes. A transcript was considered expressed in a particular cell type if it has at least 20 reads in 40% of the samples. Furthermore, using WEB-based Gene Set Analysis Toolkit (http://www.webgestalt.org/), we analyzed the enrichment for KEGG pathways or biological processes for unique transcripts expressed in these two cell types.

Results: We identified 13,001 and 12,875 genes expressed in human α- and β-cells, respectively. Interestingly, genes expressed in our α- and β-cell cohort significantly overlapped (93-94%) with previous published work by Blodgett et. al, 2015 when we reanalysis their RNA sequencing data (N=6 donors) with the same settings as ours (N=16 donors). The number of unique transcripts identified to be expressed in either α- and β-cells were 617 and 497, respectively. Transcripts uniquely expressed in α-cells show significant enrichment in biological processes such as cAMP-mediated signaling (ADCY4, ADGRB2, ADRB1 etc.), regulation of ion transport (AN06, FXYD3, KCNIP1 etc.), cell proliferation (FAM83B, FAP, KLB etc.), homeostatic process (F7, PLAUR, FGA etc.), exocytosis (DOC2A, GRIN3A, SYT3 etc.) and regulation of apoptotic process (VILI, LPAR1, AR etc.). The only significant KEGG pathway identified for unique transcripts expressed in α-cells was Protein digestion and absorption pathway (PPAP, SLC7A7, SLC3A1 etc.). Moreover, we identified significant enrichment of transcript uniquely expressed in β-cells to be involved in gland development (IGF2, NRG1, NKX3-1 etc.), cell-cell signaling (GAD1, GLP1R, SIX3 etc.), regulation of hormone levels (SLC2A2, SPP1, FOXE1 etc.), ion transport (KCNJ16, GLRA1, STAP3 etc.) and synaptic signaling(P2RX2, TMEM108, LRFN2 etc.). Next, we looked at abundantly expressed transcripts in α- and β-cells. Interestingly, ~40% of top 20 most highly expressed transcripts in both cell types are mitochondrially encoded genes (MT-CO1, MT-ND4, MT-CO3, MT-CYB, MT-ND2, MT-ATP6, MT-ND5)._

Conclusion: We identified unique genes regulating for example exocytosis and gland development to be expressed in either α- or β-cells. Our data also reveal that mitochondrially encoded genes are among the most abundantly expressed transcripts in both α- and β-cells.

Supported by: SRC, Fysiografen, EXODIAB
Disclosure: J.K. Ofori: None.
267 Genomic enhancers regulations in type 2 diabetes
E. Carcarino1, M. Didisheim1, C. Vandiedonck1, D. Girard1, R. Nielsen2, H.-J. Garchon3, H. Mambu-Manbuen3, J.-B. Julia1, L. Potier1, R. Roussel1, S. Mandrup2, J.-F. Gautier1, N. Venteelle1,
1Institut National de la Santé et de la Recherche Médicale (INSERM) U1151, Paris, France, 2Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark, 3Institut National de la Santé et de la Recherche Médicale (INSERM) U1173, Montigny le Bretonneux, France.

Background and aims: A recent classification has established 4 subgroups of type 2 diabetes (T2D) categorised according to insulin resistance, insulin secretion deficiency, age, body mass index and glycated hemoglobin. Interestingly, these T2D subtypes seem to be associated with inflammatory markers such as leukocytes and monocytes blood counts. Moreover, emerging studies revealed that genomic regulatory regions, named enhancers, are crucial to modulate immune cell gene transcription in response to environmental stimuli. In this study we aimed at 1) investigating whether immuno-inflammatory profiles of blood immune cells can define new T2D endotypes; 2) evaluating genomic enhancers regulatory impacts on T2D distinction.

Materials and methods: We recruited T2D type 2 diabetic subjects (33% females; median age: 61 years old; median diabetes duration: 13 years; median BMI: 28.3 kg/m²; median HbA1c: 7.7 %) in Lariboisière and Bichat University Hospitals (Paris, France). Isolation of venous blood from patients allowed to 1) perform immunophenotyping analysis based on antibodies-coupled flow cytometry, in order to measure patients monocytes frequencies and analyze them by k-means clustering approach; 2) perform patients monocytes immunoselection, followed by RNA-sequencing (RNA-seq) and Assay for Transposase-Accessible Chromatin (ATAC-seq) analysis, in order to combine the study of patients transcriptome and chromatin accessibilities and then evaluate the enhancers dynamics in the T2D subgroups.

Results: 3 main clusters were defined by applying k-means clustering according to blood monocyte subpopulations frequencies: classical, intermediate, and non-classical monocytes. RNA-seq analyses identified specific immune responses associated with each cluster, with an enrichment of interleukin-1B (IL-1B) expression in one of the clusters. ATAC-Seq analyses revealed that higher levels of IL-1B transcription are specifically promoted by increased chromatin accessibility of a specific enhancer, at IL-1B locus, in this sub-mentioned cluster (p<0.05). Interestingly, a common Single Nucleotide Polymorphism (SNP), already associated to regulation of IL-1B and inflammatory conditions, is located within this enhancer which may impact IL-1B transcription.

Conclusion: All together, our results provide evidence that dysregulation of a specific enhancer associated with IL-1B gene expression could contribute to the inflammatory profile of a subgroup of T2D patients.

Clinical Trial Registration Number: NCT02671864
Supported by: EFSD/Lilly Young Investigator Research Award Programme
Disclosure: E. Carcarino: None.

268 Hyperglycaemia induces endothelial dysfunction via epigenetic regulation driven by histone methyltransferase EZH2
J. Sánchez-Ceinos1, S. Hussain1, A. Waheed-Khan1,2, L. Zhang1, J. Pernow1, F. Cosentino1,
1Medicine, Solna, Cardiology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 2Diabetes, Central Clinical School, Monash University, Melbourne, Australia.

Background and aims: Post-translational modifications (PTMs) of histones are crucial epigenetic mechanisms regulating gene expression in response to environmental changes. However, in pathological conditions, this regulation may determine maladaptive molecular disturbances contributing to the development of diseases. The trimethylation of histone 3 at lysine 27 (H3K27me3) is a PTM linked to the repression of genes involved in various biological events, such as oxidative stress. The addition or removal of this PTM to the promoter of certain genes are dynamically modulated by methyltransferases EZH1 and EZH2, and demethylases KDM6A, B, and C, respectively. Since hyperglycemia-induced endothelial dysfunction is closely related to oxidative stress and inflammation, herein we investigated the role of H3K27me3 in the regulation of these processes and whether targeting chromatin-modifying enzymes may represents a valuable strategy to safeguard endothelium function.

Materials and methods: We employed human aortic endothelial cells (HAECs) exposed to either normal or high glucose and endothelial cells from diabetic individuals (D-HAECs) to test the effect of EZH2 targeting, through pharmacological inhibition with GSK126 or siRNA. Gene expression levels of H3K27me3 and related chromatin-modifying enzymes (EZH1, EZH2 and KDM6A, B and C), as well as genes involved in oxidative stress and inflammation were determined by RT-PCR, western blotting, and/or confocal studies. The binding of H3K27me3 to the promoter region of candidate genes was evaluated by chromatin immunoprecipitation (ChIP). Reactive oxygen species (ROS) production and NF-κB binding activity were measured using electron spin resonance spectroscopy and protein assay, respectively. Endothelium-dependent and -independent relaxations were assessed in aortas from male mice incubated with normal and high glucose (5 and 25 mM, respectively) by myograph.

Results: H3K27me3 levels were significantly increased in HAECs exposed to high glucose and D-HAECs as compared to HAECs cells under normal glucose conditions. ChIP assays revealed increased binding of H3K27me3 to the promoters of antioxidant genes (SOD1, SOD2, and JunD) in these cells. RT-PCR and immunoblotting studies confirmed the repression of these genes. By contrast, NOX4, a major source of oxidative stress, was upregulated. Along with an increase in ROS, HAECs exposed to high glucose and D-HAECs exhibited pro-inflammatory changes, namely activation of NF-κB and its downstream target genes. Gene expression of EZH2 was upregulated in these cells, whereas KDM6A and KDM6B were downregulated. Interestingly enough, treatment with either EZH2-specific inhibitor GSK126 or EZH2 silencing was able to promote a favourable transcriptional program rescuing the observed molecular derangements. Finally, GSK126 treatment of murine aortas incubated with high glucose restored endothelium-dependent relaxations. Gene expression of EZH2 was upregulated in these cells, whereas KDM6A and KDM6B were downregulated. Interestingly enough, treatment with either EZH2-specific inhibitor GSK126 or EZH2 silencing was able to promote a favourable transcriptional program rescuing the observed molecular derangements. Finally, GSK126 treatment of murine aortas incubated with high glucose restored endothelium-dependent relaxations.

Conclusion: Our results unravel adverse epigenetic signatures underlying endothelial dysfunction in diabetes. Targeting EZH2 may serve as a potential novel anti-atherosclerotic treatment in this setting to prevent endothelial dysfunction through attenuation of oxidative stress and pro-inflammatory mediators.

Supported by: Swedish Research Council, the Swedish Heart & Lung Foundation, and King Gustav V and Queen Victoria
Disclosure: J. Sánchez-Ceinos: None.

269 Altered H3K4me3 profile on TFAM promoter causes preadipocytes and mitochondrial alterations in first-degree relatives of type 2 diabetics
F. Zatterale1, M. Longo1, A. Desiderio1, R. Spinelli1,2, L. Parrillo1, M. Campitelli1, F. Florest1, U. Smith2, G.A. Racić1, F. Beguinot1,
1DISMET & URT of IEOS-CNR, Federico II University of Naples, Naples, Italy, 2Department of Molecular and Cellular Medicine, University of Gothenburg, Gothenburg, Sweden.

Background and aims: First-Degree Relatives of type 2 diabetics (FDR) are characterized by enlarged subcutaneous adipocytes and inaccurate...
subcutaneous adipose tissue (SAT) hypertrophy, independent of obesity and fat distribution. FDR have a risk of developing type 2 diabetes (T2D) up to 10-fold higher than age-matched subjects without a family history of the disease (CTRL). In FDR, dysfunctional adipose tissue and T2D risk are contributed by impaired adipocyte precursor cells (APCs) recruitment into the adipogenic pathway. Epigenetic regulatory mechanisms are directly involved in several steps of adipocyte differentiation biology and play an important role in this abnormality. The present study explores changes in the genome-wide tri-methylation of lysine 4 on histone H3 (H3K4me3) profile in APCs from SAT of healthy FDR and matched control individuals. H3K4me3 profile is linked to transcriptional consistency and cell identity and plays a fundamental role in stem cell biology. 

Materials and methods: Deep chromatin-immunoprecipitation sequencing (ChiP-Seq) for H3K4me3 was applied in APCs isolated from FDR (n=9) and CTRL (n=11) SAT biopsies. mRNA levels were measured by Real-time PCR (qPCR), while methylation levels by bisulfite sequencing. The mitochondrial DNA (mtDNA) amount was assessed by qPCR. Histone modifications enrichment was measured by ChiP-qPCR.

Results: ChiP-seq data analysis revealed 2644 differentially H3K4me3 enriched regions in CTRL and FDR. Cellular component analysis of annotated genes revealed significant enrichment in mitochondrial-related genes. TFAM gene, one of the most H3K4me3 differentially enriched genes that regulates mitochondrial content and stability, was chosen for further investigation. In FDR APCs, a significant reduction in H3K4me3 enrichment at the TFAM promoter was paralleled by TFAM mRNA and protein levels reduction (p<0.05). FDR APCs also exhibited reduced mtDNA content (p<0.01) and mitochondrial-encoded gene transcription (p<0.05). TFAM promoter showed no differences in DNA methylation between FDR and CTRL, while H3K27ac enrichment was detected in CTRL APCs (p<0.05). TFAM-siRNA transfection of CTRL APCs reduced TFAM mRNA (p<0.001) and protein levels (p<0.001) as well as mtDNA content (p<0.01) and mitochondrial DNA-encoded genes transcription (p<0.01), indicating a direct involvement in inducing the mitochondrial alterations observed in the FDR APCs. FDR APCs exhibited decreased adipogenic potential (p<0.001) and impaired TFAM induction during adipogenesis. Furthermore, FDR APCs show a significant decrease in mtDNA at all stages of adipogenesis (p<0.05). To test the TFAM effect on APCs differentiation capacity, CTRL APCs were differentiated and silenced throughout adipogenesis. We found that TFAM-silencing impairs APCs differentiation (p<0.05), mtDNA content (p<0.001), and mitochondrial encoded genes transcription (p<0.001), establishing a new insight into TFAM regulation of APCs differentiation.

Conclusion: We determined an epigenetic signature in FDR preadipocytes associated with increased T2D risk. Histone modification events regulate APC ability to differentiate into mature adipocyte by modulating the TFAM expression and affecting mitochondrial function.

Disclosure: F. Zatterale: None.
expression profile on pro-inflammatory and healing macrophages that can enhance macrophage sensitivity for the metabolic unwanted-self products in diabetes and can provide conditions for metabolic inflammation.

Supported by: GRK 1874: DIAMICOM (DFG)
Disclosure: L. Badillo Garcia: None.

SO 02 Pregnancy and diabetes

The impact of multiple deprivation on gestational diabetes incidence
S. Jeyaparam;
Faculty of Medicine, Imperial College London, London, UK.

Background and aims: Disparities in social class have been shown to affect a number of health outcomes, including life expectancy, recovery from myocardial infarctions and recovery from hip fractures. Importantly, deprivation has previously been shown to correlate with perinatal mortality and the incidence of type 2 diabetes. However, to date, no study has explored the relationship between deprivation and the incidence of gestational diabetes (GD). We aimed to identify the presence of any relationship between postcode Index of Multiple Deprivation (IMD) rank and incidence of GD, after accounting for age, BMI and specific ethnicity (amongst 13 different ethnic groups). Furthermore, we also examined for relationships between IMD rank and perinatal outcomes: birthweight centile; stillbirths; special care baby unit (SCBU) admissions and severe (<32 week) prematurity.

Materials and methods: We conducted a retrospective cohort analysis of 23490 pregnancies followed in a major hospital in Northwest London. The 2019 English Indices of Multiple Deprivation was used to identify the deprivation rank and decile for each maternal postcode. Of those that received an oral glucose tolerance test (OGTT) (n= 17844), 1854 were diagnosed with GD. Birthweight centile was calculated from absolute birthweight after adjusting for ethnic origin, maternal height, maternal weight, parity, sex and outcome (live birth/stillbirth). Multiple logistic regression and correlation analyses were used to identify correlations between variables.

Results: After controlling for age, BMI & ethnicity, there was no correlation between which deprivation decile a woman's postcode was and their odds of developing gestational diabetes. (Kendall's Tau b = 0.000, significance 0.932). After adjusting for the previously mentioned confounders, every standard increase in age increased the odds of developing GD by 7.6% (OR: 1.076, p<0.001); BMI similarly increased odds by 5.9% (OR: 1.059, p<0.001). After adjusting for age, BMI and IMD rank, ethnic origin greatly affected odds of developing GD, particularly for Asian women who were all over three-fold more likely to develop GD compared to white British women (ORs: Pakistani 3.332; Indian 4.675; Bangladeshi 5.824; other Asian 3.756; mixed white and Asian 3.075, p<0.001 in all cases). There was no significant correlation between IMD rank and perinatal outcomes.

Conclusion: Our study demonstrates that after adjusting for age, BMI and ethnicity, multiple deprivation did not correlate with incidence of gestational diabetes or perinatal outcomes. We have also shown the effect of age, BMI and individual ethnicity on odds of developing gestational diabetes.

Disclosure: S. Jeyaparam: None.

Exposure to non-insulin 2nd-line glucose-lowering medications in early pregnancy and risk of major congenital malformations
S. Hernandez Diaz1, R. Rotem1, K.F. Huybrechts2, B.T. Bateman3, K. Furu4, G. Chodick2, E.W. Seely5, E. Patorno2, C.E. Cesta1; 1Epidemiology, Harvard TH Chan School of Public Health, Boston, USA, 2Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA, 3Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Palo Alto, USA, 4Norwegian Institute of Public Health, Oslo, Norway, 5Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel, 6Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA, 7Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

Background and aims: The use of 2nd line non-insulin glucose-lowering drugs is increasing overall and in women of reproductive age which may result in fetal exposure in early pregnancy. However, the teratogenic risk of these drugs is unknown. We evaluated if exposure to these drugs in early pregnancy is associated with an increased risk of major congenital malformations (MCM) in the infant.

Materials and methods: We conducted a cohort study of pregnant women with type 2 diabetes and their liveborn infants in the IBM MarketScan Research Database in the US (2011-2019), Maccabi Health Services (MHS) in Israel (2009-2020), and pooled population health register data from Finland, Iceland, Norway, and Sweden (2009-2020). Exposure was defined based on ≥1 prescription fills from 90 days before the first day of the last menstrual period (LMP) to 90 days after LMP of insulin or any non-insulin 2nd line glucose-lowering drugs including sulfonylureas, dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogues, sodium-glucose co-transporter 2 (SGLT2) inhibitors, or others. Crude prevalence ratios (PR) of MCM at delivery type, Priscilla White classification and type of diabetes. Separate analysis was shown by HbA1c >6% in 3t (OR IOM 7.90; 1.55-40.23), BMI < 30 kg/m2 (OR IOM 8.33; 95%CI 1.82- 38.11) and Type 1 diabetes (OR IOM 131.21; 4.37-3930.54); and might the association be not significant by HbA1c >6% (OR 1.82- 38.11) and Type 1 diabetes (OR 131.21; 4.37-3930.54).

Results: Among 5,747,733 pregnancies, 6435 women with type 2 diabetes received insulin and 3190 a non-insulin 2nd line glucose-lowering drugs, with sulfonylureas (n=1488) and GLP-1 analogues (n=490) being the most common. The risk of MCM was 3.1% among infants born to mothers with no pregestational diabetes, 7.2% in those exposed to insulin, and 7.2% in those exposed to a non-insulin 2nd line glucose-lowering drugs with exposure to insulin in women with type 2 diabetes. Pregnancies with no pregestational diabetes were used as a secondary reference group. Pregestational diabetes, type 2 diabetes, and MCMs were identified using validated algorithms.

Conclusion: Preliminary results show a higher prevalence of MCM among infants born to mothers using non-insulin 2nd line glucose-lowering drugs in early pregnancy compared with pregnant women with no pregestational diabetes. However, the PR moves to the null when using a comparison group with the same indication (type 2 diabetes) and using the standard treatment in pregnancy (insulin). Further exploration will focus on individual 2nd-line non-insulin glucose-lowering drugs and on specific MCM groups and adjust for diabetes severity.

Supported by: NICHD (R01HD097778), Nordforskn (no.83339), Research Council of Norway (no.273366), and EU Horizon MS
Disclosure: S. Hernandez Diaz: Grants; NICHD R01HD097778.
investigate the relationship between family history of T2DM in first- and second-degree relatives in women with a diagnosis of GD. It also aimed to assess the differences in metabolic characteristics at early gestation in women with and without a family history of T2DM.

**Materials and methods:** This prospective cohort study included 1164 pregnant women. A broad risk evaluation was performed before 16+0 weeks of gestation, including assessment of maternal characteristics, detailed family history of the different types of diabetes, and a laboratory examination of glucometabolic parameters. First degree relatives were defined as parents or siblings of the pregnant woman, second degree relatives were defined as grandparents, aunts and uncles. Participants were followed-up until delivery and GDM assessed according to the latest World Health Organisation diagnostic criteria. **Statistical analysis** Continuous variables were summarized by mean ± standard deviation or as median and IQR (in case of skewed distribution). These were compared by analysis of variance or rank based inference. Categorical variables were summarized by counts and percentages, and compared by binomial logistic regression. Odds ratios and 95% confidence intervals (95%CI) were additionally calculated for binary outcomes. Tukey’s honestly significant difference (HSD) test was used for all subgroup (k=4) comparisons to achieve a 95% coverage probability. Statistical analysis was performed with R (version 4.0.2) and constructing packages (especially “multcomp” and “nparcomp”). A two-sided p-value of ≤0.05 was considered statistically significant.

**Results:** We showed that pregnant women with first- (FHD1) (n=51, 26.6% (OR 1.91, 95%CI 1.16 - 3.16, p=0.005), second- (FHD2) (n=57, 26.3% (OR 1.88, 95%CI 1.16 - 3.05, p=0.005) or both first- and second degree relatives with T2DM (FHD1+D2) (n=31, 33.3% (OR 2.64, 95%CI 1.41 - 4.94, p<0.001) had a markedly increased risk of GDM compared to those with negative family history (FHN) (n=100, 15.9%). The association was the strongest if both parents were affected (OR 4.69, 95%CI 1.33 - 16.55, p=0.009). Women with FHD1 and FHD1+D2 had adverse glucometabolic profiles for almost all parameters, except for HDL-cholesterol, already in early pregnancy, compared to those with FHN, including impaired insulin action, as well as higher glucose concentrations during the diagnostic OGTT.

**Conclusion:** We confirmed that a family history of T2DM is an important risk factor for GDM, also by applying the current diagnostic criteria. Furthermore, we showed that the degree of kinship plays an essential role in quantifying the risk. Future research should develop further available tools for prediction of GDM and integrate the degree of kinship when considering the family history of T2DM in the risk stratification.

**Disclosure:** C. Monod: None.

---

**Role of histone methyltransferase MLL1-driven H3K4me3 in the transmission of oxidative and inflammatory phenotypes to the offspring of women with gestational diabetes**


1Department of Medicine, Unit of Cardiology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden,
2Department of Medical, Oral and Biotechnological Sciences, CAST (ex CeSI-MeT), University G. d’Annunzio, Chieti, Italy,
3Department of Neonatology, Karolinska University Hospital, Stockholm, Sweden,
4Department of Medicine and Aging Sciences, University G. d’Annunzio, Chieti, Italy,
5Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, Sweden,
6Department of Oncology Hematology, Hospital Spirito Santo, Pescara, Italy.

**Background and aims:** Gestational diabetes (GD) is characterized by chronic hyperglycemia during pregnancy. Hyperglycemia-induced oxidative stress and inflammation are potent drivers of atherosclerotic cardiovascular disease (ASCVD). Recently, it is emerging that histone modifications are key players in hyperglycemia-induced ASCVD and putative mediators of the transmission of GD phenotypes to the offspring.

**Results:** For the first time, we demonstrated that MLL1-driven H3K4me3 on NF-kB p65 promoter is upstream to the activation of such inflammatory pathway. Indeed, treatment with MLL1 inhibitor (MM-102, 10 μM) blunted upregulation of both NF-kB p65 and VCAM-1 genes, as well as TNF-α-induced NF-kB p65 DNA binding activity and VCAM-1 protein expression. Furthermore, inhibition of histone methyltransferase MLL1 abolished upregulation of pro-oxidant NOX4 gene. Interestingly enough, the MLL1-driven H3K4me3 was present not only in PBMC from GD women and CBMC at birth but also in PBMC from adolescent born to GD women.

**Conclusion:** Our results suggest that MLL1-driven epigenetic mark is responsible for the maternal inflammatory and oxidative phenotypes in GD women, and it is transmitted to the offspring. The deciphering of epigenetic-induced chromatin remodeling opens the perspective for pharmacological reprogramming of adverse histone modifications to reduce the burden of early abnormal phenotypes in the offspring potentially leading to ASCVD.

**Disclosure:** N. Di pietrantonio: None.

---

**Differential epigenetic profile related to carbohydrates metabolism pathways in pregnant women with gestational diabetes**

T.M. Linares-Pineda1,2, N. Peña-Montero1, A. Fernández-Valero1, M. Suarez1-2, F. Lima1, M. Molina-Vega1, M.J. Picón1, S. Morcillo1;

1Endocrinology, Hospital Universitario Virgen de la Victoria de Málaga,
2IBIMA, Endocrinology, Hospital Universitario Regional de Málaga, Málaga, Spain.

**Background and aims:** Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance with onset during pregnancy. These women and their offspring have higher risk of develop metabolic disorders. Factor such as nutrition or the intrauterine environment may play an important role, through epigenetic mechanisms, in the development of GDM as well as in the treatment selection. The aim of this work is to identify epigenetics marks involved in mechanism or pathways related to gestational diabetes outcome.

**Materials and methods:** Gestational diabetes mellitus was diagnosed by a two-step approach: O’Sullivan test at 24-28 weeks, and those pregnant women with a positive test were carried out an OGTT-100 g between 24-30 weeks. A total of 32 pregnant women were selected, 16 of them with...
GDM and the other 16 non-GDM from EPI-DG cohort (Málaga, Spain). DNA methylation pattern were obtained from Illumina Methylation EPIC BeadChip, with samples from diagnostic visit. Raw data were analysed with ChAMP Package 2.9.10 in R. Also, the statistic and differentially methylation positions (DMPs) was obtained with limma package in R, using False Discovery Rate (FDR) <0.05 and deltaBeta>|5|%. A functional enrichment using STRING, DAVID (2021 Update) and Cytoscape was performed with those DMPs with annotated genes. Finally, a correlation analysis was made with those DMPs related to insulin and glucose metabolism (p<0.05).

**Results:** Epigenetic profile of pregnant women with GDM was compared with non-GDM group at diagnosis visit. The data were adjusted by age, previous BMI, sex of the foetus, gestational age, HOMAIR and pharmacological treatment. We obtained 1,141 DMPs. A total of 751 DMPs annotated to genes were included in a functional enrichment analysis. Results from STRING were clustered in Cytoscape and enrichment in DAVID. A total of 4 cluster were related to carbohydrate metabolism pathways. Among these cluster, we found 7 genes directly related to signalling insulin pathways, Type II diabetes mellitus, Type I diabetes mellitus, cardiopathy pathways, insulin resistance and carbohydrates absorption (GAD1, GAD2, AKT2, SOS2, CACNAID, mTOR and PRKAA2). GAD1 and GAD2 are related to Type 1 diabetes. SOS2, PRKAA2 and AKT2 are implicated in insulin signalling pathways, also AKT2 is related to diabetic cardiopathy, carbohydrates absorption and other inflammation mechanism. CACNAID has a role in the T2DM development. And finally, mTOR is implicated in many pathways related to inflammation, and insulin resistance. 4 CPGs from these 7 genes were significantly correlated with biochemical variables (Figure 1).

**Conclusion:** In conclusion, we observed a differential epigenetic profile in genes related to carbohydrate metabolism that could be involved in the development of gestational diabetes.

**Supported by:** ISCIII

**Disclosure:** T.M. Linare-Pineda: None.

---

278

A genotype-informed gestational diabetes prediction algorithm highlights importance of unified diagnostic criteria

L. Mendizabal1, M. Arregui1, J. Valerio2, A. Ramos2, N. De la Torre2, A. Barabash3, I. Urrutia3, A. Cortazar3, S. Gaztambide4, L. Castaño4, A. Martinez-Martinez5, E. Camarillo5, L. Simon5, M. Zulueta5, A. Calle-Pascual6;

1Patia, San Sebastián, Spain, 2Hospital Clínico Universitario San Carlos, Madrid, Spain, 3Cruces University Hospital, Bizkaia, Spain, 4Universidad Autónoma de Mexico, Ciudad de Mexico, Mexico.

**Background and aims:** Early risk detection might offer opportunities to improve care for women at high risk of developing GDM. Predictive models that include genetic susceptibility factors are becoming attractive, and the genetic architecture of GDM predisposition is progressively being considered in the development of predictive algorithms. However, to expand their clinical use, the importance of unified diagnostic criteria should be emphasized. Our aim was to develop a risk assessment algorithm that integrates genetic and clinical variables and test it in women diagnosed with GDM according to different criteria.

**Materials and methods:** We analyzed a cohort of 711 women from Hospital Clínico San Carlos (HCSC, Madrid, Spain), with 425 control pregnancies and 286 GDM cases diagnosed per IADPSG criteria. The HCSC cohort was randomly divided into a training/validation dataset (70% of cohort) and a test dataset (30% of cohort) for validation. We tested the model in a cohort of 157 women (89 controls, 68 cases diagnosed per NDDG criteria from Hospital Cruces (Bilbao, Spain) and in a cohort of 416 women (346 controls, 70 cases per IADPSG criteria from HMPMPS, México). A total of 114 single nucleotide polymorphisms (SNPs) were selected for this analysis after exhaustive exploration of the databases published to date of SNPs associated with GDM. Discrimination and calibration of risk scores were assessed using the receiver operating characteristic (ROC) curve in the internal and the external validation groups.

**Results:** The algorithm provided a risk score for GDM integrating 10 genetic variants, maternal age, and pre-gestational BMI. In the training dataset the AUC was 0.74, sensitivity of 77% and specificity of 64%. AUCs in the HCSC, HMPMPS and Cruces validation sets were 0.71, 0.70 and 0.62 respectively. The model performance was moderate/high in the cohorts in which GDM had been diagnosed according to the IADPSG criteria; in contrast, the robustness of the model was significantly reduced in the cohort in which the NDDG criteria had been used.

**Conclusion:** A new algorithm for GDM risk assessment was developed, indicating that the use of genetic markers in combination with clinical characteristics may improve early GDM risk evaluation. Our study highlights the importance of applying consensus criteria for the diagnosis of GDM.

**Disclosure:** L. Mendizabal: None.
SO 03 Food, drinks and spices

279

The association between pre-Ramadan diabetes education and metabolic parameters in Muslims with type 2 diabetes: a retrospective study

P.J.M. Elders1, A.A.A. van der Heijden1, M. Hassanein2, S. Bouchareb3

1Amsterdam UMC, location VU, Amsterdam, Netherlands, 2Endocrine department, Dubai Hospital, Dubai, United Arab Emirates.

Background and aims: Ramadan fasting might improve metabolic parameters, such as HbA1c, blood pressure and weight in people with type 2 diabetes (T2D). But, Ramadan fasting is also associated with an increased risk of acute complications such as hypo- and hyperglycaemia. Pre-Ramadan Education (PRE) has been shown to reduce the risk of hypoglycaemia and prevent weight gain. We aimed to: (1) compare metabolic parameters during Ramadan with periods outside Ramadan in Muslims with T2D and (2) assess the association between PRE and metabolic parameters in patients who had received PRE.

Materials and methods: For aim 1 we performed a retrospective longitudinal observational study of routine care GP data in Amsterdam in practises in which religious background was routinely noted in the medical file. Inclusion criteria were: age ≥ 18 years, a T2DM diagnosis and the indication that the patient was a muslim. Routine data of patients over a period of five years were extracted. Generalized Estimating Equations (GEE) models were used to analyse the difference of the outcome parameters measured during the period of Ramadan and the three months thereafter (Ramadan period) and the remaining 8 months of the year (non Ramadan period). For aim 2 we included people with T2D who received PRE and gave informed consent for this study. From these patients the same routine care GP data were extracted as described for aim 1. Using GEE we examined the association between PRE and metabolic parameters during the Ramadan periods before and after PRE. The GEE analyses were adjusted for age, time since baseline and diabetes duration.

Results: The characteristics of the participants is shown in table 1. Aim 1: During Ramadan significant lower systolic blood pressure (-1.7 mmHg; p= 0.000), weight (-0.32 kg/m²; p= 0.000) and BMI (-0.23 kg/m²; p= 0.000) were observed compared to outside Ramadan. Fasting glucose increased with 0.19 mmol/L (p= 0.003) during Ramadan. Hba1c (-0.61 mmol/mol; p=0.08), LDL-C -0.03 mmol/l (p=0.53) and weight (-0.55 kg; p=0.051) were not statistically significant lower during Ramadan. Aim 2: PRE was only associated with a significant decrease in weight (-0.4 kg/m² ; p= 0.048) compared to previous Ramadans.

Conclusion: Our study showed that Ramadan fasting was not associated with major metabolic dysregulation. Fasting glucose level during Ramadan is probably explained by the late eating that occurs during this period. Ramadan Education seems to have positive effects and might provide an opportunity to empower Muslims with T2D to improve their diabetes selfmanagement.

Clinical Trial Registration Number: NTR7690
Supported by: This study was supported by a grant of ZonMW

280

A beneficial effect of cinnamon and red capsicum intake on postprandial changes in plasma metabolites evoked by a high-carbohydrate meal in men with overweight/obesity

M. Ciborowski1, A. Hameed1, E. Adamska-Patruno1, J. Godzien1, P. Czajkowski1, U. Krasowska1, K. Pietrowska1, J. Fiedorczuk1, K. Miniewska1, M. Moroz1, W. Bauer1, J. Sieminska1, M. Gorska1, A. Kretowski2

1Clinical Research Centre, Medical University of Bialystok, 2Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.

Background and aims: It has been reported that a high-carbohydrate (HC) intake might be associated with an increased risk of type 2 diabetes (T2DM) development, especially among obese people. A diet rich in highly processed carbohydrates exerts unfavourable effects on lipid profile, which may have implications for metabolic syndrome and T2DM development. It has also been reported that consumption of cinnamon and capsicum can prevent or slow the development of T2DM by improving glycemic control, hyperlipidemia, and insulin resistance. In the present study postprandial metabolomics was performed to indicate differences in plasma metabolites affected by the HC or normo-carbohydrate diet between humans with normal weight (NW) or overweight/obesity (OW/OB). Moreover, we have also evaluated if the change in the level of plasma metabolites evoked by HC meal in OW/OB individuals can be lifted by the cinnamon and capsicum intake.

Materials and methods: The first part of the study was performed on a group of 24 male participants (12 with NW: BMI 24±2, 35±9 y.o. and 12 with OW/OB: BMI 31±5, 38±6 y.o.). The volunteers participated in two meal-challenge-tests visits within 2-3 weeks intervals. After fasting blood collection, subjects received a standardized HC-meal or NC-meal. During the meal, test blood was collected at 30, 60, 120, and 180 minutes after the meal. In the second study, 20 male OW/OB individuals (BMI 32±4, 46±8 y.o.) were enrolled on a double-blind, placebo-controlled trial consisting of two visits during which they received an HC meal with the capsule containing 2 g of cinnamon and 200 mg of capsicum or placebo capsule. Blood samples were collected as previously. LC-MS-based untargeted metabolomics was performed on collected plasma samples. Based on the relation between time points and metabolite intensity for each metabolite AUC was calculated. Obtained AUCs were forwarded for partial
least square discriminant analysis (PLS-DA) modelling. Based on the PLS-DA model volcano plots were built to select significant metabolites according to multivariate statistics (variable importance in projection value, VIP).

**Results:** Significant difference in metabolites’ AUC between NW and OW/OB individuals were mainly observed after the HC-meal. Among other metabolites, a substantial increase of AUC was mainly observed for lysophospholipids (+35-274%, VIP=1.06-1.88), fatty acids (+54-129%, VIP=1.21-1.77), fatty acid amides (+69-682%, VIP=1.68-3.61), sphingomyelin (SM 33:2) (+37%, VIP=1.1) or uric acid (+145%, VIP=1.4). A decrease in AUC was observed for sphinganine 16:0 (-40%, VIP=1.34), sphinganine 16:0 (-60%, VIP=1.52), and lauroylsphingolamine (-71%, VIP=2.24). The intake of cinnamon and capsicum significantly reduced the AUC of lysophospholipids (-9-34%, VIP=1.12-1.99), uric acid (-100%, VIP=1.18) and SM 33:2 (-54%, VIP=1.3).

**Conclusion:** Several metabolic pathways were found dysregulated after an HC meal in people from the OW/OB group but not the NW group. An HC meal may induce an unfavourable postprandial metabolic response in OW/OB individuals, but it can be partially lifted by the cinnamon and capsicum intake.

Clinical Trial Registration Number: NCT03792685

Supported by: EU Horizon 2020 MSC Action Grant No 754432

Disclosure: M. Ciborowski: None.

---

281

**Tea consumption and the risk of type 2 diabetes: a cohort study and updated systematic review and dose-response meta-analysis**

X. Li1, J. Zeng2, B. Chen2, Q. Yan2, Y. Cui2, W. Xu2, X. Zhang2, S. Xu2; 1College of Medicine, Wuhan University of Science and Technology, Wuhan, 2Evidence-Based Medicine Centre, Office of Academic Research, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, 3Department of Nephrology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, 4Department of Endocrinology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.

**Background and aims:** The relationship between tea-drinking and the risk of type 2 diabetes mellitus (T2DM) has been of long-term interest, but the results of published cohort studies and meta-analyses were inconsistent. The aim of this study was to define the relationship between tea consumption and future T2DM risk by a cohort study and an updated dose-response meta-analysis.

**Materials and methods:** The cohort study was based on the China Health and Nutrition Survey (CHNS). A total of 5199 adult participants without diabetes were involved in 1997 and followed up in 2009. Tea consumption data was collected using structured questionnaires, and T2DM was diagnosed according to the American Diabetes Association’s criteria. Cox proportional hazard regression models were carried out with adjustment for characteristics, diet, and lifestyle factors. Stratification analyses (e.g. according to age or sex) and sensitivity analyses (e.g. by excluding participants who developed diabetes during the first 3 years of follow-up) were conducted. A systematic literature search was performed in PubMed, Web of Science and EMBASE through September 2021. A total of 19 cohort studies (1,076,311 participants) were included in the updated dose-response meta-analysis regarding tea drinking and the risk of T2DM. In addition, we conducted subgroup analyses according to tea-drinking frequency (< 1 cup/d, 1-3 cups/d, and ≥ 4 cups/d), sex (male and female), type of tea (green tea, Oolong tea, and black tea), and the location of the study (Europe and America, or Asia).

**Results:** In cohort study, the incidence of T2DM was 10.04%, and 45.76% participants were tea-drinkers. Cox proportional hazard regression showed the hazard ratio (HR) of T2DM in tea-drinkers was 1.02 (95% confidence interval [CI]: 0.82-1.28) compared with no-tea-drinkers. In the stratification analyses and sensitivity analyses, the results did not change significantly. However, the dose-response meta-analysis showed that there was a significant linear association between tea consumption and T2DM risk (P for linear trend: 0.003), and the RR (95% CI) for an increment of 1 cup of tea per day was 0.986 (0.977-0.995), shown in Figure 1. Compared with the 0 cup/d tea-drinking group, the risks of diabetes in the < 1 cup/d, 1-3 cups/d tea-drinking, and ≥ 4 cups/d tea-drinking groups were 1.00 (95% CI: 0.98-1.02), 0.96 (95% CI: 0.91-1.00), and 0.83 (95% CI: 0.76-0.90), respectively. Tea-drinking was found not to be associated with the development of diabetes in sex, location, or type of tea subgroups.

**Conclusion:** Drinking tea was beneficial in reducing the risk of T2DM, but only at high doses (e.g. ≥ 4 cups/d). Tea is thought to be a component of a good diet, and daily adequate tea consumption seems to have clinically significant effect to reduce the risk of T2DM developing.

Supported by: the Young Talents Project of Hubei Provincial Health Commission, China

Disclosure: X. Li: None.

---

282

**Habitual intake of dietary dicarbonyls is associated with greater insulin sensitivity and lower prevalence of type 2 diabetes: the Maastricht Study**

K. Maasen1, S.J.P. Eussen2, P.C. Dagnelie2, A. Opperhuizen3,4, C.D.A. Stehouwer1, M.M.J. van Greevenbroek1, C.G. Schalkwijk4;

1CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, 2CAPRI Care and Public Health Research Institute/ CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, 3NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, 4Netherlands Food and Consumer Product Safety Authority, Utrecht, Netherlands.

**Background and aims:** Dicarbonyls are highly reactive compounds and major precursors of advanced glycation endproducts (AGEs). Dicarbonyls are formed endogenously but also during food processing. Circulating dicarbonyls are positively associated with insulin resistance and type 2 diabetes, but consequences of dietary dicarbonyls are unknown. Therefore, this study examined the associations of dietary intake of dicarbonyls with insulin sensitivity, β-cell function, and prevalence of prediabetes or type 2 diabetes.

**Materials and methods:** In 6282 participants (60 ± 9 yrs, 50% men, 23% type 2 diabetes [oversampled]) of the population-based cohort The Maastricht Study, we estimated habitual intake of the dicarbonyls methylglyoxal (MGO), glyoxal (GO), and 3-deoxyglucosone (3-DG). Food Frequency Questionnaires were linked to our food composition database, including MGO, GO, and 3-DG concentrations in >200 foods and drinks measured via UPLC-MS/MS. Insulin sensitivity, β-cell function, and glucose metabolism status were measured by a seven-point oral glucose tolerance test (available for n=2390, 2336, and 6282 respectively). Insulin sensitivity was assessed as the Matsuda index. β-cell function was assessed as C-peptidogenic index, overall insulin secretion, glucose sensitivity, potentiation factor, and rate sensitivity. Additionally, insulin sensitivity was measured as HOMA2-IR (n=2611). Cross-sectional associations of dietary dicarbonyls with insulin sensitivity, β-cell function, and glucose metabolism status were investigated using linear or logistic regression adjusting for age, sex, BMI, smoking, alcohol intake, physical activity, total energy intake, educational level, history of cardiovascular diseases, triglycerides, LDL, total cholesterol/HDL ratio, use of...
...antihypertensive- or lipid-modifying medication and insulin sensitivity (models with β-cell function as outcome only).

**Results:** Higher dietary MGO and 3-DG intakes were associated with greater insulin sensitivity after full adjustment, indicated by both a higher Matsuda index (MGO: Std. β [95% CI] = 0.08 [0.04, 0.12] and 3-DG: 0.09 [0.05, 0.13]) and a lower HOMA2-IR (MGO: Std. β = -0.05 [-0.09, -0.01] and 3-DG: -0.04 [-0.08, -0.01]). Moreover, higher MGO and 3-DG intakes were associated with lower prevalence of type 2 diabetes, after excluding individuals with previously diagnosed diabetes (OR [95% CI] = 0.78 [0.65, 0.93] and 0.81 [0.66, 0.99]). There were no consistent associations of MGO, GO, and 3-DG intakes with β-cell function.

**Conclusion:** Higher habitual consumption of the dicarboxyls MGO and 3-DG was associated with better insulin sensitivity and with lower prevalence of type 2 diabetes, after excluding individuals with known diabetes. This suggests that food-derived dicarboxyls may play a protective role in type 2 diabetes. These novel observations warrant further exploration in prospective cohorts and intervention studies.

**Supported by:** NVWA

**Disclosure:** K. Maasen: Grants; The Netherlands Food and Consumer Product Safety Authority.

---

### 283

**Circulating short chain fatty acids as potential new biomarkers for the prediction of type 2 diabetes risk**

G. Llaurado1,2, A. Junza3,2, E. Rubiñat4,2, O. Yanes3,2, X. Correig5,2, D. Mauricio6,7, J. Vendrell8, S. Fernández-Veledo1,2;

1Department of Endocrinology and Nutrition, Hospital del Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra, Barcelona, 2Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), ISCIII, Madrid, 3Department of Electronic Engineering, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Reus, 4Faculty of Nursing and Physiotherapy, University of Lleida, Lleida, 5Metabolomics Platform, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Reus, 6Department of Endocrinology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma Barcelona, Barcelona, 7Department of Endocrinología, Hospital Universitari Joan XXIII, Institut d’Investigació Sanitària Pere Virgili, Rovira i Virgili University, Tarragona, Spain.

**Background and aims:** Common diabetes risk factors offer limited ability to identify subjects at risk of developing type 2 diabetes (T2D). It becomes essential to find novel reliable biomarkers to improve the identification of subjects at risk. The aim of the study was to evaluate the role of circulating short chain fatty acids (SCFA) as potential novel biomarkers to predict T2D risk.

**Materials and methods:** The Di@bet.es study is a prospective population-based study from a random cluster sampling in the Spanish population over 18 years (n=5,072). Of these, 4,347 were free of T2D in the cross-sectional study. Follow-up losses were about 45%. The final sample for re-screening finally comprised 2,408 subjects. A metabolomics-driven analyses of SCFA (acetate, propionate, butyrate and isobutyrate) was carried out using gas chromatography-mass spectrometry in samples obtained from the Di@bet.es cohort to identify subjects who developed T2D after 7 years (median) of follow-up.

**Results:** At baseline, the circulating concentrations of propionate (3.4 [2.2–4.1] mc mol/L vs. 3.6 [1.0–4.3] mc mol/L vs. 3.6 [2.4–4.5] mc mol/L; p=0.001) and isobutyrate (0.90 [0.59–1.09] mc mol/L vs. 0.93 [0.64–1.17] mc mol/L vs. 0.94 [0.59–1.19] mc mol/L; p=0.001) were increased in parallel with the carbohydrate metabolism status (normal vs. prediabetes vs. T2D). Subjects who developed T2D (incident cases) after a median follow-up of 7 years had higher baseline circulating concentrations of butyrate (11.4 [1.6–14.1] mc mol/L vs. 12.3 [6.9–15.2] mc mol/L; p=0.040) and isobutyrate (0.90 [0.58–1.09] mc mol/L vs. 0.96 [0.72–1.23] mc mol/L; p=0.004). In the multivariate analysis, baseline circulating concentrations of butyrate (OR 1.03 [95%CI: 1.01-1.07]; p=0.037) and isobutyrate (OR 1.9 [95%CI: 1.2-3.1]; p=0.009) were independently associated with development of T2D after adjusting for age, sex, family history of T2D, prediabetes, obesity, hypertension and dyslipidemia. The C-statistics for predicting T2D was 0.777 (95%CI: 0.757–0.797) and 0.774 (95%CI: 0.754–0.794) for butyrate and isobutyrate respectively, offering a good ability to predict the development of T2D, although similar to the reference model based on traditional clinical factors (0.781 [95%CI: 0.762–0.800]).

**Conclusion:** Circulating concentrations of SCFA increase in parallel with alterations in carbohydrate metabolism and are independently associated with the development of T2D at 7 years of follow-up. However, they offer limited ability to improve risk prediction compared to traditional risk factors.

**Supported by:** PI20/00312 - ISCIII

**Disclosure:** G. Llaurado: None.

---

### 284

**Interaction between dairy product intake or phospholipid odd chain fatty acids and GAD65 autoantibodies on the incidence of adult onset diabetes**

A.-M. Lampousi, S. Carlsson, J.E. Löfvenborg, on behalf of the EPIC-InterAct consortium; Karolinska Institutet, Stockholm, Sweden.

**Background and aims:** Islet autoimmunity is associated with an increased risk of adult-onset diabetes. We investigated whether high dairy product intake or plasma phospholipid odd chain fatty acids may modify the excess risk conferred by antibodies against the 65 kDa isofrom of GAD (GAD65).

**Materials and methods:** We analysed data from the EPIC-InterAct case-cohort study including 11,124 incident cases of adult-onset diabetes and a subcohort of 14,866 individuals collected across eight European countries. Adjusted Prentice-weighted Cox regression models were used to estimate the hazard ratios (HRs) of adult-onset diabetes comparing tertiles of dairy product intake (total dairy, milk, fermented dairy) or plasma phospholipid fatty acids 15:0 and 17:0, stratified by GAD65 autoantibody status assessed in plasma samples at baseline. We evaluated additive interactions using the proportion attributable to interaction (AP), as well as interactions on the multiplicative scale, between GAD65 antibody positivity (≥65 units/mL) and high or moderate 17:0 fatty acid levels was associated with a HR of 6.08 (95% CI 3.92–9.43) for positive individuals (HR: 0.42, 95% confidence intervals (CI) 0.35-0.42) and positive individuals (HR: 0.42, 95% CI 0.27-0.64). The combination of low 17:0 fatty acid levels and high GAD65 antibody positivity compared to antibody negativity and high or moderate 17:0 fatty acid levels was associated with a HR of 6.08 (95% CI 3.92-9.43) with indication of additive (AP: 0.25, 95% CI 0.08-0.43) but not multiplicative (p=0.532) interaction. There were no clear associations between total dairy or milk intake and adult-onset diabetes. Fermented dairy was inversely associated with diabetes but only in antibody negative individuals (HR: 0.86, 95% CI 0.79-0.94).

**Results:** Overall, 3.5% of incident diabetes cases and 1.9% of non-cases were GAD65 antibody positive at baseline. High concentrations of the fatty acids, in particular 17:0, were inversely associated with adult-onset diabetes in both antibody negative (HR: 0.38, 95% confidence intervals (CI) 0.35-0.42) and positive individuals (HR: 0.42, 95% CI 0.27-0.64). The combination of low 17:0 fatty acid levels and high GAD65 antibody positivity compared to antibody negativity and high or moderate 17:0 fatty acid levels was associated with a HR of 6.08 (95% CI 3.92-9.43) with indication of additive (AP: 0.25, 95% CI 0.08-0.43) but not multiplicative (p=0.532) interaction. There were no clear associations between total dairy or milk intake and adult-onset diabetes. Fermented dairy was inversely associated with diabetes but only in antibody negative individuals (HR: 0.86, 95% CI 0.79-0.94).

**Conclusion:** Higher levels of plasma phospholipid 17:0 fatty acid may partly impede the progression from GAD65 antibody positivity to adult-onset diabetes.
Supported by: FORTE, VR and Novo N supported AML, SC and JEL
Disclosure: A. Lampousi: Grants; Swedish research council, Swedish reasearch council for health working life and welfare, Novo nordisk foundation.

285
GABA and sitagliptin prevent impairment of beta cell function caused by high-fat diet
Z. Wang1, L. Fan1, Y. Ni1, A. Ma1, D. Wu1, Y. Zhao1, J. Li1, Q. Cui1, Y. Zhou1, L. Zhang1, Y.-R. Lou2, G. Prud’homme2, Q. Wang1; 1Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China, 2Department of Clinical Pharmacy and Drug Administration, School of Pharmacy, Fudan University, Shanghai, China. 1Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, USA, 2Bio Consulting LLC, Acton, USA.

Conclusion: Increased activation of unfolded protein response (UPR) could be an important mechanism of compensatory beta-cell proliferation, and beta cells treated with GABA and sitagliptin showed greater UPR activation. Our results suggest that the combined use of these agents produces superior therapeutic outcomes.

SO 04 Starting with autoimmunity

286
Childhood screening and interception strategies: an economic cohort simulation model
J.L. Dunne1, L. Ferrat2, R.B. McQueen2, R. Neusner1, R.A. Oram2, M. Rewers2, M.R. Trusheim2; 1Janssen Research and Development, LLC, Raritan, USA, 2Institute of Biomedical and Clinical Science, Exeter, UK. 3Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, USA, 4Barbara Davis Center for Diabetes, Aurora, USA, 5Cobi-Bio Consulting LLC, Acton, USA.


Results: Real-world benchmarks for newborn screening (85%) and patient follow-up (80%) as well as rapid T1D progression (<12 months) for some children limited maximum interception at dysglycemia to 44% of children progressing to T1D by age 15 using a GRS screening strategy in the DAISY-driven (US) population progression. The IAB screening strategy simulation, assuming that 60% of the children in the US will receive IAB screening, resulted in a 32% dysglycemia interception rate. A DIPP-driven ( Finnish) population progression with younger skewed seroconversion results in a higher 48% dysglycemia interception rate for the newborn GRS screening strategy and a 43% dysglycemia interception rate for the IAB screening strategy.

Conclusion: Short-term net incremental costs in the simulated US population reach $636M at current test costs or $158K per T1D case interception. Breakeven costs could be achieved with $10 IAB test cost and $5 GRS costs with a therapeutic to delay T1D onset by 3 years. Alternatively, breakeven costs could be achieved by extending the T1D onset delay to 5 years with $25 IAB test costs and $5 GRS costs. Including potential long-term benefits of early intervention and improved glycemic control would further improve the breakeven levels.

287
Family history of type 1 diabetes is associated with incidence of multiple islet autoimmunity but not with progression to clinical type 1 diabetes: the MIDIA study
L. Stene:
Norwegian Inst. of Public Health, Oslo, Norway.

Background and aims: Type 1 diabetes (T1D) is characterized by a preclinical period of islet autoimmunity (IA) of varying length from months to over 10 years. Genetic susceptibility of T1D is mainly determined by HLA-DQ genotype with highest risk in those with the HLA DQ8/2 genotype. HLA mainly influence islet autoimmunity (IA) and to a lesser degree progression to clinical disease. We aimed to investigate whether family history of T1D was differentially associated with incidence IA and progression to T1D in children with the HLA DQ8/2 genotype.

Materials and methods: The MIDIA study HLA tested over 48000 newborns throughout Norway during 2001-2007 and followed 908 children with the HLA DQ8/2 genotype. Blood samples were scheduled at ages 3, 6, 9 and 12 months and annually thereafter (more frequent if positive for autoantibodies). Islet autoantibodies (anti-insulin, GAD65 and IA-2) were measured in all blood samples using radiobinding assays.

IA was defined as repeated positivity for at least two of three autoantibodies. Date of diagnosis of T1D by the 31 Dec, 2016 was obtained from the Norwegian Childhood Diabetes Registry. T1D a first degree relative (FDR) was ascertained by a parental questionnaire when the child was 3 months old. We estimated risk (of IA or T1D) by family history, as 1 minus the Kaplan-Meier survival estimate.

Results: The cumulative incidence of IA was much higher in those with an affected FDR (n=65) vs. those without (n=843), approximately 30% and 6% at age 10 years, respectively (Figure a). The probability of progressing from IA to clinical T1D was very similar in both groups, at approximately 60% ten years after seroconversion (Figure b).

Conclusion: Family history, probably mediated by genetics other than HLA DQ, primarily influence the incidence of islet autoimmunity and not the progression from islet autoimmunity to clinical type 1 diabetes.

Disclosure: L. Stene: None.

288
The incidence of childhood-onset type 1 diabetes, time trends and association to population composition in Sweden: a 40-year follow-up
I. Waernbaum1, T. Lind2, A. Möllsten2, G. Dahlquist1; 1Department of Statistics, Uppsala University, Uppsala, 2Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden.

Background and aims: During the 1980s and 1990s, the incidence of childhood-onset type 1 diabetes more than doubled in Sweden, followed by a plateau. In the present 40-year follow-up, we investigated if the incidence remained stable and whether this could be explained by increased migration from countries reporting lower incidences.

Materials and methods: We used 23 143 incident cases reported 1978-2019 to the nationwide, population-based, Swedish Childhood Diabetes Register and population data from Statistics Sweden. Generalized additive models and ANOVA were applied to analyze effects of onset-age, sex, time-trends, parental country of birth and interaction effects between these factors.

Results: The flattening of the incidence increase seems to remain over the period 2000-2019. When comparing the incidence for all children in Sweden with that for children with both parents born in Sweden, trends were parallel but at higher level for the latter. Comparing incidence trends between individuals with Swedish (high diabetes trait) and Asian backgrounds (low diabetes trait) showed the Asian subpopulation having a stable increase in incidence over time.

Conclusion: In Sweden, the increase in incidence seen in the late 20th century has stabilized at a high level over the last two decades. Increased immigration from countries with lower incidence does not explain the observed levelling-off.

Supported by: This study was supported by the Swedish Research Council grant number 2018-02565. I.W. was supported Disclosure: I. Waernbaum: Grants; Swedish Research Council grant number 2018-02565, Swedish Research Council grant number 2016-00703.

289
Prevalence of positivity for diabetes-associated autoantibodies in patients classified and treated as type 2 diabetes and their further characterisation
M. Rončáková1, A. Davani1, V. Mikušová2, P. Novovdorsky3,4, E. Martinka1;
1National Endocrinology and Diabetology Institute, Lubochna, Slovakia, 21st Dept. of Internal Medicine, University Hospital, Martin, Slovakia, 3Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 4Human Oncology and Metabolism, University of Sheffield, Sheffield, UK.

Background and aims: Classification of diabetes is not always straightforward. Patients with insulin resistance and overweight/obesity initially diagnosed with type 2 diabetes (T2D) might exhibit presence of autoimmune insulitis with positivity for diabetes-associated autoantibodies (AA). We sought to establish the prevalence of autoimmune insulitis in patients with poorly controlled T2D referred to a tertiary diabetes centre for further management. We aimed to characterise these patients in detail and compare them to patients without AA positivity in order to establish the characteristics linked with the presence of autoimmune insulitis.

Materials and methods: This was a prospective observational study. All patients with T2D diagnosis admitted to the NEDÚ, Lubochna, Slovakia within the first 6 months of 2016 were included in the study. Data on age, sex, anthropometric measures, BP, age at diagnosis and diabetes duration, HbA1c, c-peptide levels, biochemistry, lipid profile, hypoglycaemia, antidiabetic medication, insulin dose and time to insulin initiation, drug history, presence of diabetic complications and other comorbidities were collected. All patients were tested for anti-GAD, islet antigen-2 autoantibody (IA-2A) and insulin autoantibody (IAA). Patients with positivity for at least one AA (≥1 IU/ml) (AA+) were compared with those with negative AA (AA-).

Results: Six hundred and ninety-two individuals (387, 55.6% female) with mean (range) age 61.5 (24-83) years, mean (SD) HbA1c 9.1 (1.8)% and mean (SD) duration of diabetes 14.3 (7.9) years were analysed. One hundred and sixty-four patients (164/692, 23.7%) tested positive for at least 1 AA: 136/692 (19.6%) were positive for anti-GAD, 21/692 (3.0%) were positive for IA-2A, 28/692 (4.0%) were positive for IAA, 16/692 (2.3%) were double-positive for anti-GAD/IA-2A and 5/692 (0.7%) were double-positive for anti-GAD/IAA. Table 1 shows the comparisons between the AA+ and AA- patients in which significant differences were detected. Eighty-nine (89/692, 12.9%) patients met the current diagnostic criteria for latent autoimmune diabetes of the adults
Materials and methods: We prospectively assessed the characteristics impact of routine islet autoantibody testing in this population.

Results: Smoking increased the risk of type 2 diabetes and LADA (OR 3.33 to 5.25), IS (OR 2.49 to 3.93), compared with non-smokers. Additive interaction was estimated by attributable proportion due to interaction (AP).

Results: Smoking increased the risk of type 2 diabetes and LADA (OR 1.70 [1.37-2.09], 1.52 [1.18-1.96], respectively). In type 2 diabetes, the corresponding associations were OR 2.00 [1.16-3.45] for genetic susceptibility to type 2 diabetes (OR 3.25 [2.06-5.12]), IS (OR 3.33 [2.12-5.25]), and IR (OR 2.49 [1.58-3.93]), compared with non-smokers with low-intermediate genetic susceptibility. In LADA, corresponding associations were OR 2.00 [1.16-3.45] for genetic susceptibility to T2D, OR 2.65 [1.62-4.33] to IR, and OR 2.01 [1.15-3.51] to IS. There was additive interaction between smoking and IR-GRS in the risk of type 2 diabetes (AP 0.36 [0.02-0.70]) and LADA (AP 0.59 [0.31 −0.86]). We aim to replicate these findings using data from the Norwegian HUNT study.

Conclusion: Our findings suggest that smoking confers a stronger effect on type 2 diabetes and LADA risk in individuals with genetic susceptibility to type 2 diabetes and related traits.

Disclosure: M. Rončáková: lecture/other fees; NovoNordisk, Merck, Sanofi, Eli Lily, Boehringer Ingelheim, Abbots, Novartis, Janssen, Medtronic, Roche, Berlin Chemie Menarini. Other: NovoNordisk, Pfizer, Johnson & Johnson, Merck, Sanofi, Eli Lily, Boehringer Ingelheim, Abbots, Novartis, Janssen, Medtronic, Roche, Berlin Chemie Menarini.

290

Interaction between tobacco use and genetic susceptibility in the risk of LADA and type 2 diabetes

J. Edstorp1, E. Ahlqvist2, L. Alfredsson3,4, V. Grill4, B. Rasouli4, E.P. Sørgjerd7, T. Tuomi2, B. Asvold5,6, S. Carlsson1,1, Karlinska Institutet, Stockholm, Sweden, 2Department of Clinical Sciences in Malmo, Clinical Research Centre, Lund University, Malmo, Sweden, 3Center for Occupational and Environmental Medicine, Region Stockholm, Stockholm, Sweden, Stockholm, Sweden, 4Norwegian University of Science and Technology, Trondheim, Norway, 5HUNT Research Centre, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway, 6Institute for Molecular Medicine Finland, Helsinki University, Helsinki, Finland, 7Department of Endocrinology, Clinic of Medicine, St. Olavs Hospital, Trondheim, Norway.

Background and aims: Smoking is associated with type 2 diabetes and latent autoimmune diabetes in adults (LADA). Our aim was to investigate whether interaction with genetic susceptibility to type 2 diabetes, insulin secretion, and insulin resistance aggravates this association.

Materials and methods: We used case-control data with incident cases (LADA n=593; type 2 diabetes n=2038) and controls (n=3036). Weighted genetic risk scores were calculated for type 2 diabetes (T2D-GRS), insulin secretion (IS-GRS), and insulin resistance (IR-GRS). We derived odds ratios (OR) with 95% confidence intervals by conditional logistic regression adjusted for lifestyle factors. Additive interaction was estimated by attributable proportion due to interaction (AP).

Results: Smoking increased the risk of type 2 diabetes and LADA (OR 1.70 [1.37-2.09], 1.52 [1.18-1.96], respectively). In type 2 diabetes, the corresponding associations were OR 2.00 [1.16-3.45] for genetic susceptibility to type 2 diabetes (OR 3.25 [2.06-5.12]), IS (OR 3.33 [2.12-5.25]), and IR (OR 2.49 [1.58-3.93]), compared with non-smokers with low-intermediate genetic susceptibility. In LADA, corresponding associations were OR 2.00 [1.16-3.45] for genetic susceptibility to T2D, OR 2.65 [1.62-4.33] to IR, and OR 2.01 [1.15-3.51] to IS. There was additive interaction between smoking and IR-GRS in the risk of type 2 diabetes (AP 0.36 [0.02-0.70]) and LADA (AP 0.59 [0.31 −0.86]). We aim to replicate these findings using data from the Norwegian HUNT study.

Conclusion: Our findings suggest that smoking confers a stronger effect on type 2 diabetes and LADA risk in individuals with genetic susceptibility to type 2 diabetes and related traits.

Disclosure: M. Rončáková: lecture/other fees; NovoNordisk, Merck, Sanofi, Eli Lily, Boehringer Ingelheim, Abbots, Novartis, Janssen, Medtronic, Roche, Berlin Chemie Menarini. Other: NovoNordisk, Pfizer, Johnson & Johnson, Merck, Sanofi, Eli Lily, Boehringer Ingelheim, Abbots, Novartis, Janssen, Medtronic, Roche, Berlin Chemie Menarini.

291

Routine islet autoantibody testing in clinically diagnosed adult-onset type 1 diabetes can help identify misclassification and guide successful insulin cessation

R.J. Eason1,2, N.J. Thomas1,2, A.V. Hill2, B.A. Knight1,2, A. Carr1, A.T. Hattersley1,2, T.J. McDonald1,2, B.M. Shields1, A.G. Jones1,2, StartRight Study Group; 1University of Exeter College of Medicine & Health, 2Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.

Background and aims: Recent joint American and European diabetes association guidelines recommend routine islet autoantibody testing in all adults newly diagnosed with type 1 diabetes. We aimed to assess the impact of routine islet autoantibody testing in this population.

Materials and methods: We prospectively assessed the characteristics and progression (annual change in Urine C-peptide Creatinine Ratio (UCPCR)) associated with islet autoantibody status (GAD, IA-2 and ZNT8) in 722 adults (≥18 years old) with clinically diagnosed type 1 diabetes and duration <12 months. We also evaluated changes in treatment and glycaemic control over 2 years after informing participants and their clinicians of islet autoantibody results. We then performed a similar analysis in a further group of 91 participants in the same study with clinically suspected type 1 diabetes, defined by insulin from diagnosis, and a clinical diagnosis indicating possible type 1 diabetes (e.g., ‘uncertain type’ ‘possible type 1’). Findings were compared to 731 participants with islet antibody negative type 2 diabetes in the same cohort.

Results: 24.8% (179/722) of participants diagnosed with type 1 diabetes were islet autoantibody negative. This group had genetic and C-peptide characteristics suggestive of a high prevalence of non-autoimmune diabetes: lower mean type 1 diabetes genetic risk score (islet autoantibody negative versus positive: 10.85 vs 13.09 (p<0.001) (type 2 diabetes 10.12)) and a lower annual change in C-peptide (UCPCR) -4% vs -3.4% (p<0.001) (type 2 diabetes -6%). Both results are presented in Figure 1. After median 24-months follow up, treatment change was seen in 36.6% (60/164) of islet autoantibody negative participants: 22.6% (37/164) discontinued insulin, with a HbA1c similar to those continuing insulin (57.5 vs 60.8mmol/mol [7.4 vs 7.7%] (p=0.4)) and 14.0% (23/164) added adjuvant agents to insulin. In participants with clinically suspected type 1 diabetes, islet autoantibody negativity was associated with the characteristics of T2D: higher baseline C-peptide (islet autoantibody negative versus positive: 1159.4 vs 747.8pmol/L (p<0.05) (type 2 diabetes 1792.3pmol/L)) and lower mean type 1 diabetes genetic risk score (9.98 vs 12.60 (p<0.001)). 52.7% (29/91) of islet autoantibody
negative participants in this group successfully discontinued insulin treatment.

**Conclusion:** In adult-onset clinically diagnosed or suspected type 1 diabetes, negative islet autoantibodies should prompt careful consideration of other diabetes subtypes and, when available to clinicians, are associated with successful insulin cessation. These findings support recent recommendations for routine islet autoantibody assessment in adult-onset type 1 diabetes.

**Clinical Trial Registration Number:** NCT03737799
**Supported by:** NIHR and Diabetes UK
**Disclosure:** R.J. Eason: None.

---

**293**

Use of HOMA-IR and Matsuda Index as indicators of insulin resistance in autoantibody positive relatives of patients with type 1 diabetes

A. Petrelli\(^1\), A. Bichisechi\(^2\), D. Carnovale\(^1\), F. Cugnata\(^1\), A. Stabilini\(^1\), R. Bonfianni\(^1,2\), E. Bossi\(^1\), L. Piemonti\(^1\), J. Sosenko\(^4\);
\(^1\)Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy, \(^2\)Pediatric Department, IRCCS Ospedale San Raffaele, Milan, Italy, \(^3\)Diabetes Research Institute, University of Miami, Miami, USA.

**Materials and Methods:** We assessed the relationship between age of onset and C-peptide loss in 1793 participants with newly diagnosed type 1 diabetes in the prospective STARTRIGHT study. Islet autoantibodies (GADA, IA-2A, ZNT8A) and stimulated serum C-peptide were measured in all participants at a mean 5 months duration. A post meal urine sample for C-peptide Creatinine Ratio (UCPCR) measurement was collected annually for two years. Type 1 diabetes was defined in two ways: ≥2 positive islet-autoantibodies (regardless of clinical diagnosis)(n=385) and clinically diagnosed type 1 diabetes with a single positive islet autoantibody(n=180). Mixed-effects models were used to model annual log UCPCR split by median diagnosis age.

**Results:** Age at diagnosis was not associated with mean starting C-peptide for both type 1 diabetes definitions. When defined by ≥2 islet autoantibodies mean C-peptide was 433pmol/l (95%CI 383-480) and 432pmol/l (361-503) in those diagnosed ≤35 and >35 years respectively[p=0.7]. When defined by clinical diagnosis and a single positive islet antibody the decline was 41%(28-52%) vs 43%(34-51%) in those diagnosed ≤35 and >35 years respectively[p=0.8]. Genetic predisposition to type 1 diabetes, captured by a type 1 diabetes genetic risk score, did not differ by definition or age of diagnosis suggesting a high specificity for type 1 diabetes identification throughout (mean risk score ranging from 12.9 to 13.4)[all comparisons p>0.1](type 2 diabetes mean 10.4).

**Conclusion:** Our results suggest that when defined robustly late onset type 1 diabetes progression is rapid and does not differ from young adult onset disease. This suggests that older adults developing type 1 diabetes could be enrolled in intervention studies as long as initial clinical diagnosis is confirmed by at least one positive islet antibody or in those without an initial clinical diagnosis where two islet antibodies are positive. This would markedly increase the available study recruitment pool.

**Clinical Trial Registration Number:** NCT03737799
**Supported by:** DUK NIHR
**Disclosure:** N. Thomas: None.
Background and aims: HOMA-IR (H) and Matsuda Index (MI) are used to measure insulin resistance (IR) and insulin sensitivity (IS) in certain populations; however, their use in autoantibody positive (Aab+) relatives of patients with type 1 diabetes (T1D) is problematic, since insulin and glucose, which can be abnormal in at-risk individuals, are basic to their calculations. Here we tested whether H or MI had value for measuring IR and IS in a cohort of n=153 relatives of patients with T1D who tested positive for at least 1 Aab.

Materials and methods: At-risk subjects were stratified in 3 groups based on their H and MI levels, and BMI percentile (BMIp) was calculated for each group. H and MI were correlated with BMIp and the Insulinogenic Index (IGI), a measure of insulin deficiency. Linear mixed-effect models analysis was performed on a total of n=512 observations (including repeated measures of follow-up visits) to test the effect of age, sex, Aab≥2, fasting glucose ≥100 mg/dl, high-risk HLA-DR types, Index60, presence of anti-insulin antibodies and BMIp on H or MI.

Results: There was an inverse curvilinear association (Spearman r=-0.892) between H and MI (Figure), similar to associations described in Ab negative cohorts. BMIp was greater in the highest tertile of H than the lowest (67.8 ± 26.3 vs. 43.5 ± 32.1, p<0.01), with an inverse pattern for MI tertiles (63.6 ± 31.3 vs. 42.2 ± 31.1, p<0.01). In linear regression models H or MI were strongly associated with BMIp (p<0.001 for both) and this association was maintained also when IGI was added to the models (p<0.001 for both). Furthermore, confirming previous observations, linear mixed-effect models analysis showed that individuals with ≥2Aab had higher H and lower MI compared to relatives with <2 Aab.

Conclusion: Among Aab+ relatives of patients with T1D, H and MI could be used as relative indicators of IR and IS.

SO 05 Genetics of type 2 diabetes

294

Role of GWAS associated purinergic receptor P2RY1 gene in insulin secretion and the impact of rare variants on type 2 diabetes risk

A. Dance1, M. Derbouh1, M. Canoil1, M. Marre2, G. Charpentier2, A. Bonnefond1, P. Froguel1,2,4.

1Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, Lille University Hospital, Lille, France, 2Inserm U1138, Centre de Recherche des Cordeliers, Paris, France, 3CERITD (Centre d’Etude et de Recherche pour l’Intensification du Traitement du Diabète), Evry, France, 4Department of Metabolism, Imperial College, London, UK.

Background and aims: ATP and ADP play a key role in insulin secretion by activating in β cells the ATP-dependent potassium channels through the purinergic receptors. Genome-wide association studies (GWAS) have shown that the P2RY1 locus is associated with glucose levels variation. P2YR1 belongs to the Gq Protein Coupled Receptor (Gq GPCR) family and is highly expressed in pancreatic islets, particularly in β cells. We performed a large-scale functional genetic study in order to decipher the putative impact of rare P2RY1 variants on the risk of type 2 diabetes (T2D). We also characterized the role of P2RY1 in insulin secretion.

Materials and methods: P2RY1 coding regions were sequenced in 6,348 adults included in the French RaDiO study. To assess the functional activity of each variant, we perform 1/NFAT-RE (Nuclear factor of activated T-cell Response Element) luciferase assays on HEK293 cells overexpressing each variant, followed by P2YR1 activation by its agonists MRS2365 (methanocarba-2MeSADP) during 16 hours, but also 2/ western blots and 3/ immuno/fluorescence assays on these cells to assess expression and cellular localization of each mutant. In human pancreatic EndoCβH5 cells, we are also performing glucose-stimulated insulin secretion assays coupled to P2YR1 activation by MRS2365.

Results: We identified 16 rare missense variants in P2RY1 (including 6 novel variants) carried by 19 participants. Most of the carriers presented with T2D (0.46% of carriers among cases with T2D versus 0.17% of carriers among normal glucose controls). In 200k exome data from the UK Biobank we found 10 loss-of-function variants (Lof, nonsense or frameshift). There were three times more P2RY1 Lof carriers with T2D than carriers with normal glucose (assessed by HbA1c), confirming the association with T2D identified in the French cohort. Functional analyses of each variant found in Radio are in progress.

Conclusion: Our association studies suggest a putative role of rare coding variants of P2RY1 in T2D risk. We hypothesize that P2RY1 may play a key role in insulin secretion and the ongoing functional studies will respond to this question. P2RY1 potent and selective agonists that cannot cross the blood-brain barrier are available, and could be tested as a potential new class of insulin secretagogues.

Disclosure: A. Dance; None.

295

Effects of risk gene variants of type 2 diabetes and fatty liver disease on plasma amino acid levels in middle aged women prone to diabetes

A. Nadasdi1, Z. Kuko1, V. Gili1, T. Masszi1, A. Guttmann2, A. Patocs3, P. Igaz4,6, A. Somogyi1, G. Firneisz5,1.

1Dept. of Internal Medicine and Haematology, Semmelweis University, Budapest, 2Dept. of Molecular Biology; Institute of Biochemistry and Molecular Biology, Semmelweis University, Budapest, 3Brain Imaging Centre, Research Centre for Natural Sciences, ELKH, Hungarian Academy of Sciences, Budapest, 4Research Institute of Biomolecular and Chemical Engineering, University of Pannonia, Veszprém, 5MTA-SE Molecular Medicine Research Group, ELKH, Hungarian Academy of Sciences, Budapest, 6Dept. of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.

Supported by: JDRF

Disclosure: A. Petrelli: None.
Background and aims: Recently circulating amino acids (AAs) were implicated in the regulation of the liver-alpha cell axis contributing to inappropriate glucagon secretion in type 2 diabetes and metabolic (dysfunction) associated fatty liver disease (MAFLD). We studied the plasma levels of AAs and hepatic (HTGC) and pancreatic (PTGC) triacylglycerol contents in a type 2 diabetes prone population stratified by PNPLA3 rs738409 and TCF7L2 rs7903146 genotypes.

Materials and methods: Post hoc analysis of a genotype-based recall study on MAFLD (n=59 young-middle aged women, n=21 with history of gestational diabetes [GDM], median BMI=26.2 kg/m², age=37.0 years, targeted enrollment with rs738409 CC and GG genotypes only) was performed. TCF7L2 rs7903146 genotypes were also obtained from the prior GDM – genetic study. Routine laboratory parameters, HbA1c, glucose, insulin and glucagon values and indices of HOMA2-IR and HOMA2-B were assessed during a 75g OGTT. Protein-depleted blood plasma was lyophilized. Amino acids were conjugated with Pacific Blue dye and concentrations were determined by capillary electrophoresis.

Results: Inverse correlation was found between plasma alanine and PTGC (R=0.32, p=0.051). Plasma levels of glucogenetic precursor AAs (glutamate p=0.059, and aspartate p=0.056) and glucagon-alanine index were also increased (p=0.039) in PNPLA3 risk homozygotes (GG). Among ketogenic AAs a significant correlation was found between phenylalanine plasma levels and HTGC in PNPLA3 risk genotype group (R=0.56, p=0.026).

Conclusion: Circulating AAs (glutamate p=0.059, and aspartate p=0.056) and glucagon-alanine index were also increased (p=0.039) in PNPLA3 risk homozygotes (GG). Among ketogenic AAs a significant correlation was found between phenylalanine plasma levels and HTGC in PNPLA3 risk genotype group (R=0.56, p=0.026).

Supported by: German Center for Diabetes research (DZD) -Diabetes Research, Heinrich-Heine-University, Düsseldorf, 2Center for Diabetes Research (DZD), München-Neuherberg, 3German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Potsdam, Germany.

Allergic edema of the PPARG1C Gly482Ser shows allele-dependent causal effects on cold-induced UCP3 expression and PGC-1α protein stability in human brown adipocytes

M. Huang, H. Mulder, S. Kalamajska, P. Franks
Clinical Research Center, Lund University, Malmö, Sweden.

Background and aims: PPARG1C (PGC-1α) is a master regulator of adaptive thermogenesis in brown adipose tissue. A common polymorphism in PPARG1C rs8192678, C/T, Gly482Ser) has become a robust candidate for obesity in the context of gene and environment interaction. Experimental studies are needed to investigate allele-specific effects on human brown adipocytes.

Materials and methods: We used CRISPR-Cas9 to edit the rs8192678 locus to C/C and T/T genotypes in an immortalized human brown adipocyte cell line; we then used these cells to evaluate allele-dependent effects on UCP1 expression after mild cold exposure. We also used CRISPR-
Cas9 to generate adipocytes with C-terminally luciferase-tagged PPARG/C1A to study the effects of rs8192678 and cold exposure on PGC-1α stability.

**Results:** In both T/T and C/C adipocytes, the UCP1 expression increased after 6-hour cold exposure (32 °C vs 37 °C), but this effect was lower in C/C adipocytes (p=0.026, n=6). Furthermore, PGC-1α protein was more stable in C/C than in T/T adipocytes at 37 °C (protein half-life: 116 vs 72 minutes). At 32 °C, PGC-1α half-life increased to 277 minutes in C/C cells, but remained unchanged in T/T cells.

**Conclusion:** Our data shows gene x environment interaction between the different rs8192678 alleles and cold exposure, manifested through differential UCP1 expression. The C allele confers lower UCP1 expression increase after mild cold exposure, which coincides with the increased stability of the 482Gly PGC-1α protein variant. Our study may provide the molecular basis behind epidemiological studies that links rs8192678 polymorphism with obesity and metabolic disorders.

Supported by: ERC; CSC; VR; LUDC-IRC; The Albert Pahlsson Foundation and The Hjelt Diabetes Foundation

**Disclosure:** M. Huang: None.

---

**298**

**IPSCs derived from insulin resistant offspring of type 2 diabetes patients harbor genetic defects**

B. Memon1, A. Elsayed2, I. Bettahi2, N. Suleiman2, I. Younis2, E. Wehedy2, F. El-Ejeh2, A. Abou-Samra2, E. Abdelalim2; 1Diabetes Research Center, Hamad Bin Khalifa University, 2Hamad Medical Corporation, 3Carnegie Mellon Institute in Qatar, 4Cancer Research Center, Hamad Bin Khalifa University, Doha, Qatar.

**Background and aims:** Insulin resistance (IR) is caused by both genetic and acquired factors, however, the genetic factors are not well understood. Few clinical studies on first-degree relatives of type 2 diabetic (T2D) patients, which have the highest genetic predisposition to T2D, have given insights into the role of IR in T2D pathogenesis; without fractioning the effect of acquired factors. Induced pluripotent stem cells (iPSCs) are excellent tools for disease modeling as they can retain the genetic imprint of the disease. Therefore, in this study, we aimed to investigate the genetic perturbations associated with IR in the offspring of T2D patients, by using iPSC technology.

**Materials and methods:** iPSCs were generated from lean, IR offspring of T2D patients as well as from insulin-sensitive (IS) subjects, who were categorized based on hyperinsulinemic-euglycemic clamp. Transcriptomics was performed, followed by functional validation of target hits. IS and IR iPSCs were then differentiated to mature hepatocytes and differentially expressed proteins were assessed using the Olink platform for proteomics.

**Results:** The IS- (3 subjects) and IR-iPSCs (4 subjects) were fully characterized for pluripotency and had normal karyotyping. Transcriptomics on IR-iPSCs revealed dysregulated gene networks such as: LITLD1, RIF1, and the ZNF family members, ZNF195, ZNF770 and ZNF208 were downregulated in all IR-iPSCs whereas MFGES8, EGR1 and the lactate exporter SLC16A3 were upregulated. Our results highlight that IR-iPSCs have increased oxidative stress and a heightened response to hypoxia indicated by accumulation of reactive oxygen species and a high susceptibility to H2O2-induced apoptosis. Moreover, the IR-iPSCs also had augmented levels of lactate secretion compared to IS-iPSCs under normal conditions. Furthermore, glucose uptake assay on mature hepatocytes derived from IR-iPSCs showed that they had a diminished capacity for glucose uptake in response to insulin compared to the IS-hepatocytes. O-Link assay for IR-hepatocytes (n=6 per IR) indicated that markers regulating hepatic function, glucose metabolism, glycosylation, autophagy, inflammation and stress or those associated with IR and T2D were differentially expressed compared to IS-hepatocytes (n=6 per IS). Our results also identified that several protective genes like p53, GALNT2, DNMAB1 and PREB had high levels under serum-starved conditions in the IR-hepatocytes. However, IR-hepatocytes failed to upregulate the above genes upon stimulation with insulin, unlike the IS-hepatocytes.

**Conclusion:** Overall, our IR-iPSC model can be employed for T2D modeling and drug screening studies that target genetic perturbations associated with IR in individuals with a high risk for T2D.

Supported by: NPRP10-1221-160041

**Disclosure:** B. Memon: None.

---

**299**

**Strong association between variants in miRNA genes and risk of type 2 diabetes in a Greek population**

X. Tsekmekidou, M. Grammatiki, G. Karaliolios, E. Melidou, P. Rakiti, T. Koufakis, F. Tsetsos, M. Georgitsi, A. Roumeliotis, N. Papanas, P. Paschou, J. Yovos, K. Kotsa; 1Division of Endocrinology and Metabolism, First Internal Medicine Clinic, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, 2Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, 3Division of Nephrology and Hypertension, First Internal Medicine Clinic, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, 4Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece.

**Background and aims:** MicroRNAs (miRNAs) are small non-coding RNAs that modulate gene expression at the post-transcriptional level. They have recently emerged as attractive diagnostic and predictive biomarkers. Some miRNAs are involved in insulin secretion and others in the development of pancreatic β-cells, and therefore in the pathogenesis of Type 2 Diabetes (T2D). Our objective was to investigate a possible association between variants in miRNA genes and the risk of T2D in a case-control study design.

**Materials and methods:** The study population included 1,285 participants consisting of 716 individuals with T2D and 569 normoglycemic controls. In the control group, individuals over 65 years of age were included to minimize the probability that T2D will present at a later stage in the course of their life. The absence of T2D was documented by both HbA1c<6.5% and FPG<126mg/dl. DNA was obtained from whole blood and the samples were analyzed using the Illumina Infinium PsychArray. Variants within upstream and downstream of MIR124a, MIR27a, MIR146a, MIR34a, MIR177a, MIR28a, MIR196a2, MIR499a, MIR4513, MIR149 were genotyped and allele frequencies were compared between the groups. All statistical analyses were undertaken within PLINK and SPSS packages utilizing permutation analysis tests.

**Results:** A strong association with T2D was identified for rs1531212 (OR=1.375, p=0.018) in MIR23aHG. This is a host gene that includes MIR23a, among others. Rs6120777 in MIR17B, located upstream of MIR499a, was strongly associated with T2D (OR=1.27, p=0.018). A protective role was established against T2D for rs2425012 (OR=0.794, p=0.018) in MIR499a. This is a host gene that includes MIR499a, among others. Rs3983517 (OR=0.788, p=0.024) and rs2961920 (OR=0.80, p=0.041), both located upstream of MIR146a. Implementing the dominant model of analysis, two more strong associations were identified: Rs3746435 (OR=1.239, p=0.025) in MIR17B, located upstream of MIR499a and rs3746444 (OR=1.235,
p=0.046) in MR499a. No other variants reached the level of significance. The recessive model analysis produced insignificant results. No differences between male and female participants were observed.

Conclusion: Our findings suggest three new genetic indicators of risk for T2D, located near MR27a and MR499a. Rs1531212 is a non-coding transcript variant and rs6120777 is an intron variant in MHY7B which encodes the heavy chain 7B of myosin II. Although they both cause no direct alteration on the protein produced, they could have an indirect effect. Rs3746435 in MHY7B is a missense variant, resulting in an altered heavy chain. Larger population studies are needed to replicate our results and further clarify the role of miRNAs and MHY7B in the pathogenesis of T2D.

Supported by: CIHR. Investing in knowledge society through the European Social Fund (MIS 380273)

Disclosure: X. Tsekmekidou: None.

Investigating the effect of the HNF-1α G319S variant on liver and pancreatic function under different physiological states
M. Sebastian, T. Morrisseau, C. Doucette; Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg, Canada.

Background and aims: Genetic testing in Anishinew communities in central Canada led to the discovery of the HNF-1αG319S variant, which may contribute to youth-onset type 2 diabetes. HNF-1α is a transcription factor that controls glucose and lipid metabolism in the liver, and maintenance of pancreatic beta cell identity and function. Currently, it is unclear how the G319S variant influences these pathways. Given the metabolic demand associated with traditional lifestyle practices in central Canada, the G319S variant may instead confer an advantage to prolonged fasting. Here, we examine the impact of prolonged fasting in G319S expressing mice compared to control mice fed a standard chow diet.

Materials and methods: CRISPR/Cas9 was used to knock in the G319S variant in C57BL/6 mice, creating male and female wildtype (G/G), heterozygous (G/S), and homozygous (S/S) mice. At 3 months, mice were sacrificed either under ad libitum condition or after 24 hours fasting. Liver tissues were collected for gene expression and assessment of triglyceride contents. Islets were isolated to assess insulin secretion capacity, insulin content, and for electron micrography (EM) used to investigate morphological differences.

Results: A statistically significant reduction in liver triglycerides was observed in G/S (p=0.0237) and S/S (p=0.0185) mice compared to G/G. In addition, increased expression of genes involved in cholesterol synthesis and ketogenesis was observed, including HMGCR in G/S (p=0.0140) and S/S (p=0.0073) mice, as well as increased expression of genes involved in gluconeogenesis, including G6PT-1 in S/S mice (p=0.0290). Once fasted, a decrease in blood glucose was observed in G/S (P=0.0001), and S/S (P=0.0385) mice compared to G/G, and a trend towards increased blood ketones was also seen. In pancreatic islets, a reduction in insulin content was seen in G/S (P=0.0175) and S/S (p=0.0065) mice compared to G/G. EM images showed an increase percentage of immature insulin granules in male S/S (p=0.0157) compared to G/G.

Conclusion: Our findings indicate that the G319S variant alters fatty acid and glucose metabolism in the liver as there is a shift toward ketogenesis and gluconeogenesis, and a propensity toward insulin depletion in the islets, which may indicate that the G319S variant provides a metabolic advantage during extended periods of fasting.

Supported by: CIHR

Disclosure: M. Sebastian: None.

Monogenic diabetes in Slovakia: mutational spectrum and HNF1A functional studies
D. Gasperikova1, M. Skopkova1, T. Valkovicova1, Z. Dobiasova1, M. Sklenar1, V. Rambani1, S. Borecka1, Slovak Monogenic Diabetes Study Group, J. Stanik1,2;
1Institute of Experimental Endocrinology, Biomedical Research Center SAS, 2Department of Paediatrics, National Institute of Children’s Diseases and Faculty of Medicine, Comenius University, Bratislava, Slovakia.

Background and aims: Monogenic diabetes is a heterogeneous condition with broad mutation spectrum of various genes including large portion of identified variants with unknown significance. The aim of the study was to describe the mutational spectrum of monogenic diabetes in Slovakia and to perform functional studies of variants identified in one of the monogenic diabetes genes - HNF1A.

Materials and methods: Since 2004, DNA samples from 637 patients with suspicion on monogenic diabetes and from 704 relatives were collected throughout Slovakia. The relevant genes were analysed using Sanger sequencing, MLPA or NGS approaches. The identified variants were categorised using the ACMG guidelines. Variants in the HNF1A gene encoding transcription factor HNF1α were functionally analysed using luciferase assay, EMSA, and immunofluorescence staining for nuclear localization.

Results: Pathogenic or probably pathogenic variants were identified in 198 out of 637 probands (31%). 125 had causal variant in GCK, 39 in HNF1A, 8 in HNF4A, 6 in mtDNA (m.3243A>G), 5 in HNF1B, 2 in ABCG8, 5 in KCNJ11, 4 in the INS gene, and single cases in RFX6, WFS1, TRIM37, and EIF2AK4 genes. Subsequent analysis of family members identified further 221 patients. One third of all identified variants in the GCK, HNF1A and HNF4A genes were novel. Interestingly, the founder mutation c.-557G>C in the promoter of the GCK gene represented 26% of all identified GCK-MODY cases. Next, we functionally tested 8 HNF1A variants that were newly described or classified as variants of unknown significance (VUS) to assess their effect. The pathogenicity was proved in 5 tested variants, as they showed reduced transactivation activity (<40%) and/or decreased DNA-binding ability of HNF1α (<40% of the wild-type). Nuclear localization was not altered in any of the examined mutated proteins. As a result, we were able to reclassify 4 tested variants as likely pathogenic, and 2 variants as likely benign/benign.

Conclusion: The main cause of monogenic diabetes in Slovakia are mutations in the GCK gene (63% of probands) with founder mutation in 26% cases, followed by HNF1A (20%). Functional studies allowed correct classification of studied variants, which lead to molecular genetic diagnosis of HNF1A-MODY and subsequently to correct treatment.

Supported by: VEGA 2/0131/21, APVV-20-0236, VEGA 1/0572/21, APVV-17-0296

Disclosure: D. Gasperikova: None.

Monogenic diabetes in Japan
S. Tanaka1, H. Akagawa1, M. Ogata2, N. Iwashita2;
1Tokyo Women’s Medical University Institute for Integrated Medical Sciences (TIIMS), 2Department of Nutrition and Dietetics, Faculty of Nutrition, Tokyo Kasei University, 3Institute of Geriatrics, Tokyo Women’s Medical University, Tokyo, Japan.

Background and aims: Maturity onset diabetes of the young (MODY) is the most common type among diabetes mellitus caused by a single gene
disorder. Recent genetic analyses are moved to whole exome sequencing (WES) from Sanger sequencing or panel sequencing. Results of genetic diagnosis for monogenic diabetes using WES were found in Caucasian, Korean and Chinese, though such study has not been reported in Japan. The aim of this study was to elucidate the pathogenic variants in clinically diagnosed with MODY in Japanese by using WES.

Materials and methods: Patients who were clinically diagnosed with MODY were consented for participation in this study. Inclusion criteria were (1) age at diagnosis of diabetes < 30 years, (2) negative for GAD autoantibodies if tested, and (3) BMI < 30 m2/kg. Family history was not considered. Seventy-two patients (22 men and 50 women), including 62 subjects who were negative for previous sanger sequencing or panel sequencing for MODY1, MODY2, MODY3 and MODY5, were analyzed. Genomic DNA samples were subjected to exome enrichment using a SureSelect Human All Exon V6 kit. Enriched DNA libraries were sequenced using 150-bp paired-end reads on a NovaSeq6000® (Illumina Inc, San Diego, CA). Variants were annotated with 1000 genome, PolyPhen2, SIFT, ClinVar and gnomAD. Copy number variation Inc, San Diego, CA). Variants were annotated with 1000 genome, PolyPhen2, SIFT, ClinVar and gnomAD. Copy number variation

Results: The mean age at diagnosis of diabetes was 16.8 ± 5.3 (m ± SD) years, BMI at first visit was 21.6 ± 2.7 m2/kg. Among 10 subjects whose analyses were started by WES, pathogenic variants were found in seven subjects (three in HNF-1α, two in HNF-4α, one each in GCK and HNF-4β), and the detection rate was 70% in this group. In the second group consisted with subjects who were negative for previous sanger sequencing and panel sequencing, we found pathogenic variant each in PDX1, ABCC8, INS, and WFS1. In addition, a large genomic deletion was found in HNF-4α in one subject by XHMM and confirmed by MLPA. Thus, the tentative detection rate was 8.1% (5/62) in the second group. The WFS case was associated with compound heterozygous pathogenic variants, however, the patient did not develop diabetes insipidus nor optic nerve atrophy, indicating that diagnosis in very early phase was made.

Conclusion: Overall, 12/72 (16.7%) clinically suspected MODY subjects were found to have pathogenic variants in known monogenic diabetes genes, including a large genomic deletion in HNF-4α and WFS. At the same time, a low diagnostic rate (8.1%) was disclosed in 62 subjects who were negative in previous sanger or panel sequencing. Further systematic study including MLPA screening for exonic aberrations, and challenging for identifying unknown variants for Asian monogenic diabetes are still needed.

Supported by: Manpei Suzuki Diabetes Foundation, KAKENHI(21K06281)
Disclosure: S. Tanaka: None.

303
Clinical spectrum associated with variants in the INS gene in patients with suspected monogenic diabetes
M. Gomes Porras1, R. García Moreno2, M. Güemes Hidalgo3, R. Vallejo Monó1, M. Ruiz De Adana4, J. Gómez Zumaquero1, Á. Campos Barros2
1Endocrinology, Hospital Universitario Regional de Málaga, Málaga. 2Endocrinology, Hospital Universitario La Paz, Madrid. 3Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús, Madrid. 4Molecular Endocrinology, IBIMA, Málaga. 5Molecular Endocrinology, INGEMM, IdiPAZ, Madrid, Spain.

Background and aims: The INS gene encodes for preproinsulin, the precursor of insulin. INS mutations can cause MODY-INS (MODY10; OMIM #613370) and have been described more frequently in cases of neonatal DM. Opposite to what might be expected, the phenotypic expression reported is variable. The main objective was to clinically, biochemically and molecularly characterize patients with MODY-INS diabetes attending the Endocrinology Department of two Spanish tertiary level hospitals during the 2009-2022.

Materials and methods: Multicenter cross-sectional study that included 121 pediatric patients with suspected monogenic diabetes analyzed by targeted NGS with a custom panel including up to 482 genes associated with dysglycemia. The variants detected were classified according to ACMG criteria and prioritized using criteria of confidence and quality, coverage (20x/pb >95%), allele frequency in control population <1% (gnomAD), impact (“missense”, “nonsense”, “frameshift”, “splicing effect”) and in silico prediction of pathogenicity (CADD V1.6 score >15). Quantitative data were expressed as mean±standard deviation and qualitative data as absolute frequencies and percentages.

Results: 3/121 patients (2.5%), 2 males and 1 female, aged 15±4.58 years and BMI 21.8±3.5kg/m2, presented with heterozygous INS deleterious variants. While segregation analysis revealed that the pathogenic variants NM_000207.3:c.140G>A, (Gly47Asp) and NM_000207.3:c.163C>T,p.(Arg55Cys) in exon 2, were de novo, no allelic segregation study could be performed for the NM_000207.3:c.62C>T,p.(Pro21Leu) exon 1 variant (VUS). The two pathogenic variants are registered in HGMD, associated with MODY-INS and DM1, respectively, and none of the 3 is registered in gnomAD(V3.1.2). Diabetic debut at 12±2.6 years in the form of simple hyperglycemia, negative pancreatic autoimmunity, preserved C-peptide at diagnosis and 2/3 after 4 years from diagnosis. Initial Hba1c was 6.4±0.5% (currently 6.7±2.1%) and their lipoprotein profile was normal. None developed acute or chronic complications of diabetes after 4±2 years of follow-up. The patient with the INS p.(Pro21Leu) variant presented additional, predicted deleterious VUS in GPR183 and NRXN3. He was overweight and insulin resistance, treated with metformin. The patient with the INS p.(Gly47Asp) variant presented poor metabolic control due to poor adherence to low-dose insulin therapy, his DM was initially classified as type 1b, delaying the molecular diagnosis for about 3 years. The patient with the INS p.(Arg55Cys) variant presented good metabolic control with hygienic-dietary measures.

Conclusion: The prevalence of MODY-INS is higher than reported. Phenotypic expression occurred in early childhood, varying from mild to severe hyperglycemia with insulinopenia up to insulin resistance in relation to the association with other predicted deleterious variants in candidate genes (MODY-X). Susception of MODY-INS should be raised even in the absence of a family history of DM. The analysis of INS sequences should be included in the molecular diagnostic routine of suspected monogenic diabetes.

Supported by: Fundación SEEP
Disclosure: M. Gomes Porras: None.

304
Loss of FOXA2 induces ER stress and hepatic steatosis and alters developmental gene expression in human iPSC-derived hepatocytes
E.M. Abdelalim1, M. Aghadi2, R. Elgendy3
1Diabetes Research Center, Hamad Bin Khalifa University, Doha, Qatar. 2Discovery Biology, AstraZeneca, Gothenburg, Sweden.

Background and aims: FOXA2 has been known to play important roles in liver functions in rodents. However, its role in human hepatocytes is not fully understood. Recently, we generated FOXA2 mutant induced pluripotent stem cell (FOXA2-iPSC) lines and illustrated that deficiency of FOXA2 results in developmental defects in iPSC-derived pancreatic islet cells, which may lead to monogenic diabetes. Here, we used FOXA2-iPSC lines to understand the role of FOXA2 on development and function of human hepatocytes.

Materials and methods: Two FOXA2-iPSC lines and their WT controls were differentiated into hepatic progenitors (HP) and mature
Wolfram Syndrome (WS) is a rare genetic condition characterized by diabetes mellitus, optic atrophy, and progressive neurodegeneration. It is caused by mutations affecting the protein Wolframin, which is implicated in ER stress response, autophagy, and neurodegeneration. Wolframin plays a role in Ca++ handling: its loss provokes apoptosis in β cells, which is associated with familial young-onset diabetes. Mouse studies showed that Dach1 plays a role in the perinatal generation of most of the beta cell mass. As the knockout mice shortly die after birth, the function of Dach1 has not been studied in mature beta cells. Our aims were to establish the role of Dach1 in mature beta cells and to identify the regulatory network of Dach1.

Background and aims: Genetic variants in Dachshund family transcription factor 1 (DACH1) have been associated with familial young-onset diabetes. Mouse studies showed that Dach1 plays a role in the perinatal generation of most of the beta cell mass. As the knockout mice die shortly after birth, the function of Dach1 has not been studied in mature beta cells. Our aims were to establish the role of Dach1 in mature beta cells and to identify the regulatory network of Dach1.

Materials and methods: We used primary FACS-sorted beta cells of 10-week-old transgenic GLU-Venus x INS-Cherry male mice. Beta cells were knocked-down for Dach1 using siRNA-mediated technology and used for glucose- and KCI-stimulated insulin secretion tests. Human islets were isolated at the Geneva University Hospital (Switzerland). Total RNA was extracted from isolated mouse beta cells or cultured isolated cells. Our aims were to establish the role of Dach1 in mature beta cells and to identify the regulatory network of Dach1.

Results: Lack of FOXA2 resulted in significant alterations in the expression of key developmental and functional genes in HP and MH as well as an increase in the expression of ER stress markers. Functional assays demonstrated an increase in lipid accumulation, bile acid synthesis, and glycerol production, while a decrease in the glucose uptake, glycogen storage, and Albumin secretion. RNA-sequencing analysis further validated the findings by showing a significant increase in genes associated with lipid metabolism, bile acid secretion, and suggested the activation of hepatic stellate cells and hepatic fibrosis in MH lacking FOXA2.

Conclusion: These results indicate that the appropriate expression of FOXA2 in human hepatocytes is essential for normal hepatocyte development and protects hepatic cells from ER stress, hepatic steatosis, and bile acid toxicity. Furthermore, the in vitro human hepatocyte model presented here can be used to identify novel therapeutic targets for associated liver disorders.

Disclosure: S. Torchio: None.
Aertiology and pathogenesis of HNF1A-MODY using human islets deficient of HNF1A and a new heterozygous mouse model (Hnf1aΔe4-10) of the human disease

A. Acosta Montalvo1,2, C. Saponaro1, J. Thévenet1, M. Chira3, A. Piron2, N. Delalleau1, G. Pasquetti1, M. Moreno Lopez1, V. Gmyr1, M. Cnop5, J. Kerr-Conte1, F. Pattou1, M. Pontoglio1, A. Liston1, C. Bonner1,2,6, N. De lalley3, G. Pascuettib, S. Flanagan, A. Hattersley, K.A. Patel, Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.

307

As HNF1A is heterogeneously expressed in human islets; and (2) were born normoglycemic, but after 18 weeks developed fasting hyperglycemia (***p<0.0001). Postprandial glucose enrichments peaked within 30 minutes of the OGTT (**p<0.001), but rapidly declined thereafter. Plasma insulin levels were slightly lower (ns) while fasting, but increased after the OGTT (**p<0.05). There are no significant differences in fasting (0') and post-glucose glucagon levels, despite a reduction in renal Sglt2 expression (**p<0.1) and postprandial glucagon (>50 mg/dL). The latter which has been suggested to precede diabetes in human HNF1A mutation carriers.

Conclusion: Collectively, these findings indicate that HNF1A deficiency downregulates renal and alpha cell SGLT2 protein expression, which is associated with an alteration in glucagon secretion in response to glucose stimulation. The heterozygous Hnf1aΔe4-10 mice will also be advantageous to evaluate the efficacy of anti-diabetic drugs present and future.

Supported by: EFSD/Lilly Research Programme 2016; ISITE 2018; FWo

Disclosure: A. Acosta Montalvo: None.

308

Glucose transporters and hormone protein expression and secretion was analyzed by Western blotting and ELISA techniques. The Cre-LoxP system was used to create the Hnf1a-MODY mice. CRISPR/Cas-mediated genome editing was used to insert the lox sequences into intron 4 and after exon 10. Hnf1aΔe4-10 mice were bred with CMV-CRE mice to produce heterozygous Hnf1aΔe4-10 mice. To obtain littermate controls, Hnf1aΔe4-10 mice were bred with Hnf1aΔe4-10 mice. The measured parameters in this study were weight, fasting glucose, insulin, glucagon, glycoursia, and oral glucose tolerance tests (OGTT).

Results: We first observed that HNF1A is heterogeneously expressed in human alpha, beta, and delta cells. h-HNF1AΔe4-10 islets displayed reduced insulin secretion and content (51%), which was rescued by GLP1 treatment. HNF1A deficiency reduced SGLT2 protein expression (72%), correlating with increased glucagon content (104%) and secretion, which was not suppressed by high-glucose stimulation. Hnf1aΔe4-10 mice (n = 4) were born normoglycemic, but after 18 weeks developed fasting hyperglycemia (***p<0.0001). Postprandial glucose enrichments peaked within 30 minutes of the OGTT (**p<0.001), but rapidly declined thereafter. Plasma insulin levels were slightly lower (ns) while fasting, but increased after the OGTT (**p<0.05). There are no significant differences in fasting (0’) and post-glucose glucagon levels, despite a reduction in renal Sglt2 expression (**p<0.1) and postprandial glucagon (>50 mg/dL). The latter which has been suggested to precede diabetes in human HNF1A mutation carriers.

Conclusion: Collectively, these findings indicate that HNF1A deficiency downregulates renal and alpha cell SGLT2 protein expression, which is associated with an alteration in glucagon secretion in response to glucose stimulation. The heterozygous Hnf1aΔe4-10 mice were born normoglycemic, but after 18 weeks developed fasting hyperglycemia (***p<0.0001). Postprandial glucose enrichments peaked within 30 minutes of the OGTT (**p<0.001), but rapidly declined thereafter. Plasma insulin levels were slightly lower (ns) while fasting, but increased after the OGTT (**p<0.05). There are no significant differences in fasting (0’) and post-glucose glucagon levels, despite a reduction in renal Sglt2 expression (**p<0.1) and postprandial glucagon (>50 mg/dL). The latter which has been suggested to precede diabetes in human HNF1A mutation carriers.

Supported by: EFSD/Lilly Research Programme 2016; ISITE 2018; FWo

Disclosure: A. Acosta Montalvo: None.
Conclusion: Novel modification of the existing monogenic diabetes gene panel can identify the majority of 6q24 methylation defects. These modifications are easy to implement in existing gene panels worldwide and will greatly reduce the need to perform expensive methylation testing. Supported by: University of Exeter Expanding Excellence in England (E3) UKRI; Wellcome Trust; Diabetes UK
Disclosure: R. Kumar: None.

309 Genome-wide CRISPR screens identify therapeutic targets for HNF1A-deficient diabetes
M. Cuenca-Ardura1, M. De Vas2, D. Balboa1, J. Ferrer1;
1Centre for Genomic Regulation (CRG), Barcelona, Spain, 2Imperial College London, London, UK.

Background and aims: HNF1A encodes a transcription factor required for glucose-stimulated insulin secretion in human pancreatic β-cells. Heterozygous mutations in HNF1A cause haploinsufficiency and lead to monogenic early-onset diabetes. Moreover, hypomorphic variants in HNF1A and altered HNF1A function have been associated with increased risk of type 2 diabetes. Therefore, stimulating the expression of the wild-type HNF1A allele represents a potential therapeutic strategy in such patients. However, upstream mechanisms that regulate HNF1A in human adult β-cells remain unclear. We aim to identify candidate genes and pathways that control the expression of HNF1A.

Materials and methods: We performed two genome-wide loss-of-function and gain-of-function CRISPR screens in a human β-cell line carrying a tdTomato reporter knocked into HNF1A (EndoC-bH3 HNF1A/tdTomato). This reporter line allows modelling of clinical HNF1A haploinsufficiency as well as measuring the endogenous levels of HNF1A using a fluorescent readout. EndoC-bH3 HNF1A/tdTomato were transduced with lentiviral human CRISPR KO and CRISPRa libraries targeting all human genes with several sgRNAs. After selection, cells were sorted according to their tdTomato intensity of fluorescence. MAGeCK was used to calculate enrichment of sgRNAs in the Tomato-Low and -High populations and to select candidate genes that regulate HNF1A.

Results: We observed a high concordance between the two genetic screens. The CRISPRa screen identified 56 candidate activators and 26 candidate repressors of HNF1A at high confidence thresholds (P<0.001). The CRISPR KO screen uncovered 31 putative activators and 12 repressors of HNF1A (P<0.001). Several top candidates were validated individually in EndoC-bH3 cells by qPCR of HNF1A and some of its transcriptional targets. Functional analyses revealed an enrichment of selected pathways among candidate HNF1A activators and repressors.

Conclusion: Using an unbiased genetic approach, we have interrogated the whole genome of human pancreatic β-cells to find genes and pathways that potentially regulate HNF1A. Validations in stem-cell-derived islet models and in primary human islets are ongoing to confirm these findings. Integration of these genetic screens with two high-throughput chemical screens will further advance our understanding on core genetic pathways critical for human β-cell function, and pave the way for new precision medicine strategies to treat monogenic diabetes. Supported by: Boehringer Ingelheim Fonds (BIF)
Disclosure: M. Cuenca-Ardura: None.

310 Low-dose treatment with sulfonylureas improves hyperglucagonemia after a glucose challenge in HNF1A-MODY individuals and Hnf1a−/− mice
C. Saponaro1, I. Spiolitis2, A. Acosta-Montalvo1, L. Anguelova2, J. Thevenet3, M. Chiral3, V. Gmyr1, J. Kerr-Conte1, F. Pattou1, M. Pontoglio3, K. R. Owen2, C. Bonner1;

Background and aims: HNF1A is a transcription factor expressed in several metabolic organs involved in the maintenance of glucose homeostasis. A single mutation of HNF1A results in Maturity-onset-diabetes-of-the-Young (HNF1A-MODY), characterized by insulin secretory defects and hyperglycemia. Although endogenous glucose production has been reported, less is known about glucagon physiology in HNF1A-MODY. The first-line treatment for HNF1A-MODY patients is Sulfonylureas (SU), which increases insulin secretion by acting directly on the ATP-sensitive K+ channels of beta cells, independently of glucose. Patients on SU treatment achieve good glycaemic control, however, whether SU affect glucagon secretion in this population is unknown. Here, we aimed to determine the role of HNF1A on glucagon secretion and to establish whether low-dose gliclazide (SU) had an effect in HNF1A-MODY patients.

Materials and methods: An Oral glucose tolerance test (OGTT) was performed with 75 g of anhydrous glucose in solution in 7 HNF1A-MODY patients before and 72h after stopping gliclazide, and glycemia, c-peptide, and glucagon levels were measured. Hnf1a−/− mice compared to WT controls were fasted overnight, treated acutely with 40 mg/kg of gliclazide or vehicle 1h before the OGTT (2g/kg glucose), and glycemia, insulin, and glucagon levels were measured.

Results: In HNF1A-MODY patients glucose rose significantly off gliclazide (p=0.003), however, this was not reflected by significant changes in c-peptide or glucagon levels. However, when glucose levels were taken into account the change from baseline glucagon levels (Δ glucagon/glucose ratio) showed a significant decrease on, but not off, gliclazide (p=0.05), unlike c-peptide. Of note, HNF1A-MODY individuals, both on and off treatment, showed glucagon levels significantly below the normal range expected in healthy individuals. Hnf1a−/− mice compared to wild-type mice displayed glucose intolerance, associated with decreased plasma insulin levels and hyperglucagonemia that was not suppressed after a glucose challenge. The acute treatment with gliclazide significantly decreased glycemia after fasting and a glucose challenge compared to vehicle-treated animals. Moreover, after the OGTT insulin secretion was increased and glucagon over-secretion was suppressed in Hnf1a−/− mice treated with gliclazide compared to vehicle.

Conclusion: Collectively, these findings indicate that HNF1A is also involved in the regulation of glucagon secretion, and low-dose treatment with gliclazide improves hyperglucagonemia after glucose challenge. However, whether long-term treatment with gliclazide affects alpha cell function and glucagon secretion needs further investigations. Supported by: EFSD/Lilly Research Programme 2016; Société Francophone du Diabète
Disclosure: C. Saponaro: None.
SO 07 SARS-CoV2 and other viruses

311

Long and short isoforms of SARS-CoV-2 receptor Angiotensin-I-Converting Enzyme type 2 (ACE2) are increased in pancreatic islets of type 2 diabetes patients

D. Fignani1, G. Licata1, E. Aiello1, G.E. Grieco1, C. Formichi1, L. Nigli1, L. Marselli2, P. Marchetti2, G. Sebastiani2, F. Dotta1-3,
1Diabetes Unit, Dept. of Medicine, Surgery and Neuroscience, University of Siena; 2, Dept. of Endocrinology, University of Pisa, Pisa, Tuscany Region Centre for Precision Medicine (CReMeP), Siena, Italy.

Background and aims: SARS-CoV-2 can infect human pancreatic islets through β cell-specific expression of ACE2 receptor. We and others have previously shown that β cells do express the novel short-ACE2 (s-ACE2) isoform alongside with S-protein binding long ACE2 (l-ACE2). It is reported that type 2 diabetes (T2D) is a major comorbidity of COVID-19, and T2D patients are predisposed to poor prognosis and exacerbated altered glycometabolic control after infection. Considering the expression of ACE2 in pancreatic islets, we should take into account the hypothesis of a partial insulin deficiency due to direct damage and/or dysfunction of β cells during SARS-CoV-2 infection in T2D patients. Here, we aimed at elucidating the in-situ expression pattern of ACE2 in T2D respect to non-diabetic donors (CTR) which may account for a higher susceptibility to SARS-CoV-2.

Materials and methods: We take advantage from the large biorepository of T2D donor tissues from University of Pisa. We analyzed multiple FFPE sections from n=20 CTR (F=9 M=11; age mean±S.D.: 70.6 ±7 yrs; BMI: 26.2 Kg/m2±4.1 Kg/m2) and from n=20 T2D (F=6 M=14; age mean±S.D.: 71.7±7.6 yrs; BMI: 27.1 Kg/m2±2.7 Kg/m2), subjected to triple IFA using monoclonal mouse anti-human ACE2 (MAB933; detecting s-ACE2), polyclonal rabbit anti-human ACE2 (ab15348; detecting both ACE2 isoforms) and with polyclonal insulin. Stained sections were analyzed using confocal microscopy. Additionally, previous bulk RNA sequencing datasets of T2D and CTR islets were interrogated to evaluate ACE2 expression and other molecules involved in its upregulation.

Results: The analysis of n=1082 islets across all donors confirmed the expression of s-ACE2 and l-ACE2 in pancreatic β cells, both in T2Ds and CTRs. A higher prevalence of s-ACE2 respect to l-ACE2 in β cells was detected (mean colocalization rate in all donors s-ACE2: 10.8%; l-ACE2: 8.2%). We observed a significantly increased colocalization rate (%) between s-ACE2 [MAB933] and INS in T2D compared to CTR (T2D mean±S.D.: 12.5 ± 7.6% and CTR 9.23 ± 7.0%, p<0.001) and of l-ACE2 [ab15348] and INS in T2D compared to CTR (T2D mean±S.D.: 11.45 ± 13.7% and CTR 5.3% ± 5.3%; p<0.001). Moreover, the normalized signal intensity analysis (s-ACE2 and l-ACE2 mean pixel intensity/islet area) confirmed the upregulation of both ACE2 isoforms in T2D (grey scale values of s-ACE2 in T2D=52.5±34.6 and in CTR=37.1±28.1, p<0.001; grey scale values of l-ACE2 in T2D=53.2±63.5 and in CTR=27.3±22, p<0.001). RNA sequencing of isolated T2D islets vs CTRs confirmed the upregulation of ACE2 mRNA in T2D vs age-matched controls. Moreover, we observed an increased expression of the inflammatory signalling molecules STAT1 and NFAT in T2D vs CTRs, both involved in the transcriptional regulation of ACE2, thus implying the existence of active signalling pathways contributing to ACE2 hyperexpression in T2D.

Conclusion: We observed the upregulation of s-ACE2 and l-ACE2 in pancreatic islets of T2D donors. Higher ACE2 expression in T2D islets might increase their susceptibility to SARS-CoV-2 infection during COVID-19 disease, thus exacerbating glycometabolic demise due to a potential direct damage or dysfunction of β cells.

Disclosure: D. Fignani: None.

312

Pre-vaccination glucose time in range positively correlates with antibody response to SARS-CoV2 mRNA vaccine BNT162b2 in patients with type 1 diabetes

S. Briganti1, G. Alhama2,3, V. Viola1, M. Faraj1, C. Zannella1, G. Fransci1, C. Fusco5,6, C. Isgrò7,8, G. Leanza1, A. Spinelli1, G. Matarese10,11, P. Pozzilli1, M. Galgani12,13, R. Strollo1,
1Department of Endocrinology and Diabetes, Campus Biomedico University of Rome, Rome, Italy, 2Dasmans Diabetes Institute, Al-Asimah, Kuwait, 3Department of Medicine Sperimentale, Universita degli Studi della Campania, Naples, Italy, 4Department of Medicine Chirurgia e Odontoiatria ‘Scuola Medica Salernitana’, Università degli Studi di Salerno, Baronnisi, Italy, 5Consiglio Nazionale delle Ricerche Area di Ricerca di Napoli 1, Naples, Italy, 6Unita di Neuroimmunologia, IRCCS, Fondazione Santa Lucia, Rome, Italy, 7Department of Medicine, Campus Biomedico University of Rome, Rome, Italy, 8Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy, 9Department of Science and Technology for Humans and the Environment, Campus Biomedico University of Rome, Rome, Italy, 10Istituto per l’Endocrinologia e l’Oncologia Sperimentale “G. Salvatore”, Consiglio Nazionale delle Ricerche Area di Ricerca di Napoli 1, Naples, Italy, 11Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Naples, Italy, 12Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.

Background and aims: Poor glucose control has been associated with increased mortality in COVID-19 patients with type 1 diabetes (T1D). The aim of this study was to assess the effect of glucose control on antibody response to the SARS-CoV2 vaccine BNT162b2 in T1D.

Materials and methods: We studied 26 T1D patients scheduled to receive two doses, 21 days apart, of the BNT162b2 mRNA vaccine to SARS-CoV2. Patients were followed prospectively for six months with regular evaluation of SARS-CoV2 antibodies and glucose control. IgG to spike glycoprotein were assessed by ELISA, and serum neutralization by a live SARS-CoV2 assay (Vero E6 cells system). Continuous glucose monitoring, including time in range (TIR) and above range (TAR), and HbA1c were collected. The primary exposure and outcome measures were pre-vaccination glucose control, and antibody response after vaccination, respectively. IgG area under the curve (AUC) assessed the overall antibody response along the six-months study timeframe.

Results: Baseline TIR and TAR strongly correlated with peak-IgG, as well as with the IgG-AUC (TIR: r=0.75, p=0.02; TAR: r=-0.81, p=0.008). Furthermore, pre-vaccination TIR was associated with serum neutralization potency (r=0.49; P=0.042). Glucose control along the study timeframe was also associated with IgG response as showed by the correlation between time-dependent mean of TIR and TAR and IgG-AUC (TIR: r=0.93, P<0.0001; TAR: r=-0.84, P<0.0001). Pre-vaccination HbA1c was inversely related to peak-IgG, although the relationship did not reach statistical significance (r= -0.33; P=0.14).

Conclusion: Our findings indicate a strong relationship between glucose control and antibody response after SARS-CoV2 vaccination, highlighting the importance of achieving well-controlled blood glucose for COVID-19 prevention.

Supported by: EFSD/JDRF/Lilly Programme in T1D Research Disclosure: S. Briganti: None.

313

Association between SARS-CoV-2 infection and presymptomatic type 1 diabetes or celiac autoimmunity in general population children: Autoimmunity Screening for Kids (ASK)

M. Rewers, C. Geno Rasmussen, F. Dong, M. Stahl, L. Yu, B.J. Frohnert, K. Simmons, E. Liu, A.K. Steck, for ASK Study Group; University of Colorado, Aurora, USA.

Disclosures: None.
Background and aims: Early detection of presymptomatic type 1 diabetes (T1D) or celiac disease (CD) can prevent significant morbidity and cost associated with diagnoses that are delayed until significant clinical symptoms develop. We report outcomes of combined screening for presymptomatic T1D and CD in general population children and explore potential association of autoimmunity with SARS-CoV-2 infection.

Materials and methods: In 2017-2022, the Autoimmunity Screening for Kids program screened 29,441 children aged 1-17 y in Colorado, USA. Study participants’ race/ethnicity represented the Colorado population; only 4.9% had a first-degree relative (FDR) with T1D. Standard radiobinding assays (RBA) and electrochemiluminescence (ECL) assays were applied to detect autoantibodies to insulin, GAD, IA-2, and ZnT8 - markers of T1D autoimmunity as well as tissue transglutaminase autoantibodies (TGA) - a marker of CD. Screening positive children were invited to confirm results with repeat testing; if confirmed positive for islet autoantibodies (IA), they were monitored for development of diabetes (home BG testing, HbA1c, OGTT, CGM) and offered diabetes education, psychological support and participation in prevention trials. Those persistently TGA positive were referred to clinical services including intestinal biopsy and/or additional celiac autoantibody testing. Since July 2020, history of SARS-CoV-2 infection and immunization was collected from all study participants. In addition, antibodies to SARS-CoV-2 spike protein receptor binding domain and nucleocapsid protein were measured by ECL to distinguish response to infection from that to immunization.

Results: Presymptomatic T1D was detected in 0.97% of children (95%CI 0.86-1.09%), including 0.44% with multiple IA and 0.53% with a single high-affinity (ECL+) IA predicting, respectively, a 44% and 29% 5-y risk of clinical T1D. Multiple IA were more frequent in non-Hispanic whites than Hispanics (OR=1.81; 1.25-2.62, p=0.001) and in FDRs than non-FDRs (OR=3.64; 2.29-5.79, p<0.0001), adjusting for age, sex, and family history. However, only 14% of children with presymptomatic T1D were FDRs. During follow-up 44 children who initially screened positive progressed to clinical T1D; only 2/41 (5%) of those who completed a confirmation and enrolled in monitoring developed DKA. Overall, 764 children 2.60% (2.42-2.78%) of children without a previous diagnosis of CD screened positive for TGA. Of those, 81% were confirmed persistently positive and 197 have been diagnosed with CD, so far. Among 4717 children screened in 7/2020-12/2021,1524 had serologic evidence of SARS-CoV-2 infection. The infection was not associated with presymptomatic T1D (OR 1.50; 0.80-2.78) or TGA (OR=1.02, 0.63-1.59; p=0.95) adjusting for age, sex, race/ethnicity, and family history of, respectively T1D or CD.

Conclusion: This population-based screening program found a high prevalence of presymptomatic T1D and CD in Colorado children. There was no association between SARS-CoV-2 infection and the presence of autoantibodies. Clinical monitoring and education of children screened positive and 197 have been diagnosed with CD, so far. Among 4717 screened positive for TGA. Of those, 81% were confirmed persistently positive and 197 have been diagnosed with CD, so far. Among 4717 children screened in 7/2020-12/2021,1524 had serologic evidence of SARS-CoV-2 infection. The infection was not associated with presymptomatic T1D (OR 1.50; 0.80-2.78) or TGA (OR=1.02, 0.63-1.59; p=0.95) adjusting for age, sex, race/ethnicity, and family history of, respectively T1D or CD.

Supported by: JDRF 2-SRA-2021-1065-M-N

Disclosure: M. Rewers: Grants; JDRF 2-SRA-2021-1065-M-N.

314 Coxackie virus protease 2A alters the sorting of insulin secretory granule cargoes and induces the premature activation of cathepsins

K.-P. Knoch1, A. Kosok1, Z. Marinicova1, I. Kalaizidis1, Y. Kalaizidis2, A. Müller1, A. Sömmez1, C. Wegbrod1, K. Ganss1, M. Solimena1; 1Department of Biomedical and Clinical Sciences, Linköping university, Linköping, 2Jönköping County council, Jönköping, Sweden.

Background and aims: Enteroviruses (EVs), including Coxackieviruses B5 (CVB5), have been implicated in the pathogenesis of type 1 diabetes (T1D). CVB5-infection of β-cells inhibits the cap-independent translation of host proteins, but not the cap-independent translation of secretory granule (SG) cargoes such as insulin, ICA512/IA-2/PTPRN, PC1/3, PC2 and Cga. Several of these proteins are major targets of humoral and/or T-cell autoimmunity in T1D. Nonetheless, in CVB5-infected β-cells mature SG cargoes are depleted due to intracellular degradation. Previous studies showed that CVB5 protease 2A is responsible for this phenomenon. Proteomic analysis of CVB5 2A-transfected MIN6 insulinoma cells revealed the reduction of several factors involved in post-Golgi vesicular transport, such as Art1, GGA2, Rab3b and Syntaxin 8. However, only the knockdown of Rab3b and GGA2 generated the phenotype observed upon overexpression of CVB5 2A. Here we investigated the impact of GGA2 depletion on the sorting and maturation of SG proteins and Cathepsins.

Materials and methods: Mouse insulinoma MIN6 cells were transfected with either CVB5 protease 2A or 3C or infected with CVB5. Levels of insulin and other SG cargoes in control and CVB expressing cells were assessed by western blotting, ELISA, immunostaining and quantitative proteomics. Gga2-/- MIN6 cells were generated using CRISPR/Cas9 technology. Cathepsin B and D activity was measured by fluorometric assay. Golgi enriched fractions were isolated from cell extracts by discontinuous sucrose density gradients. The luminal pH in different compartments along the secretory pathway was measured with CFP-reporters and fluorescence life imaging microscopy.

Results: Confocal and live-time microscopy showed that in Gga2-/- MIN6 cells exit of SG cargoes and cathepsins from the TGN is delayed. GGA2 depletion was also associated with a significant drop of the pH in the lumen of the Golgi complex, and especially in the late Golgi and the TGN. Similar phenotypic changes were observed in CVB5 2A-overexpressing MIN6 cells. Furthermore, the activity of cathepsin B and D in Golgi fractions isolated from Gga2-/- MIN6 cells was increased.

Conclusion: Our data suggests the following scenario: CVB 2A-induced acidification of the late Golgi and TGN results in the premature activation of cathepsins already in these compartments. This could foster the degradation of incoming SG cargoes and the generation of new SG cargoes-derived antigenic peptides. The abundance of the latter together with the altered pH could favour their competitive displacement of peptides already preloaded on in-transit MHC class I molecules, thus altering the antigen repertoire presented by CVB5/EV-infected β-cells.

Supported by: IMM-INNODIA, D2D

Disclosure: K. Knoch: None.

315 No association between incidence of type 1 diabetes and rotavirus vaccination in Swedish children

A. Rangert1, C. Oldin2, M. Golsäter2, J. Ludvigsson1, K. Åkesson1; 1Department of Biomedical and Clinical Sciences, Linköping university, Linköping, 2Jönköping County council, Jönköping, Sweden.

Background and aims: Rotavirus may trigger type 1 diabetes (T1D) and rotavirus vaccination is hypothesized to decrease the incidence of T1D. In Sweden, rotavirus vaccination was introduced in 2014 in two regions, in some regions 2016-2018 and from 2019 in all Sweden. The aim of the study was to investigate whether rotavirus vaccination is associated with a change in incidence and clinical manifestation of T1D.

Materials and methods: All Swedish children <15 years of age (n=7893) diagnosed with T1D between 2009 and 2019 were retrieved from the SWEDIABKIDS database. Vaccine coverage was collected from Child Health Services. Three vaccine groups were created: I: Start 2014; II: Gradual start 2016-2018; III: No vaccination. Incidence of T1D before rotavirus vaccine (2009-2014) was compared to incidence rates after (2015-2019).

Results: The mean incidence of type 1 diabetes for children <15 years was 42-61 cases per 100 000 persons during the observed period. The incidence rate ratio (IRR) was 0.86 for children <5years in group I
(received vaccine), (p=0·10) when comparing the years before and after 2014. IRR was 0·88 (p=0·14) respectively 0·85 (p=0·02) for children in the same age in two other groups II, III. A similar IRR reduction was also seen among older children who received no vaccine in both group I (children 10-14·9 years: IRR =0·84, p=0·02) and in group III (children 5-9·9 years: IRR=0·85, p=0·01). We found no differences in clinical manifestation at onset associated with rotavirus vaccination.

**Conclusion:** There is no association between incidence or clinical manifestation of type 1 diabetes and rotavirus vaccination in children.

**Disclosure:** A. Rangert: None.

316

The influence of glucocorticoid therapy on glucose metrics monitored by continuous glucose monitoring in hospitalised patients with diabetes and infection

M.T. Olsen 1, C.K. Klarskov 1, A.K. Jensen 2, N.A. Windum 1, B. Lindegaard 3, P.L. Kristensen 1;

1Department of Endocrinology and Nephrology, Copenhagen University Hospital – North Zealand, Hilleroed, 2Department of Public Health, University of Copenhagen, Biostatistics, Copenhagen, 3Department of Pulmonary- and Infectious Diseases, Copenhagen University Hospital – North Zealand, Hilleroed, Denmark.

**Background and aims:** Infections and glucocorticoids (GCs) might induce hyperglycemia, however, it is unclear if the severity of infection influences glucocorticoid-induced hyperglycemia or vice versa. This study aimed to assess the effect of infection severity and GC treatment on glucose levels in hospitalized patients with diabetes mellitus (DM) using continuous glucose monitoring (CGM).

**Materials and methods:** Data were collected in a randomized controlled trial, CGM-ISO, which included hospitalized patients with DM and infection from May 2020 until February 2021. The primary endpoint was to describe daytime and nighttime glucose trajectories during treatment with prednisolone, dexamethasone, or no GC treatment when infection severity was low defined by C-reactive protein (CRP) <43.5mg/L or high CRP ≥43.5mg/L. Glucose data were obtained by the Dexcom G6 CGM. The CGM data were divided into days with and without GC treatment. A hierarchical Gaussian Process regression analysis was built to determine the influence of GCs and CRP levels on glucose levels adjusted for glucose-lowering medication (daily insulin dose). Postprandial glucose excursions (PPGE) were also assessed for days with and without GCs.

**Results:** Eighty-seven subjects were included in the analysis and 63% received GCs. In total, 210 days without GCs and 169 days with GCs (19 with prednisolone and 150 with dexamethasone) were analyzed. GC treatment was associated with increased glucose levels, especially during the daytime. High CRP levels increased glucose levels independently of GC treatment by approx. 1 mmol/L (18 mg/dL). On days with dexamethasone treatment, high CRP levels increased glucose levels by approx. 6 mmol/L (110 mg/dL) compared to days with prednisolone treatment and low CRP levels. On days with prednisolone treatment, high CRP levels increased glucose levels by approx. 1 mmol/L (18 mg/dL) compared to days with dexamethasone treatment and low CRP levels. On days with prednisolone treatment, high CRP levels increased glucose levels by approx. 6 mmol/L (110 mg/dL) compared to days with prednisolone treatment and low CRP levels. Mean PPGE (95% CI) after lunch were significantly higher during prednisolone treatment of 5.2 (3.5 to 6.9) mmol/L (94 (63 to 124) mg/dL) and dexamethasone treatment of 3.6 (3.1 to 4.1) mmol/L (65 (56 to 74) mg/dL) compared to no GC treatment of 2.0 (1.7 to 2.4) mmol/L (36 (31 to 43) mg/dL), but not at breakfast or dinner. See Figure 2.

**Conclusion:** GC treatment and high CRP levels are associated with increased daytime glucose levels, especially during prednisolone treatment. However, the effect of high CRP on glucose levels was surprisingly low during dexamethasone treatment. PPGEs were significantly higher during GC treatment at lunch (compared to no GC treatment), but not at breakfast and dinner.

Clinical Trial Registration Number: #NCT04430608

Supported by: NNF and GLFFF

Disclosure: M.T. Olsen: None.
SO 08 Benefits of a healthy lifestyle

317
Incidence of type 2 diabetes and factors associated with it in the PPP-Botnia Study
V. Ahuja1, L. Hakaste1,2, O.P. Dwivedi1, M. Lehtovirta1, B. Isomaa1,2,3, K. Lahni1, T. Tuomi1,5,
1Institute for Molecular Medicine Finland, Helsinki, 2Folkhälsan Research Center, Helsinki, 3Jakobstad Hospital, Jakobstad, 4Vasa Central Hospital, Vasa, 5Abdominal Center, Endocrinology, Helsinki University Central Hospital, Helsinki, Finland.

Background and aims: Our objective was to estimate the incidence of type 2 diabetes (T2D) and associated risk factors in the PPP-Botnia Study (Prevalence, Prediction, Prevention).

Materials and methods: The PPP-Botnia Study is a population-based prospective cohort study in Western Finland with 18-75-year-old participants randomly invited from the Finnish Population Registry in 2004-2008 (baseline study), first follow-up was conducted in 2011-2014 (the second study was started in 2018). Of 5208 baseline participants, 4844 were non-diabetic [mean age (SD) 48.97 (14.66) years; 54% women] with 24360 person-years of follow-up until the first follow-up visit (N=3850; 188 died before it). There were 153 incident cases of T2D. The subjects participated in a 2-hour oral glucose tolerance test. We used Poisson regression to obtain the crude and adjusted incidence of T2D and to evaluate the associated baseline risk factors.

Results: The crude and age-sex adjusted incidence rate ratio (IRR) for T2D with 95% CI were 6.28 (5.34-7.33) and 7.61 (4.53-12.51) per 1000 person-years. In multivariable analysis (Table) using standardized predictors, impaired fasting glycaemia/glucose tolerance (IFG/IGT) compared with normal tolerance (IRR 3.35, 95% CI 2.23-5.08), age (IRR 1.60, 95% CI 1.27-2.02), and BMI (IRR 1.30, 95% CI 1.09-1.55) significantly associated with incident T2D. Protection against T2D was independently associated with good insulin secretion evaluated by the disposition index (IRR 0.61, 95% CI 0.53-0.72) and insulin sensitivity evaluated by the Matsuda index (IRR 0.81, 95% CI 0.66-0.99). Male sex (IRR 1.41, 95% CI 1.00-1.99), family history of diabetes (IRR 1.41, 95% CI 0.99-1.98), and glutamic acid decarboxylase antibodies (IRR 1.34, 95% CI 0.40-3.30) did not reach statistical significance as predictors of incident T2D.

Conclusion: Besides abnormal glucose tolerance at baseline, age was the strongest predictor of T2D, and good beta-cell function was strongly associated with protection. While recorded family history was not a significant risk factor, in the future we will substitute it with polygenic risk scores for T2D, T1D, and the contributing traits.

Supported by: SJF, FRF, EXGENESIS, SAGF, SCFF, FDRF, FLHF, FMS, PNPF, HUCHRF, PF, OF, NHCF.
Disclosure: V. Ahuja: None.

318
Lifestyle risk factors and metabolic markers of cardiovascular diseases in Bangladeshi rural-to-urban male migrants compared with their non-migrant siblings
S.J. Mumu1,2, D. Merom1;
1Western Sydney University, 2Torrens University Australia, Sydney, Australia.

Background and aims: The increasing prevalence of cardiovascular diseases (CVDs) in developing countries like Bangladesh has been linked to progressive urbanisation. Comparisons of rural and urban populations often find a higher prevalence of CVD risk factors in the urban population, but rural-to-urban migrants might have different CVD risk profiles than either rural or urban residents. This study aimed to describe differences in CVD risk factors between migrants and non-migrants siblings and to determine whether acculturation factors were associated with CVD risk factors among migrants.

Materials and methods: Using a sibling-pair comparative study, 164 male migrant who migrated from Pirganj rural areas to Dhaka City of Bangladesh and their rural siblings (total n=328) were assessed by interview, anthropometric measurement, blood pressure and blood samples for OGTT and lipid profile. Comparisons were made using linear or logistic mixed effects models. The association between length of urban residence, categorised into tertiles, and CVD risk factors were assessed by logistic regression model.

Results: Physical inactivity, inadequate intake of fruit and vegetables and possible existence of a mental health disorder had 3.3 (1.73; 6.16), 4.3 (2.32; 7.92) and 2.9 (1.37; 6.27) times higher odds among migrants than their rural siblings, respectively. Migrants watched television on average 20 minutes (95% CI 6.17-35.08 min/day) more per day than the rural sibling group whereas PUFA intake, fruit and vegetable and fish intake of the migrants were -5.31 gm/day (-6.91; -3.70), -21.64 serving/week (-28.20; -15.09), -14.10 serving/week (-18.32; -9.87) lower than that of the rural siblings. No significant difference was observed for other variables. For acculturation, only one-third migrants use local dialect to communicate with their spouse, children and friends. When migrants were asked if
their dietary habits changed since migrating the city, most of them report-
ed increasing consumption of different unhealthy foods (60% to 76%)
and more than one-third believed they were less active than before migra-
tion. After adjusting, the risk of physical inactivity (p for trend, 0.001),
inadequate fruit and vegetable intake (p for trend, <0.001), a mental
health disorder (p for trend, 0.009) and low HDL (p for trend, <0.001)
were tended to be higher for each increasing tertile of urban life exposure
in migrants. However, diabetes was 5.5 times higher in migrants than
rural siblings in the first tertile of urban life exposure, but no clear pattern
of higher diabetes risk was found in the following tertiles.

**Conclusion:** The findings suggest that migration from rural-to-urban
environment increases CVD risk which exacerbate with time spent in
urban area due to acculturation.

**Supported by:** MoE, Bangladesh and WSU

**Disclosure:** S.J. Mumu: None.

---

**319**

**Does health-related lifestyle modify the association between type 2
diabetes and dementia risk? Finding from UK Biobank prospective
cohort study**

**J. Boonpor**1, J. Xing1, S.R. Gray1, F.K. Ho2, C. Celis-Morales1,3;
1Institute of Cardiovascular and Medical Sciences, University of
Glasgow, Glasgow, UK, 2Institute of Health and Wellbeing, University
of Glasgow, Glasgow, UK, 3Human Performance Lab, Education,
Physical Activity and Health Research Unit, Universidad Católica del
Maule, Talca, Chile.

**Background and aims:** Unhealthy lifestyle and type 2 diabetes (T2D)
accounts for a sizable increased risk of dementia. However, whether
lifestyle could modify the association between T2D and dementia risk
remains unclear. Therefore, this study aimed to investigate to what extent
the association between T2D and dementia risk is modified by lifestyle.

**Materials and methods:** 369,627 participants of UK Biobank (mean age
55.6 years; 54.6% women) were included in this prospective study. All-
cause dementia was the outcome. T2D was self-reported. A lifestyle was
derived from television viewing time, sleep duration, physical activity,
alcohol consumption, and dietary intake of processed and red meat, fruit
and vegetable, oily fish, and smoking status. The score was then
categorised into most-, moderate-and least healthy. Cox-proportional
hazard models investigated the association between lifestyle scores,
T2D and dementia.

**Results:** The median follow-up was 9.1 (IQR: 8.3-9.7) years after exclud-
ing the first two years of follow-up. Compared to non-T2D, T2D was
associated with a 28% higher risk of all-cause dementia (HR 1.28 [95%
CI 1.11, 1.47]). Those with the least healthy lifestyle had a 91% (HR 1.91
[95% CI 1.25, 2.91]) higher risk of all-cause dementia compared to those
with the healthiest lifestyle. Compared to individuals without T2D and
the healthiest lifestyle, those without and with T2D but who have the least
healthy lifestyle score had 36% (HR 1.36 [95% CI: 1.09, 1.21]) and 142%
(HR: 2.42 [95% CI 1.67, 3.50]) higher risk of all-cause dementia,
respectively.

**Conclusion:** The associations between T2D and dementia risk are accen-
tuated by poor lifestyle behaviours. This highlights that maintaining a
healthy lifestyle, especially in people with T2D, could reduce dementia
risk.
DNA methylation patterns reflect individual lifestyle independence from obesity

I. Klemp1, A. Hoffmann2, L. Müller1, T. Hagemann5, K. Horn1, J. Thiery3, M. Löfler2, R. Burkhardt3, M. Blüher1, K. Krohn5, M. Scholz3, R. Barberi2, P.W. Franks4, P. Kovacs4, M. Koller2,2; 1Medical Department III – Endocrinology, Nephrology, Rheumatology, University of Leipzig, Leipzig, Germany, 2University of Leipzig and University Hospital Leipzig, Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG), Leipzig, Germany, 3Institute for Medical Informatics, Statistics and Epidemiology, Leipzig, Germany, 4Medical Faculty, Kiel, Germany, 5Institute of Clinical Chemistry and Laboratory Medicine, Regensburg, Germany, 6Medical Faculty, Leipzig, Germany, 7LIFE Leipzig Research Center for Civilization Diseases, Leipzig, Germany, 8Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Malmö, Sweden.

**Background and aims:** Obesity is driven by modifiable lifestyle factors whose effects may be mediated by epigenetics. Therefore, we investigated lifestyle effects on blood DNA methylation in participants of the LIFE-Adult study, a well-characterized population-based cohort from Germany.

**Materials and methods:** Lifestyle Scores (LS) based on diet, physical activity, smoking and alcohol intake were calculated in 4107 participants of the LIFE-Adult study. Fifty subjects with an extremely healthy and 50 with an extremely unhealthy lifestyle, smoking and alcohol intake were calculated in 4107 participants according to low HOMA-β/high HOMA-S (insulinopenic), low HOMA-β/low HOMA-S (classic) and high HOMA-β/low HOMA-S (hyperinsulinaemic).

**Results:** Differences in DNA methylation pattern between BMI groups (<25 vs. >30 kg/m²) were rather marginal compared to inter-lifestyle differences (0 vs. 145 DMPs), which identified 4682 differentially methylated regions (DMRs; FDR<5%) annotated to 4426 unique genes. A DMR annotated to the Glutamine-Fructose-6-Phosphate Transaminase 2 (GFPT2) locus showed the strongest hypo-methylation (~6.9%) and one annotated to Glutamate Rich 1 (ERICH1) the strongest hyper-methylation (~5.4%) in healthy compared to unhealthy lifestyle individuals. Intersection analysis showed that diet, physical activity, smoking and alcohol intake are equally contributing to the observed differences, which affects, amongst others, particularly pathways related to glutamatergic synapse (adj.P<0.01) and axon guidance (adj.P<0.05). We showed that methylation age correlates with chronological age and waist-to-hip ratio with lower DNAmAge acceleration distances in participants with healthy lifestyle. Finally, two identified top DMPs for the Alanyl Aminopeptidase (ANPEP) locus also showed the strongest expression quantitative trait methylation (eQTM) in blood.

**Conclusion:** DNA methylation patterns help discriminate individuals with a healthy vs. unhealthy lifestyle, which may mask subtle methylation differences derived from obesity.

322

**Associations of physical activity and sedentary time with indices of beta cell function and insulin resistance in type 2 diabetes**

S.L. Domazet1, J. Tarp2, J.V. Stidsen1, R.W. Thomsen2, K. Højlund1, A. Groventved1, J.C. Broend2, J.S. Nielsen1; 1Clinical Research, Steno Diabetes Center Odense, Odense, 2Aarhus University, Department of Clinical Epidemiology, Aarhus, 3Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark.

**Background and aims:** The aim of this study was to investigate the associations between levels of total and intensity-specific physical activity and sedentary time with HOMA indices of beta-cell function and insulin resistance in persons with newly diagnosed type 2 diabetes (<2 years). To study the associations further, we divided the study sample into predefined pathophysiological sub-phenotypes according to beta-cell function and insulin resistance.

**Materials and methods:** We measured physical activity and sedentary time by dual monitor accelerometry in 765 persons with type 2 diabetes. We calculated HOMA indices and defined groups of sub-phenotypes according to low HOMA-β/high HOMA-S (insulinopenic), low HOMA-β/low HOMA-S (classic) and high HOMA-β/low HOMA-S (hyperinsulinaemic).

**Results:** We conducted multiple linear regression analysis with measures of time spent in total, light, moderate and vigorous physical activity and time being sedentary as explanatory variables while controlling for age and sex. An additional 10 minutes/day of light and moderate to vigorous physical activity was associated with a 0.6% (95% CI 0.3%; 0.9%) and 1.9% (95% CI 1.3%; 2.6%) higher insulin sensitivity, respectively. For each additional 1,000 steps/day insulin sensitivity was 2% (95% CI 1.0%; 3.0%) higher. Conversely, a higher physical activity level was associated with lower beta-cell function (~1.2%; -2.9%, p<0.01), while more sedentary time was associated with higher beta-cell function (0.7%, 95% CI 0.3%; 1.0%). We further regressed our predefined groups of sub-phenotypes on physical activity and sedentary time. Compared with the classic group (reference), the hyperinsulinaemic group was significantly more sedentary (24.0 min/day 95% CI 8.8; 39.2) and spent less time in light (-14.6 min/day, 95% CI -23.5; -5.8) and moderate to vigorous physical activity (-6.1 min/day, 95% CI -10.4; -1.8). The insulinopenic group was significantly more active than the other two groups (p<0.01). When we further adjusted our regression models for awake time, physical and mental well-being, comorbidities, smoking and BMI, we found that the hyperinsulinaemic group was no longer different from the classic group with respect to activity level, whereas the insulinopenic group remained less sedentary and more active than both the classic and the hyperinsulinaemic group (p<0.01).

**Conclusion:** These findings suggest that a higher degree of insulin resistance/hyperinsulinaemia is associated with more sedentary time and lower physical activity levels independent of physical and mental health, current smoking and BMI. The observed inverse association between physical activity and beta-cell function might support evidence stressing that beta-cell function is less affected by exercise. Although, a different disease etiology or genetic profile in combination with healthier lifestyle might as well explain the high physical activity level in persons with very low beta-cell function.

**Clinical Trial Registration Number:** NCT02015130

**Disclosure:** S.L. Domazet: None.
Cluster randomised trial to investigate the impact of applying a diabetes risk score in primary care on change in physical activity

E. Seidel-Jacobs1,2, F. Kohl3, M. Tamayo4, J. Rosenbauer1,2, M.B. Schulze1,2, O. Kuss1,2, W. Rathmann1,2; 1Institute for Biometrics and Epidemiology, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, 2German Center for Diabetes Research (DZD), München-Neuherberg, 3Institute for Occupational, Social and Environmental Medicine, Centre for Health and Society, Faculty of Medicine, Heinrich Heine University Düsseldorf, Düsseldorf, 4The Association of Statutory Health Insurance Physicians North Rhine, Düsseldorf, 5Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.

Background and aims: Diabetes risk scores are an adequate tool for identifying people at increased risk of diabetes, but little evidence exists on the impact of diabetes risk scores on health behaviour in clinical practice. The aim of this study was to investigate the effect of applying a non-invasive diabetes risk score in primary care as component of routine health checks on self-reported physical activity.

Materials and methods: A cluster randomised trial was conducted, in which primary care physicians (PCPs), randomised (1:1) by minimisation to an intervention and control group, enrolled participants without known diabetes, ≥35 years of age with a BMI ≥27.0 kg/m² in North-Rhine-Westphalia (Western Germany). The intervention was the application of the non-invasive validated German Diabetes Risk Score as add-on to a standard routine health check. Primary outcome was the difference in participant’s physical activity (International Physical Activity Questionnaires (IPAQ)) after 12 months between the intervention and control group. Secondary outcomes were differences in BMI, waist circumference, perceived health, anxiety, depression, and motivation for lifestyle change. Linear (for continuous outcomes) or generalized linear models with a logit link (for binary outcomes) mixed models including a random intercept to adjust for the cluster effect were fitted to assess the intervention effects.

Results: Three hundred fifteen participants (intervention: n=153, mean age 54 ± 8.1, 50% men; controls: n=162, mean age 49 ± 8.0, 64% men) were recruited by 30 PCPs (intervention: n=16; control: n=14). A slight increase in physical activity was observed in the intervention group with an adjusted mean change of 388 (95% CI: -235; 1,011) metabolic equivalents minutes per week. There were only minimal differences in BMI, waist circumference, perceived health, anxiety, depression, and motivation for lifestyle change. In both groups, constant levels of perceived health, anxiety and depression were observed over 12 months.

Conclusion: The use of a diabetes risk score alone is not effective in promoting physical activity under real life routine practice conditions. Therefore, more support is needed for people at risk to develop type 2 diabetes to increase their motivation, to change lifestyle, and to increase physical activity.

Clinical Trial Registration Number: NCT03234322, ClinicalTrials.gov Supported by: German Federal Ministry of Education and Research, BMBF to German Center for Diabetes Research, DZD Disclosure: E. Seidel-Jacobs: None.

Accelerometer-derived physical activity and sedentary time and cardiac biomarkers: the Maastricht Study

E.J. VanderCappellen1, A. Koster1, R.M.A. Henry1, C.J.H. van der Kallen1, N.C. Schaper1, H.H.C. Savelberg1, S.J.P. Eussen1, P.C. Dagnelie1, M.T. Schram1, M.M.J. van Greevenbroek1, A. Wesselsius1, S.J.R. Meek7, J.P. Kooman1, A.A. Kroon1, C.D.A. Stehouwer1; 1Internal Medicine, Maastricht University Medical Centre, 2Social medicine, Maastricht University, 3Nutrition and movement science, Maastricht University, 4Epidemiology, Maastricht University, 5Complex genetics and epidemiology, Maastricht University, 6Clinical chemistry, Maastricht University Medical Centre, Maastricht, Netherlands.

Background and aims: Cardiac troponins and NT-proBNP are biomarkers of cardiac injury that are used clinically in the diagnosis of myocardial infarction and heart failure. Type 2 diabetes is associated with chronically elevated cardiac biomarkers, which in turn are associated with adverse outcomes like lower event-free survival. It is not known whether the amount, types, and patterns of physical activity and sedentary behaviour are associated with levels of cardiac biomarkers. We investigated these relationships in people without and with type 2 diabetes.

Materials and methods: In the population-based Maastricht Study (n=2370, 51.3% male, 28.3% T2D, 15.2% prediabetes) we determined cardiac biomarkers (hs-cTnI, hs-cTnT and NT-proBNP). Physical activity and sedentary time were measured by the ActivPAL activity monitor and divided into quartiles (quarter 1 (Q1) served as reference). The weekly pattern of moderate-to-vigorous physical activity and coefficient of variation (CV) was calculated. Linear regression analyses were conducted with adjustment for demographic, lifestyle, and cardiovascular risk factors.

Results: Higher amounts of total physical activity were associated with lower levels of hs-cTnI (Q2) and higher levels of NT-proBNP. Higher levels of light intensity physical activity were associated with lower levels of hs-cTnI (Q2 and Q3) and with higher levels of hs-cTnI (Q4). Additionally, those with the highest levels of vigorous intensity physical activity had significantly higher levels of hs-cTnI and lower levels of NT-proBNP. Compared to the least sedentary, those in Q3 had significantly lower levels of hs-cTnI and individuals in Q2 and Q3 had lower levels of hs-cTnT. With regard to physical activity patterns, so-called weekend warriors and regularly actives (both groups had ≥150min of moderate-to-vigorous physical activity/week) had lower levels of NT-proBNP but not with hs-cTnI and hs-cTnT compared with inactive. A higher weekly moderate-to-vigorous physical activity CV (indicating more irregular activity) was associated with lower levels of hs-cTnI and higher levels of NT-proBNP, but not with hs-cTnT. Similar associations were found in those with and without type 2 diabetes.

Conclusion: Physical activity and sedentary time had complex associations with cardiac biomarkers. However, a minimum of 150 minutes of moderate-to-vigorous physical activity was associated with less NT-proBNP. Additionally, there was an association between the CV and NT-proBNP, implying that more regularity of moderate-to-vigorous physical activity during the week associates with lower levels of NT-proBNP. Our data suggest that performing at least 150min of moderate-to-vigorous physical activity equally divided over the week reduces NT-proBNP in individuals with and without type 2 diabetes.

Supported by: This project was partly funded through an EFSD award supported by AstraZeneca.

Disclosure: E.J. VanderCappellen: Grants; This project was partly funded through an EFSD award supported by AstraZeneca.
SO 09 Type 1 diabetes: from molecules to treatment

325

Automatising immune phenotyping of type 1 diabetes samples using a machine learning workflow

J.A. Vera-Ramos1, B. Prietl1,2, L. Herbthofer2, P. López-García2, V. Piefer1, T. Pieber1,2;
1Institute of Endocrinology and Diabetology, Medical University of Graz, 2CBmed GmbH - Center for Biomarker Research, Graz, Austria.

**Background and aims:** Autoimmune diseases share common mechanisms leading to a self-tolerance breakdown, suggesting the possibility of finding similar patterns in different diseases. These patterns can be helpful to understand disease progression and the recovery of patients. We aimed to find such patterns by inspecting the cell population distributions of samples from patients of different autoimmune diseases.

**Materials and methods:** We used machine learning (ML) to perform deep immune phenotyping of type 1 diabetes (T1D) and healthy controls to identify common patterns and dissimilarities among different autoimmune diseases. To this end, PBMCs were isolated from patients with T1D (n=69) and healthy donors (n=69). A flow cytometry approach was applied, using two different marker panels, focusing on CD4+ T cell populations. Then, a manual gating analysis was compared to a ML method implemented in R. The ML pipeline includes unsupervised pre-gating of lymphocytes using the R package flowCore, a data normalization step to improve the performance of the model, and FlowSOM clustering to group cells based on similarities in their marker expression using Self Organizing Maps (SOM). An intermediate step is done to filter samples that have a low recount of cells after filtering for CD3+CD4+ T cells using flowCore. Cell population distributions were tested for significant differences between T1D samples and controls using MANOVA.

**Results:** After applying our automated workflow on two of the panels focusing on T cells we could identify 14 cell clusters on the first panel and 16 clusters on the second one. The MANOVA test on panel 1 revealed several clusters significantly different on T1D samples: (i) a group of clusters defined by CD4pos T cells expressing high amounts of CD25 and FoxP3 and low amounts of CD15s (p=0.002); and (ii) CD4pos T cells expressing high amounts of Ki67 and CD15s (p=0.002). On the second panel, we found a trending cluster defined by CD4pos T cells with high expression of CD127 and CD307c, median amounts of CD366, LAP, PI-16, and CD45RA, and low amounts of CD95, CD147, CD25, and HLA-DR (p=0.05).

**Conclusion:** In conclusion, our high-throughput ML workflow is able to determine the cell population profile of many samples efficiently, and identify differences in the cell population abundance of different groups. This unsupervised analysis approach enables the discovery of new biomarkers complementing traditional workflows and streamlines the profiling of large datasets, for which conventional analysis is unfeasible. In the future, we plan to apply this workflow to large clinical studies to identify differences in the cell population abundance of different groups.

**Disclosure:** J.A. Vera-Ramos: Grants; JDRF.

326

Transcription and splicing regulation by NLRC5 shape the interferon response in human pancreatic beta cells

F. Szymczak1, M. Alvelos2, S. Marin-Cañas1, Á. Castela1, S. Demine2, M.L. Colli1, A. Op de Beeck1, L. Marselli2, P. Marchetti3, D.L. Eizirik1;
1ULB Center for Diabetes Research, Université Libre de Bruxelles, Anderlecht, Belgium, 2Indiana Biosciences Research Institute, Indianapolis, USA, 3Islet Cell Laboratory, University of Pisa, Pisa, Italy.

**Background and aims:** IFNα is a key regulator of the dialogue between pancreatic beta-cells and the immune system in early type 1 diabetes (T1D) via up-regulation of HLA class I and neoantigen presentation, but the molecular mechanisms regulating HLA class I expression in beta-cells remain to be clarified. To answer this question, we exposed islet-like cells derived from induced pluripotent stem cells (iPSC) - akin to the cells of a neonate - to IFNα and performed bulk and single-cell RNA-sequencing (RNA-seq) to unveil IFNα’s effect on global gene expression during the early stages of T1D. In follow up experiments, we focused on NLRC5, identified in this initial analysis as a key IFNα-regulated gene with a potential regulatory role on HLA class I expression.

**Materials and methods:** RNA-seq was performed in human iPSC-derived islet-like cells (Bulk/single-cell) and EndoC-βH1 after transfection with control siRNA or a siRNA targeting NLRC5 (Bulk), both exposed to IFNα (2,000 U/mL). The validation experiments were performed on EndoC-βH1, dispersed human islets and iPSC-derived islet-like cells. Cells were left untreated or treated with IFNα for 8 or 24h. Gene expression levels were measured by qPCR. NLRC5 protein expression was assessed by western blot. The HLA-ABC expression at the beta-cell surface was measured by flow cytometry. Alternative splicing (AS) events were also evaluated.

**Results:** RNA-seq analysis from islet-like cells exposed to IFNα evidenced induction of HLA class I expression, along with other genes involved in antigen presentation (i.e., B2M, TAP1/2 and PSMB8/9) and the transcriptional activator NLRC5; fold change >1.5; n=5; P value adjusted <0.05. This overexpression was detected in all of the islet cell types (fold change >1.5; n=5; P value adjusted < 0.05). NLRC5 depletion by siRNAs decreased IFNα-induced HLA Class I (by 41%; n=6; P value adjusted < 0.01) and genes related to antigen presentation, such as TAP2 (n=6; P value adjusted <0.001), a key peptide transporter that facilitates the
loading of antigens and stabilizes HLA at the cell surface, as well as the chemokine CXCL10 (32%; n=6; P value adjusted < 0.0001). KD of NLRC5 prevented by > than 80% IFNα-induced changes in splicing regulators (n=6; P value adjusted <0.05), including changes in NOVA1 and 2, and downstream splicing events.

**Conclusion:** The transcriptional activator NLRC5 regulates IFNα-induced expression of HLA class I expression and related genes, and of chemokines in human beta-cells. NLRC5 also mediates the effects of IFNα on AS, a potential generator of beta-cell neoantigens, suggesting that it is a central mediator of the effects of IFNα on beta-cells that may contribute to trigger and amplify autoimmunity in T1D.

**Supported by:** FRS-FNRS, WELBIO, Dutch Diabetes Research Foundation, INNODIA, EFPIA, JDRF

**Disclosure:** F. Szymczak: None.

327

Identification of circulating isomiRNAs as predictive biomarkers of beta cell decline in type 1 diabetes

G.E. Grieco1,2, S. Audidno1,2, M. Bruttini1,3, D. Fignani1,2, A. Mor1,3, E. Aiello1,2, G. Licata1,2, G. Sebastiani1,2, F. Dotta1,2

1Diabetes unit, Dept. of Medicine, Surgery and Neuroscience, University of Siena, 2Umberto Di Mario Foundation, c/o Toscana Life Sciences, 3Tuscany Region Centre for Precision Medicine (CreMeP), Siena, Italy.

**Background and aims:** Circulating biomarkers in type 1 diabetes (T1D) remain urgently needed to stratify T1D patients in the early stages of the disease and predict their progression. Iso-microRNAs (isomiRs) are post-transcriptional sequence variants of microRNAs (miRNAs) and represent an underestimated proportion of circulating RNAs in plasma. Standard bioinformatic sequencing pipelines and qPCR methods cannot efficiently distinguish circulating isomiRs from canonical miRNAs. Therefore, in this study, we aim to analyse circulating isomiRs using small RNA seq and advanced bioinformatics methods in plasma from T1D patients and control subjects to discover novel disease biomarkers associated with baseline or follow-up clinical conditions.

**Materials and methods:** We extracted RNA from 200 μl plasma from n=16 control subjects (age=28±5.4 yrs; BMI=21.3±2.3 Kg/m²) and n=16 newly diagnosed (<6 weeks) T1D patients (age=28.4±7.2 yrs; BMI=23.1±2.8 Kg/m²; ≥ Aa+b) followed for 12 months with scheduled visits every 3 months. Small RNA seq was performed using QiASEq miRNA library kit and sequenced using Illumina NOVASeq6000. Sequences of isomiRs and miRNAs were extracted using two bioinformatics pipelines (sRNAbench, miRge 3.0). Reads expressed in less than 40% of the samples with less than 6 counts per million (CPM) were removed. After normalisation with DESeq2 (Median of Ratios method), sequences shared by both bioinformatics pipelines were retained. Differential expression and association with clinical outcomes at baseline or follow-up were performed using a p-value < 0.05 (FDR corrected), absolute log2 fold-change > 1 and Spearman Rho test.

**Results:** In plasma, isomiRs account for 93% of all mapped sequences and 41% of all reads, indicating that plasma contains a higher number of isomiRNAs compared to miRNAs. We found n=179 canonical miRNAs, and n=209 isomiRs derived from n=208 canonical miRNAs. Of note, n=75 sequences were identified as isomiRs only. We identified n=66 canonical miRNAs and n=52 isomiRNAs differentially expressed between T1D and CTRs. Interestingly, n=9 sequences identified exclusively as isomiRs resulted differentially expressed. IsomiRs of mir-222-3p and mir-320a-3p, but not their canonical sequences, correlated negatively with fasting c-peptide at 3 (isomiR-222-3p: p=0.02; isomiR-320a-3p: p=0.04), 6 (isomiR-222-3p: p=0.0005; isomiR-320a-3p: p=0.003) and 12 months (isomiR-222-3p: p=0.01; isomiR-320a-3p: p=0.01) of follow-up, and also inversely correlated with MMTT c-peptide AUC at 3 (isomiR-222-3p: p=0.01; isomiR-320a-3p: p=0.01), 6 (isomiR-222-3p: p=0.03; isomiR-320a-3p: p=0.04) and 12 months (isomiR-222-3p: p=0.04; isomiR-320a-3p: p=0.02) post-diagnosis, thus predicting beta-cell functional decline during follow-up.

**Conclusion:** IsomiRs represent a large proportion of circulating RNAs. Their differentiation from canonical mirRNA is essential to identify reproducible and consistent disease biomarkers. Using an unprecedented approach, we identified several isomiRs differentially expressed in T1D able to predict beta-cell loss of function.

**Supported by:** No.115797-INNODIA and No.945268 INNODIA HARVEST

**Disclosure:** G.E. Grieco: None.

328

Plasma levels of the miR-193b/365a cluster in combination with clinical parameters predict response to Lactococcus lactis-based antigen-specific combination therapy

G. Sassi1, G. Licata2, G. Ventriglia2, D. Ellis1, N. Van Damme3, S. Caluwaerts3, A. Mori1,3, P. Rottiers3, C. Mathieu1, F. Dotta2,3, C. Gysemans1, G. Sebastiani3

1Clinical and Experimental Endocrinology, CHROMETA, KU Leuven, Leuven, Belgium, 2Diabetes Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy, 3Data Mining and Modeling for Biomedicine, VIB Center for Inflammation Research, Ghent, Belgium, 4Precigen Actobio, Zwijsaarde (Ghent), Belgium, 5Tuscany Centre for Precision Medicine (CREMeP), Siena, Italy.

**Background and aims:** Combining systemic immunomodulation with disease-relevant antigens could provide longer-term solutions for preventing and even reversing autoimmune type 1 diabetes (T1D). Our team established that a combination therapy (CT), composed of a short-course low-dose anti-CD3 treatment with oral delivery of genetically-modified Lactococcus lactis (L. lactis) bacteria secreting full proinsulin plus the anti-inflammatory cytokine IL-10 (LL-PINS+IL-10), was effective in reversing T1D in the non-obese diabetic (NOD) mouse model. Here, we aimed to identify robust peripheral biomarkers for prediction of CT response using circulating cell-free microRNAs (miRNAs). Furthermore, we exploited droplet-based CITE-sequencing (CITE-seq), a multimodal phenotyping method that simultaneously measures RNA and cell surface proteins at single cell level, to investigate the immune cell types regulated by the identified miRNA signature.

**Materials and methods:** New-onset diabetic NOD mice were injected intravenously with anti-CD3 (d0-5) and inoculated with LL-PINS+IL-10 for 6 weeks. TaqMan™ miRNA array followed by single-assay Q-PCR was performed on plasma samples taken from responder (R) and non-responder (NR) mice before CT initiation. CITE-seq was used to profile FACS-sorted circulating and pancreas-infiltrated CD45+ immune cells of new-onset diabetic NOD mice.

**Results:** Overall disease remission was 45% by the CT (n=110) compared to 0% in untreated controls (n=13; P<0.01) that remained hyperglycaemic. TaqMan™ miRNA analysis identified six miRNAs that were upregulated in plasma of NR compared to R mice before CT initiation. Of those, the miR-193b/365a cluster, composed of two paralogs, was significantly overexpressed in plasma of NR compared to R mice after different validation steps. Combining plasma expression of the miR-193b/365a cluster with clinical parameters (i.e., age and glycaemia at CT initiation) allowed prediction of CT outcome with 83% specificity and 89% sensitivity. Finally, we selected the high-confidence miR-193b/365a target genes from the Molecular Signatures Database (MSigDB) and scored their expression in CITE-seq profiled immune cells. Interestingly, increased levels of miR-365-3p and miR-193-3p in NR mice could influence several of the identified lymphoid and myeloid cell types.

**Conclusion:** The miR-193b/365a cluster may serve as a novel circulating biomarker that provides additional support for individualized therapy with the L. lactis-based CT.

**Disclosure:** G. Sassi: None.
The effect of type 1 diabetes on lumbar spinal cord transcriptome
K. Zglejc-Waszak1, A. Korytko2, M. Banach2, J. Jurank1;
1Department of Human Physiology and Pathophysiology, University of Warmia and Mazury in Olsztyn, Olsztyn; 2Department of Neurology, Jagiellonian University, Cracow, Poland.

Background and aims: Diabetic peripheral neuropathy (DPN) is characterized by numbness, reduced ability to feel pain or temperature changes and by progressive loss of neurons. The mechanism of DPN remains still unknown. However, studies in the 1960’s revealed that pathological changes may be present already in spinal cord neurons of diabetic patients before DPN symptoms occurs. Next-generation sequencing (NGS) allows for study and characterization of the transcriptomic alternations as well as molecular pathways in diabetic spinal cord. The aim of this study was to identify altered (up- or down-regulated) genes with known biological function, the most significantly altered biological pathway, gene ontology (GO) terms combined with functional annotation and interaction network of the selected set of genes in spinal cord harvested from mice with type 1 diabetes (T1D).

Materials and methods: All experiments were approved by the Local Ethical Committee in Olsztyn, Poland and were carried out in accordance with the 3R principles (Replacement, Reduction and Refinement). The data from T1D model was originally generated from male C57BL/6 wild type mice (Medical University of Białystok, Poland). Eight weeks old mice (n=10) were injected intraperitoneally with streptozotocin (n=5; STZ, 50mg/kg) or vehicle (n=5; PBS, pH=7.4) for five consecutive days and were sacrificed 24 weeks after the last injection (six months of living as a diabetic). Animals with a blood glucose level ≥13 mmol/L (260 mg/dL) were considered diabetic. Illumina NovaSeq 6000 system was used for sequencing.

Results: Analysis revealed, that among 538 differentially expressed genes (DEGs; P ≤ 0.05), 330 (208 up- and 122 down-regulated) DEGs had known biological function, according to DAVID database. The GO enrichment analysis demonstrated that DEGs were involved in biological process (BP), molecular function (MF) as well as cellular component (CC) GO terms. The analysis demonstrated that the most enriched biological pathway in diabetic spinal cord was PI3K-Akt pathway (mmu04151). The qPCR expression patterns of hydroxycid oxidase 1 (HAO1), neuroepithelial cell transforming 1 (NET1), ras homolog family member J (RHOJ), thioredoxin interacting protein (TXNIP) and cathepsin E (CTSE) aligned with NGS results. The GeneMANIA analysis of the validation genes, indicated that all of these genes as well as 20 additional related genes are connected in one network. In silico analysis revealed that CTSE, cathepsin D (CTSD), renin 1 structural (REN1), pepsinogen A5 (PGA5) and progastricsin (PGC) genes building a interactions network were involved in asparatic-type peptidase activity term, category MF.

Conclusion: Our results showed that T1D alters the transcriptomic profile of mouse spinal cord. Moreover, it may affect PI3K-Akt metabolic signaling pathway in lumbar spinal cord. Thus, regulation of this pathway and its downstream molecules may be a potential therapeutic target for the treatment of diabetic neurological complications. Our results may serve as a guide for further studies on the effect of hyperglycemic milieu on central nervous system function.

Clinical Trial Registration Number: 57/2019
Supported by: National Science Centre in Poland, grant no. UMO-2018/30/E/NSZ/00458
Disclosure: K. Zglejc-Waszak: None.

Submicron ultrasound contrast agents as therapeutic vehicles in type 1 diabetes
M. Cicciaglione1, E. Abenojar2, K. McDaniel1, M. Sticco-Ivins1, A. Michels1, A. Exner2, R. Benninger1;
1University of Colorado, Aurora, 2Case Western Reserve University, Cleveland, USA.

Background and aims: Type 1 diabetes (T1D) is an autoimmune disorder characterized by immune-mediated destruction of insulin-producing beta cells resulting in severe hyperglycemia if untreated. A promising approach for T1D prevention is antigen-specific immune therapy, which aims to promote the expansion of anti-inflammatory immune cells, such as regulatory T cells (Tregs), near the disease site. However, there has been limited investigation into optimizing the efficacy of many of these therapeutics using innovative therapeutic delivery vehicles. We investigated the usage of submicron ultrasound contrast agents (nanobubbles (NBs)) as delivery vehicles for antigen-specific peptide therapeutics in order to optimize therapeutic efficacy. NBs are small lipid-shelled bubbles that can be imaged and burst with ultrasound and have been shown to accumulate specifically in immune-infiltrated islets in mice because of high vascular permeability. We will assess if tolerogenic peptides can be incorporated into NBs, if NBs can deliver peptides specifically to islets, and if doing so can expand insulin-reactive Tregs and prevent diabetes onset.

Materials and methods: NBs were synthesized encapsulating an insulin B9-23 peptide mimotope and peptide/NB colocalization was assessed with confocal microscopy. NB echogenicity was assessed with contrast enhanced ultrasound (CEUS). Peptide bioactivity was assessed by pulsing a primary culture of antigen presenting cells with peptide and culturing with an insulin-reactive T cell hybridoma. Resulting IL-2 production was measured via ELISA. Biodistribution of peptide-NBs was assessed by infusing fluorescently-labeled NBs intravenously in NOD (T1D model) or SCID (no immune infiltration) mice and dissecting abdominal organs after 30 min. Tissue was sectioned and imaged with confocal microscopy. Immune infiltration was assessed by scoring H&E-stained sections. Expansion of insulin-reactive Tregs is determined by isolating islet lymphocytes of NOD Foxp3-EGFP mice, performing surface antibody stains and insulin-I-A(g7) tetramer stains, and analyzing with flow cytometry.

Results: Peptide palmitoylation enhanced retention in NBs: colocalization between palm-peptide and peptide/NB colocalization was assessed with confocal microscopy. NB echogenicity was assessed with contrast enhanced ultrasound (CEUS). Peptide bioactivity was assessed by pulsing a primary culture of antigen presenting cells with peptide and culturing with an insulin-reactive T cell hybridoma. Resulting IL-2 production was measured via ELISA. Biodistribution of peptide-NBs was assessed by infusing fluorescently-labeled NBs intravenously in NOD (T1D model) or SCID (no immune infiltration) mice and dissecting abdominal organs after 30 min. Tissue was sectioned and imaged with confocal microscopy. Immune infiltration was assessed by scoring H&E-stained sections. Expansion of insulin-reactive Tregs is determined by isolating islet lymphocytes of NOD Foxp3-EGFP mice, performing surface antibody stains and insulin-I-A(g7) tetramer stains, and analyzing with flow cytometry.

Conclusion: Antigen-specific therapeutics have great potential, but very few studies have optimized their efficacy using innovative routes of administration. This project serves as an important proof-of-principle for the utility of NBs for peptide delivery and has the potential to improve therapeutic intervention in T1D.
Reprogramming gastrointestinal cells: A new strategy to restore endogenous insulin production for diabetes?

C. Ayachi, T. Napolitano, S. Silvano, M. Plaisant, J. Becam, A. Sousa de veiga, E. Pichery, P. Collombat, Azur (UCA), Nice, France.

Background and aims: Type 1 Diabetes (T1D) arises as a result of a cell-mediated autoimmune loss of pancreatic insulin-producing β-cells. β-cell replacement represents a promising avenue of research for an alternative therapeutic strategy, whether it be through cell differentiation or reprogramming of different cell sources. However, to withstand a putative autoimmune attack of neo-generated β-cells, a renewable source of β-cells could be crucial. Interestingly, the gastrointestinal (GI) epithelium is a highly regenerative tissue with the potential to provide a continuous source of insulin-producing cells upon cellular reprogramming. Previous studies in the pancreas demonstrated the in vivo conversion of pancreatic glucagon-producing α-cells into functional β-like cells upon the ectopic expression of Pax4. Acknowledging that glucagon-producing cells are highly represented in the GI tract, we sought to determine whether these cells could also be turned into β-like cells.

Materials and methods: We made use of transgenic mice misexpressing Pax4 in glucagon-producing cells (Gcg_CreERT2::Pax4OE) to evaluate a putative Pax4-mediated gastrointestinal L-to-β-like cell conversion. Additionally, we implemented an ex vivo approach based on mice-derived colonoids to assess the functionality of these neo-generated β-like cells.

Results: Our results demonstrate that the in vivo ectopic expression of Pax4 in gastrointestinal glucagon-producing L-cells results in their conversion into functional insulin-producing β-like cells. Accordingly, the sole misexpression of Pax4 was found sufficient to induce a dramatic decrease in glucagon transcript contents in Gcg_CreERT2::Pax4OE GI tract (up to 98.89% depending on the GI segment analyzed, P value < 0.0001), in favor of the acquisition of a β-cell phenotype. Indeed, gastrointestinal insulin-expressing cells were detected in Gcg_CreERT2::Pax4OE animals (no insulin-expressing cells were identified in control animals). Accordingly, quantitative analyses by RT-qPCR outlined a massive increase in insulin transcript contents in Gcg_CreERT2::Pax4OE GI tract (up to 5435.5% depending on the GI segment analyzed, P value < 0.0001). Lineage-tracing approaches showed that all insulin-expressing cells arose from previous glucagon-producing L-cells, indicative of a glucagon-to-insulin cell conversion upon Pax4 misexpression. The characterization of newly formed gastrointestinal insulin-expressing cells revealed that these cells displayed most features of pancreatic β-cells. Among others, these include the expression of key β-cell factors, the production and processing of insulin, and the expression of components of the glucose-sensing machinery as outlined by an improved glucose responsiveness (P value = 0.0135). Lastly, functional tests on mice-derived colonoids established the ability of gastrointestinal β-like cells to release insulin upon glucose stimulation (P value = 0.000878).

Conclusion: From this study, we conclude that the sole expression of Pax4 appears sufficient to convert the gastrointestinal glucagon-producing L-cells into functional β-like cells in vivo, thus highlighting the potential of the GI epithelium as an innovative renewable source of insulin-producing cells to replenish the β-cell mass in T1D patients.

Supported by: The authors are supported by the JDRF.

Disclosure: C. Ayachi: None.

Continuous glucose monitoring identifies early dysglycaemia in very young children at risk of type 1 diabetes being followed in the Australian ENDIA pregnancy cohort study


Level 7, Northern Entrance, Telethon Kids Institute, Nedlands, Robinson Research Institute, Adelaide, School of Women’s and Children’s Health, Faculty of Medicine, University of New South Wales, Sydney, Institute of Endocrinology and Diabetes, The Children’s Hospital at Westmead, Sydney, Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Melbourne, Walter and Eliza Hall Institute of Medical Research, Melbourne, The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Translational Research Institute, Woolloongabba, Queensland Children’s Hospital, South Brisbane, Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Diabetes and Vascular Medicine Unit, Monash Health, Melbourne, Department of Diabetes and Endocrinology, Women’s and Children’s Hospital, Adelaide, Australia, Department of Diabetes and Endocrinology, Perth Children’s Hospital, Nedlands, Australia.

Background and aims: Prospective longitudinal studies of individuals at risk of type 1 diabetes (T1D) have shown that impaired glucose homeostasis starts months to years before symptomatic disease. No such studies have yet been conducted in young pre-school aged children, who may represent a rapidly progressive T1D phenotype. This study aims to investigate early dysglycaemia using continuous glucose monitoring (CGM) in young children with, and without, persistent islet autoimmunity being longitudinally followed in the Australian Environmental Determinants of Islet Autoimmunity (ENDIA) study.

Materials and methods: ENDIA is prospectively following 1,473 children with a first degree relative with T1D. Islet autoantibody testing (IAA, IA2A, GADA, ZnT8) is conducted 3-monthly from birth to 2 years, and 6-monthly thereafter. ENDIA children with persistent islet autoimmunity, and an age and sex matched autoantibody negative ENDIA participant, are invited to wear a blinded Dexcom G6 CGM for ≥ 14-days. CGM metrics evaluated include mean sensor glucose (SGL), standard deviation (SD) and coefficient of variation of sensor glucose (CEV) and % time in range (3.9 - 7.8 mmol/mol).

Results: 33 (19 autoantibody positive, 14 autoantibody negative) participants (mean age 4.9 ±(1.7) years) have completed a CGM session. Higher glycaemic variability was observed in children with persistent autoimmunity (Table).

Conclusion: Early dysglycaemia is detectable using CGM in young children with persistent islet autoimmunity and may be relevant for characterising metabolic progression and staging of pre-clinical T1D in this population.
SO 10 Diversity in diabetes

333 Variation in the relationship between fasting glucose and HbA1c: implications for the diagnosis of diabetes in different age and ethnic groups

Y. Ram1, Y. Xu1, T.C. Dunn1, R. Ajjan2;
1Abbott Diabetes Care, Alameda, USA, 2The University of Leeds, Leeds, UK.

Background and aims: Glycated hemoglobin (HbA1c) remains the benchmark biomarker for glycemic management. However, HbA1c can vary based on factors other than glycemia, including conditions that affect red blood cell (RBC) lifespan. The aim of this study is to examine the role of personal non-glycemic factors on the relationship between fasting plasma glucose (FPG) and HbA1c. The impact of race, age, and gender on HbA1c at FPG Diabetes Diagnosis Criteria (DDC), was analyzed by accounting for personal RBC factors with a recently-described kinetic model.

Materials and methods: The relationship between FPG and HbA1c, calibrated for National Glycohaemoglobin Standardization Program, was assessed in 12,531 individuals from the 2001-2018 National Health and Nutrition Examination Survey. FPG and HbA1c were used to calculate Apparent Glycation Ratio (AGR) for different subgroups of individuals based on age, race, and gender. AGR accounts for individual RBC glucose uptake and lifespan and characterizes a personalized relationship between glucose and HbA1c.

Results: Black individuals had higher HbA1c at FPG DDC [mean: 6.7% (95% CI: 6.7-6.8)] compared with White individuals [6.5%, (6.5-6.5); p<0.001]. Their AGRs were 72.7 mL/g (72.4-72.9) and 69.8 mL/g (69.6-70.0) respectively. Younger individuals <21 years had lower HbA1c at FPG DDC and AGR compared to >50 years of age [6.5% (6.5-6.6) and 6.57% (6.6-6.6), respectively; p<0.001] [AGR: 70.3 mL/g (70.1-70.5) and 70.8 mL/g, (70.6-71) respectively; p<0.001). Women and men also showed differences in HbA1c at FPG DDC [6.7% (6.6-6.7) and 6.5% (6.4-6.5), respectively; p<0.001] [AGR: 71.7 mL/g (71.5-71.8) and 69.3 mL/g (69.2-6.5) respectively; P<0.001]. Although there are differences between the subgroup means, there was 30 times more variation in AGR values within each group compared to differences between groups.

Conclusion: The relationship between FPG and HbA1c is affected by nonglycemic factors, which show wide inter-individual variability and are affected by race, age and gender. Assessment of AGR helps to understand individual relationship between glucose levels and HbA1c, thus increasing accuracy of HbA1c for screening and diagnosis of diabetes.


334 Subclassification of 3,529 individuals with type 2 diabetes

1Dept. of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, 2Dept. of Clinical Sciences, Genomics, Diabetes and Endocrinology unit, Lund University Diabetes Centre, Lund, Sweden,
Background and aims: A Swedish data-driven cluster study identified four distinct type 2 diabetes (T2D) clusters based on HbA1c level, BMI, age at diagnosis, and HOMA2 estimates of insulin resistance and beta-cell function. A Danish study suggested three T2D phenotypes (insulinopenic, classical, and hyperinsulinemic) based only on HOMA2 measures. We investigated and compared these two new T2D classifications using the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) cohort.

Materials and methods: In 3,529 individuals recently diagnosed with T2D, we first did a k-means cluster analysis with a forced k-value of four in order to replicate the Swedish clusters: severe insulin deficient (SIDD), severe insulin resistant (SIRD), mild obesity-related (MOD), and mild age-related (MARD) diabetes. Next, we performed an analysis open to alternative k-values (i.e. data determined the optimal number of clusters). Lastly, we compared the data-driven clusters with the three Danish T2D phenotypes.

Results: Compared with the Swedish results, the replicated SIDD cluster in DD2 comprised individuals with lower mean HbA1c (86 mmol/mol vs. 101 mmol/mol) and the MOD cluster individuals in DD2 were less obese (mean BMI 32 kg/m2 vs. 36 kg/m2). Our alternative k-value analysis suggested the most optimal number of T2D clusters in the DD2 cohort to be three (i.e. k-value of three), not identifying a MOD-like cluster (Figure, upper panel). When comparing the four replicated Swedish clusters in the DD2 to the three Danish HOMA2-based phenotypes, 81%, 79%, and 69% of the SIDD, MOD, and MARD individuals, respectively, fitted the classical T2D phenotype, whereas 70% of SIRD individuals fitted the hyperinsulinemic phenotype (Figure, lower panel). Among the three clusters identified with the alternative k-value analysis, 60% of individuals in the most insulin-resistant cluster constituted 76% of individuals with a hyperinsulinemic phenotype.

Conclusion: Different classification approaches did not classify T2D patients in a consistent manner. The T2D classes characterized by hyperinsulinemia/high insulin resistance appeared most distinct.

Supported by: Novo Nordisk Foundation

Disclosure: D.H. Christensen: Grants; The DD2 study was supported by the Novo Nordisk Foundation.

335

Socio-economic inequalities in the prevalence and incidence of pharmacologically-treated diabetes in France in 2020

M. Guion1, L. Mandereau-Bruno1, E. Cosson2, S. Fosse-Edorh2;
1Santé Publique France, Saint-Maurice, 2Department of Endocrinology-Diabetology-Nutrition, Jean-Verdier Hospital, University of Paris 13, Sorbonne Paris Cité, CRNH-IIdF, CINFO, AP-HP, Bondy, France.

Background and aims: Social inequalities in health (SIH) may impact the prevalence of diabetes and diabetes-related complications. The aim of this study was to describe the association between SIH and prevalence/incidence of pharmacologically-treated diabetes in 2020 in France including French overseas territories (FOT).

Materials and methods: Pharmacologically-treated people with diabetes were identified using a validated algorithm in the National health data system (Système National des Données de Santé: SNDS). SIH were measured via the French Deprivation index (FDep) of the 2015 version available for the Metropolitan France. Individuals living in FOT (excluding Mayotte) were considered separately. Age-standardized (2013 European standard population) prevalence and incidence rates were stratified by sex. Denominators were the French health consumers.

Results: Data were available for 65,580,975 health consumers (97.3% of the French population). Age-standardized diabetes prevalence and incidence rates were lower in women than in men in metropolitan France, but
prevalence was higher in women than men in FOT. Both prevalence and incidence were increasing by FDep quintiles (Q1 less deprived area, Q5 most deprived area) in metropolitan France and were even higher in FOT, in both genders. The Q5/Q1 ratio of age-standardized prevalence and incidence were higher in women (1.8 and 1.7 respectively) than in men (1.4 and 1.5 respectively).

**Conclusion:** SIH are positively associated with prevalence and incidence of pharmacologically-treated diabetes in metropolitan France. The association is stronger in women than in men. Diabetes prevalence and incidence are higher in FOT regardless of sex. Future studies will investigate whether the influence of SIH on diabetes epidemiology varies over years.

Supported by: These results are produced in the context of a doctoral project funded by the Fondation de France.

Disclosure: M. Guion; None.

### 336
**Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a nationwide cohort study**

**K.L. Funck**

1Department of Internal Medicine and Hematology, Semmelweis University, 2Center for Translational Medicine, Semmelweis University, 3Department of Biophysics and Radiation Biology, Semmelweis University, 4Military Hospital – State Health Centre, Budapest, Hungary.

**Background and aims:** Initiation of cardioprotective glucose-lowering drugs (GLDs) is often delayed in patients with type 2 diabetes (T2DM) and cardiovascular disease (CVD). We aimed to examine the impact of gender and specific CVD diagnosis on time-to-initiation of either an SGLT2 inhibitor or GLP1 analogue (collectively cardioprotective GLD) after a dual diagnosis of T2DM and CVD.

**Materials and methods:** In a registry-based nationwide Danish cohort study, we identified patients with a new dual diagnosis of T2DM and CVD (ischaemic heart disease, stroke, peripheral arterial disease [PAD] or heart failure) between January 1, 2012 and December 31, 2018. Index date was defined as the latest of the diagnosis of T2DM or CVD. Patients were followed until initiation of a cardioprotective GLD, death or the censor-date, whichever came first. Poisson models were used to estimate the initiation rate of cardioprotective GLD after the index date. We investigated if there was effect modification by gender on the association between CVD type and initiation rate using a Chi-Square test and estimated the initiation rate for men and women according to the type of cardiovascular disease. Final analysis was adjusted for age, HbA1c and low-density lipoprotein (LDL) cholesterol.

**Results:** We included 67,647 patients with new-onset T2DM and CVD (61% male, mean age 70±12 years, mean HbA1c 54±16 mmol/mol). During 230,000 person-years (PY) 6,344 people (9.4%) redeemed a prescription of a cardioprotective GLD-1. Initiation rates differed considerably according to the type of CVD (range 41-82 initiation during 1000 PY, Table 1) and we found effect modification by gender (p<0.05). Table 1 shows the initiation rate during 1000 PY for a man and a woman at age 70 years, with a diabetes duration of 3 years, HbA1c of 50 mmol/mol and LDL cholesterol of 2.2 mmol/L. The adjusted initiation rate ratio for men compared with women was 1.13 (95% CI: 1.03-1.24), 0.91 (95% CI: 0.78-1.06), 1.14 (95% CI: 0.92-1.42), and 1.30 (95% CI: 1.07-1.57) for ischaemic heart disease, stroke, PAD, and heart failure, respectively.

**Conclusion:** Overall, a small fraction of patients with a dual diagnosis of T2DM and CVD are initiated in cardioprotective GLD treatment. The initiation rate for men and women is comparable after diagnosis of stroke and PAD, however for heart failure and ischaemic heart disease, men are prescribed GLDs faster than women.

### Table 1

<table>
<thead>
<tr>
<th>Type of CVD</th>
<th>Male Initiation rate during 1000 PY follow-up (95% CI)</th>
<th>Female Initiation rate during 1000 PY follow-up (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischaemic heart disease</td>
<td>65.1 (61.0–70.2)</td>
<td>57.7 (52.5–63.4)</td>
</tr>
<tr>
<td>Stroke</td>
<td>61.2 (55.7–67.5)</td>
<td>45.3 (40.6–50.9)</td>
</tr>
<tr>
<td>Peripheral arterial disease</td>
<td>62.1 (59.7–64.5)</td>
<td>54.2 (49.2–59.3)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>83.1 (70.6–95.3)</td>
<td>69.8 (53.7–87.3)</td>
</tr>
</tbody>
</table>

Initiation rate during 1000 person-years (PY) for a man and a woman at age 70 years, diabetes duration of 3 years, HbA1c of 50 mmol/mol and LDL cholesterol of 2.2 mmol/L.

Supported by: Unrestricted research grant Boehringer Ingelheim Danmark A/S

Disclosure: K.L. Funck; Grants; Non-restricted research grant Boehringer Boehringer Ingelheim A/S.

### 337
**About one-in-three new onset diabetic ketosis cases is caused by ketosis-prone type 2 diabetes in adults: a systematic review and meta-analysis**

**A. Kovacs**

1Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark.

**Background and aims:** Ketosis-prone type 2 diabetes mellitus (KPD2) has been previously described in the literature. Nevertheless, only since 2019 was it defined by the World Health Organization as a hybrid form of diabetes characterized by unprovoked keto(acido)sis onset with preserved insulin secretion and absence of diabetes related autoantibodies. It mainly affects non-Caucasian ethnicity patients but the exact prevalence is unknown. Insulin treatment, although necessary at onset, may be waived in some of the KPD2 cases during disease course. We conducted a systematic review and meta-analysis to assess the prevalence and to describe the clinical characteristics of KPD2 among patients presenting with diabetic ketoacidosis or ketosis.

**Materials and methods:** The systematic search was performed in the five main databases - MEDLINE, Embase, Web of Science, Scopus and CENTRAL on 15th October, 2021 without any filters applied. For eligibility assessment we used the following definition of KPD2 (exposed group): newly diagnosed autoantibody-negative diabetic keto(acido)sis patients. The comparison group comprised typical type 1 diabetic keto(acido)sis cases with preserved beta cell function (C- peptide in the given reference range). The comparison group comprised typical type 1 diabetic keto(acido)sis patients. The random effect model was used in meta-analysis to calculate the pooled prevalence, odds ratios (ORs), mean differences (MDs) and the 95% confidence intervals (CIs). The I² value and chi-square test assessed statistical heterogeneity.

**Results:** Out of 16,962 articles 11 were eligible for the meta-analysis counting 2010 mainly adult patients. Among new onset diabetes patients...
presenting with diabetic ketoacidosis 35% (95%CI:0.24-0.49; I²=94%) belonged to the KPD2 group. When including in the analysis also the diabetic patients admitted for diabetic ketoacidosis regardless of the moment of diagnosis, the prevalence of KPD2 was 25% (95%CI:0.14-0.42; I²=97%). Patients with KPD2 were older (MD=11.55 years, 95%CI:5.5-17.6; I²=88%) and had a significantly higher BMI (MD=5.48 kg/m², 95%CI:3.25-7.72; I²=92%) by comparison with type 1 diabetes patients. HbA1c and triglyceride levels at admission, gender distribution, and family history of diabetes did not differ significantly between the two groups.

**Conclusion:** Ketosis-prone type 2 diabetes is a common type of diabetes among adult patients with diabetic ketoacidosis. Testing for C-peptide and islet cell autoantibodies in all newly diagnosed patients with diabetic ketoacidosis or ketosis at onset is essential for a proper classification and will allow an adequate long-term treatment.

**Disclosure:** A. Kovacs: None.

---

**338 Metabolically healthy obese is actually not healthy but at a risk for developing diabetes: a retrospective study**

S. Mizushiri, M. Daimon; Department of Endocrinology and Metabolism, 5 Zaifu-cho, Hirosaki, Japan.

**Background and aims:** Although obese individuals without obesity-related metabolic abnormalities are often defined as metabolically healthy, risks for developing such abnormalities have not been evaluated well. Recently, a prospective study showed that metabolically healthy obese subjects were at higher risk of diabetes, stroke, and cardiovascular disease than metabolically healthy subjects without obesity in the UK. We here analyzed the association between metabolically healthy obesity and risk for developing diabetes in a Japanese population.

**Materials and methods:** The participants were recruited from the Iwaki study, a health promotion study of Japanese people aimed to prevent lifestyle-related disease. Among 1167 participants of the Iwaki study held in 2014, 931 individuals attended at least one time from 2015 to 2019. We excluded 7 and 75 individuals without complete data sets and who were diagnosed with diabetes in 2014 respectively, thus 849 subjects were enrolled in this study. Obesity was defined as BMI >25 kg/m². We used the National Cholesterol Education Program ATP III Guideline to categorize metabolically unhealthy as participants meeting at least two criteria of metabolic abnormalities.

**Results:** In 2014, the number of metabolically healthy subjects without and with obesity were 606 and 101 respectively. Cox proportional hazard model showed metabolically healthy subjects with obesity were at higher risk of diabetes compared with those without obesity (Hazard ratio 3.70, p=0.002), even if after adjusted by age and sex (Hazard ratio 3.32, p=0.005).

**Conclusion:** Our analysis suggest an importance of encouraging people with obesity to reduce body weight even though they are metabolically healthy. We are extending such analyses in association with other lifestyle-related diseases.

**Disclosure:** S. Mizushiri: None.
SO 11 Novel biomarkers and risk factors

339 Sphingolipids in type 2 diabetes: a meta-analysis
M. Muilwijk1, T. Wong1, G. Burchell2, S. Remmelzwaal1,3, J.W.J. Beulens1; 1Epidemiology and Data Science, Amsterdam UMC, 2Faculty of Earth and Life Sciences, Vrije Universiteit Amsterdam, 3General Practice/Family Medicine, Amsterdam UMC, Amsterdam, Netherlands.

Background and aims: Evidence suggests that some sphingolipids are associated with type 2 diabetes (T2D). Past years, studies investigating sphingolipids and incident T2D rapidly increased. Therefore a meta-analysis on the association of sphingolipids and T2D is warranted.

Materials and methods: Medline, Web of Science, Embase and the Cochrane library were searched through January 2022. Prospective studies that reported associations between plasma or serum sphingolipids and incident T2D were selected amongst humans. The multivariable-adjusted relative risks of T2D were calculated analyses per study-specific SD difference in a given sphingolipid by random effects meta-analyses.

Results: A total of 18 prospective studies were identified, which included in total 18,529 individuals of whom 3,447 participants developed type 2 diabetes. Meta-analysis was performed for 19 sphingolipids, of which 10 were statistically significantly associated with type 2 diabetes. Ceramides showed consistent associations with type 2 diabetes risk with a pooled relative risk per study-specific SD increase of 1.18 [95% confidence interval 1.12-1.24]; I2=50.4%] for sphingomyelin 36:3. We were not able to e.g. the pooled relative risk per study-specific SD increase was 1.14 [95% confidence interval 1.05-1.24]; I2=44%]) for ceramide d18:1/2:0, and similar results for other ceramides. The results for sphingomyelins were mixed, e.g. the pooled relative risk per study-specific SD increase was 1.14 [95% confidence interval 1.05-1.24]; I2=50.4%] for sphingomyelin 36:1 and 0.86 [0.79-0.93]; I2=44%] for sphingomyelin 36:3. We were not able to meta-analyse complex sphingolipids such as lactosylceramides, due to limited data. [BH] Kun je gemiddelde duur van follow-up geven?

Conclusion: Several sphingolipids are consistently associated with the risk of T2D. Sphingolipids may potentially be used as biomarkers for T2D.

Supported by: EXPOSOME-NL (NWO grant number 024.004.017)
Disclosure: M. Muilwijk: None.

Materials and methods: In five independent clinical studies (n = 24 to 823), sOb-R was quantified in serum or plasma by commercial ELISA kits using monoclonal antibodies. We performed two-sample MR using publicly available summary data from genome-wide association studies of fasting glucose, fasting insulin, T2D and BMI as exposures, and sOb-R as the outcome. We performed multivariable MR to assess independent causality.

Results: In pooled, cross-sectional data (n=973), sOb-R was negatively associated with percent body fat and fasting C-peptide, a byproduct of insulin production. sOb-R decreased in response to acute hyperinsulinemia during glucose clamp in two independent clinical studies (n=61 and n=39), and immediately increased in response to both intensive exercise (n=26) and food intake (n=39). In two-sample MR, both higher fasting insulin and higher BMI were causally linked to lower sOb-R levels (Table 1). The causal effect of higher insulin on lower sOb-R persisted independently of BMI in multivariable MR (beta -1.6, p<0.001). The effect of higher BMI on lower sOb-R was unchanged (beta -0.21, p = 0.058) independently of fasting insulin. The cross-sectional study of fasting glucose and sOb-R (n=973), or effect of hyperglycemia on sOb-R (n=61) were inconclusive, in line with two-sample MR which indicated no causal relationship of fasting glucose on sOb-R.

Conclusion: Both BMI and insulin seem to causally and independently decrease sOb-R levels in blood. Conversely, intensive exercise and food intake acutely increased sOb-R. Our results may suggest that sOb-R is involved in short term regulation of leptin signaling, either directly or indirectly.

340 Role of soluble leptin receptor in diabetes prevention? Combination of cross-sectional, clinical intervention and Mendelian randomisation studies
C. Sommer1, K.G. Vangberg2, G.-H. Moen3,4, D.M. Evans5, S. Lee-Ødegård1, I.K. Blom-Høgestøl1, L. Sletner5, A.K. Jenum3, C.A. Drevon1, H.L. Gulseth2, K.I. Birkeland4; 1Oslo University Hospital, Oslo, Norway, 2Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway, 3University of Oslo, Oslo, Norway, 4University of Queensland, Brisbane, Australia, 5Akershus University Hospital, Lørenskog, Norway, 6Norwegian Institute of Public Health, Oslo, Norway.

Background and aims: Leptin is mainly produced by adipocytes, inhibits appetite, and is associated with bone metabolism, fertility, and insulin sensitivity. Signaling depends on membrane-bound leptin receptors, which via ectodomain shedding form soluble leptin receptors (sOb-R) which can be quantified in blood. High plasma sOb-R is inversely associated with gestational (GDM) and type 2 diabetes (T2D) in longitudinal observation studies. We explored associations between sOb-R and relevant metabolic markers, how sOb-R levels respond to hyperglycemia, hyperinsulinemia, acute exercise, food intake, and tested for causality using two-sample Mendelian Randomization (MR).

Disclosure: None.

Clinical Trial Registration Number: NCT00992797, NCT01803568, Supported by: Norwegian Diabetes Association

Disclosure: C. Sommer: None.

341 Plasma concentrations of complement C3 explain part of the associations of several measures of adiposity with type 2 diabetes: the Maastricht study
S. Jin1, C.G. Schalkwijk1, S.J.P. Eussen1, K. Koster3, E. Kool1, M.C.G. Brouwers1, C.D.A. Stehouwer1, M.M.J. Van Grevenbroek1; 1CARIM School for Cardiovascular Disease, Maastricht University, 2CAPRHI Care and Public Health Research Institute, Maastricht University, Maastricht, Netherlands.

Background and aims: A wealth of clinical and epidemiological evidence links obesity to type 2 diabetes (T2D), but the underlying causal pathways are not yet fully elucidated. Plasma concentration of complement C3. C3 explain part of the associations of several measures of adiposity with type 2 diabetes (T2D), the central hub in complement activation, has been identified as an independent risk factor for incident T2D. Moreover, complement C3 is expressed in adipose tissue and the plasma concentration of C3 is higher in individuals with obesity. In this study, we investigated whether and how much of the association between obesity and T2D was explained by C3.

Materials and methods: In 3544 population-based participants (51.7% men, 59.9±8.3 years, 28% T2D, oversampled), we measured C3 by ELISA in fasting EDTA plasma, body mass index (BMI) and waist circumference by standard methods, visceral (VAT) and subcutaneous adipose tissue (SAT) by MRI, insulin resistance as HOMA-IR, disturbed
glucose metabolism as fasting glucose concentration and the diagnosis of T2D by an oral glucose tolerance test. We conducted regression analyses to investigate the association of adiposity (all measures of adiposity were standardized) with insulin resistance, glucose metabolism and T2D, and evaluated the mediating effect of C3 in these associations. These regression analyses were adjusted for age, sex, socioeconomic status, and smoking habits. The 95% confidence intervals of the mediating effects were obtained by bootstrapping.

**Results:** All measures of adiposity (BMI, waist, VAT and SAT) were positively associated with insulin resistance, glucose metabolism and T2D (all P<0.001). These positive associations could be partly mediated by plasma C3. All 95% confidence intervals indicated significant mediated effects. C3 explained 26.2%, 22.3%, 25.3% and 27.5%, respectively, of the associations of BMI, waist, VAT and SAT with T2D. The strongest mediating effect of C3 in the association between adiposity and insulin resistance was seen for SAT (28.4% of the association between SAT and HOMA2-IR was explained by C3). Also in the association between adiposity and glucose metabolism, the strongest mediating effect of C3 was seen for SAT (44.6% of the association between SAT and fasting glucose was explained by C3). Additional adjustment for dietary habits and physical activity did not materially alter these observations (n=2951).

**Conclusion:** In middle-aged to elderly participants, the strong and positive association of several measures of adiposity with insulin resistance, glucose metabolism and T2D could for a substantial part be explained by the plasma concentration of complement C3. Our data thus suggest direct or indirect effects of C3 on insulin resistance and glucose metabolism contributing to T2D, starting from expanded and dysfunctional fat depots.

**Disclosure:** Supported by: CSC, EFSD Research Programme

**Disclosure:** S. Jin: None.

**342**

**Identifying biomarkers of psoriasis-driven metabolic disease**

**V. S. Gesheva**1,*2, E. Sayers1, E. Evans1, G. Bewick1, R. Andres-Ejarque1, I. Tos1,4, P. DiMeglio1,4, R. Hannen2, P. Caton1; 1Department of Diabetes, King's College London, 2Keratify Ltd., London, UK, 3St John’s Institute of Dermatology, King’s College London, 4NIHR Biomedical Research Centre, Guys & St Thomas NHS Foundation Trust & King's College London, London, UK.

**Background and aims:** Immune-mediated skin diseases such as psoriasis instigate changes in the skin secretome, which consequently result in dysfunctions of key metabolic tissues and increased risk of psoriasis comorbidities, such as type 2 diabetes (T2D). However, the potential skin secretome factors, which may induce metabolic and inflammatory effects in psoriasis remain poorly characterised. Proteomic analysis or existing gene expression datasets identified vimentin, parathymosin, prothymosin-alpha, dermcidin, desmin, interleukin 19 and interleukin 36-alpha as candidate skin secretome proteins. This project aimed to investigate the underlying events occurring in pancreatic islets and subcutaneous adipose tissue (sAT) which mediate psoriasis metabolic comorbidities and to identify novel prognostic biomarkers for early identification of psoriasis patients at increased risk of developing metabolic disorders such as T2D.

**Materials and methods:** This multi-centre, cross-sectional study was conducted in 8 sites from south, east, north, west and middle regions in China and enrolled 5,491 subjects aged 20-70 years. NB was diagnosed through the standardized interview validated by the WHO. Diabetes was ascertained by a standard 75g oral glucose tolerance test, the use of anti-diabetic medications, and/or the self-reported history. Participants with overweight or obesity were defined as those with body mass index $\geq 24$ kg/m$^2$. Binary logistic models was applied to assess the association of NB with the presence of diabetes.

**Results:** There were 411 participants diagnosed with NB. Compared with the participants without NB, the prevalence of diabetes was higher in those with NB (16.1% vs. 12.1%, p=0.020). The crude odds ratio (OR) of diabetes for participants with NB was 1.386 (95% CI 1.051, 1.828) compared with those without NB. After multiple adjustments (sex, age, BMI, TG, TC, HDL, LDL), the association still remained significant (OR 1.352, 95% CI 1.016, 1.800). Participants with NB had a larger waist circumference (86.83±10.15 vs. 85.05±10.58, p=0.001) and a higher prevalence of overweight or obesity than those without NB (65.8% vs. 65.0%, p=0.056).

**Conclusion:** Participants with NB had higher odds of diabetes and overweight/obesity in the Chinese population.

**Disclosure:** J. Wang: None.
Association between periodontitis and undiagnosed glucose intolerance status in apparently healthy young adults aged <40 years

Y. Lyu, J. Kim, S. Kim; Chosun university hospital, Gwangju, Republic of Korea.

**Background and aims:** Periodontal disease is prevalent disease in diabetic patients and untreated periodontal disease lead to raise the blood sugar and make it harder to control diabetes. Several studies report that diabetes screening of patients with periodontal disease is effective strategy, but this screening in young adults remains unclear. Thus, the aim of this study was to evaluate between periodontitis and undiagnosed glucose intolerance status in apparently healthy young adults aged <40 years.

**Materials and methods:** This study was based on the data from the Korean National Health and Nutrition Examination Survey (KNHANES), conducted by the Korean Ministry of Health and Welfare in 2010-2019. This survey is a cross-sectional and nationally representative study of noninstitutionalized civilians using a stratified, multistage, clustered probability sampling design. Of 10,654 participants, data for 1,864 subjects were included in the analysis. Multivariate logistic regression analyses were conducted separately to evaluate association with periodontal disease and undiagnosed glucose intolerance status in groups stratified by sex.

**Results:** The prevalence of undiagnosed prediabetes and undiagnosed diabetes was 20.1% and 2.7% in male, 12.4% and 0.8% in female, respectively. After fully adjusting for confounding factors, including age, smoking, alcohol, family income, education, place of residence, exercise and number of tooth brushing, Multivariate logistic regression analysis showed that periodontal disease was significantly associated with increased risk of diabetes (OR=2.595 (95% CI 1.201-5.606) in male, but, no significant associations were found in female.

**Conclusion:** Increased attention and implementation of precise strategies for identifying diabetes in young adults with periodontal disease would allow for increased wellbeing as well as reduced healthcare burdens associated with diabetes.

**Disclosure:** Y. Lyu; None.

---

The association of vital exhaustion and burnout (measures of) the metabolic syndrome and type 2 diabetes (T2D) in a systematic review and meta-analysis

S.H.M. Kremers, J.W.J. Beulens, M. Strikwerda, S. Remmelzwaal, P.J.M. Elders, F. Rutters; 1Epidemiology and Data Science, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, 2Julius Centre for Health Sciences and Primary Care, Utrecht, 3University Library, Vrije Universiteit, Amsterdam, 4General practice, Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, Netherlands.

**Background and aims:** We aimed to determine the association between social jetlag and the Metabolic Syndrome and Type 2 Diabetes (T2D) in a systematic review and meta-analysis.

**Materials and methods:** A systematic literature search was conducted in PubMed/Embase/Scopus until September 2020. Included studies described an association between social jetlag and the Metabolic Syndrome and/or T2D, were available full text and were written in English or Dutch. Data extraction and quality assessment was performed on pre-piloted forms independently by two reviewers. If three or more studies reported the same outcome, results were meta-analyzed using random-effects analysis.

**Results:** 5434 titles/abstracts were screened, 133 papers were read full-text, and 46 studies were included. One study was rated as low quality, 22 were of moderate quality, and 23 were of high methodological quality. The high quality studies showed that having social jetlag compared to no social jetlag was significantly associated with higher levels of BMI (0.39kg/m², 95% confidence interval 0.1;0.76;I²=100%) in 12 studies, higher odds of hypertension (1.16, 0.80;1.71;I²=0%) in seven studies, higher waist circumference (0.78cm, 0.22;1.35;I²=7%) in six studies, higher levels of HbA1c (0.65%, 0.12;1.18;I²=100%) in five studies, and lower odds of diabetes (0.45, 0.29;0.74;I²=53%) in four studies. No statistically significant associations were observed for abdominal obesity, High Density Lipoprotein (HDL) levels, triglycerides, blood pressure, fasting glucose levels, Metabolic Syndrome or T2D. Sensitivity analyses on health status and statistical quality did not reduce heterogeneity.

**Conclusion:** Social jetlag is associated with factors of the Metabolic Syndrome and T2D. However, high heterogeneity for some parameters complicate the interpretation of our results. Future studies should use prospective study designs to further assess cause and effect of the observed associations and try to elucidate the pathways and mechanisms that underlie this association.

**Supported by:** Diabetes Fonds, Senior Fellowship Grant

**Disclosure:** E.J. Bouman; None.
13 prospective, 4 case-control studies, 2 randomized controlled trials, and 3 had alternative designs. Preliminary results show that burnout and vital exhaustion were significantly correlated with BMI (correlation coefficient: 0.1, 95% CI: 0.0-0.1, I²=61.6%, 13 studies) and diastolic blood pressure (correlation coefficient: 0.1, 95% CI: 0.0-0.2, I²=49.9%, 9 studies). Burnout, but not vital exhaustion, was associated with elevated triglycerides, with a standardized mean difference of 0.22 mmol/L (95% CI: 0.0-0.4, I²=0%, 3 studies). Burnout and vital exhaustion were associated with hypertension, with a pooled odds ratio of 1.2 (95% CI: 1.1-1.4, I²=0.01%, 3 studies). Lastly, vital exhaustion was significantly associated with a slightly higher pooled odds of metabolic syndrome (odds ratio: 1.1, 95% CI: 1.0;1.1, I²=57.1%, 2 studies). This meta-analysis did not show significant associations of burnout and vital exhaustion with systolic blood pressure, HDL, waist-to-hip ratio, fasting glucose, and metabolic syndrome incidence, and we were unable to meta-analyse waist circumference. Most studies were considered of moderate methodological quality and have a moderate to low level of GRADE evidence, due to having cross-sectional designs.

**Conclusion:** Our meta-analysis indicates that burnout and vital exhaustion are associated with certain parameters of metabolic syndrome. However, no conclusions can be drawn about the incidence of metabolic syndrome. The results should be interpreted with caution due to moderate to low methodological quality and high heterogeneity of the included studies.

**Disclosure:** S.H.M. Kremers: None.

**Association between cholecystectomy and dysglycaemia: cross-sectional and prospective analyses**

M. Sang1, C. Xie2, Y. Liu1, S. Qu3, X. Wang4, Z. Sun1, T. Wu2;

1Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, School of Medicine, Southeast University, Nanjing, China, 2Centre of Research Excellence in Translating Nutritional Science to Good Health, Adelaide Medical School, The University of Adelaide, Adelaide, Australia, 3Department of General Practice, Zhongda Hospital, Institute of Diabetes, School of Medicine, Southeast University, Nanjing, China, 4Department of Clinical Nutrition, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.

**Background and aims:** A handful of cross-sectional studies have reported that cholecystectomy is associated with increased risk of diabetes. However, the relationship between cholecystectomy and the risk of prediabetes has not been assessed. Moreover, the association between cholecystectomy and variations in blood glucose has not been evaluated prospectively. In the current study, we conducted both cross-sectional and prospective analyses to examine the association between cholecystectomy and dysglycaemia in Chinese community-dwelling adults.

**Materials and methods:** A total of 1612 Chinese community-dwelling adults (n = 1564 without cholecystectomy and n = 48 with cholecystectomy) were surveyed for previous history of cholecystectomy and then followed up over ~3.2 years. Glycaemic status at baseline and follow-up was defined according to the World Health Organization (WHO) 1999 criteria. Percent changes (Δ) in fasting blood glucose and HbA1c from baseline at the follow-up visit were calculated to assess fluctuations in blood glucose and defined as stable (-10% ≤ Δ < 10%), improved (Δ < -10%), or worsened (Δ ≥ 10%) glycaemic control.

**Results:** The cross-sectional analyses at baseline revealed that participants with cholecystectomy were associated with a 1.9-fold increase in the risk of prediabetes (P = 0.003) and a 4-fold increase in the risk of diabetes (P < 0.001) compared to those without cholecystectomy after adjusting for age, gender, body mass index, current smoking, current drinking, hypertension, triglycerides, high-density lipoprotein, and low-density lipoprotein. The prospective analyses revealed that participants with cholecystectomy were associated with higher risk of deterioration in glycaemic control (ΔFPG ≥ 10%; 25.0% vs. 8.8%, P = 0.001 and ΔHbA1c ≥ 10%; 45.8% vs. 23.5%, P < 0.001, for participants with vs without cholecystectomy). These associations remained significant after adjusting for age, gender and baseline glycaemic status.

**Conclusion:** In Chinese community-dwelling population, individuals undergone cholecystectomy are at increased risk of prediabetes and diabetes and deterioration in glycaemic control. Therefore, cholecystectomy patients should be regularly monitored to avoid the risk of dysglycaemia.

**Supported by:** National Key R&D Program of China (2016YFC1305700)

**Disclosure:** M. Sang: None.
SO 12 Different facets of type 2 diabetes treatment

348
Prolonged use of proton pump inhibitors and risk of type 2 diabetes: results from a large population-based nested case-control study
G. Perseghin1, F. Rea2, L. Savare2, G. Morabito2, G. Corrao2, S. Ciardullo1;
1University of Milano-Bicocca, Monza, 2University of Milano-Bicocca, Milan, Italy.

Background and aims: It is still debated whether prolonged use of proton pump inhibitors (PPIs) might affect metabolic health. The aim of the present study is to investigate the relationship between prolonged use of PPIs and the risk of developing diabetes.

Materials and methods: We performed a case-control study nested into a cohort of 777,420 patients newly treated with PPIs between 2010 and 2015 in Lombardy, Italy. A total of 50,535 cases diagnosed with diabetes until 2020 were matched with an equal number of controls that were randomly selected from the cohort members according to age, sex, and clinical status. Exposure to treatment with PPIs was assessed in case-control pairs based on time of therapy. A conditional logistic regression model was fitted to estimate the odds ratios (OR) and 95% confidence intervals (CI) for the exposure-outcome association, after adjusting for several covariates. Sensitivity analyses were performed to evaluate the robustness of our findings.

Results: Compared to patients who used PPIs for <8 weeks, increased odds of diabetes of 19% (95% CI, 15-24%), 43% (38-49%), and 56% (49-64%) were observed among those who used PPIs for between 8 weeks and 6 months, 6 months and 2 years, and >2 years, respectively. The results were consistent when analyses were stratified according to age, sex and clinical profile, with higher ORs being found in younger patients and those with worse clinical complexity. Sensitivity analyses revealed that the association was consistent and robust.

Conclusion: Regular and prolonged use of PPIs is associated with a higher risk of diabetes. Physicians should therefore avoid unnecessary prescription of this class of drugs, particularly for long-term use.

Disclosure: G. Perseghin: None.

349
Risk factors for development of de novo post transplantation diabetes from 8 weeks after kidney transplantation
R. Carlsen1, A. Åsberg1,2, M. Svensson1, K.I. Birkeland1, I. Dressendorff1, H.L. Gulseth2, K. Midvind2, T.G. Jensen1,2;
1Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway, 2Department of Pharmacy, University of Oslo, Oslo, Norway, 3Department of Nephrology, Akershus University Hospital, Lørenskog, Norway, 4Department of Renal Medicine, Herlev and Gentofte Hospital, Herlev, Denmark, 5Department of Transplantation Medicine, Norwegian Institute of Public Health, Oslo, Norway, 6Faculty of Health Sciences, University of Tromsø, Tromsø, Norway.

Background and aims: Between 10 to 30% of kidney transplant recipients develop post-transplant diabetes mellitus (PTDM). PTDM is a major risk factor for cardiovascular events and death in kidney transplant recipients. At our center prednisolone doses are tapered to a low maintenance dose eight weeks after transplantation. In a retrospective single-center cohort study we investigated risk factors for development of de novo PTDM from eight weeks after kidney transplantation.

Materials and methods: Inclusion criteria were kidney transplantation, age > 18 years, no known diabetes prior to, or at the eight-week control after transplantation and with at least one year of follow up. At the eight-week control an oral glucose tolerance test (OGTT) was performed for PTDM diagnosis. De novo PTDM was defined as fasting glucose ≥ 7 mmol/L, 2-hours glucose ≥ 11.1 mmol/L at OGTT performed routinely at the one-year visit, or at least two registered dispensations of glucose lowering medication in the Norwegian Prescription Database (NorPD).

Results: In total 632 patients (median age 53 years, 62 % males) with a median follow-up of 2.7 years [1-4] were included of which 54 (8.5%) developed de novo PTDM (31 diagnosed by the OGTT at 1 year and 23 identified by glucose lowering dispensation). De novo PTDM patients were older than non-PTDM patients at transplantation (median age 63 vs 52 years), were more often males (81 % vs 61%), and had higher fasting blood glucose (mean 5.8 vs 5.3 mmol/L), 2-hour glucose (mean 8.3 vs 6.6 mmol/L) and HbA1c (median 38 vs 32 mmol/mol) at the eight-week post-transplantation control. In a multiple logistic regression analysis, significant associated factors of PTDM were age (years), OR 1.04 (CI 95%: 1.01:1.06), triglycerides (mmol/L), OR 1.42 (CI 95%: 1.10;1.81) and tacrolimus (μg/L) OR 1.23 (CI 95%: 1.03;1.46) concentrations measured at the one-year control visits, and CMV serostatus (positive donor to negative recipient), OR 2.12 (CI 95%: 1.04:4.28). Plasma magnesium, gender, BMI and plasma creatinine were not associated with development of PTDM.

Conclusion: Development of de novo PTDM from eight weeks after kidney transplantation was associated with increased age, higher triglycerides, higher tacrolimus concentrations and D+/R- CMV-serostatus.

Disclosure: R. Carlsen: None.

350
Glycated haemoglobin and diabetes treatment trajectories in type 2 diabetes: the Fremantle Diabetes Study Phase II
W.A. Davis, T.M.E. Davis;
Medical School, University of Western Australia, Fremantle, Australia.

Background and aims: No studies have examined combined HbA1c and diabetes treatment trajectories. Our aim was to explore the relationship between glycaemia and diabetes treatment complexity over 6 years in a prevalent cohort of community-based people with type 2 diabetes using group-based trajectory modelling (GBTM), and identify baseline predictors of trajectories.

Materials and methods: Sixty-one percent (899) of the 1482 participants in the Fremantle Diabetes Study Phase II (FDS2) type 2 diabetes cohort attended ≥3 biannual comprehensive assessments in the 6 years following recruitment between 2008 and 2011. Blood glucose-lowering therapy and HbA1c were documented at each assessment. GBTM identified combined HbA1c and diabetes treatment trajectory groups. To assist model selection, the Bayesian Information Criterion determined the optimum number of groups and their functional form. Other selection criteria included average posterior probabilities of group membership >0.70 and odds of correct classification ≥5. Multinomial regression identified plausible baseline predictors of group membership.

Results: At baseline, participants had a mean±SD age of 65±10.4 years, 54.4% were males, their diabetes duration was a median [inter-quartile range] 8 [2-15] years, and their HbA1c was 6.7 [6.2-7.5]% [50 [44-58] mmol/mol]; 27.5% were managed with lifestyle alone, 29.3% with single non-insulin therapy, 23.6% with multiple non-insulin therapies, and 19.6% with insulin (alone or combined with other therapies). GBTM revealed three trajectory groups (low (19.3%), medium (54.0%), high (26.8%)) corresponding to increasing HbA1c and treatment complexity (see Figure). For all groups, the average posterior probabilities were >0.98 and the odds of correct classification were >64. Over 6 years, the low group maintained an HbA1c ≤6.5% with progression from 1.7% to 17.7% on single/multiple non-insulin therapy, the medium group showed a modest increase in HbA1c (6.9% to 7.2%), and with an increase from 33.1% to 61.2% on multiple non-insulin therapy/insulin, while the high group maintained an HbA1c at 8.0% with insulin treatment progressing from
68.6% to 98.5%. Multinominal regression revealed age at diabetes diagnosis (negatively), diabetes duration, indices of obesity, and retinopathy significantly predicted membership of both the medium and high groups compared to the low group with increasing magnitude from the medium to high group.

**Conclusion:** These data show that, regardless of baseline HbA1c, glycaemic trajectories in community-based type 2 diabetes changed minimally over time despite treatment intensification. This includes the high group (>25% of the cohort) which had prolonged poor glycaemic control and experienced therapeutic inertia even though almost all progressed to insulin. People diagnosed young with long duration disease and obesity may not be managed proactively enough to maintain appropriate glycaemic targets and thus prevent microangiopathy.

**Supported by:** Australian NHMRC Project Grants; Australian NHMRC Project Grants.

**Disclosure:** W.A. Davis: Grants; Australian NHMRC Project Grants.

---

**351**

**Fracture risk in treatment with GLP-1RA compared to DPP-4i: a Danish nationwide cohort study**

Z.K. Al-Mashhadi1,2, R. Viggers3,4, R. Fuglsang-Nielsen5,6, P. Vestergaard1,2, S. Gregersen1,2, J. Starup-Linde1,2;

1Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, 2Department of Clinical Medicine, Aarhus University, Aarhus, 3Steno Diabetes Center North Jutland, Department of Endocrinology, Aalborg University Hospital, Aalborg, 4Department of Clinical Medicine, Aalborg University, Aalborg, 5Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.

**Background and aims:** Type 2 diabetes mellitus is associated with increased risk of fracture. The evidence regarding glucagon-like peptide 1 receptor agonists (GLP-1RA) and fracture risk is unsettled. We investigated the risk of major osteoporotic fractures (MOF) when comparing GLP-1RA to dipeptidyl peptidase 4 inhibitors (DPP-4i).

**Materials and methods:** We conducted a Danish population-based cohort study. Discharge diagnosis codes (ICD-10 and ICD-8-system) and redeemed drug prescriptions (ATC codes) were obtained from the Danish National Patient Registry and the Danish National Prescription Registry, respectively. We identified subjects treated with metformin in combination with either GLP-1RA or DPP-4i between 2007 and 2018. Subjects were propensity-score matched 1:1 on age, sex, and index date. Hazard rate ratios (HR) for MOF were calculated using a Cox proportional hazards model. In addition, additive rather than relative hazard effects were investigated using Aalen’s additive hazards model.

**Results:** We identified 42,816 individuals treated with either combination. After matching, 32,266 individuals remained. Median follow-up times in the GLP-1RA and DPP-4i group were 642 days and 529 days, respectively. The crude HR for MOF was 0.89 [95% CI 0.76-1.05] with GLP-1RA compared to DPP-4i. In the fully adjusted model, an unaltered HR of 0.86 [95% CI 0.73-1.03] was obtained. For hip fractures, we found a crude HR of 0.68 [95% CI 0.49-0.96] and a similar adjusted HR.

**Conclusion:** The risk of MOF tended to be slightly lower with GLP-1RA than with DPP-4i. The lower fracture risk became significant when examining hip fractures and when allowing follow-up to continue after medication change.

**Supported by:** Steno Collaborative Grant, NNF

**Disclosure:** Z.K. Al-Mashhadi: Grants; Steno Collaborative Grant, Novo Nordisk Foundation, Denmark (Grant no. NNF18OC0052064).

---

**352**

**Metformin affects DNA methylation patterns in newly-diagnosed patients with type 2 diabetes**

S. Garcia-Calzon1,2, S. Schrader1, A. Perilyev1, C. Ling1;

1Epigenetics and Diabetes Unit, Lund University Diabetes Centre, Malmö, Sweden, 2Food Science and Physiology, University of Navarra, Pamplona, Spain.

**Background and aims:** Metformin is the first line pharmacological treatment for type 2 diabetes (T2D). However, the molecular mechanisms involved in metformin action are not yet totally understood. Therefore, the aim of this study was to elucidate whether metformin therapy affects epigenetic mechanisms in newly-diagnosed individuals with T2D.

**Materials and methods:** 171 individuals with T2D from the ANDIS cohort were included. Cases were considered those subjects on metformin therapy (n=43), whereas controls (n=128) were randomly selected and matched to cases by age, sex, BMI, HbA1c, statins and antihypertensives.

**Results:** We found 1,451 sites (>2% absolute difference in methylation, FDR<0.05) differentially methylated between the two groups after adjusting for potential clinical confounders and cell composition using the reference-free Houseman method. The majority of these sites presented higher methylation levels in those individuals on metformin therapy. Notably, 13 sites showed >10% absolute difference in DNA methylation between cases and controls, and include annotated genes involved in glucose metabolism such as PFKP (9% absolute difference in methylation, cases 55.6 ± 30.4, controls 74.5 ± 22.9, q=0.015). KEGG pathway analyses of the genes annotated to the 1,451 sites yielded 6 overrepresented pathways (FDR<0.05) among which were cAMP signalling pathway, calcium signalling pathway and circadian entrainment.

**Conclusion:** Metformin therapy associates with differential DNA methylation genome-wide in newly-diagnosed T2D individuals, suggesting that metformin’s effects might involve epigenetic mechanisms.

**Supported by:** EFSD Research Programme, Novo Nordisk Foundation, ERC, H2020-MSCA, IRC15-0067, SDF

**Disclosure:** S. Garcia-Calzon: None.
353
Transcriptional and epigenetic changes in skeletal muscle of persons with diabetes after bariatric surgery
L. Kovac1, M. Ouni1, S. Gancheva2, S. Kahn2, M. Jähner1, M. Roden2, A. Schürmann1;
1Experimental Diabetology, German Institute of Human Nutrition, Nutheital, 2German Center for Diabetes Research, München-Neuherberg, Germany.

Background and aims: Bariatric surgery is known to be the most effective intervention to treat metabolic abnormalities associated with obesity and type 2 diabetes (T2D). In our recent study, it was shown that bariatric surgery alters the skeletal muscle transcriptome of obese people, in part through changes in DNA methylation. Next, we were interested in corresponding changes that occur in T2D individuals in response to bariatric surgery, and how they compare to effects detected in non-diabetic obese individuals.

Materials and methods: RNA-sequencing and DNA methylation analyses were done on skeletal muscle of 13 obese non-diabetic and 13 obese diabetic individuals, before and one year after bariatric surgery. Several in silico methods were combined for data analysis, including pathway enrichment and integrating phenotypes of knockout mice.

Results: In the muscle of participants with diabetes, 2012 genes were differentially expressed before and one year after the surgery (p<0.05). Among these, 803 genes were differentially methylated (p<0.05) and enriched in pathways linked to skeletal muscle development, hypoxia response and cell adhesion (p<0.05). The expression of 69 genes, including candidates involved in insulin signaling, lipid metabolism and glucose homeostasis, correlated with whole-body insulin sensitivity. Specifically, seven genes were previously described as T2D susceptibility genes in GWAS (e.g. ACHE, ABCC5, CAVIN1) and 26 genes associated with glucose metabolism, lipid levels and skeletal muscle function (e.g. IGFBP4, TXXLNA, LDB3), according to the phenotype data of corresponding knockout mice. Interestingly, we observed striking differences between obese and T2D transcriptional response to surgery. Prior to surgery, obese and T2D persons exhibit over 2700 differentially expressed genes(p<0.05), of which approximately 70% remain significantly different one year after surgery. Only a third of the affected genes was commonly regulated between the two groups, indicating distinctive responses of skeletal muscle to the surgery. The differences in expression were mirrored in the affected biological pathways, with insulin signaling and fatty acid metabolism genes significantly enriched among those altered in obese but not T2D participants.

Conclusion: First, we generated a comprehensive overview of transcriptional and epigenetic changes in skeletal muscle, providing molecular insights into the long-term response of T2D people to bariatric surgery. Second, our comparison of skeletal muscle transcriptome from obese and T2D individuals suggests that these two groups are significantly different before and exhibit divergent responses to the bariatric surgery.

Supported by: BMF
Disclosure: L. Kovac: Grants; 82DZD00302.
Materials and methods: This was a retrospective study. We analyzed the data of 111 T2DM patients with TIR>70% who received 48-72h CGM in Department of Endocrinology and Metabolic Disease from January 2018 to October 2019. The mean blood glucose (MBG) and glucose variability (GV) including the mean amplitude of glucose excursion (MAGE), the largest amplitude of glycemic excursion (LAGE), coefficient of variation of blood glucose (CV), mean of daily difference (MODD) and low blood glucose index (LBGI) were measured on admission using CGM. Univariate and multivariate logistic regression were used to analyze the relationship between hypoglycemia (defined as blood glucose below 70mg/dL, detected by CGM) and MBG, MAGE, LAGE, CV, MODD and LBGI. The receiver operator characteristic (ROC) curve was drawn to evaluate the ability of predicting hypoglycemia.

Results: (1) Of 111 subjects, 53 patients experienced 278 events with a glucose level<3.9 mmol/L and 63 events with a glucose level<3.0 mmol/L. The highest incidence of hypoglycemia was presented from 10pm. to 6am. (40.6%). (2) Compared to nonhypoglycemia group, MAGE, LAGE, MODD, CV and LBGI were significantly higher (t=7.46 to -3.176, all P<0.005) while MBG was lower than those in hypoglycemia group (t=2.944, P=0.004). (3) Multivariate logistic regression analysis showed that MBG (OR=0.51, P=0.007) and GV including MAGE (OR=1.79, P=0.002), LAGE (OR=1.90, P<0.001), MODD (OR=7.59, P<0.001), CV (OR=1.23, P<0.001), LBGI (OR=5.39, P=0.001) were significant and independent risk factors of hypoglycemia. (4) The ROC curve for predicting hypoglycemic events indicated that the cutoff points for MBG, MAGE, LAGE, MODD, CV and LBGI were 7.26mmol/L, 2.85mmol/L, 9.25mmol/L, 1.35mmol/L, 22.66% and 1.31. Hypoglycemia was observed only 27.4% of patients in the MBG≥7.26mmol/L group but a higher proportion of 61.2% in the MBG<7.26mmol/L group (P<0.05), meanwhile 15.9% patients developed hypoglycemia in the LBGI<1.31mmol/l group but a larger proportion 89.6% in the LBGI≥1.31mmol/l group(P<0.05). Using MBG and LBGI as hypoglycemia risk factors, the proportion of hypoglycemia patients was 3.4% without hypoglycemia risk factors, 34.8% with one risk factor, and 100% with two risk factors (P<0.001).

Conclusion: The incidence of hypoglycemia is high in T2DM patients with TIR>70%. MBG and GV including MAGE, MODD, CV, LBGI and LAGE are the significant and independent risk factors for hypoglycemia. Low MBG and large glucose excursion may possibly develop hypoglycemia. To achieve good glycemia control without inducing hypoglycemia, maintaining glucose in a euglycemia level and minimizing the glucose excursion are of great importance.

Clinical Trial Registration Number: [2020]02-107-01

Disclosure: J. Lu: None.

357 Stress hyperglycaemia is associated with an increased risk of post-acute pancreatitis diabetes
J. Zhang, Y. Lv, L. Li;
Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.

Background and aims: Acute pancreatitis is the most common cause of Pancreatic exocrine diabetes and its prevalence has increased dramatically worldwide. However, the key risk factors for diabetes secondary to acute pancreatitis remain unclear. Stress hyperglycaemia has been shown to be associated with an increased risk of diabetes in acute or critically ill patients. Therefore, we investigated whether patients with acute pancreatitis without known diabetes have a higher risk of developing subsequent diabetes compared to patients who remain normoglycemic.

Materials and methods: This retrospective observational study was conducted on 3575 in-patients with acute pancreatitis from 2016 to 2020. Among 946 patients met the inclusion criteria. Patients were stratified by stress hyperglycaemia and normoglycemic counterparts. The association between stress hyperglycaemia and evidence of diabetes was evaluated using regression modeling.

Results: There were 817 (86.4%) normoglycemic and 129 (13.6%) stress hyperglycemia patients. 41 patients (31.8%) with stress hyperglycaemia had evidence of diabetes compared with 25 patients (3.1%) without stress
hyperglycemia (P < 0.001). After multivariable adjustment including age, sex, history of diabetes, alcohol consumption, smoking, hypertension, obesity, disease severity, fatty liver disease and serological markers, Stress hyperglycemia was significantly associated with subsequent diabetes odds ratio 4.407 (95%, CI 2.377-8.172). Further adjustment of diet, exercise and recurrence of pancreatitis, stress hyperglycemia remained a predictor of diabetes mellitus.

**Conclusion:** Stress hyperglycemia was independently associated with diabetes secondary to acute pancreatitis. Accordingly, a follow-up diabetes-screening programs for AP with stress hyperglycemia is an important part of identifying the disease as soon as possible, delaying islet damage, avoiding adverse outcomes and improving the prognosis of post-acute pancreatitis diabetes mellitus.

**Disclosure:** J. Zhang: None.

---

**358**

**Fasting proinsulin independently predicts incident type 2 diabetes in the general population, particularly in subjects with hypertension or kidney dysfunction**

S. Sokooti Oskooei1, W.A. Dam1, T. Szilzi-Torok1, J. Gloerich2, A.J. van Goo2, A. Post1, M.H. de Borsa1, R.T. Gansvoort1, H.J.L. Heerspan1, R.P.F. Dullaart1, S.J.L. Bakker1,
1University Medical Center Groningen, Groningen, 2Radboud University Medical Center, Nijmegen, 3Internal Medicine, University Medical Center Groningen, Groningen, Netherlands.

**Background and aims:** Fasting proinsulin levels may serve as a marker of β-cell dysfunction and predict type 2 diabetes development. Moreover, kidneys have been found to be a major site for degradation of proinsulin. We aimed to evaluate the predictive value of proinsulin compared to insulin and C-peptide for the risk of incident type 2 diabetes added to a base model of clinical predictors and examined potential effect-modification by hypertension, eGFR and urinary albumin excretion (UAE).

**Materials and methods:** We included 5001 subjects of the Prevention of Renal and Vascular End-Stage Disease study without type 2 diabetes at baseline. Proinsulin was measured in plasma with U-PLEX platform using ELISA immunoassay. Cox proportional hazards regression and Harrell’s C-statistics were used to evaluate the association between fasting proinsulin and incident type 2 diabetes. Interaction was tested to assess potential effect-modification by hypertension, eGFR and urinary albumin excretion (UAE).

**Results:** Median fasting proinsulin was 6.89 (5.15-9.55) pmol/L. During a median of 7.2 (6.0-7.7) years follow-up, 271 individuals developed type 2 diabetes. Higher levels of proinsulin were associated with an increased risk of incident type 2 diabetes independent of glucose, insulin, C-peptide and clinical factors [HR 1.28; per 1 SD increase 95% CI: 1.08-1.52]. Moreover, Harrell’s C-index and IDI were significantly improved with the addition of proinsulin to the Framingham Offspring (FOS) risk score (Table 1). Furthermore, we found significant effect modification by hypertension (p=0.019), eGFR (p=0.020) and UAE (p=0.034), consistent with a particularly strong association in subjects with hypertension or kidney dysfunction (eGFR<90 mL/min/1.73 m² or urinary albumin excretion ≥15 mg/24 hours).

**Conclusion:** Higher fasting proinsulin level is an independent predictor of incident type 2 diabetes in the general population, particularly in subjects with hypertension or kidney dysfunction.

**Disclosure:** S. Sokooti Oskooei: None.

---

**359**

**Differential proportion trends of primary lower limb amputations associated with diabetes or peripheral arterial disease between age groups in Quebec, Canada**

S. O’Connor1, C. Blais2, E.A.L. Sidi2, J. Leclerc3,1, P. Poirier1;
1Pharmacy, Institut universitaire de cardiologie et pneumologie de Québec - Université Laval, 2Bureau d’information et d’études dans les populations, Institut national de santé publique du Québec, 3Nursing, Université du Québec à Trois-Rivières, Québec, Canada.

**Background and aims:** Lower limb amputations (LLA) represent an important complication of both diabetes and patients with peripheral arterial disease (PAD). Given the increasing risk of LLA with age, demographic changes in Quebec and recent increasing incidence of LLA in other Canadian provinces, our objective was to document proportion trends of primary LLA according to age groups in the province of Quebec, Canada, from 2006 to 2019.

**Materials and methods:** Using the Quebec Integrated Chronic Disease Surveillance System (n=4,526,798 in 2019), we identified all primary LLA among adults ≥40 years using codes from the Canadian Classification of Health Interventions and the International Classification of Diseases 10th edition. We calculated annual proportions (per 100,000) with primary cases of LLA as the numerator and the population with diabetes / PAD at risk as the denominator, with 99% CI. Proportions were stratified by age groups: (40-64, 65-79 and ≥80 years) and by type of LLA (Minor: distal to tibia; Major: tibia, knee and thigh).

**Results:** In 2019, among adults with a primary LLA associated with diabetes and / or PAD, 46.0% had diabetes alone, while 13.8% had PAD alone and 40.1% had both diabetes and PAD. In 2019, cases were on average 70±12 (SD) years old and 66.6% were ≥65 years old. Between 2006 to 2019, while the proportion of all primary LLA remained stable for the 40-64 years (2019: 115 per 100,000 [99% CI: 97-132] [n=284]) and ≥80 years age groups (2019: 160 per 100,000 [99% CI: 132-189] [n=206]), we observed a relative decline of 27% among the 65-79 years age group, despite an increase in the number of incident LLA (2006: 167 per 100,000 [99% CI: 142-192] [n=290]; 2019: 121 per 100,000 [99% CI: 105-137] [n=359]), between 2006 and 2019, annual proportion of minor LLA remained stable in all age groups (2019: 40-64 years: 96 per 100,000 [99% CI: 80-112] [n=238]; 65-79 years: 94 per 100,000 [99% CI: 80-109] [n=280]; ≥80 years: 126 per 100,000 [99% CI: 101-152] [n=162]). While the proportion of major LLA remained stable among the 40-64 years (2019: 19 per 100,000 [99% CI: 12-26] [n=46]) and ≥80 years age groups (2019: 34 per 100,000 [99% CI: 21-48] [n=44]), we observed a 56% relative reduction in the proportion of major LLA among adults from 65-79 years (Figure 1).

**Supported by:** European Union’s Horizon 2020 research and innovation program Marie Sklodowska-Curie

**Disclosure:** S. Sokooti Oskooei: None.
Conclusion: Given the aging population in Quebec, stable proportion trends and reduction of major LLA among adults between 65 and 79 years suggest that the progress in preventive care may have favorably influenced the severity of LLA among age groups at risk. However, our results also depicted the importance to further improve preventive care in order to fully prevent unnecessary LLA.

Background and aims: Patients with diabetes have increased mortality and cardiovascular morbidity compared to the general population. The hereditary trait, familial hypercholesterolemia (FH), also leads to the premature development of atherosclerotic cardiovascular disease. Whether cardiovascular risk is exacerbated in patients with combined traits is not yet known.

Materials and methods: In this nationwide, register-based cohort study, patients with diabetes were included between January 1st, 2002, and December 31st, 2020. Phenotypic FH was identified in the patients with diabetes using the Dutch Lipid Clinic Network criteria. Adjusted Cox-proportional hazards models were used to assess the risk of mortality and cardiovascular outcomes in patients with or without phenotypic FH, adjusting matched controls from the general population as the reference.

Results: A total of 45,585 patients with type 1 diabetes (227,923 controls) and 655,250 patients with type 2 diabetes (655,250 controls) were followed for a median of 14.1 and 7.9 years, respectively. Of those, 153 and 7197, respectively, had phenotypic FH. Compared to controls, patients with diabetes were more at risk of cardiovascular mortality (Type 1: hazard ratio [HR] 213, 95% confidence interval [CI] 146-310; Type 2: HR 2.40, 95%CIs 2.19-2.63) and of a cardiovascular event (Type 1: HR 15.1, 95%CIs 11.1-20.5; Type 2: HR 2.73, 95%CIs 2.58-2.89). Patients with phenotypic FH consistently had higher annual estimated mean LDL cholesterol levels throughout the whole study period (p<0.05) and were more at risk for all major cardiovascular outcomes (p<0.001) than patients without FH. The proportion of patients receiving any lipid-lowering treatment, a high intensity statin, or at least two classes of drugs was higher in patients with phenotypic FH (p<0.001).

Conclusion: Patients with both diabetes and phenotypic FH in routine clinical care are more at risk of adverse cardiovascular outcomes and have higher LDL cholesterol levels despite receiving intensified lipid-lowering therapy.

Disclosure: J. Brinck: Grants; City councils (ALF 83620).

Diabetes complications in people with and without diabetes in Tasmania, Australia

N.T.T. Dinh1,2, B. de Graaff1, J.A. Campbell1, M.D. Jose3,4, J. Burgess5, T. Saunber1, A. Kitsos1, N. Wiggins1, A.J. Palmer1;
1Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, 2Thai Nguyen University of Medicine and Pharmacy, Thai Nguyen, Viet Nam, 3School of Medicine, University of Tasmania, Hobart, Australia, 4Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia, 5Department of Endocrinology, Royal Hobart Hospital, Hobart, Australia.

Background and aims: Diabetes is a costly disease that places a huge burden on the Australian healthcare system. Most of the costs related to diabetes are due to management of complications. In order to reduce the economic burden of diabetes, it is essential to identify complications that are the key cost drivers. Additionally, estimating medical costs of complications in people with diabetes will provide essential input data for economic models to identify cost-effective interventions. Our study aimed to estimate costs of diabetes complications in the year of first occurrence and the second year, and to quantify the incremental costs of diabetes versus non-diabetes related to each complication.

Materials and methods: In this matched retrospective cohort study, people with diabetes (n=45,378) were identified based on either diabetes diagnostic criteria or diagnostic codes from a linked dataset in Tasmania, Australia between 2004-2017. Using propensity score matching, each of them was matched on age, sex, and residential areas with two matched non-diabetes people obtained from the same dataset. Direct costs (including hospital, emergency room visits and pathology costs) were calculated from the healthcare system perspective and expressed in 2020 Australian dollars. The average-per-patient costs and the incremental costs in people with diabetes were calculated for each complication. The confidence interval was derived by a bias-corrected bootstrapping method with 1,000 resamples.

Results: For people with diabetes, first-year costs of complications were: diabetes $88,476 (95% CI 79,819, 95,366), lower extremity amputations $71,258 (65,969, 76,427), kidney transplant $60,871 (46,918, 76,871), non-fatal myocardial infarction $33,196 (31,761, 34,458), foot ulcer/gangrene $32,628 (29,671, 35,606), heart failure $30,752 (29,235, 32,517), ischemic heart disease $30,538 (28,219, 32,922), non-fatal stroke $30,035 (28,606, 31,750), kidney failure $28,534 (23,398, 32,517), nephropathy $23,990 (18,471, 31,485), vitreous haemorrhage $21,630 (14,655, 29,259), ischemic stroke $20,290 (15,368, 26,711), angiography $18,347 (18,577, 22,555), jaundice $18,220 (16,416, 19,187), transient ischemic attack $17,638 (15,929, 19,850), blindness/low vision $15,607 (10,584, 21,668). The second-year costs ranged from 19% (ischemic heart disease) to 73% (dialysis) of first-year costs. Complication costs were 115%-259% higher than in people without diabetes.

Conclusion: Costs of treating complications are higher for people with diabetes versus people without diabetes. Diabetes complication treatment required substantial healthcare resources, even after the first year of occurrence. Costly complications included renal complications (especially dialysis), foot complications (especially lower extremity amputation), and macrovascular complications (especially non-fatal myocardial infarction). Our results can be used to populate diabetes simulation models and will support policy analyses to reduce the burden of diabetes.
Background and aims: As diabetes management has improved, we are beginning to see a diversification of diabetes complications. Hospitalisation rates provide one measure of the burden of diabetes complications, but this has mostly been described in terms of broad disease categories. We sought to quantify the excess risk of cause-specific hospitalisations at a narrow category level amongst Australians with type 2 diabetes (T2DM) compared to the general population.

Materials and methods: We linked Australians with T2DM registered on the National Diabetes Services Scheme (Australian Diabetes Registry) to hospitalisation datasets to determine the incidence of hospitalisations at a narrow category level for the years 2010-2017. We used the general Australian population, sourced from a National Morbidity Database, as a comparator group. Poisson regression was used to model incidence of hospitalisations. The model was sex- and cause-specific and was adjusted for age and calendar-year effects. We identified the leading causes of excess hospitalisation amongst those with T2DM. Causes were ranked according to excess admissions in the diabetes population, calculated as observed minus expected admissions after standardisation for age. Hospitalisation for T2DM (E11), including admissions for glucose disturbances such as hypoglycaemia in those with T2DM, was excluded from calculations.

Results: People with T2DM were at increased risk for hospitalisation for most diagnoses compared to the general population. The leading causes for excess hospitalisation amongst males with T2DM were stress-related disorders, iron deficiency anaemia, and pneumonia (Table). In females with T2DM, the leading causes were iron deficiency anaemia, urinary tract infections, and depressive episodes. In both sexes, there was a substantial excess risk of admissions for infections, mental health disorders, and gastrointestinal conditions amongst those with T2DM. While heart failure and other traditional diabetes complications were amongst the leading causes of excess risk in males with T2DM, not a single classical microvascular or macrovascular complication of diabetes featured in the top ten causes of excess hospitalisation for females with T2DM.

Conclusion: Diabetes management strategies may require revision to account for the substantial burden of a wide set of lesser-acknowledged diabetes complications, especially in females, such as mental health disorders, anaemia, and infection.

Table: Leading causes of excess hospitalisation amongst people with T2DM compared to the general Australian population at IC-D10-AM three digit diagnosis level

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Male</th>
<th>RI</th>
<th>Female</th>
<th>RI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stress disorders</td>
<td>2.37</td>
<td>1.17</td>
<td>1.69</td>
<td>1.49</td>
</tr>
<tr>
<td>Iron deficiency anaemia</td>
<td>2.37</td>
<td>1.52</td>
<td>1.81</td>
<td>1.41</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>1.56</td>
<td>1.60</td>
<td>1.72</td>
<td>1.72</td>
</tr>
<tr>
<td>Urinary tract infections</td>
<td>2.24</td>
<td>2.05</td>
<td>2.24</td>
<td>2.24</td>
</tr>
<tr>
<td>Hypoglycaemia</td>
<td>1.07</td>
<td>1.97</td>
<td>1.07</td>
<td>1.97</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1.45</td>
<td>2.17</td>
<td>1.45</td>
<td>2.17</td>
</tr>
</tbody>
</table>

SO 14 COVID-19 around the globe

362

Cause-specific excess risk of hospitalisation in people with type 2 diabetes compared to the general population in Australia, 2010-2017

D. Tomic, A. Salim, J.J. Morton, J.E. Shaw, D.J. Magliano; Baker Heart and Diabetes Institute, Melbourne, Australia.

Background and aims: Both diabetes and obesity are associated with severity of and risk of death from COVID-19. The underlying mechanisms, and their role in risk of prolonged post-COVID-19 symptoms (long COVID), is unclear. We therefore aimed to investigate the association of HbA1c, body mass index (BMI) and waist-to-hip ratio (WHR) measured pre-pandemic with a) self-reported COVID-19 and b) long COVID in UK prospective cohort studies.

Materials and methods: In preliminary analyses we used data from the 1958 National Child Development Study (NCDS) and the 1970 British Cohort Study (BCS70). Both are ongoing cohort studies following nationally representative samples of all births in Great Britain. HbA1c was measured in 2002 in NCDS participants, and 2016-18 in BCS70 participants. Weight, height, waist and hip circumference were also measured at this time, and questionnaires on health and lifestyle were completed. All eligible participants (NCDS, N=4793; BCS70, N=3419) completed three questionnaires during the Covid-19 pandemic (May 2020 to February 2021), of which the last one included questions on ongoing COVID-19-related symptoms. COVID-19 was self-reported based on test confirmation or strong suspicion, long COVID was defined as having symptoms that affected functioning for +4 weeks after COVID-19 and was compared to those reporting symptoms for <4 weeks. Multivariable logistic regression was used to determine associations of HbA1c, self-reported diabetes, BMI, and WHR with presence of COVID-19 and long COVID in each study. Study-level results were meta-analysed using random-effects models.

Results: Between May 2020 and February 2021, NCDS participants were aged 63 years, BCS70 51 years. In NCDS 572 (12%) participants reported ever having COVID-19 and in BCS70 599 (18%). In February 2021, 73 participants reported having long COVID (17% of COVID-19 cases) in NCDS and 64 in BCS70 (14% of COVID-19 cases). A BMI of ≥25kg/m² was associated with higher odds of COVID-19. There was no association of WHR with COVID-19. There may be a positive association of WHR with long COVID, but this result lacked precision. There was no association of categorical or continuous HbA1c with either outcome (see Figure 1).

Conclusion: In prospective analyses of two nationally representative UK cohorts a high pre-pandemic BMI was associated with a higher risk of COVID-19, while a high WHR appeared more strongly associated with a higher risk of suffering from long COVID. We found little evidence for associations of HbA1c with either COVID-19 or long COVID. We suggest that obesity-related mechanisms are responsible for the excess risks of COVID-19 in association with diabetes, rather than hyperglycaemia per se. Further research is needed to explore mechanisms underlying these associations.
Hyperglycaemia, but not previous diagnosis of diabetes, is an independent indicator of poor outcome in patients hospitalised for severe COVID-19

E. Eletto1, R. Aldigeri2, A. Dei Cas3, A. Ticinesi1, A. Nouvenne3, B. Pratt1, E. Balestrieri1, A. Vazzana1, M. Antonini1, V. Spigoni2, S. Schiro2, N. Sverzellati1, T. Meschi1, R. Bonadonna1;
1Azienda Ospedaliero-Universitaria of Parma, 2University of Parma, 3University of Parma in Parma, Italy.

Background and aims: Diabetes mellitus (DM) and hyperglycemia are strong risk factors for poor outcome(s) in patients hospitalized for COVID-19. However, their relative role in affecting patient prognosis is still under debate. Furthermore, it is unknown whether they are only proxies of organ, especially lung, damage. Aim of this study is to evaluate the predictive power of known DM and hyperglycemia, as well as indicators of lung damage, on death/admission to intensive care unit (ICU) in patients hospitalized for COVID-19 during the first wave of SARS-CoV-2 pandemic.

Materials and methods: We retrieved the clinical data/records of the patients admitted with COVID-19 between 23rd February 2020 and 31st March 2020 in the Covid-1 macro-unit of the University Hospital of Parma. Known diabetes was defined by self-reported history, electronic medical records or medications. Fasting plasma glucose, inflammatory markers and main biochemical variables were collected at admission. Patients underwent computed tomography (CT) chest and arterial blood gas analysis to calculate the SpO2/FiO2 (P/F ratio). The primary outcome was a composite of ICU admission or death. Logistic regression analysis was used to identify independent risk indicators of the primary end-point by unvariable and multivariable models. We used Receiver Operating Characteristic (ROC) curves to assess the overall predictive power of the different regression models.

Results: A total of 757 subjects were included, 143 of whom (19.2%) had known diabetes. Patients with DM were older and showed higher comorbidity rate. The primary outcome occurred in 61.5% of patients with DM compared to 43.1% in those without (log-rank test p<0.001). Among variables associated with COVID-19 severity, age, obesity, arterial hypertension, previous cardiovascular (CV) event, eGFR, glucose levels at admission (but not known diabetes), C-reactive protein, SpO2/FiO2 and HR-CT visual score of pneumonia extension, were significantly associated with risk indicators of poor outcome. In a multivariate logistic regression model older age (p<0.001), previous CV disease (p<0.001), poor eGFR (p<0.04), glucose levels ≥126 mg/dl (p<0.048) and a lower P/F ratio (p<0.001) resulted significant and independent negative prognostic factors. The ROC curve showed a very good accuracy (UC=0.91) of the model in predicting the primary composite end-point.

Conclusion: Known diabetes indicated poor COVID-19 outcomes, but not when adjusted for other baseline clinical variables and comorbidities, suggesting that its impact was mostly driven by concomitant factors and complications. Fasting hyperglycemia was an independent predictor of poor outcomes, even after taking into account the impairment of lung function. The molecular mechanism(s) underlying the tight association between high glucose and poor COVID-19 outcome remain(s) to be elucidated.

Disclosure: A. Knuppel: None.
Impacts of the COVID-19 outbreak on glycaemic control and body composition in individuals with glucose intolerance in Japan

S. Yoshiji, T. Murakami, R. Tsukaguchi, M. Ogura, K. Shide, N. Inagaki; Kyoto University, Kyoto, Japan.

Background and aims: During the coronavirus disease 2019 (COVID-19) outbreak, European countries imposed the strict lockdown, raising concerns for negative impacts on glycaemic control and body composition. In Japan, voluntary-based restrictions were imposed as a state of emergency (SoE). However, metabolic consequences of the “soft” lockdown are yet to be clarified. Here we aim to evaluate the effects of the SoE on glycaemic control and directly measured body composition in individuals with glucose intolerance (GI) in Japan.

Materials and methods: We retrospectively evaluated individuals with GI who had (i) longitudinal assessment of body composition, (ii) dietary follow-up by nutritionists and (iii) glycaemic measurement before and after the SoE in Kyoto University Hospital from January 1 2018 to May 31 2021. The SoE was declared on April 16 2020 and lasted until May 31 2021 with intermittent lifting. We evaluated whether the metabolic profiles of these patients changed after the SoE declaration by assessing the body composition and glycaemic control changes. Body composition was assessed by InBody 720 bioelectrical impedance analyzer, and measurements included body weight, fat mass, fat-free mass, and skeletal muscle mass. Nutritionists collected daily diet and exercise information.

Results: We identified 415 eligible individuals with GI (type 2 diabetes: 364, impaired glucose tolerance: 31, type 1 diabetes: 12). Baseline (January 2019 – December 2019) mean ± SD age was 64.8 ± 12.4 years, HbA1c 7.3 ± 1.2%, body mass index (BMI) 26.1 ± 4.9 kg/m², body weight 70.0 ± 16.5 kg, fat mass 22.1 ± 10.2 kg, and skeletal mass 26.2 ± 5.9 kg. Forty percent were female. After SoE (June 2020 - May 2021), BMI (Mean ± SE change: 0.13 ± 0.05 kg/m², P = 0.018), body weight (0.32 ± 0.15 kg, P = 0.034), and fat mass (0.45 ± 0.14 kg, P = 0.001) significantly increased, whereas skeletal mass (-0.12 ± 0.05 kg, P = 0.016) significantly decreased. Of note, these measurements did not significantly change from 2018 to 2019 in these patients. Although there was no overall increase in HbA1c (P = 0.197), HbA1c change significantly correlated with change in BMI (r = 0.36; P < 0.001), body weight (r = 0.37; P < 0.001), and fat mass (r = 0.41; P < 0.001). Further, there were 128 individuals whose HbA1c significantly increased by ≥0.3% after the SoE. These individuals had no significant HbA1c change from 2018 to 2019. Thus, we performed a subgroup analysis of individuals with and without HbA1c worsening of ≥0.3% (worsening group [n = 128] vs. non-worsening group [n = 287]). In the worsening group, changes in BMI (0.66 ± 0.13 vs. -0.11 ± 0.06 kg/m², P < 0.001), body weight (1.76 ± 0.95 kg vs. -0.33 ± 0.16 kg, P < 0.001), and fat mass (1.92 ± 0.61 vs. -0.20 ± 0.16 kg, P < 0.001) were significantly higher than in the non-worsening group. Regarding the dietary habits, snack intake significantly increased in the worsening group (P = 0.036), whereas exercise frequency didn’t significantly change (P = 0.880).

Conclusion: Overall, the SoE conferred unfavourable metabolic consequences in individuals with GI, highlighted by increased body weight, body fat, and decreased skeletal muscle. Individuals whose glycaemic control worsened during the SoE had increased body weight and body fat compared to those without glycaemic worsening. This can be partially due to increased snack intake. Our study indicates that even “soft” social restrictions are associated with significant metabolic worsening, which warrants clinical attention.

Clinical Trial Registration Number: R2377
Disclosure: S. Yoshiji: None.

The clinical course of Covid-19 in diabetes patients: a nationwide multistate modelling cohort study


Background and aims: The higher morbidity and mortality of Coronavirus disease 2019 (COVID-19) among diabetes patients may be influenced by their diabetes status and clinical profile. We aimed to model the clinical course of COVID-19 from positive test of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to hospitalization, admission to intensive care unit (ICU), need of mechanical ventilation and/or in-hospital death and to evaluate possible prognostic factors related to diabetes status and clinical profile.

Materials and methods: From nation-wide registers in Denmark, we identified 5078 individuals (2827 men and 2258 women) with diabetes and a positive test for SARS-CoV-2 from 27 January 2020 until 11 December 2020. The median age at time of the positive test was 61.6 years. A 6-state multistate model was built, and 10 transitions were analyzed using Poisson regression with linear effects of diabetes duration, age, as well as categorical effect of diabetes types (T1D/T2D), sex, diabetes-related complication status and medications. Cardiometabolic factors, lifestyle factors and vaccination status are prognostic factors to be evaluated.

Results: During 29,181 person-weeks, 1102 (21.7%) were hospitalized, 139 (2.6%) needed ICU treatment, 110 (2.2%) needed mechanical ventilation and 171 (3.4%) died while in hospital. For the transition from “positive test” to “hospitalization”, the incidence rate ratio (IRR) for women vs. men was 0.64, 95% CI (0.56;0.72), a one-year increase in age 1.05, 95% CI (1.05;1.06), T2D vs T1D 1.02, 95% CI (0.76;1.37), a one-year increase in diabetes duration 1.00, 95% CI (1.00;1.01), co-existing cardio-kidney complications 1.60, 95% CI (1.35;1.89) (end-stage kidney disease, chronic kidney disease, cardiovascular disease and heart failure were associated with 60-255% increased risk, respectively) and use of cardio-kidney-protective medications 0.74, 95% CI (0.65;0.85). Treatment with SGLT-2i, GLP-1, metformin, RAS-blocking agents and lipid-lowering drugs conferred a 10-30% lower risk, respectively. HbA1c was associated with a 7% increased risk (1.07, 95% CI 1.02;1.13). Conclusion: Male sex, age, cardio-kidney complications and increase in HbA1c was associated with a higher risk of hospitalization. Treatment with SGLT-2i, GLP-1, metformin, RAS-blocking agents and lipid-lowering drugs conferred a protective association for hospitalization. Longer diabetes duration slightly increased the risk of hospitalization while type of diabetes showed no association with hospitalization. Analyses on updated data (longer follow-up) and including the remaining prognostic factors will be performed also for the states ICU and need of mechanical ventilation.

Supported by: NNF20SA0063090
Disclosure: H. Amadid: None.

Temporal trends in risk of severe COVID-19 infection in persons with diabetes

J.V. Stidsen1, A. Greent2, L. Rosengaard2, K. Højlund2,3
1Steno Diabetes Center Odense, Odense University Hospital, 2Open Patient data Exploratory Network, Odense University Hospital, 3Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Background and aims: Coronavirus disease-2019 (COVID-19) affects admission risk and mortality in diabetes and diabetes-related conditions. We examined the temporal trends in admission risk and mortality in the total Danish population by diabetes and diabetes-related conditions in the two first waves of COVID-19 in Denmark.
Materials and methods: We identified all persons with diabetes in the whole Danish population using national registries. COVID-19-related risks of admission and death were assessed using Cox regression analysis in wave 1 (1 March-31 August 2020) and wave 2 (1 September 2020-28 February 2021) of the pandemic for persons with and without diabetes. Analysis were stratified according to status of hypertension, obesity, cardiovascular disease and microvascular disease.

Results: For persons without diabetes (n=5,479,755) the crude 6 month cumulative incidence of COVID-19 admission increased from 4 to 10 per 10,000 from wave 1 to 2, compared with a corresponding increase from 16 to 54 per 10,000 for persons with diabetes (n=321,933). The hazard ratio (HR) of COVID-19 admission for persons with diabetes, compared to persons without diabetes, after adjustment for co-morbidity and treatment, increased from 1.40 (95% CI 1.27, 1.55) to 1.76 (1.65, 1.87) from wave 1 to wave 2 (p<0.001 for interaction with wave). The crude 6 month mortality rate increased from 0.63 to 1.5 in 10,000 persons without diabetes and from 4.3 to 10 in 10,000 persons with diabetes. The increased HR for mortality in persons with diabetes compared to persons without, did not change according to wave (HR 1.65 [1.34, 2.03] and 1.64 [1.43, 1.88]). However, when expressed according to the hospitalized persons only, the crude mortality fell from 26.8% to 19.6% in persons with diabetes, while only a minor decrease was seen in persons without diabetes (16.7% to 15.5%). The HR for mortality, expressed according to the hospitalized persons only, in persons with diabetes compared to persons without, decreased from HR 1.27 (1.03, 1.57) in the first wave, to HR 1.07 (0.93, 1.23) in the second wave (P=0.17 for interaction with wave). Compared to persons without both diabetes and cardiovascular disease (CVD), persons with diabetes without CVD had increased mortality (HR 2.06 [1.68, 2.54]) and persons with both conditions even more (HR 5.87 [4.96, 6.96], p<0.001 for difference between diabetes with and without CVD). Similar results were seen for hypertension, obesity and microvascular disease. The results were similar for the two waves.

Conclusion: The risk of COVID-19 admission increased in persons with diabetes from wave 1 to wave 2 of the COVID-19 pandemic in the Danish population. However, the risk of mortality in persons with diabetes compared to the whole population did not change, most likely due to a reduced mortality among hospitalized persons with diabetes. For persons with diabetes, CVD conferred increased mortality risk.

Supported by: Danish Agency for Higher Education and Science (0237-00012B)

Disclosure: J.V. Stidsen: None.

369
New-onset hyperglycaemia in nondiabetic patients hospitalised for COVID-19: prevalence, risk factors and post-discharge outcomes
E. Falbo 1, M. Ferrante 1, S. Damanti 2, M. Cilia 1, J. Castellani 1, R. De Lorenzo 1, G. Vitali 2, S. Martinienghi 2, C. Magnaghì 2, E. Bosi 3, P. Rovere-Querini 1, 2, C. Conte 1, 4
1Vita-Salute San Raffaele University, Milan, 2IRCCS San Raffaele Hospital, Milan, 3San Raffaele Roma Open University, Rome, Italy.

Background and aims: New-onset hyperglycaemia (NOH) is seen in about 50% of patients hospitalized for COVID-19 despite only 7% having diabetes, suggesting that COVID-19 negatively impacts glucose metabolism. Factors associated with NOH, especially glucocorticoid (GC) therapy, have not been deeply investigated. Systemic GCs, which may cause may hyperglycaemia, are routinely used in the treatment of COVID-19 requiring oxygen support. We assessed the prevalence of NOH (defined as hyperglycaemia requiring insulin therapy) in patients without DM hospitalised for COVID-19, investigated factors associated with NOH and described in-hospital and post-discharge outcomes in these patients.

Materials and methods: This was a post-hoc analysis of data prospectively collected for a large observational study. Data from patients hospitalized for COVID-19 pneumonia without DM at the beginning of the second pandemic wave (between August and November of 2020) who returned for a 1-month follow-up visit were analysed. For each patient, we calculated the cumulative GC dose administered during hospitalization, which was converted into methylprednisolone dose equivalent (MPD), in addition to anthropometric data, comorbidities, laboratory tests and outcomes during the hospital stay and one month after discharge.

Results: A total of 156 patients were included in the analysis (median age 61 [IQR 52-76] years, 43% females, median BMI 26 kg/m² [IQR 24-30]). One hundred and forty-three (92%) patients received GC therapy during hospitalization. We compared patients with and without NOH. Thirty-seven (23.7%) patients developed NOH, all of them received GC therapy. NOH patients had significantly higher systolic blood pressure (SBP) and inflammatory markers. NOH patients received significantly higher GC doses, were more likely to need non-invasive ventilation, and had a greater risk of admission to the intensive care unit, but death rates were similar. Baseline BMI was not associated with NOH. At univariable linear regression analyses, higher plasma glucose (PG) on admission (OR 1.04 [95% CI 1.019; 1.060]) and total MPD dose per kg (OR [95% CI 1.018 - 1.330]) increased the risk of NOH. Ninety patients returned for the 1-month follow-up assessment (17 with NOH). NOH patients had significantly higher random capillary blood glucose (110 [98.2; 128.5] vs. 99.5 [90; 107] mg/dL, p=0.007) and persistently higher SBP (130 [122; 143] vs. 126 [115; 140] mmHg, p=0.048). BMI was similar between groups. However, the proportion of patients with obesity was greater in the NOH group (58% vs 12%, p=0.037).

Conclusion: PG upon admission and total cumulative MPD per kg were associated with increased risk of NOH during hospital stay, suggesting that GC therapy contributes to and may aggravate the derangements in glucose metabolism seen in COVID-19 patients. After discharge, patients with NOH had persistently higher glucose and SBP levels as compared with patients without NOH, and were more likely to have obesity. Glucose values should be monitored during GC therapy, especially in non-diabetic patients with hyperinflammation and elevated SBP. Those who develop NOH during hospital stay should be monitored for alterations in glucose metabolism and cardiometabolic risk factors after discharge.

Clinical Trial Registration Number: NCT04318366
Disclosure: E. Falbo: None.

370
COVID-19 associated hyperglycaemia relates to both insulin resistance and beta cell dysfunction
J. Gojda 1, A. Lang 2, M. Krbcová 1, A. Oufadová 1, K. Koudelková 1, V. Šebo 1, A. Gvozdeva 1, L. Slagmolen 1, J. Potočková 1, F. Karpe 2, S. Schlesinger 3
1Internal Medicine Dept., Charles University in Prague, Prague, Czech Republic, 2Institute for Biometrics and Epidemiology, Leibniz Center for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany, 3Dept. of Patophysiology, Charles University in Prague, Prague, Czech Republic

Background and aims: Hyperglycaemia is a common feature of severe acute COVID-19 and it impacts morbidity and mortality. Several mechanisms were suggested to contribute to its development: inflammation-driven hypermetabolism and insulin resistance (IR), beta-cell damage, and/or corticosteroid administration. The study aimed to compare indices of glucose homeostasis in COVID-19 patients with and without DM at the beginning of the second pandemic wave (between August and November of 2020) who returned for a 1-month follow-up visit were analysed. For each patient, we calculated the cumulative GC dose administered during hospitalization, which was converted into methylprednisolone dose equivalent (MPD), in addition to anthropometric data, comorbidities, laboratory tests and outcomes during the hospital stay and one month after discharge.

Materials and methods: Patients without a known history of diabetes were enrolled in the "Prospective cohort study into metabolic derangements associated with COVID-19" (COMETA study), where patients with acute severe COVID-19 were examined at baseline (within 4 weeks
from the onset of bilateral pneumonia with respiratory failure) and after 6 months of follow-up: clinical examination, anthropometry, bioimpedance, fasting indirect calorimetry, and OGTT. Insulin secretion and sensitivity were expressed as Matsuda insulin sensitivity index (ISI), insulinogenic Index (IGI), and disposition index (DI). Resting energy expenditure (REE) was calculated using the Weir equation and substrate preference using the respiratory quotient (RQ) and nitrogen losses.

**Results:** Thirty-seven patients (11 women) were available for the analyses; baseline examination was within 21±6.5 days after COVID-19 diagnosis, high-dose corticosteroids were administered in all. Patients were hypermetabolic at baseline (30.6 ± 4.3 kcal/kg lean mass/day, ~120% predicted values) and REE declined over the 6 months (ΔT6-T0: MD (95% CI)-5.5 (-6.9, -4.1) kcal/kg lean mass/day, p<0.0001). Prevalence of newly diagnosed pre-diabetes was 59% (22 pts.) at baseline and remained as high as 14 patients (45%) at 6 months, none had positive islet autoantibodies. When comparing patients with (H=20) and without (C=12) hyperglycaemia at baseline, we found that insulin sensitivity was comparable among groups (ISI_H=3.07 ± 1.18, ISI_C=3.23 ± 1.72, p=0.77), whereas beta cell dysfunction was present in the hyperglycaemic group only (IGI_H=1.04 ± 0.55, IGI_C=2.94 ± 1.82, p<0.001; DI_H=3.19 ± 2.16 vs DI_C=8.78 ± 6.37, p<0.01). Over the 6 months, insulin sensitivity improved only in the hyperglycaemic group (6m_ISI_H=3.07 ± 1.18 vs 6m_ISI_C=4.52 ± 2.75, p<0.01). IGI and DI did not improve in any group.

**Conclusion:** Acute severe COVID-19 was associated with hypermetabolism that did not persist over six months. A high incidence of hyperglycaemia was observed. While hyperglycaemia in the acute phase related to both insulin resistance and beta-cell dysfunction, it was increased insulin sensitivity that determined the normalization of hyperglycaemia over the follow-up. Maladapted beta cell response on hyper inflammation and exogenous corticosteroids were possible causes of hyperglycaemia.

**SO 15 Calcium signalling in the islet: we are still learning**

**371 A-cell Ca\(^{2+}\) oscillations and glucagon secretion depend on Ca\(^{2+}\) release from the endoplasmic reticulum**

S. Acreman\(^1\), G. Denwood\(^2\), R. Gao\(^1\), J. Ma\(^1\), P. Rorsman\(^1\), Q. Zhang\(^1\);
\(^1\)OCDEM, University of Oxford, \(^2\)University of Oxford, UK.

**Background and aims:** Glucagon is the principal glucose counter-regulator hormone secreted by the pancreatic α-cells. It is increasingly clear that dysregulation of glucagon secretion contributes to both hyper- and hypo-glycaemia in diabetes. Precisely how glucagon secretion is regulated remains unclear but most studies focus on glucose-dependent α-cell electrical activity and subsequent transmembrane Ca\(^{2+}\) (Ca\(^{2+}\)) influx. However, how α-cells handle intracellular Ca\(^{2+}\) ([Ca\(^{2+}\)]\(_i\)) and the role of Ca\(^{2+}\) release from the endoplasmic reticulum (ER) is not fully understood. Using transgenic animal models, we investigated membrane potential-independent regulatory mechanisms of glucagon secretion, with a specific focus on α-cell ER Ca\(^{2+}\) release.

**Materials and methods:** A-cell electrical activity and transmembrane Ca\(^{2+}\) current were monitored using the patch-clamping technique. A-cell ([Ca\(^{2+}\)]\(_i\)) dynamics were recorded using live cell Ca\(^{2+}\) imaging of islets from mice expressing a genetically encoded Ca\(^{2+}\) sensor GCaMP6f specifically in α-cells. Hormone secretion was conducted using static incubation followed by ELISA.

**Results:** The relative contributions of voltage sensitive Ca\(^{2+}\) channels (Ca\(_s\)) in α-cells were dissected using voltage-clamp experiments and specific blockers. In response to membrane depolarisation (-70 to 0 mV), ~60% of α-cell Ca\(_s\); current flows through L-type Ca\(_s\), and the remaining Ca\(^{2+}\) current is carried by N- (~20%) and P/Q-type Ca\(_s\) (~20%). L-type Ca\(_s\) are likely to contribute to α-cell action potential generation and 10 μM isradipine (L-type Ca\(_s\), blocker) completely abolished α-cell electrical activity in islets in 1 mM glucose. However, isradipine was without apparent effect on low glucose-induced glucagon secretion (0.060±0.005% vs. 0.069±0.005% of content; p=0.1) and only had marginal effect on α-cell [Ca\(^{2+}\)]\(_i\); oscillation frequency (0.79±0.09 vs. 0.68±0.08 spikes/min, P<0.005); and glucagon remained inhibited to both α-cell [Ca\(^{2+}\)]\(_i\); oscillation frequency (P>0.001) and glucagon secretion (P>0.05). Similarly, α-cell [Ca\(^{2+}\)]\(_i\); oscillations and glucagon secretion was unaffected by using α-cell membrane using 100 μM diazoxide, a K\(_{ATP}\) channel opener, in the presence of 1 or 6 mM glucose. The membrane potential-independent [Ca\(^{2+}\)]\(_i\); activity is sensitive to intracellular ATP. In α-cells voltage-clamped at resting membrane potential (-70 mV), intracellular application of 1 mM ATP stimulated α-cell [Ca\(^{2+}\)]\(_i\); activity (AUC=2424±411), and increasing the cytosolic ATP concentration to 3 mM was inhibitory (P<0.05). Blockade of sarco/endoplasmic reticulum Ca\(^{2+}\)-ATPase (SERCA) with cyclopiazonic acid (CPA, 10 μM), to deplete ER Ca\(^{2+}\), suppressed α-cell [Ca\(^{2+}\)]\(_i\); oscillations, and glucagon secretion (0.028±0.006% vs. 0.009±0.0005% of content; p<0.005) at 1 mM glucose. In comparison, in the presence of 6 mM glucose, CPA was without effect on α-cell [Ca\(^{2+}\)]\(_i\); oscillations or glucagon secretion (0.012±0.003 vs. 0.013±0.003% of content, p>0.99). 100 μM ryanodine, a blocker of intracellular Ca\(^{2+}\)-releasing channelryanodine receptor, like CPA, abolished changes in α-cell [Ca\(^{2+}\)]\(_i\); oscillations in response to glucose.

**Conclusion:** The data collectively show a significant component of glucagon secretion is independent to α-cell electrical activity. α-cell sensitivity to glucose metabolism (ATP levels) is likely to be exerted at the level of the ER, with SERCA and ryanodine receptor likely playing major roles in glucagon secretion.

**Disclosure:** S. Acreman: None.

**Supported:** EFSD Research Programme, DUK
Focal adhesion kinase and the functional consequences of beta cell polarity

D. Jevon, K. Deng, N. Hallahan, N. Flores-Rodriguez, W.J. Gan, P. Thom; University of Sydney, Sydney, Australia.

Background and aims: The Islets of Langerhans are complex micro-organs, the 3-dimensional characteristics of which have been so far under-appreciated due to limitations and difficulties in sample preparation and data collection techniques. These 3-dimensional characteristics inform spatial polarity to each β cell, and β cells form structural and secretory domains in response to their contacts with capillaries and other cells. Along beta cell capillary contacts, focal adhesion kinase is localised and activated. This research investigates the broad role of beta cell capillary contacts and the local activation of focal adhesion kinase to beta cell calcium influx and insulin secretion.

Materials and methods: Pancreatic slices were gathered from humanely sacrificed male FAKflox-Inscre, GCaMP6s-Inscre, or B6/C57 mice in accordance with ethical research standards. Slices were fixed and stained for whole islet 3D imaging by Z stacks (100-300 optical sections per islet), or cultured overnight for live cell assays. Glucose stimulated insulin secretion was measured from whole slices by HTRF assay or single cells by 2 photon microscopy. Subcellular calcium influx was measured in GCaMP6s-Inscre mice and FAKflox-Inscre or B6/C57 mice incubated with the fluorescent calcium reporter, fura-2 AM imaged by 2 photon microscopy. The focal adhesion kinase inhibitor, Y15 was used in calcium influx and glucose stimulated insulin secretion assays. Controls and experimental groups contain minimum n=3 and significance was measured by t-test and ANOVA where applicable.

Results: β cells contact capillaries with 8.8% +/- 1.5% of their total surface area and 32% +/- 1.0% of β cells form functionally equivalent secretory domains with multiple capillaries. Increased β cell capillary contact surface area is associated with higher insulin secretion (R²=0.37, p<0.0001) and characterized by local focal adhesion kinase phosphorylation. Calcium influx into β cells begins at the capillary interface and is visualised as a wave with an average velocity of 50.6 +/- 6.1 μm/s. Focal adhesion kinase inhibition with Y15 reduces the peak amplitude of calcium waves after glucose stimulation by 46% +/- 4.8% and glucose stimulated insulin secretion by 53% +/- 6.5%. Low levels of calcium activity are observed at 2.8 mM glucose in some β cells in pancreatic slices of C57Bl6 mice and not in Y15 treated slices or slices from FAKflox-Inscre mice. In B6/C57 slices, a significant increase (p<0.001) in insulin secretion is observed between 2.8 mM and 5.0 mM glucose, an increase which is not observed in Y15 treated B6/C57 slices (p>0.5) and FAKflox-Inscre slices (p>0.5).

Conclusion: Islet β cells form polar and functional secretory domains with capillary contacts and focal adhesion kinase is active in these domains. Insulin secretion is localised to these contacts, as is calcium influx, which travels as a wave across the cell. Focal adhesion kinase inhibition or constitutive knockout reduces β cell calcium activity, glucose sensitivity and glucose stimulated insulin secretion.

Disclosure: D. Jevon: None.

The beta cell primary cilium is an autonomous Ca²⁺-organelle involved in GABA signalling

T.C. Incedal, G. Sanchez, O. Idevall-Hagren; BMC box 571, Uppsala University, Uppsala, Sweden.

Background and aims: The primary cilium is an organelle present in most of the mammalian cells. It has its base at the centriole, from which microtubule bundles extend and push on the plasma membrane, generating an antenna like structure of that protrudes from the cell surface. Primary cilia orchestrate signal transduction independent from the cell body. The presence of specific ciliary receptors and effector proteins enables the generation of local ciliary signals and provides a platform for crosstalk between different pathways, often involving Ca²⁺ and cyclic adenosine monophosphate (cAMP). Islet cells are equipped with prominent primary cilia that are important for the regulation of β-cell function, but how these small structures influence cell function is not known. In the current study, we aim to identify local signalling pathways in the primary cilium of intact islets.

Materials and methods: We used intact mouse pancreatic islets of Langerhans expressing a novel cilia targeted Ca²⁺ sensor and total internal reflection fluorescence microscopy to record ciliary Ca²⁺ dynamics under different physiological conditions.

Results: Mouse islet cells were equipped with long primary cilia (9 ±0.5μm, n=249 cilia, 8 islets, 4 animals) that often clustered in the islet interstitium and exhibited diverse morphologies that included dilated tips and bifurcations. Immunofluorescence staining revealed strong enrichment of metabolotropic GABA_B1 receptors at the cilium base that were mobilized to more distal parts upon agonist binding. Addition of the GABA_B1-selective agonist baclofen or inhibition of GABA breakdown with vigabatrin caused pronounced Ca²⁺ increases in the primary cilium of mouse islet cells expressing a cilia-targeted Ca²⁺ indicator (4.1-fold, P=0.002, n=11 islets; P=0.007, n=7 islets), but was without effect on cytosolic Ca²⁺. The response to baclofen was abolished by GABA_B1 receptor knockdown and L-type channel inhibition. Cyclic nucleotides have been suggested to crosstalk with Ca²⁺ in the primary cilium. Elevation of cAMP in mouse islets expressing the light-activated adenylyl cyclase bPAC was without effect on cilia Ca²⁺, while elevation of cGMP using a light-activated guanylyl cyclase (RhGc) or addition of atrial natriuretic peptide (whose receptors is a cell membrane-bound guanylyl cyclase) triggered Ca²⁺ increases. Immunofluorescence staining revealed the presence of the cGMP-selective cyclic nucleotide-gated channel CNGA3 in primary cilium of mouse islet cells. When Ca²⁺ influx (20 mM glucose or 30 mM KCl) or release from the ER (carbachol) was triggered, the ensuing rise of cytosolic Ca²⁺ did not propagate beyond the first two μm of the cilia base. This insulation against cytosolic Ca²⁺ contrasts earlier work in non-excitable cells.

Conclusion: We show that the primary cilium of islet β-cells is a unique Ca²⁺ compartment that is isolated against cytosolic Ca²⁺, likely via a combination of efficient extrusion and buffering. Both GABA and cGMP, important regulators of β-cell function, selectively trigger Ca²⁺ increases in the primary cilium through distinct mechanisms. We propose that the primary cilium should be considered an important signalling centre in β-cells that can receive and transmit signals of relevance for cell function, the cellular implications of ciliary calcium signalling remain to be elucidated.

Supported by: Swedish Research Council, NNF, EFSDF/Lilly Research Programme, EXODIAB, Diabetesfonden

Disclosure: T.C. Incedal: None.

Optogenetic stimulation of pancreatic beta cells to investigate gap junction coupling among heterogenous subpopulations

C.H. Levitt; Bioengineering, University of Colorado Anschutz, Denver, USA.

Background and aims: Insulin secreting β-cells of the Islets of Langerhans are functionally heterogeneous. Distinct spatially organized subpopulations of β-cells have been shown to mechanically drive insulin secretion and glucose homeostasis. Electrical coupling between β-cells via gap junction protein Connexin-36 (Cx36) promotes the synchronization of electrical activity. In diabetes, it has been shown that gap junction coupling is disrupted and results in a loss of coordinated calcium influx ([Ca²⁺]i) and insulin release. The cell-specific influence that gap
junction coupling has whole islet electrical dynamics, however, is not clear. Here we will assess the degree to which disruptions in functional subpopulations of β-cells are a result of disruptions to gap junction coupling.

Materials and methods: To directly influence the electrical properties of single cells in the islet, β-cell specific channelrhodopsin-2 (Chr2) was expressed in transgenic mice. Chr2 is a light sensitive cationic channel that causes cell depolarization upon stimulation of blue light. A Ca<sup>2+</sup>-sensitive fluorescent dye was used to visualize calcium dynamics upon single cell stimulation in isolated islets. To mimic diabetogenic conditions where Cx36 coupling is disrupted, islets were treated with a 0.1X cocktail of pro-inflammatory cytokines (IL-1β, TNF-α, and IFN-γ). Recovery of gap junction function was achieved by co-treatment with a mimetic peptide (S293) that competitively inhibits cytokine mediated Cx36 phosphorlation. Islets were subject to cytokine treated, and cytokine + peptide co-treatment under conditions of basal (5mM) and elevated (11mM) glucose.

Results: Pro-inflammatory cytokines disrupt Cx36 gap junction coupling through nitric oxide regulated PKCδ activation which causes a loss of synchronized [Ca<sup>2+</sup>]. At basal glucose, we demonstrate that cytokine treatment impairs electrical recruitment of neighboring cells following single-cell Chr2 stimulation. In untreated islets, >50% of cells could recruit an area larger than the mean recruitment area of an untreated islet whereas only ~7% of cells could accomplish the same in cytokine treated. When gap junction coupling was recovered with co-treatment of cytokines and S293 peptide, the proportion of recruited cells tripled (~30%). At elevated glucose, single cell stimulation drove coordinated electrical dynamics across the islet. Under cytokine treated the driving of coordinated dynamics was decreased (decreasing in spectral power at the driving frequency) compared to co-treatment with S293.

Conclusion: At both low and high glucose conditions, pro-inflammatory cytokines induced disruptions to the coordinated activity induced by Chr2-stimulation of a single β-cell. Recovery of Cx36 by S293 and the subsequent increase in the recruitment area suggests that gap junction coupling is sufficient for coordinated regulation of [Ca<sup>2+</sup>], and overall insulin release. Taken together, these finding support the critical role of gap junction coupling allowing coordinated electrical activity driven by heterogenous subpopulations, and thus the proper regulation of insulin release.

Disclosure: C.H. Levitt: None.

375 Quantifying the relationship between emergent islet function, gap junctions, and beta cell dynamics: a network theory approach
J. Briggs, J. Dwulet, V. Kravets, D. Albers, R. Benninger;
University Of Colorado Anschutz Medical Campus, Aurora, USA.

Background and aims: Coordinated insulin release from functionally heterogeneous beta cells in the pancreatic islet is essential for proper glucose homeostasis and is disrupted in type 1 and type 2 diabetes. Network theory is a helpful tool in understanding this islet coordination and the mechanisms driving it. Coordinated insulin secretion results from the heterogeneous dynamics of individual beta cells and the intercellular interactions through the gap junctions that connect them. This emergent insulin secretion can be studied using a functional network representation and the gap junctions can be studied using a structural network. In diabetic conditions, beta-cell death or gap junction dysfunction alters the structural network. However, because the relationship between the structural and functional networks has not been well quantified, we cannot predict how specific types of disruption in structure will impact the islet function. In this presentation, we combine experimental and computational techniques to quantify the relationship between the structural and functional networks of the beta cells in the pancreatic islets.

Materials and methods: We use a computational model to simulate islet dynamics with healthy and decreased coupling conditions. This approach allows us to compare the structural and functional networks using traditional and network theory-based statistics. We then validated the findings from this simulation using concurrent calcium imaging to quantify the functional network, fluorescence recovery after photobleaching to quantify gap junction permeability to quantify the structural network, and NAD(P)H autofluorescence to quantify metabolic activity. Finally, we used Connexin36 knockout mice to quantify the functional network response to structural network changes that can also occur under diabetic conditions.

Results: Our computational and experimental data indicate that the functional network is more reflective of the metabolism than structural gap junctions. We show that functional subpopulations of beta cells, including beta cell hubs, are statically differentiated by their intrinsic metabolic activity rather than structural connections (P < 0.001). Functionally connected cells are more likely to share metabolic qualities than a gap junction (P < 0.01). Using weighted network analysis, we show that short and medium-range functionally connected cell pairs (1-5 gap junction separation) are more likely to share similar metabolic rates (P < 0.001) while long-range functionally connected pairs (6-7 gap junctions) are more likely to share a chain of highly conductive gap junctions (P < 0.01). This indicates that metabolic similarities are primarily responsible for synchronizing cells over short distances, while gap junctions are required for synchronizing cells over long distances. Last, we show that while loss of physical connections changes functional network properties, removing gap junctions is not enough to explain islet dynamics fully.

Conclusion: Altogether, our results suggest that the emergent functional network of the pancreatic islet is more reflective of variations in beta-cell metabolic activity than structural gap junction connections. These results provide insight into how to interpret the relationship between structure, function, and intrinsic cell dynamics in the pancreatic islet and how insulin secretion dynamics may be altered in diabetes.

Supported by: NSF DGE-1938058 (Briggs to JB); R01 DK102950, R01 DK106412 (to RKPB); HIRN 25B1104 (to VK)
Disclosure: J. Briggs: None.

376 Illuminating the mechanism for G<sub>δ</sub> protein-coupled receptor inhibition of beta cell Ca<sup>2+</sup> influx and insulin secretion

Background and aims: Pancreatic β-cell insulin secretion depends on Ca<sup>2+</sup> entry and is essential for maintaining glucose homeostasis. It is well-established that G<sub>δ</sub> protein-coupled receptors (G<sub>δ</sub>-GPCRs) such as somatostatin (SST) receptors (SSTRs) and x2A-adrenergic receptors (ADRs) limit excessive insulin secretion in part by reducing β-cell electrical excitability; however, the mechanisms underpinning G<sub>δ</sub>-GPCR control of β-cell function are poorly understood. Therefore, due to the importance of G<sub>δ</sub>-GPCRs in islet function and dysfunction, we set out to provide a clear understanding of how G<sub>δ</sub>-GPCRs control β-cell Ca<sup>2+</sup> handling and hormone secretion.

Materials and methods: Electrophysiology, fluorescence imaging (Ca<sup>2+</sup>, Na<sup>+</sup>, cAMP), and hormone secretion assays were employed to study G<sub>δ</sub>-GPCR regulation of islet function. A pharmacological approach and transgenic mice with pancreatic GIRQ2 knockout (KO) were used to assess contributions of G protein-gated inwardly rectifying K+ (GIRK) channels and Na<sup>+</sup>/K<sup>+</sup> ATPases (NKAs) to β-cell G<sub>δ</sub> signaling. Islets with β-/δ-cell-restricted G<sub>δ</sub>-coupled Designer Receptors Exclusively Activated by Designer Drugs (G<sub>δ</sub>-DREADDs) were used to examine islet-cell-
specific G_i signaling effects. NKA phosphorylation was probed using immunoblotting.

Results: G_i-GPCR activation (SSTRs or α2A-ADRs) stimulated β-cell Ca^{2+} oscillations and out-of-phase cAMP oscillations. SST-induced Ca^{2+} oscillations were unaffected by GIRK channel inhibition (tertiapin-Q) or GIRK2 KO; NKA inhibition (ouabain or extracellular K⁺ removal) terminated G_i-GPCR-mediated Ca^{2+} oscillations in 98±2% of islets (P<0.001). NKA inhibition also reduced SST-induced decreases in human islet Ca^{2+} by 80±16% (P<0.05). This was a β-cell-specific effect as selective activation of β-cell G_i-DREADDs stimulated Ca^{2+} oscillations in 88±9% of islets (P<0.01). β-cell G_i-DREADDD activation decreased glucose-stimulated (9mM) SST secretion by 63±4% (P<0.01); as a result of diminished SST secretion, islet Ca^{2+} oscillations sped up by 42±8% (P<0.01) and glucose-stimulated insulin secretion increased by 336±66% (P<0.001).

This was reversed by exogenous SST, suggesting that intra-islet SSTR inhibition also reduced SST-induced decreases in human islet Ca^{2+}. Glucose-stimulated insulin secretion increased by 336±66% (P<0.001).

Conclusion: Therefore, these findings reveal that NKA-mediated β-cell V_m hyperpolarization is the primary mechanism for G_i-GPCR control of β-cell Ca^{2+} handling and insulin secretion. G_i-GPCRs activate β-cell NKAs through phosphorylation by STKs as well as by decreasing cAMP levels and PKA activity. Intra-islet SSTR signaling regulates β-cell NKA activity, which tunes glucose-stimulated Ca^{2+} oscillations and presumably pulsatile insulin secretion.

Supported by: NIH NIDDK, Helmsley Charitable Trust, ADA, and JDRF

Disclosure: M.T. Dickerson: None.

377

Pancreatic delta cells switch islet Ca^{2+} oscillation modes by inhibiting endogenous glucagon from alpha cells

H. Ren, Y. Li, Y. Yu, T. Chang, W. Qian, X. Yang, L. Chen, C. Tang; Lvyzhihe building, Peking University, Beijing, China.

Background and aims: Glucose-stimulated pancreatic islets show different patterns of Ca^{2+} signaling with fast, slow and mixed fast/slow oscillations. However, it is not clear whether they are characteristic features of individual islets. And how much the paracrine perturbation switch the Ca^{2+} oscillation modes.

Materials and methods: Microfluidic chips for islet Ca^{2+} imaging; Optoinhibition of δ cells using transgenic mice (Sst-Cre; A135^flox); Pharmacologically blocking Sstr2 using CYN; 10 mM glucose stimulation and 3D images were acquired by two-photon microscopy. Each 3D image in time series is composed of several 2D images in a z-stack, which step size was between 3.7-6.5 μm and whose imaging depth was around 150 μm-200 μm, according to the sample size. (Figure A) The time resolution could stably reach 1 Hz.

Results: We showed conserved calcium wave propagation patterns of fast (period < 1 min) and slow (period > 1 min) oscillation modes upon high glucose stimulation. Fast waves behaved like traveling waves, which could be initiated by multiple conserved β-cell clusters in the periphery. In contrast, the slow oscillation wave propagation pattern was similar to “diffusion wave”, which was sharply activated by β-cells in the periphery, and the signaling gradually propagated into the core. (Figure B) The mean velocity, calculated from the average distance of the wave to propagate per second, of the fast and slow waves is 61.4 ± 22.5 μm/s and 21.1 ± 0.7 μm/s, respectively. Both wave velocity distributions of fast and slow modes and their propagation patterns implied hidden mechanisms, other than electrical coupling via gap junction, to account for β-cell synchronisation. What’s more, it was striking that the wave propagation pattern of a mixed oscillation could be decomposed into a slow wave and several fast waves, with the same pattern observed in pure fast/slow oscillations.

Conclusion: Our study highlighted the importance of δ-α cell interactions to generate tunable islet Ca^{2+} oscillation patterns. The design principle of pancreatic islet was revealed, as the minority of δ cells command the majority of α and β cells.

Disclosure: H. Ren: None.

378

Three-dimensional imaging reveals conserved patterns of calcium wave in the pancreatic islet

Y. Yu^1,2, Y. Ren^1,2, Y. Li^3, X. Yang^1, L. Chen, C. Tang^1,2;
1 Center for Quantitative Biology, Peking University; 2 Peking-Tsinghua Center for Life Sciences, Peking University; 3 College of Future Technology, Peking University, Beijing, China.

Background and aims: Global calcium wave within pancreatic islets is important to the pulsatile secretion of insulin. Recent studies focused on wave propagation in fast oscillation mode, but few of them documented the wave pattern of slow oscillation, and how fast and slow waves interact in mixed mode is almost obscure.

Materials and methods: We developed a 3D time-lapse imaging pipeline based on two-photon microscopy, microfluidic chips, and quantitative analysis to record high spatial and temporal resolution calcium waves within pancreatic islets. In brief, islets isolated from Ins1-Cre^+/GCaMP6ff/+ mice were loaded into microfluidic chips with sustained 10 mM glucose stimulation and 3D images were acquired by two-photon microscopy. Each 3D image in time series is composed of several 2D images in a z-stack, which step size was between 3.7-6.5 μm and whose imaging depth was around 150 μm-200 μm, according to the sample size. (Figure A) The time resolution could stably reach 1 Hz.

Results: We showed conserved calcium wave propagation patterns of fast (period < 1 min) and slow (period > 1 min) oscillation modes upon high glucose stimulation. Fast waves behaved like traveling waves, which could be initiated by multiple conserved β-cell clusters in the periphery. In contrast, the slow oscillation wave propagation pattern was similar to “diffusion wave”, which was sharply activated by β-cells in the periphery, and the signaling gradually propagated into the core. (Figure B) The mean velocity, calculated from the average distance of the wave to propagate per second, of the fast and slow waves is 61.4 ± 22.5 μm/s and 21.1 ± 0.7 μm/s, respectively. Both wave velocity distributions of fast and slow modes and their propagation patterns implied hidden mechanisms, other than electrical coupling via gap junction, to account for β-cell synchronisation. What’s more, it was striking that the wave propagation pattern of a mixed oscillation could be decomposed into a slow wave and several fast waves, with the same pattern observed in pure fast/slow oscillations.

Conclusion: Our study highlighted the importance of δ-α cell interactions to generate tunable islet Ca^{2+} oscillation patterns. The design principle of pancreatic islet was revealed, as the minority of δ cells command the majority of α and β cells.
SO 16 A new niche to replace beta cells

Stem cell-derived, fully differentiated islet cells for type 1 diabetes


1University of Miami Diabetes Research Institute and Cell Transplant Center, Miami, 2University of Pennsylvania, Philadelphia, 3University of Pennsylvania Perelman School of Medicine, Philadelphia, 4Vertex Pharmaceuticals, Boston, 5Boston Children’s Hospital, Boston, 6University of Southern California, Los Angeles, 7University of Chicago, Chicago, 8Massachusetts General Hospital, Boston, USA.

Background and aims: Cadaveric islet transplantation can achieve glycemic control in T1D, but cadaveric islet quantity and quality are limiting. We report the first patient administered VX-880, an investigational allogeneic stem cell-derived, fully differentiated, pancreatic islet cell replacement therapy.

Materials and methods: Following a single infusion of VX-880 at half the target dose, the patient was monitored for safety and tolerability, as assessed by adverse events (AEs) and clinical laboratory assessments, fasting and stimulated C-peptide, HbA1c, glycemic variability, interstitial glucose by continuous glucose monitoring, and exogenous insulin dose.

Results: A 64yo male with a 40y history of T1D complicated by impaired awareness of hypoglycemia with 5 severe hypoglycemic events (SHEs) the year before VX-880 was receiving 34U insulin/day at baseline (HbA1c 8.6%; undetectable fasting and stimulated C-peptide). After a single VX-880 infusion at half target dose, fasting C-peptide was detected by Day 29 and increased rapidly; HbA1c and daily insulin decreased in parallel. At Day 90, robust increases in fasting and stimulated C-peptide, improved glycemic control, and a substantial reduction in exogenous insulin administration were observed and continued to improve through last time point assessed (Table). VX-880 was generally safe and well tolerated; most AEs were mild or moderate and consistent with immunosuppression. The most common AEs were SHEs (not serious or related to VX-880) which occurred in the perioperative period. There was 1 serious AE of rash (mild, not related to VX-880) which resolved.

Conclusion: These unprecedented results are the first evidence that stem cell-derived islets can restore insulin production and glucose control in T1D. The study continues to enroll and dose patients.
An improved approach for generation of beta cell like insulin-producing cells from induced pluripotent stem cells

B. Cetin, A.D. Sanlioglu
Gene and Cell Therapy, Akdeniz University, Antalya, Turkey.

Background and aims: The necessity for increasing the effectiveness of current treatment modalities, as well as developing new therapeutic approaches for diabetes management is well acknowledged. Induced Pluripotent Stem Cells (iPSCs) hold great promise for regenerative medicine applications, including the treatment of diabetes, due to their low immunogenicity besides their high potential for self-renewability and differentiation. Studies aiming for the generation of new beta cell sources from pluripotent stem cells have paved the way for direct methodologies for differentiation of iPSCs into beta cell-like insulin-producing cells (iPCs) via small molecules activating key signaling pathways throughout beta-cell development. Yet there are still hurdles to overcome for the development of protocols with optimal efficiency and safety.

Materials and methods: We present an improved approach for the generation of iPSCs from iPSCs via use of key small molecules. TNF-Related Apoptosis-Inducing Ligand (TRAIL) molecule was included in our protocol based on its yet not-well explained protective role in diabetes development shown by the work of our group and other groups, along with possible unknown mechanisms we hypothesize to be in action on beta cells. In correlation with this, a proliferative effect of TRAIL on rodent beta cells was evident in a recent study by our group

Results: In our study, stepwise differentiation of iPSCs from human fibroblast-originated iPSCs was confirmed by the expression of Sox17 and FoxA2 (definite endoderm); PDX-1, and insulin (pancreatic differentiation); and PDX-1, insulin, NeuroD1, Pax6 and Islet-1 (differentiation into iPSCs). The inclusion of TRAIL in our protocol displayed differentiated iPSCs with increased insulin and c-peptide secretion.

Conclusion: We believe that our combined approach may be useful as an improved strategy, besides contributing to revealing of the potential of TRAIL as a candidate therapeutic molecule in diabetes.

Supported by: Akdeniz University, BAP
Disclosure: B. Cetin: None.

380

381

Endoc-βH5 human beta cells: a unique thaw and go model for accelerating diabetes research with highly functional and ready-to-use human beta cells

H. Olleik, B. Blanchi
Human Cell Design, Toulouse, France.

Background and aims: In 2021, 537 million adults were living with diabetes worldwide (90% T2D), a number that is predicted to rise to 643 million by 2040. The need for physiologically relevant human cellular models to study human beta cell function, insulin secretion and diabetes is thus greater than ever. To date, human pancreatic islets present many drawbacks related to lack of availability and reproducibility that limit their use. While animal models remain far from human reality.

Materials and methods: Different assays were used for the validation of EndocBH5. For example, microscopy and FACS analysis were performed to examine the morphology of the cells and detect the beta cell identity markers. Furthermore, GSIS and incretin pharmacology analyses were performed in 96 well plates to study the functional capacity of EndocBH5. Also siRNA, using lipofectamine, was used to knock down genes of interest for disease modeling.

Results: Specifically, EndocBH5 is a pure population of insulin expressing cells (100% INS/92.3% PDX1/90% NKX6.1). Insulin content is close to that of native pancreatic beta cells (> 5 μg/million cells). EndocBH5 cells dose dependently respond to physiological concentrations of glucose (highest potentiation of insulin secretion between 2.8 and 8 mM glucose) with elevated absolute insulin secretion values (hundreds of ng/hr/10⁶ cells) similar to native islets. Furthermore, they dose dependently respond to GLP1R agonists, GIP agonist D-ALA-2-GIP and dual agonist tirzepatide with reproducible EC₅₀ and increased insulin secretion >3-fold over high glucose. In addition, EndocBH5 cells can be assayed in 384-well plates paving the way for HTS and have been validated as 3D spheroids with extremely robust functional data. Finally, expression of diabetes related genes can be modified to produce relevant disease models.

Conclusion: Overall, EndocBH5 represent a novel human pancreatic beta cell solution with very high potential for developing human diabetes models, unraveling diabetes mechanisms in human cells and developing anti-diabetic drugs.

Disclosure: H. Olleik: None.

382

Exendin-4 enhances GSIS through upregulation of MAFA and mitochondrial oxidative phosphorylation machinery genes in hPSC-derived beta cells

A. Diane, R. Bin Abdul Mu-um-min, H.H. Al-Siddiqi
Diabetes Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Doha, Qatar.

Background and aims: Impaired insulin secretion contributes to the pathogenesis of diabetes mellitus type 1 (T1DM) through autoimmune destruction of pancreatic β-cells and the pathogenesis of diabetes mellitus type 2 (T2DM) through β-cell dedifferentiation and other mechanisms. Emerging beta-cell replacement with human pluripotent stem cell (hPSC)-derived β-cells may provide remedial cell therapy. Most protocols to differentiate hPSCs to insulin-expressing β-cells in vitro have generated hPSC-derived β-cells with either immature phenotype such as impaired or weakened glucose-stimulated insulin secretion (GSIS) relative to primary β-cells. Evidence has shown that β-cell mitochondria play a central role in coupling glucose metabolism to insulin exocytosis. Therefore, the impairment of GSIS in hPSC-derived β-cells may be attributed to mitochondrial dysfunction. The aim of this study is to investigate the effect of Exendin-4 (GLP-1 receptor analog), known to promote...
mitochondrial function, on enhancing maturation and functionality of hPSC-derived β-cells.

**Materials and methods:** Differentiation of hPSC into β-cells was carried out in a stepwise 3D differentiation protocol using 30 ml spinner flask adapted from the protocol of Veres et al. (2019). This consists of 6 stages: S1, definitive endoderm; S2, gut tube endoderm; S3, pancreatic progenitors 1; S4, pancreatic progenitors 2; S5, endocrine precursors; and S6, beta-like cell formation. The efficiency of relevant stage-specific marker expression was tested using flow cytometry. Finally, to further test the effect of GLP-1 receptor analog in promoting the maturation of β-cell phenotype, 50 nM Exendin-4 was added to the suspension culture during the last three days of differentiation. To determine the functionality of hPSC-derived β-cells, GSIS was performed. Gene expression in cell clusters was determined by RT-PCR. Data are mean ± SEM (n=3)

**Results:** Flow cytometry data for relevant stage-specific markers showed 90 % OCT4 positive, 90% SOX17 and 70% PDX1 positive cells, indicating good pluripotency, high definite endoderm and pancreatic progenitor induction, respectively. As for β-cell markers, we found 40.7% NKX6.1 positive cells during stage 6, indicating a generation of insulin-expressing β-cells. Expression profiling during differentiation confirmed the generation of insulin-expressing β-cells. However, GSIS data showed no difference in c-peptide secretion between low (2.8mM) and high (20 mM) glucose but high response to direct cellular depolarization-mediated c-peptide by KCl, suggesting a lack of functional β-cells. Interestingly, addition of Exendin-4 (50 nM) during the last 3 days of the differentiation significantly enhanced GSIS associated with increased expression of MAFA and genes encoding mitochondrial oxidative phosphorylation machinery.

**Conclusion:** Our data demonstrated for the first time in 3D differentiation of hPSC-derived β-cells using spinner flasks that addition of Exendin-4 enhances GSIS through upregulation of MAFA and mitochondrial oxidative phosphorylation machinery genes.

**Supported by:** QBRI intramural grant (BR01) to Dr. Heba H. Al-Siddiqi

**Disclosure:** A. Diane: None.

---

**383 Co-transplantation of pancreatic islets and microvascular fragments effectively restores normoglycaemia in diabetic mice**

E. Ampofo, S. Wrublewsky, A. Weinzierl, I. Hornung, M. Menger, M. Laschke; Saarland University, Homburg, Germany.

**Background and aims:** Insufficient revascularization of pancreatic islets is one of the major obstacles impairing the success of islet transplantation. To overcome this problem, we introduce in the present study a straightforward strategy to accelerate the engraftment of isolated islets. For this purpose, we combined adipose tissue-derived microvascular fragments (MVF) with pancreatic islets and co-transplanted this mixture in streptozotocin (STZ)-induced diabetic mice.

**Materials and methods:** Islets and MVF were isolated from C57BL6/N mice and their viability was assessed by calcine/propidium iodide stainings. Two hundred fifty islets and 20,000 MVF as well as 500 islets and 40,000 MVF were co-transplanted under the kidney capsule or into the subcutaneous space of diabetic mice, respectively. The revascularization and endocrine function of the grafts were determined by the determination of blood glucose levels twice a week. An intraperitoneal glucose tolerance test (IPGTT) was performed at the end of the entire observation period. The grafts' morphology, viability and cellular composition were analyzed using immunohistochemistry.

**Results:** We found that the co-transplantation of islets and MVF markedly accelerates the restoration of normoglycaemia in diabetic recipients when compared to the transplantation of islets alone. In fact, the co-transplantation of 250 islets and 20,000 MVF under the kidney capsule reversed diabetes in 88%. The subcutaneous transplantation of 500 islets and 40,000 MVF leads to normoglycaemia in all STZ-treated mice when compared to controls. Additional immunohistochemical analyses of the grafts revealed a significantly higher number of islet cells and microvessels in the co-transplantation groups at the end of the observation period.

**Conclusion:** Our findings clearly demonstrate that the co-transplantation of islets and MVF significantly accelerates the revascularization of the grafts. This not only improves the success rates of islet transplantation, but could also be easily translated into clinical practice.

**Disclosure:** E. Ampofo: None.

---

**384 Comparison of different hyaluronic acid-based matrices to maintain human islet survival in macroencapsulation devices**

D. Brandhorst1, H. Brandhorst1, D.A. Domingo-Lopez2, E. O’Cearbhaill3, L. McDonough3, F.B. Coulter1, S. Deotti1, H. Kelly5, G. Duffy5, P.R.V. Johnson1

1Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK, 2Anatomy and Regenerative Medicine Institute, National University of Ireland, Galway, Ireland, 3School of Mechanical Engineering, University College of Dublin, Dublin, Ireland, 4School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.

**Background and aims:** Encapsulation of isolated islets has the potential to enable transplantation without the requirement for life-long immunosuppression. However, to date, insufficient oxygen supply has meant that long-term graft survival of macroencapsulated islets has been challenging. The aim of this study was to investigate the efficiency of different bio-compatible matrices that can deliver oxygen, thereby facilitating early graft survival and providing a replacement for the collagenase-digested extracellular matrix.

**Materials and methods:** Isolated human islets (n = 7) were subjected to quality assessment (yield, counted as islet particle number [IN] and islet equivalents [IEQ]; viability [FDA-PI]; early apoptosis [Annexin-V] and reactive oxygen species [ROS] production [DCFH-DA]) before mixed with different matrices: (A) supplemented CMRL (control); (B) native Hyaluronic-acid (HA)-based Gel; (C) Beta (β)-Gel (HA-Gel+Perfluorodecalin-emulsion) or (D) pre-oxygenated β-Gel (β-Gel+O2).

**Results:** Following culture a massive loss of islets was noted when embedded in CMRL (11%±3% recovery, p<0.01 vs PC, vs β-Gel+O2 [81±7%]; p<0.01 vs β-Gel [63±4%]) or HA-Gel (35±8%, p<0.01). Reduction of islet yield correlated with substantially enhanced fragmentation (ratio of IN over IEQ) (421±70%, p<0.01 vs PC; 283±80%, p<0.01; 158±11%, p<0.05; 152±22%, NS) in CMRL, HA-Gel, β-Gel or β-Gel+O2, respectively. Accumulation of cell fragments was associated with increased islet ROS production (733±403%; 497±293%, p<0.05 vs CMRL; 177±89%, p<0.01; 140±64%, p<0.01) after encapsulation in CMRL, HA-Gel, β-Gel and β-Gel+O2, respectively. Compared with CMRL (75±4%, p<0.01 vs PC, vs β-Gel+O2) and HA-Gel (84±2% vs β-Gel+O2) viability was significantly better preserved in β-Gel (84±3%, p<0.05 vs PC, vs CMRL) and β-Gel+O2 (92±5%). Early apoptosis was highest in CMRL (1095±228%, p<0.01 vs PC, vs β-Gel+O2) and HA-Gel (716±193%, p<0.01 vs PC, p<0.05 vs CMRL) but lower in β-Gel (345±62%, p<0.05 vs PC, vs CMRL) or β-Gel+O2 (337±63%). Overall survival, defined as survival of viable cells only, was marginal in CMRL (8±2%, p<0.01 vs PC, vs β-Gel+O2), low in HA-Gel (29±7%, p<0.01 vs PC) but higher in β-Gel (54±6.5%,
Conclusion: Our findings demonstrate that the use of a suitable biocompatible matrix is essential to reduce inflammation and to protect the integrity of macro-encapsulated human islets. As hypoxia is the most decisive factor for islet survival, the efficient delivery of oxygen, even for a limited time, helps to promote islet survival within macrodevices.

Supported by: European Union’s Horizon 2020 grant # 643599

Disclosure: D. Brandhorst: None.

385

Proteome profiling of whole plasma and plasma-derived extracellular vesicles facilitates the detection of tissue biomarkers in the NOD mouse

V.M. Stone1, I. Diaz Lozano1, H. Sork1,2, M. Eldh3, M. Pernemalm4, S. Gabrielson1, M. Flodström-Tullberg1;
1Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden, 2Institute of Technology, Tartu, Estonia, 3Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 4Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

Background and aims: Type 1 diabetes (T1D) results from a destruction of the insulin-producing pancreatic β-cells. The discovery of protein biomarkers that are measurable in serum or plasma during the pre-diabetic period could facilitate personalised disease interventions. Recent studies have shown that extracellular vesicles (EVs) found in liquid biopsies are a source of proteins derived from different tissues. The aim of this study was to address if combined analysis of whole plasma samples and plasma-derived EV fractions increases the number of unique proteins identified by mass spectrometry (MS) compared to the analysis of whole plasma samples alone.

Materials and methods: Plasma (up to 650 μl per animal) was collected from non-diabetic NOD mice (approximately 8-10 weeks old) and either saved as whole plasma or filtered (0.8 μm) prior to enrichment of EVs by size exclusion chromatography (SEC; qEV original, Izon) or membrane affinity (MA; exoEasy, Qiagen). Particle size, structure and number were analysed by nano particle tracking analysis (NTA; NanoSight) and transmission electron microscopy (TEM). LC-MS/MS analysis was performed using EV-enriched plasma samples and high-resolution isoelectric focusing (HiRIEF) LC-MS/MS using whole plasma. For some analyses, samples were depleted of abundant plasma proteins prior to MS analysis using the Multiple Affinity Removal Spin Cartridge Mouse-3 column (Agilent Technologies). Bioinformatics analysis was performed using DAVID v6.8 and R (version 4.0.4).

Results: EVs enriched by SEC (qEV) were on average around 93 ± 9 nm in size with a mean number of 3.2 x 10^7 ± 1.6 x 10^7 particles isolated per μl of plasma. In contrast fewer particles were enriched by exoEasy (MA; 3.6 x 10^5 ± 2.5 x 10^5 particles per μl plasma) and they were on average bigger in size (mean 201 ± 24 nm). TEM analysis of exoEasy enriched fractions revealed a greater fraction of larger particles with a less-defined shaped whilst EVs with cup-shaped morphology indicative of exosomes were found in the qEV enriched fractions. HiRIEF LC-MS/MS analysis of plasma samples depleted of abundant proteins and subjected to peptide fractionation identified more than 2300 proteins, while the LC-MS/MS analysis of EV-enriched plasma samples enriched using qEV identified more than 600 proteins. Of the proteins detected in EV-enriched samples, more than a third were not identified in whole plasma samples and many were classified as either tissue-enriched or of tissue-specific origin.

Conclusion: Parallel profiling of EV-enriched plasma fractions and whole plasma samples increases the overall proteome depth and facilitates the discovery of tissue-enriched proteins in plasma from pre-diabetic NOD mice. This integrated proteome profiling scheme may be useful for the discovery of new biomarkers in T1D.

Supported by: Barndiabetesfonden, J&J & KI Partnership Program, KI, Novo Nordisk Foundation, EDF, Mobilitas Plus

Disclosure: V.M. Stone: None.
SO 17 Intracellular signalling balancing beta cell survival and death

Differential spatiotemporal GLP-1 receptor signalling in primary pancreatic beta cells
M.A. Ravier, N. Zaïmia, G. Bertrand; Institute for Functional Genomics, Univ Montpellier, CNRS, INSERM, Montpellier, France.

Background and aims: Increasing the efficacy of GLP-1 receptor (GLP-1R) agonists is currently the main challenge in type 2 diabetes research. GLP-1R is a G protein-coupled receptor (GPCR) known to be positively coupled to cAMP production and PKA/EPAC2 activations and to recruit the scaffold protein beta-arrestin2 (ARRB2), which may activate new signaling pathways such as the kinases ERK1/2. Most of the studies have investigated GLP-1R signaling in recombinant clonal non-beta cell lines. Consequently, a better understanding of the mechanisms involved in GLP-1R internalization/desensitization and signaling in primary pancreatic beta cells is necessary. In addition, special attention should be paid to the effect of therapeutic pharmacological concentrations found in type 2 diabetes patients treated with GLP-1R agonists (nM) versus circulating physiological concentrations (pM) of GLP-1.

Materials and methods: Experiments were performed in beta cells from 4-month-old Arrb2−/− and Arrb2+/+ male mice. PKA (AKAR3) and ERK1/2 (EKAR) activities, and EPAC2 recruitment underneath the plasma membrane (EPAP2-GFP), were assessed by live-cell microscopy in mouse pancreatic beta cells after genetic expression of the sensors of interest by adenoviral infection. ERK1/2 (P-ERK1/2) and CREB (P-CREB) activation were assessed by immunofluorescence. GLP-1R internalization was determined by immunofluorescence from 4% formaldehyde fixed and non-permeabilised beta cells.

Results: In beta cells, GLP-1 (10pM to 10nM) caused a rapid activation of PKA, which remained sustained during stimulation (>40min). This activation persisted (~25 min) after cessation of GLP-1 stimulation at pharmacological concentrations (slope -0.4649±0.04) but not at physiological concentrations (slope -0.826±0.11, p<0.001). Interestingly, the recovery was faster with a direct activator of the adenylyl cyclase (1μM forskolin; slope: -2.673±0.10, p<0.001) that trigger larger activation of PKA. In parallel, EPAC2 is activated at pharmacological (10nM) and not physiological (10pM) concentrations of GLP-1. This was associated with massive GLP-1R internalization (~60%, p<0.001), which remained 25 min after cessation of stimulation (~40% p<0.001) at pharmacological concentrations. In contrast, a lack of GLP-1R internalization was observed at physiological GLP-1 concentrations (10-100pM). ARRB2, known to uncouple GPCRs from G protein and induce their internalization, is not involved in this process. Finally, pharmacological concentrations of GLP-1 caused transient ARRB2-independent activation of ERK1/2 and do not activate CREB.

Conclusion: This study reports for the first time that physiological and pharmacological concentrations of GLP-1 resulted in distinct cellular spatiotemporal responses in primary beta cells. Special attention should be paid to cell signaling when generating new GLP-1R agonists to treat type2 diabetes.

Supported by: SFD research grant
Disclosure: M.A. Ravier: None.
CD47/SIRP-alpha: a critical axis that may contribute to beta cell loss in type 1 diabetes
K. Afi Leslie, S.J. Richardson, N.G. Morgan, M.A. Russell; University of Exeter Medical School, Exeter, UK.

Background and aims: Interleukin (IL)-13 enhances the expression of the transmembrane glycoprotein, Signal Regulatory Protein Alpha (SIRPα) in human β-cells via a Signal Transducer and Activation of Transcription factor (STAT)-6 dependent mechanism. SIRPα interacts with CD47 to transmit “don’t eat me” signals to macrophages but it is also expressed on both α- and β-cells in human islets suggesting a role for the CD47/SIRPα pathway in control of islet cell viability. Therefore, we have studied the expression of both CD47 and SIRPα in human pancreas sections, isolated human islets and human EndoC-βH1 cells to gain insights into their functional roles.

Materials and methods: Human pancreas sections from control subjects or those with recent-onset type 1 diabetes from within the Exeter Archival Diabetes Biobank were used for immunostaining studies. In cultured EndoC-βH1 cells, CD47 or SIRPα were knocked down using interference RNA. qRT-PCR and western blotting were employed to monitor changes in gene and protein expression, respectively in isolated islets or cell lines.

Results: Selective knockdown of either SIRPα or CD47 in EndoC-βH1 cells led to reduced viability (scrambled control: 23.6±1.4% cell death, siSIRPα 45.0±1.2%; p<.001, siCD47: 32.3±1.7% p,0.05). Immunostaining and quantification of human pancreas sections revealed higher levels of CD47 expression in β- than in α-cells of normal individuals. By contrast, in type 1 diabetes, a significant increase in α-cell expression of CD47 was seen in each of the previously described T1D endotypes (T1DE1 & 2); (control T1DE1 53.6±2.5AU, T1DE1 69.7±2.1AU p<0.001; control T1DE2 52.5±1.7AU, T1DE2 66.7±2.4AU p<0.001). Importantly, however, CD47 was differentially expressed by the β-cells of subjects with T1DE1 when compared to T1DE2. In T1DE1, β-cell CD47 was further increased above that of age matched controls (control: 63.1±1.9AU, T1DE1 beta cells 77.2±2.7AU; P<0.001), whereas, in the β-cells of people with T1DE2, the staining intensity did not exceed background levels. SIRPα was predominantly expressed in human islet β-cells in control subjects α-cells - 84.0±3.6AU, β-cells - 147.0±3.5AU, p<0.01. A significant loss of SIRPα was observed in the β-cells of subjects with T1DE1 or T1DE2 (p<0.001) while its expression was unchanged in α-cells (p=0.99).

Conclusion: Changes in the expression patterns of CD47 and SIRPα may contribute to β-cell loss in T1D but these changes occur differentially between the two disease endotypes, T1DE1 & 2. Our results imply that targeting of the CD47/SIRPα signalling pathway may offer the potential to reduce the rate of β-cell loss during progression to type 1 diabetes. However, they also suggest that care should be exercised when using therapeutic checkpoint inhibitors interacting via this pathway (e.g. anti-CD47 reagents for cancer therapy) to ensure that β-cell viability is not compromised inadvertently.

Supported by: Diabetes UK
Disclosure: K. Afi Leslie: None.
In the context of Type 1 diabetes (T1D), the role of the beta-cell enzyme RIPK1 in triggering cell death has been extensively studied. We aim to clarify if RIPK1 kinase activity is involved in T1D pathology. We evaluated RIPK1 kinase activity in mouse islets and assessed its impact on cell survival.

**Background and aims:**

RIPK1 kinase activity would present glucose abnormalities in mice lacking it. We investigated if mice lacking RIPK1 kinase activity would display any overt abnormalities and showed normal weight gain, glycemia, and body mass composition, presenting normal glucose metabolism and beta-cell function when compared to control littermates. Moreover, disease progression was not different between Ripk1S25D/S25D and Ripk1+/− mice when rendered diabetic by MLDSTZ. Both Ripk1S25D/S25D and Ripk1+/− displayed hyperglycaemia, glucose intolerance and significant loss of pancreatic insulin content, without any significant alterations caused by absence of RIPK1 kinase function. In vitro, RIPK1 enzymatic activity was highly induced by TNF+BV6+zVAD both in mice islets and human beta-cells. However, RIPK1 activation did not lead to beta-cell death.

**Conclusion:**

RIPK1 kinase does not affect glucose homeostasis nor diabetes presentation in mice. Contrary to what is described on most cell types, pancreatic beta-cells are resistant to RIPK1-dependent cell death. This may reflect an adaptation to the inability of beta-cells to proliferate and self-renewal.

**Supported by:**

- US Department of Veterans Affairs; National Institutes of Health; UW McAbee Fellowship; SFD
- None.

**Disclosure:**

- N. Esser: None.

---

**Materials and methods:**

To determine whether hIAPP increases tPA expression in macrophages, tPA mRNA levels were quantified in rat bone-marrow-derived macrophages (BMDMs) treated for 24 h with 10 μM hIAPP, non-amyloidoigenic 10 μM mouse IAPP (mIAPP) or vehicle. Further, to determine the effect of islet macrophage uptake to tPA upregulation by amyloid deposition, isolated islets from hIAPP transgenic mice (that have the propensity to form islet amyloid) and wild-type mIAPP mice (that do not form islet amyloid) were treated for 48 h with clodronate-containing liposomes (CLOD-lip) to deplete macrophages or PBS-containing liposomes (PBS-lip) as control. Islets were then cultured for 48 h in 16.7 mM glucose, which induces amyloid deposition in hIAPP, but not mIAPP islets. Islet macrophage markers (Emr1 and Ilgam) and tPA mRNA levels were quantified.

**Results:**

- hIAPP but not mIAPP increased tPA gene expression in BMDMs (4.2±1.0 vs 1.5±0.6 vs 1.0±0.5 fold, hIAPP vs mIAPP vs vehicle; p=0.25 tPA mRNA vs vehicle). As expected, islet tPA gene expression significantly increased by 2.1-fold in PBS-lip-treated hIAPP islets vs mIAPP islets (Table 1).
- In hIAPP and mIAPP islets, CLOD-lip treatment significantly abrogated Emr1 and Ilgamm expression vs PBS-lip treatment, confirming islet macrophage depletion in both genotypes (Table 1).
- CLOD-lip treatment also significantly reduced islet tPA expression vs PBS-lip in both hIAPP and mIAPP islets; however, tPA expression was still increased by 2.3-fold in CLOD-lip treated hIAPP islets vs mIAPP islets (Table 1).

**Conclusion:**

hIAPP treatment induces tPA expression in macrophages and islet macrophage depletion decreases, but does not prevent, upregulation of tPA in amyloid-laden islets. Thus, our data suggest that, in addition to macrophages, other islet cell types produce tPA in response to amyloid deposition.

---

**Table 1. Gene expression in isolated hIAPP and mIAPP islets treated with clodronate (CLOD-lip) or PBS (PBS-lip) containing liposomes and cultured for 48 hours in 16.7 mM glucose.**

<table>
<thead>
<tr>
<th>Gene expression</th>
<th>hIAPP islets</th>
<th>mIAPP islets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emr1</td>
<td>2.3±0.2</td>
<td>1.0±0.2</td>
</tr>
<tr>
<td>Ilgamm</td>
<td>1.8±0.3</td>
<td>1.0±0.2</td>
</tr>
<tr>
<td>tPA</td>
<td>3.5±0.1</td>
<td>1.0±0.2</td>
</tr>
</tbody>
</table>

**Supported by:**

- US Department of Veterans Affairs; National Institutes of Health; UW McAbee Fellowship; SFD

**Disclosure:**

- N. Esser: None.

---

**Background and aims:**

Pancreatic beta cells are resistant to RIPK1 kinase-mediated death. The rapid reversibility of recent type 2 diabetes (T2D) by very low-calorie diet in some patients correlates with a marked improvement of glucose-stimulated insulin secretion (GSIS), emphasizing the role of beta-cell dysfunction in the early stages of the disease. In search of human-specific mechanisms of beta-cell dysfunction, we extensively characterized the glucotoxic alterations of insulin secretion and upstream coupling events in human pancreatic islets cultured for 1 to 3 weeks at −5, 8, 10 or 20 mmol/l glucose and acutely stimulated by a stepwise increase in glucose concentration.

**Materials and methods:**

Islets from 46 non-diabetic (ND) and 6 type 2 diabetic (T2D) donors were obtained from 5 isolation centers over the last 10 years. The islets were precultured 3-7 days in RPMI containing 5.5, 8.5, 10.5 or 20.5 mmol/l glucose before measurements of insulin secretion during culture, islet insulin/DNA content ratio, and assessment of dynamic insulin secretion and upstream coupling events during stepwise stimulation with glucose (NADPH autofluorescence, ATP/(ATP+ADP) ratio, electrical activity, cytosolic Ca2+ concentration ([Ca2+]i)).
Results: Culture of ND-islets for 1 to 3 weeks at ~8, 10 or 20 vs 5 mmol/l glucose did not increase β-cell apoptosis or oxidative stress but concentration-dependently decreased insulin content and increased the β-cell sensitivity to subsequent stimulation with glucose. The islet glucose responsiveness (max amplitude of GSIS per islet) was larger after culture at 8 or 10 vs 5 mmol/l glucose but was markedly reduced after culture at 20 vs 5 mmol/l glucose. In the latter islets, [Ca^{2+}]_{c}, and insulin secretion responses to acute stepwise stimulation with glucose were bell-shaped, with a maximal stimulation at 5 to 10 mmol/l glucose followed by a rapid sustained inhibition above that concentration. This glucotoxic alteration was a robust characteristic of human islets. It resulted from long-term stimulation of glucose metabolism and was fully reversible after culture at 5 mmol/l glucose. Finally, acute activation/inhibition of glucokinase during perfusion of islets cultured at 20 mmol/l glucose indicated that the acute reduction of [Ca^{2+}]_{c} and insulin secretion above 10 mmol/l glucose was due to overstimulation rather than inhibition of glucose metabolism. Similar results were obtained in islets from T2D-donors.

Conclusion: Long-term exposure of human islets to mildly elevated glucose concentrations markedly increases their glucose sensitivity and reveals a bell-shaped glucose response curve for changes in [Ca^{2+}]_{c} and insulin secretion. This human-specific glucotoxic alteration may contribute to β-cell dysfunction in T2D independently from a detectable increase in β-cell apoptosis and oxidative stress.

Supported by: DiaType Project Innoviris, FRS-FNRS CDR J.0087.19 and ARC18/23-094-CfB, Brussels; SFD, Paris

Disclosure: M. Tariq: None.

Conclusion: These results suggest that chronic hyperglycaemia downregulates insulin gene expression in pancreatic beta cells via changes in glycolytic metabolites that lie downstream of glucokinase and upstream of GAPDH. Experiments with 2-deoxyglucose implicate glucose 6-phosphate as a major driver of insulin loss. The data also suggest that repression of insulin expression is not readily reversible following reversal of hyperglycaemia; recurrent episodes of hyperglycaemia could thereby contribute to a progressive impairment of beta cell function.

Supported by: BBSRC, Novo Nordisk, MRC and Wellcome Trust

Disclosure: M. Lloyd: None.

Identifying factors linking hyperglycaemia-induced metabolic dysregulation to loss of insulin biosynthesis in pancreatic beta cells

M. Lloyd, E. Haythorne, F. Ashcroft;
Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.

Background and aims: Diabetes/chronic hyperglycaemia alters glucose metabolism and reduces insulin biosynthesis in pancreatic beta cells. However, the underlying molecular mechanism(s) are poorly understood. The aim of this study was to investigate how changes in beta cell metabolism are linked to the downregulation of insulin biogenesis.

Materials and methods: INS-1 insulinoma cells were cultured at low (LG: 5 mM) or high (HG: 25 mM) glucose, ± selective glycolytic or pentose phosphate pathway enzyme inhibitors, for 48 hrs. For experiments with mitochondrial fuels, methyl pyruvate or methyl succinate was added to the media to 20 mM. Gene expression was measured by RT-qPCR. Cellular insulin content was quantified by ELISA.

Results: Chronic hyperglycaemia markedly reduced mRNA expression of the insulin genes (Ins1 and Ins2) and the associated transcription factors MafA, NeuroD1, Nkx6-1, Pax6, and Pdx1. 10 mM mannose, a glucokinase inhibitor, prevented downregulation of these genes in HG cells, but the mitochondrial substrates methyl pyruvate and methyl succinate did not cause their downregulation. LG cells cultured with 5 μM koningic acid, an irreversible inhibitor of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), showed reduced Ins1 and Ins2 expression and a 75% reduction in insulin content. These data suggest a metabolite upstream of GAPDH triggers changes in insulin gene expression. The pentose phosphate pathway is upregulated in hyperglycaemia; however, 100 μM 6-aminomonicotinamide, an inhibitor of the oxidative pentose phosphate pathway, did not affect insulin gene expression or content in HG cells. 24 hr culture of LG cells with 25 mM 2-deoxyglucose (which is metabolised to 2-deoxyglucose 6-phosphate but does not undergo further glycolysis) reduced Ins1 and Ins2 expression by >60%. Time course experiments showed Ins1 and Ins2 expression declined by >80% in HG cells after 24 hrs, and was not fully restored by subsequent transfer to LG for 24 hrs.

Disclosure: M. Lloyd: None.
SO 18 Stressing the beta cell into dysfunction

394
Gliclazide protects against oxidative stress and mitochondrial toxicity in beta cells exposed to the antiretroviral agent rilpivirine
S.C. Maandi, J.G. Mably;
Huxley Building, University of Brighton, Brighton, UK.

Background and aims: Due to the increased incidence of type 2 diabetes in the ageing HIV population, it is necessary to optimise the management of diabetes in this population. Antiretroviral therapy has been linked to increased risk of developing type 2 diabetes through insulin resistance, as well as β-cell dysfunction. Rilpivirine is a common antiretroviral drug used for the treatment of HIV, and is a potential candidate for HIV preexposure prophylaxis. However, rilpivirine has been shown to impair β-cell function through increased oxidative stress and mitochondrial toxicity. The common anti-diabetic drug gliclazide, a second-generation sulphonylurea, has been shown to exhibit secondary anti-oxidant and cell protective properties. Therefore, this study investigates whether the damaging effects of rilpivirine in β-cells can be attenuated by gliclazide.

Materials and methods: The rat β-cell line INS-1E was used in this study. INS-1E cells were subject to a 24-hour exposure to clinical concentrations of gliclazide (0 or 1 μM) alone or in addition to concentrations of rilpivirine (10 or 20 μM) that were shown to impair β-cell function and viability, respectively. Then, glucose-stimulated insulin secretion (GSIS) was assessed by ELISA and cell viability was measured using an MTT assay. INS-1E cells were stained with the dichloro-dihydro-fluorescein diacetate (DCFH-DA) fluorogenic dye and then imaged by confocal microscopy to evaluate oxidative stress. To determine changes in mitochondrial membrane potential (ΔΨm), INS-1E cells were stained with the TMRE probe and then analysed by flow cytometry. Data is expressed as mean ± SEM and statistical analysis was carried out using one-way ANOVA and Bonferroni correction. P < 0.05 was considered as significant.

Results: A 24-hour exposure to gliclazide attenuated the damaging effects of rilpivirine on GSIS and cell viability in INS-1E cells. Gliclazide improved GSIS from 26.7 ± 5% (rilpivirine 10 μM) to 63.0 ± 3% (gliclazide 1 μM in combination with rilpivirine 10 μM) (p < 0.05 vs. rilpivirine alone treatments). Gliclazide 1 μM increased cell viability from 70.1 ± 2% (rilpivirine 20 μM alone) to 81 ± 1% (gliclazide 1 μM in combination with rilpivirine 20 μM) (p < 0.05 vs. rilpivirine alone treatments). Gliclazide (1 μM) also protected against rilpivirine-mediated INS-1E apoptosis. Furthermore, gliclazide reduced rilpivirine (10 μM)-mediated ROS generation from 2.82 ± 0.32 RFU (rilpivirine 10 μM alone) to 0.49 ± 0.13 RFU (gliclazide 1 μM in combination with rilpivirine 10 μM) (p < 0.05 vs. rilpivirine alone treatments). The rilpivirine (10 μM)-mediated increase in ΔΨm (133.6 ± 11%) was prevented by 1 μM gliclazide (95.2 ± 5%) (p < 0.05 vs. rilpivirine alone treatments).

Conclusion: Our results show that gliclazide protected against the damaging effects of rilpivirine in β-cells, likely via the reduction of oxidative stress and restoration of mitochondrial function. From a clinical perspective, gliclazide may be used as anti-diabetic of choice in the management of type 2 diabetes in the ageing HIV population and individuals on HIV preexposure prophylaxis.

Disclosure: S.C. Maandi: None.

395
Alpha4 contributes to the metabolic dysfunction of the pancreatic beta cell under metabolic stress
A. Kowluru, M. Hali;
Wayne State University, Detroit, USA.

Background and aims: Extant data in several cell types have implicated alpha4 (also referred to as IGBP1) in the biogenesis, stability and activation of protein phosphatases (e.g., PP2A). Mechanistically, alpha4 binds to the catalytic subunit of PP2A (PP2Ac), thus affecting its substrate specificity. Earlier studies have also demonstrated that deletion of alpha4 leads to decreased stability of PP4c, PP6c and PP2Ac to promote loss of their corresponding phosphatase activities. Interestingly, increased expression of alpha4 has been reported in human diseases, including lung and breast cancers. Recent studies from our laboratory have identified alpha4 as one of the interacting partners of PP2Ac, and suggested that deletion of alpha4 results in suppression of high glucose (metabolic stress) induced hyperactivation of PP2A in pancreatic beta cells. The current study is undertaken to decipher the roles of alpha4 in the regulation of acute (insulin secretion) and chronic effects (cell dysfunction) of glucose in pancreatic beta cells.

Materials and methods: Rat islets were isolated by the collagenase digestion method. Human islets were from Prodo Laboratories. INS-1 832/13 cells were cultured in the presence of low (2.5 mM; LG) or high (20 mM; HG) glucose for 24 hrs. Nuclear/non-nuclear fractions and membrane/cytosolic fractions were isolated from LG and HG exposed INS-1 832/13 cells using commercially available NE-PER Nuclear and Cytoplasmic Extraction Kit and Mem-PER Plus Kit (both from Thermo Scientific), respectively. Cell death was quantified using Cell Death Detection ELISA kit from Roche. Expression of proteins involved in the alpha4 signaling axis and phosphorylation status of various stress kinases were quantified by western blotting and densitometry.

Results: Alpha4 is expressed in human islets, rat islets and INS-1 832/13 cells. Incubation of INS-1 832/13 cells with HG significantly increased the expression of alpha4 (~1.7 fold). C2-Ceramide, a biologically active sphingolipid (50 μM; 24 hrs.) also increased the expression of alpha4 (~1.8 fold). Subcellular distribution studies of alpha4 in LG and HG exposed INS-1 832/13 cells revealed that it is predominantly soluble, and its expression is significantly increased in the non-nuclear (~2.3 fold)/cytosolic (~1.45 fold) fractions in cells exposed to metabolic stress. siRNA-mediated knockdown of alpha4 (~ 80 % knockdown) exerted minimal effects on glucose- or KCI-induced insulin secretion. Deletion of alpha4 significantly increased p38MAPK and JNK1/2 phosphorylation under LG conditions, comparable to the degree seen under HG conditions. Paradoxically, a significant potentiation of HG-induced activation were significantly attenuated in cells following alpha4 knock-down. Lastly, depletion of endogenous alpha4 significantly reduced HG-induced CHOP expression (ER stress marker) and Caspase-3 activation were significantly attenuated in cells following alpha4 knock-down. Immunofluorescence imaging of HG-induced cell death in INS-1 832/13 cells.

Conclusion: Based on these findings we conclude that alpha4 contributes to HG-induced metabolic dysfunction of the islet beta cell. Our data also indicate that it plays critical roles in maintaining cell function under basal conditions since suppression of its expression promotes stress kinase activation. Additional studies are needed to further decipher roles of alpha4 and the identity of its target proteins (e.g., PP2A) in the cascade of events leading to beta cell dysregulation and demise under metabolic stress.

Supported by: Department of VA and NIH
Disclosure: A. Kowluru: None.

396
Glutamate dehydrogenase activation elicits biphasic insulin secretion and implicates a metabolic pathway with proline and glutamate in beta cell stimulus-secretion coupling
S. Gheibi;
Clinical Research Center, Lund University, Malmö, Sweden.

Background and aims: Insulin is secreted by β-cells in a biphasic manner. The rapid first phase is thought to be provoked by an influx of Ca2+ termed the triggering pathway. For insulin release to be sustained,
further metabolic events in β-cells account for the amplifying pathway. Here, several pathways and metabolites have been proposed to be involved in metabolic coupling. In view of this, glutamate and glutamate dehydrogenase (GDH) have been implicated in control of insulin secretion. Therefore, we asked which metabolic changes in β-cells are unique upon stimulation with glucose or activation of GDH.

Materials and methods: Insulin secretion was assessed in clonal INS-1 832/13 cells stimulated with 16.7 mM glucose or 20 mM 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), a non-metabolizable analog of leucine, which allosterically activates GDH. In addition, plasma membrane potential and cytosolic Ca2+ levels were measured by the dyes PMPM and Fluo4, respectively. Mitochondrial membrane potential was measured by the dye TMRE, and ATP/ADP ratio determined by the probe Perceval HR. Mitochondrial oxygen consumption rate (OCR) was determined with the Seahorse Extracellular Flux Analyzer XF24. Metabolic signatures were determined by gas chromatography/mass spectrometry.

Results: Similar to glucose, BCH provoked a robust biphasic insulin response in INS-1 832/13 cells, which was associated with elevated cytosolic Ca2+-levels and ATP/ADP ratio, plasma membrane depolarization, mitochondrial OCR, and hyperpolarization of the inner mitochondrial membrane. Metabolomics analyses revealed profound stimuli-dependent differences in metabolite profiles: stimulation with BCH increased levels of α-ketoglutarate while those of glutamate decreased. Glucose increased levels of glutamate and α-ketoglutarate as well as those of fumarate, malate, citrate and pyruvate. Interestingly, BCH enhanced formation of proline. Inhibition of this process by silencing proline 5-carboxylate (P5C) synthase, citrate and pyruvate. Interestingly, BCH enhanced formation of proline. Inhibition of this process by silencing proline 5-carboxylate (P5C) synthase, abrogated formation of proline and perturbed insulin secretion in response to BCH.

Conclusion: Activation of GDH provokes a robust biphasic insulin response. Stimulation of insulin secretion by GDH is associated with abrogated formation of proline and perturbed insulin secretion in response. Stimulation of insulin secretion by GDH is associated with abrogated formation of proline and perturbed insulin secretion in response.

Supported by: Fysiografen

Disclosure: S. Gheibi: None.

398 Vimentin as a regulator of cell survival and endoplasmic reticulum stress in pancreatic alpha and beta cells

I. Mehmeti, S. Sharifi, M. Böger, S. Lortz; Hannover Medical School, Hannover, Germany.

Background and aims: Vimentin, an intermediate filament protein, is considered a marker of mesenchymal cells. In pancreas, vimentin expression has been detected in epithelial ductal cells as well as in α- and β-cells. Recent studies have suggested that vimentin-expressing endocrine cells might be undergoing dedifferentiation, which could contribute to islet cell dysfunction and/or the onset of diabetes. Thus, our aim was to investigate whether vimentin could also be involved in α- and β-cell survival.

Materials and methods: Small interfering RNAs (inhibition >80%) were used to inhibit vimentin expression, while a plasmid encoding vimentin, an intermediate filament protein, is considered a marker of mesenchymal cells. In pancreas, vimentin expression has been detected in epithelial ductal cells as well as in α- and β-cells. Recent studies have suggested that vimentin-expressing endocrine cells might be undergoing dedifferentiation, which could contribute to islet cell dysfunction and/or the onset of diabetes. Thus, our aim was to investigate whether vimentin could also be involved in α- and β-cell survival.

Disclosure: 1. Mehmeti: None.
and BiP (n=3, p<0.05). In EndoC-βH1 β-cells, vimentin overexpression also prevented cytokine-induced apoptosis. 

**Conclusion:** These findings suggest that, besides its putative role in dedifferentiation, vimentin may play an important role in α- and β-cell survival at basal condition and against proinflammatory assaults. 

**Supported by:** Generalitat Valenciana (SEJU/2018/023) and Agencia Estatal de Investigación (PID2020-117569RA-I00) 

**Disclosure:** L. Marroqui: None.

399

The IGFBP3/TMEM219 pathway regulates homeostasis of pancreatic endocrine progenitors

E. Assi, F. D’addio, A. Maestrioni, V. Usuelli, M. Ben Nasr, C. Lorettelli, A. Abdelsalam, A. Seelam, L. Loreggian, A. Petrazzuolo, G. Zuccotti, P. Fiorina; Biomedical and Clinical Sciences, University of Milan, Milan, Italy.

**Background and aims:** Reduction in beta cell mass, mainly due to increased beta cell apoptosis and/or a failure to replenish beta cells, is a common feature of both type 1 (T1D) and type 2 (T2D) diabetes. We and other have demonstrated that targeting beta cell death is key mechanism to preserve beta cells and prevent or delay diabetes onset. Recently, the IGFBP3/TMEM219 axis has been shown to control beta cell homeostasis. Here, we will demonstrate whether TMEM219 is expressed also in beta cell endocrine progenitors thus representing a marker for beta cell in their early stage of maturation. We will also prove that rescuing TMEM219-expressing endocrine progenitors is associated with a preservation of beta cells.

**Materials and methods:** TMEM219 expression was evaluated by flow cytometry, immunoassay and immunofluorescence in undifferentiated human embryonic stem cells (h-ESCs), pancreatic progenitors, human islets and fetal pancreata. Levels of ALDH and PDX1 were assessed by qRT-PCR. Then, ALDH, PDX1, caspase 8 and HNF6 expression was evaluated by qPCR in endocrine progenitors as well as human islets after 72h treatment with IGFBP3 alone or in combination with the recombinate protein, ecto-TMEM219 (the extracellular domain of TMEM219 receptor). All experiments were run in triplicate.

**Results:** Using targeted immunoassay and flow cytometry we first discover TMEM219 protein expression in endocrine progenitors obtained from in vitro-differentiated h-ESCs. In particular, almost 50% (p<0.001) of endocrine progenitors were positive for TMEM219 expression. Of note, TMEM219 was found to be highly expressed in human fetal pancreata (5-months-old) by immunostaining and therefore may be involved in fetal remodeling of the pancreas. Moreover, addition of IGFBP3 to TMEM219-expressing h-ESC-derived endocrine progenitors in vitro induced a 2-fold (p<0.05) increase of Caspase 8 expression (2-fold) and reduce the mRNA of the progenitor markers HNF6 and PDX1. Expression of the three genes was next restored to normal in the presence of ecto-TMEM219 suggesting that IGFBP3/TMEM219 blockade in vitro acts to preserve beta cells at their early stages of maturation. Interestingly, we showed that expression of ALDH and PDX1 is still retain in TMEM219-positive cells of human mature islets suggesting the existence, even in the adult pancreas, of cells with endocrine progeniture features and the potential of renewing the beta cell mass. Here again, in the presence of IGFBP3 we observed an almost 50% (p<0.001) reduction of ALDH and PDX1 mRNA expression which was re-established to normal by ecto-TMEM219 addition (p<0.01), ultimately confirming that IGFBP3/TMEM219 signaling may also exert an effect on early-stage beta cells.

**Conclusion:** Our data demonstrate that endocrine progenitors as well as beta cells in their early stages of maturation express TMEM219, which is then retained by islet beta cells, and that these cells similarly suffer from IGFBP3-mediated Caspase 8 damage. The discovery of an axis that controls beta cells in their early stage of maturation may be relevant in understanding pathogenesis of diabetes and in designing therapeutic aimed at preserving the residual beta cells. 

**Disclosure:** E. Assi: None.

400

Mining the transcriptome of target tissues of autoimmune and degenerative pancreatic beta cell and brain diseases to identify novel therapies

X. Yi, B.M. De Souza, T. Sawatani, F. Szymczak, L. Marselli, P. Marchetti, M. Cnop, D.L. Eizirik; 1Faculty of Medicine, ULB (Université Libre De Bruxelles) Center for Diabetes Research, Brussels, Belgium, 2Department of Clinical and Experimental Medicine, and AOU Cisanello University Hospital, PISA, Italy, 3Division of Endocrinology, Erasmus hospital, Brussels, Belgium, 4WELBIO, Université Libre De Bruxelles, Brussels, Belgium.

**Background and aims:** Target tissues of autoimmune and degenerative diseases show signals of inflammation. Here we used publicly available RNA-seq data of pancreatic β-cells in type 1 (T1D) and type 2 diabetes (T2D) and neuronal tissue in multiple sclerosis (MS) and Alzheimer’s disease (AD) to identify shared inflammatory gene signatures and then mined these signatures to search for new therapies to revert them (“perturbagens”) and protect these target tissues.

**Materials and methods:** The target tissue transcriptomic data (cases vs controls for T1D: 4 vs 12; T2D: 28 vs 183; MS: 5 vs 5; AD: 122 vs 80) were re-analyzed in our pipeline, using GENCODE V36 (GRCh38.p13) as reference. Salmon (V1.4.0) for transcript quantification and DESeq 2 (V1.28.1) for differential expression. Rank-rank hypergeometric overlap (RRHO) analysis was applied to search for similar gene expression signatures in diseases pairs. The top 150 commonly up- or downregulated genes were submitted to Connectivity Map libraries containing transcriptomes of human cells exposed to chemical perturbagens, in order to reposision drugs. Drugs were tested on human islets (at least 5 preparations) exposed for 48 h to 50 U/ml interleukin-1β + 1000 U/ml interferon-γ to mimic inflammation in T1D and 0.5 mmol/l palmitate to mimic metabolic stress in T2D.

**Results:** Concordantly upregulated genes in pairs of diseases were related to inflammation (e.g., signaling by interleukins and interferons, cytokine-cytokine receptor interaction, chemokine signaling), particularly when comparing T1D vs AD. We identified bromodomain inhibitors (the most consistently ranked chemical perturbagen with [median tau scores] >90) as perturbagens that potentially revert the transcriptional signatures among the 4 diseases. The bromodomain inhibitors I-BET151 and GSK046 reduced the pro-inflammatory effects of cytokines in human islets (reduced CXCL10expression by ~30-60%, IL-6 by ~40% and IL-8 by ~40%; P<0.05) and lowered expression of the endoplasmic reticulum stress marker CHOP (by ~30-40%; P<0.05), but they did not prevent apoptosis. In palmitate-exposed islets the beneficial effects of the bromodomain inhibitors were less marked, with only a significant decrease of CXCL1/mRNA expression (~40%; P<0.005). 

**Conclusion:** Key inflammation-induced molecular mechanisms are shared between β-cells and brain in autoimmune and degenerative diseases. We identify bromodomain inhibitors as agents that may be repositioned to decrease islet inflammation. 

**Supported by:** Welbio-FNRS/WELBIO-CR-2019C-04; INNODIA (115797); INNODIA HARVEST (945268)

**Disclosure:** X. Yi: None.
Sorla is an endocytic receptor for pro-islet amyloid polypeptide and is protective against islet amyloid formation

A.Z.L. Shih1,2, Y.C. Chen3,4, C.B. Verchere1,4, T.E. Willnow1,2;
1Max-Delbrück-Center for Molecular Medicine, Berlin, Germany,
2Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany,
3BC Children’s Hospital Research Institute and Centre for Molecular Medicine and Therapeutics, Vancouver, Canada,
4Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, Canada.

Background and aims: The neuronal sorting receptor SORLA has an established function in reducing amyloid burden in the brain by preventing accumulation of amyloid-beta peptides, the main amyloidogenic agent of amyloid plaques in Alzheimer disease. Recent single-cell transcriptomic analyses show that SORLA transcripts are expressed in pancreatic islet beta cells. However, the function of SORLA in islets have not been studied previously. We hypothesized that SORLA is also involved in amyloid formation in the pancreas through regulating islet amyloid polypeptide (IAPP).

Materials and methods: We studied the effects of SORLA deficiency on islet histopathology, beta cell function and glucose homeostasis in human IAPP transgenic mice. We tested binding interactions between SORLA ectodomain with pro- and mature mouse IAPP peptides using microscale thermophoresis. Using established cell lines and primary islet cells, we further examine the mechanisms in which SORLA participates in the accumulation of IAPP.

Results: SORLA deficiency in human IAPP transgenic mice significantly increased the amount of islet amyloid deposits compared to wildtype controls (WT 0.56±0.16% vs KO 6.9±1.8% Thioflavin S positive islet area, n=9). This was accompanied with increased islet cell death (WT 1.4 ±0.6% vs KO 3.3±1.4% TUNEL positive cells, n=9). However, overall islet area, proportions of alpha and beta cells per islet remained comparable between SORLA genotypes. Interestingly, SORLA ectodomain showed stronger binding affinities to the two pro-forms of IAPP (pro-IAPP1-51 Kd ~ 268±43 nM, pro-IAPP1-70 Kd ~ 329±29 nM) as compared to mature IAPP (Kd ~ 921±177 nM). Additional studies on SORLA-overexpressing cell line demonstrated that SORLA mediated endocytosis of proIAPP peptides, but not mature IAPP, towards the endolysosomal pathway.

Conclusion: These findings demonstrated a protective role of SORLA against islet amyloid deposition, likely through clearance of extracellular proIAPP secreted by beta cells.

Supported by: ERC, Novo Nordisk Foundation, CIHR, JDRF
Disclosure: A.Z.L. Shih: None.
Neighborhood and aims: Hypoglycaemia causes activation of the immune system and is linked to an increased risk for cardiometabolic disease. We set out to determine how glycaemic parameters based on continuous glucose monitoring (CGM) affect the immune response to a hypoglycaemic event.

Materials and methods: 38 individuals with type 1 diabetes (M:F ratio 21:17, age 51±28 years, BMI 26±6 kg/m2, diabetes duration 22±25 years, HbA1c 8.0±1.3%) were recruited. Participants underwent a hyperinsulinaemic-normoglycaemic (5.2±0.1 mmol/L) hypoglycaemic (2.7±0.0 mmol/L) glucose clamp. Venous blood was drawn during the normoglycaemic phase, during the hypoglycaemic phase, and one day after the clamp to measure circulating immune cell composition and inflammatory markers. CGM data from 6 days prior to the clamp experiment were used to assess the relation between glucose variance (CV), time above range (TAR), and time below range (TBR) with immune responses to experimental hypoglycaemia.

Results: At baseline, glucose variability (CV) was positively associated with circulating granulocyte counts (p < 0.05). Participants with TBR above median had lower circulating immune cell counts as compared with those with low TBR (p < 0.05). Hypoglycaemia induced by the clamp caused inflammatory responses in all participants, as illustrated by increased levels of circulating monocytes (p < 0.01), lymphocytes (p < 0.01), and inflammatory proteins like CRP (all p < 0.05), which were sustained until one day after the clamp. Post clamp, CV was associated with increased inflammatory responses to hypoglycaemia, as reflected by the levels of circulating inflammatory proteins CRP (p < 0.01), TNFRSF9 (p < 0.05), and IL-17C (p < 0.05). TBR was positively correlated with increased circulating granulocytes (p < 0.01) and lymphocytes (p < 0.05). TBR was negatively associated with the increase in circulating granulocytes (p < 0.05), lymphocytes (p < 0.05), and IL-6 (p < 0.01) in response to hypoglycaemia.

Conclusion: Glycaemic parameters based on CGM impact on the immune response to hypoglycaemia, with the TBR having an attenuating effect and the TAR a stimulating effect on hypoglycaemia-induced inflammation. Future studies are needed to identify drivers of these altered responses.

Clinical Trial Registration Number: NCT 03 97 62 71
Supported by: This work was funded by the Innovative Medicines Initiative 2 Joint Undertaking nr 777460
Disclosure: M. Ajie: None.
pathogenesis of several autoimmune diseases. Our aim was to study the NET proteome (NETome) and bioenergetics profile of T1D neutrophils. **Materials and methods:** Peripheral blood neutrophils isolated from people with longstanding T1D (n=4; 14±7 years at T1D onset; 12±10 years disease duration; 133±37 mg/dl random glycaemia) and sex- and age-matched healthy controls (HC, n=3) were stimulated with phorbol-myristate acetate (PMA, 100 nM) or ionomycin (20 μM) for 3 hours. NETome was studied by LC-MS/MS analysis, while metabolic changes during NETosis were explored by a Seahorse extracellular flux analyzer.

**Results:** Levels of PMA- and ionomycin-stimulated NETosis were comparable in HC and T1D neutrophils (PMA: 85% vs 90%; ionomycin: 63% vs 77% respectively), as well as plasma levels of NET markers. In the PMA-stimulated NETs, a total of 370 proteins were identified in both subjects, with 70 and 22 unique to HC and T1D subjects, respectively. Upon ionomycin stimulation, we identified 321 proteins, 53 and 21 of which were unique to HC and T1D subjects, respectively. In both stimulated conditions, the NET proteins of HC and T1D subjects were found to be involved in identical biological processes and similar molecular functions. However, upon quantification with Progenesis QI software, a total of 44 proteins were differentially expressed in the NETomes of HC and T1D subjects when stimulated with PMA. Ionomycin-induced NETomes contained 27 differentially expressed proteins (1% FDR, P<0.05). Reactome analysis revealed that the proteins enriched in HC NETomes in PMA- and ionomycin- stimulated conditions were involved in neutrophil degranulation and innate immunity. In both stimulated conditions, proteins enriched in T1D NETomes were involved in glucose metabolism, such as glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, fructose-bisphosphate aldolase A, and UTP-glucose-1-phosphate uridylytransferase. Superimhetics from unstimulated and PMA- or ionomycin-stimulated T1D neutrophils contained higher levels of lactate, a byproduct of glycolysis, than HC subjects. PMA induced a similar increase in mitochondrial respiration (reported as oxygen consumption rate, OCR) in both HC and T1D neutrophils, which demonstrated little responsiveness to ionomycin stimulation. On the other hand, both PMA and especially ionomycin induced an increase in the extracellular acidification rate (ECAR), an approximate measure for lactate production by anaerobic glycolysis, with higher levels in T1D compared to HC neutrophils.

**Conclusion:** Together these data suggest possible alterations in the metabolic profile of T1D neutrophils, which can provide vital insight into their role in the pathophysiology of the disease.

**Supported by:** This work was supported by IMI-JU INNODIA & INNODIA HARVEST

**Disclosure:** S. Bissenova: None.

---

**407**

**Phase I study investigating PK and PD of highly concentrated insulin aspart AT278 U500**


1Medical University of Graz, Graz, Austria, 2HEALTH - Institute of Biomedicine and Health Sciences, Graz, Austria, 3Areco Limited, Cambridge, UK.

**Background and aims:** Concentrated insulins allow administration of high insulin doses in a smaller volume. This enables a reduction in the number of injections for people with diabetes with high insulin needs and supports miniaturisation of insulin delivery devices. The aim of the study was to compare the PK-PD profile of a novel formulation of insulin aspart (AT278 U500/mL) with that of standard insulin aspart (IAsp U100/mL). The qualitative interviews will provide insights from families and stakeholders to understand their experiences and feedback from the screening study.

**Results:** For feasibility, we will report on recruitment, relative uptake by demographics and by recruitment modality, frequencies of autoantibody positive and negative children, sensitivity and specificity of the dried blood spots, and distress experienced from a positive screening result. For acceptability, we will report on emerging themes from the qualitative interviews. Long-term follow-up will reveal type 1 diabetes incident cases and episodes of diabetic ketoacidosis following the screening study.

**Conclusion:** The outcomes of the ELSA study will determine feasibility and acceptability of autoantibody testing for type 1 diabetes in the UK. The qualitative interviews will provide insights from families and stakeholders to optimise the processes for autoantibody testing, and the screening study will identify at-risk individuals who could benefit from preventative immunotherapy trials. The ELSA study supports progress towards establishment of UK national screening for type 1 diabetes.

**Supported by:** The ELSA study is funded by NIHR, DUK and JDRF and alumni of The Birmingham General Hospital, UK.

**Disclosure:** L.M. Quinn: None.
higher insulin exposure within the first 30 min after dosing (AUC\text{Insulin,0-30min}; 95% CI: 3.29; 4.90). AT278 showed a more rapid onset of glucose-lowering effect compared with IAsp, as demonstrated by an earlier onset of action (-9.5 min, P<0.0001) and earlier t\text{Early50%GIRmax} (-20.0 min, P<0.0001) and 8.9 times higher insulin action within the first 30 min after dosing (AUC\text{GIR,0-30min}; 95% CI: 5.96; 17.46). Overall insulin exposure and action were comparable between both insulins (AUC\text{Insulin,0-9h treatment ratio} 0.98 [95% CI: 0.92; 1.00]; AUC\text{GIR,0-9h treatment ratio} 1.02 [95% CI: 0.95; 1.09]).

**Conclusion:** AT278, the novel U500 insulin aspart, maintains rapid-acting characteristics in a reduced dose volume. AT278 has the potential to enable dosing at the start of a meal, to reduce injection burden and thus to improve blood glucose management and convenience for people on high-dose insulin therapy.

**Background and aims:** An unusual high prevalence of stress hyperglycemia (SH) has been reported in hospitalized patients with COVID-19. Cytokine storm has been supposed to have a pivotal role in worsening insulin resistance, damaging beta-cells thus causing stress hyperglycemia. Further SH is associated with worse outcomes. With this study we aimed to evaluate the existing relationships between main actors of the “cytokine storm” and SH in 150 hospitalized patients with Covid-19.

**Materials and methods:** This is a cross- sectional analysis of GIRA-COVID database that was a prospective, observational study conducted in 2021 at the University of Udine. For assessment of SH, we calculate Stress Hyperglycemia ratio (SHR) defined by the ratio of admission glucose to the estimated average glucose derived from glycated hemoglobin. Patients were considered to have SH when SHR were >1.14. Values of normally distributed variables are expressed as mean ± standard deviation or median and interquartile range. Normality of distribution was assessed by the Kolmogorov-Smirnov test. Association between stress hyperglycemia and outcomes were evaluated by multivariate logistic regression model. Multivariate logistic regression analysis was performed to identify what cytokines were independent predictors of stress hyperglycemia.

**Results:** Main clinical and laboratory data are summarized in table 1. As expected patients with SH had an increased risk of mechanical ventilation and dead (OR 2.453 IC 1.078-6.010 and OR 2.781 IC 1.049 7.369) independently from the presence of diabetes and after correction for age, sex, BMI and severity of disease. Univariate analysis showed that SH were directly associated with CXCL10 (beta = 0.486; P < 0.001), IL-10 (beta = 0.409; P = 0.000), IL10/TNF alfa (beta 0.330 P 0.012). In multivariate logistic regression model log CXCL10 (OR 14.5 IC 2.5-77) log IL-10 (OR 6.7 IC 1.9-24) and IL10/TNF alfa (OR 1.5 IC 1.1-2.2) resulted independent predictors of stress hyperglycemia after correction for Age, Sex, Diabetes status, CPR and Severity of disease.

**Conclusion:** In our study SH was associated with poor outcomes independent from diabetes. Among Cytokines, CXCL10, IL-10 and IL10/ TNF alfa were associated with SH. CXCL10 have shown to be an important mediator of beta-cell apoptosis in experimental models, thus our data support that CXCL10 may have an important role in the pathogenesis of COVID-19 related stress hyperglycemia. Further SH was associated with high IL10/TNF alfa ratio, well know marker of immunoparalysis. This association could partially explain the excess of mortality seen in patients with COVID-19 and stress hyperglycemia.

**Disclosure:** E. Svehlikova: None.

408

**Relationships between cytokine storm and stress hyperglycaemia in hospitalised patients with COVID-19**

A. Da Porto1, G. Colussi1, C. Tascini2, M. Fabris3, E. Sozio2, M. Peghin2, F. Curcio3, C. Catena1, L. Sechi1; 1Internal Medicine, Clinica Medica, University of Udine, 2Medicine, Infectious Disease, University of Udine, 3Medicine, Laboratory Medicine, University of Udine, Udine, Italy.

**Clinical Trial Registration Number:** NCT04660305

**Disclosure:** A. Da Porto: None.
Impact of the COVID-19 lockdown on behaviour, stress, anxiety and glycaemic control in patients with beta cell transplantation for type 1 diabetes

C.P. Landstra1, M.M. Ruissen1, H. Regeer1, M.F. Nijhoff1, B.E.P. Ballieuex, P.J.M. van der Boog1, A.P.J. de Vries1, S.D. Huismann1, E.J.P. de Koning1

1Internal Medicine, Leiden University Medical Centre, 2Clinical Chemistry and Laboratory Medicine, Leiden University Medical Centre, Leiden, Netherlands.

Background and aims: Patients with severely complicated type 1 diabetes (T1D) who receive β-cell transplantation (Tx) have multiple risk factors for a severe course of coronavirus disease, including the use of immunosuppressive agents (IS). Lockdown strategies implemented due to the COVID-19 pandemic are known to impact both mental and physical health, but this impact is expected to be even greater in patients at high risk for a severe course of COVID-19. We therefore aimed to investigate the behavioural, mental and physical implications of the nationwide lockdown in islet and pancreas transplant recipients (referred to in this abstract as β-cell Tx).

Materials and methods: In order to study the effect of the lockdown on glycaemic control, all patients with T1D and an islet transplantation or pancreas transplantation with non-optimal graft function according to the Igs criteria using IS were eligible. As a control group, patients with T1D without IS were included. Lockdown behaviour and self-reported changes in anxiety, stress, physical activity, weight, and glycaemic control were assessed using questionnaires. HbA1c and continuous glucose monitor (CGM) metrics during lockdown were compared to measurements before lockdown.

Results: Islet and pancreas (β-cell) Tx recipients (n=51, age 55 (48 - 59) years, BMI 23.3 (20.9 - 27.4) kg/m², diabetes duration 42 (34 - 48) years) adhered more stringently to lockdown measures compared to patients with T1D alone (n=272, age 53 (37 - 62) years, BMI 25.2 (23.0 - 28.0) kg/m², diabetes duration 27 (15 - 39) years). In β-cell Tx recipients as compared to T1D, 52.1% vs 18.3% (p <0.001) reported not going out for groceries and 45.8% vs 14.0% (p <0.001) reported not leaving the house at all. Fear of coronavirus infection was higher in β-cell Tx recipients (VAS 5.0 (3.0-7.0) vs 3.0 (2.0 - 5.0), p=0.004) and glycaemic control worsened during lockdown as assessed by HbA1c (ΔHbA1c +1.67±8.74 vs -1.72±6.15 mmol/mol, p=0.006) as well as CGM (Δ time in range β-cell Tx -4.5% (-6.0% - 1.5%) vs T1D 3.0% (-2.0% - 6.0%), p=0.038; Δ time above range β-cell Tx 5.5% (-0.5% - 7.5%) vs T1D -3.0% (-7.5% - 3.0%), p=0.025). Among β-cell Tx recipients, 29.2% self-reported more difficulty with glycaemic control, 26.8% increased insulin use, 40.0% less physical activity, 41.7% weight gain, 29.2% increased anxiety and 33.3% increased stress since the start of lockdown. Having had a β-cell Tx was the most important predictor of not leaving the house during the COVID-19 lockdown.

Conclusion: Islet or pancreas transplantation (β-cell Tx) in patients with type 1 diabetes leads to additional fear of infection, more stringent social isolation behavior and deterioration of glycemic control during the COVID-19 pandemic and the subsequent lockdown. In fact, having had a β-cell transplantation was the most important determinant of social isolation during the COVID-19 lockdown. In addition, these patients experience high rates of stress and anxiety, decreased physical activity and weight gain which requires continuous awareness amongst health care professionals.

Disclosure: C.P. Landstra: None.

SO 20 The other diabetes and islet function

Single-cell sequencing reveals preserved pancreatic islet cell identity by administration of metabolite-based diet in autoimmune diabetes

V. Vandenbempt1, S.E. Eski2, M.K. Brahma1, A. Li3, S. Demine4, P. Xiao5, A.K. Cardozo6, S.P. Singh7, E. Mariño8, C. Gysemans9, E.N. Gurzov1

1Signal transduction and metabolism laboratory, Université Libre de Bruxelles, Anderlecht, Belgium, 2IRIBHM, Université Libre de Bruxelles, Anderlecht, Belgium, 3Immunological and Cell Death Signaling in Diabetes, Université Libre de Bruxelles, Anderlecht, Belgium, 4Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Melbourne, Australia, 5Clinical and Experimental Endocrinology, Department of Chronic Diseases, KU Leuven, Leuven, Belgium.

Background and aims: An altered gut bacterial composition is associated with the pathogenesis of type 1 diabetes (T1D) and short-chain fatty acids (SCFA) are known play a pivotal role in maintaining gut homeostasis. A special diet based on high-amylose maize-resistant starch modified with butyrate and butyrate metabolites (HAMSAB) provided protection from autoimmune diabetes in the NOD mouse model. We recently tested the HAMSAB diet in patients with established T1D showing improvement in glucose control. Based on these findings, we studied the molecular mechanisms and effects of SCFA in pre-diabetic pancreatic islets.

Materials and methods: EndoC-βH1 and INS-1B β-cell lines were treated with acetate (250μM), butyrate (10μM) and/or IFN-γ (1,000U/ml) + IL-1β (50U/ml). The cell viability was analyzed using SYTOX™ Green Nucleic Acid Stain assay. Five-week-old female NOD mice were fed with HAMSAB or HAMS control diet for five consecutive weeks. The pancreata were harvested, islets isolated using collagenase, and dispersed into single cells by trypsin. Single-cell RNA (scRNA)-sequencing was performed with 10x Chromium. The raw counts were analyzed using RStudio with the Seurat package. The cells were filtered based on RNA features, counts, and mitochondrial percentage and annotated by their principal component analysis using UMAP.

Results: Physiological concentrations of acetate and/or butyrate showed minimal effects on pro-inflammatory cytokine-induced cell death in EndoC-βH1 and INS-1B β-cell lines, suggesting that improved β-cell function is not due to SCFA-induced β-cell survival. To study the effect of the gut metabolites in the endothelial cells, we performed scRNA-seq in pancreatic islets isolated from pre-diabetic NOD mice fed HAMSAB or HAMS diets for five weeks. scRNA-seq analysis mapped the gene expression profiles of 4,301 and 4,113 individual islet cells from HAMSAB or HAMS fed mice, respectively. Cells were annotated into 12 clusters: 5 immune and 7 pancreatic endocrine cell types. The scRNA-seq dataset indicated that T-cells, B-cells, macrophages, and dendritic cell subsets infiltrated the islets of Langerhans from both HAMSAB and HAMS-fed mice. Interestingly, HAMSAB reduced the number of CD8+ cytotoxic cells, in line with previously described tolerogenic effects. Moreover, subclustering and differential gene expression analysis indicated that HAMSAB enhances β-cell function and decreases their stress response. In addition, the HAMSAB preserved the identity of endocrine cells evaluated by decreased dedifferntiated poly-hormonal (Ins+Gluc, Ins+Sst) cells expressing endocrine progenitor genes (MafA, Nfix) in mice fed this diet.

Conclusion: The HAMSAB diet prevents diabetes development in NOD mice, at least in part, by enhancing β-cell function and preserving cell identity of endocrine cells under inflammatory-mediated autoimmune stress.

Clinical Trial Registration Number: ACTRN12618001391268
Supported by: F.R.S-FNRS PhD Aspirant Scholarship, ERC Consolidator Grant, JDRF Career Development Award
Disclosure: V. Vandenbempt: None.
411 Immunoreactivities against different tyrosine-phosphatase 2 (IA-2) epitopes characterise distinct clinical phenotypes in LADA
L. D’Onofrio, C. Tiberti, F. Panimolle, R. Amendolara, S. Zampetti, E. Maddaloni, R. Buzzetti;
Department of Experimental Medicine, “Sapienza” University of Rome, Rome, Italy.

Background and aims: Antibodies (Abs) against intracellular epitopes of the tyrosine-phosphatase 2 (IA-2) protein are detected in type 1 diabetes (T1D). In people with latent autoimmune diabetes in adults (LADA) IA-2 Abs are mainly directed against the IA-2(256-760) portion, which contains both intra- and extracellular amino acidic sequences. We aimed to evaluate if Abs against intra- and extracellular domains of IA-2 differ between LADA and T1D and whether they might intercept different immunoreactivities related to different clinical features in people with LADA.

Materials and methods: Subjects with LADA (n=101, male 55%) and T1D (n=61, male 59%), all testing positive for IA-2(256-760)Abs, were enrolled. The evaluation of immunoreactivity for three different IA-2 epitopes (IA-2(256-760), IA-2(605-630), and IA-2(605-979) Fragments) allowed to identify whether the immunoreactivity against the IA-2(256-760) was limited to the extracellular domain of the protein (group A: positive for IA-2(256-760) and negative for IA-2(605-979) and IA-2(605-630)) or involved also the intracellular domain (group B: positive for IA-2(256-760) and positive for IA-2(605-979) or IA-2(605-630) or both of them). Clinical and biochemical features were also collected in subjects with LADA.

Results: Immunoreactivity limited to the extracellular portion of IA2-protein was found in 59.4% of people with LADA and in 14.8% of people with T1D (p=0.001). Conversely, intracellular immunoreactivity was more frequent among people with T1D (85.2%) compared to LADA (40.6%). As shown in table 1, among people with LADA, those in group A were older (p=0.01), with higher age at onset of diabetes (p=0.008), higher BMI (p=0.005), waist circumference (p=0.008) and triglycerides (p=0.006), and lower fasting blood glucose (p=0.05) and HDL cholesterol levels (p=0.005) compared to people in group B. They were also more frequently affected by hypertension (group A 57.6% Vs group B 26.8%, p=0.002) and less frequently by other autoimmune diseases (group A 57.6% Vs group B 26.8%, p=0.006), and lower fasting blood glucose (p=0.05) and HDL cholesterol levels (p=0.005) compared to people in group B. They were also more frequently affected by hypertension (group A 57.6% Vs group B 26.8%, p=0.002) and less frequently by other autoimmune diseases (group A 57.6% Vs group B 26.8%, p=0.006). Compared to the controls, acinar atrophy in Group 1 was not significant (Group 1: mean ± SD inflammation score: 0.7 ± 0.5 control: 0 ± 0, p>0.05), However, as CF progresses into the end-stage there was a significant increase in acinar atrophy (Group 1: 1.4 ± 0.5 vs Group 2: 3.0 ± 0.0, p<0.001 and vs Group 3: 3.0 ± 0.0, p=0.01). Correspondingly, the number of islets progressed. In end-stage CF, activated fibroblasts were observed in the fibrotic regions of the tissue rather than regions with infiltrating adipocytes and surrounding some acinar cells (not significantly different from controls). Presence of some inflammatory cells was confirmed (Group 1: 1, O. Govaere 1, Y. Bury 2, R. Coulthard2, D. Tianiakos1,2,3, G. Klöppel4, J.A.M. Shaw1, 2, N. Kattner1;
1Cellular and Pathology, Newcastle University, Newcastle, UK, 2Cellular and Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, 3Department of Pathology, National and Kapodistrian University of Athens, Athens, Greece, 4Institute of Pathology TUM School of Medicine, Technical University of Munich, Munich, Germany, 5Institute of Transplantation, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.

Background and aims: Cystic fibrosis (CF) is the outcome of mutations in the CF transmembrane conductance regulator gene, which leads to impaired fluid secretions in the lungs and pancreas. CF-related diabetes (CFRD) is a common secondary complication of CF, yet the underlying pathogenesis of CFRD is not fully understood. This study aimed to analyse pancreatic histopathological changes in post-mortem CF tissue and to identify possible cellular players associated with these changes.

Materials and methods: Paraffin-embedded tissue blocks were obtained from the body of post-mortem CF pancreata (age range: premature-27 years old, n=8) and normal pancreas donors (age range: 18-29 years old, n=7). All tissue slides were stained for H&E, picro sirius red, CD45 and α-smooth muscle actin (α-SMA) to identify immune cells and activated fibroblasts respectively.

Results: The CF cohort displayed 3 different abnormal morphologies where early-stage CF represented a fibrotic pattern (Group 1, 7 blocks) and the end-stage CF demonstrated lipoatrophic (Group 2, 10 blocks) and fibrotic & lipoatrophic (Group 3, 8 blocks) patterns. Histopathological scoring (0: normal, 1: mild, 2: moderate and 3: severe) was performed for inflammation, acinar atrophy, ductal dilation/loss, insular atrophy and exocrine pancreas fibrosis, followed by statistical analysis using one-way ANOVA. Group 1 pancreata demonstrated the absence of duct dilation and adipocytes replacing the exocrine tissue, but there was evidence of some α-SMA+ activated fibroblasts in areas of increased collagen deposition and surrounding some acinar cells (not significantly different from controls). Presence of some inflammatory cells was confirmed (Group 1: mean ± SD inflammation score: 0.7 ± 0.5 control: 0 ± 0, p>0.05). Compared to the controls, acinar atrophy in Group 1 was not significant (Group 1: 1.4 ± 0.5, control: 0.4 ± 0.5, p>0.05). However, as CF progresses into the end-stage there was a significant increase in acinar atrophy (Group 1: 1.4 ± 0.5 vs Group 2: 3.0 ± 0.0, p<0.001 and vs Group 3: 3.0 ± 0.0, p=0.01). Correspondingly, the number of islets decreased and surviving islets embedded in a pool of fatty or fibrotic tissue appeared more atrophic with irregular morphology and abnormal size and evidence of peri-islet activated fibroblasts as disease pathology progressed. In end-stage CF, activated fibroblasts were observed in the fibrotic regions of the tissue rather than regions with infiltrating adipocytes and this correlated with significant presence of inflammatory cells (Group 2: 2.2 ± 1.0; Group 3: 1.9 ± 1.0; control: 0.0 ± 0.0, p<0.001). Additionally, ductal dilation and exocrine fibrosis in Group 2 were not observed but extensive ductal loss was more apparent. Greatest duct dilation was observed in Group 3.

Conclusion: As CF progresses, pancreata undergo architectural remodelling including acinar and insular atrophy. Fibrotic changes are associated with inflammation and activated fibroblasts, possibly impacting on islet morphology.

Disclosure: Y. Al-Selwi: None.

Supported by: PRIN 2017: 2017L9H7H
Disclosure: L. D’Onofrio: None.
413

Insulin and glucagon doublepositive cells in islets from pancreatic resections of children with congenital hyperinsulinism

J. Schultz1, C. Wolke2, R. Waterstradt1, F. Dombrowski1, W. Bartlen4, M. Tiedge1, U. Lendecke1, S. Baltrusch1;
1Institute of Medical Biochemistry and Molecular Biology, Rostock, 2Institute of Medical Biochemistry and Molecular Biology, Greifswald, 3Institute of Pathology, University Medicine, Greifswald, 4Clinic of Pediatric Surgery, University Medicine, Greifswald, Germany.

Background and aims: Congenital hyperinsulinism (CHI) is a rare disorder characterized by severe postnatal hypoglycemia. The disease can lead to cerebral damage to the child due to uncontrolled insulin secretion, making rapid diagnosis and treatment necessary. Mutations in the ABCC8 and KCNJ11 genes have been associated with the disease but cannot causally explain the alteration. In pancreatic sections, the focal area appears as a region in which individual islets are barely recognizable and insulin-positive cells predominate. Therefore, the aim of this study was to take the next step and examine isolated islets of children from resection specimens in vivo in whom partial pancreatic resection was required because of failure of drug therapy.

Materials and methods: Pancreatic islets were isolated by collagenase digestion from focally presenting resection samples of four children who were between 2 and 12 months of age at the time of surgery. Islets were cultured on PPA slides for 4 days, resulting in outgrowth of cells. Insulin and glucagon were determined in the supernatant every 2 days by ELISA. The islets were then analysed for glucose-dependent intracellular calcium response using FURA. Finally, islets were fixed and investigated for insulin and glucagon localisation and content by immunofluorescence. Gene expression of insulin and glucagon was determined by RT-PCR.

Results: Insulin secretion was significantly 5-fold higher in islets from the focally resected area than in islets from the healthy peripheral area. While islets from the healthy peripheral area responded with a calcium increase to the glucose stimulus like adult human islets, islets isolated from the focus showed only oscillations. However, islets of children who were younger at the time of surgery showed an overall lower calcium and insulin response. These islets exhibited a high degree of heterogeneity with respect to alpha and beta cells. In addition to a varying proportion of insulin and glucagon positive cells, cells producing both hormones were detected.

Conclusion: Thus, the severity of the manifestation of CHI seems to be largely dependent on the stage of development of the endocrine pancreas. Thus, markers of early and late pancreatic development should be further investigated. Our results may also explain the large differences between CHI patients in response to drug and surgical therapy. The investigation of older and cured CHI patients, especially those after pancreatectomy, would thus also provide information on new therapeutic approaches for type 2 diabetes mellitus.

Disclosure: J. Schultz: None.

414

Investigating the role of a novel MODY-associated gain-of-function mutation in TALK-1 in islet dysfunction and glucose intolerance

A.Y. Nakhe1, J. Kim2, P.K. Dadi1, K.E. Zaborska3, D.A. Jacobson1;
1Molecular Physiology and Biophysics, Vanderbilt University, 2Chemistry, Vanderbilt University, Nashville, USA.

Background and aims: TALK-1, the most islet-restricted and abundantly expressed K+ channel of the human -cell is a key regulator of electrical activity and glucose-stimulated insulin secretion (GSIS). Recently we identified a gain-of-function (GOF) mutation near the pore domain of TALK-1 (Leu114Pro) that segregates with Maturity-Onset Diabetes of the Young (MODY) in an autosomal dominant manner, but only in a single family. The present study aimed to confirm TALK-1-Leu114Pro as the mutation that causes the MODY phenotype and investigate the impact of TALK-1 GOF on glucose homeostasis.

Materials and methods: A mouse model containing the TALK-1-Leu114Pro mutation was generated utilizing CRISPR-SpCas9 editing in the C57BL/6J background. Whole-cell currents and β-cell membrane potential (V_m) were recorded using patch-clamp electrophysiology. Intracellular Ca2+ handling was monitored using fluorescence microscopy, islet hormone secretion was measured using ELISAs and islet composition was studied by immunofluorescence staining.

Results: Interestingly, heterozygous TALK-1-Leu114Pro C57BL/6J mice and homozygous TALK-1-Leu114Pro CD-1(ICR) mice exhibit neonatal lethality; this may be due to alterations in islet hormone secretion during neonatal development, as homozygous TALK-1-Leu114Pro CD-1(ICR) neonates were severely hyperglycemic. However, the neonatal hyperglycemia was transient and eventually followed in adults by glucose intolerance. We next determined how TALK-1-Leu114Pro affects electrical activity and found blunted glucose-induced β-cell action potential firing due to a GOF in whole-cell TALK-1 currents. The hyperpolarizing TALK-1-Leu114Pro current also resulted in blunted -cell glucose-stimulated Ca2+ entry and Ca2+ oscillations (Ca2+ AUC (a.u.); Wildtype (WT) islets=213; N=5 mice and TALK-1-Leu114Pro+/-islets=10.01; N=3 mice, P=0.0008). On the endoplasmic reticulum (ER) membrane, TALK-1-Leu114Pro decreased basal [Ca2+]ER levels and enhanced IP3-induced Ca2+ release (Acetylcholine-stimulated [Ca2+]ER Release AUC (a.u.); WT=26.83; N=4 mice and TALK-1-Leu114Pro+/-=37.84; N=4 mice, P<0.0001). Islets with TALK-1-Leu114Pro showed decreased GSIS which resulted in reduced plasma insulin levels in TALK-1-Leu114Pro+/- mice. This suggests that the defect in islet Ca2+ handling and GSIS in TALK-1-Leu114Pro+/- mice results in an impairment in glucose homeostasis (ip GTT AUC: WT=12,721; N=8 mice and TALK-1-Leu114Pro+/-=4,257; N=4 mice, P=0.0038). However, TALK-1 activity in other islet cell types may also contribute to glucose dyshomeostasis in TALK-1-Leu114Pro+/- mice. For example, pancreatic α-cell area and islet glucagon secretion are increased TALK-1-Leu114Pro+/- mice. This area increase is accompanied by decreased GSIS. In adult mice, TALK-1-Leu114Pro+/- mice (α-cell area/islet (a.u.): WT=22.17; N=3 mice and TALK-1-Leu114Pro +/-=9.562; N=3 mice, P=0.0072 and glucagon secretion at 2mM glucose in pg/ml/islet: WT=3.58; N=3 mice and TALK-1-Leu114Pro+/-=1.35; N=3 mice, P=0.0072).

Conclusion: Taken together, this study shows that the MODY-associated TALK-1-Leu114Pro mutation disrupts glucose homeostasis in adult mice (which resembles a MODY phenotype) and causes neonatal lethality by potentially altering islet hormone secretion during development. Overall, these data strongly suggest that TALK-1 is an islet-restricted target for the treatment for diabetes.

Supported by: R01DK115620

Disclosure: A.Y. Nakhe: None.

415

The glucocorticoid dexamethasone strongly induces ZBTB16 expression in human insulin-secreting beta cells

A. Karagiannopoulos1,2, E. Westholm1,2, J. Ofori3,2, E. Cowan1,2, J. Esquerra1,2, L. Eliasson1,2;
1Islet Cell Exocytosis, Department of Clinical sciences, Lund University, 2Department of Clinical sciences, Skåne University Hospital, 3Epigenetics, Department of Clinical sciences, Lund University, Malmö, Sweden.

Background and aims: Glucocorticoids (GCs) are widely prescribed anti-inflammatory and immunosuppressant drugs. However, chronic or high-dose administration has been associated with diabetes onset. GCs have been found to contribute to β-cell dysfunction via activation of the Glucocorticoid Receptor (GR), and subsequent regulation of target genes, though the exact molecular mechanisms are still unclear. Previous RNA-seq data and bioinformatics analysis has shown the transcription factor
zinc finger and BTB domain-containing protein 16, ZBTB16, to be the most potent target gene of GR upon glucocorticoid treatment in β-cells. Here, we aim to investigate the conditions under which the expression of ZBTB16 is regulated with GC treatment and its potential role in β-cell function.

**Materials and methods:** All experiments were performed in human EndoC-βH1 cells with the synthetic glucocorticoid dexamethasone (Dexa). Gene and protein expression were measured with RT-qPCR and Western Blot analysis, respectively. Insulin secretion stimulated with glucose (1 or 20 mM) and 500 nM IBMX was analyzed with ELISA. Overexpression (OE) and knockdown (KD) of the ZBTB16 gene was induced via appropriate expression plasmid vector or siRNA. Chromatin immunoprecipitation (ChIP) and PCR were performed to validate GR binding sites on the ZBTB16 using an anti-GR antibody. All experimental data were analyzed by unpaired t-test, 1- or 2-way ANOVA.

**Results:** ZBTB16 expression was elevated dose-dependently with increasing Dexa concentration after treatment for 24h (0.1-1000nM). Moreover, when applying a time-dependent protocol (100 nM Dexa; 2, 8, 24, 48h) ZBTB16 expression was significantly induced within 8h (N=4, p=0.006), with a tendency towards elevated expression after 2h. The induction remained stable also after 48h. At the same time point (48h) insulin secretion at high glucose was significantly reduced compared to the treated control (N=4, p = 0.002), but overexpression of ZBTB16 alone did not affect insulin secretion or cellular apoptotic processes. To demonstrate a potential protective role of ZBTB16, we measured the expression of a key β-cell transcription factor, PDX-1 upon ZBTB16 KD in presence of Dexa. Dexa alone have earlier been shown to reduce the expression of PDX-1. Interestingly, combining ZBTB16 KD and Dexa further reduced PDX-1 expression as compared to the Dexa treated control (N=3, p=0.03). Moreover, by integrating publicly available ChIP-seq data, we identified 10 intronic sites on the ZBTB16 gene and performed validation by ChIP assay (N=3). Despite displaying a stronger binding pattern in the majority of the positions, there was no clear differential binding on the ZBTB16 gene between control and GC-treated EndoC-βH1 cells.

**Conclusion:** Although ZBTB16 expression is strongly and rapidly induced in EndoC-βH1 cells upon dexamethasone treatment, ZBTB16 is not likely directly implicated in GC-mediated β-cell dysfunction. Consequently GC-ZBTB16 co-treatment may have potential as a future strategy to alleviate diabetes associated with GC treatment.

**Supported by:** Swedish Research Council, SRA-Exodiab, Swedish Foundation for Strategic Research (LUDC-IRC)

**Disclosure:** A. Karagiannopoulos: None.

417 Mechanistic investigation into the role of type 2 diabetes-associated STARD10 in insulin secretion and pancreatic beta cells

**W. Tan**1,2, N. Amiruddin1,2, M. Hul1, S. Muralidharan2, P. Banke2, F. Torta3, N.H.J. Ng 1, G.A. Rutter 3,4, A.K.K. Teo2,1; 1Institute of Molecular and Cell Biology, A*STAR, Singapore, Singapore, 2Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, 3Imperial College London, London, UK, 4CHUM Research Centre, University of Montreal, Montreal, Canada.

**Background and aims:** Type 2 diabetes (T2D) risk-associated variants have been identified at the STARD10 locus and these non-coding variants are linked to poorer β-cell function and lower STARD10 expression in human islets. STARD10 is a lipid transfer protein that has been shown to mediate intracellular trafficking of various phospholipids between lipid vesicles. Notably, global StarD10 knockout (KO) mice had defective glucose tolerance and glucose-stimulated insulin secretion (GSIS). However, the mechanisms of how STARD10 regulates insulin secretion in β cells are still unclear. Hence, in this study, we aim to investigate the role of STARD10 in pancreatic β cells.

**Materials and methods:** The STARD10 gene was deleted in MEL-1 human embryonic stem cells (hESCs) using the CRISPR-Cas9 system and these cells were differentiated into β-like cells. Flow cytometry, transcriptomic and lipidomic analyses were carried out on these cells.

**Results:** Compared to the isogenic control, STARD10 KO β-like cells expressed lower levels of INS and had a lower percentage of insulin2 cells (p < 0.05). Transcript analysis revealed that STARD10 KO β-like cells also had lower expression of cell cycle genes such as MKI67, CCNA2, CCNB1, CCNB2, CCNE1 and CCNE2 (p < 0.05). Consistently, flow cytometry analysis then demonstrated that STARD10 KO β-like cells had lower percentage of Ki67+ cells (p < 0.05). Our findings suggest that STARD10 could be regulating β cell proliferation. To identify lipid targets of STARD10 in β cells, lipidomic analysis was performed and we found that STARD10 KO β-like cells had more than twice the amount of intracellular triglyceride levels as compared to the isogenic control (p < 0.05). In line with this, we also observed an almost complete loss of ETPB expression (p < 0.05), a mitochondrial protein that transfers
electrons to the mitochondrial respiratory chain for fatty acid oxidation, in STARD10 KO β-like cells.

**Conclusion:** As triglyceride accumulation in β cells could affect GSIS, our findings indicate that the loss of STARD10 may impair GSIS by increasing intracellular triglyceride levels with ETFB as one of the downstream mediators. The loss of STARD10 can therefore impair β cell function and expansion, contributing to increased T2D risk.

**Supported by:** NMRC OF-YIRG

**Disclosure:** W. Tan: None.

---

**SO 21 The fat burning the islets**

**418 Iset autotransplantation/total pancreatectomy vs pancreateoduodenectomy in patients at high risk for POPF: a prospective randomised trial**

L. Piemonti1,2, R. Melzi2, R. Nano2, A. Mercalli2, F. Aleotti1, G. Capretti4,5, A. Zerbì1, G. Balzano3; 1Università Vita Salute San Raffaele, Milan, 2Diabetes Research Institute, IRCCS Ospedale San Raffaele, Milan, 3Pancreas Translational & Clinical Research Center, IRCCS Ospedale San Raffaele, Milan, 4Pancreatic Surgery, IRCCS Humanitas Research Hospital, Rozzano, 5Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.

**Background and aims:** The benefit and safety of total pancreatectomy (TP) as alternative to pancreatectoduodenectomy (PD) for the treatment of cephalic pancreatic diseases remain controversial. TP does avoid anastomosis-associated morbidity, but is burdened by severe diabetes. The Islet Auto Transplantation in combination with TP (TPIAT) may mitigate this problem. The aim of this trial was to compare the outcomes of TPIAT with those of PD, when performed in patients at high risk for postoperative pancreatic fistula (POPF).

**Materials and methods:** In this randomized, open-label, controlled trial conducted in two high-volume pancreatic surgery centers in Italy, we recruited patients with a benign, premalignant, or malignant indication for PD and at high risk for POPF (i.e., soft pancreas and pancreatic duct diameter ≤3 mm). Eligible patients were randomly assigned (1:1) to undergo either PD or TPIAT. The primary endpoint of the study was the incidence of complications occurring within 90 days after surgery.

**Results:** Between October 2010 and September 2019, 61 patients were assigned to either PD (n=31) or TPIAT (n=30). In the intention-to-treat analysis, morbidity rate was 90.3% in PD and 60% in TPIAT (p=0.008). PD was associated with an increased risk of complications requiring medical [OR 7.64 (95% CI 1.35-43.3), p=0.022] or surgical treatment [OR 2.82 (95% CI 0.86-9.24), p=0.086]. The postoperative length of stay was shorter for TPIAT than for PD [median 10.5 vs 16.0 days; p<0.001] and a trend toward a reduced mortality was evident. TPIAT was associated with a higher risk to develop diabetes [HR 9.1 (95% CI 3.76-21.9); p<0.0001], but patients maintained good metabolic control and showed sustained C-peptide production over time.

**Conclusion:** TPIAT is safe, feasible and efficient and may become standard treatment in patients candidates for PD who are at high-risk for POPF.

**Clinical Trial Registration Number: NCT01346098**

**Supported by:** Italian Ministry of Health

**Disclosure:** L. Piemonti: None.

---

**419 Alterations of human islet G protein-coupled receptor expressomes in response to obesity**

Z. Lyu, M. Zhao, D. Hopkins, P. Atanes, S.J. Persaud; Department of Diabetes, King’s College London, London, UK.

**Background and aims:** G protein-coupled receptors (GPCRs) are key regulators of islet function and energy homeostasis, and they are the targets of many pharmacotherapies. Here, we have quantified GPCR mRNA expression in islets isolated from lean and obese human organ donors to determine whether islet GPCR expression is altered in obesity.

**Materials and methods:** RT-qPCR was used to quantify 384 non-olfactory GPCR mRNAs relative to five reference genes (ACTB, GAPDH, PPIA, TBP, and TFRC) in human islets isolated from lean (BMI=22.6 ±0.5 kg/m2, n=7) and obese (BMI=32±0.8 kg/m2, n=8) donors.
Results: GPR56 was the most highly expressed GPCR mRNA in islets from both obese and lean donors (obese: 0.136±0.024; lean: 0.106±0.020). Most of the abundant GPCR mRNAs displayed similar expression levels in islets from both obese and lean donors: e.g., FZD6 (obese: 0.047±0.007; lean: 0.031±0.003, NS), CXCR4 (obese: 0.040±0.003; lean: 0.037±0.006, NS), F2RL1 (obese: 0.039±0.006; lean: 0.046±0.008, NS), TAS2R45 (obese: 0.037±0.006; lean: 0.025±0.005, NS), F2R (obese: 0.038±0.010; lean: 0.027±0.011, NS). Overall, 197 and 256 GPCRs, accounting for 51.3% and 66.7% of 384 non-olfactory GPCRs, were expressed above trace level in human islets from lean and obese donors respectively, while 191 GPCR mRNAs were common to both lean and obese donor groups, 40.9% (n=157) and 27.1% (n=104) of the 384 GPCR mRNAs quantified were expressed at trace level (0.001% to 0.0001% expression compared to the five reference genes) in lean and obese donor islets. We also found that 7.8% (n=30) and 6.3% (n=24) of all quantified GPCRs were absent in islets from lean and obese donors, respectively. 117 GPCR mRNAs were upregulated at least 2-fold in islets from obese donors, and there was >2-fold downregulation of 21 GPCR mRNAs (Figure 1a). Of particular interest, as shown in Figure 1b, several receptors signalling via Gα or Gq coupled showed significant upregulation in islets from obese donors (RXFP1: 8.49±2.12-fold increase, p=0.021; PROKR2: 3.90±0.69-fold increase, p=0.0025; GPR110: 3.90±1.21-fold increase, p=0.041).

Conclusion: Under conditions of obesity human islets show significant alterations in mRNAs encoding numerous GPCRs. The increased expression of three Gα or Gq coupled receptors, which have not previously been investigated in β-cells, may lead to potentiation of insulin secretion and β-cell mass to regulate glucose homeostasis, which could circumvent the increased insulin resistance that occurs in obesity.

Disclosure: Z. Lyu: None.

420 Islet mRNA expression of GRKs, β-arrestins and RGS proteins in humans and mice under conditions of obesity

J. Starikova, P. Atanes, D. Hopkins, M. Zhao, S.J. Persaud; Department of Diabetes, King's College London, London, UK.

Background and aims: G protein-coupled receptors (GPCRs) regulate key β-cell functions, including insulin secretion, proliferation, and survival. GPCR activation and downstream signal transduction is tightly regulated by GPCR kinases (GRKs), β-arrestins, and regulator of G protein signalling (RGS) proteins, but little is known about their expression in islets and the influence of obesity on their expression. This study aimed to quantify mRNA expression of these regulatory proteins in MIN6 β-cells, and in mouse and human islets, and determine whether they are altered in obesity.

Materials and methods: Human islets were provided from the King’s Human Islet Isolation Laboratory from lean (BMI 22.2 ± 0.74 kg/m2; n=4) and obese (BMI 30.6 ± 0.61 kg/m2; n=4) non-diabetic cadaveric heart-beating donors. Mouse islets were isolated from 16-week-old C57BL/6 male mice that had been fed for 10-weeks on either standard chow (10% fat; weight: 30.6 ±0.7 g; n=4) or a high-fat diet (60% fat; weight: 47.6 ± 1.9 g; n=4). GRK, β-arrestin and RGS protein mRNA expression was determined by two-step SYBR-Green qPCR using validated primers and data are expressed relative to mRNA levels of the housekeeping gene β-actin.

Results: As expected, the phototransduction GRK mRNAs 1 and 7 were absent in human islets. GRK2, 3, 4 and 5 mRNAs were significantly upregulated in islets from obese donors (fold change, GRK2: 11.88±0.29, GRK3: 9.87±0.84, GRK4: 3.90±0.40, and GRK5: 4.25±0.49, p<0.05). Human islets expressed detectable levels of mRNAs encoding RGS1, 2, 4, 5, 7, 9, 10, 11, 12, 16, 17, 19 and 22, and RGS1 and RGS2 mRNAs were significantly decreased in obesity (fold change, RGS1: 4.12±0.66, and RGS2: 3.12±0.83, p<0.05). RGS6 (0.025±0.00054) and RGS2 (0.052±0.0048) were the most abundantly expressed GPCR regulator mRNAs in islets from lean donors, but this shifted to GRK2 (0.010±0.00025) and RGS4 (0.030±0.0064) in islets from obese donors. Mouse islets expressed mRNAs encoding Grk3, 5 and 6 and Rgs1, 2, 3, 4, 5, 7, 9, 10, 11, 12, 16 and 17, and there were no statistically significant differences in Grk or Rgs mRNA expression in islets from lean and obese mice. Grk3 was the most abundantly expressed Grk mRNA in islets from both lean (0.12±0.032) and obese (0.15±0.018) mice, as well as in MIN6 cells (0.027±0.0023). Rgs11 was the most highly expressed Rgs mRNA in lean (0.30±0.011) and obese (0.30±0.023) mouse islets, but Rgs4 was the most abundant (0.12±0.010) Rgs mRNA in MIN6 cells. Mouse and human islets and MIN6 cells expressed β-arrestin 1 and 2 mRNAs and there were no significant differences in expression under conditions of obesity. However, while βarr1 and βarr2 mRNAs were expressed at similar levels in human islets, βarr2 mRNA was more abundant than βarr1 in both mouse islets and MIN6 cells (p<0.05).

Conclusion: We have identified alterations in GRK and RGS mRNA expression in human islets related to obesity and have revealed differences between human and mouse islet responses to obesity. We have also demonstrated preferential expression of βarr2 mRNA in mouse islets and MIN6 cells, but not in human islets.

Supported by: MRC
Disclosure: J. Starikova: None.

421 Perilipin 2 protects against lipotoxicity-induced islet fibrosis by restoring islet stellate cells quiescence

Y. Zhou1, H. Wang1, Y. Wang1, Z. Sun2, J. Ma1; 1Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 2Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, School of Medicine, Southeast University, Nanjing, China.

Background and aims: We explored whether and how perilipin 2 protected islets function through against lipotoxicity-induced islet dysfunction by regulating islet stellate cell (ISC) activation.

Materials and methods: Six-week-old male rats were given a high-fat diet or a control diet for 28 weeks. Glucose metabolic phenotypes were assessed using glucose/insulin tolerance tests, masson and immunohisto-chemical staining. ISC activation levels were assessed from rats and palmitic acid (PA)-treated cultured ISCs by immunofluorescence, Oil red O staining, electron microscopy, quantitative PCR, and western blotting. Changes in ISCs phenotype of activation degree and its underlying mechanisms were assessed by target gene lentiviral infection, high performance liquid chromatography (HPLC), and western blotting.

Results: Obese rats showed glucose intolerance, decreased endocrine hormone profiles, and elevated expression of α-smooth muscle actin (α-SMA), a polygonal appearance without cytoplasmic lipid droplets (LDs) of ISCs in rats and isolated islets. PA-treated cultured ISCs exhibited faster proliferation and migration abilities with the induction of mRNA levels of lipid metabolism proteins, especially perilipin 2 (Plin2). The overexpression of Plin2 resulted in an ISC ‘re-quiescent’...

Supported by: MRC (MICINN), B2017/BMD-3684 (CAM), Spain.

Disclosure: None.

422

Short-chain fatty acids receptors modulate the function and plasticity of pancreatic alpha cells

Disclosure: Y. Zhou: None.

Background and aims: The intestinal microbiome can regulate the development of metabolic diseases, such as obesity or type 2 diabetes, through several metabolites. Among these, short-chain fatty acids (SCFAs) are the most abundant. In addition to acting as metabolic substrates, they can also signal through GPR41 (FFAR3) and GPR43 (FFAR2), G-protein-coupled receptors. Previous studies demonstrated that both receptors are expressed mainly in white adipocytes, immune cells and pancreatic β-cells. In the present study, we focused on the role of GPR41 and GPR43 on growth and function of pancreatic α-cells under both physiological and pro-obesogenic conditions.

Materials and methods: The experiments were carried out in the α-TC1.9 cell line and in isolated pancreatic islets of male Wistar rats fed a standard or high-fat (HF) diet for 12 weeks. The presence of GPR41 and GPR43 in pancreatic islet α-cells was determined by immunofluorescence and flow cytometry. The effect of specific agonists of GPR41 (AR420626) and GPR43 (PA) on genes underpinning α-cell identity was determined by RT-qPCR. GPR-mediated glucagon secretion was measured by ELISA and α-cell proliferation by in toto immunofluorescence of Ki67.

Results: Histological and flow cytometry analysis of rat islets confirmed that GPR41 and GPR43 colocalize with glucagon in α-cells. The treatment of α-TC1.9 cells with agonists of GPR41 and GPR43 increased the expression levels of Gcg (<0.001) and Pcsk2 (<0.05) but decreased Flar2 and Pcsk1 levels (<0.001). Additionally, both agonists increased glucagon secretion at low glucose levels. These results were confirmed in isolated islets from animals fed a standard diet. HF-fed animals showed hyperglucagonaemia (<0.01) and increased expression (<0.01) and secretion of glucagon, under low (<0.05) and high glucose concentrations (<0.01). When GPR41 and GPR43 receptors were activated, Gcg expression was further increased in islets from HF-fed animals but failed to potentiate glucagon release.

Conclusion: Our results suggest that both receptors, GPR41 and GPR43, are able to modulate function of α-cells becoming potential targets for the treatment of diabetes.

Supported by: CIBERDEM (ISCIII), PID2020-116134RB-I00 (MICINN), B2017/BMD-3684 (CAM), Spain.

Disclosure: A. Sánchez-Roncero: None.
424
Oxidative ER stess in beta cells: the role of ERO-1α in palmitate-mediated toxicity
S. Sharifi, I. Mehmeti;
Institute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany.

Background and aims: Prolonged exposure of pancreatic β-cells to the unsaturated long-chain fatty acid palmitate (PA) leads to β-cell dysfunction and loss in human and rat β-cells, a process known as lipotoxicity. A possible mechanism of lipotoxicity is considered to be an excessive production of H2O2. In particular, the endoplasmic reticulum (ER) as a major site of oxidative protein folding could represent a significant source of H2O2. ER oxidoreductin 1 (ERO-1) isoenzymes, ERO-1α and ERO-1β, both catalyse oxidative protein folding and generate H2O2 as a byproduct. However, whether the ERO-1-derived H2O2 is involved in lipotoxicity is still unknown. Our preliminary data revealed that both isoforms are expressed in pancreatic β-cells, but interestingly, only ERO-1α expression was significantly induced by PA. Therefore, the aim of this study was to uncover the role of ERO-1α in PA-mediated toxicity in insulin-secreting INS-1E cells.

Materials and methods: An ERO-1α knockout (KO) insulin-secreting INS-1E cell line was generated by CRISPR/Cas9 technique. The KO of ERO-1α was confirmed by Western blot. Insulin secretion and insulin content were determined by radioimmunoassay, while proinsulin was quantified by a mouse/rat proinsulin ELISA kit in the presence of 3, 10, and 30 mM glucose. For further experiments, cells were treated with increasing concentrations of PA (0.1-1.5 mM) for 24 h. Thereafter, cell viability, caspase activity, and overall oxidative stress were assessed via MTT-assay, flow cytometry, and oxidation of 2′,7′-dichlorofluorescein-diacetate (DCF-DA), respectively. Transcriptional changes were detected by RT-qPCR.

Results: Exposure of insulin-secreting INS-1E cells to PA resulted in a significant induction of ERO-1α gene expression (0.5 mM PA: 1.6-fold and 1.0 mM PA: 2-fold; p<0.01 vs untreated cells; n=4), whereas the expression of ERO-1β remained unaffected. The RT-qPCR data could also be verified on protein level. Knockout of ERO-1α had no negative effect on glucose-stimulated insulin secretion, insulin and proinsulin content compared to wild-type cells. However, KO of ERO-1α led to a significantly higher resistance of INS-1E cells against PA-mediated toxicity. ERO-1α KO cells showed a 58% residual cell viability at highest PA concentration of 1.5 mM tested, whereas wild-type cells revealed a residual cell viability of only 42% (p<0.001; n=10). Moreover, the PA-mediated overall ROS generation in ERO-1α KO cells was significantly lower compared to wild-type cells. The oxidation rate of DCFDA-H2 comprised only 143% in ERO-1α KO, while it was 228% in identically treated wild-type cells (p<0.01, p<0.001; n=6). In addition, ERO-1α KO cells exhibited lower caspase-9 and -3 activity upon PA treatment compared to wild-type cells (p<0.05; n=4).

Conclusion: The observed protection against PA-mediated toxicity by specific ERO-1α KO suggests that H2O2 formed in the ER lumen by ERO-1α is substantially involved in the induction of ER oxidative stress and subsequent β-cell death. Thus, specific KO of ERO-1α could increase the resistance of β-cells against lipotoxicity without affecting insulin folding and its glucose-stimulated insulin secretion.

Supported by: German Research Foundation (DFG, ME5567/2-1)
Disclosure: S. Sharifi: None.

425
Intrapancreatic adipose tissue accumulation is associated to beta cell dedifferentiation in humans
F. Cinti1, T. Mezza1, C. Cefalo1, S. Moffa1, F. Impronta1, G. Di Giuseppe1, U. Capece3, G. Ciccarelli1, L. Soldovieri1, I. Severi2, S. Cinti2, A. Giaccari1;
1IRCCS Fondazione Policlinico Gemelli, Rome, 2Università Politecnica delle Marche, Ancona, Italy.

Background and aims: The role of intrapancreatic fat accumulation in the development of Type 2 diabetes (T2D) is still on debate. β cell dedifferentiation is one of the mechanisms responsible of β cells failure in T2D but its role in the prediabetes state is unknown. The aim of our study was to investigate the intrapancreatic fat and beta cell dedifferentiation process before diabetes onset.

Materials and methods: 8 pancreatic samples from non diabetic patients undergoing pancreatic surgery, in whom an oral glucose tolerance test (OGTT) has been performed, have been morphologically surveyed. Based on the pre-operative OGTT, the subjects were divided into 3 glucose tolerance groups: normal (NGT, n = 3), altered (IGT, n = 3) or newly diagnosed diabetes (DM, n = 2). Dedifferentiation score has been assessed as the percentage of cells retaining endocrine features (synaptophysin immunoreactivity) but no longer containing the four endocrine hormones. The intraparenchymal white adipose tissue (WAT) score as been calculated as the % of pancreatic tissue occupied by white adipose tissue.

Results: WAT score resulted significantly higher in DM patients compared to NGT and IGT (WAT score DM 43.79 ± 20.83%, IGT 10.67 ± 8.5%, NGT 4.43 ± 4.37%; p=0.03). We observed a progressive and significant increase in dedifferentiation score, paralleling worsening glucose tolerance (from NGT through IGT to T2D: 4.8±3.8; 32.37±7.4; 40.38±19 respectively; p=0.02). Finally, we found a positive correlation between WAT score and dedifferentiation score (r=0.7; p=0.0052).

Conclusion: We observed a progressive increase in WAT and dedifferentiation score paralleling the worsening of glucose tolerance. Our data suggest that, before diabetes onset, the accumulation of WAT might be responsible for dedifferentiation process and, therefore, it might become a new potential target to curb diabetes onset.

Supported by: EFSD/AZ Mentorship Programme
Disclosure: F. Cinti: None.
SO 22 Exercise and diabetes: much to learn!

Positive effects of physical activity on prescription on glycaemic control, fitness and quality of life in newly diagnosed type 2 diabetic patients in a randomised control trial

T.N. Nguyen1,2, I. van der Ploeg3, C.J. Sundberg3,4, H.T.T. Vu1,2
1Department of Geriatrics, Hanoi Medical University, Hanoi, Viet Nam, 2Scientific Research Department, National Geriatric Hospital, Hanoi, Viet Nam, 3Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, 4Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden.

Background and aims: Type 2 diabetes (T2D) can be both prevented and treated cost-effectively with lifestyle improvements, including increasing physical activity (PA). PA on prescription (PAP) has proven to be a feasible way to increase an individual’s PA levels. The aim of the study was to compare the effects of PAP with standard care (SC) in T2D patients in Vietnam.

Materials and methods: A randomized control trial was conducted with 87 drug-naïve T2D patients. Participants were randomly assigned (1:1, similarity in demographic, anthropometric and clinical characteristics) to the PAP group (n = 44) or the SC group (n = 43). The PAP group received individualized recommendation for PA, intensive face-to-face training every two weeks and were instructed on how to use the pedometer. The SC group received the standard recommendations every two weeks and were instructed on how to use the pedometer. The SC group received the standard recommendations according to WHO guidelines for newly diagnosed T2D patients. Primary outcomes were evaluated as changes in HbA1c, fasting blood glucose (FBG), insulin resistance (Homeostasis Model Assessment - Insulin Resistance, HOMA-IR), aerobic fitness levels (VO2max measured using a submaximal exercise test) and health related quality of life (HRQoL) including two domains on physical health and mental health (SF-36 questionnaire) from baseline to 12-week follow-up. Secondary outcomes were self-reported PA levels assessed by using Global Physical Activity Questionnaire, BMI, waist circumference, blood pressure and lipid profile.

Results: The mean step-count daily of the PAP group was 6942 (SD: 1254) steps/day. Self-reported PA levels of the PAP group (3649 ± 1258 METs/week) were significantly higher than those of the SC group (2241 ± 1751 METs/week). The PFG levels of the PAP group decreased significantly compared with the SC group (difference between groups at week 12: -0.65, 95% CI: -1.02, -0.28 mmol/l), this reduction started at week 2 and maintained throughout the intervention period. The mean HbA1c levels decreased from 63.0 to 52.3 mmol/mol in the PAP group (p < 0.001) and from 60.5 to 58.1 mmol/mol in the SC group (p > 0.05). Change in HOMA-IR values over 12 weeks in the PAP group was higher than that in the SC group (difference between groups, 11.7, 95%CI: 6.8, 16.6). The VO2-max increased in the PAP group (from 2.75 ± 0.70 to 3.14 ± 0.73 L/min) as compared to SC group (from 2.51 ± 0.72 to 2.68 ± 0.71 L/min). PAP had promising effects on HRQoL: Physical health (from 60.7 to 63.5 scores) and mental health (from 60.2 to 62.1 scores), respectively. BMI, waist circumference, total cholesterol, LDL cholesterol and triglycerides were significantly more decreased in the intervention group than in the control group, p<0.05. There was no significant difference between the two groups in blood pressure.

Conclusion: PAP had positive effects on glucose control, insulin resistance, aerobic fitness, BMI, waist circumference, lipid profile and HRQoL in newly diagnosed T2D patients.

Disclosure: T.N. Nguyen: None.

427 Blood glucose response to cycling and running in individuals with type 1 diabetes: a systematic review and meta-analysis

M.L. Eckstein1, F. Aziz2, F. Aberer1, S. Böckel1, R.T. Zimmer1, M. Erlmann1, H. Sourij2, O. Moser1
1Division of Exercise Physiology and Metabolism, University of Bayreuth, Bayreuth, Germany, 2Department of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.

Background and aims: Running and cycling represent the most common types of endurance exercise in individuals with type 1 diabetes (T1D). Recommendations for glycaemic management prior to those exercises are the same even though different musculature is involved. The risk of exercise-induced hypoglycemia is evident in both exercise types, it remains unclear to which extent the blood glucose (BG) decrease differs in response to these exercise types. The aim of this systematic review and meta-analysis was to assess how running and cycling influence the magnitude of BG in individuals with T1D.

Materials and methods: A systematic literature search was conducted in EMBASE, PubMed, Cochrane Central Register of Controlled Trials, and ISI Web of Knowledge for publications from January 1950 until February 2021. Parameters included for analysis were population (adults and adolescents), exercise type, intensity, duration, and insulin preparation. The meta-analysis was performed to estimate the pooled mean with a 95% confidence interval (CI) of delta BG levels. In addition, sub-group and meta-regression analyses were performed to assess their influence on delta BG.

Results: The database search identified 3192 studies of which 71 articles were included in the meta-analysis. Due to crossover designs within each article, 153 different study results were included for analysis. Data from 1901 exercise tests from individuals with T1D with a mean age of 29 ± 4 years were included. Independent of the type of exercise, the overall pooled delta BG was -53.73 mg/dL [-59.73; -47.74] and a mean exercise duration of 46 ± 21 minutes. In cycling studies (n=111), the pooled BG decrease was -48.95 mg/dL [-54.04; -43.09] in comparison to a pooled BG decrease of -65.89 mg/dL [-80.69; -51.08] (p<0.03) in running studies (n=42). During cycle exercise, low intensity led to a BG decrease of -33.51 mg/dL [-53.27; -13.74], during moderate intensity to -55.30 mg/dL [-62.28; -48.32] and during vigorous intensity to -40.62 mg/dL [-51.56; -29.68] (p<0.021). During running, low intensity exercise led to a BG decrease of -11.85 mg/dL [-48.81; +25.10], moderate intensity to -59.01 mg/dL [-81.10; -36.93] and vigorous intensity to -82.19 mg/dL [-97.06; -67.29] (p<0.002). Cycling studies with no insulin reduction pre-exercise led to a BG decrease of -46.87 mg/dL [-54.40; -39.34] compared to studies with insulin reductions and a delta BG of -55.44 mg/dL [-61.88; -48.99] (p=0.090). Running studies with no insulin reduction led to a BG decrease of -84.54 mg/dL [-98.57; -70.51] compared to insulin reductions with a delta BG of -26.23 mg/dL [-52.32; 0.13] (p<0.001). Meta-regression analysis in cycling studies revealed that exercise duration >60 minutes (-18.07 [-34.43; -1.71]) (p=0.03) and moderate exercise intensity (-20.33 [-38.79; -1.86]) (p=0.03) were significantly influencing delta BG levels. Adults (-119.98 [-170.53; -69.44]) (p<0.001), no reduction of insulin (+57.70 [25.38; 90.02]) (p<0.001) and high-intensity interval exercise (+86.75 [55.51; 117.99]) (p<0.001) significantly influenced delta BG levels in running studies.

Conclusion: Running led to a larger decrease in BG in comparison to cycling. Active individuals with T1D should be aware that current recommendations for cycling might not be transferable to running.

Disclosure: M.L. Eckstein: None.
428 Pulmonary function in uncomplicated type 1 diabetes: blunted during exercise even though normal at rest

L. Jali1, E. Heyman1, R. Matran2, G. Marais1, A. Descatoire1, R. Rabasa-Lhoret1, M. Pawlak-Chaouch1, P. Mucci1, P. Fontaine1, G. Baquet1, S. Tagougui1;
1Univ. Lille, Univ. Artois, Univ. Littoral Côte d’Opale, ULR 7369 - URePSSS - Unité de Recherche Pluridisciplinaire Sport Sante Société, F-59000, Lille, France, 2Department of Physiology, EA 2689 & IFR 22, Lille, France, 3Regional Hospital Center of Roubaix, Roubaix, France, 4Montreal Clinical Research Institute, Montreal, Canada, 5Department of Diabetology, University hospital; EA 4489, Lille, France.

Background and aims: Type 1 diabetes (T1D) is associated with increased risk of impaired lung function and this may contribute to the impairment in aerobic fitness, a powerful marker of health status with prognostic value. We aimed to examine the pulmonary function at rest and the ventilatory response during maximal exercise in individuals with TID free from microangiopathy.

Materials and methods: Seventeen adults with T1D free from clinically detectable microangiopathy (glycated hemoglobin [HbA1c] <8.0±1.3%), and 17 adults without T1D, matched on gender, age, level of physical activity and body composition were included. Lung function was assessed by spirometry and measurements of the combined diffusing capacity for nitric oxide (DLNO) and carbon monoxide (DLCO) at rest. Subjects performed a maximal exercise test during which the respiratory parameters (maximal oxygen uptake (VO2max), breathing frequency, ventilation, tidal volume) were measured.

Results: At rest, DLCO, DLNO and its 2 components Dm (membrane diffusion capacity) and VC (pulmonary capillary volume), as well as spirometry parameters (forced vital capacity=4.8±1.0L vs. 5.4±1.0L; forced expiratory volume in 1 second=4.1±0.7L vs. 4.4±0.7L) were comparable among T1D and control group. During exercise, ventilatory response was different between the two groups: tidal volume ‘VT’ was lower in T1D vs. control group (P<0.05, VT 2.15±0.53L vs. 2.36±0.45L, respectively). Individuals with T1D showed a reduced VO2max (P=0.04) in comparison with control group. There was a negative correlation between VO2max and HbA1c level (r=-0.75, P=0.032).

Conclusion: At rest before exercise, alveolar-capillary diffusion capacity is normal in individuals with T1D. Yet, the decrease in VO2max and tidal volume during exercise in individuals with T1D seems to be associated with an alteration of the pulmonary function even before the appearance of micro-macrovascular complications.

Clinical Trial Registration Number: NCT02051504
Supported by: société francophone du diabète
Disclosure: I. Jali: None.

449 Barriers to exercise in type 1 diabetes individuals with insulin resistance

A.M. Allobaid1, M.A. Zulyniak1, M. Hopkins1, M.D. Campbell2,3; 1School of Food Science and Nutrition, University of Leeds, Leeds, 2School of Health Sciences and Wellbeing, University of Sunderland, Sunderland, 3Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.

Background and aims: Insulin resistance (IR) is prevalent in Type 1 Diabetes (T1D), and increases risk of macro and microvascular complications. Regular exercise participation improves IR, and may reduce risk of diabetes complications developing and progressing. However, there is a lack of evidence regarding the perceived benefits and barriers to exercise in those with T1D, and whether these differ between individuals with and without IR. In this study, we used estimated glucose disposal rate (eGDR) - a validated tool for assessing IR status - and the Exercise Benefits/Barriers Scale (EBBS), to examine whether perceived benefits and barriers to exercise differ among T1D individuals with and without IR.

Materials and methods: A total of eighty-six individuals with T1D (age 29±6 years; BMI 26.24±4.20 kg/m2) were included in the present analysis, with baseline pre-treatment data aggregated from two clinical studies with common experimental procedures. The cohort was categorised according to IR status using a previously published eGDR cut-point of ≤6 mg.kg.ml (41.9%) for IR and ≥6 mg.kg.ml (58.2%) for non-IR. Group differences were examined using independent t-tests for normally distributed variables, Mann-Whitney U test was applied for non-normally distributed variables, and Fisher exact tests for categorical data. Pearson correlations were used to assess interrelationships between variables and explore potential confounders. The relationship between EBBS scores and IR was also assessed using general linear regression, with sequential adjustment for age, length of diagnosis, and exercise participation. Data analysis was performed using SPSS (IBM SPSS Statistics 27), with a p-value of <0.05 deemed statistically significant.

Results: Individuals with IR tended to be older, with a longer duration of diabetes, and presented with higher HbA1c, and increased prevalence of hypertension (p<0.05; Table 1). Self-report exercise participation levels were lower in those with IR (P=0.017; Table 1), although exercise intensity (moderate vs. vigorous exercise) was comparable (p>0.05; Table 1). eGDR was positively associated with total EBBS score in the unadjusted regression model (β=4.973, 95%CI:4.070 to 5.880, p<0.001); this association remained robust following adjustment for age, length of diagnosis, and exercise participation (β=3.990, 95%CI:2.977 to 5.003, p<0.001).

Conclusion: eGDR is positively associated with total EBBS scores in individuals with T1D, meaning that those with IR demonstrate significantly lower EBBS scores. These findings suggest that habitual physical activity or exercise interventions should be adapted to consider T1D and IR-specific target behaviours.

Table 1. Participant characteristics for the whole group (n = 86) and when stratified by IR status

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>27 (19.1)</th>
<th>28 (21.2)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (kg/m2)</td>
<td>31.6±4.30</td>
<td>27.48±4.70</td>
<td>0.005</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>7.61 (1.1)</td>
<td>8.34 (2.14)</td>
<td>0.009</td>
</tr>
<tr>
<td>Length of Diagnosis</td>
<td>18.6 (4.7)</td>
<td>16.2 (1.25)</td>
<td>0.001</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>41.87 (7.72)</td>
<td>36.16 (9.63)</td>
<td>0.000</td>
</tr>
<tr>
<td>Basal Insulin Lispro A (%)</td>
<td>25.19 (9.7)</td>
<td>19.04 (5.36)</td>
<td>0.009</td>
</tr>
<tr>
<td>Basal Insulin Glargin E (%)</td>
<td>60.4 (59.6)</td>
<td>27.5 (36.9)</td>
<td>0.000</td>
</tr>
<tr>
<td>Moderate exercise</td>
<td>39.9 (97.3)</td>
<td>12.0 (33.7)</td>
<td>0.252</td>
</tr>
<tr>
<td>Vigorous exercise</td>
<td>14.4 (19.1)</td>
<td>2.7 (15.6)</td>
<td>0.151</td>
</tr>
<tr>
<td>Total EBBS</td>
<td>121 (10)</td>
<td>114 (14)</td>
<td>126 (18)</td>
</tr>
</tbody>
</table>

Disclosures: A.M. Allobaid: None.
Background and aims: Regular physical activity and exercise represent a cornerstone in the treatment of type 1 diabetes (T1D), however, exercise-induced hypoglycemia remains the major barrier to a physically active lifestyle. Therefore, the ULTRAFLExI-1 study compared two basal insulin analogues, Glargine U-300 (IGlar U300) and Degludec (IDeg), in two different doses (100% and 75% of the regular dose) when used around spontaneous exercise sessions in adults with T1D.

Materials and methods: We performed a randomized, single-center, four-period, cross-over trial and included adults with T1D treated with multiple daily insulin injections and an HbA1c ≤10% (≤86 mmol/mol). In each of the four 2-weeks-periods, participants attended six spontaneous evening cycling sessions (60 minutes, moderate intensity). The days of exercising were randomized and announced at 8 A.M. to the participants.

The basal insulin used on the exercise days during the four periods were: IGlar U300 100% or 75% of the regular dose or IDeg 100% or 75%, respectively. 100% of the regular basal insulin dose was used at all non-exercise days. Continuous glucose monitoring was performed using a blinded Dexcom G6 device. The primary outcome was the time spent in hypoglycemia (<70 mg/dl, time below range (TBR)) during the six 24-hour post-exercise periods in the four trial arms. The difference in TBR between 100% IGlar and 100% IDeg or 75% IGlar and 75% IDeg was analyzed in hierarchical order using the repeated measures linear mixed model.

Results: 25 people were enrolled (14 male), aged 41.4±11.9 years, with a mean diabetes duration of 16.8±10.4 years and a mean HbA1c of 7.5 ±0.8%. (59±9 mmol/mol). Mean TBR during the 24-hour periods follow-

Conclusion: Time spent in hypoglycemia after spontaneous exercise sessions was significantly lower in people with type 1 diabetes receiving IGlar U300 compared to 2.55±2.87% with IDeg when using the 75% dose on exercise days (p=0.720).

SO 23 Gestational diabetes and pregnancy

Impaired pregravid beta cell function is associated with adipose tissue insulin resistance and increased risk of gestational diabetes

Background and aims: Gestational diabetes mellitus (GDM) is hypothesized to partly reflect inadequate pancreatic β-cell responses to the increased insulin resistance seen in pregnancy. However, it is unclear if inadequate β-cell function in women with GDM emerges only during pregnancy, or could be present before pregnancy. To understand the aetiology of β-cell dysfunction in GDM, we first investigated the cross-sectional association of pregravid β-cell function with adipose tissue insulin resistance in the Singapore Preconception Study of Long-Term Maternal and Child Outcomes (S-PRESTO) study. Elevated adipose tissue insulin resistance could potentially expose β-cells to chronically elevated NEFA and NEFA-induced lipotoxicity. Next, we studied the temporal relationship between pregravid β-cell function and the risk of GDM.

Materials and methods: The S-PRESTO study recruited 1039 women (18-45y, Chinese, Malay or Indian ethnicities), planning to conceive within 1 year. The current analysis focuses on 326 women who conceived successfully within 1 year of recruitment and underwent GDM screening. OGTT was performed pregravid and at 28 weeks’ gestation, with GDM diagnosed using the International Association of Diabetes and Pregnancy Study Group criteria. At both visits, the insulinogenic index (ratio of the change in insulin between 0-30 min to the change in glucose between 0-30 min), and hepatic insulin resistance (measured using HOMA2-IR) were recorded. β-cell compensation for hepatic insulin resistance was assessed using the disposition index (DI; ratio of insulinogenic index to HOMA2-IR).

Results: At the pregravid visit, a 10% increase in Adipo-IR predicted a 3.5% reduction (95%C1: -5.4% to -1.5%, p = 0.001) in DI, adjusted for age, ethnicity, educational attainment, parity and pregravid BMI. 16% of the women were diagnosed with GDM. DI was consistently lower in women who were diagnosed with GDM (relative to normoglycemic women), in both the pregravid (Geometric mean (95%C1): 20.2 (15.6 to 26.1) vs 32.4 (28.9 to 36.2), p = 0.001) and the antenatal (14.3 (11.6 to 17.7) vs 27.2 (25.0 to 29.6), p=0.001) phases. Women in the lowest tertile of pregravid DI (relative to middle and upper tertiles) had a 4-fold higher odds of developing GDM (Odds Ratio (95%C1): 4.0 (1.6 to 10.3), p=0.003), adjusted for age, ethnicity, educational attainment, parity and pregravid BMI.}

Conclusion: Impaired pregravid β-cell compensation for hepatic insulin resistance (as measured by lower DI) was associated with elevated Adipo-IR and characterized women who subsequently developed GDM during pregnancy. It is plausible that chronic exposure of β-cells to elevated NEFA caused by high Adipo-IR may be involved in the blunting of β-cell responses to hepatic insulin resistance. Our findings point to a potential role for pregravid interventions targeting adipose tissue and β-cell functions for improving women’s metabolic health during pregnancy.

Clinical Trial Registration Number: NCT03531658


Disclosure: N. Michael: Grants; This work was supported by Singapore National Medical Research Council: NMRC/TCR/004-NUS/2008.
Background and aims: Diabetes complicating pregnancy increases the risk of fetal growth acceleration (LGA - Large for Gestational Age). The aim of the study was to evaluate the factors influencing birth weight in patients with DM1 treated with a personal insulin pump (IP).

Materials and methods: The study included 93 pregnant women with DM1 treated with IP, 54% used continuous glucose monitoring. Medical history, data on the course of DM1, comorbidities, insulin requirements, weight gain and glycemic outcomes were analyzed.

Results: The mean age of women was 31.2±4.33 years, diabetes duration 15.9±7.43 years, pre-pregnancy BMI 23.8 (95% CI: 23.0-24.6) kg / m2, pre-pregnancy HbA1c 7.12±1.28, 23% had HbA1c below 6.5%. In the analyzed cohort, there were 40 LGA cases and 1 SGA case, which was excluded from the analysis. The patients were divided into 2 groups - the study group consisted of 40 patients with LGA newborns, the control group consisted of 52 patients. The patients did not differ in terms of anthropometric data, comorbidities or diabetes complications. Patients in the LGA group were less frequently primiparous (45% vs 67%, p=0.03), and had earlier miscarriages (25% vs 9.4%, p=0.05). Only in the LGA group, earlier deliveries of children with macrosomia (birth weight>4000g) were observed (12.5% vs 0%, p=0.012). There were no differences in insulin requirements, HbA1c, or the percentage of patients achieving the HbA1c target in consecutive trimesters (T). Mean glycemia was slightly higher in the LGA group in individual T1s, p>0.05. Only the mean glycemia before pregnancy and the time spent above 140mg/dL in the III T were higher in the LGA group - 143±27 vs 124±26 mg/dL, respectively, p=0.05 and 37.3±19.5% vs 29.7±13.6%, p=0.05. Apart from an increased percentage of macrosomia and birth weight, no differences in obstetric outcomes were observed. In the LGA group, 23 newborns (57.5%) had macrosomia, and in the control group 5 (9.4%) newborns. Correlations between the incidence of LGA and the history of miscarriage (r=0.214), macrosomia (r=0.28) and parity (r=0.22) were observed, all p<0.005. There were correlations between the occurrence of LGA and mean glycemia before pregnancy, in II and III T (r: 0.396, 0.220, 0.299, respectively), time spent in the target range (TIR) in II and II T (r=0.214 and 0.221), maternal body weight in II and III T (r=0.20 and 0.264) and maternal weight gain in pregnancy (p=0.222), all p<0.05. There was no correlation between LGA frequency and insulin doses.

Conclusion: In women with type 1 diabetes treated with IP, the incidence of LGA is associated with the observed pre-pregnancy glycaemia, in II and III T, and TIR in these trimesters. The burden of obstetric medical history also influences the incidence of LGA.

Disclosure: M. Zurawska-Klis: None.

433 Prolactin levels associate with insulin secretion in pregnancy and are reduced in multi- vs nulliparous women

D. Löffler1,2, J. Hummel1,2, L. Sandforth1,2, A.L. Birkenfeld1,3, H. Preis1,2, A. Peter2,3, A. Fritsche1,2, R. Wagner1, M. Heni1,2, L. Fritsche1,2; 1University Hospital Tübingen, 2German Center for Diabetes Research (DZD e.V.), 3Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Germany.

Background and aims: Pregnancy is a state of physiological insulin resistance and gestational diabetes (GDM) develops when this cannot be compensated by sufficient increase in insulin secretion. To meet the increased insulin requirements, β-cells adapt during the course of pregnancy. Animal models suggest that this process is regulated in part via the hormone prolactin. While GDM risk increases with age and parity, impact of prolactin in GDM pathogenesis is currently unclear. We aimed to investigate the association of prolactin with insulin secretion and the effect of parity on prolactin levels in the last trimester of pregnancy in a cohort of deeply phenotyped women.

Materials and methods: We used data from the ongoing PREG study. Women with a singleton pregnancy had a 5-point OGTT with 75 g glucose. GDM was diagnosed according to the IADPSG criteria. Insulin sensitivity was assessed with NEFA-insulin sensitivity index and insulin secretion with AUC_C-peptide 0-30/AUC_Glucose 0-30. Fasting prolactin was measured in serum by a commercial chemiluminescence assay. Associations of prolactin with insulin sensitivity and parity were analyzed with multivariable linear regression models adjusted for age, BMI and gestational age. Models for the outcome insulin secretion were additionally adjusted for insulin sensitivity. Post hoc comparisons of level contrasts were corrected with Bonferroni method.

Results: We examined 503 women during gestational week 27.5 (SD 2.4), of these 137 were diagnosed with GDM. Women with GDM had lower insulin secretion (p<0.001), lower insulin sensitivity (p<0.001) and lower prolactin levels (131 (54) vs. 144 (61) μg/l, p=0.027). Prolactin associated negatively with insulin sensitivity (p=0.0108) and positively with insulin secretion (p=0.019). We found a significant negative association of parity with prolactin levels (p<0.001). Nulliparous women had the highest prolactin levels, while women with one or more previous pregnancies had significantly lower prolactin levels (post hoc tests 0 vs 1 pregnancy p<0.001, 0 vs 2 and more pregnancies p<0.001, 1 vs. 2 and more pregnancies p=0.0373). The negative association of number of parities with prolactin was independent of age, BMI and GDM status and was also observed in a subgroup of 209 nulli- and 209 multiparous women matched for age, BMI and gestational age.

Conclusion: Our data indicate that with each subsequent pregnancy, the physiological prolactin levels are lower. Since animal data and our correlative findings suggest a stimulatory effect on beta-cells, this phenomenon could contribute to reduced insulin secretion and higher GDM risk with increasing number of pregnancies.

Clinical Trial Registration Number: NCT04270578

Supported by: BMBF(01GI0925) to DZD

Disclosure: D. Löffler: None.
434 Hypoglycaemia increases during pregnancy after gastric bypass: the Bariatric surgery And consequences for Mother and Baby In pregnancy (BAMBI) study

L.L. Stentebjerg1,2, L.R. Madsen3,4, R.K. Stoving2,5, L.T. Andersen6,2, C.A. Vinte6, C.B. Juhl3, D.M. Jensen1,6;
1Steno Diabetes Center Odense, Odense University Hospital, Odense, 2Department of Clinical Research, University of Southern Denmark, Odense, 3Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, 4Danish Diabetes Academy, Odense University Hospital, Odense, 5Department of Endocrinology, Odense University Hospital, Odense, 6Department of Endocrinology, Hospital of South West Jutland, Esbjerg, 7Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.

Background and aims: Roux-en-Y Gastric bypass surgery (RYGB) is complicated by subsequent alterations in glucose profiles partly due to an enforced incretin response. The increased insulin resistance during pregnancy poses an additional challenge to glucose metabolism in women treated by RYGB. However, the magnitude and impact of this has only been sparsely investigated. The aims of the BAMBI study were to investigate the interstitial glucose (IG) profiles during the course of pregnancy and the incidence of hypoglycemic events in pregnant women previously treated by RYGB compared to matched controls.

Materials and methods: In the prospective BAMBI study, 23 pregnant women with RYGB and 23 BMI- and parity-matched pregnant controls were studied with continuous glucose monitoring (CGM) in the 1st, 2nd, and 3rd trimester as well as 4-6 weeks postpartum. Time in range (TIR) was defined as time with IG of 3.5-7.8 mmol/l. The primary outcomes were time below range (TBR) (%) and the incidence of hypoglycemic events (< 3.0 and 3.5 mmol/l) quantified by CGM.

Results: Pregnancies occurred 30 (IQR: 15.4-98.1) months following RYGB with a reduction of BMI from 45.2 kg/m² (IQR: 42.0-54.3) pre-surgery to 31.5 kg/m² (IQR: 26.5-39.1) pre-pregnancy. TIR was significantly lower throughout pregnancy and postpartum for the RYGB group compared to controls (87.3-89.5% vs. 93.7-96.1%, p<0.01). TBR increased from the 1st trimester (1.0%, SD 1.5) to the 2nd (2.1%, SD 3.2) and 3rd trimester (2.0%, SD 2.7) and returned to a reduced TBR postpartum (0.6%, SD 0.7). Similarly, the median weekly number of hypoglycemic events increased during pregnancy for the RYGB group with 0, 0.8, 0.4 and 0 weekly events < 3.0 mmol/l, and 1.6, 2.4, 2.9 and 1.1 weekly events < 3.5 mmol/l in the 1st, 2nd, and 3rd trimester and postpartum, respectively. The median weekly number of hypoglycemic events for the controls was 0 for both the 3.0 and 3.5 cut-off.

Conclusion: The results of the BAMBI study show that women treated by RYGB pre-pregnancy spend more time in TBR and are more exposed to hypoglycemia than matched controls. Further research is warranted investigating if the increased risk of fetal growth restriction among pregnant women treated with gastric bypass is associated with exposure to hypoglycemia during pregnancy.

Clinical Trial Registration Number: NCT03713060

Supported by: LLS received funding from the Region of Southern Denmark

Disclosure: L.L. Stentebjerg: Grants; Region of Southern Denmark.

435 Body composition and effect of insulin treatment during pregnancy in Socs2-/- mice with gestational diabetes and macrosomia

L. Hernandez-Baraza1, C. Valverde-Tercedor1, M. Diaz1, A.M. Wagnér2, L. Fernández-Pérez2, B. Guerra2, Y. Brito-Casillas2;
1Instituto Universitario en Investigaciones Biomédicas y Sanitarias, 2Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas de Gran Canaria, Spain.

Background and aims: The Suppressor of Cytokine Signaling 2 (Socs2) protein modulates cytokine response, growth, inflammatory processes, and cytokine-mediated metabolism of lipids and carbohydrates. Thus, its ablation in mice (Socs2-/-) generates gigantism and insulin-resistance as well as gestational diabetes (GDM) and macrosomia with high mortality rates (>88%). Our aim is to evaluate the body composition variations in pregnant Socs2-/- as a potential early diagnostic tool for macrosomia. Additionally, we assess the potential use of insulin to prevent foetal macrosomia.

Materials and methods: Body Weight (BW) and composition (lean, fat and fluid) were evaluated in 7 Socs2-/- and 4 C57Bl/6j pregnant females (age: 196±28 days), using an NMR-TD spectrometer (Minispec-LF90II). Basal glucose was measured at days 7 and 14 of pregnancy (first and second gestational thirds) using a glucometer (Glucomen Areo LF90II). Basal glucose did not differ between groups for the whole evaluation (Socs2-/-: 151±2.19 mg/dL; control: 144±13.63 mg/dL) (p=0.46). BW of Socs2-/- tended to be greater at day 7 compared to controls (25.9±2.2 vs 25.7±2.1, respectively; p=0.063) and was significantly higher at day 14 of pregnancy (36±3.2 vs 28.2±2.3g, respectively; p=0.006). Fat percentage was higher in controls (7d: 26.2±3.1%; 14d: 21.3±2.8%) than in Socs2-/- (7d: 10.6±2.1%; 14d: 11±2.9%) (p=0.012). Fluid content was reduced in Socs2-/- compared to controls at 7d (606±1.16 vs 93±0.7%, p=0.016), but not at 14d (10.3±1.0 vs 11.7±1.5%; p=0.16). Finally, differences were no significantly (p>0.05) in lean percentage on days 7 and 14 between control (7d: 79.9±2.9%; 14d: 80.5±3.0%) and Socs2-/- (7d: 63.3±16.3%; 14d: 71.9±6.9%). Neonates from untreated mothers were heavier than offspring of mice receiving insulin (1.5±0.2g vs 0.8±0.4g, respectively; p<0.001) and the prevalence of macrosomia was higher, too (65.9±24.01% vs 20±34.6%, respectively; p=0.007).

Conclusion: Although it is necessary to extend the analysis of body composition to more animals and later pregnancy periods to assess if these variables indeed predict macrosomia, actual results show weight, fat and fluid as parameters with potential noninvasive pre-diagnostic interest for macrosomia. Insulization of pregnant Socs2-/- resulted in almost 50% decreased occurrence of macrosomia, reinforcing a novel in vivo model for GDM. New specific insulin evaluations will be conducted to define its potential to ameliorate the severity of macrosomia. Further studies should be performed to fully elucidate the potential role of Socs2 in the development of GDM.

Disclosure: L. Hernandez-Baraza: None.

436 Insulin sensitivity, growth differentiation factor-15 and fetuin-B during pregnancy after assisted reproductive therapy in the STORK cohort

E. Qvigstad1, M.-C.P. Roland2, K. Godang1, T. Lekvå3;
1Dept of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, 2Institute of Clinical Medicine, University of Oslo, 3Dept. of Obstetrics and Gynaecology, Oslo University Hospital, 4Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.

Background and aims: Assisted reproductive therapy (ART) may increase the risk of gestational diabetes (GDM) and glucose intolerance after pregnancy. We have previously shown reduced insulin sensitivity (IS) in pregnant women after ART. To gain more insight in this
association we have investigated fetuin-B (fet-B) and growth differentiation factor-15 (GDF-15), that both increase with low IS such as in GDM, comparing pregnant women after ART with controls (CTR) with normal glucose tolerance from the STORK cohort.

Materials and methods: In STORK, 1031 healthy pregnant Norwegian women attended OGTTs at gestational week (GW) 14-16 and 30-32. 75 women had conceived after ART, and 847 women were glucose tolerant (WHO 2013 criteria), and served as CTR. From the 5-point OGTT glucose and insulin results, we calculated IS (Matsuda). In a representative subsample, we analyzed fasting plasma levels of fet-B and GDF-15 (ELISA). In addition we explored if BMI at GW 14-16 (BMI below/above 25 kg/m²) influenced these biomarkers and IS levels.

Results: The ART women were 32.8 years (SD 3.5), i.e. 1.8 years older than the CTR women (p<0.001), IS was significantly lower in ART women in GW 14-16 and GW 30-32. In addition, Fet-B differed between the groups and was 11% lower in ART at GW 30-32, p<0.05. However, by stratifying the ART women by BMI below/above 25 kg/m², we found improved IS at GW 14-16 and 30-32 in the normal weight ART women (26 and 33 % resp., both p <0.01). The effect of ART on IS remained significant after adjustment for maternal age, BMI, family history of diabetes and smoking in early pregnancy, but not at GW 30-32. The regression analysis demonstrated BMI as the main variable for IS levels at both time points, GDF-15 was also a significant factor for IS at GW 30-32 (p=0.018).

Conclusion: The reduced IS in pregnant women after ART, was not paralleled by the expected increases in the measured biomarkers in pregnancy, when compared to CTR women. Our data suggest that ART treatment exerts a negative influence on insulin sensitivity during gestation. However, as BMI remains the most important variable to explain IS, also after ART, IS might be improved by lifestyle change, similarly to proven interventions for GDM.
SO 24 Life with diabetes from conception to delivery

438 Pregnancy in women with hyperglycaemia in pregnancy: impact of multiples vulnerabilities on fetal growth
H. Bihan1, C. Nachtargue2, E. Vicaud2, M. Sal1, N. Berkane1, S. Pinto3, S. Tanalchali1, M. Ferman2, L. Carbillon2, E. Cosson1; 1Endocrinology, Diabetology, Nutrition, Avicenne Hospital, Bobigny, 2Université Denis Diderot, 75009 Paris, AP-HP, Unité de Recherche Clinique St-Louis-Lariboisière, Paris, 3Diabetology, Jean Verdier Hospital, Bondy, 4Department of Obstetrics and Gynecology, Jean Verdier Hospital, Bondy, France.

Background and aims: In women with hyperglycaemia in pregnancy (HIP), psychosocial deprivation could be associated with earlier and higher exposure to hyperglycemia and a poorer maternal-fetal prognosis. Other vulnerabilities, such as food insecurity and low French proficiency, could influence prenatal care adherence and outcomes.

Materials and methods: We analyzed the links between individual deprivation, food insecurity, national language proficiency and fetal growth (main criterion), a composite HIP-related outcomes, and other core outcomes in a multi-ethnic cohort of women who were cared for HIP (childbirth between 01/01/2012 and 31/12/2018) in a specific program in a deprived area.

Results: Among 1,168 women (36% from North Africa, 15% from sub-Saharan Africa, 17.3% from South Asia), 55.4% suffered from deprivation, 17.9% from food insecurity, and 27.5% from low national language proficiency. Insulin therapy was prescribed to 43.3% of women. The fetal growth categories (small- or adequate- or large-for-gestational-age infants: SGA/AGA/LGA, respectively) were similar regardless of the level of deprivation or food insecurity, with 11.4% of SGA, 76.5% of AGA, and 12.2% of LGA infants. Paradoxically, women with a low National Language proficiency had fewer events for composite criteria, mediated by fewer LGA (8.3%) but higher SGA infants (16.7%).

Conclusion: Optimized single-center care with specialized follow-up could contribute to reduce health inequalities in women with HIP. The higher risk of SGA in women with low National language proficiency suggests paying special attention to possible dietary restrictions by misunderstanding dietary advice.

Disclosure: H. Bihan: None.

440 The contribution of maternal glucose to birth weight is less in Uganda (sub-Saharan Africa) compared to white and black ethnic groups in the HAPO study

Background and aims: Maternal glycaemia has a significant influence on fetal birth weight and maternal and fetal morbidity. Glycaemia measured in a third-trimester oral glucose tolerance test shows a linear relationship with birth weight and other birth complications. The Hyperglycaemia Adverse Pregnancy Outcomes (HAPO) study established a similar relationship between glucose and birth weight in multiple ethnic groups, and they proposed cut-off criteria where the risk of large for gestational age (LGA) was 1.75 times greater than the population risk. However, the HAPO study did not include any cohorts from sub-Saharan Africa (SSA), where 17% of the world population lives. No studies have examined the relationship between maternal glycaemia and fetal birth weight in SSA. This study aims to address this.

Materials and methods: We compared the relationship between oral glucose tolerance test (OGTT) glucose measures and obstetric outcomes in participants from Uganda (n=2544), black participants in HAPO (n=1224) and white participants in HAPO (n=7679). We used multivariable linear regression to assess the correlation between birth weight corrected for gestational age and sex with maternal glucose concentration. Logistic regression was used to determine the association of LGA (defined as birthweight > 90th percentile) and maternal fasting glucose. We compared the relationship between oral glucose tolerance test (OGTT) glucose measures and obstetric outcomes in participants from Uganda (n=2544), black participants in HAPO (n=1224) and white participants in HAPO (n=7679). We used multivariable linear regression to assess the correlation between birth weight corrected for gestational age and sex with maternal glucose concentration. Logistic regression was used to determine the association of LGA (defined as birthweight > 90th percentile) and maternal fasting glucose.

Results: The contribution of maternal fasting glucose to birth weight is lower in Uganda than in other settings (β-coefficient (95% CI) 104(58.6 to 149)g/mmol/L in Uganda, 203(17 to 269)g/mmol/L in HAPO-black, and 239(214 to 265)g/mmol/L in HAPO-white. Likewise, the risk of LGA with higher fasting glucose was smaller in Uganda compared to the other studies (adjusted odds ratio (95% CI) 1.07 (0.94 to 1.23) in Uganda, 1.29 (1.22 to 1.38) in HAPO-white, and 1.21 (1.14 to 1.29) in HAPO-black).
S226

Supported by: MRC

C. Font
glycaemic control and pregnancy outcomes. in a cohort of pregnant women with type 1 diabetes: efficacy on

The use of intermittently scanned CGM vs sensor augmented pump

441

Disclosure: W.P. Nakanga: None.

C. Font

None.

442

Are pre-pregnancy body mass index and gestational weight gain associated with maternal and infant adverse outcomes in French women with type 1 diabetes?

A. Vambergue, V. Laurent, M. Lemaitre, C. Termynck, J. Bourry, F. Baudoux, D. Subtil;

CHRU, Lille, France.

Background and aims: Pregestational body mass index (BMI) and excessive gestational weight gain are associated with several adverse events during pregnancy. Our objective was to investigate the associations between prepregnancy BMI, gestational weight gain (GWG) and maternal-infant adverse outcomes in a French cohort of women with Type 1 diabetes (T1D).

Materials and methods: 771 women with T1D who delivered singleton infant at University Medical Center from 1997 to 2021 were included in this observational study. Regarding pregestational BMI, we defined 3 classes: normo-weight (BMI < 25 kg/m²), overweight (BMI ≥ 25 and < 30 kg/m²) and obesity (BMI ≥ 30 kg/m²) according to WHO criteria. GWG were defined (low; adequate or high) according to the 2009 Institute of Medicine guidelines. We studied the following outcomes: maternal composite criterion (at least the presence of one among the appearance or aggravation of retinopathy, proteinuria, gravidic hypertension, pre-eclampsia, post-partum hemorrhage or ketoadiasis decompensation), fetal composite criterion (at least the presence of one among prematurity, shoulder dystocia, severe malformations, respiratory distress or neonatal ICU admission) and LGA. We assessed the association of BMI and GWG with pregnancy outcomes using logistic regression models before and after adjustment in confounding factors. The results were expressed in odds ratios (OR) and their 95% confidence intervals (CI).

Results: 61.1% of women with T1D were normo-weight, 24.4% with overweight and, 13.5% with obesity. We observed no association of BMI classes with maternal or fetal composite criteria or with LGA, before or after adjustment for confounding factors. 18.3% women had a low GWG, 31.9% an adequate GWG and, 49.8% a high GWG. We didn’t find any

Conclusion: Despite some increase in hypoglycemia exposure, MDI+isCGM is equally effective and safe in terms of management and neonatal/maternal complications in comparison with the use of SAP in pregnant women with T1D.

Figure 1 Relationship between corrected birth weight with maternal glucose for Uganda (n=2844) red solid line, HAPO-Black (n=122) black solid line and HAPO-White (n=7079) black dotted line. The shading in grey reflects the 95% confidence limits of the mean. Corrected birthweight was internally calculated using birthweight corrected for gestational age and sex.

Disclosure: C. Font: None.

Chronic Disease

441

The use of intermittently scanned CGM vs sensor augmented pump in a cohort of pregnant women with type 1 diabetes: efficacy on glycaemic control and pregnancy outcomes.

C. Font1, N. Seguí1, V. Perea2, M. Rabassa3, D. Roca1, J. Bellart1, M. Giménez1, I. Conget1, I. Vinagre1;

1Hospital Clinic de Barcelona, 2Hospital Mutua Terrassa, 3Universitat de Barcelona, Barcelona, Spain.

Background and aims: SAP (sensor augmented pump) therapy has been shown to improve metabolic control and perinatal morbidity in pregnant women with type 1 diabetes (T1D). Few studies have compared the use of SAP with treatment with multiple doses of insulin (MDI) and intermittently scanned CGM (isCGM) in pregnant women with T1D. The objective of this study is to evaluate possible differences in metabolic control and maternal-fetal outcomes between both systems in these pregnant women.

Materials and methods: Cohort study in pregnant women with T1D controlled in two tertiary hospitals. The use of the SAP system (640G pump) was compared with FSL monitoring and MDI treatment in the period 2018-2021. The glucometric indicators for 14 days per trimester were expressed in odds ratios (OR) and their 95% confidence intervals (CI).

Results: 97 pregnant women (n=22 with SAP) were included. Pre-pregnancy control was higher in the SAP group, with no other significant differences between the two groups. Regarding glycemic control, in the FSL group, the % of time in range (63-140 mg/dl) was greater in the 1st trimester (62 vs. 58%, p=0.036), 2nd (64 vs. 52%, p =0.001) and 3rd trimester (73 vs. 68%, p=0.027), and mean glycemia was lower in the 1st (117 vs. 132mg/dl, p=0.007), 2nd (118 vs. 133mg/dl, p =0.001) and 3rd trimester (109 vs. 120mg/dl, p=0.001), while the % of time in hypoglycemia (<63mg/dl) was higher in the 2nd (7 vs. 4%, p=0.015) and 3rd trimester (6 vs. 4%, p=0.028). There were no differences in HbA1c or in the rate of severe hypoglycemia (Table). Regarding neonatal complications, a higher incidence of hyperbilirubinemia was observed in the SAP group (50 vs. 24.32%, p=0.021), which was not confirmed when adjusting for confounding factors (maternal age, body mass index and gestational age at first visit). There were no significant differences in the incidence of macrosomia, neonatal hypoglycemia, malformations, and perinatal mortality, or in the rate of maternal complications between the two groups.

Conclusion: We found that associations between maternal glucose and fetal birth weight are substantially lower in our SSA cohort than in countries recruited into the HAPO study. This suggests that cut-offs for pregnancy generated from other study populations need to be confirmed in SSA before they are adopted.
association between GWG and maternal or fetal composite criteria. But we observed a significant association between GWG and LGA. Using adequate GWG as reference, high GWG were associated with an increased rate of LGA (OR, 1.47; 95% CI, (1.02-2.11); p = 0.038) after adjustment in confounding factors.

Conclusion: In our study, pregestational BMI classes were not associated higher risk of adverse and infant outcomes. However, gestational weight gain greater than guidelines recommendations within recommended levels was associated with LGA.

Disclosure: A. Vambergue: None.

443
Does the prognosis of gestational diabetes whether it is diagnosed through fasting and/or post-load high glucose values?

Background and aims: Prognosis of gestational diabetes mellitus (GDM) may differ according to whether HPI has been diagnosed by high fasting glucose values only (isolated fasting GDM), post-OGTT glucose values only (isolated post-OGTT GDM) or both (fasting and post-OGTT GDM).

Materials and methods: From a multiethnic prospective study, we included women screened for GDM by a complete OGTT after 22 weeks of gestation (IADPSG/WHO criteria). We evaluated the risk for adverse pregnancy outcomes by GDM categories.

Results: We included 7,190 women, 30±5.5 years-old, body mass index 24.7±4.9 kg/m². There were 6,535 without GDM, 217 (3.0%) women with isolated fasting GDM, 310 (4.3%) with isolated post-OGTT GDM and 128 (1.8%) with fasting and post-OGTT GDM. The rates of Caesarean section were 19.4, 18.0, 27.7 and 24.2%; preeclampsia 1.8, 0.9, 1.9 and 2.3%; large-for-gestational-age (LGA) infants 8.5, 18.4, 12.3 and 20.3%; neonatal hypoglycemia 0.6, 1.0, 1.4 and 4.2% in the four groups, respectively. After adjusting for confounders (age, maternal body mass index, maternal height, ethnicity, smoking during pregnancy, family history of diabetes, parity, sex of the infant, hospitalization during pregnancy), as compared to no GDM, there was no increase in Caesarean section and preterm delivery in women with the three GDM categories. The adjusted odds ratio [95% confidence interval] for LGA infant were increased rate of LGA (OR, 1.47; 95% CI, (1.02-2.11); p = 0.038) after adjusted in confounding factors.

Conclusion: Despite glucose-lowering care (goal for fasting glucose ≤5.3 mmol/l, 2-hour post prandial glucose < 7.8 mmol/l), GDM is associated with more LGA infants than no GDM, especially when fasting plasma glucose is high during diagnostic OGTT. As GDM is diagnosed when fasting plasma glucose is ≥5.1 mmol/l or higher, it might be beneficial to lower fasting glucose value under this threshold throughout pregnancy.

Disclosure: E. Cosson: None.

444
Polyhydramnios in early pregnancy with normal OGTT is an indicator for further investigation regarding suboptimal glucose patterns in In Vitro Fertilisation pregnancies
1Diabetes Center & Clinic Hygeia General Hospital, 2Iaso Maternity Hospital, 3Mitra Maternity Hospital, 4Lito Maternity Hospital, Athens, Greece.

Background and aims: In Vitro Fertilization (IVF) has become a popular method of assisted reproduction. IVF has an increased incidence of complications, including polyhydramnios in early pregnancy. Polyhydramnios is associated with adverse pregnancy outcomes and high risk of perinatal mortality. Increased amniotic fluid is an indicator for impaired glucose metabolism. Maternal blood glucose (BG) levels have shown a strong continuous association with pregnancy complications. The aim of this study was to identify the presence of suboptimal BG patterns in IVF pregnancies with normal OGTT complicated by polyhydramnios before the 24th week of gestation. In addition, the impact of intensive glucose management on increased amniotic fluid was examined.

Materials and methods: This study presents 86 IVF pregnancies diagnosed with polyhydramnios without congenital malformations and normal OGTT before the 24th week. In this group the presence of suboptimal BG patterns (BG levels >90 fasting [FBG] or >120 md/dL 1hour postprandial [PPBG]) were detected using SMBG (70 individuals) and/or blind CGMS (16 individuals) for 7 days. Polyhydramnios was diagnosed using the 4 quadrant Amniotic Fluid Index (AFI) ≥24 cm and/or Deepest Vertical Pocket (DVP)>8cm. The CGMS BG levels were as follows Mean Sensor BG: 96.2±23 mg/dL, time>120 mg/dL: 295±38 min/24h. Clinical characteristics include the following age: 36± 4 years, BMI: 24.1±3.7 kg/m², OGTT: 0±85±5, 60±154±23, 120±128±22 mg/dL, HbA1c: 5.4±0.2%, Hadlock (BPD-AC-HC-FL) percentile: 55.8±1.2%, AFI25.1±2.8 cm, DVP: 8.7±1.2 cm. U/S polyhydramnios confirmation: 18.7±4 week. Insulin therapy was initiated to obtain tight glycemic control and was adjusted to reach the BG target <90 FBG and <120 mg/dL PPBG. Mean dosage required over the pregnancy duration was 42±20 IU. Polyhydramnios was monitored at least every 2 weeks by U/S after the initiation of insulin treatment.

Results: After insulin treatment (mean duration 30±18 days) the AFI was reduced to less than the 24cm threshold (21.7±1.3 cm - delta 3.5±1 cm) and the DVP was reduced to less than the 8cm threshold (7.3±1 cm - delta 1.4±1 cm). Fasting BG: 81.9±5 mg/dL, 1h-PPBG: 107.9±8 mg/dL. Pregnancy outcome Weight gain: 11±2 kg, Week of delivery: 37±6.1 week, birth weight: 2980±410 g, Small for Gestational age: 6.9%, Large for Gestational age: 4.6%, RDS: 13.9%, Neonatal Hypoglycemia: 5.8%, Preeclampsia rate: 4.6%, Caesarean Section (CS): 80.2%. The rate of CS was affected subjectively by the obstetricians’ and mothers’ preference.

Conclusion: Polyhydramnios is an indicator of suboptimal BG patterns in IVF pregnancies with normal OGTT and no congenital malformations. In IVF pregnancies with polyhydramnios this study suggests a need to further screen for abnormal BG patterns before the 24th week of gestation even with normal OGTT. SMBG and/or blind CGMS could be used to identify suboptimal BG patterns before the 24th week of gestation. Additional investigation of the efficacy of the current GDM screening and the target range for BG levels in IVF pregnancies must be considered. Intensive insulin therapy plays an important role in optimizing glycemic control and reducing polyhydramnios.

Disclosure: P. Thomakos: None.

445
Free fatty acid-induced alterations in hepatic glucose metabolism during gestation in prediabetic mice
M. Liebm ann, M. Asuaje Pfeifer, S. Schenreck;
Institute of Pharmacology, Toxicology and Clinical Pharmacy, Technische Universität Braunschweig, Braunschweig, Germany.

Background and aims: Gestational diabetes (GDM) is a complex metabolic disease that is typically diagnosed for the first time during pregnancy. The main characteristic of GDM is impaired glucose tolerance rather than persistent hyperglycemia, as in type 2 diabetes (T2DM). Further, GDM depends on different underlying pathomechanisms, these include

Disclosure: None.
adaptation defects in both beta cell mass and insulin secretion, severity of insulin resistance, and the presence of preconceptional (pc.) prediabetes. New Zealand obese (NZO) mice exhibit impaired glucose tolerance (IGT) before and during pregnancy, pc. hyperinsulinemia and develop hyperlipidemia with elevated plasma free fatty acids (FFA) during gestation, but no overt diabetes. In this regard, plasma FFA can be used as a marker, but they may also play a functional role in the development of GDM. Therefore, the aim of this study was to investigate the modulatory effects of FFA on the hepatic glucose metabolism in prediabetic mice during gestation.

Materials and methods: Female NZO mice and NMRI controls were examined pc. and on day 14.5 of gestation (d14.5). Animals were sacrificed at 9-10 weeks of age, livers were harvested and primary hepatocytes (PH) were cultured and examined untreated and after stimulation with insulin and co-stimulation with FFA (palmitic acid, 250 μM). AKT activity was then determined by ELISA (Ser473 phosphorylation after insulin stimulus). Hepatic glucose production was determined by fluorometric assay after overnight fasting with and without insulin stimulus. Hepatic glucose production was determined by fluorometric 2-deoxyglucose (2-DG) uptake assay, after initial glucose deprivation.

Results: Compared to the NMRI control, NZO-PH showed reduced AKT activation (pAKT/AKT ratio) after insulin stimulus both pc. (0.41 vs. 0.30 a.u., p < 0.05) and at d14.5 (0.38 vs. 0.23 a.u., p < 0.05). Stimulation with FFA reduced AKT activation in both strains (p < 0.001). The hepatic glucose production was significantly increased by FFA in NZO-PH compared to NMRI controls at both time points, pc. and at d14.5 (AUC pc.: 201.36 vs. 324.11, p < 0.01; d14.5: 219.21 vs. 319.57 a.u., p < 0.01), thus exhibiting a diminished response towards insulin stimulation. After insulin stimulation, NZO-PH showed decreased 2-DG uptake compared to controls at d14.5 (13.26 vs. 8.43 pmol/μg, p < 0.01). Co-stimulation with FFA and insulin significantly decreased 2-DG uptake in both strains, both pc. and at d14.5 (p < 0.0001), thus no apparent differences were observed between NZO-PH and NMRI controls.

Conclusion: FFA impaired AKT activation and the suppression of hepatic glucose production by insulin, while glucose uptake was still significantly reduced in NZO-PH compared to metabolic healthy NMRI controls. Since an increase in plasma FFA in vivo occurred only in pregnant NZO mice, this suggests an exacerbation of this effect. Thus, FFA are critical mediators of the prediabetic phenotype of NZO mice both pc. and during gestation. Elevated FFA during gestation could thus indicate a preexisting glucose tolerance disorder and require increased monitoring regarding future pregnancies.

Disclosure: M. Liebmann: None.

SO 25 Insulin sensitivity: lessons from cellular and animal models

Development of a 3D innervated human muscle-on-a-chip model for diabetes research

J. Son1, J. Ahn2, O.-K. Hong3, S. Lee3, S. Chung3; 1Internal Medicine, The Catholic University of Korea, Seoul, 2Mechanical Engineering, Korea University, Seoul, 3Life Sciences, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea.

Background and aims: A bioengineered three-dimensional (3D) human skeletal muscle construct that mimics structural and functional characteristics of native skeletal muscle is a promising in vitro model to evaluate muscle physiology and metabolism. In this study, we developed an innervated muscle-on-a-chip model using 3D human skeletal muscle bundles with motor neuron (MN) innervation, and then determined whether there are differences in the pattern of muscle metabolism-related gene expression and calcium flux between muscle bundles cultured with MN and those without MN.

Materials and methods: Muscle bundles were cultured with or without MN in custom-made microfluidic device. Briefly, human myoblasts were seeded into the muscle culture chamber of the device with 0.4% collagen/Matrigel mixture. After differentiation, human MN spheroid was injected into the connecting channel. Muscle bundles with or without MN were cultured additional 2-3 weeks.

Results: Muscle bundles and MNs showed the features of differentiated states. Peripheral location of the nuclei and cross-striated sarcomere pattern was showed within the cells. MNs expressed Isl1 and ChAT and projected their axons to muscle bundles. Neuromuscular junction was confirmed by co-localization of BTX+ acetylcholine receptors and NF-H+ axon. The expression levels of glucose transporter 4, PGC-1α, Myosin Heavy Chain 1 (MYH1), MYH2 and creatine kinase were significantly increased in muscle bundles cultured with MN compared to those without MN. When L-glutamate (100 μM for every 12hrs), a neurotransmitter, was treated to muscle-MN unit to mimic an exercise intervention, spontaneous muscle contraction and a time-dependent increase in intracellular calcium flux were observed in muscle bundles.

Conclusion: This 3D innervated human skeletal muscle-on-a-chip model provides an advanced in vitro model of human skeletal muscle with improved structure, function, and metabolic flux. Our model can be potential platform for studying metabolic changes of human skeletal muscle in various pathophysiological conditions, including diabetes. Supported by: This work was supported by the NRF grant, 2021RIF1A1061077 and research fund, BMCMC21LC03.

Disclosure: J. Son: None.

447 Epithelial insulin signalling: A gatekeeper of the gut barrier function?

S. Guilmene1, D. Gueddouri1, M. Cauzac1, F. Sicherre1, G. Boudry2, A.-F. Burnol1; 1Cochin Institute, INSERM U1016, Paris, 2Institut NuMeCan INRAE, INSERM, Rennes, France.

Background and aims: A common feature of obesity, associated insulin resistance and T2D, is their association with chronic low-grade inflammation and higher risk of infection. An early increase of intestinal permeability and subsequent translocation of bacterial endotoxins into circulation have been suggested to pave the road to the metaflammation that accompanies the diabesity cascade. While a comprehensive mapping of
the mechanisms that elicit or sustain such defective epithelial integrity remains poorly understood, microbial imbalance, food composition and hyperglycemia have been proposed to be at play. Because hyperglycemia and loss of insulin action are often two sides of the same coin, we hypothesize that, beyond hyperglycemia, defective intestinal insulin signaling could directly impair epithelial integrity.

Materials and methods: To address the potential role of intestinal insulin signaling per se in the regulation of gut permeability, we developed a mouse model of insulin receptor deficiency in the intestinal epithelium (IR^ΔGut^), that does not display parallel hyperglycemia or obesity, thereby allowing specifically the analysis of the functional consequences of local insulin resistance on gut permeability and gut barrier components.

Results: We first demonstrate that gut epithelial cells are highly responsive to insulin, and that intestinal insulin signaling is reduced in high fat diet-induced obese mice, suggesting that insulin-resistance directly impacts gut epithelium homeostasis. Of note, IR^ΔGut^ mice display enhanced gut permeability and deeper analyses of gut barrier components reveal a significant deterioration of antimicrobial defense by Paneth cells (PC) in IR^ΔGut^ mice, as illustrated by the drop in antimicrobial peptide expression, PC granules number and fecal lysozyme activity. Defective antimicrobial defenses upon loss of intestinal insulin action are accompanied by the onset of a significant gut microbial imbalance, that is characterized by a bloom of pro-inflammatory Proteobacteria. Moreover, the reduced expression of ISC markers and PC-derived ISC niche factors in IR^ΔGut^ mice suggests that insulin may also regulate intestinal stem cells (ISC) homeostasis. Accordingly, functional assays through quantification of intestinal organoids survival with PC-derived ISC niche factors pinpoint insulin signaling as a potential intrinsic mechanism of gut epithelial renewal. Further evaluations of the adaptive response to pathological conditions following intestinal IR loss show that IR^ΔGut^ mice display higher gut colonization by enteropathogens upon C. rodentium infections. Finally, intestinal IR deficiency is associated with a greater susceptibility to chemical-induced gut inflammation, as shown by higher and sustained weight loss, thereby reflecting inefficient re-epithelialization.

Conclusion: Together, our data indicate that intestinal insulin signaling is decreased upon obesity and acts as a gatekeeper of two essential components of the epithelial gut barrier: bactericidal and renewal capacities. Further investigations will help (i) to evaluate the mechanisms underlying functional defects of anti-microbial defense upon gut insulin resistance, and (ii) to assess whether insulin signaling represents an ISC intrinsic mechanism for gut barrier integrity maintenance.

Disclosure: S. Guilmeau: None.

448 Dietary sugar intake contributes to poor metabolic health and increased NASH-fibrosis risk in mice, regardless of glycaemic index

S.G. Lucic Fisher1, A.E. Brandon2, M. Huang3, S.M. Solon-Biet2, K.S. Bell-Anderson1
1School of Life and Environmental Science, The University of Sydney. 2School of Medical Sciences, The University of Sydney. 3Department of Anatomical Pathology, St. Vincent's Hospital, Sydney, Australia.

Background and aims: Carbohydrates are the most abundant macronutrient in the diet, their quality is paramount to good metabolic health. The glycaemic index (GI) measures carbohydrate quality based on postprandial blood glucose levels, with lower GI foods associated with better metabolic health. However, the GI has been criticized due to its characterization of fructose as Low GI regardless of its links to metabolic disease. In this study we fed mice diets containing sucrose (High GI) or isomaltulose (Low GI), two disaccharides both made up of glucose and fructose, to determine if GI could reduce metabolic dysfunction and non-alcoholic steatohepatitis (NASH) fibrosis risk after lifelong sugar exposure.

Materials and methods: C57BL/6J female mice were fed a sucrose, isomaltulose or AIN93-G diet and mated with chow males. Pups (n=10 litters/diet) continued their mother’s diet until 30 weeks. Body composition was determined by EchoMRI, feeding behaviour by BioDAQ and oral glucose tolerance tests performed. Livers were fixed in formalin, stained with H&E and Picrosirius red (PSR), and assessed for pathology. Plasma was analysed for liver enzymes. Statistical analysis was performed using a linear mixed effects model adjusted for litter effect.

Results: Both female and male pups fed sugar diets were fatter by 30-weeks compared to controls, but no difference in weight. Female sugar pups secreted more insulin in response to glucose and insulin peak was delayed in mice fed isomaltulose (AIN93-G 50.1 AUC vs sucrose 100.3 AUC p<0.05; vs 90.8 AUC isomaltulose p<0.01). At both 12- and 24-weeks, sugar fed mice ate for shorter periods of time (AIN93-G 414s/bout vs sucrose 416s/bout p<0.05; vs 420s/bout isomaltulose p=0.01) compared to AIN93-G mice but ate more frequently (AIN93-G 55 bouts/24hrs vs 75 bouts/24hrs sucrose p<0.001; vs 81 bouts/24hrs isomaltulose p<0.001) and had increased food intake over 24 hours (AIN93-G 2g vs sucrose 3.2g p<0.05; vs isomaltulose 3.4g p<0.05). Interestingly, at 24-weeks food intake was reduced, compared to 12-weeks in sugar-fed mice, but remained higher than AIN93-G mice. Utilising NAS fibrosis scoring, liver fibrosis (F3/F4) was observed in 42.8% of sucrose- and 24% of isomaltulose-fed mice compared to 0% of AIN93-G mice (AIN93-G vs sucrose p<0.01). This was corroborated by the % of red detected by PSR staining, with 3% detected in AIN93-G liver while sucrose and isomaltulose mice displayed 9% and 6.7%, respectively, at 200x magnification (AIN93-G vs sucrose p<0.01; vs isomaltulose p<0.05). Liver enzymes ALT (AIN93-G 143.2 U/L, sucrose 184.8 U/L, isomaltulose 191.5 U/L) and AST (AIN93-G 368.8 U/L, sucrose 448.5 U/L, isomaltulose 542.6 U/L) were also elevated in sugar mice. At 30-weeks AIN93-G mice had larger caecum’s than their sugar-fed counterparts (AIN93-G vs sucrose p<0.01; vs isomaltulose p<0.05).

Conclusion: These findings show that lifelong exposure to dietary sugars, regardless of their GI, can induce negative changes in metabolic health and increase NASH-fibrosis risk as confirmed by histology and liver enzymes.

Disclosure: S.G. Lucic Fisher: None.

449 A new role of endoplasmic reticulum-mitochondria calcium coupling in nutrient-induced Glucagon-Like Peptide 1 (GLP-1) secretion by L cells

A. Humbert, J. Rieuuset, CarMen Laboratory, INSERM UMR-1060, Lyon 1 University, INRA U1397, Pierre-Bénite, France.

Background and aims: Postprandial GLP-1 secretion by enteroendocrine L cells plays a major role in the regulation of glucose homeostasis, thus representing a therapeutic option of ever-growing significance for type 2 diabetes. However, the precise mechanisms linking nutrient sensing and GLP-1 secretion are incompletely elucidated. In this study, we focused on a potential new role of endoplasmic reticulum (ER)-mitochondria communication, at contact sites called MAMs (Mitochondria-Associated ER Membranes), as they are dynamically regulated by nutrients, they control cellular calcium homeostasis crucial for hormone secretion, and their miscommunication was implicated in alterations of glucose homeostasis in several tissues. This study aimed at evaluating the implication of MAMs in nutrient-induced GLP-1 secretion by L cells and at deciphering the mechanisms involved.

Materials and methods: The action of nutrients [5 mmol/l glucose, 30μmol/l deoxycholic acid (DCA), 100 μmol/l palmitoleic acid (PA) or 10 mmol/l glutamine-alanine dimer (Gln-Ala)] on MAMs (measured by...
in vitro Proximity Ligation Assay targeting VDAC1 and IP3R1) and GLP-1 secretion (ELISA, expressed as a ratio secreted GLP-1/total GLP-1) was studied in the STC-1 cell line. Treatments of 1 hour with nutrients and/or various inhibitors diluted in HEPES buffer enabled the characterisation of signalling pathways implicated in nutrient sensing. The causal role of MAMs in GLP-1 secretion has been evaluated by adenoviral expression of the organelle space protein FATE1, which disrupts MAMs. All results are expressed in % of effect (mean ± SEM, p-value, n) using appropriate statistical tests.

Results: In STC-1 cells, we confirmed that all known GLP-1 secretagogues induced GLP-1 secretion: glucose (+54 ± 20%; p<0.01; n=4 experiments (exp.)); DCA (+111 ± 18%; p<0.001; n=4 exp.); PA (+112 ± 31%; p=0.18; n=3 replicates (rep.)); Gln-Ala (+36 ± 1%; p=0.08; n=3 rep.). All of these nutrients also induced MAMs: glucose (+33 ± 1%; p<0.001; n=4 exp.); DCA (+36 ± 1.6%; p<0.001; n=4 exp.); PA (+53 ± 9%; p<0.01; n=6 exp.); Gln-Ala (+26 ± 2%; p<0.01; n=3 exp.). Adenoviral-mediated FATE1 expression, which reduced MAMs (-24% ± 4%; p<0.01; n=3 exp.), prevented glucose- and DCA-induced GLP-1 secretion. The inhibition of IP3R calcium release by 2APB (50 μmol/l) also prevented glucose- and DCA-induced GLP-1 secretion, suggesting calcium coupling effects. Mechanistically, we demonstrated that the glucose action on MAMs is electrogenic through SGLT1, as it is prevented by phloridzin (SGLT1 inhibitor, 1 mmol/l), diazoxide (KATP channel opener, 100 μmol/l) and the removal of extracellular calcium; those treatments also affected GLP1 secretion. Concerning DCA, its effect on MAMs is mediated through the TGR5-cAMP-PKA (Protein Kinase A) pathway as INT-777 (TGR5 agonist, 30 μmol/l) and forskolin (cAMP formation inducer, 10 μmol/l) mimicked DCA effects on both contacts and secretion when H89 (PKA inhibitor, 10 μmol/l) prevented them.

Conclusion: Altogether, these results demonstrate a new role of ER-mitochondria calcium coupling in nutrient-induced GLP-1 secretion in L cells. The signalling pathways involved in the regulation of MAMs vary between nutrients, with an electrogenic effect for glucose and an effect mediated through TGR5-cAMP-PKA pathway for DCA. Confirmation of these data in more physiological models is currently underway.

Supported by: EFSD Grant - ANR TriMAMvirate
Disclosure: A. Humbert: None.

450 Hexokinase-2 linked scheduled glycolysis as a driver of insulin resistance linked dysglycaemia: evidence in the murine C2C12 myotube model in vitro
M. Xue1, N. Rabbani2, P. Thorvalley1;
1Diabetes Research Center, Hamad Bin Khalifa University, 2College of Medicine, Qatar University, Doha, Qatar.

Background and aims: Insulin resistance in skeletal muscle is the major metabolic defect leading to the development of type 2 diabetes (T2DM) and represents a target of pharmacotherapy for diabetes prevention. There is currently no drug treatment addressing insulin resistance. The initiating metabolic dysfunction driving development of insulin resistance has not been discussed. Recently, stabilization of hexokinase-2 (HK2) to proteolysis by increased glucose concentration, increasing flux through early-stage glycolysis without increase in expression and activity of other glycolytic enzymes, was identified as the initiator of metabolic dysfunction in hyperglycemia in vascular cells. This creates a wave of increased glycolytic intermediates activating hexosamine and protein kinase C pathways and increasing formation of methylglyoxal. Increased glucose-6-phosphate displaces HK2 from mitochondria, producing mitochondrial hyperpolarization and dysfunction. This is termed HK2-linked unscheduled glycolysis. Skeletal muscle exposed to increased fasting plasma glucose may also stimulate this. To test this, we studied HK2 protein abundance in murine C2C12 myotubes incubated with 5.5 and 25 mM glucose for 4 days and studied the effect of glyoxalase 1 inducer, trans-resveratrol and hesperetin in combination (tRES-HESP). Protein abundances of HK2 and glycolytic enzymes in C2C12 myotube cultures incubated with low, medium and high glucose were mined from published supplementary data.

Materials and methods: Murine C2C12 myotubes were incubated in culture for 4 days with 5.5, 25 mM glucose and 25 mM glucose with 5 μM tRES-HESP. Thereafter, HK2 protein abundance was determined by Western blotting, normalized to β-actin. Protein abundances of HK2 and glycolytic enzymes in C2C12 myotube cultures incubated with 5.5, 11.1 and 25.0 mM glucose determined by label-free quantitative high resolution Orbitrap mass spectrometry proteomics were mined from published supplementary data. - Kato et al., Appl. Sci. 2022, 12, 1553. Data are mean ± SD (n = 3).

Results: In C2C12 myotubes, HK2 protein increased 46 ± 5 % in 25 mM glucose, compared to cultures with 5 mM glucose (P<0.001, n = 3; Western blotting). tRES-HESP reversed this increase. Published proteomics studies corroborated this with 1.5 and 1.8 fold increase of HK2 in 11.1 and 25.0 mM glucose cultures, compared to 5.5 mM glucose control (P<0.01, n = 3). Importantly, data mining of abundances of other glycolytic enzymes, hexokinase-1, glucose-6-phosphate isomerase, phosphofructokinase, aldolase, triosephosphate isomerase and glyceraldehyde-3-phosphate dehydrogenase, showed that abundances of all other glycolytic enzymes were unchanged.

Conclusion: We conclude that high glucose concentration in C2C12 myotubes in vitro exhibits conditions producing HK2-linked unscheduled glycolysis. Increased HK2 protein without increase of other glycolytic enzymes in myotubes with high glucose concentration supports the hypothesis of HK2-linked unscheduled glycolysis as a driver of insulin resistance. tRES-HESP may correct this. Previously in a randomized double blind, placebo controlled crossover study in overweight and obese subjects (Hats-off study), tRES-HESP corrected insulin resistance - which may be mediated by countering HK2-linked unscheduled glycolysis.

Supported by: QF funded project
Disclosure: M. Xue: None.
line (AML12) was transduced with an shRNA-Ide by means of a lentiviral vector and obtaining a stable line (AML12-shRNA-Ide). L-IDE-KO primary hepatocytes and AML12-shRNA-Ide with their respective controls were stimulated with glucagon and the signalling pathway was analysed by western blot and ELISA. Mitochondrial function and energy metabolism of AML12-shRNA-Ide and control cells were assessed by Seahorse XFe24 Analyzer with a Mito Stress assay.

**Results:** Liver extracts and primary hepatocytes from L-IDE-KO mice, compared to WT, showed decreased expression of glucagon receptor (~60%), CREB protein (~40%), and diminished phosphorylation of CREB (~50%) upon glucagon stimulation. CREB expression and CREB protein levels were reduced by ~50% in AML12-shRNA-Ide cells. At basal state, glucagon receptor, FoxO1 and CREB protein were significantly lower in AML12-shRNA-Ide cells than in control cells, (~40%, ~75% and ~75%, respectively). Glucagon stimulation resulted in less (~30%) cAMP levels and changes in the kinetic of glucagon-mediated phosphorylation of CREB and other PKA substrates in AML12-shRNA-Ide. Seahorse analyses showed that both oxygen consumption and extracellular acidification rates increased 2-fold in AML12-shRNA-Ide with a 2-fold increment of mitochondrial and glycolytic ATP production.

**Conclusion:** Reduced IDE expression in mouse hepatocytes has a deleterious effect on glucagon signalling, affecting this intracellular pathway in parallel with a shift to a more energetic phenotype. These findings suggest that IDE is necessary for a correct glucagon signalling and energy regulation in hepatocytes.

**Supported by:** LCF/PR/PRI/18/51130007 to G.P., MCIN/AEI/10.13039/501100011033 and CCVC/8485 to I.C.-C., and G.P.

**Disclosure:** C.M. González-Casimiro: Employment/Consultancy: Fellowship from the Junta de Castilla y León and the European Social Fund (ORDER EDU/574/2018).

**453**

Effects of protein restriction on glucose tolerance and large intestine morphofunction in C57Bl/6 mice

K.M. de Oliveira1, B.L. Alves1, J.A. Silva Junior1, G.M. Soares1, F. Mousovich-Neto1, R.A. Ribeiro1, E.M. Cameiro1; 1Universidade Estadual de Campinas, Campinas, Brazil.

**Background and aims:** Protein undernutrition induces damages in the gastrointestinal system and endocrine pancreas which have been correlated with the development of metabolic diseases such as type 2 diabetes mellitus. However, there is a lack of information regarding protein malnutrition actions on gut morphofunction as well as their impacts on glycemic homeostasis. Herein, we evaluated glucose homeostasis and large intestine morphofunctional parameters of protein-restricted mice.

**Materials and methods:** C57Bl/6 male mice from 30 to 120 days-old were distributed into control (C) group, which fed on a 14% protein diet; or protein restricted group (R), which fed on a 6% protein diet. Data were analyzed by Shapiro Wilk, followed by parametric (Student t) or non-parametric tests (Mann-Whitney U test); P <0.05.

**Results:** R mice had higher total food (364.2 ± 2.1 g/weeks1) intake during the experimental period when compared to C mice (298.8 ± 7.1 g/weeks1). Despite that, R group exhibited lower body weight (BW: 24.6 ± 0.6 g), feed efficiency (29.3 ± 0.3%) and Lee Index (304.6) when compared to C (27.2 ± 0.5 g, 41.4 ± 0.2%, 312.6 ± 1.5, respectively). Furthermore, protein restriction induced higher oral glucose tolerance during glucose (12175 ± 536.7mg/dL.min-1) and mixed meal (1924 ± 149.2) tolerance tests, increased insulin sensitivity (2.8 ± 0.1%min) and pancreas hypotrophy (8.0 ± 0.3 mg/g/BW) in R group when compared to C group (14291 ± 698.0 and 2970 ± 350.6 mg/dL.min-1, 2.1 ± 0.2%min and 10.4 ± 0.7 mg/g/BW, respectively). R mice exhibited a reduction in feces excretion (0.14 ± 0.03 g) and lower fecal energy content (3613 ± 33.0 kcal/g) in comparison to C (0.25 ± 0.03 g and 3698 ± 20.3 kcal/g, respectively). Also, intestinal permeability was 60% higher and claudin 2 protein expression in proximal colon was 43% lower in R group (0.3 ± 0.03 FITC μg/mL) than C group (0.5 ± 0.1 FITC μg/mL). Protein deprivation decreased cecum weight (5.3±1.3 mg/g BW) and length (0.2 ± 0.01 cm/NAL), and diminished alpha diversity in caecal microbiota in R mice (Shannon Index = 5.77) in comparison to C mice (8.3 ± 1.4 mg/g BW and 0.3 ± 0.01 cm/NAL). Proximal colon morphologic evaluation showed that R group had higher height (35.7 ± 1.9 μm) and number of colonocytes (15.0 ± 0.5 μm) than C group (21.3 ± 1.0 μm and 10.3 ± 0.3, respectively). In colonic crypts, protein restriction decreased the diameter (37.0 ± 0.8 μm), depth (138.6 ± 2 μm), and distance among crypts (57.0 ± 1.2 μm), besides that, goblet cells showed increased number (17.2 ± 0.4), but reduced area (123.3 ± 1.8 μm2) in R mice when compared to C mice (41.7 ± 1.2 μm, 143.6 ± 2.7, 60.0 ± 1.3 μm, 163.4 ± 0.4 and 215.0 ± 2.5 μm2, respectively). Finally, R mice proximal colon had a 45% decrease in mucin 2 mRNA expression, lower neutral (14.8 ± 1.0%) and acid (24.0 ± 0.5%) mucins positive areas in colonic crypts than C group (20.7 ± 1.0 and 27.5 ± 0.7%).

**Conclusion:** Protein undernutrition induced hypotrophy both in pancreas and cecum. Despite that, R mice had higher glucose tolerance due to increased insulin sensitivity, while in the cecum, the hypotrophy was associated with reduced microbiota diversity. Decreased mucin production, mucin 2 gene expression, and claudin 2 protein expression are probably linked with increased intestinal permeability, impairing intestinal barrier function in undernourished mice models.

**Supported by:** FAPESP (2020/03956-1, 2013/07607-8 and 2018/26080-4), CAPES and CNPq.

**Disclosure:** K.M. Oliveira: None.

**A hepatic vesicular glucose production dependent on Caveolin-1 controls energy and glucose metabolism**


**Background and aims:** The use of anti-diabetic drugs such as metformin to reduce hepatic gluconeogenesis is the first-line treatment for type 2 diabetes patients. Targeting hepatic gluconeogenesis is thus an efficient strategy to counteract the development of type 2 diabetes. Hepatic glucose production into the bloodstream depends on the GLUT2 transporter and a vesicular pathway. Our previous results suggested that the vesicular pathway of glucose production hinges on Caveolin-1 (Cav1). The objective of this project is to determine whether the vesicular pathway of glucose production controls energy and glucose metabolism.

**Materials and methods:** Based on a Cre-lox strategy inducible by tamoxifen, we developed a mouse model harboring a deletion of Cav1 specifically in the liver. We used three different protocols. Gene deletion was performed in 8 week-old mice by tamoxifen injections in protocols 1 and 2, then mice were fed either a standard chow diet (STD) or a high-fat, high-sugar diet (HFHS) for 15 weeks (protocol 2, L.Cav1-/-/HFHS). In protocol 3, mice were fed a HFHS diet for 12 weeks. Then, gene deletion was performed and the HFHS diet was followed for 12 weeks (HFHS.L.Cav1-/-). Wild-type mice were used as controls and received the same tamoxifen treatment. In vitro (cultured hepatocytes) and in vivo (pyruvate tolerance test) hepatic glucose production and insulin sensitivity were measured in protocol 1. Energy and carbohydrate metabolism (body weight, glucose and insulin tolerance tests, liver glycogen and enzymatic activities) were analyzed in protocols 2 and 3 and compared to wild-type mice.

**Results:** After 16 hours of fasting, hepatocytes from L.Cav1-/-/STD mice produce less glucose than wild-type hepatocytes. In vivo, pyruvate tolerance test confirms the lower fasting hepatic glucose production of L.Cav1-/-/STD compared to wild-type mice. This reduction in glucose...
production is not due to a decrease in hepatic glucose-6-phosphatase expression or activity. Insulin sensitivity is increased in L.Cav1-/--STD compared to wild-type mice. Consistently, L.Cav1-/--HFHS mice are protected from hyperinsulinemia (2.2ug/L ± 0.3 vs 3.5ug/L ± 0.5, p=0.05), impaired glucose tolerance and insulin sensitivity induced by HFHS diet. Moreover, L.Cav1-/--HFHS mice gain less weight (final body weight : 46.3g ± 1.2 vs 52.5g ± 1.0, p=0.01) and accumulate less hepatic triglycerides and cholesterol than wild-type mice, without differences in food intake or energy expenditure. The lower accumulation of lipids in the liver of L.Cav1-/--HFHS mice was parallel to an increase in the expression of genes involved in hepatic lipid oxidation. In mice previously fed with a HFHS diet (HFHS.L.Cav1-/-), deletion of Cav-1 specifically in the liver corrected hyperinsulinemia (2.2ug/L ± 0.4 vs 4.4ug/L ± 0.8, p=0.03), glucose intolerance and insulin resistance but not weight gain or hepatic steatosis induced by the diet.

**Conclusion:** Decreasing hepatic gluconeogenesis by specifically targeting the vesicular pathway of glucose production is sufficient to increase insulin sensitivity on a standard diet. This decreased hepatic glucose production prevents and corrects the deregulations of carbohydrate and energy metabolism induced by a HFHS diet, independently of a reduction in body weight. Our results highlight that the vesicular pathway of glucose production represents a promising therapeutic target in the prevention of type 2 diabetes.

**Supported by:** ANR TransGlucoPase

**Disclosure:** L. Da Costa: None.

---

**SO 26 Novel markers and omics signatures**

**454**

**Increased methylglyoxal formation in plasma and tissues during a glucose tolerance test originates from exogenous glucose and is enhanced in diabetes**


1Internal Medicine, Maastricht University, Maastricht, 2Unilever R&D, Wageningen, 3Health Council: current affiliation, The Hague, Netherlands.

**Background and aims:** The dicarbonyl compound methylglyoxal (MGO) is linked to diabetes and its vascular complications. We have previously shown that plasma MGO is increased postprandially and that individuals with type 2 diabetes (T2D) display higher postprandial MGO levels. We investigated whether postprandial MGO formation in plasma and tissues originates from exogenous glucose, and whether these changes are affected by T2D.

**Materials and methods:** In humans, we performed a stable isotope labeled oral glucose tolerance test (OGTT) in 12 healthy males (age 25 yrs, range 21-30 yrs), BMI 22.5 kg/m² (range 19.2-24.7 kg/m²). The treatment was a solution of 50 g glucose of which 2% is universally labeled D(+)13C6 glucose. Concentrations of MGO and glucose were measured in plasma at eleven time points with ultra-performance liquid chromatography-tandem mass spectrometry. In C57BL/6J and db/db mice, we performed an intraperitoneal GTT (IPGTT) with universally labeled D-13C6 glucose. Blood and pancreas, liver, spleen, kidney, visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) were collected at time 0, 30 min, 60 min, and 120 min for the measurement of concentrations of MGO at different time points of IPGTT.

**Results:** During the OGTT, plasma 12C MGO levels increased rapidly and reached a peak at 45 min, after which levels started to decline with the lowest level at 180 min post-load. After 180 min, plasma concentration of 12C MGO showed a slight increase. The plasma 13C MGO curve showed the same pattern as for 12C MGO, but the 13C MGO increase after 180 min was not observed. Plasma 12C MGO and 13C MGO followed the same pattern as for glucose. We calculated that newly formed MGO in the early phase of the OGTT is completely derived from exogenous glucose, while the increase of MGO after 180 min is not. In mice, the concentration of MGO in plasma and in tissues were 2 to 4.5-fold higher in db/db mice than lean mice. During IPGTT with D-13C6 glucose administration led to a fast increase of plasma 13C MGO concentrations and reached a peak at 30 min in control mice (189.7 ± 23.5 nmol/L) and with higher levels of increased plasma 13C MGO in db/db mice (397.8 ± 64.4 nmol/L; p<0.001). In tissues, concentrations of 13C MGO were increased in control mice for the first 30 min of the IPGTT and this was further increased in db/db mice. After 30 min, 13C MGO levels started to decrease in all tissues from control mice, while they continued to rise in pancreas, liver, spleen, and kidney or stayed high in VAT and SAT in db/db mice.

**Conclusion:** Exogenous glucose contributes to MGO formation both in plasma and in tissues during a glucose tolerance test and this was further increased in type 2 diabetes.

**Clinical Trial Registration Number:** ISRCTN42106325

**Disclosure:** X. Zhang: None.
Skeletal muscle creatine metabolism is altered in type 2 diabetes

D. Rizo-Roca1, L.A. Pendergraft3, A.V. Chibalin1, H.K.R. Karlsson1, M. Rydén2, E. Näslund3, J.R. Zierath1,4, A. Krook5;
1Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, 2Medicine (H7), Karolinska Institutet, Huddinge, 3Clinical Sciences, Karolinska Institutet, Stockholm, 4Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Background and aims: High plasma creatine levels are associated with an increased risk of developing type 2 diabetes. Skeletal muscle is the primary site of both glucose and creatine disposal; however, the mechanism controlling the crosstalk between skeletal muscle creatine metabolism and type 2 diabetes has not been clarified. Here, we investigated 1) whether intramuscular creatine and phosphocreatine (P-creatine) and related genes are altered in plasma and skeletal muscle from people with type 2 diabetes, and 2) if creatine supplementation or depletion modulates glucose metabolism in obese mice.

Materials and methods: Plasma and vastus lateralis biopsies were obtained from fasted men with normal glucose tolerance (NGT, n=25) or type 2 diabetes (n=25). Creatine and P-creatine were assessed by LC-MS (NGT, n=15; T2D, n=25). Gene expression was obtained from a microarray analysis (n=25 both groups). Further experiments were performed on 5-week-old C57BL/6 male mice fed a chow (n=10) or a high fat diet (HFD, 60% kcal from fat, n=30) for 8 weeks. During the last 2 weeks of the dietary intervention, HFD mice received a daily intraperitoneal injection of either vehicle (PBS; n=10), creatine (0.3 mg/g) or a creatine kinase competitive inhibitor (βGPA; 0.4 mg/g). Mice were randomly assigned to groups. Body composition and GTT glucose tolerance was assessed. Ex-vivo skeletal muscle glucose transport was assessed using radiolabeled glucose. Statistical difference was determined using Student’s t test or Mann-Whitney U test in human studies, and one-way ANOVA or Kruskal-Wallis in animal studies.

Results: Compared to individuals with NGT, plasma creatine was increased in people with type 2 diabetes (+49%; p=0.015), while skeletal muscle P-creatine was reduced (-32%; p=0.02). These changes were associated with reduced mRNA of the creatine transporter SLC6A8 (-18%; p=0.022) and mitochondrial creatine kinase CKMT2 (-47%; p=0.011). Plasma creatine was inversely correlated with SLC6A8 mRNA (Spearmans’ ρ =-0.63, p<0.001) and skeletal muscle P-creatine was correlated with CKMT2 mRNA (Spearmans’ ρ =-0.33, p=0.03). Fasting blood glucose was inversely associated with skeletal muscle P-creatine level in people with type 2 diabetes (Spearmans’ ρ =-0.43, p=0.04). HFD-fed mice treated with creatine had a greater increase in body weight (+4.5%, p=0.03) as compared to HFD-fed mice treated with PBS. GTT glucose tolerance was impaired in all HFD-fed mice (p=0.02). Glucose uptake was decreased in extensor digitorum longus (basal: -35%, p=0.02 vs. chow) and soleus (basal: -40%, p=0.01; insulin: -44%, p=0.002) muscle of obese HFD-fed mice, while βGPA restored glucose uptake to control levels (p=0.05 vs chow, except in insulin-stimulated soleus). HFD-fed mice (n=8-10 per group) had reduced expression of Ckm (log2 Fold-change vs Chow-PBS 0.04), Ckm2 (0.55±0.06, p=0.0002), Hk2 (0.41±0.13, p=0.024) and Igf1 (-0.55±0.06, p=0.02), while creatine treatment prevented the downregulation of gene expression.

Conclusion: Our data suggest that increased plasma creatine and reduced skeletal muscle P-creatine are a consequence, rather than a cause of insulin resistance in type 2 diabetes.

Disclosure: D. Rizo-Roca: None.
Ex vivo and in vivo experimental investigation of miR-148a-3p as a novel therapy for insulin secretion and type 2 diabetes


Background and aims: Several microRNAs are differentially expressed in diabetes and essential for β-cell function. We previously described how miR-152 influences insulin production and release, recent preliminary data from our other studies confirm miR-148a-3p as the most abundant miR-148a-152 family member in islets, and several others have pinpointed miR-148a as perturbed in diabetes. Together these findings led us to identify miR-148a-3p as a novel target for modulating β-cell insulin secretion. Here, we evaluate its role on insulin secretion and glucose metabolism in ex vivo and in vivo models of diabetes.

Materials and methods: MiR-148a-3p expression was quantified in islets from non-obese diabetic Goto-Kakizaki (GK) rats (6, 11 & 13.5 weeks) and obese diabetic db/db mice (10-12 weeks), as well as in glucolipotoxicity treated islets from standard NMRI (Naval Medical Research Institute) mice (12 weeks). LNA (locked nucleic acid) mediated miR-148a-3p silencing (50 nM) and subsequent insulin secretion and content assessments were performed in islets extracted from 7-week-old GKs. Thereafter, in vivo studies were performed for further metabolic investigations, where 5- and 11-week-old GKs were treated with LNA (two bolus injections at 20 mg/kg (Day 2 and 7) over 10 days) to silence miR-148a-3p. TargetScan (http://www.targetscan.org/) was also used to predict miR-148a-3p targets. All experimental data were analysed by unpaired t-test, 1- or 2-way ANOVA.

Results: MiR-148a-3p expression was significantly upregulated in islets from GK rats and an increasing trend was observed with increasing GK age (GK (11.5 weeks) vs GK (6 weeks): p<0.01, n=5). Furthermore, the potency of miR-148a-3p LNA mediated silencing in the GKs in vivo as well as the effects on the insulin secretory capacity in the islets of treated animals appears to increase with diabetic status. Finally, miR-148a-3p effects on insulin secretion may potentially occur via regulation of ATP6AP2 and/or GLRX5 in rodents and humans.

Conclusion: MiR-148a-3p expression is influenced by increasing diabetic phenotype independent of obesity. Adequate and specific silencing of miR-148a-3p in the islets of the GK model improves insulin secretion. Furthermore, the potency of miR-148a-3p LNA mediated silencing in the GKs in vivo as well as the effects on the insulin secretory capacity in the islets of treated animals appears to increase with diabetic status. Finally, miR-148a-3p effects on insulin secretion may potentially occur via regulation of ATP6AP2 and/or GLRX5 in rodents and humans.

Supported by: EFS/MSD Research Programme, Physiological Society Lund, SSPi(LUDC-IRC), SRC; SRA grant SFO-EXODIAB & project grants

Disclosure: E. Cowan: None.
meal tests (MMT) containing 30 g of D-xylene. First, we analyzed the association between post prandial blood glucose and serum D-xylene appearance in 74 minipigs (cross sectional study). Second, we conducted longitudinal studies to analyze the changes of post prandial blood glucose excursion and serum D-xylene appearance following MMT induced in healthy minipigs by three specific interventions: 70% intestinal resection (n = 5) (to decrease IGA), 70% pancreatectomy (n = 15) (to decrease insulin secretion), and high fat diet for 2 months (HFD) (n = 8) (to decrease insulin sensitivity). Third, to evaluate the potential bias induced by gastric emptying during MMT, we measured serum D-xylene appearance when the meal was administered in the same animals orally or directly administered in the proximal jejunum via a surgically implanted jejunal tube.

Results: Blood glucose excursion and serum D-xylene appearance during MMT are illustrated in Fig. 1a. Incremental 30 min postprandial glucose was correlated with 180 mn-area under curve of D-xylene appearance (r = 0.65; r² = 0.42; p < 0.0001) (Fig.1b). In multivariate analysis this association remained significant following adjustment to insulin secretion (insulinogenic index) and insulin sensitivity (Matsuda index) (β = 0.62 ± 0.09; r = 0.61; r² = 0.45; p < 0.0001). Longitudinal studies showed that D-xylene plasma appearance was significantly reduced after intestinal resection (55.5 ± 18.7 before vs 31.5 ± 4.8 after; p < 0.05), but remained unchanged after pancreatectomy (58.2 ± 24.4 before vs 55.5 ± 30.1 after; p = 0.35), and after HFD (43.1 ± 16.7 before vs 45.6 ± 12.6 after; p = 0.38). Finally, serum D-xylene appearance was not significantly different following oral (59.1 ± 15.3) or intrajejunal (59.0 ± 12.8) (p > 0.99).

Conclusion: In the Minipig, early postprandial glucose during MMT was correlated with D-xylene appearance, independently of insulin secretion, insulin sensitivity and gastric emptying. The results of our longitudinal experiments suggest that D-Xylene appearance could be used as a simple and reproducible proxy to evaluate IGA in large mammals.
SO 27 If you cannot measure it, you cannot improve it: novel methods in diabetes research

461
Do indices from mixed meal tolerance test follow the hyperbolic relationship between insulin sensitivity and insulin secretion?
N. Nielsen, K. Karstoft, H. Ellingsgaard, L. Lehrskov, N. Pilmark, M. Ried-Larsen;
Centre for Physical Activity Research, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

Background and aims: There is a paucity of studies investigating whether indices of insulin secretion and sensitivity derived from a mixed meal tolerance test (MMTT) follow the hyperbolic relationship and can be used to discriminate between persons with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and overt type 2 diabetes (T2D), thus we aimed to investigate this.

Materials and methods: Data were collected from seven clinical trials including persons with NGT (n=49, HbA1c <42 mmol/mol), IGT (n=59, HbA1c 42-47 mmol/mol) or T2D (n=113, HbA1c >47 mmol/mol). Prior to the investigation, the participants were fasting >10 hours and glucose-lowering medication was discontinued >48 hours prior to test. Participants consumed a 735-kcal liquid meal (25E% fat, 63E% carbohydrate and 12E% protein). Samples were collected before and until 120 min post ingestion. Indices for insulin secretion and sensitivity were calculated based on plasma glucose and insulin values. The Matsuda index (\(\Delta\text{Insulin}_{0-30}\text{min} / \Delta\text{Glucose}_{0-120}\text{min}\)) was calculated as a measure of insulin sensitivity (SI), and two different indices for insulin secretion were calculated; the early phase (\(\Delta\text{Insulin}_{0-30}\text{min} / \Delta\text{Glucose}_{0-120}\text{min}\)) and the total secretion (ratio of the area under the curve of insulin to area under the curve of glucose from 0-120 min, AUC). The association between SI and indices of insulin secretion were investigated to identify the satisfaction of the hyperbolic criteria (regression coefficient (r-value) approximately equal to -1 and the 95% confidence interval of the regression coefficient excluding 0).

Results: Mean (SD) HbA1c, age and sex were 37 (9) mmol/mol, 44 (12) years, 23 % female for NGT, 44 (5) mmol/mol, 49 (9) years, 49 % female for IGT and 50 (7) mmol/mol, 58 (10) years and 29 % female for T2D, respectively. The r-values (95%CI) for the hyperbolic relationship between SI and IGI or AUC were -0.97 IGI (-1.52 to -0.43) and -1.02 AUC (-1.19 to -0.82) for NGT, -0.12 IGI (-0.43 to 0.18) and -0.56 AUC (-0.71 to -0.41) for IGT and -0.45 IGI (-0.71 to -0.18) and -0.86 AUC (-1.07 to -0.65) for T2D. SI was 16 (1), 7 (2) and 5 (1) arbitrary units (a.u.) for NGT, IGT and T2D, respectively (P<0.01 for all between-group differences). IGI and AUC were -71% and -32% lower for T2D vs. NGT (P<0.01). For IGT vs. NGT, IGI was lower by -31%, but AUC was higher by 39% (P<0.01). \(Dl_{\text{IGI}}\) was 6408 (1290), 2170 (241) and 596 (65), and \(Dl_{\text{AUC}}\) was 905 (38), 616 (33) and 195 (12) a.u. for NGT, IGT and T2D, respectively. Both the DI and SI indices discriminated between all the classifications of NGT, IGT and T2D (all P<0.001) (figure 1).

Conclusion: The hyperbolic relationship between insulin sensitivity and insulin secretion can be established from a MMTT with a better model fit using AUC over IGI. DI derived from combinations of SI and both AUC and IGI, discriminated between stages of glucose tolerance.

462
Tissue-specific and whole-body insulin sensitivity by integrated imaging and hyperinsulinaemic euglycaemic clamp: a repeatability study in type 2 diabetes subjects
I. Laitinen1, H. Litorp2, F. Sjöberg5, H. Haraldsson1, S. Ekström5, S. Pierrou1, S. Southekall4, M. Lu3, T. Coskun5, Z. Milicevic5, L. Johansson1;
1Antaros Medical, Mölndal, Sweden, 2Clinical Trial Consultants AB, Uppsala, Sweden, 3Antaros Medical, Uppsala, Sweden, 4Avid Radiopharmaceuticals Inc, Philadelphia, USA, 5Eli Lilly, Indianapolis, USA.

Background and aims: Assessment of glucose tissue uptake by positron emission tomography (PET) imaging under hyperinsulinaemic euglycaemic clamp (HEC) is a powerful tool for quantification of tissue-specific insulin resistance. An integrated whole-body PET and MRI (magnetic resonance imaging) dynamic assessment provides quantitative readout in several tissues simultaneously. The aim of the study was to investigate the repeatability of both whole-body glucose utilisation and tissue-specific insulin sensitivity with combined dynamic PET/MRI and HEC in T2D subjects.

Materials and methods: The study included overweight or obese T2DM subjects (n=16 completers) for two repeated examinations in standardised conditions one week apart. After overnight fasting, HEC was established and maintained (Insulin 56 mU/m2/min). In steady state, fluorine-18-deoxyglucose (18F-FDG) was injected and series of PET and MRI scans were repeated. Whole-body glucose utilisation (M-value) was calculated from the duration of the PET/MRI scan (1 hour). Tissue-specific glucose uptake (GU) were calculated from merged whole-body PET images using Patlak model, in skeletal muscle, subcutaneous and visceral adipose tissue (SAT, VAT), myocardium, and brain. The repeatability was assessed by calculating the intraclass correlation coefficient (ICC method 2.1) point estimates and the 95% confidence intervals (CI). ICC levels were defined as the following: lower 95% CI of ICC ≥ 0.75 indicates excellent, 0.6 - 0.74 good, 0.4 - 0.59 fair and <0.4 poor reliability.
**Results:** Repeatability was assessed in 16 subjects (full analysis set, FAS) and in a subset of 12 subjects (per protocol set, PPS, defined by a consistent HEC over both visits). The measured M-values and tissue GU displayed varying levels of insulin resistance (Table 1). ICC of M-value was 0.84 (95% CI 0.63-0.94) for the FAS, and 0.95 (95% CI 0.86-0.99) for PPS, indicating a good to excellent reliability of the M value as an assessment of whole-body insulin sensitivity during HEC and PET/MRI experimental setup in T2DM subjects. Tissue-specific GU reliability was fair to excellent of the GU in skeletal muscle in FAS and PPS analysis sets (ICC 0.78 and 0.94 with lower 95% CI 0.50 and 0.83, respectively). For the other measured tissues, the ICC indicated fair to good reliability for SAT, VAT, myocardium, and brain (Table 1).

**Conclusion:** 18F-FDG-PET/MRI provides selective information on tissue-specific insulin sensitivity during hyperinsulinemic-euglycemic clamp with a reliability comparable to standard global M-value calculation. The method has potential to provide benefits in monitoring and evaluating T2DM treatment effects in interventional trials.

**Background and aims:** Nonalcoholic fatty liver disease (NAFLD) is strongly associated with type 2 diabetes and obesity. Insulin resistance (IR) is proposed as the driving factor. NAFLD is increasingly reported in type 1 diabetes (T1D), but the link between IR and NAFLD in this population needs elucidation. Furthermore, people with T1D are an excellent theoretical model to investigate IR in relation to NAFLD without confounders. This study aimed to assess whether IR is correlated with liver fat content (LFC) in adult people with T1D, independently from BMI. These data support the pivotal role of IR in NAFLD pathophysiology and its therapeutic potential.

**Disclosure:** J. Mertens: None.

464

**Evaluation of renal glucose uptake with [18F]FDG-PET:** methodological advancements and clinical outcomes

E. Rebello1,2, A. Mari1, V. Oikonen1, H. Iida1, P. Nuutila1, E. Ferramini2;
1Turku PET Centre, University of Turku, Turku, Finland, 2Institute of Clinical Physiology, CNR, Pisa, Italy, 3Institute of Neuroscience, CNR, Padova, Italy.

**Background and aims:** Renal metabolism has been previously assessed in humans using the arterial-venous (AV) differences technique, reporting whole-kidney glucose uptake rates ~38 μmol min⁻¹ 100g⁻¹ in healthy subjects. On the contrary, studying renal glucose metabolism non-invasively in humans has been thus far an unmet need. Positron emission tomography (PET) is the current gold standard for measuring regional tissue glucose uptake rates (GU), but the most widely used glucose analogue ([18F]FDG) is not a good substrate for sodium-glucose cotransporters (SGLTs). As a consequence, [18F]FDG spills over into the urine and [18F]FDG-PET considerably underestimates published rates of whole renal glucose uptake obtained using the arterial-venous differences technique.

**Materials and methods:** Morbidly obese and 9 lean subjects were studied with [18F]FDG-PET under fasting and insulin clamp (1mU/kg/ min) conditions. Abdominal radioactivity was acquired ~90 min from tracer injection. At the end of the studies, participants voided their bladders and radioactivity in the urine was measured and decay-corrected. Based on the amount of [18F]FDG excreted in the urine we estimated intraluminal [18F]FDG radioactivity concentration. Thin regions of interest (ROI) were drawn in the renal cortex and in the renal medulla (Figure A), and the PET data were analysed using fractional uptake rate (FUR). FUR were multiplied by plasma glucose values to obtain cortical and medullary GU rates. The estimates of intraluminal [18F]FDG radioactivity were then used to correct the GU values.

**Results:** We found that the corrected glucose uptake is consistently higher in the medulla than cortex (3.30 [4.67] vs 1.15 [3.43] μmol min⁻¹ 100ml⁻¹ in fasting (p=0.0006), and 3.32 [2.43] vs 2.05 [2.99] μmol min⁻¹ 100ml⁻¹ in insulin clamp (p<0.0001)). Both cortical and medullary glucose uptake are higher in lean than obese participants under both fasting (cortical GU: 2.2 [1.6] vs 0.1 [3.8] μmol min⁻¹ 100ml⁻¹, p=0.008; medullary GU: 6.6 [6.9] vs 2.4 [3.2], p=0.008) and insulized conditions (cortical GU: 3.8 [0.9] vs 1.2 [1.6] μmol min⁻¹ 100ml⁻¹ p=0.0008; medullary GU: 5.0 [2.9] vs 2.9 [1.3], p=0.002). Moreover, cortical but not medullary glucose uptake is increased from fasting to the insulinized condition (Figure B).

**Conclusion:** Compared to the existing literature based on the AV differences technique, [18F]FDG-PET underestimates considerably renal GU rates. However, the data show for the first time that [18F]FDG-PET can still provide relevant physiological information on regional renal glucose
uptake on the condition that $[^{18}F]FDG$ uptake is corrected for tubular radioactivity. Based on this study, we conclude that the human renal cortex is an insulin sensitive tissue.

Clinical Trial Registration Number: NCT00793143
Supported by: EFSD/MSD Research Programme
Disclosure: E. Rebelos: None.

466
Zinc-dependent insulin multimerisation: a study using FRET
R. Fritzzen1, A.J. Gourley1, C.A. Blindauer2, J. Penedo3, A.J. Stewart1;
1School of Medicine, University of St Andrews, St Andrews, UK, 2Department of Chemistry, University of Warwick, Coventry, 3School of Biology, University of St Andrews, St Andrews, UK.

Background and aims: Both physiological insulin and insulin analogues used in the treatment of diabetes, exist in different multimeric states. Physiological insulin is stored in pancreas as a hexamer but is thought to only be “active” (able to bind to cognate receptors) in its monomeric form. Formation of insulin multimers requires the coordination of Zn2+ and Ca2+ ions, where initially dimers form, before coming together to form the hexamer. Deproportionation of the hexamer after paracrine release and the factors that control this process at physiologically relevant insulin concentrations (high pM/low nM range) have not been extensively studied. This is mainly due to a lack of sensitivity in the tools and approaches that have, up until now, been used to examine this process. Förster Resonance Energy Transfer (FRET) is a physical phenomenon occurring between a donor and an acceptor fluorophore. When in the vicinity of one another (1 to 10 nm), some of the energy received by the donor upon excitation is transferred to the acceptor which emits a photon at a characteristic wavelength allowing detection. When FRET occurs, the intensities of the donor and acceptor decrease and increase respectively proportionately to the distance separating the two fluorophores. Here we have generated insulin molecules labelled with the FRET-compatible dyes, Atto532 and Atto647N to study insulin complexation and decomplexation.

Materials and methods: Human insulin was crosslinked to Atto532 and Atto647N NHS esters through bioconjugation, where covalent linkage is targeted to the LysB29 residue of insulin. Labelling efficiency was determined using time-of-flight mass spectrometry and absorbance spectrophotometry under different conditions (varying metal ion concentrations, temperature and pH).

Results: We obtained >70% monolabelled insulins with each respective dye. The insulins when mixed readily formed multimeric complexes that produced characteristic FRET signals. Mass spectrometric analysis of samples provided confirmation (and characterisation) of respective multimeric forms of insulin.

Conclusion: Here we have developed sensitive fluorescence-based tools to study insulin multimerization and decomplexation at physiologically relevant concentrations. These can be used to better understand insulin dynamics in vivo. Furthermore, the same approach may be applied to insulin analogues to study the pharmacodynamics of insulin-based therapeutics under different conditions.

Supported by: This project is supported by BBSRC (grant no. BB/V014684/1).
Disclosure: R. Fritzzen: None.

467
Mechanisms underlying nutrient sensing in human glucose-dependent insulinotropic polypeptide secreting cells
N. Guccio, E.L. Miedzybrodzka, C.A. Smith, R. Bany Bakar, F. Reimann, F.M. Gribble; Wellcome-MRC Institute of Metabolic Science-Addenbrooke’s hospital, University of Cambridge, Cambridge, UK.

Background and aims: Glucose-dependent insulinotropic polypeptide (GIP) is a hormone secreted by a subset of enteroendocrine cells, namely K cells, found in the duodenum and proximal jejunum. GIP has long been neglected in comparison to its sister incretin glucagon-like peptide-1 (GLP-1), partly because in early studies GIP was less efficient than GLP-1 in stimulating insulin secretion during hyperglycaemic clamps in diabetic volunteers. The superior weight reduction seen with dual GIPR/GLP-1R agonist in comparison to GLP-1R-only agonist in recent clinical studies has, however, rekindled interest in GIP and the aim of this study was to identify mechanisms of GIP secretion from human K-cells.

Materials and methods: CRISPR-Cas9-mediated homology directed repair (HDR) was used to insert a yellow-fluorescent protein (Venus) transgene behind a ribosomal stutter sequence (P2A) to enable bicistronic expression from the GIP locus in human duodenum-derived organoids. The newly generated organoid reporter line was then used to perform fluorescence-activated cell sorting of Venus-expressing K cells for bulk RNA-sequencing, and live single-cell imaging experiments after loading with the Ca2+-sensitive fluorescent indicator fura2-AM. GIP secretion was assessed by ELISA of cell supernatants.

Results: Comparison of the transcriptome of Venus positive K-cells and fluorescent negative cells collected in parallel demonstrated strong enrichment in GIP mRNA (102-fold), confirming correct targeting of the fluorescent protein. Whilst the sodium dependent glucose transporter SGLT1 (SLC5A1), previously implicated in glucose sensing, was similarly expressed in both cell populations, a number of G-protein coupled receptors potentially involved in nutrient sensing were enriched in K-cells (n=4). These include amino acid-sensing receptors CASR (p<0.05) and GPR142 (p<0.05), long-chain fatty acids (LCFAs) receptor FFA1 (p<0.05), monocacylglycerol-sensing receptor GPR119 (p<0.05) and bile acid-sensing receptor GPBAR1 (p<0.05). K-cell intracellular calcium levels were elevated following stimulation with 10 mM glucose (p<0.01; n=8), 20 mM L-phenylalanine (p<0.001, n=13), 20 mM L-tryptophan (p<0.0001; n=15) and 10 μM AM1638, a FFAR1 agonist (p<0.0001; n=22). Ca2+-responses correlated broadly with secretory responses, with AM1638 (10 μM) and glucose (10 mM) stimulating GIP-secretion 2- (p<0.01, n=8) and 1.8-fold (p<0.001; n=12), respectively.

Conclusion: This study has generated the first in-vitro model for studying identified human K cells. We identified a number of nutrient sensing pathways underlying human GIP secretion and the model will be employed to investigate strategies for future modulation of K-cell secretion in diabetes and/or obesity therapy.

Supported by: Wellcome Trust
Disclosure: N. Guccio: None.
SO 28 Understanding insulin sensitivity: lessons from the clinic

467 Comparison of predictive value of insulin resistance indices in young women with polycystic ovary syndrome
S. Hong1, Y.-A. Sung1, Y. Hong1, H. Lee1, K. Jeong2, H. Chung2, D. Song3, H. Jung3
1Internal Medicine, Ewha Womans University College of Medicine.
2Obstetrics and Gynecology, Ewha Womans University College of Medicine, Seoul, Republic of Korea.

Background and aims: Polycystic ovary syndrome (PCOS) is a reproductive-metabolic disorder and insulin resistance is the main pathophysiology of PCOS. We aimed to investigate the superiority of four indices of insulin resistance in young women with PCOS and controls.

Materials and methods: This cross-sectional analysis included 667 women with PCOS, diagnosed by the National Institute of Child Health and Human Disease criteria, and 289 controls regular cycling control women. Triglyceride/glucose (TyG) index, lipid accumulation product (LAP), visceral adiposity index (VAI), and triglyceride/HDL cholesterol (TG/HDL) were measured, and insulin resistance was defined as a value of homeostatic model assessment-insulin resistance (HOMA-IR) ≥ 2.5.

Results: In women with PCOS, the one-standard deviation (SD) increment of TyG index, LAP, VAI, and TG/HDL significantly increased insulin resistance (all P < 0.05). Similar trends were observed in control women, but TyG index was not statistically significant. In both groups, LAP constituted the strongest impact on detecting insulin resistance than TyG index, VAI, and TG/HDL (OR = 4.85 in PCOS, OR = 1.91 in control, respectively). All ROC curves of TyG index, LAP, VAI, TG/HDL for detecting insulin resistance were located statistically above the diagonal nondiscrimination line. The optimal cutoff values for TyG index, LAP, VAI, and TG/HDL for detecting insulin resistance were 4.320, 2.44, 1.88, and 1.85 in PCOS women and 3.344, 25.9, 1.34, and 1.70 in control women, respectively.

Conclusion: In women with PCOS, TyG index, LAP, VAI, and TG/HDL showed similar potential in detecting insulin resistance and LAP was the strongest discriminator.

Disclosure: S. Hong: None.

468 Identification of myokines potentially involved in the improvement of glucose homeostasis after bariatric surgery
L. Orioli1,2, M. Canouil3,4, K. Sawadogo5, L. Ning3,4, L. Dedieucque2, P. Lause2, M. history to baseline (HbA1c, +0.96; -0.19, p≤0.001). In women with PCOS, TyG index, LAP, VAI, and TG/HDL showed similar potential in detecting insulin resistance and LAP was the strongest discriminator.

Disclosure: L. Orioli: None.

469 Do sex differences in pediatric type 1 diabetes exist? A systematic review
S.A.G. de Vries1, C.L. Verheugt1, D. Mul2, M. Nieuwdorp1, T.C.J. Sas1,2
1Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, 2Diabetes, Rotterdam, 3Pregnancy, Erasmus University Medical Center, Amsterdam, Netherlands.

Background and aims: Sex differences are present in cardiovascular care and outcomes among adult patients with type 1 diabetes mellitus (T1DM), which typically commences in childhood. Younger age at diagnosis and longer disease duration increase risks of adverse outcomes. It is not known if sex influences care and outcomes in childhood. This systematic review provides an overview of sex differences in children with T1DM with a focus on patient and disease characteristics, treatment, comorbidities and complications.

Materials and methods: Literature in MEDLINE up to June 15, 2021 was searched, using the terms diabetes mellitus, sex characteristics, sex distribution, children and/or adolescents. Articles reporting sex differences were identified and assessed on quality with Joanna Briggs Institute critical appraisal tools. Narrative synthesis and an adapted Harvest plot were used to summarize evidence by category.

Results: A total of 8,640 articles were identified, rendering 86 studies for review. Selected studies showed higher HbA1c for girls, at diagnosis,
during treatment and HbA1c increase over time. Studies reported higher prevalence of being overweight or obese, BMI and more dyslipidemia in girls. Hypoglycemia and partial remission occurred more in boys, but ketoacidosis and hospitalization in girls. Girls used pump therapy more often and needed higher insulin doses. Most comorbidities were more common in girls. All studies reported lower quality of life in adolescent girls.

Conclusion: Sex disparities were observed in children with T1DM. Several outcomes were disadvantageous to girls, especially during adolescence. Attention for the cause and treatment of these differences may provide an opportunity for better outcomes.

Disclosure: None.

470 Effects of Lisosan-G on postprandial hypoglycemia after bariatric surgery
D. Moriconi1, S. Baldi1, L. Antonioli1, L. Pucci2, S. Taddei1, M. Nannipieri1
1Department of Clinical and Experimental Medicine, University of Pisa, 2IBBA, CNR, Pisa, Italy.

Background and aims: Postprandial hypoglycemia (PPHG) is a known late complication of bariatric surgery that increase the risk of cardiac arrhythmias and persistent cognitive deficits. Lisosan G (LG) is a fermented powder obtained from whole grains (Triticum aestivum) with beneficial effects on metabolic parameters. The aims of the study were: 1) to evaluate the effectiveness of using Lisosan G added to the diet in reducing PPHG events in patients undergoing RYGB, 2) to investigate the mechanism by which LG acts on the gut-pancreas axis.

Materials and methods: Seventeen patients self-reporting symptoms/ signs of PPHG, who had undergone gastric bypass between 2015 and 2018, were enrolled. Each patients underwent clinical examination, blood test and 5-hour oral glucose load test (OGTT). Then, subjects were kept on a free diet with 15 days of continuous glucose monitoring (CGM, Freestyle Libre, Abbott). The diet was recorded in a food diary. At the end of the period LG was added to the same dietary regimen (5 g LG-powder, bid) and CGM was repeated for another 15 days. Finally, another 5-hours OGTT was performed at the end of the treatment period. Plasma insulin and C-peptide were measured by electrochemiluminescence on a Cobas e411 instrument (Roche Diagnostics S.p.A.). Plasma total GLP-1 concentrations were measured by ELISA (Millipore Corporation). Insulin sensitivity was assayed by the oral glucose insulin sensitivity index (OGIS). PPHG was defined as a plasma glucose level of ≥60 mg/dl.

Results: The mean age was 41±7 and BMI was 43.2±5.7 kg/m² at the time of the surgery. PPHG was developed 29±8 months after RYGB and BMI was 25.8±3.7 Kg/m². During the first CGM period, PPHG episodes were 4.9[3.2-8.1] and decreased with LG administration as recorded by second CGM period 1.9[0.9-3.3], pre vs post LG respectively, p=0.008. In addition, no episodes of severe hyperglycemia (blood glucose <50 mg/dl) occurred under LG treatment. Furthermore, during LG treatment, the overall length of time with glycaemia <60 mg/dl during CGM, was reduced (210 [150-510] vs 25 [10-130], minutes, p=0.003). A marked increase in the blood glucose nadir (44±11 vs 55±10, mg/dl pre vs post respectively, p=0.033) was found during OGTT before and after administration of LG. Conversely, no difference was found in fasting glycaemia and in the time-to-nadir (142±21 vs 154±34, minutes, p=ns). There were no differences in fasting GLP-1 (42±20 vs 37±17, pmol/L, p=ns) with or without LG, while GLP-1 AUC0-∞ significantly reduced during LG treatment (12.1±4.9 vs 8.9±4.2, nmol/L×min, p= 0.032); contextually, the insulin output during the first 2-hours of the OGTT (Insulin AUC0-120) significantly decreased (57±12 vs 48±10 nmol/m², p= 0.039). Finally, insulin sensitivity remained stable before and after LG administration (514±55 vs 534±44 mL/min-1·m-2).

Conclusion: LG is effective on reducing PPHG episodes, probably by attenuating GLP-1 and insulin release in response to the glucose load. This effect leads to a reduction in the severity of hypoglycemia.

Disclosure: None.

471 Rabson-mendenhall syndrome: a rare cause of severe insulin resistance
R. Helal, T. Muammar, E.G. Fojas, N. Lessan; Imperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates.

Background and aims: Rabson-Mendenhall syndrome (RMS) is a rare autosomal recessive disorder marked by severe insulin resistance, associated with various phenotypic manifestations.

Materials and methods: We report the case of a 15 year old female with poorly-controlled diabetes who was referred to our paediatric diabetes clinic. She was diagnosed with RMS at the age of 50 days; genetic study showed homozygous mutation for R141W in INSR gene known to cause RMS. A strong family history of Rabson-Mandell syndrome in her mother’s cousins (one affected and two carriers) was noted.

Results: She was born full-term through normal vaginal delivery; birth weight was 2.19 kg. She required admission to the neonatal unit for 1 week. She was re-admitted on day 50 with diabetic ketoacidosis (DKA); insulin level was high at 737 µU/mL, IA2 and GAD antibodies negative, and C-peptide > 18 ng/ml. After recovery, patient’s blood glucose level was stabilized on high concentrated insulin dose 600-800 IU/day through continuous subcutaneous insulin infusion (CSI); Oral rosiglitazone was added after 2 months. At the age of 6 years, she was continued on CSI, with Roglitazone replaced by oral Mecasermin. At age 12, she had three further episodes of DKA, associated with acute infections- right lobar pneumonia, cellulitis of the abdominal wall, and acute gastroenteritis respectively. In each episode, she required even higher doses of intravenous insulin infusion (up to 2 IU/kg/hour). CSI treatment led to development of severe lipodystrophy at the cannula insertion sites. Therefore, on two occasions her treatment was temporarily changed to multiple daily injection therapy (MDI); Glargine 300 IU daily, Lispro 20 IU TID along with Mecasermin and SGLT2 inhibitor. Her fifth and latest episode of DKA in 2020 was precipitated by severe MRSA septicaemia, was managed with very high doses of intravenous insulin infusion, and resolved within a few hours.

Currently, the patient is on combined therapy with Mecasermin 25 units subcutaneously twice daily, oral Dapagliflozin 10 mg once daily along with CSII (Medtronic 640G) with insulin lispro (total daily dose is 261 units/day (4.6U/kg/day) with an insulin to carbohydrate ratio of 1:3 gm, and insulin sensitivity factor of 20 mg/dl. Despite patient compliance, family support, and the intensified therapy, her glycaemic control remains poor with an average blood glucose of 304 ± 86 mg/dL and HbA1c of 10.8 ± 1.2 %. She has recently started a trial of recombinant human leptin and shifted to CSII closed-loop system (Medtronic 780G), with the aim of improving her insulin resistance, glycaemic control, and quality of life.

Conclusion: In conclusion, we have presented the challenges in management of RMS. RMS is very rare, but life expectancy is short with early mortality related to diabetes-related complications, resulting from severe insulin resistance and poor glycaemic control. Using a closed-loop insulin pump together with recombinant human leptin therapy to improve insulin sensitivity and reduce hyperinsulinaemia, may offer new potentially useful lines of management.

Disclosure: R. Helal: None.

None.

None.

None.
Metformin has dual effects on insulin hypersecretion: opportunity to improve glucose metabolism in children with obesity

Q. Wen1,2, R. Stenlid1,2, A.I. Chowdhury1, I. Ciba3, B.K. Aydin2, S.Y. Cerenius1, A. Forslund2, P. Bergsten1,2; 1Medical cell biology, Uppsala University, 2Women's and Children's health, Uppsala University, Uppsala, Sweden.

Background and aims: In patients with obesity, insulin hypersecretion is proposed to precede insulin resistance. In attempts to attenuate such dysfunctional insulin secretion we reported that metformin prevented insulin hypersecretion from human isolated islets of Langerhans. In the present study, we aimed to investigate how metformin affects insulin hypersecretion with a translational approach and the window when metformin has more beneficial effects in children with obesity.

Materials and methods: Participants from the Uppsala Longitudinal Study of Childhood Obesity (ULSCO) cohort, who fulfilled the criteria of hyperinsulinemia and metformin treatment for at least six months (n=21), were evaluated retrospectively, using anthropometric measurements, OGTT, HbA1c, cholesterol and triglycerides before and after metformin treatment (mean duration 1.2 years). Beta-cell function and insulin resistance were estimated by insulinogenic index, oral disposition index and insulin AUC0-120/glucose AUC0-120 and HOMA-IR. Patients were classified as either “reducing” (n=9) or “increasing” (n=12) based on their insulin levels in OGTT before and after metformin treatment. Reduced or increased insulin AUC0-120 was used to define the groups. Isolated human islets were cultured in the presence of elevated palmitate levels, which induces insulin hypersecretion, for 0.5, 1, 2 or 3 days. Metformin was introduced after 0.5 or 1 day of palmitate exposure. After culture, islets were perfused and insulin secretion measured dynamically in the presence of 5.5 and 11 mM glucose.

Results: In the insulin “reducing” group, 2h glucose was reduced from 8.9±1.2 to 7.7±1.4 mmol/L (p=0.03) and triglycerides from 1.5±0.8 to 1.2±0.5 mmol/L (p=0.02). There was no change in these parameters in the insulin “increasing” group. No changes were observed in HOMA-IR in either group. Change in BMI was positively associated with alteration in insulin AUC0-120 (r²=0.21, p=0.03) when investigated in 21 metformin treated individuals. Accentuated glucose-stimulated insulin secretion (GSIS), 44% (n=5, p=0.03), was observed in perfused human isles cultured 1 day in palmitate compared to islets cultured in absence of palmitate. GSIS then declined during the following two days of culture. This decline in GSIS was counteracted and increased, 66% (p=0.02), when metformin was introduced after 1 day’s culture in palmitate compared to islets exposed to palmitate alone for three days. When metformin was added to islets after 0.5 day of initial culture in the presence of palmitate, insulin secretion was reduced, 18% (n=7, p=0.01), during the subsequent 0.5 day compared to islets cultured for 1 day in palmitate only.

Conclusion: Metformin has dual effects on beta-cell hypersecretion. If introduced in the early stage of insulin hypersecretion metformin attenuates insulin hypersecretion and thereby may attenuate beta-cell hyperactivity. On the other hand, if metformin is introduced in the late stage, it increases insulin secretion. Clinical implications are that early introduction of metformin to children with obesity is preferable, which may restore normal insulin responses coupled to reduction in BMI and improved glycemic control.

Supported by: European Commission’s Seventh Framework Programme, Swedish Diabetes Association
Disclosure: Q. Wen: None.
SO 29 Glucose homeostasis regulation beyond insulin

474

Carotid body: a new intervenient of GLP-1 effects in cardiometabolic homeostasis

CEDOC - CHRONIC DISEASES RESEARCH CENTER, Lisboa, Portugal.

Background and aims: GLP-1 is released by the gut in response to food intake. It binds to GLP-1 receptors (GLP-1R) stimulating insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. Additionally, GLP-1 promotes insulin sensibility, decreases gastric emptying, improves cardiac function, and decreases weight by promoting satiety. As such, GLP-1R agonists are used in type 2 diabetes (T2D) treatment for their effects in glycemic control but also for their cardiovascular and weight benefits. The carotid bodies (CBs) are peripheral chemoreceptors, defined as O2 sensors, whose activation by hypoxia induce respiratory reflexes to normalize blood gases, also regulating blood pressure. These organs are also metabolic sensors, being its overactivation involved in the development of metabolic disorders. Herein, we tested the hypothesis that GLP1 acts on the CB, being involved in the cardiorespiratory responses elicited by this organ.

Materials and methods: Experiments were performed in male Wistar rats submitted to 10 weeks of a standard (NC) or 60% lipid-rich diet (HF) followed by a sham or carotid sinus nerve (CSN) resection surgery. The effect of liraglutide, a GLP-1R agonist (200 µg/Kg, i.c.), on basal and ischemic hypoxia CB-mediated cardiorespiratory responses were evaluated. Ischemic hypoxia was induced by occlusion of the common carotid artery (OCC) during 5 and 15 sec. Minute volume (MV), heart rate (HR) and blood pressure (BP) were recorded. The presence of GLP-1R on the CB was analyzed by immunohistochemistry and the activation of its signalling pathway by Western Blot. CBs neurotransmitters release and content in the response to liraglutide were evaluated. Significance between the mean values was calculated by t-student test and ANOVA and p < 0.05 was considered as significant.

Results: GLP-1R is expressed in the CB colocalizing with tyrosine hydroxylase, a marker for type 1 cells. Liraglutide increased baseline MV in NC and HF rats by 30% and 40% respectively, while decreased BP by 20% and 15% in the same groups. Liraglutide did not modify HR in any of the groups. CSN resection abolished liraglutide effects on ventilation, decreasing its effects on MV in NC (42%, p<0.05) and HF (43%, p=0.06) animals. CSN resection attenuated the effects of liraglutide on BP. HF animals exhibited a higher ventilatory response to OCC compared to NC animals, an effect abolished in CSN resected animals. Liraglutide decreased the effect of OCC5 on MV by 39% and 49% in NC and HF animals and the effect of OCC15 by 68% (p<0.05) in HF animals. BP in response to OCC5 decreased by 14% and 13% in NC and HF animals and Liraglutide further decreased BP in response to OCC5 by 72% and 52% (p<0.05) in the same groups. Liraglutide effects on MV and BP were abolished by CSN resection.

Conclusion: GLP-1 is present in the CB and modulates differentially the spontaneous and ischemic hypoxic cardiorespiratory responses mediated by this organ. Under basal conditions, Liraglutide acts on the CB to increase ventilation and decrease BP while under ischemic hypoxia, it blunts the respiratory reflex and heightens the decrease in blood pressure. Modulation of GLP-1 function in the CB might be important for the treatment of cardiometabolic comorbidities in obesity and T2D.

Supported by: Portuguese Foundation for Science and Technology contract reference CEECIND/04266/2017

Disclosure: D. Sampaio-Pires: None.

475

Insulin resistance is associated with an elevated glucose-dependent cortisol axis response: Impact in type 2 diabetes?

M.H. Lundqvist, M.J. Pereira, J.W. Eriksson;
Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden.

Background and aims: The importance of insulin-antagonistic counterregulatory responses for glucose regulation and pathogenesis of type 2 diabetes (T2D) has been increasingly emphasized. Recently, our research group has demonstrated an augmented ACTH and cortisol response to hypoglycemia and a static elevation of glucagon levels in overweight vs lean subjects. Moreover, insulin resistance but not obesity per se was independently associated with those hormonal alterations. The aim of this study was to explore counterregulatory responses across a wide glycemic range in subjects with early T2D in comparison with control subjects without diabetes (C).

Materials and methods: Subjects with T2D; n=14, 6 males, median age 50 years (range 22-62), BMI 38.0 kg/m2 (27.4-48.8), HbA1c 48 mmol/mol (37-71), diabetes duration 18 months (0-57), 10 on metformin, 4 drug naïve; were matched (gender, age, BMI) to control subjects (C) without diabetes; n=14, 5 males, age 51 years (23-57), BMI 36.5 kg/m2 (24.1-49.5), HbA1c 35 mmol/mol (30-41). They underwent one stepwise hypoglycemic clamp (glucose nadir 2.7 mm) and one stepwise hyperglycemic clamp (max +9mM) with repeated cortisol axis measurements (cortisol, ACTH). Spearman correlations between hormonal responses and M-value, BMI and HbA1c were assessed in an extended cohort (total n=48) including additional subjects without diabetes; n=20, 5 males, age 37 years (22-60), BMI 25.2 kg/m2 (19.9-31.4), HbA1c 34 mmol/mol (27-40). Multilinear regressions (MLR) were performed with M-value, BMI and HbA1c as independent variables in every model.

Results: In the hypoglycemic clamp, neither cortisolΔAUC nor ACTHΔAUC differed significantly in T2D vs C. In the extended cohort (n=48), cortisolΔAUC (Fig) and ACTHΔAUC correlated inversely with M-value (p<0.01 and <0.001, respectively) and positively with BMI (p<0.05, <0.01). In MLR, only M-value remained significantly associated with cortisolΔAUC (std beta -0.49, p<0.05; model R2 0.193, p<0.05) and ACTHΔAUC (std beta -0.56, p<0.01, model R2=.290, model p<0.01). In the hyperglycemic clamp, the cortisol axis response did not differ in T2D vs C. In the extended cohort, ACTHΔAUC correlated positively with BMI (p<0.05), but the association did not remain significant in MLR.

Conclusion: Neither early T2D nor long-term glycemia per se was independently associated with glucose-dependent cortisol axis response. Instead, only insulin resistance was independently associated with elevated cortisol axis response to hypoglycemia, and this was seen across normoglycemic and T2D subjects. We propose that a gradual cortisol axis dysregulation can contribute to development of insulin resistance and, secondarily, T2D. Furthermore, the elevated ACTH response suggests a CNS origin behind this dysregulation.
The ghrelin-NPY system in adipose tissue as a potential therapeutic target in type 2 diabetes

**Background and aims:** Adipose tissue dysfunction and dysregulation of gut hormones secretion are two of the main hallmarks of type 2 diabetes. Both mechanisms are modulated by metabolic surgery, namely the normalization of ghrelin secretion, a hormone that promotes feeding by activating neuropeptide Y (NPY)-expressing neurons in the hypothalamus and that has been suggested as a nutrient sensor. Our hypothesis is that the ghrelin/NPY system regulates adipose tissue, being altered in subjects with obesity and metabolic syndrome, and modulated through metabolic surgery.

**Materials and methods:** To characterize the alterations of the ghrelin/NPY system in the human visceral adipose tissue samples, gene expression profile of the ghrelin/NPY system was evaluated through RT-PCR (ghrelin and NPY receptors). The effect of metabolic surgery on this system was studied in Goto-Kakizaki rats, maintained in a calorie diet and submitted to sleeve gastrectomy (SG). The direct effects of ghrelin on adipocytes were explored in the 3T3-L1 cell line.

**Results:** We found a decreased expression of Y1 and Y5 receptors with the development of type 2 diabetes, in the visceral adipose of patients with obesity versus the prediabetics (p<0.05). On the other hand, the Y2 receptor was downregulated right after insulin-resistance establishment when compared to the insulin-sensitive subjects (p<0.05). While Y1 and Y5 receptors were highly positively correlated with PPARγ expression (r= 0.679 and r=0.779 with p<0.001, respectively), Y2 was correlated with UCP-1 instead (r=0.711, p<0.001). The ghrelin/NPY system was altered in the adipose tissue of obese rats that underwent SG, with a significant increase in Y1, Y2 and ghrelin receptors compared to high-fat-fed littermates (p<0.01, p<0.05 and p<0.05, respectively). Moreover, ghrelin induced lipid accumulation and adipogenesis in adipocytes *in vitro* and increased Y1 receptor levels.

**Conclusion:** The ghrelin/NPY system is downregulated with the progression of metabolic dysregulation in obesity. We demonstrate a dichotomous association of Y1/Y5 and Y2 receptors regarding energy balance regulation in adipose and ghrelin treatment induced lipid accumulation, thus supporting its role as a nutrient sensor. The ghrelin/NPY system was restored by SG, in the visceral adipose tissue of an animal model of obesity and type 2 diabetes, further highlighting the potential as a therapeutic target to metabolic syndrome.

**Disclosure:** D. Rosendo-Silva: None.
Pentose phosphate pathway utilisation of gluconeogenic glucose-6-phosphate is increased in mice fed a high-fat/high-fructose diet compared to high-fructose alone

G. Belew1, A. Costa1, M. Meneses2, I. Viegas3, L. Tavares1, P. Oliveira4, M. Macedo2, J. Jones1;
1Metabolic Control Group, Center for Neuroscience and Cell biology, University of Coimbra, Coimbra, 2Chronic Diseases Research Centre (CEDOC), NOVA University of Lisbon, Lisbon, 3Center for Functional Ecology, University of Coimbra, Coimbra, 4Mitochondrial Toxicology and Experimental Therapeutics, Center for Neuroscience and Cell biology, University of Coimbra, Coimbra, Portugal.

Background and aims: In hepatocytes, the pentose phosphate pathway (PPP) is an important generator of NADPH for de novo lipogenesis (DNL) and for the maintenance of reduced glutathione in antioxidant defense. The development of non-alcoholic fatty liver disease (NAFLD) secondary to high sugar and/or high fat intake is characterized by elevated DNL rates and increased oxidative stress. It is not known whether PPP fluxes are modified in these settings. We developed a double tracer method that provides information on both DNL and PPP fluxes in feeding mice. We applied this to compare DNL and PPP fluxes in mice fed a normal chow diet supplemented with high-fructose corn syrup (HFCS-55) with a more obesogenic diet composed of high-fat chow supplemented with HFCS-55.

Materials and methods: Twelve C57BL/6 mice were provided with standard chow (SC) with the drinking water supplemented with 30% (w/v) of HFCS-55 (55/45 mixture of fructose and glucose) for 18 weeks. Eleven mice were placed on high-fat chow (HFC) with the same HFCS-55 supplement over the same period. At the beginning of the final evening, all mice were administered with 99% deuterated water containing the HFCS-55 fructose component was enriched to 20% with [U-13C6]fructose. On the following morning, mice were deeply anesthetized with ketamine/xylazine and sacrificed by cardiac puncture. Arterial blood was collected and centrifuged to isolate plasma, livers were freeze-clamped, and the samples were stored at -80 °C until further processing. Liver triglyceride and glycogen were purified and analyzed for 2H and 13C-enrichments by NMR. DNL rates were quantified from lipid 2H-enrichment and adjusted for liver triglyceride levels. Whole-body adiposity was estimated from body water 2H enrichment. The fraction of gluconeogenetic glucose-6-phosphate (G6P) utilized by the PPP was quantified from glycogen 13C-isotopomer analysis.

Results: Mice fed HFC + HFCS-55 has greater body weight (50 ± 1 vs 37 ± 1 g, p < 0.0001), higher whole-body adiposity (29 ± 1 vs 16 ± 2%, p < 0.0001), and higher liver triglyceride levels (15 ± 2 vs 8 ± 2 g/100 g liver, p < 0.025) compared to those fed SC + HFCS-55. DNL rates were not significantly different between the two groups although the high-fat chow mice had a tendency for higher rates (1.02 ± 0.1 vs 0.75 ± 0.1 g/100 g liver, p = 0.2109). However, the fraction of gluconeogenic G6P utilized by the PPP was significantly higher for the high-fat chow mice (17.0% versus 13.8%, p = 0.034).

Conclusion: A diet high in both fat and sugar is more obesogenic than a diet high in sugar alone. In the presence of high fat, DNL rates were sustained while PPP utilization of G6P derived from gluconeogenesis was significantly increased. This may be explained by additional demand for NADPH above and beyond that consumed by DNL, possibly in response to increased oxidative stress.

Supported by: Marie Sklodowska-Curie Action-ITN Grant Agreement No. 722619; FCT
Disclosure: G. Belew: Grants; European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 722619, Portuguese Foundation for Science and Technology (FCT-FEDER-02/SAICT/2017/028147.)
SO 30 Non-classical regulators of metabolism

479
Extracellular miRNAs related to obesity and type 2 diabetes as potential biomarkers for adipose tissue dysfunction
M. Clemente-Postigo 1,2, C. Tercero-Alcazar 1,2, M. Blasco-Montolio 1, R. Guzmán-Ruiz 1,2, M. Malagon 1,2
1Department of Cell Biology, Physiology, and Immunology, University of Córdoba; Maimónides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, 2CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.

Background and aims: Adipose tissue (AT) dysfunction is a key player in obesity-related metabolic comorbidities and even might precede type 2 diabetes (T2D) onset. miRNAs (miRNAs), small RNAs that regulate gene expression, are released to the circulation and have emerged as potential tools to identify tissue dysfunction. AT has been proposed as a main contributor of circulating miRNAs (c-miRNAs), but it has not yet been characterized those c-miRNAs associated with obesity and/or T2D that come from AT and then, may also serve as biomarkers for AT dysfunction. Early AT dysfunction diagnosis may be crucial for obesity-related co-morbidities prevention and treatment. Thus, we aimed at identifying AT-derived extracellular miRNAs related to obesity and T2D that can serve as biomarkers for AT dysfunction.

Materials and methods: Public available databases interrogation for candidate c-miRNAs selection (i.e. c-miRNAs previously related to obesity and/or T2D) was performed. An in silico analysis of candidate c-miRNAs target genes and canonical pathway prediction analyses were also performed to confirm their putative role in relevant biological processes for AT function. In vitro preadipocyte and mature adipocyte 3T3-L1 models of obesity-related conditions [inflammation (TNFα) and insulin resistance (hyperglycaemia and hyperinsulinaemia-HGHI)] were performed. In vitro AT fibrosis models with 3D cell cultures based on collagen I (COLI) hydrogels alone (control) or mixed with other AT extracellular matrix components altered in insulin resistance and obesity (i.e. COLVI and/or Lumican) were implemented. Extracellular miRNAs released in cell culture supernatant were measured and the expression of the miRNA machinery-related genes were determined.

Results: Database interrogation and in silico analysis highlighted miR-15a-5p, miR-15b-5p and miR-24-3p as potential c-miRNA candidates that can be related to AT functionality and differentially released from AT in obesity and/or T2D. Our in vitro models confirmed that adipocyte functional state affects the secretion of our candidate miRNAs with a significant decrease in extracellular levels of the three miRNAs analyzed (p<0.05) concomitant with a significant drop in the expression of genes involved in miRNA processing and secretion (Ago and Cd63) (p<0.05) under HGHI conditions compared to control in mature adipocytes. miRNA secretion was dependent on adipocyte differentiation stage. AT 3D environment also affected miRNA release compared to 2D cell cultures, especially for miR-24-3p (p<0.05). Specific fibrotic conditions (i.e. COLVI increase) significantly and specifically augmented miR-24-3p secretion from mature adipocytes compared to control (p<0.05).

Conclusion: Our candidate miRNAs are potential extracellular biomarkers of the physiological state of mature adipocytes, and miR-24-3p emerges as a specific biomarker of AT fibrosis.

Disclosure: M. Clemente-Postigo: None.

480
Investigation of small non-coding RNA modulation in islet macrophages during obesity and diabetes
C. Cosentino 1, A. Galli 2, F. Brozzi 1, R. Regazzi 1
1Università de Lausanne, Lausanne, Switzerland, 2Università di Milano, Milano, Italy.

Background and aims: Islet-resident macrophages (iMACs) play an important role in pancreatic islet development and homeostasis but their expansion and activation in obesity triggers islet inflammation, resulting in β-cell dysfunction. The gene expression profile of obese iMACs reflects a high complexity, with functional properties common to both pro- and anti-inflammatory macrophages. The activation of iMACs in obesity is likely to be elicited by unknown modulatory molecules highly sensitive to environmental changes. MicroRNAs (miRNAs) hold a key role in the control of gene expression. Moreover, the pool of transfer RNAs (tRNAs) is strictly regulated by nutrient availability and under stress conditions tRNAs can be cleaved, generating tRNA fragments (tRFs) with regulatory functions. The aim of the present work was to characterize the miRNA and tRF signatures of iMACs in obesity.

Materials and methods: Pancreatic islets were isolated from 8 weeks old overweight and hyperglycemic db/db and lean wild type (wt) mice (40.03 ±2.03 grams db/db vs 19.33±1.81 wt; 15.73±2.56 mmol/L blood glucose db/db vs 6.35±1.00 wt, p<0.001 t-test, n=8-12). CD454+, F4/80+, CD11b+ and CD11c+ iMACs were purified from dispersed islet cells using fluorescence-activated cell sorting (FACS). Bone marrow derived macrophages (BMDMs) from C57BL/6J mice were polarized in vitro to pro- and anti-inflammatory macrophages (M1 and M2, respectively). MiRNAs and tRFs differentially expressed in iMACs and BMDMs were identified by small RNA sequencing.

Results: Comparison of iMACs isolated from db/db and wt mice led to the identification of 14 differentially expressed miRNAs (≥1.5 fold change, FC), adjusted pvalue ≤ 0.05, n=4). This list was compared to the 198 differentially expressed miRNAs between M1 and M2 BMDMs. Interestingly, the anti-inflammatory miR-149-5p was the most upregulated miRNA both in obese iMACs (11.65 FC vs wt) and M2 BMDMs (37.29 FC vs M1). MiR-342-3p, previously associated with obesity, was also upregulated in db/db iMACs (2.27 FC vs wt) and more expressed in M2 compared to M1 BMDMs (2.76 FC). However, the pro-inflammatory miR-155 which is more abundant in M1 BMDM (249.3 FC vs M2) was also increased in obese iMACs (2.29 FC vs wt). tRFs analysis identified 28 of them differentially expressed in polarized BMDM and 7 in db/db iMACs (≥1.5 FC, adjusted p-value ≤ 0.05, n=4). Among the tRFs upregulated in obese iMACs, three were also enriched in M2 BMDM. The tRFs derived from tRNAAspGTC were the most modulated in both datasets (34.05 FC increase in db/db iMACs vs wt ; 10.2 FC increase in M2 vs M1).

Conclusion: Small RNA profiling of obese iMACs highlighted the overexpression of anti-, but also, pro-inflammatory miRNAs, indicating that these molecules may contribute to the complex obese iMAC phenotype. Our study provide the first complete profiling of tRFs in macrophages. tRFs analysis in BMDM suggests that during macrophage polarization tRNAs undergo different cleavage pathways. Fragments derived from tRNAAspGTC were highly modulated in obese iMACs and also strongly induced during M2 polarization. Functional investigation of the role of small RNAs, such as miR-342-3p and tRFs, in macrophage metabolism may contribute to better characterize the initial events that lead to islet inflammation and β-cell demise in obesity.

Disclosure: C. Cosentino: None.
Background and aims: The immune system is activated acutely during exercise and chronically in obesity and type 2 diabetes. Inflammatory responses are required for the beneficial adaptations to exercise training, but low-grade inflammation associated with metabolic diseases contributes to the development of insulin resistance and disease progression. Insight into the molecular events by which the immune system contributes to skeletal muscle adaptations are lacking, particularly in the context of type 2 diabetes. Here we hypothesized that an acute bout of exercise would trigger a distinct inflammatory response in skeletal muscle from individuals with type 2 diabetes compared to normal glucose tolerance. We aimed to test the role of cytokines selectively produced in individuals with type 2 diabetes in the regulation of skeletal muscle cell remodelling and metabolism.

Materials and methods: Men with type 2 diabetes (n=20) or normal glucose tolerance (n=17) performed an acute bout of exercise on a cycle ergometer (30 min, 85% of individual maximum heart rate). Skeletal muscle biopsies and plasma were taken before and after the exercise bout and analysed by RNA sequencing and immunoassays. In vitro experiments revealed that CXCL12 can be produced by endothelial cells in response to hypoxia or by macrophages in response to conditioned medium from skeletal myotubes exposed to electrical pulse stimulation. Myocytes treated with recombinant CXCL12 (100 μg/mL, 24h) exhibited increased proliferation and impaired differentiation capacity. CXCL12 inhibited cAMP production, suggesting activation of the receptor CXCR4 (coupled to Gq) and ERK signalling. Exposure to recombinant CXCL12 (100 μg/mL, 20 min) increased glucose uptake in myotubes independently of the insulin signalling pathway.

Conclusion: CXCL12/SDF-1 is induced skeletal muscle from individuals with type 2 diabetes as part of a non-canonical inflammatory response to acute aerobic exercise. Signalling of CXCL12 alters the phenotype and metabolic response of skeletal muscle cells, suggesting a role for atypical production of exerkines in regulating skeletal muscle remodelling and metabolism. Pharmacological interventions targeting selective aspects of inflammation such as CXCL12 signalling could help promote the benefits of exercise in individuals with type 2 diabetes.

Disclosure: N.J. Pillon: None.

482
Bax Inhibitor 1 protects against pancreatic beta cell death and metabolic disorders

M. Blanc1, P. Xiao2, J. Gilleron1, M. Janona1, S. Lucas-Gervais3, L. Yvan-Charvet1, P. Gaul1, A. K Cardozo2, B. Bailly-Maitre1
1Centre Méditerranéen de Médecine Moléculaire, Nice, France, 2Inflammation and Cell Death Signalling group, Experimental Gastroenterology Laboratory and Endotools - Medical Faculty, Bruxelles, Belgium, 3Centre Commun de Microscope Electronique Appliquée, Faculté des Sciences, Nice, France.

Background and aims: Hyperglycaemia, hyperlipidaemia, and the high demand in secretory protein leads to Endoplasmatic Reticulum (ER) stress in pancreatic β cell. In response to the ER stress, the Unfolded Protein Response (UPR) is mediated by three transmembrane proteins located in the ER: ATF6, PERK and IRE1α. Bax Inhibitor-1 (BI-1) is a negative regulator of inositol-requiring enzyme 1 (IRE1α), an UPR sensor endowed with kinase and endoribonuclease (RNase) activities. BI-1 can interact with IRE1α and restrains its RNase activity signalling. Taking advantage of BI-1 deficient mice, we observed that BI-1 deletion could sensitize the pancreatic β cell death and favor the onset of type 2 diabetes.

Materials and methods: Taking advantage of BI-1 deficient mice, we monitored systemic inflammation and pancreatic lipases levels in sera, glycemia and insulinemia. We performed GTT (Glucose Tolerance Test) /ITT (Insulin Test Tolerance) and GSIS (Glucose Stimulated Insulin Secretion) in fasted and fed conditions. From pancreatic sections and pancreatic islets isolated from WT and transgenic mice, we analysed pancreatic β cell death and ER stress markers by combining several approaches at structural (TEM: transmission electronic microscopy) and molecular & biochemical levels (H&E, TUNEL, MPO, qPCR and Western Blot). Statistical analyses were obtained by Mann-Whitney or Two-Way ANOVA (p-value < 0.05).

Results: BI-1 deficient mice present a glucose intolerance and a poor insulin response in steady state and under an HFD, as revealed after performing GTT and an ITT. Serum insulin levels were statistically reduced in the BI-1 KO mice. When challenged with glucose (GSIS), BI-1 deficient mice secrete significantly less insulin than BI-1 WT mice. Increased levels of TNFα, IFNγ and pancreatic lipases were statistically observed in the serum of BI-1 KO mice compared to WT mice, indicating respectively significant inflammation and pancreatic injuries in BI-1 KO mice. We observed less pancreatic islets in BI-1 KO correlating with significant increased β cell death and more infiltrated neutrophiles (MPO staining). Furthermore, BI-1 deficient mice present higher levels of inflammasome, and ER stress markers, especially IRE1α signaling in pancreatic β cells. Finally, the pharmacological inhibition of IRE1 RNase activity in HFD-BI-1 KO mice rescues pancreatic injuries, improves glucose homeostasis, and normalizes insulin levels.

Conclusion: Our data suggests that BI-1 acts as a guardian of β cells homeostasis by counteracting IRE1α dependent-inflammation (inflammasome) activation, -cell death and -metabolic disorders. We propose that normalizing BI-1 expression or pharmacologically targeting IRE1α could be effective in treating type 2 diabetes mellitus, but also in metabolic diseases associated with excessive ER stress.

Supported by: This work was supported by ANR (2019), SFD (2020) and FRM (2022).

Disclosure: M. Blanc: None.
A potential role of liver-expressed ASK1 in body weight regulation

A. Goergen1, T.D. Challa2, S. Wueest1, D. Konrad1,2;
1University Children’s Hospital Zurich, University of Zurich, 2Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.

Background and aims: The stress kinase apoptosis signal regulating kinase 1 (ASK1) has been linked to obesity-associated metabolic disorders. ASK1 is involved in the cellular stress response and confers the kinase 1 (ASK1) has been linked to obesity-associated metabolic disorders. ASK1 overexpression (ASK11+hep) and control (ASK11−/F−) mice were fed a regular chow or HFD for 20 weeks. Intraportal insulin tolerance test was performed to assess insulin sensitivity and indirect calorimetry was used to measure energy expenditure. After 20 weeks of diet intervention, organs and systemic blood were sampled and analyzed using Western blotting, qPCR, histology or ELISA. In cultured hepatocytes, ASK1 was knocked down and overexpressed using siRNA and adenovirus, respectively, and lysates were analyzed using Western blotting and qPCR.

Results: After 20 weeks of diet feeding, insulin sensitivity was similar between the genotypes in chow-fed mice, while HFD-fed ASK1+hep mice displayed significantly improved insulin sensitivity compared to control mice (AUC in mmol/l*min: 720±163 in ASK1+hep vs. 1001±118 in ASK11−/F−, p<0.01). Moreover, HFD-fed ASK11+hep mice gained significantly less body weight in comparison to littermate control mice (44.1±6.3g in ASK1+hep vs. 34.8±3.6g in ASK11−/F−, p<0.001). There was no difference in bodyweight in chow-fed mice. In line with decreased body weight gain, energy expenditure was elevated in HFD-fed ASK11+hep mice (8.1±0.5 kcal/h*min in ASK1+hep vs. 7.3±0.6 kcal/h*min in ASK11−/F−, p<0.02). Of note, hepatic fibroblast growth factor 21 (Fgf21) mRNA expression as well as circulating Fgf21 levels (690±1233 pg/ml in ASK11+hep vs. 3188±1944 pg/ml in ASK11−/F−, p<0.001) were significantly increased in ASK11+hep mice. Moreover, Fgf21 plasma levels negatively correlated with body weight. In vitro, preliminary data from gain and loss of function studies suggest that ASK1 regulates FGF21 production in hepatocytes.

Conclusion: We suggest a yet undescribed ASK1-mediated FGF21 induction in the liver, which positively affects body weight and metabolism. Given the prominent role of FGF21 in whole-body metabolism and body weight control, the identification of ASK1 as a potential cell-intrinsic Fgf21 enhancer may contribute to the development of new drugs countering obesity and associated diseases.

Supported by: Children’s research center Grant 2020
Disclosure: A. Goergen: None.

Effect of maternal age and metabolic syndrome on early embryo development in a mouse model

J. Lilao-Garzon1, Y. Brito-Casillas1, S. Munoz-Descalzo1, A. Wagner1,2;
1University Institute of Biomedical and Healthcare Research, 2Servicio Endocrinología y Nutrición. Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Las Palmas de Gran Canaria, Spain.

Background and aims: Diabetes and advanced maternal age have a negative effect on reproductive success. However, there is limited knowledge about their effect on early embryo development. Before embryo implantation in the uterus, cells differentiate into the cells that will give rise to the placenta, the yolk sack (primitive endoderm, PrE) and the embryo proper (epiblast, Epi). Here we aim to evaluate how maternal age and metabolic syndrome induced by high fat diet (HFD) affect fecundity and embryo development in a mouse model.

Materials and methods: A diet induced model based on 60% HFD for 8 weeks was chosen and normal diet (ND) was used as control. To evaluate the effect of age, mice were classified into: young adults (Y=12 weeks old; n=33) and mature adults (M=9 months old, n=41). Oral glucose and insulin tolerance tests, weight and whole body composition were used to validate the phenotype. Their fecundity was established by descriptive methods like mating and pregnancy rates together with the number and quality of early embryos (E3.5) per female in each group. Embryo staging was established by the number of cells and by the proportion of Epi and PrE cells through quantitative immunofluorescence of confocal images. Markers expression (NANOG for Epi and GATA6 for PrE) was automatically quantified with specific software (MINIS). Z-test and Mann Whitney-test were used to compare different groups.

Results: The presence of mild hyperglycaemia and obesity before pregnancy was confirmed by the phenotypic analysis. No statistical differences were observed on mating, pregnancy rates, or number of embryos per female. However, HFD early embryos showed lower proportion of PrE cells: YND=34%, YHFD=23%, MND=41%, MHFD=28%. (Z-test: YND vs YHFD, p=0.0045; MND vs MHFD, p=0.0065; YND vs MND, p=0.158). Moreover, GATA6 levels were significantly lower in embryos from HFD groups independently of the age in ICM cells (Mann Whitney-test: YND vs YHFD, p=0.0002; MND vs MHFD, p<0.0001; YND vs MND, p<0.0001). Fewer PrE cells and lower levels of GATA6 indicate a defect in PrE formation.

Conclusion: The presence of mild hyperglycaemia and obesity before pregnancy leads to fewer PrE cells and alteration in cell fate decision makers that can be associated with a delay in early embryo development in a mouse model. Our results help to explain the underlying cause of the decreased reproductive success associated with diabetes and advanced maternal age.


Effect of lipotoxic hepatocyte-derived extracellular vesicles in pancreas inflammation and beta cell functionality

R. Ailen1,2, N. Cobo-Vuilleumier3,4, B.R. Gauthier3,5, I. Garcia-Martinez1,2, A.M. Valverde1,2;
1“Alberto Sols” Biomedical Research Institute (CSIC-UAM), Madrid, 2Biomedical Research Network on Diabetes and Related Metabolic Diseases-CIBERDEM, Madrid, 3Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), Sevilla, Spain.

Background and aims: Non-alcoholic fatty liver disease (NAFLD) is a common feature of obesity and type 2 diabetes mellitus (T2DM). Lipotoxic hepatocytes increase extracellular vesicles (Hep-EVs) release which can act locally and contribute to non-alcoholic fatty liver disease (NAFLD) progression. Hep-EVs can also enter the circulation and reach other metabolic tissues such as the pancreas and affect beta cell function. Thus, Hep-EVs could be involved in T2DM pathogenesis.

Materials and methods: Primary hepatocytes were isolated from C57BL/6j male mice. Hep-EVs were obtained by differential ultracentrifugation from control hepatocytes (EVc) or stimulated with palmitic acid (EVPa). INS-1 rat insulinoma cells were incubated with Hep-EVs or with EVPa. Endoplasmic reticulum (ER) stress and inflammation pathways were

485

484
Results: Hep-EVs were internalized by INS-1 cells cultured alone or cocultured with macrophages. In mouse pancreatic islets, Hep-EVs were internalized by INS-1 cells cultured alone or co-cultured with macrophages.

Results:

EVPA promoted NF-κB nuclear translocation in macrophages and elevated Il1b mRNA levels (n=3, p<0.05) which decreased GSIS (n=4, p<0.01) compared to EVC. In mouse pancreatic islets, EVPA promoted NF-κB nuclear translocation in macrophages and elevated Il1b mRNA levels (n=3, p<0.05) which decreased GSIS (n=4, p<0.01) compared to EVC. However, a reduction in M2 polarization was observed in EVPA-injected mice. CD4+ T cells (n=6, p<0.01) recruitment and immunofluorescence.

Conclusion:

The early exposure to glycation changes breastfeeding milk composition that are associated with offspring metabolic and neurodevelopment alterations, modulating its behaviour at adolescence.

Disclosure: A. Amaro: None.
**SO 31 Gut feelings are good**

Gut-hormone ghrelin regulates female reproductive function in healthy and high-fat fed rodents

D. Khan, A. Sritdhara, P.R. Flatt, R.C. Moffett; School of Biomedical Sciences, Ulster University, Coleraine, UK.

**Background and aims:** Ghrelin, a 28 amino acid peptide predominantly secreted by endocrine cells in stomach modulates insulin secretion/action and regulates glucose metabolism, food intake and gastrointestinal motility through binding to the ghrelin receptor. Women affected by obesity and polycystic ovary syndrome (PCOS) exhibit significant reduced circulating ghrelin concentrations. Previous work from our laboratory and others indicates that high-fat diet (HFD) causes obesity and infertility in female rodents. To elucidate possible involvement of ghrelin, the present study has evaluated the effects ghrelin on reproductive function and altered reproductive hormone status in normal and high-fat fed mice.

**Materials and methods:** In the first study, effects of ghrelin on metabolic parameters and estrous cycling were evaluated in 8–10 weeks old healthy female TO-mice (n=9) administered twice daily i.p injections for 16 days of saline or ghrelin (25 nmol/kg body weight). In a second series, female TO mice (8 weeks-old) were fed with high fat diet (HFD) for 12-weeks with regular monitoring. Mice were then administered twice daily i.p injections for 21 days of saline or ghrelin (25 nmol/kg body weight). Estrous cycling and reproductive hormones were measured.

**Results:** Treatment for 16-days with ghrelin significantly (p<0.05 to p<0.01) reduced food intake by 18% and body weight by 7% with no change in blood glucose. Starting after 3-days of treatment, estrous cycling was monitored for the following 13 days. Treatment with ghrelin did not change number of estrous cycles (1.25 cycles/13 days) or cycle length (9.4 days cycle length in 13 days) compared to saline controls (1.8 cycles/13 days and 7.2 days cycle length). However, percentage of the total time spent in the various stages of estrous cycle showed reduced (p<0.05) time in metestrus (10±2%) and proestrus (10±2%) stages compared to 20±3% and 18±2% for controls. After 12 weeks of HFD, female TO mice exhibited significantly (p<0.001) 1.5-fold increased body weight without obvious change of blood glucose levels but hyperinsulinaemia, indicative of insulin resistance. 70% of the high-fat fed mice had irregular cycle lengths compared to 40% in the normal diet control group (p<0.001). Ghrelin administration in HFD fed mice reduced (p<0.05) food intake by 18% compared to saline controls but interestingly had no effect on body weight. Percentage time spent in time in metestrus was significantly (p<0.05) increased by 9% by ghrelin compared to HFD controls. Circulating levels of LH were significantly (p<0.05 to p<0.01) 3-times higher in HFD group irrespective of ghrelin administration and progesterone levels in plasma were decreased (p<0.01) by 5-times compared to normal-diet controls. However, ghrelin did not alter reproductive hormone levels when compared to the HFD group.

**Conclusion:** These data demonstrate that ghrelin affects reproductive function in females, highlighting the importance of a gut-reproductive axis in both health and high fat diet-induced obesity. Taken together with previous research, these observations suggest that modulation of key gut hormone actions in the reproductive axis could represent a novel means for treating diet induced reproductive disorders.

Supported by: DUK RD Lawrence Fellowship

Disclosure: D. Khan: None.

**489**

Relation between intestinal acetate production and plasma glucose levels in healthy subjects

M. Wijdeveld:
Internal medicine - vascular medicine, Amsterdam UMC, locatie AMC, Amsterdam, Netherlands.

**Background and aims:** Human obesity and glycemic dysregulation are increasing worldwide. Mounting evidence suggests a prominent role for the gut microbiome in pathophysiological pathways that influence the central nervous system and glucose homeostasis. In this regard, short-chain fatty acids (SCFA) have been reported to mediate host glucose metabolism, insulin secretion and central regulation of appetite. The SCFA acetate is one of the major metabolites produced by gut microbiota. In animal studies, acetate has been reported to function as a beneficial substrate in mediating glucose metabolism and appetite regulation. However, the effects of intestinal acetate production on plasma glucose levels and postprandial glucose metabolism have not yet been studied.

**Materials and methods:** We studied 60 individuals who were selected to either have a microbiota with either high or low intestinal acetate production from a sample of 429 individuals from the HELIUS cohort study. Postprandial glucose and insulin responses were compared between the two groups during a high-fiber standardized mixed meal test (SMMT). Additionally, hunger and satiety were assessed using visual analogue scale questionnaires. Finally, central craving and reward responses to virtual food cues and the receipt of palatable food were measured using fMRI.

**Results:** We observed a significant difference in microbiota composition between the groups. Applying a linear mixed model, we found a significant difference in glucose and insulin excursions upon the SMMT between the two groups (p = 0.0088 and 0.0025 respectively), with the low acetate producing group showing higher amplitude and lower baseline levels for both glucose and insulin compared to the high acetate producing group. There were no differences in insulin resistance or insulin secretion. Finally, high-calorie food stimuli invoked a higher CNS response in de caudate nucleus in the high acetate producing group, whereas anticipation of receiving palatable food invoked a higher CNS response in the putamen in the low acetate producing group (p = 0.041 and 0.011 respectively).

**Conclusion:** High acetate production appeared to be related to a change in postprandial glucose and insulin response, resulting in a lower amplitude for the high acetate producing group, however not paralleled by a change in insulin sensitivity. Our data suggest that acetate may provide a novel target for various non-invasive intervention strategies to promote metabolic health by increasing intestinal acetate. Nevertheless, more clinical intervention studies are needed to confirm this.

Clinical Trial Registration Number: 2019.211

Supported by: M. Wijdeveld is supported by the AMC MD/PhD fellowship 2017.

Disclosure: M. Wijdeveld: None.
Mechanisms underlying the beneficial effects of bariatric surgery on cardiometabolic risk in a ten-year long cohort study

S. Simati1, D. Tselingeris1, A. Angelidi1, K. Stefanakis2, N. Tentolouris1, I. Anastasiou1, A. Alexandrou3, C. Mantzoros2, A. Kokkinos1;
1First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece, 2Department of Internal Medicine, Boston VA Healthcare system and Beth Israel Deaconess Medical Center, Boston, USA, 3First Department of Surgery, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.

Background and aims: The long-term effects of bariatric surgery on cardiovascular and metabolomic profile and underlying mechanisms mediating the observed improvements in body composition and overall health remain poorly investigated.

Materials and methods: A cohort of 28 patients with morbid obesity who underwent bariatric surgery [11 Roux-en-Y gastric bypass (RYGB), 17 sleeve gastrectomy (SG)] was studied preoperatively and at 3, 6, 12 months and 10 years postoperatively. Anthropometric and body composition data, biochemical and hematological parameters, echocardiographic indices, as well as circulating traditional and exploratory markers of insulin resistance, cardiovascular risk and inflammation were obtained. We additionally examined panels of adipokines, activins/follistatins, metabolomics/lipidomics, and key gastrointestinal hormones during a mixed-meal test (MMT).

Results: Significant reductions in weight and body mass index were found in both groups, reaching a nadir at the first postoperative year and remaining significantly lower up to 10 years (mean weight difference vs baseline: -33 kg, p<0.001 for both groups). Fat mass percentage decreased and lean mass increased, remaining unchanged at 10 years after a nadir 12-month postoperatively (p<0.001 vs. baseline). Fasting glucose, triglycerides, cholesterol fractions, ApoA1, and liver function tests were significantly improved up to study completion. Significant reductions were observed in the levels of c-reactive protein, up to 1 year, and inflammation marker GlycA, up to 10 years. Indices of insulin resistance (HOMA-IR, Matsuda Index, ISSI-2, DRI), and the non-invasive Fatty Liver Index, were all improved and persisted up to 10 years (p<0.05 vs. baseline for all variables and groups). Atrial and ventricular diameters were improved and epicardial fat thickness reduced [-0.40 cm, 95% C.I. -0.56 to -0.23] at 10 years; p<0.001 vs. baseline, 6 and 12 months for both groups]. During the MMT, durable improvements in numerous aspects of the circulating metabolite profile, mainly reductions of cholesterol- and triglyceride- rich particle species. Combined metabolomic/lipidomic panels demonstrated sustained improvements in numerous aspects of the circulating metabolite profile, mainly reductions of cholesterol- and triglyceride- rich particle species.

Conclusion: Bariatric surgery exerts beneficial effects on the profiles of postprandial gastrointestinal hormone secretion, improves adipokine levels and metabolomic profile, thus driving a series of profound and long-lasting improvements in body weight and composition and overall cardiometabolic health.

Clinical Trial Registration Number: NCT04170010

Disclosure: S. Simati: None.

Analysis of intestinal morphology and incretin-producing cells using tissue optical clearing and 3-D imaging

T. Hatoko1, N. Harada1, S. Tokumoto1, S. Yamane1, E. Ikeguchi-Ogura1, T. Kato3, T. Yasuda1, H. Tatsuoka1, S. Shimazu-Kuwahara1, D. Yabe2, Y. Hayashi1, N. Inagaki1; 1Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, 2Department of Diabetes and Endocrinology, Gifu University Graduate School of Medicine, Gifu, 3Department of Endocrinology, Division of Stress Adaptation and Protection, Research Institute of Env, Nagoya University, Nagoya, Japan.

Background and aims: Intestine has various functions such as nutrient absorption, intestinal barrier, and hormone secretion. The intestine is composed of intestinal epithelial cells (IECs) such as enteroendocrine cells (ECs) including incretin-producing L cells and K cells. Immunohistological analysis of intestinal tissue sections has generally been used for evaluating the number and localization of target cells in intestine. However, it is difficult to envision the three-dimensional (3-D) structure of villi and crypts and to evaluate the number and localization of IECs and ECs under two-dimensional intestinal tissues. Tissue optical clearing methods including CUBIC protocol permits detailed evaluation of organ 3-D structure as well as that of individual cells by tissue staining and autofluorescence. The aim of our study is to evaluate intestinal morphology, IECs, L cells and K cells in reporter mice by a new intestinal evaluation method using CUBIC protocol and 3-D imaging.

Materials and methods: Villin1-Cre and Ait1t mice were cross bred and villin1 reporter mice were generated to enable visualization of IECs by tdTomato fluorescence. Analysis of intestinal morphology and IECs was performed by using villin1 reporter mice. Next, villin1 reporter mice and glucagon-GFP knock-in mice or GIP-GFP knock-in mice were cross bred to evaluate both IECs (tdTomato fluorescence) and incretin-producing cells (GFP fluorescence). Cell number and localization of incretin-producing cells in intestine were evaluated. We got transparency samples of small intestine (SI) and colon using these mice and tissue optical clearing. 3-D fluorescence images of all samples were acquired with confocal microscopy and were analyzed.

Results: The cross section of villi was spindle-shaped in the upper SI (USI) and became closer to round shape toward the lower SI (LSI). Villus length and IEC number per villus were greater in the USI than those in the LSI. Crypt shape, crypt depth, and IEC number per crypt were similar in any part of intestine. L cell number per villus was lowest in duodenum and similar in all other areas. L cell number per crypt was similar in intestine. L cells were expressed mainly in the lower villi and crypts. K cell number per villus were higher in the USI than that in the LSI. K cells were expressed mainly in the upper villi and lower crypts. Next, intestinal morphology and cell number were evaluated in high-fat diet-fed obese mice (HFD) and control-fat diet-fed lean mice (CDF). Villus length of HFD was longer in the LSI than that of CDF. IEC number per villus of HFD was higher in the USI than that of CDF. K cell number per villus of HFD was higher in the USI than that of CDF, but K cell number per IEC number in villus of HFD was similar than that of CDF.

Conclusion: 3-D evaluation of the intestine enabled us to clarify intestinal morphology and the precise number and localization of IECs and incretin-producing cells in intestine.
Disclosure: T. Hatoko: Grants; Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan Society for the Promotion of Science (JSPS), Ministry of Health, labour, and Welfare, Ministry of Agriculture, Forestry and Fisheries, Japan Diabetes Foundation, Japan Association for Diabetes Education and Care, Merck Sharp & Dohme (MSD) Life Science Foundation, Public Interest Incorporated Foundation, Suzuken Memorial Foundation.

492 Gut derived extracellular vesicles have high affinity to the liver and their enrichment in lipids is associated to the development of metabolic diseases

R.M. de Oliveira1, I. Ferreira1, I. Coelho1, F. Carli2, B. Costa-Silva3, A. Gastaldelli4, P. Macedo5
1CEDOC Chronic Disease FCM Nova, Lisbon, Portugal, 2Institute of Clinical Physiology (IFC), National Research Council (CNR), Pisa, Italy, 3Champalimaud Foundation, Lisbon, Portugal.

Background and aims: Metabolic homeostasis results from the interaction among all organs, highlighting inter-organ communication central for healthy energy balance. In particular, type 2 diabetes is a multi-organ disease and risk factor for other comorbidities. Gut-liver axis malfunction, which includes gut dysbiosis, alteration in gut hormone release, and nutrient absorption, suggest that the gut plays an important role in the etiology of diabetes. Extracellular vesicles (EVs), which transport specific cargo (proteins, DNA, microRNAs and lipids) along the circulation, are implicated in the development of metabolic diseases.

Importantly, we unveiled that gut-derived EVs (proteins, DNA, microRNAs and lipids) along the circulation, are of diabetes. Extracellular vesicles (EVs), which transport specific cargo (proteins, DNA, microRNAs and lipids) along the circulation, are implicated in the development of metabolic diseases. Important, we unveiled that gut-derived EVs’ (GDE) protein content reflects the metabolic state of the organisms. Considering the established role of EVs in communication and our findings, we hypothesize that GDE act as mediators of gut-liver axis contributing to the development of metabolic diseases like fatty liver disease and type 2 diabetes. Our aim was to clarify how the cargo transported by the GDE is translate into metabolic alterations.

Materials and methods: For this study we used two groups of C57Bl/6J mice fed with normal chow diet (NCD) or high fat diet (HFD) for 12 weeks. Upon confirmation of prediabetic phenotype by glucose tolerance test (GTT), body weight gain and liver histology, EVs were isolated by ultracentrifugation. EVs lipidic content and proteomics were profiled by LC/MS. Labeled GDEs were retro orbital injected to evaluate which organs were targeted by GDEs. Then, GDEs were injected into norglycemic animals for six weeks and their biological impact on glucose and lipid metabolism was studied.

Results: Chronic exposure of healthy mice to GDEs revealed that GDEs have affinity to the liver and are preferentially uptake by the resident hepatic macrophages, Kupffer cells (KC), which are involved in hepatic inflammatory response under metabolic stress. We observed that control mice, after receiving HFD-GDEs, had significantly higher weight gain in comparison with the control group. Moreover, we observed a positive correlation of the area under the curve (AUC) for the GTT of donor mice and the CL was good.

493 Intestinal dysbiosis and serum metabolites suggest an early progression to type 2 diabetes in patients with extreme obesity

A. Penesova1, L. Kúbanová1, I. Hric1, K. Soltyš1, Ž. Rádiková1, M. Kolisek1, V. Bielik1
1Institute of Clinical and Translational Research, Biomedical Research Center, Bratislava, 2Department of Biological and Medical Science, Faculty of Physical Education and Sport, Comenius University, Bratislava, 3Department of Microbiology and Virology, Faculty of Natural Sciences, Comenius University, Bratislava, 4Biomedical Center Martin, Jessenius Faculty of Medicine, Comenius University, Martin, Slovakia.

Background and aims: The development of Type 2 DM in obese individuals is characterized by dysregulated glucose metabolism and insulin resistance, could be related to progressive disruption of the gut microbiome associated with obesity. The purpose of this prospective cross-sectional study was to compare the composition of the gut microbiota and energy metabolites between non-diabetic individuals with extreme obesity (EO) and healthy lean controls (CL).

Materials and methods: We recruited 19 non-diabetic EO (mean±SD; age: 35.4±7.0 years, BMI: 48.8±6.7 kg.m-2) and 23 CL (age: 31.7±14.8 years, BMI: 22.2±1.7 kg.m-2). Their fecal microbiota was categorized using specific primers targeting the V1-V3 region of 16S rDNA, whereas serum metabolites were characterized by nuclear magnetic resonance spectroscopy. Multivariate statistical analysis and Random Forest models were applied to discriminate predictors with the highest variable importance.

Results: Impaired glucose regulation or prediabetes (according HbA1c between 42-47 mmol/l) was found only in 4 EO patients. We observed a significantly lower microbial α-diversity (Shannon index EO: 5.1±0.8 vs CL: 6.5±0.8; p<0.001), a relative abundance of beneficial bacterium Akkermansia (p<0.001) and the SCFA-producing bacteria Eubacterium hallii (p=0.02), Butyribrio (p=0.02), Marvinbryantia (p=0.01), and Coprococcus (p=0.05), and a higher abundance of the pathogenic bacteria Bilophila (p=0.02) and Fusobacterium (p=0.04) in EO. We observed a significantly negative association between the Shannon index and each of the following: glucose levels (rs = -0.355, p = 0.021), insulin levels (rs = -0.618, p = 0.001), IR HOMA (rs = -0.664, p = 0.001), HbA1C (rs = -0.404, p = 0.013), ALT (rs = -0.404, p = 0.008), serum citrate (rs = -0.615, p = 0.001), and serum acetate (rs = -0.544, p = 0.001). The machine learning algorithm identified citrate, acetate, alanine, IR HOMA, and insulin as important predictors and gave a ROC curve with an AUC of 0.991, indicating that their ability to discriminate probands from the EO and the CL was good.

Conclusion: Our results suggest that the shifts in gut microbiota and in serum acetate and citrate might be additional promising biomarkers of early progression to Type 2 diabetes in patients with obesity. Therefore, the non-invasive
Bile acids after bariatric surgery: a gateway to mitochondrial activation in human adipocytes

S. Heinonen1, E. Herbers1, B. Van der Kolk1, T. Saarinen2, A. Perino3, J. Kuula4, A. Hakkarainen4, H. Peltoniemi5, P.-H. Groop6, E. Pirinen1, K. Schoonjans1, M. Neuvonen2, M. Niemi7, A. Junti2, K. Pietiläinen1;
1Research Program of Clinical and Molecular Metabolism, University of Helsinki, Helsinki, Finland, 2Gastrointestinal Surgery Abdominal Center, Helsinki University Hospital, Helsinki, Finland, 3Institute of Bioengineering, Faculty of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland, 4HUS Imaging, Helsinki University Hospital, Helsinki, Finland, 5Tökkä Hospital, Helsinki, Finland, 6Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 7Clinical Pharmacology and Individualized Drug TheraPY Research Program, University of Helsinki, Helsinki, Finland.

Background and aims: Bariatric surgery is an effective therapy for morbid obesity, with significant improvements in the peripheral tissue metabolism. We previously found that an underlying event of these improvements is likely the activation of adipose tissue (AT) mitochondrial pathways. We aimed to investigate whether circulating bile acids mediate the favorable effect on AT mitochondria, potentiating weight loss and a healthy metabolism of the tissues after the surgery.

Materials and methods: We examined 43 bariatric surgery patients (25 Roux-en-Y gastric bypass, 20 One-anastomosis gastric bypass) at baseline and at 6 and 12 months post-surgery. We measured body weight, amounts of intra-abdominal-, subcutaneous- and liver fat (DEXA, MRI), circulating plasma lipids, insulin sensitivity (HOMA-index, Hba1C), inflammation (hs-CRP), and plasma bile acids (BAs, AUC mean, 95%CI) during a mixed meal test, and AT mitochondrial mtDNA mass and mitochondria-related transcripts (mean±SE). Additionally, we examined mitochondrial activation in human primary preadipocytes treated during differentiation with an agonist (INT-777) targeting TGR5 BA-receptor and with DCA, a secondary BA, by cell respiration (Seahorse extracellular flux analyzer), mtDNA mass and mitochondrial transcripts (COX1, NDS, 12S-RNA; mean±SE).

Results: Significant weight loss, improvement of intra-abdominal and liver fat, insulin sensitivity and inflammation were observed at 6 and at 12 months after the surgery. Increased levels of plasma postprandial total, primary, conjugated, hydrophobic and non-hydroxylated BAs were detected at 6 and 12 months (AUC: p<0.05 all; total BA 1400μM [1200, 1600] vs. 1900μM [1500, 2400] vs. 1800μM [1400, 2400], respectively). Fasting plasma BA levels increased from 0 to 6 and 12 months (2.2±1.8 μM vs. 4.6±5.9 μM vs. 5.6±5.5 μM [4.1, 7.0], p<0.001). AT mtDNA amount (1.1±0.03 vs. 1.27±0.07; p<0.01) and transcription of one of the main regulators of mitochondrial biogenesis in AT, PGC1α (0.5±0.03 vs. 0.75±0.04; p<0.001) were increased at 12 months compared with baseline. Differentiated human primary preadipocytes treated 10d or 24hrs with TGR5 bile acid receptor agonist against INT-777 or 24hrs with bile acid DCA showed increased mtDNA mass for INT-777 (1.1±0.04 vs. 1.32±0.1, p<0.05), and increased mitochondrial respiration (OCR) and levels of mitochondria-related transcripts (p<0.05) for INT-777 and DCA.

Conclusion: Weight loss by surgery leads to increased levels of post-prandial total, primary, conjugated, hydrophobic, non-hydroxylated and fasting BAs. AT shows signs of increased mitochondrial biogenesis after the surgery. Compounds mimicking the effects of BAs and TGR5 inducers in human adipocytes may have potential as mitochondrial activators.

Disclosure: A. Penesova: Grants; APVV-17-0099 and APVV-19-0222 and VEGA 2/0129/20 and VEGA 1/0260/21
Clinical Trial Registration Number: NCT02882685
Supported by: HUS, AF, SJF, DRF, ORF, PRF, PN, NNF
Disclosure: S. Heinonen: None.
Altered glucose tolerance conditions are associated with an activation of ER stress related responses in the gut

T.V. Fiorentino, F. De Vito, R. Marasco, E. Suraci, M.L. Hribal, F. Andreozzi, F. Lusza, G. Sesti;
1Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, 2Department of Clinical and Molecular Medicine, University Sapienza of Rome, Rome, Italy.

Background and aims: Preclinical evidence indicated that high glucose levels affect intestinal expression of tight-junction (TJ) proteins, thus leading to a disruption of intestinal epithelial integrity. Activation of endoplasmic reticulum (ER) stress plays an important role in cellular damage associated to glucotoxicity, and it has been reported to affect intestinal barrier integrity in animal studies. However, whether subjects with dysglycemic conditions have an activation of ER stress related responses in the colon has not been explored. In this study, we aimed to evaluate whether subjects with prediabetes or T2DM exhibit an activation of ER stress along with a disruption of mucosal integrity in the gut.

Materials and methods: We studied 38 Caucasian adults undergoing to a complete clinical characterization including OGTT, and colonoscopy with collection of colonic mucosa biopsies. Study participants were classified as having NGT (n=15), prediabetes (n=11) and T2DM (n=12) in accordance to the current American Diabetes Association criteria. Colonic levels of the ER stress activation markers Bip, inositol requiring kinase (IRE)-1, C/EBP homologous protein (CHOP), and phosphorylation levels of eukaryotic translation initiation factor 2 (eIF2α) and c-Jun N-terminal kinase (JNK) were assessed by Western blot (WB). Expression of TJ proteins was assessed by RT-PCR and WB. Activation of pro-inflammatory pathway was evaluated by measuring nuclear factor κB (NF-κB) activity, and expression of the cytokines IL-1β, TNFα and IL-6 by RT-PCR.

Results: Subjects with prediabetes and T2DM displayed progressively increased levels of the ER stress markers Bip, IRE-1α, phosphorylated eIF2α and CHOP in the colonic mucosa as compared to those with NGT (P<0.05). Moreover, we found a 1.5- and 2-fold increase in phosphorylation levels of the stress kinase JNK in subjects with prediabetes and T2DM as compared to NGT group (P<0.05). The intestinal upregulation of ER stress found in subjects with altered glucose tolerance was paralleled by an altered intestinal mucosa integrity. We found that subjects with prediabetes and T2DM have significantly reduced expression levels of the TJ protein zonulin (ZO)-1, claudin-1 and occludin in the colonic mucosa (-30% and -50% respectively, P<0.05), coupled with increased circulating levels of ZO-1, a surrogate indicator of increased colonic mucosa (-30% and -50% respectively, P<0.05), coupled with an altered intestinal mucosa integrity. We found that subjects with prediabetes or T2DM have significantly reduced expression levels of the TJ protein zonulin (ZO)-1, claudin-1 and occludin in the colonic mucosa (-30% and -50% respectively, P<0.05), coupled with increased circulating levels of ZO-1, a surrogate indicator of increased colonic mucosa integrity. We found that subjects with prediabetes or T2DM have significantly reduced expression levels of the TJ protein zonulin (ZO)-1, claudin-1 and occludin in the colonic mucosa (-30% and -50% respectively, P<0.05), coupled with increased circulating levels of ZO-1, a surrogate indicator of increased colonic mucosa integrity.

Conclusion: These results demonstrate that both T2DM and prediabetes are linked to an activation of ER stress along with a compromised TJ integrity, and inflammation in the colonic mucosa.

Supported by: EFSD/Lilly Young Investigator Research Award Programme
Disclosure: T.V. Fiorentino: None.

Effect of the early and postponed statin therapy after menopause on metabolic and inflammatory factors in rat model of prediabetes

M. Höttl, I. Markova, H. Malinska, D. Miklankova, T. Hlinka, J. Pitha, H. Bartuskova;
1Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 2Department of Physiology, Charles University, 3Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Background and aims: Metabolic associated fatty liver disease (MAFLD), recently discussed important risk factor for cardiovascular disease (CVD) exerts significant sex dimorphism. In MAFLD, women after menopause are affected by faster progression of liver fibrosis, higher levels of hepatocytes damage and inflammation. Early intervention of metabolic risk factors of CVD after menopause, including statin therapy, might be more effective approach. We studied whether early vs. later statin therapy after menopause changes metabolic and inflammatory parameters associated with CVD more favorably in experimental model of prediabetes.

Materials and methods: Female Hereditary Hypertriglyceridemic rats (representing a non-obese model of prediabetes with features of insulin resistance, dyslipidemia, oxidative stress and strong hepatic lipid storage) were ovariectomized at 8th week of age. Two groups treated by atorvastatin (5 mg/kg) from 2nd (early therapy) and from 14th week (later therapy) after ovariectomy were studied together with untreated control group. At the 25th week after ovariectomy the experiment was terminated.

Results: Both early and later therapy affected neither whole body weight nor the food consumption in comparison with controls. At the end of experiment, early therapy group had higher index of visceral adiposity than later therapy group (p<0.01). This corresponded with serum leptin which was also higher in early therapy group (p<0.001). In later therapy group, liver enzymes, and total cholesterol decreased more than in early therapy group and also than in controls. Serum triglycerides (TG) were significantly lower in early therapy group (~42%) and in later therapy group (~59%) than in controls; between group differences (p<0.05). In addition, early therapy surprisingly decreased fasting glucose levels and improved glucose tolerance, more than later therapy (p<0.01). Moreover, in early therapy group significantly lower HOMA-IR was observed than in later therapy group (p<0.05). Furthermore, early therapy ameliorated hepatic oxidative stress, i.e. increased the activity of antioxidant enzymes glutathione peroxidase and superoxide dismutase more than in later therapy group (p<0.001). Nevertheless, relative expressions of transcriptional factor Nrf2, a key regulator of the cell defense against oxidative stress, did not differ among study groups. In both statin-treated groups, the therapy considerably decreased hepatic TG (p<0.001). Pro-inflammatory marker (MCP-1) significantly decreased in both statins groups than in controls (p<0.01).

Conclusion: Early statin therapy vs. later statin therapy after menopause did not have favorable effects on most of metabolic and inflammatory factors associated with CVD in the experimental model of prediabetes. Moreover, statin therapy after menopause led to improved parameters of glucose metabolism irrespectively of the timing in this particular model. The definition of therapeutic window for optimal cardiovascular prevention in women after menopause seems to be more difficult than expected.

Supported by: MH CZ – DRO grant NU20-01-00083 and IKEM, IN 00023001
Disclosure: M. Höttl: None.
Impact of once-weekly subcutaneous semaglutide 2.4 mg on metabolic syndrome in the 2-year, randomised controlled STEP 5 trial

R.L. Batterham1, M. Bhatta2, T. Holst-Hansen2, K. Kandler2, G. Rigas3, W.T. Garvey4;

1Centre for Obesity Research, Division of Medicine, University College London, London, UK, 2Novo Nordisk A/S, Søborg, Denmark, 3Department of Bariatric Metabolic Surgery, St George Private Hospital, Kogarah, Australia, 4Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, USA.

Background and aims: Metabolic syndrome (MetS) is associated with an increased risk of cardiovascular disease and type 2 diabetes. Obesity is a key driver of MetS. In the STEP 5 trial, treatment with once-weekly subcutaneous semaglutide 2.4 mg resulted in 15.2% weight loss after 104 weeks vs 2.6% with placebo. This post hoc analysis of STEP 5 investigated the effect of 2 years of treatment with semaglutide on MetS.

Materials and methods: 304 adults with overweight/obesity (BMI ≥30 kg/m², or ≥27 kg/m² with ≥1 weight-related comorbidity), without diabetes, were randomised 1:1 to semaglutide 2.4 mg or placebo (both plus diet and physical activity) for 104 weeks. We assessed MetS prevalence at baseline and weeks 52 and 104, and weight loss from baseline to week 104 (<10%/≥10%). MetS was defined as the presence of ≥3 National Cholesterol Education Program Adult Treatment Panel III criteria. Results are based on observed data from the in-trial period. P values were from a chi-square test of proportions. Analyses were not adjusted for multiplicity.

Results: There were 89 participants with MetS at baseline in the semaglutide group and 79 in the placebo group. Significantly greater proportions of participants had remission of MetS at weeks 52 and 104 with semaglutide vs placebo (p<0.01; Figure), and significantly lower proportions developed MetS (1.7% vs 23.2%, week 52; 7.1% [2 of these 4 participants were off drug] vs 25.9%, week 104; both p<0.01). When considering the degree of weight loss (<10%/≥10%) in both the semaglutide and placebo groups, semaglutide led to a higher rate of MetS remission in participants with <10% weight loss than placebo at both 52 weeks (57.9% vs 25.0%) and 104 weeks (39.5% vs 15.3%), with fewer participants developing MetS (23.9% vs 28.9%, week 104). Weight loss of ≥10% led to higher MetS remission rates, which were similar in semaglutide- and placebo-treated participants (63.0% vs 66.7%, week 52; 71.1% vs 83.3%, week 104); no semaglutide-treated participants developed MetS with ≥10% weight loss (0.0% vs 22.2%, week 52; 0.0% vs 11.1%, week 104).

Conclusion: A greater proportion of participants treated with once-weekly subcutaneous semaglutide 2.4 mg achieved remission of MetS, and fewer developed incident MetS, compared with placebo. These benefits were maintained over 2 years of semaglutide treatment. These results suggest that the positive effects of semaglutide on MetS could potentially impact the progression to type 2 diabetes and cardiovascular disease while patients are taking the drug. However, these data should be interpreted with caution due to the small participant numbers involved.

499

Associations between weight loss and glycaemic control with once-weekly semaglutide 1.0 mg and 2.4 mg in the STEP 2 trial

M. Davies1, L. Fercher1, B. Goldman2, A. Pakseresht2, S. Pedersen3, J. Rosenstock4, I. Lingvay5;

1Diabetes Research Centre, Leicester, UK, 2Novo Nordisk A/S, Søborg, Denmark, 33C-ENDO Diabetes & Endocrinology Clinic Calgary, Calgary, Canada, 4Dallas Diabetes Research Center at Medical City, Dallas, USA, 5Departments of Internal Medicine/Endocrinology and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Background and aims: Weight loss achieved via lifestyle intervention or bariatric surgery has been shown to improve glycaemic control in people with type 2 diabetes (T2D) and may help to achieve normoglycaemia. We aimed to assess the relationship between body weight loss and glycaemic control in participants with overweight/obesity and T2D receiving semaglutide pharmacotherapy.
Materials and methods: In the STEP 2 trial, 1210 adults with overweight/obesity (BMI ≥27 kg/m²), with T2D, were randomised 1:1:1 to semaglutide 2.4 mg (n=404), semaglutide 1.0 mg (n=403) or placebo (n=403), plus a reduced calorie diet and increased physical activity, for 68 weeks. Exploratory evaluations of data from the STEP 2 trial included mean change in body weight (%) from baseline to week 68 for participants achieving HbA₁c <5.7% at week 20 and at week 68, and the proportions of participants with HbA₁c <5.7%, <6.5% or <7.0% at week 68 by categories of body weight loss (≥5%, ≥10%, ≥15%), for semaglutide 2.4 mg, semaglutide 1.0 mg and placebo. Results are based on observed data for the on-treatment period.

Results: Mean body weight reductions at week 68 were 16.7% (semaglutide 2.4 mg [n=87]), 13.5% (semaglutide 1.0 mg [n=63]) and 11.6% (placebo [n=7]) in participants who achieved HbA₁c <5.7% at week 20 vs 10.0% (n=308), 7.2% (n=323) and 3.2% (n=344), respectively, for those who did not achieve HbA₁c <5.7% at week 20. Mean body weight reductions at week 68 were 16.7% (semaglutide 2.4 mg [n=87]), 13.5% (semaglutide 1.0 mg [n=63]) and 11.6% (placebo [n=7]) in participants who achieved HbA₁c <5.7% at week 68 vs 8.8% (n=263), 6.2% (n=258) and 2.9% (n=330), respectively, for those who did not achieve HbA₁c <5.7% at week 68. The proportions of participants with HbA₁c <5.7% at week 20/week 68 were 14%/25% (semaglutide 2.4 mg), 10%/18% (semaglutide 1.0 mg) and 3%/2% (placebo). In addition, the proportions of participants achieving categories of body weight loss (≥5%, ≥10%, ≥15%) and HbA₁c (<5.7%, <6.5%, <7.0%) were higher with semaglutide 2.4 mg and 1.0 mg than with placebo (Figure).

Conclusion: In people with overweight/obesity and T2D, greater weight loss was associated with a greater chance of achieving HbA₁c <5.7% at both 20 and 68 weeks, with further benefits seen at the latter time point. Greater reductions in body weight were associated with higher proportions of participants achieving HbA₁c thresholds of <5.7%, <6.5% and <7.0% across all treatment groups.

500
Dapagliflozin protects human cardiac progenitor cells from deleterious effects of the secretome from visceral adipose cells of obese subjects

G. Palma1, C. Caccioppoli2, R. D’Oria1, V.A. Genchi1, I. Calderoni1, A. Braun2, G. Santarpino2, A. Milano1, A. Cignarelli1, A. Natalichio1, L. Laviola1, A. Pezzolla1, F. Giorgino1, S. Perrini1
1University of Bari Aldo Moro, 2General Surgery GVM Bari, Bari, Italy.

Background and aims: Dysfunction of visceral and epicardial adipose tissue may alter heart performance and promote adverse cardiovascular outcomes in obesity and diabetes. The aim of this study is to assess whether the secretome from abdominal visceral (AV) and epicardial (E) adipose stem cells (ASC) and from AV mature adipocytes might affect the viability of human cardiac progenitor cells (CPC) in human obesity, as well as to evaluate the effects of dapagliflozin (DAPA), a selective SGLT-2 inhibitor.

Materials and methods: ASC and mature adipocytes were isolated from AV adipose tissue biopsies of 27 obese (Ob) and 13 non-Ob subjects undergoing abdominal surgery, and from E adipose tissue biopsies of 8 Ob and 8 non-Ob subjects undergoing cardiac surgery. Human CPC were isolated from right auricle biopsies of non-Ob, non-diabetic donors undergoing cardiac surgery. Human CPC were pretreated with 10 μM DAPA for 24 h or left untreated, and then exposed to the conditioned media (CM) of AV-ASC, E-ASC, and AV mature adipocytes. Apoptosis was evaluated by ELISA assay for cytoplasmic oligonucleosomes. Impairment of organization of actin filaments was assessed by indirect immunofluorescence. JNK activation was studied by immunoblotting of c-Jun phosphorylation.

Results: The CM of AV-ASC, E-ASC, and AV mature adipocytes from Ob subjects induced apoptosis in human CPC after 24 h (p<0.05). Exposure of human CPC to the CM of AV-ASC, E-ASC, and AV mature adipocytes for 24 h also resulted in impaired organization of the human CPC actin filaments. In addition, the CM of AV-ASC, E-ASC, and AV mature adipocytes induced c-Jun phosphorylation after 4 h and 8 h (p<0.05). Importantly, these effects were not observed when the human CPC were exposed to the CM of AV-ASC, E-ASC, and AV mature adipocytes from non-Ob subjects. Pretreatment of human CPC with DAPA resulted in reduced apoptosis (p<0.05), and less impairment of actin filaments following exposure to the CM of AV-ASC, E-ASC, and AV mature adipocytes, as well as in reduced c-Jun phosphorylation (p<0.05).

Conclusion: In human obesity, the secretome of both AV and E ASC and mature adipocytes induces stress kinase activation in human CPC and impairs their viability and functionality, and these effects can be counteracted by SGLT-2 inhibitors directly acting on the human CPC.

Disclosure: G. Palma: None.

501
The effects of MS-275, HDAC Class I inhibitor, in diabetic skeletal muscle atrophy

J. Jeon1, S.-E. Choi2, J. Jeong1, S. Park2, Y. Kang2, T. Kim3, S.-Y. Ahn4, H. Kim1, S. Han1, N. Lee1, D. Kim1, K.-W. Lee1
1Department of Endocrinology and Metabolism, Ajou university, Suwon, 2Department of Physiology, Ajou university, Suwon, 3Division of Endocrinology and Metabolism, Seoul Medical Center, Seoul, 4Department of Internal Medicine, Busan Bumin Hospital, Busan, Republic of Korea.
Background and aims: Histone Deacetylase (HDAC) is considered one of the pathogenic factors that induces muscle atrophy. HDAC inhibitor, which regulates gene expressions by inhibiting the deacetylation of histones and non-histone proteins, plays an important role in many physiological processes, including muscle contraction, mitochondrial metabolism, and decision of cell fate. Recently it was reported that some of HDAC inhibitor prevented muscle atrophy, insulin resistance, and diabetes. However, the effects of MS-275 in diabetic skeletal muscle atrophy have not been well studied. In this study, we investigated the preventive effects of MS-275 and molecular mechanisms in diabetic muscle atrophy using db/db mice.

Materials and methods: To investigate the effects of MS-275 on diabetic muscle atrophy, db/db mice were randomly divided into three groups: control group, db/db group, and db/db plus MS-275 group. The mice were administered MS-275 (7 mg/kg i.p.) for 4 weeks. The body weight of the mice was checked. After the mice were sacrificed, muscle tissue was excised, dissected, and weighed. Each muscle tissue was stained with hematoxylin and eosin. The H&E stained sections were measured for cross-sectional area analyses using Image J software. To investigate the molecular mechanisms of MS-275, several factors related with muscle atrophy were tested using RT-PCR.

Results: Administration of MS-275 to db/db mice suppressed muscle weight loss and insulin resistance. As a result of examining muscle mass and fat accumulation in the hindlimb by MRI, we found MS-275 reduced fat accumulation and improved muscle loss. Tibialis anterior (TA) muscle and gastrocnemius (GA) muscle had significantly induced muscle atrophy in db/db mice. However, treatment with MS-275 prevented weight loss of TA and GA muscles and it also recovered reduction of muscle fiber size. Interestingly, MS-275 dramatically reduced atrophy related gene expressions such as MURF1 and Atrogin-1 in TA muscle.

Conclusion: In this study, we investigated the effects of MS-275 on diabetic muscle atrophy using db/db mice. MS-275 ameliorated muscle atrophy through a reduction of atrophy related gene expressions in db/db mice. These results suggest MS-275 may be a basis for the development of therapeutic drugs as applied to atrophy-related muscular or metabolic diseases.

Disclosure: J. Jeon: None.

502
Svep1-based peptide as a potential therapeutic agent against adipose tissue dysfunction
N. Kislev, D. Benayahu;
Developmental and Cell Biology, Tel Aviv University, Tel Aviv, Israel.

Background and aims: Adipose tissue dysfunction lies at the center of obesity pathogenesis. It is associated with surpassing the storage capacity of adipose cells, which leads to metabolic impairment and systemic meta-inflammation. Proteins involved in this process have drawn much attention due to their ability to affect the inflammatory response and alter the metabolic state. Sushi, von Willebrand factor type A, EGF, and pentraxin 1 (SVEP1) is a multidomain protein with potential metabolic and immune functions. It is an adhesion molecule found mainly in the extracellular matrix of mesenchymal tissues and was previously shown to play a role in several metabolic conditions such as diabetes, obesity, and cardiovascular diseases. SVEP1 has only one known receptor, an integrin molecule that also plays a role in adhesion and migration; their interaction potentially affects the inflammatory status found in the center of these metabolic conditions. The previously studied binding site of SVEP1 to the integrin is a nine amino acids long peptide with potential inhibitory capabilities over the integrin’s axes. In this study, we characterized the function of SVEP1 and its integrin receptor in adipose tissue and identified the SVEP1-based peptide as a possible therapeutic agent against adipose tissue inflammation.

Materials and methods: Fluorescently labeled and unlabeled peptides were generated based on the SVEP1 binding site to its receptor. RAW264.7 cells were used to study the peptide’s binding affinity and functional effect using extensive morphological and molecular phenotyping. In order to understand the function and impact of the peptide in adipose tissue, as well as its binding affinity, High fat and normal fat diet-fed C57BL/6 mice were used.

Results: We found that the integrin receptor is expressed on specific adipose tissue macrophages subpopulations upregulated in high fat diet mice with the ability to promote inflammation. We then generated a peptide based on the SVEP1 binding site and characterized its binding properties in silico using a structural protein-protein interaction prediction. In vitro accumulation assay indicated time and dose-dependent binding properties, while in vivo assays showed a specific binding capacity to immune subpopulations in adipose tissue. Our results, using the peptide, showed that it significantly inhibited the migration and adhesion of the cell, with a reduction of 30% in adhesiveness and motility. The peptide also affected the activation of the cells as co-incubation of the peptide with activated cells resulted in reduced nitrite production and inflammatory maker's expression levels compared to lipopolysaccharide activated macrophage-like cells.

Conclusion: This project will provide a valuable opportunity to advance the understanding of potential metabolic and immune mediators in adipose tissue and may serve as the foundation for future SVEP1-based therapeutics.

Disclosure: N. Kislev: None.

503
Effects of the bile acid TUDCA on glucose metabolism and skeletal muscle loss in senile mice
M. Carvalho, L. Zangerolamo, L.B. Santos, H.C.L. Barbosa;
University of Campinas, Campinas, Brazil.

Background and aims: Aging is often associated with the development of metabolic disorders and body changes, such as type II diabetes, increased adiposity, and muscle mass loss. For the treatment of these complications, bile acids have been standing out, among them, the tauroursodeoxycholic acid (TUDCA). TUDCA is an endogenous bile acid capable of improving insulin secretion and sensitivity, reducing body weight and blood glucose, and inhibiting cell death and endoplasmic reticulum stress in different experimental models. Recent studies have also demonstrated a new role for TUDCA, acting in the reversal of dexamethasone-induced skeletal muscle atrophy. Here, we aimed to investigate the effects of TUDCA on glucose homeostasis and muscle mass and function in aged mice.

Materials and methods: In this study, 3-month-old (Ctl) and 18-month-old (Old) C57BL/6 mice were used. To evaluate the effects of TUDCA, Old mice were treated for 20 days with an intraperitoneal injection of TUDCA at 300 mg/kg (Old+TUDCA) or its vehicle. We evaluated glucose homeostasis through glucose and insulin tolerance tests. In addition, we evaluated the muscle strength of these animals through a maximum voluntary carrying capacity (MVCC) and Kondziela’s inverted screen test. At the time of euthanasia, body and fat depots weights were obtained, as well as the weight of gastrocnemius, soleus, and tibialis anterior (TA) skeletal muscles. Molecular analyses to identify the expression of proteins that activate protein syntheses, such as p-mTOR and p-P70S6K, were obtained by western blotting. Data were analyzed by one-way ANOVA. Data are mean ± SEM and the difference between the groups was considered statistically significant if P ≤ 0.05.

Results: Old mice presented an increase in body weight (BW) (g) (29.20 ± 0.678 Ctl x 33.08 ± 1.025 Old x 29.54 ± 0.841 Old+TUDCA), as well as in adiposity (% BW) (epididimal fat: 0.70 ± 0.28 Ctl x 1.34 ± 0.09 Old x 0.69 ± 0.39 Old+TUDCA; inguinal fat: 0.65 ± 0.07 Ctl x 0.91 ± 0.04
Old x 0.66 ± 0.04 Old+TUDCA). Moreover, Old mice presented reduced skeletal muscle weight (% BW) (gastrocnemius: 0.54 ± 0.015 Ctl x 0.427 ± 0.014 Old x 0.498 ± 0.023 Old+TUDCA; soleus: 0.207 ± 0.0006 Ctl x 0.20 ± 0.001 Old x 0.20 ± 0.001 Old+TUDCA; TA: 0.179 ± 0.009 Ctl x 0.12 ± 0.004 Old x 0.161 ± 0.006 Old+TUDCA) and loss of muscle function, judging by a lower MVVC (% BW) (151.0 ± 7.83 Ctl x 77.4 ± 6.55 Old x 106.1 ± 7.54 Old+TUDCA) and lower time score on Kondziela’s test (seconds) (121.9 ± 7.08 Ctl x 7.3 ± 1.43 Old x 39.84 ± 7.34 Old+TUDCA). The reduction in muscle weight in these mice was accompanied by lower protein content of phosphorylated mTOR (0.482 ± 0.101 Old x 1.18 ± 0.158 Old+TUDCA, fold change of Ctl) and P70S6K (0.323 ± 0.092 Old x 0.756 ± 0.108 Old+TUDCA, fold change of Ctl), indicating a reduction in protein synthesis signaling. TUDCA treatment also improved glucose tolerance (area under the curve) (17284 ± 446 Ctl x 23179 ± 518 Old x 15224 ± 691 Old+ TUDCA), and insulin sensitivity KITT (%/min) (5.16 ± 0.32 Ctl x 1.84 ± 0.12 Old x 4.30 ± 0.27 Old+TUDCA) in Old mice. Once insulin plays a crucial role in activating protein synthesis signaling in skeletal muscle, the improvement in insulin sensitivity may be involved, at least in part, in the higher muscle mass observed in Old mice.

Conclusion: Our results show that the bile acid TUDCA attenuates skeletal muscle loss and improves glucose metabolism in Old mice, pointing TUDCA as a promising compound to treat aging-associated disorders.

Supported by: FAPESP

Disclosure: M. Carvalho: Grants; FAPESP - 2021/13917-6.

SGLT2 inhibition prevents high fat diet-induced glucose intolerance, but not weight gain, in C57BL/6 male mice

T. Li1, W. Zhu1, Z. Sun1, C. Rayner2, R. Young3, T. Wu1,2; 1Southeast University, Medical School, Affiliated Zhongda Hospital, Nanjing, China, 2Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia.

Background and aims: Excessive intake of dietary fat is linked to increased risk of obesity and type 2 diabetes, but the underlying mechanisms remain incompletely understood. Dietary fat has been shown to upregulate renal glucose transporters and augment renal glucose reabsorption, which may contribute to metabolic derangement. This study determined the effects of a high fat diet (HFD) on body weight, glucose tolerance and expression of renal glucose transporters in C57BL/6 male mice, and whether these were modified by the SGLT-2 inhibitor, empagliflozin.

Materials and methods: Two independent studies were performed in six-week old C57BL/6 mice. In Study 1, mice were fed either a HFD (Research Diet #D12492, USA; 60% fat, 20% carbohydrate and 20% protein; 5.24 kcal/g) or normal chow diet (NCD) for 12 weeks (n = 5 per group), followed by both an intraperitoneal glucose tolerance test (IPGTT) and an intraperitoneal insulin tolerance test (IPITT). Renal expression of glucose transporters, including SGLT1, SGLT2, GLUT1 and GLUT2, at Week 12 was assessed by the real-time quantitative PCR and western blot. In Study 2, mice were fed either a HFD or NCD, with oral gavage of empagliflozin (10mg/kg) or vehicle once daily, for 12 weeks (n = 5 per group). Body weight, fasting blood glucose, and glucose tolerance during an IPGTT were assessed at Weeks 6 and 12.

Results: In HHTg rats, empagliflozin administration did not affect body weight, the weight of epididymal as well as perirenal adipose tissue, but markedly decreased non-fasting glucose and insulin (P<0.01). In addition, empagliflozin reduced serum triglycerides levels (P<0.001) and to significantly decreased ectopic triglycerides (P<0.05) and cholesterol accumulation (P<0.01) in kidney cortex. According to target urinary proteomics, empagliflozin treatment significantly decreased inflammatory marker (MCP-1, IL-6, IL-8; leukotrienes C4, D4 and E4 class) together with decreased proinflammatory marker - epidemal growth factor (P<0.01). In addition, metabolic analyses revealed decreased urinary secretion of indole and p-cresol related to improved aromatic amino acid metabolism in empagliflozin-treated HHTg rats compared to untreated animals. Empagliflozin also decreased albuminuria and concentration of NGAL in urine (P<0.05), however plasma creatinine was not affected. In kidney cortex, relative mRNA expression as well as the concentration of MCP-1 (P<0.05) were decreased in empagliflozin-treated HHTg rats. To renoprotective mechanism of empagliflozin can contribute markedly improved oxidative parameters in kidney cortex: elevated level of glutathione (p<0.01) and increased activity of antioxidant enzymes glutathione peroxidase and superoxide dismutase (P<0.05), however, gene expression of transcription factor Nrf2 was not affected. Significantly increased gene expression of β-hydroxybutyrate dehydrogenase 1 in kidney cortex (P<0.01) can contribute to higher ketone body utilization and can improved renal fuel efficiency.

Conclusion: Alleviation of inflammation, oxidative stress and the improvement of renal lipid metabolism may be involved in the mechanism of the renoprotective effects of empagliflozin. Metabolic changes in the kidneys correlated well with the results of targeted urinary proteomics, which could be used as a suitable indicator of empagliflozin treatment as well as initial renal disorders in prediabetic conditions.

Supported by: Czech Science Foundation, project 19-06199S and the MII CZ – DRO grant (IKEM, IN 00023001)

Disclosure: H. Malinska: None.
iAUC for blood glucose induced by the HFD at both Weeks 6 and 12 ($P < 0.001$), without affecting weight gain.

**Conclusion:** These observations reveal that the renal SGLT-2 pathway is primarily responsible for HFD-induced glucose intolerance in mic and support the concept of inhibiting SGLT2 to prevent obesogenic diet-induced dysglycaemia.

**Disclosure:** T. Li: None.

---

506

**Metreleptin robustly increases resting-state brain connectivity in patients with lipodystrophy**

H. Schlögl¹, A. Villringer², K. Miehle¹, M. Stumvoll¹, K. Mueller²;
¹Endocrinology, University Hospital Leipzig, ²Neurology, Max-Planck-Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.

**Background and aims:** In recent years, knowledge about the rare disease lipodystrophy (LD) has improved, and with recombinant leptin (metreleptin) a causal treatment option is now available. Research in LD and substitution with metreleptin not only helped LD patients, but also opened new directions in investigating leptin’s role in insulin signalling, fatty acid metabolism and regulation of eating behavior. Previously, in a study with LD patients undergoing metreleptin substitution using functional magnetic resonance imaging (fMRI), we found significantly increased resting-state connectivity in the three brain areas hypothalamus, insula/superior temporal gyrus, and medial prefrontal cortex. However, as LD is very rare, studies on brain effects of metreleptin have very low case numbers, ranging from one to ten. In addition, fMRI is a scientific method susceptible to false positive results, nevertheless, it is still the best possibility to investigate changes in brain areas like the hypothalamus. Thus, reproducibility of findings is seen as one of the key indicators for scientifically meaningful results. In this study, we aimed to reproduce our fMRI findings in an independent sample and compare results to a healthy control group.

**Materials and methods:** Measurements in four LD patients and three healthy control persons were performed at four different time points (see Figure legend) on a 3-T MAGNETOM Skyra scanner (Siemens Healthineers). To identify treatment-related connectivity changes, eigenvector centrality (EC) mapping was performed using the fastECM software. Within SPM 12, the statistical analysis was performed on the group level using all four EC maps for all patients using the general linear model with a flexible factorial design with factors subject and time. Furthermore, a flexible factorial model was used with the three factors subject, group (patient or control), and time.

**Results:** In LD patients, we found a significant EC increase over all four measurements in the hypothalamus (cluster-level $P = 0.006$, cluster size $k_E = 160$, cluster maximum at $[-6 8 -14]$, $T = 11.96$, $Z = 4.94$). In addition, two further clusters were found in the precentral (left: $P = 0.007$, $k_E = 151$, $[-14 -62 28]$, $T = 10.84$, $Z = 4.77$; right: $P = 0.007$, $k_E = 155$, $[12 -60 32]$, $T = 9.71$, $Z = 4.58$). Using the three-factorial model, a significant interaction between group and time was found in the hypothalamus ($P = 0.020$, $k_E = 94$, $[-4 6 -14]$, $F = 27.99$, $Z = 4.30$) (Figure).

**Conclusion:** Here we reproduce in an independent sample of LD patients the increase in connectivity in hedonic and homeostatic central nervous networks through metreleptin treatment. The effects were specific for metreleptin treated LD patients and did not occur in healthy controls. These results are an important contribution to ascertain brain leptin action and build the foundation for further research of central nervous effect of this important metabolic hormone.

**Clinical Trial Registration Number:** Registered at the ethics committee of the University of Leipzig, approval no. 147/10-ek

**Supported by:** DZD, Germany; BMBF, Germany

**Disclosure:** H. Schlögl: Employment/Consultancy; Consultancy for Aegerion Pharmaceuticals in 2018.
SO 33 Insulin in action

507
Different CD36 subcellular localisation in beta cells between diabetes-prone and -resistant mice: possible involvement of CD36 in beta cell dysfunction
M. Nagao1,2, A. Asai1, M. Okazaki-Hada1, H. Sugihara1, L. Eliasson2, S. Oikawa1
1Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, 2Islet Cell Endocytosis, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.

Background and aims: Type 2 diabetes (T2D) is associated with impaired insulin secretion. We have previously shown higher gene and protein expression of fatty acid translocase/CD36 in human islets from obese T2D donors. Moreover, overexpression of CD36induced impaired insulin secretion (GSIS/KSIS), associated with suppressed insulin signaling and exocytosis dysfunction (e.g., defects in insulin granule docking), in INS-1 clonal β-cells. To further investigate the importance of CD36 in diabetes development, we aimed to study the implications of CD36 expression for the different insulin secretion capacity between Oikawa-Nagao Diabetes-Prone (ON-OP) and Diabetes-Resistant (ON-DR) mouse islets. These two mouse lines, established by us through selective breeding, have different susceptibilities to diet-induced diabetes. We previously demonstrated that pancreatic islets of pre-diabetic ON-OP mice show higher gene expression of CD36 and lower GSIS/KSIS compared to those of ON-DR mice, which make this a good model for further investigations.

Materials and methods: Islets were isolated from ON-OP and ON-DR mice at 5 weeks of age by collagenase digestion. Protein expression was evaluated by Western blotting. Islet triacylglycerol (TG) content was analyzed by gas-liquid chromatography. Insulin granule distribution in β-cells was assessed in the islet transmission electron micrographs. For subcellular localization analysis of CD36, islet cells were dispersed into single cells and stained immunocytochemically. P<0.05 was considered statistically significant by Student’s t test.

Results: ON-OP mouse islets showed 2.2-fold higher CD36 protein level (n=6, p<0.001 vs ON-DR), 1.6-fold higher TG content (p=0.02), and 50% lower AKT Ser473 phosphorylation level (p<0.01). The number of insulin granules docked to the plasma membrane was smaller by 70% in β-cells of ON-OP mice (n=4, p=0.012). Immunocytochemical analysis revealed that CD36 was expressed in almost all insulin-positive β-cells. Interestingly, while CD36 was widely distributed in the plasma membrane and cytoplasm in β-cells of ON-OP mice, it was localized more centrally in those of ON-DR mice. The ratio of the plasma membrane to cytoplasmic CD36 signal intensity in β-cells of ON-OP mice was 1.8-fold higher than those of ON-DR mice (n=3, p=0.042).

Conclusion: Our data highlight the role of CD36 in lipid accumulation, insulin signaling attenuation, and exocytotic machinery impairments in pancreatic β-cells. The novel finding of different CD36 subcellular localization in β-cells between ON-OP and ON-DR mice provides new insight into the pathophysiological role of CD36 for the development of T2D in relation to obesity.

Supported by: JSPS KAKENHI, ONO Medical Foundation, Swedish Research Council
Disclosure: M. Nagao: None.

508
Preservation of glucose homeostasis in mice with conditional beta cell specific deletion of the dual leucine zipper kinase in a prediabetic condition
J. Duque Escobar1,2, K.A. Köster1,2, M. Dethlefs1,2, S. Schröder1, E. Oetjen1,2
1Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, 2DZHK, partner site Hamburg/Kiel/ Lübeck, Hamburg, Germany.

Background and aims: Our previous studies in a beta-cell line showed that activation of the dual leucine zipper kinase (MAP3K12) by prediabetic signals contributes to the loss of beta-cell function and mass and thereby to the pathogenesis of diabetes mellitus type 2. In line, high glucose-induced apoptosis was reduced in isolated islets from mice with a conditional beta-cell specific Dlk deletion (beta-DLK−/−) compared with islets from Dlkfl/fl and RIP-Cre transgenic mice as controls. Hence, it was investigated whether beta-DLK−/− mice maintain physiological glucose homeostasis despite western diet (WD) induced prediabetes.

Materials and methods: Eight-week old mice (strain Bl6J) with beta-DLK−/−, Dlkfl/fl and RIP-Cre genotype were fed a WD (21.2% fat, 33.2% sucrose) and sacrificed after 20 weeks of diet. HbAlc, blood glucose, and serum insulin were measured using commercial kits. Ki67, insulin and glucagon staining was assessed by immunohistochemistry or -fluorescence of paraffin-embedded pancreatic slides.

Results: Irrespective of their genotype, all mice gained more weight under WD than under normal diet (ND) (85 ± 3.2% vs 39 ± 2.2%). In histological analysis, the islets of beta-DLK−/− and of RIP-Cre mice showed increased cell proliferation, measured as Ki67 positive cells, and islet area under WD. Consistently, in pancreatic section of beta-DLK−/− and RIP-Cre mice after WD, the number of insulin- and glucagon positive cells was higher in the same extent with 2.75/2.72-fold and 2/2.0-fold increase, respectively. At the end of the WD, only in beta-DLK−/− mice no diet-depending increase in HbAlc was detected, however, no difference between the genotypes under ND was observed. Moreover, in RIP-Cre (171 ± 6.2 mg/dl to 213 ± 9.0 mg/dl; p = 0.0003) and in Dlkfl/fl (166 ± 6.2 mg/dl to 203 ± 6.7 mg/dl; p = 0.0007) mice, but not in beta-DLK−/− mice (148 ± 5.9 mg/dl to 168 ± 5.6 mg/dl; p = 0.1013) glucose levels were elevated under WD. In line, insulin serum levels after WD were significantly higher in beta-DLK−/− mice (6.3 ± 1.1 μg/ml) than in RIP-Cre (2.2 ± 0.4 μg/ml; p < 0.0001 vs beta-DLK−/−) or Dlkfl/fl (3.7 ± 0.8 μg/ml; p = 0.0101 vs beta-DLK−/−) mice. Consequently, the insulin/glucose ratio was significantly increased in beta-DLK−/− (4.6 ± 0.8-fold) compared to RIP-Cre (2.4 ± 0.4-fold; p < 0.0001 vs beta-DLK−/−) and Dlkfl/fl (2.7 ± 0.6-fold; p = 0.0009 vs beta-DLK−/−) mice, respectively.

Conclusion: These results show that deletion of Dlk in beta-cells preserves their ability to compensate increased insulin demand in a prediabetic condition and maintain normoglycemia. Thus, the inhibition of Dlk will sustain beta-cell function under prediabetic conditions. Inhibition of Dlk might therefore be a novel and promising target for the treatment of diabetes.

Supported by: DFG Deutsche Forschungsgemeinschaft
Disclosure: J. Duque Escobar: Grants; Deutsche Forschungsgemeinschaft (DGF): OE181/5-1, DZHK travel grant.

 Springer
509
Impaired insulin secretion by decreased potassium conductance of beta cells in a prediabetic mouse model
M. Asuaje Pfeifer, K. Grupe, M. Liebmann, I. Rustenbeck, S. Scherneck;
Institute of Pharmacology, Toxicology and Clinical Pharmacy, Technische Universität Braunschweig, Braunschweig, Germany.

Background and aims: Female New Zealand obese (NZO) mice exhibit both impaired glucose-stimulated insulin secretion and impaired glucose tolerance, but do not develop a manifest diabetes. Gene expression data suggest dysfunctional oxidative phosphorylation in the islets of Langerhans, which could lead to disturbances in the function of the ATP-dependent potassium channels (K_{ATP} channels). Therefore, the contribution of mitochondrial metabolism and subsequently the K_{ATP} channels to this phenotype were investigated.

Materials and methods: Islets of Langerhans from female NZO and NMRI mice (control) were isolated by collagenase digestion. Single cells were harvested by calcium-free incubation and cultured overnight in RPMI 1640 containing 10% FCS and 5 mM glucose. The transmembrane current of single β-cells was measured by the patch-clamp technique in the perforated-patch configuration. Mitochondrial membrane potential was determined in perfused, freshly isolated islets by TMRE fluorescence. Insulin secretion was measured by ELISA and ATP as well as ADP content were determined by luciferase luminescence after static incubation of freshly isolated islets.

Results: In the presence of 1 mM glucose, the outward current was lower in NZO β-cells than in NMRI β-cells (15.47 vs. 34.69 pA, p < 0.001). Blockade of K_{ATP} channels by 500 μM tolbutamide reduced it to equal levels, while opening by 250 μM diazoxide enhanced the currents difference (34.77 vs. 73.44 pA, p < 0.01). Insulin secretion was blunted by 250 μM diazoxide in both strains (NMRI: 0.22 vs. 2.41 ng/islet/h, p < 0.01; NZO: 0.37 vs. 1.07 ng/islet/h, p = 0.53). A concentration of 500 μM tolbutamide tended to increased insulin secretion in the NZRI strain but not in NZO mice. Raising the glucose concentration from 1 mM to 20 mM resulted in a comparable elevation of TMRE fluorescence in both NZO and NMRI islets. Compared to 1 mM, 20 mM Glucose increased the ATP content and the ATP/ADP ratio in NMRI (ATP: 12.85 vs. 10.07 pmol/islet, p < 0.05; ATP/ADP: 2.24 vs. 1.65, p < 0.01) and NZO mice (ATP: 7.57 vs. 4.55 pmol/islet, p < 0.01; ATP/ADP: 2.95 vs. 2.15, p < 0.01). The ATP and ADP contents were significantly decreased in NZO islets compared to NMRI islets after incubation with 1 and 20 mM Glucose, while the ATP/ADP ratio was markedly increased in NZO mice.

Conclusion: The altered insulin secretion profile of the NZO mice fits to the decreased outward current of the β-cells at low glucose, which in turn results from a dysfunction of the K_{ATP} channels, as evidenced by the use of potassium channel blockers and openers. This could be due to the chronically increased ATP/ADP ratio, which in conjunction with the diminished adenine nucleotide contents suggests a defective regulation of the citrate cycle or the respiratory chain.

Supported by: DDG
Disclosure: M. Asuaje Pfeifer: None.

510
Endogenous glucose-dependent insulinotropic polypeptide (GIP) facilitates postprandial intestinal lipid uptake
1University of Copenhagen, Copenhagen N, 2Gentofte Hospital, Hellerup, 3Antag Therapeutics Aps, Copenhagen N, 4Steno Diabetes Center Copenhagen, Herlev, 5Bispebjerg Hospital, Copenhagen N, 6Kopenhagen University, 3Kyungpook National University School of Medicine, 7Technische Universität Braunschweig, Braunschweig, Germany.

Background and aims: The gut incretin hormone glucose-dependent insulinotropic polypeptide (GIP) increases triglyceride deposition in subcutaneous adipose tissue when administered to healthy individuals but these effects are attenuated both in patients with type 2 diabetes (T2D) and obesity. Using the selective GIP receptor antagonist GIP(3-30)NH2, we investigated the effect of endogenous GIP on circulating lipoproteins during a meal in healthy men and patients with T2D.

Materials and methods: We measured apolipoprotein B48 (ApoB48) as a marker of chylomicron count and plasma lipoprotein (chylomicrons, VLDL, LDL, HDL) triglyceride and cholesterol content during two four-hour liquid meal tests (1,894 kJ) with double-blind infusions of GIP(3-30)NH2 or placebo (saline) in randomized order in 12 healthy men (19-65 years, BMI 20.3-25.5 kg/m²) and in 10 men with T2D (44-72 years, HbA1c 7.0-8.2%, BMI 27.4-41.2 kg/m²). Increment AUC (iAUC) values were compared with Wilcoxon paired test.

Results: GIP(3-30)NH2 reached ~1,000 higher plasma levels than GIP(1-42) (data previously published). Compared to placebo, the GIP(3-30)NH2 infusion lowered postprandial levels of ApoB48 (iAUC0-180 min (median (95% CI): 215 (156-258) vs 404 (363-541) mg ×10^-3× min, p = 0.0049) (Figure A), chylomicron-triglyceride content (iAUC0-270 min: 32.7 (-2.32-27.21) vs 49.5 (1.21-170) mmol × 10^-3 × min p = 0.083) and LDL-triglyceride content (iAUC0-270min: -0.90 (-1.95-0.18) vs 0.95 (-0.72-3.95) mmol × 10^-3 × min, p = 0.016). In patients with T2D, infusion of GIP(3-30)NH2 did not change postprandial levels of ApoB48 (Figure B) or lipoprotein-triglyceride content. In both groups, there were no differences in lipoprotein-cholesterol contents.

Conclusion: We show that GIP receptor antagonism reduces postprandial circulating chylomicrons (ApoB48 levels) and HDL-triglyceride content in healthy individuals suggesting that endogenous GIP facilitates intestinal lipid uptake during a meal; an effect which seems to be reduced in patients with T2D.

Clinical Trial Registration Number: NCT03702660 // NCT03013296 Supported by: EFSDF/Lilly Research Programmes; Gangstedfonden; Herlev-Gentofte Hospital; University of Copenhagen

511
Inhibition of pyruvate dehydrogenase kinase 4 alleviates insulin resistance through the PI3K/AKT signalling pathway
M.-J. Kim1, R. Kim2, S. Kwon1, J.-H. Jeon1,2, I.-K. Lee3,4, I.
1Internal Medicine, Kyungpook National University Chilgok Hospital, 2Biomedical Science, The Graduate School of Kyungpook National University, 3Kyunpook National University School of Medicine,
**Background and aims:** Insulin resistance is the main characteristic of type 2 diabetes mellitus. The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway is considered to be the core of the insulin signaling pathway, the PI3K/AKT signaling pathway is downregulated during hepatic insulin resistance. Previous studies have shown that pyruvate dehydrogenase kinase 4 (PDK4) expression is dramatically increased in the liver and muscle of insulin-resistant patients and rodents.

**Materials and methods:** We used AML12 hepatocyte used for quantitative real-time PCR, western blot and glucose production assay. Two mouse models of insulin resistance (5 weeks old male KKAY and high fat diet-induced obesity, DIO mice) were used to determine the role of PDK4 in insulin resistance. We performed the indicate tests of insulin resistance and studied its mechanism through pharmacological treatment of PDK4 inhibitors.

**Results:** We confirmed that the gene expression of PDK4 was significantly increased and AKT pathway was attenuated in the palmitate treated AML12 using publicly available transcriptionomics dataset analysis (GSE74059). PDK4 expression was induced obviously after treatment of palmitate in AML12 hepatocytes, shown remarkable decreased AKT phosphorylation. Treatment of two different PDK4 inhibitors ameliorated phosphorylation of ser293 and ser300 in pyruvate dehydrogenase E1α (PDHE1α) and increased AKT activity, respectively. Pharmacological inhibition of PDK4 reduced the levels of fasting blood glucose and the level, increased the insulin levels and significantly improved insulin resistance (glucose tolerance test, GTT), insulin tolerance test (ITT) and homeostasis model assessment of insulin resistance (HOMA-IR), all P<0.05 in the KKAY mice and DIO mice. We compared with commercial anti-diabetic drug, sitagliptin. We found that this novel PDK inhibitors were either more effective or non-inferior for improving insulin resistance.

**Conclusion:** PDK4 inhibitor regulates PI3K/AKT signaling pathway and alleviates insulin resistance in diabetic KKAY and DIO mice. Targeting PDK4 may be a potential treatment option for diabetes treatment via reducing insulin resistance.

**Disclosure:** M. Kim: None.

---

**Materials and methods:** Cross-sectional data from a subset of The Maastricht Study enriched with (pre)diabetes individuals (n=1130, 49.4% women, 60±8 yrs) were analyzed. tCys was measured in fasted EDTA plasma with LC-MS/MS. Outcomes included BMI, waist circumference, total and limb fat mass, subcutaneous and visceral adipose tissues (SAT and VAT), and insulin resistance (Matsuda index and HOMA-IR). Two SCD activity indices were estimated as product/precursor ratios of fatty acids in total serum lipids with 16 and 18 carbon atoms, respectively, assayed with GC with flame ionization detection. Serum appetite (ghrelin and satiety (PYY, GIP, GLP-1, PP)) hormones where measured by immunoassays. SCD activity indices and satiety hormones, respectively, were combined in two standardized scores. Two mediation models with z-standardized main exposure (tCys) and outcomes (adiposity measures) were used to examine the mediation effect by SCD activity and appetite/satiety hormones, respectively, with adjustment for cohort structure, demographics and lifestyle. Mediation models by SCD activity were further adjusted for serum triglycerides, since these might affect serum SCD activity index; these analyses might however be overadjusted.

**Results:** Plasma tCys was associated with all measures of adiposity (e.g., BMI [β=0.27; 95% CI: 0.21, 0.32], limb fat [0.27; 0.22, 0.33] and VAT [0.14; 0.09, 0.19]) and insulin resistance (Matsuda index [-0.19; -0.25, -0.13] and HOMA-IR [0.19; 0.13, 0.25]). SCD activity explained a significant proportion of all associations, with mediated effects (ME) ranging from 5.9% for limb fat [indirect effect: 0.02; 0.01, 0.03] to 19.7% for VAT [0.03; 0.02, 0.04]. Ghrelin mediated all associations, with ME ranging from 2.4% for limb fat [0.01; 0.00, 0.01] to 5.6% for VAT [0.01; 0.01, 0.02]. Similar ME were found in the associations of tCys with Matsuda index (SCD: 14.3% [-0.03; -0.04, -0.01]; ghrelin: 5.4% [-0.01; -0.02, -0.00]) and HOMA-IR (SCD: 18% [0.03; 0.02, 0.05]; ghrelin: 5.4% [0.01; 0.00, 0.02]). No mediation by satiety hormones was found. Adjustment for triglycerides substantially attenuated all MEs by SCD activity index that became non-significant.

**Conclusion:** Higher SCD enzyme activity and serum ghrelin may represent two pathways by which plasma tCys relates to obesity and insulin resistance. Further research is warranted to confirm these findings and identify effective strategies to limit the effects of tCys on obesity and T2D.

**Supported by:** JPI and Health~Holland

**Disclosure:** E.C. Tore: Grants; JPI, Health~Holland.

---

**512 The roles of SCD enzyme and appetite hormones in the associations of plasma cysteine with obesity and insulin resistance: The Maastricht Study**


1 Internal Medicine, CARIM School for Cardiovascular Disease, Maastricht University, Maastricht, Netherlands; 2Pharmacology, University of Oxford, Oxford, UK; 3Epidemiology, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, Netherlands; 4Vitas Analytical Services AS, Oslo, Norway; 5Radiology & Nuclear Medicine, CARIM School for Cardiovascular Disease, Maastricht University Medical Center, Maastricht, Netherlands; 6Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.

**Background and aims:** Growing evidence links high plasma total cysteine (tCys) concentrations to obesity and type 2 diabetes (T2D). We aimed to examine if potential underlying mechanisms involve the stearoyl-CoA desaturase (SCD) enzyme, a regulator of lipid metabolism, and hormones regulators of food intake.

**Materials and methods:** Cross-sectional data from a subset of The Maastricht Study enriched with (pre)diabetes individuals (n=1130, 49.4% women, 60±8 yrs) were analyzed. tCys was measured in fasted EDTA plasma with LC-MS/MS. Outcomes included BMI, waist circumference, total and limb fat mass, subcutaneous and visceral adipose tissues (SAT and VAT), and insulin resistance (Matsuda index and HOMA-IR). Two SCD activity indices were estimated as product/precursor ratios of fatty acids in total serum lipids with 16 and 18 carbon atoms, respectively, assayed with GC with flame ionization detection. Serum appetite (ghrelin and satiety (PYY, GIP, GLP-1, PP)) hormones where measured by immunoassays. SCD activity indices and satiety hormones, respectively, were combined in two standardized scores. Two mediation models with z-standardized main exposure (tCys) and outcomes (adiposity measures) were used to examine the mediation effect by SCD activity and appetite/satiety hormones, respectively, with adjustment for cohort structure, demographics and lifestyle. Mediation models by SCD activity were further adjusted for serum triglycerides, since these might affect serum SCD activity index; these analyses might however be overadjusted.

**Results:** Plasma tCys was associated with all measures of adiposity (e.g., BMI [β=0.27; 95% CI: 0.21, 0.32], limb fat [0.27; 0.22, 0.33] and VAT [0.14; 0.09, 0.19]) and insulin resistance (Matsuda index [-0.19; -0.25, -0.13] and HOMA-IR [0.19; 0.13, 0.25]). SCD activity explained a significant proportion of all associations, with mediated effects (ME) ranging from 5.9% for limb fat [indirect effect: 0.02; 0.01, 0.03] to 19.7% for VAT [0.03; 0.02, 0.04]. Ghrelin mediated all associations, with ME ranging from 2.4% for limb fat [0.01; 0.00, 0.01] to 5.6% for VAT [0.01; 0.01, 0.02]. Similar ME were found in the associations of tCys with Matsuda index (SCD: 14.3% [-0.03; -0.04, -0.01]; ghrelin: 5.4% [-0.01; -0.02, -0.00]) and HOMA-IR (SCD: 18% [0.03; 0.02, 0.05]; ghrelin: 5.4% [0.01; 0.00, 0.02]). No mediation by satiety hormones was found. Adjustment for triglycerides substantially attenuated all MEs by SCD activity index that became non-significant.

**Conclusion:** Higher SCD enzyme activity and serum ghrelin may represent two pathways by which plasma tCys relates to obesity and insulin resistance. Further research is warranted to confirm these findings and identify effective strategies to limit the effects of tCys on obesity and T2D.

**Supported by:** JPI and Health~Holland

**Disclosure:** E.C. Tore: Grants; JPI, Health~Holland.
Materials and methods: The study included obese 31 subjects (mean age: 38.9±10.95 years) who underwent the bariatric surgery and were divided into subjects without MS (n=15) and with MS (n=16). The mRNA expressions of BMP4, BMPRIA, insulin signaling pathway genes (IRS1, IRS2, PIK3CA, AKT2, SLC2A4) and adipogenesis markers (CEBPAP, CEBPB, PPARG, ADIPOQ) were measured in SAT and VAT. In another subgroup of 18 males (mean age: 25.56±3.22 years; mean BMI:27.29±5.0 kg/m2) with normal glucose tolerance the 6-h hyperinsulinemic-euglycemic clamp was performed and after one week another 6-h clamp with the concurrent Intralipid/heparin infusion was conducted. Biopsy of SAT was performed to assess the expression of BMP4 and BMPRIA1 before and after each 6-h clamp.

Results: In obese subjects with MS the expression of BMP4 (p=0.02) and BMPRIA (p=0.02) in VAT was lower compared to obese subjects without MS. In the entire group, BMP4 expression in VAT was correlated negatively with BMI (r=-0.41, p=0.02), waist circumference (r=-0.55, p=0.005), systolic blood pressure (r=-0.45, p=0.01), triglyceride (r=-0.44, p=0.02), fasting insulin (r=-0.57, p=0.002), HOMA-IR (r=-0.57, p=0.002), and positively with HDL-cholesterol (r=0.52, p=0.003). BMPRIA expression in VAT was correlated negatively with triglyceride (p=-0.40, p=0.03), fasting insulin (r=-0.40, p=0.04), HOMA-IR (r=-0.42, p=0.03). BMP4 and BMPRIA1 expression in VAT was correlated positively with IRS1 expression (r=0.40, p=0.03 and r=0.40, p=0.03, respectively) and BMPRIA expression was also correlated with SLC2A4 expression (r=0.54, p=0.002). In SAT, BMP4 expression was correlated positively with ADIPOQ (r=0.49, p=0.006) and IRS1 (r=0.48, p=0.007) expression, and BMPRIA expression with PPARG (r=0.43, p=0.02), ADIPOQ (r=0.41, p=0.02), IRS2 (r=0.56, p=0.001), PIK3CA (r=0.50, p=0.004) expression. All these correlations were independent of BMI. In subgroup of 18 males insulin infusion resulted in a decrease expression of both BMP4 (p=0.03) and BMPRIA (p=0.0016) in SAT, but this effect was not observed during the clamp with Intralipid/heparin infusion.

Conclusion: The BMP4/BMPRIA pathway in VAT may play an important role in the induction of metabolic disturbances in obesity. BMP4 may be an important regulator of white adipogenesis in humans. Acute hyperinsulinemia decreases the expression of BMP4/BMPRIA1 in SAT, but infusion of FFA abolishes this effect.

Supported by: The subsidy of Medical University of Białystok

Disclosure: M. Dobrzycka: None.

514 Interleukin-33 (IL33) inhibits glucose uptake in human adipocytes and its expression in adipose tissue is elevated in insulin resistance and type 2 diabetes

M.J. Pereira1, A. Azim1, B.N. Jui1, J. Kullberg2,3, M.H. Lundqvist1, J.W. Eriksson1;
1Dept Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala. 2Dept Surgical Sciences, Section of Radiology, Uppsala University, Uppsala. 3Antaros Medical, Malmö, Sweden.

Background and aims: Interleukin-33 (IL33) is expressed in human adipose tissue and is released upon tissue damage to mediate local immune activation of Th2 cells. IL33 has been associated with obesity-related inflammation and complications. However, to what extent IL33 contributes to metabolic disorders in humans still requires further investigation. We aimed to investigate the expression levels of IL33 in human subcutaneous adipose tissue (SAT) in subjects with and without T2D, its association with genes involved in adipose tissue metabolism and effects of IL33 on human adipocyte glucose uptake.

Materials and methods: Abdominal SAT needle biopsies were collected from 20 control and 20 metformin-treated subjects with T2D matched for sex (F/M 10/10, age (58 ± 11 vs 58 ± 9 yr) and BMI (30.8 ± 4.6 vs 30.7 ± 4.9 kg/m²). IL33 and its receptor (IL1 receptor-like 1, IL1RL1) mRNA levels were measured using transcriptomics and were correlated with markers of insulin resistance and obesity and with the expression of genes involved in lipid storage and differentiation. MRI of body and tissue fat volumes was performed. Furthermore, SAT of 7 healthy control subjects was incubated for 24h without (control) or with human recombinant IL33 (200 and 1000 pg/mL), and adipocytes were isolated to measure effects on glucose uptake.

Results: The T2D group had 1.7-fold higher IL33 mRNA expression in SAT than the control group (P<0.001). IL33 expression in SAT was positively correlated with markers of dysglycemia (fasting glucose, glucose AUC during OGTT, and HBA1c; all P<0.01), insulin resistance HOMA-IR (P<0.001), FFA AUC during OGTT (P=0.01), liver and pancreas fat% (P<0.05), whereas it was negatively correlated with the Matsuda insulin sensitivity index (P<0.001). No associations were found between IL33 with BMI or SAT/VAT volume. Following multivariate analyses, HOMA-IR (st beta coeff= 0.541, P=0.018) remained a predictor of IL33 expression (P<0.001, adjusted R²=0.45, model: glucose, FFA AUC, liver fat%, and T2D status). Expression of the IL33 receptor, IL1RL1, did not correlate with any of the glycemic or insulin resistance parameters but was positively associated with BMI (P=0.009) and the pro-inflammatory cytokine IL1B (P<0.002). Both IL33 and IL1RL1 genes were negatively associated with expression of genes promoting lipid storage and adipogenesis (e.g. FASN, AGPAT1/2/3, DGAT1/2, CEBPA, PPARG, FABP4; P<0.05). In addition, IL33 expression was negatively correlated with adipocyte glucose uptake (basal and insulin-stimulated; P<0.05) and with several genes for glucose transport and insulin signaling (e.g. SLC2A1, SLC2A4, and AKT1; P<0.01). Conversely, following 24h of incubation of SAT with IL33 (1000 pg/ml), both basal and insulin-stimulated glucose uptake in adipocytes were reduced by about 30% (P<0.05) relative to control.

Conclusion: Our findings suggest that T2D patients have higher IL33 expression in SAT compared to healthy controls, and this is associated with insulin resistance and reduced lipid storage and adipogenesis markers. IL33 may reduce adipocyte glucose uptake. These findings open up a potential pharmacological route for reversing insulin resistance associated with obesity.

Supported by: EXODIAB, AstraZeneca, SW DiabFond, Ernfors Found, ALF, Marie Skłodowska Curie TREATMENT, Rudberg AM

Disclosure: M.J. Pereira: None.
SO 34 The hepato-skeletal impact on metabolic control

515
Hepatic OPA1 deficiency impacts mitochondrial plasticity, lipoprotein metabolism and liver steatosis
G. Norata1, A. Moregola1, P. Uboldi1, L. Scorrano1, L. Da Dalt1;
1University of Milan, Milan, 2University of Padua, Padua, Italy.

Background and aims: In liver, mitochondria continuously undergo biogenesis, fusion, fission and mitophagy, and thus participate to the regulation of energy metabolism, calcium homeostasis and lipid metabolism. Aim of this study was to test the role of selective deletion of a key protein involved in inner mitochondrial membrane fusion (OPA1) in hepatocytes on mitochondrial function and lipid metabolism.

Materials and methods: Liver selective OPA-1 deficient mice (Opa1LKO) were generated by crossing OPA-1 flox/flox mice with albumin-CRE+ mice. Opa1LKO and OPA1 flox/flox (controls) mice were fed a high fat diet for 20 weeks and then in vivo metabolic responses, liver and fat characteristics and proteomic signature were profiled.

Results: Opa1LKO mice fed with HFD display reduced weight and weight gain compared to controls. Liver, Visceral Adipose tissue (VAT) and Subcutaneous Adipose Tissue (SCAT) weight to total body weight was also reduced. Opa1LKO presented a significant reduction in fasting glycaemia as well as improved glucose tolerance and insulin tolerance compared to Opa1 WT. Moreover, plasma cholesterol levels and cholesterol distribution in lipoprotein fractions was reduced in Opa1LKO compared to Opa1 WT and the same was true for triglycerides. In vivo metabolic cages experiments revealed a reduced oxygen consumption and increased respiratory exchange rate in Opa1LKO compared to Opa1 WT. Moreover, the liver from Opa1LKO mice presented an increased prevalence of smaller LD compared to Opa1 WT suggesting that diminished lipid accumulation and smaller LDs could be associated to changes in liver morphology and structure. In parallel Opa1LKO presented smaller adipocytes both in VAT and in SCAT compared to Opa1 WT. Next we investigated further changes in liver morphology and observed that Opa1LKO develop fibrosis associated to specific signs of cholestasis, potentially suggesting that that Opa1LKO liver could present an impairment in sterol metabolism and bile acid homeostasis. Shotgun liver proteomics was therefore performed to profile proteins involved in bile acids synthesis and maturation as well as proteins involved in lipoprotein metabolism. Interestingly, proteins involved in bile acids Bile Acid-CoA:Acyl-CoA N-Acyltransferase (BAAT) and 3-Oxosteroid 5β-Reductase (Akr1d1) synthesis and transport such as bile acid CoA ligase (SCL27A5) were reduced in Opa1LKO liver compared to Opa1 WT, in parallel also proteins involved in lipoproteins uptake, lipoprotein synthesis (MTPP) and apolipoproteins (apoA-I, apoA, apoB) were reduced.

Conclusion: Our data suggest that the impairment of mitochondrial fusion could rewire liver metabolism and leads to cholestasis. This could be the consequence of altered bile acid synthesis, due to impaired mitochondrial activity, which results in reduced lipid absorption and limited liver lipid accumulation under HFD conditions.

Disclosure: G. Norata: None.

516
Adenosine: a new functional marker and therapeutic target for the link insulin resistance-non-alcoholic fatty liver disease
R.E. Figueiredo1, F.O. Martins1, R.O. Oliveira2, S.V. Conde1;
1CEDOC- Edificio CEDOC II, 2Unidade de Cirurgia Metabólica e Bariátrica, CTO, Hospital Cruz Vermelha de Lisboa, Lisboa, Portugal.

Background and aims: Nonalcoholic Fatty Liver Disease (NAFLD) is the most common liver disease worldwide, affecting 20-25% of the adult population. It represents a spectrum of diseases ranging from hepatic steatosis (HS) to nonalcoholic steatohepatitis (NASH). NAFLD is the hepatic manifestation of type 2 diabetes mellitus (T2DM), and this association is associated with insulin resistance. Adenosine is known to act on hepatic glucose production and insulin action. In dysmetabolic states, adenosine receptors are known to be altered, having a key function in inflammation and carcinogenesis. The present work aims to investigate the role of adenosine and the adenosinergic system in the pathological paradigm linking insulin resistance and obesity to fibrosis in the settlement and development of NAFLD.

Materials and methods: Human liver biopsies from patients submitted to bariatric surgery were compared with liver biopsies collected from normal weight controls undergoing different types of surgeries. Anthropometric and blood biochemical analysis were performed for the evaluation of body mass index (BMI) and parameters related with dysmetabolism such as glycaemia, insulin and triglycerides. The clinical study followed the Helsinki Declaration and was approved by the ethical committee of Hospital da Cruz Vermelha and Nova Medical School. Written informed consent was obtained from all individuals. We evaluated by Western Blot the levels of Adenosine receptors: (A2A and A2B), a protein related to inflammation (interleukin-1 receptor, IL-1R), insulin signaling markers (Insulin receptor, IR) and the levels of Glucokinase. Additionally, hematoxylin-eosin and masson’s trichrome staining were performed to evaluate lipid deposition and fibrosis, and immunohistochemistry to colocalize A2aR within the different liver cell types. Inflammatory profile in plasma samples will be evaluated as well as liver adenosine levels.

Results: Obese individuals present a tendency to decrease in the levels of A2aR in the liver (% from control: CTL= 100.0 ± 8.4; Obese= 89.3 ± 28.1), with obese class III individuals showing the highest A2aR levels decrease (% of decrease from control: Ob Class I= 6%; Ob Class II= 10.2%; Ob Class III=24.4%). A2aR were colocalized within both Kupffer cells and hepatocytes. In contrast, A2bR levels tendentially increased in hepatic tissue from obese individuals (CTL= 100.0 ± 42.6; Obese= 211.9 ± 169.8), without evident dependency on obesity degree. Hepatic levels of IL-1R, IR and GCK were elevated in obese patients, showing that inflammation (IL-1R % from control: CTL= 100.0 ± 0; Obese= 285.5 ± 50.2, p<0.05), insulin resistance (IR % from control: CTL= 100.0 ± 0; Obese= 164.3 ± 13.9, p<0.01) and de novo lipogenesis (GCK % from control: CTL= 100.0 ± 0; Obese= 131.8 ± 55.4) are increased in these subjects.

Conclusion: We have demonstrated that obese patients with hepatic insulin resistance and dysmetabolism have alterations in adenosinergic system, both A2aR and A2bR. Adenosine metabolism should be further investigated as well as liver adenosine levels.

Disclosure: R.E. Figueiredo: None.

517
Disturbance of hepatic tight junctions by hypercaloric diets precedes intestinal barrier disruption
M.J. Menezes1, 2, B. Patricio3, G.D. Belew4, F. Carli5, J.G. Jones5, A. Gastaldelli6, M.P. Macedo1, 2, 3, 4, 6;
1Chronic Diseases Research Centre (CEDOC), NOVA Medical School, Faculdade de Ciencias Medicas, Universidade NOVA de Lisboa, Lisboa, Portugal, 2ADP-ERC - Diabetes Portugal Education and Research Center, Lisbon, Portugal, 3National Research Council (CNR), Institute of Clinical Physiology (IFC), Pisa, Italy, 4Center for Neurosciences and Cell Biology, University of Coimbra, Coimbra, Portugal.

Written informed consent was obtained from all individuals. We evaluated by Western Blot the levels of Adenosine receptors: (A2A and A2B), a protein related to inflammation (interleukin-1 receptor, IL-1R), insulin signaling markers (Insulin receptor, IR) and the levels of Glucokinase. Additionally, hematoxylin-eosin and masson’s trichrome staining were performed to evaluate lipid deposition and fibrosis, and immunohistochemistry to colocalize A2aR within the different liver cell types. Inflammatory profile in plasma samples will be evaluated as well as liver adenosine levels.

Disclosure: R.E. Figueiredo: None.
Background and aims: Diets high in lipids and carbohydrates are associated with dysbiosis, dysmetabolism and increased intestinal permeability impacting on tight junctions’ integrity. The passage of pro-inflammatory factors into the circulation is one of the risk factors for the development of non-alcoholic fatty liver disease (NAFL). However, hepatic tight junctions (TJ) are also crucial for homeostasis by separating the basolateral domain drained by sinusoidal blood flow and sealing the apical side of adjacent cells to form bile canaliculi. Disruption of hepatic TJ was already described in hepatitis and cancer, but little is known about the effects of diet on hepatic TJ. The hypothesis of this work is that diets rich in lipids and/or carbohydrates alter TJ not only in the intestine, but also in the liver. These changes are associated with alterations in proteins and lipids essential for maintaining the integrity of these TJ.

Materials and methods: C57BL/6J male mice were fed for 18 weeks with standard chow (CTR; n=12), high fat chow (HF; n=12), or with high sucrose (30% in drinking water, i.e., 55% fructose/45% glucose) added to standard diet (HS; n=11) or high fat chow (HFHS; n=11). Intestinal and liver tissues were histologically analyzed, and the levels of proteins involved in occlusion junctions were assessed. Given the importance of lipids for the composition of cell membranes and thus for tight junctions’ integrity, lipidomics of liver tissue was evaluated.

Results: All experimental groups except CTR developed hepatic steatosis. Both HS and HFHS presented decreased hepatic levels of oleocin when compared to CTR (p<0.01 and p<0.05, respectively) and HF (p<0.01), indicating sugar-induced damage towards oleocin. Besides, HFHS animals also had decreased hepatic expression of tricellulin when compared to CTR (p<0.05). Interestingly, although we found alterations in hepatic TJ, the exposure of the animals to the hypercaloric diets for 18 weeks did not lead to changes in intestinal tissue TJ. HS presented increased hepatic lysophosphatidylcholine C16:0 and C18:0 compared to the CTR (p<0.001) and an overall decrease in hepatic ceramides compared to CTR, especially the long chain (C16-18; p<0.01), which were previously found to negatively impact on membrane permeability and intestinal TJ. On the other hand, HFHS did not show changes in ceramides, rather an overall decrease in hepatic lysophosphatidylcholines compared to the CTR, namely PC 34:1 and PC 34:2 (p<0.001).

Conclusion: Hypercaloric diets, rich in sucrose, with/without lipids, negatively impact on hepatic TJ proteins oleocin and tricellulin before affecting intestinal TJ. These changes are accompanied by changes in membrane lipids, known to be essential for TJ integrity and appropriate permeability.

Supporting by: Marie Sklodowska-Curie Grant Agreement No. 722619 & 734719; FCT

Disclosure: M.J. Meneses: Grants; mtFoieGras Marie Sklodowska-Curie RISE Grant Agreement No. 734719, FOIEGRAS Marie Sklodowska-Curie Grant Agreement No. 722619, Portuguese Diabetology Society, iNOVA4Health UIDB/Multi/04462/2020.

518 Fetuin-a promotes lipid induced DPP4 expression in pancreatic beta cells
S. Nag, S. Mandal, R. Kundu;
Department of zoology, Visva-bharati university, Santiniketan, India.

Background and aims: Dipeptidyl peptidase 4 (DPP4) is a ubiquitous proteolytic enzyme that inactivates incretin hormones, GLP-1 and GIP, leading to reduced insulin secretion from beta cells (also called incretin effects). DPP4 is present in endothelial cells and expressed in tissues such as liver, lung, kidney and more recently has been reported in pancreatic beta cells. Palmitate treatment shows upregulation of DPP4 expression in beta cells. The aim of this present study is to investigate the role of fetuin-A, a hepato-adipokine, in DPP4 expression in presence of lipid and its consequence in impaired insulin secretion. Fetuin-A has been extensively studied by our group for quite a few years and has been found to be an endogenous ligand for TLR4. Beta cells incubated with DPP4 inhibitors shows reduced inflammation following TLR4 route and restores insulin secretion from beta cells. Therefore, this present observation focuses on the role of Fetuin-A in DPP4 expression and insulin secretory defects in the beta cells.

Materials and methods: Western blotting was used to study expression of DPP4 and other signal molecules involved in palmitate and palmitate+Fetuin-A treatment in MIN6 cells, a mouse insulinoma cell line. TLR4 and NF-κB inhibitors and gene specific siRNAs (DPP4, fetuin-A, TLR4 etc) were used to see alterations in the gene expressions. Immunofluorescence technique was used to see the expression and localization of DPP4 in palmitate+Fetuin-A treated cells. GSIS (Glucose Stimulated Insulin Secretion) and other ELISA analysis were performed to study the effect of DPP4 inhibitor vildagliptin (20μM), in palmitate treated MIN6. Oil O Red staining was done to see the accumulation of lipid droplets in MIN6 cells. Pancreatic islets collected from standard diet (SD) and 12 weeks HDF fed male mice, C57BL/6J, were subjected to western blot analysis for DPP4, fetuin-A, TLR4 and other relevant proteins. GTT, ITT and HOMA-IR were measured for insulin resistance.

Results: Palmitate treatment for 4h dose dependently (0.25, 0.50 and 0.75mM) increased DPP4 expression (~1.5 fold at 0.75mM palmitate) in beta cells which was abrogated by TLR4 and NF-κB inhibitors. Palmitate also increased phosphoNF-κBp65, IL-6 and IL-1beta levels. When fetuin-A (100ug/ml) was used in combination with palmitate, DPP4 expression was found to be increased by ~3 folds and augments its membrane localization. Inhibition of TLR4 and NF-κB by inhibitors or siRNAs, repressed DPP4 levels by ~1.7 fold. DPP4 inhibitor, vildagliptin (20μM), restored insulin secretion by ~1.5 fold, reduced TLR4, NF-κB, IL-6, IL-1beta and Fetuin-A (~1.4 fold) expression and also upregulates insulin gene transcription, Pdx1, in palmitate+fetuin-A treated cells. Vildagliptin significantly reduced lipid accumulation in the beta cells showing its multipronged effects. Islets isolated from 12 weeks HDF mice showed increased DPP4 expression (~1.5 fold) compared to SD mice. Also, there were increased expression of TLR4, pNF-κBp65 and Fetuin-A in the HDF islets. GTT, ITT and HOMA-IR score indicated degree of insulin resistance in HDF.

Conclusion: The results indicated palmitate with Fetuin-A potentiate DPP4 expression in pancreatic beta cells following TLR4-NF-κb pathway. Use of DPP4 inhibitor, Vildagliptin, repress fetuin-A level in beta cells, subside inflammatory cytokines and reduce fat accumulation in palmitate+Fetuin-A treatment indicating restoration of insulin secretion and beta cell function.

Supported by: SERB grant no. ECR/2017/001028

Disclosure: S. Nag: Grants; SERB grant no. ECR/2017/001028 & UGC fellowship awarded to SN.

519 The effects of deferoxamine (DFO) on DEX-induced muscle atrophy in C57BL/6J mice
K.-W. Lee1, S.-E. Choi2, J. Jeong1, S. Park2, M. Song1, Y. Son2, Y. Kang2, T. Kim1, S.-Y. Ahn1, H. Kim1, S. Han1, J. Jeon1, N. Lee1, D. Kim1;
1Department of Endocrinology and Metabolism, Ajou university, Suwon, 2Department of Physiology, Ajou university, Suwon, 3Division of Endocrinology and Metabolism, Seoul Medical Center, Seoul, 4Department of Internal Medicine, Busan Bumin Hospital, Busan, Republic of Korea.

Background and aims: Muscle atrophy is caused by various factors such as aging, insulin resistance, and diabetes. During these events, the balance between protein synthesis and degradation is disrupted and finally muscle loss is induced. This has been reported to occur via the ubiquitin-proteasome dependent pathway. Recently, many studies related to muscle loss have been reported, but the reality is no drug has been approved by the FDA yet. In this study, we investigated the effects of deferoxamine (DFO) on DEX-induced muscle atrophy in C57BL/6J mice.

Materials and methods: To investigate the effects of DFO on muscle atrophy, C57BL/6J male mice (8-week-old) were randomly divided into three groups: 2 Springer Diabetologia (2022) 65 (Suppl 1):S1–S469
520 Meta-inflammation and de novo lipogenesis markers are involved in metabolic associated fatty liver disease progression in BTBR ob/ob mice
S. Mas;
IIS-FJD / CIBERDEM, Madrid, Spain.

Background and aims: Metabolic associated fatty liver disease (MAFLD) is a hepatic manifestation of metabolic syndrome and usually associated with obesity and diabetes. Our aim is to characterize the pathophysiological mechanism involved in MAFLD development in Black Tan and brachyuric (BTBR) insulin-resistant mice in combination with leptin deficiency (ob/ob).

Materials and methods: We studied liver morphology and biochemistry on our diabetic and obese mice model (BTBR ob/ob) as well as a diabetic non-obese control (BTBR + streptozotocin) and non-diabetic control mice (BTBR wild type) from 4-22 weeks. Lipid composition was assessed and lipid related pathways were studied at transcriptional and protein level.

Results: Microvesicular steatosis was evident in BTBR ob/ob from week 6, progressing to macrovesicular in the following weeks. At 12th week, inflammatory clusters, activation of STAT3 and Nrf2 signaling pathways, and hepatocellular ballooning. At 22 weeks, the histopathological features previously observed were maintained and no signs of fibrosis were detected. Lipidomic analysis showed profiles associated with de novo lipogenesis (DNL).

Conclusion: BTBR ob/ob mice develop MAFLD profile that resemble pathological features observed in humans, with overactivation of inflammatory response, oxidative stress and DNL signaling pathways. Therefore, BTBR ob/ob mouse is an excellent model for the study of the steatosis to steatohepatitis transition.

Supported by: ISCIII PI20/00487

Disclosure: S. Mas: None.

521 Skeletal muscle mitochondrial inertia is associated with carnitine acetyltransferase protein activity and physical function in humans
M.K.C. Hesselink1, R. Mancilla2, L. Lindeboom2, L. Grevendonk1, J. Hoeks3, T.R. Koves2, D.M. Muoio1, P. Schnauwen1, V.B. Schnauwen-Hinderling5;

1Dept. of Nutrition and Movement Sciences, Maastricht University, Maastricht, Netherlands, 2Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre, Maastricht, Netherlands, 3Duke University School of Medicine, Durham, USA, 4Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre, Maastricht, Netherlands.

Background and aims: At the onset of exercise, PCr decreases and restabilizes at a steady-state exercise intensity. The speed of this phenomenon (PCR on-kinetics) reflects the readiness to activate mitochondrial ATP synthesis, which in turn is secondary to acetyl-CoA availability. We hypothesized that PCR on-kinetics is slower in metabolically compromised and older individuals and associates with low carnitine acetyltransferase (CrAT) activity and markers of physical function.

Materials and methods: In study 1, PCR on-kinetics (quantified as halftime of the mono-exponential change of PCR) and ADP levels were assessed by 31P-Magnetic Resonance Spectroscopy at the onset of exercise in all individuals in this study. In muscle biopsies from individuals with type 2 diabetes (T2D, n=9, 64 ± 7 years), obese sedentary (OB, n=8, 59 ± 7 years), untrained (UT, n=9, 22 ± 4 years and endurance-trained (T, n=12, 25 ± 4 years) CrAT activity and acetylcarnitine levels were measured. In study 2, we examined PCR on kinetics and its relationship with muscle oxidative capacity (measured as post-exercise PCR resynthesis rate) and markers of physical function and exercise efficiency in young (Y, n=10, 23 ± 5 years), older (O, n=15, 70 ± 2 years) and older trained (OT, n=17, 69 ± 2 years) volunteers.

Results: PCR on-kinetics, i.e. half-time of PCR at the onset of exercise, was significantly longer in T2D (49.2 ± 4.3 s) and OB (38.9 ± 2.6 s) compared to T (19.6 ± 2.1 s; P < 0.001). Furthermore, it was significantly longer in T2D as compared to UT (28.3 ± 3.2 s; P < 0.001). PCR on-kinetics strongly associated with skeletal muscle CrAT protein activity (r = -0.56; P = 0.001), in vivo skeletal muscle acetylcarnitine content (r = -0.47; P = 0.005) and ADP levels during exercise (r = 0.70; P < 0.001). This association remained after adjusting for PCR resynthesis rate (r = 0.61; P < 0.001). PCR on kinetics was significantly longer in O (33.1 ± 1.8 s) compared to OT (24.7 ± 1.8 s; P = 0.005) and Y (24.9 ± 2.2 s; P = 0.02). Interestingly, PCR on-kinetics correlated strongly with walking speed (r = -0.48; P = 0.002), chair sit-stand test performance (r = 0.54; P < 0.001) and exercise gross (r = -0.56; P < 0.001) and net efficiency (r = -0.53; P < 0.001) in study 2.

Conclusion: PCR on-kinetics is significantly slower in metabolically compromised and older individuals compared to young, healthy volunteers, regardless of in vivo skeletal muscle mitochondrial PCR recovery rate. Thus, mitochondrial inertia is more pronounced in metabolically compromised older individuals. Lower acetyl-CoA availability (due to lower CrAT protein function) or a lower sensitivity to ADP may contribute to deferred mitochondrial activation at the onset of exercise. Functionally, mitochondrial inertia affects performance in daily life physical function parameters and hence is a relevant interventional target in metabolically compromised individuals and in elderly with compromised physical function.

Disclosure: M.K.C. Hesselink: None.
SO 35 Metabolic inflexibility and complications in humans

522
A genetic polymorphism with structural impact, blood levels, expression in adipose tissue, and engineered adipocytes functionally link Olfactomedin 2 to obesity

A. Luch1, 2, J. Latore1, 2, I. Espadas2, J. Moreno-Navarrete1, 2, A. Martín-Montalvo1, J. Fernández-Real1, 2, F. Ortega1, 2,
1Unit of Diabetes, Endocrinology and Nutrition (UDEN), Institut d’Investigació Biomèdica de Girona (IDIBGI), Girona, 2CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, 3Department of Cell Therapy and Regeneration, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), Junta de Andalucía-University of Pablo de Olavide-University of Seville-CSIC, Sevilla, Spain.

Background and aims: Olfactomedin 2 (OLFM2) is a pleiotropic glycoprotein with a major role in brain development. Recently, we identified central OLFM2 as a new actor in the regulation of whole-body energy homeostasis. Highly expressed in neurons, our pioneering findings also locate OLFM2 in adipose tissue, specifically in fat cells. The current work investigates the role of this molecule in adipocyte biology and adipose tissue function, laying emphasis on the mechanism of action and the relationship with obesity.

Materials and methods: This study primarily stems from observations of highly increased OLFM2 in the adipose tissue of severe obese women following surgery-induced weight loss. These results were validated in cross-sectional samples by real-time PCR (n ~ 200). OLFM2 was also evaluated in ex vivo isolated and in vivo cultured adipocytes. Engineered 3T3-L1, together with changes in the expression patterns (microarrays) of human adipocytes challenged with small interfering (si)RNAs against OLFM2 were used to deepen into the mechanistic consequences of impaired OLFM2 in obese adipocytes. In parallel, circulating measures (ELISA), and the functional consequences of a structural polymorphism previously linked to OLFM2 activity (rs2303100) were assessed in independent cohorts.

Results: In partial agreement with the Olfm2 null mice, significant changes in the polymorphism rs2303100 (c.317G→A), which encodes an arginine to glutamine swift (R106Q), link OLFM2 to obesity (OR = 1.38 [1.02-1.86], p = 0.028; n = 1,808). Also circulating variations in subjects with a wide range of body mass index (BMI) associate OLFM2 with the amount of fat. Concurrently, decreased OLFM2 expression in visceral and subcutaneous depots of adipose tissues run in parallel to an obese phenotype. These variations are likely related to sex (sexual dimorphism) and age, and mainly determined by the predominant expression of OLFM2 in adipocytes, according to our pioneering observations in isolated fat cells. In fact, OLFM2 in human adipocytes is strongly conditioned by the hormonal milieu and compromised by inflammation. Mechanically, we demonstrate that the loss of OLFM2 in adipose cells displays inflammatory issues and deranged adipogenesis as a result of a rapid and transient deregulation of genes related to cell cycle, also coupled to impaired fatty acid anabolism and energy storage.

Conclusion: Overall, current findings first identify OLFM2 as a new molecular key actor and signalling molecule of relevance in adipocyte biology for proper functioning of fat depots.

Supported by: ISCIII (CP19/00109, PI18/00550), PFIS (FI19/00045), FEDER

Disclosure: A. Luch: None.

523
Development of a predictive model for short and medium-term weight loss in people with type 2 diabetes attending a weight management programme

L. Al-Abdullah1, P. Welsh1, J. Logue2;
1University of Glasgow, Glasgow, 2Lancaster University, Lancaster, UK.

Background and aims: Behavioural weight management programmes are effective in helping some but not all obese patients to lose weight. With emerging novel pharmacological options for weight loss, it may be advantageous to be able to predict successful short and medium-term weight loss within traditional weight management programmes, so patients who are unsuccessful in these programmes can be moved to other therapies at an earlier stage.

Materials and methods: We used routine electronic health records collected in the Greater Glasgow and Clyde health board of the UK National Heath Serv, covering 1.2 million people. We conducted a longitudinal study between 2004-2014 including 1658 adult patients with obesity and type 2 diabetes referred to and attending the Glasgow Weight Management Service. Successful short term outcome was defined as attending 7/9 weight management sessions over 16 weeks and losing >5% body weight. Successful medium-term outcome was defined as losing >5% body weight at 3 years after also attaining successful short term weight loss. As an exposure/predictor, early weight change in programme is defined as weight change in the first 3 session of the programme. Binary logistic regression analysis was used to estimate the strength of association between predictor variables (including demographic and clinical) and successful short and medium term completion. Discrimination of predictors was determined by using area under the receiver operator curve (AUROC).

Results: The mean age of the participants was 57.8 years, 60% were female. T2DM had been diagnosed for a median of 5.31 years and the median BMI was 40.2 kg/m2 (IQR = 35.9 - 44.8). In the short term 333 participants successfully lost weight (20.0%) and of 1152 participants with medium-term outcome data, 139 successfully lost weight over 3 years (12.1%). For the short term outcome, the only clinical or demographic variable associated with short term successful completion was weight change in the first 3 sessions (each 1% weight loss OR 2.86 (95%CI 2.5-3.23) for successful short term completion) and the AUROC curve for the model was 0.839 (95%CI 0.812-0.866). Losing 0.5% weight in the first 3 sessions predicted successful short term completion with sensitivity 90.4% and specificity 53.6% (negative predictive value 95.7%). The only independent predictor of medium term weight loss was also weight change in the first three sessions (each 1% weight loss OR 2.22 (95%CI 1.92-2.56)) and the AUROC curve for the model was 0.816 (95%CI 0.775-0.856). Losing 0.5% weight in the first 3 sessions predicted successful medium-term weight loss success with sensitivity 89.9% and specificity 50.5% (negative predictive value 97.3%).

Conclusion: Demographic and clinical variables do not allow prediction of successful weight loss using a clinical structured weight management programme. However, in programme early weight loss is strongly associated with short term and medium-term success. A threshold of failing to achieve 0.5% body weight loss in the first three sessions is sufficient to identify participants who are unlikely to succeed in programme (>95% accuracy). Such patients may benefit from being switched to other interventions while they are still engaged.

Disclosure: L. Al-Abdullah: None.
Metabolic inflexibility in type 2 diabetes is supported by untargeted metabolomics during OGTT

G. Fanni, J.W. Eriksson, M.J. Pereira; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Background and aims: Metabolic inflexibility, i.e. the inability to efficiently adapt metabolic processes to physiological and nutritional conditions, is a hallmark of insulin resistance and can be explored extensively with high-throughput metabolomics techniques. These can be integrated with dynamic tests, such as the oral glucose tolerance test (OGTT), to better capture the perturbations of the whole metabolome upon an oral glucose load. We aimed to identify metabolic alterations in response to an OGTT in individuals with type 2 diabetes (T2D) using an untargeted metabolomic and lipidomic approach for the first time on both plasma and subcutaneous adipose tissue (SAT) samples.

Materials and methods: 20 individuals with T2D and 20 healthy controls matched for sex (20F/20M), age (58±9 vs 58±11 years), and BMI (30.7±4.7 vs 30.8±4.6 kg/m²) were metabolically profiled with high-throughput metabolomics and lipidomics analysis both in plasma and in the SAT, during fasting and 90 minutes after an OGTT. We identified 854 known metabolites in plasma samples and 692 metabolites in SAT samples. We compared concentration changes 90 minutes after the glucose load versus fasting levels in all metabolites between patients with T2D and controls. Post-hoc analyses were performed to explore the associations between metabolites that significantly differ in response to OGTT between T2D and controls and markers of obesity, glucose metabolism, sex, and age.

Results: In controls, the glucose load caused a reduction in the plasma concentration of several acylcarnitines (fold-change 0.41 to 0.50), acyl ethanolamines (0.48 to 0.59), xanthine (0.80), mannose (0.79), BCAAs (0.67 to 0.84), and other amino acids (0.78 to 0.94), but this effect was significantly blunted in patients with T2D (all p<0.05; figure 1). Also, patients with T2D had an increased response during OGTT in glucose and fructose levels compared to controls (both p<0.05). Only glucose had significantly different plasma concentrations at fasting between T2D and controls. No differences were seen in the adipose tissue metabolism in response to the glucose challenge between T2D and controls. In multiple regression analyses, the plasma concentration change 90 minutes after the glucose load versus fasting levels in all metabolites displayed attenuated metabolite responses in plasma during an OGTT. This partly depends on metabolic health status and obesity. In T2D, these findings are not directly associated with changes in adipose tissue metabolism, thus other tissues like muscle and liver may be of importance.

Conclusion: Using a metabolomic approach, we show that T2D patients display attenuated metabolite responses in plasma during an OGTT. This concerns several metabolite families, e.g. amino acids and fatty acid derivatives. This supports inflexibility in several metabolic pathways which can contribute to dysregulated substrate partitioning and turnover in T2D. These findings are not directly associated with changes in adipose tissue metabolism, thus other tissues like muscle and liver may be of importance.

The relationship between obesity and depression is partly dependent on metabolic status: a nationwide inpatient sample database study

Z. Wang, J. Zhao, X. Fan; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, Jinan, China.

Background and aims: Studies have found a close association between obesity and depression, whereas others have not. As we know, obese have different metabolic characteristics and exhibit different metabolic obesity phenotypes. These differences might be a possible explanation for these inconsistent results. Some obese individuals do not develop metabolic disorders and are described as having metabolically healthy obesity (MHO). In addition, many obese individuals with an abnormal metabolic health status are known to have metabolically unhealthy obesity (MUNO). Up to date, evidence about the joint effects of obesity and different metabolic profiles on the risk of depression is limited. In addition, whether this association is modified by sex is also worth investigating. Thus, we combined obesity and metabolism by focusing on metabolic obesity phenotypes and analyzed the Nationwide Inpatient Sample database to comprehensively investigate the relationship of obesity and metabolism with depression.

Materials and methods: This was a cross-sectional study using data from 2016 to 2018 that were obtained from the Nationwide Inpatient Sample (NIS) database. In total, 11,364,644 participants were enrolled. BMI ≥ 25 kg/m² was used to define obesity. Metabolic risk factors were defined as the following three components of metabolic syndrome based on the diagnostic criteria for metabolic syndrome: (1) hypertension, (2) dyslipidemia (including hypertriglyceridemia and hypercholesterolemia), and (3) hyperglycemia (including prediabetes and diabetes). Participants were classified as one of four obesity phenotypes based on their obesity and metabolic statuses: (1) metabolically healthy nonobesity (MUNO); patients were nonobese and had fewer than two metabolic risk factors; (2) MHO: patients were obese and had fewer than two metabolic risk factors; (3) MUNO: patients were nonobese and had at least two metabolic risk factors; and (4) metabolically unhealthy obesity (MUNO): patients were obese and had at least two metabolic risk factors.

Results: Among all participants, a higher risk of depression was observed for MUNO, MHO and MUNO than for MUNO. The risk was highest for MUNO (OR = 1.709; 95% CI = 1.698, 1.720). However, the association between MHO and depression was different for men and women (OR = 1.937, men; OR = 1.452, women). MHO was related to the risk of depression among women but the opposite associations were observed among men.

Conclusion: The increased risk of obesity-related depression appears to partly depend on metabolic health status. Our findings highlight the importance of both metabolic health status and obesity in depression and suggest a compelling need to improve metabolic health status regardless of the presence of obesity. Furthermore, our results might provide a basis for further studies to investigate individualized MetS-related treatment strategies for depression.

Supported by: National Key Research and Development Program of China 2017YFC1309800
526  
Oxytocin correlates with body dysmorphic concerns and predicts weight loss in patients with obesity after a very low carbohydrate ketogenic diet

R. Tozzi1, R. Rossetti2, S. Bascian1, D. Masi2, R. Risi2, A. Balena2, M. Spoltore2, M. Watanabe2, S. Mariani2, L. Gnassi2, C. Lubrano2;  
1Department of Molecular Medicine, Sapienza, University of Rome,  
2Department of Experimental Medicine, Sapienza, University of Rome, Rome, Italy.

Background and aims: Oxytocin (OXT) enhances glucose uptake and lipid utilization in adipose tissue and skeletal muscle. Dysfunction of the OXT system could underlie the pathogenesis of weight gain. In addition, its involvement in social-cognitive processes and as a neurotransmitter of the emotional system has recently emerged, also in relation to body image awareness. Men and women with obesity show higher OXT blood levels and are often characterized by eating disorders and altered body perception. In contrast, metabolic syndrome has been associated with reduced fasting serum oxytocin in larger scale mixed gender studies. The purpose of our study was to investigate the concentrations of OXT in a population affected by obesity before and after a very low carbohydrate ketogenic diet (VLCKD) induced weight loss. Moreover, we aimed to investigate the relationship between peripheral OXT levels and the presence of altered perception of physical appearance.

Materials and methods: Subjects with obesity were enrolled at the Center of High Specialization for the treatment of Obesity. At baseline (t0) and after eight weeks of VLCKD (t1), all patients underwent clinical evaluation, biochemical routine assessment, DXA examination for body composition (Hologic Inc., Bedford, MA, USA, QDR 4500W) and venous blood sampling in EDTA plus 500 KIU/mL of aprotinin (Abcam ab146286) for plasma OXT determination (Abcam, Ab133050, ELISA kit). Achievement of ketosis was monitored by measuring urinary seton bodies. For psychometric evaluation, all patients were administered the Body Uneasiness Test-2 (BUT2) for dysmorphophobia assessment.

Results: 40 patients (26 females and 14 males) suffering from obesity were enrolled, (age = 55.5 ±7 years and BMI = 35.7± 4.3 Kg/m²). OXT level at baseline (t0) was 1166 ±403 pg/ml, with no differences between males and females. At t0 OXT positively correlated with BMI, hip circumference and with the BUT2 specific subsection for Positive Symptom Distress Index - PSDI (r=0.43, p<0.05). After VLCKD, a significant weight reduction was seen (mean BMI = 32.7 kg/m², mean weight loss = -8.8 kg) and OXT (t1) significantly decreased (728.2± 201.7 pg/ml, p=0.001). Baseline OXT positively correlated with urinary keton bodies, after adjustment for age (r= 0.335, p=0.046). A strong inverse- age adjusted correlation between weight loss and baseline OXT was also reported (r = -0.458, p<0.005). A regression analysis showed that the reduction in OXT between t0 and t1, the grade of ketosis and baseline % fat mass were all predictors of weight loss (R² = 0.422; p=0.025).

Conclusion: Our study demonstrates that higher OXT levels associate with dysmorphophobia, BMI and ketosis induction. A lower OXT reduction during a VLCKD seems to be unfavorable in achieving weight loss. Ketosis, by reducing oxytocin levels, suggested to be a valid diet treatment to reduce body perception disorders. Differences in assay method used for measuring OXT, as well as expression patterns of oxytocin receptors could explain the partial discrepancy of our results with those in literature. Peripheral actions of oxytocin deserve further investigations.

Disclosure: R. Tozzi: None.

527  
Type 2 diabetes is associated with decreased activation and increased cytokine production by blood lymphocytes: a human flow cytometry study

D. Gašparini1, 2, I. Kavazovic1, Ž. Mijolović1, I. Klarić2, A. Prunk Dmić2, V. Peršić2,1, F.M. Wensveen1, T. Turk Wensveen2,1;  
1Faculty of Medicine, University of Rijeka, Rijeka, 2Thalassotherapia Opatija, Opatija, Croatia.

Background and aims: Chronic and systemic low-grade inflammation has been recognized as a prominent feature of type 2 diabetes and its complications. Recent studies on the novel coronavirus disease have shown that elevated blood levels of proinflammatory cytokines in patients with diabetes are contributing to an increased risk of morbidity and mortality after viral infection. However, which immune cells are involved in the underlying mechanism is mostly unknown. The aim of this study is to characterize peripheral blood lymphocytes and determine the nature of diabetes-induced changes in the antiviral arm of the immune system, specifically CD8+ T cells, natural killer (NK) cells and gamma delta T cells.

Materials and methods: Study participants underwent initial clinical and laboratory evaluation to exclude subjects whose immune system could be affected by advanced liver or kidney disease, neoplastic or inflammatory disorders and medication use. After signed informed consents were obtained, peripheral blood mononuclear cells were isolated from the blood of patients with diabetes (N=22) and age-matched control subjects (N=11). Multiparametric flow cytometry was used to analyze the phenotype and cytokine production by CD8+ T, NK and gamma delta T cells after in vitro stimulation with Phorbol 12-myristate 13-acetate and Ionomycin. Unpaired t-test was used to determine statistical significance.

Results: The mean age of study participants was 61 (35-72) and 63 (23-79) years old in the control and diabetes groups, respectively. Approximately one-sixth of patients with diabetes were newly-diagnosed, whereas others had a mean disease duration of 10 years (2-40). The mean percentage of glycated hemoglobin A1C in patients with diabetes was 7.6% (5.1%-11.1%). Phenotypic analysis of peripheral blood mononuclear cells showed only minor differences in the percentage of lymphocyte subpopulations between study groups. However, a significantly increased production of tumor necrosis factor by CD8+ T cells (p=0.025, 95%CI 2.30-32.11) and Granzyme B by NK cells and gamma delta T cells after stimulation (p=0.002, 95%CI 5.97-24.68; p=0.032, 95%CI 1.76-37.31, respectively) was observed in patients with diabetes in comparison to control group. Notably, the expression of CD69, the activation marker, on the surface of NK cells and gamma delta T cells was decreased in patients with diabetes compared to control subjects (p=0.063, 95%CI -43.94 to 1.23; p=0.022, 95%CI -39.24 to -3.23, respectively).
Conclusion: Our findings suggest that cytotoxic immune cells permanently change their functional profile in the context of diabetes and may therefore play an important role in diabetes-induced immune dysfunction. Supported by: UniRi grant 19-AI-1551; HRZZ projects: IP-2016-06-8027, IP-CORONA-2020-04-2045, IP-2020-02-7928. Disclosure: D. Gašparini: None.

Materials and methods: Oligonucleotide-directed mutagenesis was used to prepare constructs encoding the human albumin proteins (wild-type, H9A, H67A, H247A and a triple mutant Y150F/R257A/S287A involving residues known to be important for NEFA binding at FA2) and resultant clones were transformed into <i>Pichia pastoris</i> competent cells. Recombinant mutant proteins were expressed and purified using a HiTrap Blue HP column. ITC was used to investigate the Zn<sup>2+</sup>-binding capacity of each protein in the presence and absence of the saturated fatty acid, palmitate (C16:0).

Results: Two Zn<sup>2+</sup>-binding sites on HSA were captured by ITC, with a high-affinity site (site A with <i>K<sub>ITC</sub> = 4.0 x 10<sup>-5</sup> M<sup>-1</sup>), and a lower-affinity binding site (site B with <i>K<sub>ITC</sub> = 8.8 x 10<sup>-7</sup> M<sup>-1</sup>). As expected, the Zn<sup>2+</sup>-binding capacity at the primary site exhibited marked reduction (almost no binding was seen) in H67A and H247A mutant forms of HSA, with the binding capacity of site B unaffected. This confirms that His67 and His247 play a significant role in Zn<sup>2+</sup> binding under physiological conditions. However, only a small reduction of Zn<sup>2+</sup>-binding capacity was observed in H9A, consistent with the fact that His9 forms part of the secondary Zn<sup>2+</sup>-binding site. Zn<sup>2+</sup> binding to HSA was greatly compromised by the presence of the long-chain NEFA, palmitate (C16). Upon addition of 5 mol. eq. of palmitate, Zn<sup>2+</sup> binding to HSA and H9A was greatly perturbed. However, loading of H67A and H247 with 5 mol. eq. of palmitate had a relatively minor effect on Zn<sup>2+</sup> binding. Additionally, the Zn<sup>2+</sup> binding ability of the Y150F/R257A/S287A HSA mutant was not adversely affected by the binding of palmitate.

Conclusion: NEFAs influence Zn<sup>2+</sup>-binding at the primary site but not the secondary site and NEFAs exert this influence solely by binding at the FA2 site which lies close to site A. Previous studies on bovine serum albumin suggested NEFAs influenced Zn<sup>2+</sup> binding at both sites, suggesting some differences in this dynamic between species. This work greatly aids understanding of the interplay between circulatory transport of NEFA and Zn<sup>2+</sup> in obesity and type-2 diabetes.

Supported by: We thank BBSRC (grant no. BB/V014684/1) and BHF (grant no. FS20/3/34956) for funding. Disclosure: A.J. Stewart: None.
SO 36 Modelling obesity and type 2 diabetes

530
Arrest of long-chain acylcarnitine synthesis prevents inflammation and insulin resistance in adipose tissue of high-fat diet-fed TMLHE knockout mice


Background and aims: Lipid overload contributes to obesity-associated insulin resistance and inflammation in adipose tissue. Fatty acid intermediates long-chain acylcarnitines induce insulin resistance in muscles and heart, however, it is not yet studied whether acylcarnitines participate in immunometabolic crosstalk in adipose tissue. The tissue levels of long-chain acylcarnitines can be regulated through controlling enzymatic activity of enzymes involved in biosynthesis of carnitine. N6-trimethyllysine dioxygenase (TMLH) is the first enzyme in the carnitine/acylcarnitine biosynthesis pathway. Here we tested whether lower levels of long-chain acylcarnitines in TMLHE KO mice can prevent metabolic disturbances and inflammation in adipose tissue.

Materials and methods: Two-month old C57BL/6J and TMLHE KO male and female mice were fed either a control diet (containing 10% calories from fat) or a high-fat diet (HFD) (containing 45% of calories from fat) for 20 weeks.

Results: In wild-type (WT) mice HFD intake induced macrophage shift to inflammatory M1 phenotype and by 70% reduced glucose uptake in adipose tissue Which resulted in hyperinsulinemia, hyperleptinemia, and disturbed glucose and insulin tolerance. In addition, significantly reduced mitochondrial OXPHOS-dependent respiration rate and OXPHOS coupling efficiency were observed in HFD-fed WT mice adipocytes. TMLHE gene inactivation lowered the content of long-chain acylcarnitines in a diverse mixture of specialized immune cells, peripheral blood mononuclear cells, and adipose tissues by 3-fold. In HFD treated TMLH KO mice glucose uptake, insulin sensitivity, and mitochondrial function of adipose tissue were fully preserved and were similar to parameters in chow control mice. In addition to significantly lowered adipose tissue macrophage count and a marked shift in macrophage phenotype to M2-like polarization was observed in HFD-fed TMLH KO mice.

Conclusion: Taken together, our results demonstrate that metabolic correction by lowered long-chain acylcarnitine contents can prevent lipid overload-induced macrophage M1-like polarization characteristic for the adipose tissue inflammation and contribute to preserved insulin sensitivity of adipose tissue.

Supported by: FAT4BRAIN No 857394
Disclosure: E. Liepins: None.

531
Haematopoietic cell-derived Oncostatin M regulates metabolic responses to high-fat diet in mice

M. Albiero1,2, S. Cicliiot3, A. Rodella1,2, L. Migliozzi1,2, F.I. Amendolagine1, G. Zuccolotto2, A. Rosato3, G.P. Fadini1,2;

1Department of Medicine, University of Padova, Padova, 2Veneto Institute of Molecular Medicine, Padova, 3University of Pavia, Pavia, 4Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, 5Veneto Institute of Oncology - IOV-IRCCS, Padova, Italy.

Background and aims: Innate immune cells infiltrate the growing adipose and propagate inflammatory clues to metabolically distant tissues, thereby promoting unhealthy obesity and insulin resistance. Among such signals, cytokines of the IL-6 family and gp130 ligands have attracted attention. Contrasting findings exist regarding the role played by Oncostatin M (OSM) in the metabolic consequences of overfeeding, largely because the broad distribution of its receptors with tissue-specific sub-unit combinations. Furthermore, the existing models did not allow dissecting OSM sources. Therefore, we aimed to better elucidate the metabolic role of OSM using the high fat diet (HFD)-induced model of obesity in ubiquitous Osm−/− mice. More importantly, using a hematopoietic-restricted Osm−/− mice, we tested the hypothesis that hematopoietic cell-derived OSM contributes to systemic metabolic regulation.

Materials and methods: Wild type and Osm−/− mice, were fed with a control diet or a HFD for 12 weeks before performing a thorough characterization encompassing metabolic cages phenotyping, glucose and insulin tolerance tests, body composition, tissue glucose uptake, adipose tissue and liver histology and gene expression analysis. Hematopoietic-restricted Osm−/− mice and control mice were generated by transplanting Osm−/− or wild type bone marrow cells, respectively, into lethally irradiated wild type recipients. After bone marrow reconstitution, animals received HFD and were characterized.

Results: OSM deletion did not affect weight gain and adipose tissue remodelling induced by HFD but severely worsened glucose tolerance compared to wild type mice. Furthermore, Osm−/− mice showed worsened liver damage and increased expression of pro-inflammatory cytokines such as Il-1ß and IL-6. The deletion of OSM from hematopoietic cells recapitulated the detrimental metabolic milieu of ubiquitous Osm−/− mice on HFD. Interestingly, Hematopoietic-restricted Osm−/− mice phenocopied the liver inflammatory fingerprint induced by HFD and the the increase in aspartate aminotransferase observed in ubiquitous Osm−/− mice.

Conclusion: Despite being canonically associated with inflammation, our new data support a protective role for OSM in limiting metabolic derangement under western diet. We have also demonstrated that hematopoietic-derived OSM can regulate metabolism, possibly through a crosstalk between immune-inflammatory cells and the liver. Notwithstanding with the evidence that inflammatory cells are recruited during the development of obesity, OSM could represent an exploitable target to treat metabolic diseases once OSM-target cells and the downstream mechanisms regulating metabolism will be fully elucidated.

Disclosure: M. Albiero: None.

532
Irisin protects against obesity-related kidney disease by regulating perirenal adipose tissue function in obese mice

X. Sun, F. Han, C. Kan, N. Hou; Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.

Background and aims: More studies demonstrated perirenal adipose tissue (PRAT) has a closer association with kidney disease than other visceral fat deposits in obesity. PRAT could predict microalbuminuria and may be an independent predictor of early kidney damage in patients with obesity. Irisin is a novel hormone secreted by myocytes and has been proposed to mediate the beneficial effects of exercise on obesity. We aimed to determine whether irisin reduced urinary albumin excretion and provided renal protective effects by regulating PRAT function in obese mice.

Materials and methods: Six-week male C57BL/6J mice were randomly assigned to control, high-fat diet (HFD) and irisin groups. Mice in the control group were fed a regular diet, while mice in the other groups were
Background and aims: F-59000, Lille, France. Previously showed that CDKN2A function in the regulation of the cell cycle and energy metabolism. We expression is increased in obese subjects. Overall, this locus has a dual fat/weight (26.08 ± 1.09%, P<0.05), fat mass (11.75 ± 0.78 g, P<0.05), fat/weight (26.08 ± 1.09% vs. 29.37 ± 0.75%, P<0.05), but not PRAT mass. Besides, irisin significantly improved glucose hemostasis decreased free fatty acids (0.85±0.04 mmol/L vs.1.33±0.11 mmol/L, P<0.05). Furthermore, irisin decreased UACR (14.47 ± 1.92 μg vs. 45.16 ± 10.21 μg, P<0.05), attenuated renal fibrosis and lipid deposition. Treatment with irisin increased proteins related to browning in PRAT, including SIRT1, uncoupling protein-1, haem-oxygenase-1 and adiponectin. Pre-treated HFD mice-derived PRAT and glomeruli with irisin ex vivo also activated these proteins in PRAT. Additionally, irisin significantly reduced glomerular VEGF levels and increased nitric oxide production, restoring the glomerular VEGF-nitric oxide axis.

Conclusion: Irisin treatment improved metabolic disorders and protected against obesity-related kidney disease by regulating the PRAT-kidney axes. These findings provide a novel mechanism for the protective effects of irisin on kidneys in obesity.

Supported by: NSFC (81870593 and 82170865) Disclosure: X. Sun: None.

The adipocyte-specific deletion of the tumor suppressor gene CDKN2A improves glucose tolerance in high-fat diet-fed mice

Y. Kahoul1, J. Montagne1, E. Caron2, A. Bongiovanni3, F. Oger2, P. Fronguel2, A. Bonnefond1, J.-S. Annicotte4, C. Breton5; 1INSERM UMR1283, CNRS UMR8199, EGIS, Université de Lille, Institut Pasteur de Lille, Lille, France, 2INSERM U1172, Développement et plasticité du cerveau neuroendocrine Lille Neuroscience et Cognition, Lille, France, 3Plate-forme d’imagerie cellulaire-UMS 2014-US 41, Lille, France, 4Université de Lille, INSERM, Institut Pasteur de Lille, CHU Lille, UMR1167 – RID-AGE, F-59000, Lille, France.

Background and aims: Genetic association studies (GWAS) have established that the tumor suppressor locus CDKN2A (cyclin dependent kinase inhibitor 2a) locus is associated with T2D risk but the underlying mechanisms remain elusive. CDKN2A is expressed in adipose tissue and the expression is increased in obese subjects. Overall, this locus has a dual function in the regulation of the cell cycle and energy metabolism. We previously showed that Cdkn2a-deficient mice (Cdkn2a−/−) exhibit increased energy expenditure via browning of white adipose tissue (WAT) and have improved insulin sensitivity under high-fat diet (DIO). To assess whether adipose browning is cell-autonomously controlled by Cdkn2a and due to the transdifferentiation of mature adipocyte and/or the recruitment of adipocyte precursors, we analyzed the effect of Cdkn2a deficiency restricted to mature adipocytes in mice (Cdkn2a+/-). Materials and methods: Metabolic studies were performed under chow diet and DIO. Metabolic, hormonal, histological parameters as well as glucose homeostasis were assessed. Histological studies of adipose tissues were also performed. The adipose tissue transcriptome was analyzed by RNA-sequencing. Results: Although metabolic parameters were comparable between wild-type and mutant animals in chow diet, metabolic, hormonal, histological parameters as well as glucose homeostasis were significantly different in Cdkn2a+/- DIO mice compared to control littermates. Despite normal food intake and body fat pad weights, Cdkn2a+/- DIO mice displayed improved metabolic profiles with increased energy expenditure (p<0.01) and improved glucose tolerance (p<0.05) without any changes in insulin sensitivity. Mice also exhibited reduced circulating levels of leptin and resistin (p<0.05). Histological analysis revealed epidymal WAT hypertrophy and inguinal WAT hypoplasia (p<0.05) without effects on proliferation or browning. Transcriptomic analysis of epidymal WAT showed a global increase in metabolic pathways involved in energy substrate utilization, especially glucose metabolism. In particular, a decrease in p70S6K signaling pathway (-log(p-value) 5.540), which is known to reduce insulin signaling, suggests a better use of glucose in Cdkn2a-deficient adipocytes.

Conclusion: Our results suggest that the deletion of Cdkn2a in fully differentiated adipocytes is not sufficient to induce WAT browning. However, the Cdkn2a locus does play a role in energy metabolism regulation in mature adipocytes, and might contribute to alleviate the deleterious effects of obesity on insulin resistance and glucose homeostasis.


Nb4 locus on mouse chromosome 4 harbors candidate genes which protect from fat accumulation and obesity

J. Khuong1,2, D. Altenhofen1,2, T. Kuhn1,2, S. Görgök1,2, S. Lebèk1,2, B. Knebel1, A. Schürmann1,2, A. Chad1,2, H. Al-Hasani1,2; 1Institute of clinical biochemistry and pathobiology, German Diabetes Center (DDZ), Düsseldorf, 2German Center for Diabetes Research (DDZ), München-Neuherberg, 3Experimental Diabetology, German Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany.

Background and aims: Obesity represents a major risk factor for the development of insulin resistance and type 2 diabetes (T2D). The polygenic factors promoting obesity and T2D remain to be identified. Previously, we conducted linkage analyses in a backcross population generated with T2D-prone New Zealand Obese (NZO) and T2D-resistant C3H/HeJ mice. We detected a quantitative trait locus (QTL) on chromosome 4 (Nb4, NZO body weight on chromosome 4, 10-30 cM, LOD: 8) that conferred protection from high-fat diet (HFD)-induced obesity. The aim of the current study is to identify the underlying genetic variants and to assess their molecular functions in energy metabolism. Materials and methods: Repetitive backcrossing steps were performed to generate a recombinant congenic mouse line (RCS) harboring the locus on Chromosome 4 from C3H on a NZO background. Genotypes were confirmed using a high-density SNP panel. RCS mice were fed a high-fat diet (45% fat/Kcal) and underwent measurements of blood glucose and body composition at different stages of life. At 13 weeks of age, mice were sacrificed and tissues were harvested for gene expression analysis. Blood samples were collected for blood glucose and plasma insulin measurements. Transcriptome analysis conducted in the parental mouse

533

534
strains combined with in silico sequence analysis were used for the identification of gene variants potentially linked to the phenotype. **3T3-L1** cells were differentiated for 14 days and harvested for gene expression analysis.

**Results:** Homozygous carriers of the *Nbw4-C3H* allele (C3H/C3H) demonstrated a significantly lower body weight compared to *Nbw4-NZO* allele carriers (NZO/NZO), starting at 6 weeks of age (34.7 ± 0.6 g vs. 41.09 ± 2.6 g; p<0.03 n=8-19). The difference in body weight was attributed by a higher fat mass (16.6 ± 0.5 g NZO/NZO vs. 9.2 ± 0.6 g C3H/C3H; p<0.0001 n=8-19, 10 weeks of age). Both random and fasting blood glucose levels were not different among the groups, but NZO/NZO mice presented significantly higher plasma insulin levels (10.6 ± 1.6 ng/mL vs. 6.5 ± 0.6 ng/mL; p<0.01 n=9-13, 13 weeks of age) when compared to C3H/C3H animals. Gene expression profiling in white adipose tissue (WAT) showed differential expression levels of genes from the Orosomucoid (Alpha-1-Acid Glycoprotein) family (*Orm1, Orm2, Orm3*) between NZO and C3H mice. Haplotype analysis followed by in silico predictions of gene/protein function revealed a potentially deleterious mutation R15Q in the NZO *Orm1* gene variant, predicted to impair structure and function (SIFT: 0.01) and studies in **3T3-L1** pre-adipocytes show upregulation of *Orm1* during differentiation to mature adipocytes.

**Conclusion:** Here we identify a novel obesity locus on Chromosome 4 with large effect size on body fat. Recombinant congenic mice carrying the C3H allele of *Nbw4* on a NZO background are protected from HFD-induced obesity. Gene expression studies show strain-specific expression of the secreted Orm family genes in WAT, where expression correlated with protection from obesity.

**Disclosure:** J. Khuong: None.

535

**Identification of candidate genes for metabolic traits in an obese mouse model integrating multimics data**

**D. Hesse,** M. Delpero, M. Sprechert, D. Arends, G.A. Brockmann; Breeding Biology and Molecular Genetics, Humboldt-Universität zu Berlin, Berlin, Germany.

**Background and aims:** The Berlin Fat Mouse Inbred line (BFMI) is a polygenic mouse model for obesity and related traits such as insulin resistance and fatty liver. It was selected over more than 50 generations. Subsequently, several sub-strains were generated that are genetically close related but differ in several metabolic traits (see figure). A gene on chromosome 3 (chr), *Bbs7*, was identified to be primarily responsible for obesity. To help unravel the complicated network contributing to the metabolic syndrome, this study aimed to identify the most likely causal genes associated with differences in traits of the metabolic syndrome in two sub-strains of the BFMI (BFMI861-S1 and BFMI861-S2) independently of the obesity locus on chr 3.

**Materials and methods:** An advanced intercross line (AIL) was generated from the cross BFMI861-S1 x BFMI861-S2. In generation 10, several traits were collected in 397 male mice at 25 weeks. To perform QTL-analysis, mice with the collected traits were genotyped using GigaMUGA SNP chip and KASP assays. For candidate gene identification, a prioritization tree was applied using whole-genome sequencing, transcriptomics, and proteomics data of the parental lines together with literature. In addition, pathway enrichment was performed integrating transcriptomics and proteomics.

**Results:** QTL mapping identified causal regions on different chromosomes for many traits (chr3:93.5-100.8Mb: adipose tissue weight and blood glucose; chr5:32-37Mb and chr11:114-122Mb: plasma cholesterol; chr15:32-37Mb and chr16:5-21Mb: body weight; chr17:9.4-25.3Mb: adipose tissue weight, liver weight, hepatic triglycerides, pancreatic insulin content, plasma insulin, and glucose). The association of the chr17 QTL region with many traits reflects the high correlation between the investigated traits. Hierarchical clustering using both transcriptomics and proteomics data indicated gonadal adipose tissue as driver tissue for the metabolic phenotype. In particular, transcriptomics identified 5,477 differentially expressed genes in the adipose tissue between the parental lines, while only 325 were differentially expressed in the liver. The proteomics data analysis showed comparable results: 2,138 differentially expressed proteins in adipose tissue and only 140 differentially expressed in the liver. Pathway analysis in gonadal adipose tissue revealed an overrepresentation of “lysosome” (23 %, p=3.49x10^-14), pointing towards an adipose tissue dysfunction in BFMI861-S1 likely caused by elevated lysosomal activity.

**Conclusion:** Performing QTL mapping together with a detailed prioritization approach using multimics data, we identified several QTL regions, including strong candidate genes associated with metabolic traits in BFMI mice. Future experiments will clarify the impact of the identified candidates.

**Disclosure:** D. Hesse: None.

536

**Neurometabolic changes in the hippocampus of type 2 diabetic rats: an imaging perspective towards clinical applications**

**B. Caramelo**1, T. Monteiro-Alfredo1, J. Martins2, J. Sereno2, B. Manadas3, M. Castelo-Branco2, P. Matafome1; 1Institute of Clinical and Biomedical Research (iCBR), Institute of Physiology, Faculty of Medicine, University of Coimbra, 2Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, 3Centre for Neurosciences and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal.

**Disclosure:** D. Hesse: None.
**Background and aims:** Type 2 diabetes (T2DM) induces neurologic comorbidities that include neurotoxicity induced by the imbalance between excitatory glutamatergic signalling and gamma-aminobutyric acid (GABA)-induced inhibitory activity. Our objectives were to evaluate the early alterations of such mechanisms in animal models and apply imaging methods that can ensure clinical application.

**Materials and methods:** Experimental groups: 1) Control group of male Wistar rats only fed standard diet (SD, 10 weeks); 2) high fat diet (HFD)-induced obese rats; 3) Obese rats induced to T2DM by a low dose (35 mg/kg, i.p., 4th week) of streptozotocin (STZ). Rats were subjected to magnetic resonance spectroscopy (MRS) and their hippocampus and visual cortex (VC) were collected for biochemical experiments.

**Results:** Glutamine, but not glutamate, levels are elevated in the VC of the HFD+STZ group, as well as in the hippocampus of the HFD group ($p = 0.0769$) and HFD+STZ group. Moreover, HFD potentiates the N-acetylaspartylglutamic acid (NAAG) formation, through the conversion of alanine ($r = -0.5430$), in the hippocampus, being also correlated to glutathione (GSH) ($r = 0.6826$). Such suggests that NAAG prevents Glu release, redirecting it into the formation of GSH. However, GABA levels and GABA$_{	ext{A}}$ receptor were not altered. No changes were observed for catalase, glyoxalase-1, heme-oxygenase and nitrotyrosine, nor the marker for cellular viability N-acetylaspartate (NAA).

**Conclusion:** In the hippocampus of the HFD model, Glu synthesis is not affected. Through the inhibitory effect of NAAG, Glu release into the synaptic cleft is apparently prevented in order to redirect the excitatory neurotransmitter into the formation of GSH as a compensatory mechanism. However, this effect is lost in the HFD+STZ model, showing the noxious effects of diabetes in the brain even before a compromised cellular viability. The metabolite NAAG may be a valuable early marker of neurologic comorbidities.

**Supported by:** EFSD/Sanofi Research Grants

**Disclosure:** B. Caramelo: Grants; European Foundation for the Study of Diabetes.

---

**SO 37 Dietary and nutritional interventions**

**537**

**Ketogenic diet administration to mice after a high fat diet regimen promotes histone β-hydroxybutyrylation associated to weight loss and improved metabolic fitness**

S. Nasser$^1$, T. Solé$^2$, N. Vega$^1$, A. Balcerczyk$^3$, M. Strigini$^2$, L. Pirola$^1$; $^1$South Lyon Medical Faculty, INSERM Unit 1060, Pierre Bénite, France; $^2$INSERM U1059 SAINBIOSE, UdL/UJM Saint-Etienne, University Hospital CHU, St-tienne, France; $^3$Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.

**Background and aims:** Ketogenic diets, consisting in the almost complete elimination of dietary carbohydrates, induce the body to rely on ketone bodies as primary energy source. The ketogenic diet (KD), characterized by a very limited carbohydrate content, it used as nutritional treatment for GLUT1-deficiency syndromes and pharmacologically refractory epilepsy. The increase of ketone bodies in the bloodstream at physiological doses confers multiple metabolic, anti-inflammatory and antioxidant benefits. Therefore, the ketogenic diet could be a valuable nutritional option to counter several pathological conditions, including non-alcoholic fatty liver disease, insulin resistance, obesity and osteoarthritis. The objective of this study is to investigate the beneficial impact of the ketogenic diet to promote weight loss and improve metabolic fitness.

**Materials and methods:** Males C57Bl6/J mice aged 6 weeks were fed a high fat diet for 10 weeks followed by a 8 weeks dietary switch to a chow diet (CD), ketogenic diet (KD) or continuation on a high fat diet (HFD). Body weight, kidney weight, body fat content and serum glucose and β-hydroxybutyrate (BHB) concentrations were evaluated. In liver and kidney, protein expression and histone post-translational modifications were assessed by western blot, and gene expression by quantitative real-time PCR.

**Results:** After the initial HDF feeding, administration for 8 weeks of a KD or CD induced a comparable weight loss and decrease in fat mass, with better glycemic normalization in the KD group. Histone β - hydroxybutyrylation, but not histone acetylation, was increased in the liver and kidney of mice fed the KD and the rate-limiting ketogenic enzyme HMGCS2 was upregulated - at the gene and protein level - in liver and, to an even greater extent, in kidney. KD-induced HMGCS2 overexpression may be dependent on FGF21, whose expression was dramatically increased by KD in liver. Moreover, we observe a general mild pro-inflammatory effect in the liver of the KD group, which is correlated with increased expression of the NLPR3 inflammasome subunit and an increase of pro-inflammatory IL-1β and Socs3.

**Conclusion:** Over a period of 8 weeks, KD is equally effective than a chow diet in inducing weight loss, but glycemic normalization was superior. Besides acting as a fuel molecule, BHB may exert its metabolic effects through modulation of the epigenome, via histone β-hydroxybutyrylation and transcriptional modulation in liver and kidney of ketogenic genes. These data show that a transiently administered ketogenic diet may improve the metabolic status after previous exposure to a high fat diet.
A 36-month high-protein and high-unsaturated fatty-acid dietary intervention improves HbA1c in subjects aged 50-80y: preliminary results of the NutriAct Trial


Background and aims: It is still unclear whether a long-term dietary intervention not aiming weight loss with high-protein- and unsaturated fatty-acid intake improves glucose parameters and insulin sensitivity in a population aged 50-80y at risk for age-related diseases.

Materials and methods: Within the 36-month dietary intervention trial NutriAct, 502 participants were randomized into either usual care control group including dietary recommendations of the German Nutrition Society (GNS) or an intervention group, which used supplementation of rapeseed oil and specifically designed foods as well as repetitive nutritional counseling to implement a food pattern based on high intake of predominantly plant proteins, UFA and fiber. Fasting glucose, a 3h-oral glucose tolerance test (OGTT) and HbA1c were carried out both at baseline and at month 36. The insulin-sensitivity-index (ISI) based on post-prandial insulin and glucose levels (OGIS), as well as the HOMA-IR were calculated. Independent t-tests and linear regression analyses were carried out to study the effect of the intervention as well as of changes in macronutrients in the mentioned outcomes.

Results: 394 participants (204/190 control/intervention, 37% male, median age 66y, 18% with T2DM, 43% obese) with OGTT/HbA1c/fasting glucose data at baseline and at month 36 were included in the present analyses. HbA1c increased (mean +0.09%) in the control group and decreased (mean -0.02%) in the intervention group (p<0.05 for changes between groups). Changes in the HOMA-Index, OGIS-index and fasting glucose did not differ between intervention and control group in this population (p>0.05). A mild, but similar decline in BMI was seen in control and intervention group (-0.24 kg vs. -0.44 kg, p=0.11). Changes in HbA1c between the intervention groups was attenuated and failed to reach significance (p=0.09) after adjustment for age, sex and BMI changes. Changes in intake of individual macronutrients were not associated with changes in estimates of insulin sensitivity, HbA1c or fasting glucose.

Conclusion: The 36-month NutriAct intervention led to an improvement in the HbA1c in community-dwelling participants aged 50-80y, compared to the usual care group. No changes in insulin sensitivity or fasting glucose were observed. Mechanistic pathways leading to the observed improvements require further research.
Conclusion: The 5:2 diet was feasible to follow for 6 months with a low drop out and had an equally good effect on weight reduction and improvement on metabolic and hormonal CVD associated risk factors in overweight subjects with and without T2D. These observations support previous studies that the 5:2 diet can be recommended to patients with T2D not treated with SU or insulin.

Clinical Trial Registration Number: NCT02435097
Supported by: Erling Perssons Stiftelse. ALF
Disclosure: A. Hellberg: None.

540
Short term isocaloric ketogenic diet modulates NLRP3 inflammasome via β-hydroxybutyrate and fibroblast growth factor 21

S. Woo;
Department of Endocrinology, Severance Hospital, Seoul, Republic of Korea.

Background and aims: A ketogenic diet (KD) is known to have beneficial health effects. Various types of KD interventions have been applied to manage metabolic syndrome based on modification of diet parameters such as duration of intervention, macronutrient components, and total calories. Nevertheless, the beneficial health impact of isocaloric KD is largely unknown, especially in healthy subjects.

Materials and methods: The present study investigated the acute effects of a 3-day isocaloric KD. In this non-randomised intervention study, we recruited 15 healthy volunteers aged 24-38 years (7 men and 8 women) and placed them on an isocaloric KD restricting intake of carbohydrates but not energy (75% fat, 20% protein, 5% carbohydrate) for 3 days. Biochemical profiles and laboratory measurements were performed. Peripheral blood mononuclear cells were cultured, and measured cell stimulated cytokines.

Results: After short-term isocaloric KD, subjects lost body weight and serum free fatty acid levels were increased. These results accompanied elevated serum β-hydroxybutyrate (BHB) concentration and fibroblast growth factor 21 (FGF21) levels and improved insulin sensitivity. Regarding the direct effect of BHB on inflammasome activation, interleukin-1β (IL-1β) and tumor necrosis factor-α secretion in response to adenosine triphosphate or palmitate stimulation in human macrophages decreased significantly after isocaloric KD. In ex-vivo experiments with macrophages, both FGF21 and BHB synergistically reduced IL-1β secretion compared to either BHB or FGF21 alone. The inhibitory effect of FGF21 on IL-1β secretion was blunted with bafilomycin treatment, which blocked autophagy flux.

Conclusion: Isocaloric KD for 3 days is a promising approach to improve metabolic and inflammatory status.

Clinical Trial Registration Number: NCT02964572
Supported by: Severance Hospital Research fund for Clinical excellence (SHRC)
Disclosure: S. Woo: None.

541
Pre-meal low-dose whey protein microgel increases bioavailability of branched chain amino acids in people with type 2 diabetes: a randomised, PBO-controlled crossover study

1Nestlé Health Science, Vevey, Switzerland, 2University of Lund, Lund, Sweden, 3Analytical Science, Société de Produits Nestlé S.A, Lausanne, Switzerland, 4Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA), University Hospitals Cleveland Medical Center, Cleveland, USA.

Background and aims: Whey proteins (WPs) are found in dairy products, and are rich in branched chain amino acids (BCCA) and bioactive peptides. BCCA are key WP-ingredients with demonstrated biomodulatory effects, e.g., pancreatic beta-cell insulin-stimulatory effects and effects on gastric emptying. We recently reported that a highly-concentrated low-dose (10g, 40 Cal) pre-meal drink (125 mL), generated with novel micelle-technology (WP microgel [WPM]), ingested 15 min ahead of a pizza-meal (622 Cal), vs placebo (PBO), reduced the 2h incremental area under the glucose curve (iAUC) by 22%, increased 2h GLP-1 iAUC by 61% and, delayed 1h gastric emptying with 17%, in 26 people with type 2 diabetes. To better understand the physiologic effects of this novel WPM, we conducted an exploratory analysis of BCAA profiles following a premeal shot of WPM vs PBO.

Materials and methods: This single-intervention crossover study was conducted in 26 individuals with drug-naïve or metformin-treated type 2 diabetes who received 10g WPM (40 kcal) or PBO (0 kcal), provided as a 125 mL shot 15 min ahead of a 250 g pizza meal (622 kcal [29.0 g protein, 22.6 g fat, 72.6 g carbohydrates]). We analyzed 2h free plasma BCAA trajectories using high-performance liquid chromatography/mass spectrometry in 25 persons with available samples (mean age 62 yrs, HbA1c 58 mmol/mol [7.5%], BMI 29 kg/m²) that completed this single dose study.

Results: The pre-meal WPM drink significantly altered the BCAA trajectory vs. PBO (Figure). For leucine, ΔiAUCWPM vs PBO increased by 267%, with a shorter time to maximum (median ΔTmax [min, max]: -60 [-120,0] min, p<0.0001), and peak concentration (mean ΔCmax [SD]: 123 [49] μmol/L, p<0.0001). A similar pattern was seen for isoleucine (ΔiAUC +240%, ΔTmax: -60 [-120,0], p<0.0001, ΔCmax: 68 [3], p<0.0001) and valine (ΔiAUC +194%, ΔTmax: -60 [-120, 30], p < 0.0001, ΔCmax: 63 [38], p<0.0001).

Conclusion: We conclude that 10g WPM as a pre-meal drink, induced a rapid plasma increase, and high bioavailability, of BCAAs in people with type 2 diabetes. The rapid BCAA availability might be a likely factor for the metabolic modulatory effects observed with WPM.

Clinical Trial Registration Number: NCT04639726
Supported by: Nestlé Health Science
Disclosure: O. Johansen: Employment/Consultancy; I am employed by Nestlé Health Science.

542
Effects of 10-h time-restricted eating on body weight and cardiometabolic health in individuals at high risk of type 2 diabetes (RESET): a randomised controlled trial

J.S. Quist1,2; H. Pedersen2,3, M.M. Jensen1,4, K.K.B. Clemmensen1,5, J. Storling1,6, N.J. Wever Albrechtsen2,7, J.J. Holst6,8, S.S. Torekov6,8, D. Vistisen2,9, M.E. Jørgensen1,10, S. Panda11, C. Brock1,12, G. Finlayson1,12, M.B. Blond1, K. Færch1,6.

Background and aims: The 5:2 diet was feasible to follow for 6 months with a low drop out and had an equally good effect on weight reduction and improvement on metabolic and hormonal CVD associated risk factors in overweight subjects with and without T2D. These observations support previous studies that the 5:2 diet can be recommended to patients with T2D not treated with SU or insulin.

Clinical Trial Registration Number: NCT02435097
Supported by: Nestlé Health Science.
Disclosure: A. Hellberg: None.
Background and aims: Time-restricted eating (TRE) has been suggested as a strategy to lose weight. We investigated the effects of a 3-months TRE intervention vs. control on change in body weight and other clinical outcomes in individuals at high risk of type 2 diabetes.

Materials and methods: We randomized 100 men and women aged 30-70 years with (a) overweight (BMI ≥25 kg/m²) with concomitant prediabetes (HbA1c 39.4-47 mmol/mol) or (b) obesity (BMI ≥30 kg/m²) to 3 months of TRE or control (habitual living) followed by a follow-up period for 3 months. The TRE group was instructed to consume all foods and beverages (except water) within a self-selected time window of 10 hours/day within 06:00 and 20:00. The primary outcome was change in body weight after 3 months.

Results: After 3 months the baseline corrected differences between the groups were: Body weight: -0.8 kg (95% CI: -1.7, 0.2), p=0.105; body fat: -1.0 kg (95% CI: -1.6, -0.3), p=0.007; body fat percentage: -0.6% (95% CI: -1.0, -0.1), p=0.013; fat-free mass: 0.1 kg (95% CI: -0.5, 0.6), p=0.839; HbA1c: -0.7 mmol/mol (95% CI: -1.3, -0.1), p=0.025; fasting plasma glucose: -0.1 mmol/L (95% CI: -0.2, 0.1), p=0.205; LDL cholesterol: 0.1 (95% CI: -0.1, 0.4), p=0.306. After adjustment for multiple testing, there were no statistically significant changes from baseline to neither 3 nor 6 months. Adherence to the TRE-intervention remains to be evaluated.

Conclusion: We found no clinically relevant effects of a 3-month 10-h TRE intervention on body weight reduction and other clinical outcomes in individuals at high risk of type 2 diabetes.

Figure 1: Mean changes (95%CI) in body weight in the two groups from baseline to 1.5, 3 and 6 months.

Clinical Trial Registration Number: NCT03854656
Supported by: NNF (NNF17OC0027822); Aalborg University; Innovation Fund Denmark
Disclosure: J.S. Quist: Grants; Novo Nordisk Foundation (NNF17OC0027822), Innovation Fund Denmark. Other; PhD scholarship from Aalborg University, Denmark.
Vegetable juice preload ameliorates postprandial glucose concentration in healthy women: a randomised cross-over trial

S. Imai1, S. Kajiyama2, T. Miyawaki3, N. Ozasa4, S. Kajiyama4, Y. Hashimoto5, M. Fukui5; 1Kyoto Women’s University, 2Kajiyama Clinic, 3Kyoto University, Kyoto, Japan, 4Japanese Red Cross Kyoto Daini Hospital, 5Kyoto Prefectural University of Medicine, Kyoto, Japan.

Background and aims: Consuming vegetables before carbohydrates was effective to suppress the postprandial glucose concentrations and insulin secretion in people with and without diabetes as we have reported. However, average amounts of vegetable intake in Japan and U.S.A. were under the target of recommendations, due to economical reason, limited cooking time and skills, and low availability of fresh products. In order to explore the benefit of drinking vegetable juice as a substitute of vegetable, we examined the effect of drinking vegetable juice 20 min before consuming carbohydrate on postprandial glucose concentrations in young healthy women.

Materials and methods: This was a randomized controlled three-treatment cross-over open-labeled trial within-participant. The participants consumed 200 g of vegetable juice, 190 g of fresh vegetable (tomato and broccoli), or 200 g of water (control) 20 min before consuming 200 g of boiled white rice for 3 separate days. The test meals of energy, carbohydrate, and dietary fiber in vegetable (energy 380 kcal, carbohydrate 83.7 g, fiber 6.4 g) and vegetable juice (energy 379 kcal, carbohydrate 83.7 g, fiber 4.8 g) were almost equal, but those in water (energy 340 kcal, carbohydrate 74.9 g, fiber 3.4 g) were less than vegetable and vegetable juice. All participants performed the capillary finger pricks and blood glucose concentrations were analyzed by self-monitoring blood glucose device. Pre- and post-meal blood glucose concentrations were measured at -20, 0, 15, 30, 45, 60, 120, and 180 min. The mean blood glucose concentration, standard deviation for blood glucose, large amplitude of blood glucose excursion (LAGE), and other glycaemic parameters were compared among 3 days.

Results: Twenty-four women [age 21.3 ± 0.6 years, HbA1c 35 mmol/mol (5.4 ± 0.2%), mean ± SD] completed the study. The incremental glucose peak at 45 min (vegetable juice 48.3 ± 4.1, vegetable 47.4 ± 3.3 vs. water 66.8 ± 4.3 mmol/L, both p < 0.01, mean ± SEM) and LAGE (vegetable juice 57.1 ± 3.1, vegetable 58.3 ± 3.6 vs. water 78.3 ± 4.3 mmol/L, both p < 0.05) in consuming vegetable juice and vegetable at 20 min before carbohydrate were all significantly lower than those of water. On the other hand, there was no significant difference in glycaemic parameters between vegetable juice and vegetable.

Conclusion: Drinking vegetable juice 20 min before carbohydrate ameliorates the postprandial blood glucose concentrations as well as vegetable preload, despite total amounts of energy and carbohydrate of vegetable juice or vegetable are higher than those of water. Vegetable juice preload is easy, practical, and cost-effective method to lower the postprandial glucose concentrations in women without type 2 diabetes.

Clinical Trial Registration Number: UMIN 00003494
Supported by: KAKENHIA and Kyoto Women’s University
Disclosure: S. Imai: None.
SO 38 SGLT2 inhibitors and renal outcomes

545

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney outcome guided by HbA1c, and predicted risk of kidney failure

S. Tye1, N. Jong1, S.G. Coca2, J. Sundström3, C. Amott4,5, B. Neal5, V. Perkovic6, P. Var1, H.J. Lamberts Heerspink1.

1Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, Netherlands, 2Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA, 3Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 4Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia, 5The George Institute for Global Health, UNSW Sydney, Sydney, Australia.

Background and aims: The use of sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of kidney and heart failure events independent of glycemic effects. We assessed whether SGLT2 inhibitors initiation guided by multivariable predicted risk based on clinical characteristics and novel biomarkers is more efficient to prevent clinical outcomes compared to a strategy guided by HbA1c alone.

Materials and methods: We performed a post-hoc analysis of the CANVAS trial including 3713 patients with available biomarker measurements. We compared the number of composite kidney outcomes (defined as a sustained 40% decline in eGFR, chronic dialysis, kidney transplantation, or kidney death) prevented per 5 years when canagliflozin was initiated in patients with HbA1c ≥7.5%, versus in patients defined by a multivariable predicted risk model consisting of (1) clinical characteristics or (2) clinical characteristics and novel biomarkers. The difference between models was compared by C statistics.

Results: After a median follow-up of 6.1 years, 137 kidney events were recorded. The clinical risk model included age, previous history of CV disease, systolic blood pressure, urinary albumin creatinine ratio, hemoglobin, body weight, albumin, estimated glomerular filtration rate (eGFR), and treatment variable. The novel biomarkers model included all clinical characteristics, tumor necrosis factor receptor-1, kidney injury molecule-1, matrix metallopeptidase-7, and interleukin-6. Treating all patients with HbA1c ≥7.5% (n=2809) for a median of 6.1 years, 33 kidney outcomes would be prevented. Treating 2809 patients with the clinical and clinical/novel biomarker model resulted in the prevention of 57.0 (95% CI 53.6 to 60.4) and 60.0 (95% CI 56.2 to 63.8) kidney events. The C-statistic for the HbA1c strategy to predict the composite kidney outcome was 0.54 (95% CI 0.50, 0.59). For the clinical and clinical/novel biomarker models, the C statistic was 0.80 (95% CI 0.75, 0.84) and 0.81 (95% CI 0.76, 0.86), respectively.

Conclusion: Initiation of canagliflozin based on an estimated risk-based approach prevented more kidney events than a strategy based on HbA1c alone. The incremental gain of adding novel biomarkers to the clinical risk model was marginal. This finding supports the use of clinical risk-based assessment to guide the initiation of SGLT2 inhibitors in patients with type 2 diabetes.

Clinical Trial Registration Number: NCT01032629
Supported by: EU’s Horizon 2020 under Marie Skłodowska-Curie grant agreement No 754425
Disclosure: S. Tye: None.

546

Effects of dietary sodium and protein intake on early dip of GFR levels in subjects with type 2 diabetes treated with SGLT2 inhibitors

M. Seghieri1, C. Colombi1, C. Gaudio2, C. Merciai2, A. Rosati2, C.M. Baggio1.

1Diabetes Unit, Nuovo San Giovanni di Dio Hospital, 2Nephrology Unit, Nuovo San Giovanni di Dio Hospital, Firenze, Italy.

Background and aims: SGLT2 inhibitors (SGLT2i) are able to decrease proteinuria and to slow down kidney function decline in patients with type 2 diabetes (T2D). The effect is mainly obtained by increase of natriuresis and glucose-induced osmotic diuresis, resulting in a reduction of intraglomerular pressure. These hemodynamic changes are beneficial in long-term period but up to 28% of patients experience an acute, usually transient, estimated GFR (eGFR) reduction of more than 10%. Moreover, in some case the decrease of eGFR can be more pronounced and compromise the maintenance of therapy. High sodium and protein intake can lead to intraglomerular pressure increase and predispose to a deeper fall of eGFR. We aimed at investigating whether measured creatinine clearance (CICr) is a more sensitive method to detect the initial dip of GFR and if dietary sodium and protein intake can influence the extent of the early change in GFR.

Materials and methods: Subjects with T2D were consecutively recruited among those referring to the inpatients of combined Nephrology and Diabetology clinic in years 2020-2021. Those eligible for treatment with SGLT2i were asked to collect 24h urinary samples for sodium and urea determination to estimate sodium and protein intake respectively before and 1, 3 and 6 months after drug initiation. Taking account that nephroprotection by these drugs is related a class-effect, a single molecule was not chosen. Creatinine Clearance variation (Δ CCr) is the primary outcome, was calculated as CCr at 1.3,6 months minus baseline CCr or as a percentage (Δ CCr/baseline CCr×100).

Results: At baseline 28 patients (M 24/ F 4; age 69±7 years; BMI 28.2 ±3.6 kg/m²; HbA1c 56±16 mmol/mol) had a CICr of 83.23±25.52 ml/min/1.73 m² (eGFR 67.32±16.07), which dropped by 19% at month 1 (eGFR by 6%; although not significantly) and then increased to comparable baseline values at month 6. Exploring the potential correlation between changes in renal function and salt intake, Δ CICr and baseline urinary sodium were inversely related at month 1 (r =-0.61; p<0.01), at month 3 (r =-0.51; p=0.01) and month 6 (r =-0.48; p<0.05). Likewise, an inverse correlation between Δ CICr and baseline urinary urea was demonstrated at month 1 and 3 (r =-0.46; p<0.05 for both), at month 6 a similar, not significant, trend was observed (r =-0.47; p =0.054). A multivariate analysis including age, sex and BMI demonstrated that Δ CICr increased by one month of treatment was significantly negatively correlated with the interaction of baseline sodium and urea urinary excretion but not with the single terms (beta std=2.09, p<0.04; p=0.04 for the model). Proteinuria showed a significant reduction from baseline (p<0.05), however no significant relationship between change in proteinuria and urinary sodium or urea was observed.

Conclusion: The present study suggests that a higher dietary sodium and protein intake may amplify the extent of early dip in glomerular filtration rate, detected with measured CrCl, in diabetic patients undergoing SGLT2i treatment. We believe that creatinine clearance is a very sensitive method to detect it. Further studies are needed to confirm the results of our pilot study.

Disclosure: M. Seghieri: None.

547

Real-world safety of dapagliflozin in elderly patients with type 2 diabetes in China: post-hoc analysis of the DONATE study

L. Guo1, J. Wang2, L. Li3, L. Yuan4, S. Chen5, H. Wang6, T. Li7,8, L. Qiu9, H. Yang10.

1Beijing Hospital, Beijing, 2Weifang Municipal Official Hospital, Weifang, 3Ningbo First Hospital, Ningbo, 4Zhuhai People’s Hospital, Zhuhai, 5The People’s Hospital of Liuyang, Liuyang, 6Yancheng Tonghu People’s Hospital, Yancheng, 7The Second Hospital of Nanjing, Nanjing, 8The 81st Hospital of People’s Liberation Army, Nanjing, 9Beijing Yinhua Hospital, Beijing, 10Zhejiang Ru’an People’s Hospital, Ru’an, China.
**Background and aims:** Dagaglitazin significantly improves glycaemic control, weight loss and blood pressure (BP) in the patients with type 2 diabetes mellitus (T2DM), but data on dagaglitazin safety in the Chinese patients with T2DM aged ≥65 years are insufficient. We investigated the real-world safety of dagaglitazin in the elderly Chinese patients with T2DM enrolled in the DONATE study.

**Materials and methods:** The observational DONATE study investigated the safety of dagaglitazin in the patients with T2DM from 88 hospitals in China, who received ≥1 dose of dagaglitazin between August 2017 and July 2020. In this post-hoc analysis, baseline patient characteristics and 24-week safety outcomes, including adverse event (AE)/Serious AE (SAE), and adverse events of special interest (AESI), were analysed by age subgroups (≤65 and ≥65 years).

**Results:** Of the 2,990 patients included in the safety analysis set, 2,482 and 508 patients were aged <65 years and ≥65 years, respectively; mean (SD) age and duration of T2DM were 49.1 (9.6) vs 70.1 (4.8) years, and 7.4 (6.5) vs 13.0 (7.9) years, respectively. There was a higher proportion of male patients in the <65 vs ≥65 years subgroup (68.3% vs 53.3%). Vital signs, including body weight, waist circumference, BMI, BP, and metabolic factors, such as HbA1c and fasting plasma glucose, were similar between age groups at study enrolment. The mean (SD) eGFR was 130.0 (41.1) vs 108.0 (35.5) mL/min/1.73m² in patients aged <65 and ≥65 years, respectively. Almost half of elderly patients (45.7%) had a history of cardiac disorders, compared with 19.2% of patients aged <65 years. Mean (SD) duration of dagaglitazin exposure was 63.7 (145.8) days and 71.9 (150.0) days in patients aged <65 and ≥65 years, respectively. Overall, 34.5% and 39.8% of patients aged <65 and ≥65 years, respectively, reported ≥1 adverse event (AE) during the 6-month follow-up. Among these, 8.9% vs 9.4% were related to treatment, 5.6% vs 9.4% were serious, and 4.1% vs 7.9% led to treatment discontinuation. The proportion of patients experiencing AESI was similar between age groups (6.0% vs 6.9%), with low rates of hypoglycaemia (1.1% vs 0.8%), urinary tract infections (UTI) (2.3% vs 2.4%), and genital tract infections (GTI) (1.4% vs 1.0%). There were no diabetic ketoacidosis (DKA) events reported in patients aged ≥65 years, while there were two (0.1%) events in patients aged <65 years. Rates of other AESI were also low in patients aged <65 and ≥65 years, respectively: volume depletion (0.2% vs 0.8%), abnormal electrolytes (0% vs 0%), polyuria (0.6% vs 1.2%), renal impairment (0.2% vs 0.6%), hepatic impairment (0.2% vs 0.2%), and haematuria (0.2% vs 0.2%).

**Conclusion:** Findings from this post-hoc analysis reveal that dagaglitazin safety profile in elderly Chinese patients with T2DM is consistent with that in younger patients. Our data confirm that dagaglitazin is well-tolerated in real-world clinical practice in China, regardless of age.

**Clinical Trial Registration Number:** NCT03156985

**Supported by:** This study was funded by AstraZeneca.

**Disclosure:** L. Guo: None.

---

**549**

**Combination treatment impacts levels of endotrophin in the drug combinations for rewriting trajectories of renal pathologies in type 2 diabetes (DC-Ren) study**

F. Genovesi, A.L. Møller, S. Thiø, F. Keller, S. Sharifi, D.G.K. Rasmussen, G. Mayer; 1Nordic Bioscience, Herlev, Denmark, 2Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, 3Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria.

**Background and aims:** DC-Ren focuses on diabetic kidney disease (DKD), a severe complication of type 2 diabetes mellitus (T2DM) often accompanied by cardiovascular disease (CVD). Despite therapeutic advances, new biomarkers for identifying patients at increased risk of disease progression and for predicting response to treatment are of major importance to develop the concept of precision medicine. Increased...
collagen type VI (COL6) formation has been associated with increased risk of renal and cardiovascular complications and mortality in patients with T2DM. For the first time, we investigate the potential of endothphin, a pro-fibrotic molecule generated during COL6 formation, as a pharmacodynamic marker in patients with T2DM treated with different treatments.

Materials and methods: Endothphin was measured by the PRO-C6 ELISA in plasma collected at baseline, and on average after years 1, 2, and 3 from 456 individuals with T2DM enrolled in the DC-Ren study. All individuals were on renin-angiotensin system inhibitor (RASI) treatment at baseline and during follow-up. While some patients remained on RASI treatment only, others received one of the following target drugs on top of RASI: sodium-glucose cotransporter-2 inhibitor (SGLT2i), glucagon-like peptide-1 receptor agonist (GLP-1RA), or mineralocorticoid receptor antagonist (MCRA). 256 patients had at least three follow-ups.

Results: The cohort consisted of 53% males, the age was 67±9.0 and the eGFR was 64±18 ml/min/1.73 m² (all mean±SD). Higher baseline levels of plasma endothphin were associated with lower eGFR and higher UACR, respectively, and this relation remained consistent over time. Interestingly, levels of plasma endothphin were significantly lower in patients treated with SGLT2i in combination with RASI compared to RASI alone, whereas levels increased significantly with MCRA treatment on top of RASI. In patients treated with a SGLT2i on top of RASI, the increase in plasma endothphin was less pronounced over time which was accompanied by a slower decline in eGFR. In adjusted linear models (for the group on RASI only) a significant association of current plasma endothphin was found, indicating that plasma endothphin is a prognostic risk marker for kidney function decline.

Conclusion: Levels of plasma endotrophin decreased with treatment, indicating that RASI in combination with SGLT2i affects COL6 formation and levels of endotrophin. The degree of kidney disease severity increased with increasing plasma endotrophin levels at baseline, indicating that the biomarker identifies patients with high disease activity where the potential of anti-fibrotic effect of treatment becomes more prominent. Further research is needed to understand the mechanism for the treatment’s effect on fibrosis and the association of endotrophin with cardiorenal outcome, mortality, and treatment response in the DC-Ren study.

Supported by: This work was supported by The Innovation Fund Denmark (0172-00270B)

Disclosure: F. Genovese: None.

Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: data from the CANVAS Program and CREDENCE

J. Seufert1, V. Woo2, M.A. Tsoukas3, S.W. Tobe4, A. Slee5, W. Rapattoni6, F.G. Ang7, D.C. Wheeler8;
1University Hospital Freiburg, Freiburg, Germany, 2University of Manitoba, Winnipeg, Canada, 3McGill University Health Centre, Montreal, Canada, 4Sunnybrook Research Institute, Toronto, Canada, 5New York University, New York, USA, 6Janssen, Inc., Toronto, Canada, 7The George Institute for Global Health, UNSW, Sydney, Australia, 8University College London, London, UK.

Background and aims: In type 2 diabetes (T2D), treatment targets include maintaining HbA1c ≤7.0%, low-density lipoprotein cholesterol (LDL-C) <2 mmol/L (<77 mg/dL), and blood pressure (BP) <130/80 mmHg. It is also recommended to improve urinary albumin:creatinine ratio (UACR), a marker of renal damage and cardiovascular (CV) risk. We examined effects of canagliflozin versus placebo on CV and kidney outcomes in patients with T2D and high CV risk and/or chronic kidney disease according to baseline treatment targets and risk factors.

Materials and methods: Pooled data from the CANVAS Program (N=10,142) and the CREDENCE trial (N=4401) were analyzed according to treatment target achievement and by number of targets achieved at

© Springer
baseline. Hazard ratios and 95% confidence intervals were estimated using Cox regression models.

**Results:** Of 14,432 participants at baseline, 3683 (26%) had achieved 0, 5851 (41%) had achieved 1, 3680 (25%) had achieved 2, and 1218 (8%) had achieved either 3 or 4 targets. At baseline, 8415 (58%) participants had UACR >2 mg/mmol. Canagliflozin consistently reduced risk of major adverse cardiovascular events (MACE), the composite of hospitalization for heart failure (HHF) or CV death, and the composite of end-stage kidney disease (ESKD) or doubling of serum creatinine (dSCr) versus placebo, regardless of whether baseline targets were met or if UACR was elevated (Figure). The number of uncontrolled targets at baseline did not impact the beneficial effect of canagliflozin on CV and kidney outcomes (all \(P_{\text{interaction}} >0.17\)).

**Conclusion:** Overall, canagliflozin demonstrated consistent CV and renal benefits in patients with T2D, regardless of risk factor control.

---

**Clinical Trial Registration Number:** NCT01032629, NCT01989754, NCT02065791

Supported by: Janssen, Inc.

Disclosure: J. Seufert: None.

---

### 552 Albuminuria lowering effect of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease a randomised cross-over clinical trial

**M. Provenzano**¹, H.J.L. Heerspink¹, M. Puchades², C. Garofalo³, N. Jongs¹, M. Adreucci², L. De Nicola¹, J. Gorriz²;

¹University Medical Centre Groningen, Groningen, Netherlands, ²University of Valencia, Valencia, Spain, ³University of Campania “Luigi Vanvitelli”, Naples, Italy, ⁴Magna Graecia University of Catanzaro, Catanzaro, Italy.

**Background and aims:** SGLT2 inhibitors and MRAs reduce urinary albumin-to-creatinine ratio (UACR) and confer kidney and cardiovascular protection in patients with chronic kidney disease (CKD). We assessed the efficacy and safety of the SGLT2 inhibitor dapagliflozin and MRA eplerenone alone and in combination in patients with CKD with and without type 2 diabetes.

**Materials and methods:** We conducted a randomized open-label cross-over trial in patients with urinary albumin excretion ≥100 mg/24-hour, eGFR 30-90 mL/min/1.73m² who had been receiving maximum tolerated stable doses of ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB). Patients were assigned to 4-weeks treatment periods with dapagliflozin 10 mg/day, eplerenone 50 mg/day or their combination in random order, separated by 4-week wash-out periods. Primary outcome was the correlation in UACR changes between treatments. Secondary outcome was the percent change in 24-hour UACR from baseline.

**Results:** Of 57 patients screened, 46 were randomly assigned (mean eGFR 58.1 mL/min/1.73m², median UACR 401 mg/g) of whom 32 had type 2 diabetes and 14 did not have diabetes. Mean percentage change from baseline in UACR after 4 weeks treatment with dapagliflozin, eplerenone, and dapagliflozin-eplerenone treatment was -19.6% (95%CI -34.3, -1.5), -33.7% (95%CI -46.1, -18.5), and -53.0% (95%CI -61.7, -42.4; \(p<0.001\) vs dapagliflozin; \(p=0.0127\) vs eplerenone). The change in UACR after 4 weeks treatment with dapagliflozin-eplerenone was consistent in patients with type 2 diabetes (-54.5% [95%CI -64.6, -41.5]) and without diabetes (-49.1[95% -65.1, -28.2]). UACR change during dapagliflozin or eplerenone treatment did not correlate with UACR change during dapagliflozin-eplerenone (\(r=-0.13; p=0.473; r=-0.08; p=0.658\) respectively). Hyperkalemia was more frequently reported with eplerenone (N=8, [17.4%]) compared to dapagliflozin (N=0, [0%]), or dapagliflozin-eplerenone (N=2, [4.3%]; \(P_{\text{between-group}}=0.0033\)).

**Conclusion:** Albuminuria changes in response to dapagliflozin and eplerenone did not correlate supporting systematic rotation of these therapies to optimize treatment. Combining dapagliflozin with eplerenone resulted in a robust additive UACR lowering effect which was similar between patients with and without type 2 diabetes. A larger trial in this population is required to confirm long-term efficacy and safety of combined SGLT2 inhibitor and MRA treatment.

**Clinical Trial Registration Number:** NTR5602

**Disclosure:** M. Provenzano: None.
SO 39 Newer agents - cardiovascular outcomes

553 Interleukin-6 and cardiovascular outcome in patients with type 2 diabetes: new insights from CANVAS
A. Koshino1, M. Schechter2, T. Sen2, B.L. Neuen2, C. Amott2, B. Neal2, V. Perkovic4, P.M. Ridker3, K.R. Tuttle3, M.K. Hansen2, H.J.L. Heerspink1,2,1 University of Groningen, Groningen, Netherlands, 2The George Institute for Global Health, Sydney, Australia, 3Brigham and Women’s Hospital, Harvard Medical School, Boston, USA, 4Providence Medical Research Center, Providence Health Care, Spokane, USA, 5Janssen Research & Development, LLC, Spring House, USA.

Background and aims: Chronic low-grade inflammation is present in both type 2 diabetes (T2D) and chronic kidney disease. Increases in the inflammatory cytokine interleukin-6 (IL-6) were associated with cardiovascular (CV) outcomes in various populations. However, data in patients with T2D are limited. We assessed in a post-hoc analysis of the CANVAS trial the association of circulating IL-6 with CV outcome overall and by baseline kidney function.

Materials and methods: Participants with T2D at high CV risk were randomly assigned to canagliflozin (CANA) or placebo. Plasma IL-6 was measured at baseline and at year 1, 3, and 6 after randomization using electrochemiluminescence. We categorized eGFR at baseline into three strata: ≥90, 60-<90, <60 mL/min/1.73 m². The CV outcome was defined as a composite of non-fatal myocardial infarction or stroke, or CV death. We used multivariable adjusted Cox proportional hazard regression to estimate the association between baseline IL-6 and the CV outcome adjusted for demographic, clinical, and laboratory characteristics. The change in IL-6 over time and the effect of CANA compared to placebo was assessed with a repeated measures mixed effect model.

Results: Of 4,330 CANVAS trial participants, 3,501 (80.9%) had an available IL-6 measurement at baseline. Among them, 1,105 (31.6%), 1,902 (54.3%), or 494 (14.1%) had eGFR ≥90, 60-<90, or <60 mL/min/1.73 m², respectively. Higher IL-6 was observed in patients within the lower eGFR subgroups, with respective median (IQR) of 1.55 pg/mL (1.09, 2.22), 1.64 (1.18, 2.39), 1.85 (1.30, 2.77) (p trend<0.01). The CV outcome occurred in 548 (15.6%) individuals over 6.1 years median follow up. Each doubling of baseline IL-6 was associated with 14% (95% CI 10%, 17%) increased risk for the CV outcome in the overall population. The association between baseline IL-6 and the CV outcome was stronger in the eGFR <60 subgroup and absent among patients with eGFR ≥90 mL/min/1.73 m² (p trend=0.02; Figure). Over 6 years, IL-6 increased by 5.8% (95% CI 3.4, 8.3) in the placebo group. CANA modestly attenuated IL-6 increases by 4.4% (95% CI 1.3, 9.9; p=0.01) compared to placebo, with no evidence that this effect varied by baseline eGFR (p interaction=0.21).

Conclusion: In patients with T2D at high CV risk, higher IL-6 was associated with increased risk for adverse CV outcome. This association was stronger in patients with reduced kidney function. The ongoing ZEUS trial tests whether directed IL-6 lowering therapy improves CV outcomes in patients with CV disease, reduced kidney function, and evidence of inflammation.

Clinical Trial Registration Number: NCT01032629
Supported by: Janssen Research & Development, LLC
Disclosure: A. Koshino: None.

554 Cardiovascular effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists in routine care of frail people with type 2 diabetes
A. Kutz, C. Gopalakrishnan, D.H. Kim, E. Patomo;
Department of Medicine, Brigham and Women’s Hospital, Boston, USA.

Background and aims: Frailty is important in diabetes management but its impact on the cardiovascular effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA) as used in routine care is unexplored. We therefore evaluated the cardiovascular effectiveness of SGLT-2i, GLP-1 RA, and dipeptidyl peptidase 4 inhibitors (DPP-4i) in older adults with type 2 diabetes across different strata of frailty.

Materials and methods: In this comparative effectiveness study using Medicare claims data, we identified three pairwise cohorts of older patients with type 2 diabetes who initiated a SGLT-2i, a GLP-1 RA, or a DPP-4i between 04/2013-12/2018, and stratified each cohort by three levels of frailty (non-frail, <0.15; pre-frail, 0.15-0.24; frail, >0.25), using a validated claims-based frailty index. Within each frailty stratum, we estimated the propensity score (PS) based on >150 baseline covariates and performed a 1:1 PS matching. The primary outcome was a composite of major adverse cardiovascular events (MACE) including acute myocardial infarction, ischemic stroke, hospitalization for heart failure, and all-cause mortality. For each PS-matched frailty stratum, we estimated hazard ratios (HR), absolute rate differences (RD) per 1,000 person-years, with their 95% confidence intervals (CI), and number needed to treat (NNT). We used the Wald test for homogeneity to assess treatment heterogeneity across frailty strata.

Results: Over a mean follow-up of approximately 9 months, the HR for MACE associated with SGLT-2i vs. DPP-4i (overall, n=91’141 PS-matched pairs; mean age 72.1 years) was 0.82 (95% CI 0.72 to 0.93) in frail, 0.71 (0.67 to 0.75) in pre-frail, and 0.78 (0.71 to 0.86) in non-frail people (p for homogeneity = 0.033). The HR for MACE associated with
GLP-1 RA vs. DPP-4i (n=90,988 pairs; age 71.8 years) was 0.84 (0.76 to 0.93) in frail, 0.77 (0.73 to 0.81) in pre-frail, and 0.82 (0.74 to 0.91) in non-frail people (p for homogeneity = 0.150). The HR for MACE associated with SGLT-2i vs. GLP-1 RA (n=67,967 pairs; age 71.7 years) was 0.87 (0.75 to 1.01) in frail, 0.93 (0.87 to 1.01) in pre-frail, and 0.90 (0.79 to 1.03) in non-frail people (p for homogeneity = 0.692). Compared to DPP-4i, the absolute benefit of either SGLT-2i or GLP-1 RA was largest in frail people [RD, -25.0 (-42.1 to -7.9), p for homogeneity <0.001, NNT=40; and RD, -24.9 (-39.0 to -10.7), p for homogeneity <0.001, NNT=41; respectively].

Conclusion: In this population-based study of older adults with type 2 diabetes, while, compared to DPP-4i, SGLT-2i and GLP-1 RA were associated with similar relative risk reductions in MACE among people with and without frailty, their absolute benefits were largest in frail people. There was a similar risk of MACE in patients initiating SGLT-2i vs. GLP-1 RA, regardless of frailty level.

Supported by: AK was supported from the Swiss National Science Foundation and Novo Nordisk.

Disclosure: A. Kutz: Grants; Postdoc.Mobility-Grant Nr. P400PM_194479 by the Swiss National Science Foundation. Educational Grant from Novo Nordisk.

554

GIP infusion acutely decreases blood pressure and increases heart rate in men with type 2 diabetes, concomitantly with increased pro-atrial natriuretic peptide levels

N. M. Serum1, L.-S. Gasbjerg1,2, M. M. Andersen1, S. M. N. Heimbürger1,2, L. S. Krogh1, J. J. Holst1,2, T. Vilsbøll1,2, A. Lund1, D. Terzic3, N. C. Bergmann1, F. K. Knø1,2

1Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, 2Department of Biomedical Sciences, University of Copenhagen, Copenhagen, 3Zealand Pharma A/S, Søborg, 4Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 5Steno Diabetes Center Copenhagen, Herlev, 6Department of Clinical Biochemistry, Copenhagen University Hospital, Copenhagen, Denmark.

Background and aims: While dual glucagon-like peptide 1 (GLP-1) receptor / glucose-dependent insulinoptrophic polypeptide (GIP) receptor agonists have shown promising results regarding glycaemic control and weight loss in people with type 2 diabetes (T2D), the independent cardiovascular effects of GIP remain unclear. In this study we examined the effect of acute GIP infusion on blood pressure (BP), heart rate (HR) and circulating pro-atrial natriuretic peptide (proANP) in overweight / obese men with metformin and long-acting GLP-1 receptor agonist-treated T2D. ProANP results were compared with results from a cohort of healthy men also receiving acute GIP infusion.

Materials and methods: Thirteen men with metformin and long-acting GLP-1 receptor agonist-treated T2D received a double-blind continuous infusion of GIP (6 pmol/kg/min) and saline (placebo), respectively, on separate experimental days. After 60 minutes of infusion, the participants ingested a standardised liquid mixed meal (300 kcal). BP, HR, and plasma levels of proANP (measured as mid-regional proANP) were measured regularly throughout the 270 minutes infusion period. Plasma from 10 healthy men undergoing 60 minutes of GIP infusion (1.5 pmol/kg/min) was analysed for proANP levels at baseline and regularly during infusion.

Results: Compared to placebo, GIP infusion decreased mean arterial pressure (MAP) (95±1.8 vs 89±1.5 mmHg, p<0.004), mean systolic BP (SBP) (132±2.2 vs 125±2.9 mmHg, p=0.017) and mean diastolic BP (DBP) (77±2.0 vs 72±1.4 mmHg, p=0.003) and increased HR (67±2.2 vs 76±3.4 beats per minute, p<0.001). Plasma proANP increased following GIP infusion (baseline-subtracted AUC 262±79 vs 988±342 minutes×pmol/l, p=0.002). A similar trend was seen in the healthy cohort (316±51 vs 576±159 minutes×pmol/l, p=0.065).

Conclusion: Infusion of GIP in overweight / obese men with metformin and long-acting GLP-1 receptor agonist-treated T2D decreased MAP, SBP, and DBP and increased HR pointing to potentially additive haemodynamic effects of GIP receptor and GLP-1 receptor co-agonism. As plasma levels of proANP increased following GIP infusion, the BP reduction could be mediated by proANP.
Sustainability of HbA1c control of tirzepatide vs insulin glargine in people with type 2 diabetes and increased cardiovascular risk: SURPASS-4
S.E. Kahn¹, S. Del Prato², I. Pavo³, D.R. Franco³, Z. Yang³, R.J. Wiese³, E.R. Pearson⁵; ¹VA Puget Sound Health Care System and University of Washington, Seattle, USA, ²Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ³Eli Lilly and Company, Indianapolis, USA, ⁴CPCLIN, Clinical Research Center, Sao Paulo, Brazil, ⁵University of Dundee, Scotland, UK.

Background and aims: Tirzepatide (TZP) is a novel dual GIP/GLP-1 receptor agonist in development for glucose-lowering in type 2 diabetes (T2D). The open-label SURPASS-4 trial examined TZP vs insulin glargine (iGlar) in adults with T2D inadequately controlled on oral medications.

Materials and methods: Participants (N=1989) with baseline HbA1c 58–91 mmol/mol (7.5–10.5%) and BMI ≥ 25 kg/m² were randomised 1:1:1:3 to once weekly TZP (5, 10, 15 mg) or iGlar (100 U/mL) titrated to <5.6 mmol/L (<100 mg/dL) fasting glucose. This post hoc analysis evaluated the sustainability of glycaemic control after the 52-week (wk) primary endpoint (last on-treatment visit post-52 wks, up to 104 wks), (median=85 wks).

Results: After achieving the 52-wk HbA1c targets of <53 mmol/mol (7%), ≤ 48 mmol/mol (6.5%), or <39 mmol/mol (5.7%), a participant was considered to have sustained long-term HbA1c control if the final, post-52-wk, on-treatment HbA1c measurement increased ≤ 2.0 mmol/mol from the 52-wk HbA1c target (Table). More participants in all 3 TZP dose groups maintained each of the 3 HbA1c targets beyond 52 wks vs iGlar (all TZP, p<0.05). Thus, even for the lowest TZP dose (5 mg), 59% of participants achieved an HbA1c ≤ 48 mmol/mol (6.5%) at 52 wks, with 75% of these having ≤ 2.0 mmol/mol increase at their last visit. In contrast, for iGlar, 29% achieved an HbA1c ≤ 48 mmol/mol (6.5%), with 66% of these having ≤ 2.0 mmol/mol increase.

Conclusion: In conclusion, TZP treatment results in improved long-term HbA1c control for a significantly greater percentage of adults with T2D compared to iGlar.

Systolic blood pressure reduction with tirzepatide across SURPASS programme: a mediation analysis using weight loss as a factor
O. Mosenzon¹, I. Lingvay ², K. Brown¹, X. Cui¹, L. Fernández Landó², H. Patel³; ¹The Hadassah University Hospital-Ein Kerem, Jerusalem, Israel, ²Southwestern Medical Center, Dallas, USA, ³Eli Lilly and Company, Indianapolis, USA.

Background and aims: Tirzepatide (TZP) is a novel dual GIP/GLP-1 receptor agonist in development for the treatment of type 2 diabetes. Across the SURPASS 1-5 clinical studies, TZP 5, 10 and 15 mg demonstrated significant improvements in HbA1c (-20.77 to -28.42 mmol/mol) (-1.9 to -2.6%), body weight (-6.6 to -13.9%) and systolic blood pressure (SBP) (-2.8 to -12.6 mmHg) at primary endpoint.

Materials and methods: Patients were randomised 1:1:1:1 to TZP 5 mg, 10 mg, 15 mg or comparator, except in the SURPASS-4 study where patients were randomised 1:1:1:3. Primary endpoint was 40-weeks for (SURPASS-1, 2 and 5) and 52-weeks for (SURPASS-3 and 4). Post-hoc mediation analyses were conducted to evaluate weight loss dependent (WL-D) and independent (WL-IND) effects of TZP on SBP reductions across 5 SURPASS studies. Weight loss was considered an indirect effect (mediator), the effect not mediated by weight loss was considered a direct effect of tirzepatide on SBP. Correlation between SBP change and weight change was also conducted with pooled data of SURPASS 1 to 5.

Results: Concomitant antihypertensive medications were allowed during the SURPASS studies and 47% (SURPASS-1) to 93% (SURPASS-4) of patients were using anti-hypertensive medications at baseline. The difference in mean SBP change from baseline at 40-weeks (Total effect) between TZP and comparator group was -1.3 to -5.1 mmHg (TZP 5 mg), -1.7 to -6.5 mmHg (TZP 10 mg) and -3.1 to -11.5 mmHg (TZP 15 mg). The contribution of WL-D and WL-IND effects on these treatment differences are presented below (Figure). In SURPASS-4 study which enrolled patients with established cardiovascular disease, WL-IND effects explained 33% to 57% of difference in SBP change between
TZP and insulin glargine groups, with the remainder of 67% to 43% of the effect being WL-D. In a pooled analysis of SURPASS 1-5 studies, there was a significant (p<0.001) but weak correlation (r = 0.18 to 0.22) between change in body weight and SBP.

Conclusion: In conclusion, TZP induced SBP reduction was largely mediated through weight loss, with different degrees of contributions from weight loss independent effects across the different trials.

Disclosure: O. Mosenzon: Raptis1, I. Konomidou2; Kapodistrian University of Athens, Attikon University hospital, 2Second Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, AstraZeneca. Grants; AstraZeneca, Novo Nordisk. Lecture/other fees; AstraZeneca, Novo Nordisk, Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim.

559

Dapagliflozin improves arterial stiffness, myocardial performance and endothelial glycocalyx in patients with type 1 diabetes after four months treatment

V. Lambadiari1, A. Kountouri1, K. Katogiannis2, G. Pavlidis2, E. Korakas1, L. Plouta1, G. Kostelli1, K. Balamanis1, J. Thymis3, A. Raptis1, I. Konomidou2;
1Second Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Attikon University hospital, 2Second Cardiology Department, Medical School, National and Kapodistrian University of Athens, Attikon University hospital, Athens, Greece.

Background and aims: Patients with type 1 diabetes mellitus (T1DM) present signs of vascular and endothelial dysfunction earlier compared to healthy individuals. According to clinical studies, sodium-glucose-contrasporter-2 inhibitors (SGLT-2i) favorably affect cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM). However, the data regarding the efficacy of SGLT-2i on cardiovascular markers in patients with T1DM are scarce. We investigated the effects of dapagliflozin on endothelial and cardiovascular function in patients with T1DM.

Materials and methods: We recruited in total 30 patients with T1DM and four glycemic control who were under medication with insulin and receiving dapagliflozin (n=15) or intensification of insulin treatment (n=15) (control group). We measured at baseline and at four months post-treatment the: a) Carotid-femoral pulse wave velocity (PWV-Compilior; ALAM Medical) b) Central systolic blood pressure (cSBP) c) Pulsed boundary region (PBR) of the sublingual arterial microvessels (marker of endothelial glycocalyx thickness) and d) Left ventricular global longitudinal strain (GLS) using speckle-tracking echocardiography.

Results: At baseline, patients among the two groups had similar age, sex, HbA1c and markers of endothelial and cardiovascular function (p>0.05). After four months treatment, patients who received dapagliflozin displayed an improvement in PWV (10.72±3.28 vs 9.58±3.35 m/s, p=0.020), in cSBP (127±17 vs 119±12 mmHg, p=0.041), in GLS (-19.74±1.94 vs -20.70±1.54, p=0.022) and in PBR (2.02±0.28 vs 1.74±0.2, p=0.022) compared to baseline. However, we did not observe any statistically significant change in PVW (10.19±3.28 vs 10.38±3.72 m/s, p=0.606), in cSBP (124±13 vs. 121±13 mmHg, p=0.364), in GLS (-19.76±1.28 vs -19.13±1.60, p=0.113) and in PBR (2.01±0.34 vs. 2.06±0.32, p=0.535) in control group. Changes of PBR after four months treatment with dapagliflozin correlated with a concomitant reduction of PWV and cSBP (p<0.05).

Conclusion: Four-months treatment with dapagliflozin improves endothelial glycocalyx and cardiovascular function in patients with T1DM, independently of glycemic control.

Disclosure: V. Lambadiari: None.

560

Impact of empagliflozin on insulin use in patients with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes: sub-analysis from EMPEROR-Preserved trial

J. Butler1, J.B. Green2, J. Rosenstock3, on behalf of the EMPEROR Trial Committees and Investigators;
1Baylor Scott & White Health, Dallas, 2Duke University School of Medicine, Durham, 3Dallas Diabetes Research Center at Medical City, Dallas, USA.

Background and aims: Type 2 diabetes (T2DM) is highly prevalent among patients with heart failure (HF) and a preserved ejection fraction (HFpEF), often requiring insulin therapy. We assessed the impact of empagliflozin on the need for insulin, and on clinical outcomes according to insulin use in the EMPEROR-Preserved trial.

Materials and methods: Of the 5988 trial patients randomised to empagliflozin 10 mg or placebo, 2938 (49%) had T2DM and 1980 (33%) had preDM at baseline and were included in these analyses. We analysed the effects of empagliflozin vs placebo on time to first sustained insulin initiation (≥2 consecutive study visits) in patients with T2DM or preDM not using insulin at baseline. Further, we analysed the effect on the primary trial endpoint (first hospitalisation for HF [HHF] or cardiovascular [CV] death), first HHF, total HHF, and CV death in patients with T2DM at baseline according to baseline subgroups of insulin use. All time to event analyses were performed using Cox regression, and total HHF's was analysed by a Joint Frailty Model.

Results: At baseline, 861 patients (434 in empagliflozin, 427 in placebo) were using insulin. Compared with those not using insulin, patients on insulin were slightly younger (69.7 vs 71.5 years), had a longer DM duration (17.6 vs 9.4 years), lower eGFR (54.6 vs 61.9 ml/min/1.73 m²), and had more co-morbidities such as coronary artery disease (47.3 vs 38.0%) and macroalbuminuria (28.2 vs 11.2%). During a median observation time of 26 months, among patients with T2DM or preDM not using insulin at baseline, empagliflozin reduced the risk of sustained initiation of insulin by 31% (HR 0.69 [95% CI 0.49, 0.98], p=0.038). Among patients with T2DM, those using insulin at baseline had higher incidence rates of the primary endpoint, total HHF's and first HHF (p-values for comparison within the placebo group: 0.0001, <0.0001, and 0.0002, respectively) that were reduced by empagliflozin but still remained higher than in the placebo arm of those not using insulin (Figure). The beneficial effects of empagliflozin vs placebo on CV outcomes did not differ by baseline insulin use (Figure).

Conclusion: In EMPEROR-Preserved, empagliflozin reduced the rate of insulin initiation by 31% in patients with HFpEF and T2DM or preDM. Insulin-users at baseline were at significantly higher risk of adverse CV outcomes; still, the effects of empagliflozin on CV outcomes were consistent in patients with T2DM irrespective of insulin treatment.
Background and aims: Tirzepatide (TZP) is a dual GIP/GLP-1 receptor agonist under development for the treatment of type 2 diabetes (T2D). In the SURPASS-3 MRI substudy, people with T2D (metformin ± SGLT-2i, HbA1c 7-10.5%, BMI ≥25kg/m², fatty liver index value ≥60) were treated with once-weekly TZP 5 mg (N=71), 10 mg (N=79), 15 mg (N=72) or once-daily insulin degludec (IDeg) (N=74). Overall, TZP showed a mean weight loss of -9.6 kg at week 52 and concurrent reductions of visceral adipose tissue (VAT), abdominal subcutaneous adipose tissue (aSAT) and liver fat (LF) assessed by MRI, while people treated with IDeg experienced an overall weight gain (mean +3.2 kg) with increase in VAT and aSAT, and a smaller decrease in LF than TZP. The aim of the current study is to describe overall fat distribution pattern at baseline and week 52 and relate actual changes in fat depots to the changes predicted by the difference in two virtual controls groups (VCGs) matching baseline and 52-week data.

Materials and methods: For each study participant at baseline and week 52, a VCG of ≥150 participants with the same sex, and similar body size (height, weight, BMI) were identified from the UK Biobank imaging study (N=40,174). Expected levels of VAT, aSAT and LF and deviation from the expected levels (standardized normal z-scores (VAT z, aSAT z, LF z); units = standard deviation [SD]) were calculated based on individualized matched VCG. The z-score changes from baseline to week 52 were calculated to describe changes in fat distribution pattern, the magnitude of changes in VAT, aSAT and LF, and were compared to that described by the observed weight change.

Results: Baseline fat distribution pattern was similar across pooled TZP and IDeg arms. Compared to matched VCG, study participants had higher baseline VAT (mean (SD) VAT z=0.42 (1.23), p<0.001) and LF (LF z=1.24 (0.92), p<0.001) and LF (LF z=1.24 (0.92), p<0.001), but similar aSAT (aSAT z=-0.13 (1.11), p=0.083). People treated with TZP had a significant decrease in VAT z (-0.18 (0.58), p=0.001) and LF z (-0.54 (0.84), p<0.001) while aSAT z increased (0.11 (0.50), p=0.011), indicating greater loss of VAT and LF, and smaller loss of aSAT than predicted by their observed weight loss. Comparison with the matched VCG showed people treated with TZP on average lost 0.31 L more VAT (p<0.001), 5.64 percent points more LF (p<0.001) and 0.16 L less aSAT (p=0.018) than would be predicted by observed weight loss.

Conclusion: In people with T2D and a skewed fat distribution pattern characterized by higher VAT and LF compared to matched VCG, treatment with TZP resulted in a greater reduction of VAT and LF than would be predicted by observed weight loss alone, indicating a targeted and potentially beneficial shift in fat distribution pattern.
Background and aims: The effect of once-weekly s.c. semaglutide 2.4 mg on the risk of developing type 2 diabetes (T2D) in people with obesity is unknown. Using data from the Semaglutide Treatment Effect in People with obesity (STEP) programme (STEP 1 and STEP 4) we assessed the risk of developing T2D over 10 years.

Materials and methods: Weight management with semaglutide 2.4 mg vs placebo plus diet and exercise was assessed in participants with overweight or obesity in STEP 1 (68 weeks) and STEP 4 (20-week run-in on semaglutide 2.4 mg, 48-week randomised withdrawal). To determine the percentage chance of an individual developing T2D in the next 10 years, the 10-year T2D risk was calculated using Cardiometabolic Disease Staging (CMDS), which is a validated staging tool that uses Bayesian logistic regression of T2D risk factors including age, sex, race, BMI, triglycerides, HDL, blood pressure, and blood glucose, to predict an individual’s percentage risk of developing T2D in the next 10 years.

Results: In STEP 1 the 10-year risk scores of developing T2D after 68 weeks of treatment decreased from 18.2% to 7.1% with semaglutide 2.4 mg, and 17.8% to 15.6% with placebo (61% vs 13% reduction [p<0.01]; Figure). In STEP 4, most of the risk score reduction with semaglutide 2.4 mg occurred during weeks 0-20, from 20.6% to 11.4%; risk score decreased further to 7.7% with continued semaglutide 2.4 mg during weeks 20-68 but increased to 15.4% with switch to placebo (32% reduction vs 41% increase [p<0.01]; Figure). In STEP 1, week 0 risk scores were higher in participants with prediabetes vs normoglycaemia (Figure), but treatment effects were comparable at week 68 (p=0.45 for interaction in both groups). In STEP 1, risk score changes mirrored weight loss, which was 17% with semaglutide 2.4 mg vs 3% with placebo. In STEP 4, weight loss was 11% for weeks 0-20 with semaglutide 2.4 mg, and a further 9% with continued semaglutide 2.4 mg vs a 6% regain with switch to placebo for weeks 20-68.

Conclusion: In summary, treatment with semaglutide 2.4 mg reduces the 10-year risk of T2D by ~60% regardless of initial glycaemic status, with sustained treatment required to maintain this benefit. These data suggest semaglutide 2.4 mg could help prevent T2D in people with obesity.
565 Changes in abdominal fat and clinical/analytical parameters in tirzepatide- or insulin degludec-treated patients with type 2 diabetes (SURPASS-3 MRI)

A. Gastaldelli, K. Curi, L. Fernández Landó, R. Bray, A. Torcello-Gómez, B. Brouwers, Á. Rodríguez

1Institute of Clinical Physiology, CNR, Pisa, Italy, 2Division of Endocrinology, Diabetes and Metabolism, The University of Florida, Gainesville, USA, 3Eli Lilly and Company, Indianapolis, USA.

Background and aims: Tirzepatide (TZP), a novel dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced liver fat content and volumes of visceral and abdominal subcutaneous adipose tissue (VAT and ASAT) vs insulin degludec (IDeg) in a subpopulation of patients with type 2 diabetes (T2D) in the SURPASS-3 trial. Changes in several biomarkers associated with adipose tissue metabolism and clinical parameters and correlations with changes in abdominal fat were assessed herein.

Materials and methods: This randomised, double-blind, parallel study compared the effects of TZP 15 mg QW (N=45), semaglutide (SEMA) 1 mg QW (N=44) and placebo (PBO) (N=28) on energy intake (assessed by an ad libitum lunch), appetite (visual analog scale [VAS] ratings of hunger, satiety, prospective food consumption [PFC], and fullness) and body composition (air displacement plethysmography) at baseline and at 28 weeks of treatment.

Results: At 28 weeks, reductions in body weight from baseline were observed with TZP 15 mg (-11.2 kg) and SEMA 1 mg (-6.9 kg), and significantly differed between treatment groups (4.3 kg [95% confidence interval [CI]: -6.8, -1.9]; p<0.001). Reductions in fat mass from baseline were observed with TZP 15 mg (-9.7 kg) and SEMA 1 mg (-5.9 kg), and significantly differed between treatment groups (-3.8 kg [95% CI: -6.2, -1.4]; p=0.002). Energy intake reductions from baseline observed with TZP 15 mg (-348.4 kcal) and SEMA 1 mg (-284.1 kcal) did not differ between treatment groups (-64.3 kcal [95% CI: -160.3, 31.7]; p=0.187). TZP reduced overall appetite by increasing satiety with decreased PFC (all p<0.05). Appetite ratings did not differ between TZP and SEMA.

Conclusion: TZP achieved greater weight loss than SEMA 1 mg, a selective GLP-1 RA, mostly driven by fat mass loss. Significant and clinically meaningful reductions in fasting overall appetite and energy intake were observed with both TZP and selective GLP-1 RA. As appetite and energy intake reduction were not significantly different between treatments, additional mechanisms might contribute to the superior weight loss with TZP. Ongoing studies will further elucidate the mechanism of weight loss with TZP.

Clinical Trial Registration Number: NCT03951753


564 Tirzepatide reduces appetite, energy intake and fat mass in people with type 2 diabetes


1Eli Lilly and Company, Indianapolis, USA, 2Profil, Neuss, Germany, 3Faculty of Medicine, Academic Medical Center, Amsterdam, Netherlands.

Background and aims: Tirzepatide (TZP), a dual GIP and GLP-1 receptor agonist (RA) has shown superior improvement in glycaemic control and body weight, than selective GLP-1 RA. Rodent models indicate that GIP RA augments GLP-1 RA induced food intake suppression and causes body weight loss, mainly by reducing fat mass.

Materials and methods: This randomised, double-blind, parallel study compared the effects of TZP 15 mg QW (N=45), semaglutide (SEMA) 1 mg QW (N=44) and placebo (PBO) (N=28) on energy intake (assessed by an ad libitum lunch), appetite (visual analog scale [VAS] ratings of hunger, satiety, prospective food consumption [PFC], and fullness) and body composition (air displacement plethysmography) at baseline and at 28 weeks of treatment.

Results: At 28 weeks, reductions in body weight from baseline were observed with TZP 15 mg (-11.2 kg) and SEMA 1 mg (-6.9 kg), and significantly differed between treatment groups (-4.3 kg [95% confidence interval [CI]: -6.8, -1.9]; p<0.001). Reductions in fat mass from baseline were observed with TZP 15 mg (-9.7 kg) and SEMA 1 mg (-5.9 kg), and significantly differed between treatment groups (-3.8 kg [95% CI: -6.2, -1.4]; p=0.002). Energy intake reductions from baseline observed with TZP 15 mg (-348.4 kcal) and SEMA 1 mg (-284.1 kcal) did not differ between treatment groups (-64.3 kcal [95% CI: -160.3, 31.7]; p=0.187). TZP reduced overall appetite by increasing satiety with decreased PFC (all p<0.05). Appetite ratings did not differ between TZP and SEMA.

Conclusion: TZP achieved greater weight loss than SEMA 1 mg, a selective GLP-1 RA, mostly driven by fat mass loss. Significant and clinically meaningful reductions in fasting overall appetite and energy intake were observed with both TZP and selective GLP-1 RA. As appetite and energy intake reduction were not significantly different between treatments, additional mechanisms might contribute to the superior weight loss with TZP. Ongoing studies will further elucidate the mechanism of weight loss with TZP.

Clinical Trial Registration Number: NCT03951753

2.01% to -2.33%) vs IDeg (-13.2 mmol/mol [-1.21%]). At Week 52, TZP 10 and 15 mg significantly decreased triglycerides and increased HDL cholesterol vs IDeg (Table). All TZP doses increased adiponectin and decreased leptin levels vs IDeg and TZP 10 and 15 mg significantly (p<0.05) decreased Adipo-IR from baseline (Table). There were significant correlations (p<0.05) between changes in VAT or ASAT, respectively, and changes in weight (p=0.76/0.85), HbA1c (p=0.29/0.31), HDL cholesterol (p=0.21/0.25), and adiponectin (p=0.38/0.28) with TZP. Changes in ASAT were also significantly correlated (p<0.05) with changes in leptin (p=0.40), insulin (p=0.30), and HOMA-IR (p=0.22) with TZP. Changes in VAT were also significantly correlated (p<0.05) with changes in triglycerides (p=0.18) with TZP.

**Results:** In this subpopulation of the SURPASS-3 study, TZP demonstrated significant reductions in VAT and ASAT volumes vs IDeg, which were correlated with improvements in several biomarkers of adipose tissue dysfunction, weight, and HbA1c.

**Conclusion:** In this subpopulation of the SURPASS-3 study, TZP demonstrated significant reductions in VAT and ASAT volumes vs IDeg, which were correlated with improvements in several biomarkers of adipose tissue dysfunction, weight, and HbA1c.

**Clinical Trial Registration Number:** NCT03882970

**Supported by:** Eli Lilly and Company

**Disclosure:** A. Gastaldelli: Employment/Consultancy; Consultant for Inventiva. Honorarium; Eli Lilly and Company, Gilead Sciences, Novo Nordisk and Pfizer. Other; Boehringer Ingelheim and Novo Nordisk.

---

**566**

**Tirzepatide induces weight loss in patients with type 2 diabetes regardless of baseline BMI: a post hoc analysis of SURPASS-1 through SURPASS-5 studies**

**J.P.H. Wilding**, A.Y.M. Kwan, J.M. Maldonado, H. Wang, N. Rasouli

1University Hospital Aintree, Liverpool, UK, 2Eli Lilly and Company, Indianapolis, USA, 3University of Colorado School of Medicine, Denver, USA, 4University of North Carolina School of Medicine, Chapel Hill, USA.

**Background and aims:** Tirzepatide (TZP) is a novel once-weekly dual GIP and GLP-1 receptor agonist evaluated in patients with type 2 diabetes (T2D). Five Phase 3 SURPASS trials have demonstrated safety and shown robust efficacy of TZP in improvement of glycaemic control and body weight (BW) in adults with T2D. To understand whether the weight-lowering effects of TZP are dependent on baseline BMI, we conducted subgroup analyses of SURPASS-1 through 5.

**Materials and methods:** BW change in the BMI subgroups (Subgroup 1 [<27 or ≥27 kg/m²] and Subgroup 2 [<30: ≥30 to <35; ≥35 kg/m²]) at primary endpoint was assessed in patients while on treatment without rescue medication (efficacy estimand) in the modified intention-to-treat (mITT) population, defined as all randomised patients who received at least one dose of study drug.

**Results:** All TZP doses (5, 10, 15 mg) lowered BW in patients with T2D irrespective of baseline BMI in both subgroups (p<0.001). The weight reductions were generally dose-dependent and absolute weight change was generally greater in higher BMI categories. The changes in weight for Subgroup 1 are shown in Figure 1 (SURPASS-1 [S-1] vs placebo; SURPASS-2 [S-2] vs semaglutide 1 mg, add-on to metformin; SURPASS-3 [S-3] vs insulin degludec, add-on to metformin ± sulfonylurea; SURPASS-4 [S-4] vs insulin glargin ± metformin; SURPASS-5 [S-5] vs placebo, add-on to insulin glargine ± metformin). In Subgroup 2, the changes in weight for participants with baseline BMI <30 kg/m² (S-1 through S-5) ranged from -5.4 kg to -5.9 kg (TZP 5 mg), -7.0 kg to -8.9 kg (TZP 10 mg), -7.5 kg to -11.2 kg (TZP 15 mg), and -5.2 kg to +3.0 kg (comparators); with baseline BMI 30 to <35 kg/m² (S-1 through S-5) ranged from -6.6 kg to -8.0 kg (TZP 5 mg), -8.0 kg to -9.8 kg (TZP 10 mg), -8.2 kg to -12.8 kg (TZP 15 mg), and -6.1 kg to +2.5 kg (comparators); with baseline BMI ≥35 kg/m² (S-1 through S-5) ranged from -6.4 kg to -10.2 kg (TZP 5 mg), -7.8 kg to -12.9 kg (TZP 10 mg), -10.8 kg to -15.5 kg (TZP 15 mg), and -6.9 kg to +2.5 kg (comparators).

**Conclusion:** TZP-treated patients with T2D experienced weight loss across a spectrum of mean baseline BMI values in SURPASS-1 through -5 studies. The most frequent adverse events were gastrointestinal-related events that were mild to moderate in severity and occurred during the dose-escalation period.

---

**567**

**Effect of once-weekly semaglutide 2 mg vs 1 mg on HbA1c and body weight by baseline demographic subgroups: SUSTAIN FORTE post hoc analysis**

**J.P. Frias**, L. Bardtrum, Y. Hansen, I. Lingvay, S. Macura, N. Tentolouris, J.B. Buse

1Velocity Clinical Research, Los Angeles, USA, 2Novo Nordisk A/S, Søborg, Denmark, 3University of Texas Southwestern Medical Center, Dallas, USA, 4National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece, 5University of North Carolina School of Medicine, Chapel Hill, USA.

**Background and aims:** Once-weekly (OW) s.c semaglutide 1 mg is an effective treatment option for type 2 diabetes (T2D). However, in the SUSTAIN programme, 20-30% of patients did not reach a target HbA1c <7%. A higher dose of OW s.c. semaglutide was therefore explored in the SUSTAIN FORTE trial, in which superior HbA1c lowering and addition of body weight (BW) was demonstrated with the 2 mg vs the 1 mg dose of OW semaglutide: estimated treatment difference (trial product estimand) [95% CI] for HbA1c -0.23% [-0.36; -0.11] and BW -0.93 kg [-1.68; 0.18]. The safety and tolerability profile of the two doses were comparable. Previous analysis showed consistent efficacy across
dichotomous subgroups by HbA1c <9% or ≥9% and BMI <35 or ≥35 kg/m². This post hoc analysis evaluated the effect of semaglutide 2 mg vs 1 mg on glycaemic control and BW across a broader range of baseline demographic subgroups.

Materials and methods: SUSTAIN FORTE was a 40-week, randomised, double-blind, phase 3b trial. Participants with inadequately controlled T2D (mean baseline HbA1c 8.9% and BW 99.3 kg) on a stable dose of metformin alone or in combination with a sulphonylurea were randomised to receive semaglutide 2 mg (n=880) or 1 mg (n=881). HbA1c and BW changes from baseline to end-of-treatment were analysed in the full analysis set in the on-treatment without rescue medication period by ANCOVA (adjusting for either baseline HbA1c or BW) across the following baseline demographic subgroups: age, sex, diabetes duration, HbA1c, BMI, kidney function, background antihyperglycaemic medication and region. No adjustment for multiplicity was made.

Results: This post hoc analysis indicates that greater HbA1c reductions were provided by semaglutide 2 mg vs 1 mg generally across subgroups (Figure). Similar results were observed for BW (data not shown), an exception being the small subgroup of participants with moderately impaired kidney function (n=14), where semaglutide 2 mg did not provide greater BW reduction; thought to be a chance finding driven by a pronounced weight change in the semaglutide 1 mg arm. Except for BW reduction by kidney function subgroup, interaction test p-values indicated no significantly different treatment effect from one level of a subgroup to another.

Conclusion: OW semaglutide 2 mg improved glycaemic control and reduced BW to a greater extent than OW semaglutide 1 mg across baseline demographic subgroups. The results of this post hoc analysis reinforce semaglutide 2 mg as a valuable treatment option for a broad range of patients with T2D, and as a potential treatment intensification option for patients treated with OW semaglutide 1 mg.

568
Tirzepatide-induced weight loss in type 2 diabetes is independent of nausea, vomiting, or diarrhoea

H. Patel1, K. Khunti2, H.W. Rodbard3, H.S. Bajaj4, R. Bray1, Z. Kindrachuk1, A. Rodriguez5;
1Eli Lilly and Company, Indianapolis, USA, 2Diabetes Research Centre, University of Leicester, Leicester, UK, 3Endocrine and Metabolic Consultants, Rockville, USA, 4LMC Diabetes and Endocrinology, Brampton, Canada, 5Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Canada.

Background and aims: Tirzepatide (TZP), a novel dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist, demonstrated superior reduction in HbA1c, and body weight vs comparators in participants with type 2 diabetes (T2D) across the SURPASS 1-5 randomised clinical trials. The most common adverse events (AEs) in TZP-treated participants were gastrointestinal (GI) in nature. This post hoc analysis evaluated the impact of nausea, vomiting, or diarrhoea AEs on weight loss with TZP across the SURPASS 1-5 trials.

Materials and methods: The phase 3 SURPASS 1-5 trials included participants with T2D (drug-naïve or on background antihyperglycaemic medications). Trial participants were randomised (1:1:1:1, except in SURPASS-4 with 1:1:1:3 randomisation) to once-weekly TZP (5, 10, or 15 mg) or comparator (placebo, semaglutide 1 mg once weekly, or titrated daily basal insulins). Participants within trials were subdivided by self-reporting (yes/no) of any nausea, vomiting, or diarrhoea. Change from baseline in body weight at the primary endpoint was assessed within each trial and subgroup. Mediation analyses were conducted to evaluate the contribution of direct and indirect (mediated by nausea, vomiting, or diarrhoea) effects of TZP on weight change vs comparators.

Results: Across the SURPASS 1-5 trials (SURPASS 1, N=475; SURPASS 2, N=1876; SURPASS 3, N=1435; SURPASS 4, N=1989; SURPASS 5, N=471), 19%-36% of TZP-treated participants reported nausea, vomiting, or diarrhoea vs 5%-26% of those in the comparator arms. Mean weight loss at the primary endpoint with TZP was similar in participants reporting nausea, vomiting, or diarrhoea (-6.16 to -14.86 kg) vs those who did not report these GI AEs (-6.17 to -13.29 kg). Mediation analyses (Figure) suggest that the estimated treatment difference (ETD) of change from baseline in weight (95% confidence interval [CI]) favoured all doses of TZP (total and direct effects). The contribution of nausea, vomiting, or diarrhoea (indirect effects) to TZP-induced weight loss was minimal (Figure), if any, representing ≤5% of the total effect across all trials. In some instances, TZP vs comparators led to slightly greater weight loss in participants without GI AEs compared with those reporting GI AEs, leading to positive ETD values for indirect effects (Figure).

Conclusion: Superior weight loss with TZP appears to be independent of reported nausea, vomiting, or diarrhoea AEs across the SURPASS 1-5 clinical trials.
SO 41 Incretins: basic science

569

Comprehensive characterisation of the human gain-of-function GLP-1r variant Ala316Thr in pancreatic beta cells

L. El Eid1, R.-M. Rujan2, G. Deganuzzi2, B. Jones3, C. Reynolds2, A. Tomas1;

1Section of Cell Biology and Functional Genomics, Imperial College London, 2Centre for Sport, Exercise and Life Sciences, Faculty of Health and Life Sciences, Coventry University, 3Section of Endocrinology and Investigative Medicine, Imperial College London, London, UK.

Background and aims: The glucagon-like peptide-1 (GLP-1) is an important pharmacological target for type 2 diabetes (T2D) due to its insulinotropic effects on pancreatic beta cells and weight lowering actions. GLP-1R action, including signalling and trafficking is modulated by factors such as ligand bias and single nucleotide polymorphisms (SNPs) that alter receptor structure. Here we comprehensively characterise the effect of the GLP-1R missense mutation Ala316Thr (A316T), associated with reduced T2D risk, in pancreatic beta cells by performing atomic level conformational modelling, signalling, and trafficking analyses of the mutant compared to wild type receptor.

Materials and methods: We utilised confocal microscopy and high-content microscopy assays to determine differences in cell surface expression and agonist-induced trafficking responses of wild type versus Thr316GLP-1Rs in INS-1 832/3 rat pancreatic beta cells, while molecular dynamic (MD) simulations was used to model the conformational space of GLP-1R. We additionally used NanoBiT complementation assays to determine total and endosomal Gαs coupling and β-arrestin2 recruitment propensities for the endogenous agonist GLP-1 as well as the stable analogue exendin-4, and closely related and oppositely biased agonists exendin-phe1 and exendin-asp3.

Results: Consistent with previous studies in HEK and CHO cells, the A316T mutation led to a significant loss of cell surface receptor expression in beta cells (p=0.0114). Moreover, MD simulations revealed that the mutant receptor exhibits altered mobility and flexibility of the extracellular domain (ECD) and important transmembrane regions pre-and post-activation, distinct to each agonist-bound state. Results also revealed a significant decrease in receptor recycling (p=0.0431), associated with increased internalisation (p=0.024) and degradation (p=0.0323) upon GLP-1 binding. We also demonstrate significantly augmented mini-Gαs recruitment in response to GLP-1 (p=0.0002), exendin-4 (p=0.0019), exendin-phe1 (p=0.0386), but not for the β-arrestin biased agonist exendin-asp3 by the Thr316 variant versus the wild type. Strikingly, the variant also exhibits significantly increased efficacy (p=0.0083) and potency (p=0.0281) for endosomal over plasma membrane Gαs coupling compared to wild type receptors. Assessment of Gαs coupling vs β-arrestin2 recruitment propensities reveal that mutant receptors exhibit a significant bias towards Gαs coupling versus wild types in response to GLP-1 (p=0.0001), exendin-4 (p=0.0003), and exendin-phe1 (p=0.0001), but not with exendin-asp3 (p=0.5640).

Conclusion: The GLP-1R A316T polymorphism is a determinant of pharmacological responses to GLP-1R-targeting compounds, including biased agonists, with varying responses associated to differentially biased compounds. The mutation causes significant changes in receptor conformational dynamics, signalling, and trafficking signatures highlighting the importance of the precise molecular characterization of GLP-1R variants to predict individual responses to specific GLP-1R therapies.

Disclosure: L. El Eid: None.
Background and aims: Obesity is a serious global health challenge with a need for safe and effective pharmaceutical interventions. GCG and GLP-1 are peptide hormones that regulate body weight by increasing energy expenditure and reducing energy intake, respectively. We describe the structural properties and pharmacology of the novel GCGR/GLP-1R dual agonist BI 456906.

Materials and methods: In vitro potency of BI 456906 for the GCGR and GLP-1R was determined in cells of recombinant and endogenous receptor expression and in hepatocytes and islets for functional agonism based on glycogen synthesis inhibition and insulin secretion, respectively. In vivo, GLP-1R engagement by BI 456906 was assessed in lean mice for food intake, gastric emptying, and oral glucose tolerance. Subchronic efficacy of BI 456906 on body weight and energy expenditure was investigated in diet-induced obese (DIO) mice. Simultaneous engagement of the GLP-1R and GCGR in vivo was demonstrated in CRE-Luc reporter mice. Liver mRNA sequencing was combined with a computational biology approach to generate mechanistic understanding of GCGR agonism by BI 456906.

Results: BI 456906 is a 29-amino acid peptide designed based on the glucagon sequence. Its in vivo half-life was optimized by integration of an unnatural amino acid and a glycine-serine linker containing a C18 di-acid. BI 456906 on body weight and energy expenditure was investigated in diet-induced obese (DIO) mice. Simultaneous engagement of the GLP-1R and GCGR in vivo was demonstrated in CRE-Luc reporter mice. Liver mRNA sequencing was combined with a computational biology approach to generate mechanistic understanding of GCGR agonism by BI 456906.

Conclusion: BI 456906, structural properties and pharmacology of the novel glucagon and glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist

R. Augustin1, T. Zimmermann1, L. Thomas1, T. Baader-Pagler1, P. Haebel1, E. Simon1, H. Klein1, R. Santhanam1, W. Reindl1, B. Bajrami1, W. Rist1, I. Uphues1, D. Hamprecht2, H. Neubauer4; 1Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, 2Pharmaxis Ltd, Frenchs Forest NSW, Australia.

Disclosure: R. Augustin: None.
with 7-fold higher AUC0-24 peripheral distribution and 6-fold lower brain kg PO BID) demonstrated similar weight loss (-16.5%) to rimonabant but demonstrated a 24-fold decrease in C max and 50-fold decrease in brain/tirzepatide dose). Blood and liver were collected at end of study.

Materials and methods: The DIO mouse model, C57BL/6J mice were fed a continuous high fat diet for 22 weeks and during 28 days of treatment. CRB-913 and rimonabant brain exposure were determined in both DIO mice (CRB-913 BID PO for 28-day at 2.5 mg/kg or 5 mg/kg and rimonabant at 10 mg/kg PO QD) and lean mice (single dose CRB-913 and rimonabant at 10 mg/kg PO). Control, single agent CRB-913 (BID PO at 2.5 mg/kg or 5 mg/kg) and combination cohorts with semaglutide (Q3D SC at 0.04 mg/kg or 0.12 mg/kg) or tirzepatide (0.024 mg/kg), CRB-913 (2.5 mg/kg) led to additive weight loss in independent of a blood glucose lowering effect in a type 1 diabetes rat model. Liraglutide treatment attenuates inflammation markers in the cardiac, cerebral and renal microvasculature in streptozotocin-induced diabetic rats

Background and aims: Diabetes mellitus (DM) induces cardiac and cerebral microvascular dysfunction via increased glycation, oxidative stress and endothelial activation. Liraglutide, a glucagon-like peptide-1 receptor analogue, inhibited the reactive oxygen species producing enzyme NOX2 and adhesion molecules in isolated endothelial cells. Here we have studied how Liraglutide affects advanced glycation, NOX expression and inflammatory status of the cardiac and cerebral microvasculature in vivo in diabetic rats.

Materials and methods: DM was induced in Sprague Dawley rats (n=15) via intraperitoneal streptozotocin (STZ) injection (60 mg/kg body weight). 10 control rats remained non-diabetic. From day 9 post-STZ injection, Liraglutide (200 μg/kg bodyweight; n=7) or vehicle (n=8) was injected subcutaneously daily until termination on day 29. The advanced glycation end-product Nε-(carboxymethyl)lysine (CML), NOX2, NOX4, ICAM-1 and VCAM-1 were subsequently analysed using immunohistochemistry and quantified to compare Liraglutide treatment to placebo.

Results: DM increased CML, NOX2, ICAM-1 and VCAM-1 in the intramyocardial vasculature, although not significant for NOX2. NOX4 was not significantly increased in the ventricles and absent in the atria. In the cerebral vasculature, CML, NOX2 and NOX4 were significantly increased, but not ICAM-1 and VCAM-1. DM significantly increased ICAM-1 and VCAM-1 positive vessels in the kidney, as well as the percentage of ICAM-1 and VCAM-1 positive glomeruli. Liraglutide significantly reduced the DM-associated CML accumulation and expression of NOX2, ICAM-1 and VCAM-1 in the intramyocardial, and CML, NOX2 and NOX4 in the cerebral vasculature. In the renal vasculature, Liraglutide significantly decreased the percentage of VCAM-1 positive glomeruli. Liraglutide had these effects without changing blood glucose levels or body weight.

Conclusion: Our study implies that Liraglutide protects the cardiac, cerebral and renal microvasculature against diabetes-induced dysfunction, independent of a blood glucose lowering effect in a type 1 diabetes rat model.
Background and aims: Dual amylin and calcitonin receptor agonists (DACRAs) are novel candidates for treatment of obesity and type 2 diabetes (T2D) due to their beneficial effects on both body weight, glucose control and insulin action. However, the extent to which they protect the cardio-renal system against damage remains unknown. Here we utilize biomarkers of cardiovascular and kidney damage to characterize the potential of a novel long-acting DACRA as treatment for obesity, T2D and related comorbidities.

Materials and methods: Rat models of both T2D (ZDF) and high fat diet (HFD) induced obesity were treated with the long-acting DACRA KBP to assess the effect on body weight, food intake, fasting glycemia, HbA1c levels as well as glucose tolerance. Furthermore, serum biomarkers of cardiovascular disease (PRO-C6) and kidney complications (Tumstatin) were evaluated to assess the impact of DACRA treatment on these important co-morbidities.

Results: In HFD rats, chronic treatment with KBP resulted in reduced food intake (p<0.01), a significant body weight loss (p<0.001) and improved glucose tolerance (p<0.001). In diabetic ZDF rats, KBP treatment improved glucose control and preserved plasma insulin compared to vehicle (p<0.001), which was reflected in the HbA1c levels at study end (p<0.001). Importantly, the marker of cardiovascular disease, PRO-C6 (endotrophin, a marker of collagen type VI formation) increased during the study in the vehicle treated rats reflecting the disease progression, while KBP treatment attenuated this increase resulting in significantly lower PRO-C6 levels compared to vehicle at study end (p<0.05).

Similarly, the marker of kidney damage TUM (tumstatin, a matrikine derived from collagen type IV α3) was also increased over time in the control group, and KBP-treatment led to normalization hereof (p<0.05).

Conclusion: These preclinical studies confirm that long-acting DACRAs have beneficial effects on weight and glucose control, but more importantly also show highly relevant effects on biomarkers associated with cardiovascular and kidney complications. Taken together, these findings highlight KBP as a promising treatment of these late complications related to T2D and obesity.

Disclosure: Supported by: The work was supported by the Danish Research Foundation (SAM) and the Innovation Fund Denmark (ATL). A.T. Larsen: Employment/Consultancy: All authors are employed by Nordic Bioscience A/S. Grants: The studies were funded by grants from the Danish Research Foundation (Den Danske Forskningsfond) and the Innovation Fund Denmark. Stock/Shareholding: Morten A. Karsdal and Kim Henriksen own stock in Nordic Bioscience A/S.
cells transfected with CIRL1, BW-GLP-1 was without effect in assays of cAMP and Ca\(^{2+}\).

**Conclusion:** BW-GLP-1 fails to signal through CIRL1 but is a GLP-1R agonist with insulin secretagogue properties when tested using human islets. The hybrid peptide AL07 is also a GLP-1R agonist, thereby demonstrating that amino acid motifs present within alpha-latrotoxin can be exploited for construction of novel peptides with GPCR activating properties.

Supported by: NIH/NIDDK R01DK128443

Disclosure: G.G. Holz: None.

---

576

**Empagliflozin protects from diet-induced obesity, insulin resistance and hepatic steatosis in mice**

B. Radlinger\(^{1,2}\), C. Resl\(^{1,2}\), S. Folie\(^{1,2}\), K. Salzmann\(^{1,2}\), W. Salvenmoser\(^{1}\), M. Graber\(^{4}\), J. Hirsch\(^{4}\), J. Holfeld\(^{4}\), C. Kremser\(^{1,2}\), P. Moser\(^{6}\), G. Staudacher\(^{1,2}\), T. Jelenik\(^{2}\), M. Roden\(^{2,6}\), H. Tilg\(^{1}\), S. Kasel\(^{1,2}\);

\(^{1}\)Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria, \(^{2}\)Christian Doppler Laboratory for Metabolic CROStalk, Innsbruck, Austria, \(^{3}\)Institute of Zoology and Center of Molecular Biosciences Innsbruck (CBMI), Innsbruck, Austria, \(^{4}\)Department of Cardiac Surgery, Medical University Innsbruck, Innsbruck, Austria, \(^{5}\)Department of Radiology, Medical University Innsbruck, Innsbruck, Austria, \(^{6}\)Innpath GmbH, Innsbruck, Austria, \(^{7}\)Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, \(^{8}\)Department of Endocrinology and Diabetology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.

**Background and aims:** Chronic overnutrition, obesity, insulin resistance and ultimately type 2 diabetes are a major global health problem. We hypothesize that SGLT2 inhibition might be beneficial in a preventive setup to ameliorate metabolic dysregulation induced by a western-type diet.

**Materials and methods:** C57Bl/6 mice were fed a western type diet with (WDE) or without (WD) empagliflozin added to the diet. To control for diet-specific effects a standard diet with (SDE) and without empagliflozin (SD) was used. After 10 weeks metabolic phenotyping including assessment of insulin sensitivity via hyperinsulinemic euglycemic clamps, histological analysis of liver tissue samples, analysis of hepatic insulin signaling and analysis of skeletal muscle mitochondria was performed.

**Results:** Addition of empagliflozin for 10 weeks prevented significant overweight in WDE mice (mean weight 39.4 g (WD) vs. 32.7 g (WDE), p=0.0001). WDE mice were hyperglycemic and hyperinsulinemic compared to WD mice (mean blood glucose 215.3 mg/dl (WD) vs. 171.3 mg/dl (WDE), p=0.0147; median insulin 1.02 ng/ml (WD) vs. 0.56 ng/ml (WDE), p=0.0191). Confirmatory, hyperinsulinemic euglycemic clamps revealed increased insulin sensitivity in WDE mice (mean glucose infusion rate 28.01 mg/kg/min (WD) vs. 45.97 mg/kg/min (WDE), p=0.0384). Addition of empagliflozin was associated with less hepatic steatosis in WDE mice compared to WD mice (median steatosis score 1.8 (WD) vs. 0.2 (WDE), p=0.0341; median liver triglyceride content 39.4 µg/ml (WD) vs. 14.1 µg/ml (WDE), p=0.0504). S473 AKT phosphorylation was nearly twice as high in WDE mice compared to WD mice indicating increased hepatic insulin sensitivity (median p-AKT / total AKT ratio 0.785 a.u. (WD) vs. 1.675 a.u. (WDE), p=0.0065). Finally, skeletal muscle citrate synthase activity was increased in WDE mice compared to WD mice indicating a larger mitochondrial mass (mean citrate synthase activity 7.126 µmol/ml/min (WD) vs. 9.560 µmol/ml/min (WDE), p=0.0123). Transmission electron microscopy revealed larger mitochondria in WDE and SDE mice compared to WD and SD respectively (median area in type 2 skeletal muscle fiber / individual subsarcolemmal mitochondrion 0.1990 µm\(^2\) (WD) vs. 0.3170 µm\(^2\) (WDE), p=<0.0001; 0.1360 µm\(^2\) (SD) vs. 0.2460 µm\(^2\) (SDE), p=<0.0001).

**Conclusion:** SGLT2 inhibition with empagliflozin prevented diet induced overweight, hepatic steatosis and insulin resistance in C57Bl/6 mice after 10 weeks on a western-type diet. Diet independent effects on skeletal muscle mitochondria might contribute to metabolic effects.

Supported by: Austrian BMDW, Austrian FTE, Boehringer Ingelheim

Disclosure: B. Radlinger: None.
Patients with type 2 diabetes present similar immunological response to COVID-19 BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech) with healthy subjects: a prospective cohort study

Background and aims: If a compromised immune response to SARS-CoV-2 is probably a reason for the increased risk for severe COVID-19 in patients with type 2 diabetes mellitus (T2DM), the question whether these patients do also face an impaired immunological response to vaccination is crucial. The aim of this study was to compare the kinetics of neutralizing antibodies (NAbs) against SARS-CoV-2 after vaccination with BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech) between patients with T2DM and healthy controls.

Materials and methods: This is a single-center prospective cohort study. NAbs levels after BNT162b2 mRNA vaccination were compared between 50 patients with non-insulin treated T2DM (42% men) and 50 age, gender and body mass index (BMI) matched healthy controls (44% men) from the day of the first dose until a period of up to three months after the second dose. NAbs against SARS-CoV-2 were quantified using an FDA approved method (ELISA, cPassTM SARS-CoV-2 NAbs Detection Kit; GenScript, Piscataway, NJ, USA). The median age of both groups was 70 years, and the median BMI value was 29.7 kg/m2 and 27.6 kg/m2 for the T2DM and control group, respectively.

Results: At day 1, the mean NAbs of the control and T2DM groups were 11.13% and 13.82%, respectively (p value=0.926), indicating that participants in both groups started from the same baseline values. Three weeks later, just before the second vaccination dose, the mean NAbs values were 34.39% in the control group and 37.14% in participants with T2DM (p value=0.698). One month after the second vaccination, mean NAbs values increased to 95.12% in the control group and 95.66% in the T2DM group. Three months after the second vaccine dose, the mean inhibitory titers decreased to 90.48% (control group) and 82.56% (T2DM group). It is worth noting that 3 months after the second vaccination, 48 subjects (96%) in the control group and 46 patients with T2DM (92%) were still highly or very highly protected. On all occasions, no significant difference was found between the two groups (all p values>0.05).

Conclusion: This study provided evidence that patients with T2DM present similar immunological response to COVID-19 BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech) with healthy subjects.

Disclosure: S. Paschou: None.

Clinically relevant predictors of cardiovascular events in patients with type 2 diabetes: a pooled analysis from clinical studies

Background and aims: Patients with type 2 diabetes mellitus (T2DM) are more likely to develop cardiovascular disease (CVD). This study aims to explore the association between several baseline parameters and risk of cardiovascular (CV) events in patients with T2DM and whether evidence from clinical data at T2DM onset could be useful in identifying patients at risk of subsequent CV events.

Materials and methods: Data for baseline visits were extracted from 34 globally conducted clinical studies. The CV risk at baseline was assessed using Framingham risk equation.

Results: At baseline, 2130 (13.6%) patients from the total pooled population (n=18,076) had CV history. The mean (SD) age of the patients was 56.8 (10.7) years, and the total cholesterol, low-density lipoprotein (LDL) and the systolic blood pressure (SBP) was 196.4 (41.0) mg/dL, 115.4 (36.8) mg/dL and 132.7 (14.6) mmHg, respectively. The disease duration was 5.08 (5.10) years, and the Framingham risk score (FRS) was 20.71 (12.68). Patients with none or multiple risk factors had an incremental risk for subsequent CV events. Patients having CV history and FRS ≥20% were significantly associated with a higher risk of CV events (HR [95% CI]: 7.8 [5.0, 12.3]; p<0.001; Figure).

Conclusion: Overall, these findings show that clinical data collected at the onset and follow-up of T2DM, such as CV history, high LDL and SBP, may aid in identifying patients at high risk of subsequent CV events.

Supported by: Novartis

Dramatic changes in use of glucose-lowering drugs in Denmark from 2005 through 2021: a nationwide study

T. Vilsbøll1, J.H. Andersen2, J. Søndergaard1, R.W. Thomsen1, A. Pottegaard2;

1Clinical Research, Steno Diabetes Center Copenhagen, University of Copenhagen, Copenhagen, 2Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense.

Background and aims: The landscape of available type 2 diabetes pharmacotherapy has changed dramatically over the last one-and-a-half decade. We investigated changes in use patterns of glucose-lowering therapy in Denmark during 2005 through 2021.

Materials and methods: Nationwide population-based drug utilization study based on prospective medical databases covering the entire Danish population (~5.8 million). We assessed incident and prevalent use patterns among the 441,205 individuals using at least one non-insulin glucose-lowering drug 2005-2021. Drugs with a primary weight loss indication were excluded.

Results: The rate of new users of glucose-lowering drugs increased from 2005, peaked in 2011, and decreased to a stable level during 2013-2019 and finally increased dramatically in 2020-2021. In parallel, the total prevalence of use increased steadily from 2.1% in 2005 to 5.0% in 2021 of the entire adult population. Metformin comprised 39% of all glucose-lowering drug consumption in 2021 followed by insulin (17%), sodium-glucose cotransporter-2 inhibitors (SGLT2i) (17%), glucagon-like peptide 1 receptor agonists (GLP-1RA) (16%), and dipeptidyl peptidase 4 inhibitors (7.5%) (Figure, upper panel). Overall, in 2021 57% were on monotherapy, 28% used dual therapy while 12% and 2.4% used three and four drug classes, respectively. Both intensity and diversity of therapies increased substantially over time, with 15 different treatment regimens each covering >1% of users in 2021, an increase from 5 regimens in 2005. General practitioners prescribed 88% of all glucose-lowering drugs in 2021. The distribution of first-line treatments (Figure, bottom panel) initiated by general practitioners versus hospital physicians changed over time, with dramatic changes in initiation of especially GLP-1RAs (general practitioners) and SGLT-2i (hospital physicians) in 2021.

Conclusion: The rate of new users of glucose-lowering drugs is increasing in recent years and the total prevalence of glucose-lowering drug use also increases steadily. Glucose-lowering drugs are mainly prescribed by general practitioners and both the intensity and diversity of glucose-lowering treatment is increasing, with recent dramatic changes in prescribing of GLP-1RAs and SGLT-2i.

Disclosure: T. Vilsbøll: Grants; Novo Nordisk, Lilly, Boehringer. Honorarium; Amgen, Boehringer, BMS, GSK, Gilead, Mundipharma, Novo Nordisk, Lilly, Sun Pharmaceuticals.

Higher adherence and persistence for dulaglutide compared to oral semaglutide at 6-months follow-up with U.S. real-world data

R. Paczkowski1, M.M. Hoog1, J. Peleshok1, M. Yu1, A. Huang2, B. Linone3, J. Manjelievskaya4;

1Eli Lilly and Company, Indianapolis, 2Tigermed-BDM, Somerset, 3IBM Watson Health, Cambridge, USA.

Background and aims: A retrospective, observational analysis of administrative claims data from the IBM MarketScan Databases assessed adherence and persistence among GLP-1 RA naive adult patients with type 2 diabetes (T2D) newly initiating dulaglutide (DU) or oral semaglutide (OS) between Sept 2019 and Nov 2020.

Materials and methods: Patients had continuous enrolment in the 6-month pre-index period and 6-month follow-up periods. The DU patients were propensity-score matched 1:1 to OS patients (6,166 pairs). The median age was 54 years at index date, and 48% were female. At pre-index, mean aDCSI was 0.6 and 10% of patients had ASCVD. Most patients used oral anti-hyperglycaemic medication (87%); a smaller proportion used insulin (15%). The most common prescribing provider was primary care (62%).
Results: More DU patients were adherent (proportion days covered [PDC] ≥80%) (65% vs. 50%, p<0.001) and had higher mean PDC vs. OS (0.78 vs. 0.68, p<0.001). More DU patients were persistent on therapy compared to OS patients (72% vs. 57% p<0.001) and had longer mean duration of persistence (148 vs. 128, p<0.001). Among patients with ≥2 fills of their index drug, 73% of DU and 62% of OS patients were adherent.

Conclusion: During the 6-mo follow-up period, DU patients had significantly higher adherence and persistence compared to OS patients.

Table: Adherence and persistence at 6-months follow-up among patients stratified by adherence rate and gestational age

| Table 1: Adherence and persistence at 6-months follow-up among patients stratified by adherence rate and gestational age
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Time (Month)</td>
<td>N (DU)</td>
<td>N (OS)</td>
<td>N (DU)</td>
</tr>
<tr>
<td>1st trimester</td>
<td>205</td>
<td>192</td>
<td>163</td>
</tr>
<tr>
<td>2nd trimester</td>
<td>201</td>
<td>190</td>
<td>160</td>
</tr>
<tr>
<td>3rd trimester</td>
<td>200</td>
<td>190</td>
<td>160</td>
</tr>
</tbody>
</table>

Conclusion: Use of metformin in pregnant women with polycystic ovarian syndrome (PCOS): a cohort study in the United Kingdom

581

Use of metformin in pregnant women with polycystic ovarian syndrome (PCOS): a cohort study in the United Kingdom
K. Brand, C. Foch, E. Boutmy; Merck Healthcare KGaA, Darmstadt, Germany.

Background and aims: International guidelines support the use of metformin for PCOS-related anovulatory infertility, although other treatment options may have better outcomes (Teede. Fertil. Steril. 2018). Likewise, in the UK, the National Health Services indicate that metformin may have better outcomes (Teede. Fertil. Steril. 2018). International guidelines support the use of metformin for PCOS-related anovulatory infertility, although other treatment options may have better outcomes (Teede. Fertil. Steril. 2018).

Materials and methods: A cohort of all pregnant women diagnosed with PCOS and with a last menstrual period (LMP) date between January 2005 and February 2019 was selected in the Clinical Research Practice DataLink (CPRD) and linked to the Pregnancy Registry. The CPRD is a UK database of anonymised medical records from general practitioners. Pregnancies were followed from the LMP date, through the earliest of end of pregnancy (whatever the termination event), or mother’s death.

Results: A total of 2,778 pregnancies were included. Median age was 30 years (q1, q3: 26, 33), and median BMI 30 kg/m² (25, 36). A total of 528 (19%) pregnancies had already experienced one recorded spontaneous abortion, and 178 (6.4%) at least two. In the 6-month prior the pregnancy, 151 (5.4%) were prescribed clomifene, 222 (8.0%) combined hormonal contraceptives, 114 (4.1%) oral progesterone-only contraceptives, and 329 (11.8%) antidepressants. Overall, 2,519 (90.7%) pregnancies resulted in live birth, 200 (7.2%) in spontaneous abortion, and 11 (0.4%) in stillbirth. Metformin was prescribed in 525 (18.9%) pregnancies: 405 (77.1%) were already treated in the periconceptional period (90 days prior LMP), 63 (12.0%), 14 (2.7%), and 43 (8.2%) initiated metformin during the 1st, 2nd and 3rd trimester, respectively. Among those treated in the periconceptional period, 276 (68.1%) were still exposed after. Metformin was discontinued prior pregnancy end in most of the cases (447 [85.1%]). The median number of prescriptions per pregnancy was 2 (1, 4), and pregnancies were exposed for a median of 100 days (5, 144). Table 1 displays results per trimester.

Conclusion: Use of metformin in pregnant women with polycystic ovarian syndrome (PCOS): a cohort study in the United Kingdom

582

Metformin and B12 deficiency: a retrospective study of the prevalence of B12 deficiency in patients on metformin
L. Young, R. Rasheed, H. Bibi; General Practice, Research & Medical Education, Chapel Street Surgery, Rigg Milner Medical Centre & Corringham Health, Tilbury, UK.

Materials and methods: Diabetic patients were identified from the SystmOne electronic clinical system disease registers. Their records were examined to assess the levels of vitamin B12 in patients prescribed metformin to assess the prevalence of B12 deficiency.

Results: Across a population of circa 10,000 patients there were n=718 diabetic patients with a practice prevalence of 7.18 % across three primary care sites versus a national prevalence of 7.1%. 500 consecutive patient records were examined to review their biochemistry. A total of 96 patients (19%) were B12 deficient and 84 of these patients (16.8%) had been prescribed metformin. Of these, 36 (7.2%) were currently still taking metformin, whereas 41(8.2%) had discontinued metformin due to side effects. The mean interval from starting metformin and developing B12 deficiency was 7.4 years, and this was a dose related effect as 27 patients (75%) were on a dose of 1.5g or higher at the time of their diagnosis. 51(60.7%) patients were male and 33(39.3%) were female. The mean age was 71.2 years with a standard deviation of 12.4 years. Also, we found 12 patients were B12 deficient but had never been on metformin, and 7 developed B12 deficiency prior to being prescribed metformin.

Conclusion: Metformin and B12 deficiency: a retrospective study of the prevalence of B12 deficiency in patients on metformin

583

Support by: Eli Lilly and Company
commencement of therapy of this potential side effect. B12 deficiency can co-exist in patients not on metformin. Awareness to screen for B12 deficiency is necessary to prevent iatrogenic harm from undetected B12 deficiency which could potentially cause neuropathy. This should be part of routine medication reviews and shared decision making in patients commenced upon this therapy.

Disclosure: L. Young: None.

583
HbA1c and weight changes with semaglutide at 6- and 12-months post commencement: updated results from the ABCD semaglutide audit

B.C.T. Field1, T.S.J. Crabtree2, K. Adamson3, D. Barnes4, S. Sivappriyan4, A. Bickerton5, A. Gallagher6, I.W. Gallen7, I. Idris8, R.E.J. Ryder9;
1Faculty of Medical and Health Sciences, University of Surrey, Guildford, 2University of Nottingham, Derby, 3St John's Hospital, Livingston, 4Maidstone & Tunbridge Wells NHS Trust, Kent, 5Yeovil District Hospital NHS Trust, Yeovil, 6University Hospitals of Leicester NHS Trust, Leicester, 7Royal Berkshire Hospitals NHS Trust, Reading, 8Diabetes & Endocrinology, Royal Derby Hospital, University Hospitals of Derby and Burton NHS Trust, UK, Derby, 9Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK.

Background and aims: Real-world outcomes derived from the previous UK nationwide ABCD glucagon-like peptide 1 receptor agonist audit have demonstrated significant HbA1c and weight improvements at first follow-up. Notably, individuals from this audit have higher HbA1c levels and weights than those recruited from randomised controlled trials, and hence more representative of routine clinical practice. We present updated analysis to report changes observed up to one year after commencing semaglutide.

Materials and methods: Data were extracted from the ABCD semaglutide audit and included relevant baseline and at least one set of follow-up data that had been recorded. Data were analysed at 6 and 12 months. Changes from baseline for HbA1c and weight were assessed using paired t-test and ANOVA between groups in Stata 16 SE. Additional stratified analyses by previous GLP1RA exposure were performed.

Results: Data for 1,652 individuals were extracted of which 797 had sufficient data for inclusion. Those included had mean±SD for: age 59.2±10.6 years; BMI ±7.3kg/m2 and eGFR 87±26mL/min/1.73m2. Median diabetes duration was 11.2 years (IQR 6.4-19.9). 49.8% were male. HbA1c was reduced by 4.1±-6.7, p<0.0001) at 6 and 12-months respectively. Where paired results were available, further weight reductions occurred between 6 and 12-months by 2.4kg (95% CI 1.4-3.3, p<0.0001). In the GLP1RA naïve, weight reductions were 2.2kg (95% CI 1.1-3.3, p<0.0001) greater at 6-months compared to those switched from an alternative GLP1RA drug. No statistical significance was noted between these groups at 12-months (p=0.07).

Conclusion: Our observational data suggest that HbA1c reductions associated with semaglutide observed in the first 6-months persist at one year. Weight appears to continue to be lost beyond the initial 6-month period. Although weight and HbA1c changes are smaller in those switched from alternative GLP1RA therapies to semaglutide at 6-months, for weight these differences diminish out to 12-months. Reasons for this are unclear and ongoing work will be needed to clarify this observation.

Supported by: The ABCD audits is supported by an unrestricted grant from NoveNordisk


584
Costs associated with healthcare resources utilisation among empagliflozin vs GLP-1RAs initiators in routine clinical care in Denmark

R.W. Thomsen1, L.W.B. Christensen1, J. Kahler1, J.S. Knudsen1, A. Ustuygoya2, S. Sandgaard3, P. Holmgaard4, L.H. Ehlers4, H.T. Sørensen5; 1Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, 2Boehringer Ingelheim International GmbH, Ingelheim, Germany, 3Boehringer Ingelheim A/S, Copenhagen, Denmark, 4Nordic Institute of Health Economics, Aarhus, Denmark.

Background and aims: The sodium-glucose cotransporter 2 inhibitor (SGLT2) empagliflozin has shown reductions in major adverse cardiac events (MACE) similar to glucagon-like peptide-1 receptor agonists (GLP-1RAs) in routine care in Denmark. There is limited evidence how these therapies compare regarding overall costs associated with healthcare resource utilization. We aimed to assess the total average healthcare costs per patient after drug initiation with empagliflozin versus GLP-1RAs in Denmark.

Materials and methods: Nationwide population-based comparative cohort study based on linked prospective healthcare databases for the entire population in Denmark (current population 5.8 million) during Jan 1, 2015, and to Dec 31, 2018. We included 13,249 new users of empagliflozin and 13,747 new users of GLP-1RAs. Propensity scores were applied to balance potential confounders across the two treatment groups through inverse probability treatment weighting (IPTW).

We assessed total average costs per year associated with all healthcare resource utilization (inpatient, emergency room, and outpatient clinic hospital care, primary care health services, and prescription medications costs at pharmacies) among drug initiators while on-treatment (i.e., while covered by filled drug prescriptions including a grace period of 60 days).

Results: The two IPTW cohorts were well-balanced at baseline (median age 61 years, 60% men, diabetes duration of 6.7 years, 19% with pre-existing ischemic heart disease, 8% with history of cerebrovascular disease). Healthcare costs in the year prior to drug initiation were also well-balanced. Mean follow-up on-treatment after initiation was 11.3 months (SD 9.8 months) in empagliflozin vs 12.3 (SD 10.9) months in GLP-1 RA initiators, with a total of 12,657 years of drug exposure with empagliflozin and 13,554 years with GLP-1RAs. Average costs per patient per year were very similar in empagliflozin and GLP-1 RA initiators regarding inpatient hospitalizations (13,565 DKK versus 13,275 DKK), hospital outpatient clinic visits (12,007 DKK versus 12,152 DKK), emergency room visits (370 DKK versus 399 DKK), and primary care services (4,108 DKK versus 4,302 DKK). Total costs of any prescription drugs were lower in empagliflozin initiators (8,946 DKK versus 14,029 DKK). Total healthcare costs on-treatment were lower in empagliflozin initiators at 38,995 DKK per person-year than in GLP-1 RA initiators at 44,157 DKK per person-year, respectively.

Conclusion: In this nationwide population-based study, average healthcare costs after drug initiation and while on treatment were lower for empagliflozin than GLP-1RAs initiators, driven by lower costs of prescription drugs.

Clinical Trial Registration Number: NCT03993132

Supported by: The study was a NIS study sponsored by Boehringer Ingelheim in collaboration with Aarhus University.

Disclosure: R.W. Thomsen: Grants; The study was a NIS study sponsored by Boehringer Ingelheim in collaboration with Aarhus University.
SO 43 Glucose lowering agents

585
Achievement of HbA1c ≤ 6.5% (47.5 mmol/mol), with ≥ 10% weight loss, without hypoglycaemia in patients treated with tirzepatide vs comparators in SURPASS program

J.A. Levine1, A. Cheng2, P. Choudhary3, I. Lingyay4, E. Gomez Valderas1, S.E. Allen1, K. Ranta1, V.T. Thieu1;
1 Eli Lilly and Company, Indianapolis, USA, 2 Department of Medicine, St Michael’s Hospital, Toronto, Canada, 3 Diabetes Research Centre, University of Toronto, Toronto, Canada, 4 Credit Valley Hospital, Michael’s Hospital, Toronto, Canada, 5 Department of Medicine, University of Texas Southwestern Medical Center, Dallas, USA.

Background and aims: In the phase 3 SURPASS studies tirzepatide (TZP), a novel dual GIP/GLP-1 receptor agonist in development for type 2 diabetes (T2D) treatment, 66-86% of TZP-treated participants achieved HbA1c ≤ 6.5% (47.5 mmol/mol) and 21-69% achieved ≥ 10% weight loss. Tirzepatide showed a similar safety profile to that of GLP-1 receptor agonists. The purpose of this post-hoc analysis was to compare the percentage of patients who achieved a composite endpoint of HbA1c ≤ 6.5% (47.5 mmol/mol) with ≥ 10% weight loss without hypoglycaemia in the SURPASS studies.

Materials and methods: We compared the proportion of participants achieving the triple endpoint between the tirzepatide (5, 10, or 15 mg) and respective comparator groups using the efficacy analysis dataset while patients are on treatment and without rescue medication. End of treatment HbA1c and weight were evaluated at week 40 (SURPASS-1, 2, 3) and week 52 (SURPASS-3, 4). Hypoglycaemia included blood glucose level ≤ 54 mg/dl. Missing endpoint measures were imputed by predictions using observed data in the efficacy analysis set from the same treatment group.

Results: More participants treated with any dose of TZP achieved the triple endpoint compared to placebo or active comparators in SURPASS 1-5 (FIG). As monotherapy, TZP treatment (5, 10, 15 mg) led to 25%, 36%, 44% of participants achieving the triple endpoint compared to 0% with placebo in SURPASS-1. As add-on to metformin, TZP treatment (5, 10, 15 mg) led to 33%, 50%, 59% achieving the same compared to 22% with basal insulin 1 mg in SURPASS-2. When compared to basal insulin, TZP treatment (5, 10, 15 mg) led to 33%, 50%, 64% achieving the triple endpoint compared to 3% with degludec (SURPASS-3; add-on to metformin) and when added to 1-3 oral antihyperglycemics, TZP treatment (5, 10, 15 mg) led to 28%, 44%, 53% achieving the triple endpoint compared to 1% with glargine U100 (SURPASS-4). Finally, as add-on to basal insulin, TZP treatment (5, 10, 15 mg) led to 16%, 35%, 40% achieving the triple endpoint compared to 1% with placebo in SURPASS-5.

Conclusion: Significantly more participants treated with TZP achieved a HbA1c ≤ 6.5% (47.5 mmol/mol) with ≥ 10% weight loss without hypoglycaemia than those treated with placebo, semaglutide, or basal insulin in SURPASS-1, 2, 3, 4, and 5 studies.

Clinical Trial Registration Number: NCT03954834/NCT03987919/NCT03882970/NCT03730662/NCT04039503
Supported by: Eli Lilly and Company
Disclosure: J.A. Levine: Employment/Consultancy; Joshua A. Levine is an employee and shareholder of Eli Lilly and Company.

586
Tirzepatide leads to significant improvement in postprandial glycaemic control in people with type 2 diabetes (SURPASS 1-5)

C.J. Lee1, E. Spanakiss1, R. Bray1, K. Brown1, L.K. Billings3, K. Chivukula1, A. Rodriguez2, F. Giorgino3;
1 Eli Lilly and Company, Indianapolis, USA, 2 University of Maryland School of Medicine, Baltimore, USA, 3 Department of Medicine, NorthShore University HealthSystem/University of Chicago Pritzker School of Medicine, Skokie, USA, 4 University of Bari Aldo Moro, Bari, Italy.

Background and aims: In people with type 2 diabetes (T2D), tirzepatide led to greater reductions in HbA1c, fasting blood glucose, and body weight versus active comparator or placebo in Phase 3 trials (SURPASS 1-5) and a higher percentage of Time in Range (3.9-10 mmol/L) (TIR) in a subpopulation of patients in SURPASS-3 with continuous glucose monitoring (CGM) data on tirzepatide vs insulin degludec. Tirzepatide showed a similar safety profile to that of GLP-1 receptor agonists. In this post hoc analysis, we aimed to assess the change in postprandial glucose excursion with tirzepatide vs comparators.

Materials and methods: Self-monitored blood glucose (SMBG) data were collected at baseline and at primary end point for patients randomized across SURPASS 1-5 (baseline characteristics; mean age 54.1-63.6 yrs, duration of T2D 4.7-13.3 yrs, HbA1c 7.9-8.5%/63.3-69.7 mmol/mol, bodyweight 85.9-95.2 kg, BMI 31.9-34.2 kg/m²). For tirzepatide groups vs. comparator, we compared the change from baseline in pre-meal to 2-hour postmeal excursion daily mean and the proportion of patients achieving 2-hour postprandial SMBG target goal of <10 mmol/L and euglycemic goal of <7.8 mmol/L. From the SURPASS-3 CGM substudy...
Results: Compared to active comparator or placebo, all three doses of tirzepatide led to significant improvement in postprandial glucose excursion (FIG A). All three doses also led to a significantly higher proportion of patients at primary end point achieving 2-hour postprandial SMBG of <10 mmol/L (91.9-99.4% tirzepatide vs 61.7-91.2% comparators, p≤0.019 for all comparisons except tirzepatide 5 mg vs semaglutide 1 mg in SURPASS-2 [96.3% tirzepatide vs 94.9% semaglutide, p=0.276]) and SMBG<7.8 mmol/L (64.6-89.7% tirzepatide vs 12.6-62.1% comparator, p≤0.011) (FIG B). Similarly, for the SURPASS-3 subgroup who completed CGM, all three doses of tirzepatide led to a significantly higher proportion of patients achieving 2-hour postprandial IG in TIR (76.3-91.0% tirzepatide vs 63.3% insulin degludec, p≤0.017) and TITR (48.6-69.4% tirzepatide vs 35.7% insulin degludec, p=0.041) at Week 52.

Conclusion: Tirzepatide treatment led to a significant improvement in postprandial glycemic control with greater proportions of patients achieving target (<10 mmol/L) and euglycemic (<7.8 mmol/L) goals compared to placebo or active comparator in people with T2D.

Results: A total of 51 patients received LY and 17 received placebo. Baseline characteristics were generally balanced between groups. The most commonly reported treatment-emergent adverse events among LY-treated patients were nausea (47.1%), decreased appetite (45.1%), and vomiting (43.1%); these occurred early in the treatment paradigm and decreased over time. One patient reported 2 severe gastrointestinal events (1 each of nausea and vomiting); all other events were mild or moderate. No clinically relevant liver abnormalities or LY-related serious adverse events were reported. Across dose levels on Day 84, Cmax ranged from 60 to 236 ng/mL; median tmax was 4 to 8 hours. On Day 84, mean change from baseline ranged from 1.5% to -1.8% across LY dose levels vs -0.4% with placebo for HbA1c, and -1.6 to -5.0 kg across LY doses vs 0.5 kg with placebo for body weight.

Conclusion: Treatment with the novel oral non-peptide GLP-1 receptor agonist LY showed a safety profile comparable to injectable agents, with robust glucose lowering and substantial reductions in body weight by pharmacokinetics that allow once-daily dosing. These data support further clinical development.

Clinical Trial Registration Number: NCT04426474
Disclosure: E. Pratt: Employment/Consultancy; Lilly Centre for Clinical Pharmacology Pte Ltd.

588

Efficacy, safety and tolerability of danuglipron (PF-06882961) over 12 weeks in adults with type 2 diabetes

D.N. Gorman1, A.R. Saxena2, J. Frias3, R.N. Lopez4, N. Tsamandouras5, M.J. Birnbaum6;
1Pfizer Worldwide Research and Development, Cambridge, UK, 2Pfizer Worldwide Research, Development, and Medical, Cambridge, USA, 3Velocity Clinical Research, Los Angeles, USA, 4Pfizer Inc, Groton, USA.

Background and aims: Danuglipron (PF-06882961) is an oral small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist. This Phase 2a, randomised, double-blind, placebo-controlled, parallel-group study assessed the tolerability, safety and pharmacodynamic effects over 12 weeks of different titration schemes of danuglipron in adults with type 2 diabetes mellitus (T2DM) treated with metformin.

Materials and methods: Participants with T2DM (n=123) were randomised to placebo or 1 of 5 danuglipron titration schemes (to 80, 120 or 200 mg BID, with titration steps of 1 or 2 weeks). Participants with obesity without T2DM (n=28) were enrolled to placebo or danuglipron titration to 200 mg BID for comparison.

Results: In participants with T2DM, robust declines in HbA1c, fasting plasma glucose (FPG) and body weight were observed at multiple dose levels of danuglipron at 12 weeks (Table). The majority of adverse events were mild, with nausea, vomiting and diarrhoea most commonly reported, and a higher incidence of nausea and vomiting at higher doses. In participants with obesity without T2DM, observed weight loss was
greater on danuglipron vs placebo; rates of nausea and vomiting were higher vs T2DM. No clinically significant, adverse trends in laboratory measures, electrocardiogram or vital sign abnormalities were apparent.

**Conclusion:** In adults with T2DM, danuglipron robustly reduced HbA1c, FPG and body weight over 12 weeks. In adults with obesity without T2DM, treatment with danuglipron resulted in greater reductions in body weight vs placebo. In both populations, danuglipron was safe, with a tolerability profile of danuglipron consistent with the mechanism of action.

**Materials and methods:** A total of 411 participants with T2DM (91% on metformin background therapy) were randomised and dosed across 6 arms (placebo or 1 of 5 dose levels of danuglipron); 316 (77%) completed double-blind treatment. HbA1c, fasting plasma glucose (FPG) and body weight were measured at all clinic visits over 16 weeks.

**Results:** In adult participants with T2DM, lowering of HbA1c, FPG and body weight at Week 16 was demonstrated at multiple danuglipron dose levels (Table). The majority of adverse events were mild, with nausea, diarrhoea and vomiting most commonly reported. No episodes of severe hypoglycaemia were reported. No clinically significant, adverse trends in laboratory measures, electrocardiogram or vital sign abnormalities were apparent.

**Conclusion:** In adults with T2DM, danuglipron robustly reduced HbA1c, FPG and body weight over 16 weeks, and was safe, with a tolerability profile consistent with the mechanism of action.

**Disclosure:** A.R. Saxena: Employment/Consultancy; Pfizer Inc. Stock/Shareholding; Pfizer Inc.

---

**589**

**Oral small molecule GLP-1 receptor agonist danuglipron (PF-06882961) results in glucose lowering and body weight loss over 16 weeks in adults with type 2 diabetes**

A.R. Saxena1, J. Frias2, L.S. Brown3, D.N. Gorman4, N. Tsamandouras1, M.J. Birnbaum5;

1Pfizer Worldwide Research, Development, and Medical, Cambridge, USA,
2Velocity Clinical Research, Los Angeles, USA,
3Pfizer Worldwide Research and Development, Collegeville, USA, 4Pfizer Worldwide Research and Development, Cambridge, UK.

**Background and aims:** Danuglipron (PF-06882961) is an oral small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist with efficacy in nonclinical models comparable to injectable GLP-1R agonists. This proof of concept, Phase 2b, multicentre, randomised, double-blind, placebo-controlled, parallel-group, dose-ranging study examined the effect of danuglipron on efficacy, safety, tolerability and pharmacokinetics over 16 weeks in adults with type 2 diabetes mellitus (T2DM).

**Materials and methods:** A total of 411 participants with T2DM (91% on metformin background therapy) were randomised and dosed across 6 arms (placebo or 1 of 5 dose levels of danuglipron); 316 (77%) completed double-blind treatment. HbA1c, fasting plasma glucose (FPG) and body weight were assessed at all clinic visits over 16 weeks.

**Results:** In adult participants with T2DM, lowering of HbA1c, FPG and body weight at Week 16 was demonstrated at multiple danuglipron dose levels (Table). The majority of adverse events were mild, with nausea, diarrhoea and vomiting most commonly reported. No episodes of severe hypoglycaemia were reported. No clinically significant, adverse trends in laboratory measures, electrocardiogram or vital sign abnormalities were apparent.

**Conclusion:** In adults with T2DM, danuglipron robustly reduced HbA1c, FPG and body weight over 16 weeks, and was safe, with a tolerability profile consistent with the mechanism of action.

**Disclosure:** A.R. Saxena: Employment/Consultancy; Pfizer Inc. Stock/Shareholding; Pfizer Inc.
591

Patients with type 2 diabetes reach glycaemic targets faster with tirzepatide compared to semaglutide and titrated insulin degludec

A. Viljoen1, K.M. Pantalone2, R.J. Galindo3, X. Cui4, R. Huh5, L. Fernández Lando6, H. Patel7;
1Department of Metabolic Medicine/Chemical Pathology, North & East Hertfordshire Hospitals Trust, Stevenage, UK, 2Endocrinology and Metabolism Institute, Cleveland Clinic, Cleveland, USA, 3Division of Endocrinology, Emory University School of Medicine, Atlanta, USA, 4Eli Lilly and Company, Indianapolis, USA.

**Background and aims:** Tirzepatide (TZP) is a novel dual GIP/GLP-1 receptor agonist in development for treatment of type 2 diabetes (T2D). TZP 5 mg, 10 mg, and 15 mg demonstrated superiority versus semaglutide (SEMA) and titrated insulin degludec (iDeg) in HbA1c change from baseline and proportion of patients reaching HbA1c <53 mmol/mol (7%), <48 mmol/mol (6.5%), and <39 mmol/mol (5.7%) at 40-weeks (SURPASS-2) and 52-weeks (SURPASS-3), respectively.

**Materials and methods:** In SURPASS-2 and 3, TZP was initiated at 2.5 mg once weekly and increased by 2.5 mg every 4 weeks until the assigned dose was reached and maintained for the duration of the study. Semaglutide was initiated at 0.25 mg once weekly and the dose doubled every 4 weeks until 1 mg was reached and maintained for the duration of the study. Insulin degludec was initiated at 10 U/day and titrated weekly to a fasting blood glucose of <5.0 mmol/L following a treat-to-target algorithm. In an exploratory pre-planned analysis, time to achieve glycaemic targets was estimated using Kaplan Meier method and hazard ratio between treatment was calculated using cox proportional-hazards model.

**Results:** TZP was significantly faster than SEMA and iDeg in time to reach HbA1c ≤53 mmol/mol (7%) and ≤48 mmol/mol (6.5%) (Table). Median time to achieve HbA1c ≤53 mmol/mol (7%) was 8.1 weeks for all TZP doses versus 12.0 weeks for SEMA, and to reach ≤48 mmol/mol (6.5%) was 12.1 weeks versus 15.7 weeks, respectively. Additionally, TZP was significantly faster than SEMA in time to lose 5% body weight (Table). Consistently, median time to reach HbA1c ≤53 mmol/mol (7%) was 8.1 weeks for all TZP doses versus 12.1 weeks for iDeg, and to reach ≤48 mmol/mol (6.5%) was 12.1 weeks versus 24.1 weeks, respectively. Mild to moderate gastrointestinal adverse events were associated with TZP and primarily occurred during the dose escalation period.

**Conclusion:** In conclusion, patients with T2D reached glycaemic targets faster with TZP compared to SEMA 1 mg and titrated iDeg.

**Disclosure:** A. Viljoen: Grants; Sanofi. Lecture/other fees; Novartis, Boehringer Ingelheim, Napp, Non-financial support; Lilly, Novo Nordisk, AstraZeneca.

592

Oxymontomodulin analog LY3305677 (LY) improves glycaemic control and weight loss in healthy volunteers and subjects with type 2 diabetes

C. Benson1, L. Tham2, Y. Du2, S. Gurbuz2, K.J. Mather3, C. Tang4, D.A. Robins1, M.K. Thomas3;
1Eli Lilly and Company, Indianapolis, USA, 2Lilly Centre for Clinical Pharmacology, Singapore, Singapore.

**Background and aims:** Oxymontomodulin Analog LY3305677 (LY) is an acylated peptide analog of oxymontomodulin, a dual glucagon and GLP-1 receptor agonist. We conducted 2 randomised, double-blind, phase 1 multiple ascending subcutaneous dosing studies in healthy subjects (S1) and in type 2 diabetes (T2D) patients (S2) to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics.

**Materials and methods:** In S1, 4 cohorts of healthy subjects received placebo or LY once-weekly (QW) for 4 weeks. In S2, T2D subjects received placebo or LY QW in 2 cohorts with doses escalated over 12 or 16 weeks. A total of 54 subjects completed S1 and 24 patients completed S2.

**Results:** The most common treatment-emergent adverse events in both studies (decreased appetite, nausea, and diarrhoea) were mostly mild in severity, and no deaths or serious adverse events were reported. Pharmacokinetic results were consistent between healthy subjects and T2D patients and supported weekly dosing. In healthy subjects, fasting glucose levels were decreased from baseline with increasing LY doses, and reductions in mean body weight from baseline were generally seen with increasing doses, with the largest change observed on Day 29. In T2D subjects during weeks 12-16, preliminary results of mean HbA1c changes from baseline ranged from -17.1 mmol/mol to -23.6 mmol/mol (~1.56% to -2.16%) in LY-treated vs -4.7 mmol/mol to -7.7 mmol/mol (~0.43% to -0.70%) in placebo subjects, and mean body weight changes from baseline ranged from -2.30 kg to -11.24 kg in LY-treated vs -0.35 kg to -2.03 kg in placebo subjects. Fasting glucose, triglycerides, cholesterol, and glucagon levels were decreased from baseline with LY vs placebo at weeks 12-16.

**Conclusion:** We conclude that LY was well tolerated in both studies, with a safety profile similar to selective GLP-1 receptor agonists. LY has a promising pharmacodynamic profile with potential for therapeutic benefit in T2D, obesity, or other metabolic diseases.

**Clinical Trial Registration Number:** NCT03928379

**Supported by:** Eli Lilly and Company

**Disclosure:** C. Benson: Employment/Consultancy; Eli Lilly and Company. Stock/Shareholding; Eli Lilly and Company.
SO 44 Lessons from trials

593
Finnerone in patients across the spectrum of CKD and type 2 diabetes by GLP-1RA use

M.L. Caramori1, P. Rossing2, S. Anker3, G. Filipatos4, B. Pitt4, V. Fonseca5, G.E. Umpierrez6, M. Lambelet6, P. Viswanathan8, R. Lawatscheck9, A. Joseph10, G. Bakris11, 1Department of Medicine and Department of Pediatrics, University of Minnesota, Minneapolis, USA, 2Steno Diabetes Center Copenhagen, Copenhagen, Denmark, 3Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, Charité Universitätsmedizin, Berlin, Germany, 4Department of Cardiology, National and Kapodistrian University of Athens, Athens, Greece, 5Department of Medicine, University of Michigan School of Medicine, Ann Arbor, USA, 6Tulane University Health Sciences Center, New Orleans, USA, 7Emory University, Atlanta, USA, 8Chrestos Concept GmbH & Co. KG, Essen, Germany, 9Research and Development, Clinical Development & Operations, Bayer U.S. LLC, Whippany, USA, 10Medical Affairs & Pharmacovigilance, Bayer AG, Berlin, Germany, 11Research and Development, Clinical Development Operations, Bayer AG, Wuppertal, Germany, 12Department of Medicine, University of Chicago Medicine, Chicago, USA.

Background and aims: In FIDELITY, a prespecified pooled analysis of the FIDELIO-DKD and FIGARO-DKD trials, finerenone reduced the risk of cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). In FIDELIO-DKD, the effects of finerenone were consistent irrespective of glagagon-like peptide-1 receptor agonist (GLP-1RA) use. This FIDELITY post hoc analysis explores outcomes in a larger CKD population with broader inclusion criteria.

Materials and methods: Patients with T2D and CKD (urine albumin-to-creatinine ratio [UACR] ≥30-<300 mg/g and estimated glomerular filtration rate [eGFR] ≥25-<60 ml/min/1.73 m² or UACR ≥300-<5000 mg/g and eGFR ≥25 ml/min/1.73 m²), treated with optimised renin-angiotensin system blockade were randomised to finerenone or placebo. The efficacy of finerenone on cardiovascular (CV; CV death, non-fatal myocardial infarction, non-fatal stroke, or hospitalisation for heart failure) and kidney (kidney failure, sustained myocardial infarction, non-fatal stroke, or hospitalisation for heart failure) outcomes in patients across the spectrum of CKD and type 2 diabetes by GLP-1RA use.

Results: Of 13,026 patients, 944 (7.2%) received a GLP-1RA at baseline. Of 13,026 patients, 944 (7.2%) received a GLP-1RA at baseline. HRs for risk of MACE favoured semaglutide vs placebo across a continuum of baseline HbA1c values (≥6.5-<12.6% [≥48-<114 mmol/mol]). When assessing individual MACE components by baseline HbA1c and FIGARO-DKD (NCT02545093) and FIGARO-DKD (NCT02545094)

Supported by: BayerAG supported this analysis, who funded the FIDELIO-DKD & FIGARO-DKD studies & combined analysis

Disclosure: M.L. Caramori: Grants; grants and personal fees from Bayer and grants from Novartis, all these paid to her institution. She has received personal fees from Boheringer Ingelheim and AstraZeneca.

594
Effect of semaglutide versus placebo on cardiovascular outcomes by baseline HbA1c: SUSTAIN 6 and PIONEER 6 post hoc analysis

L.G. Mellbin1, D.L. Bhatt2, J.-P. David3, M.C. Petrie4, S. Rasmussen5, P.A. Schytz1, T. Vilsbøll1, 1Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 2Brigham and Women’s Hospital, Harvard Medical School, USA, 3Novo Nordisk A/S, Sabborg, Denmark, 4University of Glasgow, Glasgow, UK, 5Steno Diabetes Center Copenhagen, Herlev, Denmark.

Background and aims: Cardiovascular (CV) outcome trials have demonstrated cardiovascular benefits with once-weekly semaglutide vs placebo (SUSTAIN 6), and non-inferiority for reduction in major adverse CV events (MACE) with oral semaglutide vs placebo (PIONEER 6) in people with type 2 diabetes (T2D) at high CV risk. Given the recommended use of glucagon-like peptide-1 receptor agonists in people with T2D and CV risk regardless of HbA1c values, the potential for HbA1c levels to modify treatment effect on CV outcomes is of interest.

Materials and methods: Using pooled data from SUSTAIN 6 and PIONEER 6, MACE (a composite of death from CV causes, nonfatal myocardial infarction [MI] and nonfatal stroke) with semaglutide vs placebo was evaluated across baseline HbA1c values. A quadratic spline function of baseline HbA1c by treatment was used to analyse treatment effect on time to first MACE across a continuum of baseline HbA1c values. The cardiorenal benefits of finerenone on composite CV outcomes is of interest. This post hoc analysis of SUSTAIN 6 and PIONEER 6 evaluated the treatment effect of semaglutide vs placebo on MACE by baseline HbA1c.

Materials and methods: Using pooled data from SUSTAIN 6 and PIONEER 6, MACE (a composite of death from CV causes, nonfatal myocardial infarction [MI] and nonfatal stroke) with semaglutide vs placebo was evaluated across baseline HbA1c values. A quadratic spline function of baseline HbA1c by treatment was used to analyse treatment effect on time to first MACE across a continuum of baseline HbA1c values. The cardiorenal benefits of finerenone on composite CV outcomes is of interest. This post hoc analysis of SUSTAIN 6 and PIONEER 6 evaluated the treatment effect of semaglutide vs placebo on MACE by baseline HbA1c.

Results: Of 13,026 patients, 944 (7.2%) received a GLP-1RA at baseline. Of 13,026 patients, 944 (7.2%) received a GLP-1RA at baseline. HRs for risk of MACE favoured semaglutide vs placebo across a continuum of baseline HbA1c values (≥6.5-<12.6% [≥48-<114 mmol/mol]). When assessing individual MACE components by baseline HbA1c subgroups (<8% [<64 mmol/mol]; cut-off selected as close to the median), the test for heterogeneity in treatment effect across baseline HbA1c subgroups was indicated by interaction p-values.

Results: HRs for risk of MACE favoured at baseline HbA1c values (≥6.5-<12.6% [≥48-<114 mmol/mol]). When assessing individual MACE components by baseline HbA1c subgroups, interaction p-values were all >0.05, indicating no statistically significant difference in treatment effect on any CV outcome between baseline HbA1c subgroups (consistent between adjusted and unadjusted analyses). HRs for all CV outcomes were consistently <1.0 with semaglutide vs placebo. HRs in the adjusted analysis [95% CI] for MACE, death from CV causes, nonfatal MI and nonfatal stroke were 0.80 [0.57;1.11], 0.87 [0.49;1.56], 0.98 [0.60;1.59] and 0.52 [0.26;1.05], respectively, with baseline HbA1c <8%, and 0.72 [0.56;0.93], 0.70 [0.46;1.07], 0.83 [0.57;1.20] and 0.74 [0.44;1.22], respectively, with baseline HbA1c ≥8%.

Conclusion: The effect of semaglutide vs placebo on MACE and its components was consistent across baseline HbA1c in the SUSTAIN 6 and PIONEER 6 pooled T2D population. These data indicate that the beneficial CV effect of semaglutide is consistent regardless of HbA1c values.
Tirzepatide reduces serum triglyceride concentrations irrespective of concomitant fibrate use in SURPASS-4 participants with type 2 diabetes at high cardiovascular risk

T. Várkonyi1, S. Del Prato2, I. Pavo3, C. Nicolay1, R.J. Wiese1, S.E. Kahn1; 1University of Szeged, Szeged, Hungary, 2University of Pisa, Pisa, Italy, 3Eli Lilly and Company, Indianapolis, USA, 4University of Washington, Seattle, USA.

Background and aims: In the SURPASS-4 trial, participants with type 2 diabetes (T2D) inadequately controlled with 1-3 oral glucose-lowering medications and high cardiovascular (CV) risk (coronary heart disease, peripheral arterial disease, cerebrovascular disease, chronic kidney disease, or congestive heart failure) received the once weekly dual GIP/GLP-1 receptor agonist tirzepatide (TZP) or titrated insulin glargine (iGlar). In the study, TZP reduced serum triglycerides and low-density lipoproteins cholesterol (LDL-C) levels significantly more than iGlar. In participants with T2D and high CV risk, TZP lowered triglycerides and LDL-C more effectively than iGlar, regardless of concomitant use of fibrates or statins.

Materials and methods: Participants (N=2,002) were randomized 1:1:1:3 to once weekly TZP (5, 10, 15 mg) or once daily iGlar. Lipoproteins were measured at baseline, 42, 52, (primary endpoint), 78 weeks and study end (median 85 weeks). This post-hoc analysis assessed percent change from baseline in lipids across subgroup categories in participants while on assigned treatment without rescue medication (efficacy estimand) using mixed-model repeated measures. Participants with baseline and at least 1 post-baseline measurement were included in the analysis.

Results: Overall, 12.4% and 77.8% of the participants were receiving fibrates or statins at baseline (Table). These reductions were maintained until 78 weeks (N = 574 for TZP). TZP dose-dependently reduced serum triglycerides, with the reductions being similar in those on fibrates/statins or not. The marked reduction in triglycerides (14-24%) for TZP in the presence of fibrate therapy and no change for iGlar was clinically meaningful as the participants receiving fibrates still had elevated triglycerides at baseline. In general, TZP also reduced LDL-C more than iGlar. No differential treatment effects (TZP vs iGlar) on the reduction of triglycerides or LDL-C were observed for either fibrate or statin use.

Conclusions: In participants with T2D and high CV risk, TZP lowered triglycerides and LDL-C more effectively than iGlar, regardless of concomitant use of fibrates or statins.
nor HbA1c effects of TZP. The percentage of TE ADA+ and TE ADA- patients with hypersensitivity reactions was similar. A higher proportion of TE ADA+ patients reported injection site reactions, of which all were nonserious and non-severe, and the vast majority were mild in severity and occurred and/or resolved irrespective of TE ADA status or titerv level. **Conclusion:** Overall, immunogenicity was not associated with any impact on TZP PK, efficacy, or safety.

**Clinical Trial Registration Number:** NCT03954834; NCT039587919; NCT03882970; NCT03736062; NCT04039503; NCT03861052; NCT03861039

**Supported by:** Eli Lilly and Company

**Disclosure:** B. Calderon: Employment/Consultancy; Employed by Eli Lilly and Company. Stock/Shareholding; Shareholder of Eli Lilly and Company.

---

**597 Greater time spent in glycaemic control with oral semaglutide vs oral comparators**

**F.K. Knoep, B. Cariou, J. Eliasson, G. Frappin, M.S. Kaltoft, E. Montanya, J. Rosenstock**

1 Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark, 2 Steno Diabetes Center Copenhagen, Gentofte, Denmark, 3 Nantes University, CHU Nantes, CNRS, Inserm, l’institut du thorax, Nantes, France, 4 Novo Nordisk A/S, Søborg, Denmark, 5 Hospital Universitari Bellvitge-IDIBELL, CIBERDEM, and University of Barcelona, Barcelona, Spain, 6 Dallas Diabetes Research Center at Medical City, Dallas, USA.

**Background and aims:** This exploratory analysis aimed to determine how long patients spent with HbA1c <7.0% (53 mmol/mol), and how likely patients were to maintain this glycaemic target in PIONEER efficacy trials of ≥52 weeks’ duration.

**Materials and methods:** Patients with uncontrolled type 2 diabetes in the PIONEER 2, 3, 4 and 7 trials were randomised to oral semaglutide vs active comparators (emepagliflozin 25 mg, sitagliptin 100 mg, liraglutide 1.8 mg once daily). Oral semaglutide dose was escalated, starting at 3 mg once daily and increasing to 7 mg after 4 weeks and then to 14 mg after 8 weeks in all trials except PIONEER 7, which used a flexible dose adjustment approach based on HbA1c and gastrointestinal tolerability. Empagliflozin was initiated at 10 mg and escalated to 25 mg after 8 weeks. Sitagliptin was initiated at 100 mg and not escalated. Liraglutide was initiated at 0.6 mg and escalated to 1.2 mg and then 1.8 mg after 1 and 2 weeks, respectively. Outcomes were evaluated for oral semaglutide vs active comparators using on-treatment without rescue medication data for all randomised patients. A binary endpoint of achieving HbA1c <7.0% (53 mmol/mol) at both week 26 and 52 of each trial (and at week 78 for PIONEER 3) was analysed using a logistic regression model, with treatment, region and strata as categorical fixed effects and baseline value as a covariate.

**Results:** Mean baseline HbA1c ranged from 8.0 to 8.3% (64–67 mmol/ mol) across all trials and was greater with oral semaglutide (26.3–33.7 weeks) vs oral comparators (0–10.9 weeks) (Table). The mean duration of time spent with HbA1c <7.0% (53 mmol/mol) was also greater for oral semaglutide vs oral comparators (Table). The mean and median duration of time spent in glycaemic control with oral semaglutide was similar to that seen with liraglutide. Greater proportions of patients had HbA1c <7.0% (53 mmol/mol) for ≥38 weeks with oral semaglutide than with emepagliflozin (46% vs 28%, respectively) and sitagliptin (PIONEER 3: 45% vs 28%, respectively; PIONEER 7: 27% vs 14%, respectively) but not liraglutide (46% vs 48%, respectively). The odds of patients achieving HbA1c <7.0% (53 mmol/mol) at both week 26 and 52 were significantly greater with oral semaglutide vs comparators (Table).

**Conclusion:** In PIONEER trials of ≥52 weeks, oral semaglutide resulted in greater time spent at glycaemic target and a greater likelihood of maintaining glycaemic control vs oral comparators. Patients receiving oral semaglutide spent a similar time in glycaemic control vs liraglutide, despite a longer dose-escalation with oral semaglutide.

**Clinical Trial Registration Number:** NCT02863328, NCT02607865, NCT02863419; NCT02849080

**Supported by:** Funded by Novo Nordisk A/S.


---

**598 Patient characteristics associated with achievement of normoglycaemia following treatment with tirzepatide in the SURPASS 1–4 trials**


1 Hospital Marqués de Valdecilla, Santander, Spain, 2 Dallas Diabetes Research Center at Medical City, Dallas, USA, 3 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 4 CPCLIN/DASA, Clinical Research Center, Sao Paulo, Brazil, 5 Eli Lilly and Company, Indianapolis, USA.

**Background and aims:** Throughout the SURPASS program 23% to 62% of adults with type 2 diabetes (T2D) treated with tirzepatide, a novel dual GIP/GLP-1 receptor agonist, achieved an HbA1c value below the upper limit of the normal range <38.8 mmol/mol (<5.7%) at the primary endpoints. Here, we have performed exploratory analysis to identify baseline characteristics that could be associated with increased odds of achieving a normal HbA1c following treatment with tirzepatide in the SURPASS 1–4 clinical trials.

**Materials and methods:** Compliant patients (≥75% doses received), on treatment without rescue medication were included in the analyses (N=32,229). Background medication at baseline included metformin only (63%), combination of oral anti-diabetic medication (OAM) (26%), and no treatment (9%). Logistic regression models with tirzepatide doses (5 mg, 10 mg, and 15 mg) adjusted as a covariate, were used to obtain odds ratios and assess the impact of individual baseline variables on achieving an HbA1c <38.8 mmol/mol (<5.7%). A multivariate logistic regression model was fitted to further assess the joint impact of these variables.

**Results:** Higher tirzepatide doses were significantly associated with higher odds of achieving an HbA1c <38.8 mmol/mol (<5.7%). Duration of diabetes, HbA1c, fasting serum glucose (FSG), eGFR and age showed significant associations when assessed by univariate logistic
regression models adjusted by tirzepatide doses (Table). Odds of achieving an HbA1c <38.8 mmol/mol (<5.7%) at week 40 was reduced by 13% for a total 52 weeks of treatment. At week 52, treatment with evogliptin add-on to DAPA/MET resulted in a greater mean HbA1c reduction than placebo (least square [LS] mean difference -0.55 % [95 % confidence interval [CI] -0.71, -0.39]; p<0.0001). The proportion of patients achieving HbA1c <7% was significantly higher in evogliptin group (32.14 % versus 8.51 % in placebo; odds ratio of 5.62; p<0.0001). Evogliptin treatment also significantly reduced the fasting glucose levels and mean daily glucose levels with the improvement of HOMA-ß (LS mean difference 9.04 [95% CI 1.86, 16.21]; p=0.0138) compared to placebo. Adverse events were similar between groups, and no serious adverse drug reactions were reported in evogliptin group.

Conclusion: Long-term triple combination with evogliptin add-on to dapagliflozin plus metformin showed superior HbA1c reduction and glycemic control compared to placebo at 52 weeks, and is well tolerated to patients with type 2 diabetes who are not adequately controlled with DAPA/MET.

Clinical Trial Registration Number: NCT04170998
Supported by: Dong-A ST
Disclosure: J. Moon: None.

599

Long-term efficacy and safety of evogliptin add-on therapy to dapagliflozin plus metformin combinations in poorly controlled patients with type 2 diabetes

J. Moon1, H. Kim2, C. Chung3, K. Won4, K. Han5, C. Park6, J. Won6, D. Kim7, G. Koh8, E. Kim9, J. Yu10, E. Hong11, C. Lee12, K. Yoon13;
1Department of Internal Medicine, Yeungnam University Hospital, Daegu, 2Department of Internal Medicine, Ajou University Hospital, Suwon, 3Department of Internal Medicine, Wonju Severance Christian Hospital, Wonju, 4Department of Internal Medicine, Nowon Eulji Medical Center, Seoul, 5Department of Internal Medicine, Kangbuk Samsung Hospital, Seoul, 6Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, 7Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, 8Department of Internal Medicine, Jeju National University Hospital, Jeju, 9Department of Internal Medicine, Ulsan University Hospital, Ulsan, 10Department of Internal Medicine, Hanlim University Kangnam Sacred Heart Hospital, Seoul, 11Department of Internal Medicine, Hanlim University Dongtan Sacred Heart Hospital, Hwaseong, 12Department of Internal Medicine, Hanyang University Guri Hospital, Guri, 13Department of Internal Medicine, Catholic University Seoul St. Mary’s Hospital, Seoul, Republic of Korea.

Background and aims: We aimed to investigate the long-term efficacy and safety of evogliptin add-on therapy in patients with type 2 diabetes who were inadequately controlled by metformin and dapagliflozin combinations.

Materials and methods: In this multi-center, double-blind, randomized, placebo-controlled phase 3 trial, patients with HbA1c 7.0 - 10.5 % (n=283) who had used dapagliflozin 10mg plus metformin (≥1,000 mg) (DAPA/MET) for at least 8 weeks were randomly assigned evogliptin 5 mg once daily or placebo (1:1). The primary endpoint was change from baseline in HbA1c at week 24, and the efficacy and safety of evogliptin over 52 weeks were exploratory endpoints in this extension.

Results: Of 283 randomized participants, 234 patients entered the long-term extension and 229 patients completed the 28-week extension period for a total 52 weeks of treatment. At week 52, treatment with evogliptin add-on to DAPA/MET resulted in a greater mean HbA1c reduction than placebo (least square [LS] mean difference -0.55 % [95 % confidence interval [CI] -0.71, -0.39]; p<0.0001). The proportion of patients achieving HbA1c <7% was significantly higher in evogliptin group (32.14 % versus 8.51 % in placebo; odds ratio of 5.62; p<0.0001). Evogliptin treatment also significantly reduced the fasting glucose levels and mean daily glucose levels with the improvement of HOMA-ß (LS mean difference 9.04 [95% CI 1.86, 16.21]; p=0.0138) compared to placebo. Adverse events were similar between groups, and no serious adverse drug reactions were reported in evogliptin group.

Conclusion: Long-term triple combination with evogliptin add-on to dapagliflozin plus metformin showed superior HbA1c reduction and glycemic control compared to placebo at 52 weeks, and is well tolerated to patients with type 2 diabetes who are not adequately controlled with DAPA/MET.

Clinical Trial Registration Number: NCT04170998
Supported by: Dong-A ST
Disclosure: J. Moon: None.
change of HbA1c from baseline in the overall population were consistent when assessed by baseline duration of diabetes category (≤5 years, 5 to 10 years, >10 years) in patients while they were on-treatment and without rescue medication (efficacy estimand).

Results: For all 5 studies, analysis of change from baseline in HbA1c at 40 or 52 weeks for all 3 duration of diabetes subgroups were consistent with primary study results, with the treatment differences favoring all 3 doses of TZP compared with placebo or active comparator (Figure). The most frequent adverse events were mild-to-moderate, gastrointestinal-related and occurred during the dose-escalation period.

Conclusion: In conclusion, these results suggest that TZP was effective for mean change from baseline HbA1c for patients regardless of baseline duration of diabetes consistent with the overall patient population across the 5 SURPASS studies.

Disclosure: J. Kiljanski: Employment/Consultancy; Eli Lilly and Company. Stock/Shareholding; Eli Lilly and Company.

SO 45 Beta cell function and glucose control

Empagliflozin improves beta cell function independently of relief of glucotoxicity in patients with type 2 diabetes

1Department of Endocrinology, Amager Hvidovre Hospital, Hvidovre, 2Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, 3Department of Clinical Biochemistry, Rigshospitalet, Hvidovre, 4Department of Clinical, Amager Hvidovre Hospital, Hvidovre, 5Department of Cardiology, Herlev Gentofte Hospital, Herlev, 6Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.

Background and aims: SGLT2-inhibitors improve beta-cell glucose sensitivity (BGS) and insulin sensitivity in patients with type 2 diabetes (T2D). This effect has been attributed to relief of glucotoxicity, but very few studies have controlled for differences in glycemia. Here, we explore the effects of empagliflozin on BGS first, and peripheral insulin sensitivity (IS) second, compared to similar glycemic control with insulin treatment.

Materials and methods: 17 subjects with T2D (13 males, 58±3 years (mean±sem), BMI 32.9±0.9 kg/m2, HbA1c 52.4±2.4 mmol/L, T2D duration 8.9±1.3 years) were treated with empagliflozin (E) and NPH-insulin (I) for 5 weeks in a randomized cross-over study design with 3 weeks of washout. Insulin was titrated to obtain similar glycemic control as obtained with empagliflozin. An OGTT with stable iv and oral glucose tracers was performed prior to and at the end of each treatment.

Results: Glycemia was similarly reduced on both treatments (Δfasting glucose: E: -1.3±0.2, p<0.01; I: -0.8±0.2, p<0.01; E vs I: psNS). Fasting insulin concentrations were lower with empagliflozin and higher with insulin (E: 92±12 vs 180±27 pmol/L, p<0.001). Fasting glucagon concentrations were similar during both treatments (E: 19±1, I: 19.5±1 pmol/L) yielding a higher glucagon-to-insulin ratio on empagliflozin than on insulin treatment (E: 0.24±0.03 vs I: 0.14±0.02, p<0.001). Prehepatic insulin secretion (ISR) in response to the OGTT was greater on Empagliflozin compared to insulin treatment (E: AUC ISR 1814±170 pmol/kg, I: 1599±144 pmol/kg, p=0.02), while postprandial glucose excursions did not significantly differ between treatments. As a result, BGS was greater with empagliflozin compared to insulin treatment (E: 0.82±0.1, I: 0.59±0.07 pmol/(kg·min·mM), p=0.001), but postprandial incretin hormone secretion was similar during both treatments (AUC GLP-1: E: 3922±302; I: 3765±262 pmol·min/L; AUC GIP: E:6926±903; I: 6954±565).Fasting hepatic glucose production (HGP) was increased with empagliflozin compared to insulin (E: 19.5±0.8, I: 16.6±0.6 pmol/kg/min, p<0.001), but postprandial HGP did not differ between treatments. IS (AUC Glucose R_g tissue /AUC Insulin) was numerically lower with empagliflozin, but decreased with insulin.
compared to washout (0.09±0.01 vs 0.11±0.02 μmol/kg FF M·pM·min, p=0.025). Fatty tissue insulin resistance (Adipo-IR: fasting FFA x fasting insulin) was lower with empagliflozin compared to insulin (E: 77±11, 1:110±17 mmol/L x pmol/L, p=0.01). AUC glucagon during the OGTT was higher on empagliflozin treatment compared to insulin (E: 5286±255, I: 4818±345 pmol x min/L, p=0.04).

Conclusion: Improved beta-cell function during empagliflozin treatment is not a result of relieved glucotoxicity or increased incretin secretion. Peripheral hyperinsulinemia may induce insulin resistance.

Clinical Trial Registration Number: EudraCT no. 2017-002101-35
Supported by: Boehringer Ingelheim
Disclosure: N.B. Jørgensen: Grants; Boehringer Ingelheim

602 Fasting 32-33 split proinsulin and intact proinsulin levels are reduced by liraglutide and metformin in combination. A randomised double-blind trial
C. Anholm1, P. Kumarathurai2, M. Skytte1, O.W. Nielsen2, O.P. Kristiansen2, K. Burling3, P. Barker4, M. Fenger5, S. Madsbad6, A. Sajadieh2, S.B. Hauagga1
1Department of Endocrinology and Nefrology, University Hospital Nordsjælland Hillerød, Hillerød, Denmark, 2Department of Cardiology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark, 3Department of Endocrinology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark, 4Core Biochemical Assay Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, 5Department of Clinical Biochemistry, Copenhagen University Hospital, Hvidovre, Copenhagen, Denmark, 6Department of Endocrinology, Copenhagen University Hospital, Hvidovre, Copenhagen, Denmark.

Background and aims: Insulin hypersecretion associates to obesity and type 2 diabetes (T2DM) in its initial stage. Higher circulating concentrations of intact and split proinsulin in absolute amounts and as proportions of insulin and C-peptide suggests defective beta-cell function. The glucagon-like peptide-1 receptor agonist liraglutide increases insulin secretion but reduces the amount of circulating total proinsulin. However, there is no data present of the effects on fasting levels of 32-33 Split Proinsulin (SP) and Intact Proinsulin (IP). We investigated the effects of liraglutide combined with metformin on fasting concentration of IP and SP in patients with newly diagnosed well-controlled T2DM.

Materials and methods: A randomized, double-blind, placebo-controlled, cross-over trial in 12 + 12 weeks periods with ≥2-weeks wash-out before and between intervention periods. Population: Subjects with established coronary artery disease and newly diagnosed T2DM. Intervention: liraglutide/metformin vs. placebo/metformin. Biochemical analysis was done at the beginning and end of each 12-weeks periods. We report data from fasting plasma samples on insulin, C-peptide, IP, SP and glucose.

Results: Of 41 patients randomized data from 28 patients were available for the paired analysis. Data reported as median (IQR). Baseline levels of IP and SP were: 6.3 (3.4:10.7) and 13.4 (8.4:23.9) pmol/L, respectively. Fasting insulin and C-peptide levels were unchanged, but glucose was reduced by liraglutide combined to metformin. Plasma IP was reduced by 29%, i.e. -1.8 (-3.7:-0.3) pmol/L (p = 0.005) and SP by 34%, i.e. -4.6 (-7.7:-1.5) pmol/L (p = 0.005). IP + SP to insulin ratio was reduced by 29%, i.e. -1.8 (-3.7:-0.3) pmol/L (p = 0.005) and SP by 34%, i.e. -4.6 (-7.7:-1.5) pmol/L (p = 0.005). IP + SP to C-peptide ratio by 30% (p = 0.0003), but SP to IP ratio was unchanged.

Conclusion: In patients with newly diagnosed T2DM liraglutide in combination with metformin substantially reduced postabsorptive levels of proinsulin-like molecules and its ratios to insulin and C-peptide suggesting an improvement of beta-cell health.

Clinical Trial Registration Number: ClinicalTrials.gov Identifier: NCT01593789
Supported by: Novo Nordisk

Disclosure: C. Anholm: Grants; Novo Nordisk, The AP Møller Foundation, The Bispebjerg Hospital Research Foundation, The Danish Heart Foundation, Department of Internal Medicine at Amager Hospital, Clinical Research Centre Hvidovre Hospital.

603 Tirzepatide improved markers of islet cell function and insulin sensitivity compared to semaglutide in people with type 2 diabetes
Eli Lilly and Company, Indianapolis, USA.

Background and aims: Tirzepatide (TZP) achieved significantly greater HbA1c and weight reductions with all doses (5, 10 and 15 mg) vs semaglutide 1 mg (SEMA) in a Phase 3 trial of 1879 people with type 2 diabetes (T2D) on background metformin (mean age 56.6 years; T2D duration 8.6 years; baseline HbA1c 8.3% [67 mmol/mol]; BMI 34.2 kg/m2) (SURPASS-2).

Materials and methods: Changes in fasting markers of islet cell function (fasting glucagon and HOMA2-B) and insulin sensitivity (fasting insulin and HOMA2-IR) were assessed by mixed model repeated measures in the modified intent-to-treat population.

Results: At 40 weeks, all TZP doses improved HOMA2-B, calculated with C-peptide, as indicated by a significant increase by 97-120% on average with TZP, compared to 84% with SEMA. Fasting glucagon levels, adjusted for fasting serum glucose, significantly decreased by 53-55% on average with TZP 10 and 15 mg doses compared with SEMA (48%). All TZP doses improved insulin sensitivity as reflected by a significant decrease by 16-24% on average of HOMA2-IR, calculated with insulin, compared to a decrease by 5% with SEMA. Fasting insulin levels were also significantly reduced by 9-21% on average with all TZP doses compared to an increase of 0.6% with SEMA.

Conclusion: Dual GIP/GLP-1 receptor agonist TZP significantly improved markers of islet cell function and insulin sensitivity compared to selective GLP-1 RA SEMA in people with T2D.
Background and aims: We aimed to evaluate the role of polymorphisms in TCF7L2, CTRB1/2 and GLP-1R genes in the glycemic and weight loss response to treatment with glucagon-like peptide-1 receptor agonists (GLP-1-RAs) among Greek individuals with type 2 diabetes (T2D).

Materials and methods: 191 adults with T2D (52% female, mean age and BMI 69.3±10.6 years and 35.8±5.7 kg/m², respectively), who had been treated with metformin, exenatide, or lixisenatide for at least 6 months were included. Participants were genotyped for TCF7L2 rs7903146 (C>T), CTRB1/2 rs7202877 (T>G) and GLP-1R rs367543060 (C>T) polymorphisms. Clinical and laboratory parameters were measured at baseline, 3 and 6 months after the initiation of GLP-1 RA. Good glycemic responders were defined as patients fulfilling one of the following criteria: i) HbA1c <7% at 3 or 6 months after the initiation of treatment, ii) reduction of baseline HbA1c by ≥1% after 3 or 6 months of GLP-1 RA administration, and iii) maintenance of HbA1c <7% that a patient had before switching to GLP-1 RA, after 3 or 6 months of treatment. Weight loss responders were defined as subjects who lost ≥3% of their baseline weight after 3 or 6 months of GLP-1 RA use. The dominant genetic model was used in all analyses.

Results: The minor allele frequencies for TCF7L2 rs7903146, CTRB1/2 rs7202877 and GLP-1R rs367543060 were 79.1, 15.7, and 0%, respectively. 136 (71.2%) and 125 (65.4%) individuals were classified as glycemic responders and GLP-1R allele; thus, no comparisons were feasible. Both glycemic responders and GLP-1R

disclosure:
P. Lapuerta, S. Urbina, A. Wittl, J. He, C. Li, T. Li; Youngene Therapeutics Co., Ltd., Shanghai, China; ProSciento, Inc, Chula Vista, USA; Atorus Research, Inc, Chula Vista, USA.

Background and aims: YG1699 is a dual inhibitor of SGLT1 and SGLT2. This phase 2a study compared the effects of YG-1699 to dapagliflozin 10 mg (dapa) in subjects with T1D on insulin pump therapy.

Materials and methods: Subjects with type 1 diabetes in this crossover study received insulin alone for one week (the no treatment period, or NTP), followed by three treatment periods of insulin plus blinded study drug (dapa, YG1699 10 mg, YG1699 25 mg) given in a randomized order, each given once daily and orally for 7 days. There was a washout interval of one week between each treatment period. A mixed meal tolerance test (MMTT) was done at Day 6 of each period. The glucose area under the curve over 120 minutes (AUC120) and GLP-1 AUC180 were measured in the MMTT as measures of SGLT1 activity. The primary endpoint was glucose AUC120 on treatment expressed as a percentage of the NTP value. Insulin withdrawal of up to 6 hours was performed on Day 7 and stopped for capillary ketones ≥2.5 mmol/L, plasma glucose ≥350 mg/dL, carbon dioxide <18 mmol/L, or subject symptoms.

Results: 19 subjects enrolled and 18 completed all three treatment periods. Characteristics included mean age 38, BMI 24, 53% female, and baseline hemoglobin A1C 7.4%. The following values are presented (means or %) in the order of YG1699 10 mg, YG1699 25 mg, and dapa 10 mg, respectively. Glucose AUC120 values as a percentage of NTP were: 89.5%, 84.8%, and 102.1% (p=0.0003 for YG1699 10 mg vs. dapa 10 mg, and p<0.0001 for YG1699 25 mg vs. dapa 10 mg). Glucose values at 120 minutes were: 128, 115, and 141 mg/dL. Incremental GLP-1 AUC180 values (above the NTP) were: 213, 320, and 142 mg*min/L. Urinary glucose excretion totals during the MMTT were: 6.3, 8.4, and 7.6 g/3 hours (vs. 0.2 in the NTP). Times to stopping insulin withdrawal were: 321, 338, and 328 minutes (vs. 342 in the NTP). Incidences of adverse events were: 94%, 95%, and 95% (mostly mild and moderate hypoglycaemia). Incidences of moderate hypoglycaemia were: 44.4%, 57.9%, and 57.9%. There were no serious adverse events. There was no DKA (diabetic ketoacidosis).

Conclusion: YG1699 reduced post-prandial glucose significantly more than dapagliflozin in subjects with T1D and was well-tolerated in this study. The pattern of lower post-prandial glucose, a greater GLP-1 response, and similar urinary glucose excretion compared to dapagliflozin in the MMTT indicate that YG1699 provided dual inhibition of SGLT1 and SGLT2.

Disclosure: P. Lapuerta: Employment/Consultancy; I am employee of Youngene. Stock/Shareholding; And I may own common stock or have been granted stock options or other equity incentive awards.
607

Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and meta-analysis of randomised controlled trials

L. He, J. Wang, N. Yang, L. Xu, W. Li, F. Ping, J. Huang, Y. Li, H. Zhang;
Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking U, Beijing, China.

Background and aims: Previous studies showed that both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) might impact postprandial gallbladder motility, possibly increasing risks of gallbladder or biliary diseases. Since dipeptidyl peptidase-4 (DPP-4) inhibitors enhance the bioavailability of endogenous GLP-1 and GIP-1, we aimed to examine the association between DPP-4 inhibitors and gallbladder or biliary diseases in adults with type 2 diabetes (T2DM).

Materials and methods: We conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) that compared DPP-4 inhibitors with placebo or non-incretin drugs in adults with T2DM. We searched PubMed, EMBASE, Web of Science, and Cochrane Library from inception to 30 June 2021. The primary outcome was the gallbladder or biliary diseases, and the secondary outcomes were cholecystolithiasis, cholecystitis, and biliary diseases. Overall relative risk (RR) and 95% confidence interval (CI) were calculated.

Results: A total of 82 randomized controlled trials (RCTs) with 104,833 participants were included in the pairwise meta-analysis. Compared with placebo or non-incretin drugs, DPP-4 inhibitors were significantly associated with an increased risk of the composite of gallbladder or biliary diseases (odds ratio 1.22 (95% confidence interval 1.04 to 1.43); risk difference, 11 more (2 to 21 more) events per 10,000 persons in a year) and cholecystitis (odds ratio 1.43 (95% confidence interval 1.14 to 1.79); risk difference, 15 more (5 to 27 more) events per 10,000 persons in a year) but were not with the risk of cholecystolithiasis and biliary disease. The associations tended to be observed in patients with a longer duration of DPP-4 inhibitors treatment.

Conclusion: DPP-4 inhibitors increased the risk of cholecystitis in RCTs, especially with a longer treatment duration, which requires more attention from physicians in clinical practice.


Supported by: Natural Science Foundation of Beijing Municipality Beijing (M22014)

Disclosure: L. He: None.

608

Glycaemic response to meals with a high glycaemic index consumed in the morning and evening among students with early and late chronotype-ChroNu Study

B. Stutz1, B. Krueger1, J. Goletzke1, N. Jankowicz2, C. Herder3, U. Alexy4, A.E. Buyken1;
1Faculty of Natural Sciences, Paderborn University, Paderborn, 2Department of Nutrition and Food Sciences, Rheinische Friedrich-Wilhelms-University Bonn, Dortmund, 3German Center for Diabetes Research, Düsseldorf, Germany.

Background and aims: Glucose homeostasis is known to deteriorate during the day even among healthy individuals, hence meals with a high glycaemic index (GI) consumed in the evening may be particularly

Materials and methods: Among 320 students aged 18-25 years those with the earliest (n=22) and latest (n=23) chronotype as determined by the Munich Chronotype Questionnaire were invited to participate in a 4-day randomized controlled cross-over nutrition trial in autumn 2020. On the intervention days (separated by a wash-out day), participants received a high GI meal (GI=72) either at breakfast (7 a.m.) or at dinner (8 p.m.). All other meals had a medium GI (46-59). Glucose responses were recorded by a continuous glucose monitoring device (G6, Dexcom, Inc., San Diego, CA). The outcomes 2-h pp incremental area under the curve (iAUC) and glycemic variability (mean amplitude of glucose excursion, MAGE) were compared using paired T-Test.

Results: Among earlier chronotypes (median mid-point of sleep 3:43 a.m. (Q1; Q3: 3:10; 4:15)) 2-h pp iAUC responses were higher in the evening than in the morning: iAUC 236 (± 90) vs. 198 (± 87) mmol/L, p=0.04, yet MAGE was comparable: 3.4 (± 1.3) vs. 3.0 (± 1.8) mmol/L, p=0.6. In contrast, later chronotypes (median mid-point of sleep 5:37 a.m. (Q1; Q3: 5:10; 6:20)) showed comparable 2-h pp glucose responses in the morning and in evening: iAUC 213 (± 112) vs. 208 (± 96) mmol/L, p=0.96, MAGE: 3.1 (± 1.6) vs. 3.2 (± 1.2) mmol/L, p=0.9.

Conclusion: The present study illustrates that diurnal variations in glucose response to a high GI meal differ between earlier and later chronotypes. In line with a deteriorating glucose homeostasis over the day, earlier chronotypes were vulnerable for higher glucose excursions to a high GI meal consumed late in the evening. The fact that this was not seen among later chronotypes suggests that glucose homeostasis was adversely affected also early in the morning following a high GI against the inner clock.

Clinical Trial Registration Number: NCT04302922

Supported by: This research was supported by the German Research Foundation (DFG), BU 1807/3-2

Disclosure: B. Stutz: None.

SO 46 Incretins everywhere

609 Multifactorial risk reduction with oral semaglutide vs comparators in the treatment of type 2 diabetes

V.R. Aroda1, J. Eliasson2, B. Malling2, J.J. Meier3, L.L. Nielsen2, T. Vilsboll4, K. Khunti5

1Brigham and Women's Hospital, Harvard Medical School, Boston, USA, 2Novo Nordisk A/S, Soborg, Denmark, 3St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany, 4Clinical Research, Steno Diabetes Center Copenhagen, Gentofte Hospital, University of Copenhagen, Herlev, Denmark, 5Leicester Diabetes Centre, Diabetes Research Centre, Leicester General Hospital, Leicester, UK.

Background and aims: Therapies that address multiple risk factors may help patients with type 2 diabetes (T2D) to improve their cardiometabolic risk profile. This exploratory analysis aimed to evaluate the efficacy of oral semaglutide in improving multiple cardiometabolic risk factors vs comparators.

Materials and methods: In the PIONEER phase 3a clinical trial programme, patients with T2D were randomised to oral semaglutide 14 mg/flex (flexible dose adjustment for PIONEER 7 only) or comparators (empagliflozin 25 mg, sitagliptin 100 mg, liraglutide 1.8 mg or placebo [pbo]). This post hoc analysis evaluated the proportion of patients who achieved specific cardiometabolic endpoints (reductions in HbA1c ≥ 1%, body weight ≥ 5%, systolic BP ≥ 5 mmHg or LDL cholesterol ≥ 0.5 mmol/L, or an increase in eGFR ≥ 20 mL/min/1.73 m²) by the end of the PIONEER 1-8 trials, and the proportion achieving 2, 3 and 4 or more of these endpoints. Data were analysed using a logistic regression model with treatment, strata (PIONEER 3-8), interaction strata (PIONEER 5 and 8) and region as categorical fixed effects and baseline value as covariate for the on-treatment without rescue medication data for all randomised patients.

Results: Across trials, greater proportions of patients achieved each endpoint with oral semaglutide vs comparators. Reductions in HbA1c ≥ 1% occurred in 47.3-77.1% with oral semaglutide vs 32.8-51.4% with active comparators or 8.5-23.7% with pbo. Reductions in body weight ≥ 5% occurred in 30.8-49.8% with oral semaglutide vs 12.7-41.0% with active comparators or 5.4-16.3% with pbo. Reductions in systolic BP ≥ 5 mmHg occurred in 47.9-62.5% with oral semaglutide vs 48.8-59.7% with active comparators or 40.1-57.9% with pbo. Reductions in LDL cholesterol ≥ 0.5 mmol/L occurred in 20.2-27.4% with oral semaglutide vs 13.7-21.1% with active comparators or 12.7-21.7% with pbo. Increases in eGFR ≥ 20 mL/min/1.73 m² occurred in 45.1-54.6% with oral semaglutide vs 37.0-50.0% with active comparators or 32.4-44.5% with pbo. Significantly greater proportions of patients achieved improvements in 2, 3 or 4 or more endpoints with oral semaglutide vs comparators across all trials, except for the achievement of 2 endpoints with oral semaglutide 14 mg vs liraglutide 1.8 mg in PIONEER 4 (Table 1).

Conclusion: Multifactorial risk factor management is fundamental to long-term risk reduction in patients with T2D. Oral semaglutide was more effective at improving multiple cardiometabolic risk factors vs comparators, indicating its potential to help address the full cardiometabolic profile for patients with T2D.
Clinical Trial Registration Number: NCT02906930; NCT02863328; NCT02607865; NCT02863419; NCT02827708; NCT02692716; NCT02849080; NCT03021187.

Supported by: Funded by Novo Nordisk A/S.


610 Reduced risk of kidney function loss in patients with type 2 diabetes treated with GLP-1 receptor agonists versus basal insulin

C. Melzer Cohen1, M. Schechter2,3, I. Yanuv2,3, A. Rozenberg2,3, G. Chodick4,5, T. Abrahamse4, A. Clark6,7, J. Lawson8, A. Karasik6,9, O. Mosenzon2,3,1

1Maccabi Institute for Research and Innovation, Maccabi Health Services, Tel Aviv, Israel, 2Diabetes Unit, Hadassah Medical Center, Jerusalem, Israel, 3Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel, 4School of Public Health Sackler, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 5Novo Nordisk A/S, Copenhagen, Denmark, 6Tel Aviv University, Tel Aviv, Israel.

Background and aims: Several GLP-1 receptor agonists (GLP-1 RAs) have been shown to reduce albuminuria in populations with type 2 diabetes (T2D), with data also suggesting that they may reduce the rate of kidney function decline. This study used data from Maccabi Healthcare Services, a large Israeli state-mandated care provider, to assess changes in kidney function among initiators of GLP-1 RAs compared with matched patients (mean age, 59.4 years [SD, 9.4]; 45% women; 49% had T2D for more than 10 years; 21% with history of cardiovascular disease).

Materials and methods: Adults with T2D using basal insulin (BI) and those initiated on any GLP-1 RA drugs were matched 1:1 based on age group (<52, 52-62, 62-72 years), sex, duration of T2D (0-5, 5-10, >10 years), cardiovascular disease status (yes/no), and baseline eGFR (≥90, 60-89, <60 mL/min/1.73 m2). The study population was generally healthy from a kidney perspective, with a mean eGFR of 90.6 mL/min/1.73 m2 [SD 19.3] and median UACR of 14.6 mg/g [IQR, 0.0-54.9]. The median follow-up times were 8.22 months (ITT) and 22.6 months (AT). Compared with BI, initiation of GLP-1 RA was associated with a lower risk of categorical increase in UACR in both the ITT (hazard ratio (HR) [95% CI] 0.90 [0.83-0.97]) and AT (HR: 0.85 [0.76-0.96]) analyses. The HR of the composite outcome of confirmed ≥40% eGFR decline or new ESKD was 0.96 [0.82-1.11] and 0.71 [0.54-0.95] in the ITT and AT analyses, respectively. The HR for 30%, 40%, 50%, and 57% confirmed eGFR decline in the ITT analyses were 0.98 [0.87-1.11], 0.96 [0.82-1.12], 1.11 [0.91-1.37] and 1.04 [0.80-1.34]. In the AT analyses, the respective HRs were 0.74 [0.60-0.91], 0.73 [0.54-0.97], 0.74 [0.49-1.12] and 0.62 [0.35-1.10], respectively.

Conclusion: The findings suggest that continuous use of GLP-1 RA may be associated with improved kidney outcomes, including a lower risk for kidney function loss, among patients with type 2 diabetes and preserved baseline kidney function. The ongoing FLOW trial will directly determine whether the GLP-1 RA once-weekly subcutaneous semaglutide reduces the risk of kidney disease progression in people with T2D and CKD.

Supported by: Novo Nordisk A/S

Disclosure: C. Melzer Cohen: None.

611 Chronic administration of the novel hypoglycaemic peptide exhibits robust efficacy in a diet-induced model of obesity and type 2 diabetes

N. Mitkin, V. Pavshintsev, I. Doronin, G. Bakbin, A. Malyshiev; Metabico, Inc., Newton, USA.

Background and aims: CHM-273S is a novel peptide, which in recent studies provided pronounced blood glucose lowering effect in the rats with metabolic syndrome during acute administration. This effect was accompanied by improvement of insulin resistance index (HOMA-IR) and induction of insulin signaling pathway in the liver, that indicates the ability of the peptide to enhance insulin sensitivity. In the present work, we aimed to study chronic effects of the peptide in animals affected by diet-induced metabolic disorder.

Materials and methods: The metabolic syndrome was modeled in male C57BL/6 mice, which were kept on a 45% high-fat diet (HFD) for 16 weeks. 40 mice with the maximum weight gain were selected for the subsequent experiment. The control group (n=10) was kept on a standard diet (STD) during this period. Chronic CHM-273S effects were studied in result of its administration for 4 weeks (i.o. or i.p. administration, 5 mg/kg, once-daily) compared with metformin (p.o. administration, 250 mg/kg, once-daily). STD and HFD controls were i.p. injected with saline in the same regimen. Bodyweight was monitored three times a week. At the end of the study, blood and visceral adipose tissue samples were collected. Blood serum samples were analyzed for glucose level, insulin concentration, and TNF-α level. Visceral fat mass was measured, and adipocyte size was estimated applying histological analysis.

Results: HFD for 16 weeks resulted in a 35% and 30% increase in blood glucose level and body weight respectively. Administering CHM-273S (both i.o. and i.p.) for four weeks reduced blood glucose levels by more than 12% demonstrating an effect comparable to that of metformin. In addition, treatment with CHM-273S led to the normalization of HOMA-IR, which was significantly increased after HFD. These data suggest strong hypoglycemic properties of CHM-273S and its ability to attenuate insulin resistance. Animals treated with CHM-273S (i.o. and p.o.) exhibited a 30% loss of excess body weight compared to untreated mice, while administration of CHM-273S (i.o. and i.p.) resulted in a loss of 10%. Chronic CHM-273S (i.o. and i.p.) treatment led to a decreased visceral fat weight, and the linear size of adipocytes compared to the HFD control group, that indicates the association of bodyweight loss with the reduction of fat mass. Serum levels of pro-inflammatory TNF-α cytokine were increased.
significantly increased in HFD control mice, indicating systemic inflammation. Chronic i.n. CHM-273S administration reduced TNF-α concentration to the STD control level in the same manner as metformin.

**Conclusion:** Chronic CHM-273S peptide administration effectively alleviates symptoms of metabolic syndrome induced by the HFD in C57BL/6 mice.

**Disclosure:** N. Mitkin: None.

### 612
**Effectiveness and tolerability of once-weekly GLP-1 receptor agonists in clinical practice: a focus on switching between once-weekly molecules in type 2 diabetes**

G. Formoso, G. Di Dalmazi, S. Coluzzi, M.P.A. Baldassarre, A. Ghiri, G. Graziano, M.C. Rossì, B. Ciappini, M. Milo, F. Carrié, A. Nicolucci, A. Consoli

1Department of Medicine and Aging Sciences, “G. d’Annunzio” University of Chieti-Pescara, Chieti, 2Center for Advanced Studies and Technology (CAST), “G. d’Annunzio” University of Chieti-Pescara, Chieti, 3Endocrinology and Metabolic Disease Clinic of Pescara, Pescara, 4CORESEARCH-Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy.

**Background and aims:** To date, just a few phase III randomized controlled trials (RCTs) directly compared the efficacy of different glucagon-like peptide receptor agonists (GLP-1RAs). In addition, direct comparisons among GLP-1RAs have been relatively limited in Real World Data. Thus, there is the need for a real-world setting comparative analysis of available once-weekly (OW) GLP-1RAs, in order to support data from RCTs and to provide information that may aid physicians in their decision process. Aims of this study were to evaluate the effectiveness and tolerability of OW GLP-1RAs and to assess the clinical benefits of switching from one GLP-1RA to another (switchers) in a routine clinical setting.

**Materials and methods:** Retrospective, real-world cohort study, based on electronic medical records utilized in one Italian diabetes clinic. Estimated mean changes in HbA1c and body weight after 6 and 12 months from the first prescription of a OW GLP1-RA were evaluated using longitudinal linear mixed models for repeated measures. The effectiveness of the three OW GLP1-RA was compared separately in the GLP1-RA naïve and switchers cohorts, after propensity score adjustment.

**Results:** A total of 1,001 patients with type 2 diabetes treated with an OW GLP-1RA were included in this study. Among these, 379 (37.9%) patients received OW semaglutide, 435 (43.4%) dulaglutide or 187 OW exenatide (18.7%). Initiating a long-acting GLP-1RA was associated with the most marked reduction (-0.84%; 95%CI -1.03; -0.65 and -6.29 Kg; 95%CI -7.94;-4.63). In the switchers’ cohort, statistically significant improvements in HbA1c (-1%) and body weight (-5.8 Kg; 95%CI -8.05;-3.55) at 6 months, maintained at 12 months (-4.4 Kg; 95%CI -6.11;-2.75). Drop-out rates were 9.2%, 28.5%, and 41.7% in semaglutide, dulaglutide, and exenatide groups, respectively.

**Conclusion:** The effectiveness and tolerability of the OW GLP-1RAs in the real world were documented. OW semaglutide was associated with the highest response without impact on safety. Clinical improvements were obtained even in switchers, especially in those switching to OW semaglutide.

**Disclosure:** G. Formoso: None.
**Conclusion:** The GCGR/GLP-1R dual agonist, BI 456906, effectively lowered HbA1c up to −1.9% (1.8 mg qw) after 16 weeks in patients with T2D. HbA1c reductions were in line with semaglutide 1.0 mg qw (−1.5%). GI adverse events are expected to be mitigated with slower dose escalations.

Clinical Trial Registration Number: NCT04153929

Supported by: BI

Disclosure: J. Rosenstock: Non-financial support; Medical writing support.

---

**614**

**Glycaemic control with tirzepatide in people with type 2 diabetes by baseline HbA1c ≤ 69.4 mmol/mol or >69.4 mmol/mol**

C. De Block1, G. Aleppo2, J.A. Levine3, E.G. Valderas3, B.D. Benneyworth2;

1Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, Antwerp, Belgium, 2Feinberg School of Medicine, Northwestern University, Chicago, USA, 3Eli Lilly and Company, Indianapolis, USA.

**Background and aims:** Tirzepatide, a once weekly GIP/GLP-1 receptor agonist in development for type 2 diabetes (T2D), demonstrated superior glycaemic control in the Phase 3 SURPASS clinical trial program. This post-hoc analysis assessed glycaemic control with tirzepatide in participants stratified by baseline (BL) HbA1c (≤69.4 mmol/mol [8.5%], >69.4 mmol/mol [8.5%]).

**Materials and methods:** Mean change from BL in HbA1c was assessed in tirzepatide-treated participants (5, 10 or 15 mg) from SURPASS-1 (monotherapy), SURPASS-2 (add-on to MET), SURPASS-3 (add-on to MET + SGLT2i), SURPASS-4 (add-on to MET, SGLT2i, or sulfonylurea) and SURPASS-5 (add-on to insulin glargine ± MET) at trial endpoints (40 or 52 weeks). Safety was also presented. Treatment comparisons were estimated using data while participants were on treatment and without rescue medications (efficacy estimand).

**Results:** Across each SURPASS trial, ranges in mean BL HbA1c were 63.3-69.6 mmol/mol (7.94-8.52%), mean BMI were 31.9-34.2 kg/m2 and mean diabetes duration were 4.7-13.3 years. At trial endpoints, HbA1c reductions from BL ranged from 16.9-23.4 mmol/mol (1.55-2.14%) in the BL HbA1c ≤69.4 mmol/mol (8.5%) subgroup and 29.5-37.8 mmol/mol (2.70-3.46%) in the BL HbA1c >69.4 mmol/mol (8.5%) subgroup (Table). Gastrointestinal side effects were similar to those reported in the incretin class and hypoglycaemic events (blood glucose <3.00 mmol/l [54 mg/dL]) or severe) were low.

**Conclusion:** In conclusion, significant and clinically meaningful HbA1c reductions were observed with tirzepatide, irrespective of BL HbA1c.

Disclosure: C. De Block: Honorarium; Abbott, AstraZeneca, Boehringer Ingelheim, Menarini Diagnostics, Eli Lilly, Medtronic, Novo Nordisk and Roche. Lecture/other fees; Abbott, AstraZeneca, Boehringer Ingelheim, Menarini Diagnostics, Eli Lilly, Medtronic, Novo Nordisk and Roche.

---

**615**

**The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): 24-m clinical characteristics and treatment patterns**


1Lilly France SAS, Neuilly Sur Seine, France, 2University Hospital of Nancy, Vandœuvre Lès Nancy, France, 3University of Bari Aldo Moro, Bari, Italy, 4Eli Lilly and Company, Indianapolis, USA, 5Marienplatz Diabetes Center, Munich, Germany, 6Lilly Deutschland GmbH, Bad Homburg, Germany, 7HaaPACS GmbH, Schriesheim, Germany, 8Eli Lilly Italia SpA, Sesto Fiorentino, Italy, 9Eli Lilly Canada Inc., Toronto, Canada, 10Lilly, S.A., Alcobendas, Spain.

**Background and aims:** The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes (T2D) Patients (TROPHIES) was a 24-month, prospective, non-comparative, observational study in adult patients with T2D initiating Dulaglutide (DU) or Liraglutide (LIRA) as their first injectable glucose-lowering treatment. Clinical outcomes and treatment patterns in this real-world setting are presented here.

**Materials and methods:** Adult patients with T2D started with once-weekly DU (DU; N=1,014) or once-daily LIRA (LIRA; N=991), as per usual practice, in France, Germany and Italy. Secondary objectives included assessments of HbA1c, body weight and treatment patterns.

**Results:** Clinical characteristics of the DU and LIRA cohorts at 24 months are described in the Table. Most patients receiving DU (856/1,014) initiated treatment at 1.5 mg/week and, among 286 patients with a significant treatment change, 237 were still receiving 1.5 mg/week. In the LIRA cohort, most patients (809/991) initiated at the starting dose 0.6 mg/day and 45% increased dose to 1.2 mg/day by Day 90; however, 17% of patients were already receiving 1.8 mg/day by Day 90. At the first significant treatment change 285/448 patients in the LIRA cohort were receiving 1.2 mg/day. Insulin was initiated by 79 and 97 patients in the DU and LIRA cohorts, respectively.

**Conclusion:** Both treatments showed clinically meaningful effectiveness on HbA1c and weight, maintained over the 24-month study period, consistent with results of clinical trials.
Effects of a novel long acting GIP/GLP-1/Glucagon tri-receptor agonist, HISHS-3001, on HbA1c, body weight and lipid metabolism

R. Thennati1, V. Burade1, A. Garcia-Ocana2, R. Pratley3, G. Rutter4, T. Vilsbøll5, B. Thorens6; 1High Impact Innovations - Sustainable Health Solutions; Sun Pharmaceutical Industries Ltd, Vadodara, India, 2Ichan School of Medicine at Mount Sinai, Diabetes Obesity and Metabolism Institute, Orlando, USA, 3Department for Metabolism, Digestion, Reproduction, CR-CHUM, University of Montreal, Montreal and London, Canada, 4Clinical Research, Steno Diabetes Centre Copenhagen, Harlev, Copenhagen, Denmark, 5Centre for Integrative Genomics, University of Lausanne, Lausanne, Switzerland.

Background and aims: HISHS-3001 is a novel long-acting, Gastric inhibitory peptide (GIP)/Glucagon like peptide-1 (GLP-1)/Glucagon tri-receptor agonist. HISHS-3001 was evaluated in db/db mouse model for its anti-diabetic potentials.

Materials and methods: HISHS-3001, a synthetic peptide, was evaluated for functional assay on GLP-1, GIP and Glucagon receptor expressing cells. Effect on HbA1c, body weight change, triglyceride and Liver FGF-21 was studied in type 2 diabetes model of db/db mouse.

Results: An in-vitro cyclic AMP assay in human receptor-expressing CHO-K1 cells demonstrated that HISHS-3001 had a half-maximal effective concentration 2.9 and 6.5 fold higher than exendin-4 or GIP, respectively, and 355-fold lower than glucagon. Subcutaneous dosing every third day for 4 weeks in diabetic db/db mice of HISHS-3001 at 3 and 20 nmol/kg reduced HbA1c, body weight, triglycerides and glucagon levels robustly and markedly more than tirzepatide (Table). Treatment with HISHS-3001 also led to an increase in serum and liver Fibroblast Growth Factor-21 (FGF-21) levels vs. tirzepatide.

Conclusion: In conclusion, HISHS-3001 is a potent, long acting GIP/GLP-1/glucagon tri-receptor agonist, with higher effects on glucose homeostasis and metabolic biomarkers in diabetic mice than tirzepatide.

Disclosure: R. Thennati: None.
618
Cardiorenal and safety outcomes with finerenone in patients with obesity, CKD and type 2 diabetes

1NorthShore University Health System/ UChicago Pritzker School of Medicine, Chicago, USA, 2Charité Universitätsmedizin, Berlin, Germany, 3UChicago Medicine, Chicago, USA, 4Uni of Athens, Attikon University Hospital, Athens, Greece, 5Uni Michigan, Ann Arbor, USA, 6Institute of Research i+12, Madrid, Spain, 7Duke University School of Medicine and Duke Clinical Research Institute, Durham, USA, 8Diabetes Unit, Hadassah Medical Center, Jerusalem, Israel, 9Endocrinology and Metabolism Institute, Endocrinology Metabolism Institute, Cleveland, USA, 10Bayer AG, Berlin, Germany, 11Bayer AG, São Paulo, Brazil, 12Bayer AG, Barcelona, Spain, 13Uni Copenhagen, Copenhagen, Denmark.

Background and aims: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist (MRA), reduced the risk of cardiovascular (CV) and kidney outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) in FIDELITY, a prespecified pooled analysis of the FIDELIO-DKD and FIGARO-DKD trials. Patients with visceral adiposity have been shown previously to respond better to MRAs than patients without visceral adiposity; here, we explore the efficacy and safety of finerenone in patients with obesity.

Materials and methods: Patients with T2D and CKD (with urine albumin-to-creatinine ratio [UACR] ≥30-5000 mg/g and estimated glomerular filtration rate [eGFR] ≥25 ml/min/1.73 m²), receiving optimised renin-angiotensin system blockade, were randomised 1:1 to finerenone or placebo. The efficacy of finerenone vs placebo on composite CV outcomes (CV death, non-fatal myocardial infarction, non-fatal stroke, or hospitalisation for heart failure) was assessed, and effects of WHR category (substantially increased: HR 0.84, 95% CI 0.77-0.93; not substantially increased: HR 0.88, 95% CI 0.83-0.93) were explored. Of the patients with substantially increased WHR, 56% had a BMI ≥30 kg/m². There was a numerically higher rate of CV events observed in patients with substantially increased WHR compared to those without (substantially increased, 13.8% [1671/12,124] of patients; not substantially increased, 10.1% [85/844] of patients). The effect of finerenone on the CV composite outcome was not modified by WHR category (substantially increased: HR 0.84, 95% CI 0.77-0.93; not substantially increased: HR 1.15, 95% CI 0.74-1.80). Overall, treatment-emergent adverse events were balanced between finerenone and placebo, and across WHR subgroups. The incidence of hyperkalaemia leading to treatment discontinuation with finerenone vs placebo was 1.7% vs 0.5% and 1.1% vs 1.2% in patients with a substantially increased and not substantially increased WHR, respectively.

Conclusion: In FIDELITY, the efficacy and safety of finerenone in patients with CKD, T2D and obesity (as defined by substantially increased WHR) was broadly consistent with the overall population.

Clinical Trial Registration Number: FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049)

Supported by: Bayer AG supported this analysis, who funded the FIDELIO-DKD & FIGARO-DKD studies & combined analysis

Disclosure: L.K. Billings: Honorarium; has received honoraria from Eli Lilly, Sanofi, Novo Nordisk, Xeris and Bayer.

619
Betaine: a regulator of mitochondria and endoplasmic reticulum contact points (MAMs) of the hepatocytes

A. Alves1, F. Lamarche2, E. Meugnier3, S. Pesenti1, R. Lembrun4, A. Bassol5, E. Loizon1, C. Moinard6, B. Morio1;
1CarMeN Laboratory U1060 INSERM INRA 1397, Pierre Benite, France, 2LBFA Laboratory INSERM U1055, Saint-Martin-d’Hére, France, 3Department of Cell Biology, Faculty of Medicine and Dentistry, Edmonton, Canada.

Background and aims: Contact points between mitochondria and the endoplasmic reticulum (ER), called MAMs for Mitochondria-Associated Membranes, have a crucial role in the control of hepatocyte homeostasis. Recent data show that MAMs are altered in the liver of mouse models of insulin resistance and steatosis indicating that MAMs could be a novel therapeutic target for the prevention or treatment of metabolic liver disorders. These dynamic platforms can be regulated by different factors, including nutrients. We hypothesized that betaine, through its biochemical properties, could modulate the structure and function of MAMs of the hepatocytes.

Materials and methods: Primary hepatocytes from 3-month-old male Wistar rats (n=6) were isolated by a collagenase perfusion method and cultured in complete DMEM (3 g/L glucose). Cells were incubated for 18h in the culture medium with 500μM/L of BSA or palmitate (lipotoxicity model), supplemented or not with betaine (5mmol/L). MAMs structure was explored by transmission electronic microscopy (TEM) and in situ proximity ligation assay (PLA) for the functional unit of MAMs (VDAC1, mitofusin 2: Mfn2, and the chaperone protein Bcl2). Cells were also stimulated with insulin (100μM/L) for 15 min to explore the response to insulin by Western blot (PKB phosphor-ration). Matrigel seeded with an oleate/palmitate mixture (1mmol/L, 2:1), in order to assess triglyceride storage in hepatocytes by lipotoxicity assay (Triglyceride Method GPO, Biolabo). Mitochondrial respiration was measured by oxygen consumption on permeabilized cells with the substrates glutamate (5 mmol/L)/malate (2.5 mmol/L) and succinate (5 mmol/L)/rotenone (5 μmol/L). Gene expression and protein content of key actors at the MAMs (VDAC1, mitofusin 2: Mfn2, and the chaperone Gro75) were also analyzed. Statistical analysis was performed with 2 Way ANOVA and Bonferroni post hoc test, p-value<0.05.

Results: Betaine promoted MAM integrity compared to control. MAM length measured by TEM relative to mitochondrial circumference was increased by 41% under betaine compared to control (betaine 16.2% vs.
Effects of finerenone in patients with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability and duration of diabetes

J.B. McGill1, R. Agarwal2, S.D. Anker3, G.L. Bakris4, G. Filipatos5, B. Prit6, L.M. Ruliope7, A.L. Birkenfeld8, M. Carom9, M. Brinker10, A. Joseph11, A. Lage12, R. Lawatscheck11, C. Scott13, P. Rossing14; M. L. Caramo, M. Brinker, A. Joseph, A. Lage, R. Lawatscheck, C. Scott, P. Rossing; M2) were randomised to finerenone or placebo. Effects of finerenone vs placebo on CV (CV death, nonfatal myocardial infarction, nonfatal stroke or hospitalisation for heart failure) and kidney (kidney failure, sustained ≥5000 mg/g and eGFR ≤25 ml/min/1.73 m²) were consistent across HbA1c condition (p=0.001), and by 38% and 24% in palmitate condition (p<0.01), but it did not significantly impact the protein expression of the proteins.

Conclusion: Our results support our hypothesis that betaine promotes MAM integrity and insulin response in primary hepatocytes. The increase in cellular respiration evidences a beneficial effect of improved MAM integrity on mitochondrial oxidative function.

Supported by: SFD

Disclosure: A. Alves: None.

620

Effects of ertugliflozin on uric acid and gout-related outcomes: post hoc analyses from VERTIS CV

V.S. Sridhar1, F. Cosentino2, S. Dagogo-Jack3, R. Pratley4, R. Frederich5, M. Noyes Essex6, M. Maldonado7, C.-C. Liu8, J.P. Mancuso9, D.J. Chemey10; J.B. McGill: Grants; research funding paid to Washington University from NIH, Beta Bionics, Dexcom and Novo Nordisk. Honorarium; member of steering committees for Bayer and the Jaeb Center, data safety monitoring committees for NIH and the Jaeb Center, and is an associate editor of the Journal of the Endocrine Society & BMJDRC. Non-financial support; personal fees and non-financial support from Bayer, personal fees from Boehringer Ingelheim, Dexcom, Mannkind, Novo Nordisk and Prevention Bio.

Materials and methods: Patients with T2D and CKD (urine albumin-creatinine ratio [UACR] ≥30-≤5000 mg/g and eGFR ≥25 ml/min/1.73 m²) were randomised to finerenone or placebo. Effects of finerenone vs placebo on CV (CV death, nonfatal myocardial infarction, nonfatal stroke or hospitalisation for heart failure) and kidney (kidney failure, sustained eGFR decline from baseline or renal death) composite outcomes were analysed by baseline HbA1c quartiles, HbA1c variability (first year of treatment) and diabetes duration quartiles.

Results: In 13,026 analysed patients mean baseline HbA1c was 7.7% and diabetes duration was 15.4 years. Higher baseline HbA1c quartiles had longer diabetes duration and more diabetes-related complications. Risk reductions in the CV and kidney composite outcomes with finerenone vs placebo were consistent across HbA1c (p-interaction 0.52 and 0.09, respectively) and diabetes duration quartiles (p-interaction 0.12 and 0.75). HbA1c variability in the first year of treatment was associated with higher cardio renal risks; each 1 unit increase in mean absolute residual of HbA1c was associated with a 20% increased risk of a CV event (HR 1.20; 95% CI 1.07-1.35; p=0.0016) and a 36% increased risk of a kidney event (HR 1.36; 95% CI 1.21-1.52; p<0.001). The CV and kidney benefits of finerenone were not modified by HbA1c variability (p-interaction 0.48 and 0.09, respectively).

Conclusion: Greater variability in HbA1c was associated with increased risks of cardio renal outcomes. Cardio renal risk reductions with finerenone in patients with CKD and T2D were not modified by baseline HbA1c, HbA1c variability or duration of diabetes.
Conclusion: Treatment with ertugliflozin was associated with reductions from baseline in serum uric acid, and a non-significant reduction in gout-related outcome events, compared with placebo.

Clinical Trial Registration Number: NCT01986881
Supported by: Merck Sharp & Dohme Corp., Kenilworth, NJ, USA; Pfizer Inc., New York, NY, USA
Disclosure: V.S. Sridhar: None.

622 Interactions between early DPP-4is initiation and HbA1c variability with risk of insulin requirement in type 2 diabetes: real-world evidence from a prospective cohort
A. Yang1, J. Cheung1, H. Wu1, E.S. Lau1, R.C. Ma1, A.P. Kong1, W.Y. So1, A.O. Luk1, J.C. Chan1, E. Chow1;
1The Chinese University of Hong Kong, 2Hong Kong Hospital Authority Head Office, Hong Kong, Hong Kong.

Background and aims: Insufficient insulin secretion and non-suppression of glucagon are key features in type 2 diabetes (T2D). Dipeptidyl peptidase-4 inhibitors (DPP-4is) inhibit degradation of glucagon-like peptide-1 (GLP-1) which suppresses glucagon and augments prandial insulin secretion. Early combination therapy using metformin and DPP-4is reduced treatment escalation and delayed insulin requirement, whilst glycemic variability (GV) might accelerate β-cell loss and worsen glycemic control. Using real-world evidence, we evaluated the interactions between early DPP-4is initiation and HbA1c variability on risk of insulin requirement in T2D.

Materials and methods: This is a territory-wide, population-based prospective cohort including 103,744 patients with T2D initiated on DPP-4is in 2007-2018 followed up till 2019 in Hong Kong. We excluded patients treated with insulin at baseline and those with less than five HbA1c measurements during follow-up. We defined 1-year period before the first date of dispensing of DPP-4is as baseline. Insulin requirement was defined as continuous insulin treatment for at least six months during follow-up. We used Cox models adjusted for baseline and time-dependent variables including medications, risk factors and co-morbidities to compare risk of insulin requirement between patients started early (HbA1c<7.5%) or late (HbA1c≥7.5%) with DPP-4is as well as their interactions with HbA1c variability on outcome. We calculated the HbA1c variability score (HVS) defined as percentage of HbA1c values varying by 0.5% compared with the preceding value.

Results: Of 24,147 patients (53.3% men, age: 63.9±11.6 years, HbA1c: 8.3±1.3%, diabetes duration: 12.3±7.1 years) fulfilling inclusion criteria, 90.1% and 87.4% were treated with metformin and sulphonylureas respectively at baseline. During a mean follow-up of 4.1 years, 20.6% required insulin treatment. Early DPP-4is initiation was associated with lower risk of insulin requirement compared with late initiation with a hazard ratio [HR] of 0.71 (95% CI: 0.66-0.77). Stratified by median HVS value (42.8), the low HVS group had lower risk of insulin requirement than the high HVS group with a HR of 0.59 (0.56-0.63). The lowest risk was observed in patients with early initiation of DPP-4is and low-HVS (P interaction <0.001, Figure 1).

Conclusion: Early initiation of DPP-4is as combination therapy might delay insulin requirement especially in those with low HbA1c variability, possibly through preservation of beta-cell function.

623 Effects of acute and sub-chronic treatment with metformin on postprandial blood pressure and heart rate in diet-controlled type 2 diabetes
D.R. Quast1, C. Xie2, M.J. Bound2, J. Grivelli2, K.L. Jones2, M. Horowitz2, C.K. Rayner2, M.A. Nauck1, J.J. Meier3, L. Phillips2, T. Wu2;
1Diabetes Division, St. Josef-Hospital Bochum, Bochum, Germany, 2Centre of Research Excellence (CRE) in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia, 3Augusta-Hospital, Bochum, Germany.

Background and aims: There is a high prevalence of postprandial hypertension (PPH) (a fall in systolic blood pressure (BP) of ≥20 mmHg within two hours of a meal) in type 2 diabetes (T2D), which is associated with syncope, falls and increased mortality. A single dose of metformin (1 g), administered intraduodenally, has been shown to attenuate the fall in
blood pressure (BP) induced by an oral glucose drink in T2D patients, suggesting that metformin may reduce the risk of PPH, potentially by slowing of gastric emptying (GE) and stimulation of glucagon-like peptide-1 (GLP-1). We have now investigated the effects of a single dose (acute) and one-week (sub-acute) treatment of oral metformin on postprandial BP and heart rate (HR) in T2D.

**Materials and methods:** Diet-controlled T2D patients were treated with either metformin (850 mg twice daily) or matching placebo over 7 days in a double-blind, randomised, crossover design; each treatment period was separated by a two-week 'washout'. At both baseline and the end of each treatment period, a 24-hour ambulatory BP recording was performed to detect PPH (i.e., following standardised breakfast, lunch and dinner). On days 1 and 7 of both treatment periods, participants ingested 850 mg metformin or placebo 30 min before a 75 g glucose drink. BP and HR, GE (scintigraphy), and plasma glucose and total GLP-1 were evaluated at intervals over 4 hours.

**Results:** 16 T2D patients (5 female, age 69.0 ± 1.5 years, duration of known diabetes 7.8 ± 1.3 years, HbA1C 46.3 ± 1.2 mmol/mol (6.4 ± 2.3 %), BMI 27.2 ± 0.9 kg/m²) were studied. In participants who had PPH at baseline, the probability of PPH was lower during treatment with metformin versus placebo (n = 13 out of 16 (81.3 %); 13 events during 38 post-meal periods recorded (34.2 %) events on metformin vs. 23/38 (60.5 %) events on placebo, P=0.038). After one-week of metformin treatment, HR following 75 g oral glucose was higher compared to placebo (ΔHR +2.4 ± 0.9 bpm, P=0.024), although the magnitude of the reduction in systolic BP (~12 mmHg) did not differ between metformin and placebo. Metformin delayed GE (half emptying time (T50) after both acute (82.1 ± 6.8 min vs. 102.3 ± 7.2 min, P<0.001) and sub-acute treatment (83.0 ± 5.3 min vs. 102.4 ± 6.8 min, P<0.001). Following the glucose drink, plasma glucose was reduced by both acute dosing (treatment by time: P<0.001) and sub-acute treatment (treatment effect: P<0.001) of metformin. Plasma GLP-1 was unaffected by acute dosing of metformin but increased after one-week of treatment (area under the curve over 4 hours: 8411 ± 803 pmol/L*min on metformin vs. 6493 ± 610 pmol/L*min on placebo, P<0.001).

**Conclusion:** In diet-controlled T2D, oral metformin attenuates the hypotensive response to meals to reduce the probability of PPH, in association with augmentation of GLP-1 secretion and slowing of GE.

**Clinical Trial Registration Number:** ACTRN12619001060134

**Supported by:** Central Adelaide Local Health Network Inc. and the Royal Adelaide Hospital Research Committee

**Disclosure:** B.R. Quast: None.

**Materials and methods:** We used three groups of Male Wistar rats: a control group submitted to 25 weeks of a standard chow, a high fat + high sucrose (HFHSu) group submitted to 25 weeks of 60 % lipid-rich diet + 35% sucrose in drinking water and a HFHSu group submitted to a caffeine intake (1g/kg) in drinking sucrose in the last 11 weeks of diet. Rats were evaluated for body weight gain, insulin sensitivity, by insulin tolerance test (ITT), and glucose tolerance, by oral glucose tolerance test (OGTT), throughout the 25 weeks. BAT samples were collected at the end and used for western blot analysis of the levels of hypoxia-inducible factor2-alpha (Hif-2α), equilibrative nucleoside transporter 1 (ENT1), adenosine receptors (A1, A2A and A2B), inflammation markers as interleukin-1 receptor (IL-1r) and angiogenesis markers as vascular endothelial growth factor VEGF.

**Results:** HFHSu diet increased weight gain and promoted whole-body insulin resistance and glucose intolerance. Caffeine intake prevented HFHSu-induced increase in weight gain and attenuated insulin resistance, without affecting glucose tolerance in HFHSu animals. In BAT, there was no alteration in A1 receptor levels in HFHSu or HFHSuCAF animals. HFHSu diet decreased the levels of A2B receptor, an effect reverted by caffeine treatment (CTL = 100% ± 29.93; HFHSu = 63.43% ± 19.30, p<0.05 comparing to CTL; HFHSuCAF = 109.77% ± 33.72, p<0.01 comparing to HFHSu). ENT1 levels expression increased with HFHSu diet while caffeine treatment decreased these levels (CTL = 100% ± 25.06; HFHSu = 159.4% ± 59.45, p<0.01 comparing to control; HFHSuCAF = 69.78% ± 24.72, p<0.01 comparing to HFHSu). Hif-2α levels showed a significant increase with the HFHSu diet, effect attenuated by caffeine treatment (CTL = 100% ± 20.15; HFHSu = 162.8% ± 55.48, p<0.05 comparing to CTL; HFHSuCAF = 130.4% ± 21.66). HFHSu diet significantly reduced VEGF levels and caffeine attenuated this reduction (CTL = 100% ± 21.68; HFHSu = 76.98% ± 19.32, p<0.05 comparing to CTL; HFHSuCAF = 90.43% ± 21.45). IL-1r levels increased by HFHSu diet, being this decreased by caffeine (CTL = 100% ± 21.72; HFHSu = 148% ± 74.20, p<0.05 comparing to CTL; HFHSuCAF = 64.13% ± 21.13, p<0.05 comparing to HFHSu).

**Conclusion:** Caffeine improvements in weight gain and insulin resistance were accompanied by the reversion of diet-induced dysfunction in BAT. Modulation of BAT adenosinergic system can be a therapeutic target for the treatment of obesity and insulin resistance.

**Supported by:** PCT, FOM: CEECIND/04266/2017.

**Disclosure:** A.C.F. Soares: None.
SO 48 Hypoglycaemia: hip hip hooray yet to come

625 Hypo-metrics: associations between hypoglycaemia awareness, blood glucose range and patient-reported hypoglycaemia symptoms in type 1 diabetes

G. Martine-Edith1, P. Divilly1, N. Zaremba1, U. Soholm1,2, Z. Mahmoudi3, M. Gomes3, M. Bradley2, J. Speight2,4, S.A. Amiel1, F. Pouwer2,4, P. Choudhary1,2, Hypo-RESOLVE Consortium;
1Department of Diabetes, King’s College London, London, UK, 2Department of Psychology, University of Southern Denmark, Odense, Denmark, 3Department of Digitalization and Modelling, Novo Nordisk A/S, Copenhagen, Denmark, 4Deakin University, Geelong, Australia, 5Diabetes Research Centre, University of Leicester, Leicester, UK.

Background and aims: The experiences of hypoglycaemia vary between- and within-individuals with diabetes. Yet, we lack a tool to measure and document hypoglycaemia symptoms experienced in daily life. Using preliminary data from a novel mobile-phone based app developed for participants to record hypoglycaemia symptom intensity in real time for the Hypo-METRICS study, we evaluated the associations between hypoglycaemia awareness, blood glucose range and patient-reported hypoglycaemia symptoms.

Materials and methods: In the 10-week study, participants with type 1 diabetes used the app to record all episodes of symptomatic or measured hypoglycaemia. At, or near, the time of the hypoglycaemic event, participants reported hypoglycaemia symptoms (e.g., sweating, heart palpitations shaking and hunger) and measured glucose (<2 mmol/L, 2-2.9mmol/L, 3-3.9mmol/L and >3.9mmol/L). A symptom was considered to be absent if participants rated its intensity as ‘Not at all’ and present if rated as ‘A little bit’, ‘Somewhat’, ‘Quite a bit’ or ‘Very much’. Adjusting for capillary or continuous glucose monitoring, we used mixed-effects logistic regression to model the associations between hypoglycaemia awareness (defined by Gold score), glucose range and the presence of autonomic symptoms of hypoglycaemia.

Results: 142 participants (72% using Flash/continuous glucose monitoring and 24% with impaired awareness of hypoglycaemia (IAH)) reported 3,994 hypoglycaemia episodes. Median(IQR) age was 49(37-60) years and diabetes duration 23(11-37) years. Participants with IAH had lower odds of reporting shaking (OR 0.29 (95% CI 0.14-0.61)) than those with normal awareness. As shown in Figure 1, except for hunger, participants had higher odds of reporting autonomic symptoms at lower glucose levels.

Conclusion: Using Hypo-METRICS app data, we identified quantitative differences in the reporting of hypoglycaemia autonomic symptoms according to hypoglycaemia awareness and glucose range. As there is potential to also assess variability in symptom intensity, the app provides a comprehensive tool to evaluate hypoglycaemia symptoms.

Clinical Trial Registration Number: NCT04304963
Supported by: IMI

626 Persistence of impaired awareness of hypoglycaemia, severe hypoglycaemic events and suboptimal glycaemic control despite advanced diabetes technologies

1Yale University School of Medicine, New Haven, 2T1D Exchange, Boston, 3Vertex Pharmaceuticals, Boston, 4Evidera PPD, Waltham, 5University of California San Diego, San Diego, USA.

Background and aims: Trials of continuous glucose monitors (CGMs) and hybrid closed-loop systems (HCLS) demonstrate improvements in glycaemia with reductions in hypoglycaemia in T1D, but there is a paucity of real-world data on how these technologies impact prevalence of impaired awareness of hypoglycaemia (IAH), severe hypoglycaemic events (SHEs), and glycaemic control.

Figure 1. Associations between blood glucose range and presence of hypoglycaemic autonomic symptoms

Clinical Trial Registration Number: NCT04304963
Supported by: IMI
Materials and methods: We conducted a one-time online survey of adults with T1D in the T1D Exchange registry and online communities. Self-reported medical histories (insulin delivery method, HbA1c, IAH, SHEs) and CGM data were collected.

Results: 2,044 patients (mean age 43 y, mean T1D duration 26 y, 72% female, 95% White) completed the survey. Most reported using CGM (92%); 953 also used HCLS. Mean HbA1c was 6.89%, 41.5% had a HbA1c of ≥ 7%, 30.7% reported IAH, 19.8% had ≥ 1 SHE in the prior year, 12.0% had ≥ 2 SHEs in the prior year, 9.6% had IAH + ≥ 1 SHE, and 6.6% had IAH + ≥ 2 SHEs (Table). Rates of SHEs and IAH + SHEs were lower in CGM users and in CGM + HCLS users compared to non-CGM users; however, among CGM + HCLS users, 16.6% reported ≥ 1 SHE, 8.7% ≥ 2 SHEs, 7.8% IAH + ≥ 1 SHE, and 4.7% IAH + ≥ 2 SHEs. Also, 35.6% of CGM + HCLS users had a HbA1c of ≥ 7%.

Conclusion: In a patient cohort with high rates of technology adoption, rates of SHEs and IAH remained high, with a significant proportion of patients not achieving targeted glycaemic control, indicating the need for novel T1D treatments.

Table. Proportion (%) of patients (95% CI) with SHE, IAH, and inadequate glycaemic control, overall and by method of glycemic monitoring. We aimed to survey the prevalence of IAH in the adult T1D clinic of a tertiary teaching hospital and identify factors associated with risk of IAH.

Materials and methods: Adults (age ≥18 years) with a diagnosis of T1D for ≥2 years were approached. They completed a questionnaire which included a Gold score, a Clarke score and questions about history of SH and technology use. Health records were reviewed to collect data on: diabetes history, HbA1c, sex, Scottish Index of Multiple Deprivation (SIMD) quintile and diabetes-related hospital admissions in the previous 12 months. Outcomes were compared between groups with normal awareness of hypoglycaemia and IAH (defined as a Gold score ≥4). Normally distributed data was compared using the independent t-test and non-normally distributed the Mann-Whitney U Test. Categorical data was compared using chi-squared.

Results: 150 people with T1D (59.7% female) completed the survey. Of these 44.7% were insulin pump users and 87.3% used intermittently scanned continuous glucose monitors. 12% of responders were using real-time continuous glucose monitoring and 2.7% hybrid closed-loop therapy. The mean (SD) age of the responders was 40.9 (14.9) years, the time since diagnosis 22 (13.6) years and the age at diagnosis 18.8 (11.2) years. IAH was defined as a Gold or Clarke score ≥4. The proportion of responders with IAH was 18.7%. SH in the previous 12 months was more common in responders with IAH, with 8 (29.6%) vs 13 (10.7%) (p=0.027) reporting an episode. Responders with IAH were more likely to have required treatment with intravenous glucose (p=0.030) and to come from a more deprived SIMD quintile (p=0.007). There was no group difference in the use of diabetes technologies.

Conclusion: This survey has demonstrated that despite advances in the management of T1D the prevalence of IAH has remained unchanged. The fact that there was no group difference in the use of technology highlights the need for further studies exploring the benefit of these systems for people with IAH. The survey also demonstrated that those with IAH are still at increased risk of SH, although the overall number of episodes was low. The use of the more advanced technologies, such as HCL, in this patient cohort was low but this is reflective of technology use in our patient population, where reimbursement for isCGM and CSII is more common. Worryingly this survey has highlighted ongoing socioeconomic disparities, with those living in the most deprived areas more likely to have IAH.

627 The prevalence of hypoglycaemia remains unchanged despite advances in the management of type 1 diabetes

F.A. Baxter1, N. Baillie1, A.R. Dover2, R.H. Stimson1,2, F.W. Gibb1,2, S. Forbes1,2.
1BHF Centre for Cardiovascular Science, University of Edinburgh, 2Department of Diabetes, Royal Infirmary Edinburgh, Edinburgh, UK.

Background and aims: Hypoglycaemia is a well described side-effect of insulin treatment in type 1 diabetes (T1D). Recurrent hypoglycaemia can lead to impaired awareness of hypoglycaemia (IAH) which increases the risk of severe hypoglycaemia (SH), linked to morbidity and mortality. Diabetes technologies have been shown to reduce exposure to hypoglycaemia, however there is little evidence of their impact on IAH.

Supported by: Vertex Pharmaceuticals

Disclosure: J. Sherr: Other; J.Sherr has conducted clinical trials for Eli Lilly, Insulet, and Medtronic and has consulted for Eli Lilly, Insulet, and Medtronic and has received in-kind support for research studies from Dexcom and Medtronic. She has consulted for Eli Lilly, Lexicon, Medtronic, Sanofi, and Zealand. She has been a member of advisory boards for Bigfoot Biomedical, Cecelia Health, Eli Lilly, Insulet, the T1D Fund, and Vertex.

Supported by: FA Baxter and N Baillie are supported by a grant for the Helmsley Charitable Trust

Disclosure: F.A. Baxter: None.
629
Real-world estimates of severe hypoglycaemia and associated healthcare utilisation in the US: prospective, longitudinal results of the INPHORM study
A. Ratzki-Leewing1, J. Black1, A. Kahkoska2, B. Ryan1, S. Harris1;
1Western University, London, Canada, 2UNC School of Medicine, Chapel Hill, USA.

Background and aims: Severe hypoglycaemia (SH) surveillance in the United States (US) often uses data from electronic medical or claims records. However, these sources fail to capture hypoglycemia events not requiring healthcare utilization (i.e., paramedical services, emergency department [ED] care, hospitalization). To better understand SH burden in the US, we quantified real-world SH rates and associated healthcare utilization using prospective, longitudinal, self-reported data from the INPHORM study.

Materials and methods: Adults (18-90 years old) with insulin- and/or secretagogue-treated type 1 or 2 diabetes (T1D, T2D) were recruited from a US-wide probability-based internet panel. Twelve monthly online questionnaires were distributed assessing respondents’ socio-demographic and clinical characteristics, as well as self-reported SH events. Between February 2020 and March 2021, annual crude SH incidence rates and proportions were estimated using negative binomial regression and Wilson’s confidence intervals for binomial proportions, respectively. Frequencies were computed overall, and by diabetes type, medication regimen, and type of healthcare utilization required.

Results: Data from 985 participants were analyzed (T1D: 17%; age: 51 [SD: 14.3] years; male: 49.5%; T1D/T2D duration: 12 [IQR: 14] years; retention rate: 88.6%). Among T2D respondents at baseline, 38% were on insulin alone, 38% secretagogues alone, and 24% insulin plus secretagogues. Overall, the rate of SH was 4.99 (95% CI: 4.14 to 6.01) events per person-year (EPPY), and 33.1% (95% CI: 30.2 to 36.0%) reported ≥1 event. Fewer participants with T2D than T1D reported experiencing ≥1 SH event over follow-up (30.9% [95% CI: 27.9 to 34.1%] vs. 44.2% [95% CI: 36.9 to 51.9%]), respectively; however, their SH rates were comparatively higher (T2D: 5.27 [95% CI: 4.25 to 6.53] EPPY; T1D: 3.55 [95% CI: 2.49 to 5.08] EPPY). Among participants with T2D, those using insulin plus secretagogues reported experiencing higher crude rates (14.6 [95% CI: 10.9 to 19.7] EPPY) than those using insulin alone (1.67 [95% CI: 1.23 to 2.26] EPPY) or secretagogues alone (3.78 [95% CI: 2.50 to 5.73] EPPY). Of all SH events (n=4012), over half (62.9%) were treated outside of hospital. ED care was required in 9.1% of events (T1D: 2.7%; T2D: 9.9%), and only 4.6% of events (T1D: 1.6%; T2D: 4.9%) resulted in hospitalization. Participants with T2D, as compared to T1D, reported higher SH frequencies resulting in paramedical services, ED care, or hospitalization (1.34 [95% CI: 0.95 to 1.88] EPPY versus 0.18 [95% CI: 0.07 to 0.41] EPPY, respectively). Rates of SH resulting in healthcare utilization were highest among people with T2D taking insulin plus secretagogues (3.98 [95% CI: 2.85 to 5.55] EPPY) versus insulin alone (0.22 [95% CI: 0.08 to 0.60] EPPY) or secretagogues alone (1.07 [95% CI: 0.52 to 2.21] EPPY).

Conclusion: This analysis offers the first prospective, longitudinal data on self-reported SH rates in the US and associated healthcare utilization. In this study, SH was an alarmingly common issue that affected both T1D and T2D. A minority of events resulted in healthcare utilization, suggesting that surveillance based on healthcare records underestimate the true real-world burden of SH. Future studies should integrate self-reported data with clinical and administrative records to improve epidemiological studies and SH prevention in the real world.

Clinical Trial Registration Number: NCT04219514
Supported by: Sanofi Global Disclosure: A. Ratzki-Leewing: Grants; Sanofi Global, Honorarium; Eli Lilly, Novo Nordisk, Sanofi Canada.
Background and aims: Physical activity (PA) has been proposed to improve the counterregulatory response to hypoglycaemia. Therefore, PA may have the potential to improve hypoglycaemia awareness and reduce the risk of severe hypoglycaemia. However, the interplay between awareness status, PA and risk of severe hypoglycaemia is poorly described. The aim of this study was to investigate the association between self-reported PA and risk of severe hypoglycaemia in people with type 1 diabetes (T1D).

Materials and methods: This was a cross-sectional study with data from a survey and patient records. We approached adults with T1D from the outpatient clinics at Northern General Hospital in Sheffield (UK), Nordsjællands Hospital (DK) and Steno Diabetes Center Aarhus (DK). Data on self-reported PA were collected using the Saltin-Grimby scale. Hypoglycaemia awareness was assessed using the Pedersen-Bjergaard method, and clinical variables were collected in patient records. Respondents were stratified into three PA groups: moderate-vigorous PA, light PA, and physically inactive. A log-linear negative binomial method, and clinical variables were collected in patient records.

Results: In total we included questionnaires from 338 persons with T1D (31% from UK and 69% from DK, 47% females, age 47±18 (mean±SD) years, duration of diabetes 23±16 years, 29% on insulin pumps). 83% had experienced zero episodes of severe hypoglycaemia in the preceding year, 10% had experienced 1-3 episodes, and 7% had experienced 4 or more episodes. In the univariate model, decreasing age (0.022 [0.005; 0.039], p<0.010), normal hypoglycaemia awareness vs unawareness (-0.85 [-1.6; -0.1], p=0.033), and moderate-vigorous PA vs inactivity (-2.1 [-2.8; -1.4], p<0.001) were associated with reduced episodes of severe hypoglycaemia. In the adjusted analysis, moderate-vigorous PA vs inactivity (-2.1 [-2.8; -1.4], p<0.001) was associated with reduced episodes of severe hypoglycaemia, in a dose dependent way. Hypoglycaemia awareness and age were not associated with episodes of severe hypoglycaemia in the adjusted model.

Conclusion: A lifestyle with a low level of physical activity is associated with increased risk of severe hypoglycaemia, even after adjustment for hypoglycaemia awareness status, HbA1c and age. While this suggests a link between physical activity and hypoglycaemia awareness, potential causality and mechanism of action remains to be established.

Materials and methods: Data came from 2 exercise studies (EXTOD education and EXTOD 101) with each having data on age, sex, length of diabetes, body mass index, HbA1c, C-peptide and time, length, intensity (BORG scale) and type (aerobic, anaerobic and mixed) of exercise sessions. EXTOD education had 2 weeks of Dexcom G6 data from 54 participants and EXTOD 101 8 weeks of Freestyle Libre data from 34 participants. In total there were 976 bouts of exercise. The thresholds for low glucose and high glucose were set to 7 and 15mmol/L. A single reading below or above the threshold was considered as a positive event. 486 bouts contained a glucose reading below 7 and 151 had glucose reading above 15mmol/L. 80% of this data was used to train an ML algorithm (XGBoost) which then determined how important each measure was and what was the best combination. This was then tested on the remaining 20% of data using area under the receiver operator curve (ROC AUC) score as the validation metric.

Results: For predicting a glucose reading below 7mmol/L, the addition of the best 6 measures identified by ML resulted in a ROC AUC score 0.902. These, in order of importance, were glucose at start of exercise (starting glucose), duration of exercise, type of exercise, intensity, time of day and C-peptide. For predicting glucose above 15mmol/L, incorporating the best 7 measures resulted in a ROC score of 0.973. These were start glucose, duration, intensity, sex, years since diagnosis, C-peptide, and time of day. The two most important measures were start glucose and duration of exercise bout in both contexts. Using only these features, a ROC AUC score of 0.890 was achieved for predicting low glucose and 0.968 for high glucose. The model accuracy and sensitivity-specificity intersect was 0.804 and 0.804 for low glucose and 0.949 and 0.900 for high. Using logistic analysis, we have taken these two measures to develop a heat map that can help patients predict their risk of going below 7 or above 15mmol/L during an exercise.

Conclusion: ML has produced a simple heat map to predict risk of glucose going below 7 or above 15mmol/L during exercise. We will go on to look at whether it can predict lower glucose levels during exercise and at times further away from the start of exercise.

Table 1

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariate</th>
<th>Multivariate</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>0.022 [0.005; 0.039]</td>
<td>0.010</td>
<td>0.018 [0.006; 0.036]</td>
</tr>
<tr>
<td>HbA1c (mmol/mol)</td>
<td>0.012 [-0.010; 0.034]</td>
<td>0.275</td>
<td>0.006 [-0.023; 0.023]</td>
</tr>
<tr>
<td>Awareness status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Unawareness</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Normal awareness</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Hypoglycaemia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Activity level last year</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Light active</td>
<td>-2.1 [-2.8; -1.4]</td>
<td>-0.001</td>
<td>-2.4 [-3.3; -1.4]</td>
</tr>
<tr>
<td>- Moderate-vigorous active</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Disclosure: P.L. Kristensen: None.
Background and aims: Hypoglycaemia acutely activates the immune system and is associated with an increased risk for atherosclerotic disease. Since atherosclerosis is driven by chronic inflammation, we set out to determine the duration of the pro-inflammatory response to a hypoglycaemic event in people with or without diabetes.

Materials and methods: Adults with type 1 diabetes (n = 47) or insulin-treated type 2 diabetes (n = 15), and age-matched controls without diabetes (n = 32) underwent a hyperinsulinaemic-euglycaemic (5.2 ± 0.4 mmol/L) glucose clamp. Participants were 54% male, had an average age of 51 (±17) years, BMI of 26 (±4) kg/m², HbA1c of 53 (±16) mmol/mol and a disease duration of 20 (±13) years. Before, during and up to a week thereafter, blood was drawn to determine circulating immune cell composition using flow cytometry combined with measurements of circulating hscarb concentrations and a proteomics panel consisting of 92 circulating inflammatory markers.

Results: In response to hypoglycaemia, absolute numbers of lymphocytes (1.57 ± 0.53 vs 2.69 ± 0.95·10³/μL) and monocytes (0.40 ± 0.14 vs 0.62 ± 0.22·10³/μL) increased acutely and remained elevated for one week in all subgroups (all p < 0.001). During hypoglycaemia, the proportion of pro-inflammatory CD16⁺-monocytes increased from 26.9 ± 13.3% to 38.1 ± 14.9% and the proportion of phagocytotic CD14⁺-monocytes decreased (1.57 ± 0.53 vs 2.69 ± 0.95·10³/μL) and remained elevated until 7 days in all subgroups (all p < 0.001). Hscarb concentrations increased from 2.07 ± 3.20 to 2.71 ± 3.57 μmol/L 1 day after the clamp (p < 0.001) and remained elevated for one week (p < 0.001) to similar extent in all subgroups. Furthermore, 33 inflammatory proteins increased during hypoglycaemia (corrected p-value<0.05), including IL-10 and IL-6. Most inflammatory proteins, increased after 1 day (37 proteins) and remained elevated until 7 days in all subgroups (corrected p-value<0.05). Other proteins, such as IFN-gamma, reached their peak after 7 days (correct p-value<0.05).

Conclusion: Hypoglycaemia induces a prolonged immune response both at the protein and the cellular level in humans, independent of the presence of type 1 or type 2 diabetes.

Clinical Trial Registration Number: NCT03976271
Supported by: Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 777460
Disclosure: J.I.P. van Heck: None.

Impact of polymorphism in the beta-2 receptor gene on the metabolic response to epinephrine in healthy humans

K.Z. Rokamp1,2, N.V. Olsen3,4, F. Dela5,6, L. Gronlykke2, N.H. Secher7, B. Thorsteinsson1, U. Pedersen-Bjergaard1,8.
1Department of Endocrinology, Copenhagen University Hospital, Nordsjælland Hospital, Hillerød, 2Department of Anesthesia, Zealand University Hospital-Koge, Koge, 3Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, 4Department of Neuroanesthesiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, 5Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 6Department of Geriatrics, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark, 7Department of Anesthesiology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital, Rigshospitalet, Hillerød, 8Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Background and aims: The beta-2 adrenergic receptor mediates the metabolic response to epinephrine. The Arg16 variant of the single nucleotide polymorphism Gly16Arg in the beta-2 adrenergic receptor gene (ADRB2) has been associated with an increased risk of severe hypoglycaemia in type 1 diabetes. This study investigates the impact of the Arg16 variant on the metabolic response to epinephrine before and after repetitive hypoglycaemia.

Materials and methods: Twenty-five healthy male subjects selected according to ADRB2 genotype being homozygous for either Gly16 (GG; n=12) or Arg16 (AA; n=13) participated in 4 trial days (D1-4), D1pre and D4post with epinephrine 0.06 μg·kg⁻¹·min⁻¹ infusion, and D2hypog1-2 and D3hypog3 with three periods of hypoglycaemia by an insulin-glucose clamp.

Results: At D1pre, the insulin (44 ± 8 vs. 93 ± 13 pmol l⁻¹ h; P = 0.0051) and glycerol (79 ± 12 vs. 115 ± 14 μmol l⁻¹ h; P = 0.041) and free fatty acids (FFA) (724 ± 96 vs. 1113 ± 140 μmol l⁻¹ h; P = 0.033) responses (mean ± SEM of area under the curve) to epinephrine were decreased in AA subjects compared to GG subjects but without difference in glucose response. The glycerol and FFA responses were attenuated in GG subjects at D4post compared to D1pre and without difference between genotype groups at D4post.

Conclusion: The initial metabolic substrate response to epinephrine is decreased in AA subjects, but GG subjects are more prone to adrenergic desensitization, with no difference between genotype groups in response to epinephrine after antecedent hypoglycaemia.

Supported by: The Novo Nordisk Foundation and the JAscha Foundation.
Disclosure: K.Z. Rokamp: None.
SO 49 Is newer (insulin) always better?

634
Ado09, a co-formulation of pramlintide and insulin A21G, improves body weight and treatment satisfaction compared to insulin lispro in people with type 1 diabetes (PwT1D)

R. Eloy1, M. Gaudier2, E. Baumgaertner2, C. Seroussi1, C. Mégret1, B. Kronshage3, Y.-P. Chan1, O. Soulé1, T. Heise3, G. Andersen4;
1Adocia, Lyon, France, 2Profil Mainz, Mainz, 3Profil Neuss, Neuss, Germany.

Background and aims: Pramlintide in conjunction with insulin has been shown to improve post-prandial glucose control, but requires additional injections. Ado09 is a co-formulation of pramlintide and insulin (insulin A21G) allowing use of pramlintide-insulin combination therapy without increased injection frequency. This open label, multi-centric, two-arm parallel phase 2 trial investigated the efficacy and safety of Ado09 versus insulin lispro (LIS) in people with type 1 diabetes.

Materials and methods: During a run-in period of 2–4 weeks, basal insulin was switched to insulin degludec or glargine and continuous glucose monitoring (CGM) initiated. Thereafter, baseline assessments including CGM were done over a 3-week period. The treatment period consisted of a 4-week titration period for adjustment of prandial and basal doses followed by a 12-week maintenance period. Dose titration was guided by a Data Monitoring Committee recommending adjustments of insulin doses to PwT1D based on CGM data.

Results: Eighty PwT1D (63 male, 17 female, age 44.2 ± 12.3 years (mean ± SD), BMI 28.6 ± 2.6 kg/m², body weight 90.2 ± 13.5 kg, HbA1c 7.7 ± 0.6%) were randomised 1:1 to Ado09 or LIS. There were no clinically relevant changes in HbA1c with either treatment (LIS mean change from baseline 0.13% vs. 0.11% (ADO09 vs. LIS), p=0.81), but Ado09 reduced body weight significantly compared to baseline over the 4 months of treatment while LIS did not (-2.51±3.0 kg vs -0.45±3.1 kg, LSMean difference -2.13 kg, p=0.0045). The incidence of hypoglycaemic events was comparable between both treatments (331 episodes in 31 (77.5%) subjects with Ado09 vs. 326 episodes in 30 (75.0%) subjects with LIS). Severe hypoglycaemia was rare (2 events with Ado09, 1 event with LIS). Both treatments were well tolerated with transient, gastrointestinal adverse events predominantly of mild intensity with Ado09 (15 vs 0 subjects), consistent with the known side effect profile of pramlintide. Other adverse events were similar between treatments. Study participants expressed higher treatment satisfaction with Ado09 versus LIS at the end of the treatment period (standardised questionnaire with 6-point Likert scale). More subjects on Ado09 than on LIS strongly agreed that blood glucose control was more predictable (12.5% vs. 5%) and 45% agreed or strongly agreed that appetite control was easier with Ado09 (LIS 20%). Likewise, 37.5% of PwT1D agreed or strongly agreed that they would like to continue taking Ado09 (LIS 25%) and 30% of study participants agreed or strongly agreed that Ado09 provided benefits that their standard insulin therapy had not provided (LIS 17.5%).

Conclusion: In this 4 months treatment study in PwT1D, Ado09 showed similar overall effects on glycaemic control and hypoglycaemia to LIS, but significantly lowered body weight and improved treatment satisfaction.
Materials and methods: The present study is a secondary analysis of the prospective, multinational cohort of 2088 pregnant women with type 1 diabetes in a real-world setting treated with pump (n = 750) or MDI (n=1338), EVOLVE study. Odds ratios (OR) for offspring with congenital malformations, perinatal or neonatal death were analysed on crude data and using logistic regression on propensity score-matched data.

Results: At enrolment (gestational week 8 (95%CI: 4.14), pump users had higher educational level (university degree: 43.0% vs. 27.4%; P<0.001), better average glycaemic control (HbA1c: 51 (10) mmol/mol (6.8 (0.9)%) vs. 54 (14) mmol/mol (7.1 (1.3)%), P<0.001). Moreover, a greater proportion of pump users had HbA1c level below 75 mmol/mol (9%) (97.6% vs. 91.9%, P<0.001) and were more often reporting taking folic acid supplementation compared with MDI users (86.3% vs. 74.9%; P<0.001). All clinically important potential confounders were balanced after propensity score matching and Hba1c remained lower in pump users. The proportion of fetuses with at least one malformation was 13.5% (pump) vs. 11.2% (MDI) (crude OR 1.23 [95%CI 0.94;1.61], P=0.03; propensity score matched (adjusted) OR 1.11 [95%CI 0.81;1.52], P=0.52). The proportion of fetuses with at least one major malformations was 2.8% vs. 3.1% (crude OR 0.89 [95%CI 0.52;1.51], P=0.66; adjusted OR 0.78 [95%CI 0.42;1.45], P=0.43), and fetuses carrying ≥1 minor malformations (but no major) were 10.7% vs. 8.1%; (crude OR 1.36 [95%CI 1.00;1.84]; P=0.05; adjusted OR 1.25 [95%CI 0.87;1.75], P=0.25). The proportions of perinatal and neonatal death were 1.6% vs. 1.3% (crude OR 1.23 [95%CI 0.57;2.67], P=0.59; adjusted OR 2.02 [95%CI 0.69;5.93], P=0.20) and 0.3% vs. 0.3% (crude OR 0.90 [95%CI 0.16;4.91], P=0.90; adjusted OR 1.00 [95%CI 0.14;7.12], P=1.00), respectively.

Conclusion: Insulin pump treatment in pregnant women with T1D was associated with similar risk of congenital malformations, despite better glycaemic control in early pregnancy compared with MDI in this prospective cohort study. Further studies exploring the efficacy and safety of using pump treatment during pregnancy are needed.

Clinical Trial Registration Number: NCT01892319

Supported by: The study was funded by Novo Nordisk A/S

Disclosure: I.H. Thorius: Employment/Consultancy; Novo Nordisk A/ S. Stock/Shareholding; Novo Nordisk A/S.

637

Patient and physician experience of hypoglycaemia during basal insulin titration in type 2 diabetes in the US


1Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Canada, 2Faculty of Medicine, University of Bordeaux, Bordeaux, France, 3Sanofi, Bridgewater, USA, 4Optum, Minnesota, USA, 5Faculty of Medicine, University of Freiburg, Freiburg, Germany, 6The Frist Clinic, Nashville, USA.

Background and aims: Hypoglycaemia after BI initiation can negatively impact adherence to titration and glycaemic target achievement. We report on 2 surveys to better understand patient and physician perspectives/ experiences of hypoglycaemia during BI titration.

Materials and methods: Adults with T2D (PWT2D) and ≥2 claims (≥30 days apart in last 12 months) in the Optum Research Database who initiated BI (February-April 2021), and physicians who treated ≥30 PWT2D, ≥1 initiating BI (October 2020-March 2021), completed a mailed survey.

Results: Responders were 416 PWT2D (51% male, 71% white, mean age 70 years, 72% >10 years T2D duration) and 386 physicians (45% general practice). Most physicians reported discussing hypoglycaemia signs/symptoms (93%) and how to titrate BI in response to blood glucose (BG) levels (81%) with PWT2D. Of the 414 responders, 49%...
experienced hypoglycaemia; 37 (19%) of 194 responders had severe hypoglycaemia. Out of 187 responders experiencing hypoglycaemia, 57% felt very/extremely confident titrating BI during hypoglycaemia (Figure). Only 35% of all patients meeting BG (FBG) targets. Diabetes Treatment Satisfaction Questionnaire hypoglycaemia score (1.34/6) suggests patients felt hypoglycaemia was infrequent.

**Conclusion:** While physicians educate PWT2D on hypoglycaemia awareness and BI titration, nearly half of people surveyed experienced hypoglycaemia during titration, and only a third met FBG targets, suggesting new strategies and tools are needed for effective BI titration.

**Figure:** Participants experience of hypoglycaemia during BI titration

<table>
<thead>
<tr>
<th>Frequency during one-week trial</th>
<th>10 times</th>
<th>5 times</th>
<th>3 times</th>
<th>1 or 2 times</th>
<th>No at all</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percentage of respondents (%)</td>
<td>5</td>
<td>10</td>
<td>15</td>
<td>20</td>
<td>50</td>
</tr>
</tbody>
</table>

**Supported by:** Sanofi

**Disclosure:** S. Harris: Other; Consultant: Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Sanofi, Research support: Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, HLS Therapeutics, Janssen, Novo Nordisk, Sanofi.

---

**638**

Impact of hypoglycaemia on insulin titration and fasting plasma glucose in basal insulin-treated type 2 diabetes: a subanalysis of the SoliMix trial

**R. Ritzel**1, R.J. McCrimmon2, J. Rosenstock3, O. Deyneli4, A. Alvarez5, E. Southam6, L. Melas-Molf7, F. Giorgino8; 1Klinikum Schwabing and Klinikum Bogenhausen, Munich, Germany, 2University of Dundee, Dundee, UK, 3Dallas Diabetes Research Center at Medical City, Dallas, USA, 4Koc University School of Medicine, Istanbul, Turkey, 5Sanofi, Buenos Aires, Argentina, 6Sanofi, Paris, France, 7IviData LIFE SCIENCES, Levallois-Perret, France, 8University of Barlo Aldo Moro, Bari, Italy.

**Background and aims:** The SoliMix trial (EudraCT: 2017-003370-13) found better HbA1c with weight benefit and lower hypoglycaemia risk for iGlarLixi (insulin glargine 100 U/mL + lixisenatide) vs premix BIAsp 30 (biphasic insulin aspart 30) in people with type 2 diabetes advancing from basal insulin plus oral antihyperglycaemic drugs. This exploratory analysis investigated whether hypoglycaemia influenced insulin titration and achievement of fasting plasma glucose (FPG) targets with each therapeutic option.

**Materials and methods:** Total insulin dose changes from baseline to Week 12 were stratified by hypoglycaemia (yes/no) in each treatment arm and ADA Level 2 hypoglycaemia (<54 mg/dL=[<3.0 mmol/L]) event rates during Weeks 0-12 were modeled according to FPG at Week 12 (when most insulin titration occurred).

**Results:** Lesser insulin dose increases occurred in both treatment groups for those who experienced hypoglycaemia (mean ± SD iGlarLixi: 3.9 ± 12.5 U; BIAsp 30: 11.0 ± 18.8 U) vs those who did not (mean ± SD iGlarLixi: 11.2 ± 9.9 U; BIAsp 30: 19.4 ± 19.3 U). While higher FPG at Week 12 correlated with greater event rates of hypoglycaemia in both treatment arms, event rates were higher for BIAsp 30 than for iGlarLixi irrespective of FPG (Figure).

**Conclusion:** More frequent hypoglycaemia with premix BIAsp 30 than with iGlarLixi may result in lower insulin doses, thus hampering insulin titration and resulting in higher FPG.

---

**Clinical Trial Registration Number:** EudraCT 2017-003370-13

**Disclosure:** R. Ritzel: Honorarium; Novo Nordisk, Sanofi, MSD, AstraZeneca, Lilly, Novartis, and Pfizer. Other: Advisory board/ Speaker bureau; Novo Nordisk, Sanofi, MSD, AstraZeneca, Lilly, Novartis, and Pfizer.

---

**639**

Once-weekly insulin icodec: comparable total exposure following administration in different subcutaneous injection regions

**L. Plum-Mörschel**1, L.R. Andersen2, S. Hansen2, U. Hövelmann2, P. Krawietz2, N.R. Kristensen4, L.L. Lehnkov4, H. Haahr5; 1Profil, Mainz, Germany, 2Profil, Neuss, Germany, 3Research, Aalborg, Denmark, 4Novo Nordisk, Aalborg, Denmark, 5Novo Nordisk, Seborg, Denmark.

**Background and aims:** Individuals with diabetes may administer subcutaneous insulin in different body regions. In order to address if the choice of injection region affects insulin icodec exposure and glucose-lowering effect, this study compared insulin icodec administration in different subcutaneous injection regions.

**Materials and methods:** In a randomised, open-label, three-period crossover trial, 25 individuals with type 2 diabetes on basal insulin (22 males; mean±standard deviation age 60±7 years, BMI 30.7±4.6 kg/m²) received single subcutaneous doses of insulin icodec (5.6 U/kg) in the thigh, abdomen and upper arm (separated by 9-13 weeks washout). Blood was sampled for pharmacokinetic analysis until 840 h (35 days) post-dose. Glucose-lowering effect was assessed at 36-60 h post-dose in an automated glucose clamp (glucose plasma target level of 7.5 mmol/L).

**Results:** Total insulin icodec exposure (AUC0-∞,SD) was similar after single-dose subcutaneous injection in the thigh, abdomen and upper arm (Table). Maximum concentration (Cmax,SD) was higher for abdomen and upper arm versus thigh. Extrapolation of pharmacokinetic profiles to steady state using a pharmacokinetic model showed smaller differences in maximum concentration (Cmax,SD) for abdomen and upper arm versus thigh than after a single dose. Partial glucose-lowering effect at 36-60 h after single dose (AUCGIR,36-60h,SD) was comparable across injection regions (geometric mean [CV%] of 1961 [51], 2130 [52] and 2391 [40] mg/kg for thigh, abdomen and upper arm).
Conclusion: Insulin icodec can be administered subcutaneously in the thigh, abdomen or upper arm with essentially similar exposure and glucose-lowering effect.

Clinical Trial Registration Number: NCT04582448 (ClinicalTrials.gov)
Supported by: Novo Nordisk
Disclosure: L. Plum-Mörschel: Grants; Novo Nordisk. Lecture/other fees; Novo Nordisk.

640
A novel once weekly basal insulin Fc achieved similar glycaemic control with a comparable safety profile versus insulin degludec in patients with type 1 diabetes
C. Kazda1, J. Bue-Valleskey1, J. Chien1, Q. Zhang1, E. Chigutsa1, W. Landschulz1, P. Wullenweber1, A. Haupt1, D. Dahl2; 1Eli Lilly and Company, Indianapolis, USA, 2Gemeinschaftspraxis für Innere Medizin und Diabetologie, Hamburg, Germany.

Background and aims: Once weekly Basal Insulin Fc (BIF; LY3209590; insulin efsitora alfa) combines a novel single-chain insulin variant with a human IgG2 Fc domain and is designed for once weekly subcutaneous administration. BIF has a 17-day half-life and low peak-to-trough ratio of 1.14. This is the first large Phase 2 trial in T1D for any once-weekly basal insulin. The primary aim of this study was to assess the efficacy and safety of BIF compared with insulin degludec in patients with T1D.

Materials and methods: This randomised, open-label, parallel trial enrolled patients with T1D who were using multiple daily insulin injections for at least 3 months prior to screening. BIF was injected once weekly for the 26-week treatment period, and insulin degludec was injected once daily. Both groups were titrated to fasting blood glucose levels ≤5.6 mmol/L (100 mg/dL). The primary endpoint was HbA1c change from baseline to Week 26 (non-inferiority margin=0.4%).

Results: Patients were randomised to receive BIF (N=139) or insulin degludec (N=126). The baseline characteristics were generally well balanced among treatment groups. The mean±SD age of patients was 46.4±14.5 yrs, the baseline HbA1c was 58.4±9.3 mmol/mol (7.5 ±0.9%), and the daily basal insulin dose was 28.9±13.3 IU and 27.8 ±13.7 IU for BIF and insulin degludec, respectively. The HbA1c change from baseline to Week 26 treatment difference for BIF versus insulin degludec was 1.9 mmol/mol (0.17%); [90% CI = 0.01, 0.32]; p = 0.07; Figure 1), meeting the non-inferiority margin. The rates of patient-reported Level 1 hypoglycaemia (≥3.0 and <3.9 mmol/L) were not significantly different between BIF (109.6 events/pt/yr) and insulin degludec (103.3 events/pt/yr; p = 0.59). Similarly, there was no significant difference between the rate of Level 2 hypoglycaemia (<3.0 mmol/L) between BIF (20.1 events/pt/yr) and insulin degludec (18.4 events/pt/yr; p = 0.55). A total of three severe hypoglycemic events occurred during the trial (two after administration of insulin degludec and one after BIF). No difference in the proportion of recurrent or continuous hypoglycaemia has been observed between treatment arms. The occurrence of serious adverse events was not significantly different between BIF and insulin degludec. There was no significant difference in the increase in body weight from baseline to study endpoint for BIF (0.1 kg) and insulin degludec (0.5 kg) (treatment difference = -0.4 [-1.0, 0.1]; p=0.198).

Conclusion: Once weekly BIF demonstrated similar glycaemic control compared with once daily insulin degludec and no difference in hypoglycaemia or other safety findings in patients with T1D. These findings support continued development of BIF in Phase 3.

Clinical Trial Registration Number: NCT04450407
Supported by: Eli Lilly and Company
Disclosure: C. Kazda: Employment/Consultancy; Eli Lilly and Company. Stock/Shareholding; Eli Lilly and Company.

641
Comparison of day and night closed-loop with faster-acting insulin aspart vs insulin aspart mimicking under-estimation of carbohydrates or missed meal bolus
H. Thabit1, W. Mubita1, M.E. Wilinska2, J. Rubio1, M. Karuppan1, J. Schofield1, R. Hovorka2, L. Leelarathna1; 1Manchester Diabetes, Endocrinology and Metabolism Centre, Manchester Royal Infirmary, Manchester, 2Institute of Metabolic Science, University of Cambridge, Cambridge, UK.

Background and aims: The need to estimate carbohydrate content and deliver pre-meal boluses remains a burden for many people with type 1 diabetes. The aim of this study was to determine whether closed-loop using faster-acting insulin aspart will improve glucose control over a 24-hour period compared to insulin aspart under conditions mimicking under-estimation of carbohydrates or missed meal bolus.
Materials and methods: In an open-label, randomised crossover trial, 16 adults with type 1 diabetes on insulin pump therapy (9 females, age 31 ± 9 yrs, diabetes duration 17 ± 8 yrs HbA1c 66 ± 6 mmol/mol) underwent two 23 hour inpatient stays during which glucose levels were controlled by closed-loop with either faster-acting insulin aspart or insulin aspart. During the study periods, participants received standardised meals with half of their usual meal bolus for the evening meals and no meal bolus for lunchtime meals. Primary endpoint was proportion of time in range (3.9 - 10mmol/l) as recorded by sensor glucose during inpatient stay.

Results: Time in range during the study period was comparable in both faster-acting insulin aspart and insulin aspart (61.8 ± 14.3 vs. 61.5 ± 12.8%, p=0.35). Time in hyperglycaemia >10mmol/l (35.5 ±14.9 vs. 35.7 ± 14.8%, p=0.67) and area above the curve >10mmol/l (1.2 ± 0.8 vs. 1.2 ± 0.5 mmol/l/min, p=0.60) were similar. Time in hypoglycaemia <3.9mmol/l [median (IQR); 1.5 (0.0, 3.1) vs. 1.6 (0.0, 3.1), p=0.91] was not significantly different, while % time and AUC < 3.0 were both low and comparable. Algorithm driven insulin infusion (29.1 ± 9.0 vs. 29.2 ± 11.4 U, p=0.70) and bolus delivered (11.5 ±3.9 vs. 10.9 ± 3.5 U, p=0.76) were not statistically different for both arms.

Conclusion: Glycaemic control during closed-loop with faster-acting insulin aspart was comparable with insulin aspart under conditions mimicking under-estimation of carbohydrates or missed meal bolus. Further improvement in faster-acting insulin action profile is still needed, to enhance the effectiveness and feasibility of fully closed-loop in clinical practice.

Clinical Trial Registration Number: NCT03579615
Supported by: Novo Nordisk A/S
Disclosure: H. Thabit: None.

SO 50 Is longer better? Looking for different basal insulin approaches

Effect of insulin degludec vs insulin glargine U100 on continuous glucose monitoring recorded metrics in people with type 1 diabetes and nocturnal severe hypoglycaemia


1Department of Endocrinology and Nephrology, Copenhagen University Hospital - North Zealand, Hillerød, 2Novo Nordisk A/S, Søborg, 3Steno Diabetes Center Copenhagen, Herlev, 4Steno Diabetes Center Nordjylland, Aalborg, 5Steno Diabetes Center Aarhus, Aarhus, 6Department of internal medicine, Zealand University Hospital, Koge, 7Department of Endocrinology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, 8Department of medicine, Sydvestjysk Sygehus, Esbjerg, 9Department of Endocrinology, Odense University Hospital, Odense, 10Department of Diabetes and Hormonal diseases, Lillebælt Hospital, Kolding, 11Steno Diabetes Center Sjælland, Holbæk, Denmark.

Background and aims: Insulin Degludec (IDeg), in comparison with Insulin Glargine U100 (IGla), reduces the risk of hypoglycaemic events in people with type 1 diabetes (T1D). The impact on CGM assessed metrics such as CV, time in range (TIR), time below range (TBR), and time-above range (TAR) is less known. We present CGM-recorded data from the HypoDeg trial comparing treatment with I Deg and IGla in people with T1D and recurrent nocturnal severe hypoglycaemia.

Materials and methods: This is a pre-defined optional substudy of the HypoDeg trial: a 2-year investigator-initiated, randomized, cross-over trial comparing treatment with I Deg or IGla in 149 participants with T1D and at least one nocturnal severe hypoglycaemic event within the last two years. Participants underwent 2 x 6 days of blinded CGM (Medtronic iPro) during each treatment after 6 and 12 months of treatment. Seventy-four participants completed at least one CGM period in each treatment arm. The endpoints were CV, TIR (3.9 - 10.1 mmol/L), TBR at level 2 (< 3.0mmol/L), and TAR (>10.0, > 13.9 mmol/L). Time spent in ranges is provided as a percentage of readings. In a linear mixed regression model, accounting for repeated measures, we compared the effect of treatments on endpoints.

Results: We collected 261 CGM traces with a mean (SD) observation period of 5.9 (0.7) days. The CV was lower with I Deg than IGla, with a mean (SE) CV of 40.5% (0.9) and 42.5% (0.9), respectively (p=0.009). A difference in CV during the night (23:00h - 07:00h) drove this difference, with a mean CV of 35.7% (1.1) for I Deg versus 39.6% (1.1) for IGla (p=0.001) (Figure 1). There was a significant reduction of all-day TBR at level 2 (< 3.0mmol/L), and TAR (>10.0, > 13.9 mmol/L). Time spent in ranges is provided as a percentage of readings. In a linear mixed regression model, accounting for repeated measures, we compared the effect of treatments on endpoints.

Conclusion: In people with T1D prone to nocturnal severe hypoglycaemia, treatment with I Deg results in a lower mean CV, reaching the definition of stable glucose levels during the night, and a lower all-day TBR at level 2 as compared to IGla.
Efficacy and safety of insulin icodec in patients with type 2 diabetes: a meta-analysis of randomised phase II trials

D. Dimayuga, M. Villa, M. Maningat-Goco; Center for Diabetes, Thyroid and Endocrine Disorders, St. Luke’s Medical Center - Global City, Taguig, Philippines.

Background and aims: Icodec is a novel, long-acting, once-a-week insulin analog. Early evidence on icodec in type 2 diabetes mellitus (T2D) is conflicting. We aimed to conduct a meta-analysis of published randomized controlled trials (RCTs) on the efficacy and safety of icodec in patients with uncontrolled T2D (HbA1c > 7%).

Materials and methods: A systematic search in major online databases was conducted to identify relevant RCTs. Two authors independently performed the study selection and extracted study data. Data on glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), time-in-range of 70-140 mg/dL (TIR), adverse events and hypoglycemia events were noted. Significance level of 95% was used to provide pooled estimates. Random effects model was used for analysis with significant heterogeneity (I²>50%).

Results: Three trials with 606 patients were included. Pooled analysis of available data showed that icodec resulted in a significantly greater mean reduction of HbA1c (mean difference (MD) 0.18 [0.13,0.22], p < 0.00001, I²=84%), mean reduction of FPG (MD=3.87mg/dl [3.18, 4.57], p<0.00001, I²=0%), longer TIR (MD=4.39% [3.94, 4.85], p<0.00001, I²=0%), but had significantly greater propensity to lead to level 1 hypoglycemia (Odds Ratio (OR)=1.59 [1.11, 2.28], p=0.01, I²=29%) when compared to glargine U100. Funnel plot analysis on the propensity for icodec to lead to any hypoglycemia event decreased the I² statistic from 78% to 0% and showed significantly greater hypoglycemia events with icodec (OR=2.59 [1.67,4.01], p<0.001). There was no significant difference in the number of patients with end-of-trial HbA1c <7%, and any adverse event, or hypoglycemia level 2 or 3. Only 1 hypoglycemia level 3 event was noted (patient on icodec).

Conclusion: Once-weekly icodec had significantly better glycemic control compared to daily glargine U100, but had significantly greater hypoglycemia events. Data from ongoing trials on this novel drug can be added to the analysis as they become available.

Disclosure: D. Dimayuga: None.

Iglarlixi vs basal plus rapid-acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: the SoliSimplify real-world study

R.J. McCrimmon, A.Y.Y. Cheng, G. Galstyan, K. Djaballah, X. Li, M. Coudert, J. Fries; 1University of Dundee, Dundee, UK, 2University of Toronto, Toronto, Canada, 3Endocrinology Research Center, Moscow, Russian Federation, 4Sanofi, Paris, France, 5Sanofi, Bridgewater, USA, 6National Research Institute, Los Angeles, USA.

Background and aims: Indirect evidence suggests iGlarLixi (insulin glargine 100 U/mL + lixisenatide) is as efficacious as basal insulin (BI) + rapid-acting insulin (RAI) for management of type 2 diabetes (T2D). However, there are no direct comparisons of iGlarLixi (once-daily [QD]) vs a BI + RAI regimen (multiple daily injections [MDI]). SoliSimplify compared these treatments using real-world data from a US database.

Materials and methods: Electronic medical records were analysed retrospectively using propensity score matching (PSM) to compare therapy advancement with iGlarLixi or BI + RAI in adults ≥18 years with T2D on BI and ≥1HbA1c available value at baseline and 6-month follow-up. The primary objective was non-inferiority of iGlarLixi to BI + RAI in HbA1c change from baseline to 6 months (margin 0.3%).

Results: PSM generated cohorts with balanced baseline characteristics (N=814 in each group). Participants in both cohorts had a mean age of 61 years and a mean weight of 100 kg, with 27-28% participants having obesity. Almost all participants were prescribed insulin analogues in the baseline period, with insulin glargine (~78%) being the most common, followed by insulin determir (~18%) and insulin degludec (~14-16%). More than 40% of participants received one antihyperglycaemic drug (OAD) and around 39% received ≥2 OADs. HbA1c reduction from baseline to 6 months with iGlarLixi was non-inferior to BI + RAI (p<0.025) (Table). At 6 months, weight gain was significantly lower with iGlarLixi than with BI + RAI (p<0.05 for the difference between treatment groups).
HbA1c <7% without hypoglycaemia and weight gain was similar between groups at 6 months. Hypoglycaemia was low in both groups, likely due to underreporting. 

**Conclusion:** In this real-world study, QD iGlarLixi was as effective as MDI BI + RAI in HbA1c reduction and had a favourable body weight benefit.

---

**Materials and methods:** A systematic literature review with predefined criteria was carried out in MEDLINE®, Embase, and CENTRAL (inception to April 23, 2021). RCTs evaluating OD Gla-300 or Premix in insulin naïve PWT2D inadequately controlled on OADs were included. The heterogeneity of the included trials was vetted in a feasibility assessment, which examined the distributions of trial and participant characteristics, and observed treatment effects. Random effects meta-analyses were conducted using the metafor package for R. The Bucher ITC method was used to indirectly compare Gla-300 with Premix by taking the difference between their respective pooled treatment effects vs Gla-100 OD. Changes in HbA1c and body weight, final insulin dose, and hypoglycaemia incidence and rate were assessed at 24-26 weeks.

**Results:** Six RCTs involving 3,309 insulin naïve PWT2D were eligible for the ITC: two with Gla-300 and four with Premix, all studies were Gla-100 controlled. Baseline BMI (kg/m²) differed between the Asian (25.1-25.6) and intercontinental (29.1-33.0) studies, and mean HbA1c ranged from 8.2-8.9%. Concomitant OADs included metformin (n = 2), pre-study OADs (n = 2), and metformin + glimepiride (n = 1). There was no significant difference for change in HbA1c (mean difference [MD]: 0.13%; 95% CI: −0.04%, 0.31%; p = 0.1), change in weight (MD: −0.42 kg; 95% CI: −1.54, 0.69; p = 0.5), or final insulin dose (MD: 1.31 U; 95% CI: −4.81, 7.44; p = 0.7). The risk of any hypoglycaemia was significantly lower with Gla-300, both with respect to incidence (odds ratio [OR]: 0.64; 95% CI: 0.47, 0.86; p = 0.004) and event rate (rate ratio [RR]: 0.74; 95% CI: 0.57, 0.96; p = 0.02). Additionally, the incidence of confirmed (PG <3.0-3.1 mmol/L) any time hypoglycaemia was lower with Gla-300 (OR: 0.49; 95% CI: 0.33, 0.73; p = 0.0005), as was the rate of confirmed (PG <3.0-3.1 mmol/L) anytime hypoglycaemia (RR: 0.37; 95% CI: 0.16, 0.88; p = 0.02). No differences were observed for either severe or nocturnal hypoglycaemia.

**Conclusion:** These findings suggest that insulin naïve PWT2D inadequately controlled on OADs commencing Gla-300 OD or Premix OD achieve similar glycaemic improvement and differences in insulin dose after 26 weeks, but with a lower risk of clinically significant confirmed (PG <3.0-3.1 mmol/L) or any hypoglycaemia with Gla-300 OD.

**Disclosure:** Supported by: Sanofi

---

**Materials and methods:** To ease the burden of type 1 diabetes (T1D), multiple diabetic devices for insulin delivery and measurement of glucose levels have been developed during the last decades. The aim of this study was to compare glycemetic related outcomes for three types of insulin delivery devices in patients with T1D, using continuous glucose monitor (CGM).

**Background and aims:** There are no head-to-head randomised clinical trials (RCTs) comparing the efficacy and safety of insulin glargine 300 U/mL (Gla-300), a second-generation basal insulin analogue, with once-daily (OD) insulin premix. An ITC was conducted to fill this gap and compare the efficacy and safety of Gla-300 OD vs Premix OD in people with type 2 diabetes (PWT2D) inadequately controlled on oral antidiabetic drugs (OADs).

**Materials and methods:** A systematic literature review with predefined criteria was carried out in MEDLINE®, Embase, and CENTRAL (inception to April 23, 2021). RCTs evaluating OD Gla-300 or Premix in insulin naïve PWT2D inadequately controlled on OADs were included. The heterogeneity of the included trials was vetted in a feasibility assessment, which examined the distributions of trial and participant characteristics, and observed treatment effects. Random effects meta-analyses were conducted using the metafor package for R. The Bucher ITC method was used to indirectly compare Gla-300 with Premix by taking the difference between their respective pooled treatment effects vs Gla-100 OD. Changes in HbA1c and body weight, final insulin dose, and hypoglycaemia incidence and rate were assessed at 24-26 weeks.

**Results:** Six RCTs involving 3,309 insulin naïve PWT2D were eligible for the ITC: two with Gla-300 and four with Premix, all studies were Gla-100 controlled. Baseline BMI (kg/m²) differed between the Asian (25.1-25.6) and intercontinental (29.1-33.0) studies, and mean HbA1c ranged from 8.2-8.9%. Concomitant OADs included metformin (n = 2), pre-study OADs (n = 2), and metformin + glimepiride (n = 1). There was no significant difference for change in HbA1c (mean difference [MD]: 0.13%; 95% CI: −0.04%, 0.31%; p = 0.1), change in weight (MD: −0.42 kg; 95% CI: −1.54, 0.69; p = 0.5), or final insulin dose (MD: 1.31 U; 95% CI: −4.81, 7.44; p = 0.7). The risk of any hypoglycaemia was significantly lower with Gla-300, both with respect to incidence (odds ratio [OR]: 0.64; 95% CI: 0.47, 0.86; p = 0.004) and event rate (rate ratio [RR]: 0.74; 95% CI: 0.57, 0.96; p = 0.02). Additionally, the incidence of confirmed (PG <3.0-3.1 mmol/L) anytime hypoglycaemia was lower with Gla-300 (OR: 0.49; 95% CI: 0.33, 0.73; p = 0.0005), as was the rate of confirmed (PG <3.0-3.1 mmol/L) anytime hypoglycaemia (RR: 0.37; 95% CI: 0.16, 0.88; p = 0.02). No differences were observed for either severe or nocturnal hypoglycaemia.

**Conclusion:** These findings suggest that insulin naïve PWT2D inadequately controlled on OADs commencing Gla-300 OD or Premix OD achieve similar glycaemic improvement and differences in insulin dose after 26 weeks, but with a lower risk of clinically significant confirmed (PG <3.0-3.1 mmol/L) or any hypoglycaemia with Gla-300 OD.

**Disclosure:** Supported by: Sanofi
questionnaire. To test for differences between groups, ANOVA analyses and an equality-of-median test were performed. ANOVA analyses were adjusted for age, sex, and diabetes duration above or below 3 years. Additionally, analysis for HFS-II and PAID-5 were also adjusted for presence of hypoglycaemia during the final year.

Results: Of 5840 participants who received the questionnaire, 1484 CGM users (25%) have to date responded (IPe =1094; IPu =250; HCL =134). Mean (SD) age was 55 (15) years, mean diabetes duration was 27 (16) years, and 45% were women. TIR was reported by 998 participants. Mean was lowest for HCL and highest for IPE (HCL: 61% (20), n=752); IPu: 64% (23), n=156; HCL: 75% (13), n=90). TIR was highest for HCL and lowest for IPE (IPE vs. HCL (p<0.001); IPu vs. HCL (p=0.001); IPE vs. IPu (p<0.01)). TAR was reported by 968 participants. Mean was lowest for HCL and identical for IPE and IPu (IPE: 31% (19), n=722; IPE: 31% (22), n=154; HCL: 22% (14), n=91). TAR was lowest for HCL and highest for IPE (IPE vs HCL (p<0.001); IPu vs HCL (p=0.001); IPE vs IPu (ns)). TBR was reported by 973 participants. Mean was lowest for HCL and highest for IPE (IPE: 5% (7), n=726; IPE: 3% (4), n=156; HCL: 2% (4), n=91). TBR was lowest for HCL and highest for IPE (IPE vs HCL (p<0.001); IPu vs IPE (p<0.01); IPu vs HCL (ns)). During the last year, 87 out of 1484 participants had minimum one incidence of severe hypoglycaemia. Mean number of hypoglycaemias were 0.36 for IPE (n=1094), 0.552 for IPU (n=250) and 0.007 for HCL (n=134) (p=0.002). There were no differences between groups for FoH and DD (HFS-II (n=1478); IPE: 11 (7); IPU: 11(7); HCL: 10 (7) and PAID-5 (n=1478); IPE: 6(5); IPu: 7(4); HCL 6(5).

Conclusion: Patients with T2D using HCL experienced significantly better glycaemic control based on TIR, TAR and TBR, compared to pen and pump users. Users of both kinds of pumps had significantly better TIR and TAR compared to pen users. Furthermore, they experienced significantly less hypoglycaemic events than pen users. Scores for HFS-II and PAID did not differ between the groups.


647 Hypoglycaemia frequency and physiological response to double or triple doses of once-weekly insulin icodex versus once-daily insulin glargine in type 2 diabetes

T.R. Pieber 1, N. Arfelt 2, R. Cailleteau 2, K.M. Due Thomsen 3, M. Hart 1, I. Mursic 1, E. Svehlikova 1, M. Urschitz 1, H. Haahr 1

1Medical University of Graz, Graz, Austria, 2Novo Nordisk, Søborg, Denmark, 3Novo Nordisk, Aalborg, Denmark.

Background and aims: Insulin icodex is a basal insulin in development for once-weekly administration. The aim of this study was to compare the hypoglycaemia frequency and physiological response after double or triple doses of insulin icodex versus insulin glargine U100.

Materials and methods: In a randomised, open-label, two-period crossover trial, 43 individuals with type 2 diabetes on basal insulin metformin (mean±SD age 56±9 years, HbA1c 7.2±0.7%) received once-weekly insulin icodex for 6 weeks and once-daily insulin glargine U100 for 12 days. Total weekly doses were equimolar and based on the individual daily running dose of once-weekly insulin glargine U100 (mean 30±14 U) titrated to a fasting self-measured plasma glucose target of 4.4-7.2 mmol/L. After reaching steady state, double and triple doses of insulin icodex or insulin glargine U100 were administered. Hypoglycaemia was induced 44 h (insulin icodex) or 7 h (insulin glargine U100) post-dose (the expected time of maximum glucose-lowering effect), as described in the following. First, euglycaemia was maintained at 5.5 mmol/L by variable i.v. glucose. Then, i.v. glucose was terminated and plasma glucose was allowed to decrease to a nadir target of 2.5 mmol/L, whereafter plasma glucose was maintained at nadir for 15 min by re-initiating variable i.v. glucose. Euglycaemia was then restored by constant i.v. glucose infusion. Hypoglycaemic symptoms score (HSS) and concentration of counterregulatory hormones were assessed at plasma glucose 5.5 mmol/L and at predefined plasma glucose levels until nadir plasma glucose.

Results: Following a double dose, clinically significant hypoglycaemia (plasma glucose≤3.0 mmol/L) occurred in 40% versus 36% of subjects for insulin icodex versus insulin glargine U100 (odds ratio 1.28; 95% CI [0.46;3.52]; p=0.63), a decline in plasma glucose to ≤2.5 mmol/L occurred in 5% versus 7% of subjects, and mean nadir plasma glucose was 3.2 mmol/L versus 3.3 mmol/L (treatment ratio 0.97; 95% CI [0.94;1.00]; p=0.07). Following a triple dose, clinically significant hypoglycaemia occurred in 53% versus 70% of subjects (odds ratio 0.48; 95% CI [0.18;1.28]; p=0.14), a decline in plasma glucose to ≤2.5 mmol/L occurred in 3% versus 25% of subjects, and mean nadir plasma glucose was 3.1 mmol/L versus 2.9 mmol/L (treatment ratio 1.07; 95% CI [1.04;1.11]; p<0.001) for insulin icodex versus insulin glargine U100. Among the subjects experiencing clinically significant hypoglycaemia after a triple dose, change in HSS at nadir plasma glucose was comparable for insulin icodex versus insulin glargine U100 (treatment difference 0.46; 95% CI [-2.72;3.64]; p=0.77), responses in adrenaline, noradrenaline and cortisol during hypoglycaemia development were greater for insulin icodex versus insulin glargine U100, while glucagon and growth hormone levels increased similarly.

Conclusion: Double or triple doses of once-weekly insulin icodex do not lead to increased risk of hypoglycaemia compared to double or triple doses of once-daily insulin glargine U100. During hypoglycaemia, a comparable symptomatic response and a moderately greater endocrine response were seen for insulin icodex versus insulin glargine U100. Clinical Trial Registration Number: NCT03945656 (ClinicalTrials.gov)


648 Glycaemic control in people with type 2 diabetes (T2D) switching from NPH to insulin glargine 300 U/mL (Gla-300): REALI pooled database

D. Müller-Wieland 1, N. Freemantle 2, R. Bonadonna 3, C. Mauquois 4, G. Bigot 5, M. Bonnemasse 6, P. Gourdy 7, D. Mauricio 8

1Department of Medicine, University Hospital, Aachen, Germany, 2Institute of Clinical Trials and Methodology, University College London, London, UK, 3University of Parma, Parma, Italy, 4Clinical Trial Consulting, International Drug Development Institute, Louvain-la-Neuve, Belgium, 5VIDATA, Paris, France, 6General Medicines, Sanofi, Paris, France, 7Institute of Metabolic and Cardiovascular Diseases, Toulouse University, Toulouse, France, 8Department of Endocrinology & Nutrition, Hospital of Santa Cruz i Sant Pau, Barcelona, Spain.

Background and aims: The effectiveness of Gla-300 in people with T2D switching from NPH is not widely documented.

Materials and methods: The European REALI pooled database included patient-level data from 14 European prospective interventional and non-interventional studies in people with T2D treated with Gla-300. The present analysis evaluated the impact of Gla-300 on HbA1c improvements in people with T2D, previously uncontrolled on basal insulin (BI).

Results: This analysis included data from people with T2D uncontrolled on prior BI: 1,282 switching from NPH and 2,899 from other non-NPH BIs (mainly glargine 100 U/mL, 67%) to Gla-300. In the NPH group, mean±SD age was 63±9.4 years, BMI 32.5±5.8 kg/m², and median diabetes duration 12 years. The majority previously used biguanides (71%), followed by sulfonylureas (20%), and dipeptidyl peptidase 4 inhibitors (16%) years, and 45% were women. TIR was reported by 998 participants. Mean was lowest for HCL and highest for IPE (IPE vs HCL (p<0.001); IPu vs HCL (p=0.001); IPE vs IPu (ns)). During the last year, 87 out of 1484 participants had minimum one incidence of severe hypoglycaemia. Mean number of hypoglycaemias were 0.36 for IPE (n=1094), 0.552 for IPU (n=250) and 0.007 for HCL (n=134) (p=0.002). There were no differences between groups for FoH and DD (HFS-II (n=1478); IPE: 11 (7); IPU: 11(7); HCL: 10 (7) and PAID-5 (n=1478); IPE: 6(5); IPu: 7(4); HCL 6(5).

Conclusion: Patients with T1D using HCL experienced significantly better glycaemic control based on TIR, TAR and TBR, compared to pen and pump users. Users of both kinds of pumps had significantly better TIR and TAR compared to pen users. Furthermore, they experienced significantly less hypoglycaemic events than pen users. Scores for HFS-II and PAID did not differ between the groups.

characteristics were comparable to those in the NPH group, except for higher baseline HbA1c and FPG in the latter. Figure 1B illustrates HbA1c improvement in the non-NPH BI group, at a mean Gla-300 starting dose of 35.4 U/day (0.37 U/Kg/day) increasing to 41.7 U/day (0.44 U/Kg/day) at Week 24, with no body weight change. Hypoglycaemia was similarly low in both groups.

Conclusion: This analysis shows that people with T2D, previously uncontrolled on BI, benefited from switching to Gla-300 in terms of HbA1c improvement, and this was especially observed in those previously treated with NPH.

Results: Patients randomised to BIF (N=129) and DEG (N=135) had a mean age of 58.4 years and baseline HbA1c of 63.9 mmol/mol (8.0%). After 26 wks, BIF showed non-inferiority vs DEG for HbA1c CFBL with a treatment difference of 0.06% (90% CI = -0.11, 0.24; P=0.56). Flash glucose monitoring performed at baseline and endpoint showed that both groups significantly increased time in range (3.9-10.0 mmol/L [70-180 mg/dL]) from baseline and reported a similar mean % time in range at Wk 26 of 76.0% and 77.4% for BIF and DEG respectively. Both BIF and DEG significantly reduced FPG from baseline with BIF resulting in a small but significantly higher FPG at study endpoint (treatment difference = 0.26 mmol/L [90% CI = 0.01,0.52]; P= 0.09). No severe hypoglycaemia was reported and the rate of Level 2 hypoglycaemia was low and not significantly different (BIF = 0.22; DEG = 0.15 events/pt/yr). Occurrence of treatment-emergent adverse events was similar between BIF and DEG.

Conclusion: BIF injected QW achieved excellent glycaemic control similar to DEG with no concerning hypoglycaemia or other safety findings, supporting continued development of BIF in Phase 3.

Supported by: Funded by Sanofi
Disclosure: D. Müller-Wieland: Employment/Consultancy; Acted as a consultant and has served on the speaker bureau for Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi.

Clinical Trial Registration Number: NCT04450394

Background and aims: Basal Insulin Fc (BIF; LY3209590), a fusion protein combining a novel single-chain variant of insulin with a human IgG Fc domain, is designed for once weekly (QW) administration. This randomised, parallel, open-label Phase 2 study assessed safety and efficacy of BIF vs DEG in insulin-naive patients with type 2 diabetes (T2D) previously treated with oral antihyperglycaemic medication.

Materials and methods: BIF was injected QW, and DEG was injected QD. Both groups were titrated to fasting blood glucose (FBG) ≤5.6 mmol/L (100 mg/dL). The primary endpoint was HbA1c change from baseline (CFBL) to Wk 26 (non-inferiority margin=0.4%).
SO 51 Even "old dogs" can learn new tricks

650
Efficacy of therapeutic patient education interventions in metabolic disorders: a systematic review and meta-analysis

J.C. Correia 1, A. Waqas2, K. Garcia1, F.R. Jornayvaz1, Z. Patak1;
1Department of Medicine, Geneva University Hospitals, Geneva, Switzerland, 2Institute of Population Health, Liverpool, UK.

Background and aims: Recent studies have shown the impact of therapeutic patient education (TPE) as a clinically and cost-effective solution to improve biomedical and psychosocial outcomes among people with metabolic disorders. The present systematic review and meta-analysis presents a critical synthesis of development of TPE interventions for obesity and diabetes mellitus (DM) and the efficacy of these interventions across a range of biomedical, psychosocial and psychological outcomes.

Materials and methods: Using a pretested search strategy, the database search for the systematic review was performed in Web of Science, MEDLINE, CINAHL, PsycINFO and COCHRANE database, from inception until August 2019. We considered all those studies which presented the effectiveness of TPE interventions in obesity and diabetes mellitus. We considered randomized and cluster randomized controlled trials conducted among adults > 18 years old. We considered biological parameters, psychological symptomology and quality of life indicators.

Results: A total of 54 RCTs were identified with 46 (85.19%) focused on DM, 6 (11.11%) on obesity and overweight and 2 (3.70%) on hypoglycemia. These interventions were delivered by allied health workers (n= 28), multidisciplinary teams (n=17), research teams (n= 6), peers and peer leaders (n=2) and doctors (n=1). Different delivery formats were used including in groups (n=16), individually (n= 15), electronically (n= 8) and mixed formats (n= 12). Main taught components included prevention of complications (n=49), managing complications (n= 48), implementation of lifestyle changes (n= 45) and self-monitoring (n= 41). There was substantial heterogeneity in reporting of these outcomes (I²= 88.35%, Q= 317.64). We found significant improvement in biomedical outcomes (body weight, glycemia and HbA1c) in the intervention group (SMD=0.36, 95% CI: 0.23 to 0.49) as well as increased adherence to treatment (SMD= 0.310, 95% CI: 0.05 to 0.57). Regarding patient knowledge, although the effect size showed improvement in favor of the intervention group, it was statistically non-significant (SMD= 2.60, 95% CI: -1.44 to 6.64). Similarly, quality of life did not reveal statically significant improvement in favor of the intervention group (SMD= 1.57, 95% CI: -0.54 to 3.68, I²= 98.05%, Q= 51.32). The effect sizes were comparable across interventions delivered by different modes and delivery agents. Risk of bias was low in selective reporting (n= 51), attrition bias (n=38), random sequence generation (n=20), and allocation concealment.

Conclusion: The present systematic review and meta-analysis highlights how TPE interventions are an essential and effective component of the treatment of chronic metabolic disorders. It also revealed that TPE interventions delivered through different media and delivery formats may be equally effective. Therefore, these interventions can be tailored to the setting according to availability of human and financial resources.

Disclosure: J.C. Correia: None.
652 What are people’s preferences for the ‘choice talk’ in the diabetes treatment decision-making process?

A. Tichler1,2, D.F.L. Hertrofts1,2, M.C.G. Brouwer3,2, D. Ruwaard1,2, M.J.C. Hiligsmann1,2, J.D. de Jong2,1, A.M.J. Elissen1,2;

1Health Services Research, Maastricht University, Maastricht, 2Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, 3Department of Internal Medicine, Division of Endocrinology and Metabolic Disease, Maastricht University Medical Center+, Maastricht, 4The Netherlands Institute for Health Services Research (NIVEL), Utrecht, Netherlands.

Background and aims: Individuals with type 2 diabetes and their healthcare providers are faced with more difficult treatment decisions due to the increase in choice and complexity of glucose-lowering treatment. Knowledge of individuals’ preferences regarding the treatment decision-making process can support shared decision-making and guide person-centred care. This study aimed to identify what treatment attributes patients find important to discuss in the treatment decision-making process and whether this differs between individuals with different demographic and disease characteristics (e.g. medication use and HbA1c value).

Materials and methods: An object best-worst scaling survey was distributed to all individuals with self-reported diabetes participating in the Dutch Health Care Consumer Panel (N=600) of the Netherlands Institute for Health Services Research. The survey included sixteen choice tasks, each consisting of four attributes and differed in the particular subset of attributes shown. Per choice task, respondents were asked to identify the attribute that they consider most and least important in the treatment decision-making process. Hierarchical Bayes analyses were performed to determine the relative importance score (RIS) of each attribute. A higher RIS indicates a higher level of perceived importance of the attribute. Subgroup analyses were performed to explore whether individuals’ demographic and disease characteristics influence their attribute preferences.

Results: Individuals with type 2 diabetes value ‘quality of life’ (RIS 11.97; 95% CI 11.77-12.16), ‘clinical outcomes’ (RIS 10.40; 95% CI 10.16-10.64), ‘long-term diabetes complications’ (RIS 9.83; 95% CI 9.50-10.16) and ‘short-term adverse events of medication’ (RIS 7.72; 95% CI 7.38-8.07) as most important in the decision-making process for the treatment of type 2 diabetes. Subgroup analyses showed for almost every subgroup the same four attributes valued as most important. The analyses also revealed heterogeneity in the attribute preferences for age, level of education, HbA1c value and medication use. For example, the attribute ‘medication withdrawal’ was considered less important in the decision-making process by individuals aged above 75 years (RIS 5.16; 95% CI 4.48-5.85) compared to individuals aged between 60-75 years (RIS 6.47; 95% CI 5.88-7.06) and individuals aged below 60 years (RIS 8.39; 95% CI 7.58-10.20).

Conclusion: Quality of life is valued as most important by individuals with type 2 diabetes to discuss in the treatment decision-making process, followed by ‘clinical outcomes’ and long-term diabetes complications’. The identified heterogeneity in attribute preference emphasizes the importance of taking people’s values, needs and preferences into account in the treatment decision-making process. It highlights the need for shared decision-making.

Clinical Trial Registration Number: NL8948

Supported by: MSD

Disclosure: A. Tichler: None.

653 Comprehensive diabetes education in care homes: 1 year analysis of impact from the CARES diabetes in care homes national programme

A. Puttanna1, J. Ridgeway2, L. Willcocks2, S. Gregory2, L. Heggies2;

1General Medicines, Sanoft UK, Reading, 2EDEN, Leicester, UK.

Background and aims: People with diabetes living in a care home setting are a clinically vulnerable population with a higher risk of diabetes related complications and hospital admission. In the UK, there is currently no standardised education programme for care home facilities to ensure appropriate knowledge and understanding of diabetes. EDEN (Effective Diabetes Education Now) has previously identified that diabetes education to staff has a positive impact for service users with diabetes. As a result, a targeted diabetes education programme for care home facilities was created (CARES).

The aim of this project was to provide a standardised and structured diabetes education programme across all care homes in the UK to improve on baseline knowledge and confidence in diabetes care.

Materials and methods: A structured education programme focussing on diabetes care and knowledge in the care home setting was created. Care homes were invited to register and participate in the programme on a voluntary basis. All participants undertook a learning journey via an online platform which consisted of a short recorded lesson, 3 eLearning modules and a group mentoring session. To identify if the project aims had been met, each participant completed a pre and post programme questionnaire assessing confidence in competencies on a Likert scale (1 = not confident, 5 = very confident). Data was analysed through Python statistical analysis software.

Results: 458 participants from care homes across the UK registered in the education programme with 105 completing the programme at 1 year. Table 1 identifies the key findings from pre and post attendance questionnaires on basic diabetes competencies. Additionally, competency in checking blood sugars increased from 54% of participants pre-programme to 71% post programme (p = 0.001) whereas competency in insulin initiation went from 45% pre-programme to 50% post programme (p=0.279). There was an increase in the presence of a ‘hypo box’ on site from 47% to 55% of participants pre and post programme respectively (p<0.0001). Significant reductions in ambulance call outs and hospital admissions for diabetes related problems (self-reported) were noted (p<0.0001).

Conclusion: As one of the first known standardised national diabetes education programme for care home settings, CARES has highlighted that structured diabetes education in care homes increased knowledge and confidence in a broad range of basic diabetes competencies. It also suggests that structured education may result in better care of patients through better treatment of hypoglycaemia (via presence of hypo boxes), reduced ambulance callouts and hospital admissions. Standardised and structured diabetes education should be mandatory for all care homes involved in managing patients with diabetes.

<table>
<thead>
<tr>
<th>Competency</th>
<th>Mean score pre-programme</th>
<th>Mean score post-programme</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recognition of diabetes type</td>
<td>3.62</td>
<td>4.25</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hypoglycaemia recognition</td>
<td>3.14</td>
<td>4.30</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Emotional and mental wellbeing</td>
<td>3.12</td>
<td>4.27</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Insulin technique and self insulin use</td>
<td>2.95</td>
<td>4.01</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Blood glucose monitoring</td>
<td>3.45</td>
<td>4.47</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Annual care review</td>
<td>2.87</td>
<td>4.19</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hypoglycaemia recognition</td>
<td>3.14</td>
<td>4.30</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Foot care</td>
<td>3.04</td>
<td>4.37</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>P-value:</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

None.

Disclosure: A. Puttanna: None.
654
Legacy effects of sleep education programme in people with type 2 diabetes and short sleep duration: a prospective follow-up study
J. Cheung\textsuperscript{1}, K. Woo\textsuperscript{1}, R. Cheung\textsuperscript{1}, M. Lee\textsuperscript{1}, E. Lau\textsuperscript{1}, C. Chiu\textsuperscript{1}, E. Chow\textsuperscript{1}, A. Luk\textsuperscript{1}, R. Ma\textsuperscript{1}, J. Chan\textsuperscript{1}, Y. Wing\textsuperscript{2}, A. Kong\textsuperscript{1};
\textsuperscript{1}Medicine and Therapeutics, The Chinese University of Hong Kong
\textsuperscript{2}Psychiatry, The Chinese University of Hong Kong, Hong Kong, Hong Kong.

**Background and aims:** Pilot study suggests that sleep education improves sleep quality and glycemia in people with type 2 diabetes (T2D). Here, we aimed to investigate the legacy effects of sleep education on sleep duration and glycemic control in T2D with short sleep duration.

**Materials and methods:** People with T2D and short sleep duration, defined as weekday sleep duration <7 hours/day, exited from a randomized controlled trial in which intervention was sleep education program for 30 minutes through group education followed by an additional 180 minutes individual counseling through telephone (15 minutes per month for 12 months), were evaluated in this follow-up study. Sleep habits were measured by a validated sleep questionnaire through phone interview. Anthropometric index [body mass index (BMI)] and biochemical parameters including fasting plasma glucose (FPG), glycated hemoglobin (HbA\textsubscript{1C}), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were retrieved from electronic medical record within 3 months of phone interview. The primary outcome was the changes of sleep duration from baseline, whereas secondary outcome was the changes of glycemia as measured by FPG and HbA\textsubscript{1C}. Generalized estimating equations (GEE) model was used to examine differential changes of sleep duration and HbA\textsubscript{1C} across the time points at baseline and follow up time.

**Results:** After a median follow-up of 6.2 years [interquartile range (IQR) 5.0-8.0], 179 out of 267 (n=88 out of 137 in control group; n=91 out of 130 in intervention group) T2D were studied (overall response rate of 67.5%). There were no significant differences at baseline, in terms of clinical profile and sleep patterns, between the responders and non-responders. Among the responders studied at follow-up, 48.7% were men with mean age ± standard deviation (SD): 59.0 ± 8.6 years, BMI: 23.4 ± 7.8 kg/m\textsuperscript{2}, weekday sleep duration: 7.0 ± 1.6 hours, weekend sleep duration: 7.7 ± 1.7 hours, FPG: 6.9 ± 1.8 mmol/L and HbA\textsubscript{1C}: 7.2 ± 1.0%. T2D exited from intervention group had improved weekend sleep duration when compared to their counterparts in the control group (β 2021 weekday sleep duration 0.914, 95% Confidence Interval [CI] 0.077 to 1.751, p = 0.032), but there was no difference for weekday sleep duration between the two groups (β 2021 weekday sleep duration 0.371, CI -0.288 to 1.030, p = 0.270), after adjusted for potential confounders, including age, BMI, HbA\textsubscript{1C}, LDL-C, and TG. Moreover, T2D exited from intervention group had a significantly lower FPG than control group [6.9 mmol/L (IQR 6.1-8.3) versus 7.1 mmol/L (IQR 6.0-8.7), p = 0.027]. However, there was no significant difference of HbA\textsubscript{1C} between the two groups (p = 0.282).

**Conclusion:** Previous participation in sleep education program was associated with increased weekend sleep duration and decreased fasting glycemia among T2D with short sleep duration.

**Supported by:** Research Grants Council of the Hong Kong Special Administrative Region, China. Project no. CUHK46671

**Disclosure:** J. Cheung: None.

655
The importance of education for diabetes control in patients with type 1 diabetes using intermittently scanned continuous glucose monitoring

**Background and aims:** Intermittently scanned continuous glucose monitoring (isCGM) is a new evolving technology used in the management of Type 1 diabetes leading to improved diabetes control and reduction of hypoglycemia. Education of patients using isCGM should lead to further improvement of glycemia and other parameters of diabetes control. The aim of the study was to assess the effect of structured educational course on diabetes control parameters in patients with type 1 diabetes using isCGM.

**Materials and methods:** 125 patients with type 1 diabetes (88 with multiple daily injections of insulin (MDI) and 37 with insulin pump) using isCGM treated in our Diabetes Department were enrolled in the present study between January 2019 and February 2022. All patients completed a 2-hour structured educational course focused on the use of isCGM, including isCGM application, scanning frequency, working with trend arrows, regular downloading and data evaluation. Diabetes control was assessed by the following parameters: HbA1c, mean glycemia, time in range (TIR) of glucose between 3.9 and 10 mmol/L. The parameters were evaluated before initiating isCGM, at the time of educational course and during regular visits in the diabetes outpatient clinic with a frequency of 3 months for 1 year.

**Results:** There was no significant improvement of diabetes control during the period between the start of isCGM use and educational course (mean 8.2 months; HbA1c 8.2±1.7 vs 8.0±1.1% ; mean glycemia 9.2±2 vs. 9.0±1.9 mmol/L; TIR 53±19 vs. 54±19), but there was a significantly better diabetes control 12 months following the education course (HbA1c 7.6±1.3%, p<0.01 vs. before isCGM and p<0.05 before course; mean glycemia 8.6±1.5 mmol/L, p<0.05 and p<0.01; TIR 60±17 p<0.05 and p<0.05). There were no significant differences between patient using MDI of insulin pump.

**Conclusion:** In our study, we demonstrated the essential part of education in the improvement of glycemic parameters in patients with type 1 diabetes using isCGM.

**Supported by:** MHCR IN 00023001

**Disclosure:** R. Bem: None.

656
Resources used by HCPs to educate PWD about TIR
A. Sommi\textsuperscript{1}, N. Sainz\textsuperscript{2}, A. Asamo\textsuperscript{2,3}, E. Shoget\textsuperscript{2}, R. Wood\textsuperscript{2}, C. Alexander\textsuperscript{4};
\textsuperscript{1}The diaTribe Foundation, \textsuperscript{2}dQ&A – The Diabetes Research Company, San Francisco, USA.

**Background and aims:** Previous studies have shown that the method of communication used by healthcare professionals (HCPs) can influence patient outcomes. The present study aimed to assess the resources used by different types of HCPs when they educate patients about time in range (TIR).

**Materials and methods:** In an online survey in September 2021, 303 HCPs, each with a minimum of 30 patients with diabetes every month, were asked a series of questions related to their use of TIR and continuous glucose monitoring (CGM), and their challenges, evaluation, and goal-setting when discussing diabetes management with their patients. Respondents were classified as endocrinologists (Endos, n=98), diabetes educators (DEs, n=106), or primary care providers (PCPs, n=99) and by their use of TIR (TIR users, n=234) and CGM (CGM users, n=298) in practice. Respondents received $30-$50 USD for completing the survey. Statistical significance was tested at the 95% confidence level (p<0.05).

**Results:** There was significant variation in resources used among DEs, Endos, and PCPs. In response to an open-ended question about resources HCPs use to educate patients about TIR, DEs were more likely to use CGM reports than PCPs (57% vs 31%). When discussing CGM data, DEs and Endos were more likely to use a computer printout than PCPs (Endo 78%, DE 70% vs PCP 28%, p<0.0005) while PCPs preferred to provide a verbal summary (PCP 52% vs Endo 27%, DE 29%, p<0.01).
DEs were most likely to recommend CGM for all patients (DE 57% vs. Endo 34% vs. PCP 15%; \( p < 0.05 \)) and more likely than Endos to discuss TIR with patients not using CGM (56% vs. 34%, \( p = 0.003 \)).

Conclusion: This data highlights differences in TIR use among HCPs. DEs relied more heavily on TIR and CGM reports while PCPs more often relied on verbal instructions. Interestingly among non-CGM users, a large discrepancy exists between DEs and Endos regarding TIR discussions. This study emphasizes opportunities to bring greater alignment among DEs, Endos, and PCPs to provide standardized quality care to all people with diabetes.

Disclosure: A. Sommi: None.

Results: Most HCPs agreed that TIR is changing the course of diabetes management (strongly agreed/somewhat agreed: SP, 90%; GP, 86%; NP, 93%) and is likely to become the standard metric for diabetes management in the future (very likely/somewhat likely: SP, 93%; GP, 87%; NP, 96%). Compared with GPs, SPs and NPs have greater knowledge (know a lot/know a fair amount: SP, 73%; NP, 53% vs GP, 30%; both \( p < 0.05 \)) and comfort using TIR (very comfortable/comfortable: SP, 76%; NP, 63% vs GP, 42%; both \( p < 0.05 \)), and this correlates with experience of using ambulatory glucose profiles (used many times/used a few times: SP, 63%; NP, 49%; vs GP, 28%; both \( p < 0.05 \)). Perceived benefits of TIR include making it easier to manage patients using virtual/telehealth (SP, 60%; GP, 54%; NP, 63%) and saving time for patients and HCPs (SP, 58%; GP, 59%; NP, 72%). Most HCPs believe that TIR is very effective or effective in providing accurate information about hypoglycaemia (SP, 84%; GP, 81%; NP, 87%), optimising insulin regimens (SP, 87%; GP, 83%; NP, 87%) and optimising non-insulin regimens in type 2 diabetes (SP, 61%; GP, 52%; NP, 66%). The most frequently reported barrier to wider TIR adoption was limited access to CGM (SP, 65%; GP, 74%; NP, 69%), followed by lack of training/education (SP, 45%; GP, 59%; NP, 51%). Factors considered most important in facilitating increased TIR use are shown in the Figure.

Conclusion: Overall, HCPs agreed on the benefits of using TIR for diabetes management. As well as raising awareness among HCPs and patients, healthcare system updates are needed to facilitate increased TIR use including integration into clinical guidelines and recognition by regulators and payors.

Supported by: Novo Nordisk A/S

SO 52 Money isn't everything?

658

Speed of recovery of testing for management of diabetes in the aftermath of COVID-19 is slower in areas of greater social deprivation: findings from a UK study
D. Holland1, A. Heal2, F. Hanna3, P. Wu4, A. Fryer5;
1The Benchmarking Partnership, Alsager, 2Salford Royal Foundation Trust, Salford, Manchester, 3University Hospital of North Midlands, Staffordshire, 4Keele University, Staffordshire, UK.

Background and aims: We have previously shown that, during the first 6 months of the UK COVID-19-associated lockdown, >6.6M HbA1c tests were missed/delayed, including 1.41M missed/delayed in people with diabetes (0.51M in those with suboptimal control). Studies suggest that COVID-19 has a more significant impact on people with diabetes and those from more deprived backgrounds. We here show data on the variability in speed of recovery of HbA1c testing across 7 UK sites, and its association with demographic characteristics, including deprivation status.

Materials and methods: We examined all HbA1c tests across 570 general practices (GPs; 4.57M population) requested between Jan 2019 and Dec 2021. We compared differences in monthly requests during 4 periods (Apr-Jun 2020 [lockdown 1], Jul-Dec 2020 [inter-lockdown period], Jan-Mar 2021 [lockdown 2] and Apr-Dec 2021 [recovery period]), with their equivalent pre-covid period in 2019. We then examined the effect of practice size, diabetes prevalence, proportion aged over 65 year and deprivation index on these differences for each period.

Results: We showed that, for all 7 centres, monthly requests dropped to 10.6-14.8% of the mean monthly request numbers in April 2020. During the following 3 periods, degree of recovery to pre-pandemic levels, as well as the drop during lockdown 2, showed greater variability between centres (inter-lockdown period: 74.0-93.2%, lockdown 2: 78.6-94.2%, recovery period: 89.0-105.7%). When examined at a GP practice level, we did not identify any link between age, practice size or diabetes prevalence and post-pandemic recovery. However, we did observe that return to pre-pandemic levels was associated with social deprivation status. Thus, compared with the equivalent pre-pandemic period, levels of HbA1c testing during period 4 (Apr-Dec 2021) were lower in those areas with higher levels of deprivation (91.3-93.5% of 2019 levels for deciles 6-10) than those with lower deprivation (96.2-99.7% of 2019 levels for deciles 1-5) (see figure). Similar findings were also noted during period 2 (inter-lockdown period Jul-Dec 2020): deprivation deciles 6-10 were 78.2-82.6% of 2019 levels compared with 83.8-88.9% for deciles 1-5. This trend was less evident during lockdown periods 1 and 2.

Conclusion: Our findings reinforce that the COVID-19 pandemic continues to have a major impact on diabetes management, with some centres having yet to return to pre-pandemic levels. This ongoing impact appears most significant in areas of greatest deprivation, thereby adding to the increasing body of evidence showing that those from poorer backgrounds continue to be disproportionately disadvantaged in the context of SARS-CoV-2. There is therefore an onus on healthcare services to implement urgent measures to redress this imbalance.

659

Direct and indirect costs of peripheral artery disease in type 2 diabetes: a matched case-control study
K. Nilsson1, K. Carlsson1,2, M. Faurby3, M. Wolden3;
1The Swedish Institute for Health Economics (IHE), Lund, Sweden, 2Lund University, Lund, Sweden, 3Novo Nordisk A/S, Søborg, Denmark.

Background and aims: Peripheral artery disease (PAD) is a risk factor for amputation and other morbidity and mortality, and its prevalence among people with type 2 diabetes (T2D) has been estimated to be 45%. We used national health and social insurance data to quantify direct healthcare costs, indirect costs and other outcomes in people with T2D and PAD, compared with matched controls.

Materials and methods: In this 5-year closed cohort study, individuals ≥16 years old with T2D living in Sweden on 1 January 2012 were identified in an existing database at the Swedish Institute for Health Economics. Individuals with a record of hospital-based care for PAD, including procedure codes related to amputation, in the National Patient Register (1997-2011) were matched pairwise by age, sex and educational status to individuals with T2D without PAD. Study variables included costs of selected hospital-based care and prescription drugs, and mortality from the National Board of Health and Welfare; demographic and socio-economic information from Statistics Sweden; and work absences from Försäkringsskassan, the Swedish Social Insurance Agency. We compared cumulative direct healthcare costs (inpatient, outpatient and drug costs) and indirect costs from lost productivity, and risks of early retirement, cardiovascular events and mortality.

Results: After matching there were 15,397 individuals in each cohort; mean age was 68 years, two-thirds were men, and 41% had completed compulsory education. For each year (2012-2016), cumulative per-person direct costs for people with T2D and PAD were three- to fourfold
Early death and loss of life expectancy years in type 2 diabetes are linked to the effective management of health comorbidities

M. Whyte1, M. Stedman2, A.H. Heald3, I. Laing4

1Metabolic Medicine, University of Surrey, Salford, UK, 2Res Consortium, Andover, 3Salford Royal Hospital, Salford, 4Department of Clinical Biochemistry, Royal Preston Hospital, Preston, UK.

Background and aims: The age-standardised mortality ratio (SMR) for people with diabetes in England is 1.5-1.7. Intensive, multimodal treatment is believed to have contributed to declining mortality, besides the growth and aging of populations. There are few data quantifying the impact of the management of diabetes co-morbidities on SMR.

Materials and methods: Data from patients with type 2 diabetes in North-West of England were extracted for a 2010 cohort, followed until end 2020, or death. Annual expected deaths were calculated from Office of National Statistics (ONS) mortality rate and life expectancy based upon age, gender and index of multiple deprivation (IMD) which was based on the Lower Layer Super Output Area (LSOA). Linear regression provided a relationship between local IMD and SMR, which was used to calculate a local deprivation factor and adjust the expected national mortality rate for each patient given their LSOA. Comparing the sum of expected patient mortalities with actual deaths provided SMR adjusted for deprivation (SMRd) for the cohort. A life expectancy value multiplied by fractions of expected deaths can be subtracted to ascertain the total net life expectancy years lost. This value divided by total patient years within that set and multiplied by fifty-two gives an estimate for the life expectancy weeks lost (LEWL) for each patient-year within that group. Average data 2010 to year analysed was termed Historic Average (HA).

Results: The 2020 cohort comprised 9,511 (M 5,228; F 4,283) patients. There were n=3,599 (M=1913, F=1686) deaths to end 2020. The crude SMR was 1.68 (M=1.6, F=1.78), the SMRd was 1.39 (M=1.47, F=1.32), and LEWL was 11.7 weeks (M=11.1, F=13). Patients with HA HbA1c 49-58 mmol/mol (30% of total cohort) had the lowest SMRd (1.25; M=1.17, W=1.36) and LEWL (M=10, W=11 weeks). Those with HA HbA1c <48 mmol/mol had SMRd = 1.45 and LEWL 15 weeks. If >86 mmol/mol the SMRd = 2.37 & LEWL 26 weeks. Patients with HA-Total Cholesterol (TC) 4-5 mmol/L (37% of total) had SMRd = 1.14, LEWL = 6 weeks. If HA TC was <3 mmol/L, the SMRd = 1.95 (M=1.68, F=3.10) LEWL=37 weeks. If HA TC >6 mmol/L, SMRd=1.39 and LEWL =10 weeks. SMRd falls as HA-Diastolic blood pressure (DBP) increases, HA DBP of 70-80 mmHg had SMRd = 1.21, if DBP 90-100 mmHg SMRd = 1.1 (M=1.0, F=1.2) LEWL =4 weeks. If DBP 50-60 mmHg the SMRd = 1.74 and LEWL 25 weeks.

Conclusion: Optimum control of HbA1c for SMRd is at 48-59 mmol/mol, while reduction through higher medication in cholesterol and DBP past the optimum is associated with higher SMR.

Disclosure: M. Whyte: None.
Disclosure: None.

Early death and loss of life expectancy years in type 2 diabetes are linked to local population demographics and lifestyle

M. Stedman1, A.H. Heald2, M. Whyte3;
1Res Consortium, Andover, 2Salford Royal Hospital, Salford, 3University of Surrey, Basingstoke, UK.

Background and aims: The age-standardised mortality ratio (SMR) for people with diabetes in England is 1.5-1.7. Little work has been carried out on quantifying the impact of the various factors that affect SMR; this can be done by examining sufficient real-world patient records over a reasonable period.

Materials and methods: Data from patients with type 2 diabetes for the Salford region of England was extracted for a 2010 cohort until 2020 or death. Annual expected deaths were calculated from the annual Office of National Statistics (ONS) mortality rate and life expectancy by age and gender plus recorded deaths and population within the 37,400 Lower Layer Super Output Area (LSOA), where the Index of Multiple Deprivation (IMD) are provided. Linear regression provided a relationship between local LSOA IMD and SMR, which was used to calculate a local deprivation factor and adjust the expected national mortality rate for each patient given their LSOA. Comparing the sum of expected patient mortalities with actual deaths provided SMR adjusted for deprivation (SMRD) for the selected cohort. A life expectancy value multiplied by each actual death added together and then life expectancy values multiplied by fractions of expected deaths can be subtracted to ascertain a total net life expectancy years lost. This value divided by total patient years lost (LEWL) for each patient-year within that group. The impact of demographic and lifestyle factors such as age, sex, BMI, deprivation and smoking on the SMRD was evaluated on a uni-variant basis.

Results: The cohort with T2D and ASCVD (n = 80,305) had mean age 67 years; 67% were men and 39% had completed only compulsory Swedish Multi-generation Register). A mixed-effects model for statistical analysis was chosen. Annual long-term trends of HbA1c were stratified for parental sex and then for education, income and marital status.

Results: Parental educational level had the strongest association to the glycemic control. Paternal and maternal educational level showed similar results. An increase in HbA1c was seen during puberty (age - years), but not in children to parents with >12 years of education who also showed a larger decrease in HbA1c during the last two decades compared to children where parents had a lower educational level. Children to married parents had a marginally lower HbA1c during puberty compared to children to divorced or single parents. No clear association between glycemic control and income was shown.

Conclusion: Both the fathers’ and the mothers’ level of education is important for the degree of glycemic control in their children. Families with less educated parents need extra support from health care.

Disclosure: None.

Direct and indirect costs of atherosclerotic CVD in type 2 diabetes: a matched case-control study in 160,000 individuals

K. Steen Carlsson1,2, K. Nilsson3, M. Lyng Wolden4, M. Faurby5;
1Lund University, Lund, Sweden, 2The Swedish Institute for Health Economics (IHE), Lund, Sweden, 3Novo Nordisk A/S, Søborg, Denmark.

Background and aims: Type 2 diabetes (T2D) is associated with risk of atherosclerotic CVD (ASCVD), which is linked to significant morbidity and mortality. We compared direct healthcare costs, indirect costs and other outcomes in people with T2D with and without ASCVD.

Materials and methods: This was a 5-year closed cohort study. Individuals ≥16 years old with T2D alive and resident in Sweden on 1 January 2012 were identified in an existing database at the Swedish Institute for Health Economics. Individuals with ASCVD, defined as ≥1 inpatient admission or outpatient visit with a main or sub-diagnosis relating to stroke, ischaemic heart disease or peripheral artery disease, or procedure codes related to revascularization or amputation, in the National Patient Register (1997-2011), were propensity score matched 1:1 to controls with T2D and without ASCVD by year of birth, sex and educational status. Study variables included costs of selected hospital-based care and prescription drugs, and mortality from the National Board of Health and Welfare; demographic and socioeconomic information from Statistics Sweden; and work absences from Försäkringskassan, the Swedish Social Insurance Agency. We compared annual direct healthcare costs and indirect costs from lost productivity, and risks of early retirement, cardiovascular events and mortality. HRs were estimated using Cox proportional regression adjusted for baseline age, sex, comorbidities, education and marital status.

Results: The cohort with T2D and ASCVD (n = 80,305) had mean age 67 years; 67% were men and 39% had completed only compulsory
education. Over the study period, mean annual total direct costs for individuals with T2D and ASCVD were nearly double the costs for controls with T2D and no ASCVD; indirect costs were also 77% higher for those with ASCVD than for those without (Figure). In cases and controls, indirect costs accounted for more than half of total costs. In the group with T2D and ASCVD, inpatient costs constituted 71% of total direct costs, whereas outpatient costs and drug costs contributed 16% and 13%, respectively. In controls with T2D without ASCVD, total direct costs comprised 68% inpatient costs, 15% outpatient costs and 18% drug costs. All-cause mortality was 81% higher in individuals with T2D and ASCVD than in controls (HR 1.81 [95% CI 1.77, 1.86]). Individuals with T2D and ASCVD were also more likely to experience stroke (1.81 [1.73, 1.89]), myocardial infarction (2.61 [2.50, 2.73]) and early retirement (2.23 [2.01, 2.48]).

Conclusion: Individuals with T2D and ASCVD incurred nearly double the total costs of people with T2D and no ASCVD, and had a greater risk of death and other CV events. Efforts to prevent and slow ASCVD in individuals with T2D are needed to reduce mortality, morbidity and the economic impact on healthcare systems and society.

Figure, Mean annual direct and indirect costs in individuals with T2D and ASCVD and matched controls with T2D without ASCVD over the 5-year study period

Data are mean costs in the study period among all people, regardless of gender or age at baseline. ASCVD, atherosclerotic cardiovascular disease; T2D, type 2 diabetes.

Supported by: Grant from Novo Nordisk A/S to the Swedish Institute for Health Economics.

Disclosure: K. Steen Carlsson: Employment/Consultancy; KSC is an employee of the Swedish Institute for Health Economics. Grants; Novo Nordisk A/S.

664 Cumulative cardiovascular or renal disease (CVRD) hospital costs for type 2 diabetes free of CVRD at baseline: a 5-year cohort study in the SNDS nationwide claims database

P. Zaoui1, P. Blin2, M. Joubert1, E. Guiard2, D. Sark2, C. Dureau-Pournin2, M.A. Bernard2, R. Lassalle2, F. Thomas-Delecourt1, S. Bineau2, N. Moore2, C. Droz-Perroteau1, P. Jourdain1;

1CHU Grenoble, Grenoble, 2Bordeaux PharmacoEpi INSERM-P CIC1401, University of Bordeaux, Bordeaux, 3CHU Caen, Caen, 4AstraZeneca, Courbevoie, 5Hôpital Kremlin-Bicêtre, Paris, France.

Background and aims: Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal disease (CVRD) complications for type 2 diabetes (T2D). The objective was to estimate the 5-year cumulative costs of CVRD hospitalizations for T2D patients free of CVRD at baseline.

Materials and methods: A cohort study of all French T2D patients free of CVRD (5-year history) as of January 1st, 2014, identified and followed-up for 5 years within the French SNDS nationwide claims database. The 5-year cumulative CRVD hospital costs for T2D patients without CVRD at baseline, was estimated for each CVRD over time from the perspective of all payers and taking into account primary and associated diagnoses.

Results: From about 2 million T2D patients without cancer or transplantation, 76.5% were free of CVRD at baseline with a mean age of 65 years, 52% of women, 46% T2D for more than four years and 7% of diabetic complications. For the whole cohort, the 5-year global cost of all CVRD hospitalizations was 3.875 billion € (BE) with an increase weakly exponential over time for specific CVRD manifestations (Figure 1). The 5-year cumulative hospital costs were 1.954 BE for CKD and 1.169 BE for HF, respectively 6.6 and 4.0 times more costly than for MI (0.295 BE), 3.2 and 1.9 times more costly than for stroke (0.614 BE), 2.8 and 1.7 times more costly than for PAD (0.690 BE). Hospitalizations with HF or CKD diagnoses together were 1.8 times more costly than for MI, stroke and PAD together (2.742 vs 1.549 BE); sum of hospital costs of each specific CVRD was 21.9% higher than the overall cost because some hospitalizations may involve 2 or more CVRD diagnoses when considering primary and associated diagnoses.

Conclusion: The 5-year global CVRD complication cumulative hospital cost in France was about 2 billion € for those without CVRD at baseline. HF and CKD hospitalizations together were twice as expensive than the classic MI, stroke and PAD complications together. This should encourage the development of specific preventive strategies.

Figure 1: 5-year cumulative specific CVRD hospitalization costs according to all-payer perspective

Supported by: Study performed with unconditional funding from AstraZeneca

Disclosure: P. Zaoui: Honorarium; AstraZeneca.

665 Real world healthcare costs among patients using self-monitoring blood glucose compared to continuous glucose monitoring in non-intensively treated type 2 diabetes

F. Giorgino1, E. Repetto2, J. Rötschke3, E. Acmet4, G. Bergman5, R. Maroun6, A. Wu7, I. Duncan8, D. Kerr9;

1Division of Endocrinology, University Hospital Policlinico Consorziale, Bari, Italy, 2Roche Diabetes Care, Inc., Indianapolis, USA, 3Roche Diabetes Care GmbH, Mannheim, Germany, 4Roche Diabetes Care Italy S.p.A., Monza, Italy, 5Roche Diabetes Care B.V., Almere, Netherlands, 6Roche Diagnostics A.G., Bazel, Switzerland, 7Roche Diagnostics, Inc., Santa Clara, USA, 8University of California, Santa Barbara, USA, 9Sansum Diabetes Research Institute, Santa Barbara, USA.
Background and aims: Type 2 diabetes (T2DM) poses a significant economic burden to healthcare systems. The increasing use of continuous glucose monitoring (CGM) in T2DM raises questions about its appropriateness and sustainability in this clinical setting. The aim of this study was to compare all-cause costs and healthcare resource utilization (HCRU) for T2DM individuals treated with oral agents or basal insulin using Self-Monitoring of Blood Glucose (SMBG) compared with CGM.

Materials and methods: A retrospective cost-analysis using the IBM® MarketScan® Databases was performed. Commercially insured T2DM US patients aged ≥18 years who were using SMBG or initiated CGM between Jan 2018 and March 2019 were compared. Inclusion criteria included two consecutive claims for T2DM or one claim for T2DM and a claim for glucose-lowering therapy, at least one pharmacy claim for SMBG strips or CGM sensors, and continuous enrollment for 12 months before and after the index date. Individuals with evidence of CGM in the pre-index period, pregnancy, rapid-acting insulin, glucagon, T1DM, gestational or secondary diabetes were excluded. The analysis examined all-cause costs and HCRU among two subgroups: 1) orally treated T2DM subjects taking oral monotherapy or oral combination therapy, and 2) basal insulin-treated T2DM subjects, including those in combination with oral therapy, but not with other injectables (e.g. GLP-1 and amylin analogues). For each subgroup, SMBG and CGM users were compared using a propensity score matching approach, and all-cause costs during a 12-month follow-up period were evaluated adopting a payer’s perspective.

Results: 1,449 patients were included in each matched cohort in the orally treated subgroup. The average total healthcare costs per person/year were $2,917 less in SMBG users vs CGM users (p<0.001). SMBG users also had lower pharmacy costs (-$1,945, p<0.001), outpatient costs (-$473, p<0.001), and glucose-lowering medication costs (-$1,207, p<0.001). 583 patients were included in each matched cohort in the basal treated subgroup. The total healthcare costs per person/year were $4,426 less in SMBG users vs CGM users (p<0.001). SMBG users had also lower outpatient costs (-$388, p<0.001). In both subgroups, SMBG and CGM cohorts had similar rates for emergency room attendance.

Conclusion: This analysis shows that SMBG is less costly than CGM in T2DM treated by oral or basal insulin regimens. These findings may have implications regarding glucose monitoring technologies resource allocation for non-intensively managed T2D patients.

Disclosure: F. Giorgino: None.

666
Smart insulin pen caps versus standard of care: a Canadian cost-effectiveness analysis
K. Quansah1, K. Hansen1, K. Chan1, S. Muratov2, S. Khoudigian2, M. Lamotte2
1Novo Nordisk Canada Inc, Mississauga, Canada, 2IQVIA Canada, Mississauga, Canada, 3IQVIA Global, Zaventem, Belgium.

Background and aims: There is growing interest in novel insulin management systems that improve glycemic control without increasing the risk of hypoglycemia. A Bluetooth-enabled smart pen cap for disposable insulin pens allows the user to access data on insulin dose, type and time of injection resulting in safer insulin therapy. This study has evaluated the cost-effectiveness of smart insulin pen caps versus standard of care (SOC) insulin pens in the management of adult patients with type 1 diabetes (T1D) from a Canadian societal perspective.

Materials and methods: The well-validated IQVIA Core Diabetes Model (CDM) version 9.0 was utilized to conduct the analyses. Based on a previously published Swedish non-interventional study, the smart insulin pen cap arm was assumed to bear greater reductions (-0.67%) in glycated hemoglobin from baseline (obtained through a conversion from time in range) and have lower hypoglycemic events compared to the standard arm (-32.87 events per year). Cardiovascular and microvascular risks were predicted using the Epidemiology of Diabetes Interventions and Complications (EDIC) study data. Costs (inflated to 2021 Canadian dollars (CAD)) and utilities were sourced from literature. Core outcomes of the model estimated life years (LYs) and quality-adjusted life-years (QALYs). QALYs were assessed using the additive minimum approach method. The Lauridsen et al diminishing approach was used to estimate disutility for hypoglycemic events. The societal perspective included costs to publicly funded healthcare payer and costs of lost productivity. Both costs and effects were discounted at 1.5% over a 60-year time horizon in the base case. Uncertainty was explored in 18 scenario analyses and a probabilistic sensitivity analysis.

Results: The smart insulin pen cap was associated with lower mean discounted total costs ($221,943 CAD vs. 266,199, $-44,256 CAD), improvements in mean life expectancy (25.78 vs. 24.29, +1.49 years) and gains in QALYs (18.48 vs. 16.74, +1.75 QALYs) over the patient’s lifetime. The scenario analyses either confirmed the dominance of the smart insulin pen cap arm or demonstrated its cost-effectiveness at the willingness to pay threshold of $50,000 CAD. The probabilistic analysis showed dominance in 99.5% of cases and cost-effectiveness in 100% of cases.

Conclusion: For adults with T1D in Canada, a smart insulin pen cap is likely to be a cost-effective treatment option associated with greater clinical benefits and lower costs relative to a standard disposable pen.

Disclosure: K. Quansah: Employment/Consultancy; Employee of Novo Nordisk Canada Inc.
SO 53 Pumping, looping, freeing

667 Predictors of time in target glucose range in real-world users of the MiniMed™ 780G system

J. Castaneda1, A. Arrieta1, T. van den Heuvel1, O. Cohen2,
1Bakken Research Center, Medtronic, Maastricht, Netherlands, 2Medtronic International Trading Sàrl, Medtronic, Tolochenaz, Switzerland.

Background and aims: Automated insulin delivery use has demonstrated improved glycaemic control in people with type 1 diabetes mellitus. The present analysis investigated predictors of improved sensor glucose (SG) time-in-range (TIR 70-180 mg/dL) based on real-world use of the MiniMed™ 780G advanced hybrid closed-loop (AHCL) system.

Materials and methods: Data uploaded from August 2020-July 2021 by de-identified MiniMed™ 780G system users (in Europe, Middle East and Africa) were analyzed using univariate and multivariable models to identify baseline (pre-AHCL initiation) glycaemic metrics, demographics and system use characteristics associated with TIR post-AHCL initiation. System settings associated with improved TIR post-AHCL were identified and their impact on time spent at <70mg/dL (TBR) was explored. Glycaemic outcomes (e.g., mean±SD of SG, the glucose management indicator (GMI), and mean time spent at SG ranges) post-AHCL were also analyzed.

Results: 12,870 users were included, of whom 2,977 had baseline SG data. Baseline mean TIR and time in AHCL were positively associated with TIR post-AHCL, with higher values predicting greater TIR post-AHCL. Characteristics inversely associated with TIR post-AHCL included percentage of daily basal insulin dose, daily auto correction dose, number of daily AHCL exits triggered by the system and number of daily alarms, wherein higher values predicted lower mean TIR post-AHCL. Settings that predicted the highest TIR post-AHCL were active insulin time (AIT) of 2hrs and glucose target of 100mg/dL. Associations were based on the multivariable model (all p<0.001). Figure 1 shows the glycaemic outcomes for subjects with optimized modifiable factors: 5-6 boluses per day, AIT of 2hrs, and 100mg/dL glucose target. Same predictors were found for TBR post-AHCL, except for AIT (p= 0.3104).

Conclusion: Modifiable factors including optimized pump settings can allow users to achieve glycaemic targets with >80% TIR, while maintaining low TBR. The findings from this analysis will potentially guide the optimal use of the MiniMed™ 780G system and facilitate meaningful improvements in safe glycaemic control.

Figure 1. Glycemic outcomes of users based on optimized modifiable settings (e.g., insulin bolus, active insulin time and glucose target)

Data are presented as mean ± mean±SD

Disclosure: J. Castaneda: Employment/Consultancy; Employer of Medtronic.

668 New ex-vivo method to assess subcutaneous absorption events during basal administration through pump: proof of concept

P. Jacqueymer1, Y. Retory2, A. Schmidt2, C. Virbel-Fleischman2, J. Cuenco1, A. Ostertag1, M. Cohen Solal1, J.-B. Julla1, L. Potier3, N. Ventecler1, J.-F. Gautier1, J.-P. Riveline1;
1IMMEDIAB, Institut Necker Enfants Malades, 2Air Liquide Healthcare, Bagneux, France, 3Hôpital Lariboisière APHP, 4Hôpital Bichat APHP, Paris, France.

Background and aims: Glycemic variability and hypoglycemia are still an issue among type 1 diabetic pump users and cannot always be explained by patient co-morbidity or behavior. Erratic subcutaneous (SC) absorption and poor diffusion at the injection site are often among the suspected causes for this phenomenon. However assessing insulin SC propagation is a challenge when it is administrated by basal rate through pump and was scarcely studied. We propose a descriptive method linking pump delivery and SC propagation of insulin through continuous follow-up of catheter pressure and high-precision time-spread imaging to screen for events potentially disturbing delivery.

Materials and methods: Administration of insulin (Aspart®) and contrast agent was performed via a pump (t:slim x2, Tandem®) at 1UI/h basal rate in ex vivo human skin explants from bariatric surgery. The sample was placed in a micro-CT scanner (uCT). A 20Hz pressure sensor was inserted between the pump and the sample. 3D images were taken every 5 min via μCT during 3h. Insulin depot was numerically isolated by comparison with image of explant before injection, linear enhancement of histogram and thresholding.

Results: Total opacity of explant images grew linearly with time through all of injection. Insulin impulsions can be detected upon pressure measurements. Pressure build-ups lasting 33.5 min in average (minimum 10 min, maximum 88 min) were detected in 33% of injections. In all other injections, no pressure build-up was observed. First images showed various shapes of insulin depots and different propagation pathways. Different propagation configurations were observed: intra-dermal injections, propagation along interlobular fascia when the cannula was within hypodermis and close to a fat lobule limits (as displayed in the image, both in 3D and 2D, for the same sample), and bubbles during injection were made clearly visible, as they were once imprisoned in the tissue.

Conclusion: The observation of pressure build-ups in the catheter suggest events in the tissue, but the linearity of opacification indicates a regular delivery, excluding catheter occlusions. The ongoing morphological analysis of insulin depots will enable us to understand the mechanisms of SC propagation and establish if there is a link with pressure events. Analysis of basal rate impact and interpatient variability are to be explored.
Recently diagnosed with type 1 diabetes: glycaemic outcomes with the Omnipod® Automated Insulin Delivery System

G.P. Forlenza1, D.J. DeSalvo2, B.W. Bode1, A.B. Criego3, S.A. Brown1, M.J. Schooler4, S.N. Mehta5, L.M. Laffel6, S.A. MacLeish1, L.M. Huyett7, J. Boyd8, R.E. Gurlin1, T.T. Ly9, Omnipod 5 Research Group; 1Barbara Davis Center, Aurora, 2Baylor College of Medicine, Houston, 3Atlanta Diabetes Associates, Atlanta, 4International Diabetes Center, Minneapolis, 5University of Virginia, Charlottesville, 6Joslin Diabetes Center, Boston, 7Rainbow Babies and Children’s Hospital, Cleveland, 8Insulet Corporation, Acton, USA.

Background and aims: The diagnosis of type 1 diabetes (T1D) is a major life event requiring the rapid acquisition of complex knowledge and skills to safely manage the condition. Automated insulin delivery (AID) systems may improve health and safety while reducing the daily burden of T1D self-management. In the US, an estimated 400,000 people are diagnosed with T1D each year; however, there is little data available evaluating AID use in those recently diagnosed partly due to clinical study design, which typically has required a T1D duration of ≥6mo in children aged <6y, or ≥1y in those aged ≥6y. In this sub-analysis of the Omnipod 5 AID System pivotal trial, we evaluated outcomes of participants who were diagnosed within 1y prior to enrollment.

Materials and methods: Participants were in 3 age groups: 2-5.9y, 6-13.9y, and 14-70y with screening A1C<10% (86 mmol/mol). Inclusion criteria for the pivotal trial were any T1D duration for children <6y, or T1D duration ≥6mo for ages ≥6y. This sub-analysis was restricted to participants with T1D duration <1y prior to study enrollment. In the trial, participants used AID for 3mo at home after 14d of their standard therapy (ST, pump therapy or multiple daily injections [MDI]). Safety endpoints were occurrence of severe hypoglycemia (SH) and diabetic ketoacidosis (DKA). Efficacy endpoints included A1C at end of study compared with baseline and time in range (TIR, % 70-180 mg/dL [3.9-10.0 mmol/L]) during AID compared with the ST phase.

Results: At baseline, participants (N=22, 50% male) had a median age of 5.0y (IQR: 3.2-9.3y, range: 2-43y) with T1D duration (mean±SD) 0.7±0.3y (range: 0.11-0.99y) and a ST total daily insulin dose of 0.56±0.22 U/kg (range: 0.19-0.95 U/kg). Eight participants (36%) were prior MDI users and 3 (14%) were new to continuous glucose monitor (CGM) use. There were no episodes of SH or DKA during the 3-month AID phase in this cohort. With AID, mean A1C improved from baseline to 3 months by 0.8% [8.7 mmol/mol] (p<0.05, Table). TIR improved from 58±18% during ST to 68±11% with AID (p<0.05, Table), equating to an additional 2.4h/d TIR. Median percent time <54 mg/dL (3.0 mmol/L) increased; however, this median time was very low (0.15%), below target, and lower than the full study cohorts (2.5-9y, 6-13.9y, and 14-70y) during AID.

Conclusion: The Omnipod 5 AID system was safe and effective in a cohort of recently diagnosed persons with T1D. The absence of SH and DKA are encouraging and suggest that AID could be safe in those without long-term self-management experience. These data support the early adoption of AID.

Table. Primary and secondary outcomes for people with recently diagnosed type 1 diabetes (N=22) at baseline (A1C) or during the standard therapy phase (CGM outcomes and insulin use) compared with Omnipod 5 Automated Insulin Delivery (AID) System use

<table>
<thead>
<tr>
<th>Glycemic Outcomes</th>
<th>Baseline / Standard Therapy</th>
<th>AID</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1C, % (mmol/mol)</td>
<td>7.8 ± 0.9 (62 ± 9.8)</td>
<td>7.0 ± 0.6 (53 ± 6.5)*</td>
</tr>
<tr>
<td>Mean glucose, mg/dL (mmol/L)</td>
<td>175 ± 33 (9.7 ± 1.8)</td>
<td>160 ± 16 (8.9 ± 0.9)*</td>
</tr>
<tr>
<td>Percent time in range, %</td>
<td>0.05 [0.00, 0.16]</td>
<td>0.13 [0.07, 0.34]*</td>
</tr>
<tr>
<td>&lt;54 mg/dL</td>
<td>1.07 [0.40, 1.71]</td>
<td>3.13 [0.64, 1.58]</td>
</tr>
<tr>
<td>&lt;70 mg/dL</td>
<td>3.9-10.0 mmol/L</td>
<td>58.2 ± 18.4</td>
</tr>
<tr>
<td>&gt;180 mg/dL</td>
<td>10.0 mmol/L</td>
<td>39.8 ± 18.7</td>
</tr>
<tr>
<td>≤250 mg/dL</td>
<td>13.9 mmol/L</td>
<td>11.4 [5.0, 15.9]</td>
</tr>
</tbody>
</table>

Insulin Use
- Total daily dose (U) | 14.1 ± 8.3 |
- Total daily dose (U/kg) | 0.56 ± 0.22 |

Data are mean ± SD or median [IQR].

* Significant change from baseline/standard therapy as assessed by two-sided Wilcoxon signed rank or paired t-test, p<0.05.

were sustained through 15 months of system use compared with standard therapy ($p<0.05$, Table).

**Conclusion:** The safety and improved glycemic outcomes from the 3-month pivotal study persisted for an additional 12 months, indicating the potential long-term benefit of the Omnipod 5 AID System.

**Clinical Trial Registration Number:** NCT04196140

**Supported by:** Insulet Corporation

**Disclosure:** A. Criego: Grants; Insulet, Dexcom, Medtronic, Abbott Diabetes, Sanofi, Eli Lilly. Lecture/other fees; Medtronic, Sanofi, Eli Lilly, Medscape.

---

Advanced hybrid closed-loop system rapidly achieves and maintains good glycemic control in type 1 diabetes adults despite of previous treatment

**C. Quiros, A.-C. Nuria, R. Silvia, P. Verónica; Hospital Universitari Mutua de Terrassa, Terrassa, Spain.**

**Background and aims:** In last years, the improvement in continuous glucose monitoring (CGM) has changed type 1 diabetes (T1D) treatment allowing the automatization of glucose control. The advanced hybrid closed-loop (ACHL) system Minimed 780G adapts basal infusion rates and delivers autocorrection boluses in order to achieve a glucose target decided by the user (100, 110 or 120mg/dL). The aim was to evaluate the effectiveness of Medtronic 780G system in real-life conditions for 6 months.

**Materials and methods:** Prospective study that includes T1D individuals previously treated with insulin pump without CGM (pump group) or with sensor-augmented pump with predictive low-glucose suspend (SAP-PLGS group) that started Minimed 780G system. Baseline, 1-, 3- and 6-months sensor and pump data were downloaded. Baseline and at 6 months HbA1c were recorded.

**Results:** Fifty T1D subjects were included. 25 were SAP-PLGS 640G previously users and 25 were using 640G without CGM. Sixty percent were females, with 48.6 (40-57) years and 20 (12-31.5) years of diabetes duration. Time in range (TIR) improved in total cohort from baseline to 6 months (69 (57.7-76) vs 74 (70-82) %; $p=0.01$ as well as HbA1c (7.6 (7.1-7.8) vs 7.0 (6.8-7.5) %; $p<0.001$), with improvement in times <54, >180 and >250 mg/dL. Outcomes at 6 months were not different between groups ($p<0.05$) although SAP-PLGS subjects were prone-to-hypoglycemia individuals and subjects in pump-group had mainly suboptimal metabolic control. All glucose outcomes are depicted in Table 1.

**Conclusion:** The AHCL system Medtronic Minimed 780G rapidly achieves and maintains good glycemic control during 6 months in real-life conditions in different profiles of type 1 diabetes individuals.

**Disclosure:** C. Quiros: None.

---

Comparison of hybrid closed-loop systems, AndroidAPS and Control-IQ in patients with type 1 diabetes: the CODIAC study


**1**3rd Department of Internal Medicine, 1st Faculty of Medicine Charles University, Prague, Czech Republic, **2**Department of Internal Medicine, 1st Faculty of Medicine Charles University, Prague, Czech Republic, **3**Grunberger Diabetes Institute, Bloomfield Hills, USA, **4**CGParkin Communications, Inc, Henderson, USA.

**Background and aims:** The number of patients with type 1 diabetes (T1D) using non-certified “Do-It-Yourself” (DIY) automated insulin delivery (AID) systems is rapidly increasing. Non-certified technology has been suggested to bring better treatment outcomes than a certified system. However, there are no studies supporting this statement. Therefore, we compared two AID systems - certified Control-IQ technology (CIQ) and non-certified AndroidAPS (AAPS) in maintaining optimal glycemic control.

**Materials and methods:** In this prospective open-label single-arm clinical trial, adults with T1D, who had been using the AAPS by their own decision were switched to the CIQ technology for 12 weeks. Results of
this treatment were compared with the prior 3-month period on AAPS. The primary endpoint was non-inferiority in time in range (%TIR) at 12 weeks. Time below range (%TBR), time above range (%TAR), mean sensor glucose and glycated hemoglobin (HbA1c) were selected as secondary endpoints.

**Results:** Twenty-two adults with T1D (mean age 36 ± 10 years; HbA1c 44.8 ± 7.6 mmol/mol [6.2 ± 0.68%]) participated in this study. All participants completed the study. After 12 weeks, there was no difference in %TIR (3.9-10.0 mmol/L [70-180 mg/dL]) between CIQ and AAPS (p = 0.269) but %TBR (<3.9 mmol/L [<70 mg/dL]) was lower with CIQ. (Figure 1) %TAR (>10 mmol/L [180 mg/dL]) was not different between CIQ and AAPS (10.3 ± 6.0 vs. 10.4 ± 8.0, p=0.92). Mean sensor glucose was not different between AAPS and CIQ (6.91 ± 0.87 mmol/L [124.38 ± 15.66 mg/dL]) vs. 7.18 ± 0.62 mmol/L [129.24 ± 11.16 mg/dL], respectively, p=0.1. No differences in HbA1c were observed between AAPS and CIQ (44.8 ± 7.6 mmol/mol [6.3 ± 0.68%] vs 45.1 ± 6.1 mmol/mol [6.3 ± 0.55%], respectively, p=0.86) at 12-week. No episodes of severe hypoglycemia or diabetic ketoacidosis were reported.

**Conclusion:** To our knowledge, this is the first prospective study to compare AAPS and CIQ technology in patients with T1D. The results showed that CIQ and AAPS are non-inferior in achieving time in range. However, patients spent less time in the hypoglycemic range with CIQ use. We believe that these findings will provide further guidance for clinicians and patients when discussing treatment options and contribute to the decision-making process.

**Clinical Trial Registration Number:** NCT05165615

**Supported by:** Ministry of Health, Czech Republic

**Disclosure:** D.Q. Dat: None.

**673**

**Exploring characteristics and real-world experiences using the software updatable t:slim X2 insulin pump in people with diabetes living with disabilities**

H. Singh, G. Alencar, M. Manning, H. Sanchez, S. Habib; Behavioral Sciences, Tandem Diabetes Care, San Diego, USA.

**Background and aims:** Diabetes is associated with an increased risk of disabilities including functional, mobility, and work-related impairments. Glycemic and quality of life outcomes may be compromised in people with diabetes living with disabilities as self-care and day-to-day management can become more challenging. Unfortunately, there is very little published data exploring the impact of disabilities on diabetes management and patients’ experiences of different therapy modalities, especially use of advanced diabetes technologies like state-of-the-art, software updatable insulin pumps.

**Materials and methods:** People with type 1 (T1D) and type 2 diabetes (T2D) using the t:slim X2 insulin pump who were registered with the company’s customer relations management system were sent an email invitation in October 2021 to complete an online survey exploring their experiences using their insulin pump. For purposes of this study, we analyzed demographics, self-reported glycemic data (HbA1c), and patient-reported outcomes (PROs) from US participants reporting one (D1) or more disabilities (D1+) as part of this survey.

**Results:** In all 28,238 (T1D=25,928; T2D=2310) completed surveys were received. The majority of T1D (85%) and T2D participants (78%) were using the t:slim X2 insulin pump with Control-IQ technology. Of all T1D completers, 26.5% (n=6,882) reported one or more disabilities compared to 39.6% of all PWT2D (n=914). Comparing groups D1 (56.9%) and D1+ (43.1%) from the T1D cohort, D1 participants were younger (mean age=53.9 (18.5) vs. 55.9 (16.7), p<0.001) and reported shorter duration of diabetes (31.8 years (16.7) vs. 33.6 (16.7), p<0.001). The D1+ group was more likely to report HbA1c ≥8% vs. D1 (p<0.001).

In contrast there were no significant differences between age and duration of diabetes for T2D participants in the D1 (mean age=63.8 (11.7), duration of diabetes=24.2 (11.1)) and D1+ groups (mean age=62.5 (12.8), duration of diabetes=24.6 (13.)). Additionally, no significant difference was observed in number of participants reporting HbA1c ≥8% in both D1 (46.5%) and D1+ (48.6%) groups for the T2D cohort. Vision impairment was the most frequently reported disability in T1D participants (D1=29.5%, D1+=53.1%) while mobility/physical disability was more frequently reported by the T2D group (D1=30%, D1+=65.2%). In terms of PROs, all participants irrespective of type of diabetes and number of disabilities, reported high pump-related satisfaction and trust (scores > 4 out of 5). However, D1 participants from the T1D cohort reported significantly higher pump-related satisfaction (4.44 (0.79) vs. 4.38 (0.84), p=0.002) and trust (4.49 (0.79) vs. 4.44 (0.82), p<0.05) compared to the D1+ group. The T2D cohort did not show significant differences on these variables.

**Conclusion:** To the best of our knowledge, this is the first study exploring the experience of living with disabilities in people with diabetes using advanced diabetes management technologies. Future, more in-depth research is encouraged to understand how different types of disabilities impact diabetes management including choice of therapy in people with diabetes.

**Disclosure:** H. Singh: Employment/Consultancy; Tandem Diabetes Care. Stock/Shareholding; Tandem Diabetes Care.

**674**

**Differences in the efficacy of an advanced hybrid closed-loop system in type 1 diabetes subjects with previous pump therapy experience compared to MDI**

P.I. Beato-Vibora, A. Ambrojo-López, M. Fernández-Bueso, E. Gil-Poch, I. Martín-Romo, F.J. Arroyo-Diez; Badajoz University Hospital, Badajoz, Spain.

**Background and aims:** The Advanced Hybrid Closed-Loop system (AHCL) MiniMed™ 780G automatically infuses insulin according to interstitial sensor glucose values and it delivers auto-correction boluses. The performance of the system in different subpopulations of people with type 1 diabetes (T1D) needs to be further explored. The aim of the study was to analyse the difference in glycaemic outcomes in previous pump users compared to subjects coming directly from multiple daily injections (MDI), in an adult and paediatric population.

**Materials and methods:** A prospective longitudinal intervention study was performed. Subjects with T1D consecutively initiated the use of the system. Two-week downloads were collected at baseline and at the last clinical visit. TIR (70-180 mg/dL), time in hyperglycaemia and time in hypoglycaemia were compared, at baseline and end of follow-up for each group (pump group and MDI group) and between groups.

**Results:** 160 T1D subjects were included (age: 34 ± 15 years, from 7 to 65 years-old, sex: 66% (n = 105) females, children and adolescents: 21% (n = 34), diabetes duration: 21 ± 12 years, baseline HbA1c: 7.27 ± 0.79%, previous treatment: pump therapy 71% (n = 114), MDI 29% (n = 46). Follow-up was 9 [6-12] months.At the end of follow-up, bolus insulin was 57 ± 7%, autocorrection insulin was 31 ± 12% of bolus insulin (27 ± 10 boluses per day). 86% (n = 137) of the participants had a glucose target...
of 100 mg/dl and 83% (n = 132) had an active insulin time of 2 hours. The percentage of patients with TIR (70–180 mg/dl) > 70% increased from 38% at baseline to 84% at the end of follow-up (p < 0.001). The percentage of patients with TIR (70–180 mg/dl) > 70% and time < 70 mg/dl < 4% increased from 23% at baseline to 55% in the last clinical visit (p < 0.001). The percentage of patients with TIR (70–180 mg/dl) > 70% and time < 54 mg/dl < 1% increased from 20% at baseline to 49% (p = < 0.001). No severe hypoglycaemia or DKA episodes occurred during follow-up. Outcomes at the end of follow-up in subjects coming from pump therapy compared to subjects previously on MDI are summarised in Table 1. In both groups, TIR (70–180 mg/dl) increased, compared to baseline: MDI group (14.11 ± 9.15%, from 63.24 ± 11.91% to 77.35 ± 7.92%, p < 0.001) and pump group (10.30 ± 10.04%, from 67.67 ± 11.91% to 77.97 ± 8.01%, p < 0.001); this increase was higher in MDI patients (p = 0.028). Time in hypoglycaemia was reduced significantly in the MDI group: time < 70 mg/dl: from 3.63 ± 3.86% to 2.22 ± 2.11% (p = 0.009); time < 54 mg/dl: from 0.85 ± 1.46% to 0.43 ± 0.66% (p = 0.031), but not in the pump group: time < 70 mg/dl: from 3.25 ± 3.23% to 3.10 ± 2.97% (p = 0.580); time < 54 mg/dl: from 0.82 ± 0.78% to 0.78 ± 1.17% (p = 0.781), although baseline time in hypoglycaemia < 70 mg/dl and < 54 mg/dl was not significantly different in both groups.

Conclusion: The AHCL MiniMedSTM 780G improves glycaemic control independently of the previous experience in pump therapy and the improvement in time in hypoglycaemia could be greater in MDI patients.

Table 1. Outcomes at the end of follow-up in patients with previous pump therapy compared to MDI.

<table>
<thead>
<tr>
<th></th>
<th>MDI group (n = 154)</th>
<th>MDI group (n = 40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GM (%)</td>
<td>6.47 ± 0.32</td>
<td>8.17 ± 0.37</td>
</tr>
<tr>
<td>Time &gt; 70 mg/dl (%)</td>
<td>72.37 ± 6.43</td>
<td>77.35 ± 7.92</td>
</tr>
<tr>
<td>Time &gt; 180 mg/dl (%)</td>
<td>19.35 ± 6.10</td>
<td>26.23 ± 7.96</td>
</tr>
<tr>
<td>Time &gt; 250 mg/dl (%)</td>
<td>5.64 ± 2.70</td>
<td>5.77 ± 3.60</td>
</tr>
<tr>
<td>Time &gt; 70 mg/dl (%)</td>
<td>5.10 ± 2.97</td>
<td>7.23 ± 4.11</td>
</tr>
<tr>
<td>Time &gt; 54 mg/dl (%)</td>
<td>0.19 ± 0.27</td>
<td>0.73 ± 0.96</td>
</tr>
<tr>
<td>Serum glucose (mg/dl)</td>
<td>100.67 ± 13.99</td>
<td>124.90 ± 11.36</td>
</tr>
<tr>
<td>SD of sensor glucose (mg/dl)</td>
<td>56.56 ± 9.43</td>
<td>61.33 ± 11.60</td>
</tr>
<tr>
<td>CV of sensor glucose (%)</td>
<td>53.47 ± 4.89</td>
<td>58.01 ± 5.91</td>
</tr>
<tr>
<td>Serum use (%)</td>
<td>51.20 ± 6.28</td>
<td>53.09 ± 6.57</td>
</tr>
<tr>
<td>Time in autoreview (%)</td>
<td>96.19 ± 6.92</td>
<td>96.24 ± 5.68</td>
</tr>
<tr>
<td>Feeds to manual mode [per week]</td>
<td>5.39 ± 0.20</td>
<td>5.98 ± 1.20</td>
</tr>
</tbody>
</table>

Results of the DTSQ show that patient satisfaction with their care increased since joining the virtual service, from an average of 26.68 at baseline to 30.25 at 6 months (MD=-2.07; p=0.000) and to 30.68 at 12 months (MD=-3.57; p=0.002) and costs related to clinic visits (e.g., travel, time off work) was higher at 12 months in comparison to their previous clinical setting, mainly in relation to: the number of times they were physically required to go to the clinic (MD=7.92%; p=0.009) and the nurse (MD=-1.32; p=0.006) beyond their regular appointments; the diverse ways in which they can communicate with the healthcare team (e.g., telephone, email, text) (MD=-1.27; p=0.002); and costs related to clinic visits (e.g., travel, time off work) (MD=2.07; p=0.000).

Conclusion: Virtual clinics can help type 1 diabetes patients cope with the challenges of managing their disease. Improved satisfaction with care can facilitate patient involvement and improve outcomes.

Disclosure: P.I. Beato-Vibora: None.
A pragmatic health informatics systems approach for aiding clinical prioritisation in a hospital based cohort of 4013 people with diabetes

**Background and aims:** The backlog of diabetes care due to COVID-19 pandemic and subsequent challenges in resource stretched health care systems highlight the need for innovative data driven approaches to facilitate risk stratification and clinical prioritisation. Our aim was to develop a pragmatic health informatics based approach to guide clinicians to prioritise those at highest need.

**Materials and methods:** We identified modifiable risk factors that could be addressed in 4013 adult people (48% female) with diabetes (type 1 diabetes 20%) attending outpatient clinics in a large university teaching hospital in London. Using data routinely collected from hospital electronic health care records we identified people who had one or more events from six risk (red flag) criteria as agreed by panel of diabetes specialists. These six red flag criteria were new clinical events/results (occurring after their last diabetes clinic attendance): 1. A diabetes related emergency department visit/ hospitalisation. 2. HbA1c >96 mmol/mmol. 3. Concerning HbA1c trend (HbA1c rise >20 mmol/mol) 4. estimated GFR <30 ml/min. 5. Concerning eGFR trend (eGFR fall >15 ml/min), or 6. Treatment for advanced diabetic eye disease (e.g. photocoagulation). People with high risk defined as one or more of the six red flag criteria are flagged on a dashboard system. Those who did not have any red flags and who had encouraging HbA1c and eGFR data/trends were categorised as lower risk. We also documented upcoming appointment dates to enable clinicians to decide if given their flagged status whether there was a need for red flagged people to be seen sooner than previously thought and vice versa those with green flags (lower risk) could be seen later than originally intended.

**Results:** The above criteria were assessed in 4013 people. One third of people were non-Caucasian and this reflects our local population. Of the 4013 people, 656 (16.3%) were identified as having one or more red flags. People with red flags were more likely to be non-Caucasian and had greater deprivation as measured by indices of multiple deprivation. Of the 656 red flagged people, 248 (6.2%) did not have an appointment within 3 months of the review date. These ‘higher risk’ people will be individually assessed and re-prioritised for their next appointment. Similarly a further 364 people (9.1%) had ‘lower risk’ (green flag) and of these 174 (4.3%) were due to be seen within 3 months, and might be considered for rescheduling to enable those at higher risk to be prioritised within currently available clinical resources. The remainder of the cohort (2993, 74.6%) did not have any new risk data for assessment and were therefore not scored as part of this pilot exercise. User feedback from a multidisciplinary group of health care workers including nurses, dieticians, junior doctors and administrative staff was positive.

**Conclusion:** A pragmatic data-driven method is helpful in identifying people with diabetes at highest need for clinical prioritisation. The related dashboard is a visual aid that can help clinicians assess trends and patterns in risk criteria and guide clinical decision making. Health informatics approaches such as ours are an important tool to enhance care and improve efficiency of clinical service delivery for people with diabetes.

**Disclosure:** None.
Perceived benefits of TIR varies between patient CGM users vs HCPs

N. Sainz1, A. Sommi1, E. Asamo2, E. Shoger2, R. Wood2, C. Alexander1;
1The diaTribe Foundation, 2DQ&A - The Diabetes Research Company, San Francisco, USA.

Background and aims: Previous studies have highlighted the positive patient reported outcomes, both physiological and psychosocial, of using time in range (TIR) among continuous glucose monitoring (CGM) users. The present study aimed to compare the perceived benefits of using TIR among CGM users and healthcare professionals (HCPs).

Materials and methods: 234 HCPs who use TIR to monitor patients’ diabetes (each with 30+ patients with diabetes per month), completed an online survey in September 2021. 253 adults with diabetes who use CGM and TIR and 16 caregivers of children and/or adults with diabetes, completed a separate online survey in October 2021. HCPs and PWD were both asked about their perceived benefits of TIR use. HCPs were classified as either Endocrinologists (Endos, n=88), Diabetes Educators (DEs, n=100), or primary care providers (PCPs, n=46). HCPs received $30-$50 USD and PWD received $10 USD for survey completion.

HCPs were both asked about their perceived benefits of TIR use. HCPs were classified as either Endocrinologists (Endos, n=88), Diabetes Educators (DEs, n=100), or primary care providers (PCPs, n=46). HCPs received $30-$50 USD and PWD received $10 USD for survey completion.

Conclusion: This study highlights differences in perceived TIR benefits between HCPs and PWD who use CGM. When considering the benefits of TIR, PWD value the simplicity and clarity of TIR whereas HCPs value the information and management help that TIR provides. An increased and comprehensive understanding of the benefits that TIR can offer may be helpful for patients and providers when assessing the value of TIR.

Introduction of isCGM with glucose alarms to regular isCGM users under real-life conditions: What is the benefit?

D.A. Hochfellner, P.M. Baumann, A.K. Reinhard, J.K. Mader; Division of Endocrinology and Diabetology, Medical University Graz, Graz, Austria.

Background and aims: Intermittently scanned continuous glucose monitoring (isCGM) has proven improvement in glycaemic control, comfort and quality of life in people living with diabetes (PLWD). Alarms for imminent hypo- or hyperglycaemia have been established to emulate continuous glucose monitoring (CGM) technology. Aim of the present analysis was to evaluate the effect of introducing isCGM with alarms to isCGM without alarms in PLWD under real-life conditions.

Materials and methods: A diabetes technology registry at a tertiary centre in Austria was searched for isCGM users (Freestyle Libre, Abbott Laboratories, Chicago, IL, USA) that were introduced to isCGM with alarm functions (Freestyle Libre 2, Abbott Laboratories, Chicago, IL, USA). CSV data of 90 before and 90 days after isCGM switch were analysed to calculate CGM metrics such as Time in Range (TIR), Glucose Monitoring Indicator (GMI), average glucose levels. The local ethics committee approved this investigation (No.: 34-184 ex 21/22).

Results: 18 PLWD were included in the analysis (Age: 41.0, 27.5-48.25 years, female gender: 27.8%, BMI: 24.5, 23.8-26.7 kg/m², C-peptide: 0.02, 0.00-0.05 ng/dL, Creatinine: 0.9, 0.9-1.0 mg/dL). TIR (70-180mg/dL) was 56.6, 46.9-73.5% during isCGM use without alarms and 58.7, 47.1-72.4% with alarms. Time below range (TBR <70mg/dL) was 35.1, 27.9-46.6% vs. 47.3, 39.2-56.2% with alarms. TIR provided improved patient and provider comfort and quality of life in people living with diabetes. The present analysis aimed to evaluate the effect of introducing isCGM with alarms to isCGM without alarms in PLWD under real-life conditions.

Continuous glucose monitoring metrics and pregnancy outcomes in insulin treated diabetes: a post-hoc analysis of the GlucoMOMS trial

A. van der Wel1, D. Rademaker1, R. van Eekelen1, GlucoMOMS Study Group, I. Evers1, A. Franx2, S. Siegelaar1, B. van Rijn1, H. DeVries1, R. Painter1;
1Obstetrics & Gynecology, Amsterdam UMC, Amsterdam, 2Obstetrics & Gynecology, MeanderMC, Amersfoort, 3Obstetrics & Gynecology, Erasmus University, Rotterdam, Netherlands.

Background and aims: Worldwide the incidence of diabetes in pregnancy is rapidly increasing. To date, no accurate risk indicator of maternal glycaemia for frequent complications of diabetes in pregnancy, like large for gestational age and neonatal hypoglycaemia, has been identified. Glycaemic metrics derived from continuous glucose monitoring may give more insight in the relationships between maternal glucose patterns and the risk of pregnancy complications. The objective of this analysis was to investigate the association between continuous glucose monitoring...
metrics and perinatal outcomes in insulin dependent diabetes mellitus in pregnancy.

**Materials and methods:** We conducted a post-hoc analysis of the GlucoMOMS randomised controlled trial which investigated the value of continuous glucose monitoring in pregnancy with diabetes. Associations between continuous glucose monitoring metrics or HbA1c and perinatal outcomes were analysed per trimester and type of diabetes (type 1 diabetes and a composite group of type 2 or gestational diabetes) using multivariable binary logistic regression analysis. Outcomes of interest were preeclampsia, preterm birth, large for gestational age, neonatal hypoglycaemia, and Neonatal Intensive Care Unit admission.

**Results:** The current analysis reports the results of 115 participants (n = 42 type 1 diabetes, n = 73 type 2 diabetes or gestational diabetes) who were originally allocated to the continued glucose monitoring study arm of the GlucoMOMS randomised controlled trial. Continuous glucose monitoring metrics and HbA1c values varied between trimesters and type of diabetes. In general, women with type 1 diabetes showed the highest glucose and HbA1c levels, and spent less time in Range (3.5-7.8 mmol/l) compared to women with type 2 diabetes or gestational diabetes. Mean glucose in type 1 diabetes was 6.3 mmol/L in first trimester and 6.8 in second and third trimester. For the composite group of type 2 diabetes and gestational diabetes mean glucose was 5.8, 6.1 and 6.0 mmol/L in respectively the first, second and third trimester. We found that in pregnancies complicated by type 1 diabetes, greater Time Above Range in second and third trimester was associated with increased large for gestational age (ORs 1.1 (95% CI 1.0-1.1), 1.1 (95% CI 1.0-1.1) respectively). High mean glucose was also related to LGA in second (OR 2.6 (95% CI 1.1-6.2)) and third (OR 2.3 (95% CI 1.0-5.2)) trimester. In contrast, in type 2 diabetes and gestational diabetes, none of the continuous glucose monitoring metrics related to large for gestational age (Time Above Range ORs first and second trimester: 1.0 (95% CI 0.9-1.1) and third trimester: 1.1 (95% CI 1.0-1.1)), neonatal hypoglycaemia, preeclampsia, preterm birth and Neonatal Intensive Care admission rates. HbA1c showed no relation with pregnancy outcome in type 1 diabetes nor in type 2 diabetes or gestational diabetes.

**Conclusion:** Continuous glucose monitoring metrics identify pregnancies at risk for large for gestational age in type 1 diabetes. The novelty of this study is that in type 2 diabetes and gestational diabetes, continuous glucose monitoring metrics seem not to identify pregnancies at risk.

Clinical Trial Registration Number: NTR2996

Supported by: ZonMw, project number 80-82310-97-11157

Disclosure: A. van der Wel: None.

682

**Glycaemic control using intermittently scanned CGM in severe COVID-19 patients with diabetes requiring methylprednisolone therapy: a retrospective observational study**

M.M. Gomes1, N. Kodani1, R. Bouchi1,2, S. Saito3, Y. Miyazato3, N. Ihana-Sugiyama3,2, M. Ohsugi1,2, A. Tanabe1, K. Ueki1,4, M. Hojo5, H. Kajio1,*

1Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, 2Department of Molecular Diabetic Medicine, Research Institute, National Center for Global Health and Medicine, 3Department for Global Health and Medicine, 4Department of Molecular Medicine, Research Institute, National Center for Global Health and Medicine, 5Department of Respiratory Medicine, National Center for Global Health and Medicine, Shinjuku-ku, Japan.

**Background and aims:** In patients with severe coronavirus disease 2019 (COVID-19), methylprednisolone therapy is effective in reducing mortality. However, in patients with diabetes, hyperglycaemia induced by methylprednisolone is often difficult to control, and there is still no well-established insulin regimen to control hyperglycaemia. This study aimed to examine the efficacy of intermittently scanned continuous glucose monitoring (isCGM) in controlling hyperglycaemia induced by methylprednisolone therapy in patients with severe COVID-19 with diabetes.

**Materials and methods:** This retrospective observational study analyzed patients with severe COVID-19 who had diabetes and were hospitalized and treated with methylprednisolone between April 1, 2021, and August...
18, 2021, at the National Hospital in Tokyo, Japan. Glycemic control in patients who used isCGM in addition to blood glucose monitoring (BGM) was compared with patients only with BGM. Blood glucose levels were measured before each meal and at bedtime using a glucometer. Total daily insulin requirement was also examined.

**Results:** During the study period, isCGM was used in five patients, and BGM in 14 patients, who were adjusted for age and severity. The total daily insulin dose from the second to the fourth day after administration was significantly higher in the isCGM group as compared to the BGM group (104.2 ± 61.0 units/day vs 39.5 ± 27.2 units/day, p=0.005), without causing hypoglycemia. Patients with isCGM had a significantly lower average blood glucose level during the 7 days of methylprednisolone therapy than those without isCGM (197.4 ± 29.3 mg/dl vs 239.0 ± 24.9 mg/dl, p = 0.007).

**Conclusion:** Hyperglycemia induced by methylprednisolone therapy in patients with COVID-19 with diabetes can be effectively and safely managed using isCGM.

**Disclosure:** M. Uchihara: None.

---

683 Comparing the rates and duration of sensor detected hypoglycaemia and patient reported hypoglycaemia based on diabetes type and awareness status: Hypo-METRICS trial

P.M. Divilly1, G. Martine-Edith1, Z. Mahmoudi1, N. Zaremba1, U. Soholm1, F. Pouwer2, S.A. Aami1, P. Choudhary1; 1Diabetes Research Group, Denmark Hill, Kings College London, London, UK, 2Department of Psychology, University of Southern Denmark, Odense, Denmark.

**Background and aims:** Continuous glucose monitoring (CGM) is increasingly used to report hypoglycaemia, but many episodes of sensor detected hypoglycaemia (SDH) are asymptomatic. As part of the HypoMETRICS study, we are comparing rates of SDH and patient reported hypoglycaemia (PRH) in real time in people living with Type I (T1D) and Type 2 diabetes (T2D) with impaired (IAH) and normal awareness of hypoglycaemia (NAH).

**Materials and methods:** Data were collected from 244 participants with T1D (n=158; 72 % using CGM/Flash) or T2D (n=88; 33% using CGM/Flash) who had experienced ≥1 hypoglycaemic episode in the last month. Hypoglycaemic awareness was assessed by Gold score (37 T1D and 20 T2D were IAH). Participants continued their usual method of glucose monitoring, with additional blinded CGM and reported episodes of PRH (episodes with symptoms that resolved with carbohydrate ingestion OR measured ≤3.9 mmol/l (70mg/dl) on the HypoMETRICS app for 10 weeks. Mann-Whitney U tests and Kruskal-Wallis tests were used.

**Results:** During 400,608 hours of CGM, participants reported 7307 PRH, 15,530 SDH 3.9mmol/l, 4421 SDH 3.0mmol/l, 385 prolonged (>2hours) SDH 3.0mmol/l and 187 SDH 2.2mmol/l, compared to T1D. Median (interquartile range) glucose 8.7mmol/l (3.7), time in range 61.8% (47.25) and time below range (TBR) 3.5% (11.25). T2D reported fewer SDH 3.9mmol/l (7.08 vs 2.54 events/week, p=>0.001), SDH 3.0mmol/l (1.74 vs 0.4 events/week; p=0.001) and PRH (3.1 vs 1.05 events/week; p=0.001). There were no differences between T1D IAH and NAH for TBR (5.7% vs 4.5%; p=0.3243), SDH 3.9mmol/l (8.48 vs 6.77 events/week; p=0.229), SDH 3.0mmol/l (2.2 vs 1.72 events/week; p=0.135) or PRH (3.1 vs 3.1 events/week; p=0.56). Similarly, no differences in TBR (1.9% vs 1.6%; p=0.866), SDH 3.9mmol/l (2.84 vs 2.42 events/week; p=0.834), SDH 3.0mmol/l (0.4 vs 0.4 events/week; p=0.723) or PRH (1.1 vs 1.05 events/week; p=0.563) were seen between T2D IAH vs NAH. Duration of SDH at all thresholds were not significantly different between all four groups.

**Conclusion:** T1D has higher rates of hypoglycaemia than T2D, but we found no difference in the TBR, frequency and duration of hypoglycaemia events between IAH and NAH, within T1D and T2D groups. This suggests CGM data does not differentiate awareness status.

**Clinical Trial Registration Number:** NCT04304963
684
Indirect Treatment Comparison (ITC) of three ready-to-use glucagon treatments for severe hypoglycaemia: nasal glucagon, glucagon injection, and dasiglucagon injection
M. Giménez1, K. Khunti2, K. Syring3, L. Baker3, S. Chenji3, R. Threlkel3, Y. Yan4, M. Matsuhashi4; 1Hospital Clinic, Barcelona, Spain, 2University of Leicester, Leicester, UK, 3Eli Lilly and Company, Indianapolis, 4Tokushima University, Tokushima, Japan.

Background and aims: To evaluate and compare the efficacy and safety of 3 ready-to-use glucagon treatments for severe hypoglycaemia in adults and children with diabetes: nasal glucagon, glucagon injection, and dasiglucagon injection.

Materials and methods: A systematic literature review was conducted to identify randomised clinical trials assessing the efficacy and safety of ready-to-use glucagon vs reconstituted injectable glucagon. Bayesian fixed-effect network meta-analysis was used to perform the ITC of glucagon injection and dasiglucagon vs nasal glucagon. Endpoints included the proportion of participants achieving treatment success, maximum blood glucose, and treatment-emergent adverse events (TEAEs). Mean time to treatment success and to maximum blood glucose were also analysed for glucagon injection vs nasal glucagon, but not for dasiglucagon due to reporting differences (mean vs median).

Results: Ten clinical trials were included in the ITC, including 4 for nasal glucagon, 3 for glucagon injection, and 3 for dasiglucagon. Nasal glucagon had comparable efficacy with glucagon injection and with dasiglucagon (Table), and all 3 treatments achieved high proportions of treatment success (>98%) in adults and children with diabetes. In adults, results from the combined T1D and T2D analysis were consistent with the T1D analysis, except a statistically significant shorter mean time to achieve treatment success for nasal glucagon vs glucagon injection in the combined analysis. There was a trend towards a lower percentage of participants treated with nasal glucagon experiencing at least one TEAE compared to glucagon injection or dasiglucagon, but no statistical significance was reached.

Conclusion: This study suggests that nasal glucagon, glucagon injection, and dasiglucagon had comparable efficacy in reversing insulin-induced hypoglycaemia, with a shorter mean time to achieve treatment success for nasal glucagon compared to glucagon injection. The findings from this ITC may help discussions between healthcare professionals and patients as they consider available ready-to-use glucagon treatment options.

Supported by: Eli Lilly and Company
Disclosure: M. Giménez: Lecture/other fees; Eli Lilly and Company, Medtronic Inc, Novo Nordisk A/S, Sanofi Aventis, AstraZeneca, MSD.

685
Incretin hormone and glucoregulatory responses to nutrients in individuals with and without post-bariatic hypoglycaemia: a systematic review
R.J. Jalleh1, M. Umaphathysivan1, J. Louise1, M.P. Plummer2, A. Deane2, K.L. Jones3, M. Horowitz4; 1Adelaide Medical School, The University of Adelaide, Adelaide, 2Intensive Care Unit, Royal Melbourne Hospital, Victoria, Australia.

Background and aims: Bariatric surgery is the most effective treatment to achieve remission of type 2 diabetes. Post-bariatric hypoglycaemia is an increasingly recognised complication for which management remains suboptimal because of a poor understanding of the underlying pathophysiology. The changes in glucoregulatory hormone responses to nutrients in individuals with and without post-bariatic hypoglycaemia have not been systematically examined. We hypothesised that individuals with post-bariatric hypoglycaemia have a greater glucagon-like peptide-1 (GLP-1) and insulin response to nutrients and conducted a systematic review and meta-analysis to evaluate this.

Materials and methods: The study protocol was prospectively registered with PROSPERO. PubMed, EMBASE, Web of Science and the Cochrane databases were searched for publications between January 1990 and November 2021 using MeSH terms related to post-bariatic hypoglycaemia. Studies were included if they evaluated individuals who had bariatric surgery and had measurements of GLP-1, glucose-dependent insulinotropic polypeptide (GIP), insulin, C-peptide or glucagon following a nutrient load and assessed individuals with and without post-bariatric hypoglycaemia. The mean difference in glycated haemoglobin (HbA1c) was also evaluated. A random-effects meta-analysis was performed, and Hedge’s g (standardised mean difference) and 95% confidence interval is reported for all outcomes for which sufficient studies were available. The τ² estimate and I² statistic were used as tests for heterogeneity and a funnel plot with the Egger regression-based test was used to evaluate for publication bias.

Results: From 377 identified publications, 13 studies were included in the analysis. In all included studies, the form of bariatric surgery used was Roux-en-Y gastric bypass. Comparing individuals with and without post-bariatric hypoglycaemia, the standardised mean difference in peak GLP-1 following a nutrient load was 0.57 (0.32, 0.82), peak GIP 0.05 (-0.26, 0.36), peak insulin 0.91 (0.52, 1.3), peak C-peptide 0.69 (0.28, 1.1), peak glucagon 0.05 (-0.26, 0.36) and HbA1c -0.46 (-0.78, -0.15). There was no significant heterogeneity in any outcome except for peak insulin: τ² = 0.23, I² = 56.6. No publication bias was evident.

Conclusion: Following Roux-en-Y gastric bypass, peak concentrations of GLP-1, insulin and C-peptide were greater after a nutrient load in individuals with post-bariatric hypoglycaemia. The HbA1c was less in those with post-bariatric hypoglycaemia. These observations suggest that antagonism of GLP-1 represents a potential intervention to prevent in hypoglycaemia in patients who suffer from post-bariatric hypoglycaemia after Roux-en-Y gastric bypass.
686 Predictive value of fasting C-peptide levels and continuous glucose monitoring-defined coefficient of variation for hypoglycaemia in each stage of chronic kidney disease

S. Kwon1, J. Park2, S. Cho1, S. Park1, Y.-B. Lee1, G. Kim1, K. Hur1, J. Kim1, S.-M. Jin1

1Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 2Division of Endocrinology and Metabolism, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.

Background and aims: Although fasting C-peptide levels and continuous glucose monitoring-defined coefficient of variation (CV) are clinically important indicators for the risk of hypoglycaemia, their usefulness in advanced stage of CKD has not been determined.

Materials and methods: We analyzed data from 1,186 participants with type 1 and type 2 diabetes who underwent professional continuous glucose monitoring (CGM) between January 2009 and May 2021 at outpatient clinics. Youden indices from receiver operating characteristic (ROC) analyses were used to determine cut-off values of CV and fasting C-peptide levels for the prediction of level 1 and level 2 hypoglycaemia, and cut-off values of fasting C-peptide levels for the prediction of CV 36%, in each CKD stage.

Results: For the prediction of level 1 and level 2 hypoglycaemia by CV (%), the area under the ROC curve (AUC) was 0.790 (95% CI 0.761-0.818; cut-off value, 30.5) and 0.846 (95% CI 0.818-0.873; cut-off value, 30.5) in stage 1/2 (n = 933), 0.850 (95% CI 0.776-0.925; cut-off value, 31.0) and 0.820 (95% CI 0.721-0.918; cut-off value, 31.0) in stage 3A, 0.845 (95% CI 0.742-0.949; cut-off value, 31.3) and 0.717 (95% CI 0.566-0.868; cut-off value, 31.3) in stage 3B, and 0.782 (95% CI 0.686-0.879; cut-off value, 31.4) and 0.846 (95% CI 0.745-0.947; cut-off value, 37.5) in stage 4/5, respectively. For the prediction of level 1, level 2 hypoglycaemia, and CV 36% by C-peptide levels, the AUC was 0.866 (95% CI 0.807-0.921; cut-off value, 0.33 mmol/l), 0.743 (95% CI 0.690-0.788; cut-off value, 0.44 mmol/l) in CKD1/2, respectively. C-peptide levels did not have significant predictive value in other CKD stages.

Conclusion: CV has predictive value for both level 1 and 2 hypoglycaemia in people with T1DM, although a 40% dose reduction may reduce the risk of next-day hypoglycaemia without increasing the risk of hyperglycaemia. These data argue against standard insulin degludec dose adjustment after exercise.

Disclosure: S. Kwon: None.

Clinical Trial Registration Number: EudraCT number: 2019-004222-22
Supported by: Novo Nordisk B.V.
Disclosure: L.C.A. Drenthen: Other; Novo Nordisk B.V.
Glycaemic control with Ultra Rapid Lispro (URLi) vs lispro in children and adolescents with type 1 diabetes: PRONTO-Peds

D.R. Franco1, R. Wadwa2, L.M. Laflè1, M.A. Deliva1, R.K. Pollom2; 1CPCLIN/DASA Clinical Research Center, São Paulo, Brazil, 2Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, USA, 3Joslin Diabetes Center, Harvard Medical School, Boston, USA, 4Eli Lilly and Company, Indianapolis, USA.

Background and aims: This phase 3, treat-to-target study evaluated efficacy and safety of URLi vs lispro in 716 pediatric patients (pts) with type 1 diabetes (T1D).

Materials and methods: After 4-week lead-in to optimise basal insulin, pts were randomised to double-blind URLi (n=280) or lispro (n=298) injected 0-2 min prior to meals, or open-label URLi (n=138) injected up to 20 min after meals (URLi+20). Pts remained on prestudy basal insulin (degludec, detemir, or glargine). Primary endpoint was HbA1c change from baseline after 26 weeks.

Results: Noninferiority was shown in HbA1c change with URLi vs lispro: estimated treatment difference (ETD) -0.02% (95% CI -0.17, 0.13) and with URLi+20 vs lispro: ETD -0.02% (95% CI -0.20, 0.17). Postprandial glucose (PPG) measured by self-monitored blood glucose (SMBG) was lower with URLi vs lispro 1 h after breakfast (p<0.001) and dinner (p=0.006). URLi significantly reduced 1 h postmeal glucose daily mean vs lispro (p=0.001). Total daily insulin dose was similar between treatments. There were no significant differences among treatments in rate or incidence of severe, nocturnal or documented hypoglycaemia (<3.00 mmol/L [<54 mg/dL]). With URLi vs lispro, rate of postdose hypoglycaemia (<3.00 mmol/L [<54 mg/dL]) was lower at ≤2 h (p=0.034). Incidence of treatment-emergent adverse events was similar between groups. More pts reported an injection site reaction related event with URLi (7.9%) and URLi+20 (2.9%) vs lispro (2.7%). All injection site reactions were mild or moderate in severity. Two URLi patients discontinued the study due to injection site reactions.

Conclusion: In children and adolescents with T1D, URLi demonstrated similar overall glycaemic control and greater PPG lowering with an acceptable safety and tolerability profile compared with lispro. URLi dosed at the start of meals or up to 20 min after the start of meals showed noninferiority for HbA1c change from baseline vs lispro. URLi dosed at the beginning of meals showed lower PPG at 1 h after breakfast and dinner and lower 1 h postmeal glucose daily mean vs lispro. Clinical Trial Registration Number: NCT03740919

Supported by: Eli Lilly and Company


Titrination patterns of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes and clinical outcomes: a subgroup analysis of ATOS study

A. Tiros1, A. Singh2, H. Vargas-Uricoechea2, M.A. Mabunay3, G. Bigot1, M. Naqvii6, G. Galstyan7; 1Division of Endocrinology, Diabetes and Metabolism, Chaim Sheba Medical Center, Tel-Aviv University, Tel Hashomer, Israel, 2G.D Hospital and Diabetes Institute, Kolkata, India, 3Division of Endocrinology and Metabolism, Department of Internal Medicine, Universidad del Cauca, Popayan, Colombia, 4Sanofi, Singapore, Singapore, 5iviData LIFE SCIENCES, Levallois-Perret, France, 6Sanofi, Mumbai, India, 7Endocrinology Research Centre of Health Care Ministry of Russian Federation, Dmitriy Ulyanova, Moscow, Russian Federation.

Background and aims: ATOS, a 12-month prospective observational study conducted in Asia, Middle East, North Africa, Latin America, and Eastern Europe, showed that initiation of insulin glargine 300 U/mL (Gla-300) in insulin-naïve people with type 2 diabetes (T2D) resulted in improved glycaemic control with low rates of hypoglycaemia and minimal weight change. This post hoc analysis aimed to explore the baseline factors and outcomes associated with different magnitudes of Gla-300 titration in people initiating basal insulin.

Materials and methods: Participants were categorized based on the magnitude of Gla-300 dose change from baseline to Month 3: no/minimal titration (0-2 U; Group A) and the groups that uptitrated 2-6 U (Group B); 6-10 U (Group C) and ≥10 U (Group D).

Results: This analysis included 3651 participants; Group A, 1210 (33.1%); Group B, 1076 (29.5%); Group C, 585 (16.0%) and Group D, 780 (21.4%). Age and BMI increased from groups A to D. Baseline HbA1c was 9.31 %, 9.23%, 9.26% and 9.27%, respectively. Group A had lowest usage of sulfonylureas and highest use of dipeptidyl-peptidase 4 inhibitors at baseline compared to the other groups. Baseline dose was highest in Group A. At Month 6, the individualised HbA1c target achievement was 24.0% in Group A and showed an increasing trend from Group B (21.5%) to Group C (23.4%) and to Group D (34.4%). At Month 12, the proportions of participants reaching target were 36.6%, 44.3%, 49.7% and 54.6% in Groups A, B, C and D respectively (Table). Clinically meaningful improvements were seen in HbA1c, fasting plasma glucose and self-monitored blood glucose at 6 and 12 months across the groups. Insulin dose increased over time in the groups at month 6 and 12 with minimal changes in Group A. The hypoglycaemia incidence was low across all groups during the study period (1.3%, 1.6%, 2.1% and 2.7% in Groups A, B, C and D respectively).

Conclusion: This post hoc analysis showed that in a real-world clinical setting, a large proportion of participants have no to minimal titration. Among those who titrate, insulin dose titration occurred gradually and continued beyond 12 weeks. Baseline factors appear to impact the titration patterns. Over the course of time more participants reached HbA1c target with increasing magnitude of titration with low incidence of hypoglycaemia across the groups and no increase in clinically meaningful hypoglycaemia. Basal insulin treatment should be individualised, and titration could be further optimised.

Table: Baseline characteristics and results of Month 6 and 12 by the magnitude of Gla-300 U/mL dose change from baseline to Month 3

Supported by: Sanofi

Disclosure: A. Tiros: Grants; Medtronic. Honorarium; Member of the ATOS Steering Committee and have received honoraria in relation to ATOS study, Sanofi, NovoNordisk, MSD, AstraZeneca, Boehringer Ingelheim. Lecture/other fees; Sanofi, NovoNordisk, MSD, AstraZeneca, Medtronic.

Clinical Trial Registration Number: NCT03703869

Diabetologia (2022) 65 (Suppl 1):S1–S469

S355
Early deescalation with IDegLira in patients with type 2 diabetes using short-term intensive insulin therapy to correct severe hyperglycaemia

Z. Taybani1, B. Bótyik1, A. Veres1, R. Szerencsi1, K. Fehértemplomi1, M. Zatykó1, G. Csáki1, B. Géczi1, M. Katko2, T. Varkonyi3; 1Békés County Central Hospital, Dr. Réthy Pál Member Hospital, Bekescsaba, 2Department of Internal Medicine – Division of Endocrinology, University of Debrecen, Debrecen, 3Department of Internal Medicine, University of Szeged, Szeged, Hungary.

Background and aims: In selected patients with type 2 diabetes (T2DM) complex insulin regimens initiated for correcting hyperglycaemia and applied at least for 3 months can be safely deescalated with IDegLira. As basal-bolus therapy (BBT) can reverse glucotoxicity in a few days theoretically deescalation can be performed much earlier, even within the first week after the initiation of intensive insulin intervention. We examined prospectively the efficacy and safety of early deescalation with IDegLira in patients with T2DM treated with short-term intensive insulin therapy to correct severe hyperglycaemia.

Materials and methods: Human BBT initiated for severe hyperglycaemia (HbA1c>11% or Hba1c>9%) with clinical symptoms of hyperglycaemia and/or fasting glucose>13.9mmol/L or random glucose>16.7mmol/L) was replaced with IDegLira after reaching a blood glucose range below 10 mmol/L usually on the first week of therapy if the previously insulin-naive patient had a c-peptide value >1.1ng/ml, the daily dose of BBT was <60 IU and insulin requirement was <0.6 IU/kg. Patients are followed during the routine ambulatory diabetes care every 4 months.

Results: Between February 2020 and December 2021 early deescalation with IDegLira was performed in 73 adult patients with T2DM. The first 4-month outpatient control visit has so far been performed in 55 patients (62% newly diagnosed T2DM, mean age 60.4±13 years, 49% women, mean BMI 30.8±6.1 kg/m²). During the follow-up HbA1c decreased from 12.3±1.8% at baseline to 6.3±0.9% at 4-month (p<0.001) and body weight changed from 87.6±17.9 kg to 86.2±16.9 kg (p=0.299). The mean daily dose of BBT was 42.4±10.3 IU before deescalation, and the dose of IDegLira was 20.6±5.7 units at the 4-month visit. Adverse events (AE) were rare, and severe AEs did not occur. After switching to IDegLira 10 (18%) patients reported at least one episode and 6 (10%) patients had more than one episode of mild hypoglycaemia. At the 4-month visit the proportion of individuals reaching an HbA1c<7% without hypoglycaemia was 73%.

Conclusion: Early deescalation with IDegLira in selected patients with T2DM using short-term intensive insulin therapy to correct severe hyperglycaemia is safe and results in significant glycemic improvement in the short-term.

Disclosure: Z. Taybani: None.
Disclosures: J.M. van den Berg: None.

692
Depression in type 1 diabetes and type 2 diabetes: linking patient experience with clinical records

U. Waheed 1, A.H. Heald 2, A. Paisley 1, K. Grady 3, E. Solomon 4, M.P. Stedman 5

1 Endocrinology & Diabetes, Salford Royal NHS Foundation Trust, Salford, 2 Endocrinology & Diabetes, Salford Royal NHS Foundation Trust, Manchester, 3 Research for the Future Research and Innovation, Salford Royal NHS Foundation Trust, Salford, 4 Department of Clinical Health Psychology, Salford Royal NHS Foundation Trust, Salford, 5 Health Research, Res Consortium, Andover, UK.

Background and aims: Diabetes impacts on mental health. The presence of symptoms of depression in people with diabetes is associated with reduced self-care compared to people with diabetes alone. Depressive symptoms are also associated with adverse health outcomes, such as less good blood glucose control. We investigated patient characteristics of those most at risk and consequences for glycaemic control.

Materials and methods: Depression (PHQ-9), Diabetes Distress Screening Scale (DDSS) and Quality of Life (EQ5D) on-line questionnaires were completed by people with diabetes and linked to data extracted from responders’ clinical records. Sources of distress were also considered through evaluating sub-scales Emotional, Physician, Regimen and Interpersonal DDSS scores.

Results: 130 responses with 34% T1DM, 56% women, median age 59 (IQR47-67) years were recorded. The median scores were EQ5D=0.74 (IQR 0.64 - 0.85) UK median 0.83; DDSS=1.9 (IQR1.3-2.7) (IQR47-67) years were recorded. The median scores were EQ5D=0.74

Conclusion: Physician related DDSS higher scores came from women, younger age, overweight, early years after diagnosis, plus history of anti-depressant use. This is potentially remediable. Level of distress is associated/may be required in achieving and maintaining lower HbA1c. The impact on the mental health of younger women/people with shorter diabetes duration should be noted when considering psychosocial intervention/behaviour change messaging to support diabetes management.

Disclosure: U. Waheed: None.
Retrospective analysis of daily basal bolus insulin requirement in people with type 2 diabetes in non-ICU care

S. Krishnamoorthy1, L. Balakrishnan2, A. Ravi3;
1Department of Internal Medicine, Karunya Sugalaya Diabetes Care & Research Centre Pvt Ltd, 2Department of Diabetology, Karunya Sugalaya Diabetes Care & Research Centre Pvt Ltd, 3Department of Clinical Research, Karunya Sugalaya Diabetes Care & Research Centre Pvt Ltd, Kumbakonam, India.

Background and aims: This study aims to determine the total daily dose of insulin requirement, the proportion of daily basal-bolus insulin requirement in India where people have more carbohydrates in their diet. Incidence of hypoglycaemia in non-ICU care and the prescription pattern of insulin ± oral antidiabetic medications needed at the time of discharge in a secondary care centre in south India were also determined.

Materials and methods: A retrospective observational study was conducted at a diabetes care hospital for a period of 6 months. The study included those who have Type 2 Diabetes for at least 6 months, aged 18 years and above, who have been on oral antidiabetic medications and/or insulins, and admitted for various reasons (nonsurgical, non-ICU) who stayed for at least 2 days for glycemic control and managed with analogue basal-bolus insulin therapy. Type 1 diabetes, Gestational diabetes and those who administered steroids for other coexisting illnesses, as well as those who were treated in the hospital exclusively with Premix insulin or oral glucose-lowering agents, were excluded.

Results: A total of 122 patients were enrolled. Males were 31% and females were 69%. The mean ± standard deviation (SD) of age, the duration of diabetes, Body Mass Index were 58.1±9.8, 13.4 ± 6.8 years, 25.5 ± 4.4 respectively. The mean insulin dose required for optimal control is 1.2 ± 0.6 units per kg of body weight/day. The total daily dose of insulin was 49.6 ± 21.1 units. The average length of hospital stay was 3 days. Of the total cases treated, 11.4% were treated with Oral antidiabetic agents, 2.4% were administered with 0.6mg of liraglutide at bedtime. 69.7% of patients required a higher bolus (>50% of Total Daily dose) than basal insulin (30.3%). 7.4% had level 1 hypoglycaemia and 2.4% had level 2 hypoglycaemia. There is a significant difference (p-value <0.05) in the capillary blood glucose values on discharge (CBG: Baseline-319.9 ± 110.8, Endpoint 168.4 ± 60.29). On discharge, 14.7% were prescribed only oral antidiabetic agents, 50% were prescribed only insulin (basal-bolus:38.5%, Premix:11.5%), 35.3% were prescribed with both insulin and Oral antidiabetic agents (basal-bolus:14%, Premix:21.5%).

Conclusion: Basal insulin requirement was strikingly similar in most, regardless of duration of diabetes with a mean of 22.2 ± 0.1% units/day. Most of the people required more bolus insulin to address prandial glucose excursion. It is observed from this study that, at the time of discharge, people who were preferring fewer pricks were prescribed premix insulin along with oral antidiabetic agents. Incidence of hypoglycaemia is low when analogue basal bolus insulin regimen was used in hospital glycemic management.

Disclosure: S. Krishnamoorthy: None.
The impact of fasting Ramadan on glycaemic indices in people with type 1 diabetes using flash glucose monitoring: an observational study

E.Y. Alyusuf, A. Alrajeh, M.E. Al-Sofiani, A.M. Alguwaihes; King Saud University, Riyadh, Saudi Arabia.

Background and aims: Fasting in Ramadan remains a challenge for patients with type 1 diabetes (T1D). Our aim was to evaluate the changes in continuous glucose monitoring (CGM) metrics during fasting Ramadan and to identify the potentially contributing factors of changes in glycemic control.

Materials and methods: Flash CGM metrics from 89 individuals with T1D who attempted fasting in Ramadan 2021 were retrospectively compared at three 4-week periods: pre-, during, and post-Ramadan. The association of potential factors with changes of CGM metrics were analyzed.

Results: The sample comprised intermittently-scanned CGM users with ≥ 70% active sensor time (59.6% female, age 28.1±10.3 years, diabetes duration 11.6±8.5 years, 32.6% insulin pump users, and 68.5% received Diabetes-Ramadan-oriented education. During Ramadan, basal insulin was decreased by 2.17 units and nutritional insulin was decreased by 10.73 units. Comparing pre- and during Ramadan, there was a significant increase in average sensor glucose by 9.02 mg/dl (95%CI= 4.25 to 13.79; p <0.001) during Ramadan with a daily average glucose curve typically followed a pattern that was characterized by rapid glucose excursion after sunset meal (Iftar) which was sustained overnight and a second rise after pre-dawn meal (Suhoor) followed by a gradual decline during the fasting hours. Comparing pre- and during Ramadan, glucose management indicator (GMI), time above range (TAR)181-250 mg/dl, and TAR>250 mg/dl have increased significantly by 0.22% (95%CI= 0.1 to 0.34), 2.25% (95%CI= 0.86 to 3.64), and 2.76% (95%CI= 0.81 to 4.71); respectively, all p<0.05; whereas time in range (TIR) dropped significantly by 3.98% (95%CI= -6.18 to -1.77); p=0.001 without significant change in HbA1c, time below range (TBR) <70 mg/dl, glucose variability, or average scans/day. In contrast, no statistically significant differences were detected in all CGM metrics or HbA1c comparing pre- vs. post-Ramadan. Longer diabetes duration and higher average sensor glucose before Ramadan were associated with increased average sensor glucose during Ramadan β=0.209 (95%CI=0.04 to 1.06); p=0.034 and β=0.676 (95%CI= -0.71 to -0.17); p=0.002, respectively. Comparing to infrequent scanners (≤ 10 scans/day), frequent scanners during Ramadan (>10 sensor scans/day) had significantly higher TIR (49.3±16.5 vs. 57.9±16.8%, p=0.015), lower TAR >250mg/dl (18.2±13.9 vs. 11.9±14.2%, p=0.036), and lower glucose variability (38.4±8.2 vs. 34.8±8.1%, p=0.035), with comparable TBR<70mg/dl, TAR 181-250 mg/dl, average sensor glucose, and GMI.

Conclusion: Ramadan fasting is associated with worsening glycemic control in people with T1D with no change in time spent in hypoglycemia. While Hypoglycemia is a common concern during fasting Ramadan, hyperglycemia should not be overlooked particularly post-Iftar and Suhoor. Improving pre-Ramadan glycemic control and glucose monitoring with frequent sensor scanning during Ramadan may maintain better glycemic control.

Empathy and linguistics in digital health interactions to prevent gestational diabetes in women at risk: a pilot study

E. Rey Velasco1,2, H. Søderup Pedersen1, T.C. Skinner1;
1Department of Psychology, University of Copenhagen, 2Liva Healthcare, Copenhagen, Denmark.

Background and aims: Lifestyle-related diseases, such as type 2 and gestational diabetes, are among the leading causes of death and disability. Their rapid increase worldwide has called for low-cost, scalable solutions to promote health behavior changes. Digital health coaching has proved to be effective to this aim, with the rising use of text-based interventions. State-of-the-art research has considered wording but lacks meaning and grammar analysis. Furthermore, empathy should be considered as a basis for a good coach-user relationship and positive patient outcomes. We aim to analyze patient cues in a digital health intervention and contribute to future research on coach communication.

Materials and methods: We tested a combination of an empathic and a linguistic approach to code 148 text messages sent by 20 women in the intervention arm of a randomized trial on tele-coaching for gestational diabetes prevention and postnatal weight loss support. The tele-coaching programme was based on the behavior change techniques taxonomy and the motivational interviewing and self-determination theory frameworks.

Results: We identified 143 empathic opportunities present in 42.37% of the corpus. These were mainly negative (82.2%) and implicit (60%). Most of the wording was found in the content (86.2%) with a declarative structure (86.3%). Our transitivity analysis showed that half of the identified processes, or verbal groups, (22.4%) were material (10.7%) and related to food and diet (26.9%), physical activity (26.9%), and lifestyle goals (11.2%).

Conclusion: The combination of empathy and linguistic analysis showed promising results. The identified verbal processes in these patient text messages were in line with the expressed empathic categories. Our findings reveal preliminary insights on the coach-user relationship within a
tele-health setting for prevention of gestational diabetes. The absence of explicit empathic opportunities and direct questions could be attributed to a lack of trust or information on the coach’s abilities throughout the intervention. We will be conducting further research to explore additional linguistic features and code coach messages.

Clinical Trial Registration Number: ACTRN12620001240932
Supported by: Industrial PhD Programme
Disclosure: E. Rey Velasco: Employment/Consultancy; The author is employed at Liva Healthcare. Grants; The author received an Industrial PhD funding from Innovationsfonden Danmark to conduct the research.

Correlation between the regression of microalbuminuria, blood pressure reduction and remission of type 2 diabetes: results of six month RCCT with whole-body digital twin technology

S. Joshi1, J. Mohammed2, M. Mohammed3, T. Poon2, M. Dharmalingam4, B. Saboo5, S. Damodharan6, A. Vadavi7, M. Thajudeen7, A. Keshavamurthy8, S. Mohammed9, P. Shamanna10

1Joshi Clinic and Lilavati Hospital, Mumbai, India, 2Twin Health Inc, Mountain View, USA, 3Twin Health, Bangalore, India, 4MS Ramaiah Medical College, Bangalore, India, 5Dia-Care Diabetes Centre, Ahmedabad, India, 6Ramakrishna Hospital and Harvey Specialty clinic, Coimbatore, India, 7Sudha Prevention Center, Bangalore, India, 8Bangalore Diabetes Centre, Bangalore, India.

Background and aims: The prospective study was designed to determine the effect of Twin Precision Treatment Technology (TPT) vs standard care on change in A1C and T2DM remission and regression of microalbuminuria and reduction of blood pressure. The TPT intervention uses the Whole-Body Digital Twin Platform, with AI and Internet of Things, to integrate multi-dimensional data to give precision nutrition and health recommendations via the TPT app and by coaches.

Materials and methods: We analysed the data at six months (intervention n= 206, control n= 71). Intervention arm patients were on TPT: a novel whole-body digital twin enabled precision nutrition that measures weight, physical activity, sleep, and sensor glucose values, for achieving remission. Microalbuminuria (MIC) was defined as urinary albumin excretion of 30-300 mg/day

Results: The mean duration of diabetes was 3.6 years (±2.6, 95% CI 3.3 to 4.04, minimum 0.1, maximum 8). The mean age was 43.3 years (±8.8, 95% CI 42.1 to 44.4, minimum 17, maximum 70). There were 62 patients with microalbuminuria at baseline. Based on the ADA criteria, overall 83.4% (n=172/206) achieved diabetes remission as compared to 71.4% (n=10/14) in the MIC group and 84.3% (n=161/191) in the group without MIC; p=0.257 (NS). One patient had macroalbuminuria. The mean reductions at follow up at six months in MIC -27 mg/day (±92, 95% CI -51 to -4.1, minimum -214, maximum 599), A1c -2.9% (±2.3, 95% CI -3.5 to -2.3, minimum -7.1, maximum 0.9), SBP -9 mmHg (±15, 95% CI -13 to -5.2, minimum -7.1, maximum 0.9) and DBP -6.2 mmHg (±8.5, 95% CI -8.4 to -4.1, minimum -25, maximum 14). There was no significant correlation between the reduction in MIC and Systolic BP (Pearson r 0.33, 95% CI 0.091 to 0.53, p=0.008). However, there was no significant correlation between the reduction in MIC and Diastolic BP (Pearson r 0.17, 95% CI -0.07 to 0.40, p=0.17). (Refer Image)

Conclusion: There is a significant number of subjects achieving remission of T2DM associated with a significant number of patients achieving regression of microalbuminuria. The reduction in HbA1c and microalbuminuria were independent of each other. The positive correlation between the reduction in Systolic BP and microalbuminuria indicates the additive benefits of TPT yielding synergism for the common pathophysiological pathways in patients with diabetic kidney disease

Clinical Trial Registration Number: CTRI/2020/08/027072
Disclosure: S. Joshi: None.
SO 57 Type 1 diabetes: still the challenge number one

Effect of 24 months of optimised glucose control on residual C-peptide secretion in youth with new onset type 1 diabetes

J. Ware1,2, C.K. Boughton1,2, J.M. Allen1,2, M.E. Wilinska1,2, A. Thankamony1, T. Randell1, A. Ghatak1, R.E.J. Besser3, D. Eller4, A. N. Trevelyan5, P.M. Campbell6, R. Bailey7, G. Dunseath2, R. Hovorka1, on behalf of the CLOuD Consortium;

1Wellcome-MRC Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, UK, 2Department of Paediatrics, University of Cambridge, Cambridge, UK, 3Wolfson Diabetes and Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, 4Department of Paediatric Diabetes and Endocrinology, Nottingham Children's Hospital, Nottingham, Nottingham, UK, 5Department of Diabetes, Alder Hey Children's NHS Foundation Trust, Liverpool, UK, 6Department of Paediatrics, University of Oxford, Oxford, UK, 7NIHR Oxford Biomedical Research Centre, Oxford, UK, 8Department of Diabetes, Royal Hospital for Sick Children, Edinburgh, UK, 9Paediatric Diabetes, Southampton Children's Hospital, Southampton, UK, 10Department of Paediatric Diabetes, Leeds Children's Hospital, Leeds, UK, 11Jaeb Center for Health Research, Tampa, USA, 12Diabetes Research Group, Swansea University, Swansea, UK.

Background and aims: We assessed whether improved glucose control with hybrid closed-loop can preserve C-peptide secretion compared to standard insulin therapy in youth with new onset type 1 diabetes.

Materials and methods: In an open-label, multicentre, randomised, parallel trial, youth aged 10 to <17 years were randomised within 21 days of type 1 diabetes diagnosis to hybrid closed-loop using the Cambridge algorithm or standard insulin therapy (control) for 24 months. Primary endpoint was the difference in mixed meal C-peptide AUC 12 months post diagnosis. Analysis was by intention to treat.

Results: We randomised 97 participants (mean±SD age 12±2 yrs), 51 to closed-loop and 46 to control therapy. There was no difference in C-peptide AUC at 12 months (primary endpoint) or 24 months between groups (geometric mean [95% CI] 12 months closed-loop: 0.35 pmol/mL [0.27, 0.43] vs control: 0.46 pmol/mL [0.33, 0.61]; mean adjusted difference -0.06 [-0.14 to 0.03]; p=0.19 and 24 months closed-loop: 0.18 pmol/mL [0.12, 0.24] vs control: 0.24 pmol/mL [0.12, 0.37]; mean adjusted difference -0.04 [-0.14 to 0.06]). Glycated haemoglobin was lower in the closed-loop group by 4 mmol/mol [0.4%] (95% CI 0 to 8 mmol/mol [0.0 to 0.7%]) at 12 months, and 11 mmol/mol [1.0%], (95% CI 7 to 15 mmol/mol [0.5 to 1.5%]; p<0.001) at 24 months. Five severe hypoglycaemic events occurred in closed-loop group (3 participants), and one in control group; one diabetic ketoacidosis occurred in the closed-loop group.

Conclusion: In youth with new onset type 1 diabetes, optimising glucose control for 24 months does not appear to prevent the decline in residual C-peptide secretion.

Figure 1. The area under the curve for plasma C-peptide in response to a mixed-meal tolerance test at baseline, 6, 12 and 24 months post diagnosis of type 1 diabetes (panel A; geometric mean [IQR]) and the glycated haemoglobin from baseline to 24 months (panel B; median [IQR]).

Clinical Trial Registration Number: NCT02871089
Supported by: NIHR EME, Helmsley Trust, JDRF, additional support from NIHR BRC
Disclosure: J. Ware: None.

Sociodemographic differences in physical activity in people with type 1 diabetes

S. Elton Sander1, S. Molsted1, S. Caunt2, E. Sandegaard3, R.F. Johansen3, S. Heller4, P.L. Kristensen5;
1Department of Clinical Research, Nordsjællands Hospital, Hillerød, Denmark, 2Academic Directorate of Diabetes and Endocrinology, Sheffield Teaching Hospital NHS, Sheffield, UK, 3Steno Diabetes Center, Aarhus, Denmark, 4Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK, 5Department of Endocrinology and Nephrology, Nordsjællands Hospital, Hillerød, Denmark.

Background and aims: In the general population, the risks of health-related outcomes are unequally distributed between socio-demographic variables including sex, marital status and educational level. This also applies to people with type 1 diabetes (T1D). It is unknown if these inequalities also apply to physical activity (PA) in people with T1D. We
investigated the impact of socio-demographic factors on level of PA in T1D, and patient perceived challenges and barriers to PA.

Materials and methods: This was a cross-sectional study. Participants with T1D (>18 years) were recruited from the outpatient clinics at two hospitals in Denmark and one in the UK. Data on self-reported leisure time PA were collected using the Saltin-Grimby scale and stratified into two categories: moderate-vigorous PA, or physically inactive/light PA. Education level was measured using the International Standard Classification of Education, and highest level was used to stratify into three levels. Participants were asked whether they wanted to be more active, if they had PA related glucose challenges, and if they had received help from health care professionals to manage blood glucose in relation to PA. Multivariate logistic regression analyses identified associations between exposure variables sex and education level on the outcomes. The analyses were adjusted for age and marital status.

Results: 334 people with T1D were included in the analyses (69% and 31% from DK and UK, respectively, 47% female, age 50 (30-61) median (IQR) years, Education levels were short in 10%, medium in 34%, and high in 57%. 44% reported moderate-vigorous PA levels, 67% reported that they wanted to be more active, and 60% reported having experienced PA related blood glucose challenges. 47% reported that they had not received help from health care professionals to manage PA related blood glucose challenges. More men than women were moderate-vigorous physically active (51% vs 35%, p=0.004), and more women wanted to be more active (77% vs 59%, p=0.001). More women reported having PA related blood glucose challenges (53% vs 48%, p=0.008). There were no sex differences in the participants' reporting of having received help from health care professionals to manage blood glucose in relation to PA. When the participants were stratified by education level, there were no differences in PA level, whether they wanted to become more active, whether they experienced PA related blood glucose challenges, or whether they received help from health care professionals to manage these challenges. In a multivariate logistic regression analysis, being woman was associated with low PA level OR 2.1 [95% CI 1.3; 3.4, p=0.002] and wanting to be more active OR 2.1 [1.3; 3.6, p=0.007]. In the same adjusted model, medium vs high education level was associated with the low PA level OR 1.9 [1.1; 3.02, p=0.018].

Conclusion: Education level was not associated with any of the outcomes. However, there were sex related inequalities, and being woman was associated with a lower PA level and wanting to be more active and experiencing more PA related blood glucose challenges.

Disclosure: S. Elton Sander: None.
703 Development of non-invasive saliva glucose measuring device (D-Salife) and clinical evaluation according to ISO 15197:2013 criteria
K. Han1, I.-S. Jang2, M.-S. Kwon2, J.-W. Kye2, E. Shim2, D.-C. Kim2, K. Min1;  
1Diabetes Center, Nowon Eulji University Hospital, 2Dongwoon Anatech, Seoul, Republic of Korea.

Background and aims: Glucose is detected not only in blood and interstitial fluid, but also in saliva. If the amount of glucose in saliva could be quantified, noninvasive testing using saliva could be alternative to conventional invasive capillary blood glucose testing. Therefore, we developed a new device D-Salife (Saliva Glucose Monitoring System for self-testing, a prototype of Dongwoon Anatech) that allows consumers to easily measure saliva glucose. The purpose of this study was to investigate the correlation and the precision with which between salivary glucose level measured with D-Salife (D-Salife glucose) and the capillary whole blood glucose level (CB glucose), and those also between two different saliva measurements (D-salife vs iron chromatography).

Materials and methods: Fasting saliva and capillary glucose were measured simultaneously in a fasting state from a total of 114 subjects, including non-diabetic, pre-diabetics, and diabetic patients. Oral saliva was collected using a sterile dental sponge. Saliva glucose was measured 6 times with D-Salife and with IC (Model Thermo Scientific DIONEX ICS-6000 IC System), and CB glucose was with a glucometer (Roche Accu-Chek Performa). The Precision was evaluated the repeatability and intermediate measurement precision, according to ISO 15197:2013 consensus Error Grid.

Results: The regression analysis showed that there was a direct correlation between CB glucose and D-Salife glucose (p < 0.001) (adjusted R² =0.9325, the regression coefficient = 0.95849), Error grid analysis showed that 76 (66.7%) from D-Salife were in zone A, the remaining 38 (33.3%) were in section B, thus meeting the ISO15197 international performance standard for glucose meters. D-Salife glucose showed a high correlation with the IC glucose (Y=23.466x, P<0.001, R²=0.872), and the precision was also excellent according to the ISO_CEG standard (A zone ; 76%; B zone ; 24%). In the repeatability analysis of 6 measurements of D-Salife glucose, the pooled standard deviation showed 8.7 mg/dL in the sugar concentration range below 100 mg/dL, 5.8 mg/dL in the pooled standard deviation range in the sugar concentration range above 100 mg/dL, and 4.9% in the pooled coefficient of variation.

Conclusion: The D-Salife showed good performance according to the ISO15197 international performance standard for glucose meters, and the acceptable level of repeatability comparable to popular capillary glucometer. So it could be a clinically useful noninvasive self-testing glucometer.

Disclosure: M. Raoux: None.

704 Cognitive assessment in elderly with type 1 diabetes on insulin pump: a cross-sectional observational study
A. Rizzi1, L. Tartaglione1, F. L’Abbate2, G. Masone Iacobucci2, D. Quaranta2, L. Leo1, G.E. Rizzo1, D. Pitocco1;  
1Diabetes Care Unit, Catholic University School of Medicine, 2Institute of Neurology, Catholic University School of Medicine, Rome, Italy.

Background and aims: Aim of the study was to investigate cognitive performance in elderly with type 1 diabetes (TIDM) on insulin pump (CSII) and the correlation between time in range (TIR) and cognitive scores (CS). Differences in CS according to duration of disease were also investigated.

Materials and methods: Subjects with TIDM older than 65 years, on CSII were included. Participants underwent following tests: Rey Auditory Verbal Learning Test (RAVLT), Rey-Osterrieth Figure Test, Verbal Fluency Test, Stroop Color and Word Test and Trail Making Test (TMT) A and B. At visit data from continuous glucose monitoring, according to 2019 Advanced Technology and Treatments in Diabetes Consensus, data on diabetic history and blood tests were collected.

Results: We enrolled 45 subjects, 22 women (49%), mean age 69.5 years. Median duration of disease was 30 years; mean HbA1c was 58 mmol/mol (7.4%). Mean TIR was 66%, mean time below range was 2.62% and time above range (TAR) 29.9%. 5 subjects (11%) presented CS compatible with mild cognitive impairment. No correlation between TIR and CS was detected. Dividing study population on median duration of disease, subjects with longer history presented lower TIR (59.7% (20.2) vs 71.1% (16.3), p=0.05) and higher TAR (35.7% (17.8) vs 25.2% (15.3), p=0.05). In both groups 26% were using advanced hybrid closed loop systems. Subjects with longer history presented lower scores at RAVLT-Immediate recall (30.1 (12.6) vs 39.3 (13.4), p<0.001) and RAVLT-Accuracy (0.89 (0.09) vs 0.93 (0.05), p=0.08) and longer time at Stroop Test (28.8 (8.13) vs 20.0 (7.36), p<0.001) and TMT-B (131 (64.2) vs 104 (32.2), p=0.08) test. Groups were comparable for school age (>30 years 12.9 years vs <30 years 13.1, p=0.80).

Conclusion: Elderly with TIDM presented good TIR and at a deep evaluation, they presented good CS. Those with longer history presented lower CS in executive and attentive functions, expression of subcortical damage. No association between TIR and CS was detected.

Disclosure: A. Rizzi: None.
Background and aims: Regular exercise is associated with physical and mental health benefits. However, maintaining adequate glucose control around exercise is challenging and the risk of exercise-related hypoglycemia frequently leads people living with type 1 diabetes (PWT1D) to remain sedentary. Strategies such as insulin basal rate reduction (BRR) can limit this risk. However, the impact of physical activity on glycemia varies depending on the type of exercise and the optimal BRR to limit the risk of hypoglycemia during different types of exercises has not been evaluated. We aim to assess the optimal BRR to minimize the risk of hypoglycemia during two types of exercise (High intensity intermittent exercise (INT) and continuous moderate intensity exercise (CONT)) known to have different impacts on glycose profiles.

Materials and methods: Twenty-nine PWT1D treated with insulin pump (20 adults, 9 adolescents; HbA1c = 7.4 ± 1.0%) were included. Participants performed two 60-min exercise sessions matched for energy expenditure (CONT, 60% of VO2peak vs. INT, 2-min, 50%/2-min, 85% of VO2peak). Insulin basal rate was reduced by either 40% or 80%, 90-min before exercise start. The four interventions were carried out in a randomized fashion. Blood glucose was measured every 10-min during exercise.

Results: For CONT, there were no differences in the time spent in hypoglycemia (8.5 ± 15.9, CONT-40%; 9.8 ± 15.9, CONT-80%) or in the number of hypoglycemic episodes (10, CONT-40% vs. 11, CONT-80%). Glucose reduction tended to be higher with 40% BRR (-3.3 ± 2.4, CONT-40% vs. -2.8 ± 2.8, CONT-80%, p=0.9). Time to first hypoglycemic episode was similar in both conditions (36.2 ± 17.5, CONT-40% vs. 40.0 ± 15.9, CONT-80%, p=0.6). For INT, time spent in hypoglycemia was significantly lower with 80% BRR (9.2 ± 16.5, INT-40% vs. 4.9 ± 11.0, INT-80%, p<0.05) as well as the number of hypoglycemic episodes (9, INT-40% vs. 6, INT-80%, p<0.05). Time to first hypoglycemic event was similar in both conditions (44.0 ± 11.3, CONT-40% vs. 46.2 ± 7.5, CONT-80%, p=0.6).

Conclusion: For CONT exercise, reducing insulin basal rate by either 40% or 80% 90 min prior to exercise had no impact on hypoglycemic risk. For INT exercise reducing basal rate by 80% should be preferred. To further reduce hypoglycemic risk, favoring exercise sessions of less than 40min and/or combining basal rate reduction with carbohydrate intake is probably required.

Clinical Trial Registration Number: NCT03845114

Supported by: IRSC/CMDO

Disclosure: J. Molveau: None.
SO 58 Autonomic rhythm

707 Prevalence of peripheral and cardiovascular autonomic neuropathy in Greenlanders with diabetes and prediabetes based on national normative reference data

M.M.B. Christensen1,2, C.S. Hansen3, D. Vistisen1,4, J. Fleischer5,6, D.R. Witte2,5, M.E. Jørgensen7,8;
1Clinical epidemiology research, Steno Diabetes Center Copenhagen, Herlev, Denmark, 2Department of Public Health, Aarhus University, Aarhus, Denmark, 3Complications research, Steno Diabetes Center Copenhagen, Herlev, Denmark, 4Department of Public Health, University of Copenhagen, Copenhagen, Denmark, 5Steno Diabetes Center Aarhus, Aarhus, Denmark, 6Steno Diabetes Center Zealand, Holbæk, Denmark, 7Steno Diabetes Center Greenland, Herlev, Greenland, 8National Institute of Public Health, University of Southern Denmark, Herlev, Denmark.

Background and aims: Prevalence of diabetes is increasing in Greenland. However, studies on the prevalence of diabetic peripheral neuropathy (DPN) and cardiovascular autonomic neuropathy (CAN) in Greenland are scarce. Our aim was to determine the prevalence of DPN and CAN in Greenlanders with diabetes and prediabetes by establishment and application of normative reference data from the Greenlandic background population.

Materials and methods: We evaluated the prevalence DPN and CAN among Greenlanders with diabetes and prediabetes who participated in the nationwide Greenlandic Population Survey 2018. DPN was assessed by perception of monofilament and vibration threshold (VPT). A composite measure (DPN composite) for abnormal monofilament and/or VPT was applied. Cardiovascular autonomic reflex tests and power spectral analysis of heart rate variability (HRV) were applied to assess CAN. Normative reference data specific for the Greenlandic population were used to determine the prevalence of DPN and CAN. We estimated normal ranges for VPT and CAN in Greenlanders without diabetes by using piecewise linear quantile regression models at the 5th percentile. The model for normal threshold of VPT was adjusted for age and height. Models for CAN limits were adjusted for age.

Results: A total of 369 participants with either diabetes (37.7%) or prediabetes (62.3%) were examined for DPN and CAN. Women comprised 54.2% and mean age was 60.6 years. DPN composite was diagnosed in 54.2% and mean duration of diabetes was 7.4±0.5 years, HbA1c level 7.3±0.18%. The diagnosis of CAN was based on the results of 5 standard cardiovascular reflex tests, 24-hour heart rate variability was evaluated using ECG “EC-3H” (“Labtech”), arterial stiffness monitoring - TensioMedTM Arteriograph 24 (Hamburg). Homeostasis model assessment IR (HOMA-IR) was calculated: fasting glucose (mmol/L) x fasting immunoreactive insulin (mIU/ml)/22.5. Melatonin in saliva (nocturnal measurement), NT-proBNP and endothelin-1 (ET-1) levels among patients with CAN. The mean duration of diabetes was 7.4±0.5 years. HbA1c level 7.3±0.18%. The diagnosis of CAN was based on the results of 5 standard cardiovascular reflex tests, 24-hour heart rate variability was evaluated using ECG “EC-3H” (“Labtech”), arterial stiffness monitoring - TensioMedTM Arteriograph 24 (Hamburg). Homeostasis model assessment IR (HOMA-IR) was calculated: fasting glucose (mmol/L) x fasting immunoreactive insulin (mIU/ml)/22.5. Melatonin in saliva (nocturnal measurement), NT-proBNP and endothelin-1 (ET-1) levels among patients with CAN.

Conclusion: When compared to prevalence of DPN and CAN in the Western World we have identified a relatively low prevalence of DPN and CAN in Greenlanders with diabetes and prediabetes. However, estimated normative values for VPT and CAN show lower threshold values for peripheral and autonomic function in Greenlanders without diabetes compared to Europeans which may have resulted in an underestimated prevalence of DPN and CAN. This warrants studies investigating the underlying pathophysiology to low nerve function and prevalence of neuropathy in Greenlanders with and without diabetes, respectively.
ventricular mass index, showed an independent inverse association of melatonin levels with HOMA-IR and PWV (p<0.001).

**Conclusion:** Development of CAN is associated with increased NT-proBNP levels, IR and arterial stiffness parameters, violation of BP profile and decrease of melatonin levels. Nocturnal melatonin secretion is independently and inversely associated with IR, violation of BP profile and increase of arterial stiffness. Further work is needed to validate this association and perform a prospective analysis to assess whether melatonin supplementation may modify insulin resistance, blood pressure patterns and arterial wall rigidity.

**Disclosure:** V.A. Serhiyenko: None.

---

**Collagen turnover is associated with cardiovascular autonomic and peripheral neuropathy in type 1 diabetes: Novel pathophysiological mechanism?**

C. Hansen¹, D.G.K. Rasmussen², T.W. Hansen¹, S.H. Nielsen²,³, S. Theilade¹,², M.A. Karsdal³, F. Genovesè², P. Rossing¹,⁴. ¹Complications Research, Steno Diabetes Center Copenhagen, Herlev, ²Nordic Bioscience, Herlev, ³Technical University of Denmark, Lyngby, ⁴Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

**Background and aims:** Diabetic cardiovascular autonomic neuropathy (CAN) and distal symmetric polyneuropathy (DSPN) affect millions of people and increase the risk of morbidity and mortality. Identifying new risk factors for these complications is needed to develop means of intervention. Collagen type VI (COL6) and III (COL3) have been associated with nerve function. We aim to investigate the possible associations between serum markers of COL6 and COL3 and diabetic neuropathy in people with type 1 diabetes (T1DM).

**Materials and methods:** In a cross-sectional study of 300 people with T1DM, serum PRO-C6 (marker of COL6 formation) and C3M (marker of COL3 degradation) were obtained. CAN was assessed by cardiovascular reflex tests (CARTs): heart rate response to deep breathing (E/I ratio), to standing (30/15 ratio) and to the Valsalva manoeuvre (VM). Two or three pathological CARTs constituted CAN. Peripheral neuropathy was assessed by biothesiometry, where symmetrical vibration sensation threshold above 25 volts constituted DSPN.

**Results:** Patients were (mean (SD)) 55.7 (9.3) years, 51% where males, diabetes duration was 40.1 (8.9) years, HbA1c was 62.9 (1.9) mmol/mol, estimated glomerular filtration ratio (eGFR) 78.1 (24.8) ml/min/1.73m² with (median(IQR)) serum PRO-C6 7.8 (6.2;11.0) ng/ml and C3M 8.3 (7.1;10.0) ng/ml. Of 259 persons with CARTs measured, 34% was diagnosed with CAN, even though the significance was lost when factoring in eGFR. A doubling of serum PRO-C6, was significantly associated with odds ratio (OD) > 2 for CAN and > 1 for DSPN, respectively. Significance was retained after additional adjustment for eGFR (model 3) for CAN (OD 1.7 (95%CI 1.0;2.7 p=0.035), not for DSPN (OD 1.2 (95%CI 0.8;1.0 p=0.404) (Figure 1, Panel A). A doubling of serum C3M was associated with a higher OD for CAN only in model 2 (OD 1.7 (95%CI 1.2;2.6 p=0.004) and 1.8 (95%CI 1.2;2.7 p=0.040), C3M was not associated to DSPN in any model (Figure 1, Panel B).

**Conclusion:** Our results show previously undescribed associations between collagen remodelling biomarkers and diabetic CAN and DSPN in T1DM, where higher serum levels of PRO-C6 was associated with both CAN and DSPN, and higher levels of C3M was associated with CAN, even though the significance was lost when factoring in eGFR. The pathological mechanisms between collagen remodelling and diabetic neuropathy remain to be explored.

**Disclosure:** None.

---

**Background and aims:** Cardiovascular autonomic neuropathy (CAN) is a prevalent serious complication in individuals with type 1 diabetes (T1D). Low-grade inflammation has emerged as a potential mechanism in the development of neuropathy from both experimental and clinical studies. We aimed to assess the role of chronic inflammation in the pathogenesis of CAN in T1D.

**Materials and methods:** We leveraged an ongoing randomized, placebo-controlled clinical trial targeting inflammation with salsalate in individuals with T1D, to measure a panel of 40 inflammatory markers analyzed on a Luminex xMAP instrument (Luminex Corporation, Austin, TX) (Figure) in baseline samples. Measures of CAN included standardized cardiovascular autonomic reflex tests (CARTs) (E/I, Valsalva, 30:15 ratios) and indices of heart rate variability (HRV). We used Spearman-rank to assess the correlations between inflammatory markers and CAN measures, and linear regression to adjust for age and hemoglobin A1c.

**Results:** The Figure displays the correlation between biomarkers and CAN measures in 58 T1D participants (mean age 51 ± 13 years, mean diabetes duration 31 ± 15 years, and HbA1c 8.4 ± 1.8%). Amongst all biomarkers, we noted a singular negative correlation between soluble uricase plasminogen activator receptor (suPAR) and measures of CAN, which remained significant in multivariable analysis (E/I ratio p=0.005, Valsalva p=0.037, RFA p=0.019, LFA p=0.023).

**Conclusion:** Amongst a large panel of inflammatory markers, we found suPAR to have a notable association with CAN. SuPAR is an immune-mediated signaling glycoprotein which levels are strong predictors of risk in patients with diabetes, which role in CAN warrants further exploration.

**Disclosure:** None.
Clinical Trial Registration Number: NCT02936843
Supported by: NIDDK-1-R01-DK-107956-01
Disclosure: R. Pop-Busui: Grants; NIH/NIDDK.

711
Visceral adiposity is associated with autonomic dysfunction in adults with autoimmune diabetes
E. Maddaloni, M. Watanabe, R. Cassano Cassano, D. Masi, R. Amendolara, S. Sterpetti, L. D’Onofrio, C. Moretti, A. Siena, L. Gnassi, R. Buzzetti; Sapienza University, Rome, Italy.

Background and aims: The prevalence of overweight and obesity is increasing among people with autoimmune diabetes, but little is known about their impact on the risk of chronic complications. We have previously shown that low HDL-cholesterol levels are a major modifiable risk factor of cardiac autonomic neuropathy (CAN), a frequent diabetic complication associated with decreased quality of life and increased risk of death. In this study we aimed to evaluate whether visceral adiposity, another relevant component of metabolic syndrome and a risk factor for dyslipidemia and low HDL-cholesterol levels, is associated with autonomic dysfunction in people with autoimmunity diabetes.

Materials and methods: Body mass composition was assessed in 63 adults with autoimmune diabetes (37 females; mean age ± SD: 49.7 ± 12.5 years; disease duration: 16.4 ± 15.7 years; body mass index [BMI]: 25.7 ± 4.9 Kg/m²) using dual energy X-ray absorptiometry (DXA). The Composite Autonomic Symptom Score 31 (COMPASS31) was used to assess the presence of symptoms of autonomic dysfunction in six domains (orthostatic, vasomotor, secretomotor, gastrointestinal, bladder and pupillomotor). Cardiac autonomic reflex tests (CART) were performed to investigate the presence of CAN in 49 participants (14 subjects were not able to perform CART because of contraindications, concomitant therapies, or physical inability). Medical history and biochemical data were retrieved from medical records.

Results: DXA scans showed a mean fat mass of 19.1 ± 8.3 Kg (26.1 ±7.6% of total body mass), with an estimated mean visceral adipose tissue (VAT) mass of 401.7 ± 226.7 g. Mean weighted COMPASS31 was 15.9 ±13.2 and CAN was diagnosed in 22 (44.9%) participants. After adjustment for age, sex, HbA1c and HDL cholesterol levels, higher VAT mass was associated with higher COMPASS31 in the gastrointestinal domain (adjusted beta coefficient [95% confidence intervals]: 1.69 [0.14-3.23], p=0.033), but not with total COMPASS31 (adjusted beta coefficient [95% confidence intervals]: -0.30 [-0.76-16.0], p=0.19). Participants with CAN showed higher VAT mass than those without CAN (512.8±217.2 g vs 366.0±221.9 g, p=0.037 after adjustment for age, sex, HbA1c and HDL cholesterol). Conversely, total body fat mass was not associated with autonomic symptoms nor with the presence of CAN.

Conclusion: This study shows that VAT, but not total body fat, is associated with autonomic dysfunction in people with autoimmune diabetes. This observation strengthens the importance of avoiding the accumulation of visceral adiposity in people with diabetes, and also highlights the need for research into the interrelated consequences of obesity among people with autoimmune diabetes.

Supported by: Sapienza University Starting Grant
Disclosure: E. Maddaloni: None.

712
Association of premature ejaculation with diabetic peripheral neuropathy among patients with type 2 diabetes attending at a tertiary level hospital of Bangladesh
M. Ahmed, F. Yasmin*, A. Morshed, T. Islam;
1Medicine, BIRDEM General Hospital, 2Paediatric cardiology, Ibrahim Cardiac Hospital and research Institute, 3Psychiatry, Dr. Sirajul Islam Medical College, 4Psychiatry, Sir Salimullah Medical College, Dhaka, Bangladesh.

Background and aims: Diabetes is an important determinant of the risks of premature ejaculation (PE). In patients with diabetes premature ejaculation is three times higher and its onset is 10 to 15 years earlier than non-diabetic person. Diabetes can also affect the blood vessels, leading to sexual dysfunction including premature ejaculation. In addition, a condition called diabetic neuropathy, which involves damage to the nerves, may also causes orgasm without ejaculation. The aim of this study was to find out the association of premature ejaculation with diabetic peripheral neuropathy among patients with Type 2 DM attending at a tertiary care hospital of Bangladesh.

Materials and methods: This descriptive cross sectional study was conducted in BIRDEM general hospital from July 2017 to June 2018. This study was conducted in full accordance with the World Medical Association Declaration of Helsinki, was given a detailed verbal and written description of the proposed study in their own language and signed consent for participation was obtained. Ethical approval for the study was obtained from ethical review committee. All participants’ sexual history had assessed using the Bengali index of Premature Ejaculation Diagnostic Tool. A total of 225 adult patients with type 2 DM were recruited and diagnosis was confirmed as per ADA 2016 criteria. A face to face interview was conducted using premature ejaculation diagnostic
tool (PEDT). Diabetic peripheral neuropathy was confirmed by bedside neurological examination including monofilament test and other sensory examination. Data were analyzed by computer with the help of Statistical Package for Social Sciences (SPSS) version 20.0.

Results: Mean age of respondents 39.13 yrs±12.52 and age range was (21-65) years. Most of the respondents were married (73.3%). Among the study population, the prevalence of PE was 55.6%. Mean age of patients having PE was 38.36±8.89 year and age group of 21-30 years had higher incidence rate. Mean age of severe PE (within 15 sec) was found 41.17± 9.17 year and age group of 31-40 years had higher incidence rate. Almost half PE patients (48%) had severe PE (within 15 seconds). Among total 225 respondent 135 had neuropathy (60%) and 90 respondent had not develop neuropathy yet (40%). Among those having neuropathy 85 respondent (63%) have premature ejaculation while 10 of them (7.4%) have probable premature ejaculation and 40 respondent (29.6%) are lucky enough to develop premature ejaculation yet. Among those 90 respondent yet to develop neuropathy 40 respondent (44.4%) have developed premature ejaculation already while 15 of them (16.7%) have suffering from probable premature ejaculation and rest 35 respondent (38.9%) have yet to become unlucky.

Conclusion: Erectile dysfunction and PE are very common in DM and may be one of the earliest signs of diabetic neuropathy. PE, which increases in frequency with the age of the patient and the duration of diabetes, may occur in the absence of other signs of diabetic autonomic neuropathy. The health system needs to develop appropriate strategies including early diagnosis, awareness, and health education programs for appropriate treatment.

Disclosure: M. Ahmed: None.

713
Co-existence of peripheral and autonomic neuropathy in type 1 diabetes with and without pain
C.D. Morch1, J. Roeikjer2, S. Santhiapillai Croosu3, T.M. Hansen3, J.B. Friskjaer4, C. Brock5, N. Ejskjaer6;
1Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Aalborg University, 2Department of Health Science and Technology, Aalborg University, Aalborg University Hospital, 3Department of Radiology, Aalborg University Hospital, 4Dept of Radiology, Aalborg University Hospital, 5Department of Gastroenterology, Aalborg University, 6Steno Diabetes Center North Denmark, Depts of Endocrinology and Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark.

Background and aims: Diabetic neuropathy is a complex condition that affects multiple organs. However, the condition is in the literature primarily described as either peripheral (DPN) or autonomic. This study aimed to investigate the association between these two distinct presentations, while also assessing the impact of painful diabetic peripheral neuropathy (PDPN).

Materials and methods: 80 participants (20 type 1 diabetes (T1DM)+PDPN, 20 T1DM+painless DPN, 20 T1DM without DPN or pain and 20 healthy controls (HC)) underwent detailed neurophysiological investigations (including quantitative sensory testing, cardiac autonomic reflex tests (CARTs), and conventional nerve conduction). Cardiac autonomic neuropathy (CAN) was defined as ≥ 2 abnormal CARTs. Differences between groups were analysed with Fischer’s exact tests with Bonferroni correction. After the initial analysis, the participants with diabetes were re-grouped twice based on the presence or absence of small- and large fibre neuropathy.

Results: The prevalence of CAN was highest in T1DM+PDPN (50%), followed by T1DM+DPN (25%) and T1DM-DPN and HC (0%). There was a difference between T1DM+PDPN and T1DM-DPN and HC (p<0.001), while the statistical significance was lost after correction for multiple testing between T1DM+PDPN and T1DM+DPN (p=0.031). When re-grouping based on the presence of small- (SFN) or large fibre neuropathy (LFN), 58% and 55% of the populations had CAN respectively, while no participants without either SFN or LFN had CAN.

Conclusion: This study suggests that CAN only exist when there is concomitant DPN. This appears to be true whether the assessment is based on a clinical assessment or fibre-specific tests. However, larger studies are needed to confirm this relationship.

Disclosure: C. D. Morch: None.
SO 59 Getting a grip on nerves

714
Retinal neurodegeneration as a marker of diabetic peripheral neuropathy and cognitive impairment in type 2 diabetes
F. Picconi1, M. Mendini1, A. Maiorino1, M. Parravano2, B. Russo1, N. Lois3, R. Simo’ Canonge 4, S. Froontoni1
1Unit of Endocrinology, Diabetes and Metabolism, S. Giovanni Calibita Fatebenefratelli Hospital, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, 2ICCCS-G.B. Bietti Foundation Rome, Rome, Italy, 3The Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University, Belfast, Ireland, 4Diabetes and Metabolism Research Unit, Vall d’Hebron Research Institute, Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Universitat Autònoma de Barcelona, Barcelona, Spain.

Background and aims: The neuropathic process is not only confined to the peripheral sensory nerves but involves the whole nervous system. We suggest that retinal neurodegeneration could parallel brain and peripheral nervous system alterations and therefore retina could be viewed as a new window of the neurodegenerative process. The aim of the study is to evaluate the relationship between the morphological and functional alterations of the neuroretina and both peripheral diabetic neuropathy (DPN) and mild cognitive impairment (MCI) in patients with type 2 diabetes mellitus (DM2).

Materials and methods: 56 DM2 patients (65-90 years), with a disease duration greater than 5 years, with mild diabetic retinopathy were enrolled. DPN was investigated using the Michigan Diabetes Neuropathy Instruments (MNSI), vibration perception threshold (VPT) and warm and cold thermal perception thresholds. Based on the presence of two abnormalities among symptoms and signs, VPT or thermal thresholds we identified two groups: without (DPN-, n:15) or with probable DPN (DPN+, n:41). Participants were also classified in MCI (n:42) or controls (C, n:14), according to Montreal Cognitive Assessment Test (MoCA) (cut-off < 26). All patients underwent microperimetry measuring retinal sensitivity and average threshold macular sensitivity (ATMS), multifocal electroretinogram (mERG) with implicit time B wave of flash response evaluation and spectral domain optical coherence tomography (SD-OCT), with analysis of retinal central subfield, ganglion cell layer (GCL) plus inner plexiform layer (IPL) and retinal nerve fiber layer (RNFL) thickness.

Results: In DPN+ group (n=41), ATMS and the GCL+IPL average thickness were significantly reduced in MCI versus C (respectively 24.66 vs. 26.0 Db; p=0.01 and 71.5 μm vs. 79.7 μm; p=0.03). The implicit time B wave of flash response and the implicit time of flicker response were significantly increased in MCI versus C (respectively 28.4 ms vs. 30.9 ms p =0.05 and 31.1 ms vs. 22.8 ms; p= 0.05). No significant differences were observed in the DPN- group between MCI and C. In MCI patients of the DPN+ group, a positive correlation between VPT and implicit time B wave of flash response (r=0.9, p=0.04) and between VPT and the implicit time of flicker response (r=0.9, p=0.03) were observed. We also found a negative correlation between VPT and ATMS (r=-0.4, p=0.05) and between VPT and the GCL+IPL average thickness (r=-0.6, p=0.03).

Conclusion: Morphological and functional alterations of neuroretina are observed in DM2 patients affected by MCI and DPN. A significant relation between neuroretina dysfunction and peripheral neuropathy signs was also evident in MCI with DPN. These results allow to consider the retina as a window for the evolution of peripheral and central neuropathy in the patient with DM2.

Disclosure: F. Picconi: None.

715
Serum 25-hydroxyvitamin D levels in relation to the risk of peripheral neuropathy in Chinese patients with type 2 diabetes
Y. Yang, J. Wang, Y. Ding, L. Zhang
Qingdao Endocrine&Diabetes Hospital, Qingdao, China.

Background and aims: Vitamin D deficiency is not only related to bone-related diseases but also associated with cardiovascular disease, diabetes, cancer and autoimmune diseases. Previous studies show that vitamin D deficiency increases risk of diabetic peripheral neuropathy (DPN). Data is limited among Chinese patients with type 2 diabetes.

Materials and methods: In this cross-sectional study, we enrolled 5362 patients (2595 men and 3003 women aged 30 to 89 yrs) with type 2 diabetes from Jan 1, 2016 to Oct 31, 2018. Serum 25-hydroxyvitamin D [25(OH)D] level was measured by electrochemiluminescence assay. Vitamin D deficiency was defined as serum 25(OH)D level < 20 ng/mL according to the Endocrine Society Clinical Practice Guideline 2011. Diabetic peripheral neuropathy was diagnosed by motor/sensory nerve conduction velocity.

Results: Patients with diabetic peripheral neuropathy had lower serum 25(OH)D concentration (16.81±3.83 ng/mL v.s 18.05±4.11 ng/mL, P<0.05) compared with those without neuropathy. The prevalence of vitamin D deficiency was higher in patient with neuropathy than those without the complication (83.2% v.s 71.4%, P≤0.05). We did not find gender difference on the prevalence of vitamin D deficiency. In the logistical regression model, vitamin D deficiency was associated with increased risk of diabetic neuropathy, after multi-adjustment of age, gender, duration of diabetes, smoking, body mass index, systolic blood pressure, fasting glucose, HbA1c, fasting C-peptide, total cholesterol, and microalbuminuria. The corresponding odds ratio was 1.76 (1.05-3.73) (P=0.05).

Conclusion: Vitamin D deficiency, a common hypovitaminosis in Chinese patients with type 2 diabetes, is independently associated with increased risk for diabetic peripheral neuropathy. Whether vitamin D supplementation improves diabetic peripheral neuropathy deserves further study.

Disclosure: Y. Yang: None.

716
Periodic fasting might delay progression of thermal hypoalgesia in patients with type 2 diabetes and diabetic neuropathy
E. von Rauchhaupt1,2, S. Kopf1-2, Z. Kender1,2, V. Longo1,4, P.P. Nawroth1,2, J. Szendroedi1,2, A. Sulaj1,2
1Department of Endocrinology, Diabetology, Metabolism and Clinical Chemistry (Internal Medicine 1), Heidelberg University Hospital, Heidelberg, Germany, 2German Center of Diabetes Research (DZD), Neuherberg, Germany, 3Department of Biological Sciences, Longevity Institute, School of Gerontology, University of Southern California, USA, 4FIRC Institute of Molecular Oncology, Italian Foundation for Cancer Research Institute of Molecular Oncology, Milan, Italy.

Background and aims: Fasting protocols are rapidly emerging as beneficial interventions inducing ketogenesis and ketone utilization for cell energy. Preclinical studies have shown that ketogenic diets can provide protective effects to peripheral axons and sensory dysfunction. The purpose of this pilot study was to examine the effects of periodic fasting on somatosensory nerve function in patients with type 2 diabetes and diabetic neuropathy.

Materials and methods: Somatosensory nerve function was assessed in thirty-one patients with type 2 diabetes (HbA1c 7.8±1.3% [61.4±14.3 mmol/mol]) before and after a six-month diet intervention, either with a fasting-mimicking diet (FMD) (n=15) or a control Mediterranean diet (n=16). Outcome measures included clinical neuropathy disability score (NDS), neuropathy symptoms score (NSS), nerve conduction velocity
and quantitative sensory testing. The pre- and post-intervention comparison was done by a two-sided paired t test with level of significance set at α = 0.05.

**Results:** Baseline values of clinical neuropathy scores were comparable with values after six-month diet intervention between study groups (NDS in the control group 4.0 [2.5, 5.5] vs. 5.4 [3.4, 7.4]; P=0.31 and NDS in the FMD group 3.7 [2.3, 5.2] vs. 3.4 [1.9, 4.8]; P=0.74, NSS in the control group 5.2 [3.7, 6.7] vs. 5.8 [4.1, 7.5]; P=0.39 and NSS in the FMD group 5.6 [4.0, 7.2] vs. 4.1 [1.9, 6.2]; P=0.18). No significant change was observed between study groups in nerve conduction velocity. In quantitative sensory testing the control group showed a decrease by 47% in heat pain threshold, as a parameter assessing thermal pain (Z-score -0.74 [-1.38, -0.10] vs. -1.09 [-1.72, -0.47]; P=0.03), whereas no such change was observed in the FMD group (Z-score -0.02 [-0.78, 0.73] vs. -0.47 [-1.35, 0.41]; P=0.41). Values of thermal detection, mechanical detection and mechanical pain after six months were comparable with baseline values and did not differ between study groups.

**Conclusion:** Six-month periodic fasting might delay progression of thermal hypoalgesia in patients with type 2 diabetes and diabetic neuropathy. The role of ketogenesis and utilization of ketone bodies for cell energy in patients with diabetic neuropathy should be further investigated in future studies.

*Disclosure:* Supported by: German Research Foundation in the Collaborative Clinical Trial Registration Number: NCT03022721

*Clinical Trial Registration Number: DRKS-ID: DRKS00014287* Supported by: German Research Foundation DFG (SFB 1118), German Center for Diabetes Research DZD (82/DDZ07C2G)

*Disclosure: E. von Rauchhaupt:* None.

### 717

Sciatic nerve fractional anisotropy and neurofilament light chain protein are related to sensorimotor deficit of the upper and lower limbs in patients with type 2 diabetes

Z. Kender1 2, J.M.E. Jende1, F.T. Kurz3 4, D. Tsilingiris1 2, L. Schimpfle1, A. Sulaj1 2, E. von Rauchhaupt1, P.P. Nawroth1 2, M. Bendszus1, J. Szendrödi1 2, S. Kopf1 2, 1Neuroradiology, University Hospital Heidelberg, 2Endocrinology, Diabetology and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, 3German Center of Diabetes Research (DZD), München-Neuherberg, 4Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, 4German Cancer Research Center, Heidelberg, Germany.

**Background and aims:** Diabetic neuropathy (DPN) is one of the most prevalent and poorly understood microvascular complication of diabetes mellitus. Recent studies have found that fractional anisotropy (FA), a surrogate marker for microstructure of peripheral nerves, is a sensitive parameter for structural and functional nerve damage in patients with DPN. The aim of this study was to investigate the significance of the sciatic nerve’s FA on different nerve fiber deficits of the upper and lower limbs and its correlation with a recently established biomarker of neuronal damage, neurofilament light chain protein (NFL).

**Materials and methods:** Sixty-four patients with type 2 diabetes and 27 healthy controls underwent detailed clinical and electrophysiological assessments, and complete quantitative sensory testing (QST) as well as diffusion-weighted magnetic resonance neurography (MRN) of the sciatic nerve with subsequent automated calculation of the nerve’s fractional anisotropy (FA), a marker for microstructural nerve integrity. NFL was measured in the serum of all participants.

**Results:** Patients with DPN showed a 19% decrease in lower sciatic microstructural integrity compared to healthy controls (p<0.001). FA correlated with tibial and peroneal motor nerve conduction velocity (NCV) (r=0.6; p<0.001 and r=0.5; p=0.001) as well as sural sensory NCV (r=0.3; p=0.04). Participants with reduced microstructural nerve integrity of the sciatic nerve showed a loss of function of mechanical and thermal sensation of the upper (r=0.3; p<0.05 and r=0.3; p<0.05) and lower (r=0.5; p<0.001 and r=0.3; p=0.001) limb as well as reduced functional performance of the upper limb (Purdue Pegboard Test for both hands; r=0.4; p<0.001). Increased levels of NFL were associated with loss of sciatic nerve FA (r=0.4; p<0.001). Increased HbA1c (r=0.3; p<0.01) and microvascular surrogate markers (high sensitive Troponin T and urinary albumin-creatinine ratio) were associated with decreased FA (r=0.4; p<0.001 and -0.4; p<0.001, respectively). There was no correlation between sciatic FA and neuropathic symptoms or pain.

**Conclusion:** This is the first study showing that non-invasive assessments of microstructural nerve integrity and microvascular markers are associated with nerve fiber damage in diabetic neuropathy. The nerve fiber damage of the lower limb is also associated with functional nerve fiber deficits of the upper and lower limbs, suggesting that diabetic nerve damage involves structural changes of peripheral nerves of upper limbs too. Furthermore, these findings show that proximal nerve damage is related to distal nerve function even before clinical symptoms occur.

*Disclosure: Z. Kender:* None.

### 718

Dynamic contrast enhanced MRI reveals adverse effects of glucose control on perfusion of the sciatic nerve in type 2 diabetes patients with and without diabetic polyneuropathy

C.M. Mooshage1, L. Schimpfle2, Z. Kender2, J. Szendrödi2, S. Heiland3, M. Bendszus1, S. Kopf2, F.T. Kurz2 4, M.J.E. Jende1, 1Neuroradiology, University Hospital Heidelberg, 2Endocrinology, Diabetology and Clinical Chemistry (Internal Medicine 1), University Hospital Heidelberg, 3Division of Experimental Radiology, Neuroradiology, University Hospital Heidelberg, 4German Cancer Research Center, Heidelberg, Germany.

**Background and aims:** The pathophysiology of diabetic polyneuropathy (DPN) remains poorly understood, with a lack of causal therapeutic options. Hence, therapy is limited to optimization of serum glucose and modification of risk factors. Clinical studies have come to heterogeneous results with regard to the effectiveness of intensified glucose control as a preventive measure for DPN in patients with Diabetes Type 2 (T2D). In particular, it is still uncertain in how far glycemic control modifies microvascular permeability and perfusion in T2D patients with and without DPN. This study aimed to assess associations of glucose control with parameters of nerve perfusion in patients with T2D using dynamic contrast enhanced (DCE) MRI at 3 Tesla.

**Materials and methods:** 72 patients with T2D were enrolled in this study. DPN was diagnosed based on electrophysiological criteria (no DPN: 19 women, 19 men; DPN: 18 men, 2 women). Groups were matched for age, BMI, HbA1c, duration of diabetes and eGFR. A complete neurological examination, standard serological and electrophysiological testing and DCE MRI of the sciatic nerve at mid-thigh level were performed. ImageJ and MATLAB were used for post-processing and the constant of the examined nerve’s capillary permeability (Ktrans), the volume fraction of the plasma space (vP), and the volume fraction of the extravascular extracellular space (ve) were determined in accordance with the extended Tofts model.

**Results:** In patients with DPN Ktrans was lower compared to patients without DPN (DPN 0.034 ± 0.006 min⁻¹; without DPN 0.041 ± 0.014 min⁻¹; p=0.036). In patients with DPN we found positive correlations of Ktrans with HbA1c (r=0.55; p=0.015), ve (r=0.72; p<0.001) and tibial nerve conduction velocity (NCV; r=0.45; p=0.047). No such correlations were found for age or BMI. In patients without DPN negative correlations were found for Ktrans with HbA1c (r=-0.43; p=0.012), while positive correlations were found for peroneal NCV (r=0.47; p=0.004), ve (r=0.83; p<0.001), and BMI (r=0.45; p=0.004). In a partial correlation
Circulating metabolites associated with diabetic sensorimotor peripheral neuropathy among individuals with type 1 diabetes

B.A. Sørland1,2, C.S. Hansen1, K. Sulek1, C. Legido-Quigley1, P. Rossing1,2, T.S. Ahluwalia1,2;
1Steno Diabetes Center Copenhagen, Herlev, 2University of Copenhagen, Copenhagen, Denmark.

Background and aims: Diabetic sensorimotor polyneuropathy (DSPN) is a common complication of diabetes mellitus associated with risk of amputations, foot ulcers and mortality. DSPN is generally diagnosed in the late stage using present screening methods. Early detection of patients at risk of DSPN development could prevent irreversible nerve damage and support clinical decision making, improving quality of life, and lowering the cost of healthcare. Metabolomics is the study of small biochemicals within the body, in the control of biologic functions such as disease progression. Here, we identified n=71 circulating metabolites and examined those for association with DSPN in subjects with type 1 diabetes (T1D). Knowledge of metabolites associating with DSPN could present new neuropathy risk factors and enable early detection of high risk patients.

Materials and methods: Non targeted serum metabolites (n = 71) and clinical data from 219 individuals with T1D from Steno Diabetes Center Copenhagen were assessed at baseline using gas chromatography coupled to mass spectrometry. Participants had a mean age of 56.4 (IQR 49.6, 64.0) years, 48.0 % (n = 105) were male, 83.6% were smokers (n = 183), 62.6% received statin treatment (n = 137), mean diabetes duration 40.9 (34.3, 47.1) years, BMI 24.7 (22.3, 26.5), HbA1c 63.1 (56.3, 59.4) mmol/mol and total cholesterol 4.8 (4.0, 5.0) mmol/L. DSPN was defined as bilateral vibration sensation threshold >=25V using Biothesiometry test. Association between single metabolites and DPSN were assessed by linear regression models fitted with and without adjustments for clinical factors (age, gender, smoking status, statin use, diabetes duration, BMI, HbA1c and total cholesterol) and corrected for multiple testing. All analysis was performed with R > 4.1.0. Benjamini-Hochberg (BH) was used to correct for multiple testing, p_{BH} < 0.05 were considered significant.

Results: We identified 5 metabolites associated with DSPN in the unadjusted model significant after correction for multiple testing (myo-inositol, 2,4 dihydroxy-butanic acid, ribitol, 3,4 dihydroxy-butanic acid, ribonic acid). Increased levels of these 5 metabolites were associated with DSPN. After adjustment for clinical factors 3 metabolites were found to be associated with DSPN, that were earlier not identified by the unadjusted model (p < 0.05; arachidonic acid, heptadecanoic acid, stearic acid). Decreased levels of these 3 metabolites were associated with DSPN. Although these were interesting findings, the adjusted results did not go through multiple testing correction.

Conclusion: In this study we identified circulating metabolites associated to DSPN before multiple testing correction. Results suggest that circulating long chain fatty acids might have a role in DSPN pathogenesis. Further studies validating these findings and investigating their potential role using longitudinal data are warranted.

Disclosure: B.A. Sørland: None.

Perception threshold tracking: a novel methods for assessing the function of large and small nerve fibers in diabetic peripheral neuropathy

J. Roikjer1–2, S.S. Croosu3, J.B. Frøkjær3,4, T.M. Hansen3,4, N. Ejskjaer1–4, C.D. Mørch2,5;
1Steno Diabetes Center North Denmark, Aalborg University Hospital, 2Department of Health Science and Technology, Aalborg University, 3Department of Radiology, Aalborg University Hospital, 4Department of Clinical Medicine, Aalborg University, 5Center for Neuroplasticity and Pain (CNAP), Aalborg University, Aalborg, Denmark.

Background and aims: Small nerve fibers are important when searching for early signs of diabetic peripheral neuropathy (DPN). The current methods for assessment either have several inherent limitations or are limited to examination of the extent of structural damage. Therefore, the present study aims to assess nerve function.

Materials and methods: We utilized a novel perception threshold tracking technique to selectively assess the function of large and small nerve fibers in four age- and sex-matched groups consisting of 20 participants with type 1 diabetes (T1DM) and: painful DPN (T1DM+DPN), painless DPN (T1DM+DPN), no DPN or pain (T1DM-DPN), and 20 healthy controls (HC). Nerve fiber function was assessed using weak electrical currents with varying intensity by two different skin electrodes activating large- and small fibers, respectively. Nerve fiber activation was indicated by participants pressing a button. The minimal current needed to activate the nerve fibers were analyzed as the rheobase. Differences between groups were analyzed by Wilcoxon Signed-rank tests.

Results: The rheobase for the large fibers was highest for T1DM+DPN: 3.94 mA [IQR 1.99-25.0], followed by T1DM+DPN: 2.49 mA [1.74-4.09], T1DM-DPN: 1.68 mA [1.16-1.89], and HC: 1.09 mA [1.02-1.36]. The rheobase for the small fibers was highest for T1DM+PDPN: 1.09 mA [0.52-25.0], followed by T1DM+DPN: 0.78 mA [0.19-1.17], T1DM-DPN: 0.25 mA [0.14-0.45] and HC: 0.14 mA [0.08-0.24]. There was a significant difference in rheobase between all groups and fibre-types (all p<0.05), apart from between large fibres of T1DM+PDPN versus T1DM+DPN and T1DM-DPN versus HC and the rheobase of the small fibres between T1DM-DPN versus HC and T1DM+DPN versus T1DM-DPN.

Conclusion: Perception threshold tracking reveals differences in large- and small nerve fiber function between groups with and without T1DM and pain.

Clinical Trial Registration Number: NCT04078516
Disclosure: J. Roikjer: None.
SO 60 Preventing microvascular complications

272

The use of the IDx-DR software as a simple screening tool for the detection of diabetic retinopathy in patients at the diabetes outpatient clinic

S. Huber1, V. Parzer2, A. Pollreisz3, B. Ludvik4, J. Brix5
1Klinik Landstraße, 2Medizinische Universität Wien, Vienna, Austria.

Background and aims: About 200 people in Austria lose their sight every year due to diabetes mellitus. IDx-DR is an algorithm-based software for the screening of diabetic retinopathy (DR). The software provides three different outcomes: negative, moderate DR and visually threatening DR. The aim of this study was to evaluate the benefits of the IDx-DR software as a simple screening tool in diabetes patients at the diabetes outpatient clinic.

Materials and methods: This observational cross-sectional study at our diabetes outpatient clinic started in March 2021. In total, 896 people with diabetes have been included so far (46% women, 54% men, median age 57 years, median BMI 29.7 kg/m², median HbA1c 7.3%, positive smoking history 66.7% with an average of 20 pack years).

Results: A total of 62% of all patients reported an ophthalmologist visit within the last year. The IDx-DR screening showed a DR in 20% of the patients of which 50% had a visually threatening DR. In about 50% of the patients with a positive IDx-DR result no history of eye disease was known. Moreover, a significant difference was found between the baseline HbA1c level (for HbA1c values ≥ 7%) and the presence of DR (p = 0.00018). Even no significance could be detected between the regularity of ophthalmological controls (related to an annual control) and the presence of DR, a higher rate was found in patients without annual checks (15% with DR without annual control vs. 6% with DR with annual control). In 20.5%, the software did not provide a result, due to a significant association to known cataract disease (p = 0.003).

Conclusion: Even in a specialized diabetes outpatient clinic, almost 40% (about 2/5) of patients did not have regular check-ups with an ophthalmologist. In 50%, a DR was newly detected, and in the case of a visually threatening DR, an immediate, specialist transfer was made. The detection ability seems to be limited in the case of a pre-existing cataract. The IDx-DR screening might be a promising tool in the early detection of DR, even for internal specialists.

Disclosure: S. Huber: None.

273

Screening of diabetic retinopathy with Aireen medical device: high sensitivity and agreement with ophthalmologists

M. Prázný1, M. Sliva2, T. Humel2, J. Bayer2, M. Šin3, R. Ženíšková3, D. Fillova5, L. Valesová3, J. Hlaváček6;
13rd Dept. of Internal Medicine, Charles University, 1st Faculty of Medicine, 2Aireen, 3Department of Ophthalmology, Military University Hospital and Charles University, 1st Faculty of Medicine, 4Eye center Prague, 5NeoVize Prague, Prague, Czech Republic.

Background and aims: About 200 people in Austria lose their sight every year due to diabetes mellitus. IDx-DR is an algorithm-based software for the screening of diabetic retinopathy (DR). The software provides three different outcomes: negative, moderate DR and visually threatening DR. The aim of this study was to evaluate the benefits of the IDx-DR software as a simple screening tool in diabetes patients at the diabetes outpatient clinic.

Materials and methods: This observational cross-sectional study at our diabetes outpatient clinic started in March 2021. In total, 896 people with diabetes have been included so far (46% women, 54% men, median age 57 years, median BMI 29.7 kg/m², median HbA1c 7.3%, positive smoking history 66.7% with an average of 20 pack years).

Results: A total of 62% of all patients reported an ophthalmologist visit within the last year. The IDx-DR screening showed a DR in 20% of the patients of which 50% had a visually threatening DR. In about 50% of the patients with a positive IDx-DR result no history of eye disease was known. Moreover, a significant difference was found between the baseline HbA1c level (for HbA1c values ≥ 7%) and the presence of DR (p = 0.00018). Even no significance could be detected between the regularity of ophthalmological controls (related to an annual control) and the presence of DR, a higher rate was found in patients without annual checks (15% with DR without annual control vs. 6% with DR with annual control). In 20.5%, the software did not provide a result, due to a significant association to known cataract disease (p = 0.003).

Conclusion: Even in a specialized diabetes outpatient clinic, almost 40% (about 2/5) of patients did not have regular check-ups with an ophthalmologist. In 50%, a DR was newly detected, and in the case of a visually threatening DR, an immediate, specialist transfer was made. The detection ability seems to be limited in the case of a pre-existing cataract. The IDx-DR screening might be a promising tool in the early detection of DR, even for internal specialists.

Disclosure: S. Huber: None.
Disclosure: M. Prázný: Employment/Consultancy; Aireen, a.s.

724 Why has the incidence of certifications for sight and severe sight impairment due to diabetic retinopathy increased in Wales: Could the National Diabetes Audit hold the key?

R.L. Thomas1, A. Zeke2, R.V. North3, R. Reynolds4, G. Williams2, D. Flanagan2, C. Bunce5, S.D. Luzio1, D.R. Owens1; 1Diabetes Research Group, Swansea University, Swansea, 2Moorfields Eye Hospital, London, 3Cardiff University, Cardiff, 4Department of Ophthalmology, Aneurin Bevan University Health Board, Newport, 5Department of Ophthalmology, Swansea Bay University Health Board, Swansea, 6The Royal Marsden NHS Foundation Trust, London, UK.

Background and aims: The World Health Organisation highlighted the importance of reporting trends and progress in preventing avoidable blindness in order to evaluate the impact of different strategies. This study aims to understand the trends in the incidence of sight (SI) and severe sight impairment (SSI) certifications over a decade prior to the Covid-19 pandemic.

Materials and methods: Certifications for SI and SSI in England and Wales are received by the certification’s office at Moorfields Eye Hospital, London for 2010 - 2020. National Diabetes audit (NDA) data collects data from primary and secondary care across England and Wales about the recommended 8 care processes people with diabetes receive annually (HbA1c, blood pressure, cholesterol, foot surveillance, urine albumin, serum creatinine, weight and smoking cessation).

Results: Since 2010 there has been a gradual reduction in certifications for SI and SSI in England and Wales from 72.8 to 41.3 per100,000 people with diabetes in England and from 82.3 to 55.5 per 100,000 in Wales. However, in Wales since 2016 there has been a gradual increase from 54.07 and p < 0.0001 showing significant dependency and a very high level of agreement between the Aireen’s results and ophthalmologist’s evaluation in the screening of DR (table 1).

Conclusion: The screening of DR with Aireen medical device brings a remarkably high level of correlation with ophthalmologist trained in the management of DR. This may identify patients suitable for screening of DR with ophthalmologist and in a substantial proportion limit the burden of patients and ophthalmologist from unnecessary examinations. A clinical study aimed at the screening of DR with Aireen in T2DM patients is planned to start soon and bring more data on the clinical effectiveness and safety of this DR screening method.

Table 1. A contingency table with the pilot results of the screening for DR performed by two ophthalmologists and Aireen medical device in a total of 1143 pictures taken from 384 T2DM patients showing a remarkably high level of agreement (p<0.0001). DR – diabetic retinopathy

<table>
<thead>
<tr>
<th>Aireen medical device</th>
<th>Ophthalmologists</th>
</tr>
</thead>
<tbody>
<tr>
<td>DR No DR Total</td>
<td>DR No DR Total</td>
</tr>
<tr>
<td>No DR 942</td>
<td>94 1036</td>
</tr>
<tr>
<td>DR 1 106</td>
<td>107</td>
</tr>
<tr>
<td>Total 943</td>
<td>200 1143</td>
</tr>
</tbody>
</table>

725 How a simple clinical scoring system complements COMPASS 31 questionnaire in predicting cardiovascular autonomic neuropathy in type 1 and 2 diabetes

I. D’Ippolito, M. Menduni, C. D’Amato, C. Greco, M. Leoni, D. Lauro, V. Spallone; Endocrinology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Background and aims: The Composite Autonomic Symptom Score 31 (COMPASS 31) questionnaire has been validated for autonomic symptoms of diabetic neuropathy with a better diagnostic accuracy in type 1 than in type 2 diabetes. A clinical-based scoring system (CAN Risk Score) has been built to predict the presence of cardiovascular autonomic neuropathy (CAN) with sensitivity and specificity for CAN up to 88% and 78% in type 1 and up to 79% and 77% in type 2 diabetes.
Quantitative sensory testing may identify clinical phenotypes with high risk of progression to sensory loss in diabetic neuropathy

**D. Tsilingiris**1,2, L. Schimpfle1, A. Sulaj1,2, E. von Rauchhaupt1, P. Nawroth1, S. Kopf1,2, Z. Kender1,2

1Department of Endocrinology, Diabetology, Metabolic diseases and Clinical Chemistry, University Hospital Heidelberg, Heidelberg, Germany.
2German Center for Diabetes Research (DZD), Munich-Neueherberg, Germany.

**Background and aims:** Quantitative sensory testing (QST) allows for sensory profiling in peripheral neuropathy. Sensory loss (SL) is the most common phenotype in diabetic neuropathy (DN). For mechanical hyperalgesia (MH) and thermal hyperalgesia (TH), sensory loss in the lower extremities is related to the manifestation of the diabetic foot syndrome. Our aim was to assess the evolution of lower extremity sensory phenotype among patients with diabetes mellitus (DM) and investigate the course of sensory loss development in the frame of DN.

**Materials and methods:** We studied a cohort of 287 individuals with DM (Age 59.3±13.9, 38.3% females, 21.3%, T1DM, 78.7% T2DM), of which 225 attended follow-up visits after 1, 2 and 4 years. Allocation into four sensory phenotypes (healthy, TH, MH, and SL) at every timepoint was based on the z-scores of the 13 domains of QST on the right foot, according to published algorithms. Additional measures included the clinical neuropathy assessment (via the neuropathy symptom and disability scores-NSS/NDS, according to clinical practice guidelines) and nerve conduction studies of Suralis, Peroneus and Tibialis nerves.

**Results:** Among all participants studied at baseline, 76 (26.5%), 84 (29.3%), 69 (24.0%) and 58 (20.2%) were categorized as Healthy, TH, MH, and SL, respectively. The overall prevalence of clinical neuropathy based on NSS/NDS was 33.8%, and across the groups 9.2%, 21.4%, 42.0% and 74.1%, respectively (p for trend <0.001). Accordingly, electrophysiological studies showed an increasing severity of neuropathic findings across healthy, TH, MH, and SL groups. After a mean follow-up of 2.68±1.30 years, 119 of 225 longitudinally followed-up participants showed a cluster change. Those classified as healthy at baseline changed predominantly to TH (37.7%, p<0.05 vs. MH or SL), those as TH at baseline to MH (32.3%, p<0.05 vs. Healthy or SL), those with SL on baseline to MH (20.9%, p=0.01 vs. healthy, p=0.08 vs. TH), while those with MH changed equally towards TH and SL (28.6% each, p=0.003 vs. healthy). Among those without SL on baseline, there were 35 new cases of SL in the course of follow-up, corresponding to an incidence of 8.13 cases/100 person*years. Compared to the healthy subgroup, the HRs for SL occurrence were 3.40 (95% c.i. 1.10-10.56, p=0.034) for those classified at baseline as TH and 6.06 (2.06-17.83, p=0.001) for those as MH. After adjustment for age and gender, only the MH phenotype remained a significant predictor of SL development (aHR 4.44, 1.48-13.36, p=0.007). Among baseline QST values, the z-score of cold detection threshold (zCDT) showed the best performance for identification of SL occurrence (AUC ROC 0.729, zCDT <-1.00: Sensitivity 70.2%, Specificity 77.1%).

**Conclusion:** Our findings signify thermal and mechanical hyperalgesia as potential consecutive transitional phenotypes in the course between healthy and sensory loss in DN. This may have profound implications for the use of QST for identification of high-risk patients and primary prevention of diabetic foot, while it may further serve to identify those most likely to benefit from current and future interventions to prevent DN progression.

Clinical Trial Registration Number: NCT03022721

Supported by: SFB 1158

Disclosure: D. Tsilingiris: None.

---

**Background and aims:** Type 2 diabetes (T2DM) is a key risk factor for the development and progression of chronic kidney disease (CKD), and diabetes is now the leading cause of CKD and kidney failure globally.

---

**Disclosure:** None.
Regular screening is recommended within diabetic populations to identify and manage undiagnosed CKD. Many patients do not undergo screening according to the recommended protocols and frequency. We have, therefore, developed pre-screening models using UK general practice data that identify people with T2DM most at risk of having reduced kidney function (eGFR < 60ml/min/1.73m²) or albuminuria (urine albumin to creatinine ratio (UACR) > 30mg/g) using readily available patient information. These models can be used to better target CKD screening within T2DM populations, particularly in low- and middle-income countries where resources may be limited. The goal of the present study is to validate our models within global populations, and identify any regional variation in performance.

Materials and methods: We applied our eGFR model to the 3-year observational DISCOVER data study (covering 37 countries in 6 regions globally), and our UACR model to the AstraZeneca TakeCaReoMe programme data (5 countries), and quantified the positive predictive value (PPV) at thresholds that ensured a sensitivity of at least 80%. We compared minimal-resource (MR) models (using only easily obtained patient information) against the screen-all approach using a complete case analysis.

Results: 5123 patients had valid serum creatinine values and were included in the validation of the eGFR model. The screen-all approach for eGFR<60ml/min/1.73m² resulted in a PPV of 9.5% [95% CI: 8.7% - 10.2%]. Using our MR model, this increased to a PPV of 14.5% [95% CI:13.1% - 15.8%] (a relative increase of 53.0%) at a sensitivity of 83.8% [95% CI: 80.3%, 87.2%].9720 patients were included in the UACR validation. The screen-all approach for UACR > 30mg/g resulted in a PPV of 33.5% [95% CI: 32.6% - 34.4%]. The MR model increased the PPV to 36.2% [95% CI: 35.2% - 37.2%] (a relative increase of 8.0%) at a sensitivity of 81.8% [95% CI: 80.6% - 83.3%]. Regional variation was observed across both renal measures.

Conclusion: It is possible to pre-screen people with T2DM for kidney function impairment using models that require only basic patient information, and models developed using UK data perform well in global populations. These models could be used to conduct more targeted screening where resources are limited, and to prioritize screening of high-risk individuals. The models should be adapted and re-calibrated to local populations to ensure adequate performance. Our model to detect albuminuria did not offer significant gains in PPV. This finding highlights the importance of following the recommended guidelines on UACR screening for all people with T2DM.

Disclosure: R. Sisk: None.

SO 61 Saving the feet

Temporal trends in major, minor and recurrent lower extremity amputations in Belgium from 2009 to 2018

1Department of thoracic and vascular surgery, Antwerp University Hospital, Antwerp, 2Clinical Trial Center, Antwerp University Hospital, Antwerp, 3Landbond der Christelijke Mutualiteiten/Alliance Nationale des Mutualités Chrétiennes, Brussel, 4Internautisch Agentschap/Agence InterMutualiste, Brussel, 5Department of endocrinology, Onze Lieve Vrouwe Ziekenhuis Aalst, Aalst, 6Centre Multidisciplinaire du Pied Diabetique, Ransart, 7Department of orthopedic surgery, Leuven University Hospital, Leuven, 8Department of endocrinology, CHR de la Citadelle, Liège, 9Department of endocrinology, diabetology and metabolism, Antwerp University Hospital, Edegem, Belgium.

Background and aims: In Western countries, diabetes-related complications are the main indication for lower extremity amputations (LEAs). Multidisciplinary diabetic foot clinics (MDFCs) have been implemented to reduce this number. Temporal trends in the incidence of total, major, and minor LEA in people with and without diabetes from 2009 to 2018 in Belgium, and secondary amputation rates were studied.

Materials and methods: Data on all Belgian citizens, both those undergoing LEA and those remaining amputation-free, were collected from the InterMutualistisch Agentschap/Agence InterMutualiste, Sex- and age-adjusted annual incidence rates were calculated. Time trends were analysed in negative binomial models. Secondary interventions, defined as an amputation executed on the ipsilateral and/or contralateral limb at any point later in time after the initial amputation, were also studied, with death as competing risk.

Results: In individuals with diabetes, the amputation risk decreased from 143.6/100 000 person-years in 2009 to 109.7 in 2018 (p<0.001). The incidence of major LEAs decreased from 56.2 to 30.7/100 000 person-years (p<0.001); the incidence of minor amputations showed a declining trend in women (54.3 to 45.0/100 000 person-years, p=0.024), but didn’t change significantly for the total population (99.9 to 87.5/100 000 person-years). In individuals without diabetes, the incidence of major amputation didn’t change significantly (6.1 to 5.1/100 000 person-years), whereas minor amputation incidence increased (8.0 to 10.6/100 000 person-years, p<0.001). In individuals with diabetes, one-year secondary intervention rates were high (31.3% after minor LEA, 18.4% after major LEA); the incidence of secondary amputations didn’t change.

Conclusion: In Belgium, with nationwide accreditation of MDFCs since 2005, there was a significant decline in the incidence rate of major LEA in people with diabetes between 2009 and 2018. This decline is particularly successful since it was not accompanied by a significant rise in minor LEA. Nevertheless, secondary interventions were frequent and their incidence remained stable.
Mortality rates after lower extremity amputation in Belgium from 2009 to 2018


1. Antwerp University Hospital, Antwerp, 2. Clinical Trial Center, Antwerp University Hospital, Antwerp, 3. Landesbond der Christelijke Mutualiteiten/Alliance Nationale des Mutualités Christiennes, Brussel, 4. Intermutualistisch Agentschap/Agence Intermutualiste, Brussel, 5. Department of endocrinology, Onze Lieve Vrouw Ziekenhuis Aalst, 6. Centre Multidisciplinaire du Pied Diabetique, Ransart, 7. Department of orthopedic surgery, Leuven University Hospital, Leuven, 8. Department of endocrinology, CHR de la Citadelle, Antwerp, 9. Department of thoracic and vascular surgery, Antwerp University Hospital, Antwerp, Belgium.

Background and aims: Diabetes mellitus and peripheral arterial disease are the main indication for lower extremity amputations (LEA) in Western countries. Reported mortality rates after LEA are high, particularly with more proximal amputation level and older age. The influence of diabetes is more ambiguous. In this national study, short and long-term mortality after minor and major LEA in people with and without diabetes, compared to controls without LEA, was assessed between 2009 and 2018. Temporal trends in one-year mortality rates were studied as well.

Materials and methods: Data on all Belgian citizens undergoing LEA in the study period, and a group of matched controls without LEA, were collected. Age- and sex-adjusted survival curves were calculated. A Cox proportional hazard model was used to estimate the relative likelihood of mortality after LEA in individuals with and without diabetes, after correction for age, gender, and district. Matched individuals with and without diabetes but remaining amputation-free were used as controls. Time trends were analysed in negative binomial models.

Results: 41304 amputations (13247 major, 28057 minor) were performed in 26526 individuals. Thirty-day, 1-year, and 5-year mortality rates (deaths per 1000 individuals) in people with diabetes after major amputation were 17, 38, and 65, and 4.9, 21, and 48 after minor amputation. Diabetes was significantly related to reduced survival: hazard ratios for mortality for controls without LEA, minor LEA and major LEA were 1.77 (95% CI 1.56-2.00), 1.40 (95% CI 1.24-1.58) and 1.26 (95% CI 1.12-1.41) respectively. Over the ten-year study period, mortality rates after LEA decreased only for individuals without diabetes.

Conclusion: Early and late mortality rates after LEA were high in Belgium, both in individuals with and without diabetes.
**Results:** Of the 2496 identified patients below 70 years of age with a history of type 2 diabetes and a first diagnosis of PAD between 2016 and 2020, 1403 (56.2%) had been prescribed neither an SGLT2 inhibitor nor a GLP1-RA, while 13.6% was prescribed an SGLT2 inhibitor, 13.5% a GLP1-RA and 16.7% drugs from both these classes. During the follow-up period (median 2.9 years), 566 events (22.7%) occurred. The five-year mortality is given in Figure 1.

**Conclusion:** In this population of younger people with type diabetes and a first diagnosis of PAD between 2016 and 2020, the lowest mortality was seen in the group prescribed both a GLP1-RA and an SGLT2 inhibitor, followed by single-use of an SGLT2 inhibitor. These data suggest that early use of SGLT2 inhibitors in people with type 2 diabetes and PAD seems to be efficient.

---

**731**

The effectiveness of an affordable Toa Uzito (offloading) device for improving diabetic foot ulcer in the developing world

Z.G. Abbas1,2, J.K. Lutale1, L.K. Archibald1;

1MUHAS, Dar es Salaam, United Republic of Tanzania, 2AMC, Dar es Salaam, United Republic of Tanzania, 3University of Florida, Gainesville, USA.

**Background and aims:** Diabetic foot ulcer (DFU) disease is common in Sub-Saharan Africa (SSA). Callus formation, often seen in persons with peripheral neuropathy, plays a key role in the pathogenesis of DFU by increasing local pressure in susceptible areas on the plantar aspect of the foot. Because callus formation can inhibit DFU healing, offloading remains one of the most useful conservative measures to facilitate DFU healing. Prohibitive costs and paucity of personnel with the required training to implement and manage off-loading devices often preclude this therapeutic option in SSA. For all these reasons, we devised an offloading device that requires no special training to use, is easy to implement, and is very affordable (10 US cents each). We named this device Toa Uzito (Swahili translation for offloading) and carried out this study to ascertain its utility and effectiveness in the management of DFU in cases treated with off-loading was significantly higher than controls to start with. Toa Uzito is an affordable offloading device and an effective adjunct to DFU management. It renders instant offloading and contributes positively towards DFU healing with potential reduction of amputation rates. This device is simple to implement and is easily adaptable for use at the grass root level anywhere in the developing world.

**Disclosure:** Z.G. Abbas: None.

---

**732**

Exploring MMP9 as a prognostic marker in post debridement wound fluid of diabetes related foot ulcers, and the possibility of a point-of-care test

M.S.G. Longfield1, V. Nube2, J.M. White2,3, S.V. McLennan1,4, P. Boughton1, D. Min1,2, S.M. Twigg2,2;

1Greg Brown Diabetes and Endocrinology Research Laboratory, University of Sydney, 2Department of Endocrinology, Royal Prince Alfred Hospital, 3Podiatry Department, Sydney Local Health District, 4NSW Health Pathology, 5Sydney Spine Institute & Sydney Pharmacy School, University of Sydney, Sydney, Australia.

**Background and aims:** While most diabetes related foot ulcers (DFRU) heal with conservative management, a significant minority do not. Wound grading and wound closure rate (WCR), have some predictive value, helping to identify hard to heal wounds, but a definitive marker of healing has not been integrated into clinical assessment. Evidence in the literature suggests that the pro-inflammatory matrix metalloproteinase-9 (MMP9), is elevated in post debridement wound fluid in DRFU less likely to heal. Therefore, a point-of-care test (POCT) for MMP9 could offer at clinic ulcer healing prediction to guide therapy. This study aimed to determine whether MMP9 concentration in post debridement wound fluid has clinical utility as a predictor of healing outcome and whether a rapid POCT for MMP9 can be adapted and utilised in this setting.

**Materials and methods:** Post debridement wound fluid was collected by Paperpoint® from 28 DRFU managed at our high risk foot service, as a sub-study of the Diabetes Debridement Study, at three time points, initial visit, week 2, and week 4. Clinical ulcer healing by 12 weeks was then determined. Total MMP9 was quantitated in wound-fluid samples by ELISA and the pro and active MMP9 measured by gelatin-zymography. Subsequently, an MMP9 POCT obtained from a commercial source, for tear fluid measures of total MMP9 was adapted to assess its ability to predict DRFU outcome.

**Results:** Overall, 10 DRFU healed (H) and 18 failed to heal (NH) by 12 weeks. Of those with available samples at week 0 (nH=7, nNH=14), active MMP9 was significantly higher in NH compared to H (10.7(6.02-24.6) vs 2.86(1.91-3.43)mg/mL, P=0.036), with no statistically significant analyses were performed using SAS 9.4 Statistical Software (SAS Institute Inc, Cary, NC, USA). A Cox proportional hazards regression model was used to relate various exposures, considered simultaneously, to time taken for complete healing.

**Disclosure:** None.
difference in total MMP9 or pro MMP9. These active MMP9 differences were predictive of wound healing with AUROC of 0.786 (P=0.037). At week 4 (nH=5, nNH=16), active MMP9 was no longer differentially expressed between groups however total MMP9 was found to be higher in NH wounds (209 (87.6-335) vs 20.69±62.9ng/mL, P=0.015), and was also predictive wound healing with AUROC of 0.867 (P=0.016). Both findings show clinical merit in measuring MMP9 or its derivatives to predict week 12 healing outcome. However, these laboratory-based methods of MMP9 measurement yield little clinical value due to the required equipment and time frame of result turn around. From the ELISA results a 1:2 dilution was determined to test the efficacy of the POCT in wound fluid. Results showed 90.5% accuracy (19/21 correct) reflecting the ELISA results, and a predictive ability for DRFU healing with 71.4% true readings consistent with ROC predictions.

**Conclusion:** These results indicate that whilst active MMP9 may have an earlier predictive capacity, total MMP9 measured at week 4 shows more clinical utility because of the availability of a relevant POCT. Future large clinical studies should aim to evaluate the POCT in a bedside manner, and thresholds should be examined in fresh collected wound fluid. Additionally, there is potential benefit to designing a POCT, for active MMP9, to predict healing at earlier time-points.

**Clinical Trial Registration Number:** ACTRN12618000703202

**Supported by:** TRGS, SMSF-EDRF University of Sydney

**Disclosure:** None.

---

### Effect of human amniotic membrane on umbilical vein endothelial cells of gestational diabetic mothers: new insight in wound healing and diabetic foot ulcer

**C. Pipino.** I. Cappelletti, P. Di Tomo, A. Bernabé-García, J. Stelling-Férez, N. Di Pietrantonio, L. Pelusio, M.P.A. Baldassarre, F.J. Nicolás, A. Pandolfi, M. Petkovic, A.E. Sørensen, E.C. Leal, R.J. Willemoes, H. Jensen, T.S. Ahluwalia, A. Rasmussen, E. Carvalho, L.T. Dalgaard, Roskilde University, Roskilde, Denmark, 2University of Coimbra, Coimbra, Portugal, 3Copenhagen University, Copenhagen, Denmark, 4Department of Biology, University of Copenhagen, Copenhagen, Denmark, 5Steno Diabetes Center Copenhagen, Copenhagen, Denmark.

**Background and aims:** Diabetic foot ulcer (DFU), a severe diabetes complication affecting 15% of patients with advanced stages of the disease, is the main cause of abnormal wound healing leading to lower limb amputation. This condition, characterized by chronic inflammation and oxidative stress, results in reduced peripheral blood flow and neovascularization. Amniotic membrane (AM) has biological properties that have been found beneficial to the wound healing process in DFU. Here, the potential role of AM on endothelial cells isolated from umbilical cords of gestational diabetes affected women (GD-HUVECs) has been investigated. Indeed, GD-HUVECs have shown a pro-inflammatory phenotype, reduced migration capability and lower vessel formation on Matrigel compared to control HUVECs (C-HUVECs), thus representing a valuable model for studying the role of AM in cell migration and neovascularization of chronic non-healing wounds.

**Materials and methods:** For GD-HUVECs, stimulated with low doses of the pro-inflammatory Tumour Necrosis Factor-α (TNF-α, 1ng/ml), monocytes adhesion assay was performed to assess the adhesion of monocytes to endothelial cells. In parallel, Vascular and Intercellular adhesion molecules 1 (VCAM-1, ICAM-1), E-selectin (SELE) and chemokine CC ligand-2 (CCL2) gene expression were evaluated by real time PCR. VCAM-1 and ICAM-1 membrane exposure was analysed by flow cytometry. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) nuclear translocation was evaluated by immunofluorescence staining. Nitric oxide/cyclic guanosine monophosphate (NO/cGMP) levels were measured by ELISA. Cell migration was performed by scratch assay and by measuring proteins involved in the focal adhesion turn-over such as Paxillin and Vinculin. Vessel formation was evaluated by Matrigel tube formation assay.

**Results:** AM significantly reduced TNF-α stimulated monocyte-endothelium interaction and VCAM-1, ICAM-1, SELE and CCL2 expression in C- and GD-HUVECs (p<0.0001 and p<0.01, respectively). That was further confirmed by a reduction on membrane exposure of VCAM-1 and ICAM-1 in both cell types following AM stimulation. Of note, this was associated with a significant decrease of NF-kB cytoplasm-nucleus translocation. Furthermore, AM treatment improved cell migration and vessel formation in GD-HUVECs. Finally, AM-increased NO bioavailability (p<0.01) was affected by endothelial Nitric Oxide Synthase (eNOS) inhibitor L-NAME, suggesting that AM activation of eNOS could be a possible way of regulating this phenomenon. ANOVA and Tukey’s multiple comparison tests were used (n≥3, significance p<0.05).

**Conclusion:** Overall these results indicate that, in our *in vitro* cell model, AM attenuates TNF-α-increased inflammation and improves angiogenesis, possibly through the modulation of NO bioavailability, which plays a key role in the vascular homeostasis balance. This study suggests that AM chronic wound healing improvement may be due to endothelial proper management, therefore explaining its clinical benefit on diabetic foot ulcers.

**Disclosure:** C. Pipino: None.

---

### Proteomic signature reveals potential diagnostic biomarkers for chronic diabetic foot ulcers

**M. Petkovic, A.E. Sørensen, E.C. Leal, R.J. Willemoes, H. Jensen, T.S. Ahluwalia, A. Rasmussen, E. Carvalho, L.T. Dalgaard, Roskilde University, Roskilde, Denmark, 2University of Coimbra, Coimbra, Portugal, 3Copenhagen University, Copenhagen, Denmark, 4Department of Biology, University of Copenhagen, Copenhagen, Denmark, 5Steno Diabetes Center Copenhagen, Copenhagen, Denmark.

**Background and aims:** Chronic foot ulcers (DFU) are a common problem associated with diabetes. Healing outcome is challenging to anticipate in clinical settings, complicating personalized treatment; thus, efficient predictive biomarkers are needed to improve DFU risk stratification and treatment. We aimed to evaluate the proteomic profile of mouse diabetic skin biopsies and human wound swabs from newly detected DFUs and identify prognostic biomarkers for chronic wounds.

**Materials and methods:** Diabetes was induced in C57BL/6 mice using 5 low dose streptozotocin injections, and skin punch biopsies (n=5) were harvested at days 0, 3 and 10 post-wounding. MicroPredict Study involved 112 diabetic patients with DFU, during a six-month accrual period, admitted to the foot clinic, Steno Diabetes Center Copenhagen. Enrolled patients were categorized according to healing time: rapidly healing (RH, <40 days), slow-healing (SH, >40 days; <6 months) and chronic (CH, >6 months). Wound sampling was performed by brush grafting. Patient wounds (12 RH and 12 CH), matched for sex and age, were preliminarily assessed. Potential proteomic hints of DFU were identified using Liquid Chromatography-Mass Spectrometry (LCMS). MaxQuant analysis was followed by Gene ontology pathway analysis using Perseus.

**Results:** The animal model revealed the downregulation of adherens and anchoring junctions Elongation factor 1-a2 (EEF1A2), Filamin-C (FLNC), Galectin-1 (LGALS1), Periplakin (PPL) and Filagrin-2 (FLG2) (3-5-fold) while catalytic Creatine kinase 2 (CK2) and Adenylate kinase 1 (AK1), were 2-fold upregulated in 3 days wounds. The advanced stage of 10 days post wounding was characterized by lowered levels of tubulin chains (TUBA1B) and Myosin-9 (MYH9), while levels of COL1A2A were elevated. Mice skin proteome pathway analysis revealed > 100x upregulated phagocytic activities, at day 3, and cytoskeletal rearrangements 35-fold upregulated 10 days post-wounding. Human swaps analyses identified persistently upregulated NETosis.
associated Neutrophil elastase (NE) and lactoferrin (LF), as well as 2-fold higher levels of dermcidin, in CH compared to the RH group. SERPINs D1/B4 were exclusively detected in the CH wounds, in contrast to tissue repair SERPIN A1/A3, and angiogenic SERPINF1, present in RH wounds only. Furthermore, neutrophil degranulation Annexin A3 was solely detected in the CH. Immunomodulators S100A8/A9 were detected at higher levels in CH over RH wounds. GO: CC and GO: BB pathway analysis revealed over 70-fold upregulation of neutrophil defensin 3 (DEFA3) in RH compared to CH wounds.

**Conclusion:** The proteomic profile of diabetic mice wounds revealed a decrease in cell adhesion junctions and an increase in phagocytic vesicle processing at the inflammatory wound stage, while predominant proteins in the later healing stages were associated with cytoskeletal rearrangements. The human study showed substantial differences between RH and CH wounds, with pronounced apoptosis, catalytic activity, and host-defense responses increased in CH. Our findings indicate potential biomarkers of chronic wounds for a better, personalized approach, thus merit further investigation.

**Clinical Trial Registration Number:** H-17018891

**Supported by:** EFSD/Lilly EXPAND Programme, DDA, SPD

**Disclosure:** M. Petkovic: None.

---

**Nomogram model for predicting the risk of sepsis in diabetic foot patients**

**P. Huang, X. Zhao, Y. Gu;**

Affiliated Hospital of Nantong University, Nantong, China.

**Background and aims:** To establish an individualized nomogram model for predicting the risk of sepsis in diabetic foot (DF) patients, and provide a reference for clinical prevention and treatment.

**Materials and methods:** A total of 144 DF patients hospitalized from March 2019 to February 2022 were enrolled in this retrospective study. The general clinical and anthropometric information of participants including height, weight, waist circumference, duration of diabetes and so on were collected. Fasting plasma glucose, glycosylated hemoglobin, serum albumin and other blood biochemical parameters were detected. The pathogenic bacteria in serum and at the site of infection were detected. Firstly, random forest analysis was used to find the primary predictive factors of sepsis in DF patients. Secondly, multiple factor logistic regression analysis was employed to screen the independent influencing factors of sepsis. Thirdly, a nomogram containing these factors was established to predict the sepsis incidence in DF patients. Finally, the performance of the prediction model was evaluated and verified by receiver working characteristic (ROC) curve, corrected calibration curve, and clinical decision curve.

**Results:** Logistic regression analysis showed that CRP, hypoproteinemia, and Wagner ≥ 3 were risk factors for sepsis in DF (P < 0.01). The area under the ROC curve (AUC) of the nomogram model after internal verification was 0.974 (0.953-0.995). The P value of Hosmer-Lemeshow test was 0.98, indicating that the predicted probability of sepsis in the nomogram was consistent with the actual occurrence of sepsis. The standardized net benefit of the nomogram was highest when the predicted probability was between 0.1 and 1.0.

**Conclusion:** The risk factors for sepsis in DF are CRP, hypoproteinemia, and Wagner ≥ 3. The nomogram model drawn on these risk factors has good predictive accuracy and can assist clinicians in formulating targeted sepsis prevention strategies for patients.

**Clinical Trial Registration Number:** 2018-k016

**Supported by:** Nantong Municipal Science and Technology Project (MS22019005)

**Disclosure:** P. Huang: None.
SO 62 Brain, nerve, and heart interaction

736

Functional brain alterations in regions involved in sensory processing in diabetic peripheral neuropathy and neuropathic pain

S.S. Croosu1,2,3, J. Rinken2,3, C.D. March1, N. Ejskjaer2,4, J.B. Frokjer1,4, T.M. Hansen1,4.
1Department of Radiology, Aalborg University Hospital, 2Steno Diabetes Center North Denmark, Aalborg University Hospital, 3Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Aalborg University, 4Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Background and aims: The pathogenesis of diabetic peripheral neuropathy and neuropathic pain are poorly understood, but the involvement of the central nervous system has been suggested. This study investigated functional connectivity in brain regions involved in sensory processing, including thalamus, primary somatosensory cortex, and insula in type 1 diabetes mellitus with and without diabetic peripheral neuropathy (DPN) and neuropathic pain. The associations between the functional connectivity to peripheral nerve function and pain scores were further investigated.

Materials and methods: This cross-sectional study included 60 individuals with type 1 diabetes and 20 healthy controls. Resting-state functional MRI was utilized to investigate the functional connectivity of thalamus, primary somatosensory cortex, and insula to other brain areas. Nineteen individuals with type 1 diabetes and neuropathic pain, 19 with type 1 diabetes and DPN, 18 with type 1 diabetes without DPN, and 20 healthy controls were included in the seed-based connectivity analysis. The connectivity parameters were used for correlation analysis to peripheral nerve functions and pain scores.

Results: Overall, the thalamus and primary somatosensory cortex showed higher connectivity to motor areas in diabetes individuals without DPN compared to diabetes individuals with neuropathic pain and healthy controls (all p≤0.029). Poorer peripheral nerve functions and higher pain scores were associated with lower thalamus-to-motor area connectivity and lower primary somatosensory cortex-to-motor area connectivity (all p≤0.043). No connectivity differences were found in insula (all p>0.071).

Conclusion: The current study demonstrated higher connectivity of thalamus and primary somatosensory cortex to other brain regions in diabetes individuals not having neuropathic complications. The thalamic/primary somatosensory cortex connectivity was associated with peripheral nerve functions and pain intensity. It was possible to distinguish between type 1 diabetes with DPN/neuropathic pain and type 1 diabetes without DPN/neuropathic pain based on thalamic connectivity. These findings may raise the question of whether a higher connectivity pattern of the thalamus and primary somatosensory cortex might maintain normal sensory profiling and whether lower connectivity might contribute to the pathogenesis of DPN and neuropathic pain. The current study contributes to a further understanding of functional alterations of regions involved in sensory processing in diabetes. Longitudinal studies are needed to confirm our findings.

Clinical Trial Registration Number: NCT04078516
Supported by: Augustinus Fonden, Denmark
Disclosure: S.S. Croosu: None.

737

Identification of painful diabetic neuropathy subtypes from functional connectivity resting state MRI patterns: a novel data driven machine learning approach

1University of Sheffield, 2Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, 3Diabetes Research Department, Sheffield Teaching Hospitals, Sheffield, UK.

Background and aims: The traditional approach for studying the neurobiology of painful diabetic neuropathy (painful-DN) has followed a diagnostic/clinical framework through case-control studies whereby carefully phenotyped patients are compared with controls. This approach has failed to deliver on hoped-for biomarkers due to the high biological heterogeneity among painful-DN patients and among controls. Our primary aim was to delineate the neurobiological heterogeneity in painful-DN by first defining the functional connectivity subtypes in patients then assessed the clinical significance with respect to prediction of clinical outcome with treatment.

Materials and methods: 82 painful-DN subjects and 36 healthy controls underwent detailed clinical and neurophysiological assessment and resting state functional magnetic resonance imaging (RS-fMRI). Painful-DN subjects were divided into training (n=48) and testing (n=34) datasets. Painful-DN disease subtypes were identified by analysing, via unsupervised and supervised machine learning (k-means algorithm), the RS-fMRI functional connectivity of key somatosensory/nociceptive brain regions. Patients in our testing dataset were divided into responders (VAS<4; n=23) and non-responders (VAS>4; n=11). Data analysis was performed using the NITRC Functional Connectivity Toolbox and SPM8 in MATLAB and Scikit Learn.

Results: RS-fMRI functional connectivity defines two clinically relevant painful-DN subtypes. The two subtypes were characterised by strong functional connectivity differences in the postcentral (p<0.001, 95%CI=0.22:0.65) and precentral (p=0.002, 95%CI=0.15:0.59) parietal cortex functional connectivity. The interhemispheric connectivity between homologous regions was also notable. RS-fMRI functional connectivity differences in the default mode network (p=0.002; 95%CI=0.35:0.08) was also identified. The performance of our unsupervised k-means model to predict treatment response was: accuracy=0.77, recall=0.83, precision=0.83 and an AUC=0.73.

Conclusion: We have identified neurobiological markers of clinically relevant subtypes of painful DN from RS-fMRI functional connectivity using an unsupervised data-driven approach. The subtype whose functional connectivity differed most from healthy controls failed to respond to neuropathic pain treatment. Our data-driven approach may constitute a generalisable solution to elucidate the clinical heterogeneity of painful DN.

Supported by: National Institute of Health Research Efficacy and Mechanism Evaluation Programme (NIHR 129921)
Disclosure: K. Teh: None.

738

Mood disorders are related to thalamic H1-MRS metabolite parameters in type 1 diabetes

M. Gregi1, G. Sloan1, P.R. Shillo2, D. Selvarajah1, I.D. Wilkinson1, S. Tesfaye3,1.
1Sheffield Teaching Hospitals, Royal Hallamshire Hospital, Sheffield, 2Department of Diabetes, Chesterfield Royal Hospital, Chesterfield, 3Diabetes, University of Sheffield, Sheffield, 4University of Sheffield, Sheffield, UK.

Background and aims: We have previously demonstrated preservation of proton Magnetic Resonance Spectroscopy (1H-MRS) neuronal metabolite ratios and increased thalamic blood volume in painful diabetic peripheral neuropathy (pDPN). We hypothesised that perfusion measures and neuronal function measured by metabolite ratios may be related. However, as brain metabolite ratios may also be affected by mood disorders, common in pDPN, this may be a significant confounding factor.

Materials and methods: 52 type 1 diabetes (T1D) subjects (18 pDPN, 23 DPN, 13 without neuropathy-DMNN) and 18 healthy volunteers (HV) were recruited. 1H-MRS was performed at 3T (Philips, Netherlands). Single voxel spectra were obtained from a 2.25cm3 (15x10x15mm) volume of interest within the thalamus, TE=135ms, TR=1600ms,
Results: There was significant negative correlation between NAA/Cr (a measure of neuronal function) and measures of depression: Hospital Anxiety and Depression Scale R = -0.33 (p=0.01), Beck’s Depression Inventory R = -0.25 (p=0.04); and anxiety: State-Trait Anxiety Inventory-State (STAI-S) R = -0.37 (p=0.002), STAI- Trait (T) R = -0.32 (p=0.01) and Behavioural Inhibition R = -0.25 (p=0.04). There were no differences in metabolite ratios between groups and no significant correlations between perfusion measures and metabolite ratios.

Conclusion: This is the first study to showthalamic 1H MRS metabolite ratios are correlated with measures of mood disorders in T1D. The high prevalence of mood disorders in pDPN and DPN have confounded previous 1H MRS studies and may explain conflicting reports in the literature. The link between neuropathy and mood disorders needs further research to understand whether both may arise from a common neurobiological pathway.

Supported by: EFSD/Novo Nordisk Programme
Disclosure: M. Greg: None.

740
Arterial baroreflex vs vascular blood pressure buffering mechanism, potential implication to treat unstable hypertension in diabetes
J. Gmitrov1,2;
1Diabetology Clinic, Krompachy Hospital, Agel SK inc., Slovakia, Krompachy, Slovakia, 2National Institute of Public Health, Tokyo, Japan.

Background and aims: A mounting evidence suggests that enhanced blood pressure (BP) variability including its most dangerous form the catecholamine-induced sudden BP elevation is a major, independent cardiovascular (CV) risk factor especially in the condition of distorted CV autonomic regulation in diabetes. The goal was to compare the effect of the carotid baroreceptor (CB) magnetic stimulation with verapamil, a potent vascular calcium channel blocking agent, effect on sudden, high BP elevation in conjunction with arterial baroreflex sensitivity (BRS) and microvascular dilation, aimed to explain their relationship and potential implementation in diabetic BP regulatory dysfunction.

Materials and methods: Forty-four experiments were performed on conscious rabbits (20 with verapamil, 14 with SMF, and 10 control experiments) sedated using pentobarbital i.v. infusion (5 mg kg⁻¹ h⁻¹). Mean femoral artery BP (MAP), heart rate, BRS and ear lobe skin microcirculation were simultaneously measured after a 40 min CB exposure to 350 mT SMF, generated by Nd₂-Fe₁₄-B alloy magnets, or after 30 min of verapamil-induced i.v. infusion (20 µg kg⁻¹ h⁻¹). BRS was assessed from heart rate and MAP responses to i.v. bolus injection of nitroprusside and phenylephrine.

Results: CB magnetic stimulation significantly increased BRS (74.5%) and microcirculation (23.8%); and decreased resting MAP (-5.8%) and phenylephrine-induced MAP abrupt elevation (MAPₙ₀₋₁₉₂=-19.1%). Verapamil significantly increased microcirculation (24.87%), decreased MAP (-17.4%), BRS (~34.84%), and MAPₙ₀₋₁₉₂ (-35.7%) in significantly larger degree than after SMF exposure, Fig. 1. The decrement of the ΔMAPₙ₀₋₁₉₂ inversely correlated with verapamil-induced significant increase in microcirculation ΔMPPG (r = -0.53, p < 0.000) and with SMF-induced increase in ΔBRS (p = 0.016).

Conclusion: Verapamil-potentiated vascular BP buffering mechanism seems to be more effective than SMF baroreflex-mediated, with potential benefit in cardiovascular conditions with sudden, high BP rise. SMF-induced notable increase of microvascular dilation in response to the same dose i.v. nitroprusside, which exercises its vasodilator property as a spontaneous nitric oxide (NO) donor, indicates augmentation of the vessel sensitivity to NO dilatory effect, Fig. 1. We suggest that both, verapamil (by vascular Ca²⁺ channel blockade) and SMF (throughout...
Decrement of the vascular sympathetic drive), boosters endothelial shear stress NO-dependent BP buffering mechanism, which by enhancement of the vessel compliance impeded sudden BP rise. The elaboration of pharmacological and non-pharmacological approaches aimed to reinforce intrinsic BP regulatory mechanisms suggested to be the universal solution how to complexly adjust arterial hypertension in its array of diabetic manifestations.

Fig. 1.

Disclosure: J. Gmitrov: None.

Impact of reduced eGFR, high HbA1c, and cardiovascular disease on mortality in people with Charcot foot

J. Schoug, P. Katzman, M. Löndahl; Clinical Sciences in Lund, Lund University and Department of Endocrinology, Skåne University Hospital, Lund, Sweden.

Background and aims: Charcot foot (CF) is a potentially devastating foot complication in diabetes mellitus with underlying peripheral neuropathy. The prevalence of risk factors and comorbidities in CF and their impact on mortality have not been fully described. This study aims to review the patient cohort diagnosed with acute CF between 2006-2017 at our University Hospital pertaining to patient characteristics and comorbidities at baseline and whether mortality was affected by cardiovascular disease, renal impairment, or glycemic control.

Materials and methods: Patients with an acute episode of CF admitted between 2006-2017 were retrospectively studied using medical records. Data for diabetes type, sex, age, history of smoking, previous diagnosis of peripheral arterial disease (PAD), ischemic heart disease (IHD), cerebrovascular disease (CVD), systolic left ventricular heart failure (HFrEF; assessed by echocardiography), diabetic foot ulcer (DFU), HbA1c, eGFR (based on creatinine level using revised Lund-Malmö formula), dialysis and kidney transplantation were collected. Death within 5 and 10 years from admission was noted. Medical records were reviewed up to May 28th, 2020. Continuous data are given as median (IQR). Log Rank tests were used for survival analysis (data given as mean and SEM), and Cox regression for estimating hazard ratios. A minimum number of events per variable number of 10 was used for multivariate Cox regression analysis. In case of a limited number of events, a cardiovascular (CV) composite factor was used, combining HFrEF, IHD, CVD, and PAD at the time of referral. A two-tailed p-value < 0.05 was considered statistically significant.

Results: 158 patients, aged 61 (53-68) years, were included and followed for 75 (44-111) months. 66 patients (42%) were women and 60 patients (38%) had type 1 diabetes. Ten patients (6.3%) had a history of kidney transplantation, and eight (5.1%) were on dialysis. The 5-year mortality was 23% (36 deaths) for the entire cohort, and the 10-year mortality was 32% (50 deaths). The prevalence of risk factors, comorbidities, and their association with 10-year mortality risk are given in Table 1. Age, diabetes type, eGFR < 60 ml/min/1.73 m², and all cardiovascular diseases were associated with higher 10-year mortality. HbA1c > 70 mmol/mol was associated with higher 5-year mortality (p = 0.015), but not 10-year mortality. In a multivariate Cox regression model with age, diabetes type, eGFR, HbA1c, and cardiovascular disease composite, eGFR < 60 ml/min/1.73 m² and HbA1c > 70 mmol/mol were statistically significant predictors of 10-year mortality. Patients with reduced eGFR had a 10-year mortality risk of 55% compared to 16% in those without reduced eGFR.

Conclusion: In this Swedish cohort of people affected by acute Charcot Foot, reduced eGFR was a more prevalent and stronger predictor of increased 10-year mortality compared to high HbA1c and cardiovascular disease.

Disclosure: J. Schoug: None.
SO 63 Diversity of the diabetic kidney

742
Chronic kidney disease in a contemporary nationwide register of patients with and without type 2 diabetes
T.G. Jenssen1,2, K. Sveen3, J. Bodegård4, M. Thuresson5, K.I. Birkeland1,2;
1Dept. of Transplantation Medicine, Oslo University Hospital, Oslo, Norway, 2University of Oslo, Oslo, Norway, 3Dept. of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway, 4AstraZeneca Nordic, Oslo, Norway, 5Statisticon AB, Uppsala, Sweden.

Background and aims: Chronic kidney disease (CKD) is an important risk factor for cardiovascular disease and premature mortality regardless of diabetes. Recently, randomized controlled trials have reported beneficial effects of three different sodium glucose transporter-2 inhibitors (SGLT2-is) on progression of CKD in patients with type 2 diabetes (T2D) and those without diabetes, herein referred to as CKD with and without diabetes. We aimed to assess and compare clinical characteristics of diagnosed CKD patients with and without diabetes and the impact of diabetes in a contemporary nationwide cohort.

Materials and methods: Patients with a CKD diagnosis before the index date, 1st January 2020, were identified in the Norwegian Patient Register that covers all in- and out-patient hospital visits, and then linked with the Norwegian Prescription Database and the Cause of death register. Comorbidities were searched in all available data and drug treatment 1-year prior to index. CKD stages were derived from hospital diagnoses, covering 80% of all patients with a CKD diagnosis. Event rates during the year after index were calculated for the first of each outcome and reported as events per 100 patient-years. The following outcomes were reported: All-cause and cardiovascular death as well as inpatient hospitalization for CKD (7.1 vs 4.8), HHF (5.7 vs 3.9) and myocardial infarction, respectively. Standardized differences >10% at baseline were considered to show non negligible difference.

Results: After exclusion of patients with type 1 diabetes, we identified 100 397 patients with CKD, of which 25 589 (25%) had T2D. CKD patients with diabetes were slightly older, 72 vs 70 years, and had more prevalent atherosclerotic cardiovascular disease and heart failure than patients without diabetes (Table). During 1-year follow up, the event rates of hospital stays for CKD (7.1 vs 4.8), HHF (5.7 vs 3.9) and myocardial infarction (3.0 vs 1.7) were higher in diabetes patients, despite more prevalent use of statins (65 vs 40%) and renin angiotensin system inhibitors (62 vs 47%) compared to those without diabetes. All-cause mortality and cardiovascular mortality risks were similar in patients with and without diabetes (10.2 vs 9.8) and (3.1 vs 2.9) respectively. Only 10% of patients with CKD and type 2 diabetes used SGLT2-is.

Conclusion: One out of four patients registered with a CKD diagnosis in the Norwegian National Patient Register has type 2 diabetes. The CKD-patients with type 2 diabetes have more co-morbidities, and higher event rates, particularly for cardioenal events (HHF or CKD), than non-diabetic CKD patients. Only a minority received treatment with SGLT2-i, and there may be a potential for increased use of therapies that delay progression of renal failure.

Supported by: KIB Grant from AstraZeneca to University of Oslo
Disclosure: T.G. Jenssen: Honorarium; AstraZeneca, Boehringer Ingelheim.

743
Relationship between genetic risk scores for type 2 diabetes and kidney function and adverse diabetes outcomes
L. Pacal1, D. Galuška1, K. Chalásová1, J.A. Hubáček2, V. Lánská2, K. Kaňková2;
1Department of Pathophysiology, Masaryk University, Brno, 2Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Background and aims: Diabetic kidney disease (DKD) represents a serious diabetic complication with several risk factors contributing to its development or progression (e.g. glucose control, hypertension, dyslipidaemia). Genetic predisposition is also involved, however it is still insufficiently explored. Number of genome-wide association studies (GWAS) identified single nucleotide polymorphisms (SNP) associated type 2 diabetes (T2DM) and also with the kidney function. We selected 21 risk SNPs for T2DM and 9 SNPs associated with kidney function and/or chronic kidney disease and constructed genetic risk scores (GRS). The aim of the work was to find out whether GRS or individual SNPs might predict the progression of DKD or cardiovascular morbidity and mortality in patients with T2DM in the Czech population.

Materials and methods: A total of 400 patients (205 men and 195 women) with T2DM and variable stage of DKD were included with subsequent follow-up for a median of 54.6 (IQR 27.8 - 91) months. Time-to-event analysis considered three end-points: 1. DKD progression (based on GFR), 2. major adverse cardiovascular events (MACE) and 3. all-cause mortality (ACM). DNA was isolated from peripheral blood. 21 T2DM risk SNPs and 9 SNPs associated with kidney function and/or chronic kidney disease were selected for this study. SNPs were determined by quantitative PCR (TaqMan® Genotyping Assay).

Results: At the end of the follow-up period, the cumulative incidence was 49.5 %, 21.5 % and 41.5 % for DKD, MACE and ACM, respectively. We calculated weighted and unweighted GRS for T2DM risk alleles and unweighted GRS for kidney function. Unweighted GRS was calculated by summing-up the number of risk alleles. Weighted GRS considered OR of individual SNPs. First, we analysed the potential correlation between GRS and age, T2DM duration, HbA1c, creatinine and GFR. No statistically significant differences were ascertained (all P > 0.05, Spearman). For further analyses patients were stratified by median and quartiles into two and four groups, respectively. Time-to-event analysis using Kaplan-Mayer curves did not show any statistically significant differences

S383
between two or four groups, respectively (P>0.05). Two variants (WSF1 and MTNR1B) were associated with the risk of DKD (P=0.004 and 0.04). WSF1 was associated with MACE (P=0.01) and CDKN2A/B with ACM (P=0.03). Of the variants associated with kidney function CANCAS1 represents a risk for ACM (P=0.04).

Conclusion: The aim of this work was to determine the predictive power of GRS composed of selected SNPs associated with the presence of T2DM and with kidney function in patients with T2DM. The results suggest that GRS does not predict DKD, MACE or ACM in our cohort. Only several SNPs seem to have a minor effect.

Supported by: Grant from Guys and st. Thomas Hospital Charity

Disclosure: S.A.M. Ayis: None.

745

The inflection point of the estimated glomerular filtration rate is higher in people with an increasing to decreasing trend than in people with different trends

S. Katoh1, K. Yokoyamaa, M. Zeniya1, Y. Sakamoto4, K. Utsunomiya1, R. Nishimura1

1Div. of Diabetes, Metabolism & Endocrinology, The Jikei University School of Medicine, 2Harumi Triton Clinic, The Jikei University School of Medicine, 3Sanno Medical Clinic, 4The Jikei University School of Medicine, Tokyo, Japan.

Background and aims: Last year, we showed that baseline hyperfiltration in the estimated glomerular filtration rate calculated from serum creatinine (eGFR) is dominantly associated with a subsequent decline in eGFR. This year, we compared the inflection point of the eGFR among groups of people with different trends.

Materials and methods: This retrospective study comprised 4 periods: from April 2005 to September 2006, from April 2009 to September 2010, from April 2013 to September 2014, and from April 2017 to September 2018. The study involved 4258 people (2843 men and 1415 women; mean age, 49 years) who underwent comprehensive medical check-ups in 3 of the 4 periods for 3-point data analysis. They were assigned to either a Period I-II-III group or a Period II-III-IV group with a midpoint examination in Periods II and III, respectively. We assessed the trends in the ΔeGFR—increasing (Inc) or decreasing (Dec)—from baseline to midpoint and from midpoint to endpoint. Participants were thereby allocated into Inc-Inc, Inc-Dec, Dec-Dec, or Dec-Inc groups in accordance with the ΔeGFR.

Results: There were 34,779 person-years of observation, and the mean observation period was 8.2 years. The baseline eGFR, midpoint eGFR, endpoint eGFR, ΔeGFR from baseline to midpoint, and ΔeGFR from midpoint to endpoint were not significantly different between diabetic (n = 480) and non-diabetic (n = 3778) people. The midpoint eGFR of the Inc-Dec group (79±14 ml/min/1.73 m^2, n=767) was significantly higher (Bonferroni correction) than that of the Inc-Inc group (75±14 ml/min/1.73 m^2, n=330, p<0.001), Dec-Dec group (73±13 ml/min/1.73 m^2, n=1401, p<0.001), and Dec-Inc group (69±11 ml/min/1.73 m^2, n=1760, p<0.001). In receiver operating characteristic curve (ROC) analysis of the entire sample, the threshold of the midpoint eGFR between the Inc-Inc and Inc-Dec groups was 75.5 ml/min/1.73 m^2 (sensitivity 0.57, specificity 0.54, AUC 0.571, p<0.001). The midpoint eGFR was not significantly different between diabetic and non-diabetic people in the 4 trend groups. Nevertheless, in people with diabetes, the midpoint eGFR was not significantly higher in the Inc-Dec group (81±16 ml/min/1.73 m^2, n=83) than in the Inc-Inc group (77±15 ml/min/1.73 m^2, n=39, p=0.139). Regression analysis in the Inc-Dec group revealed that the presence of diabetes was significantly associated (standardized β (Sβ) = 0.143, p<0.001) with the midpoint eGFR as well as midpoint ALT (U/L) (Sβ = 0.180, p = 0.004), smoking index (cigarettes per day × years of smoking) (Sβ = 0.076, p = 0.023), age (Sβ = -0.407, p<0.001), uric acid (mg/dL) (Sβ = -0.210, p<0.001), BMI (kg/m^2) (Sβ = -0.157, p = 0.028), exercise habit (min/week) (Sβ = -0.069, p = 0.034), while female sex, systolic blood pressure,
Association of microvascular complications with death in patients with diabetes and COVID-19: international effort -CORONADO, ABCD-COVID19, AMERICADO studies

S. Hadjadi1, P.-J. Saulnier2, Y. Ruan3, X. Zhu1, R. Rea4, P. Gourdy6, B. Cariou4, A. Myers8, K. Huntas2, for the CORONADO, the ABCD COVID-19 diabetes national audit and AMERICADO investigators; 1UMR 1087, L’institut du thorax, Université de Nantes, CHU Nantes, CNRS, Inserm, Nantes, France, 2Centre d’Investigation Clinique CIC 1402, Université de Poitiers, Inserm, CHU de Poitiers, Poitiers, France, 3Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, 4Oxford NIHR Biomedical Research Centre, Oxford, UK, 5Institute of Health System Science, Feinstein Institutes for Medical Research, Manhasset, USA, 6CHU de Toulouse & UMR1048/12MC, Université de Toulouse, Toulouse, France, 7L’Institut du thorax, Université de Nantes, CHU Nantes, CNRS, Inserm, Nantes, France, 8Department of Medicine, Division of Endocrinology, Northwell Health, Manhasset, USA, 9University Hospitals of Leicester NHS Trust, Diabetes Research Centre, Leicester General Hospital, Leicester, UK.

Background and aims: The prognostic role of microvascular complications for all-cause death in patients with diabetes hospitalized for coronavirus disease-2019 (COVID-19) has been suggested. However, no detailed analysis of the microvascular burden in these patients is available so far.

Materials and methods: We analyzed data from the French CORONADO initiative and the United Kingdom ABCD Covid-19 audit, two nationwide multicenter studies, and the AMERICADO, a multicenter study in New York area. We assessed the association between the risk of in-hospital death and microvascular complications, in patients with diabetes hospitalized for COVID-19: diabetic retinopathy, presence/absence and/or diabetic kidney disease, and/or history of diabetic foot ulcer.

Results: Among 2951 CORONADO, 3387 ABCD Covid-19 audit and 9327 AMERICADO patients, the status for microvascular diabetic complications was ascertained for 1314 (44.5%), 1809 (53.4%) and 7367 (79.0%) patients: 1010, 1059 and 1800 with ≥1 severe microvascular complication(s) and 304, 750 and 5567 participants free of any complications, respectively. Focusing on patients with DR, after adjustment for age, sex, hypertension and cardiovascular disease, patients with specific microvascular complications had an increased risk of death in the CORONADO, the ABCD COVID-19 diabetes national audit and the AMERICADO participants: adjOR: 2.78 (2.60-2.97), adjOR: 1.25 (1.03-1.52) and adjOR: 1.21 (1.07-1.37), respectively. When meta-analyzing the 3 studies, compared to those patients free of complication, those with specific microvascular complications had an OR for death of 2.03 (1.41-2.92) which decreased to 1.51 (1.08-2.11) after adjustment for age, sex, hypertension and cardiovascular disease.

Conclusion: Microvascular burden is associated with an increased risk of death in patients hospitalized for COVID-19.

Clinical Trial Registration Number: NCT04324736

Supported by: FFRD, SFd, DGOS, CORONADO emergency grant, Novonordisk

Glucose and c-peptide peak times are associated with chronic complications in patients with type 2 diabetes

Y.Q. Jiang1, X.L. Wang1, X.Q. Zhao1, Y. Sun1, P. Huang1, S.H. Ji1, R.Y. Hu1, Y.J. Gu1,2;
1Department of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, 2Department of health medicine, Health and disease management center, Affiliated Hospital of Nantong University, Nantong, China.

Background and aims: To assess the association of chronic complications in patients with type 2 diabetes mellitus (T2DM) with the peak time of glucose and C-peptide (C-p) during the standard steamed bread meal test.

Materials and methods: A total of 1,095 patients with T2DM were divided into two groups: (1) peak time of glucose: Group G1: ≤60 minutes (n=84), Group G2: >60 minutes and ≤120 minutes (n=648), and Group G3: >120 minutes (n=363); (2) peak time of C-p: Group C1: ≤60 minutes (n=14), Group C2: >60 minutes and ≤120 minutes (n=350), and Group C3: >120 minutes (n=731). Anthropometric and biochemical metabolic parameters, B-cell function and indicators of chronic T2DM complications were compared.

Results: Among patients with delayed glucose peak time, urine albumin-creatinine ratio (UACR) and those with diabetic retinopathy (DR) increased (all P<0.05), while fasting and 120-minute C-p, the area under the curve for C-p (AUC C-p), insulinogenic index and modified B-cell function index decreased (all P<0.05). Meanwhile, in patients with delayed C-p peak time, UACR and those with DR increased (all P<0.05), whereas C-p index and AUC C-p/AUC for glucose decreased (all P<0.05). On multimodal logistic regression analysis, age and the proportion of patients with DR correlated with delayed glucose and C-p peak time; however, estimated glomerular filtration rate and UACR were correlated with delayed C-p peak time (all P<0.05).

Conclusion: Indicators of diabetic nephropathy were related to delayed C-p peak time while DR was related to both delayed glucose and C-p peak time. Delayed glucose and C-p peak time in patients with T2DM could be early predictors for diabetic microvascular disease.

Kidney biopsy in patients with diabetes and nephrotic range-proteinuria; clinical value and correlation with clinical and laboratory findings

T. Stratigou1, E. Kardalas1, A. Paikopoulou2, D.A. Vassiliadi1, G. Ioannidis1, C. Christodoulidou2, S. Tsagarakis1;
1Endocrinology, Diabetes and Metabolism Department, Evangelismos General Hospital, 2Nephrology Department, Evangelismos General Hospital, Athens, Greece.

Disclosure: Y.Q. Jiang: None.

Kidney biopsy in patients with diabetes mellitus and nephrotic range-proteinuria; clinical value and correlation with clinical and laboratory findings

T. Stratigou1, E. Kardalas1, A. Paikopoulou2, D.A. Vassiliadi1, G. Ioannidis1, C. Christodoulidou2, S. Tsagarakis1;
1Endocrinology, Diabetes and Metabolism Department, Evangelismos General Hospital, 2Nephrology Department, Evangelismos General Hospital, Athens, Greece.

Disclosure: T. Stratigou: None.
SO 64 New treatment avenues for the diabetic kidney

750
Albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes: a randomised cross-over clinical trial
A.B. van der Aart-van der Beek1,2, E. Apperloo3, N. Jongs3, D.B. Rouw2, D. Sjöström4, D.H. van Raalte5, K. Hoogenberg2, H.J.L. Heerspink1
1University of Groningen, Groningen, Netherlands, 2Martini Hospital, Groningen, Netherlands, 3Isala Hospital, Groningen, Netherlands, 4AstraZeneca, Gothenburg, Sweden, 5Amsterdam UMC, Amsterdam, Netherlands.

Background and aims: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors and glucagon-like peptide receptor agonists (GLP1-RA) reduce albuminuria in people with type 2 diabetes (T2D). It is unknown whether the combination of both drug classes confers a more beneficial effect than either treatment alone. We conducted a prospective clinical trial to determine the albuminuria lowering effect of the GLP1-RA exenatide (EXE), SGLT-2 inhibitor dapagliflozin (DAPA) and their combination (COMB) in patients with T2D and albuminuria.

Materials and methods: Patients with T2D, eGFR > 30 ml/min/1.73m² and urinary albumin:creatinine ratio (UACR) >3.5mg/mmol and ≤100 mg/mmol were randomly assigned to treatment regimen consisting of three 6-week treatment periods in which DAPA 10 mg/day, EXE 2 mg/week and COMB were given in random order. Primary outcome was change in UACR from baseline. Secondary outcomes were correlation between changes in UACR during each treatment period and changes from baseline in Hba1c, body weight (BW), blood pressure (BP) and eGFR. Generalized linear mixed effects models were used to determine change from baseline in primary and secondary outcomes.

Results: Between January 2019 and April 2021 we screened 24 participants of whom 20 were randomized. Median UACR at baseline was 15.4 mg/mmol (IQR 9.4-44.6); mean eGFR 60 ml/min/1.73m² (SD 18.8) and pants of whom 20 were randomized. Median UACR at baseline was 15.4

Conclusion: This study suggests that COMB has modestly larger effects in various cardiovascular and renal risk factors as compared to DAPA or EXE alone. A larger study is required to assess whether this translates into improved clinical outcomes.

Clinical Trial Registration Number: NL6662 (NTR6839)
Disclosure: A.B. van der Aart-van der Beek: None.

SO 66 New treatment avenues for the diabetic kidney

751
Design of the COMBination Effect of Finerenone anD EmpagliflozIN in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE)
1Duke University School of Medicine and Duke Clinical Research Institute, Durham, USA, 2University of North Carolina Kidney Center, UNC School of Medicine, Chapel Hill, USA, 3University of Chicago Medicine, Chicago, USA, 4Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, Netherlands, 5KfH Kidney Center, Munich, Germany, 6Division of Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis, School of Medicine, St. Louis, USA, 7The University of Tokyo Graduate School of Medicine, Tokyo, Japan, 8Steno Diabetes Center Copenhagen, Gentofte, Denmark, 9Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, 10Data Science and Analytics, Bayer PLC, Reading, UK, 11Medical Affairs & Pharmacovigilance, Pharmaceuticals, Bayer AG, Berlin, Germany, 12Richard L. Roudebush VA Medical Center and Indiana University, Indianapolis, USA.

Background and aims: Despite available interventions, people with type 2 diabetes (T2D) remain at risk of chronic kidney disease (CKD). Finerenone, a potent and selective nonsteroidal mineralocorticoid receptor antagonist, and sodium-glucose co-transporter 2 inhibitors (SGLT2is) may reduce both kidney and cardiovascular risks in people with CKD and T2D. It is unknown whether dual therapy with finerenone and a SGLT2i is superior to either agent alone. We outline the design of a study addressing this clinical question.

Materials and methods: The CONFIDENCE study is a randomised, controlled, double-blind, double-dummy, international, multicentre, three-armed, parallel-group, phase II study of 8 months’ duration in approximately 807 adults with CKD and T2D, a urinary albumin-to-creatinine ratio (UACR) of ≥300-<5000 mg/g and an estimated glomerular filtration rate of 30-90 ml/min/1.73 m² (Figure). The primary objective is to demonstrate that dual therapy comprising finerenone and the SGLT2i empagliflozin is superior for reducing the UACR compared with either monotherapy.

Results: The primary outcome is the relative change from baseline in UACR to 180 days. Secondary outcomes will further characterise the efficacy and safety of dual therapy including reduction in UACR >30% from baseline at 180 days, incidence of hyperkalaemia and acute kidney injury and the assessment of initial and longer-term changes in eGFR.

Table. Change in primary and secondary outcomes from baseline to week 6 within each treatment period. Data are given as mean (standard error) unless stated otherwise.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Dapagliflozin</th>
<th>Exenatide</th>
<th>Dapagliflozin + Exenatide</th>
</tr>
</thead>
<tbody>
<tr>
<td>UACR, mg/mmol</td>
<td>-4 (2.9)</td>
<td>-4 (2.9)</td>
<td>-2 (2.5)</td>
</tr>
<tr>
<td>eGFR, ml/min/1.73m²</td>
<td>-8 (2.3)</td>
<td>-3 (1.9)</td>
<td>-8 (2.2)</td>
</tr>
<tr>
<td>BP, mmHg</td>
<td>-5 (10)</td>
<td>-10 (15)</td>
<td>-10 (15)</td>
</tr>
<tr>
<td>BW, kg</td>
<td>-1.5 (0.5)</td>
<td>-3.5 (1.0)</td>
<td>-3.5 (1.0)</td>
</tr>
</tbody>
</table>

Clinical Trial Registration Number: NL6662 (NTR6839)
Considering drop-out and screen-failure rates, 269 participants per arm will provide 80% power to reject the null hypothesis of equal means for dual therapy versus either monotherapy.

**Conclusion:** The CONFIDENCE study will evaluate the additive efficacy, safety and tolerability of finerenone plus a SGLT2i in adults with CKD and T2D. Should an additive effect be shown, early and efficient intervention with dual finerenone and SGLT2i therapy could slow disease progression and provide long-term benefits for people with CKD and T2D.

**Results:** There was substantial between person variation in the best performing drug: telmisartan was best performing in 33 (52%) participants, followed by empagliflozin and linagliptin in 11 (17%) participants each, and baricitinib in 8 (13%) participants. The individual best performing drug changed UACR during the first exposure by -39.6% (95% CI -44.8, -33.8, p<0.001) and by -22.4% (95% CI -29.7, -12.5, p<0.001) at re-exposure (between exposure difference: 22.1% [95% CI 12.5, 30.8; p<0.001]). The difference in UACR response between the individual best performing drug and the other three drugs was -40.5% (95% CI -45.9, -34.6, p<0.001 vs. between exposure difference). The correlation in UACR response of the best performing drug at exposure and re-exposure was r=0.389, p=0.017.

**Conclusion:** We demonstrated a large and reproducible variation in UACR lowering responses to different drug classes reinforcing the need for personalized therapy approaches to overcome therapy resistance to guideline recommended treatment.

**Clinical Trial Registration Number:** NTR5602 and NTR5602

**Disclosure:** V. Rotbain Curovic: None.

---

**752**

Optimisation of albuminuria lowering treatment by cross-over rotation to four different drug classes

V. Rotbain Curovic1, M.Y.A. Kroonen2, N. Jongs2, E.H. Zobel1, T.W. Hansen1, G.D. Laverman1, A. Kooy3, F. Persson1, P. Rossing1, H.J.L. Heerspink2

1Steno Diabetes Center Copenhagen, Herlev, Denmark; 2Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, Netherlands; 3ZiekenhuisGroep Twente, Almelo, Netherlands; 4Bethesda Diabetes Research Center, Hoogeveen, Netherlands.

**Background and aims:** Renin-angiotensin system (RAS) inhibitors decrease urinary albumin:creatinine ratio (UACR) and are guideline recommended drugs for kidney protection but are ineffective in lowering UACR in up to 40% of cases. We hypothesized that rotation to another drug class overcomes resistance to RAS inhibition and tested this hypothesis in a randomized cross-over trial.

**Materials and methods:** We assigned 26 adults with type 1 diabetes and 37 with type 2 diabetes and UACR ≥30 and ≤500 mg/g to 4-week treatment periods with telmisartan 80 mg, empagliflozin 10 mg, linagliptin 5 mg, and baricitinib 2 mg in random order, separated by 4-week wash-out periods. Participants were then re-exposed for 4-weeks to the individual drug that induced the largest UACR reduction. Primary outcome was the difference in UACR response between the first and second exposure to the best performing drug, versus the difference in UACR response between the best performing drug and the other three drugs.

**Results:** Intent- to- treat (n=18600) and PP (n=18166) analysis for treatment completers during the 12 Week observation period for HbA1c, FPG, PPBG and proteinuria variables receiving metformin (1000 mg/d) at background therapy was carried out. Baseline demographics included Age (55.0 ± 9.8 y); BMI (30.1 ± 20.1 kg/m²); Hypertension (n=12048, 66.3%); Dyslipidemia (n=8505, 45.6%); Stroke/TIA (n=3505, 19.3%); Chronic Heart Failure (n=1113, 6.1%); Myocardial infarction (n=742, 4.1%); CKD (n=18166). After 12 week of treatment, the mean change in HbA1c for Dapagliflozin combination therapy was -1.35 ± 1.1% (p<0.001); -1.32 ± 0.9% (p<0.001); -1.19 ± 1.0% (p<0.001); -1.36 ± 1.1% (p<0.001) in overall, Patients with >2 risk factors (RF), microalbuminuria (<300 mg/g) and macroalbuminuria (> 300 mg/g) group respectively. After 12 week of treatment, the mean change in HbA1c for Dapagliflozin combination therapy was -1.35 ± 1.1% (p<0.001); -1.32 ± 0.9% (p<0.001); -1.19 ± 1.0% (p<0.001); -1.36 ± 1.1% (p<0.001) in overall, Patients with >2 risk factors (RF), microalbuminuria (<300 mg/g) and macroalbuminuria (> 300 mg/g) group respectively. After 12 week of treatment, the mean change in HbA1c for Dapagliflozin combination therapy was -1.35 ± 1.1% (p<0.001); -1.32 ± 0.9% (p<0.001); -1.19 ± 1.0% (p<0.001); -1.36 ± 1.1% (p<0.001) in overall, Patients with >2 risk factors (RF), microalbuminuria (<300 mg/g) and macroalbuminuria (> 300 mg/g) group respectively. After 12 week of treatment, the mean change in HbA1c for Dapagliflozin combination therapy was -1.35 ± 1.1% (p<0.001); -1.32 ± 0.9% (p<0.001); -1.19 ± 1.0% (p<0.001); -1.36 ± 1.1% (p<0.001) in overall, Patients with >2 risk factors (RF), microalbuminuria (<300 mg/g) and macroalbuminuria (> 300 mg/g) group respectively.

**Conclusion:** We demonstrated a large and reproducible variation in each, and baricitinib in 8 (13%) participants. The individual best performing drug changed UACR during the first exposure by -39.6% (95% CI -44.8, -33.8, p<0.001) and by -22.4% (95% CI -29.7, -12.5, p<0.001) at re-exposure (between exposure difference: 22.1% [95% CI 12.5, 30.8; p<0.001]). The difference in UACR response between the individual best performing drug and the other three drugs was -40.5% (95% CI -45.9, -34.6, p<0.001 vs. between exposure difference). The correlation in UACR response of the best performing drug at exposure and re-exposure was r=0.389, p=0.017.

**Conclusion:** We demonstrated a large and reproducible variation in UACR lowering responses to different drug classes reinforcing the need for personalized therapy approaches to overcome therapy resistance to guideline recommended treatment.

Clinical Trial Registration Number: NTR5602 and NTR5602

Disclosure: None.
treatment modification or withdrawal of Dapagliflozin 10 mg. There were no other SAEs.

**Conclusion:** In patients with DKD, Dapagliflozin shows significant improvement in HbA1c, FPG and PPBG. These improvements were consistent in subgroup analysis of high-risk Indian DKD cases with metabolic traits, obesity or albuminuria.

**Disclosure:** C. Wetzel: None.

---

**754**

**Anserine is a H2S releasing molecule and therefore a therapeutic agent in diabetic nephropathy**

C. Wetzel1, T. Pfeffer1, J. Zemva2, R. Bulkescher2, K. Klingbeil1, C.P. Schmitt1, V. Peters1;

1Centre for Paediatric and Adolescent Medicine, University of Heidelberg, 2Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany.

**Background and aims:** Inflammation and oxidative stress are tightly linked and are emerging as key factors in diabetic nephropathy. Hydrogen sulfide (H2S), a gaseous signalling molecule, and anserine, a dipeptide, have several cytoprotective properties. Understanding the interrelation may lead to new therapeutic interventions. We therefore studied a putative interaction between renal anserine and H2S metabolism in mice with increased anserine concentration via Carnosinase 1 knockout (Cndp1-KO) under diabetic conditions.

**Materials and methods:** Diabetes mellitus type 1 was induced by Streptozotocin (STZ) in Wildtype (WT) and Cndp1-KO mice. Diabetic mice were treated with insulin and sacrificed after 12 weeks of diabetes (23-25 weeks old). Maximal H2S synthesis capacity was measured in vitro in human proximal tubular cells (HK2), primary human umbilical artery and vein endothelial cells (HUAEC, HUVEC), in WT and for shock protein 70 knockout (Hsp70-KO) immortalized murine cardiac endothelial cells (MCEC) and ex vivo in murine renal tissue lysate. For H2S detection a colorimetric assay was used. Anserine concentration was determined via HPLC.

**Results:** In HK2 cells, addition of anserine dose-dependently increased H2S formation (p<0.0001). Incubation with 1 mM anserine increased H2S formation by 1.5-fold in HK2, HUAEC and HUVEC (p<0.0001; p≤0.0001; p≤0.0001) and by 1.3-fold in MCEC (p≤0.0001) compared to untreated cells. In Hsp70-KO MCEC, H2S formation was 60% lower compared to MCEC WT cells (p≤0.001), incubation with anserine had no effect on H2S formation (all p=n.s.). In WT mice, renal H2S formation was independent on gender (p=n.s.). In Cndp1-KO mice, renal anserine concentration was 5-fold increased in females (3.872 ± 0.7719 nmol/mg protein, p≤0.001) and by 30% in male (1.453 ± 0.2907 nmol/mg protein, p=n.s.) compared to non-diabetic Cndp1-KO mice, but was still 2.5-fold higher in female and 1.9-fold higher in male compared to WT mice (p=n.s.). In diabetic Cndp1-KO mice, renal anserine concentration was reduced by 50% in female (1.67 ± 0.7719 nmol/mg protein, p≤0.05) and by 30% in male (1.453 ± 0.2907 nmol/mg protein, p=n.s.) compared to non-diabetic Cndp1-KO mice, but was still 2.5-fold higher in female and 1.9-fold higher in male compared to WT mice (p=n.s.). In diabetic Cndp1-KO mice, reduced H2S formation correlated with decreased anserine concentration (r=0.6519). In renal tissue lysate of female Hsp70-KO mice, H2S formation was halved (p≤0.0001) in comparison to WT.

**Conclusion:** We provide evidence that anserine is a H2S-releasing molecule, in part Hsp70-dependent, and underline its potential role as a promising therapeutic agent in diabetic nephropathy.

**Supported by:** DFG, SFB1118

**Disclosure:** C. Wetzel: None.

---

**755**

**Therapeutic blocking of NPRC, a podocyte - expressed target, is kidney protective in diabetic nephropathy**

D. Babaghi1, E. Charrin1, M. La2, J. Patrakka1;

1Laboratory Medicine, Karolinska Institutet, Stockholm, 2Bioscience Renal, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca, Gothenburg, Sweden.

**Background and aims:** Renal glomerulus is the main target of injury in diabetic nephropathy (DN). Especially, terminally differentiated glomerular podocyte cells play a key role in the progression of DN. Molecular mechanisms of DN-associated glomerulopathy are poorly understood. Natriuretic peptide (NP) system is a key player in the regulation of blood pressure. NP-system has three receptors: NP-receptors A and B (NPRA/B) activate guanyl cyclase to generate key secondary messenger cGMP, whereas NP-receptor C (NPRC) acts as a clearance receptor. Mouse studies have shown that local NP-signalling in the glomerulus is important for the maintenance of renal homeostasis. In patients with DN, transcriptomics studies have shown down-regulation of NPRA and NPRC in the glomerulus. In this study, we aimed to elucidate the role of NPRC in the pathogenesis of glomerulopathies and explore whether glomerular NP-signalling could be a novel therapeutic target for DN.

**Materials and methods:** Expression of NPRC was studied using qPCR and immunohistochemistry. The functional role of NPRC was analysed using a novel mouse line in which NPRC was inactivated specifically in podocytes (NPRCKO-podokO). NPRC was targeted pharmacologically using a NPRC blocking peptide in a rat model of DN (uninephrectomized obese ZSF-1 rats (UNx ZSF-1 rats)), followed by studies in a mouse glomerulopathy model.

**Results:** NPRC was highly expressed by glomerular podocyte cells. NPRC-KO mice showed normal kidney morphology and function, and NPRC-deficiency did not affect the outcome of mouse glomerulopathy model. In diabetic UNx ZSF-1 rats, pharmaceutical targeting with NPRC-antagonist resulted in an increased urinary and plasma cGMP levels, indicating successful target engagement. Histological evaluation of diabetic rats treated only with the antagonist showed an unsignificant trend towards reduced glomerular damage. However, when NPRC blocking was combined with losartan (angiotensin receptor blocker), it potentiated significantly the ameliorative effects on albuminuria and glomerular sclerosis. In line with this, the NPRC-antagonist showed renoprotective effects in a mouse glomerulopathy model as shown by decreased glomerulosclerosis and reduced podocyte loss.
Conclusion: NPRC is highly expressed by renal podocyte cells and its pharmaceutical targeting seems to mediate renoprotective effects in DN. More studies are clearly needed to understand molecular mechanisms of NP-signalling in the glomerulus and to explore whether chronic NPRC inhibition can be a suitable modality to treat DN.

Supported by: AstraZeneca, SSMF, Diabetesfonden

Disclosure: D. Dabaghie: Grants; AstraZeneca, SSMF, Diabetesfonden

756

Effect of dapagliflozin on arterial stiffness and biomarkers of arterial ageing in people with type 2 diabetes and kidney disease


Background and aims: Sodium glucose co-transporter 2 (SGLT-2) inhibitors have demonstrated renal benefits in people with type 2 diabetes (T2DM). The exact mechanisms that explain these impressive results remain unclear. Arterial stiffness as measured by aortic pulse wave velocity (Ao-PWV) is an index of arterial ageing and independent predictor of cardio-renal outcomes. The effect of SGLT-2 inhibitors on Ao-PWV and other markers of arterial ageing remains to be defined.

Materials and methods: We performed a 24-week single center randomized controlled trial comparing dapagliflozin and ramipril (D + R) versus ramipril only (R) on markers of arterial ageing in people with T2DM with residual microalbuminuria despite maximum tolerated renin angiotensin system (RAS) inhibition. All participants had estimated glomerular filtration rate >60 ml/min. The study was powered for the primary endpoint of change in urine albumin excretion rate (AER). Secondary endpoints included Ao-PWV (by applanation tonometry), central aortic blood pressure, mediators of the RAS (plasma renin activity, aldosterone, ACE-2 and Angiotensin 1-7/1-9 levels) and bio-markers of arterial ageing [soluble Klotho (sKlotho) and fibroblast growth factor 23 (FGF-23)].

Results: In total, 33 participants (male 72.7%) mean age of 58 years (range 42 to 75 years) were randomized to Dapagliflozin and Ramipril (D+R n=17) or Ramipril (R n=16). After 24 weeks of treatment, AER fell significantly [mean (95% confidence interval)] only in D + R by 43.5% (-57.36% to 29.56%) (p value: <0.01) as compared to 5% (-48.3% to 38.5%) (p value: 0.36) in R. However, Ao-PWV (mean ±SD) did not change significantly from baseline after 24 weeks treatment [D + R 9.06 ±1.91 to 9.13 ±2.03 vs R 9.88 ±2.12 to 10.0 ±1.84]. Similarly, we do not observe any significant changes in central aortic blood pressure, augmentation index, sKlotho or FGF-23. HbA1c fell significantly only in D + R arm, while a modest but significant fall in Angiotensin 1-7 was also noted.

Conclusion: The combination of Dapagliflozin and Ramipril for 24 weeks significantly reduces albuminuria, but did not impact on Ao-PWV or other mediators/bio-markers of arterial ageing. Our data suggest that the early cardio-renal benefits of SGLT-2 inhibitors in people with T2DM are unlikely to be related to improvement in arterial ageing.

Clinical Trial Registration Number: 2013-004042-42

Supported by: AZ

Disclosure: D. Stathi: None.
SO 65 Translating signals in the diabetic kidney

Reduced mitochondrial DNA copy number (mtDNA-CN) in type 1 diabetes and kidney damage and correlates thereof and mtDNA-CN changes over time

Background and aims: Mitochondrial DNA (mtDNA) copy number (mtDNA-CN), reflecting the amount of mt vs. nuclear DNA in a cell, is a potential marker / mediator of diabetic kidney disease (DKD). Most studies are in Type 2 diabetes. We determined mtDNA-CN in Type 1 diabetes (T1D) and non-diabetic (CON) adults and associations with T1D complications and risk factors.

Materials and methods: In a cross-sectional study mtDNA-CN was measured in T1D and CON subjects and in a T1D subset was measured at ≥2 time-points. mtDNA-CN was quantified by RT-PCR (ScienCell, Carlsbad, CA) and DNA isolated (Qiagen, Hilden, Germany) from whole venous blood (EDTA) from fasted adults: 178 T1D and 132 CON. C-peptide was measured by ELISA (Merodia, Uppsala, Sweden), with lower limit of detection 1.25 pM (0.0038 ng/mL). Metabolic syndrome (MS) was defined as in exosomes. The urinary cell has higher nucleic acid content and is relatively unaffected by humoral metabolic factors than supernatant urine. Exosomes are extracellular vesicles that are involved in cell-to-cell communication and act as cargo for the transport of proteins and nucleic acids. In animal models with diabetes and kidney disease, there is dysregulation of several lncRNA. This has not been explored in humans with biopsy-proven kidney disease in T2 DM. Aims: To determine the expression of lncRNA from urine to evaluate if this could be used as non-invasive markers to differentiate DKD from NDKD.

Results: Using a discovery cohort of 178 T1D and 132 CON, MALAT1 had a specificity of 86% and 93% sensitivity to diagnose DKD. Using a second cohort. Using a discovery cohort of 178 T1D and 132 CON, MALAT1 had a specificity of 86% and 93% sensitivity to diagnose DKD. Using a second cohort. Using a discovery cohort of 178 T1D and 132 CON, MALAT1 had a specificity of 86% and 93% sensitivity to diagnose DKD. Using a second cohort. Using a discovery cohort of 178 T1D and 132 CON, MALAT1 had a specificity of 86% and 93% sensitivity to diagnose DKD. Using a second cohort.
Background and aims: Exogenous carnosine and anserine mitigate diabetic nephropathy (DN) in rodents. The underlying mechanism, i.e., direct renal protective action versus systemic effects remains unclear. The effect of increased renal carnosine/anserine concentrations in Carnosinasine 1 KO (Cndp1-KO) mice under diabetic conditions was analysed in this study.

Materials and methods: Type 1 diabetes mellitus was established in Cndp1-KO and B6 WT mice by Streptozotocin (STZ) with high fat (HFD) and normal diet (ND). Mice were treated for 32 weeks with insulin; body mass (BM), energy and liquid intake, blood sugar, urinary albumin-creatinine ratio (ACR) were monthly assessed; at sacrifice kidneys were harvested for histopathology and molecular studies.

Results: Renal carnosine concentration was increased 9-fold and renal anserine concentration was increased 5-fold in Cndp1-KO compared to WT mice. Under diabetic conditions (STZ), carnosine and anserine concentrations were reduced, but still both 2.9-fold higher in Cndp1-KO. In Cndp1-KO mice, HFD increased renal carnosine and anserine concentration by 3.6- and 2.2-fold compared to Cndp1-KO mice under ND (p=0.002/p=0.04). In diabetic Cndp1-KO, HFD led to a less pronounced decrease of carnosine and anserine (21/48%) compared to diabetic Cndp1-KO mice under ND. Carnosine-synthase protein expression was not altered between WT and Cndp1-KO mice, independent of the diet. Oxidative stress (4-HNE) was reduced in diabetic Cndp1-KO mice (STZ and STZ+HFD) compared to the respective WT controls (50/86%, p=0.005/p=0.01). Interstitial fibrosis was reduced in STZ+HFD Cndp1-KO vs. WT (40%, p=0.01), thus not altered under ND and STZ, while Tgf-β mRNA, phospho-SMAD2/3 and TSP-1 protein expression were unchanged. Mesangial expansion was increased in Cndp1-KO vs WT by 25% (p=0.009). Renal vessel/lumen ratio, a marker of vasculopathy, was unaltered in all groups. Body mass, energy/liquid intake, glucose homeostasis, insulin-need/BM and organ weight or ACR were not different between any of the studied groups.

Conclusion: Increased renal anserine/carnosine concentrations reduced renal oxidative stress and interstitial fibrosis, but did not alter glucose metabolism.

Supported by: DFG, SFB1118
Disclosure: T. Pfeffer: None.

761
Association between plasma hypoxanthine and diabetic kidney disease (DKD) in a Japanese population
M. Yamamoto1, S. Harada2, T. Okamura2, K. Fujihara1, S. Kodama1, T. Yamada1, H. Sone1, T. Takebayashi3
1Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, 2Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan.

Background and aims: Some plasma metabolites in the purine metabolism were reportedly associated with DKD, although results were inconsistent among studies. Also, few studies examined the association between plasma hypoxanthine and DKD in community dwellers. Hypoxanthine is one of the most important derivatives of purine metabolism, and is associated with many diseases including kidney diseases. However, the association between plasma hypoxanthine concentration and the status of DKD including its subtypes in community dwellers is not fully understood.

Materials and methods: To address this, we divided patients with DKD into 3 subtypes: [a] reduced eGFR (eGFR <60 ml/min/1.73m²) and non-proteinuria, [b] normal eGFR (eGFR ≥60 ml/min/1.73m²) and proteinuria, and [c] both reduced eGFR (eGFR <60 ml/min/1.73m²) and proteinuria. We used the metabolite database from the Tsuruoka Metabolomics Cohort Study, which had global metabolomics in Japan using capillary electrophoresis-mass spectrometry. Among 10,933 participants, cross-sectionally analyzed were 1,005 who had diabetes mellitus (DM) defined by HbA1c ≥6.5%, and/or fasting blood glucose ≥126 mg/dl and/or anti-diabetic drug use. Of these, 231 had DKD, which was defined by eGFR <60 ml/min/1.73m² and/or test-strip positive proteinuria ([a] 144, [b] 58, and [c] 29 participants). 774 participants did not have DKD.

Results: Baseline characteristics of the total study participants were mean age 64 y, mean HbA1c 6.8±0.9%, mean BMI 25.1±3.8, and mean eGFR 73.4±16.0 ml/min/1.73m². 87 participants had overt proteinuria (9% of total participants). Plasma hypoxanthine level was positively associated with DKD (Spearman’s rank correlation coefficients 0.129, p<0.001). Univariate and multivariate logistic regression models were used to identify the association between plasma hypoxanthine and DKD including its three subtypes in DM patients. Multivariate logistic regression models investigating the association between plasma hypoxanthine and DKD were 1.42 (95% confidence interval, 1.22-1.65) after adjustment for possible confounders: age, sex, BMI, alcohol intake, smoking habit, energy intake and history of hypertension or dyslipidemia. In addition, we found that plasma hypoxanthine was associated with all 3 subtypes of DKD. Multivariate logistic regression models investigating the association between plasma hypoxanthine and DKD subtypes showed that odds ratios per 1 μmol/l increase in hypoxanthine for DKD were 1.42 (95% confidence interval, 1.22-1.65) after adjustment for possible confounders: age, sex, BMI, alcohol intake, smoking habit, energy intake and history of hypertension or dyslipidemia. In addition, we found that plasma hypoxanthine was associated with all 3 subtypes of DKD. Multivariate logistic regression models investigating the association between plasma hypoxanthine and DKD subtypes showed that odds ratios per 1 μmol/l increase in hypoxanthine for DKD subtypes were 1.28 (1.08-1.52) in (a), 1.63 (1.27-2.08) in (b), and 1.69 (1.23-2.34) in (c) as continuous variables.

Conclusion: The results showed that plasma hypoxanthine was elevated in all subtypes of DKD regardless of various differences in pathophysiology. High plasma hypoxanthine levels increase risk of DKD, regardless of its types. These relationships are not affected by covariates. These results implied that plasma hypoxanthine could be a screening marker for DKD regardless of its stage and status, although future prospective studies are required.

Disclosure: M. Yamamoto: None.

762
Advanced glycation endproducts in chronic kidney disease in subjects with and without diabetes: AGEs highly responsive to renal function decline and diabetes
N. Rabbani1, S. Panagiotopoulos2, R.J. Macksaac2,3, D. Yue4, G.R. Fulcher5, M.A. Roberts5, E. Ekinci6, P.J. Thornalley6
1College of Medicine, Qatar University, Doha, Qatar, 2Endocrine Centre, University of Melbourne, Melbourne, Australia, 3Department of Endocrinology & Diabetes, St Vincent’s Hospital Melbourne, Melbourne, Australia, 4Diabetes Centre, Royal Prince Alfred Hospital, Sydney, Australia, 5Department of Diabetes, Endocrinology & Metabolism, The Royal North Shore Hospital and Sydney Medical School, University of Sydney, Sydney, Australia, 6Eastern Health Clinical School, Monash University, Melbourne, Australia, 7Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Doha, Qatar.

Background and aims: Impairment of renal function with and without diabetes has been associated with increased serum levels of advanced glycation endproducts (AGEs). AGEs are formed by degradation of fructosamines, protein modification by glyoxal, methylglyoxal (MG), 3-deoxyglucosone (3DG), and other processes. Serum contains glycation
adduct residues in protein and glycation free adducts (glycated amino acids) - the latter formed by proteolysis of damaged proteins with also contributions from absorption of glycated amino acids from digested proteins in food. The aim of this study was to identify which type of AGE is most responsive to stage of chronic kidney disease (CKD) with assay methodology transferrable for assessment by clinical chemistry.

Materials and methods: Study participants were subjects with diabetes (n = 64, 6 type 1 and 58 type 2) or without diabetes (n = 71) in 4 categories of estimated GFR (ml/min/1.73 m²): normal and CKD stages 2, 3 and 4 (n = 7 - 29 per category). Fasting serum samples were obtained prior to a routine clinic visit and stored at -20°C until assay. Analytes were assayed by stable isotopic dilution analysis liquid chromatography tandem-mass spectrometry (LC-MS/MS): AGEs - CML, CEL, G-H1, MG-H1, 3DG-H, CMA, pentosidine, GOLD and MOLD, and oxidative damage markers - N-formylkynurenine, dityrosine and 3-nitrotirosine. Free adducts were assayed by analysis of 12 kDa ultrafiltrate and protein adducts after exhaustive enzymatic hydrolysis of serum protein. Study group medians are compared.

Results: Glycation free adducts were the most responsive to decline in renal function: protein AGE residues increased up to 3-fold in stage 4 CKD whereas AGE free adducts increased up to 8-fold in subjects without diabetes and 30-fold with diabetes. MG-derived MG-H1 free adduct was most responsive to decline in renal function. Glomerular filtration flux of MG-H1 free adduct was increased ca. 5-fold in patients with diabetes. Median, lower - upper quartile (nmol/min): control 11.1 (6.9 - 16.7) versus diabetes 51.7 (32.4 - 67.5), P = 3 x 10^-15, Mann-Whitney U. MG-H1 free adduct is readily measured: sample preparation time 60 min, assay time 15 min, with calibration and internal standards available commercially.

Conclusion: AGEs accumulate with decline in renal function with AGE free adducts being the most responsive. MG-H1 free adduct was the AGE free adduct of highest concentration in serum, increased most markedly with decline in renal function and was higher in subjects with diabetes, compared to subjects without diabetes, at all stages of CKD studied. The 5-fold increase in glomerular filtration flux of MG-H1 free adduct in diabetes suggests patients with diabetes have marked increased exposure to this AGE, independent of renal function. Analytical aspects suggest measurement of MG-H1 free adduct by LC-MS/MS is practicable for clinical chemistry profiling.

Supported by: NHMRC and QF
Disclosure: N. Rabbani: None.

763
Use of spot urine urea nitrogen to estimate protein intake in patients with diabetic chronic kidney disease
J.Y. Lee1, Y.H. Kim1, S.J. Kim1, S.S. Kang2, S.B. Kim1;
1Nephrology, internal medicine, Asan medical center, 2Dietetics and nutrition service, Asan medical center, Seoul, Republic of Korea.

Background and aims: Reducing protein intake is important in slowing the progression and in the symptomatic treatment of advanced uremia in patients with diabetic chronic kidney disease (DCKD).

Materials and methods: This cross-sectional study enrolled 305 DCKD patients, none on dialysis, who visited the Nephrology Clinic at the Asan Medical Center. This study evaluated use of spot UUN concentrations in estimating 24 h UUN and daily protein intake in DCKD patients. We calculated a linear regression equation to determine the relationship between spot UUN and 24 h UUN. Correlations between variables were assessed by Pearson’s correlation coefficient (r). Gender differences, assessed according to CKD stage, were compared with the Chi square test.

Results: 24 h UUN and spot UUN were significantly lower in patients with more advanced CKD (p < 0.001 each). Total protein intake assessed by dietary recall, but not protein nutrient density (g protein/1000 kcal), differed significantly among the groups of patients with different stages of CKD (p < 0.001). Protein intake was significantly correlated with 24 h UUN (r = 0.689, p < 0.0001). The correlation coefficient between 24 h UUN and spot UUN was 0.465 (p < 0.001) and that between protein intake and spot UUN was 0.378 (p < 0.001). There was a linear relationship between spot UUN and 24 h UUN as follows: spot UUN (mg/dl)=40.5×24 h UUN(g) +273.8. Therefore, a 24 h UUN of 7.8 g (protein intake 50 g/day) corresponds to a mean spot UUN concentration of 590 mg/dl.

Conclusion: Measurement of spot urine urea nitrogen is a simple and effective method for monitoring protein intake in DCKD patients. A daily protein intake of 50 g corresponds to a spot urine urea nitrogen concentration of approximately 590 mg/dl in DCKD patients.

Disclosure: J.Y. Lee: None.

764
Standards of diabetes care in people with diabetes on peritoneal dialysis: an audit at three large university hospital foundation trusts
M. Ouyema1, H. Esid2, N.B. Paray1, J. Dick1, D. Moutzouris2, J. Williams3, P. Vas1, J. Karaliedde2;
1King’s College Hospital, London. 2Guy’s and St Thomas’ Hospital, London. 3Royal Devon and Exeter NHS Trust, Exeter, UK.

Background and aims: The number of people with diabetes on peritoneal dialysis as preferred renal replacement therapy is increasing globally. More than 10% of people on dialysis worldwide are on peritoneal dialysis. People with diabetes on all forms of dialysis are at risk of fragmented diabetes care. Moreover the management of their diabetes can be complex and challenging as they have a high predisposition to glycaemic variability and hypoglycaemia. Peritoneal dialysis can further make optimising diabetes control difficult due the use of glucose containing solutions. There is limited information on the standards of diabetes care received by people with diabetes on peritoneal dialysis.

Materials and methods: We audited the care of all people with diabetes on peritoneal dialysis at 3 large university hospital foundation trusts between December 2021-January 2022 against the standards set in the UK Diabetes in Haemodialysis guidance (as no specific guidelines for peritoneal dialysis are currently available) which are: 100% of people should have annual review of glycaemic control by a diabetes specialist, annual eye screening, annual foot risk assessment, target HbA1c 58-68mmol/mol, (>80mmol/mol poor glycaemic control or if ≤58mmol/mol reduction in treatment should be considered)

Results: In total 65 participant records (type 1 diabetes n=15) were examined, and their demographics were broadly similar across the sites except for ethnicity. All participants except one were on glucose containing
dialysis regimes. The percentage of people with diabetes on peritoneal dialysis seen at least annually varied between 63% and 94%. Of those people seen less than annually 58% were on insulin. Of the cohort 92% were in a retinal screening program with at least annual review, 77% had at least an annual foot review, which were broadly similar across the three sites. HbA1c results in a clinically ‘acceptable’ range of 58–80 mmol/mol was observed in 32% of people and 9% had poor control (defined as >80 mmol/mol). Of the 58% of people who had HbA1c <58 mmol/mol, 66% were on a treatment that could be associated with hypoglycaemia (sulphonylurea or insulin). Self-reported hypoglycaemic events (at least 1 event per month) were reported by 21% of the cohort. Of the 65 people 2 had a diabetes related admission in the preceding 12 months.

**Conclusion:** We observed that frequency with which people with diabetes on peritoneal dialysis were seen by a diabetes specialist team varied both within and between centres. Overall adherence to the retinal screening aims was good but the frequency of foot review was sub-optimal. Indeed, more frequent foot checks should be considered in view of high risk of diabetic foot disease in end stage kidney disease. We observed that frequency with which people with diabetes care for people with diabetes on peritoneal dialysis.

**Disclosure:** M. Onyema: None.

**SO 66 Mechanisms of diabetic kidney disease**

**765**

**System\(\chi\)-overexpression protects renal tubular epithelial cells from oxidative damage by GSH depletion**

**S. Yoo** 1,2; M. Kim 1,2; J. Ba 1; J. Choi 3,4; J. Bang 2; H. Chin 2; G. Koh 1,2; 1Department of Internal Medicine, College of Medicine, Jeju National University; 2Department of Internal Medicine, Jeju National University Hospital; 3Department of Rehabilitation Medicine, College of Medicine, Jeju National University; 4Department of Rehabilitation Medicine, Jeju National University Hospital; 5Department of Internal Medicine, Jeju Medical Center, Jeju-si, Republic of Korea.

**Background and aims:** Oxidative stress in renal tubular cells is known to be one of the etiologies of diabetic nephropathy. 2-Deoxy-D-ribose (dRib) causes oxidative damage by depleting GSH in cells, including beta cells. System \(\chi\)- is a membrane transporter that moves extracellular cystine into cells independent of sodium, and cystine uptake through system \(\chi\)- is a rate-limiting step for intracellular GSH synthesis, which is important for protecting cells from oxidative stress. We conducted this study to determine whether dRib causes oxidative damage in renal tubular cells and, specifically, to investigate the mechanism through which dRib increases oxidative stress.

**Materials and methods:** L-[\(^{14}\)C]cystine uptake, GSH content, reactive oxygen species (ROS) levels, and cell viability were measured in NRK-52E cells, a renal tubular cell line, and the mRNA and protein expression of xCT, the functional unit of system \(\chi\)-, were investigated. The xCT gene was then overexpressed in NRK-52E cells using lentivirus. L-[\(^{14}\)C]cystine uptake, GSH, and cell viability were also measured in primary renal tubular epithelial cells isolated from rats.

**Results:** When NRK-52E cells were stimulated with various concentrations of dRib, L-[\(^{14}\)C]cystine uptake decreased, mRNA and protein expression of xCT increased, and intracellular GSH and ROS levels and cell viability were significantly decreased in a dose-dependent manner. L-[\(^{14}\)C]cystine uptake, intracellular GSH and ROS levels, and cell viability reduced by dRib were all significantly recovered by xCT overexpression. In primary renal tubular epithelial cells, dRib also significantly reduced L-[\(^{14}\)C]cystine uptake, GSH content, and cell viability, and these were almost completely recovered by pretreatment with 2-mercaptoethanol, a cystine uptake enhancer.

**Conclusion:** In renal tubular epithelial cells, dRib depletes GSH by reducing cystine uptake through inhibition of xCT. The resulting oxidative damage can be prevented by overexpressing xCT. Therefore, it is thought that the oxidative damage in renal tubular cells can be prevented through system\(\chi\)- regulation.

**Disclosure:** S. Yoo: None.

**766**

**Tunneling nanotubes-mediated lysosome transfer protects podocytes from diabetes-induced injury**

**F. Barutta**; S. Bellini, I. Gesmundo, G. Togliatto, G. Gruden; University of Turin, Turin, Italy.

**Background and aims:** Podocyte injury leading to albuminuria is a characteristic feature of diabetic nephropathy (DN). Dysfunction of the autophagy lysosomal pathway has been implicated in the pathogenesis of the podocyte damage in DN. There is thus increasing interest on novel therapeutic strategies of lysosome replacement/repair. Tunneling nanotubes (TNTs) are membrane channels that interconnect cells and allow transfer of organelles, including lysosomes, from donor to recipient injured cells. The cytosolic protein M-Sec plays a key role in TNT formation and we have previously reported that deletion of M-Sec exacerbates...
experimental DN. The aim of the present study was to investigate the underlying mechanisms of the detrimental effects of M-Sec deletion focusing specifically on TNT-mediated lysosome transfer and autophagy.

**Materials and methods:** *In vivo study:* the study was performed on WT and M-Sec-KO C57Bl6 mice. Animals were made diabetic by streptozotocin injection. Expression of LC3-II (autophagosome marker), p62, and autophagy inducers (beclin, ATG5, ATG7) was assessed by RNA, immunohistochemistry, and real-time PCR. *In vitro study:* M-Sec+/−/M-Sec− podocytes were exposed to vehicle, high glucose (HG), or advanced glycation end-products (AGEs) in parallel with control cells. Expression of LC3-II (autophagosome marker), p62, and M-Sec-KO C57Bl6 mice. Animals were made diabetic by streptozotocin injection. Expression of LC3-II (autophagosome marker), p62 (autophagy substrate), and autophagy inducers (beclin, ATG5, ATG7) was assessed by WB, immunohistochemistry, and real-time PCR. *In vitro study:* M-Sec+/−/M-Sec− podocytes were exposed to vehicle, high glucose (HG), or advanced glycation end-products (AGEs). Subset of experiments were carried out on podocytes over/re-expressing M-Sec or treated with latrunculin-B to prevent TNT formation. Autophagy (LC3-II, p62, tandem fluorescent-tagged LC3), lysosomal membrane permeabilisation (acridine orange, cathepsin D distribution), lysosome function (cathepsin D activity), and apoptosis (TUNEL assay/Annexin V staining) were studied by WB, immuno-fluorescence, and functional assays. Formation of TNTs in WGA-stained podocytes was evaluated by both fluorescent and DIC microscopy. TNT-mediated lysosome transfer was assessed by flow cytometry in Cell Tracker Blue-labelled podocytes (recipient cells) exposed to HG/AGEs and co-cultured with donor podocytes carrying GFP-labelled lysosomes and pre-exposed to either vehicle or leupeptin.

**Results:** Neither diabetes nor M-Sec deletion altered the expression of autophagy inducers. However, M-Sec deletion worsened diabetes-induced glomerular LC3-II/p62 overexpression, indicating blockade of the autophagy flux. Exposure of podocytes to HG/AGEs caused lysosome damage, autophagy blockade, and enhanced apoptosis. Podocyte incubation with HG/AGEs also induced formation of TNTs in a M-Sec-dependent manner and enhanced TNT-mediated transfer of lysosomes from donor cells. Inhibition of TNT formation by either M-Sec deletion or latrunculin-B aggravated HG/AGE-induced lysosome/autophagy dysfunction and apoptosis. On the contrary, these alterations were ameliorated by overexpression of M-Sec and co-culturing with healthy donor podocytes. Pre-treatment with leupeptin that causes lysosome dysfunction abolished the rescuing effect of donor podocytes.

**Conclusion:** M-Sec deletion aggravated diabetes-induced blockade of the autophagy lysosomal degradation pathway in both cultured podocytes and a model of experimental DN. Collectively, our in vitro results suggest that in the context of diabetes M-Sec is cytoprotective because it allows replacement of diabetes-injured lysosomes via TNTs, thus ameliorating autophagy and reducing apoptosis.

**Supported by:** JDRF, EFSD/Lilly Research Programme Disclosure: F. Barutta: None.

### 768

**Changes in body composition after kidney-pancreas transplantation and its association with 25-OH vitamin D3 in type 1 diabetes**

E.B. Parente1,2, S. Mutter1,2, C. Forsblom1,3, V. Harjutsalo1,3, P.-H. Groop1,3, on behalf of the FinnDiane Study Group;

1Folkhalsan Research Center, 2Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, 3Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

**Background and aims:** Diabetes is a progressive chronic disease. Unfortunately, some individuals will develop kidney failure, therefore, requiring kidney transplantation (TX). Considering that after kidney-pancreas TX, individuals with type 1 diabetes are cured of two diseases that impact body composition, in the present study, we evaluated the changes in body fat, muscle and bone tissues after kidney-pancreas TX. Furthermore, since 25-OH vitamin D3 [25(OH)D3] is important for the health of bone and muscle tissues, we analyzed the associations between pre-TX serum 25(OH)D3 concentration and the changes in body composition.
Materials and methods: This observational prospective study included 83 adults with T1D from the Finnish Diabetic Nephropathy Study referred to kidney-pancreas TX. Body composition was assessed by dual-energy X-ray absorptiometry (DXA) and visceral fat was measured by the CoreScan software pre- and post-TX. Changes in body composition were calculated as the difference (delta) between post-TX and pre-TX body compartment measurements and assessed by the Wilcoxon rank test. Linear regression models adjusted for covariates (sex, pre-TX age and BMI) were used to evaluate the associations between pre-TX serum 25(OH)D3 and the changes in body composition. A p-value below 0.05 was considered significant.

Results: The median age pre-TX was 45 (IQR 36.50) years, 66% were men and 35% of the individuals had pre-TX serum 25(OH)D3 below the normal threshold (50 nmol/l). After a median follow-up of 204 (IQR 177, 263) days after kidney-pancreas TX, BMI decreased (median 24.4 to 23.5 kg/m², p=0.002), but no change was seen in the waist-height ratio. Reductions in total bone mass (TBM) (2.4 to 2.3 kg, p<0.001), bone mineral density (BMD) (1.107 to 1.100, p=0.001), total muscle mass (TMM) (49.2 to 46.5 kg, p<0.001), legs’ muscle mass (LegMM) (15.2 to 14.5 kg, p<0.001), and legs’ fat mass (LegFM) (6.2 to 5.1 kg, p=0.019) were observed. No changes occurred in total fat mass or visceral fat mass. Pre-TX 25(OH)D3 was associated with changes in TMM (r²=0.16, β=0.271, p=0.014) and LegMM (r²=0.11, β=0.236, p=0.036). Therefore, the lower pre-TX 25(OH)D3, the lower the delta of TMM and LegMM, which means higher muscle loss. No association was seen between pre-TX 25(OH)D3 and changes in body composition outcomes. Supported by: Folkhälsoforskning Foundation, Academy of Finland Disclosure: E.B. Parente: None.

769
Up-regulation of dopamine β-hydroxylase and phenylethanolamine N-methyltransferase by intermittent hypoxia via down-regulation of miRNA-375 in neuronal cells

Background and aims: Sleep apnea syndrome (SAS) is characterized by recurrent episodes of oxygen desaturation and reoxygenation (intermittent hypoxia [IH]) and is a risk factor for hypertension and insulin resistance. However, why hypertension is induced by IH has been elusive. Here, we investigated the direct effect of IH on the gene expression(s) of catecholamine synthesizing enzymes in neuronal cells.

Materials and methods: Human and mouse neuronal cells, NB-1 and Neuro-2a cells, were exposed either to normoxia (5% CO₂, 21% O₂) or 70 cycles/24 h of IH (5 min hypoxia [1% O₂]/10 min normoxia), mimicking SAS patients, for 24 h. After the treatment, the mRNA levels of catecholamine synthesizing enzymes, tyrosine hydroxylase, L-3,4-dihydroxyphenylalanine decarboxylase, dopamine β-hydroxylase (DBH), and phenylethanolamine N-methyltransferase (PNMT) in human NB-1 and mouse Neuro-2a cells were measured by real-time RT-PCR. The protein levels of DBH and PNMT in NB-1 cells were measured by Western blot analysis. Reporter plasmids were prepared by inserting the promoter fragments of human DBH (-1018→+10) and PNMT (-600→+67) upstream of a firefly luciferase reporter gene in pGL4.17 vector. After the reporter plasmids were transfected into NB-1 cells, the cells were exposed either to IH or normoxia for 24 h, and lysed, and the promoter activities were measured. MicroRNA (miR)-375 levels were measured by real-time RT-PCR. To clarify the role of miR-375, miR-375 mimic and non-specific control RNA (miR-375 mimic NC) were introduced into NB-1 cells just before IH/normoxia exposure, and the mRNA levels of DBH and PNMT were measured by real-time RT-PCR.

Results: (1) The mRNA levels of DBH were significantly increased by IH in Neuro-2a (P=0.0135) and NB-1 cells (P=0.0271). (2) The mRNA levels of PNMT were significantly increased by IH in Neuro-2a (P=0.0341) and NB-1 cells (P<0.0001). (3) The protein levels of DBH and PNMT in IH-treated NB-1 cells were significantly increased (P=0.0296 and P=0.0007, respectively). (4) The promoter activities of DBH and PNMT were not increased by IH. (5) Target mRNA search of miR using MicroRNA.org program revealed that both miRNAs have a potential target sequence for miR-375. (6) The miR-375 level of IH-treated cells was significantly decreased than that of normoxia-treated cells (P=0.0222). (7) The IH-induced up-regulation of DBH and PNMT was abolished by introduction of miR-375 mimic but not by miR-375 mimic NC.

Conclusion: These results indicate that IH stress down-regulates the miR-375 in neuronal cells, resulting in the increased levels of DBH and PNMT mRNA via the inhibition of the miR-375-mediated mRNA degradation, leading SAS patients to hypertension as well as diabetes.

Disclosure: S. Takasawa: None.

770
Alternative splicing of the apoptosis gene Bcl-x in diabetic nephropathy
S. Oltene, M. Ayine, M. Stevens; University of Exeter Medical School, Exeter, UK.

Background and aims: There are several splice events associated with the progression of diabetic nephropathy. Understanding how they are regulated and how they contribute to disease pathogenesis may open new therapeutic avenues. An alternative splicing (AS) event occurring in exon 2 of the Bcl-x gene produces two splice isoforms of antagonistic effect. Use of the proximal 5’ splice site produces the long Bcl-xL isoform, known to be anti-apoptotic while the pro-apoptotic isoform Bcl-xS is formed with the use distal 5’ splice site. IL-6 is an inflammatory cytokine known to drive the progression of diabetic nephropathy (DN) that has also been implicated in the alternative splicing of Bcl-x; however, its mechanism is not fully understood yet. The aim of this study is to investigate the regulation of this AS event in kidney cells grown in a diabetic environment as well as the correlation of Bcl-xS/Bcl-xL splicing ratio with various degrees of severity in DN.

Materials and methods: Immortalised Human Embryonic Kidney cells (HEK293) exposed to three different high glucose environment: High Glucose (HG-25mM), Oscillating High Glucose (OHG), Glucose Soup (GS*25mM with TNFα 1ng/ml, IL-6 1ng/ml and insulin 100nM), Oscillating Glucose Soup (OGS*), Glucose Soup without IL-6 (GS), and Oscillating Glucose Soup without IL-6 (OGS*-25mM with TNFα 1ng/ml and insulin 100mM). The treatments were compared to Normal Glucose (NG) and Mannitol osmotic control (M). Oscillating treatment involves changing media from NG to a high glucose environment back and forth every 12 hours till 48 hours is reached. The cells were treated for 48 hours and splice isoforms analysed using RT-PCR followed by bioanalyser quantification. Urine samples were obtained from type I and type II diabetic patients enrolled on the Biomarker Enterprise to Attack DKD (BEAT-DKD) and VIBE (Exeter) studies with varying stages of renal disease. RNA was extracted from the urinary sediment
for RT-PCR analysis of Bcl-x splice isoforms. A shift in the Bcl-xS/Bcl-xL splicing ratio was be compared between the glucose environments and controls; for patients’ samples, the Bcl splicing ratio was correlated with various clinical parameters.

**Results:** A dose-dependent IL-6 treatment caused an increase in the Bcl-xS/Bcl-xL ratio, suggesting an influence of IL-6 on Bcl-x splicing. RT-PCR followed by bioanalyer analysis showed an upregulation of the Bcl-xS/Bcl-xL ratio. Furthermore, pilot data from a small cohort of patients with varying stages of nephropathy indicated that an increase in the pro-apoptotic Bcl-xS in RNA extracted from urinary cells correlated with a decline in GFR, implicating Bcl-x AS as a potential biomarker for DN severity.

**Conclusion:** High glucose levels combined with IL-6 causes an increase in the pro-apoptotic Bcl-xS splice isoform in HEK 293 cells. Furthermore, detection of the Bcl-x splicing event in the urinary sediment of DN patients indicates that increased Bcl-xS expression correlates with a decline renal function, implicating this AS event as a potential biomarker for DN severity.

**Supported by:** Diabetes UK

**Disclosure:** S. Oltean: None.

---

**771**

**Pegph20 attenuates hyaluronan-CD44 mediated renal injury in obesity related glomerulopathy**

B. Qi1,2, V. Musále2, K. Li3;

1Department of Endocrinology, Jilin Province People’s Hospital, Changchun, China, 2Division of Systems Medicine, School of Medicine, University of Dundee, Dundee, UK.

**Background and aims:** Obesity is considered as one of the biggest public health threats worldwide and increases the risk of incident chronic kidney disease. Hyaluronan (HA) is a major component of the extracellular matrix (ECM). We hypothesised that HA content was increased in the ECM of Obesity-Related Glomerulopathy (ORG) and PEGPH20, a human recombinant PEGylated hyaluronidase PH-20, reversed high-fat (HF) diet-induced HA accumulation and renal dysfunction. We further investigated whether its renal protective effect was dependent upon the main HA receptor, CD44.

**Materials and methods:** C57BL/6 mice, global CD44-deficient (cd44−/−) mice, and their wildtype littermate controls (cd44+/+) were fed a Chow diet or HF diet for 16 weeks. HF diet-fed mice received injections of either vehicle or PEGPH20 once every 3 days for 24 days. After treatment, mice or HF diet for 16 weeks. HF diet-fed mice received injections of either vehicle or PEGPH20 once every 3 days for 24 days. After treatment, mice

**Results:** HF diet feeding in C57BL/6 mice led to an increase in CD44 expression, HA accumulation, glomerular area and tubular injury score in the renal tissue, as well as an increase in serum creatinine levels. PEGPH20 treatment ameliorated some of these adverse effects including reducing renal CD44 expression (3.02 ± 0.33 (Vehicle HF) vs 1.49 ± 0.16 (PEGPH20 HF) fold increase relative to Chow-fed mice, p = 0.0092), HA accumulation (31.39 ± 3.48 vs 13.58 ± 1.81 %, p = 0.0078), tubular injury score (3.28 ± 0.15 vs 1.39 ± 0.06, p = 0.0003) and serum creatinine levels (1.40 ± 0.09 vs 0.79 ± 0.07 mg/dl, p = 0.0002), without affecting glomerular area. Furthermore, PEGPH20-treated obese mice had reduced renal fibrosis evidenced by decreased α-SMA expression (5.18 ± 0.17 vs 1.21 ± 0.11 %, p = 0.0001) and collagen deposition (9.76 ± 0.76 vs 6.30 ± 0.23 %, p = 0.0164) compared with obese mice receiving vehicle. Global deletion of cd44 gene in HF-fed mice significantly reduced renal CD44 expression (1.00 ± 0.05 (cd44−/− HF) vs 0.13 ± 0.02 (cd44−/− HF) fold change, p = 0.0001), HA accumulation (24.44 ± 3.33 vs 6.60 ± 0.58 %, p = 0.0001) and tubular injury score (3.28 ± 0.20 vs 1.89 ± 0.06, p = 0.0001), as well as reduced α-SMA expression (5.02 ± 0.16 vs 0.43 ± 0.06 %, p = 0.0001) and collagen deposition (9.48 ± 0.29 vs 6.08 ± 0.73 %, p = 0.0063). PEGPH20 caused further reductions in serum creatinine levels, in HF-fed cd44−/− mice (0.67 ± 0.08 mg/dl) when compared with HF-fed cd44−/− mice (1.63 ± 0.05 mg/dl, p = 0.0001).

**Conclusion:** PEGPH20 treatment and global cd44 deletion suppressed HA accumulation during ORG, which prevented obesity-associated renal fibrosis and dysfunction. Our results demonstrate that HA plays an important role in the pathogenesis of ORG, perhaps in part through binding to receptor CD44.

**Supported by:** BHF Project Grant PG/18/56/33935, BX Qi is supported by a scholarship from CSC

**Disclosure:** B. Qi: None.

---

**772**

**Functional and morphological renal changes in a Göttingen Minipig model of obesity-related and diabetic nephropathy**

B. O. Christoffersen1, C.A. Kristensen2, R. Lindgaard3, R.K. Kirk1, B.M. Viuff1, P.H. Kvist1, H.D. Pedersen1, T.P. Ludvigsen1, T. Skovgaard1, J.J. Fels1, T. Martinussen1, L.B. Christiansen2, S. Cirera2, L.H. Olsen2;

1Novo Nordisk A/S, Maaløe, 2Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, 3Department of Public Health, Copenhagen University, Frederiksberg, Denmark.

**Background and aims:** Obesity-related glomerulopathy (ORG) and diabetic nephropathy (DN) are serious complications to metabolic syndrome and diabetes. Here, the effects of a fat, fructose and cholesterol-rich (FFC) diet on kidney biomarkers and morphology were investigated in Göttingen Minipigs with and without streptozotocin-induced diabetes.

**Materials and methods:** Castrated male Göttingen Minipigs were divided into 4 groups: SD (standard diet, n=8), FFC (FFC diet, n=16), FFC-DIA (FFC diet + diabetes, n=14), FFC-DIA+S (FFC diet with extra salt + diabetes, n=14). Body composition, blood and urine biomarkers, glomerular filtration rate (GFR), blood pressure (BP), heart rate (HR) and resistive index (RI) were evaluated after 6-7 months (T1) and 12-13 months (T2). Histology (glomerular area, fibrosis area and mesangial expansion (ME) scoring), electron microscopy and gene expression profiling (the latter excluding FFC-DIA+S) were performed at T2. T2 data are given below as median and interquartile range [Q1-Q3] in the following order: SD, FFC, FFD-DIA, FFC-DIA+S.

**Results:** Fat percentage was significantly higher in the three FFC-groups compared to SD (27.6[24.0-30.7] vs. 64.2[61.4-67.6] vs. 54.8[52.7-56.0] vs. 53.1[47.9-61.0] %), and the two diabetic groups had higher plasma glucose than FFC and SD (3.6[3.3-3.9] vs. 3.7[3.6-3.8] vs. 15.4[14.7-19.0] vs. 13.7[13.0-15.6] mM). No differences were observed between groups in BP, whereas HR was higher in the diabetic groups compared to FFC and SD (72[69-80] vs. 72[71-75] vs. 96[83-102] vs. 86[76-105] beats/min). Minipigs fed FFC diet displayed glomerulomegaly compared to SD, and induction of diabetes on top of the FFC diet appeared to further increase the average glomerular area (11383[9202-11602] vs. 14907[13174-21771] vs. 21839[18518-30269] vs. 18262[16066-25095] μm²). The ME score was increased in all FFC groups compared to SD but was not increased further in the presence of diabetes (% glomeruli with a score of 0/1/2/3: 100/0/0/0 vs. 51/22/16/10 vs. 30/31/15/24 vs. 26/33/20/21). GFR was increased in FFC-DIA compared to SD and FFC (40.7[32.9-45.0] vs. 72.6[61.8-76.4] vs. 84.2[78.6-93.5] vs. 67.0[55.9-76.4] ml/min/kg lean mass). RI was increased in all three FFC-fed groups compared to SD (0.37[0.36-0.42] vs. 0.47[0.44-0.50] vs. 0.49[0.44-0.51].
Urinary albumin:creatinine ratio. Four genes relevant for human DN were deregulated in the FFC-DIA group (117 [76.2-132.2] vs. 96.1 [70.2-115.9] vs. 2181 [130.2-461.1] vs. 115.9 [106.9-224.7] mg/g). No significant differences were found in protein:creatinine ratio was only increased in the FFC-DIA group (117 [76.2-132.2] vs. 96.1 [70.4-115.9] vs. 2181 [130.2-461.1] vs. 115.9 [106.9-224.7] mg/g). No significant differences were found in urinary albumin:creatinine ratio. Four genes relevant for human DN were deregulated in the FFC-DIA group (117 [76.2-132.2] vs. 96.1 [70.2-115.9] vs. 2181 [130.2-461.1] vs. 115.9 [106.9-224.7] mg/g). No significant differences were found in protein:creatinine ratio was only increased in the FFC-DIA group (117 [76.2-132.2] vs. 96.1 [70.4-115.9] vs. 2181 [130.2-461.1] vs. 115.9 [106.9-224.7] mg/g).

Conclusion: Göttingen Minipigs fed FFC diet displayed some of the characteristic features of human ORG. Presence of diabetes on top of FFC diet, lead to changes resembling the early phases of human DN.

Disclosure: B.O. Christoffersen: Non-financial support; Kits for NGAL measurements were provided for free from BioPorto Diagnostics A/S, Hellerup, Denmark.

Materials and methods: We used mice models of NASH (high fat diet, choline-deficient high fat diet) or fibrosis (CCl4), isolated liver macrophages from these mice and performed single-cell RNA sequencing (scRNAseq) analyses. Metabolic tests and histology were carried out to examine the metabolic status of the mice and the extent of liver damage while flow cytometry was used to characterize into more details the different macrophage populations.

Results: Using scRNAseq, we found several sub-populations of liver macrophages. We observed the existence of two populations of KCs, and one population of monocyte-derived macrophages. The relative proportions of these populations changed during NAFLD, with a one sub-population of KCs being less abundant during NAFLD resolution. This sub-population of KCs, that we named oxKCs, was characterized by high expression of metabolism-related genes, which prompted us to study liver macrophage metabolism during NAFLD. We therefore studied macrophage metabolic activity, and more particularly the glycolytic activity and the intensity of mitochondrial respiration. We did not see any change in these metabolic parameters during NAFLD progression. We thus focused on understanding the differential role of the two different KCs populations in the physiopathology of NAFLD. We identified KLF6 as a transcriptional factor particularly expressed by oxKCs in comparison with the other KC population and thus postulated it was pivotal in their function. Using a model of mice expressing the Cre recombinase in macrophages and gRNAs directed KLF6, we plan on identifying KLF6 target genes in macrophages. We also plan on examining the importance of KLF6 in the macrophage response to cellular stressors involved in NAFLD such as lipid overload.

Conclusion: In conclusion, we found that three populations of liver macrophages could be identified. In particular, one particular KC population could be pivotal in NAFLD. This population highly expresses KLF6 which could thus be an interesting therapeutic target. More generally, understanding macrophage diversity and role in NAFLD could lead to the development of therapeutical approaches for management of NAFLD.

Disclosure: R. Thibaut: Grants; EFSD/Lilly Young Investigator Research Award Application.
Sexually dimorphic metabolic response to an obesogenic diet according to the amino acid source in mice

C. Rives1, V. Alquier-Bacquie1, S. Ellero-Simatos1, A. Polizzi1, F. Lasserre1, T. Levade2, F. Sabourdy2, M. Huillet1, N. Loiseau1, H. Guillou1, A. Fougerat1, L. Payrastre1; 1INRAE Toxalim, 2Institut Fédératif de Biologie, CHU, Toulouse, France.

Background and aims: Non-alcoholic fatty liver disease (NAFLD) frequently co-exists with metabolic syndrome and thus is often defined as the liver expression of dyslipidemia, insulin resistance, and obesity. NAFLD is the most common chronic liver disease and affects approximately 25% of the global population. Of note, dietary constituents are key factors in NAFLD pathogenesis. Such factors include a high intake of calories and an excessive consumption of saturated fats and refined carbohydrates. More recently, studies have shown that protein source could also play a role. In this work, we investigated the metabolic effects of different amino acid sources in response to an obesogenic diet in male and female mice.

Materials and methods: The study has been carried out along the “Principles of laboratory animal care” (NIH Publication no. 85-23, revised 1985). Male (n = 12) and female (n = 12) C57BL/6J mice were fed either a Control Diet (CD) or a Western Diet (WD) for 15 weeks. In each diet, amino acid source was either from casein (CD-CAS or WD-CAS) or a free amino acid mixture identical to casein amino acid composition (CD-AA or WD-AA). For each cage, food and water consumption and body weight were evaluated weekly. Plasma, liver, caecum, subcutaneous and epididymal white adipose tissue (WAT) samples were collected.

Results: Male mice fed a WD-AA show reduced WD-induced body weight, glucose intolerance and insulin resistance compared to WD-CAS fed male mice. In addition, hepatic damages (AST and ALT activities), lipid accumulation, expression of genes involved in lipogenesis, β-oxidation and oxidative stress, induced upon WD-CAS feeding were not observed in males fed the WD-AA. By contrast, the metabolic consequences of the WD in female mice were observed regardless of the amino acid source. Besides, males and females fed the WD-CAS showed a decreased caecum weight compared to animal fed a CD-CAS, whereas caecum weight was unchanged in WD-AA fed male and female mice compared to respective controls.

Conclusion: Altogether, these results show that the source of dietary amino acids plays a major role in the metabolic response to an obesogenic diet in mice and is sex-dependent. Microbiota composition and activity, untargeted hepatic genome expression and metabolome are under investigation to identify the mechanisms involved in the distinct metabolic responses to WD according to the amino acid source and sex.

Supported by: FRM
Disclosure: C. Rives: None.

Inflammation may prevent hepatocyte damage promoted by steatosis

G. Perrot, C. Ardon-Zitoun, A. Lang, G. Mithieux, F. Rajas; Laboratoire Nutrition diabète et cerveau, Université Claude Bernard Lyon 1, Lyon, France.

Background and aims: Non-alcoholic fatty liver disease (NAFLD) is a common consequence of metabolic stress induced in type 2 diabetes. Usually, NAFLD progresses from simple steatosis to non-alcoholic steatohepatitis, cirrhosis and possibly to hepatocellular carcinomas (HCC). However, some studies reported the development of hepatic tumors, generally hepatocellular adenomas (HCA), on fatty liver associated with low-grade inflammation/fibrosis. Interestingly, HCA/HCC occurs on fatty liver in the absence of inflammation and fibrosis in patients with Glycogen Storage Disease Type 1a (GSD1a), characterized by the loss of glucose-6-phosphatase catalytic subunit (G6P1). In both GSD1a and type 2 diabetes, the increased flux downstream of glucose-6-phosphate leads to a metabolic reprogramming very similar to that in tumor cells. Here, we used a mouse model of GSD1a to better characterize the inflammatory process in the liver under conditions that favor fibrosis.

Materials and methods: Mice with genetic ablation of G6pc1, specifically in the liver (L.G6pc−/− mice), and wild type (WT) mice were fed either a high fat-methionine and choline deficient diet (HF-MCD), known to promote hepatic fibrosis, or a Chow diet. Hepatic tumor development was followed by microscan after injection of contrast agent. Inflammatory and fibrotic parameters were characterized by histology (HPS and Masson’s staining) and marker’s gene expression was analyzed by RT-qPCR and western blot in the mouse livers. Neutrophils (MPO), T lymphocytes (CD3) and Kupffer’s cells (F4/80) were quantified by immunostaining of livers.

Results: After 3 months on HF-MCD diet, no hepatic tumor was detected in WT or L.G6pc−/− mice. As expected, HF-MCD diet promoted inflammatory (Mcp1, Il6, Tnfα) and fibrotic (Col1a1, Tgfβ1, Paj) gene expression in WT mice. Surprisingly, histological analyses showed that inflammation and fibrosis were discrete in livers of L.G6pc−/− mice fed a HF-MCD diet. Moreover, the expression of inflammation/fibrosis markers was lower in L.G6pc−/− mice fed a HF-MCD diet compared to WT mice. Furthermore, in response to MCD diet, Kupffer’s cells and T lymphocytes were highly recruited in the liver of WT mice, while the recruitment of T lymphocytes was drastically decreased in L.G6pc−/− liver. However, Kupffer’s cell population was not affected in L.G6pc−/− liver. In both genotypes, neutrophil recruitment was increased under HF-MCD diet. Finally, it is noteworthy that plasma transaminase activities were strongly increased in L.G6pc−/− mice fed a HF-MCD diet compared to WT mice.

Conclusion: The metabolic perturbations linked to G6P-activated pathways promote steatosis associated or not with inflammation/fibrosis. Our results show that hepatocyte injuries were more important in GSD1a mice, a model of steatosis associated with low-grade inflammation, than in WT mice, in which HF-MCD promoted inflammation/fibrosis. These data strongly support the idea that fine regulation of immune cell activation is essential for the control of hepatic disease and maintenance of liver homeostasis.

Supported by: Fondation pour la Recherche Médicale, Gen et Zic, Association Francophone des Glycogénoses
Disclosure: G. Perrot: None.
more severe NASH fibrosis compared with control strain mice, in our established NASH fibrosis mouse model induced by high fat feeding and diabetes.

**Materials and methods:** Male Control mice (4-6 weeks; B6.Cg-Tg(AlbCre)21Mgn/J (AlbCre) and homozygous CCN1<sup>fl/fl</sup> (CCN1<sup>fl/fl</sup>) and hepatocyte-specific CCN1 knockout mice (CCN1<sup>x/fl</sup>B6.Cg-Tg(AlbCre)21Mgn/J (CCN1-KO)) were fed either standard chow or high fat diet (HFD; 45% kcal fat). After 15 weeks, HFD mice were rendered diabetic (HFD+DM) with low dose streptozotocin (2.3 x 65 mg/kg ip) and maintained for a further 10 weeks. Liver fibrosis was assessed with Picro Sirius Red (PSR) staining. Gene expression of fibrosis markers were measured by RT-qPCR. Biochemical assays were performed. Data were analysed by two-way ANOVA and shown as mean±SEM.

**Results:** CCN1-KO HFD+DM mice had ~two-fold increased fibrosis area by PSR staining compared with Control (AlbCre+CCN1<sup>fl/fl</sup>) HFD+DM mice, including at the Central Vein and Portal Tact zones (Table 1). CCN1-KO HFD+DM mice had increased gene expression of fibrosis markers collagen-I (3.33±1.62 v 5.51±2.32, p<0.001), collagen-III (2.95±0.36 v 4.95±0.71, p<0.001), collagen-IV (1.27±0.19 v 3.90±0.32, p<0.001), collagen-VI (2.09±0.21 v 3.83±0.56, p<0.001) and TGFβ1 (1.76±0.09 v 2.27±0.18, p<0.02), but no change in inflammatory markers TNFα or MCP-1, compared with Control HFD+DM mice. Plasma CCN1 concentration was increased by HFD+DM in the Control mice (0.55±0.04 v 0.78±0.06 mg/mL, p=0.006) but not in the CCN1-KO mice (0.60±0.03 v 0.64±0.05 mg/mL). CCN1-KO HFD+DM mice had greater total body weight (42.19±1.80 v 48.85±1.71 g, p=0.02), fasting insulin (131.25±11.75 v 262.55±48.88 PM, p=0.01) and insulin resistance (HOMA-IR; 17.69±1.26 v 28.44±4.78, p=0.02), but had less hyperglycaemia (19.31±1.18 v 15.48±1.13 mmol/L, p=0.03), compared with the Control HFD+DM mice.

**Conclusion:** Hepatocyte-specific CCN1-KO HFD+DM mice developed more severe NASH fibrosis than Control HFD+DM mice. An atypical metabolic phenotype was identified in the CCN1-KO HFD+DM mice. Studies are now required to determine if the absence of hepatocyte CCN1 has a direct or a systemic effect on the liver. This research indicates hepatocyte CCN1 may have a protective role against NASH fibrosis in the presence of T2D, implicating it as a potential therapy.

**Table 1:** Liver fibrosis (% area PSR-positive stained tissue of 4-6 fields per magnification, per mouse).

<table>
<thead>
<tr>
<th>Magnification</th>
<th>Chow (n=17)</th>
<th>HFD+DM (n=23)</th>
<th>Chow (n=10)</th>
<th>HFD+DM (n=14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>100x</td>
<td>0.350±0.04</td>
<td>1.85±0.30</td>
<td>0.36±0.04</td>
<td>2.98±0.50</td>
</tr>
<tr>
<td>400x Central Vein</td>
<td>0.54±0.12</td>
<td>2.32±0.34</td>
<td>0.54±0.11</td>
<td>5.7±5.7*</td>
</tr>
<tr>
<td>400x Portal Tact</td>
<td>0.60±0.12</td>
<td>2.60±1.08</td>
<td>0.60±0.12</td>
<td>4.3±1.63*</td>
</tr>
</tbody>
</table>

Means±SEM, *p<0.05, significantly different to Control HFD+DM by two-way ANOVA with Tukey’s correction for multiple comparisons.

**Disclosure:** S.N. Parry: None.

777 Elevated liver fibrosis in non-diabetic obese individuals: comparison of liver fibrosis measured by magnetic resonance imaging

A. Askeland<sup>1,2</sup>, M. Gjel<sup>1,3</sup>, R.W. Rasmussen<sup>1</sup>, K. Højlund<sup>3</sup>, M. Møllergaard<sup>1</sup>, J.B. Frøkjær<sup>2,3</sup>, A. Handberg<sup>1,2</sup>;

<sup>1</sup>Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg; <sup>2</sup>Department of Clinical Medicine, Aalborg University, Aalborg; <sup>3</sup>Department of Radiology, Aalborg University Hospital, Aalborg; *Steno Diabetes Center Odense, Odense, Denmark.

**Background and aims:** Obesity is a major risk factor for developing non-alcoholic fatty liver disease (NAFLD). NAFLD represents a spectrum of liver pathologies, including hepatic steatosis and fibrosis.

Technological advancements within the field of magnetic resonance imaging (MRI) enable precise and non-invasive quantification of liver steatosis and fibrosis. As such, the aim of this study was to investigate and compare liver steatosis and fibrosis measured by MRI in lean and non-diabetic obese individuals.

**Materials and methods:** We conducted an observational case-control study comparing hepatic steatosis and fibrosis in age (30-60 years) and gender matched healthy lean (n = 23) and non-diabetic obese individuals (n = 60). Obese individuals were divided into a low-risk (n = 28) and high-risk obesity (n = 32) groups, where participants in the high-risk group had both NAFLD (liver steatosis ≥5%) and metabolic syndrome (IDF criteria). Using a 3T MRI, hepatic proton density fat fraction (PDFF) and T1 relaxation time mapping (T1 mapping) were assessed for evaluation of hepatic steatosis and fibrosis, respectively. Furthermore, the FIB-4 index, a surrogate measure of liver fibrosis, was calculated for participants over the age of 35 years.

**Results:** Average liver fat fraction (PDFF) was 2.2% (range: 1.2-4.8%) in the lean group, 3.6% (range: 1.6-13.6%) in the low-risk obese group, and 13.7% (range: 5.1-36.1%) in the high-risk obese group. Comparing liver fibrosis (T1 mapping), high- and low-risk obese individuals had a 19.7% (mean±sd: 896±73ms, t-test: p < 0.001) and 8.1% (mean±sd: 810±65au, t-test: p = 0.038) increase compared with lean controls (mean±sd: 749±70ms), respectively. Comparing only the obese groups, liver fibrosis was 10.7% higher in high-risk obese compared with low-risk obese individuals (t-test: p < 0.001). Liver fibrosis showed a positive correlation with liver fat fraction in the combined cohort (Pearson: r = 0.69, p < 0.001). BMI mean was similar in the low- (mean: 35.2 kg/m²) and high risk obese groups (mean: 36 kg/m²). The FIB-4 index was similar between all groups.

**Conclusion:** In our cohort, both the low-risk and the high-risk obese individuals had increasingly higher MRI-determined liver fibrosis compared with lean controls. These differences were not mirrored in the FIB-4 index. The MRI-measurements revealed a strong association between liver fibrosis and fat fraction, the two major pathologies underlying NAFLD. Further studies are needed to define specific cut-off values for pathological liver fibrosis as determined by T1-mapping, and the clinical relevance of these measures in obesity and related disorders.

**Supported by:** This work was supported by a research grant from the Danish Diabetes Academy (NNF17SA0031406).

**Disclosure:** A. Askeland: None.
were analysed. To unveil the underlying MoAs, mechanistic study was performed in THP-1 and LX2 cells.

**Results:** In TAA mice, HM15211 treatment significantly reduced the hepatic hydroxyproline (-31% vs. vehicle, p<0.01), Sirius red positive area (-35% vs. vehicle, p<0.001), and fibrosis score (0.7 for HM15211 vs. 3.0 for vehicle, p<0.001). Considering a baseline fibrosis score of TAA mice at week 2 (1.0), HM15211 treatment could confer both potential reversal effect on pre-existing fibrosis and prevention effect on fibrogenesis. Consistently, expression of hepatic marker genes for fibrosis (i.e. collagen-1α1) and inflammation (i.e. F4/80, TNF-α) were significantly attenuated by HM15211 treatment. Furthermore, multiplex cytokine analysis revealed that HM15211 treatment was associated with robust reduction across blood pro-inflammatory cytokines including TNF-β, IL-1β, and IL-6. Profound reduction in blood level of liver enzymes was also confirmed. Mechanistically, PMA/LPS-induced pro-inflammatory cytokine secretion of THP-1 cells (human monocytes) was significantly attenuated by HM15211, and TGF-β-induced collagen production was also significantly reduced in LX2 cells (human hepatic stellate cells).

**Conclusion:** HM15211 effectively improved liver inflammation and fibrosis in TAA mice, and related mechanism was elaborated by in vitro studies. Thus, HM15211 could be a novel therapeutic option for fibrosis caused by NASH. Human study is ongoing to assess the clinical relevance of these promising results.

**Disclosure:** J. Kim: None.

---

**Anti-fibrotic potential of a novel long-acting GLP-1/GCG/FGF21/IL-1RA tetra-specific drug (OGB21502) in preclinical mice models**

**M. Hwang, J. Kim, N. Chang, M. Kim, Y. Kim, D. Im, S. Park; Onegene Biotechnology Inc., Suwon-si, Republic of Korea.**

**Background and aims:** Non-alcoholic steatohepatitis (NASH) is a complex disease of chronic liver injury and inflammation, causing increased fibrogenesis and ultimately cirrhosis by multiple mechanism. We hypothesized that the simultaneous regulation of multi-target in disease microenvironment is a holistic approach to cure NASH with fibrosis. OGB21502 is a novel tetra-agonist at the GLP-1, GCG, FGF21, and IL-1RA. It efficiently improves hepatic steatosis, inflammation, and fibrosis by regulating lipotoxicity and macrophage/hepatic stellate cell activation. In our previous study, OGB21502 reduced lipid accumulation including triglyceride and cholesterol in DIO mice. OGB21502 also improved cirrhosis progression in 80% of the group in CCl4 model, and the fibrosis score was 2.4 against 4.0 in the vehicle. Here, we evaluated the steatosis resolution and anti-fibrotic effect of OGB21502 in mice models of NASH and fibrosis.

**Materials and methods:** All animal protocols were completed in agreement through internationally accepted principles of care. To induce NASH, the mice were fed with methionine-choline deficient diet (MCD) for 8 weeks and OGB21502 was subcutaneously administered during the last 4 weeks. Liraglutide and dulaglutide were used as comparative controls. In the second study, CCl4-liver fibrosis model was induced by intraperitoneal injections of CCl4 for 6 weeks. The OGB21502 or comparative control such as Fc-FFG21(RGE) and Ocaliva (OCA) was subcutaneously administered for the last 4 weeks. After treatment, liver tissues and blood samples were prepared and the histopathological feature was evaluated to determine NAS score and the degree of fibrosis. In addition, ELISA and quantitative PCR analysis were performed to determine the steatosis and fibrosis markers. Gene expression profile was analyzed by extracting total RNA from liver tissues in CCl4 model.

**Results:** In MCD mice, OGB21502 treatment induced decreased of blood ALT (-45.2% vs. vehicle). Histopathological analysis revealed that OGB21502 reduced NAS score (1.1 in OGB21502 vs. 3.4 in vehicle), steatosis score (-57.1% vs. vehicle), and inflammation score (-84.6% vs. vehicle). In CCl4 mice, OGB21502 was associated with the reduced mRNA expression of hepatic fibrosis markers compared to Fc-FFG21(RGE) and OCA in dose-dependent manner. In particular, OGB21502 at a dose of 30 nmol/kg further reduced the expression of TGF-β (-15%), α-SMA (-35%), LOXL2 (-30%) and Coll1A1 (-50%) than Fc-FFG21(RGE). In gene expression profile, OGB21502 more efficiently decreased fibrotic and inflammatory gene expressions compared to Fc-FFG21(RGE). We also confirmed that tetra-specific drug, OGB21502 had more synergistic effects on improving liver fibrosis and inflammation than dual (GLP-1/GCG) or triple (GLP-1/GCG/FGF21) treatment in gene profile. Moreover, LPS-induced pro-inflammatory cytokines were downregulated in Kupffer cells and HSC activation markers by TGF-β were lowered in OGB21502 treated group.

**Conclusion:** Overall, the composite mechanism of action of OGB21502 significant improved inflammation as well as fibrosis through multiple animal models. It is also expected to be effective in fibrosis in other organs. Therefore, these findings prompt the evaluation of a novel multi-specific therapeutic potential of OGB21502 for NASH with liver fibrosis and other fibrotic diseases.

**Disclosure:** M. Hwang: None.
smoking status, alcohol consumption, physical activity, income, body weight, hypertension, dyslipidemia, fasting glucose, and number of oral hypoglycemic agents used.

**Results:** Incident hepatic steatosis was associated with increased development of stroke, HF, mortality compared to non-NAFLD (HR [95% CI], stroke 1.47 (1.23 - 1.75), HF 1.36 (1.17 - 1.57), mortality 1.41 (1.20 - 1.65)). Regression of hepatic steatosis was associated with increased risk of MI, stroke, HF and mortality compared to non-NAFLD, and decreased risk of HF and mortality compared to persistent hepatic steatosis (all p<0.05). Persistent hepatic steatosis had increased risk of MI, stroke, HF, and mortality compared to non-NAFLD (HR [95% CI], MI 1.27 (1.10 - 1.47), stroke 1.39 (1.23 - 1.58), HF 1.42 (1.28 - 1.57), mortality 1.66 (1.50 - 1.84)). Persistent advanced fibrosis was associated with increased risk of stroke, HF, and mortality compared to group without advanced fibrosis (all p<0.05). Compared to persistent advanced hepatic fibrosis, regression of hepatic fibrosis was associated with increased risk of MI, stroke, HF, and decreased risk of HF and mortality compared to persistent hepatic steatosis (all p<0.05). Persistent hepatic steatosis had increased risk of MI, stroke, HF, and mortality compared to non-NAFLD (HR [95% CI], MI 1.27 (1.10 - 1.47), stroke 1.39 (1.23 - 1.58), HF 1.42 (1.28 - 1.57), mortality 1.66 (1.50 - 1.84)).

**Conclusion:** Changes in FLI or BARD score were significantly associated with CVD outcomes and mortality in new-onset T2DM.

**Disclosure:** J. Park: None.

---

**SO 68 From brain circulation to cognitive dysfunction**

**781 Inhibition of NLRP3 ameliorates lipid accumulation in diabetic-associated cognitive dysfunction**

W. Zhu1,2, T. Niu1,2, T. Li1,2, H. Zhang3, S. Wang1;
1Affiliated Zhongda Hospital of Southeast University, Nanjing, 2Southeast University, Nanjing, 3The First Affiliated Hospital of China University of science and technology, Hefei, China.

**Background and aims:** Accumulating evidences suggest that type 2 diabetes (T2D) predisposes to neurophysiological alterations including inflammatory responses and lipid deposition in brain that eventually culminates into cognitive impairment. Nucleotide leukin-rich polypeptide 3 (NLRP3) is documented as a potent target for treating metabolic diseases and inflammatory disorders. Earlier reports have suggested that NLRP3 deficiency prevents the accumulation of renal cholesterol in diabetic nephropathy. This study was to investigate the effect of NLRP3 on lipid accumulation in the hippocampus and the underlying mechanism in diabetic cognitive impairment.

**Materials and methods:** In vivo, C57BL/6 mice and NLRP3 knockout mice were fed for 6 months with normal chew diet or high fat diet (60 kJ% from fat) with/without intraperitoneal injections of streptozotocin (STZ) to induce diabetes. After 24 weeks, Morris Water Maze and New Object Recognition Test had be performed to evaluate the learning and memory ability of mice. And the normal and diabetic mice were sacrified to evaluated the protein expression of NLRP3, Interleukin-1β (IL-1β), Tumor necrosis factor α (TNF-α), Interleukin-6 (IL-6) and Hydroxymethyl glutaryl-CoA reductase (HMGCR) by western blot, as well as intracellular lipid droplet deposition in the hippocampal tissues. In vitro, BV2 cells (mouse microglial) were treated with AGEs and palmitic acid over 24 hours. Common microscope was used to observe the activation of BV2 cells. And the expression of NLRP3, inflammatory factors, HMGCR and lipid deposition were also detected.

**Results:** Diabetic mice with or without NLRP3 knockout showed impaired glucose tolerance. Compared with the normal mice, diabetic mice exhibited reduced learning and memory abilities, and NLRP3, IL-1β, IL-6, TNF-α and HMGCR level were increased, accompanied by lipid accumulation. High-glucose and high-lipid intervention promoted the activation of BV2 cells, the expression of NLRP3, IL-1β, IL-6, TNF-α and HMGCR, as well as lipid accumulation.

**Conclusion:** In diabetes, activation of NLRP3 may promote lipid accumulation in the hippocampus.

Supported by: 81870568

**Disclosure:** W. Zhu: None.

---

**782 Cardio-metabolic factors and risk of dementia in people with type 2 diabetes in England: a large retrospective cohort study**

E.P. Vamos1, H. Lai1, M. Sharabiani2, E.W. Gregg1, J. Valabhji2, L. Middleton1, C. Millett1, A. Majeed1, A. Bottle1, K. Chang1;
1School of Public Health, Imperial College London, 2Division of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.

**Background and aims:** Type 2 diabetes (T2D) is a known risk factor for dementia but links between cardio-metabolic factors and T2D-related dementia risk are less well-understood. This study aims to explore and quantify associations of routinely collected cardio-metabolic factors and dementia risk in people with T2D.

**Materials and methods:** In this retrospective cohort study, we used data from the UK Clinical Practice Research Datalink from 1999 to 2018,
enrolling 249,958 adults with T2D aged ≥ 42 years. Continuous cardio-metabolic measures were modelled linearly as well as using tail restricted cubic splines with Cox proportional hazards regression models to estimate hazard ratios (HR) and 95% CI for dementia risk, with age as timescale. Categorised cardio-metabolic measures were also analysed using Cox regression. Models were adjusted for socio-demographic characteristics, duration of diabetes, co-morbid conditions and medications. Analyses were further stratified by follow-up time segmented into three groups (<5, 5-10 and >10 years).

Results: During a median follow-up of 4.0 years, 22,492 people (9%) developed dementia. For patients with ≥10 years follow-up, increased levels of body mass index (BMI) were associated with higher dementia risk (HR 1.03 [95% CI 1.03-1.04] per 1 kg/m² increment). Cubic splines indicated an increased risk of dementia from 29 kg/m² onwards compared with BMI <25 kg/m². Furthermore, BMI in the obesity range was linked to an increased dementia risk (BMI ≥30 kg/m²; HR 1.43 [95% CI 1.31-1.56]). Systolic blood pressure (SBP) level was linked to a 5% lower dementia risk per 10 mm Hg increment, with cubic splines showing an inverse association between SBP and dementia risk throughout the whole range of SBP values. Fasting plasma glucose (FPG) and HbA1c were associated with a 2% and 4% increased dementia risk, respectively (per 1 mmol/L and 5 mmol/mol increments, respectively). No evidence of association was found for total cholesterol and low-density lipoprotein (LDL) while higher levels of high-density lipoprotein (HDL) were linked to a lower dementia risk (0.98 [0.97-0.99] per 0.1 mmol/L increment).

Conclusion: Higher BMI and glycaemic values measured over 10 years before dementia diagnosis were linked to increased dementia risk among people with T2D. The results highlight the importance of long follow-up times to reduce reverse causation. The results may also show the potential importance of modifiable cardio-metabolic risk factors in preventing or delaying dementia, in a patient population at increased risk of dementia.

Supported by: Diabetes UK (Grant No: 18/0005851).

Disclosure: E.P. Vamos: None.

Insulin resistance and systemic low-grade inflammation reduce risk of developing dementia in a nationwide cohort study of type 2 diabetes patients

J.S. Nielsen1, N.J. Jensen2, L.W.B. Christensen3, H.T. Sørensen1, K. Højlund1, R.W. Thomsen1, J. Rungby3;

1Odense University Hospital, Odense, 2Bispebjerg University Hospital, Copenhagen, 3Aarhus University Hospital, Aarhus, Denmark.

Background and aims: We examined the hypothesis that increased insulin resistance and systemic low-grade inflammation measured close to diabetes diagnosis associate with future risk of dementia.

Materials and methods: In the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) cohort of patients with recently diagnosed type 2 diabetes, we identified all patients enrolled between 2010-2018 without a previous diagnosis of dementia and with a fasting HOMA2-IR (insulin resistance) and valid hsCRP (low-grade inflammation) measurement. For each of the two exposures the relative risk of receiving a first diagnosis of any type of dementia was computed for each quartile using Cox proportional hazard analysis.

Results: Among 4,579 patients with newly diagnosed type 2 diabetes (median age, 62.4 years; 58.2% males), 52 (1.1%) developed dementia over a median follow-up period of 5.1 (IQR, 4.4-5.9) years. The incidence rate of developing dementia was highest in patients with lowest HOMA2-IR values (1st quartile 3.0 [95% CI, 1.8; 4.8] vs. 2nd quartile 2.2 [1.2; 3.7], 3rd quartile 1.9 [0.9; 0.35], and 4th quartile 1.8 [0.8; 3.2] per 1,000 person-years. This corresponded to an age- and sex-adjusted hazard ratio of 1.47 [0.83; 2.60] when comparing the 1st quartile with 2nd-4th quartiles (Figure 1.A). Similarly, dementia incidence was highest in patients with lowest hsCRP values (1st quartile 3.1 [1.8; 4.9] vs. 2nd quartile 2.1 [1.1; 3.6], 3rd quartile 1.7 [0.8; 3.2], and 4th quartile 2.1 [1.1; 3.6] per 1,000 person-years); which resulted in an age- and sex-adjusted hazard ratio of 1.40 [0.79; 2.49] when comparing the 1st quartile with 2nd-4th quartiles (Figure 1.B).

Conclusion: In contrast to our hypothesis, the risk of developing dementia was about 40% higher in diabetes patients with the lowest degrees of insulin resistance and low-grade inflammation at time of diabetes diagnosis. However, the still low number of dementia cases and short follow-up time in the DD2 cohort limit statistical precision and increase risk of reverse causality.

Disclosure: J.S. Nielsen: None.

784 Retinal microperimetry: a useful tool to predict and monitor the cognitive decline in patients with type 2 diabetes ≥65 years: a 3 years follow-up study

A. Ciudin1,2, A. Ortiz-Zuñiga1, J. Vasquez-de Sebastian3, C. Tejero3, O. Simó-Servat1, C. Hernandez1, R. Simó1;

1Endocrinology and Nutrition, Vall Hebron University Hospital, Vall Hebron Research Institute-VHIR, Barcelona, 2CIBERDEM, Madrid, 3RE-FIT Barcelona Research Group, Institut de Recerca Vall Hebron-VHIR & Parc Sanitari Pere Virgili, Barcelona, 4Endocrinology and Nutrition, RE-FIT Barcelona Research Group, Institut de Recerca Vall Hebron-VHIR & Parc Sanitari Pere Virgili, Barcelona, Spain.

Background and aims: Current guidelines for management of type 2 diabetes (T2D) recommend screening and annual monitoring for the cognitive function in patients ≥65 years. T2D acts as accelerator from normal cognition (NC) to mild cognitive impairment (MCI) and from MCI to dementia. However, the accurate assessment of the cognitive status is based on complex neuropsychological tests that cannot be largely incorporated to the current clinical practice. Additionally, at present, there are no reliable biomarkers to identify T2D patients with NC at higher risk of developing MCI. Our group has previously shown that retinal microperimetry (MAIA) is useful for discriminating NC and MCI in patients with T2D, but there are no data on its usefulness as either predictive biomarker of cognitive decline or for its monitoring. On these bases, we performed the present study aimed at exploring the role of retinal microperimetry both as a predictor of cognitive impairment and for the annual monitoring of the cognitive function in patients with T2D ≥65 years.

Materials and methods: Prospective observational study, including patients with T2D ≥65 years without known cognitive impairment, attending the outpatient clinic of our center between March-October 2018, with a 3-year follow-up after the baseline visit. At baseline and after 3 years the following items were assessed: anthropometric data, biochemical analysis, complete neuropsychological battery (RBANS)
and retinal microperimetry MAIA 3rd generation (retinal sensitivity [dB]), gaze fixation: P1%, P2%, Bacea63, Bacea95). MAIA was also performed at 12 months.

**Results:** 50 patients were evaluated and identified 36 T2D-NC, 10 T2D-MCI and 4 T2D with dementia. Patients with dementia were excluded. Regarding the MAIA, no significant changes were found in retinal Sb was after 12-month, while all gaze fixation parameters significantly worsened in both groups (NC and MCI). After 3 years’ follow-up, all the patients presented a significant worsening in the RBANS score and gaze fixation MAIA parameters (Bacea95), while retinal Sb significantly changed only in the NC group (24.5±0.6 vs 21.6±4.2, p = 0.041). The evolution of the RBANS score significantly correlated with the gaze fixation Bacea95 (r = -0.617, CI [-0.406–0.773], p = 0.006). In the NC group, 18 patients converted to MCI after 3 years. These patients had significantly lower baseline retinal Sb (20.6±3.8Db vs 23.8±0.9Db, p<0.001) and worse gaze fixation (Bacea95 23.9±18.1 vs 6.04±5.8°, p = 0.017) than subject who remained with normal cognition. The cut-off of 21.15 dB in basal retinal Sb predicted the risk of conversion from NC to MCI at 3 years with a sensitivity and specificity of 100%.

**Conclusion:** Our data suggest that retinal microperimetry, in particular gaze fixation parameter, is a useful tool for monitoring the cognitive decline both in T2D patients with NC or MCI. Additionally, retinal sensitivity is a useful tool to predict cognitive impairment after 3 years in T2D patients with NC.

**Disclosure:** A. Ciudin: None.

---

786 Type 2 diabetes and mood, anxiety and stress-related disorders: a genetically informative register-based cohort study

S. Liu1, M. Leone1, J.F. Ludvigsson1, S. Gudbjörnsdottir2, P. Lichtenstein1, S. Bergen1, H. Larsson1, R. Kuja-Halkola1, A. Butwicka1, 1Department of Medical epidemiology and biostatistic, Karolinska Institute, Solna, 2Swedish National Diabetes Register, Gothenburg, Sweden.

**Background and aims:** Mental health problems, especially mood, anxiety, and stress-related disorders, are common in people with type 2 diabetes (T2D). Yet, limited evidence is available for people with early-onset T2D (diagnosed before age 45), and the underlying factors that contribute to the concomitant occurrence between T2D and these psychiatric disorders remain unclear. To assess the association and familial co-aggregation of early-onset T2D with mood, anxiety, and stress-related disorders and estimate the contribution of genetic and environmental factors to their co-occurrence.

**Materials and methods:** This nationwide population-based cohort study was conducted using several Swedish national registers. Individuals born in Sweden from 1968 to 1998 were included and followed up to 31st Dec 2013. Within the study cohort, we identified pairs of full-, maternal and paternal half-siblings and cousins. Early-onset T2D and psychiatric disorders were diagnosed before age 45 using the International Classification of Disease, versions 9 and 10. Associations and familial co-aggregations of T2D with mood (including unipolar depression, bipolar disorder), anxiety, and stress-related disorders were estimated by Logistic regression models. Relative contributions of genetic and environmental factors to the association were estimated by quantitative genetic modeling.

**Results:** Of a total of 3,061,192 individuals, 7896 (0.3%) were diagnosed with T2D before age 45. All shared environmental factors including family size, socioeconomic status, smoking, and alcohol consumption were adjusted for age, gender and education in the analyses. No significant associations were found with AD. The analyses were adjusted for age, gender and education in Model 1 and the same factors and additionally APOE ε2 and APOE ε4 genotype (0, 1 or 2 alleles) in Model 2. See Figure 1 where bars that rise above the dotted line represent

**Conclusion:** Our findings expand the present understanding of the shared etiological liability of the co-occurrence of early-onset type 2 diabetes with mood, anxiety, and stress-related disorders, which could direct future research aiming at identifying the shared biological pathways, environmental risk factors, and intervention targets.
Materials and methods: Polygenic risk of type 2 diabetes is associated with dementia risk, with stronger associations for VaD, in particular in non-carriers of APOE ε4. However, the MR findings did not support a causal relationship between genetic risk markers of type 2 diabetes and VaD.

Conclusion: APOE ε4 is a strong genetic risk factor for both diabetes and dementia. The MR findings did not support a causal relationship between genetic risk markers of type 2 diabetes and VaD.

Discussion: The findings suggest that the role of APOE ε4 in the pathogenesis of type 2 diabetes and dementia may be complex and additional genetic and environmental factors need to be considered.

Supported by: The Swedish Diabetes Fund

Disclosure: E. Dybjer: None.

787

Cerebral microcirculation and cerebrovascular reactivity in type 2 diabetes and obesity, influence of haptoglobin polymorphism

M. Káplár1, B. Cogo1, R. Esze1, L. Rajnai1, Z. Képes2, S. Somodi1, G. Paraghi1, M. Katko1, M. Emri1, I. Garai2;

1University of Debrecen, 2ScanoMed Ltd, Debrecen, Hungary.

Background and aims: Microcirculation is damaged in diabetic patients, and it has also been observed in obesity. Decreased cerebrovascular reactivity has already been published in type 2 diabetes mellitus (T2DM). Haptoglobin (Hp) modulates atherosclerosis given its antioxidant effect. Hp(1-1) provides a stronger antioxidant effect as compared to Hp(1-2) and Hp(2-2) polymorphisms. A strong association between haptoglobin polymorphism and coronary sclerosis, furthermore carotid artery intima-media thickness has been reported previously, however, no data regarding the impact of Hp-polyorphism on cerebral microcirculation and cerebrovascular reactivity are available. Increased platelet activity and advanced glycation end products (AGEs) fundamentally influence vascular function. Our main aim was to investigate the cerebral microcirculation and the cerebrovascular reactivity and to find any association with haptoglobin polymorphism, platelet activity and AGEs levels in obesity and T2DM.

Materials and methods: Participants (diabetic group: 51 patients, mean age: 50.6±7.7 year, BMI: 33.59±5.91 kg/m²; obesity group: 46 patients, mean age: 51.5±9.7 year, BMI: 37.97±6.08 kg/m²) were involved after a written consent was obtained. Tc99m HMPAO dynamic SPECT/CT studies were performed to assess resting cerebral microcirculation. Cerebrovascular reactivity was measured from middle cerebral arteries using transcranial Doppler with the breath-holding method and results were expressed as breath-holding index (BHI). Serum AGEs and P-selectin levels were determined by autofluorescence and ELISA, respectively.

Results: There were no significant differences in hemispheric and regional brain perfusion at rest either between T2DM and obese patients or between groups with different haptoglobin polymorphisms. However, significant differences in BHI between Hp(1-1,1-2) and Hp(2-2) polymorphisms were found both in the whole study group (p=0.005), and in the obese group when evaluating the results separately (p=0.037). The difference in BHI between the two sides correlated negatively and significantly with AGEs levels in patients with Hp(1-1,1-2) polymorphism. There was a significant inverse correlation between BHI and P-selectin levels in those with Hp(2-2) polymorphism.

Conclusion: Hp(2-2) polymorphism significantly reduces the cerebrovascular reactivity of middle cerebral arteries in obese subjects. AGEs and platelet activity have only partial effect on BHI.

Disclosure: M. Káplár: None.
SO 69 Type 1 diabetes: new findings and complications

790 Exercise-related hypoglycaemia induces hypercoagulable changes in patients with type 1 diabetes

P.G. Hagelquist1, A. Andersen1, K. Maytham1, S. Engberg2, U. Pedersen-Bjergaard3, P.I. Johansson4, F.K. Knop5, T. Vilsbøll1

In cell research, AGEs were used to treat BV2 cells (Cell line of microglia) and HT22 cells (Hippocampal neuron cell line) as well as primary microglia and neurons. Additionally, medium from neurons with AGEs were used to treat microglia. Furthermore, medium from neurons with AGEs and FPS-ZM1 were also used to treat microglia. Finally, mRNA levels of tumor necrosis factor (TNF-α), interleukin (IL)-1β and IL-6 in BV2 cells and primary microglia as well as HMGB1 in cytoplasm, nuclear and medium were tested. In animal experiment, 15 weeks old KK-Ay mice were used as the model of diabetic cognitive impairment and neuroinflammation. Age matched C57/BL6j mice were used as control. Additionally, FPS-ZM1 was utilized to block the function of AGEs receptor. Levels of AGEs peptide in plasma as well as TNF-α, IL-1β and IL-6 mRNA in hippocampus tissue were measured. HMGB1 levels in cytoplasm and nuclear were observed. For the estimation of microglia activation, immunofluorescence was used to detect IBA-1 and CD68 in the brain of mice.

Results: In vitro study, low dose of AGEs cannot stimulate neuroinflammation in BV2 cells or primary microglia of neurons from new born mice. While low dose AGEs increased levels of HMGB1 in cytoplasm and medium, it could not regulate HMGB1 levels in nuclear of HT22 cells and primary neurons from fetal mice. Additionally, medium from AGEs treated HT22 cells and primary neurons increased the inflammatory factors including TNF-α, IL-1β and IL-6 of BV2 cells and primary microglia. Moreover, FPS-ZM1 treatment decreased levels of HMGB1 in cytoplasm and medium of HT22 cells and primary neurons. Compared with medium from AGEs treated HT22 cells and primary neurons, those with AGEs and FPS-ZM1 showed reduced levels of TNF-α, IL-1β and IL-6 of BV2 cells and primary microglia. In vivo, microglia associated neuroinflammation was activated. In addition, HMGB1 levels of cytoplasm were elevated in KK-Ay mice with diabetes. Moreover, FPS-ZM1 not only decreased HMGB1 levels of cytoplasm but also reduced activation of microglia and levels of TNF-α, IL-1β and IL-6.

Conclusion: HMGB1, derived from AGEs stressed neurons, mediated the cross-talk between neuron and microglia and stimulated the microglia associated neuroinflammation in diabetic mice with cognitive impairment.

Disclosure: H. Zhang: None.
Clinical Trial Registration Number: NCT04650646

Support: DFF, Grosserer LF. Fogle's foundation.

Disclosure: P.G. Hagelqvist: None.

Supported by: Folkhälsan Research Center

Disclosure: S. Satuli-Autere: None.

Table 1. Standard incidence ratios (SIR) for different neurodegenerative diseases among individuals with type 1 diabetes

<table>
<thead>
<tr>
<th>Disease</th>
<th>SIR 95%CI</th>
<th>No.</th>
<th>SIR 95%CI</th>
<th>No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer's disease</td>
<td>2.13 (1.41-3.58)</td>
<td>1545</td>
<td>2.13 (1.41-3.58)</td>
<td>1545</td>
</tr>
<tr>
<td>Parkinson's disease</td>
<td>2.62 (1.83-3.45)</td>
<td>1545</td>
<td>2.62 (1.83-3.45)</td>
<td>1545</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>1.81 (1.76-1.85)</td>
<td>1545</td>
<td>1.81 (1.76-1.85)</td>
<td>1545</td>
</tr>
</tbody>
</table>

Table 1 shows the impact of diabetic complications. Incidence of any dementia was increased already in individuals without diabetes. The incidence of different NDs among individuals with type 1 diabetes, compared to the background population, and to evaluate the impact of diabetic vascular complications. We hypothesize that deficiency in MBL-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway, will protect against diabetes-induced kidney damage. Mannan-binding lectin (MBL) initiates the lectin pathway, which is linked to albuminuria and mortality in patients with diabetes. We analyzed the renal effects of diabetes, i.e., interaction. The results showed that MASP-2 deficiency and the development of diabetic kidney disease in a mouse model of type 1 diabetes. MASP-2-deficient (Masp2−/−) mice and wild-type (WT) mice were divided into a diabetic group and a non-diabetic group. Renal hypertrophy, albumin excretion, glomerular volume, mesangial area, plasma levels of lectin pathway proteins, and specific mRNA expressions in the renal cortex were measured after 8 and 12 weeks of diabetes. By two-way ANOVA it was tested if MASP-2 modulated the renal effects of diabetes, i.e., interaction. Results: Diabetes-induced effects were observed in WT mice and Masp2−/− mice on kidney-to-body weight, albumin-to-creatinine ratio, mesangial area, plasma MBL-C, plasma C3, and renal mRNA expressions of both fibrotic and oxidative stress markers. After 12 weeks of diabetes Masp2−/− diabetic mice had a smaller mesangium at 21.1% of presence of diabetic complications, especially diabetic kidney disease and cardiovascular disease, further increased the incidence of dementia.
the glomerular area (95% CI 19.7, 22.6) when compared with WT diabetic mice, 25.2% (95% CI 23.2, 27.2), p=0.001. After 8 weeks of diabetes, plasma cystatin C was 261.5 ng/ml (95% CI 229.6, 297.8) in the WT diabetic group compared to 459.9 ng/ml (95% CI 385.7, 548.3) in non-diabetic WT mice, p=0.001. By contrast, no difference in plasma cystatin C levels was found between the Masp2−/− diabetic mice, 288.2 ng/ml (95% CI 260.6, 318.6) and Masp2−/− non-diabetic mice, 293.5 ng/ml (95% CI 221.0, 389.7), p=0.86 and p(interaction)=0.001.

**Conclusion:** We demonstrated a protective effect of MASP-2 deficiency on mesangial hypertrophy after 12 weeks of diabetes as well as an effect on plasma cystatin C level. MASP-2 deficiency did, however, fail to protect against diabetes-induced alterations of kidney weight, albuminuria, and renal mRNA expression of fibrotic- and oxidative stress markers.

**Background and aims:** The association between type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) is well known. Some studies indicate a relevant prevalence also in type 1 diabetes mellitus (T1DM), but so far there is only limited data. The aim of this study is to estimate the prevalence of NAFLD in patients with T1DM using non-invasive scores and compare baseline characteristics of patients with steatosis versus those without it.

**Materials and methods:** This is a retrospective observational study of 289 T1DM patients of our outpatient clinic of endocrinology. Exclusion criteria were alcohol consumption, pre-existing chronic liver disease (viral or autoimmune hepatitis) and use of chronic steatogenic medication. To predict the prevalence of NAFLD, we calculated the hepatic steatosis index (HSI). NAFLD score, FIB-4 index, GOT-Platelet Related Index (APRI), and GOT/GPT ratio were calculated for every patient and used to estimate the prevalence of advanced fibrosis. The baseline characteristics of patients with steatosis, versus those without it, were compared.

**Results:** Of the 289 patients included in the analysis 126 were women (43.6%) and 163 (56.4%) men with a mean age of 40.9 ± 12.5 years. The mean duration of DM was 19.7 years (0.5 to 54 years). 254 were on basal-bolus treatment and 35 on continuous subcutaneous insulin infusion (CSII). They had a mean BMI of 26.3 ± 4.4 kg/m², being 58.1% of the individuals under consideration above normal weight (BMI>25 kg/m²). NAFLD based on HSI > 36 was present in 61.9% of patients. Advanced fibrosis was present in 2.07% based on NFS > 0.676, 0.69% based on FIB-4 > 2.67, 0.69% based on APRI > 1.5, and 11.4% based on AST/ALT > 1.4. Compared to non NAFLD subjects, NAFLD subjects had significantly higher: age (42.9 ± 11.9 years vs 37.6 ± 12.9 years, p<0.001), BMI (28.5 ± 3.8 kg/m² vs 22.6 ± 2.1 kg/m², p<0.001), diabetes duration (21.2 ± 11.7 years vs 17.2 ±12.8 years, p=0.001), HbA1c (7.7 ± 1.3% vs 7.3 ± 1.1%, p = .0006), GPT (28 ± 15 U/l vs 19 ± 11 U/l, p<0.001) and triglycerides (108 ± 96 mg/dl vs 76 ± 42 mg/dl, p<0.001) while HDL levels were lower (50 ± 14 mg/dl vs 57 ± 15 mg/dl, p=0.002) in NAFLD patients. NAFLD subjects had higher prevalence of high blood pressure (27.9% vs 10.9%, p=.0006), retinopathy (22.35% vs 9.09%, p=.003) and statin use (53.6% vs 28.1%, p<0.0001). Doses of insulin/kg was significantly higher in NAFLD subjects (0.64 ± 0.26 vs 0.53 ± 0.2, p=.0001) and the use of CSII is less prevalent in NAFLD patients compared to non NAFLD patients (8.9% vs 17.3%, p=0.03).

**Conclusion:** In our sample, a remarkable percentage of the individuals showed a BMI higher than normal. Using non-invasive scores, our data reveal a remarkable prevalence of NAFLD, but not of advanced fibrosis, in T1DM. Furthermore, a significant association was found between hepatic steatosis (according to HSI) and age, hypertension, BMI, retinopathy, HbA1c, GOT, HDL, and TGs.

**Disclosure:** I. Moreno-Ruiz: None.

---

**793 Non-alcoholic fatty liver disease and type 1 diabetes**

I. Moreno-Ruiz1, I. Martín-Timón1, J. Modamio-Molina1, S. Bacete-Cebrian1, M. Zubillaga-Gómez2, L. Zeng1, O. Meizoso-Pita1, V. Triviño-Yannuzzi1, I. Huguet-Moreno1, M. Llaverio-Valero1, C. Lara-Moreno2, C. Sellvallano-Collantes2;

1Endocrinology, Hospital Universitario Infanta Leonor, 2School of Medicine, UCM, Madrid, Spain.

**Background and aims:** Cardiovascular disease (CVD) is a leading cause of death worldwide with type 1 and type 2 diabetes as known risk factors. Recent studies have shown deep learning (DL) predictors of CVD risk factors based on fundus images are significantly associated with CVD risk independently of the same risk factors. However, reported increment in CVD risk prediction of the DL models compared to a model using...
The contribution of insulin resistance and glycaemia on fibrin related clot parameters in young adults with type 1 diabetes

S.M. Pearson1, N. Kietsiriroje2, R.C. Sagar1, M.D. Campbell2, D.D. Stocken1, S. Plein1, R.A. Ajan1
1Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, 2Faculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland, UK.

Background and aims: CVD is a major problem in individuals with diabetes. Changes in clot density and fibrinolysis (fibrin related clot parameters) can predict adverse outcome following a vascular event in those with type 2 diabetes (T2D) and are also abnormal in type 1 diabetes (T1D). Individuals with T1D can develop insulin resistance which may exacerbate vascular risk. Estimated glucose disposal rate (eGDR) is a validated clinical marker of insulin resistance which predicts mortality in T1D. We hypothesised that insulin resistance in T1D further increases fibrin-related thrombosis risk and we aimed to explore the relative contribution of glycaemia and insulin resistance to changes in fibrin related clot parameters in young adults with T1D.

Materials and methods: Study participants were recruited from an adolescent diabetes clinic in the UK following informed consent. All had established T1D (>3 years) without macrovascular complication. Anthropometric data and a single blood sample were collected and participants were fitted with a blinded continuous glucose monitoring system (FreeStyle Libre Pro) for 14 days. Citrated plasma samples were analysed using a validated turbidimetric assay with clot maximum absorbance (Max OD, a measure of clot density) and time to 50% clot lysis (a measure of fibrinolysis potential) measured. Time in range (TIR) and time below range (TBR) was assessed according to international consensus. Two linear regression models were used to identify factors associated with Max OD and 50% lysis time. Model parameters were adjusted by sex and diabetes duration >10 years as potential confounders. Mean values for each variable were calculated and participants were dichotomised accordingly.

Results: A total of 69 participants were recruited with mean±SD age 24.6±3.5 years (n=43 males), diabetes duration 13.2±6.9 years and HbA1c of 6.5±16.6 mmol/mol. Mean eGDR was 7.96mg/kg/min±2.34. Mean TIR was 49.1%±18.9 and TBR 9.3%±8.3 with 15 patients with sensor wear <7 days excluded from analysis. Max OD was significantly affected by lower eGDR (β=0.063 95%CI: 0.037 to 0.085, p<0.001) and higher WC (β=0.049, 95%CI: 0.021 to 0.079, p<0.001) 50% lysis time was observed in all patients and was affected by the same variables (β =184sec, 95% CI: 45-332 and β =183sec, 95% CI: 44-321, all p<0.01) TIR, TBR and random glucose had no effect on either variable but higher HbA1c was associated with increased Max OD (0.33Au; 0.044-0.62, p=0.028). Hypertension was associated with higher Max OD (0.043Au; 0.017-0.075, p=0.012) but not lysis time. Data is shown in figure 1.

Conclusion: In this study of young adults with T1D markers of insulin resistance (eGDR, hypertension and WC) had the strongest impact on fibrin related clot parameters. Consideration to improving insulin sensitivity should be given when providing care to this group of patients.
Sustained QT prolongation 60-min post hypoglycaemic recovery in patients with type 1 diabetes
C.R. Andreasen1, A. Andersen1, P.G. Hagelqvist1, K. Maytham1, J. Lauritsen2, S. Engberg2, B. Hartmann3, J. Faber5, U. Pedersen-Bjergaard3, F.K. Knop2, T. Vilsbøll1;
1Clinical Research, Steno Diabetes Center Copenhagen, University of Copenhagen, Herlev, 2Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, 3Novo Nordisk A/S, Søborg, 4Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 5Department of Endocrinology, Herlev Hospital, University of Copenhagen, Herlev, 6Department of Endocrinology and Nephrology, Nordsjællands Hospital Hillerød, University of Copenhagen, Hillerød, Denmark.

Background and aims: Previous trials suggest that hypoglycaemia may prolong cardiac repolarisation, causing insulin-treated patients with type 1 diabetes to be vulnerable to fatal cardiac arrhythmias. We investigated the effects of recovery from insulin-induced hypoglycaemia to either rebound hyperglycaemia or euglycaemia on cardiac repolarisation in patients with type 1 diabetes.

Materials and methods: We included patients with type 1 diabetes (n=24, [mean±SD] age 53±11 years, HbA1c 57.6±8.9 mmol/mol [7.5±0.8%], diabetes duration 23±14 years, BMI 25.7±3.1 kg/m2), who underwent two experimental clamps in a crossover design. The two clamps consisted of three steady-state phases: 1) baseline euglycaemia (5-8 mmol/l) for 45 minutes, 2) hypoglycaemia (2.5 mmol/l) for 60 minutes, and 3) recovery hyperglycaemia (clamp A, 20 mmol/l) or euglycaemia (clamp B, 5-8 mmol/l) for 60 minutes.

Results: During hypoglycaemia, heart rate-corrected QT (QTc) (Fridericia’s formula) progressively increased from baseline on both clamp days (Table). In the recovery phase, QTc remained increased during hyperglycaemia and euglycaemia, with no difference between recovery to hyperglycaemia compared to euglycaemia. No significant changes from baseline were observed in QTc dispersion (heterogeneity of myocardial repolarization) during hypoglycaemia or in the recovery phases. Epinephrine levels were increased during hypoglycaemia, with no change from baseline during recovery and no difference between clamps. Potassium decreased during hypoglycaemia with no change from baseline during recovery. However, the potassium levels during recovery were higher during hyperglycaemia than in euglycaemia.

Conclusion: We found clinically significant QT prolongation during hypoglycaemia in patients with type 1 diabetes. The QT interval remained prolonged during a 60-minute recovery from hypoglycaemia with no difference between recovery to hyperglycaemia or euglycaemia. Our findings suggest that vulnerability to serious cardiac arrhythmias and sudden cardiac death may extend beyond a hypoglycaemic event itself.

797
The presence and extent of microvascular disease is independently associated with subclinical atherosclerosis in patients with type 1 diabetes
A. Barmpagianni1, A. Kountouri2, V. Lambadiari2, S. Liatis1;
1First Department of Propaedeutic Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 2nd Department of Internal Medicine, Propaedeutic and Research Institute, Athens University Medical School, “Attikon” University Hospital, Athens, Greece.

Background and aims: Cardiovascular atherosclerotic disease is a common cause of morbidity and mortality in patients with type 1 diabetes (T1D). Detection of subclinical atherosclerosis can be useful in order to identify individuals at high-risk to develop future cardiovascular events. The exact role of microvascular disease in the progression of atherosclerosis as well as its importance in predicting clinical cardiovascular disease has not been fully established. Aim of the present study is to examine the association between the presence and extent of diabetic microangiopathy and subclinical atherosclerosis in patients with T1D.

Materials and methods: We studied 235 consecutive patients with T1D from two academic diabetes outpatient clinics in Athens, without clinical macrovascular disease. The presence of retinopathy was assessed by an Ophthalmologist, nephropathy was defined as an albumin/creatinine ratio (ACR) ≥ 30mg/g and/or eGFR < 60ml/min and cardiac autonomic neuropathy was measured through the battery of three cardiac autonomic tests as previously described. Subclinical atherosclerosis was assessed by measuring pulse wave velocity (PWV) between the common carotid and femoral arteries and its presence was defined according to previously described age-specific PWV limits.
Results: The present analysis was performed in 219 patients with completed data regarding the presence and extent of microvascular disease (76 [34.7%] males with mean age [SD] of 35.2 [12.8] years and median diabetes duration [IQR] of 16 [10-25] years. Seventy-five (34.2%) patients had at least one manifestation of microvascular disease, while 19 (8.7%) and 2 (0.9%) had two and three manifestations respectively. Subclinical atherosclerosis (as expressed by abnormal age-specific PWV value) was detected in 54 (24.7%) individuals, and was significantly related to higher systolic blood pressure (SBP), longer duration of diabetes, higher BMI and the presence of every single microvascular disease manifestation. No association was found between subclinical atherosclerosis and gender, HbA1c, lipid profile and insulin needs. In multivariable analysis, subclinical atherosclerosis was independently associated to the presence and extent of microvascular disease (OR [95% CI]: 2.4 [1.1-5.2] for one manifestation; and 9.5 [3.2-28.4] for ≥2 manifestations). SBP (OR [95% CI]: 1.03 [1.01-1.05] for each mmHg increase), was the only other factor significantly associated with subclinical atherosclerosis.

Conclusion: The presence and extent of microvascular disease is significantly and independently associated with subclinical atherosclerosis in patients with T1D, free of clinical macrovascular complications. Prospective studies are needed in order to examine a possible predictive value of diabetic microangiopathy on future cardiovascular events.

Disclosure: A. Barmpagianni: None.

SO 70 Circulating markers of cardiovascular risk

Long-chain polyphosphates cause a distinct kidney injury phenotype and exacerbate LPS-induced acute kidney injury in mouse

A. Pirttiniemi1,2, H. Salmenkari1,3, J. Lindén4, K. Adeshara1,3, S. Lehtonen5, P.-H. Groop1,6, M. Lehto1,3,

1Folkhålsan Institute of Genetics, Folkhålsan Research Center, Helsinki, Finland, 2Research Program for Clinical and Molecular Metabolism, University of Helsinki, Helsinki, Finland, 3Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 4Finnish Centre for Laboratory Animal Pathology, University of Helsinki, Helsinki, Finland, 5Department of Pathology, University of Helsinki, Helsinki, Finland, 6Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.

Background and aims: Diabetes and other metabolic disorders are often accompanied by an increased rate of infections and chronic low-grade inflammation, which may participate in the development and progression of kidney disease. Our study in The FinnDiane Study Group aims to assess the renotoxic effects of long-chain polyphosphates, which are commonly found in pathogenic gram-negative bacteria, alongside the more well-known endotoxin, lipopolysaccharide (LPS).

Materials and methods: We used an in vivo experimental acute kidney injury (AKI) mouse model to assess renal damage caused by bacterial components, LPS, and long-chain polyphosphates. AKI was induced by injecting the mice with LPS (5 mg/kg, intraperitoneal injection) and long-chain polyphosphate (700 orthophosphate residues, P700, 10.2 mg/kg intravenous injection). The treatment groups were: [1] healthy control (n=8), [2] LPS treated (n=8), [3] P700 treated (n=4), and [4] LPS + P700 treated (n=8). The mice were sacrificed 20 hours after injection, and the kidneys, sera and urine of the mice were collected for subsequent analysis. The study was conducted using 9-week-old wild-type male BALB/c mice (BALB/cAnNCrl; Scanbur, Karlsunde, Denmark).

Kidney injury was assessed based on urine albumin-creatinine ratio (uACR, ELISA/enzymatic assays) as well as assessment of histopathological changes detectable in Hematoxylin-Eosin (H&E) and immunofluorescence (IF) microscopy analysis of the kidneys.

Results: Our study showed all treatment groups to have elevated uACR compared to the healthy control group: LPS (4.5-fold, p<0.001), P700 (8.7-fold, p<0.01), LPS + P700 (25.9-fold, p<0.01). Histopathological analysis (H&E) of the P700-treated mice showed foci of acute tubular necrosis in the outer medulla. The LPS + P700 treated mice exhibited additionally extensive acute tubular necrosis in the cortex, manifested as cytoplasmic eosinophilia, pyknotic nuclei and tubular casts. Further IF-staining revealed P700 and LPS + P700 treated mice to have de-localized and granular deposits of the podocyte marker, nephrin, at the podocyte foot process bifurcations (varying number and degree of affected glomeruli per kidney section). Interestingly, only LPS and LPS + P700 treated mice displayed clinical sepsis-like signs, while P700 treated mice showed no sepsis-like signs despite their observed kidney injury.

Conclusion: Long-chain polyphosphates, P700, worsen LPS-induced AKI and clinical signs of sepsis in mice. P700-treatment alone promotes albuminuria, and a distinct histopathological kidney phenotype with glomerular delocalization of nephrin, without causing clinical signs of sepsis. These findings demonstrate a novel role of polyphosphates for renal damage in mice, implying they could also serve as potential treatment targets for acute and chronic kidney disease associated with bacterial infections in humans.

Supported by: Uni. Helsinki DSHealth, Folkhålsan Research Center Disclosure: A. Pirttiniemi: Employment/Consultancy; Employment contract by University of Helsinki, The Doctoral School in Health Sciences. Grants; Funding for material costs has been provided by The Folkhålsan Research Center.
In this study 662 participants with type 1 diabetes were recruited between 2009 and 2011 for a prospective cohort study. Plasma samples were collected at baseline and mass spectrometry was performed, measuring four ceramides. Cox regression analysis was carried out investigating ceramides, and their ratio to Cer(24:0), against composite cardiovascular events, end-stage kidney disease, as well as all-cause mortality. Hazard ratios (HRs) are reported per doubling in concentration.

Results: The median follow-up time was 6.3 (IQR 0.8) years, during which 94 participants experienced cardiovascular events, 23 progressed to end-stage kidney disease and 58 participants deceased. Cer(16:0) and Cer(18:0) were associated with cardiovascular events with HRs of 2.6 (CI 1.3-5.4, \( p = 0.007 \)) and 2.0 (1.2-3.4, \( p = 0.005 \)). The ratios Cer(18:0)/Cer(24:0) and Cer(24:1)/Cer(24:0) were also associated with cardiovascular events with HRs 1.7 (1.1-2.6, \( p = 0.012 \)) and 2.7 (1.4-5.2, \( p = 0.002 \)), respectively. Cer(16:0) and the ratio of Cer(24:1)/Cer(24:0) were associated with end-stage kidney disease with HRs 5.4 (1.2-23.5, \( p = 0.0024 \)) and 8.8 (2.4-32.6, \( p = 0.001 \)), respectively. Finally, Cer(24:0) and the ratios Cer(16:0)/Cer(24:0), Cer(18:0)/Cer(24:0) and Cer(24:1)/Cer(24:0) were all associated with all-cause mortality with HRs 1.4 (CI 0.6-3.2), 3.3 (2.0-5.5), 3.3 (1.9-5.7) and 5.3 (2.3-12.1) (all \( p \)-values < 0.0001).

Conclusion: Specific ceramides were associated with increase in the 6-year risk of complications in a type 1 diabetes population. This highlights the strength of single ceramide association to vascular complications and presents a new potential tool for early risk assessment.
The correlation between mannose and insulin resistance, glycated hemoglobin, fasting plasma glucose and two-hour postload glucose was low as it was for BMI, waist girth, and smoking. Mannose levels were significantly associated with MI in participants with NGT (adjusted Odds Ratio (OR) patients vs controls: 2.27 (95% Confidence Interval (CI) 1.34 - 3.83), however, this was not apparent in dysglycaemic participants i.e. with IGT, newly detected or known DM (adjusted OR: 1.50, 95% CI 0.80 - 2.82).

Conclusion: Mannose increased with increasing levels of dysglycaemia. Overall, the concentrations were significantly higher in patients with a first MI than in controls, but independently associated with MI only in NGT patients. These results reinforce previous findings that mannose is related to coronary atherosclerosis and glucose perturbations, adding that it may be a more sensible marker of risk for a first MI than glucose-related expressions for dysglycaemia. Thus, the prognostic value of mannose in patients at high cardiovascular risk deserves further evaluation.

801 Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program


Background and aims: Raised liver function tests (LFTs) have been correlated with multiple metabolic abnormalities and variably associated with cardiorenal outcomes. We sought to systematically test the relationship between LFT levels within the accepted range and major cardiorenal outcomes in a large clinical trial in type 2 diabetes (T2D), and the possible impact of placebo-controlled canagliflozin treatment.

Materials and methods: We measured serum ALT, AST, γGT, ALP, and bilirubin concentrations in 10,142 patients, at baseline and repeatedly over follow-up. The relation of LFTs to first hospitalized heart failure (HHF), cardiovascular (CV) and all-cause mortality, and progression of renal impairment was investigated using multivariate proportional-hazards models.

Results: In univariate association, ALT was reciprocally predictive, and AST, and γGT over time. In a fully adjusted model including updated LFT levels and treatment, γGT was independently associated with CV and all-cause mortality, ALP with renal dysfunction progression, and canagliflozin treatment with significant reduction in HHF and renal risk. Conclusion: Higher γGT levels are top LFT markers of risk of HHF and death in patients with T2D and high CV risk, while ALT are protective. Canagliflozin lowers the risk of HHF and renal damage independently of LFTs and potential confounders.

Clinical Trial Registration Number: NCT01032629
Supported by: Janssen Research & Development, LLC.
Disclosure: E. Ferrannini: Grants; Janssen Research and Development.

802 Therapeutic potential of Crispr/Cas-9 gene edited apolipoprotein B-null cells and insulin signalling in lipoprotein metabolism

Q. Su, H. Wade; Queen's University Belfast, Belfast, UK.

Background and aims: Hyperlipidaemia, an abnormal high level of very low-density lipoprotein (VLDL) in the blood, is one of the most important risk factors for cardiovascular disease (CVD) in type-2 diabetes patients. A key contributing factor underlying hyperlipidaemia is the overproduction of hepatic apolipoprotein B (ApoB), a key structural protein of VLDL. Due to the embryonic lethality upon genetic depletion of apoB, generation of an ApoB-null mouse model had failed, which hinders the development of effective research approaches to investigate the pathophysiological function of ApoB. The advancement of cutting-edge gene-editing tool, Crispr/Cas-9 system, has enabled to deplete ApoB gene in hepatocytes. This greatly broadens the potentials to study the pathological function of VLDL-ApoB and the associated atherosclerosis. Therefore, the objective of this study is to genetically disrupt ApoB in hepatocyte using Crispr/Cas-9 gene editing technology and determine the impact of ApoB on hepatic lipoprotein metabolism and the regulation of insulin on atherogenesis.

Materials and methods: The cellular ApoB in both human and mouse hepatocytes were disrupted by Crispr/cas-9 gene editing technology. The ApoB-null cells were further subjected to transcriptome analysis by RNA-sequencing and bioinformatics analysis. A number of molecular biological technology, including q-RT-PCR and immunoblotting analysis, was used to determine regulation of insulin signalling on lipoprotein metabolism.

Results: Transcriptome profile of wild type (WT) and ApoB-null hepatocytes by RNA-sequencing revealed that depletion of ApoB significantly suppressed expression of several apolipoproteins that are key components of VLDL particles, including ApoE and ApoC-1 (P<0.001). Analysing genes involved in vascular endothelial inflammation and atherogenesis we further found that mRNA expression of Toll-like receptor (TLR) -2 (TLR-2), TLR-4, and Icam-1 were markedly reduced in ApoB-null cells compared to WT cells (P<0.001). These indicate the essential role of ApoB in lipoprotein metabolism and the reduced risk of atherogenesis upon ApoB-depletion. Induction of insulin resistance in the WT and ApoB-null cells revealed that expression of TLR-2, TLR-4, Icam-1 and ApoC-1 were significantly upregulated in the WT cells but not in the ApoB-null cells, implicating the lower susceptibility of the ApoB-null cells to metabolic inflammation and atherogenesis at the insulin resistant state. We further reconstituted ApoB function in the ApoB-null cells by transfecting an ApoB expressing plasmid for 48 hours and found that restoration of ApoB upregulated expression of TLR-2, TLR-4, Icam-1, ApoE and ApoC-1 in the transected ApoB-null cells compared to the un-transfected null cells (P<0.05). These data confirmed the anti-atherogenic effect of ApoB-depletion.

Conclusion: This is the first study that disrupts ApoB function in hepatocytes using Crispr/Cas-9 gene editing system and characterizes the pathophysiological function of ApoB and the regulation of insulin
signalling in this context. Novel finding from this study provides mechanistic evidence for developing therapeutic strategy to target ApoB in human subjects with diabetes associated dyslipidaemia and atherosclerosis.

Supported by: BHF
Disclosure: Q. Su: None.

803
Leptin correlates with pulse wave velocity independently of BMI, inflammation, home blood pressure and HbA1c in both men and women in a large population-based cohort
C. Vavruch, C. Östgren, J. Engvall, F.H. Nyström, L. Jonasson; Department of Health, Medicine and Caring Sciences, Faculty of Medicine and Health Sciences, Linköping, Sweden.

Background and aims: New and clinically useful biomarkers of cardiovascular risk are of essence, since ischemic heart disease is a leading cause of death in the population. Pulse wave velocity (PWV) is one of the most powerful clinical physiological markers of cardiovascular disease and risk, but is currently not regularly used clinically for risk assessment in Sweden. We aimed to find out whether leptin can be used as a marker for PWV.

Materials and methods: We analyzed baseline data from 1 580 men and 1 623 women who participated in “The Swedish CARDioPulmonary biImage study” (SCAPIS), a population-based multicenter study. This study was performed with data from only the Linköping cohort, recruited during year 2016 to 2018, aged 50-65. Prevalent diabetes, hypertension, dyslipidemia, and smoking status, as well as sleep data, were based on self-reported health in combination with laboratory results. Blood pressure was measured at home, once in the morning and once in the afternoon, for seven consecutive days, for a total of 13 times. Carotid-femoral pulse wave velocity was measured by tonometry to determine arterial stiffness.

Results: In a bivariate correlation, leptin, IL18, and hsCRP were all correlated with a p < 0.001 in both men and women. Log transformed leptin correlated positively with PWV, independent of mean systolic blood pressure, IL18, smoking, LDL/HDL cholesterol ratio, BMI, age, and HbA1c (men: p = <0.001, 95% CI 0.093-0.233; women: p = 0.001, CI 0.056-0.223). In a linear regression with hsCRP instead of IL18 as the marker of inflammation, leptin still associated (men: p = < 0.001, 95% CI 0.095-0.232; women: p = 0.002, 95% CI 0.050-0.213).

Conclusion: Our data support the use of leptin as a marker of PWV and arterial stiffness, that is independent of inflammation, BMI, glucose homeostasis as measured by HbA1c, and traditional risk markers. This has not previously been demonstrated in such a large cohort based on randomized recruitment of participants.

Supported by: The Swedish Heart Lung Foundation
Disclosure: C. Vavruch: None.

804
Low-density lipoprotein-cholesterol levels in migrants and native Danes with type 2 diabetes
A.A. Isaksen1, A. Sandbaek1,2, M.V. Skriver1, G.S. Andersen3, L. Bjerg2; 1Department of Public Health, Aarhus University, Aarhus, 2Steno Diabetes Center Aarhus, Aarhus, 3Steno Diabetes Center Copenhagen, Copenhagen, Denmark.

Background and aims: Elevated low-density lipoprotein-cholesterol (LDL-C) levels is a risk factor for complications and death in type 2 diabetes (T2D), and identification of subgroups with elevated levels is important for appropriate care. We aimed to describe LDL-C levels among migrants with T2D in Denmark, and the risk of exceeding a target level recommended by Danish clinical guidelines.

Materials and methods: In a registry-based nationwide Danish cohort study, we identified individuals with T2D on January 1 2018. Analyses were restricted to individuals with a diabetes duration of at least six months, in order to allow time for clinical measurement of LDL-C, initiation of lipid-lowering treatment and subsequent stabilization of LDL-C levels in newly-diagnosed. The LDL-C level was defined at the most recent measurement, and migrant status was classified based on country of birth and citizenship, and categorized into nine groups. The empirical cumulative distribution (ECD) of LDL-C levels was computed with 95% confidence intervals. The relative risk of having an LDL-C ≥ 2.6 mmol/L was computed in Poisson regression models with robust sandwich variance estimates: model 1 adjusted for sex, age, diabetes duration and prevalent complications (macrovascular complications or diabetic kidney disease), while model 2 additionally adjusted for employment status, equivalised disposable family income, duration of residence and region of residence.

Results: In the origin groups assessed, 254,097 individuals had T2D with a duration of at least six months on January 1 2018 (native Danes: 225,750 (88.8 %), Middle East: 7,865 (3.1 %), Europe: 6,396 (2.5 %), Turkey: 4,472 (1.8 %), Former Yugoslavia: 3,509 (1.4 %), Pakistan: 2,715 (1.1 %), Sri Lanka: 1,653 (0.7 %), Somalia: 957 (0.4 %), Vietnam: 780 (0.3 %)). In this population, 248,813 (97.9 %) had a prior measurement of LDL-C and were included in the analyses. Figure 1 shows the ECD of LDL-C levels, and the RR of exceeding 2.6 mmol/L in each group. In summary, 28.3% of native Danes had an LDL-C ≥ 2.6 mmol/L, and the crude risk of having an LDL-C ≥ 2.6 mmol/L was increased in most migrant groups (RRs from 1.08 [95%CI: 1.03-1.14] in the Former Yugoslavia-group to 1.78 [95%CI: 1.67-1.90] in the Somalia-group). This pattern appeared consistent in the ECD across a
range of alternative target values from 2.6 mmol/L to 1.8 mmol/L. In the fully adjusted model, the RR remained elevated in the Middle East, Europe, Pakistan, and Somalia groups (RRs from 1.07 [95%CI: 1.01-1.13] in the Pakistan-group to 1.44 [95%CI: 1.35-1.54] in the Somalia-group).

**Conclusion:** In the T2D population of Denmark, high levels of LDL-C were common, and most migrant groups had higher levels of LDL-C than native Danes. Migrants from Somalia had particularly high levels of LDL-C, and were almost twice as likely to exceed a guideline target level compared to native Danes.

**Supported by:** Support provided by Steno Diabetes Center Aarhus & the Public Health in Central Denmark Region

**Disclosure:** A.A. Isaksen: Grants; Support provided by the Steno Diabetes Center Aarhus (SDCA) which is partially funded by an unrestricted donation from the Novo Nordisk Foundation, Support provided by the Public Health in Central Denmark Region-foundation.

---

**805**

**Serum sphingolipidomic profile and high density lipoprotein subfractions in obese dyslipidemic type 2 diabetic patients**

**M. Aslan**¹, I. Aslan², D. Aydan², Y. Koç³, Ç. Yılmaz¹, T. Çeker¹, A. Öztüzün¹; ¹Medical Biochemistry, Akdeniz University Faculty of Medicine, ²Endocrinology Clinic, The University of Health Sciences, ³Internal Medicine Clinic, The University of Health Sciences, Antalya, Turkey.

**Background and aims:** Obese patients with type 2 diabetes mellitus (T2DM) show an altered lipid profile and a certain degree of insulin resistance, which might contribute to changes in both serum sphingolipidomic profile and high-density lipoprotein (HDL) subfractions. We aimed to investigate changes in serum sphingolipid levels and HDL subspecies in relation to low-density lipoprotein cholesterol (LDL-C), non-HDL-C and triglyceride (TG) levels in type 2 diabetic patients.

**Materials and methods:** Serum was collected from 60 T2DM patients. Levels of C16-C24 sphingomyelins (SMs), C16-C24 ceramides (CERs), sphingosine-1-phosphate (S1P) and C16 CER-1P were determined by an optimized multiple reaction monitoring (MRM) method using ultra fast liquid chromatography (UFLC) coupled with tandem mass spectrometry (MS/MS). HDL subfraction analysis was done by continuous disk polyacrylamide gel electrophoresis.

**Results:** C16-C24 SM, C16-C24 CER and C16 CER-1P levels showed a statistically significant increase in T2DM patients with LDL-C above 160 mg/dL compared to those with LDL-C below 100 mg/dL. C16-C24 SM, C22-C24 CER, C16 CER and C16 CER-1P levels showed a statistically significant increase in T2DM patients with non HDL-C above 130 mg/dL compared to those with non HDL-C below 130 mg/dL. C24:C16 SM and C24:C16 CER ratio showed a significant correlation with both LDL-C and non HDL-C levels. Obese T2DM patients (BMI>30) had significantly higher circulating levels of C24 SM, C18-C24 CER compared to those with BMI<30. Type 2 diabetic patients with fasting TG levels above 150 mg/dL showed a significant decrease in HDL-large and a significant increase in HDL-small fractions compared to those with TG levels below 150 mg/dL. Analysis of HDL subfractions independent of TG concentrations showed that HDL large subfractions were significantly higher in female T2DM patients compared to males. Type 2 diabetic patients on steroid therapy had significantly higher levels of HDL large subfractions compared to those who were not treated with steroids.

**Conclusion:** Plasma sphingomyelins, ceramides and HDL-small fractions are elevated in obese dyslipidemic T2DM patients. Serum long chain CERs, C24:C16 SM, C24:C16 CER ratio and alterations in HDL subfractions may serve as prognostic and diagnostic markers in type 2 diabetic dyslipidemia.

**Supported by:** Akdeniz University Research Foundation TTU-2021-5605

**Disclosure:** M. Aslan: None.
SO 71 Prevention and treatment of cardiovascular complications

806 Risk of stroke in patients with type 2 diabetes receiving semaglutide or a dipeptidyl peptidase-4 inhibitor: a real-world US claims database analysis

M. Evans1, M. Husain2, O. Frenkel3, K. Mangla4, A. Srivastava4, I. Lingvay5;
1University Hospital, Llandough, Penarth, Cardiff, UK, 2Ted Rogers Centre for Heart Research, Department of Medicine, University of Toronto, Toronto, Canada. 3Novo Nordisk A/S, Søborg, Denmark, 4Novo Nordisk Global Business Services, Bengaluru, India, 5Department of Internal Medicine and Department of Population and Data Sciences, UT Southwestern Medical Center, Dallas, USA.

Background and aims: People with type 2 diabetes (T2D) have a higher risk of stroke and worse outcomes than those without T2D. A meta-analysis of RCT data has shown that glucagon-like peptide-1 receptor agonists are associated with a significant reduction in the risk of stroke, but there remains a specific evidence gap for the real-world effect of semaglutide. We compared risk of incident stroke in patients with T2D or T2D + atherosclerotic CVD (ASCVD) initiating either semaglutide or a dipeptidyl peptidase-4 inhibitor (DPP-4i).

Materials and methods: Adults (≥18 years) in a US claims database with a claim indicating initiation of semaglutide or a DPP-4i (index date) during the index period (1/1/18-30/9/20), a diagnosis code for T2D on or before index date, and 12 months’ continuous enrolment pre-index were included. Exclusion criteria were a claim for semaglutide, DPP-4i or injectable glucose-lowering medication, or a diagnosis code for type 1 or secondary diabetes in the 12 months pre-index; or a claim associated with pregnancy or gestational diabetes at any time during the study period. Patients were propensity score matched 1:1 on baseline demographic and clinical characteristics (27 variables for T2D; 26 for T2D+ASCVD). Primary outcome was time to first stroke event during follow-up (medical claim with stroke as primary diagnosis during inpatient or emergency room visit).

Results: Post-matching, there were 17,920 pairs with T2D and 4234 pairs with T2D+ASCVD. The groups were well matched on baseline characteristics. Patients with T2D initiating semaglutide had a lower risk of stroke than those initiating a DPP-4i (HR 0.63 [95% CI 0.41, 0.95]; p = 0.029). This was more pronounced for T2D+ASCVD (HR 0.45 [0.24, 0.86]; p = 0.015). Overall, 34 patients with T2D receiving semaglutide (0.2%) experienced a stroke event (incidence rate [IR] per 100 person-years 0.25), compared with 60 patients receiving a DPP-4i (0.3%; IR 0.40; IR ratio [IRR] 0.62 [95% CI 0.40, 0.95]). For T2D+ASCVD, 13 patients receiving semaglutide (0.3%; IR 0.40) and 32 receiving a DPP-4i (0.8%; IR 0.90) experienced a stroke event (IRR 0.44 [0.23-0.85]). The Figure shows cumulative incidence of stroke over the follow-up period (median 237-258 days).

Conclusion: Our results provide preliminary information regarding the potential of semaglutide to reduce stroke in patients with T2D in a real-world setting. Analyses with additional comparison groups and longer follow-up are needed to determine the broader clinical and economic implications.

Supported by: Novo Nordisk A/S
Disclosure: M. Evans: Grants; This study was funded by Novo Nordisk A/S. Honorarium; ME has received honoraria from AstraZeneca, Boehringer Ingelheim and Novo Nordisk.
Background and aims: Glucagon-like peptide-1 receptor agonist (GLP-1ra) and sodium glucose cotransporter-2 inhibitors (SGLT-2i) have each shown cardiovascular and nephroprotective effects. However, the underlying mechanisms are poorly understood, and it is not clear whether combined treatment has synergistic favorable effects on cardiovascular function. In this 32-week randomized, placebo-controlled trial we compared the individual and combined effects of the GLP-1ra semaglutide and the SGLT-2i empagliflozin on measures of cardiovascular function.

Materials and methods: 120 participants with type 2 diabetes were randomized into one of four arms: placebo (n=30), empagliflozin (n=30), semaglutide + placebo (n=30) or the combination of semaglutide + empagliflozin (n=30). Empagliflozin treatment was double blinded. Outcomes comprised: arterial stiffness (carotid-femoral pulse wave velocity [cf-PWV]), including 24h PWV measurements, 24h-blood pressure (BP), central BP, and urinary albumin/creatinine ratio (UACR).

Results: cf-PWV did not change in any of the groups (placebo -0.2 ± 0.22 m/s, p=0.36, empagliflozin 0.07 ± 0.21 m/s, p=0.74, semaglutide 0.4 ± 0.21 m/s, p=0.07 and combination -0.07 ± 0.21 m/s, p=0.75, with no significant intergroup differences). During 24h measurements daytime PWV was reduced in the combination group (-0.23 ± 0.07 m/s, p=0.002, p<0.05 compared to placebo, empagliflozin and semaglutide). At week 32, 24h-systolic blood pressure was reduced with 10 ± 2 mmHg (p<0.001) in the combination group which was significantly different compared to both placebo and either treatment alone (p<0.05), Figure 1A. Similar changes were seen in central systolic BP (SBP) (-10 ± 2 mmHg, p<0.001 in the combination group, p<0.05 compared to placebo, empagliflozin and semaglutide). Combination treatment resulted in significant reductions in HbA1c and BMI (data not shown), but controlling for these changes did not affect the BP reductions substantially. UACR decreased in all three treatment groups, Figure 1B. The reduction in the combination arm from baseline was 40% [-55;11], p<0.001 which was significantly higher than the reduction in the placebo arm (difference between placebo and combination; 56 % [4;133], p<0.03).

Conclusion: To our knowledge, this is the first demonstration of combination treatment with semaglutide and empagliflozin leading to substantial and clinically important sympathetic reductions in 24h and central blood pressure. Furthermore, UACR was significantly reduced by the combination treatment. We found no significant effect of treatment with empagliflozin, semaglutide or their combination on arterial stiffness, except for a small reduction in daytime PWV in the combination group (probably driven by the reduction in BP).

808
Lesser improvement of physical activity after a cardiac rehabilitation program in patients at risk of diabetes or increased artery stiffness

P. Valensi¹, M. Nguyen¹, M. Duval¹, M. Sylvã², G. Amah³, N. Chaib³, S. Gagey², C. Guiti², K. Abdenbib²;
¹Unit of Endocrinology-Diabetology-Nutrition, Jean Verdier hospital, Paris-Nord University, CRNH-IDF, CINFO, Bondy, ²Centre de Réadaptation cardiovasculaire, hôpital Léopold Bellan, Paris, France.

Background and aims: Artery stiffness, an early marker of atherosclerosis, was reported to be increased in individuals with diabetes, prediabetes or with low physical activity. We hypothesized that prediabetes and higher artery stiffness might be limiting factors for the improvement of aerobic performance after a one-month cardiac rehabilitation program.

Materials and methods: We included 838 patients (men 79%), most of them with coronary artery disease (mostly after an acute coronary syndrome). In the 463 patients without known diabetes, Findrisk score was calculated and an oral glucose tolerance test (OGTT) was performed at admission in the program; artery stiffness was analyzed by measuring carotid-to-femoral pulse wave velocity (PWV) and central blood pressure (Compilor®), and a stress test with VO2max measurement was performed at admission and at the end of the program.

Results: Based on OGTT results, 41% of the 463 patients were diagnosed with diabetes or prediabetes. Findrisk score correlated strongly (p<0.0001) with plasma glucose at fasting and 2 hours after glucose load but did not correlate with PWV. VO2max increased significantly after the rehabilitation program (p<0.001) while PWV decreased slightly (p=-0.06). VO2max before and after the program correlated negatively with Findrisk score (p<0.0001), more strongly than with glucose levels. Before the program, VO2max correlated negatively with PWV and brachial and central pulse pressure (p<0.0001). Multivariate analyses showed that before the program lower VO2max was associated with both higher Findrisk score and PWV, independently from age and gender. After the program VO2max and its change (difference after-before) correlated negatively with PWV after the program (p=0.0001 and p=0.003).

Conclusion: In this cohort of patients included in a cardiac rehabilitation program the data show the high prevalence of previously unknown glycemic disorders, and the role of OGTT for their detection. The risk of diabetes (Findrisk) and artery stiffness were associated with a lower physical capacity and might act as limiting factors for the improvement of aerobic performance after rehabilitation.

Disclosure: P. Valensi: None.
index (LVMI) measured by sequential magnetic resonance imaging (MRI). Patients with T2D, LVH and stage 3 CKD, on stable renin angiotensin aldosterone system blockade, with raised intact parathyroid hormone (iPTH) level between 30-300 pg/ml were eligible. Secondary endpoints included urine albumin/creatinine ratio, serum calcium, phosphate levels, iPTH, eGFR, and interstitial myocardial fibrosis (using MRI with gadolinium).

**Results:** In total, 45 (male 73%) patients with T2D and stage 3 CKD were randomised (calcitriol n=19 or placebo n=26). Baseline, characteristics, mean (standard deviation) or median [interquartile range], respectively in the placebo and calcitriol group were: for age (years) 64.3 (9.76) and 70.3 (8.5), for eGFR (ml/min/1.73 m²) 42.3 (7.75) and 45.1 (9.3), for iPTH (pg/ml) 157 [65-227] and 142 [80-293], for high sensitivity (hs) C-reactive protein (CRP) (mg/L) 6 [1.6-11.4] and 2 [0.7-6.4], and for LVMI (gr/m²) 50.11 (14.74) and 47.28 (12.1). Following 48-week treatment with calcitriol, iPTH was significantly reduced only in the calcitriol group from 142 [80-293] to 76 [41-204] (p=0.04). Changes in LVMI using an analysis of covariance (ANCOVA) with baseline LVMI as covariate was not significantly different between the placebo and calcitriol arms. No significant differences were observed for hsCRP, urine albumin/creatinine ratio, interstitial myocardial fibrosis and eGFR between groups. Calcitriol was well tolerated and of the patients enrolled in the calcitriol group, 3 patients (15%) had the calcitriol dose reduced to 0.5 mcg on alternate days as per protocol due to mild hypercalcemia (defined as calcium >2.6 but <2.8 mmol/L).

**Conclusion:** In patients with T2D, LVH and stage 3 CKD, 48-week treatment with calcitriol as compared to placebo does not improve LVMI. Our data does not support the routine use of active vitamin D for cardiovascular protection in patients with T2D and stage 3 CKD.

**Clinical Trial Registration Number:** EudraCT Number 2011-003025-10

**Supported by:** EFSD Clinical Research Grants

**Disclosure:** L. Gnudi: None.

---

**810**

**Four months treatment with dapagliflozin or dulaglutide improves cardiovascular function in patients with type 2 diabetes and ischemic stroke**

A. Kountouri1, I. Ikonomidis2, V. Prentza1, K. Katogiannis2, G. Pavlidis2, E. Konakas1, L. Plouta1, G. Kostelli1, E. Michalopoulou1, J. Thymis2, K. Balampanis2, A. Raptis2, G. Tsvigoulis1, V. Lambadiari1;
1Second Department of Internal Medicine, National and Kapodistrian University of Athens, Attikon hospital, 2Second Cardiology Department, National and Kapodistrian University of Athens, Attikon hospital, 3Second Department of Neurology, National and Kapodistrian University of Athens, Attikon hospital, Athens, Greece.

**Background and aims:** Patients with type 2 diabetes mellitus (T2DM) and ischemic stroke present impaired markers of vascular and endothelial function. Glucagon-like peptide-1 receptor agonists (GLP-1) and sodium-glucose cotransporter-2 inhibitors (SGLT-2) are novel antidiabetic agents reducing the risk of cardiovascular complications. The aim of the study is to investigate the effect of treatment with GLP-1 or SGLT2 on arterial stiffness, on cardiac performance and on endothelial glycocalyx in patients with T2DM and ischemic stroke.

**Materials and methods:** We recruited in total 81 patients with T2DM and ischemic stroke who received dulaglutide (n=27), dapagliflozin (n=27) or insulin (n=27). We measured at baseline and at 4 months post-treatment the: a) Carotid-femoral pulse wave velocity (PWV-Compil; ALAM Medical) b) Augmentation index (Aix) c) Central systolic blood pressure (eSBP) and d) Perfused boundary region (PBR) of the sublingual arterial microvessels (marker of endothelial glycocalyx thickness) e) Left ventricular global longitudinal strain (GLS) using speckle-tracking echocardiography.

**Results:** At baseline, patients among the three groups had similar age, sex, HbA1c and markers of endothelial and vascular function (p>0.05). After four months treatment, patients on dapagliflozin and on dulaglutide displayed a greater reduction of PWV (12.98±3.23 vs 11.62±1.74m/s, p=0.017, 14.77±1.97 vs. 13.59±2.20m/s, p=0.042 respectively), eSBP (132.15±14.03 vs 120.27±10.05mmHg, p=0.035, 139±7.25 vs 129±7.75mmHg, p=0.045 respectively), Aix (17.10±17.83 vs 5.97±28.99, p=0.028, 8.59±20 vs 7.46±6.36, p=0.039 respectively) and GLS (-16.87±3.28 vs -18.76±3.35, p=0.001, -16.31±3.42 vs -17.48±3.14, p=0.004 respectively) compared to patients on insulin, despite a similar glycosylated hemoglobin reduction (P>0.05). Patients on dapagliflozin displayed a greater reduction of PWV (-10%), Aix (-65%), eSBP (-39%) and GLS (+11%) compared to patients on dulaglutide or on insulin (PWV, -8% and -1%; Aix, -13% and -3%; eSBP, -8% and +1%; GLS, +7%, and +5%), (P<0.05 for all comparisons). PBR values were improved only in patients who received dulaglutide (2.10±0.16 vs 2.00±0.14, p=0.025 vs dapagliflozin;2.04±0.23 vs 2.00±0.11, p=0.696 vs insulin;2.13±0.3 vs 2.15±0.3, p=0.567).

**Conclusion:** Four-month treatment with dulaglutide or dapagliflozin improves arterial stiffness and cardiac performance, but only dulaglutide improves endothelial glycocalyx in patients with T2DM and ischemic stroke. Patients treated with dapagliflozin had greater reduction of PWV and central SBP than patients under insulin or dulaglutide.

**Disclosure:** A. Kountouri: None.
proportions of MACE and HHF events prevented are also depicted within each bar). Estimated GLP-1RA- and SGLT2i-mediated reductions in CVD events were similar at low-intermediate MACE or HHF risk, but tended to favour SGLT2is at higher risk levels of both scores. **Conclusion:** HHF is relatively uncommon in low-intermediate CVD risk settings, so GLP-1RA and SGLT2i treatment can be expected to offer similar CV protection. However, the greater rise in HHF relative to MACE with progressively higher CVD risk - irrespective of the risk score applied - increasingly favoured SGLT2i treatment. Thus, SGLT2is may offer greater CVD protection in those at highest CVD risk, not just those at highest risk of HHF alone.

**Results:** Overall, the median adherence rate for polypharmacy was 75% (IQR 61%, 85%), and 37% of the individuals had good, 54% intermediate and 9% a poor adherence rate. In the whole cohort, the good (OR 0.56 [95% CI 0.37, 0.84], \( p = 0.006 \)) and intermediate (0.55 [0.38, 0.81], \( p = 0.003 \)) adherence rates were associated with lower occurrence of CVD events compared to the poor adherence rate. Similarly, in individuals with moderate albuminuria, both good (0.22 [0.09, 0.51], \( p = 0.0005 \)) and intermediate (0.31 [0.14, 0.67], \( p = 0.003 \)) adherence rates were associated with lower occurrence of CVD events than poor adherence rate. However, no differences between the good and poor or between the intermediate and poor adherence rates were observed in those with normal AER or severe albuminuria.

**Conclusion:** In adults with type 1 diabetes, a refill adherence rate above 50% to prescribed AHT and lipid-lowering treatments is associated with reduced odds of CVD events. These findings are especially important for individuals with moderate albuminuria. This highlights the relevance of ensuring overall adherence to medications in clinical practice, and especially in those individuals at the early stage of kidney disease, who already carry an increased CVD risk.

Supported by: Folkhälsan Research Foundation

Disclosure: R. Lithiuvas: None.

813

**Metformin therapy is associated with higher myocardial perfusion reserve and improved survival in patients with type 2 diabetes: a multicentre study**

N. Sharrack1, K.D. Knott2, J.L. Yeo3, T. Kotecha4, S. Thirunavukarasu1, A. Chowdhary4, E. Level1, J. Moon2, G.P. McCann2, M. Fontana2, P. Kellman2, C.P. Gale2, J.P. Greenwood1, P.P. Sowobra1, S. Plein1; 1Leeds Institute of Cardiovascular and Metabolic Medicine, Leeds, UK, 2Barts Heart Centre, London, UK, 3Department of Cardiovascular Sciences, University of Leicester, Leicester, UK, 4Royal Free Hospital, London, UK. 1National Heart, Lung, and Blood Institute, Bethesda, USA, 6Division of epidemiology and biostatistics, Leeds, UK.

**Background and aims:** Metformin is a potent antihyperglycemic agent widely used in the management of type 2 diabetes mellitus (T2DM). Patients with T2DM are at increased risk of cardiovascular disease, including epicardial coronary heart disease, silent myocardial infarction (MI), and coronary microvascular dysfunction (CMD), all of which can be quantified using cardiac magnetic resonance (CMR). We sought to explore the association between metformin use, myocardial perfusion reserve and clinical outcomes in patients with T2DM.

**Materials and methods:** This was a multicentre, prospective longitudinal cohort study in patients with T2DM. Subjects underwent baseline multiparametric CMR including adenosine stress perfusion imaging with automated inline quantitative myocardial perfusion assessment deriving global myocardial blood flow (MBF) and myocardial perfusion reserve (MPR). Diagnosis of T2DM was based on HbA1c >48mmol/l or a known diagnosis of T2DM. Patients were followed up for death and major adverse cardiovascular events (MACE), including MI, non-fatal stroke, heart failure hospitalisations and death. Kaplan-Meier curves and log rank testing sought associations between baseline metformin use and death and MACE.

**Results:** A total of 630 patients with T2DM were included (n=412 [67%] on metformin) with a median follow-up of 650 days (interquartile range 422,923) days. There were 27 (4.3%) deaths and 76 MACE events in 62 (12.1%) patients. Baseline characteristics and CMR data, stratified by metformin use, are presented in table 1. Patients on metformin tended to favour SGLT2is at higher risk levels of both scores.

**Conclusion:** Metformin is associated with lower occurrence of CVD events than poor adherence rate. However, no differences between the good and poor or between the intermediate and poor adherence rates were observed in those with normal AER or severe albuminuria.

Supported by: Folkhälsan Research Foundation

Disclosure: R. Lithiuvas: None.

812

**Adherence to antihypertensive and lipid-lowering treatment is associated with better CVD outcomes in individuals with type 1 diabetes and moderate albuminuria**

R. Lithiuvas1,2, S. Mutter1,2, E.B. Parente1,2, V. Harjutsalo1,2, P.-H. Groop1,2; 1Folkhalsan Institute of Genetics, 2Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

**Background and aims:** Individuals with type 1 diabetes are at high lifetime risk of CVD. To gain full benefit of the pharmacological therapies for CVD protection, it is important to ascertain adherence to all prescribed medications. Non-adherence may negatively affect the incidence rates of CVD. While previous studies have estimated adherence to single-drug classes only, data on adherence to concomitant antihypertensive (AHT) and lipid-lowering drugs are limited. Therefore, it is crucial to investigate the adherence to polypharmacy and its impact on CVD outcomes in adults with type 1 diabetes.

**Materials and methods:** This Finnish Diabetic Nephropathy Study followed 2,708 individuals with type 1 diabetes (mean age 39.0 ± 11.4 years, mean duration of diabetes 22.7 ± 11.7, 54% men), who had purchased AHT or lipid-lowering drugs (based on the Drug Prescription Register) until the first CVD event, death, or the end of 2015 (465 CVD events, median follow-up 14.8 years). Refill adherence was defined as an overall refill adherence to AHT drug classes and lipid-modifying agents, based on the proportion of days covered (PDC) method. The adherence rate was classified into good (> 80%), intermediate (50 - 80%) and poor (< 50%) adherence. Multivariable logistic regression analyses, adjusted for age, sex, duration of diabetes, systolic BP, triglycerides, LDL-cholesterol, HbA1c, waist-to-height ratio, smoking, albuminuria stage and eGFR were performed. Further analyses were done based on urinary AER at baseline: normal AER (AER <20 µg/min or <30 mg/24h; \( n = 1654 \)), moderate (AER 20 - 200 µg/min or 30 - 300 mg/24h; \( n = 504 \)) or severe albuminuria (AER >200 µg/min or >300 mg/24h; \( n = 548 \)).
significance in all-cause mortality between the groups, $\chi^2 (2) = 8.74$, $P=0.003$. There was no significant difference in MACE events between patients not taking metformin, 22/218 (10%) and patients on metformin, 36/412 (9%).

**Conclusion:** In patients with T2DM, metformin use is associated with increased MPR measured automatically using inline artificial intelligence perfusion mapping, as well as statistical improvement in all-cause mortality. We show for the first time that metformin use associates with higher coronary microvascular function and overall survival.

**SO 72 Diabetes dysmetabolism dialogues with the cardiovascular component**

814

Oleate prevents palmitate-induced abnormalities in insulin signalling in human cardiac progenitor cells by inhibiting p38 MAPK and c-Jun phosphorylation

L. Laviola¹, R. D'Onofrio¹, I. Calderoni¹, C. Caccioppi¹, V.A. Genchi¹, G. Santarpino², A.D. Milano¹, A. Leonardi¹, A. Natalicchio¹, S. Perrini¹, A. Cignarelli¹, F. Giorgino¹; ¹University of Bari Aldo Moro, ²General Surgery GVM Bari, Bari, Italy.

**Background and aims:** Elevated saturated fatty acid deposition in the heart results in insulin resistance, stress kinase activation, and increased cardiovascular risk in humans. The viability of human cardiac progenitor cells (CPC) is essential for myocardium homeostasis. This study investigates the ability of palmitate, a saturated fatty acid, to impair insulin signaling in human CPC, and the potential protective effects of oleate, a mono-unsaturated fatty acid, on palmitate-induced abnormalities.

**Materials and methods:** Human CPC were obtained from non-diabetic and non-obese subjects undergoing cardiac surgery for coronary artery bypass grafting and/or valve surgery. Human CPC were exposed to 0.25 mM palmitate and/or 0.1 mM oleate for 24 h, and then exposed to 100 nM insulin for the last 15 minutes. Expression of insulin receptor (IR) isoforms, A (IR-A) and B (IR-B), was evaluated by quantitative real-time PCR. IR and Akt protein levels, as well as Akt (S473), p38 MAPK (T180/Y182), and c-Jun (S63) phosphorylation levels were assessed by immunoblotting. p38 MAPK and JNK inhibition was achieved using 15 μM SB202190 and 20 μM SP600125 for 1 h, respectively.

**Results:** Human CPC were found to express both IR-A and IR-B, with higher IR-A:IR-B ratio. Exposure of human CPC to insulin induced Akt (S473) phosphorylation ($p<0.05$). Treatment with palmitate, but not with oleate, resulted in impaired insulin-activated Akt phosphorylation ($p<0.05$), with no effect on total Akt protein levels, and in downregulation of IR protein levels ($p<0.05$), increased expression of total IR mRNA, IR-A, IR-B, and increased IR-A/IR-B ratio ($p<0.05$). Palmitate, but not oleate, also induced p38 MAPK (T180/Y182) and c-Jun (S63) phosphorylation ($p<0.05$). Pretreatment with SB202190 or with SP600125 significantly inhibited the ability of palmitate to impair insulin-activated Akt phosphorylation ($p<0.05$), but not downregulation of IR protein levels. Interestingly, co-incubation of palmitate with oleate abolished the palmitate-induced p38 MAPK ($p<0.05$) and c-Jun phosphorylation ($p<0.05$), and inhibition of insulin-activated Akt phosphorylation ($p<0.05$). Co-incubation with oleate also prevented the palmitate-induced changes in IR ($p<0.05$).

**Conclusion:** Oleate prevents the palmitate-induced abnormalities in insulin signalling in human CPC, largely by counteracting p38 MAPK and JNK activation. Hence, oleate supplementation might limit lipotoxicity in cardiac progenitor cells, thus contributing to cardiac protection.

**Disclosure:** N. Sharrack: None.

815

The effect of methylglyoxal on the pro-angiogenic function of mouse adipose-derived stem cells (mADSCs)


**Background and aims:** Over the past years, great attention has been paid to the potential role of adipose-derived stem cells (ADSCs) in regenerative medicine. Several studies have demonstrated their crucial role in the repair of damaged tissues, like ischemic wound in diabetic patients. ADSCs play a

---

**Supported by:** REC ID 14/EE/0007, 17/WM/0192, 18/YH/0168, 18/YH/0190, 17/YH/0300

**Disclosure:** N. Sharrack: None.

**SO 72 Diabetes dysmetabolism dialogues with the cardiovascular component**

814

Oleate prevents palmitate-induced abnormalities in insulin signalling in human cardiac progenitor cells by inhibiting p38 MAPK and c-Jun phosphorylation

L. Laviola¹, R. D’Onofrio¹, I. Calderoni¹, C. Caccioppi¹, V.A. Genchi¹, G. Santarpino², A.D. Milano¹, A. Leonardi¹, A. Natalicchio¹, S. Perrini¹, A. Cignarelli¹, F. Giorgino¹; ¹University of Bari Aldo Moro, ²General Surgery GVM Bari, Bari, Italy.

**Background and aims:** Elevated saturated fatty acid deposition in the heart results in insulin resistance, stress kinase activation, and increased cardiovascular risk in humans. The viability of human cardiac progenitor cells (CPC) is essential for myocardium homeostasis. This study investigates the ability of palmitate, a saturated fatty acid, to impair insulin signaling in human CPC, and the potential protective effects of oleate, a mono-unsaturated fatty acid, on palmitate-induced abnormalities.

**Materials and methods:** Human CPC were obtained from non-diabetic and non-obese subjects undergoing cardiac surgery for coronary artery bypass grafting and/or valve surgery. Human CPC were exposed to 0.25 mM palmitate and/or 0.1 mM oleate for 24 h, and then exposed to 100 nM insulin for the last 15 minutes. Expression of insulin receptor (IR) isoforms, A (IR-A) and B (IR-B), was evaluated by quantitative real-time PCR. IR and Akt protein levels, as well as Akt (S473), p38 MAPK (T180/Y182), and c-Jun (S63) phosphorylation levels were assessed by immunoblotting. p38 MAPK and JNK inhibition was achieved using 15 μM SB202190 and 20 μM SP600125 for 1 h, respectively.

**Results:** Human CPC were found to express both IR-A and IR-B, with higher IR-A:IR-B ratio. Exposure of human CPC to insulin induced Akt (S473) phosphorylation ($p<0.05$). Treatment with palmitate, but not with oleate, resulted in impaired insulin-activated Akt phosphorylation ($p<0.05$), with no effect on total Akt protein levels, and in downregulation of IR protein levels ($p<0.05$), increased expression of total IR mRNA, IR-A, IR-B, and increased IR-A/IR-B ratio ($p<0.05$). Palmitate, but not oleate, also induced p38 MAPK (T180/Y182) and c-Jun (S63) phosphorylation ($p<0.05$). Pretreatment with SB202190 or with SP600125 significantly inhibited the ability of palmitate to impair insulin-activated Akt phosphorylation ($p<0.05$), but not downregulation of IR protein levels. Interestingly, co-incubation of palmitate with oleate abolished the palmitate-induced p38 MAPK ($p<0.05$) and c-Jun phosphorylation ($p<0.05$), and inhibition of insulin-activated Akt phosphorylation ($p<0.05$). Co-incubation with oleate also prevented the palmitate-induced changes in IR ($p<0.05$).

**Conclusion:** Oleate prevents the palmitate-induced abnormalities in insulin signalling in human CPC, largely by counteracting p38 MAPK and JNK activation. Hence, oleate supplementation might limit lipotoxicity in cardiac progenitor cells, thus contributing to cardiac protection.

**Disclosure:** L. Laviola: None.
pivotal role in angiogenesis, through the activation and recruitment of endo-
geneous cells involved in this process and the stabilization of new formed vessels. However, in pathological conditions, including diabetes, ADSCs function is compromised. This represents the main limit for their use in regenerative medicine. Methyglyoxal (MG), a highly reactive dicarbonyl formed as byproduct of glycolysis in chronic hyperglycemia, has harmful effects on vascular function. MG causes cellular dysfunction through several molecular mechanisms including the activation of senescence pathways. This work aims at evaluating MG effect on ADSCs pro-angiogenic function and the molecular mediators involved.

Materials and methods: ADSCs were isolated from the subcutaneous adipose tissue of C57Bl6 mice. The presence of CD29, CD44, CD45 and CD31 markers was evaluated by FACS. Adipogenic differentiation was evaluated through the analysis of PPARγ2, GLUT4, AP2 and ADIPOQ mRNA levels by qRT-PCR, and the lipid staining with Oil Red-O. mADSCs viability was evaluated by MTT assay, while the accumulation of MG-adducts and protein levels of p-p38 by western blot. Migration ability was analyzed by transwell assays, p53 and p21 mRNA levels were evaluated by qRT-PCR.

Results: mADSCs were characterized by analyzing the presence of surface markers and their differentiation ability. mADSCs show a 98% and 96% positivity for CD29 and CD44, respectively, while positivity for CD31 and CD45 is less than 1%. mADSCs are able to differentiate into adipocytes as indicated by a 16, 148, 609, and 619-fold increase of PPARγ2 (p=0.03), GLUT4 (p=0.004), AP2 (p=0.001) and ADIPOQ (p>0.001) genes expression, respectively, and by a 5-fold increase of Oil Red-O staining (p=0.001). Treatment with MG 100μM for 16h does not impair mADSCs viability and induces a 50% increase of MG-adducts in mADSCs (p=0.006). mADSCs in co-culture with human retinal endothelial cells (hRECs) induce hRECs migration, which is reduced by 40% (p=0.05) in the presence of MG-treated mADSCs. Conditioned medium (CM) from mADSCs induces hREC migration, which is reduced by 30% in response to CM from MG-treated mADSCs (p<0.001). Impaired migration in response to MG treatment associates with reduced p38 activation in hRECs. These data have been also validated in mouse coronary artery endothelial cells. Furthermore, preliminary results indicate that p53 and p21 mRNA levels are increased by 1.7-fold in MG-treated mADSCs compared to control cells.

Conclusion: These results show that MG impairs the pro-angiogenic ability of mADSCs at least in part through the alteration of soluble factors release. This effect associates with the increase of senescence markers in MG-treated mADSCs. The identification of crucial mediators will be useful for optimizing therapeutic strategies involving the use of autologous ADSCs for treatment of diabetic vascular defects.

Disclosure: A. Leone: None.

817
Cell-specific role of insulin in a model of restenosis under insulin sensitive and insulin resistant conditions

M. Gonzalez Medina, Z. Liu, A. Giaconia;
Physiology, University of Toronto, Toronto, Canada.

Background and aims: Angioplasty and stenting are widely used in the treatment of atherosclerosis. However, these procedures may fail due to post-angioplasty restenosis, which remains a problem for patients with diabetes. Currently, the vascular role of insulin is unclear. Its role on endothelial cells (EC) is vasculoprotective, whereas its effects on vascular smooth muscle cells (SMC) are mainly mitogenic according to in vitro data. We have previously shown a suppressive effect of insulin treatment on neointimal growth in rodent models of restenosis in insulin sensitive conditions that was abolished in insulin resistant conditions. Thus, the objective of this study was to determine the EC-and SMC-specific effects of insulin treatment on neointimal growth in a murine model of restenosis in insulin sensitive and insulin resistant conditions.

Materials and methods: Mice were generated by crossing insulin receptor (IR) floxed mice with mice expressing tamoxifen inducible Cre recombinase under the control of Cdhs (vascular endothelial cadherin) or SMMHC (smooth muscle heavy chain) promoters. Mice were fed with a low-fat (LFD) or a high-fat-high-sucrose (HFSD) diet starting at four weeks of age and were treated with tamoxifen (50 mg/kg of body weight) at five weeks for ten consecutive days. Mice were then implanted with insulin pellet (0.05 U/day to achieve a 3-fold elevation of plasma insulin) or vehicle (control) three days prior to femoral artery wire injury, which was performed at eight weeks. Following surgery, metabolic parameters were measured until sacrifice. Insulin tolerance test (ITT, 0.5U/kg insulin i.p.) was performed five...
days prior to sacrifice to examine the effects of diet, insulin treatment and the potential systemic effects of EC- or SMC-specific IR knockdown. Mice were sacrificed 28 days post-surgery for vessel collection following fixation perfusion, and the primary endpoint was neointimal growth.

**Results:** Compared to controls, tamoxifen-induced IR<sup>FL-Cdh5-Cre+</sup> or IR<sup>L-SMMHC-Cre+</sup> mice showed a 94% and 80% decrease in IR expression in ECs or SMCs, respectively. Body weight, fasting and fed plasma glucose levels were significantly higher in HFD-fed mice regardless of genotype or insulin treatment. Additionally, ITT revealed insulin resistance in HFD-fed mice regardless of genotype or insulin treatment. In LFD-fed insulin sensitive conditions, insulin decreased neointimal area (NA) and intima-to-media ratio (IMR) in controls but not in endothelial and SMC IR deficient mice. In HFD-fed insulin resistant conditions, insulin had no effect in either controls or endothelial and SMC IR deficient mice.

**Conclusion:** These data demonstrate that insulin action in both ECs and SMCs is required for the anti-restenotic effect of insulin in insulin sensitive conditions. This vasculoprotective effect is abolished but not reversed in insulin resistance even when endothelial IR is deficient. Accordingly, deficiency of IR did not restore the vasculoprotective effect of insulin in insulin resistance. Thus, our results suggest that insulin treatment may be beneficial in ECs and VSMCs in insulin sensitive patients with diabetes undergoing revascularization. However, in insulin resistant patients with diabetes undergoing percutaneous intervention, high doses of insulin may be required for its beneficial effects on both ECs and VSMCs. Alternatively, insulin sensitizing agents that could bypass vascular insulin resistance may be preferable to insulin treatment.

**Supported by:** HS Foundation of Canada

**Disclosure:** M. Gonzalez Medina: None.

---

**P61**

**Chronic hyperglycaemia inhibits TCA cycle in GLUT4 overexpressing H9C2 cells**

B. Stratmann<sup>1</sup>, B. Eggers<sup>2,3</sup>, Y. Mattern<sup>1</sup>, T. Silva de Carvalho<sup>1</sup>, K. Marcus<sup>2,3</sup>, D. Tschope<sup>1,4</sup>,

<sup>1</sup>HDZ NRW, Ruhr-Universität Bochum, Bad Oeynhausen, <sup>2</sup>Ruhr-University Bochum, Medizinisches Proteom-Centre, Bochum, <sup>3</sup>Medical Proteome Analysis, Centre for Protein diagnostics (PRODI), Ruhr-University Bochum, Bochum, <sup>4</sup>Stiftung DHD (Der herzkrankte Diabetiker) Stiftung in der Deutschen Diabetes-Stiftung, Bad Oeynhausen, Germany.

**Background and aims:** Oversupply of nutrients with loss of metabolic flexibility is a hallmark of diabetic cardiomyopathy. Even if excess substrate is offered, the heart suffers energy depletion as metabolic fluxes are diminished. To study effects of high glucose, a stably GLUT4-overexpressing cell line derived from H9C2 (KE2) was established presenting a diabetic cardiomyopathy-like phenotype. Long-term hyperglycaemia effects in KE2 were analysed and compared to H9C2.

**Materials and methods:** Rat cardiomyoblasts stably overexpressing GLUT4 (KE2) were cultured under cell-specific, normo- (20mM glucose, 20) and hyperglycaemic conditions (30mM glucose, 30) for 9 months. Expression profiles of proteins were compared to non-transfected H9C2 (WT) using RT-qPCR, proteomics-based analysis or Western blotting. GLUT4 surface analysis, glucose uptake, and apoptosis measurements were performed by flow cytometry. BNP levels, ROS formation, glucose consumption and lactate production were quantified.

**Results:** Hyperglycaemia increased induced GLUT4 presence on the cell surface and exaggerated glucose influx in KE2. The GLUT4 presence was increased in normo- and hyperglycaemic KE2 if compared to WT (2fold, WT30 vs. KE230, p<0.0001; 1.4fold, WT20 vs. KE220, p<0.0001, t-test). By measuring 2-NBDG-uptake, KE2 proved to increase glucose uptake (3fold, WT30 vs. KE230/1.7fold, WT20 vs. KE220, p<0.0001, t-test). The glucose consumption similarly increased for the same cells (1.6fold, WT30 vs. KE230, p<0.0001/ 1.6fold, WT20 vs. KE220, p<0.01, t-test) and production of L-lactate was doubled (2fold, WT30 vs. KE230L, p<0.0001/ 2fold, WT20L vs. KE220L, p<0.0001, one-way ANOVA). Hyperglycaemia affected the TCA cycle with significantly increased levels of fumarate after chronic hyperglycaemia in KE2 when compared with WT (1.22fold less, WT20 vs. KE220, p<0.01/ 1.9fold more, WT30 vs. KE230, p<0.001, t-test), mainly due to decreased fumarase levels in KE2, which, regardless the glucose concentration, had less protein expression of fumarase when compared with WT (1.36fold, WT20L vs. KE220L, p<0.05/ 2.10fold, WT30L vs. KE230L, p<0.001, t-test). Hyperglycaemic KE2 showed significant overexpression of BNP when compared with hyperglycaemic WT (8.5fold, WT30 vs. KE230, p<0.0001) or among KE2 (2.5fold, p<0.0001, one-way ANOVA). KE2 showed significantly increased oxidative stress when compared with WT cells (6.9fold, WT20 vs. KE220, p<0.0001; 1.7fold, WT30 vs. KE230, p<0.0001, t-test) or among KE2 (p<0.01) after long-term hyperglycaemia. Increased levels of apoptosis were detected (1.7fold, WT30 vs. KE230, p<0.0001/ 1.6fold, KE220 vs. KE230, p<0.0001, one-way ANOVA).

**Conclusion:** Chronic glucose overload in cardiomyoblasts induced by GLUT4 overexpression and hyperglycaemia resulted in metabolically stimulated proteome changes and metabolic alterations on TCA level. This indicates that these cells develop DC upon hyperglycaemic stress and reproduce the multi-faceted metabolic effects from chronic hyperglycaemia on cardiomyocyte protein profile and function.

**Disclosure:** B. Stratmann: None.

---

**P69**

**O-glycnaclation attenuated ages-induced neuroinflammation by inhibiting NF-kB p65/NLRP3 inflammatory signalling pathway**

T. Niu<sup>1,2</sup>, W. Zhu<sup>2</sup>, H. Zhang<sup>1</sup>, S. Wang<sup>1,2</sup>,

1 Southeast University, Nanjingjiangsu Province, 2Affiliated Zhongda Hospital of Southeast University, Nanjing, Jiangsu Province, 3The First Affiliated Hospital of China University of science and technology, Hefei,Anhui Province, China.

**Background and aims:** The neuroinflammation induced by activation of microglia is one of the major causes of diabetes-related cognitive impairment. The advanced glycation end products (AGEs) induced by hyperglycaemia could cause neuroinflammation in microglia. O-GlcNAcylation, which is upregulated by O-GlcNAc tansf erase (OGT) and down-regulated by O-GlcNAcase (OGA), exhibits neuroprotective effect in the brain. We aim to investigate the role of O-GlcNAcylation in AGEs-induced neuroinflammation.

**Materials and methods:** To induce neuroinflammation, primary microglia were isolated from newborn mice, and treated with AGEs. Then, Thiamet G (TMG) was administered to inhibit O-GlcNAcylase. Protein and mRNA levels of OGT, Nuclear factor κB p65 (NF-κB P65), NLRP3(NOD-like receptor protein 3), Tumor necrosis factor α(TNF-α), Interleukin-1β(IL-1β) and Interleukin-6(IL-6) were measured by Western blot and Real-time PCR, respectively. Immunofluorescence of CD68 and Iba1 were detected and observed by confocal microscopy, The interaction between OGT and NF-κB P65 was verified by immuno precipitation.

**Results:** AGEs increased CD68 levels in Iba1 positive microglial cells. Additionally, mRNA and protein levels of NF-κB P65, NLRP3, TNF-α, IL-1β and IL-6 were up-regulated, while those of OGT were down-regulated by AGEs. However, the treatment of TMG reversed the effect of AGEs. OGT and NF-κB P65 were observed in the mixture pulled by confocal microscopy, The interaction between OGT and NF-κB P65 was verified by immuno precipitation.

**Conclusion:** O-GlcNAcylation may alleviate AGES-induced neuroinflammation by inhibiting NF-κB P65/NLRP3 signalling pathway in primary microglia.

**Supported by:** 81870568

**Disclosure:** T. Niu: None.
820
HDL particles' function of cholesterol efflux capacity in newly diagnosed type 1 diabetes: prospective \textit{InLipoDiab1} study

A. Uruska\textsuperscript{1}, A. Rohatgi\textsuperscript{2}, A. Grzelka-Wozniak\textsuperscript{1}, S. Saldanha\textsuperscript{1}, J. Flotynska\textsuperscript{3}, A. Cieluch\textsuperscript{1}, A. Kaczmarek\textsuperscript{1}, A. Pypec\textsuperscript{1}, D. Zozulinska-Ziolkiewicz\textsuperscript{1};
\textsuperscript{1}Poznan University of Medical Sciences, Poznan, Poland, \textsuperscript{2}University of Texas, Southwestern Medical Center, Dallas, USA.

\textbf{Background and aims:} People with type 1 diabetes are characterized by high serum HDL concentration, which does not translate into a better prognosis in this group. It is probably related to the impaired function of HDL particles. One of the main functions of HDL is the anti-atherosclerotic role related to the promotion of reverse cholesterol transport from macrophages in arterial walls (cholesterol efflux capacity-CEC). The initiation of insulin therapy increases serum HDL-cholesterol levels within the first year of therapy. It is not known whether the quantitative changes are accompanied by an improvement in HDL function. Aim: To evaluate HDL cholesterol efflux capacity in adults with newly diagnosed type 1 diabetes in response to insulin initiation.

\textbf{Materials and methods:} The analysis comprised 125 patients (83 men, 66\%) with newly diagnosed type 1 diabetes confirmed by the presence of autoantibodies, recruited to the Insulin Therapy and Lipoproteins' Profile in Type 1 Diabetes (\textit{InLipoDiab1}) study. The median age at onset was 26 (IQR: 22-32) years. Cholesterol efflux capacity was assessed by measuring the efflux of radiolabelled cholesterol from murine J774 macrophages to apolipoprotein B-depleted serum. The study was performed at two points: before the first administration of exogenous insulin and after one year of using intensive insulin therapy.

\textbf{Results:} After one year of observation, a significant increase in serum HDL concentration [46 (36-55) vs 66 (55-82) mg/dl; p<0.0001] and no change in CEC [1.29 (1.11-1.42) vs 1.24 (1.14-1.41); p=0.6] were demonstrated.

\textbf{Conclusion:} In patients with type 1 diabetes, in the first year of the disease, there is no improvement in CEC, a key anti-atherosclerotic HDL function, despite a significant increase in serum HDL concentration. Further prospective studies should be done to explain these discordant findings.

\textit{Clinical Trial Registration Number: NCT02306005}
Supported by: Kischusko Foundation
Disclosure: A. Uruska; None.

821
Serum metabolites and cerebral small-vessel disease in type 1 diabetes

S. Mutter\textsuperscript{1,2}, J. Inkeri\textsuperscript{1,3}, L. Thorn\textsuperscript{1,2}, G.L. King\textsuperscript{4}, H. Shah\textsuperscript{1}, P.-H. Groop\textsuperscript{1,3}, J. Putaat\textsuperscript{1}, J. Martola\textsuperscript{1}, N. Sandholin\textsuperscript{1,2}, D. Gordin\textsuperscript{5,7}, on behalf of the FinnDiane Study Group;
\textsuperscript{1}Folkhålsan Research Center, Helsinki, Finland, \textsuperscript{2}Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland, \textsuperscript{3}HUS Medical Imaging Center, Radiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, \textsuperscript{4}Joslin Diabetes Center, Harvard Medical School, Boston, USA, \textsuperscript{5}Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, \textsuperscript{6}Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, \textsuperscript{7}Minerva Foundation Institute for Medical Research, Helsinki, Finland.

\textbf{Background and aims:} Cerebral small-vessel disease (SVD) is frequent in neurologically asymptomatic individuals with type 1 diabetes (T1D). Previous studies in T1D on BP and albuminuria only moderately explained these findings with no association found with glycaemic control. The severity of diabetic retinopathy was associated with SVD, but the findings might reflect general changes to the microvasculature.

Thus, we aim to assess potential mechanisms underlying SVD in T1D by using serum metabolites.

\textbf{Materials and methods:} Our Finnish Diabetic Nephropathy substudy included 189 individuals with T1D (19-51 years of age, diabetes onset < 40 years). Brain MRIs from a 3.0 T scanner were assessed by a neuroradiologist for SVD (n = 66) characterized by white matter hyperintensities (WMH, ≥ 1 on the Fazekas scale) or microbleeds. From non-targeted serum metabolomics, 1,246 out of 1,277 metabolites passed quality control, were normalised and log transformed. Logistic regressions were performed for each metabolite separately (adjusted for sex, age, BP, HDL cholesterol, albuminuria, eGFR, antihypertensive (AHT) and lipid-lowering drugs). Multivariable logistic adaptive LASSO regression was used to define a panel of metabolites that best associated with SVD. A P-value < 2.89 × 10^{-4} was considered significant as 173 metabolites cover 99\% of the variance.

\textbf{Results:} Individuals with SVD were older (41 vs. 37 years), had a higher BP (134 vs. 128 mmHg), were more likely to take AHT drugs (49 vs. 29\%) and less likely to have a normal AER (72\% vs. 88\%). No metabolites were significantly associated with SVD (Figure 1). Oleoylcarnitine (OR 0.53 per 1 SD [95\% CI 0.36, 0.76], p = 0.001) and phenylacetate (1.91 [1.29, 2.91], p = 0.002) were suggestively associated with SVD. Phenylacetate was the strongest individual predictor (β = 0.59) in a panel of 29 metabolites that classified individuals according to SVD with a panel AUC of 0.64. Oleoylcarnitine was not selected into the panel. A pathway look-up showed that phenylacetate is linked to hydroxyphenylpyruvate, a suggested marker of WMH.

\textbf{Conclusion:} In T1D serum metabolites show suggestive associations with SVD beyond standard clinical biomarkers. These are linked to known findings and might shed more light on SVD than clinical biomarkers alone.

\textit{Supported by: Academy of Finland, Folkhålsan, Juselius Foundation, Stockman Foundation, University of Helsinki}
Disclosure: S. Mutter; None.
SO 73 Diabetes in the vessels

822
Endotrophin as a risk marker of complications in a type 2 diabetes cohort
1Steno Diabetes Center Copenhagen, 2Nordic Bioscience A/S, Herlev, Denmark.

Background and aims: Hyperglycemia-mediated tissue injury eventually leads to fibrosis affecting various organ systems. The pro-fibrotic hormone endotrophin reflects collagen type VI formation. Higher level of serum endotrophin has been associated with increased risk of kidney function decline, cardiovascular events and mortality in selected persons with type 2 diabetes and microalbuminuria. We investigate whether endotrophin level in serum and urine is associated with the risk of developing micro- and macrovascular complications in an unselected type 2 diabetes population.

Materials and methods: Endotrophin was measured in serum and urine collected at baseline from individuals enrolled in a cohort study including 774 persons with type 2 diabetes recruited from Steno Diabetes Center Copenhagen. Denmark between 2012 and 2016. Urinary values were normalized to urine creatinine levels. Outcomes were identified through national registries and medical records and included a kidney endpoint (≥40% decline in kidney function or kidney failure), first major adverse cardiovascular event (MACE), all-cause mortality, progression of albuminuria, incident heart failure and sight-threatening eye disease. Cox proportional hazards models with adjustment for conventional risk factors were applied.

Results: The cohort consisted of 254 (33%) females, and the mean age was 65 (±12) years. Depending on event, median follow-up ranged from 3.0 to 6.0 years. A doubling of serum endotrophin was independently associated with the kidney endpoint (n: 49, HR: 1.80, 95% CI: 1.13-2.87), first MACE (n: 66, HR: 1.54, 95% CI: 1.04-2.28), all-cause mortality (n: 156, HR: 1.69, 95% CI: 1.31-2.19) and incident heart failure (n: 42, HR: 1.63 95% CI: 1.02-2.60), but not with progression of albuminuria (n: 85, HR: 1.18, 95% CI: 1.01-1.38) and incident heart failure (n: 40, HR: 1.79, 95% CI: 1.09-2.95), but not with the other endpoints.

Conclusion: Serum endotrophin was an independent risk marker of mortality, kidney and cardiovascular complications in type 2 diabetes. Disclosure: N.H. Tougaard: None.

823
Mitogenic signalling pathways in valvular interstitial cells and their dependency from diabetic conditions
J. I. Selig1, F. A. Krafft1, E. Adler1, D. M. Ouwens2, A. Lichtenberg1, P. Akhyari1, M. Barth2.
1Department of Cardiac Surgery, University Hospital of the Heinrich-Heine-University Düsseldorf, Düsseldorf, 2Institute for Clinical Biochemistry and Pathobiocchemistry, German Diabetes Center (DDZ), Düsseldorf, 3German Center for Diabetes Research (DZD), München-Neuherberg, Germany.

Background and aims: Type 2 diabetes mellitus is an independent risk factor for the development of calcific aortic valve disease, a progressive disorder that leads to the loss of valve function. Previous analyses showed that valvular interstitial cells (VIC) are sensitive to insulin. Elevated insulin and glucose levels induce insulin resistance with reduced AKT phosphorylation after insulin stimulation. However, knowledge about downstream signalling pathways of insulin and their role in mitogenic processes associated with valve degeneration is still scarce.

Materials and methods: Primary ovine VIC (n=9) were transfected with custom-designed siRNA targeting FOXO1, mTOR, ERK1 and ERK2 one day and four days after seeding. The cells were cultivated either under normoglycaemic conditions (NG; 100 mg/dl glucose) or under diabetic conditions with hyperglycaemia and hyperinsulinemia (HG+HI; 450 mg/dl glucose and 100 nM insulin). VIC transfected with non-targeting siRNA cultivated under NG served as control. After six days, cell differentiation and degeneration as well as extracellular matrix remodelling were examined with qRT-PCR, Western blot analyses and colorimetric assay systems.

Results: All four siRNA targets were significantly downregulated both at mRNA (p<0.001) and protein level (p<0.01). Downregulation of mTOR, ERK1 and ERK2 in combination with HG+HI was associated with an activation of VIC indicated by an increased α-smooth muscle actin expression (mTOR: p<0.01; ERK1: p<0.001; ERK2: p<0.05), while downregulation of FOXO1 led to an elevated expression of the degeneration marker osteopontin (p<0.05). Furthermore, downregulation of mTOR and FOXO1 increased hyaluronan synthase 2 expression (NG: p<0.05; HG+HI: p<0.05) and decreased decorin expression (NG: p<0.0975; HG+HI: p<0.05), respectively. ERK1 and ERK2 in contrast did not influence the extracellular matrix composition. Moreover, a versatile interaction was observed between the different signalling molecules. Downregulation of mTOR caused an upregulation of all three other proteins (FOXO1: p<0.05; ERK1/2: p<0.01). FOXO1 downregulation in contrast caused an upregulation of ERK2 (p<0.01), but did not affect ERK1 or mTOR. In turn, ERK1 and ERK2 downregulation did not influence the expression of mTOR and FOXO1.

Conclusion: AKT downstream signalling pathways as well as MAPK signalling pathways are involved in the homeostasis of VIC and participate putatively in degeneration and remodelling of aortic valves. Additional diabetic conditions can intensify these effects and thus may contribute to a rapid progression of the disorder. Further analysis of signalling pathways involved in mitogenic processes is of particular importance to develop therapeutic treatments for calcified aortic valve disease in future.

Supported by: DFG
Disclosure: J.I. Selig: Grants; German Research Foundation (DFG).

824
Dulaglutide prevents high-glucose induced endothelial senescence and the capture of microvesicles by endothelial cells
F. Moschovaki Filippidou1, N. Sabat1, F. Zobairi1, F. Toti1,2, L. Kessler1,3.
1Inserm UMR, Regenerative Nanomedicine, University of Strasbourg, 2Faculty of Pharmacy, University of Strasbourg, 3Diabetology, Department of Diabetology, University Hospital of Strasbourg, Strasbourg, France.

Background and aims: In patients with diabetes, higher cardiovascular risk has been associated with release of MV with endothelial origin. The cardiovascular benefit of a treatment by GLP1 receptor agonists (GLP1RA) has been demonstrated in various clinical trials. Because senescence shifts the endothelium to an athero-thrombogenic surface, we investigated the effect of dulaglutide, a GLP1RA, on high-glucose induced senescence in primary coronary artery endothelial cells.

Materials and methods: Porcine coronary artery young endothelial cells (PCEACs) were treated with 1,2 and 3 μM dulaglutide and challenged by high glucose concentration (HG 25mmol/L) for 48 or 96 hours. Senescence was monitored by the SA-β-gal activity and expression of p53 and p21 by western blot. The expression of GLP1R was studied by western blot and confocal microscopy. The effect of dulaglutide on the relative expression of a variety of genes encoding markers and actors in
HG-induced endothelial responses was evaluated by RT-qPCR. Endothelial procoagulant MVs were measured by prothrombinase assay in culture medium. In a crosstalk model, effector properties of MVs were studied after 48 hours incubation with naïve young PACECs at the concentration of 10nM. Kinetics of the MVs’ capture by naïve target cells was monitored by flow cytometry after MVs were labelled with the fluorescent PKH26 lipid probe.

**Results:** Dulaglutide (1 μM) significantly attenuates the HG-induced endothelial senescence measured after 96h by SA-β-gal activity to baseline values in normal glucose (113.7±2.9 vs. 103.9±2.1, % of Control, p=0.02, n=8). A dose response effect was observed with higher dulaglutide concentrations, as increasing dulaglutide concentration to 3 μM lead to an early reduction already detectable at 72h by SA-β-gal activity (HG: 337.6, HG+Dula: 289, Mean fluorescence A.U., p=0.0088, n=3). Down-regulation of p21, the p53 down-stream senescence marker (p=0.03, n=5), confirmed HG-induced senescence inhibition after 96h. GLP1R expression remained unchanged under conditions of HG and dulaglutide treatment at 48h and 96h. Analysis of the gene expression levels confirmed the protective effect of dulaglutide on HG-induced senescence. *Shcl*, encoding protein p66, was downregulated by 34% (p=0.05, n=4) after 48h, while a 26% reduction in *Ncf1* gene, encoding p47phox, nearly reached significance after 96h (p=0.087, n=3). HG-induced expression levels were elevated for *CdkN1A*, encoding p21, after 48h (p=0.042, n=4) and *IL6* after 96h (p=0.0255, n=3), thereby confirming the ongoing process of endothelial damage. Dulaglutide did not alter the shedding of MVs in response to HG. Nevertheless, in MV-mediated crosstalk experiments, the percentage of PKH26-labelled target cells was reduced when MVs were isolated from dulaglutide-treated cultures (95.98±0.66 vs. 92.04±1.08, p=0.010, n=6).

**Conclusion:** Dulaglutide may delay HG-induced endothelial senescence, and possibly inhibits the capture of MVs by naïve endothelial cells. Endothelial senescence may be considered as a new target in the prevention of cardiovascular diseases in diabetic patients.

**Disclosure:** F. Moschovaki Filipidou: Grants; Eli Lilly and Company, France.

825 High glucose concentration-induced dicarbonyl stress in human aortal endothelial cells activates the unfolded protein response and NLRP3 Inflammasome

P. Thornalley1, M. Xue1, N. Rabbani2; 1Diabetes Research Center, Hamad Bin Khalifa University, 2College of Medicine, Qatar University, Doha, Qatar.

**Background and aims:** Metabolic dysfunction of endothelial cells in hyperglycemia contributes to the development of vascular complications of diabetes. High glucose concentration produces hexokinase-2 linked glycolytic overload, leading to the increased formation and accumulation of the reactive glucose-derived metabolite, methylglyoxal (MG) - called dicarbonyl stress - and other metabolic dysfunction. MG-modified proteins are unfolded and prospective physiological activators of the unfolded protein response (UPR). MG is metabolized by glyoxalase 1 (Glo1) of the glyoxalase system. We investigated the role of dicarbonyl stress in activation of the UPR and NLRP3 inflammasome in endothelial cells during model hyperglycemia in vitro by siRNA silencing of Glo1.

**Materials and methods:** Human aortal endothelial cells (HAECs) were cultured under an atmosphere of air with 5% CO2, 100% humidity at 37 °C in human large blood vessel endothelial cell growth medium with growth supplements and antibiotics according to the manufacturer’s instructions; used during passages 4 - 6 to maintain the endothelial phenotype. Cultures had low glucose (4.1 mM, LG) and high glucose (20 mM, HG) concentration incubated for 72 h, with and without prior treatment with 25 nM Glo1 siRNA (Glo1KD) and protein abundance of UPR pathway mediators, XBP1, PERK and ATF6, and markers of downstream UPR and NLRP3 inflammasome inflammatory signaling, monocyte chemotactic-1 (MCP-1), interleukin-8 (IL8) and thiorodoxin-interacting proteins (TXNIP). Data are mean ± SD (n = 3). The role of the UPR sensor, inositol-requiring enzyme-1α (IRE1α), was explored by use of the specific inhibitor 4μ8C, and role of XBP1 by siRNA silencing.

**Results:** Glo1 protein was decreased by 92% and 75% in LG and HG cultures, respectively, with siRNA silencing, XBP1 protein was increased 43 ± 16% by Glo1KD in LG (P<0.05), increased 68 ± 3% in HG (P<0.01) and further increased 153 ± 21% by Glo1KD in HG (P<0.001). PERK protein was decreased 58 ± 4% by Glo1KD in LG (P<0.05), decreased 21 ± 2% in HG (P<0.01) and further decreased 63 ± 2% by Glo1KD in HG (P<0.001). PERK is thought to contribute to VEGF-mediated endothelial cell viability. ATF6 protein was unchanged in HG. NLRP3 inflammasome component, TXNIP, was increased 54 ± 21% by Glo1KD in LG (P<0.05), increased 112 ± 12% in HG (P<0.001) and further increased 159 ± 9% by Glo1KD in HG. Inhibition of IRE1α by 1 μM 4μ8C prevented increase of XBP1, TXNIP and MCP-1 mRNA in HG cultures. TXNIP is increased through IRE1α-mediated decrease of miR-17 which de-stabilizes TXNIP mRNA. Surprisingly, silencing of XBP1 potentiated the increase of TXNIP, MCP1 and IL8 in HG. This may suggest MCP1 and IL8 are increased via the NLRP3 inflammasome rather than the XBP1 pathway of the UPR; knockdown of XBP1 mRNA removing a competing substrate for the cleavage of miR-17 by IRE1α.

**Conclusion:** We conclude that dicarbonyl stress induced in human aortal endothelial cells in high glucose concentration activates both the UPR and, via IRE1α increase of TXNIP, also the NLRP3 inflammasome. Concurrent decrease of PERK may impair endothelial cell viability and survival. These responses likely contribute to vascular inflammation and endothelial dysfunction in diabetes.

Supported by: QF funded project

Disclosure: P. Thornalley: None.

826 Alpha-tubulin deacetylation impairs angiogenesis and induces endothelial-to-mesenchymal transition

J. Kim, W. Ham, W. Lee; Chung-Ang University, Seoul, Republic of Korea.

**Background and aims:** Microtubules are one of the intracellular cytoskeletons which composed of α- and β-tubulin subunits. These proteins form a cellular framework with key roles in cell shaping, division, and intracellular transport. Acetylation of α-tubulin subunits on lysine 40 catalyzed by α-tubulin N-acetyltransferase 1 (αTAT1) has been known to be an essential post-translational modification that regulates microtubule stability. Diabetes is associated with endothelial dysfunction which causes progressive vascular complications. How, however, functional consequences of tubulin acetylation/deacetylation were mostly remained elusive in endothelium.

**Materials and methods:** We generated endothelial cell-specific inducible αTAT1 KO mice by crossing αTAT1 floxed mice with Tie2-CreERT2 mice. Eight-week-old male mice were injected i.p. with tamoxifen (40 μg/g) for 4 days and sacrificed after 2 weeks. In vitro, human umbilical vein cells (HUVECs) subjected to αTAT1 knockdown by siRNA.

**Results:** Endothelial cells isolated from αTAT1 KO mouse lungs showed robust decrease of α-tubulin acetylation levels compared to wild-type. αTAT1 KO mice showed impaired microvessels sprouting based on ex vivo aortic ring assay. αTAT1 siRNA treated HUVECs significantly reduced VEGF-induced tube formation, cell migration, and proliferation compared to the controls. Furthermore, αTAT1 silenced cells showed marked spindle-like morphological changes and upregulation of mesenchymal markers indicating endothelial-to-mesenchymal transition (EndMT).

**Conclusion:** Our results demonstrate that tubulin deacetylation in endothelial cells has a pathological role by which impaired angiogenesis and
induction of EndMT and could contribute to diabetic vascular complications.  
Supported by: National Research Foundation of Korea  
Disclosure: J. Kim: None.

827  
A six-month low-carbohydrate diet high in fat in patients with type 2 diabetes does not affect the vasodilatory reactivity of the brachial artery  
E.M. Gram-Kampmann1, T.B. Olesen1, C.D. Hansen2, M.B. Hugger2, J.M. Jensen2, P. Hermann3, M.H. Olsen4, A. Krag2, K. Højlund1;  
1STENO Diabetes Center Odense (SDCO), Odense University Hospital, Odense C, 2Department of Gastroenterology and Hepatology, Odense University Hospital, Odense C, 3Department of Internal Medicine, Holbæk Hospital, Holbæk, Denmark.

Background and aims: One of the major causes of mortality in type 2 diabetes (T2D) is cardiovascular disease (CVD). Endothelial dysfunction (ED) is an early sign of atherosclerosis which is present before overt clinical CVD. In non-diabetic subjects, low-carbohydrate diets (LCDs) have been demonstrated to improve vasodilatory reactivity in the endothelium, but in T2D patients, the effect of a LCD on measures of ED is mixed. The aim of this study was to examine the effect of a non-calorie-restricted LCD high in fat for six months on measures of ED in T2D.

Materials and methods: Patients with T2D were randomized 2:1 to either a LCD with a max. of 20 E% (percentage of total energy intake) from carbohydrates and min. 50 E% from fat (n = 49) or a control diet with 50-60 E% from carbohydrates (n = 22) for 6 months. Both diets were non-calorie restricted. Flow-mediated vasodilation (FMD) and nitroglycerine-induced vasodilation (NID) were assessed at baseline and after six months using B-mode ultrasound scans of the brachial artery and are reported as dilation in percentage (%). Blood samples were collected and dual-energy x-ray absorptiometry (DXA) and anthropometrics were assessed at baseline and after six months. We report baselines differences and the mean difference in change (MDIC) between groups from baseline to six months.

Results: Participants on the LCD reduced their self-reported carbohydrate intake to ~14 E% and increased their fat intake to ~63 E% including a 2.7 fold increase in saturated fatty acids (SFA). The LCD caused a clinically relevant decrease in HbA1c (MDIC: -8.9 ± 1.7 mmol/mol; P < 0.001), a reduction in weight (MDIC: -3.9 ± 1.0 kg; P < 0.01) and improved body composition (P<0.05) after 6 months compared with the control diet. Forty-seven brachial ultrasound scans from the LCD group and 19 from the control group were available for analyses at baseline, and 44 and 18, respectively, at follow-up. At baseline, FMD (5.1 ± 0.3 vs. 4.2 ± 0.4 %; P = 0.046), NID (16.3 ± 0.5 vs. 13.8 ± 1.2 %; P = 0.012) and systolic blood pressure (p<0.05) were higher in the LCD group than in the control group. Baseline FMD was positively associated with NID (P = 0.001), but negatively associated with age and systolic blood pressure (all P < 0.05). Six months of LCD did not significantly change either FMD (MDIC: -0.0 ± 0.0 %; p = 0.82) or NID (MDIC: 1.0 ± 1.0 %; P = 0.29) compared with the control diet.

Conclusion: A non-calorie-restricted LCD high in fat for 6 months does not affect either FMD or NID in patients with T2D. While these results could not confirm a beneficial effect of LCD on ED as observed in non-diabetic individuals, the data also suggest that the higher intake of fat, in particular SFA, associated with a LCD, does not adversely affect endothelial function and hence cardiovascular risk in patients with T2D.  
Clinical Trial Registration Number: NCT03068078  
Supported by: Novo Nordisk Foundation, Danish Diabetes Academy, Region of Southern Denmark, A.P. Møller  
Disclosure: E.M. Gram-Kampmann: None.

828  
Perivascular adipose tissue remodelling impairs vasoreactivity in thermoneutral-housed rats  
A.C. Keller1, M.M. Henckel1, J. Chun2, L.A. Knaub1, G.B. Pott1, G.G. James1, L.A. Walker4, J.E. Reusch1;  
1Department of Medicine/Research, University of Colorado/Rocky Mountain Regional VA Medical Center, Aurora, 2Aquillius Corporation, San Diego, 3Department of Medicine/Research, University of Colorado/Rocky Mountain Regional VA Medical Center, Aurora, 3Cornell College, Mount Vernon, 4Department of Medicine, University of Colorado, Aurora, USA.

Background and aims: Diabetes increases cardiovascular disease (CVD) risk and impacts men and women differently. Vascular pathology, characterized by impaired vasoreactivity and mitochondrial function, also differs between the sexes. We reported that housing rats at thermoneutral (TN) conditions causes vascular dysfunction and perturbed metabolism. We hypothesized that perivascular adipose tissue (PVAT), a vasoregulatory adipose depot with a brown adipose tissue (BAT) phenotype, remodels to a white adipose (WAT) phenotype at TN, driving diminished vasoreactivity and mitochondrial function in a sex-dependent manner.

Materials and methods: Male and female Wistar rats were housed at either room temperature (RT) or TN. Endpoints included vasoreactivity in response to acetylcholine and phenylephrine in vessels with intact PVAT or transferred to PVAT of the oppositely-housed animal; vessel mitochondrial respiration; signaling to mitochondrial biogenesis and OXPHOS proteins; PVAT morphology and adiponectin.

Results: TN animals displayed significantly diminished aorta vasodilation (16.7 ± 4.4% dilation in TN animals vs. 36.9 ± 6.0% dilation in RT animals with 20 μM ACh, p<0.05), lessened by the presence of PVAT in males. Switching PVAT from RT rats onto aorta from TN rats in females corrected vasodilation (42.7 ± 13.8% vs. 11.3 ± 7.2% in control rats with 20 μM ACh) and over-constriction (2.3 ± 0.5 mN/mg vs. 3.4 ± 0.8 mN/mg in control rats, p<0.05 for both). In aorta of all animals housed at TN versus those housed at RT, mitochondrial respiration was significantly diminished in lipid substrate experiments (state 3= 21.5 ± 1.0 pmol/s/mg vs. 26.8 ± 1.6 pmol/s/mg, state 4=15.3 ± 1.0 pmol/s/mg vs. 21.3 ± 1.5 pmol/s/mg and uncoupled=32.9 ± 1.6 pmol/s/mg vs. 41.8 ± 2.0 pmol/s/mg, p<0.05 for all). In aorta from animals at TN, there was significantly less expression of pAMPK (p<0.05), p-eNOS (p<0.001), and mitochondrial complexes I (p<0.01) and IV (p<0.05). Male rat aorta had a higher content of mitochondrial biogenesis and OXPHOS proteins; PGC1-α (p<0.0001), MnSOD (p<0.0001), eNOS (p<0.0001), pCaMKII α/β (p<0.0001), and mitochondrial protein complexes II (p<0.05), III (p<0.01), and V (p<0.05). Remodeled PVAT occurred in rats housed at TN: TN rats had 19.7% less BAT phenotype overall as compared with RT rats (p<0.05). UCP-1, a marker of BAT, was less in animals housed at TN (p<0.06). Adiponectin concentrations were significantly lower in those housed at TN (p<0.05), more pronounced in females (0.74 ± 0.08 ng/ml vs. 0.97 ± 0.14 ng/ml).

Conclusion: TN housing leads to impaired vasoreactivity and vascular mitochondrial content; TN housing also leads to decreased adiponectin and UCP-1, more significant in females. Exposure of TN aorta to RT PVAT corrects vasodilation in females. These data support a model wherein diminished adipokine production and signaling from remodeled PVAT to the vasculature causes dysfunctional vasoreactivity via the dampening of nutrient sensor AMPK and/or eNOS activity, in a sex-dependent manner. These results provide insights into sex differences in vascular disease mediated by the adventitia.  
Supported by: The authors wish to acknowledge the following funding sources: NIH/NCRR CCTSI UL1 RR025780, VA Merit  
Disclosure: A.C. Keller: None.
One-year treatment with dulaglutide and dapagliflozin improves endothelial function and albuminuria compared to DPP-4 inhibitors

E. Korakas1, I. Ikonomidou2, J. Thymis2, A. Kountouri1, K. Katogiannis3, P. Pavlidis2, D. Tsilivarakis2, V. Pretzsa1, K. Balamanis1, L. Pliota1, F. Kousathana1, G. Kostelli2, G. Dimitriadis3, A. Raptis1, V. Lambadiari1;
1Second Dept of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, 2Second Cardiology Department, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Chaidari, Greece.

Background and aims: Dulaglutide and dapagliflozin have favorable effects on albuminuria and arterial stiffness, while Dipeptidyl-peptidase 4 inhibitors (DPP-4is) exert rather neutral actions. In this study, we aimed to compare the early combination of dulaglutide and dapagliflozin with DPP-4is as an add-on to metformin monotherapy in terms of endothelial function and albuminuria in type 2 diabetes mellitus (T2DM).

Materials and methods: Overall, 45 patients with T2DM and albuminuria were included in our study. 23 patients received the combination of dulaglutide and dapagliflozin and were followed immediately prior (baseline), 4 and 12 months afterwards. 22 patients, matched for sex, age and glycemic control, received DPP-4is. In each visit we measured a) Carotid-femoral PWV b) central systolic blood pressure (cSBP) c) perfused boundary region (PBR) of the sublingual arterial microvessels, d) urinary albumin-to-creatinine ratio (UACR), e) glycylated hemoglobin (HbA1c).

Results: After 4 and 12 months, patients on dulaglutide/dapagliflozin combination significantly improved HbA1c (8±1.5% vs 6.7±0.73% vs 6.6±0.69%, p<0.001), PBR (2.2±0.29 vs 2.1±0.28 vs 1.9±0.28, μm, p<0.05), PWV (11.9±3.2 vs 11.2±2.2 vs 11.2±2.4 μm/s, p<0.05), cSBP (128.8±24.2 vs 121.7±16.3 vs 121.2±12.3 mmHg, p<0.05) and UACR (36.5±34.1 vs 241±195.7 vs 148.8±97.2 mg/g, p<0.001). On the contrary, no statistically significant differences in PBR (2.1±0.32 vs 2.2 ±0.31 μm vs 2.1±0.27, p>0.05), PWV (11.2±3.5 vs 11.8±3.1 vs 12.9±7.1 μm/s, p>0.05), cSBP (125.2±18.3 vs 126.4±18.6 vs 129.0±19.7 mmHg, p>0.05) were noted in the DPP-4is group, despite significant improvements of HbA1c (8.0±1.7 vs 7.2±1.2 vs 6.8±2.2%, p<0.01) and UACR (242.1±96.9 vs 206±106.4 vs 201±111.6 mg/g, p<0.01).

Conclusion: The combination of dulaglutide and dapagliflozin as an add-on treatment to metformin early in the course of treatment has sustainable favorable effects on endothelial function and albuminuria compared to DPP-4is in patients with T2DM.

Disclosure: E. Korakas: None.

SO 74 Weighing risks of cardiovascular complications

Assessment of skin autofluorescence association with glycated haemoglobin, cardiovascular risk markers and concomitant chronic diseases in children with type 1 diabetes

B. Mianowska1, M. Jankowska2; I. Pietrak1, J. Chrzanowski2, J. Solek3, A. Szadkowski4; 1Dept. of Pediatrics, Diabetology, Endocrinology and Nephrology, Medical University, 2Dept. of Developmental Neurology and Epileptology, Polish Mothers’ Memorial Institute Research Hospital, 3Dept. of Biostatistics and Translational Medicine, Medical University, Lodz, Poland.

Background and aims: Advanced glycation end products (AGEs) are long-lived proteins that play a role in the pathogenesis of chronic diabetes complications. Skin autofluorescence (sAF) is a non-invasive method used to measure tissue AGEs accumulation. It was shown that in adults with type 1 or type 2 diabetes sAF correlates with long term glycemic control and may be regarded as a surrogate marker of chronic diabetes complications, including cardiovascular (CV). This study aim was to assess sAF association with glycated hemoglobin (HbA1c) values, CV risk markers and comorbidity of autoimmune thyroiditis or celiac disease in children with type 1 diabetes (T1D).

Materials and methods: Patients aged 3-18 years with ≥6 months T1D duration participated. sAF (in arbitrary units, AU) was measured with AGE Reader (Diagnostics BV, Netherlands). Total cholesterol and its fractions (low and high density), triglycerides, HbA1c, C-reactive protein (CRP), ambulatory blood pressure monitoring (ABPM; Spacelabs 90217 Monitor, Spacelabs, USA) records, body mass index (BMI) Z-score and body composition parameters (MC-980MA analyzer, TANITA, Japan) were analysed.

Results: Altogether 348 patients were included in the analysis (182 boys, 166 girls; median age 14.3 years [IQR 11.2-17.1]; T1D duration 5.5 years [3.1-8.3]). Median HbA1c was 7.3% [6.7-8.1%] (56 mmol/mol [50-65 mmol/mol]), 244 patients were treated with insulin pumps. Median sAF was 1.40AU [1.27-1.53] and positively correlated with current HbA1c, mean of previous (since T1D diagnosis) HbA1cs, age, and T1D duration (respectively rho: 0.27, 0.22, 0.15, 0.14, all p<0.01). sAF was significantly higher in girls than in boys (respectively 1.40AU [1.3-1.6] vs 1.37AU [1.27-1.50], p=0.011) and in patients with than without celiac disease (1.53AU [1.43-1.63] vs 1.40AU [1.27-1.53], p=0.001). Moreover, sAF positively correlated with percentage of body fat, body impedance and CRP; and negatively correlated with basic metabolic rate (BMR) in kcal (respectively rho: 0.12, 0.14, 0.17 and -0.16, all p<0.05). No significant correlations were found between sAF and: lipids, BMI Z-score, blood pressure load measures (percentages of daytime and nighttime systolic or diastolic readings >95th percentile for sex and height) or nighttime decrease of systolic or diastolic pressure (dipping status). sAF did not differ between patients with (1.40AU [1.27-1.60AU], p=0.707) or without autoimmune thyroiditis (1.40AU [1.27-1.53AU]). In the final multiple regression model, parameters that remained positively correlated with sAF were: age (β=0.40, p<0.0001), historical HbA1c (β=0.24, p<0.0001), CRP (β=0.15, p=0.014), female sex (β=0.26, p=0.034), and presence of celiac disease (β=0.11, p=0.062); while BMR (β=0.51, p<0.0001) remained negatively correlated.

Conclusion: In young patients with T1D whose diabetes duration is relatively short sAF reflects well previous glycemic control represented by historical average HbA1c however its associations with classic CV-risk markers are not evident. sAF negative correlation with BMR and positive with celiac disease deserve further research.

Disclosure: B. Mianowska: None.
First occurred cardiovascular or renal disease (CVRD) cumulative incidence for type 2 diabetes free of CVRD at baseline: a 5-year SNDS nationwide claims database cohort study

P. Blin1, M. Joubert1, P. Zaoui3, E. Guiard1, D. Sark1, C. Dureau-Pournin1, M.A. Bernard1, R. Lassalle1, F. Thomas-Delecourt1, S. Bineau2, N. Moore4, C. Droz-Peiroteau1, P. Joudain2; 1Bordeaux PharmacoEpi INSERM-P CIC1401, University of Bordeaux, Bordeaux, 2CHU Caen, Caen, 3CHU Grenoble, Grenoble, 4AstraZeneca, Courbevoie, 5Hôpital Kremlin-Bicêtre, Paris, France.

Background and aims: Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal disease (CVRD) manifestations for type 2 diabetes (T2D). The main objective was to assess the 5-year incidence of the first occurred CVRD manifestation for T2D patients free of CVRD at baseline, that is currently not well known.

Materials and methods: A cohort study of all French T2D patients free of CVRD (5-year history) as of January 1st, 2014, identified and followed-up for 5 years within the French SNDS nationwide claims database. The cumulative incidence of the first occurred CVRD manifestation (MI, stroke, PAD, HF or CKD) was estimated using the cumulative incidence function, with other CVRD manifestations and death as a competing risk.

Results: From about 2 million T2D patients without cancer or transplantation, 76.5% were free of CVRD at baseline with a mean age of 65 years, 52% of women, 46% T2D for more than four years and 7% of diabetic complications. The most frequent first occurred CVRD manifestation during the 5-year follow-up was CKD followed by HF, then PAD, stroke and MI with a constant linear increase over time (figure 1). After 5 years of follow-up, CKD represented 40.6% of first CVRD manifestation, HF 23.0%, PAD 13.5%, stroke 13.2% and MI 9.7%. HF and CKD together reached about 1 patient out of ten and represented 63.6% of first CVRD manifestations. The cumulative incidence increased with age, and similar proportion of CVRD manifestation was observed whatever the age-class, except for HF which presented a clear increased with age from 14% of the events before 65 years to twice more (30.7%) for those ≥75 years.

Conclusion: While MI, stroke and PAD remain classic major risks of complications for CVRD free T2D patients, HF and CKD nowadays represent a higher risk of CVRD manifestation. This should encourage the development of specific preventive strategies.

Figure 1: 5-year cumulative incidence of the first occurred CVRD manifestation

Supported by: Study performed with unconditional funding from AstraZeneca
Disclosure: P. Blin: None.

The association between hemoglobin A1c and development of cardiovascular disease in males and females without diabetes at baseline: a population inception cohort study

P. Kaul1, L. Chu2, D.A. Dover1, R.O. Yeung1, D.T. Eurich1, P. Senior1, S. Butalia2; 1University of Alberta, Edmonton, 2Alberta Health Services, Edmonton, 3University of Calgary, Calgary, Canada.

Background and aims: To examine the association between HbA1c and development of CVD in males and females in a large, population-based inception cohort without diabetes at baseline, in a universal health care setting.

Materials and methods: The study population consisted of an inception cohort of individuals between 40 and 80 years without diabetes or CVD on April 1, 2013 in the province of Alberta, Canada (N=1,419,558). Individuals who died, left the province, developed CVD or did not have an HbA1c test during the 3-year enrollment period (April 1, 2013 and March 31, 2016) were excluded. The remaining males and females were divided into the following categories based on their maximum HbA1c during the enrollment period: HbA1c < 5.0%, 5.0 to 5.4%, 5.6 to 5.9%, prediabetes 6.0 to 6.4%, and diabetes ≥6.5%. HbA1c categories for prediabetes and diabetes were based on Canadian diabetes guidelines. The primary outcome of interest was a CVD hospitalization (defined as a hospitalization with a primary diagnosis of heart failure, acute coronary syndromes, cerebrovascular disorders, atrial fibrillation and flutter, ventricular arrhythmia, or sudden cardiac death) over a 5-year follow-up period until March 31, 2021. Cox-proportional hazards models were used to estimate the association (presented as adjusted hazard ratio with 95% CI) between HbA1c categories and outcomes in males and females after adjusting for age, hypertension, material deprivation, urban/rural residence, and comorbidity burden.

Results: A total of 624,096 individuals (55% female) were included in the study. During the enrollment period, 15% and 5.2% of females developed prediabetes and diabetes, respectively, and 15.9% and 8.2% of males developed prediabetes and diabetes, respectively. Compared to the reference category of 5.0% to 5.4%, males with normal HbA1c (5.5% to 5.9%) had an increased risk of CVD hospitalization (aHR 1.16; 95% CI 1.1 to 1.23) whereas females did not (aHR 1.04; 95% CI 1.0 to 1.12) (Figure). Males with prediabetes had a higher risk of CVD hospitalization compared to females (aHR 1.38; 95% CI 1.28 to 1.47 in males; aHR 1.13, 95% CI 1.04 to 1.23 in females). Males and females who developed diabetes during the enrollment period had the highest risk of CVD.

Conclusion: Normal glycemia and prediabetes conferred a higher risk of CVD hospitalization in males than in females. These findings highlight the importance of optimizing cardiovascular risk profiles, particularly in males at all levels of glycemia.

Supported by: Canadian Institutes of Health Research
Disclosure: P. Kaul: None.
833
Association between age at diagnosis of type 2 diabetes and cardiovascular and mortality risks: a nationwide population-based study
D. Seo1, M. Kim2, Y. Cho1, S. Ahn1, S. Hong1, S. Kim1;
1Inha University School of Medicine, Incheon, 2Hanmi Pharm. Co., Ltd., Seoul, Republic of Korea.

Background and aims: The incidence of type 2 diabetes mellitus (T2DM) among young adults is increasing and individuals with young onset T2DM are known to have increased risk of vascular complications. We aimed to investigate the association between mortality and cardiovascular (CVD) outcomes in relation to the age at diagnosis of T2DM.

Materials and methods: In this population cohort study with Korean National Health Insurance Service data (2012-2014), a total of 634,350 patients with newly diagnosed T2DM were included. Controls were randomly selected from the general population and matched for age, sex, and previous history of CVD, using the propensity score matching analysis (1:2 ratio). Participants were followed for CVD outcomes, death or until 2019. Outcomes of interest were total mortality, CVD mortality, coronary heart disease (CHD), acute myocardial infarction (AMI), stroke, hospitalization for heart failure (HHF) and 3-point MACE. We conducted the primary analyses using Cox proportional hazards models in those with no previous CVD and repeated the analysis in the entire cohort.

Results: During a 5.67 years follow-up period, patients with T2DM diagnosed at ≤40 years had the highest excess risk for most outcomes relative to controls with adjusted hazard ratio (HR) (95% CI) of 6.08 (5.50-6.72) for total mortality, 5.53 (4.29-7.14) for CVD-related mortality, 7.19 (6.72-7.70) for HHF, and 5.10 (4.91-5.30) for CHD. All risks attenuated progressively with each increasing decade at diagnostic age but remained significant: by the time T2DM was diagnosed at ≥91 years, the adjusted HR (95% CI) of 1.29 (1.21-1.37) for total mortality, 1.32 (1.15-1.51) for CVD-related mortality, 2.95 (2.54-3.42) for HHF, and 3.66 (3.16-4.24) for CHD.

Conclusion: In this population-based cohort study, younger age at diagnosis of T2DM was associated with a higher risk of mortality and CVD outcomes especially in those without previous CVD. Therefore, awareness should be raised to prevent or delay T2DM in younger individuals.

Supported by: INHA UNIVERSITY Research Grant
Disclosure: D. Seo: None.

834
The added value of ECG abnormalities in predicting incident cardiovascular disease risk for people with type 2 diabetes: the Hoorn Diabetes Care System cohort
P.P. Harms1,2, R.A.R. Herings1,2, S.J.G. Welten1,2, S. Remmelzwaal1,2, F. Rutters1,2, J.W.J. Beulens3,4, G. Nijpels3,4, P.P.J. Elders1,2, M.T. Blom1,2;
1Department of General Practice Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, 2Health behaviors & chronic diseases, Amsterdam Public Health research institute, Amsterdam, 3Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, 4Department of Epidemiology and Data Science, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.

Background and aims: Cardiovascular disease (CVD) is an important complication and cause of mortality in people with type 2 diabetes. Guidelines recommend the use of prediction models to estimate individualised risk of CVD and help clinicians make informed personalised treatment decisions. However, prediction models currently recommended by various international guidelines perform only moderately in people with type 2 diabetes, with c-statistics for discrimination typically around or below 0.7 (theoretical range: 0.5-1.0). ECG abnormalities are good candidates for improving prediction because they are associated with incident CVD, are common in people with type 2 diabetes without pre-existent CVD, and might be part of the pathophysiology. We aimed to investigate if adding ECG abnormalities as a predictor improves performance of currently recommended incident CVD prediction models for people with type 2 diabetes.

Materials and methods: We evaluated the ASCVD, AD-ON, and ADVANCE Cox-prediction models that are recommended for use by the guidelines of the American College of Cardiology/American Heart Association (ACC/AHA), the European Society of Cardiology (ESC), and the Dutch Society of General Practitioners (NHG), respectively, in 11,277 people with type 2 diabetes without CVD (CHD, heart failure, stroke, thrombosis) from the dynamic Hoorn Diabetes Care System cohort (1998-2018). Baseline measurements, taken at entry into the cohort, included CVD risk factors and ECG abnormalities coded according to the Minnesota Classification as minor or major. Annual follow-up for CVD continued until 2018. After calibration to ensure good model fit, performance of the prediction models was assessed with and without the addition of ECG abnormalities, and compared using c-statistics, net reclassification index (NRI), and the integrated discrimination index (IDI). Prediction horizons and categoric NRI cut-off values were adopted from the guidelines.

Results: For all three models, c-statistics and classification or estimation of people’s individual CVD risk improved with ECG abnormalities as an additional predictor (Table 1).

Conclusion: The addition of ECG abnormalities to incident CVD risk prediction models consistently improves model performance and the ability of models to correctly classify people with type 2 diabetes in the appropriate CVD risk category.

Table 1: Performance and reclassification of the prediction models

<table>
<thead>
<tr>
<th>Prediction model</th>
<th>C-statistic</th>
<th>C-statistic with ECG</th>
<th>C-statistic change (%)</th>
<th>Categorical NRI (%)</th>
<th>Continuous IDI (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASCVD</td>
<td>0.67</td>
<td>0.71</td>
<td>0.04</td>
<td>2.85</td>
<td>1.63</td>
</tr>
<tr>
<td>AD-ON</td>
<td>0.71</td>
<td>0.76</td>
<td>0.05</td>
<td>3.42</td>
<td>2.04</td>
</tr>
<tr>
<td>ADVANCE</td>
<td>0.74</td>
<td>0.78</td>
<td>0.04</td>
<td>2.90</td>
<td>1.59</td>
</tr>
</tbody>
</table>

Based on the same risk group cut-off values as used by the model developers and in the guidelines. ASCVD in AC/C/AHA guideline, >5%, CI: 0.67-0.74; ECG: 0.67-0.74; IDI: 0.8-1.0; NRI: 0.8-1.0. Higher values are preferred.

Data were weighted according to the European Research Infrastructure for Cardiovascular Disease (ERIC) guidelines: CHD: ≥1% prevalence, stroke: ≥0.5% prevalence, diabetes: ≥5% prevalence. The analysis was performed using 1:2 ratio and repeated with propensity score matching.

Supported by: EFSD European Pilot Research Grants for Innovative Measurement of Diabetes Outcomes
Disclosure: P.P. Harms: None.

835
Cardiovascular risk factor control in patients with type 2 diabetes and coronary artery disease versus stroke
P. Balasubramanian1, W. Kernan2, K.N. Sheth3, A.P. Ofstad4, M. Matteus5, N. Marx6, S.E. Inzucchi7;
1Section of Endocrinology, Yale School of Medicine, New Haven, USA, 2Department of Medicine, Yale School of Medicine, New Haven, USA, 3Department of Neurology, Yale School of Medicine, New Haven, USA, 4Boehringer Ingelheim Norway KS, Asker, Norway, 5Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany, 6Department of Internal Medicine, University Hospital RWTH Aachen, Aachen, Germany.

Background and aims: Stroke and coronary artery disease (CAD) share several cardiovascular (CV) risk factors, including type 2 diabetes. Risk factor control is vital for secondary prevention of both conditions, but systems for care of patients after stroke or CAD events differ, and distinctions in care for these patients have not been examined. The aim of this study was to compare CV risk factor control in patients with CAD versus
stroke at baseline in three recent large CV outcome trials (CVOTs) involving 11,622 patients with type 2 diabetes at high CV risk.

Materials and methods: We analysed baseline data from the (1) EMPA-REG OUTCOME, (2) CAROLINA, and (3) CARMELINA trials. Risk factors assessed included dyslipidaemia, hypertension, smoking, and use of anti-platelet/anti-coagulant drugs. Risk factor control was defined as (a) low-density lipoprotein cholesterol <100 mg/dL or statin use, (b) systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg, (c) use of anti-platelet/anti-coagulant drugs, and (d) not smoking. The quality of CV risk factor goal attainment was defined as the odds of having 3-4 versus 0-2 risk factors controlled. We calculated the odds ratio (OR) across macrovascular disease groups at baseline and by subgroups of age, sex, and region in the trials, based on logistic regression.

Results: The ORs (95% confidence intervals [CIs]) for CV risk factor control in patients with CAD alone were higher than in patients with stroke alone across all three trials: (1) 2.60 (2.19-3.08), (2) 1.59 (1.18-2.15), and (3) 2.20 (1.81-2.67), respectively. The respective ORs (95% CIs) were lower (and rendered non-significant in CAROLINA) when risk factor control in patients with both CAD and stroke was compared to patients with stroke alone: (1) 2.00 (1.52-2.64), (2) 1.13 (0.72-1.79), and (3) 1.42 (1.08-1.86). Results were consistent across all subgroups.

Conclusion: We found significant disparities in CV risk factor control based on history of CAD and/or stroke in three contemporary CVOTs in patients with type 2 diabetes, with less optimal control in stroke patients, particularly in those with stroke alone. The intermediate results in patients with both CAD and stroke suggest a role for clinician factors. These findings require further study to understand their origins but emphasise the need for improved secondary prevention strategies in patients with stroke.

Clinical Trial Registration Number: EMPA-REG OUTCOME (NCT01131676), CAROLINA (NCT01243424), CARMELINA (NCT01897532)

Supported by: Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Disclosure: P. Balasubramanian: None.

836

Deviations from the ADA/EASD treatment algorithm is associated with higher cardiovascular events and death in type 2 diabetes under routine care

M.L. Morieri, E. Longato, B. di Camillo, G. Sparacino, A. Avogaro, G.P. Fadini; University of Padova, Padova, Italy.

Background and aims: Since current treatment algorithms are only partially evidence-based, we examined whether deviations from therapeutic recommendations for the management of T2D has an impact on long-term outcomes.

Materials and methods: This study was conducted on an outpatient clinical-administrative database in years 2008-2018. We defined 6 domains of inadequate treatment prescription (ITP) based on the 2018 ADA/EASD algorithm: first-line and second-line treatment, intensification, use of insulin, cardioprotective, and weight-affecting drugs. Patients were divided according to presence/absence of ITP at each visit. Study outcomes were major adverse CVD events (MACE) and death. We used Cox proportional hazard models with time-dependent covariates or Cox marginal structural models (Cox MSMs).

Results: We included 5419 patients, on average 66-year old, 41% women, with a diabetes duration of 7.6 years and only 11.7% had pre-existing CVD. At study entry, 57.3% of patients had ITP in at least one domain. By the end of the study (after a median of 7.3 years and 12 visits/patient), 85.8% of subjects had at least one visit with ITP in one or more domains. Overall 1325 MACE occurred (in 1117 subjects [20.6%]), and 917 deaths were observed. As shown in figure 1, in the fully adjusted model, being always on ITP was associated with an 81% relative higher risk of MACE as compared to being always with appropriate treatment. The association was confirmed with Cox MSMs (weighted for the same covariates used in model 3) where ITP was associated with a 57% relative higher risk of MACE (HR 1.57; 95% C.I. 1.39-1.78; p<0.0001). Cumulative ITP was associated with a corresponding 79% higher mortality risk (confirmed also with Cox MSMs - HR: 1.59; 95% C.I. 1.37-1.85; p<0.0001). No individual domain or combination of two explained all the prognostic effect of ITP, which remained significant in all subgroups analyses when population was stratified by key baseline characteristics.

Conclusion: Deviations from internationally recommended standards in the management of T2D is associated with higher risk of MACE and premature mortality. These data provide a validation of the current treatment algorithm. Figure 1 Legend: Estimated impact on MACE (A) and death (B) of cumulative ITP time (i.e., the proportion of time being on ITP up to each visit, ranging from 0 to 1) according to multivariable-adjusted models (Model 1: age, sex, study entry year, diabetes duration, and time-varying covariates: CVD history, kidney disease, macro- and microvascular disease. Model 2: Model 1 with the addition of: line of treatment, latest BMI and HbA1c, other non-diabetic medications, presence of obesity, and presence of HbA1c levels > 10%. Model 3: Model 2 with the addition of: history of cancer, chronic pulmonary disease, systemic inflammatory disease, and hepatic steatosis.

837

High levels of physical activity are associated with a reduced risk of CVD regardless of sedentary time among type 2 diabetes patients

Y. Wu, W. Wang, J. Zhao, The MiDiab Study Group; 1Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 2National Center for Chronic and Noncommunicable Disease Control and Prevention, Beijing, China.

Background and aims: With the rapid development of technology and social economy level, people’s lifestyles are changing. It was estimated that there were 451 million diabetic patients worldwide in 2017, and this
number was expected to reach 693 million by 2045. The increasing prevalence of diabetes will inevitably lead to an increase in the proportion of complications of diabetes, especially cardiovascular disease (CVD). Previous studies have illustrated that both a higher level of physical activity and decreased sedentary (SED) behavior were associated with a lower risk of CVD. The aim of this study was to explore the associations of moderate-to-vigorous intensity physical activity (MVPA) time and SED time with multifactorial control status and CVD risk among type 2 diabetes mellitus (T2DM) patients in China.

Materials and methods: A cross-sectional analysis of 9152 diabetic patients from the Multifactorial Intervention on Type 2 Diabetes (MIDIaB) Study was performed. These patients covered a total of 223 hospitals and were grouped according to their self-reported MVPA time (low, <150 min/w; moderate, 150-450 min/w; high, ≥450 min/w) and SED time (low, <4 h/d; moderate, 4-8 h/d; high, ≥8 h/d). Multifactorial control status involved blood pressure (BP), body mass index (BMI), low-density lipoprotein cholesterol (LDL-C) and HbA1C. Multivariable logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) for multifactorial control status and CVD risk.

Results: Participants had a mean ± SD age of 60.87±8.44 years and 25.1% had CVD. The prevalence of CVD decreased with the increase in MVPA time. With the increase in MVPA time, the multifactor control rate showed a positive trend. After adjustment for potential confounding factors, an inverse association between a high physical activity level and CVD risk that was independent of SED time was found, whereas this association was not observed in the moderate-MVPA group. Compared with the referent group (i.e., those with a SED time <4 h/d and MVPA time <450 min/w), CVD risk was higher in the low-MVPA group than in the other groups; the OR associated with a SED time <4 h/d was 1.344 (95% CI 1.100-1.624), with a SED time of 4 to <8 h/d was 1.280 (95% CI 1.039-1.578), and with a SED time ≥8 h/d was 1.554 (95% CI 1.193-2.025), full details were shown in the attached table.

Conclusion: In conclusion, high levels of physical activity (i.e., more than 450 min/week MVPA) were associated with a reduced risk of CVD regardless of SED time. Meanwhile, this high physical level seemed to eliminate the increased risk of CVD associated with high SED time in patients with T2DM. These results may provide practical and relatively detailed lifestyle intervention for T2DM patients, thus further improving the multifactor control rate, delaying the occurrence and progress of CVD and relieving the disease burden.

SO 75 Emerging comorbidities in diabetes: clinical associations and mechanisms

838 Anti-fibrotic potential of a novel long-acting Glucagon/GIP/GLP-1 triple agonist (HM15211) in preclinical models of idiopathic pulmonary fibrosis

S. Lee, J. Kim, J. Lee, J. Kim, Y.-H. Ban, J. Lee, S. Bae, D. Kim, S. Lee, I. Choi


Background and aims: Idiopathic pulmonary fibrosis (IPF) is an irreversible and progressive pulmonary disorder of unknown causes in which scarring of lung tissue eventually leads to death. A large number of studies have demonstrated that the core mechanisms of fibrosis across various organs are similar. Previously, excellent preclinical efficacy of HM15211, a novel long-acting Glucagon/GIP/GLP-1 triple agonist, on liver fibrosis was confirmed. Since the major distributed tissues of HM15211 were found to be in liver and lung, such findings prompted us to hypothesize that HM15211 could be also a promising drug candidate for IPF. In the present study, its effect on pulmonary function and mortality was evaluated in bleomycin (BLM)-induced mouse model of IPF.

Materials and methods: To investigate the therapeutic effect of HM15211 on IPF-induced pulmonary function impairment as well as mortality, BLM induced mouse model of lung fibrosis was established. Briefly, at day 0, 1.5 U/kg and 2.5 U/kg of BLM were intratracheally injected to impair pulmonary function and to increase mortality, respectively. HM15211 treatment was initiated from day 7, and continued until day 14 ~ day 21, followed by monitoring the saturation of peripheral oxygen (SpO2) and survival rate. To highlight the therapeutic benefits of HM15211, pirfenidone (PIRF) and nintedanib (NINT) treated groups were included as comparative control.

Results: In 1.5 U/kg BLM mice, markedly impaired lung function was observed at day 7 as indicated by SpO2 (84.0 ± 95.6% for normal), which was further exacerbated until day 14 (77.1% vs. 96.0% for normal). Interestingly, while PIRF (81.9%) and NINT (81.3%), FDA-approved drugs for IPF management, prevented additional lung function impairment, without statistical significance, HM15211 treatment significantly restored the impaired lung function close to normal level at day 14 (91.5%, p < 0.001 vs. BLM, vehicle), demonstrating HM15211’s disease modifying potential. In addition, at 21 days after 2.5 U/kg BLM treatment, substantial decline in survival rate (17%) was effectively inhibited by HM15211, NINT, and PIRF. Notably, HM15211 (61%, p < 0.05 vs. BLM, vehicle) showed improved survival rate compared to NINT (33%, no significant) and PIRF (28%, no significant), suggesting potential superiority of HM15211 over current IPF drugs.

Conclusion: HM15211 could possess therapeutic potential for IPF with improved treatment effects over current standard of care. On-going mechanistic studies will elucidate the underlying mode of actions, and human study should be followed up (required) to assess the clinical relevance of these findings.

Disclosure: S. Lee: None.

839 Disruption of the intestinal barrier is associated with markers of kidney injury in DSS-induced colitis in mice

H. Salmenkari1,2, K. Adeshara1,2, A. Pirttiniemi1,2, J. Lindén3, S. Lehtonen4,2, P.-H. Groop1,5, M. Lehto1,5

1Folkhälsan Institute of Genetics, Folkhälsan Research Center, 2Research Program for Clinical and Molecular Metabolism, University of Helsinki, 3Department of Basic Veterinary Sciences, HiLiFE, University of Helsinki, 4Department of Pathology, University of Helsinki, 5Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Background and aims: Intestinal permeability is increased in individuals with diabetes, and this can lead to an increased systemic load of bacterial toxins. On the other hand, increased rate of bacterial infections and use of antibiotics are associated with the progression of microvascular complications, such as diabetic kidney disease. Our aim at the FinnDiane study group was to study how a compromised intestinal barrier may contribute to the development of kidney damage.

Materials and methods: To induce colitis and translocation of bacteria and bacterial products, 7-week-old male BALB/c mice (n=6) were treated with 5% dextran sodium sulfate (DSS) in the drinking water over 7 days followed by four days of fresh water. Healthy mice (n=6) were used as controls. Colitis progression was measured as a change in body weight, colon shortening, and disease scoring by combining stool consistency, colonic bleeding, and colonic edema. Kidney damage was assessed by measuring kidney weight, albuminuria by ELISA, kidney inflammatory infiltration by using immunofluorescence staining for CD45, and RT-qPCR analysis of the proinflammatory cytokines, infiltration by using immunofluorescence staining for CD45, and RT-qPCR analysis of the proinflammatory cytokines, interleukin 1 beta (IL1B) and tumor necrosis factor-alpha (TNfa), tissue damage markers kidney injury molecule -1 (Kim-1) and lipocalin 2/Neutrophil gelatinase-associated lipocalin (Lcn2/Ngal) as well as kininogen 2 (Kng2), encoding a propeptide participating in coagulation and inflammation pathways.

Results: The mice in the colitis group lost an average of 19.8% of their body weight while the control mice gained 2.0%. The colon lengths were shorter in the colitis group than in the healthy mice (5.2 ± 0.8 cm, p = 0.0002) and the disease scores were increased (6.5 (3-9) vs 0, p = 0.0055). Colitis led to a reduction in kidney weights (0.27 ± 0.02 vs 0.32 ± 0.03 g, p = 0.0048) and an increase in albuminuria (153 ± 72 vs 58 ± 13 mg/l, p = 0.016), when compared with healthy controls. CD45-positive cells, indicative of inflammatory infiltration, were observed around individual distal tubules in the colitis group. Transcriptomic levels of kidney tissue injury markers Lcn2 (8.65-fold, p = 0.006) and Kim-1 (2.02-fold, p = 0.006), as well as the pro-inflammatory cytokine IL1B (2.05-fold, p = 0.006) were increased in the colitis group, while Tnfa transcription was unchanged. Colitis also caused a small but significant induction of Kng2 mRNA (1.4-fold, p = 0.013) expression.

Conclusion: Intestinal barrier disruption leads to inflammatory responses in the kidneys and an increase in clinically relevant markers of kidney injury, including albuminuria and induction of Kim-1 and Lcn2. This implies that a defective gut barrier function followed by translocation of bacterial products may lead to kidney insults, potentially predisposing individuals to the development and progression of renal damage, such as diabetic kidney disease.

Supported by: Diabetes Research Foundation, Päivikki and Sakari Sohlberg Foundation, Manuaisäätiö
Disclosure: H. Salmenkari: None.

Materials and methods: A retrospective open cohort study in IQVIA Medical Research Data - UK was performed estimating the risk of gout in patients with T2DM who were new users of SGLT2i and comparing this to the risk in propensity score (PS)-matched patients who were new users of DPP4i (1st Nov 2012 to 31st Dec 2018). Propensity scores (PS) were estimated from logistic regression model using an extended list of clinical, laboratory and demographic covariates. Proportional hazards were used to estimate the hazard ratios (HRs) and 95% CIs of the outcome (gout), using both intention to treat and at treatment analysis.

Results: A total of 99 incident cases of gout were recorded over 30,577 person-years of observation in 13,617 new users of SGLT2i and 29,426 new users of DPP4i. Crude incidence rates (IR) per 1000 person-years were found to be 3.31 and 3.16 for SGLT2i and DPP4i new users respectively. Unadjusted hazard ratio (HR) was 1.05 [95% Confidence Interval (CI): 0.70-1.55]. After further adjustment for all covariates used in the PS model, the aHR was 1.11 (0.74-1.67). In the at-treatment analysis, crude IRs per 1000 person-years were found to be 2.93 and 3.24 for SGLT2i and DPP4i users respectively. In the fully adjusted model, the adjusted HR was 0.95 (95% CI: 0.58-1.55).

Conclusion: In this nation-wide study, no significant difference in the incidence of gout was documented in patients with diabetes treated with SGLT2i compared to DPP4i users after propensity-score matching. This neutral finding was consistent in both intention-to-treat and at-treatment analyses.

Support by: MN
Disclosure: A. Subramanian: None.

840
Sodium/glucose co-transporter-2 inhibitors and the risk of gout in patients with type 2 diabetes: a propensity score matched, prevalent-new user design study

Background and aims: SGLT2i-induced glycosuria may induce changes in renal handling of urate. The putative effect of SGLT2i on uric acid levels and thus the incidence of gout is of clinical interest in the context of the prevalence of hyperuricaemia and gout in patients with type 2 diabetes mellitus. However, evidence from studies remains inconclusive. To address this discrepancy, we undertook an observational study to explore the incidence of gout in patients with T2DM who are treated with SGLT2i.

Increased glycaemic variability evaluated by continuous glucose monitoring is associated with osteoporosis in type 2 diabetes patients

R. Huang, H. Wang, Z. Shen, T. Cai, Y. Zhou, Y. Wang, J. Wu, J. Ma; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

Background and aims: Subjects with type 2 diabetes mellitus (T2DM) are susceptible to osteoporosis. This study was conducted to evaluate the association between glycemic variability evaluated by continuous glucose monitoring (CGM) and osteoporosis in type 2 diabetic patient.

Materials and methods: A total of 362 type 2 diabetic subjects who underwent bone mineral density (BMD) measurement and were monitored by a CGM system from Jan 2019 to May 2020 were enrolled in this cross-sectional study. Glycemic variability was calculated with the Easy GV software, including 24-hour mean blood glucose (24-h MBG), the standard deviation of 24-h MBG (SDBG), coefficient of variation (CV), mean amplitude of glycemic excursions (MAGE), and time in range between 3.9 and 10.0 mmol/L (TIR). Other potential influence factors for osteoporosis were also examined.

Results: Based on the T-scores of BMD measurement, there were 190 patients with normal bone mass, 132 patients with osteopenia and 40 patients with osteoporosis. T2DM patients with osteoporosis showed a higher 24-h MBG, SDBG, CV, and MAGE, but a lower TIR (all p < 0.05). Multivariate logistic regression analysis revealed that age, female, body mass index (BMI), low-density lipoprotein cholesterol (LDL-C), serum uric acid (SUA) and MAGE independently contribute to osteoporosis, and corresponding odds ratio (95% confidence interval (CI)) was 1.129 (1.072-1.190), 4.215 (1.613-11.012), 0.801 (0.712-0.901), 2.743 (1.385-5.431), 0.993 (0.988-0.999), and 1.380 (1.026-1.857), respectively. Further receiver operating characteristic analysis indicated that the area under the curve and its 95% CI were 0.673 and 0.604-0.742, with the optimal cut-off value of MAGE predicting osteoporosis being 4.31 mmol/L.

Conclusion: In addition to conventional influence factors including age, female, BMI, LDL-C and SUA, increased glycaemic variability assessed by MAGE is associated with osteoporosis in type 2 diabetic patients.

Supported by: NKRDP (No. 2018IFC1314100)

Disclosure: R. Huang: None.
Materials and methods: In national registries, we identified all patients with non-valvular AF in Sweden (n=309,611) during 2013-2014. Using propensity score matching based on age and comorbidities, in total 12 variables including all the components of CHA2DS2-VASc score, we matched 90222 men and 90222 women with AF without diabetes, 757 men and 757 women with AF and T1DM and 20034 men and 20034 women with AF and T2DM. Cox regression was used in the matched cohorts to calculate the hazard ratios (HR) and 95% confidence intervals (CI) for all-cause mortality and competing risk regression for myocardial infarction, ischemic stroke and first-ever diagnosis of heart failure and dementia with all-cause mortality as competing risk in women without diabetes, T1DM and T2DM, using men in the respective group as reference. The follow-up time for mortality was until 27 March 2017 and for the other endpoints until 31 December 2015.

Results: After matching, the median age for patients without diabetes was 77 years (69-84), for patients with T1DM 72 (65-78) and for T2DM 78 (72-84) years. Women were less often treated with warfarin than men in both the cohort without diabetes (35.7 vs. 39.8%, p<0.001), the cohort with T1DM (30.4 vs. 41.6%, p<0.001) and the cohort with T2DM (43.6 vs. 47.1%, p<0.001). Among those without diabetes, women had a better prognosis than men (Figure) regarding all-cause mortality [HR:95% CI: 0.89 (0.88-0.91)], heart failure [0.93 (0.90-0.96)] and myocardial infarction [0.83 (0.79-0.88)] but worse prognosis regarding stroke [1.12 (1.07-1.16)]. Among those with T1DM, women had worse prognosis than men regarding heart failure [1.42 (1.09-1.86)] and myocardial infarction [1.50 (1.09-2.06)]. Among those with T2DM, women had worse prognosis than men for stroke [1.14 (1.06-1.23)] and similar risks for the other events. The risk for dementia was similar regardless of sex, presence or type of diabetes with a trend (non-significant) for lower risk in women with T1DM.

Conclusion: Women with AF without diabetes had generally lower risk than men for death and other events except for stroke risk which was increased. In the presence of diabetes, regardless of type, this apparent benefit for women was even more pronounced than men for death and other events except for stroke risk which was increased. Among those with T2DM, women had worse prognosis than men for stroke [1.14 (1.06-1.23)] and similar risks for the other events.

Materials and methods: Male Wistar Rats were divided into 2 groups: control group (NC) and obese group (HF) fed with 60% lipid-rich diet for 12 weeks. Half of the groups were submitted to a CIH paradigm (40s, 5% O2 /80s air, 8h/day) for 14 days. Liver samples were evaluated by western blot for the levels of oxidative phosphorylation complexes (OXPHOS) and proteins involved in inflammation, hypoxia, glucose homeostasis, insulin signalling and oxidative stress. Hepatic histological and immunohistochemical analyses were performed to evaluate lipid deposition, fibrosis, angiogenesis, mitochondrial density, hypoxia, and macrophages markers. Energy status of the cell was assessed by measuring nucleotide levels by HPLC.

Results: CIH promoted insulin resistance and glucose intolerance and exacerbated metabolic dysfunction and hepatic lipid deposition in HF animals. HF diet increased insulin receptor levels by 55.3% (p<0.01), and CIH and HF diet showed a tendency to decrease the levels of insulin degrading enzyme. Glut 2 levels increased by 29.60% (p<0.05) and 46.10% (p<0.05) in HF and HF/HI groups. No significant alterations in NO production leading to liver inflammation. We hypothesize that mitochondrial dysfunction and oxidative stress in the liver play a role in the development of CIH-induced dysmetabolism.

Conclusion: Mitochondrial dysfunction and hepatic oxidative stress may contribute to metabolic dysfunction associated with CIH, justifying the relationship between insulin resistance, hepatic steatosis and OSA. Targeting these mechanisms might be a therapeutic approach to prevent/treat metabolic dysfunction in sleep apnea.

846
The impact of obesity and diabetes chronic complications in COVID 19 patients
A. Andrita1, A.-M. Militaru1, A. Nica2, E. Rusu2, C. Dobrianschi1, G. Radulian1;
1Department of Diabetes, Nutrition and metabolic diseases, "Nicole Malaxa" Clinical Hospital, 2Diabetes, Nutrition and metabolic diseases, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

Background and aims: Obesity, chronic micro and macrovascular complications were observed to be risk factors for COVID 19 poorer outcome in patients with diabetes mellitus. The aim of the study is to

Disclosure: S. Karayianides: None.

845
Insulin resistance in obstructive sleep apnea: Is there a role for mitochondrial dysfunction in the liver?
1Neuronal Control of Metabolic Diseases: Therapeutic Strategies, CEDOC - Centro de Estudos de Doenças Crónicas, Lisboa, Portugal, 2Departamento de Enfermía, Universidad de Valladolid, Valladolid, Spain, 3Departamento de Bioquimica, Biologia Molecular y Fisiologia, Universidad de Valladolid, Valladolid, Spain.

Background and aims: The relationship between obstructive sleep apnea (OSA) and metabolic diseases is unequivocal, however the mechanisms behind this relationship are not consensual. Mitochondrial dysfunction and oxidative stress in the liver play a major role in the development of metabolic diseases. Chronic intermittent hypoxia (CIH), one of the key features of OSA, induces whole-body metabolic dysfunction with an increase in Glut2 in the liver and lipid peroxidation and ROS production leading to liver inflammation. We hypothesize that mitochondrial dysfunction and oxidative stress in the liver play a role in the development of CIH-induced dysmetabolism.

Disclosure: J.L. Fernandes: None.

Disclosure: None.

846
The impact of obesity and diabetes chronic complications in COVID 19 patients
A. Andrita1, A.-M. Militaru1, A. Nica2, E. Rusu2, C. Dobrianschi1, G. Radulian1;
1Department of Diabetes, Nutrition and metabolic diseases, "Nicole Malaxa" Clinical Hospital, 2Diabetes, Nutrition and metabolic diseases, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
The results suggest that the inflammatory syndrome due to micro (p = 0.331) or macrovascular complications (p = 0.229) significantly correlated with hypoglycemic treatment involving neither patients (p = 0.018). On the other hand, COVID 19 severity was not (p = 0.011). Ferritin was statistically significantly lower in insulin-treated Microvascular complications were correlated with elevated ferritin values and stroke (p <0.001) were correlated with length of stay in hospital. Acute myocardial infarction (p = 0.006) and oxygen therapy (p = 0,049). C-reactive protein was statistically significant correlations between D-dimer (p = 0.004), procalcitonin (p = 0.002), erythrocyte sedimentation rate (p = 0.029) and obesity. Furthermore, correlations between D-dimer (p=0.012), procalcitonin (p = 0.049) and the presence of macrovascular complications were highlighted. Acute myocardial infarction (p = 0.006) and stroke (p <0.001) were correlated with length of stay in hospital. Microvascular complications were correlated with elevated ferritin values (p = 0.011). Ferritin was statistically significantly lower in insulin-treated patients (p = 0.018). On the other hand, COVID 19 severity was not significantly correlated with hypoglycemic treatment involving neither metformin (p = 0.433) or insulin (p = 0.747) nor with the presence of micro (p = 0.331) or macrovascular complications (p = 0.229).

Conclusion: The results suggest that the inflammatory syndrome due to COVID 19 infection is correlated with both weight status, also with the presence of diabetes chronic complications. Although no significant correlation has been identified between diabetes chronic complications and viral infection severity, they may impact the length of stay in hospital of diabetes patients.

Disclosure: A. Andrita: None.

SO 76 Cancer and type 2 diabetes: interconnections and mortality

847 The impact of diabetes associated risk factors on survival among individuals with type 2 diabetes and breast-, lung-, colorectal- or prostate cancer

T. Laurberg1, D.R. Witte1, L. Zinna1, F. D’Alterio1, S. Gudbjörnsdottir7, B. Eliasson4, 5, L. Bjerre1,2
1Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus N, Denmark, 2Department of Public Health, Aarhus University, Aarhus, Denmark, 3Department of Molecular and Clinical Medicine, The Wallenberg laboratory, Institution of medicine, Gothenburg University, Gothenburg, Sweden, 4Sahlgrenska University Hospital, Gothenburg, Sweden, 5Swedish National Diabetes Register, Gothenburg, Sweden.

Background and aims: Premature death in diabetes is no longer caused by cardiovascular disease to the same extent as before, but increasingly by cancer. The objectives of this study were to estimate the excess mortality, when individuals with type 2 diabetes (T2DM) were diagnosed with the most common cancer diagnosis (breast-, lung-, prostate- and colorectal cancer), and to examine how mortality risk was associated with modifiable diabetes-related risk factors such as HbA1c, cholesterol, LDL cholesterol, hypertension, BMI, smoking and physical activity.

Materials and methods: This longitudinal nationwide cohort study included individuals with T2DM registered in the Swedish National Diabetes Register any time between 1998 -2019. Each individual was followed and classified according to their time-updated cancer status by cardiovascular disease to the same extent as before, but increasingly by cancer. The most significant risk factors associated to mortality among individuals with T2DM and a diagnosis of cancer were low physical activity, 1.59 (1.57-1.61) and smoking, 2.15 (2.08-2.22), whereas HbA1c, cholesterol, LDL cholesterol, hypertension, and BMI had weaker associations with survival. In those without a cancer diagnosis, all estimates pointed in the same direction as in those with both T2DM and cancer, and physical activity and smoking were likewise the strongest risk factors.

Conclusion: In a future with more patients with T2DM and a cancer diagnosis, these results suggest that smoking and physical activity may be the two most salient risk factors for mortality in people with type 2 diabetes, both with and without cancer.

Supported by: Danish Diabetes Academy, NNF17SA0031406
Disclosure: T. Laurberg: None.

848 Versican proteoglycan as new link between type 2 diabetes and breast cancer

A. Parascandolo1,2, V. D’Esposito1,2, M.R. Ambrosio1,2, T. Migliaccio1, M.F. Di Tolla1, F. D’Alterio1, L. Zinna1,2, P. Mirm1,2, C. Miele1,2, L. Insabato1, M. Pace1, D. Russo3, S. Pignatiello3, F. Beguinot1,2, P. Formisano1,2
1Department of Translational Medicine, University of Naples, “Federico II”, 2Institute of Experimental Endocrinology and Oncology, National Council of Research (CNR), 3Department of Advanced Biomedical Sciences, University of Naples, “Federico II”, 4UOC Pathological Anatomy, PO Ospedale del Mare Asl Napoli 1 Centro, Naples, Italy.
Background and aims: Type 2 diabetes increases incidence, progression and death for several cancers including breast cancer (BC). Patients affected by diabetes and early BC, had larger tumors and a worse outcome with respect to patients without diabetes. Hyperglycemia, the hallmark of T2D, acts directly on cancer cells, but also on tumor microenvironment that in mammary gland is highly represented by adipose tissue (AT) leading to imbalanced production proinflammatory factors. However, mechanisms related to mammary AT (MAT) changes induced by T2D and their connection to BC progression need to be clarified. Versican (VCAN) is a chondroitin sulfate proteoglycan within the extracellular matrix involved in inflammation, vascular diseases and different kind of cancers. Interestingly, VCAN has been identified as a hub gene with a key role in diabetic kidney and diabetic bone disease. All together these evidence pointed out VCAN as a target molecule with a strategical role in the connection between diabetes and BC progression. Therefore, the aim of our work is based on the study of VCAN as an AT biomarker involved in BC-MAT bidirectional communication.

Materials and methods: MAT biopsies have been obtained from healthy women undergoing surgical mammary reduction (H-MAT; N=15) and from patients with BC underwent surgical resection (C-MAT; N=20). Total RNA and protein lysates have been collected and analyzed for VCAN expression by qPCR and Western blot analysis respectively. Mesenchymal stem cells (MSC) have been isolated by H-MAT and co-cultured with MCF7 BC cells in transwell systems. VCAN content was investigated by immunohistochemistry (IHC). Data were analyzed using GraphPad Prism 7.

Results: In MSC isolated from H-MAT, VCAN mRNA and protein levels positively correlated with glycemia (p<0.01 ***). Moreover, in co-culture with MCF7, MSC expressing high levels of VCAN displayed increased Interleukin 6 (IL6) levels and induced Matrix Metalloproteinase-9 (MMP9) expression in BC cells, compared with MSC expressing lower VCAN levels. In C-MAT, VCAN mRNA expression levels were higher compared with H-MAT (p<0.0001 ***). Finally, in C-MAT VCAN was detected by IHC at higher extent in the proximity of the tumor, compared to more distant sites (p<0.0001 ***).

Conclusion: VCAN is expressed in adipose progenitors and positively correlates with glycemia. Its higher expression levels in C-MAT suggest a role in the connection between T2D and breast cancer. Characterization of VCAN in AT surrounding BC may lead to identify a novel biomarker associated to BC progression in metabolically perturbed peri-tumoral AT.

Supported by: This research was funded by Regione CampaniaPORFESR2014–2020 COEPICA Project and by AIRC Association

Disclosure: A. Parascandolo: None.

850
A pan-cancer analysis of the oncogenic role of regenerating protein1 alpha(REG1A) in human tumors
H. Wang, L. Li;
Department of Endocrinology, Zhongda Hospital, Southeast University, Nanjing, China.

Background and aims: Regenerating 1 alpha (REG1A) is a secreted protein containing 166 amino acids that belongs to the calcium-dependent lectin superfamily. In humans, four different REG gene isoforms are known: REG1A, REG1B, REG3A and REG4. Regenerating protein 1 alpha(REG1A) is a member of the regenerating gene (Reg) and first derived from the regenerating islet. REG1A was originally identified by screening a cdNA library of regenerating rat islet cells and was mainly associated with regeneration of pancreatic b-cells and improvement of diabetes. Now it is considered REG1A plays a pivotal role in promoting cell proliferation, differentiation, anti-apoptosis and inflammatory response. REG1A has been implicated in a gamut of maladies including diabetes, various types of cancer. Multiple clinical studies have shown that REG1A is elevated in the serum of patients with a variety of tumors, and the expression of the gene is strongly correlated with the disease progression of patients. Clinical studies suggest that REG1A has the potential to become a new tumor marker. The closely association with REG1A and tumorigenesis and prognosis of has been confirmed, but there is no available pan-cancer analysis of REG1A. Therefore, we explored the potential oncogenic role of REG1A in 33 tumors.

Materials and methods: Raw data on REG1A expression in cancer patients were obtained from TCGA and GTEx databases. Combining the data for normal tissues from databases, we investigated genomic changes, expression patterns and survival analysis of REG1A in pan-cancer including Gene DE module of TIMER2 and HEPIA2. We used the ‘Survival Map’ module of GEPIA2 to acquire the OS (Overall survival) and DFS (Disease-free survival) significance map data of REG1A across all TCGA tumors. The eBioPortal database is used to analyse genetic alteration of REG1A. The relationship between REG1A expression and tumor immune invasion was analyzed by TIMER. The proportion of tumor-infiltrating immune cells (TIICs) and the number of stromal and immune components were assessed from the TCGA database using CIBERSORT, QUANTISEQ, XCELL, MCPCOUNTER and EPIC computational methods. STRING website and GEPIA2 were used to obtain REG1A-correlated targeting genes and protein. Go (Gene ontology) enrichment analysis was performed in REG1A-binding and interacted genes.
Results: Overall, expression levels of REG1A were higher in 22 types of tumor tissues than in normal tissues, especially in CHOL (Cholangiocarcinoma), COAD (Colon adenocarcinoma), KICH (Kidney Chromophobe), KIRC (Kidney renal clear cell carcinoma), LIHC (Liver hepatocellular carcinoma), LUAD (Lung adenocarcinoma), LUSC (Lung squamous cell carcinoma), READ (Rectum adenocarcinoma), HNSC (Head and Neck squamous cell carcinoma). Low REG1A expression was associated with poor clinical scenarios of OS and RFS. Here we found significant negative correlations between REG1A expression and TICs, including CD8+ T cells, CD4+ T cells, B cells, fibroblast, neutrophils and macrophage. The phosphorylation of REG1A was a validated marker in some tumors, such as clear cell carcinoma. REG1A was related to triglycerides metabolism. The effect of REG1A on tumor pathogenesis may be related to the metabolic pathway.

Conclusion: We observed phosphorylation of REG1A protein had a decreased level in some tumors, such as clear cell carcinoma. Our first pan-cancer study provides a relatively comprehensive understanding of the oncogenic role of REG1A in different cancer.

Disclosure: H. Wang: None.

851
Insulin receptors in pancreatic acinar cells contribute to pancreatic cancer development
A. Zhang, K.H. Chu, Y. Xia, T. Ruiter, J. Yang, J. Lin, N. Chen, D.F. Schaeffer, J.L. Kopp, J.D. Johnson; ¹Department of Cellular and Physiological Sciences, University of British Columbia, ²Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.

Background and aims: Epidemiological studies showed hyperinsulinemia, a cardinal feature of obesity and type 2 diabetes, is independently associated with an increased risk of pancreatic ductal adenocarcinoma (PDAC). Complementing these epidemiological associations, our previous in vivo studies showed a ~50% reduction in pancreatic intraepithelial neoplasia (PanIN) pre-cancerous lesions in mice with genetically reduced insulin production. Our single-cell transcriptomic analyses suggested that hyperinsulinemia might indirectly promote PDAC development by affecting multiple cell types in the neoplastic microenvironment. However, it remains unclear whether hyperinsulinemia directly accelerates PDAC development through insulin receptor (Insr) and its downstream signaling cascades in pancreatic acinar cells, which are the cellular origins of PDAC.

Materials and methods: We generated PdlaCreERT2; LSL-KrasG12D, lnTnG mice (a PDAC mouse model) with an Insr<sup>lox/lox</sup> (PK-Insr<sup><i>wt/wt</i></sup>), Insr<sup>cre/cre</sup> (PK-Insr<sup><i>f/f</i></sup>) or Insr<sup>cre/cre</sup> (PK-Insr<sup><i>wt/f</i></sup>) genotype to reduce insulin receptor gene dosage by 0%, 50%, or 100% in acinar cells. All mice were fed with a high-fat diet to induce hyperinsulinemia. Body weight, fasting glucose, and insulin levels were tracked throughout the study period. The mice were euthanized at 3 months or 10 months, and we performed blinded histopathological analyses and quantification to assess PanIN formation. To investigate the underlying molecular mechanisms, pancreata from each genotype were used for proteomic and phosphoproteomic analyses.

Results: Loss of Insr from acinar cells did not significantly influence body weight, fasting glucose, or insulin levels. Unbiased quantification of PanIN area for mice euthanized at 10 months old showed a ~2.9-fold significant reduction in PanIN and tumor area in PK-Insr<sup><i>wt/wt</i></sup> (n=6) male mice compared to PK-Insr<sup><i>wt/wt</i></sup> (n=5) male mice (16.58 ± 5.53% vs 47.92 ± 4.05%, p<0.01), and ~1.8-fold reduction compared to PK-Insr<sup><i>wt/f</i></sup> (n=10) male mice (30.54 ± 4.14%). In addition, we found a significant reduction in PanIN and tumor area in PK-Insr<sup><i>wt/+</i></sup> (n=9) female mice in comparison to PK-Insr<sup><i>wt/wt</i></sup> (n=16) and PK-Insr<sup><i>wt/wt</i></sup> (n=8) female mice (8.96 ± 4.28% vs 24.45 ± 4.48% vs 47.19 ± 5.67%, respectively, p<0.001). By assessing the mice euthanized at 12 weeks of age, we found PK-Insr<sup><i>wt</i></sup> (n=4-9) had a 5.3-fold and 6.3-fold reduction in PanIN area in males (0.31 ± 0.19%) and females (0.23 ± 0.039%), respectively, compared to PK-Insr<sup><i>wt/wt</i></sup> (n=3-4) male (1.64 ± 0.16%, p<0.05) and female (1.46 ± 0.77%) control mice. Unbiased proteomic analysis at 12 weeks of age demonstrated that compared to PK-Insr<sup><i>wt/wt</i></sup> mice, Reg proteins (like Reg3g, Reg3b, and Reg3a) which increase during pancreas injury or inflammation, and digestive enzymes (like Amy1, Cela1, and Prss2), which are secreted by acinar cells were significantly downregulated in PK-Insr<sup><i>wt</i></sup> mice.

Conclusion: Collectively, our data suggest that Insr in acinar cells promotes both PanIN initiation and development, possibly by decreasing digestive enzyme production in acinar cells and the inflammation associated with those enzymes release during damage. Thus, prophylactic approaches targeting Insr signaling pathways, or hyperinsulinemia itself, may be beneficial in preventing pancreatic cancer.

Supported by: CIHR
Disclosure: A. Zhang: None.
CKD, retinopathy and peripheral neuropathy, HRs still increased with the rising of the TyG index for major CVD (T3 vs T1, 1.960, 95% CI 1.438-2.672, p<0.0001; with independent effects for age, DD, male sex, BMI, smoking, fibrinogen, prior CVD, CKD, retinopathy and peripheral neuropathy), and for CHD (T3 vs T1, 2.029, 1.404-2.934, p<0.0001; with independent effects for age, DD, male sex, fibrinogen, prior CVD, CKD and retinopathy).

Conclusion: The triglyceride-glucose (TyG) index was significantly and independently associated with both major CVD and CHD, suggesting that it may be a valid marker for risk stratification in subjects with T2D.

Disclosure: P. Falcetta: None.

853
The prognostic impact of HbA1c and diabetes on mortality in chronic heart failure
K. Sveen1,2, M. Grundtvig3,4, L. Gallestad5,6, K.I. Birkeland1,7,  
1Oslo University Hospital, Oslo, 2Oslo Diabetes Research Center, Oslo,  
3Department of Medicine and health care, St. Olavs university hospital, Trondheim, 4dept. Medicine, Innlandet Hospital Trust, Lillehammer, 5Department of Cardiology, Oslo University Hospital, Oslo, 6KG Jebsen Cardiac research Center and Center for Heart Failure Research, Oslo University Hospital, Oslo, 7Institute of clinical medicine, University of Oslo, Oslo, Norway.

Background and aims: Diabetes is associated with an increased cardiovascular morbidity and mortality in chronic heart failure. Previous trials and registries have mostly used definition of diabetes in categories of either present or not from self-reported data or medical records, while less is known about the impact of levels of HbA1c on HF and mortality. Our aim was therefore to examine the prognostic impact of HbA1c and diabetes mellitus (DM) on mortality in a large cohort of outpatients with HF.

Materials and methods: A total of 13768 outpatients with heart failure from the Norwegian Cardiovascular Disease Registry, which is part of the Norwegian Cardiovascular Disease Registry, were registered from 1993 until 1st January 2020. After excluding 1170 with missing HbA1c measurements, 12598 patients were included. We evaluated the impact of glycemic control (HbA1c) on all-cause mortality according to the presence of DM or not. Cox proportional hazard regression models were used to develop predictors for all-cause mortality and significant variables were entered in a multivariable model to evaluate the association between HbA1c and DM and all-cause mortality during follow-up.

Results: The prevalence of DM in the registry was 34.1% (3984/12598), and 26.6% of the patients were pre-diagnosed with DM and an additional 5% (n=624) were added due to HbA1c ≥ 48 mmol/mol. During a median (25-75 percentiles) follow up time of 28 (14.6-46.3) months in survivors, 21.8% died. In univariate analyses 26.9% of individuals with DM had died versus 20.2% without DM (p<0.001). Among patients with DM and adjusting for confounders, individuals with HbA1c <48 mmol/mol (n=826) had the worst outcome with HR for death 1.36 (95% CI 1.16-1.60), p<0.001. Individuals with diabetes and HbA1c >64 mmol/mol (n=841) also had a worse prognosis compared to those within HbA1c 48-53 mmol/mol, HR 1.17 (1.05-1.31), p<0.001. HbA1c was not a significant predictor for mortality in patients without diabetes (p=0.12).

Conclusion: This study demonstrates that diabetes is a significant independent predictor for all-cause mortality in outpatients with heart failure. In patients with diabetes, mortality was increased in patients with very low and high levels of HbA1c.

854
Age-related difference in the impact of diabetes on all-cause mortality after acute myocardial infarction
P.-S. Song, J.O. Jeong  
Division of Cardiology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea.

Background and aims: Given the paucity of data on the frequency and prognostic implications of diabetes among patients with acute myocardial infarction (AMI) at a young age, we sought to determine the prevalence of diabetes and associated outcomes in a more contemporary cohort of patients presenting with AMI at age ≤55 years (young group). Also, this study aimed to compare the baseline characteristics and clinical outcomes of diabetic and non-diabetic patients with AMI by age.

Materials and methods: A total of 12,600 AMI patients from the Korea Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH) between November 2011 and December 2015 was classified into young (n=3,590 [28.5%]) and old (n=9,010 [71.5%]). We performed comparisons of baseline characteristics, in-hospital treatments, and long-term clinical outcomes between patients with and without diabetes after stratification according to age group.

Results: The overall prevalence of diabetes mellitus was 34.1%, and 19.7% of individuals were diagnosed newly with diabetes at the index admission. The prevalence of diabetes mellitus was 26.5% in the young AMI group. Diabetic patients were less likely to receive percutaneous coronary intervention with or without coronary stenting in the old group but not in the young group (interaction effect p<0.05). In the entire study cohort, all-cause mortality (539 [12.6%]) vs. 566 [6.8%]; adjusted hazard ratio [HR], 1.318; 95% confidence interval [CI], 1.138-1.526; p<0.001), cardiac mortality (284 [6.6%] vs. 283 [3.4%]; adjusted HR, 1.293; 95% CI, 1.050-1.593; p=0.001), recurrent myocardial infarction (219 [5.1%] vs. 247 [3.0%]; adjusted HR, 1.378; 95% CI, 1.125-1.689; p=0.002), and major adverse cardiac events (MACE), a composite of all-cause mortality, recurrent myocardial infarction, and re-hospitalization for heart failure (851 [19.8%] vs. 965 [11.6%]; adjusted HR, 1.173; 95% CI, 1.049-1.311; p=0.005) were significantly higher in diabetic patients than in non-diabetic patients over the three-year clinical follow-up after multiple adjustments. When the entire cohort was subdivided into two age groups, young diabetic patients showed a 107.0% higher mortality rate than those without diabetes (adjusted HR, 2.070; 95% CI, 1.150-3.724; p=0.015).
Meanwhile, elderly diabetic patients had a 25.3% higher risk of mortality than non-diabetic patients (adjusted HR, 1.253; 95% CI, 1.076-1.459; \( p = 0.004 \)). The interaction of diabetes with age was statistically significant (adjusted \( p \) for interaction = 0.008). Cardiac mortality and MACE of secondary outcomes were similar to the primary endpoint of all-cause mortality over the three-year clinical follow-up.

**Conclusion:** Diabetes mellitus is not uncommon in younger AMI patients, and the relative risk of long-term mortality is significantly higher in young patients than in older counterparts. More aggressive treatments are needed to prevent future cardiovascular events in younger patients after AMI.

**Disclosure:** P. Song: None.

---

**SO 77 Disclosing fatty liver disease mechanisms**

**855**

**Extracellular vesicle-mediated crosstalk between hepatocytes and endothelial cells in non-alcoholic fatty liver disease condition**


**Background and aims:** Non-alcoholic fatty liver disease (NAFLD) is an independent risk factor for cardiovascular disease (CVD), although the mechanism of association is still unclear. Extracellular vesicle (EV) is a biological nanoparticle that contains various cargos and plays critical roles in inter-organ crosstalk. We aimed to investigate the role of hepatocyte-derived EVs on endothelial cells in NAFLD condition.

**Materials and methods:** Primary hepatocytes isolated from C57BL6 mice were exposed to palmitic acid (PA). Hepatocytes-derived EVs were isolated using sequential ultracentrifugation technique and characterized by nanoparticle tracking analysis, western blotting and transmission electron microscopy. Human umbilical vein endothelial cells (HUVEC) and human aortic endothelial cells (HAEC) were treated with EVs released from hepatocytes.

**Results:** PA treatment increased the expression of genes associated with lipid synthesis, inflammation and oxidative stress in hepatocytes. The amount of EVs derived from PA-treated hepatocytes was greater than the EVs from control hepatocytes. Fluorescence-labeled hepatic EVs uptake were detected in human endothelial cells. Treatment of EVs derived from PA-exposed hepatocytes induced endothelial dysfunction with subsequent upregulation of inflammatory cytokines, adhesion molecules, and oxidative stress markers in HUVEC and HAEC. Small RNA profiling of miRNA isolated from hepatic EVs identified 23 upregulated and 4 downregulated miRNAs (fold change \( \geq 5 \) and normalized data (log2) \( \geq 4 \)) in PA-treated hepatocytes. miR-23b-3p, miR-30b-5p, and miR-30c-5p were identified as possible candidate cargos confirmed by qPCR.

**Conclusion:** Our findings suggest a novel role of hepatic EVs that regulate crosstalk between hepatocytes and endothelial cells. This may explain the independent relationship between NAFLD and CVD.

**Supported by:** National Research Foundation of Korea (2018R1D1A1B07043223, 2021R1F1A1061197)

**Disclosure:** S. Lee: None.

---

**856**

**Impact of phenylacetic acid, a microbiota-derived metabolite, on hepatic endoplasmic reticulum-mitochondria interactions and steatosis**

R. Lefebvre1, C. Causse1, J. Rieusset1;
1CarMeN Laboratory, UMR INSERM U1060/INRA U1393, 2Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France.

**Background and aims:** The gut-liver axis has emerged as an important factor in the development of non-alcoholic fatty liver diseases (NAFLD). Microbiota-derived metabolites such as phenylacetic acid (PAA) have been shown to trigger hepatic steatosis in human primary hepatocytes but the molecular mechanism involved is not elucidated. Moreover, mitochondrial dysfunction is also a key component of NAFLD and oxidative capacities of mitochondria are regulated by the communication of this organelle with endoplasmic reticulum at contact points named mitochondria-associated membranes (MAMs). Hence, MAMs are nutrient sensitive controlling mitochondrial oxidative metabolism and ER-mitochondria miscommunication was associated with hepatic insulin resistance and steatosis. We hypothesized that PAA may induce hepatic steatosis through a disruption of MAMs integrity (Figure 1).

**Materials and methods:** We investigated the impact of PAA (500 \( \mu \)mol/l) on MAMs integrity and steatosis in Huh7 cell line and primary mouse
Disclosure: College of Nanjing Medical University, 2Department of Endocrinology, 1Department of Endocrinology, Nanjing Drum Tower Hospital Clinical

tions were measured by in situ proximity ligation assay (PLA) targeting VDAC1 (mitochondrial protein) and IP3R1 (reticular protein) proximity and BODIPY labelling was used to quantify mitochondria-endoplasmic reticulum contacts and lipid droplets size respectively. All experiments were performed in a single time triplicate.

Results: Treatment with PAA reduced MAMs in Huh7 (n = 30 photos, fold change = -72 ± 0.025 %, p = 0.0001) and PMH (n = 30 photos, fold change = -23 ± 0.064 %, p < 0.0001), it also induced lipid accumulation in Huh7 (n = 30 photos, fold change = +20 ± 0.035 %, p = 0.0001) and PMH (n = 20 photos, fold change = +35 ± 0.047 %, p = 0.0001). The effect of PAA on MAM integrity is observed as soon as one hour of treatment (n = 30 photos, fold change = -39% ± 0.29%, p < 0.0001) in Huh7. This effect is fully prevented by diazoxide which inhibits membrane depolarization (n = 30 photos, fold change = +9% ± 0.066 % with diazoxide versus -30 ± 0.042 % without it, p < 0.0001) and partially by EGTA treatment, a Ca²⁺ chelation agent, (n = 30 photos, fold change = -29 ± 0.044 % with EGTA versus -50 ± 0.022 % without it, p < 0.0007). These results suggest an electrogenic mechanism of PAA action on MAMs.

Conclusion: PAA, a gut-microbiome derived metabolite, induces MAM disruption and hepatocyte lipid accumulation. The effect of PAA on MAMs is mediated through an electrogenic mechanism. Whether preventing the electrogenic effect of PAA impacts hepatic steatosis is under investigation.

Figure 1: Potential electrogenic effect of PAA leading to MAMs disruption and hepatic steatosis

Disclosure: R. Lefebvre: None.

857

Lower serum PRL is associated with the development of non-alcoholic fatty liver disease
P. Xu1,2, P. Zhang2, Y. Zhu2, Y. Bi1,2;
1Department of Endocrinology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, 2Department of Endocrinology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.

Background and aims: Non-alcoholic fatty liver disease (NAFLD) has become a worldwide epidemic and associated with a series of metabolic co-morbidities. Prolactin (PRL) is a multifunctional polypeptide with effects on mammary gland development and lactation, and has recently been found to have an important effect on metabolic diseases. Studies have shown that low PRL levels are a risk factor for the prevalent of NAFLD, but a causal relationship is not well-understood. Here we investigated the causative relationship between PRL and NAFLD occurrence.

Materials and methods: In a retrospective cohort study, we studied 355 patients without NAFLD at baseline [215 men and 140 women; mean age 56 (49, 64) years] who had undergone serum PRL testing at 8.00 a.m. and abdominal ultrasonography. NAFLD was diagnosed by abdominal ultrasonography. The patients were divided into the non-NAFLD group and the NAFLD group according to the status of their follow-up endpoint.

Results: This study enrolled 355 persons over a mean 32 (19, 46) months of follow-up, 72 (20.28%) patients who eventually developed NAFLD. Compared with those in the non-NAFLD group, serum PRL levels of patients were lower in the NAFLD group in both genders [male: 7.35 (5.48, 10.60)ug/L vs. 9.13 (6.92, 12.50) ug/L, P = 0.002; female: 5.66 (4.67, 9.03)ug/L vs. 9.01 (6.31, 11.60) ug/L, P = 0.009]. A significant decrease in the prevalence of NAFLD was noted in both genders along with the increased quartile of basal serum PRL levels (P < 0.05). In multivariate logistic regression, basal serum PRL concentration was independently associated with NAFLD development [male: OR, 0.863 (0.777, 0.960), P = 0.006; female: OR, 0.746 (0.601, 0.925), P = 0.008].

Conclusion: Our study is the first to find that basal serum PRL level can predict the occurrence of NAFLD and it may be a potential biomarker to prevent and treat NAFLD.

Disclosure: P. Xu: None.

858

Association between visceral adipocyte size and non-alcoholic fatty liver disease in subjects with different degrees of adiposity
H. Sun, T. Gu, D. Fang, Y. Yuan, H. Wang, Y. Bi;
Department of Endocrinology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China, Nanjing, China.

Background and aims: With the epidemic of high-caloric diet and obesity, non-alcoholic fatty liver disease (NAFLD) has grown rapidly around the world. Adipose tissue morphology alterations are associated with metabolic diseases, including NAFLD. Previous studies have shown that adipocyte size is associated with liver steatosis. However, few study evaluated the influence of adiposity status on the relationship between adipocyte size and NAFLD. Here, we investigated the association between visceral adipocyte size and the histological severity of non-alcoholic fatty liver disease (NAFLD) in subjects with different degrees of adiposity.

Materials and methods: Omental adipose tissue and liver biopsy were collected from 275 obese subjects. NAFLD was defined according to the NASH Clinical Research Network (NASH-CRN) scoring system. Adipocyte size were measured through pathological section analysis. Adipose tissue insulin resistance (Adipo-IR) was calculated as fasting insulin (pmol/L) × fasting Free fatty acid concentration (mmol/L).

Results: In total, 275 obese patients (206 females and 69 males) were involved in this study. In females, 158 subjects were classified as biopsy-NAFLD, and 58 individuals in males were diagnosed with NAFLD. NAFLD patients presented higher levels of fasting glucose, HbA1c, HOMA-IR, ALT and AST (all p<0.05). The adipocyte size was significantly larger in NAFLD subjects in mild to moderate obesity (Q1-
**Background and aims:** Numerous studies validated frequent glucose dysfunction in patients with acute pancreatitis (AP). However, the prevalence of new-onset diabetes in individuals after a first episode of AP varies widely among previous studies. This study aimed to determine the incidence of post-acute pancreatitis diabetes mellitus (PPDM-A) in Chinese people and further identify potential risk factors that influence diabetes development in patients with AP.

**Materials and methods:** This was a multi-center retrospective cohort study including 6009 inpatients with a first attack of AP. A total of 1804 patients with AP without known endocrine pancreatic disorders or other pancreatic exocrine diseases were eligible for analysis. Data was collected from medical records by hospital information system and telephone follow-ups after discharge. The multiple logistic regression analysis was established to evaluate the potential influencing factors of PPDM-A.

**Results:** The prevalence of newly diagnosed diabetes in Chinese patients after a first episode of AP was 6.2%. Data showed that patients who developed PPDM-A were characterized by younger age, longer hospital stays, a higher frequency of overweight or obesity, stress hyperglycemia on admission, accompanied by hyperlipidemia and non-alcoholic fatty liver disease (NAFLD), more likely to be hyperlipidemic AP, and had a higher degree of severity and recurrence rate of AP compared to those with normal glycemia. Regression analysis indicated that stress hyperglycemia, hyperlipidemia, NAFLD and recurrent pancreatitis were the independent influence factors for developing PPDM-A.

**Conclusion:** Our study first demonstrated the prevalence of secondary diabetes in Chinese patients after AP. The disorder of glucose metabolism in individuals with AP should be regularly evaluated in clinical practice. Further studies are needed to verify the relationship between liver and pancreas in keeping glucose homeostasis under AP condition.

---

**Background and aims:** Non-alcoholic fatty liver disease (NAFLD) is a rapidly growing metabolic disease that presents with a wide range of clinical manifestations from simple fatty liver to hepatocellular carcinoma (HCC). However, NAFLD researchers are limited by the lack of appropriate animal model that can reflect the full range of the disease in a manageable method with physiological relevance. In this study, we used a controllable method to generate a mouse model of NAFLD and subsequent HCC that closely recapitulates human disease and its physiological relevance.

**Materials and methods:** To generate NAFLD mouse model, we modified the STAM mouse model (mSTAM). Briefly, male C57BL/6j mice were injected with low dose Streptozotocin (40 mg/kg) for 5 consecutive days from 7 weeks of age. Control mice were fed normal chow diet (NCD) and mSTAM mice were fed high fat diet (HFD) from 8 weeks of age. Hepatic histology, transcriptomes and metabolic phenotypes were evaluated at multiple time points. Mouse transcriptomic data were also compared to human transcriptomic data with similar hepatic histology. Results: Control mice showed mild hepatic inflammation transiently without hepatic steatosis or fibrosis. In contrast, mSTAM mice developed hepatic steatosis, steatohepatitis, progressive hepatic fibrosis, and HCC at 14, 20, 32, and 38 weeks of age, respectively. HCCs developed in mSTAM mice showed histological features of steatohepatitic variant, characteristically found in human patients with metabolic disease, including ballooning of cancer cells, inflammatory cell infiltration and intratumoral fibrosis. They accompanied multiple physiological features of human NAFLD patients including hyperglycemia, obesity, dyslipidemia, adipocyte hypertrophy and adipose tissue inflammation. In terms of overall gene expression alterations at a transcriptome level, there was a substantial association between mSTAM mice and human NAFLD patients with similar liver histology. Furthermore, they shared the key signaling pathways in NAFLD progression, including fatty acid degradation and the p53 signaling pathway.

**Conclusion:** We have developed a novel and easily manageable mouse model of NAFLD and subsequent NAFLD-related HCC. This model mimics physiological, metabolic, histologic and transcriptomic alterations that occur in human patients as NAFLD progresses.
Increased hepatic dicarbonyl stress decreases expression of the drug metabolising enzymes cytochrome (CYP) p450 3A4 and carboxylesterase 1

M. Maandi1, S.C. Maandi2, J.G. Mabley1;
1School of Applied Sciences, University of Brighton, Brighton, 2School of Applied Sciences, University of Brighton, Hove, UK.

Background and aims: Type 2 diabetes mellitus (T2DM) has been linked to hepatic complications including impairment of drug metabolising enzyme activity, which may alter hepatic xenobiotic metabolism capacity. Hyperglycaemia-mediated increase in methylglyoxal levels and the resulting dicarbonyl stress plays a key role in diabetic complications and cellular dysfunction. However, the potential impact of dicarbonyl stress on drug metabolising enzymes has yet to be elucidated. Therefore, the aim of this study was to analyse the effect of dicarbonyl stress induced via glyoxalase I inhibition on the expression of phase I (cytochrome (CYP) P450 3A4) and phase II (carboxylesterase 1 (CES1)) metabolising enzymes.

Materials and methods: The human hepatoma cell line HepG2 was treated with 20 μM S-p-Bromobenzylglutathione cyclopentyl diester (BBGC), a glyoxalase I inhibitor, to induce dicarbonyl stress via increased intracellular methylglyoxal levels. HepG2 cells were treated with BBGC for 24 hours before measuring CYP3A4, CES1 and Interleukin (IL)-8 mRNA levels and protein expression. Nuclear factor kappa B (NF-κB) expression and translocation was analysed, using immunocytochemistry, after treating the cells with BBGC for 4 hours. Data are expressed as mean (or 2(-ΔΔCt) for mRNA expression) ± SEM from n= 5-6 independent experiments. Statistically significant differences were determined using one-way ANOVA with Bonferroni post hoc test or a Student’s t-test.

Results: Increased dicarbonyl stress significantly (p<0.01) decreased mRNA expression of both CYP3A4 (0.67 ± 0. 0.052) and CES1 (0.6 ± 0. 0.096), and this was associated with a decrease in protein expression. Dicarbonyl stress also had a proinflammatory effect significantly increasing both IL-8 mRNA expression (2.64 ± 0.23, p<0.05) and secretion (from 2.3 ± 0.18 to 5.33 ± 0.43 pg/µg of protein p<0.01), coupled with an increased expression and translocation of NF-κB (146.7 ± 2.51 %, p<0.05).

Conclusion: In the present study, hepatocytes exposed to increased dicarbonyl stress directly impaired the expression of both Phase I and Phase II drug metabolising enzymes. The increased NF-κB activation and inflammation observed following increased dicarbonyl stress may be mediating the effects on both CES 1 and CYP3A4 expression. Dicarbonyl stress through increased hepatocyte methylglyoxal levels in diabetics may impact drug clearance and therapeutic care.

Disclosure: M. Maandi: None.

Lipotoxicity-induced hepatic injury is prevented by a novel allosteric modulator of the GABA<sub>Å</sub> receptor

E. Rohbeck1, A. Stein1, C. Niersmann1,2, A. Romero1, B. Knebel1, M. Roden1,4, T. Romacho7, J. Eckel1,6
1Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, 2German Center for Diabetes Research (DZD), Partner Düsseldorf, München-Neuherberg, Germany, 3Institute for Clinical Biochemistry and Pathobi chemistry, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, 4Department of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, 5ChroCoDiL Group, Department of Nursery Sciences, Physiotherapy and Medicine, Faculty of Health Sciences, University Almería, Almeria, Spain, 6CureDiab Metabolic Research GmbH, Düsseldorf, Germany.

Background and aims: NAFLD is a highly prevalent condition currently lacking an approved pharmacological therapy. Exposure to GABA has been proposed to protect from liver toxicity in both in vivo and in vitro models. Therefore, we aimed to determine if the thioacrylamide-derivative HK4, a novel positive allosteric modulator of the GABA<sub>Å</sub> receptor, protects human hepatocytes against lipotoxicity-induced injury.

Materials and methods: AllostERIC modulation of the GABA<sub>Å</sub> receptor was determined by patch clamp in HEK-293 cells, calcium influx measurements in INS-1E cells, and by using the specific GABA<sub>Å</sub> channel blocker picrotoxin in HepG2 cells. Next generation sequencing was performed of HepG2 cells treated with palmitate in the presence or absence of HK4. Phosphorylated STAT3 and NF-κB, PDI, cleaved caspase 7 and PARP-1 were detected by Western blotting or apoptosis array. Caspase 3/7 activity measurement and TUNEL assay were performed in HepG2 cells and/or human primary hepatocytes.

Results: Patch clamping, calcium influx measurements and assays with the non-competitive GABA<sub>Å</sub> channel blocker picrotoxin confirmed HK4 as a selective modulator of the GABA<sub>Å</sub> receptor. Hepatocytes were found to display the main pharmacologically-relevant subunits of the GABA<sub>Å</sub> receptor. A preventive effect of HK4 on palmitate-induced apoptosis was demonstrated by reduced caspase 3/7 activity both in HepG2 (47.32 ± 6.92 % vs. 1065 ± 98.68 %, p≤0.0001) and human primary hepatocytes (58.73±16.86 % vs. 147.3 ± 31.3 %, p≤0.05). This effect was further confirmed by TUNEL assay (6.41 ± 1.42 % vs. 11.62 ± 0.99 % TUNEL positive cells, p≤0.01). HK4 reduced cleaved PARP-1 expression and upregulated the ER chaperone PDI (both p≤0.05). The protective effect of HK4 was mediated by prominent inhibition of STAT3 and NF-κB phosphorylation. Transcriptomic analysis showed substantial alterations in gene expression in response to palmitate treatment. For a number of genes, a nearly complete correction of dysregulation was observed in the presence of HK4.

Conclusion: GABAergic signaling reduces lipotoxic-induced apoptosis in hepatocytes by preventing inflammation, DNA damage and ER stress. The effect of HK4 might be mediated by the transcription factors STAT3 and NF-κB. Consequently, HK4 may arise as an innovative pharmacological tool to treat or prevent NAFLD as a first-in-class drug.

Disclosure: E. Rohbeck: None.
SO 78 Screening tools, lipids and novel biomarkers

863 Measures of insulin resistance as a screening tool for dysglycaemia in patients with coronary artery disease: a report from the EUROASPIRE V population

G. Ferrannini1,2, D. De Baecker2, I. Erlund3, V. Gyetvay1, K. Kotsi1,4, L. Mellbin1,5, A. Norhammar1,6, O. Schnell8, J. Tuomilehto3,9, T. Vihervaara1, D. Wood6, L. Ryden1
1Medicine, Karolinska Institutet, Stockholm, Sweden, 2Ghent University, Ghent, Belgium, 3Finnish Institute for Health and Welfare, Helsinki, Finland, 4National University of Ireland-Galway, Galway, Ireland, 5Imperial College Healthcare NHS Trust, London, UK, 6Karolinska University Hospital, Stockholm, Sweden, 7Capio St Görans Hospital, Stockholm, Sweden, 8Forschgruppe Diabetes e.V., Munich, Germany, 9King Abdulaziz University, Jeddah, Saudi Arabia.

Background and aims: The optimal screening strategy for dysglycaemia, including type 2 diabetes (T2DM) and impaired glucose tolerance (IGT), in patients with coronary artery disease (CAD) is debated. We tested the hypothesis that measures of insulin resistance by homeostasis model assessment (HOMA) indexes may constitute accurate screening methods in a CAD population.

Materials and methods: Insulin, C-peptide, glycated haemoglobin A1c (HbA1c) and an oral glucose tolerance test (OGTT) were centrally assessed in 3534 CAD patients without known dysglycaemia from the EUROASPIRE V survey. Three different HOMA indexes were calculated: HOMA-IR, HOMA2 based on insulin (HOMA2-ins), and HOMA2 based on C-peptide (HOMA2-Cpep). Dysglycaemia was diagnosed based on the two-hour postload glucose (2hPG) value obtained from the OGTT. Information on study participants was obtained by standardised visits. The optimal thresholds of the three HOMA indexes for dysglycaemia diagnosis were obtained by the maximum value of Youden’s J statistic on receiver operator characteristics curves. The diagnostic performance of such thresholds was tested for both T2DM (i.e. in reference to a 2hPG value ≥11 mmol/L) and dysglycaemia (i.e. in reference to 2hPG value ≥7.8 mmol/L) and their correlation with several clinical parameters was assessed by Spearman’s coefficients.

Results: The mean age of the patients was 63 years and 25% were women. Fifty-four percent of the patients had central obesity, 18% were current smokers, mean blood pressure was 133/80 mmHg and mean LDL-cholesterol 2.4 mmol/L. The OGTT revealed that 41% were dysglycaemic (IGT = 24% and T2DM = 16%). Mean insulin, C-peptide and HOMA indexes were significantly higher in patients with vs. without newly detected dysglycaemia (all p<0.0001). Sensitivity and specificity of the three HOMA indexes for the diagnosis of dysglycaemia were low and the associations between 2hPG and the other parameters in the total sample were weak, with Spearman correlation coefficients of 0.15 for fasting insulin, 0.19 for C-peptide, 0.24 for HOMA-IR, 0.18 for HOMA2-ins and 0.22 for HOMA2-Cpep. HOMA-IR, HOMA2-ins and C-peptide were strongly correlated with body mass index and waist circumference (Spearman correlation coefficients ranging 0.43-0.47).

Conclusion: Screening for dysglycaemia in CAD patients by insulin, C-peptide, HOMA-IR, HOMA2-ins and HOMA2-Cpep had insufficient diagnostic performance to detect dysglycaemia with reference to the yield of the OGTT, which should still be prioritized. Further studies are warranted to assess whether measures of insulin resistance might be better markers of unfavourable metabolic derangement beyond dysglycaemia.

Supported by: European Society of Cardiology, Erling-Perssons Stiftelse (GF, LR) and Iristadsska Stiftelsen (LR)

Disclosure: G. Ferrannini: Grants; Erling-Perssons Stiftelse. Honorarium; European Society of Cardiology.

864 Impact of RAGE and IL-6 polymorphisms in the progression for angiopathy in patients with type 2 diabetes

M. Bicho1,2, C. Fonseca1, A.C. Santos1,2, J.F. Raposo1, A. Valente3
1Genetics Laboratory, Environmental Health Institute, Faculdade de Medicina, Universidade de Lisboa, 2Instituto de Investigação Científica Bento da Rocha Cabral, 3Faculdade de Medicina, Universidade de Lisboa, 4Associação Protetora dos Diabéticos de Portugal, 5Atlântica - Instituto Universitário, Lisbon, Portugal.

Background and aims: Type 2 diabetes mellitus (T2DM) is an inflammatory condition related to an increased expression of pro-inflammatory cytokines, namely interleukin-6 (IL-6), which induces the appearance of microvascular and macro complications, kidney disease and anemia. High levels of circulating IL-6 promote an anti-erythropoietic effect and consequent decrease in the number of circulating erythrocytes. Persistent high blood glucose levels stimulate the formation of the irreversible advanced glycation end products (RAGE), resulting in non-enzymatic glycation and oxidation of proteins and lipids and platelet hyperactivity associated with a high risk of vascular complications. The interaction between RAGE with its ligands results in the activation of multiple signalling pathways, which, in turn, also can increase the secretion of pro-inflammatory cytokines such as IL-6 in T2DM patients. The IL-6 (rs1800795) and RAGE (rs1800624) are functional polymorphisms and have been associated with cardiovascular risk and diabetes comorbidities. This study aimed to evaluate the possible effect of these polymorphisms with anemia and hematological parameters in people with T2DM with the angiopathic disease.

Materials and methods: 148 Portuguese adults (40-75 years) with T2DM. Patients were divided into two groups: GI-n=75 with T2DM and angiopathy and GII-n=73 with T2DM without angiopathy. IL-6 and RAGE genotypes were identified by the endpoint analysis® method. The statistical analysis was performed in SPSS®. Results were considered statistically significant for p<0.05.

Results: Between groups, there were no differences in genotypic and allelic frequencies of the studied polymorphisms. In this cohort, for IL-6 polymorphism, were observed high values of: Mean Corpuscular Volume (MCV) (p=0.026) and Mean Corpuscular Hemoglobin (MCH) (p=0.015) in CC genotype carriers and monocyte/HDL-Cholesterol ratio (MHR) (p=0.038) in C allele carriers (CC+ GC). No differences were observed between hematological parameters and RAGE polymorphism. Selecting the patients by groups and comparing the hematological parameters and the IL-6 polymorphism, it was verified in GI: increased values of MCH (p=0.009) for carriers of the CC genotype. For the RAGE polymorphism, increased values were observed in GI for monocytes (p=0.016) and MHR (p=0.038) in carriers of the AA genotype. Analyzing the relationship of hematological parameters between groups, it was found for IL-6 increased values in GI of MCV (p=0.033) and monocytes (p=0.007) in carriers of the G allele (GG+GC) and MHR in GC genotype carriers (p=0.019); in the RAGE polymorphism, high values of: Mean Corpuscular Hemoglobin Concentration (p=0.020) were found in carriers of the AA genotype in the GI. In GII, increased monocyte values (p=0.034) and MHR (p=0.005) were observed in carriers of the T (TT+TA).

Conclusion: IL-6 and RAGE polymorphisms appear to influence susceptibility to angiopathy in T2DM patients modulating the disease-associated hematological parameters important to understanding the impact of anemia in these patients.

Supported by: FCT
Disclosure: M. Bicho: None.
865  
Erythrocyte membrane fluidity as a novel biomarker for a quantitative evaluation of residual cardiovascular risk in diabetic patients  
G. Bianchetti1,2, C. Cefalo3,4, C. Ferreri1, A. Sansone1, C. Serantoni1,2, A. Abetino1,2, T. Mezza1,2, P. Ferraro3, M. De Spirito1,2, A. Giaccai1,4, G. Maulucci1,2.
1Department of Neuroscience - Biophysics Section, Università Cattolica del Sacro Cuore, Rome, 2Fondazione Policlinico "A. Gemelli" IRCCS, Rome, 3Dipartimento di Scienze Mediche e Chirurgiche - Centro per le Malattie Endocrino-Metaboliche, Fondazione Policlinico "A. Gemelli" IRCCS, Rome, 4Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, 5CNR ISOF, Consiglio Nazionale delle Ricerche ISOF, Bologna, 6U.O.C. di Nefrologia, Fondazione Policlinico "A. Gemelli" IRCCS, Rome, Italy.

Background and aims: Many factors, such as hyperglycemia, atherogenic lipid profile, obesity, and hypertension have been closely associated with the development of cardiovascular diseases (CVD) in type 2 diabetes (T2D). However, despite effective control of the main known variables, a considerable residual cardiovascular risk is still not predictable in diabetic subjects. Here, we propose erythrocyte (RBC) membrane fluidity, reflecting the state of a more complex network of regulatory processes activated in the disease, as a valid biomarker for a quantitative evaluation of residual cardiovascular risk.

Materials and methods: To test whether changes in erythrocyte membrane fluidity may be associated with the development of CVD in diabetic patients, we developed a bioimaging system able to measure with high spatial resolution plasma membrane modifications. Erythrocyte membrane fluidity, quantified by the generalized polarization (GP) index, has been measured on blood samples of 234 diabetic subjects, 86 of whom reported a major cardiovascular event in clinical history, and 32 non-diabetic subjects. Fatty acids (FAs) membrane composition of RBC was obtained for a set of sampled controls and T2D with and without CVD through a gas chromatography-flame ionization detector.

Results: Relying on GP values, ranging from -1 (high fluidity) to +1 (low fluidity), an unsupervised hierarchical clustering method was applied, leading to the determination of a GEL cluster characterized by GP=0.46 ±0.01 and a High-Risk cluster (HR) characterized by a lower GP value (GP=0.40±.03, p=0.05). Though having comparable CVD risk factors according to the UKPDS engine, as well as the same glycaemic and lipid profile, GEL and HR clusters differ in the percentage of patients reporting a major cardiovascular event (GEL: 24%±6%; HR: 41%±4%, p<0.05). The characterization of the RBC FA profile reveals that patients with more fluid membranes (HR) present a clear shift towards a pro-inflammatory condition, reflected in an increased ω6/ω3 inflammatory risk index (HR: 3.6±0.5; GEL: 2.5±0.8, p=0.04), mainly due to higher levels of arachidonic acid (AA-HR=21.6±1.4%; AA-GEL=19.1±2.5%, p=0.02), which is a well-known precursor of inflammatory mediators.

Conclusion: In conclusion, the hereby proposed analysis of RBC membrane fluidity, combining confocal imaging and FA-based lipidomic studies, paves the way for the introduction of RBC fluidity both as a powerful biomarker for CVD and a potential therapeutic target for personalized intervention. Additional studies, following up specific nutritional protocols, will be necessary to further investigate the effect of RBC fluidity normalization in modulating CVD and reducing its associated risk.

Supported by: EFSD and Sanofi European Grants for "Innovative Measurements of Diabetes Outcomes" (2018)
Disclosure: G. Bianchetti: None.

866  
Comparison of effects of canagliflozin, dapagliflozin and empagliflozin on cardio-renal biomarkers in 150 patients with type 2 diabetes  
V. Teli, V. Gupta; Tardeo, VG-ADVANTAGE Diabetes Thyroid and Endocrine Center, Mumbai, India.

Background and aims: The aim was to compare the effects of 3 SGLT2i (Canagliflozin {C}, Empagliflozin {E} & dapagliflozin {D} on cardio-renal biomarkers in T2DM patients followed for 1 year.

Materials and methods: Between January to March 20, 150 T2DM patients irrespective of A1c on SGLT2i (dapagliflozin {D} emapagliflozin {E} or canagliflozin {C}) therapy, aged 18-75yrs were included and analysed. They were divided in 3 groups: D (50 on D) E (50 on E) & C (50 on C). Patients were evaluated for cardio-renal {CR} biomarkers [BMI-kg/m², systolic (S) BP, diastolic (D) BP {mm in Hg}, Lipid profile mg/dl, Hs-CRP [mg/L], NT-ProBNP pg/mL, creatinine [Cr], Cystatin-C [Cy-C] eGFR, UACR] & followed 2-3 monthly for 1 yr. Baseline characteristics: analysed using descriptive statistics. Data analysis: SPSS 26, represented as mean ± SE & independent sample t-test used. P value <0.05 considered significant (S).

Results: Baseline (B) characters: well matched D gr: B - 12 mths: S reduction in BMI, SBP, Alc, TC, LDL, TG, Cr, UACR, hs-CRP. E gr: B - 12 mths: S reduction in BMI, SBP, DBP, Alc, TC, LDL, TG, eGFR, UACR & hs-CRP. C gr: B - 12 mths: S reduction in BMI, SBP, DBP, TC, LDL, TG, Apo-B, hs-CRP.

Differences at 12 mths: S reduction in BMI (D 1.606±0.2935, E 0.698 ±0.2096, C 1.114±0.2964, p<0.038), DBP (D 1.280±1.571, E 5.840 ±1.877, C 6.52±1.177, p<0.040) & Apo-B (D 1.182±3.0408, E 0.6062 ±0.7705, C 12.087±3.2951, p<0.023). Group D Versus E: S reduction in D gr [Wt (-2.0282±0.84, p<0.017) & BMI (-0.9866±0.36, p<0.007)], Group E Vs C: None. Group D Vs C: S reduction: SBP (7.480±3.755, p<0.049), DBP 5.24±1.963, p<0.009), Apo-B (10.904±4.913, p<0.029) & hs-CRP (1.574±0.636, p<0.015) favouring C.

Conclusion: Canagliflozin S reduces DBP & Apo-B compared to dapagliflozin & empagliflozin. Canagliflozin S reduces hs-CRP, SBP, DBP & Apo-B compared to dapagliflozin.

Disclosure: V. Teli: None.

867  
Prevalence of lipodystrophy and agreement between clinical and radiological imaging methods in diagnosing lipodystrophy in insulin requiring subjects with diabetes  
A. Baidya1, S. Dey2, R. Bhadra3;
1Endocrinology, Nil Ratan Sircar Medical College & Hospital, 2Radiodiagnosis, Nil Ratan Sircar Medical College & Hospital, Kolkata, India.

Background and aims: Subjects with diabetes on subcutaneous insulin having lipodystrophy have an almost 6 fold higher incidence of hypoglycaemia compared with subjects without lipodystrophy and 7 fold higher incidence of glycaemic variability which increases the risk of chronic complications of diabetes.1 To study the prevalence of lipodystrophy in insulin requiring subjects with diabetes by clinical and radiological imaging methods. 2 To study the agreement between clinical and imaging methods [Ultrasoundography(USG) and Magnetic Resonance Imaging(MRI)] in the diagnosing lipodystrophy.

Materials and methods: Inspection and palpation of insulin injection sites of 362 subjects on subcutaneous insulin for more than 6 months were done. All subjects were subjected to USG for confirmation of lipodystrophy and proper characterization of the lesions. In 25 subjects, for whom USG was not helpful in proper characterization of lipodystrophy lesions, MRI was performed.
Results: Prevalence of lipodystrophy by clinical and radiological methods is 78.18% and 82.04% respectively. Clinical examination revealed nodular, diffuse hypertrophic, lipoatrophic, lipodystrophy, diffuse plus nodular pattern in 26.5%, 23.7%, 7.4%, 7.4% and 5% patients respectively. Radiological methods revealed diffuse lipohypertrophy, nodular, lipodystrophy, diffuse plus nodular and lipoatrophy pattern in 37.5%, 24.3%, 18.6%, 12.6% and 7.4% patients respectively. In 10 patients MRI helped in the diagnosis of lipodystrophy and in another 10 patients MRI helped in proper subtyping of lipodystrophy. There is a strong agreement between clinical and radiological imaging methods in diagnosing lipodystrophy (Kappa value 0.862; P<0.001).

Conclusion: Prevalence of lipodystrophy is high in insulin requiring subjects with diabetes. There is a strong agreement between clinical and radiological imaging methods in diagnosing lipodystrophy.

Disclosure: A. Baidya: None.
among the population aged ≥ 65 for rHHF; HRs of TyG index for rHHF were 1.413 (95% CI 1.067-1.872) in lower and 0.922 (95% CI 0.675-1.258) in middle tertile, respectively, but not among the population aged < 65.

**Conclusion:** Paradoxically, a lower TyG index appeared to be a worse prognostic factor on 3-year rHHF after AMI, and this issue was more prominent among the older population. Future studies are needed to understand the mechanisms underlying the TyG index paradox and to characterize the TyG index paradox in certain patient subgroups.

**Disclosure:** J. Jeong: None.

---

**870**

**Effects of polyphenols on cholesterol efflux and insulin secretion in MIN6 cells**

Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

**Background and aims:** Diabetic dyslipidemia is characterized by elevated levels of triglyceride-rich lipoproteins and reduced levels of HDL-cholesterol (HDL-C). Low levels of HDL-C are associated with an increased risk of atherosclerotic cardiovascular disease, because HDL protects against atherosclerosis through multiple mechanisms including removal of excess cholesterol from macrophages. HDL can also influence cholesterol homeostasis in pancreatic β-cell. It is noteworthy that absence of ATP-binding cassette transporter A1 (ABCA1), which is a cellular cholesterol transporter and regulates islet cholesterol efflux, results in islet cholesterol overload and impaired insulin release in mice. We examined the associations of cholesterol efflux and insulin secretion in MIN6 cells with polyphenols that is reported to increase cholesterol efflux.

**Materials and methods:** Murine MIN6 cells were labeled with 3H-cholesterol and incubated with ApoA1 (10 μg/ml) or HDL (25 μg/ml) for 24 hours. The percentage cholesterol efflux was calculated by dividing the media-derived radioactivity by the sum of the radioactivity in the media and the cells. The effect of polyphenols on the cholesterol efflux was studied, adding that into the medium before the analysis of the cholesterol efflux. Insulin secretion was assessed by ELISA as the concentration of insulin in the culture medium. The mRNA expression of ABCA1 and ABCG1 were determined by real-time Quantitative RT-PCR.

**Results:** Under the existence of polyphenols (isorhamnetin), the ApoA1 and HDL-mediated cholesterol efflux had significantly increased by 1.4% or 1.8%, respectively (n=4, p<0.01). Isorhamnetin increased insulin secretion by 882 ng/mg protein/h (n=3, p<0.05) and significantly decreased ABCA1 and ABCG1 expressions.

**Conclusion:** These data suggest that isorhamnetin increases cholesterol efflux and insulin secretion in MIN6 cells. Iisorhamnetin could be the interesting candidate to investigate the new treatment for patients with diabetes mellitus.

**Supported by:** This work was supported by JSPS KAKENHI Grant Number JP20K11549

**Disclosure:** K. Matsuki: None.

---

**871**

**Metabolism of valvular interstitial cells is glucose dependent and susceptible to different diabetic conditions**

M. Barth1, J.I. Selig1, H.V. Krug1, C. Küppers1, D.M. Ouwens2,3, A. Lichtenberg1, P. Akhyar1; 
1Department of Cardiac Surgery, University Hospital of the Heinrich-Heine-University Düsseldorf, Düsseldorf, 2Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center (DDZ), Düsseldorf, 3German Center for Diabetes Research (DZD), München-Neuherberg, Germany.

**Background and aims:** Diabetes is a risk factor for the development of calcific aortic valve disease. Previous studies showed that the main cell type of aortic heart valves, the valvular interstitial cells (VIC), are susceptible to diabetic conditions such as hyperglycaemia and hyperinsulinemia in terms of impaired glycolysis and mitochondrial respiration. Since knowledge about VIC metabolism especially in the context of diabetes is still scarce, the aim of the present study was to evaluate the utilization and dependency of different fuels of VIC under diabetic conditions.

**Materials and methods:** Primary VIC of n = 6-7 individual sheep were cultured under normoglycemic and under diabetic conditions (4.5 g/L glucose and 100 nM insulin) for six days. Mitochondrial function and determinants of glycolysis dependent on different mitochondrial fuels like glucose, glutamine and fatty acids were measured using a Seahorse XF96 extracellular flux analyser. Glycolytic metabolites were analysed by determination of glucose-6-phosphate, pyruvate and lactate with respect to a detailed examination of the impact of hyperinsulinemia (HI), hyperglycaemia (HG) and the combination of both (HI+HG).

**Results:** Analysis of the glycolytic rate of VIC showed that basal glycolysis is increased by diabetic conditions (p<0.001) independent of the offered fuel. Induced glycolysis was upregulated under diabetic conditions when VIC were restricted to glutamine (p<0.01) or fatty acids (p<0.0001). Analysis of mitochondrial respiration showed that basal respiration is increased by diabetic conditions (p<0.0001) independent of different fuels. Restriction to fatty acids led to a reduction in maximal respiration (p<0.05) and spare respiratory capacity (p<0.01) of VIC under diabetic conditions. ATP production, in contrast, was not altered by the offered fuels but significantly increased by diabetic conditions (p<0.001). Glycolytic metabolism was significantly increased by HG (p=0.009) but not by HI (p>0.9999) or HI+HG (p=0.059). Pyruvate concentration was significantly decreased by HI (p=0.005), but not by HG (p>0.9999) or HI+HG (p=0.384). Relative quotients of lactate/protein remained unchanged.

**Conclusion:** Basal mitochondrial respiration and glycolysis is impaired by diabetic conditions, whereas VIC are able to compensate fuel restrictions. Restriction to glutamine or fatty acids, in contrast, impairs the ability of VIC to maintain their metabolic potential under diabetic conditions. These findings are indicative for glucose being the main metabolic fuel of VIC. Moreover, the content of VIC glucose metabolites is affected by different diabetic stimuli, indicating that glucose metabolism of VIC is diversely susceptible to HI and HG.

**Supported by:** DFG

**Disclosure:** M. Barth: Grants; German Research Foundation (DFG).
**872**

Influence of glycaemic status on the risk of cardiovascular events after a myocardial infarction


1Linköping University, Norrköping, Sweden, 2Brigham and Women’s Hospital, Harvard Medical School, Boston, USA, 3Dokuz Eylül University, Izmir, Turkey, 4University Hospital Antwerp, Edegem, Belgium, 5Flinders Medical Centre, Adelaide, Australia, 6Asian Heart Institute and Research Center, Mumbai, India, 7Cardiocentro Ticino, Lugano, Switzerland, 8University of Cape Town, Cape Town, South Africa, 9National Heart Centre, Singapore, Singapore, 10Teaching Hospital of J.A. Reiman, Prešov, Slovakia, 11Medical University of Plovdiv, Plovdiv, Bulgaria, 12Newcastle University, Newcastle, UK, 13Novartis Pharmaceutical Corporation, East Hanover, USA, 14Stanford University School of Medicine, Palo Alto, USA.

**Background and aims:** Survivors of myocardial infarction (MI) with a prior diagnosis of diabetes are more likely to develop heart failure (HF) and to experience other cardiovascular (CV) events. Less is known about the CV risk in MI survivors with pre-diabetes or screen-detected diabetes. The aim of this study was to assess the association between glycemic status and CV events in a population of patients with a recent MI and elevated risk of HF.

**Materials and methods:** In 5661 participants in the PARADISE-MI (Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction) trial, glycemic status was determined at baseline according to prior medical history and HbA1c values (no diabetes=no prior diagnosis of diabetes and HbA1c <5.7%, pre-diabetes=no prior diagnosis of diabetes and HbA1c ≥5.7% but ≤6.4%, screen-detected diabetes=no prior diagnosis of diabetes and HbA1c >6.5%, prior diabetes=prior diagnosis of diabetes regardless of HbA1c). Incidence rates for two adjudicated composite outcomes (CV death/outpatient symptomatic HF/HF leading to hospitalization, and CV death/MI/stroke) were estimated.

**Results:** During a median follow-up time of 22 months, the incidence rates of HF or CV death was 4.6/100 person-years in those without diabetes (n=1401), 6.5/100 person-years in those with pre-diabetes (n=1576), 7.8/100 person-years in those with screen-detected diabetes (n=283) and 9.0/100 person-years in those with a prior diagnosis of diabetes (n=2401). The corresponding incidence rates for MI/stroke/CV death were 4.4, 5.7, 6.3 and 8.4 per 100 person-years, respectively. After adjustment for additional markers of increased risk, only prior diabetes remained significantly associated with increased risk for both outcomes (adjusted HR for HF/CV death: 1.87, 95% CI 1.52-2.31, P<0.001, and for MI/stroke/CV death: 1.81, 95% CI 1.46-2.23, P<0.001).

**Conclusion:** In people with a recent MI and additional risk factors for development of HF, incidence rates of CV events were higher in those with a more severe hyperglycemic phenotype. This underscores the importance of early detection of glycemic abnormalities after an MI.

Clinical Trial Registration Number: NCT02924727

Supported by: The PARADISE-MI study was funded by Novartis

Disclosure: M. Wijkman: Lecture/other fees; Advisory boards or lectured for MSD, Lilly, NovoNordisk, and Sanofi.

---

**873**

Physical activity and diastolic dysfunction in people with type 2 diabetes

A.G. Hoek1, I.R. Jankipersad1, E. Dal Canto1,2, N.R. den Braver1, R. Meer1, P.J.M. Elders3, J.W.J. Beulens1,4; 

1Epidemiology & Data Science, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, 2Department of Experimental Cardiology, University Medical Center Utrecht, Utrecht, 3Department of General Practice and Elderly Care Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, 4Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, Utrecht, Netherlands.

**Background and aims:** Heart failure with preserved ejection fraction (HFpEF) is an emerging epidemic, which is especially prevalent in people with type 2 diabetes. In the general population, lower levels of physical activity (PA) have been associated with a higher risk of overall heart failure and left ventricular diastolic dysfunction (LVDD). However, the association between PA, HFpEF and LVDD has never been investigated in a population of people with type 2 diabetes.

**Materials and methods:** We performed a cross-sectional analysis on 239 participants with type 2 diabetes from the Diabetes Care System cohort, who had no prior diagnosis of heart failure. Percentage of time in moderate-to-vigorous (% in MVPA) of total PA was assessed with accelerometers, wore for 7 days. LVDD was echocardiographically assessed by measuring E/e’ ratio, pulmonary artery pressure, left ventricular mass.
index and left atrial volume index. Furthermore, the continuous H2FPEF score estimating the probability of HFpEF - using the estimated pulmonary artery pressure, E/e' ratio, presence of atrial fibrillation, age and body mass index (BMI) - was calculated. Multivariate linear regression models, adjusted for sex, age, BMI, hypertension, hyperlipidemia and diabetes duration were used to analyze the cross-sectional relationship between PA and echocardiographic markers, and effect modification for sex was investigated. For the cross-sectional analysis between PA and the continuous H2FPEF score a similar analysis was used, but BMI was left out of the models since it is embedded in the H2FPEF score.

Results: A 1.0% higher MVPA was significantly associated with a 9.0% decrease in the H2FPEF score (95% CI -14.09; -4.09) for women in the fully adjusted model. For men, no associations were found (-0.67; 95% CI: -3.07; 1.73). However, in a separate analysis, a strong association between % in MVPA and BMI (-0.98; 95% CI: -1.54; -0.41) was found, suggesting that the results might be partly driven by BMI. No associations were found between PA and single markers of LVDD; mean E/e' between % in MVPA and BMI (-0.98; 95% CI: -1.54; -0.41) was found, 95% CI: -3.07; 1.73). However, in a separate analysis, a strong association between % in MVPA and BMI (-0.98; 95% CI: -1.54; -0.41) was found, suggesting that the results might be partly driven by BMI. No associations were found between PA and single markers of LVDD; mean E/e' (-0.003; 95% CI: -0.016; 0.010); left atrial volume index (0.013; 95% CI: 0.061; -0.001); left ventricular mass index (0.006; 95% CI: -0.005; 0.016) and estimated pulmonary artery pressure (-0.01; 95% CI: -0.048; 0.027).

Conclusion: In this study we found that increased PA was associated with a lower H2FPEF score in women with type 2 diabetes. This association was not confirmed when investigating the separate echocardiographic markers of LVDD. Given the strong association between % in MVPA and BMI the found association with the H2FPEF score might be partly driven by BMI.

Supported by: ZonMW NWO-Vidi grant (91 71 8304)

Disclosure: A.G. Hoek: None.

874 Glycaemic variability is associated with diastolic dysfunction in patients with type 2 diabetes
Y.Y. Dzhun1, G.B. Mankovsky1, N.M. Rudenko1,2, Y.Y. Marushko1, Y.A. Saenko1,2, B.M. Mankovsky1,2;
1Government Institution “The Scientific and Practical Medical Center of Pediatric Cardiology and Cardiac Surgery of the Ministry of Health of Ukraine”; 2Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine.

Background and aims: There is convincing body of evidences that diabetes mellitus is associated with an increased risk of heart failure. However, the exact mechanisms of pathogenetic role of diabetes in the development and progression of heart failure remain not fully elucidated. In the last decade, with the widely use of continuous glucose monitoring, indicators of glycaemic variability have been increasingly taken into consideration. Glycemic variability could be one of the reason predisposing to heart failure in subjects with diabetes. The aim of the study is evaluation of the relationship between glycemic variability and diastolic dysfunction in patients with type 2 diabetes mellitus without coronary artery disease.

Materials and methods: Seventy-eight patients with heart failure with preserved left ventricular ejection fraction and type 2 diabetes mellitus were examined. Exclusion criteria were: clinically manifesting coronary artery disease, LV ejection fraction <50%, morbid obesity, atrial fibrillation, anemia, severe valvular heart disease (severe mitral, tricuspid, aortic, and/or pulmonary valve insufficiency or stenosis), hypertension, hypertrophic or restrictive cardiomyopathy. Diastolic function was assessed by echocardiography; glycemic variability was evaluated by continuous monitoring of glucose. According to the glycemic variability all studied patients were divided into two groups: group I - SD> 2 (high glycemic variability), n = 40; group II - SD ≤ 1.9 (normal glycemic variability), n = 38.

Results: Group I were older (49 (9) vs 46 (5); p<0.05 (the results of the study are presented as mean (SD) or absolute number (%)), with a longer duration of DM (10 (9.5) vs 6 (5.5); p<0.01). In group I compared to group II there were more patients with grade 2 of diastolic dysfunction (25 (62.5%) vs 10 (26.3%); p<0.05). Patients in group I had more severe diastolic dysfunction which was characterized by an increased values of E/e', early transmural flow rate and peak rate of tricuspid regurgitation (E/e': 14.2 (4.2) vs 12.1 (3.5); p<0.01; E, cm/s: 85 (19) vs 75.2 (22); p<0.05 and V max TR, m/s: 2.4 (0.6) vs 2.1 (0.4); p<0.05 in the 2 groups of subjects studied, respectively). In group I patients insulin and sulfonlureas were used more often (11 (27.5%) vs 0 p = 0.0001; 25 (62.5%) vs 10 (26.3%); p<0.01, respectively); patients of group II were more often treated with sGLT2 (2 (5%) vs 13 (34.2%); p<0.01).

Conclusion: Increased glycemic variability is associated with diastolic dysfunction and could predispose to development and progression of heart failure with preserved ejection fraction.

Disclosure: Y.Y. Dzhun: None.
Assessment of cardiovascular events in a real-world high-risk cohort with type 2 diabetes or atherosclerotic cardiovascular disease in Germany

M. Verket1, N. Kossack2, J. Brandts1, T. Schönfelder2,3, K. Schütt1, D. Häckl2,4, N. Marx1, D. Müller-Wieland2

1Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, 2WIG2 – Scientific Institute for Health Economics and Health System Research, Leipzig, 3Chair Health Sciences/Public Health, Medical Faculty, TU Dresden, Dresden, 4Faculty of Economics and Management Science, University Leipzig, Leipzig, Germany.

Background and aims: Heart failure (HF) and peripheral arterial disease (PAD) are common diseases with an impact on healthcare burden. We assessed the incidence of hospitalization for HF, myocardial infarction (MI), stroke and PAD in a real-world high-risk cohort with type 2 diabetes (T2DM) or atherosclerotic cardiovascular disease (ASCVD) on a standard statin treatment in Germany from 2017-2019.

Materials and methods: The present retrospective longitudinal analyses are based on an anonymized validated research database of WIG2, which contains linkable billing and social data of about 4 million German statutory health insured persons. We selected three cohorts from 2017-2019 with a follow-up (FU) of 12 months: patients with ASCVD and T2DM, patients with T2DM and a risk factor, respectively. The cumulative incidence function (CIF) of HF hospitalization over the FU of 12 months is about 2.9%, 1.5% and 0.56% in patients with ASCVD and T2DM, patients with ASCVD without T2DM and patients with T2DM and a risk factor, respectively (Fig. 1A). There were no differences among ASCVD patients with or without T2DM in CIF of hospitalisation for MI (1.41% and 1.16%, respectively) and stroke (1.64% and 1.27%, respectively). However, CIF of MI and stroke hospitalisation is lower in patients with T2DM and a risk factor (0.08% and 0.1%, respectively) compared to 2 other cohorts. Furthermore, CIF of PAD hospitalization is about 2.3%, 1.4% and 0.03% in patients with ASCVD and T2DM, patients with ASCVD and without T2DM and patients with T2DM and a risk factor, respectively (Fig. 1B).

Conclusion: This German health insured data show that diabetes is a main driver for HF or PAD hospitalization in patients with ASCVD within 12 months. This aspect should be considered in ASCVD risk thresholds.
were new cases. When overall incident CVD served as the outcome, the number of people in low, middle and high risk group was 22, 305 and 211 in males and 42, 242 and 220 in females. Kaplan-Meier curves (Figure 1) indicated that generally SCORE2-OP could discriminate the high CVD risk group from the middle and low risk group in males, but it had a poor discriminative performance in females. The slope of calibration was 0.90 (95% CI: 0.52, 1.28) and 0.83 (95% CI: 0.37, 1.28) and c-statistics was 0.60 (95% CI: 0.56, 0.65) and 0.61 (95% CI: 0.55, 0.66) for males and females respectively. Likewise, after prevalent CVD cases at baseline were excluded, the slope of calibration was 1.23 (95% CI: 0.64, 1.83) and 0.44 (95% CI: -0.13, 1.00) and c-statistics was 0.64 (95% CI: 0.58, 0.71) and 0.56 (95% CI: 0.49, 0.64) for males and females.

Conclusion: The predictive performance of SCORE2-OP in an older population with type 2 diabetes was poor, and using this score to predict 10-year CVD risk in this population might not be appropriate. Further independent validations of SCORE2-OP in people with diabetes are warranted.

---

**Background and aims:** The association between body weight fluctuation and the risk of cardiovascular disease (CVD) has been investigated previously with controversial findings. However, there is no extensive study which systematically evaluates the current evidence. Furthermore, the impact of ethnicity and type 2 diabetes on this phenomena has not yet been investigated. Therefore, the aim of this study is to comprehensively evaluate the effect of weight fluctuation on risk of CVD (any cardiovascular (CV) event, composite CV outcome, CV death, Stroke, Myocardial Infarction) and the influence of ethnicity and type 2 diabetes status on the observed association.

**Materials and methods:** A systematic review and meta-analysis was performed according to the meta-analyses of observational studies in epidemiology (MOOSE) guidelines. The electronic databases PubMed, Web of Science, and the Cochrane Library were searched for studies that investigated the relationship between body weight or BMI fluctuation and CV diseases using Medical Subject Headings (MeSH) terms and keywords. The relative risks (RRs) for the outcomes were collected from studies, pooled, and analysed using a random-effects model to estimate the overall relative risk.

**Results:** Of 5645 articles screened, 23 studies with a total population of 15,382,537 fulfilled the prespecified criteria and were included. Individuals in the highest strata of body weight fluctuation were found to have significantly increased risk of any CV events (RR = 1.21; 95% Confidence Interval (CI) 1.13 - 1.28), cardiovascular death (RR = 1.24; 95% CI 1.02 - 1.46), myocardial infarction (RR = 1.14; 95% CI 1.10 - 1.18), stroke (RR = 1.21; 95% CI 1.19 - 1.24), and compound CVD outcomes (RR = 1.40; 95% CI 1.09 - 1.71). Similar RRs were observed regarding BMI fluctuation and per unit standard deviation (SD) increase in body weight fluctuation. This effect was observed regardless of ethnicity or diabetes status.

**Conclusion:** Appropriate interventions to maintain stable weight could positively influence CVD. Future research is needed to prove a causative link between weight cycling and CVD risk.

**Disclosure:** R.J. Massey: None.